PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	McCarron, MO; Muir, KW; Weir, CJ; Dyker, AG; Bone, I; Nicoll, JAR; Lees, KR				McCarron, MO; Muir, KW; Weir, CJ; Dyker, AG; Bone, I; Nicoll, JAR; Lees, KR			The apolipoprotein E epsilon 4 allele and outcome in cerebrovascular disease	STROKE			English	Article						apolipoproteins; stroke outcome	CEREBRAL AMYLOID ANGIOPATHY; CORONARY HEART-DISEASE; E POLYMORPHISM; ISCHEMIC STROKE; DEFICIENT MICE; HEMORRHAGE; INJURY; APOE; RISK; RAT	Background and Purpose-Polymorphism of the apolipoprotein E gene (APOE) may influence outcome after traumatic brain injury and intracerebral hemorrhage, with the epsilon 4 allele being associated with poorer prognosis. We investigated APOE allele distribution in acute stroke and the effect of the epsilon 4 allele on outcome. Methods-APOE genotypes were determined in 714 stroke patients: 640 ischemic stroke and 74 intracerebral hemorrhage patients. The survival effect of the epsilon 4 allele was assessed with the use of a stratified log-rank test. A Cox proportional hazards regression model was used to estimate the independent effect of epsilon 4 dose (0, 1, or 2) on survival, and logistic regression was used to determine the effect on 3-month outcome (good if alive at home, poor if in care or dead). Results-Allele distribution matched the general population with no difference between the ischemic and hemorrhagic groups. Survival in the entire cohort was unaffected by epsilon 4 dose. Improved survival with increasing epsilon 4 dose was found in the ischemic group (relative hazard=0.76 per allele; P=0.04). If transient ischemic attacks were excluded, a trend for improved survival persisted (P=0.06). With intracerebral hemorrhage, a trend was seen toward reduced survival with epsilon 4 (P=0.07, log-rank test). Three-month outcome in the ischemic group was unaffected by epsilon 4 dose, and a trend toward poorer outcome with epsilon 4 was Seen for intracerebral hemorrhage (P=0.10). Conclusions-The APOE epsilon 4 allele had divergent effects on survival and outcome in ischemic and hemorrhagic strokes in this population The reported adverse effect on patients with intracerebral hemorrhage was supported. The favorable survival effect on ischemic stroke patients requires further study.	So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland		Nicoll, JAR (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland.	JARN1H@clinmed.gla.ac.uk	Muir, Keith W/A-7670-2011; Nicoll, James/I-9253-2017	Muir, Keith W/0000-0001-9535-022X; Nicoll, James/0000-0002-9444-7246; Weir, Christopher/0000-0002-6494-4903			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; CORIA F, 1995, STROKE, V26, P2375; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; Ferrucci L, 1997, STROKE, V28, P2410, DOI 10.1161/01.STR.28.12.2410; Ford I, 1995, J CLIN EPIDEMIOL, V48, P1441; Greenberg SM, 1996, NEW ENGL J MED, V335, P189, DOI 10.1056/NEJM199607183350308; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; Greenberg SM, 1997, ANN NEUROL, V41, P701, DOI 10.1002/ana.410410604; Hachinski V, 1996, ARCH NEUROL-CHICAGO, V53, P303, DOI 10.1001/archneur.1996.00550040031011; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 1995, LANCET, V346, P1424, DOI 10.1016/S0140-6736(95)92437-X; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KENDRICK S, 1993, HLTH B EDINB, V51, P1; KERVINEN K, 1994, ATHEROSCLEROSIS, V105, P89, DOI 10.1016/0021-9150(94)90011-6; Kessler C, 1997, ARTERIOSCL THROM VAS, V17, P2880, DOI 10.1161/01.ATV.17.11.2880; KUUSISTO J, 1995, ARTERIOSCL THROM VAS, V15, P1280, DOI 10.1161/01.ATV.15.9.1280; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; MAHIEUX F, 1990, STROKE S1, V21, P115; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Muir KW, 1996, STROKE, V27, P1817, DOI 10.1161/01.STR.27.10.1817; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Puttfarcken PS, 1997, J NEUROCHEM, V68, P760; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; WENHAM PR, 1991, LANCET, V41, P479	47	100	100	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0039-2499			STROKE	Stroke	SEP	1998	29	9					1882	1887		10.1161/01.STR.29.9.1882			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	115FA	WOS:000075651800024	9731613	Bronze			2022-02-06	
J	Mesenge, C; Margaill, I; Verrecchia, C; Allix, M; Boulu, RG; Plotkine, M				Mesenge, C; Margaill, I; Verrecchia, C; Allix, M; Boulu, RG; Plotkine, M			Protective effect of melatonin in a model of traumatic brain injury in mice	JOURNAL OF PINEAL RESEARCH			English	Article						head injury; melatonin; free radicals	EXPERIMENTAL HEAD-INJURY; LIPID-PEROXIDATION; NITRIC-OXIDE; INDUCED SEIZURES; DAMAGE; RAT; SUPEROXIDE; RADICALS	The pineal hormone melatonin has recently been shown to exert neuroprotective activity in a variety of experimental neuropathologies in which free radicals are involved. This neuroprotective effect has been attributed to the antioxidant properties of melatonin. Considering that free radicals also play a deleterious role in traumatic brain injury (TBI), the purpose of the present study was to determine whether melatonin would have a beneficial effect in this pathology. Head injury was induced in mice and the neurological deficit was evaluated at 24 hr by a grip test. In this model, the free radical scavenger, alpha-phenyl-tert-butyl-nitrone (2 x 100 mg/ kg, i.p.) given 5 min and repeated at 4 hr after TBI was neuroprotective. Melatonin(l.25 mg/kg, i.p.) given 5 min and repeated at i, 2, and 3 hr after head trauma also significantly reduced the neurological deficit. This beneficial effect was not due to melatonin-induced hypothermia since repeated treatment with melatonin did not modify the colonic temperature of mice. This study shows that melatonin exerts a beneficial effect on the neurological deficit induced by traumatic brain injury in mice. The mechanisms of this neuroprotection remains to be established, and more particularly, the contribution of the antioxidant activity of melatonin.	Univ Rene Descartes, Pharmacol Lab, F-75270 Paris 06, France		Mesenge, C (corresponding author), Univ Rene Descartes, Pharmacol Lab, 4 Ave Observ, F-75270 Paris 06, France.		MARCHAND-LEROUX, Catherine/L-7453-2017; Margaill, Isabelle/ABA-4362-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Margaill, Isabelle/0000-0002-7941-6644			ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; LEBARS D, 1991, NUCL MED BIOL, V18, P357; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; McIntosh TK, 1996, LAB INVEST, V74, P315; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Norlund JJ, 1977, J CLIN ENDOCR METAB, V45, P768; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; PIERREFICHE G, 1995, EXP GERONTOL, V30, P213, DOI 10.1016/0531-5565(94)00036-3; POZO D, 1994, LIFE SCI, V55, P455; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter R J, 1997, Adv Pharmacol, V38, P103; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; REITER RJ, 1981, ENDOCRINOLOGY, V109, P1796; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Verrecchia C, 1995, ADV NEUROIMMUNOL, V5, P359, DOI 10.1016/0960-5428(95)00023-2; Yamamoto H, 1996, J PINEAL RES, V21, P108, DOI 10.1111/j.1600-079X.1996.tb00277.x; Yamamoto HA, 1996, NEUROSCI LETT, V207, P89, DOI 10.1016/0304-3940(96)12493-9; [No title captured]; [No title captured]	37	100	103	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0742-3098			J PINEAL RES	J. Pineal Res.	AUG	1998	25	1					41	46		10.1111/j.1600-079X.1998.tb00384.x			6	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	ZY668	WOS:000074647200007	9694403				2022-02-06	
J	Giacino, JT; Zasler, ND; Katz, DI; Kelly, JP; Rosenberg, JH; Filley, CM				Giacino, JT; Zasler, ND; Katz, DI; Kelly, JP; Rosenberg, JH; Filley, CM			Development of practice guidelines for assessment and management of the vegetative and minimally conscious states	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						minimally conscious state; practice guidelines; rehabilitation; traumatic brain injury; vegetative state	INJURED PATIENTS	The Aspen Neurobehavioral Conference was convened as a venue to consider interactions of mind and brain with regard to health and disease. The primary purpose of the conference was to provide a forum for discussion and scientific collaboration, particularly in areas marked by uncertainty and controversy, with eventual dissemination of conclusions. One of the selected topics for the inaugural session of the conference concerned the development of guidelines for evaluation and management of the vegetative and minimally conscious states. The purpose of this article is to acquaint neurorehabilitation specialists with the unique approach to consensus-based guideline development utilized at the Aspen Conference and to summarize the proceedings of the Aspen Workgroup on the Vegetative and Minimally Conscious States conducted since 1994.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHYS MED & REHABIL, PISCATAWAY, NJ 08854 USA; NATL NEUROREHABIL CONSORTIUM INC, RICHMOND, VA USA; CONCUSS CARE CTR VIRGINIA, RICHMOND, VA USA; BRAINTREE REHABIL HOSP, TRAUMAT HEAD INJURY PROGRAM, TBI PROGRAM, BRAINTREE, MA USA; BRAINTREE REHABIL HOSP, TRAUMAT HEAD INJURY PROGRAM, STROKE PROGRAM, BRAINTREE, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; NORTHWESTERN UNIV, SCH MED,DEPT REHABIL,REHABIL INST CHICAGO, BRAIN INJURY PROGRAM, CHICAGO, IL USA; NORTHWESTERN UNIV, SCH MED,DEPT NEUROL,REHABIL INST CHICAGO, BRAIN INJURY PROGRAM, CHICAGO, IL 60611 USA; SO CALIF PERMANENTE MED GRP, DEPT NEUROL, SAN DIEGO, CA 92120 USA; UNIV COLORADO, HLTH SCI CTR, DEPT NEUROL, DENVER, CO 80262 USA		Giacino, JT (corresponding author), JFK JOHNSON REHABIL INST, CTR HEAD INJURIES, COGNIT REHABIL PROGRAM, 2048 OAK TREE RD, EDISON, NJ 08820 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ANSELL BJ, 1995, ARCH PHYS MED REHAB, V76, P726, DOI 10.1016/S0003-9993(95)80526-5; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; DiPasquale MC, 1996, J HEAD TRAUMA REHAB, V11, P9, DOI 10.1097/00001199-199612000-00004; Elovic E, 1996, NEUROREHABILITATION, V6, P57, DOI 10.3233/NRE-1996-6107; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; HALL M E, 1992, Brain Injury, V6, P435, DOI 10.3109/02699059209008139; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; KANNO T, 1987, PACE, V10, P207, DOI 10.1111/j.1540-8159.1987.tb05949.x; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Plum F., 1982, DIAGNOSIS STUPOR COM, V3rd; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; Tsubokawa T, 1990, Brain Inj, V4, P315; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112	27	100	108	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1997	12	4					79	89		10.1097/00001199-199708000-00008			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	XP104	WOS:A1997XP10400008					2022-02-06	
J	Becker, R; Alberti, O; Bauer, BL				Becker, R; Alberti, O; Bauer, BL			Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury	JOURNAL OF NEUROLOGY			English	Article						intrathecal infusion; baclofen; supraspinal spasticity; cerebral palsy; implantable pump	SPINAL-CORD; CEREBRAL-PALSY; ORIGIN	Severe spinal spasticity has been shown to be a good indication for continuous intrathecal baclofen infusion (CIBI), but then is only limited experience with this treatment in patients with supraspinal spasticity. Eighteen patients with severe spasticity from traumatic or hypoxic brain injury were treated with CIBI. In all patients spasticity could be reduced significantly. The mean Ashworth score was reduced from 4.5 to 2.33 and the mean Spasm frequency score from 2.16 to 0.94. This reduction of spasticity led to a marked pain reduction. Nursing, perineal care and mobilization became much easier. The complication rate was low. In this series we saw one infection in the pump pocket, one epileptic seizure after a bolus application of baclofen and one spinal catheter displacement. The results are similar to those reported from series of patients with spinal spasticity and correspond to the limited experience we have so far with supraspinal spasticity patients. To prevent limb contractures CIBI should be performed as soon as the patient is in a stable clinical condition after brain injury. Further prospective clinical trials will be necessary to obtain more experience with patients suffering from supraspinal spasticity.			Becker, R (corresponding author), UNIV MARBURG HOSP, DEPT NEUROSURG, BALDINGERSTR, D-35033 MARBURG, GERMANY.						Abbott R, 1991, NEUROSURGERY SPASTIC, P215; ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; BITTIGER H, 1989, TREATING SPASTICITY : PHARMACOLOGICAL ADVANCES, P20; BOISSON D, 1991, NEUROSURGERY SPASTIC, P59; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DAVIDOFF RA, 1985, ANN NEUROL, V17, P107, DOI 10.1002/ana.410170202; DRALLE D, 1985, LANCET, V2, P1003; Feldman RG, 1980, SPASTICITY DISORDERE, P41; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; M?ller H., 1988, LOCAL SPINAL THERAPY, P223; MATHE JF, 1991, NEUROSURGERY SPASTIC, P63; MERTENS P, 1991, NEUROSURGERY SPASTIC, P119; MULLER H, 1992, DEV MED CHILD NEUROL, V34, P739; NANCE P, 1995, CAN J NEUROL SCI, V22, P22, DOI 10.1017/S0317167100040452; OCHS G, 1989, J NEUROL NEUROSUR PS, V52, P933, DOI 10.1136/jnnp.52.8.933; OTSUKA M, 1980, J EXP BIOL, V89, P201; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1985, LANCET, V2, P125; PENN RD, 1988, ANN NY ACAD SCI, V531, P157, DOI 10.1111/j.1749-6632.1988.tb31822.x; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1984, LANCET, V1, P1078; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Rifici C, 1994, Funct Neurol, V9, P29; SINDOU M, 1991, NEUROSURGERY SPASTIC, P211; Zieglgansberger W, 1988, LOCAL SPINAL THERAPY, P37; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	30	100	104	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAR	1997	244	3					160	166		10.1007/s004150050067			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL933	WOS:A1997WL93300004	9050956				2022-02-06	
J	Waterloo, K; Ingebrigtsen, T; Romner, B				Waterloo, K; Ingebrigtsen, T; Romner, B			Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury	ACTA NEUROCHIRURGICA			English	Article						head injury; protein S-100; cognitive dysfunction	FIBRILLARY ACIDIC PROTEIN; HUMAN CEREBROSPINAL-FLUID; NEURON-SPECIFIC ENOLASE; CENTRAL NERVOUS-SYSTEM; RECOVERY; IMPAIRMENT; CONCUSSION; DEFICITS; ANTIGEN; DAMAGE	Protein S-100 is a calcium binding protein, synthetized in astroglial cells in all parts of the central nervous system (CNS). We have previously reported high serum levels of protein S-100 in patients after minor head injury (MHI). A battery of conventional and computerized neuropsychological measures was administered to two groups of MHI patients. Neuropsychological outcome at 12 months postinjury was examined in a group of 7 patients with increased serum levels of protein S-100 after MHI and 7 age- and sex-matched controls without detectable S-100 in serum after MHI. Our results demonstrate no overall cognitive dysfunction in either of the two groups. Our findings indicate specific dysfunction on measures of reaction time, attention and speed of information processing for the S-100 group. Posttraumatic depression does not explain the neuropsychological differences between the groups. These findings support that increased serum levels of protein S-100 may be of predictive and prognostic value for longlasting neurocognitive abnormalities after minor head injury. Presence of S-100 in serum may indicate the presence of diffuse brain damage. Our results suggest that information processing measures in computerized neuropsychological assessment are more sensitive for detecting small signs of neurocognitive abnormalities after MHI than conventional test batteries.	UNIV TROMSO HOSP, DEPT NEUROSURG, N-9038 TROMSO, NORWAY; UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN		Waterloo, K (corresponding author), UNIV TROMSO HOSP, DEPT NEUROL, N-9038 TROMSO, NORWAY.			Ingebrigtsen, Tor/0000-0001-5966-9786			AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; AURELL A, 1989, J NEUROL SCI, V89, P157, DOI 10.1016/0022-510X(89)90017-8; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Edna T H, 1987, J Oslo City Hosp, V37, P41; FAGNART OC, 1988, CLIN CHEM, V34, P1387; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GRONWALL D, 1974, LANCET, V2, P2605; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; KATO K, 1982, BIOMED RES-TOKYO, V3, P24; KELLY R, 1981, J ROY SOC MED, V74, P242; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H.S., 1989, MILD HEAD INJURY; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEVIN HS, 1992, J TRAUMA, V33, P385; LEZAK MD, 1995, NEUROPSYCHIOLOGICAL; LEZAK MD, 1989, CLIN NEUROSCIENCE, V7; MICHETTI F, 1980, J NEUROL SCI, V44, P259, DOI 10.1016/0022-510X(80)90133-1; MICHETTI F, 1979, NEUROSCI LETT, V11, P171, DOI 10.1016/0304-3940(79)90122-8; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER EN, 1991, NEUROLOGY, V41, P1608, DOI 10.1212/WNL.41.10.1608; MILLER EN, 1993, CALIFORNIA COMPUTERI; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SINDIC CJM, 1982, J NEUROL NEUROSUR PS, V45, P1130, DOI 10.1136/jnnp.45.12.1130; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANGORP WG, 1994, NEUROLOGY, V44, P929, DOI 10.1212/WNL.44.5.929; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WECHSLER D, 1987, MANUAL MEMORY SCALE; Wetzel JW, 1984, CLIN HDB DEPRESSION; Wolfson, 1993, HALSTEAD REITAN NEUR	46	100	103	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1997	139	1					26	31		10.1007/BF01850864			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	WF448	WOS:A1997WF44800010	9059708				2022-02-06	
J	Crawford, S; Wenden, FJ; Wade, DT				Crawford, S; Wenden, FJ; Wade, DT			The Rivermead head injury follow up questionnaire: A study of a new rating scale and other measures to evaluate outcome after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury follow up; head injury assessment questionnaire; outcome	SEQUELAE; SYMPTOMS	Objective-To develop and evaluate a short (10 item) simple measure of outcome mainly for use with patients with mild to moderate head injuries. Design-Two studies on patients at three and six months after injury, comparing different methods of administration (two raters and postal questionnaire), and comparing ratings with other assessments. Subjects-Forty three patients seen three months after injury and 46 seen six months after injury: both groups had head injuries covering a range of severity from minor to severe. Main outcome measures-Differences between ratings in different groups of patients (Mann-Whitney U test); differences in ratings using different methods of administration (Wilcoxon signed rank test); and correlations between ratings from the same patient (Spearman r). Results-The sum total ratings were consistent between raters and between methods (postal questionnaire v face to face interview) with no evidence of selective bias between raters or methods. Ratings on individual items were also reasonably consistent. The sum total ratings varied as anticipated between groups divided by clinical judgement of recovery and patient assessment of recovery, and related as expected to the extent of post;concussion symptomatology. The 10 items included covered the most important problem areas reported by patients. Conclusion-The Rivermead head injury follow up questionnaire (RHFUQ) is a short, simple, adequately reliable, and valid measure of outcome, across the entire range of severity, but particularly after mild to moderate head injury.			Crawford, S (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Collin C, 1988, Int Disabil Stud, V10, P61; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Fleiss J, 1981, STAT METHODS RATES P, V2nd; HAWTHORNE VM, 1975, SCOT MED J, V1, P23; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Moss NE., 1994, CLIN REHABIL, V8, P149; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; *WORK PART REP MED, 1988, MAN TRAUM BRAIN INJ; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; [No title captured]	20	100	100	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1996	60	5					510	514		10.1136/jnnp.60.5.510			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	UJ915	WOS:A1996UJ91500007	8778254	Bronze, Green Published			2022-02-06	
J	GOPINATH, SP; ROBERTSON, CS; CONTANT, CF; NARAYAN, RK; GROSSMAN, RG; CHANCE, B				GOPINATH, SP; ROBERTSON, CS; CONTANT, CF; NARAYAN, RK; GROSSMAN, RG; CHANCE, B			EARLY DETECTION OF DELAYED TRAUMATIC INTRACRANIAL HEMATOMAS USING NEAR-INFRARED SPECTROSCOPY	JOURNAL OF NEUROSURGERY			English	Article						NEAR-INFRARED SPECTROSCOPY; HEAD INJURY; SUBDURAL HEMATOMA; EPIDURAL HEMATOMA; INTRACEREBRAL HEMATOMA; DELAYED TRAUMATIC HEMATOMA	SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; INTRACEREBRAL HEMATOMAS; COMPUTERIZED-TOMOGRAPHY; CEREBRAL HEMATOMAS; CT SCAN; ONSET	Delayed intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Early identification and treatment of these lesions, which appear or enlarge after the initial computerized tomography (CT) scan, may improve neurological outcome. Serial examinations using near-infrared spectroscopy (NIRS) to detect the development of delayed hematomas were performed in 167 patients. The difference in absorbance of light (Delta OD) at 760 nm between the normal and the hematoma side was measured serially during the first 3 days after injury. Twenty-seven (16%) of the patients developed a type of late hematoma: intracerebral hematoma in eight, extracerebral hematoma in six, and postoperative hematoma in 13 patients. Eighteen of the delayed hematomas caused significant mass effect and required surgical evacuation. The hematomas appeared between 2 and 72 hours after admission. In 24 of the 27 patients, a significant increase (> 0.3) in the Delta OD occurred prior to an increase in intracranial pressure, a change in the neurological examination, or a change on CT scan. A favorable outcome occurred in 67% of the patients with delayed hematomas, which suggests that early diagnosis using NIRS may allow early treatment and reduce secondary injury caused by delayed hematomas.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104		GOPINATH, SP (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616, P01-NS27346] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027346, P01NS027616] Funding Source: NIH RePORTER		ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; ANDREWS BT, 1988, CONT NEUROSURG, V10, P1; BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; FUKAMACHI A, 1985, ACTA NEUROCHIR, V74, P35, DOI 10.1007/BF01413274; Gentleman D, 1989, Br J Neurosurg, V3, P367, DOI 10.3109/02688698909002817; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1995, IN PRESS NEUROTRAUMA; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; NINCHOJI T, 1984, ACTA NEUROCHIR, V71, P69, DOI 10.1007/BF01401152; PIEPMEIER JM, 1982, J TRAUMA, V22, P455, DOI 10.1097/00005373-198206000-00003; RICHARDS T, 1974, SURGERY, V75, P253; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SAKAI H, 1986, INTRACRANIAL PRESSUR, V6, P652; SAWADA Y, 1984, J NEUROL NEUROSUR PS, V47, P1125, DOI 10.1136/jnnp.47.10.1125; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	29	100	105	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1995	83	3					438	444		10.3171/jns.1995.83.3.0438			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	RR001	WOS:A1995RR00100009	7666220				2022-02-06	
J	HEINEMANN, AW; WHITENECK, GG				HEINEMANN, AW; WHITENECK, GG			RELATIONSHIPS AMONG IMPAIRMENT, DISABILITY, HANDICAP, AND LIFE SATISFACTION IN PERSONS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; FOLLOW-UP	Four regional brain injury centers sun eyed 758 individuals with loss of consciousness from head trauma who were living in the community. Relationships among demographic characteristics, severity of impairment, severity of disability, extent of handicap, and life satisfaction were assessed with multiple regression. While the demographic and impairment variables were relatively weak predictors of disability, the combination of these variables was a much stronger predictor of handicap. In turn, 13% of the adjusted variance in life satisfaction was accounted for by these variables. These results support the World Health Organization model of impairment, disability, and handicap and suggest that efforts to remediate disability have a direct benefit in reducing handicap and enhancing life satisfaction.	NORTHWESTERN UNIV,SCH MED,DEPT PHYS MED & REHABIL,CHICAGO,IL 60611; CRAIG HOSP,ENGLEWOOD,CO 80110		HEINEMANN, AW (corresponding author), REHABIL INST CHICAGO,REHABIL SERV EVALUAT UNIT,CHICAGO,IL 60611, USA.		Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			Brown S. C., 1993, J DISABIL POLICY STU, V4, P57; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HALL MK, 1993, J HEAD TRAUMA REHABI, V8, P60; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LINACRE JM, 1991, BIGSTEPS RASCH PROGR; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; RASCH G, 1990, PROBABILISTIC MODELS; RINTALA DH, 1993, MAY AM SPIN INJ ASS; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHITENECK GG, 1994, JUN ANN M AM C REH M; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLER BS, 1993, BRAIN INJURY REHABIL; World Health Organization, 1980, INT CLASS IMP DIS HA; Wright BD., 1982, RATING SCALE ANAL	24	100	101	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1995	10	4					54	63		10.1097/00001199-199508000-00006			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	RN010	WOS:A1995RN01000006					2022-02-06	
J	YOUNGJOHN, JR; BURROWS, L; ERDAL, K				YOUNGJOHN, JR; BURROWS, L; ERDAL, K			BRAIN-DAMAGE OR COMPENSATION NEUROSIS - THE CONTROVERSIAL POST-CONCUSSION SYNDROME	CLINICAL NEUROPSYCHOLOGIST			English	Article							MINOR HEAD-INJURY; DIGIT RECOGNITION TEST; MILD CONCUSSION; IMPAIRMENT; MEMORY; TRAUMA; SYMPTOMS; DEFICITS	Neuropsychological evaluations were performed on 55 consecutive patients with persisting post-concussion syndrome (PCS). All were in litigation or were pursuing/receiving financial compensation for their injuries. No PCS patients who were not in litigation or compensated were referred over the 2-year span of the study. Many patients had deficits on neuropsychological testing. However, 15% of the patients were shown to be unconsciously or consciously motivated to do poorly on the Portland Digit Recognition Test (PDRT) and 33% fell below the cut-offs suggesting poor motivation reported by previous investigators. Only 28% of the PCS patients performed at or above the levels of patients with documented brain damage, established by previous investigators. When an additional measure of cooperation was considered (the Dot Counting Test), 48% of all patients had questionable motivation during testing. The average MMPI-2 profile of the entire PCS group suggested the presence of somatization and functional overlay. The PCS group's average MMPI-2 T scores on scales Hs and Hy were well above the average MMPI T scores of patients with proven brain damage reported by previous investigators. These results suggest that the predominant causes of persisting PCS after minor or mild head injury in many patients are likely to be functional rather than organic.	ARIZONA STATE UNIV,SCOTTSDALE,AZ 85251								Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; AUERBACH AH, 1967, DIS NERV SYST, V28, P110; Barth JT, 1989, MILD HEAD INJURY, P257; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1992, ARCH CLIN NEUROPSYCH, V7, P155, DOI 10.1016/0887-6177(92)90009-C; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1993, CLIN NEUROPSYCHOL, V7, P104, DOI DOI 10.1080/13854049308401892; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Butcher J, 1989, MANUAL ADM SCORING M; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; FAUST E, 1988, PROFESSIONAL PSYCHOL, V14, P508; FAUST E, 1988, J CONSULT CLIN PSYCH, V5, P578; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GREIFFENSTEIN MF, 1994, FEB INT NEUR SOC ANN; GRONWALL D, 1974, LANCET, V2, P605; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hathaway S.R., 1989, MINNESOTA MULTIPHASI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KAY T, 1992, REHABILITATION POST, P109; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER B, 1992, REHABILITATION POST, P169; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MILLER H, 1972, LANCET, V1, P445; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; Reitan R, 1985, HALSTEAD REITAN NEUR; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROMANO JL, 1992, REHABILITATION POST, P193; SNOW WG, 1992, FEB INT NEURO SOC AN; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; Wechsler, 1997, WECHSLER ADULT INTEL; WYLIE TF, 1990, INT NEUROPSYCHOLOGIC; YOUNG E, 1991, NEW STATESMAN SOC, V4, P29; 1978, MENTAL DISORDERS GLO; [No title captured]	47	100	100	0	14	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1995	9	2					112	123		10.1080/13854049508401593			12	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	QV547	WOS:A1995QV54700002					2022-02-06	
J	MENDEZ, MF				MENDEZ, MF			THE NEUROPSYCHIATRIC ASPECTS OF BOXING	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						BOXING; PUGILISM; DEMENTIA PUGILISTICA; PUNCH DRUNK; HEAD TRAUMA; CHRONIC TRAUMATIC ENCEPHALOPATHY; CLOSED HEAD INJURY; CONCUSSION; POST-CONCUSSION SYNDROME	CHRONIC BRAIN-DAMAGE; ACTIVE AMATEUR BOXERS; DEMENTIA-PUGILISTICA; HEAD-INJURY; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; PROFESSIONAL BOXERS; COMPUTED-TOMOGRAPHY; LEAD; CT	Objective: To review the neuropsychiatry of boxing. Method: This update considers the clinical, neuropsychological, diagnostic, neurobiological, and management aspects of boxing-related brain injury. Results: Professional boxers with multiple bouts and repeated head blows are prone to chronic traumatic encephalopathy (CTE). Repeated head blows produce rotational acceleration of the brain, diffuse axonal injury, and other neuropathological features. CTE includes motor changes such as tremor, dysarthria, and parkinsonism; cognitive changes such as mental slowing and memory deficits; and psychiatric changes such as explosive behavior, morbid jealousy, pathological intoxication, and paranoia. Screening with neuropsychological tests and neuroimaging may help predict those boxers at risk for CTE. Conclusions: Boxing results in a spectrum of CTE ranging from mild, nonprogressive motor changes to dementia pugilistica. Recent emphasis on safety in the ring, rehabilitation techniques, and other interventions do not eliminate the risk for CTE. For this reason, there is an active movement to ban boxing.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA		MENDEZ, MF (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, NEUROBEHAV UNIT 691116AF, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA.						ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P348; BRAYNE CEG, 1982, LANCET, V2, P1308; BRETON F, 1990, BIOL PSYCHOL, V31, P57, DOI 10.1016/0301-0511(90)90078-B; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; CHARNAS L, 1990, JAMA-J AM MED ASSOC, V264, P1532, DOI 10.1001/jama.264.12.1532; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CORSELLIS JAN, 1989, BRIT MED J, V298, P318; COWART VS, 1989, JAMA-J AM MED ASSOC, V261, P14, DOI 10.1001/jama.261.1.14; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; ENZENAUER RW, 1989, JAMA-J AM MED ASSOC, V261, P1463, DOI 10.1001/jama.261.10.1463; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; JORDAN BD, 1985, MED SCI SPORT EXER, V17, P212, DOI 10.1249/00005768-198504000-00142; KASTE M, 1982, LANCET, V2, P1186; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P2483, DOI 10.1001/jama.255.18.2483; MACPHERSON P, 1988, NEURORADIOLOGY, V30, P506, DOI 10.1007/BF00339691; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; MCCOWN IA, 1979, PHYSICIAN SPORTSMED, V7, P75; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; PEARCE JMS, 1984, BRIT MED J, V288, P933, DOI 10.1136/bmj.288.6421.933-a; RICHARDS NG, 1984, NEUROLOGY, V34, P1485, DOI 10.1212/WNL.34.11.1485; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1988, LANCET, V2, P1456; RODRIGUEZ G, 1983, LANCET, V2, P858; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SPILLANE JD, 1962, BRIT MED J, P1205; STILLER JW, 1985, PSYCHIAT CLIN N AM, V8, P339; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; UHL GR, 1982, ANN NEUROL, V12, P99; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, V23, P531; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; [No title captured]; 1983, JAMA-J AM MED ASSOC, V249, P254	75	100	103	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2174	1541-3527		INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1995	25	3					249	262		10.2190/CUMK-THT1-X98M-WB4C			14	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	TF010	WOS:A1995TF01000003	8567192				2022-02-06	
J	MCINTOSH, TK; YU, T; GENNARELLI, TA				MCINTOSH, TK; YU, T; GENNARELLI, TA			ALTERATIONS IN REGIONAL BRAIN CATECHOLAMINE CONCENTRATIONS AFTER EXPERIMENTAL BRAIN INJURY IN THE RAT	JOURNAL OF NEUROCHEMISTRY			English	Article						BRAIN INJURY; CATECHOLAMINES; FLUID; PERCUSSION; RAT	SENSORIMOTOR CORTEX INJURY; TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL BLOOD-FLOW; CORTICAL INJURY; STRIATAL DOPAMINE; SELECTIVE LESIONS; BEAM-WALKING; HEAD-INJURY; CIRCULATING CATECHOLAMINES; CEREBELLAR NOREPINEPHRINE	Although activation of brain catecholaminergic: systems has been implicated in the cerebrovascular and metabolic changes during subarachnoid hemorrhage, cerebral ischemia, cortical ablation, and cortical freeze lesions, little is known of the response of regional brain catecholamine systems to traumatic brain injury. The present study was designed to characterize the temporal changes in concentrations of norepinephrine (NE), dopamine (DA), and epinephrine (E) in discrete brain regions following experimental fluid-percussion traumatic brain injury in rats. Anesthetized rats were subjected to fluid-percussion brain injury of moderate severity (2.2-2.3 atm) and killed at 1 h, 6 h, 24 h, 1 week, and 2 weeks postinjury (n = 6 per timepoint). Control animals (surgery and anesthesia without injury) were killed at identical timepoints (n = 6 per timepoint). Tissue concentrations of NE, DA, and E were evaluated using HPLC. Following brain injury, an acute decrease was observed in DA concentrations in the injured cortex (p < 0.05) at 1 h postinjury, which persisted up to 2 weeks postinjury. Striatal concentrations of DA were significantly increased (p < 0.05) only at 6 h postinjury. Hypothalamic concentrations of DA and NE increased significantly beginning al 1 h postinjury (p < 0.05 and p < 0.05, respectively) and persisted up to 24 h for DA (p < 0.05) and 1 week (p < 0.05) for NE. These data suggest that acute alterations occur in regional concentrations of brain catecholamines following brain trauma, which may persist for prolonged periods postinjury.			MCINTOSH, TK (corresponding author), UNIV PENN, DIV NEUROSURG, CNS INJURY LAB, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818, P01NS008803, R55NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		ADACHI N, 1991, J NEUROCHEM, V57, P61, DOI 10.1111/j.1471-4159.1991.tb02099.x; BENFENATI F, 1989, BRAIN RES, V498, P376, DOI 10.1016/0006-8993(89)91120-7; BLOOMQUIST P, 1985, NEUROSCI LETT, V58, P353; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1985, EXP NEUROL, V89, P479, DOI 10.1016/0014-4886(85)90107-4; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BUCHWEITZ E, 1982, J PHARMACOL EXP THER, V223, P322; BURKE RE, 1991, DEV BRAIN RES, V58, P171, DOI 10.1016/0165-3806(91)90003-2; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CALDERINI G, 1978, BRAIN RES, V157, P303, DOI 10.1016/0006-8993(78)90032-X; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CROWDER JM, 1983, EUR J PHARMACOL, V343, P352; CVEJIC V, 1980, ACTA NEUROPATHOL, V51, P71, DOI 10.1007/BF00688852; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P600, DOI 10.1038/jcbfm.1986.107; ESCHUN G, 1992, SURG NEUROL, V37, P101, DOI 10.1016/0090-3019(92)90184-O; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; FEENEY DM, 1988, PHARM APPROACHES TRE, P78; FINKLESTEIN S, 1983, BRAIN RES, V271, P279, DOI 10.1016/0006-8993(83)90290-1; GAUDET R, 1978, J NEUROCHEM, V30, P751, DOI 10.1111/j.1471-4159.1978.tb10781.x; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARIK SI, 1986, NEUROLOGY, V36, P971, DOI 10.1212/WNL.36.7.971; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOHNSTON MV, 1983, ANN NEUROL, V13, P511, DOI 10.1002/ana.410130507; KOBAYASHI H, 1985, EXPERIENTIA, V41, P427, DOI 10.1007/BF01966140; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LANGFITT TW, 1966, HEAD INJURY, P172; Lowry O. H., 1972, A Flexible System of Enzymatic Analysis, P146; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MARTIN JB, 1990, CLIN NEUROENDOCRINOL; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALAZZOLO DL, 1990, J CHROMATOGR, V518, P258, DOI 10.1016/S0021-9673(01)93185-1; PALKOVITZ M, 1988, MAP GUIDE MICRODISSE; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; RICHARDSON DJ, 1993, J HELMINTHOL SOC W, V60, P128, DOI 10.1111/j.1471-4159.1993.tb05830.x; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROBINSON RG, 1975, NATURE, V255, P332, DOI 10.1038/255332a0; Romhanyi R, 1990, J NEUROTRAUM, V9, P164; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STANTON PK, 1989, EXP BRAIN RES, V77, P517; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SVENDGAARD NA, 1987, J CEREBR BLOOD F MET, V7, P21, DOI 10.1038/jcbfm.1987.4; SVENDGAARD NA, 1986, J CEREBR BLOOD F MET, V6, P650, DOI 10.1038/jcbfm.1986.120; Tandian D, 1990, J NEUROTRAUM, V9, P174; VEINOT JP, 1987, EXP NEUROL, V97, P207, DOI 10.1016/0014-4886(87)90295-0; WEAVER MS, 1988, SOC NEUR ABSTR, V14, P1451; WEISS HR, 1988, EUR J PHARMACOL, V148, P107, DOI 10.1016/0014-2999(88)90459-1; WOODWARD DJ, 1979, FED PROC, V38, P2109; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	79	100	103	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	1994	63	4					1426	1433					8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH202	WOS:A1994PH20200029	7931293				2022-02-06	
J	SCHALEN, W; MESSETER, K; NORDSTROM, CH				SCHALEN, W; MESSETER, K; NORDSTROM, CH			COMPLICATIONS AND SIDE-EFFECTS DURING THIOPENTONE THERAPY IN PATIENTS WITH SEVERE HEAD-INJURIES	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						BARBITURATE THERAPY; HEAD INJURY; INTENSIVE CARE COMPLICATIONS; SIDE EFFECTS	DOSE BARBITURATE THERAPY; CEREBRAL BLOOD-FLOW; INTRACRANIAL HYPERTENSION; AGGRESSIVE TREATMENT; PRESSURE; BRAIN; ANESTHESIA; METABOLISM; PNEUMONIA; NUTRITION	This study reports all complications and side effects occurring in 38 patients with severe traumatic brain lesions treated with barbiturate coma because of a dangerous increase in intracranial pressure. The treatment was induced by intravenous infusion of thiopentone (5-11 mg.kg-1) followed by a continuous infusion of 4-8 mg.kg-1.h-1. The subsequent rate of thiopentone infusion was governed by the level of the intracranial pressure with the intention of keeping ICP below 20 mmHg (2.7 kPa). The duration of treatment was 1-15 days. Arterial hypotension occurred in 58%, hypokalemia in 82%, respiratory complications in 76%, infections in 55%, hepatic dysfunction in 87% and renal dysfunction in 47% of the patients. Twenty patients survived. Mortality in 17 patients was caused by an untreatable increase in intracranial pressure. In one patient complications due to barbiturate treatment may have contributed to the fatal outcome. In none of the other cases were the noted complications and side effects associated with any permanent symptoms or dysfunctions.	UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT ANESTHESIOL, S-22185 LUND, SWEDEN								BECKER KE, 1978, ANESTHESIOLOGY, V49, P197, DOI 10.1097/00000542-197809000-00009; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; BREIVIK H, 1978, CRIT CARE MED, V6, P228, DOI 10.1097/00003246-197807000-00004; CARLSSON C, 1975, Acta Anaesthesiologica Scandinavica Supplementum, V57, P7; CHAPMAN AG, 1978, ANESTHESIOLOGY, V48, P175, DOI 10.1097/00000542-197803000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; DAUCH WA, 1989, J NEUROSURG, V70, P862, DOI 10.3171/jns.1989.70.6.0862; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ESPERSEN F, 1981, J INFECT DIS, V144, P19, DOI 10.1093/infdis/144.1.19; FERRER CFS, 1987, BRAIN RES, V411, P304; FORBES AR, 1979, ANESTH ANALG, V58, P387; GOLDBERG LI, 1985, CIRCULATION, V72, P245, DOI 10.1161/01.CIR.72.2.245; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; HARP JR, 1985, BASIS PRACTICE NEURO, P83; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LAMBERT JR, 1985, JPEN-PARENTER ENTER, V9, P501, DOI 10.1177/0148607185009004501; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARIN J, 1981, J NEUROSURG, V54, P521, DOI 10.3171/jns.1981.54.4.0521; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MESSETER K, 1972, ACTA PHYSIOL SCAND, V85, P174, DOI 10.1111/j.1748-1716.1972.tb05248.x; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; NORDBY HK, 1984, ACTA NEUROCHIR, V72, P157, DOI 10.1007/BF01406868; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; NORDSTROM CH, 1990, 41ST P ANN M SCAND N; PIATT JH, 1984, NEUROSURGERY, V15, P427, DOI 10.1227/00006123-198409000-00023; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON JFR, 1986, JPEN-PARENTER ENTER, V10, P172, DOI 10.1177/0148607186010002172; ROCKOFF MA, 1979, ANN NEUROL, V6, P194, DOI 10.1002/ana.410060303; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SELTZER JL, 1980, BRIT J ANAESTH, V52, P527, DOI 10.1093/bja/52.5.527; SMITH AL, 1972, ANESTHESIOLOGY, V36, P378, DOI 10.1097/00000542-197204000-00015; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; TRAEGER SM, 1983, CRIT CARE MED, V11, P697, DOI 10.1097/00003246-198309000-00005; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383	46	100	100	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	1992	36	4					369	377		10.1111/j.1399-6576.1992.tb03483.x			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	HR870	WOS:A1992HR87000014	1595344				2022-02-06	
J	MCINTOSH, TK; FADEN, AI; BENDALL, MR; VINK, R				MCINTOSH, TK; FADEN, AI; BENDALL, MR; VINK, R			TRAUMATIC BRAIN INJURY IN THE RAT - ALTERATIONS IN BRAIN LACTATE AND PH AS CHARACTERIZED BY H-1 AND P-31 NUCLEAR-MAGNETIC-RESONANCE	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; GRIFFITH UNIV,SCH SCI,BRISBANE,AUSTRALIA		MCINTOSH, TK (corresponding author), VET ADM MED CTR,CTR NEURAL INJURY 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM34690-02A1] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [902269] Funding Source: Medline		ACKERMAN JJH, 1984, J MAGN RESON, V56, P318, DOI 10.1016/0022-2364(84)90109-4; ALBIN MS, 1969, J TRAUM, V9, P1000, DOI 10.1097/00005373-196912000-00004; BAX A, 1979, J MAGN RESON, V35, P167, DOI 10.1016/0022-2364(79)90088-X; BECKER DP, 1985, CENTRAL NERVOUS SYST, P229; BENDALL MR, 1986, B MAGN RESON, V8, P17; BENDALL MR, 1984, BIOMEDICAL MAGNETIC, P99; BERGER JP, 1979, LACTATE ACUTE CONDIT, P115; BLENNOW G, 1977, ACTA PHYSIOL SCAND, V100, P126, DOI 10.1111/j.1748-1716.1977.tb05929.x; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; COLLINS RC, 1970, AM J PHYSIOL, V218, P943, DOI 10.1152/ajplegacy.1970.218.4.943; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1980, SOC NEUR ABSTR, V6, P80; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUFFY TE, 1975, J NEUROCHEM, V24, P925, DOI 10.1111/j.1471-4159.1975.tb03657.x; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; GULATI SC, 1980, ACTA NEUROCHIR, V53, P39, DOI 10.1007/BF02074519; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HANSTOCK CC, 1987, IN PRESS J CEREB BLO; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HETHERINGTON HP, 1985, P NATL ACAD SCI USA, V82, P3115, DOI 10.1073/pnas.82.10.3115; HETHERINGTON HP, 1984, J MAGN RESON, V65, P348; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HORE PJ, 1983, J MAGN RESON, V55, P293; HOWSE DC, 1974, AM J PHYSIOL, V227, P1444, DOI 10.1152/ajplegacy.1974.227.6.1444; ISHIGE M, 1986, P SOC MAG RESON MED, V4, P1355; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; KOGURE K, 1980, BRAIN, V97, P104; KUSHMERICK MJ, 1985, AM J PHYSIOL, V248, pC542, DOI 10.1152/ajpcell.1985.248.5.C542; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; MACMILLAN V, 1973, J NEUROCHEM, V21, P1283, DOI 10.1111/j.1471-4159.1973.tb07582.x; MCINTOSH TK, 1987, UNPUB NEUROSCIENCE; MCINTOSH TK, 1987, IN PRESS AM J PHYSL; MYERS RE, 1979, ADV PERINATAL NEUROL, P88; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; PETROFF OAC, 1986, ANN NEUROL, V20, P185, DOI 10.1002/ana.410200203; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PRITCHARD JW, 1986, ANN REV NEUROSCI, V9, P61; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; ROTHMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P6330, DOI 10.1073/pnas.81.20.6330; Siesj? BK., 1978, BRAIN ENERGY METABOL; SIESJO BK, 1972, J NEUROCHEM, V19, P2483, DOI 10.1111/j.1471-4159.1972.tb01308.x; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; VINK R, 1987, IN PRESS J CEREB BLO; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHIDA S, 1985, J CEREBR BLOOD F MET, V5, P490, DOI 10.1038/jcbfm.1985.75	60	100	100	1	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	1987	49	5					1530	1540					11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	K4248	WOS:A1987K424800029	3668537				2022-02-06	
J	Olivier, J; Creighton, P				Olivier, Jake; Creighton, Prudence			Bicycle injuries and helmet use: a systematic review and meta-analysis	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						Cycling; injury; helmet; meta-analysis; systematic review	TRAUMATIC BRAIN-INJURY; PREVENTING HEAD-INJURY; NEW-SOUTH-WALES; SAFETY HELMETS; PUBLICATION BIAS; RISK-FACTORS; ALCOHOL-CONSUMPTION; ROAD TRAUMA; ACCIDENTS; CYCLISTS	Background: The research literature was systematically reviewed and results were summarized from studies assessing bicycle helmet effectiveness to mitigate head, serious head, face, neck and fatal head injury in a crash or fall. Methods: Four electronic databases (MEDLINE, EMBASE, COMPENDEX and SCOPUS) were searched for relevant, peer-reviewed articles in English. Included studies reported medically diagnosed head, face and neck injuries where helmet use was known. Non-approved helmets were excluded where possible. Summary odds ratios (OR) were obtained using multivariate meta-regression models stratified by injury type and severity. Time trends and publication bias were assessed. Results: A total of 43 studies met inclusion criteria and 40 studies were included in the meta-analysis with data from over 64 000 injured cyclists. For cyclists involved in a crash or fall, helmet use was associated with odds reductions for head (OR = 0.49, 95% confidence interval (CI): 0.42-0.57), serious head (OR = 0.31, 95% CI: 0.25-0.37), face (OR = 0.67, 95% CI: 0.56-0.81) and fatal head injury (OR = 0.35, 95% CI: 0.14-0.88). No clear evidence of an association between helmet use and neck injury was found (OR = 0.96, 95% CI: 0.74-1.25). There was no evidence of time trends or publication bias. Conclusions: Bicycle helmet use was associated with reduced odds of head injury, serious head injury, facial injury and fatal head injury. The reduction was greater for serious or fatal head injury. Neck injury was rare and not associated with helmet use. These results support the use of strategies to increase the uptake of bicycle helmets as part of a comprehensive cycling safety plan.	[Olivier, Jake; Creighton, Prudence] Univ New South Wales, Sch Math & Stat, Sydney, NSW, Australia		Olivier, J (corresponding author), Univ New South Wales, Sch Math & Stat, Red Ctr, Sydney, NSW 2052, Australia.	j.olivier@unsw.edu.au	Olivier, Jake/D-2034-2012	Olivier, Jake/0000-0002-3144-4507			Abu-Zidan FM, 2007, EMERG MED AUSTRALAS, V19, P366, DOI 10.1111/j.1742-6723.2007.00967.x; Acton C H, 1995, Inj Prev, V1, P86, DOI 10.1136/ip.1.2.86; Acton CHC, 1996, MED J AUSTRALIA, V165, P249, DOI 10.5694/j.1326-5377.1996.tb124957.x; Adams J, 2001, Inj Prev, V7, P89, DOI 10.1136/ip.7.2.89; Airaksinen Noora, 2010, Ann Adv Automot Med, V54, P267; Amoros E, 2009, CYCLISTES VICTIMES 2, P28; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Bambach MR, 2011, J TRANSP SAF SECUR, V3, P222; BEGG DJ, 1991, NEW ZEAL MED J, V104, P60; Bergenstal John, 2012, W V Med J, V108, P78; Bonander C, 2014, J SAFETY RES, V51, P15, DOI 10.1016/j.jsr.2014.07.001; Borglund S T, 1999, J Emerg Nurs, V25, P496, DOI 10.1016/S0099-1767(99)70013-9; Brand S, 2013, TRAFFIC INJ PREV, V14, P56, DOI 10.1080/15389588.2012.688152; Bressan S, 2015, EMERG MED AUSTRALAS, V27, P1; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; Castle SL, 2012, J SURG RES, V173, P327, DOI 10.1016/j.jss.2010.10.031; COOKE CT, 1993, MED J AUSTRALIA, V159, P783, DOI 10.5694/j.1326-5377.1993.tb141349.x; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Crocker P, 2012, J EMERG MED, V43, P244, DOI 10.1016/j.jemermed.2011.05.029; Crocker P, 2010, AM J EMERG MED, V28, P68, DOI 10.1016/j.ajem.2008.09.011; CUSHMAN R, 1990, CAN MED ASSOC J, V143, P108; Dagher JH, 2016, CAN J NEUROL SCI, V43, P56, DOI 10.1017/cjn.2015.281; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; De Silva L, 2014, J NEUROTRAUM, V31, pA34; Dennis J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2674; Dinh MM, 2015, EMERG MED AUSTRALAS, V27, P323, DOI 10.1111/1742-6723.12407; Dinh MM, 2013, MED J AUSTRALIA, V198, P415, DOI 10.5694/mja12.11580; Dinh MM, 2010, MED J AUSTRALIA, V193, P619, DOI 10.5694/j.1326-5377.2010.tb04078.x; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Eid H. O., 2007, SMJ Singapore Medical Journal, V48, P884; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Elvik R, 2013, ACCIDENT ANAL PREV, V60, P245, DOI 10.1016/j.aap.2012.12.003; Fahlstedt M, 2016, ACCIDENT ANAL PREV, V91, P135, DOI 10.1016/j.aap.2016.02.025; Finvers KA, 1996, CLIN J SPORT MED, V6, P102, DOI 10.1097/00042752-199604000-00007; FRANK E, 1995, ACAD EMERG MED, V2, P200, DOI 10.1111/j.1553-2712.1995.tb03198.x; Furukawa M, 2013, CLIN J SPORT MED, V23, P138; Grauke L, 2010, EMERG RADIOL, V17, P522; Grimard G, 1995, Inj Prev, V1, P21, DOI 10.1136/ip.1.1.21; Gulack BC, 2015, SURGERY, V158, P556, DOI 10.1016/j.surg.2015.02.025; Hagel BE, 2015, ACCIDENT ANAL PREV, V78, P165, DOI 10.1016/j.aap.2015.03.002; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Harada MY, 2015, INT J SURG, V24, P14, DOI 10.1016/j.ijsu.2015.10.013; Hausotter W., 2000, VERSICHERUNGSMEDIZIN, V52; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; Heyer JH, 2015, AM J PUBLIC HEALTH, V105, P2131, DOI 10.2105/AJPH.2015.302738; Hooten KG, 2014, J NEUROTRAUM, V31, P1329, DOI 10.1089/neu.2013.3253; Hooten KG, 2013, J NEUROSURG, V119, pA570; Hwang K, 2015, ARCH PLAST SURG-APS, V42, P407, DOI 10.5999/aps.2015.42.4.407; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Joseph B, 2014, EUR J TRAUMA EMERG S, V40, P729, DOI 10.1007/s00068-014-0453-0; Juhra C, 2012, INJURY, V43, P2026, DOI 10.1016/j.injury.2011.10.016; Karkhaneh M, 2013, ACCIDENT ANAL PREV, V59, P206, DOI 10.1016/j.aap.2013.05.027; Kaushik Ruchi, 2015, Inj Epidemiol, V2, P16; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; Kiss K, 2010, ACCIDENT ANAL PREV, V42, P1566, DOI 10.1016/j.aap.2010.03.014; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; Lima SM, 2012, J ORAL MAXIL SURG, V70, P577, DOI 10.1016/j.joms.2011.03.035; Lindsay H, 2014, CHRON DIS INJ CAN, V34, P74; Linn S, 1998, Inj Prev, V4, P122; Liu HT, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2075-9; MACKELLAR A, 1989, J PEDIATR SURG, V24, P577, DOI 10.1016/S0022-3468(89)80510-X; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Malczyk A, 2014, INT RES COUNC BIOM I; Marshall SW, 2008, EPIDEMIOLOGY, V19, P277, DOI 10.1097/EDE.0b013e3181632700; Matsui Y, 2015, SAE 2015 WORLD C EXH; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2013, J AUSTRALAS COLL ROA, V24, P11; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; Messiah A, 2012, AM J PUBLIC HEALTH, V102, pS204, DOI 10.2105/AJPH.2012.300711; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535, 10.1371/journal.pmed.1000217, 10.1016/j.ijsu.2010.02.007]; NAKAYAMA DK, 1990, AM J DIS CHILD, V144, P928, DOI 10.1001/archpedi.1990.02150320092035; Nicaj L, 2009, TRAFFIC INJ PREV, V10, P157, DOI 10.1080/15389580802641761; Olivier J, 2014, J AUSTRALAS COLL ROA, V25, P10; Olofsson E, 2015, SAFETY SCI, DOI [10.1016/j.ssci.2015.11.024, DOI 10.1016/J.SSCI.2015.11.024.]; Orsi C, 2014, ACCIDENT ANAL PREV, V65, P97, DOI 10.1016/j.aap.2013.12.019; Otte D, 2014, SAE INT J TRANSP SAF, V2, P257, DOI 10.4271/2014-01-0517; Otte D, 2010, INT J CRASHWORTHINES, V15, P211, DOI 10.1080/13588260903102484; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Poulos RG, 2015, ACCIDENT ANAL PREV, V78, P29, DOI 10.1016/j.aap.2015.02.009; Powell EC, 1997, ANN EMERG MED, V30, P260, DOI 10.1016/S0196-0644(97)70159-8; Puranik S, 1998, SOUTHERN MED J, V91, P1033, DOI 10.1097/00007611-199811000-00008; Richter M, 2007, J TRAUMA, V62, P1118, DOI 10.1097/01.ta.0000221060.78894.cb; Rivara FP, 1997, J FAM PRACTICE, V44, P481; Rivara FP, 2015, INJURY PREV, V21, P47, DOI 10.1136/injprev-00002-0038rep; Rizzi M, 2013, P INT RES COUNC BIOM; ROWE BH, 1995, CAN MED ASSOC J, V152, P45; SELBST SM, 1987, AM J DIS CHILD, V141, P140, DOI 10.1001/archpedi.1987.04460020030021; Sethi M, 2015, INJURY, V46, P2483, DOI 10.1016/j.injury.2015.07.030; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988; Skarin D, 2015, EMERG MED AUSTRALAS, V27, P30; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; Standards Australia, 2008, 2063 ASNZS; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Sze NN, 2011, HONG KONG J EMERG ME, V18, P136, DOI 10.1177/102490791101800302; Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson D C, 2001, Inj Prev, V7, P86, DOI 10.1136/ip.7.2.86; Thompson D C, 2000, Cochrane Database Syst Rev, pCD001855; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wagner J, 2012, AM SURGEON, V78, P1066; Wall SP, 2015, ANN EMERG MED, V1, pS124; Walter SR, 2011, ACCIDENT ANAL PREV, V43, P2064, DOI 10.1016/j.aap.2011.05.029; Wang C, 2015, TRAFFIC INJ PREV, V16, P507, DOI 10.1080/15389588.2014.969802; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; Webman R, 2013, J TRAUMA ACUTE CARE, V75, P877, DOI 10.1097/TA.0b013e3182a85f97; Yeung JHH, 2009, INJURY, V40, P555, DOI 10.1016/j.injury.2008.08.015; Yilmaz P, 2013, INJURY, V44, P848, DOI 10.1016/j.injury.2013.03.007; Zibung E, 2015, EUR J TRAUMA EMERG S, V41, P517, DOI 10.1007/s00068-014-0471-y	122	99	100	4	44	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2017	46	1					278	292		10.1093/ije/dyw153			15	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	EW7VB	WOS:000402724100038	27450862	Bronze	Y	N	2022-02-06	
J	Stamm, JM; Koerte, IK; Muehlmann, M; Pasternak, O; Bourlas, AP; Baugh, CM; Giwerc, MY; Zhu, AN; Coleman, MJ; Bouix, S; Fritts, NG; Martin, BM; Chaisson, C; McClean, MD; Lin, AP; Cantu, RC; Tripodis, Y; Stern, RA; Shenton, ME				Stamm, Julie M.; Koerte, Inga K.; Muehlmann, Marc; Pasternak, Ofer; Bourlas, Alexandra P.; Baugh, Christine M.; Giwerc, Michelle Y.; Zhu, Anni; Coleman, Michael J.; Bouix, Sylvain; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; McClean, Michael D.; Lin, Alexander P.; Cantu, Robert C.; Tripodis, Yorghos; Stern, Robert A.; Shenton, Martha E.			Age at First Exposure to Football Is Associated with Altered Corpus Callosum White Matter Microstructure in Former Professional Football Players	JOURNAL OF NEUROTRAUMA			English	Article						age at first exposure; American football; corpus callosum; diffusion tensor imaging; repetitive head impacts	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; HUMAN CEREBRAL-CORTEX; NEUROPSYCHOMETRIC TESTS; RECURRENT CONCUSSION; UNMYELINATED AXONS; YOUTH FOOTBALL; DIFFUSION; CHILDREN; MILD	Youth football players may incur hundreds of repetitive head impacts (RHI) in one season. Our recent research suggests that exposure to RHI during a critical neurodevelopmental period prior to age 12 may lead to greater later-life mood, behavioral, and cognitive impairments. Here, we examine the relationship between age of first exposure (AFE) to RHI through tackle football and later-life corpus callosum (CC) microstructure using magnetic resonance diffusion tensor imaging (DTI). Forty retired National Football League (NFL) players, ages 40-65, were matched by age and divided into two groups based on their AFE to tackle football: before age 12 or at age 12 or older. Participants underwent DTI on a 3 Tesla Siemens (TIM-Verio) magnet. The whole CC and five subregions were defined and seeded using deterministic tractography. Dependent measures were fractional anisotropy (FA), trace, axial diffusivity, and radial diffusivity. Results showed that former NFL players in the AFE <12 group had significantly lower FA in anterior three CC regions and higher radial diffusivity in the most anterior CC region than those in the AFE 12 group. This is the first study to find a relationship between AFE to RHI and later-life CC microstructure. These results suggest that incurring RHI during critical periods of CC development may disrupt neurodevelopmental processes, including myelination, resulting in altered CC microstructure.	[Stamm, Julie M.; Bourlas, Alexandra P.; Baugh, Christine M.; Fritts, Nathan G.; Chaisson, Christine; Cantu, Robert C.; Tripodis, Yorghos; Stern, Robert A.] Boston Univ, CTE Ctr, Sch Med, Boston, MA 02118 USA; [Stamm, Julie M.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Bourlas, Alexandra P.; Chaisson, Christine; Tripodis, Yorghos; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stamm, Julie M.; Koerte, Inga K.; Muehlmann, Marc; Pasternak, Ofer; Giwerc, Michelle Y.; Zhu, Anni; Coleman, Michael J.; Bouix, Sylvain; Lin, Alexander P.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Clin Spect, Boston, MA 02115 USA; [Pasternak, Ofer] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Martin, Brett M.; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Chaisson, Christine; Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA		Stern, RA (corresponding author), Boston Univ, CTE Ctr, Sch Med, 72 East Concord St,B7800, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020; Shenton, Martha/V-8780-2019; Koerte, Inga Katharina/AAW-3031-2021; Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, F31 NS 081957, P30 AG13846, UL1-TR000157, P41 EB015902, T32MH019733]; JetBlue Airlines; National Football League (NFL); NFL Players Association; Else Kroner-Fresenius Foundation, Germany; VA Merit AwardUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337, F31NS081957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	The authors extend their appreciation to the study participants who make this work possible. This study was supported by the National Institutes of Health (R01 NS 078337; F31 NS 081957 [J.M.S.]; P30 AG13846; UL1-TR000157, P41 EB015902 [O.P.]; T32MH019733 [C.M.B.]), and participant travel was funded by gifts from JetBlue Airlines, the National Football League (NFL), and the NFL Players Association. This study was also partly supported by the Else Kroner-Fresenius Foundation, Germany (I.K., M.M.), and by a VA Merit Award (M.E.S., M.C., L.L., A.Z.).	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Andersen SL, 2008, TRENDS NEUROSCI, V31, P183, DOI 10.1016/j.tins.2008.01.004; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bardin J, 2012, NATURE, V487, P24, DOI 10.1038/487024a; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bourlas A. P., 2014, BRAIN INJURY, V28, P517; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Chen Z, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00716; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Dahler D., 2014, CBS NEWS; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Grieve SM, 2011, NEUROIMAGE, V55, P868, DOI 10.1016/j.neuroimage.2010.12.087; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Kaller CP, 2012, NEUROIMAGE, V63, P1454, DOI 10.1016/j.neuroimage.2012.08.032; Kelly AMC, 2009, CEREB CORTEX, V19, P640, DOI 10.1093/cercor/bhn117; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lebel C, 2011, J NEUROSCI, V31, P10937, DOI 10.1523/JNEUROSCI.5302-10.2011; Lebel C, 2010, NEUROIMAGE, V52, P20, DOI 10.1016/j.neuroimage.2010.03.072; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Lenroot RK, 2009, HUM BRAIN MAPP, V30, P163, DOI 10.1002/hbm.20494; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Council of Youth Sports, 2008, REP TRENDS PART ORG; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu JS, 2013, HUM BRAIN MAPP, V34, P1044, DOI 10.1002/hbm.21491; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	77	99	101	2	43	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1768	1776		10.1089/neu.2014.3822			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500007	26200068	Green Published			2022-02-06	
J	Nielson, JL; Paquette, J; Liu, AW; Guandique, CF; Tovar, CA; Inoue, T; Irvine, KA; Gensel, JC; Kloke, J; Petrossian, TC; Lum, PY; Carlsson, GE; Manley, GT; Young, W; Beattie, MS; Bresnahan, JC; Ferguson, AR				Nielson, Jessica L.; Paquette, Jesse; Liu, Aiwen W.; Guandique, Cristian F.; Tovar, C. Amy; Inoue, Tomoo; Irvine, Karen-Amanda; Gensel, John C.; Kloke, Jennifer; Petrossian, Tanya C.; Lum, Pek Y.; Carlsson, Gunnar E.; Manley, Geoffrey T.; Young, Wise; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.			Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury	NATURE COMMUNICATIONS			English	Article							BIG DATA; RATING-SCALE; CELL-DEATH; RECOVERY; CONSEQUENCES; TRANSLATION; MECHANISMS; MANAGEMENT; LOCOMOTOR; SEVERITY	Data-driven discovery in complex neurological disorders has potential to extract meaningful syndromic knowledge from large, heterogeneous data sets to enhance potential for precision medicine. Here we describe the application of topological data analysis (TDA) for data-driven discovery in preclinical traumatic brain injury (TBI) and spinal cord injury (SCI) data sets mined from the Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION-SCI) repository. Through direct visualization of inter-related histopathological, functional and health outcomes, TDA detected novel patterns across the syndromic network, uncovering interactions between SCI and co-occurring TBI, as well as detrimental drug effects in unpublished multicentre preclinical drug trial data in SCI. TDA also revealed that perioperative hypertension predicted long-term recovery better than any tested drug after thoracic SCI in rats. TDA-based data-driven discovery has great potential application for decision-support for basic research and clinical problems such as outcome assessment, neurocritical care, treatment planning and rapid, precision-diagnosis.	[Nielson, Jessica L.; Liu, Aiwen W.; Guandique, Cristian F.; Manley, Geoffrey T.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurosurg, San Francisco, CA 94143 USA; [Paquette, Jesse] Tagb Io, San Francisco, CA 94131 USA; [Tovar, C. Amy] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Inoue, Tomoo] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9800856, Japan; [Irvine, Karen-Amanda] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA 94110 USA; [Gensel, John C.] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Dept Physiol, Lexington, KY 40536 USA; [Kloke, Jennifer; Carlsson, Gunnar E.] Ayasdi Inc, Menlo Pk, CA 94025 USA; [Petrossian, Tanya C.] GenePeeks Inc, New York, NY 10001 USA; [Lum, Pek Y.] Capella Biosci, Palo Alto, CA 94301 USA; [Carlsson, Gunnar E.] Stanford Univ, Dept Math, Stanford, CA 94305 USA; [Young, Wise] Rutgers State Univ, Dept Cell Biol & Neurosci, WM Keck Ctr Collaborat Neurosci, Piscataway, NJ 08854 USA; [Ferguson, Adam R.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurosurg, San Francisco, CA 94110 USA		Ferguson, AR (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA.	adam.ferguson@ucsf.edu		Nielson, Jessica/0000-0002-3677-3959; Petrossian, Tanya/0000-0002-1205-9144; Ferguson, Adam/0000-0001-7102-1608	Craig H. Neilsen Foundation [224308]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067092, NS069537, NS038079, NS031193, AG032518, NS079030, NS032000]; NYSCoRE [CO19772]; Department of Defense (DoD)United States Department of Defense [W81XWH-10-1-0910, W81XWH-13-1-0297]; Wings for Life Foundation [WFLUS008/12, WFLUS006/14]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031193, F32NS079030, R01NS067092, R01NS032000, R01NS069537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG032518] Funding Source: NIH RePORTER	This work was funded by the Craig H. Neilsen Foundation Grant 224308, the National Institutes of Health (NIH) NS067092 (A.R.F.), NS069537 (A.R.F), NS038079 (J.C.B. and M.S.B.), NS031193 and AG032518 (M.S.B. and J.C.B.), NS079030 (J.L.N.), NS032000 (W.Y.; M.S.B. site PI, multicentre study); NYSCoRE CO19772 (M.S.B. and J.C.B.), the Department of Defense (DoD) grants W81XWH-10-1-0910 (M.S.B.) and W81XWH-13-1-0297 (M.S.B.), and Wings for Life Foundation grants WFLUS008/12 and WFLUS006/14 (A.R.F.). We thank J.R. Huie and J. Haefeli for useful comments, and A. Lin and S. Visuthikraisee for technical support.	Akil H, 2011, SCIENCE, V331, P708, DOI 10.1126/science.1199305; Bacchetti P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001628; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Burke DA, 2013, J NEUROTRAUM, V30, P797, DOI 10.1089/neu.2012.2704; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; Celi LA, 2013, AM J RESP CRIT CARE, V187, P1157, DOI 10.1164/rccm.201212-2311ED; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Fasy BT, 2014, TDA STAT TOOLS TOPOL; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; Ferguson AR, 2014, NAT NEUROSCI, V17, P1442, DOI 10.1038/nn.3838; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Ferguson AR, 2004, J NEUROTRAUM, V21, P1601, DOI 10.1089/neu.2004.21.1601; Filli L, 2012, ANN NEUROL, V72, P491, DOI 10.1002/ana.23630; Fox P, 2011, SCIENCE, V331, P705, DOI 10.1126/science.1197654; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Gorelick PB, 2002, LANCET NEUROL, V1, P149, DOI 10.1016/S1474-4422(02)00070-4; Gough Nancy R, 2011, Sci Signal, V4, peg2, DOI 10.1126/scisignal.2001871; GUHA A, 1989, STROKE, V20, P372, DOI 10.1161/01.STR.20.3.372; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Hawryluk G, 2015, J NEUROTRAUM, V32, P1958, DOI 10.1089/neu.2014.3778; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Hou SP, 2014, COMPR PHYSIOL, V4, P1419, DOI 10.1002/cphy.c130045; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Inoue T, 2013, EXP NEUROL, V248, P136, DOI 10.1016/j.expneurol.2013.06.006; Irvine KA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00116; Irvine Karen-Amanda, 2010, J Vis Exp, DOI 10.3791/2246; Kong CY, 2013, SPINAL CORD, V51, P466, DOI 10.1038/sc.2013.32; Larson EB, 2013, JAMA-J AM MED ASSOC, V309, P2443, DOI 10.1001/jama.2013.5914; Lee H, 2012, IEEE T MED IMAGING, V31, P2267, DOI 10.1109/TMI.2012.2219590; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; MACCALLUM RC, 1992, PSYCHOL BULL, V111, P490, DOI 10.1037/0033-2909.111.3.490; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Martinez M, 2009, J NEUROTRAUM, V26, P1043, DOI 10.1089/neu.2008.0717; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Nielson JL, 2014, J NEUROTRAUM, V31, P1789, DOI 10.1089/neu.2014.3399; Nout YS, 2012, J NEUROTRAUM, V29, P990, DOI 10.1089/neu.2011.1845; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Ramer LM, 2014, LANCET NEUROL, V13, P1241, DOI 10.1016/S1474-4422(14)70144-9; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Sarikonda G, 2014, J AUTOIMMUN, V50, P77, DOI 10.1016/j.jaut.2013.12.003; Scallan J, 2010, CAPILLARY FLUID EXCH; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Siddiqui AM, 2015, PROG BRAIN RES, V218, P15, DOI 10.1016/bs.pbr.2014.12.007; Singh G, 2007, PROC SPBG, P91, DOI [10.2312/SPBG/SPBG07/091-100, DOI 10.2312/SPBG/SPBG07/091-100]; Singh G, 2008, J VISION, V8, DOI 10.1167/8.8.11; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Yao Y, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3103496; Young W, 2002, PROG BRAIN RES, V137, P231	55	99	100	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	OCT	2015	6								8581	10.1038/ncomms9581			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW4AD	WOS:000364932600028	26466022	Green Published, gold			2022-02-06	
J	Maissan, IM; Dirven, PJAC; Haitsma, IK; Hoeks, SE; Gommers, D; Stolker, RJ				Maissan, Iscander M.; Dirven, Perjan J. A. C.; Haitsma, Iain K.; Hoeks, Sanne E.; Gommers, Diederik; Stolker, Robert Jan			Ultrasonographic measured optic nerve sheath diameter as an accurate and quick monitor for changes in intracranial pressure	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; trauma; head trauma; neurotrauma; ONSD; optic nerve sheath; diagnostic and operative techniques	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; EMERGENCY-DEPARTMENT; OCULAR ULTRASOUND; HYPERTENSION; MANAGEMENT; CRANIOSYNOSTOSIS; CHILDREN	OBJECT Ultrasonographic measurement of the optic nerve sheath diameter (ONSD) is known to be an accurate monitor of elevated intracranial pressure (ICP). However, it is yet unknown whether fluctuations in ICP result in direct changes in ONSD. Therefore, the authors researched whether ONSD and ICP simultaneously change during tracheal manipulation in patients in the intensive care unit (ICU) who have suffered a traumatic brain injury (TBI). MATERIALS The authors included 18 ICP-monitored patients who had sustained TBI and were admitted to the ICU. They examined the optic nerve sheath by performing ultrasound before, during, and after tracheal manipulation, which is known to increase ICP. The correlation between ONSD and ICP measurements was determined, and the diagnostic performance of ONSD measurement was tested using receiver operating characteristic curve analysis. RESULTS In all patients ICP increased above 20 mm Hg during manipulation of the trachea, and this increase was directly associated with a dilation of the ONSD of > 5.0 mm. After tracheal manipulation stopped, ICP as well as ONSD decreased immediately to baseline levels. The correlation between ICP and ONSD was high (R-2 = 0.80); at a cutoff of >= 5.0 mm ONSD, a sensitivity of 94%, a specificity of 98%, and an area under the curve of 0.99 (95% CI 0.97-1.00) for detecting elevated ICP were determined. CONCLUSIONS In patients who have sustained a TBI, ultrasonography of the ONSD is an accurate, simple, and rapid measurement for detecting elevated ICP as well as immediate changes in ICP. Therefore, it might be a useful tool to monitor ICP, especially in conditions in which invasive ICP monitoring is not available, such as at trauma scenes.	[Maissan, Iscander M.; Dirven, Perjan J. A. C.; Hoeks, Sanne E.; Stolker, Robert Jan] Erasmus MC, Dept Anesthesiol, NL-3014 CE Rotterdam, Netherlands; [Haitsma, Iain K.] Erasmus MC, Dept Neurosurg, NL-3014 CE Rotterdam, Netherlands; [Gommers, Diederik] Erasmus MC, Dept Intens Care, NL-3014 CE Rotterdam, Netherlands		Maissan, IM (corresponding author), Erasmus MC, Dept Anesthesiol, Rm H-1386,S Gravedijkwal 230, NL-3014 CE Rotterdam, Netherlands.	i.maissan@erasmusmc.nl	Hoeks, Sanne/AAM-3313-2020				AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Copetti R, 2009, INTENS CARE MED, V35, P1488, DOI 10.1007/s00134-009-1494-4; Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901; Driessen C, 2012, PLAST RECONSTR SURG, V130, p448E, DOI 10.1097/PRS.0b013e31825dc1f1; Driessen C, 2011, J NEUROSURG-PEDIATR, V8, P329, DOI 10.3171/2011.6.PEDS10547; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Qayyum H, 2013, EUR J EMERG MED, V20, P91, DOI 10.1097/MEJ.0b013e32835105c8; Raboel PH, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/950393; Rajajee V, 2012, CRIT CARE, V16, DOI [10.1186/cc11336, 10.1186/CC11336]; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040	19	99	104	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2015	123	3					743	747		10.3171/2014.10.JNS141197			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CP6VZ	WOS:000360027600031	25955869	Bronze			2022-02-06	
J	Guiza, F; Depreitere, B; Piper, I; Citerio, G; Chambers, I; Jones, PA; Lo, TYM; Enblad, P; Nillson, P; Feyen, B; Jorens, P; Maas, A; Schuhmann, MU; Donald, R; Moss, L; Van den Berghe, G; Meyfroidt, G				Guiza, Fabian; Depreitere, Bart; Piper, Ian; Citerio, Giuseppe; Chambers, Iain; Jones, Patricia A.; Lo, Tsz-Yan Milly; Enblad, Per; Nillson, Pelle; Feyen, Bart; Jorens, Philippe; Maas, Andrew; Schuhmann, Martin U.; Donald, Rob; Moss, Laura; Van den Berghe, Greet; Meyfroidt, Geert			Visualizing the pressure and time burden of intracranial hypertension in adult and paediatric traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Traumatic brain injury; Adults; Children; Intracranial pressure; Cerebral perfusion pressure; Cerebrovascular autoregulation	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; CENTERS YEAR 2001; AGGRESSIVE TREATMENT; EUROPEAN BRAIN; INTENSIVE-CARE; MANAGEMENT; AUTOREGULATION; THRESHOLDS; REACTIVITY	To assess the impact of the duration and intensity of episodes of increased intracranial pressure on 6-month neurological outcome in adult and paediatric traumatic brain injury. Analysis of prospectively collected minute-by-minute intracranial pressure and mean arterial blood pressure data of 261 adult and 99 paediatric traumatic brain injury patients from multiple European centres. The relationship of episodes of elevated intracranial pressure (defined as a pressure above a certain threshold during a certain time) with 6-month Glasgow Outcome Scale was visualized in a colour-coded plot. The colour-coded plot illustrates the intuitive concept that episodes of higher intracranial pressure can only be tolerated for shorter durations: the curve that delineates the duration and intensity of those intracranial pressure episodes associated with worse outcome is an approximately exponential decay curve. In children, the curve resembles that of adults, but the delineation between episodes associated with worse outcome occurs at lower intracranial pressure thresholds. Intracranial pressures above 20 mmHg lasting longer than 37 min in adults, and longer than 8 min in children, are associated with worse outcomes. In a multivariate model, together with known baseline risk factors for outcome in severe traumatic brain injury, the cumulative intracranial pressure-time burden is independently associated with mortality. When cerebrovascular autoregulation, assessed with the low-frequency autoregulation index, is impaired, the ability to tolerate elevated intracranial pressures is reduced. When the cerebral perfusion pressure is below 50 mmHg, all intracranial pressure insults, regardless of duration, are associated with worse outcome. The intracranial pressure-time burden associated with worse outcome is visualised in a colour-coded plot. In children, secondary injury occurs at lower intracranial pressure thresholds as compared to adults. Impaired cerebrovascular autoregulation reduces the ability to tolerate intracranial pressure insults. Thus, 50 mmHg might be the lower acceptable threshold for cerebral perfusion pressure.	[Guiza, Fabian; Van den Berghe, Greet; Meyfroidt, Geert] Univ Hosp Leuven, Dept Intens Care Med, B-3000 Leuven, Belgium; [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, B-3000 Leuven, Belgium; [Piper, Ian] So Gen Hosp, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; [Citerio, Giuseppe] San Gerardo Hosp, Monza, Italy; [Chambers, Iain] James Cook Univ Hosp, Med Phys, Middlesbrough, England; [Jones, Patricia A.] Royal Hosp Sick Children, Dept Paediat Neurol, Edinburgh EH9 1LF, Midlothian, Scotland; [Lo, Tsz-Yan Milly] Royal Hosp Sick Children, Dept Paediat Intens Care, Edinburgh EH9 1LF, Midlothian, Scotland; [Enblad, Per; Nillson, Pelle] Dept Neurosurg, Neurosurg, Uppsala, Sweden; [Feyen, Bart; Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Jorens, Philippe] Univ Antwerp Hosp, Dept Intens Care Med, Edegem, Belgium; [Schuhmann, Martin U.] Univ Klinikum Tubingen, Klin Neurochirurg, Tubingen, Germany; [Donald, Rob] Univ Glasgow, Sch Math & Stat, Glasgow, Lanark, Scotland; [Moss, Laura] NHS Greater Glasgow & Clyde, Dept Clin Phys & Bioengn, Glasgow, Lanark, Scotland		Meyfroidt, G (corresponding author), Univ Hosp Leuven, Dept Intens Care Med, Herestr 49, B-3000 Leuven, Belgium.	geert.meyfroidt@uzleuven.be	Citerio, Giuseppe/B-1839-2015; Van den Berghe, Greet/J-6788-2018; Depreitere, Bart/AAA-9846-2020	Citerio, Giuseppe/0000-0002-5374-3161; Van den Berghe, Greet/0000-0002-5320-1362; Depreitere, Bart/0000-0002-7458-0648; Donald, Rob/0000-0001-5301-0219; Guiza, Fabian/0000-0001-7026-0957; Moss, Laura/0000-0003-4968-0900	Foundation for Scientific Research Flanders (FWO)FWO [G. 0904.11]; FWOFWO [1846113N]; Methusalem program by Flemish Government [METH/08/07]; European Framework Programme [FP5-QLRI-2000-00454, QLGT-2002-00160, FP7-IST-2007-217049]; Flemish Government Agency for Innovation by Science and Technology (IWT)-Applied Biomedical Research (TBM) program	We wish to acknowledge the non-co-author members of the BrainIT steering group: Barbara Gregson, Tim Howells, Karl Kiening, Julia Mattern, Arminas Ragauskas and Juan Sahuquillo, for collecting data and granting permission through the steering group to use them for this project. Similarly, we would also like to acknowledge the contributors to the original study resulting in the paediatric database used here: R.J. Forsyth, B. Fulton, P.J.D. Andrews, A.D. Mendelow and R.A. Minns. The present study was supported by the Foundation for Scientific Research Flanders (FWO) (Research project G. 0904.11). Geert Meyfroidt receives funding from FWO as senior clinical investigator (1846113N). Greet Van den Berghe receives long-term structural research financing via the Methusalem program funded by the Flemish Government (METH/08/07). BrainIT was funded by the European Framework Programme (FP5-QLRI-2000-00454, QLGT-2002-00160 AND FP7-IST-2007-217049). The NEMO project in the University Hospital Edegem (Antwerp), Belgium was funded by the Flemish Government Agency for Innovation by Science and Technology (IWT)-Applied Biomedical Research (TBM) program.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; [Anonymous], 2015, INT MISS PROGN AN CL; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chesnut RM, 2015, WHAT BEST TRIP STUDY; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Feyen BFE, 2012, MINERVA ANESTESIOL, V78, P949; Guiza F, 2014, INTENS CARE MED, V40, pS18; GUILLAUME J, 1951, REV NEUROL, V84, P131; Guiza F, 2014, CRIT CARE S1, V18, pP458; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Le Roux P, 2014, CURR OPIN CRIT CARE, V20, P141, DOI 10.1097/MCC.0000000000000078; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nilsson P, 2005, ACTA NEUROCHIR SUPPL, V95, P51; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Rosenfeld JV, 2005, LANCET, V366, P1509, DOI 10.1016/S0140-6736(05)67609-X; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Sigurta A, 2013, INTENS CARE MED, V39, P129, DOI 10.1007/s00134-012-2748-0; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	38	99	100	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2015	41	6					1067	1076		10.1007/s00134-015-3806-1			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL2UO	WOS:000356801200011	25894624	Green Accepted			2022-02-06	
J	Geurts, M; Macleod, MR; Kollmar, R; Kremer, PHC; van der Worp, HB				Geurts, Marjolein; Macleod, Malcolm R.; Kollmar, Rainer; Kremer, Philip H. C.; van der Worp, H. Bart			Therapeutic Hypothermia and the Risk of Infection: A Systematic Review and Meta-Analysis	CRITICAL CARE MEDICINE			English	Article						hypothermia; infection; respiratory tract infections; sepsis; temperature; urinary tract infections	TRAUMATIC BRAIN-INJURY; HOSPITAL CARDIAC-ARREST; ACUTE ISCHEMIC-STROKE; NORMOTHERMIC CARDIOPULMONARY BYPASS; MILD HYPOTHERMIA; SURGERY; COMPLICATIONS; SAFETY; TRIAL; THROMBOLYSIS	Objective: Observational studies suggest that infections are a common complication of therapeutic hypothermia. We performed a systematic review and meta-analysis of randomized trials to examine the risk of infections in patients treated with hypothermia. Data Sources: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were systematically searched for eligible studies up to October 1, 2012. Study Selection: We included randomized controlled clinical trials of therapeutic hypothermia induced in adults for any indication, which reported the prevalence of infection in each treatment group. Data Extraction: For each study, we collected information about the baseline characteristics of patients, cooling strategy, and infections. Data Synthesis: Twenty-three studies were identified, which included 2,820 patients, of whom 1,398 (49.6%) were randomized to hypothermia. Data from another 31 randomized trials, involving 4,004 patients, could not be included because the occurrence of infection was not reported with sufficient detail or not at all. The risk of bias in the included studies was high because information on the method of randomization and definitions of infections lacked in most cases, and assessment of infections was not blinded. In patients treated with hypothermia, the prevalence of all infections was not increased (rate ratio, 1.21 [95% CI, 0.95-1.54]), but there was an increased risk of pneumonia and sepsis (risk ratios, 1.44 [95% CI, 1.10-1.90]; 1.80 [95% CI, 1.04-3.10], respectively). Conclusion: The available evidence, subject to its limitations, strongly suggests an association between therapeutic hypothermia and the risk of pneumonia and sepsis, whereas no increase in the overall risk of infection was observed. All future randomized trials of hypothermia should report on this important complication.	[Geurts, Marjolein; Kremer, Philip H. C.; van der Worp, H. Bart] Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Macleod, Malcolm R.] Univ Edinburgh, Dept Clin Neurosci, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Kollmar, Rainer] Klinikum Darmstadt, Klin Neurol & Neurogeriatrie, Darmstadt, Germany		Geurts, M (corresponding author), Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Neurol & Neurosurg, Utrecht, Netherlands.	m.geurts-2@umcutrecht.nl	Macleod, Malcolm Robert/B-2052-2010; Geurts, Marjolein/AAP-4148-2020	Macleod, Malcolm Robert/0000-0001-9187-9839; 	Dutch Heart FoundationNetherlands Heart Foundation [2010B239, 2010T075]; FP7 for EuroHYP-1; 7th Framework Programme European Union; Chest Heart and Stroke Scotland [Res09/A121] Funding Source: researchfish	Dr. Geurts is supported by grant (2010B239) from the Dutch Heart Foundation. Dr. Macleod received grant support from FP7 for EuroHYP-1 and is employed by the University of Edinburgh. Dr. Kollmar consulted for Zoll and received support for travel from Zoll, Bard, and Elvido. Dr. van der Worp received grant support from the Dutch Heart Foundation (2010T075 and 2010B239) and 7th Framework Programme European Union. Drs. Geurts and van der Worp are the coordinator and principal investigator, respectively, of the ongoing randomized phase II cooling trial COOLIST (NTR 2616), and Drs. Macleod, Kollmar, and van der Worp are coprincipal investigators of the randomized phase III cooling trial EuroHYP-1. Dr. Kremer has disclosed that he does not have any potential conflicts of interest.	Arrich J, 2012, COCHRANE DATABASE SY, V9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bi M, 2011, CLIN NEUROL NEUROSUR, V113, P768, DOI 10.1016/j.clineuro.2011.08.010; Boldt J, 1996, J CARDIOTHOR VASC AN, V10, P342, DOI 10.1016/S1053-0770(96)80094-2; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Boodhwani M, 2009, ANN THORAC SURG, V87, P489, DOI 10.1016/j.athoracsur.2008.10.078; Broessner G, 2010, STROKE, V41, P2969, DOI 10.1161/STROKEAHA.110.591933; Broessner G, 2009, CRIT CARE MED, V37, P1886, DOI 10.1097/CCM.0b013e31819ffd7f; Chouhan RS, 2006, J ANAESTH CLIN PHARM, V22, P21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Den Hertog HM, 2009, COCHRANE DATABASE SY, V1; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Gotberg M, 2010, CIRC-CARDIOVASC INTE, V3, P400, DOI 10.1161/CIRCINTERVENTIONS.110.957902; Grimm M, 2000, EUR J CARDIO-THORAC, V18, P270, DOI 10.1016/S1010-7940(00)00510-8; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; Honore PM, 2001, CRIT CARE MED, V29, P1903, DOI 10.1097/00003246-200110000-00009; Jacobs S, 2007, COCHRANE DATABASE SY, V4; Jarrah S, 2011, NEUROCRIT CARE, V14, P382, DOI 10.1007/s12028-011-9506-y; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lee HC, 2010, WORLD NEUROSURG, V74, P654, DOI 10.1016/j.wneu.2010.06.019; Li LR, 2012, COCHRANE DATABASE SY, V2; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.ijsu.2011.10.001, 10.1016/j.jclinepi.2010.03.004]; Mongardon N, 2011, CRIT CARE MED, V39, P1359, DOI 10.1097/CCM.0b013e3182120b56; Nathan HJ, 2004, J THORAC CARDIOV SUR, V127, P1270, DOI 10.1016/j.jtcvs.2003.07.018; Nielsen N, 2011, INTENS CARE MED, V37, pS28; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Stone GW, 2011, AM J CARDIOL, V108, P741, DOI 10.1016/j.amjcard.2011.04.026; Sydenham E, 2009, COCHRANE DATABASE SY, P2; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tsai MS, 2005, INTENS CARE MED, V31, P621, DOI 10.1007/s00134-005-2612-6; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Weber UJ, 2008, THESIS U COPENHAGEN; Xiao GG, 2013, EMERG MED J, V30, P91, DOI 10.1136/emermed-2012-201120	53	99	104	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2014	42	2					231	242		10.1097/CCM.0b013e3182a276e8			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291WS	WOS:000329863400018	23989182				2022-02-06	
J	Schmidt, JD; Register-Mihalik, JK; Mihalk, JP; Kerr, ZY; Guskiewicz, KM				Schmidt, Julianne D.; Register-Mihalik, Johna K.; Mihalk, Jason P.; Kerr, Zachary Y.; Guskiewicz, Kevin M.			Identifying Impairments after Concussion: Normative Data versus Individualized Baselines	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						NEUROCOGNITION; POSTURAL CONTROL; CONCUSSION EVALUATION; INJURY MANAGEMENT; MILD TRAUMATIC BRAIN INJURY	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; ERROR SCORING SYSTEM; NEUROCOGNITIVE TEST-PERFORMANCE; SENSORY ORGANIZATION TEST; BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POSTURAL STABILITY; NCAA CONCUSSION; YOUNG-ADULTS	SCHMIDT, J. D., J. K. REGISTER-MIHALIK, J. P. MIHALIK, Z. Y. KERR, and K. M. GUSKIEWICZ. Impairments after Concussion: Normative Data versus Individualized Baselines. Med. Sci. Sports Exerc., Vol. 44, No. 9, pp. 1621-1628, 2012. Purpose: This study aimed to determine whether agreement exists between baseline comparison (comparison of postconcussion scores to individualized baseline scores) and normative comparison (comparison of postconcussion scores to a normative mean) in identifying impairments after concussion. Methods: A total of 1060 collegiate student-athletes completed baseline testing as part of an ongoing clinical program. Gender-specific normative means were obtained from a subset of 673 athletes with no history of self-reported concussion, learning disabilities, or attention-deficit disorders. Concussions were later diagnosed in 258 athletes who had completed baseline testing. The athletes completed their first assessment within 10 d after injury. Athletes completed a computerized neurocognitive test (Automated Neuropsychological Assessment Metrics), postural control assessment (Sensory Organization Test), and a 15-item graded symptom checklist at baseline and again after injury. We computed two postconcussion difference scores for each outcome measure: 1) baseline difference = postconcussion score individualized baseline score and 2) normative difference = postconcussion score normative mean. Athletes were considered impaired if postconcussion difference exceeded the reliable change parameters. McNemar tests were used to assess agreement on impairment status (impaired and unimpaired) between comparison methods for each outcome measure. Results: The baseline comparison method identified 2.6 times more impairments than the normative comparison method for the Simple Reaction Time Test I (P = 0.043). The normative comparison method identified 7.6 times more impairments than the baseline comparison method for Mathematical Processing (P < 0.001). No other disagreements were observed for postural control or symptom severity. Conclusions: Our findings suggest that, when using these concussion assessment tools, clinicians may consider using normative data in lieu of individualized baseline measures. This may be especially useful to clinicians with limited resources and an inability to capture valid baselines on all athletes.	[Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Kerr, Zachary/0000-0003-1423-1259; Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Balint S, 2009, PSYCHOL MED, V39, P1337, DOI 10.1017/S0033291708004236; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown CN, 2007, J ATHL TRAINING, V42, P515; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Dickin DC, 2010, CLIN J SPORT MED, V20, P278, DOI 10.1097/JSM.0b013e3181e8f8b1; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Kaminski TW, 2009, J CLIN EXP NEUROPSYC, V31, P689, DOI 10.1080/13803390802484771; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van der Werf YD, 2011, PROG BRAIN RES, V193, P245, DOI 10.1016/B978-0-444-53839-0.00016-8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wyrwich KW, 2000, J EVAL CLIN PRACT, V6, P39, DOI 10.1046/j.1365-2753.2000.00238.x	40	99	99	0	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2012	44	9					1621	1628		10.1249/MSS.0b013e318258a9fb			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	990IQ	WOS:000307624600001	22525765				2022-02-06	
J	Moser, RS; Schatz, P; Neidzwski, K; Ott, SD				Moser, Rosemarie Scolaro; Schatz, Philip; Neidzwski, Katherine; Ott, Summer D.			Group Versus Individual Administration Affects Baseline Neurocognitive Test Performance	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline testing; neurocognitive testing; concussion testing; computerized testing; group administration	SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL ASSESSMENT; SOCIAL FACILITATION; FOOTBALL; DISTRACTION; ATTENTION; IMPACT; NOISE	Background: Computer-based tests are widely used for the purpose of documenting baseline neurocognitive function, and athletes are often tested in groups. At present, there is limited research on the effects of administering these tests in a group versus individual setting. Hypothesis: Athletes assessed with neurocognitive tests in groups would show decreased performance compared with those assessed individually. Study Design: Cohort study; Level of evidence, 3. Methods: High school athletes completed preseason baseline neurocognitive tests either in groups in their school or individually in a private neuropsychological clinic (with no significant between-group differences in sex, history of concussion, and attention deficit disorder/learning disability). All athletes completed the ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) test battery on 1 occasion, which yielded scores in the area of verbal memory, visual memory, motor processing speed, reaction time, and symptom scores. Results: Athletes in the group setting scored significantly lower on verbal memory (mean 83.4 vs 86.5; P = .003), visual memory (mean 71.6 vs 76.7; P = .0001), motor processing speed (mean 35.6 vs 38.4; P = .0001), and reaction time (mean 0.61 vs 0.57; P = .001), but not symptom scores (mean 6.1 vs 4.4; P = .11), and exhibited a greater rate of invalid baselines. Similar results were obtained after excluding athletes with attention deficit disorder/learning disability and/or a history of concussion. Conclusion: Administering baseline neurocognitive testing to athletes in a group setting may introduce extraneous error, negatively affecting test performance.	[Moser, Rosemarie Scolaro] Sports Concuss Ctr New Jersey, Lawrenceville, NJ 08648 USA; St Josephs Univ, Philadelphia, PA 19131 USA		Moser, RS (corresponding author), Sports Concuss Ctr New Jersey, 3131 Princeton Pike,Bldg 5,110, Lawrenceville, NJ 08648 USA.	moserrs@comcast.net		Schatz, Philip/0000-0002-6222-6545			ALVES WM, 1987, CLIN SPORT MED, V6, P211; BARON RS, 1978, J PERS SOC PSYCHOL, V36, P816, DOI 10.1037/0022-3514.36.8.816; BUSHNELL DD, 1978, ALTERING TEST ENV RE; CARVER CS, 1978, J PERS SOC PSYCHOL, V36, P324, DOI 10.1037/0022-3514.36.3.324; Chen Z, 2006, J EXP PSYCHOL HUMAN, V32, P1452, DOI 10.1037/0096-1523.32.6.1452; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Dashiell JF, 1930, J ABNORM SOC PSYCH, V25, P190, DOI 10.1037/h0075144; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; GOLDSTEIN DJ, 1978, PSYCHOL REP, V42, P111, DOI 10.2466/pr0.1978.42.1.111; Hovey HB, 1928, AM J PSYCHOL, V40, P585, DOI 10.2307/1414337; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, IMPACT ONLINE VERSIO; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; *NEUR SYST, 2000, IMPACT IMM POST CONC; *NJSIAA, CONC ID MAN RET TO P; PFISTER HP, 1995, AUST PSYCHOL, V30, P24, DOI 10.1080/00050069508259599; PIERCE RC, 1963, J CONSULT PSYCHOL, V27, P536, DOI 10.1037/h0038844; ROSZKOWSKI MJ, 1984, PSYCHOL REP, V54, P482, DOI 10.2466/pr0.1984.54.2.482; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; *SPSS INC, 2009, SPSS MAC REL 16; Stevens J.P, 2009, APPL MULTIVARIATE ST; Trimmel M, 2006, ERGONOMICS, V49, P202, DOI 10.1080/00140130500434986; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEINSTEIN ND, 1974, J APPL PSYCHOL, V59, P548, DOI 10.1037/h0037338; ZAJONC RB, 1965, SCIENCE, V149, P269, DOI 10.1126/science.149.3681.269	30	99	99	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2325	2330		10.1177/0363546511417114			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	838KG	WOS:000296287900006	21828367				2022-02-06	
J	Smits, M; Houston, GC; Dippel, DWJ; Wielopolski, PA; Vernooij, MW; Koudstaal, PJ; Hunink, MGM; van der Lugt, A				Smits, Marion; Houston, Gavin C.; Dippel, Diederik W. J.; Wielopolski, Piotr A.; Vernooij, Meike W.; Koudstaal, Peter J.; Hunink, M. G. Myriam; van der Lugt, Aad			Microstructural brain injury in post-concussion syndrome after minor head injury	NEURORADIOLOGY			English	Article						Craniocerebral trauma; Post-concussion syndrome; Diffusion tensor imaging; Magnetic resonance imaging; Cognition disorder	DIFFUSE AXONAL INJURY; POSTCONCUSSION SYNDROME; NEUROPSYCHOLOGICAL DEFICITS; CEREBRAL MICROBLEEDS; WORKING-MEMORY; SYMPTOMS; LESIONS; PREDICTORS; MRI; NEUROPATHOLOGY	After minor head injury (MHI), post-concussive symptoms commonly occur. The purpose of this study was to correlate the severity of post-concussive symptoms in MHI patients with MRI measures of microstructural brain injury, namely mean diffusivity (MD) and fractional anisotropy (FA), as well as the presence of microhaemorrhages. Twenty MHI patients and 12 healthy controls were scanned at 3 T using diffusion tensor imaging (DTI) and high-resolution gradient recalled echo (HRGRE) T2*-weighted sequences. One patient was excluded from the analysis because of bilateral subdural haematomas. DTI data were preprocessed using Tract Based Spatial Statistics. The resulting MD and FA images were correlated with the severity of post-concussive symptoms evaluated with the Rivermead Postconcussion Symptoms Questionnaire. The number and location of microhaemorrhages were assessed on the HRGRE T2*-weighted images. Comparing patients with controls, there were no differences in MD. FA was decreased in the right temporal subcortical white matter. MD was increased in association with the severity of post-concussive symptoms in the inferior fronto-occipital fasciculus (IFO), the inferior longitudinal fasciculus and the superior longitudinal fasciculus. FA was reduced in association with the severity of post-concussive symptoms in the uncinate fasciculus, the IFO, the internal capsule and the corpus callosum, as well as in the parietal and frontal subcortical white matter. Microhaemorrhages were observed in one patient only. The severity of post-concussive symptoms after MHI was significantly correlated with a reduction of white matter integrity, providing evidence of microstructural brain injury as a neuropathological substrate of the post-concussion syndrome.	[Smits, Marion; Wielopolski, Piotr A.; Vernooij, Meike W.; Hunink, M. G. Myriam; van der Lugt, Aad] Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol Hs 224, NL-3000 CA Rotterdam, Netherlands; [Houston, Gavin C.] GE Healthcare, Appl Sci Lab, sHertogenbosch, Netherlands; [Dippel, Diederik W. J.; Koudstaal, Peter J.] Erasmus MC Univ Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. Myriam] Erasmus MC Univ Med Ctr Rotterdam, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. Myriam] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA		Smits, M (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol Hs 224, POB 2040, NL-3000 CA Rotterdam, Netherlands.	marion.smits@erasmusmc.nl	Smits, Marion/AAB-3985-2019; Dippel, Diederik/AAJ-2192-2020; Vernooij, Meike Willemijn/E-4061-2016; Smits, Marion/E-4795-2011	Smits, Marion/0000-0001-5563-2871; Dippel, Diederik/0000-0002-9234-3515; Houston, Graeme/0000-0002-9786-7975; Vernooij, Meike/0000-0003-4658-2176			Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, P623; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Rauscher A, 2005, MAGNET RESON MED, V54, P87, DOI 10.1002/mrm.20520; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; RUECKERT D, 2007, IMAGE REGISTRATIONT; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vernooij MW, 2008, NEUROLOGY, V70, P1208, DOI 10.1212/01.wnl.0000307750.41970.d9; Vernooij MW, 2008, RADIOLOGY, V248, P272, DOI 10.1148/radiol.2481071158; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; World Health Organization, 1993, ICD 10 CLASS MENT BE; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	68	99	101	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	AUG	2011	53	8					553	563		10.1007/s00234-010-0774-6			11	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	794IS	WOS:000292889500001	20924757	Green Published, Green Submitted, hybrid			2022-02-06	
J	Maas, AI; Harrison-Felix, CL; Menon, D; Adelson, PD; Balkin, T; Bullock, R; Engel, DC; Gordon, W; Orman, JL; Lew, HL; Robertson, C; Temkin, N; Valadka, A; Verfaellie, M; Wainwright, M; Wright, DW; Schwab, K				Maas, Andrew I.; Harrison-Felix, Cynthia L.; Menon, David; Adelson, P. David; Balkin, Tom; Bullock, Ross; Engel, Doortje C.; Gordon, Wayne; Orman, Jean Langlois; Lew, Henry L.; Robertson, Claudia; Temkin, Nancy; Valadka, Alex; Verfaellie, Mieke; Wainwright, Mark; Wright, David W.; Schwab, Karen			Common Data Elements for Traumatic Brain Injury: Recommendations From the Interagency Working Group on Demographics and Clinical Assessment	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Clinical protocols; Clinical studies; Data collection; Forms and records control; Rehabilitation; Standardization; Traumatic brain injury	PROGNOSTIC VALUE; INTRACRANIAL-PRESSURE; SECONDARY INSULTS; RACE; RACE/ETHNICITY; ETHNICITY; DESIGN	Comparing results across studies in traumatic brain injury (TB!) has been difficult because of the variability in data coding, definitions, and collection procedures. The global aim of the Working Group on Demographics and Clinical Assessment was to develop recommendations on the coding of clinical and demographic variables for TBI studies applicable across the broad spectrum of TBI, and to classify these as core, supplemental, or emerging. The process was consensus driven, with input from experts over a broad range of disciplines. Special consideration was given to military and pediatric TBI. Categorizing clinical elements as core versus supplemental proved difficult, given the great variation in types of studies and their interests. The data elements are contained in modules, which are grouped together in categories. Three levels of detail for coding data elements were developed: basic, intermediate, and advanced, with the greatest level of detail in the advanced version. In every case, the more detailed coding can be collapsed into the basic version. Templates were produced to summarize coding formats, motivation of choices, and recommendations for procedures. Work is ongoing to include more international participation and to provide an electronic data entry format with pull-down menus and automated data checks. This proposed standardization will facilitate comparison of research findings across studies and encourage high-quality meta-analysis of individual patient data.	[Maas, Andrew I.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Harrison-Felix, Cynthia L.] Craig Hosp, Englewood, CO USA; [Menon, David] Univ Cambridge, Cambridge, England; [Adelson, P. David] Phoenix Childrens Neurosci Inst, Phoenix, AZ USA; [Balkin, Tom] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; [Bullock, Ross] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Engel, Doortje C.] Univ Heidelberg Hosp, Heidelberg, Germany; [Gordon, Wayne] Mt Sinai Sch Med, New York, NY USA; [Orman, Jean Langlois] Rehabil Res & Dev Serv, Dept Vet Affairs, Washington, DC USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA; [Robertson, Claudia] Baylor Coll Med, Houston, TX 77030 USA; [Temkin, Nancy] Univ Washington, Seattle, WA 98195 USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA; [Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA; [Verfaellie, Mieke] Boston VA Hlth Care Syst, Boston, MA USA; [Wainwright, Mark] Northwestern Univ, Chicago, IL 60611 USA; [Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Schwab, Karen] Def & Vet Brain Injury Ctr, Washington, DC USA		Maas, AI (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013; Wright, David/F-1209-2013; Adelson, David/W-2083-2019	Maas, Andrew IR/0000-0003-1612-1264; Wright, David/0000-0002-7145-9105; Verfaellie, Mieke/0000-0001-5535-4584	National Institutes of Health-National Institute of Neurological Disorders and Stroke [NIH-NINDS]United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691]; National Institute on Disability and Rehabilitation Research; Department of Veterans AffairsUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Defense Centers of Excellence; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237, G0600986] Funding Source: UKRI	Support for the meetings and activities of the Working Group on Demographics and Clinical Assessment was funded in the context of the interagency initiative toward "an integrated approach to Research in Psychological Health and Traumatic Brain Injury" (National Institutes of Health-National Institute of Neurological Disorders and Stroke [NIH-NINDS]; the National Institute on Disability and Rehabilitation Research; the Department of Veterans Affairs; the Defense and Veterans Brain Injury Center and the Defense Centers of Excellence). The development of CDEs was further supported by a supplemental grant from NIH-NINDS (grant no. NS 042691).	Armed Forces Health Surveillance Center, 2007, MED SURVEILL MON REP, V14, P2; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bhopal R, 1998, AM J PUBLIC HEALTH, V88, P1303, DOI 10.2105/AJPH.88.9.1303; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Caulfield T, 2009, GENOME MED, V1, DOI 10.1186/gm8; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Haga SB, 2003, SCIENCE, V301, P466, DOI 10.1126/science.1087004; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaycox, 2008, INVISIBLE WOUNDS WAR; Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ma IWY, 2007, J CLIN EPIDEMIOL, V60, P572, DOI 10.1016/j.jclinepi.2006.11.009; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2009, CRIT CARE, V13, DOI 10.1186/cc8163; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; *MED AFTAOA, 1990, ABBR INJ SCAL 1990 R, P15; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Smart A, 2008, SOC STUD SCI, V38, P407, DOI 10.1177/0306312707083759; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Suarez-Kurtz G, 2005, TRENDS PHARMACOL SCI, V26, P196, DOI 10.1016/j.tips.2005.02.008; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tutton R, 2008, J LAW MED ETHICS, V36, P464, DOI 10.1111/j.1748-720X.2008.292.x; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; WILDE EA, ARCH PHYS MED REHABI, P1650; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; WRIGHT L, 1994, NEW YORKER      0725, P46; Wynia MK, 2010, NEW ENGL J MED, V362, P846, DOI 10.1056/NEJMsb0910799	33	99	100	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1641	1649		10.1016/j.apmr.2010.07.232			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400003	21044707				2022-02-06	
J	Walker, PA; Shah, SK; Jimenez, F; Gerber, MH; Xue, HS; Cutrone, R; Hamilton, JA; Mays, RW; Deans, R; Pati, S; Dash, PK; Cox, CS				Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Gerber, Michael H.; Xue, Hasen; Cutrone, Rochelle; Hamilton, Jason A.; Mays, Robert W.; Deans, Robert; Pati, Shibani; Dash, Pramod K.; Cox, Charles S., Jr.			Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes	EXPERIMENTAL NEUROLOGY			English	Article						Multipotent adult progenitor cells; Traumatic brain injury; Stem cells; Splenocytes; Blood brain barrier	MESENCHYMAL STEM-CELLS; BONE-MARROW; EXPERIMENTAL STROKE; TRANSPLANTATION	Recent investigation has shown an interaction between transplanted progenitor cells and resident splenocytes leading to the modulation of the immunologic response in neurological injury. We hypothesize that the intravenous injection of multipotent adult progenitor cells (MAPC) confers neurovascular protection after traumatic brain injury through an interaction with resident splenocytes, subsequently leading to preservation of the blood brain barrier. Four groups of rats underwent controlled cortical impact injury (3 groups) or sham injury (1 group). MAPC were injected via the tail vein at two doses (2*10(6) MAPC/kg or 10*10(6) MAPC/kg) 2 and 24 h after injury. Blood brain barrier permeability was assessed by measuring Evans blue dye extravasation (n = 6/group). Additionally, splenic mass was measured (n = 12/group) followed by splenocyte characterization (n = 9/group) including: cell cycle analysis (n = 6/group), apoptosis index (n = 6/group), cell proliferation (n = 6/group), and inflammatory cytokine measurements (n = 6/group). Vascular architecture was determined by immunohistochemistry (n = 3/group). Traumatic brain injury results in a decrease in splenic mass and increased blood brain barrier permeability. Intravenous infusion of MAPC preserved splenic mass and returned blood brain barrier permeability towards control sham injured levels. Splenocyte characterization indicated an increase in the number and proliferative rate of CD4+ T cells as well as an increase in IL-4 and IL-10 production in stimulated splenocytes isolated from the MAPC treatment groups. Immunohistochemistry demonstrated stabilization of the vascular architecture in the pen-lesion area. Traumatic brain injury causes a reduction in splenic mass that correlates with an increase in circulating immune cells leading to increased blood brain barrier permeability. The intravenous injection of MAPC preserves splenic mass and the integrity of the blood brain barrier. Furthermore, the co-localization of transplanted MAPC and resident CD4+ splenocytes is associated with a global increase in IL-4 and IL-10 production and stabilization of the cerebral microvasculature tight junction proteins. (C) 2010 Elsevier Inc. All rights reserved.	[Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Shah, Shinil K.; Gerber, Michael H.; Xue, Hasen; Pati, Shibani; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Gerber, Michael H.; Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Cutrone, Rochelle; Hamilton, Jason A.; Mays, Robert W.; Deans, Robert] Athersys Inc, Dept Regenerat Med, Cleveland, OH USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM 08 79201, M01 RR 02558]; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; Athersys, Inc.; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work was supported by grants from NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; Athersys, Inc.	Ajmo CT, 2009, EXP NEUROL, V218, P47, DOI 10.1016/j.expneurol.2009.03.044; Boozer Sherry, 2009, J Stem Cells, V4, P17, DOI jsc.2009.4.1.17; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2008, BRAIN, V131, DOI 10.1093/brain/awn142; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lim JH, 2007, J VET SCI, V8, P275, DOI 10.4142/jvs.2007.8.3.275; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; PATI S, STEM CELLS IN PRESS; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	25	99	102	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2010	225	2					341	352		10.1016/j.expneurol.2010.07.005			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	654SV	WOS:000282191500014	20637752	Green Accepted			2022-02-06	
J	Dawson, HN; Cantillana, V; Jansen, M; Wang, H; Vitek, MP; Wilcock, DM; Lynch, JR; Laskowitz, DT				Dawson, H. N.; Cantillana, V.; Jansen, M.; Wang, H.; Vitek, M. P.; Wilcock, D. M.; Lynch, J. R.; Laskowitz, D. T.			LOSS OF TAU ELICITS AXONAL DEGENERATION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE	NEUROSCIENCE			English	Article						Tau; APP; axonal degeneration; spheroids; head injury; immunization	PROGRESSIVE SUPRANUCLEAR PALSY; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; A-BETA-PEPTIDE; TRAUMATIC BRAIN-INJURY; TRANSGENIC MICE; HEAD-INJURY; FRONTOTEMPORAL DEMENTIA; CORTICOBASAL DEGENERATION; STEREOLOGICAL ESTIMATION	A central issue in the pathogenesis of tauopathy is the question of how tau protein dysfunction leads to neurodegeneration. We have previously demonstrated that the absence of tau protein is associated with destabilization of microtubules and impaired neurite outgrowth (Dawson et al., 2001; Rapoport et al., 2002). We now hypothesize that the absence of functional tau protein may render the central nervous system more vulnerable to secondary insults such as the overexpression of mutated beta amyloid precursor protein (APP) and traumatic brain injury. We therefore crossed tau knockout mice (Dawson et al., 2001) to mice overexpressing a mutated human APP (APP(670,671), A(SW)) (Hsiao et al., 1996) and created a mouse model (A(sw)/mTau(-/-)) that provides evidence that the loss of tau function causes degeneration of neuronal processes. The overexpression of APP(670,671) in tau knockout mice, elicits the extensive formation of axonal spheroids. While spheroids are only found associated with A beta plaques in mice expressing APP(670,671) on an endogenous mouse tau background (Irizarry et al., 1997), A(sw)/mTau(-/-) mice have spheroids not only surrounding A beta plaques but also in white matter tracks and in the neuropil. Plaque associated and neuropil dystrophic neurites and spheroids are prominent features of Alzheimer's disease (Masliah et al., 1993; Terry, 1996; Stokin et al., 2005), and our current data suggests that loss of tau function may lead to neurodegeneration. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Dawson, H. N.; Cantillana, V.; Jansen, M.; Wang, H.; Vitek, M. P.; Wilcock, D. M.; Laskowitz, D. T.] Duke Univ, Div Neurol, Durham, NC 27710 USA; [Vitek, M. P.] Cognosci Inc, Res Triangle Pk, NC 27709 USA; [Lynch, J. R.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53266 USA		Dawson, HN (corresponding author), Duke Univ, Div Neurol, Durham, NC 27710 USA.	dawso009@mc.duke.edu	Wilcock, Donna M/J-7517-2016	Vitek, Michael/0000-0001-8140-8048	Alzheimer's AssociationAlzheimer's Association [II3-02-4160]; Institute for Study of Aging/ADDF [261102.01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08-AG22230-03]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG022230] Funding Source: NIH RePORTER	This work was supported in part by Alzheimer's Association Grant II3-02-4160 HND, Institute for Study of Aging/ADDF 261102.01 DTL and NIH K08-AG22230-03 JRL. We thank Dr. Anyang Sun for providing his expertise in axonal degeneration. We thank Dr. Van Nostram's laboratory for performing A beta the elisa.	Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Black MM, 1996, J NEUROSCI, V16, P3601; Brendza RP, 2003, NEUROBIOL AGING, V24, P1071, DOI 10.1016/j.neurobiolaging.2003.04.008; Brendza RP, 2003, J COMP NEUROL, V456, P375, DOI 10.1002/cne.10536; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Crawley JN, 2000, WHATS WRONG MY MOUSE; Dai JP, 2002, BRAIN RES, V948, P138, DOI 10.1016/S0006-8993(02)03152-9; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Dawson HN, 2001, J CELL SCI, V114, P1179; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Dikranian K, 2001, NEUROBIOL DIS, V8, P359, DOI 10.1006/nbdi.2001.0411; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Goedert M, 1999, AM J PATHOL, V154, P1, DOI 10.1016/S0002-9440(10)65242-X; Gomez-Ramos P, 2007, J ALZHEIMERS DIS, V11, P53; Gordon MN, 2001, NEUROBIOL AGING, V22, P377, DOI 10.1016/S0197-4580(00)00249-9; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hernandez F, 2007, CELL MOL LIFE SCI, V64, P2219, DOI 10.1007/s00018-007-7220-x; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JONES RSG, 1993, TRENDS NEUROSCI, V16, P58, DOI 10.1016/0166-2236(93)90018-H; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Katsuse O, 2003, ACTA NEUROPATHOL, V106, P251, DOI 10.1007/s00401-003-0728-8; Kempf M, 1996, J NEUROSCI, V16, P5583; Kobayashi DT, 2005, GENES BRAIN BEHAV, V4, P173, DOI 10.1111/j.1601-183X.2005.00124.x; Kosaka Satoru, 2004, Osaka City Medical Journal, V50, P19; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Long JM, 1998, J NEUROSCI METH, V84, P101, DOI 10.1016/S0165-0270(98)00100-9; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; Miao JT, 2005, J NEUROSCI, V25, P6271, DOI 10.1523/JNEUROSCI.1306-05.2005; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morris HR, 2003, NEUROLOGY, V61, P102, DOI 10.1212/01.WNL.0000072325.27824.A5; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Qing H, 2008, J EXP MED, V205, P2781, DOI 10.1084/jem.20081588; Rademakers R, 2004, HUM MUTAT, V24, P277, DOI 10.1002/humu.20086; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Stokin GB, 2008, HUM MOL GENET, V17, P3474, DOI 10.1093/hmg/ddn240; Takahashi T, 1997, ACTA NEUROPATHOL, V94, P294, DOI 10.1007/s004010050707; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x; Vershinin M, 2008, TRAFFIC, V9, P882, DOI 10.1111/j.1600-0854.2008.00741.x; Vershinin M, 2007, P NATL ACAD SCI USA, V104, P87, DOI 10.1073/pnas.0607919104; Villain N, 2008, J NEUROSCI, V28, P6174, DOI 10.1523/JNEUROSCI.1392-08.2008; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Wirths O, 2006, ACTA NEUROPATHOL, V111, P312, DOI 10.1007/s00401-006-0041-4; Wirths O, 2004, J NEUROCHEM, V91, P513, DOI 10.1111/j.1471-4159.2004.02737.x; Wirths O, 2008, NEUROBIOL AGING, V29, P891, DOI 10.1016/j.neurobiolaging.2006.12.004; Wozniak DF, 1996, BRAIN RES, V707, P165, DOI 10.1016/0006-8993(95)01230-3; Zhukareva V, 2001, ANN NEUROL, V49, P165, DOI 10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3	87	99	100	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	AUG 11	2010	169	1					516	531		10.1016/j.neuroscience.2010.04.037			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	621LB	WOS:000279579200052	20434528	Green Accepted			2022-02-06	
J	Dash, PK; Orsi, SA; Moore, AN				Dash, P. K.; Orsi, S. A.; Moore, A. N.			HISTONE DEACTYLASE INHIBITION COMBINED WITH BEHAVIORAL THERAPY ENHANCES LEARNING AND MEMORY FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						traumatic brain injury; HDAC; Morris water maze; hippocampus; delay fear conditioning	CORTICAL IMPACT INJURY; ENVIRONMENTAL ENRICHMENT; SYNAPTIC PLASTICITY; GENE-EXPRESSION; HIPPOCAMPAL-NEURONS; COGNITIVE DEFICITS; H3 ACETYLATION; RATS; RECOVERY; METHYLATION	Traumatic brain injury (TBI) induces a number of pathological events ranging from neuronal degeneration and tissue loss to impaired neuronal plasticity and neurochemical dysregulation. In rodents, exposure of brain-injured animals to environmental enrichment has been shown to be an effective means of enhancing learning and memory post-injury. Recently, it has been discovered that environmental enrichment may enhance neuronal plasticity through epigenetic changes that involve enhanced histone acetylation, a property that can be mimicked by the use of histone deactylase (HDAC) inhibitors. We therefore evaluated the consequences of the HDAC inhibitor sodium butyrate on the learning and memory of brain-injured mice. In contrast to a previous report using a mouse neurodegeneration model, sodium butyrate (1.2 g/kg daily for four weeks) did not improve learning and memory when tested after the completion of the drug treatment paradigm. In addition, sodium butyrate administration during the reported period of neurodegeneration (days 0-5) also offered no benefit. However, when administered concurrently with training in the Morris water maze task (beginning on day 14 post-injury), sodium butyrate improved learning and memory in brain-injured mice. Interestingly, when these mice were subsequently tested in an associative fear conditioning task, an improvement was observed. Taken together, our findings indicate that HDAC inhibition may mimic some of the cognitive improvements seen following enriched environment exposure, and that the improvement is observed when the treatment is carried out current with behavioral testing. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Dash, P. K.; Orsi, S. A.; Moore, A. N.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049160, NS053588, MH072933]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160, R01NS053588] Funding Source: NIH RePORTER	The authors would like to thank Jing Zhao, Hyung Jin Ahn, and Min Zhang for technical assistance in performing the cortical impact injury and behavioral studies. This work was supported, in part, by grants from the NIH (NS049160, NS053588, MH072933).	Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Levenson JM, 2006, J BIOL CHEM, V281, P15763, DOI 10.1074/jbc.M511767200; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Miller CA, 2008, NEUROBIOL LEARN MEM, V89, P599, DOI 10.1016/j.nlm.2007.07.016; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	28	99	101	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	SEP 29	2009	163	1					1	8		10.1016/j.neuroscience.2009.06.028			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	489FD	WOS:000269404600001	19531374	Green Accepted			2022-02-06	
J	Donkin, JJ; Nimmo, AJ; Cernak, I; Blumbergs, PC; Vink, R				Donkin, James J.; Nimmo, Alan J.; Cernak, Ibolja; Blumbergs, Peter C.; Vink, Robert			Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cerebral edema; neurogenic inflammation; neuropeptides	SPINAL-CORD ASTROCYTES; NEUROGENIC INFLAMMATION; MAGNESIUM-DEFICIENCY; TIME-COURSE; RECEPTOR; RATS; TACHYKININ; VASODILATATION; PATHOBIOLOGY; ANTAGONIST	Brain edema and swelling is a critical factor in the high mortality and morbidity associated with traumatic brain injury (TBI). Despite this, the mechanisms associated with its development are poorly understood and interventions have not changed in over 30 years. Although neuropeptides and neurogenic inflammation have been implicated in peripheral edema formation, their role in the development of central nervous system edema after brain trauma has not been investigated. This study examines the role of the neuropeptide, substance P (SP), in the development of edema and functional deficits after brain trauma in rats. After severe diffuse TBI in adult male rats, neuronal and perivascular SP immunoreactivity were increased markedly. Perivascular SP colocalized with exogenously administered Evans blue, supporting a role for SP in vascular permeability. Inhibition of SP action by administration of the neurokinin-1 (NK1) antagonist, N-acetyl-L-tryptophan, at 30 mins after trauma attenuated vascular permeability and edema formation. Administration of the NK1 antagonist also improved both motor and cognitive neurologic outcomes. These findings suggest that SP release is integrally linked to the increased vascular permeability and edema formation after brain trauma, and that treatment with an NK1 receptor antagonist reduces edema and improves neurologic outcome. Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1388-1398; doi: 10.1038/jcbfm.2009.63; published online 13 May 2009	[Donkin, James J.; Nimmo, Alan J.; Vink, Robert] Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA; [Blumbergs, Peter C.; Vink, Robert] Hanson Inst Ctr Neurol Dis, Adelaide, SA, Australia		Vink, R (corresponding author), Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GAUMANN DM, 1990, NEUROSCIENCE, V39, P761, DOI 10.1016/0306-4522(90)90259-7; HAFSTROM I, 1989, J RHEUMATOL, V16, P1033; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Jacobs G., 2000, ESTIMATING GLOBAL RO; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; Kramer JH, 1997, J MOL CELL CARDIOL, V29, P97, DOI 10.1006/jmcc.1996.0255; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; McIntosh TK, 1996, LAB INVEST, V74, P315; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; PERSSON MG, 1991, EUR J PHARMACOL, V205, P295, DOI 10.1016/0014-2999(91)90913-B; POTHOULAKIS C, 1994, P NATL ACAD SCI USA, V91, P947, DOI 10.1073/pnas.91.3.947; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; Saria A, 1999, EUR J PHARMACOL, V375, P51, DOI 10.1016/S0014-2999(99)00259-9; SARIA A, 1984, BRIT J PHARMACOL, V82, P217, DOI 10.1111/j.1476-5381.1984.tb16461.x; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Towler PK, 1998, NEUROREPORT, V9, P1513, DOI 10.1097/00001756-199805110-00049; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734; WOIE K, 1993, CIRC RES, V73, P839, DOI 10.1161/01.RES.73.5.839; YONEHARA N, 1987, J PHARMACOL EXP THER, V242, P1071; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006	42	99	102	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2009	29	8					1388	1398		10.1038/jcbfm.2009.63			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	477JO	WOS:000268515500004	19436311	Bronze, Green Accepted			2022-02-06	
J	Christensen, BK; Colella, B; Illness, E; Hebert, D; Monette, G; Bayley, M; Green, RE				Christensen, Bruce K.; Colella, Brenda; Illness, Elizabeth; Hebert, Deborah; Monette, Georges; Bayley, Mark; Green, Robin E.			Recovery of Cognitive Function After Traumatic Brain Injury: A Multilevel Modeling Analysis of Canadian Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Longitudinal studies; Neuropsychology; Rehabilitation	SEVERE HEAD-INJURY; FOLLOW-UP; NEUROPSYCHOLOGICAL RECOVERY; COMMUNITY INTEGRATION; POSTTRAUMATIC AMNESIA; PROGNOSTIC VALUE; OLDER-ADULTS; REHABILITATION; SEVERITY; MODERATE	Objective: To ascertain patterns of cognitive recovery during the first year after traumatic brain injury (TBI). Specifically, differential recovery across cognitive domains was investigated. Design: Prospective, longitudinal, naturalistic, 1-year follow-up study. Setting: Large, urban inpatient neurorehabilitation program. Participants: Patients (N=75) with moderate to severe TB I. Interventions: Not applicable. Main Outcome Measures: Patients with TBI were followed over the course of 1 year, during which participants' neuropsychological status was repeatedly evaluated at 3 time points (2, 5, and 12 months postinjury). Results: Multilevel modeling results were consistent with previous research, demonstrating that recovery in the first year postinjury is asymptotic in nature, with more accelerated recovery occurring during the first 5 to 6 months. Importantly, results also suggest that recovery is not uniform across cognitive domains. From 2 to 5 months postinjury, steeper recovery curves were revealed for indices of memory, speeded executive function, verbal abstraction, and manual dexterity relative to untimed tests of executive function and word knowledge. Recovery trajectories did not significantly vary as a function of cognitive domain over the course of the last 5 to 12 months. Conclusions: These results are the first to explore trajectories of recovery directly as a function of multiple cognitive domains. They are expected to have implications for rehabilitative efforts as well as our understanding of the architecture of natural recovery after TBI.	[Colella, Brenda; Illness, Elizabeth; Hebert, Deborah; Bayley, Mark; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Christensen, Bruce K.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8S 4L8, Canada; [Illness, Elizabeth; Hebert, Deborah; Bayley, Mark; Green, Robin E.] Univ Toronto, Toronto, ON, Canada; [Monette, Georges] York Univ, Dept Math & Stat, N York, ON M3J 1P3, Canada		Green, RE (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehab.on.ca		Green, Robin/0000-0001-9451-3963; Inness, Elizabeth L./0000-0002-9217-4619; Bayley, Mark/0000-0001-7860-9463	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians' Services Inc [MOP-67072, 05-50]	Supported by the Canadian Institutes of Health Research and the Physicians' Services Inc (grant nos. MOP-67072, 05-50).	Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; BENE JF, 2007, BRAIN INJURY, V21, P395; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brooks D N, 1979, Int Rehabil Med, V1, P166; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; DeBow SB, 2004, CAN J PHYSIOL PHARM, V82, P231, DOI 10.1139/Y04-013; Deutsch PM, 2006, NEUROREHABILITATION, V21, P305; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Galwey N. W., 2006, INTRO MIXED MODELLIN; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Green REA, 2006, BRAIN COGNITION, V60, P199; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hebb MO, 2007, J NEUROTRAUM, V24, P579, DOI 10.1089/neu.2006.0146; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hughes C, 2000, J CHILD PSYCHOL PSYC, V41, P483, DOI 10.1111/1469-7610.00633; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; KOLB B, 2004, MECH CORTICAL PLASTI; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Lau AFC, 2003, INT J REHABIL RES, V26, P251, DOI 10.1097/00004356-200312000-00001; LEVERE ND, 1982, PHYSIOL PSYCHOL, V10, P165; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nelles G, 1999, ANN NEUROL, V46, P901, DOI 10.1002/1531-8249(199912)46:6<901::AID-ANA13>3.0.CO;2-7; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Poon WS, 2005, ACT NEUR S, V93, P207; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V1; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Taub E, 2001, Curr Atheroscler Rep, V3, P279, DOI 10.1007/s11883-001-0020-0; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; TOFL S, 1996, BRAIN INJURY, V10, P901; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	96	99	100	0	31	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S3	S15		10.1016/j.apmr.2008.10.002			13	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	388DB	WOS:000261999400002	19081439				2022-02-06	
J	Schnakers, C; Majerus, S; Giacino, J; Vanhaudenhuyse, A; Bruno, MA; Boly, M; Moonen, G; Damas, P; Lambermont, B; Lamy, M; Damas, F; Ventura, M; Laureys, S				Schnakers, Caroline; Majerus, Steve; Giacino, Joseph; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Boly, Melanie; Moonen, Gustave; Damas, Pierre; Lambermont, Bernard; Lamy, Maurice; Damas, Francois; Ventura, Manfredi; Laureys, Steven			A French validation study of the Coma Recovery Scale-Revised (CRS-R)	BRAIN INJURY			English	Article						vegetative state; minimally conscious state; neurobehavioural; closed head injury	SENSORY MODALITY ASSESSMENT; MINIMALLY CONSCIOUS STATE; WESSEX HEAD-INJURY; VEGETATIVE STATE; REHABILITATION TECHNIQUE; MISDIAGNOSIS; DIAGNOSIS; ACCURACY; MATRIX	Primary objective: The aim of the present study was to explore the concurrent validity, inter-rater agreement and diagnostic sensitivity of a French adaptation of the Coma Recovery Scale-Revised (CRS-R) as compared to other coma scales such as the Glasgow Coma Scale (GCS), the Full Outline of UnResponsiveness scale (FOUR) and the Wessex Head Injury Matrix (WHIM). Research design: Multi-centric prospective study. Method and procedures: To test concurrent validity and diagnostic sensitivity, the four behavioural scales were administered in a randomized order in 77 vegetative and minimally conscious patients. Twenty-four clinicians with different professional backgrounds, levels of expertise and CRS-R experience were recruited to assess inter-rater agreement. Main outcomes and results: Good concurrent validity was obtained between the CRS-R and the three other standardized behavioural scales. Inter-rater reliability for the CRS-R total score and sub-scores was good, indicating that the scale yields reproducible findings across examiners and does not appear to be systematically biased by profession, level of expertise or CRS-R experience. Finally, the CRS-R demonstrated a significantly higher sensitivity to detect MCS patients, as compared to the GCS, the FOUR and the WHIM. Conclusion: The results show that the French version of the CRS-R is a valid and sensitive scale which can be used in severely brain damaged patients by all members of the medical staff.	[Schnakers, Caroline; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Boly, Melanie; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Majerus, Steve] Univ Liege, Dept Cognit Sci, B-4000 Liege, Belgium; [Giacino, Joseph] New Jersey Neurosci Inst, Edison, NJ USA; [Boly, Melanie; Moonen, Gustave; Laureys, Steven] Univ Sart Tilman, Ctr Hosp, Dept Neurol, Liege, Belgium; [Damas, Pierre; Lambermont, Bernard; Lamy, Maurice] Univ Sart Tilman, Ctr Hosp, Dept Intens Care, Liege, Belgium; [Damas, Francois] Citadelle Reg Hosp Liege, Dept Intens Care, Liege, Belgium; [Ventura, Manfredi] Univ Libre Bruxelles, CTR Neurorehabil Ctr, Brussels, Belgium		Schnakers, C (corresponding author), Univ Liege, Ctr Rech Cyclotron, Sart Tilman,B30, B-4000 Liege, Belgium.	c.schnakers@student.ulg.ac.be	Laureys, Steven/AAN-2097-2021; Majerus, Steve/D-4678-2009; Ventura, Manfredi/AAG-9123-2019; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/A-3349-2011; Giacino, Joseph/AAF-1952-2021	Laureys, Steven/0000-0002-3096-3807; Giacino, Joseph/0000-0002-7916-9698; Boly, Melanie/0000-0001-9584-0907; Majerus, Steve/0000-0002-8206-8097	Belgian Federal Public Service for Public Health; Belgian 'Fonds National de la Recherche Scientifique' (FNRS)Fonds de la Recherche Scientifique - FNRS; 'Centre Hospitalier' of the University of LiegeUniversity of Liege	This study was supported by funds from the Belgian Federal Public Service for Public Health, Belgian 'Fonds National de la Recherche Scientifique' (FNRS), 'Centre Hospitalier' of the University of Liege, French Speaking Community of Belgium Concerted Research Action, the J. S. McDonnell Foundation, the European Commission, Mind Science Foundation, TX. SL, SM and MB are, respectively, Senior Research Associate, Research Associate, and Research Fellow at the FNRS. CS is funded by the 'Fonds Leon Fredericq' (University of Liege) and the FNRS.	Andrews K, 2005, NEUROPSYCHOL REHABIL, V15, P461, DOI 10.1080/09602010443000326; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; JAGGER J, 1983, LANCET, V2, P97; LANDIS JR, 1977, BIOMETRICS, V33, P174; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606	23	99	105	1	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	10					786	792		10.1080/02699050802403557			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400009	18787989				2022-02-06	
J	Wymann, NME; Holzle, A; Zachariou, Z; Iizuka, T				Wymann, Nicole M. Eggensperger; Hoelzle, Alexander; Zachariou, Zacharias; Iizuka, Tateyuki			Pediatric craniofacial trauma	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							FACIAL FRACTURES; MAXILLOFACIAL FRACTURES; JAW FRACTURES; CHILDREN; SKELETON; ETIOLOGY; INJURIES; AGE; PATTERNS; NIGERIA	Purpose: Maxillofacial and skull fractures occur with concomitant injuries in pediatric trauma patients. The aim of this study was to determine the causes and distributions of maxillofacial and skull fractures as well as concomitant injuries of pediatric patients in Switzerland. Results were compared with worldwide studies. Materials and Methods: A retrospective review was conducted of 291 pediatric patients with maxillofacial and skull fractures presenting to a level-I trauma center over a 3-year span. Data concerning the mechanism of the accident and the topographic location of the injuries were analyzed. Results: The most common causes were falls (64%), followed by traffic (22%) and sports-related accidents (9%). Fifty-four percent of the fractures occurred in the skull vault and 37% in the upper and middle facial third. One third of the patients (n = 95) suffered concomitant injuries, mostly cerebral concussions (n = 94). Conclusions: The spectrum of craniofacial injuries is related to the specific developmental stage of the craniofacial skeleton. It is probable that national prevention programs will have a positive effect on reducing the incidence of falls. Standardization of studies is needed for international comparison. (C) 2008 American Association of Oral and Maxillofacial Surgeons.	[Wymann, Nicole M. Eggensperger; Hoelzle, Alexander; Iizuka, Tateyuki] Univ Bern, Dept Craniomaxillofacial Surg, Inselspital, CH-3010 Bern, Switzerland; [Zachariou, Zacharias] Univ Bern, Inselspital, Dept Pediat Surg, CH-3010 Bern, Switzerland		Wymann, NME (corresponding author), Univ Bern, Dept Craniomaxillofacial Surg, Inselspital, CH-3010 Bern, Switzerland.	nicole.eggensperger@insel.ch					ADEKEYE EO, 1980, J ORAL SURG, V38, P355; ANDERSON PJ, 1995, INJURY, V26, P47, DOI 10.1016/0020-1383(95)90552-9; Bamjee Y, 1996, BRIT J ORAL MAX SURG, V34, P298, DOI 10.1016/S0266-4356(96)90006-6; Bataineh AB, 1998, ORAL SURG ORAL MED O, V86, P31, DOI 10.1016/S1079-2104(98)90146-9; CARROLL MJ, 1987, BRIT DENT J, V163, P289, DOI 10.1038/sj.bdj.4806278; Chan J, 2004, INT J PEDIATR OTORHI, V68, P877, DOI 10.1016/j.ijporl.2004.01.021; CHIDZONGA MM, 1987, CENT AFR J MED, V33, P274; Gassner R, 2004, J ORAL MAXIL SURG, V62, P399, DOI 10.1016/j.joms.2003.05.013; GUSSACK GS, 1987, LARYNGOSCOPE, V97, P925; GUVEN O, 1992, J CRANIO MAXILL SURG, V20, P244, DOI 10.1016/S1010-5182(05)80435-4; Haug RH, 2000, ORAL SURG ORAL MED O, V90, P126, DOI 10.1067/moe.2000.107974; Holland AJA, 2001, PEDIATR EMERG CARE, V17, P157, DOI 10.1097/00006565-200106000-00002; Iida S, 2001, INT J ORAL MAX SURG, V30, P286, DOI 10.1054/ijom.2001.0056; Jaber M A, 1997, Int J Paediatr Dent, V7, P39; Jarupoonphol Vithya, 2001, Journal of the Medical Association of Thailand, V84, P1541; KILLEY HC, 1988, BANKS; Klenk G, 2003, J CRANIOFAC SURG, V14, P78, DOI 10.1097/00001665-200301000-00014; Koltai PJ, 1996, PEDIATR CLIN N AM, V43, P1253, DOI 10.1016/S0031-3955(05)70518-6; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; Le Fort R, 1901, REV CHIRURG, V23, P208; MCGRAW BL, 1990, ARCH OTOLARYNGOL, V116, P41; Motamedi MHK, 2003, J ORAL MAXIL SURG, V61, P61, DOI 10.1053/joms.2003.50049; Oji C, 1999, BRIT J ORAL MAX SURG, V37, P106, DOI 10.1054/bjom.1997.0083; PORTER SR, 1987, BRIT DENT J, V163, P144, DOI 10.1038/sj.bdj.4806222; POSNICK JC, 1993, J ORAL MAXIL SURG, V51, P836, DOI 10.1016/S0278-2391(10)80098-9; Qudah MA, 2002, ORAL SURG ORAL MED O, V94, P310, DOI 10.1067/moe.2002.127406; ROWE NL, 1968, J ORAL SURG, V26, P505; STARKHAMMAR H, 1982, CLIN OTOLARYNGOL, V7, P405, DOI 10.1111/j.1365-2273.1982.tb01404.x; STYLOGIANNI L, 1991, BRIT J ORAL MAX SURG, V29, P9, DOI 10.1016/0266-4356(91)90164-Z; Tan W.K.S., 1999, Annals Academy of Medicine Singapore, V28, P625; TANAKA N, 1993, J CRANIO MAXILL SURG, V21, P289, DOI 10.1016/S1010-5182(05)80349-X; THALLER SR, 1992, ANN PLAS SURG, V29, P348, DOI 10.1097/00000637-199210000-00012; VOSS R, 1982, J MAXILLOFAC SURG, V10, P146, DOI 10.1016/S0301-0503(82)80031-3; WAITE DE, 1973, PEDIATRICS, V51, P551; ZACHARIADES N, 1990, J CRANIO MAXILL SURG, V18, P151, DOI 10.1016/S1010-5182(05)80509-8; Zerfowski M, 1998, Clin Oral Investig, V2, P120, DOI 10.1007/s007840050056	36	99	101	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JAN	2008	66	1					58	64		10.1016/j.joms.2007.04.023			7	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	245VG	WOS:000251966300010	18083416				2022-02-06	
J	Yen, K; Loblad, KO; Scheurer, E; Ozdoba, C; Thali, MJ; Aghayev, E; Jackowski, C; Anon, J; Frickey, N; Zwygart, K; Weis, J; Dirnhofer, R				Yen, Kathrin; Loeblad, Karl-Olof; Scheurer, Eva; Ozdoba, Christoph; Thali, Michael J.; Aghayev, Emin; Jackowski, Christian; Anon, Javier; Frickey, Nathalie; Zwygart, Karin; Weis, Joachim; Dirnhofer, Richard			Post-mortem forensic neuroimaging: Correlation of MSCT and MRI findings with autopsy results	FORENSIC SCIENCE INTERNATIONAL			English	Article						CT; MRI; forensic imaging; virtopsy; post-mortem neuroradiology	MULTISLICE COMPUTED-TOMOGRAPHY; RESONANCE-IMAGING MRI; TRAUMATIC BRAIN-INJURY; CLINICAL-EXPERIENCE; VIRTUAL AUTOPSY; CT; EPIDEMIOLOGY; VIRTOPSY; VICTIMS; HEMORRHAGE	Multislice-computed tomography (MSCT) and magnetic resonance imaging (MRI) are increasingly used for forensic purposes. Based on broad experience in clinical neuroimaging, post-mortem MSCT and MRI were performed in 57 forensic cases with the goal to evaluate the radiological methods concerning their usability for forensic head and brain examination. An experienced clinical radiologist evaluated the imaging data. The results were compared to the autopsy findings that served as the gold standard with regard to common forensic neurotrauma findings such as skull fractures, soft tissue lesions of the scalp, various forms of intracranial hemorrhage or signs of increased brain pressure. The sensitivity of the imaging methods ranged from 100% (e.g., heat-induced alterations, intracranial gas) to zero (e.g., mediobasal impression marks as a sign of increased brain pressure, plaques jaunes). The agreement between MRI and CT was 69%. The radiological methods prevalently failed in the detection of lesions smaller than 3 mm of size, whereas they were generally satisfactory concerning the evaluation of intracranial hemorrhage. Due to its advanced 2D and 3D post-processing possibilities, CT in particular possessed certain advantages in comparison with autopsy with regard to forensic reconstruction. MRI showed forensically relevant findings not seen during autopsy in several cases. The partly limited sensitivity of imaging that was observed in this retrospective study was based on several factors: besides general technical limitations it became apparent that clinical radiologists require a sound basic forensic background in order to detect specific signs. Focused teaching sessions will be essential to improve the outcome in future examinations. On the other hand, the autopsy protocols should be further standardized to allow an exact comparison of imaging and autopsy data. In consideration of these facts, MRI and CT have the power to play an important role in future forensic neuropathological examination. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Med Univ Graz, Ctr Clin Theoret Med, Dept Forens Radiol, A-8010 Graz, Austria; Univ Bern, Inst Forens Med, CH-3012 Bern, Switzerland; Univ Geneva, Dept Neuroradiol, Geneva, Switzerland; Insel Hosp Bern, Dept Radiol, Bern, Switzerland; Univ Hosp Vienna, Dept Anesthesiol & Intens Care, Vienna, Austria; Univ Bern, Dept Clin Res Magnet Resonance Spectroscopy & M, Bern, Switzerland; Rhein Westfal TH Univ, Inst Neuropathol, Aachen, Germany		Yen, K (corresponding author), Med Univ Graz, Ctr Clin Theoret Med, Dept Forens Radiol, Harrachgasse 21, A-8010 Graz, Austria.	kathrin.yen@medtini-graz.at	Scheurer, Eva/C-6536-2011; Scheurer, Eva/AAE-6161-2019; Weis, Joachim/G-1984-2014	Scheurer, Eva/0000-0002-2742-0422; Weis, Joachim/0000-0003-3280-6773; lovblad, karl-olof/0000-0003-2768-9779			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Aghayev E, 2004, NEURORADIOLOGY, V46, P559, DOI 10.1007/s00234-004-1212-4; Bardainne M, 1996, ARCH PEDIATRIE, V3, P661, DOI 10.1016/0929-693X(96)87086-2; Blamire AM, 1999, ACTA RADIOL, V40, P593, DOI 10.3109/02841859909175593; BOYKO OB, 1994, ARCH PATHOL LAB MED, V118, P219; Brogdon, 1998, FORENSIC RADIOLOGY; Brookes JAS, 1996, LANCET, V348, P1139, DOI 10.1016/S0140-6736(96)02287-8; DONCHIN Y, 1994, J TRAUMA, V37, P552, DOI 10.1097/00005373-199410000-00006; Englund E, 2004, J NEUROL, V251, P350, DOI 10.1007/s00415-004-0318-2; Ezawa H, 2003, PATHOL INT, V53, P865, DOI 10.1046/j.1440-1827.2003.01573.x; Griffiths PD, 2003, AM J NEURORADIOL, V24, P22; HARRIS LS, 1991, FORENSIC SCI INT, V50, P179, DOI 10.1016/0379-0738(91)90149-D; Hart BL, 1996, AM J FOREN MED PATH, V17, P217, DOI 10.1097/00000433-199609000-00008; IWAMA T, 1994, NEURORADIOLOGY, V36, P33, DOI 10.1007/BF00599191; Iwase H, 1998, FORENSIC SCI INT, V94, P9, DOI 10.1016/S0379-0738(98)00055-3; Jackowski C, 2005, J FORENSIC SCI, V50, P1175; Lovblad KO, 2006, EUR RADIOL, V16, P1253, DOI 10.1007/s00330-005-0103-3; Lovblad KO, 2000, STROKE, V31, P539, DOI 10.1161/01.STR.31.2.539; LUDWIG B, 1983, AM J NEURORADIOL, V4, P27; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; Messori A, 2003, STROKE, V34, P376, DOI 10.1161/01.STR.0000055022.86811.10; Myers JC, 1999, INT J LEGAL MED, V113, P33, DOI 10.1007/s004140050275; *NEUR GROUP MRC CF, 2004, APPL NEUROBIOL, V30, P385; Oliver J, 1999, Australas Radiol, V43, P37, DOI 10.1046/j.1440-1673.1999.00615.x; Orakcioglu B, 2005, EXP NEUROL, V193, P369, DOI 10.1016/j.expneurol.2005.01.017; OZDOBA C, 2004, AM J NEURORADIOL, V47, P411; PAPE KE, 1983, J PEDIATR-US, V102, P275, DOI 10.1016/S0022-3476(83)80543-5; Paperno S, 2005, ROFO-FORTSCHR RONTG, V177, P130, DOI 10.1055/s-2004-813735; Parizel PM, 2002, INTENS CARE MED, V28, P85, DOI 10.1007/s00134-001-1160-y; Patriquin L, 2001, J MAGN RESON IMAGING, V13, P277, DOI 10.1002/1522-2586(200102)13:2<277::AID-JMRI1040>3.0.CO;2-W; ROS PR, 1990, MAGN RESON IMAGING, V8, P303, DOI 10.1016/0730-725X(90)90103-9; SCHUMACHER M, 1983, FORTSCHR RONTG NEUEN, V139, P58, DOI 10.1055/s-2008-1055840; Schumacher M, 1985, Beitr Gerichtl Med, V43, P95; Shen W C, 1993, Gaoxiong Yi Xue Ke Xue Za Zhi, V9, P690; Stein KM, 2000, INT J LEGAL MED, V114, P15, DOI 10.1007/s004149900124; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; SUNGSTROM T, 2005, TIDSSKR NOR LAEGEFOR, V125, P1310; Thali MJ, 2003, FORENSIC SCI INT, V138, P8, DOI 10.1016/S0379-0738(03)00225-1; Thali MJ, 2003, J FORENSIC SCI, V48, P386; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; von Wild KRH, 2005, ACTA NEUROCHIR SUPPL, V93, P15; WALLACE SK, 1994, RADIOLOGY, V193, P263, DOI 10.1148/radiology.193.1.8090904; WHITBY EH, 2005, IMAGING FETUS ADJUNC; Woodward PJ, 1997, AM J ROENTGENOL, V168, P41, DOI 10.2214/ajr.168.1.8976917; Yen K, 2006, AM J NEURORADIOL, V27, P70; Yen K, 2005, INT J LEGAL MED, V119, P129, DOI 10.1007/s00414-004-0507-7; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	48	99	108	0	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	NOV 15	2007	173	1					21	35		10.1016/j.forsciint.2007.01.027			15	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	220YM	WOS:000250193300004	17336008				2022-02-06	
J	Chen, G; Shi, JX; Hang, CH; Me, WY; Liu, J; Liu, XM				Chen, Gang; Shi, Ji Xin; Hang, Chun Hua; Me, Weiying; Liu, Jian; Liu, Xiaoming			Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: A potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO)	NEUROSCIENCE LETTERS			English	Article						erythropoietin; traumatic brain injury; cerebral inflammation	NF-KAPPA-B; EXPRESSION; ISCHEMIA; APOPTOSIS; BARRIER; EDEMA	Erythropoietin (EPO) has recently been shown to have a neuroprotective effect in animal models of traumatic brain injury (TBI). However, the precise mechanisms remain unclear. Cerebral inflammation plays an important role in the pathogenesis of secondary brain injury after TBI. We, therefore, tried to analyze how recombinant human erythropoietin (rhEPO) might effect the inflammation-related factors common to TBI: nuclear factor kappa B (NF-kappa B), interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM- 1) in a rat TBI model. Male rats were given 0 or 5000 units/kg injections of rhEPO I It post-injury and on days 1, 2 and 3 after surgery. Brain samples were extracted at 3 days after trauma. We measured NF-kappa B by electrophoretic mobility shift assay (EMSA); IL-1 beta, TNF-alpha and IL-6 by enzyme-linked immunosorbent assay (ELISA); ICAM- I by immunohistochemistry; brain edema by wet/dry method; blood-brain barrier (BBB) permeability by Evans blue extravasation and cortical apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method. We found that NF-kappa B, pro-inflammatory cytokines and ICAM-1 were increased in all injured animals. In animals given rhEPO post-TBI, NF-kappa B, IL-1 beta, TNF-alpha and ICAM-I were decreased in comparison to vehicle-treated animals. Measures of IL-6 showed no change after rhEPO treatment. Administration of rhEPO reduced brain edema, BBB permeability and apoptotic cells in the injured brain. In conclusion, post-TBI rhEPO administration may attenuate inflammatory response in the injured rat brain, and this may be one mechanism by which rhEPO improves outcome following TBI. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; Nanjing Univ, Sch Med, Jinling Hosp, Dept Anaesthesiol, Nanjing 210002, Jiangsu, Peoples R China		Chen, G (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	nju_neurosurgery@163.com		Chen, Gang/0000-0002-0758-1907			Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beaumont A, 2002, ACT NEUR S, V81, P217; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Conti AC, 1998, J NEUROSCI, V18, P5663; Erbayraktar S, 2006, MOL MED, V12, P74, DOI 10.2119/2006-00042.Erbayraktar; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Keswani SC, 2004, NEUROSCI LETT, V371, P102, DOI 10.1016/j.neulet.2004.08.080; Liu XM, 2006, LIFE SCI, V78, P2255, DOI 10.1016/j.lfs.2005.09.053; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Okutan O, 2007, J CLIN NEUROSCI, V14, P364, DOI 10.1016/j.jocn.2006.01.022; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Spandou E, 2004, NEUROSCI LETT, V366, P24, DOI 10.1016/j.neulet.2004.05.032; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Vink R, 2003, ACT NEUR S, V86, P257; Xie WY, 2006, NEUROSCI LETT, V393, P255, DOI 10.1016/j.neulet.2005.09.077; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yidirim E, 2005, J TRAUMA, V58, P1252, DOI 10.1097/01.TA.0000169803.09482.F8; Yu YP, 2005, NEUROSCI LETT, V387, P5, DOI 10.1016/j.neulet.2005.07.008	32	99	104	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 2	2007	425	3					177	182		10.1016/j.neulet.2007.08.022			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	224ET	WOS:000250431000009	17825990				2022-02-06	
J	Newcombe, VFJ; Williams, GB; Nortje, J; Bradley, PG; Harding, SG; Smielewski, P; Coles, JP; Maiya, B; Gillard, JH; Hutchinson, PJ; Pickard, JD; Carpenter, TA; Menon, DK				Newcombe, V. F. J.; Williams, G. B.; Nortje, J.; Bradley, P. G.; Harding, S. G.; Smielewski, P.; Coles, J. P.; Maiya, B.; Gillard, J. H.; Hutchinson, P. J.; Pickard, J. D.; Carpenter, T. A.; Menon, D. K.			Analysis of acute traumatic axonal injury using diffusion tensor imaging	BRITISH JOURNAL OF NEUROSURGERY			English	Article						traumatic axonal injury (TAI); traumatic brain injury (TBI); diffusion tensor imaging (DTI); magnetic resonance imaging (MRI)	WHITE-MATTER INJURY; CLOSED-HEAD INJURY; BRAIN-INJURY; PRACTICAL SCALE; MRI; SEVERITY; SCORE; NEUROPATHOLOGY; DISCONNECTION; COEFFICIENT	Traumatic axonal injury (TAI) contributes significantly to mortality and morbidity following traumatic brain injury (TBI), but is poorly characterized by conventional imaging techniques. Diffusion tensor imaging (DTI) may provide better detection as well as insights into the mechanisms of white matter injury. DTI data from 33 patients with moderate-to-severe TBI, acquired at a median of 32 h postinjury, were compared with data from 28 age-matched controls. The global burden of whole brain white matter injury (GB(WMI)) was quantified by measuring the proportion of voxels that lay below a critical fractional anisotropy (FA) threshold, identified from control data. Mechanisms of change in FA maps were explored using an Eigenvalue analysis of the diffusion tensor. When compared with controls, patients showed significantly reduced mean FA (P < 0.001) and increased apparent diffusion coefficient (ADC; p = 0.017). GB(WMI) was significantly greater in patients than in controls (p < 0.01), but did not distinguish patients with obvious white matter lesions seen on structural imaging. It predicted classification of DTI images as head injury with a high degree of accuracy. Eigenvalue analysis showed that reductions in FA were predominantly the result of increases in radial diffusivity (p < 0.001). DTI may help quantify the overall burden of white matter injury in TBI and provide insights into underlying pathophysiology. Eigenvalue analysis suggests that the early imaging changes seen in white matter are consistent with axonal swelling rather than axonal truncation. This technique holds promise for examining disease progression, and may help define therapeutic windows for the treatment of diffuse brain injury.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Univ Div Anaesthesia, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Radiol, Cambridge, England		Williams, GB (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 65,Hills Rd, Cambridge CB2 2QQ, England.	gbwlOOO@wbic.cam.ac.uk		Newcombe, Virginia/0000-0001-6044-9035; Smielewski, Peter/0000-0001-5096-3938; Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390, G0001237, G0600986] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986, G0001237, G0601025] Funding Source: UKRI		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BENNETT M, 1995, IRISH MED J, V88, P59; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Graham DI, 2005, NEUROPSYCHOL REHABIL, V15, P198, DOI 10.1080/09602010443000452; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kawamata T, 2002, ACTA NEUROCHIR SUPPL, V81, P281; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MEDA SA, 2006, P INT SOC MAG RESON, V14, P2712; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Papadakis NG, 1999, J MAGN RESON, V137, P67, DOI 10.1006/jmre.1998.1673; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schaefer P W, 2000, Top Magn Reson Imaging, V11, P300, DOI 10.1097/00002142-200010000-00006; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Smith RB, 2002, NEUROREHABILITATION, V17, P3; TEASDALE G, 1974, LANCET, V2, P81; WAGNER DP, 1984, MED DECIS MAKING, V4, P297, DOI 10.1177/0272989X8400400305; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	37	99	100	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	AUG	2007	21	4					340	348		10.1080/02688690701400882			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	207JJ	WOS:000249247100007	17676452				2022-02-06	
J	Zhang, ZQ; Ottens, AK; Sadasivan, S; Kobeissy, FH; Fang, T; Hayes, RL; Wang, KKW				Zhang, Zhiqun; Ottens, Andrew K.; Sadasivan, Shankar; Kobeissy, Firas H.; Fang, Tie; Hayes, Ronald L.; Wang, Kevin K. W.			Calpain-mediated collapsin response mediator protein-1,-2, and-4 proteolysis after neurotoxic and traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						calpain; CRMP; excitotoxicity; proteolysis; TBI	CULTURED HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; CELL-DEATH; NEUROBLASTOMA-CELLS; SIGNALING PATHWAYS; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; RHO-KINASE; CRMP-2; RAT	Collapsin response mediator proteins (CRMPs) are important molecules in neurite outgrowth and axonal guidance. Within the CRMP family, CRMP-2 has been implicated in several neurological diseases (Alzheimer's, epilepsy, and ischemia). Here, we investigated the integrity of CRMPs (CRMP-1, -2, -4, -5) after in vitro neurotoxin treatment and in vivo traumatic brain injury (TBI). After maitotoxin (MTX) and NMDA treatment of primary cortical neurons, a dramatic decrease of intact CRMP-1, -2 and -4 proteins were observed, accompanied by the appearance of distinct 55-kDa and 58-kDa breakdown products (BDP) for CRMP-2 and -4, respectively. Inhibition of calpain activation prevented NMDA-induced CRMP-2 proteolysis and redistribution of CRMP-2 from the neurites to the cell body, while attenuating neurite damage and neuronal cell injury. Similarly, CRMP-1, -2, and -4 were also found degraded in rat cortex and hippocampus following controlled cortical impact (CCI), an in vivo model of TBI. The appearance of the 55-kDa CRMP-2 BDP was observed to increase, in a time-dependent manner, between 24 and 48 h in the ipsilateral cortex, and by 48 hours in the hippocampus. The observed 55-kDa CRMP-2 BDP following TBI was reproduced by in vitro incubation of naive brain lysate with activated calpain-2, but not activated caspase-3. Sequence analysis revealed several possible cleavage sites near the C-terminus of CRMP-2. Collectively, this study demonstrated that CRMP-1, -2, and -4 are degraded following both acute traumatic and neurotoxic injury. Furthermore, calpain-2 was identified as the possible proteolytic mediator of CRMP-2 following excitotoxic injury and TBI, which appears to correlate well with neuronal cell injury and neurite damage. It is possible that the calpain-mediated truncation of CRMPs following TBI may be an inhibiting factor for post-injury neurite regeneration.	Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, Gainesville, FL 32610 USA		Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, POB 100256,100 W Newell Dr, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017; Ottens, Andrew/K-3352-2012; Sadasivan, Shankar/C-9620-2009	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01-A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER		Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Araujo IM, 2004, J NEUROCHEM, V91, P1322, DOI 10.1111/j.1471-4159.2004.02811.x; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Barzilai A, 2000, ADV RES NEURODEGENER, V8, P59; Bretin S, 2005, J COMP NEUROL, V486, P1, DOI 10.1002/cne.20465; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Chiesa R, 1998, J NEUROCHEM, V70, P1474; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Czech T, 2004, NEUROCHEM RES, V29, P2189, DOI 10.1007/s11064-004-7025-3; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hou ST, 2006, J NEUROSCI, V26, P2241, DOI 10.1523/JNEUROSCI.4485-05.2006; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Johnston-Wilson NL, 2000, MOL PSYCHIATR, V5, P142, DOI 10.1038/sj.mp.4000696; Khawaja X, 2004, J NEUROSCI RES, V75, P451, DOI 10.1002/jnr.10869; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Kowara R, 2005, J NEUROCHEM, V95, P466, DOI 10.1111/j.1471-4159.2005.03383.x; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Liu CP, 2003, ACTA PHARMACOL SIN, V24, P1205; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Llansola M, 2000, J PHARMACOL EXP THER, V292, P870; Lopez-Picon FR, 2006, EUR J NEUROSCI, V23, P2686, DOI 10.1111/j.1460-9568.2006.04793.x; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; Mizuno N, 1998, ENDOCRINOLOGY, V139, P1429, DOI 10.1210/en.139.3.1429; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; POHORECKI R, 1990, BRAIN RES, V528, P133, DOI 10.1016/0006-8993(90)90205-P; Quach TT, 2004, MOL CELL NEUROSCI, V25, P433, DOI 10.1016/j.mcn.2003.11.006; Riss TL, 2004, ASSAY DRUG DEV TECHN, V2, P51, DOI 10.1089/154065804322966315; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schweitzer J, 2005, GENE EXPR PATTERNS, V5, P809, DOI 10.1016/j.modgep.2005.03.009; Tahimic CGT, 2006, BIOCHEM BIOPH RES CO, V340, P1244, DOI 10.1016/j.bbrc.2005.12.132; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Weitzdoerfer R, 2001, J NEURAL TRANSM-SUPP, P95; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang Z, 2006, CELL MOL BIOL LETT, V11, P12, DOI 10.2478/s11658-006-0002-x	58	99	102	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2007	24	3					460	472		10.1089/neu.2006.0078			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	152RQ	WOS:000245379900003	17402852				2022-02-06	
J	Goodrich, GL; Kirby, J; Cockerham, G; Ingalla, SP; Lew, HL				Goodrich, Gregory L.; Kirby, Jennine; Cockerham, Glenn; Ingalla, Shanida P.; Lew, Henry L.			Visual function in patients of a polytrauma rehabilitation center: A descriptive study	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						adult; blast injury; brain injury; mechanism of injury; ocular refraction; polytrauma; rehabilitation; vision; visual impairment; visual perception	TRAUMATIC BRAIN-INJURY; LOW-VISION; IMPAIRMENT; CARE; OUTCOMES; HEALTH; IMPACT	Little is known about the visual function deficits associated with polytrauma injury. In this retrospective descriptive study, we examined the records of a clinic established to assess visual function in patients experiencing deployment-related polytrauma. We describe the clinical findings and present a vision examination protocol that may be useful for screening polytrauma patients in other settings. Data from our sample suggested that self-reported vision complaints were common (74%) and confirmed that visual impairment occurred in 38% of all cases. When examining the mechanism of injury, we found that polytrauma due to blast injuries appeared to more than double the risk of visual impairment compared with all other polytrauma causes (i.e., motor vehicle accidents, gunshot and/or shrapnel, assault, falls, or anoxia). The rate of visual impairment in blast-related injury was 52% compared with 20% for all other sources of injury. Visual complaints and impairments were common in the polytrauma patients studied. This finding suggests that comprehensive eye examinations should be routinely administered, particularly when the mechanism of injury involves a blast.	[Goodrich, Gregory L.; Kirby, Jennine] VAPAHCS, Psychol Serv, Palo Alto, CA 94304 USA; [Goodrich, Gregory L.; Kirby, Jennine] VAPAHCS, Western Blind Rehabil Ctr, Palo Alto, CA 94304 USA; [Cockerham, Glenn; Ingalla, Shanida P.] VAPAHCS, Ophthalmol Serv, Palo Alto, CA 94304 USA; [Cockerham, Glenn; Lew, Henry L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Lew, Henry L.] VAPAHCS, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA		Goodrich, GL (corresponding author), VAPAHCS, Psychol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	Gregory.Goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019				Biehl JW, 1999, MIL MED, V164, P780, DOI 10.1093/milmed/164.11.780; Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27; GIANUTSOS R, 1997, FUNCTIONAL VISUAL BE, P267; Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595; Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633; JACK CIA, 1995, GERONTOLOGY, V41, P280; Jacobs JM, 2005, AGING CLIN EXP RES, V17, P281; Kerkhoff G, 2000, J NEUROL NEUROSUR PS, V68, P691, DOI 10.1136/jnnp.68.6.691; Lee DJ, 2005, OPHTHAL EPIDEMIOL, V12, P13, DOI 10.1080/09286580490907751; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Morse AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P943; Nguyen Quan Dong, 2002, International Ophthalmology Clinics, V42, P167, DOI 10.1097/00004397-200207000-00018; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Stelmack JA, 2006, INVEST OPHTH VIS SCI, V47, P3253, DOI 10.1167/iovs.05-1319; WARD TP, 1999, OPHTHALMOL CLIN N AM, V12, P421; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2; ZIHL J, 1989, NEUROPSYCHOLOGY VISU, P35	19	99	101	1	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					929	936		10.1682/JRRD.2007.01.0003			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	253NL	WOS:000252524800006	18075950	Bronze			2022-02-06	
J	Gilbert, A; Pivato, G; Kheiralla, T				Gilbert, A; Pivato, G; Kheiralla, T			Long-term results of primary repair of brachial plexus lesions in children	MICROSURGERY			English	Article							SURGICAL-TREATMENT; BIRTH PALSY	The results of brachial plexus reconstruction in adults are poor, despite the sophistication of the various methods used. However, the same methods used in neonates after obstetrical brachial plexus injury will give far better results. because of the shorter distance, stronger potential of regeneration, and capacity of brain adaptation. Complete paralyses, associated root ruptures, and avulsions are very severe, and the end results cannot be evaluated before the end of growth. Although the end results show that the shoulder and elbow do not do as well as in upper-type lesions, the results at the level of the hand are encouraging, showing 75% with useful function after 8 years, even in patients with avulsion injuries of the lower roots. These results demonstrate the value of the early exploration and repair of the obstetric plexus. We also review our series of traumatic brachial plexus palsy in children. The results are poorer than in neonates, where may be related, in part, to a greater percentage of associated lesions in these patients. (c) 2006 Wiley-Liss, Inc.	Inst Main, F-75016 Paris, France		Gilbert, A (corresponding author), Inst Main, 6 Sq Jouvenet, F-75016 Paris, France.	agilbert@wanadoo.fr					ALNOT JY, 1977, REV CHIR ORTHOP, V63, P5; ALQUATTAN MM, 1994, J HAND SURG-BRIT, V19, P673; DUMONTIER C, 1990, Annales de Chirurgie de la Main et du Membre Superieur, V9, P351, DOI 10.1016/S0753-9053(05)80508-3; El-Gammal TA, 2003, MICROSURG, V23, P14, DOI 10.1002/micr.10084; Erb W, 1874, NATURHIST MED VER HE, V2, P130; GILBERT A, 1984, CHIRURGIE, V110, P70; GILBERT A, 1991, CLIN ORTHOP RELAT R, P39; Gupta KS, 2000, GROWING HAND DIAGNOS, P653; HAERLE M, 2003, J PEDIATR ORTHOPED, V23, P1; KAWABATA H, 1987, CLIN ORTHOP RELAT R, P233; KENNEDY B, 1903, BRIT MED J, V1, P298; Klumpke A, 1885, REV MED-PARIS, V5, P591; Merle dAubigne R, 1967, REV CHIR ORTHOP, V53, P23; Narakas A, 1982, Ann Chir Main, V1, P101, DOI 10.1016/S0753-9053(82)80066-5; Rigault P, 1969, Rev Chir Orthop Reparatrice Appar Mot, V55, P125; SEDEL L, 1977, REV CHIR ORTHOP, V63, P651; TASSIN JL, 1984, PARALYSIES OBSTETRIC; TERZIS JK, 1986, HAND CLIN, V2, P773	18	99	107	0	2	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0738-1085			MICROSURG	Microsurgery		2006	26	4					334	342		10.1002/micr.20248			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	050FG	WOS:000238072300018	16634084				2022-02-06	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M				Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M			Human marrow stromal cell treatment provides long-lasting benefit after traumatic brain injury in rats	NEUROSURGERY			English	Article						functional improvement; human marrow stromal cells; traumatic brain injury	ADULT RATS; STEM-CELLS; FUNCTIONAL RECOVERY; TRANSPLANTATION; NEUROTROPHINS; DIFFERENTIATION; EXPRESSION; SURVIVAL; THERAPY; MODEL	OBJECTIVE: This study was designed to investigate the effects of human bone marrow stromal cell (hMSC) administration in rats for 3 months after traumatic brain injury (TBI). METHODS: Adult male Wistar rats (n = 60) were injured with controlled cortical impact and divided into four groups. The three treatment groups (n = 10 each) were injected with 2 X 10(6), 4 X 10(6), and 8 X 10(6) hMSCs, respectively, intravenously, whereas the control group (n = 30) received phosphate-buffered saline. All injections were performed 1 day after injury into the tail veins of rats. Neurological functional evaluation of animals was performed before and after injury by use of Neurological Severity Scores. Animals were sacrificed 3 months after TBI, and brain sections were stained by immunohistochernistry. RESULTS: Statistically significant improvement in functional outcome was observed in all three treatment groups compared with control values (P < 0.05). This benefit was visible 14 days after TBI and persisted until 3 months (end of trial). There was no difference in functional outcome among the three treatment groups. Histological analysis showed that hMSCs were present in the lesion boundary zone at 3 months with all three doses tested. CONCLUSION: hMSCs injected in rats after TBI survive until 3 months and provide long-lasting functional benefit. Functional improvement may be attributed to stimulation of endogenous neurorestorative functions such as neurogenesis and synaptogenesis.	Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259, P01NS042345] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS042345, P01 NS042345-01A20002, R01 NS042259-04] Funding Source: Medline		Borlongan CV, 1996, NEUROL RES, V18, P297; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MEMBERG SP, 1995, MOL CELL NEUROSCI, V6, P323, DOI 10.1006/mcne.1995.1025; Newman MP, 2000, NEUROSCIENCE, V99, P343, DOI 10.1016/S0306-4522(00)00194-9; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Postmantur R., 1997, NEUROSCIENCE, V77, P765; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Song S, 2004, EXP NEUROL, V185, P191, DOI 10.1016/j.expneurol.2003.09.003; VESELY DL, 1992, RENAL PHYSIOL BIOCH, V15, P23; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	26	99	106	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2005	57	5					1026	1030		10.1227/01.NEU.0000181369.76323.50			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	982PF	WOS:000233173400044	16284572	Green Accepted			2022-02-06	
J	Bazarian, JJ; McClung, J; Cheng, YT; Flesher, W; Schneider, SM				Bazarian, JJ; McClung, J; Cheng, YT; Flesher, W; Schneider, SM			Emergency department management of mild traumatic brain injury in the USA	EMERGENCY MEDICINE JOURNAL			English	Article							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; PAIN MANAGEMENT; FOLLOW-UP; EFNS	Objective: To describe the emergency department (ED) management of isolated mild traumatic brain injury (TBI) in the USA and to examine variation in care across age and insurance types. Methods: A secondary analysis of ED visits for isolated mild TBI in the National Hospital Ambulatory Medical Care Survey 1998-2000 was performed. Mild TBI was defined by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes for skull fracture, concussion, intracranial injury (unspecified), and head injury (unspecified). Available ED care variables were analysed by patient age and insurance categories using multivariate logistic regression. Results: The incidence of isolated mild TBI cases attending ED was 153 296 per year, or 56.4/100000 people. Of the patients with isolated mild TBI, 44.3% underwent computed tomography, 23.9% underwent other non-extremity, non-chest x rays, 17.1% received wound care and 14.1% received intravenous fluids. However, only 43.8% had an assessment of pain. Of those with documented pain, only 45.5% received analgesics in the ED. Nearly 38% were discharged without recommendations for specific follow up. Several aspects of ED care varied by age but not by insurance type. Conclusion: Substantial ED resources are devoted to the care of isolated mild TBI. The present study identified deficiencies in and variation around several important aspects of ED care. The development of guidelines specific for mild TBI could reduce variation and improve emergency care for this injury.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; Hosp Max Peralta, San Jose, Costa Rica; Univ Rochester, Med Ctr, Dept Community & Prevent Med, Rochester, NY 14642 USA		Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 K23 NS 41952-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER		Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Centers for Disease Control and Prevention National Center for Health Statistics, NAT HOSP AMB MED CAR; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; FIELD MJ, 1992, NATL ACAD SCI, P1; Gutu V, 2000, J EMERG MED, V18, P7, DOI 10.1016/S0736-4679(99)00153-5; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Jay G W, 1996, J Insur Med, V27, P262; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; Von Wild K, 2001, BRAIN INJURY, V15, P273; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	36	99	99	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	JUL 1	2005	22	7					473	477		10.1136/emj.2004.019273			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	939ZO	WOS:000230113300005	15983080	Green Published, Bronze			2022-02-06	
J	Gall, B; Parkhouse, W; Goodman, D				Gall, B; Parkhouse, W; Goodman, D			Heart rate variability of recently concussed athletes at rest and exercise	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						uncoupling; spectral analysis; autonomic nervous system; cardiovascular system	TRAUMATIC BRAIN INJURY; AUTONOMIC CONTROL; DYSFUNCTION; SYMPTOMS	Purpose: The objective of this study was to assess the neuroautonomic cardiovascular regulation in recently concussed athletes at rest and in response to low-moderate steady-state exercise, using heart rate variability (HRV). Methods: A 5-min ECG sample was taken at rest from the 14 concussed athletes at 1.8 (+/- 0.2) days postinjury and again at 5 d later. Once asymptomatic at rest, the concussed athletes and their matched controls (N = 14) participated in an exercise protocol. The protocol consisted of a 2-min warm-up with a pedaling frequency between 50 and 60 rpm against a load of 40 W. After the warm-up, the athletes engaged in a low-moderate intensity steady state 10-min exercise bout where the pedaling frequency and load increased to 80-90 rpm and 1.5 W(.)kg(-1) body weight, respectively. The protocol was repeated 5 d later. A 5-min ECG sample from minutes 4 to 9 of the low-moderate intensity steady state exercise bout was used to assess HRV during exercise. Mixed model ANOVA were used to analyze the data. Results: No difference at rest was detected between the concussed athletes and their matched controls in any of the HRV variables measured. However, across both exercise tests, the concussed group demonstrated a significant decrease in the mean RR interval, and low- and high-frequency power (P < 0.05) in relation to their matched controls. Conclusion: Low-moderate steady-state exercise elicits a neuroautonomic cardiovascular dysfunction in concussed athletes that is not present in a rested state. This dysfunction alludes to an exercise induced uncoupling between the autonomic and cardiovascular systems.	Simon Fraser Univ, Sch Kinesiol, Burnaby, BC V5A 1S6, Canada		Parkhouse, W (corresponding author), Simon Fraser Univ, Sch Kinesiol, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	parkhous@sfu.ca					AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BREUER HWM, 1993, BRIT HEART J, V70, P144; Camm AJ, 1996, CIRCULATION, V93, P1043; *CAN HOCK ASS, 1999, GAT CAN HOCK SAF PRO, P85; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Cerutti S, 1995, HEART RATE VARIABILI, P63; FARDY PS, 1969, RES QUART, V40, P502, DOI 10.1080/10671188.1969.10614869; Fries I, 1998, J APICULT RES, V37, P85, DOI 10.1080/00218839.1998.11100959; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goldsmith RL, 2000, CORONARY ARTERY DIS, V11, P129, DOI 10.1097/00019501-200003000-00007; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1996, ACTA NEUROL SCAND, V94, P337, DOI 10.1111/j.1600-0404.1996.tb07076.x; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; Meglic B, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000047605; Mujika I, 2001, MED SCI SPORT EXER, V33, P413, DOI 10.1097/00005768-200103000-00013; NAKAMURA Y, 1993, J APPL PHYSIOL, V74, P875, DOI 10.1152/jappl.1993.74.2.875; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967, DOI 10.1152/ajpheart.1990.258.4.H967; RIMOLDI O, 1992, CHEST, V101, pS226, DOI 10.1378/chest.101.5.226S	26	99	102	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2004	36	8					1269	1274		10.1249/01.MSS.0000135787.73757.4D			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	843XC	WOS:000223119300001	15292731				2022-02-06	
J	Savola, O; Hillbom, M				Savola, O; Hillbom, M			Early predictors of post-concussion symptoms in patients with mild head injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						mild head injury; post-concussion symptoms; protein S-100B	S-100 PROTEIN MEASUREMENTS; TRAUMATIC BRAIN INJURY; POSTCONCUSSION SYMPTOMS; EPIDEMIOLOGY; INTOXICATION; MODERATE; ALCOHOL; DAMAGE; WORK	A small proportion of patients with mild head injury (MHI) develop post-concussion symptoms (PCSs). We searched simple measures for the early detection of patients who are probable to develop PCSs. We recorded signs and symptoms, history of previous diseases, medications, and lifestyle factors and measured serum protein S-100B on admission in a series of 172 consecutive MHI patients admitted into the emergency room of a general hospital. A modified Rivermead Post-Concussion Symptoms Questionnaire was used to identify the patients with and without PCSs 1 month after the injury. We identified 37 patients with MHI who developed PCSs (22%). Odds ratios (OR) and 95% confidence intervals (CI) after adjustment for possible confounding variables were calculated by logistic regression. Independent early risk factors for PCSs in the MHI patients were skull fracture (OR 8.0, 95% CI 2.6-24.6), serum protein S-100B greater than or equal to 0.50 mug/l (OR 5.5, 95% CI 1.6-18.6), dizziness (OR 3.1, 95% CI 1.2-8.0), and headache (OR 2.6, 95% CI 1.0-6.5). Serum protein S-100B proved to be a specific, but not sensitive predictor of PCSs. The presence of skull fracture, elevated serum protein S-100B, dizziness, and headache may help the emergency room physician to identify patients at risk of PCSs and to refer them for further examination and follow-up.	Oulu Univ Hosp, Dept Neurol, FIN-90029 Oulu, Finland		Hillbom, M (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, FIN-90029 Oulu, Finland.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DACEY RG, 1986, J NEUROSURG, V65, P302; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DICMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P315; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	35	99	102	0	7	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAR	2003	10	2					175	181		10.1046/j.1468-1331.2003.00552.x			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	649VZ	WOS:000181229800009	12603294				2022-02-06	
J	Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH				Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH			Overexpression of SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating mitochondrial cytochrome c release	FASEB JOURNAL			English	Article						superoxide dismutase; superoxide; reactive oxygen species; caspase-9	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; CASPASE-3 APOPTOTIC CASCADE; CUZN-SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; GLIAL APOPTOSIS; UP-REGULATION; MOUSE MODEL	Defective Cu,Zn-superoxide dismutase (SOD1) is responsible for some types of amyotrophic lateral sclerosis, and ventral horn motor neurons (VMN) have been shown to die through a mitochondria-dependent apoptotic pathway after chronic exposure to high levels of reactive oxygen species (ROS). VMN are also selectively vulnerable to mild spinal cord injury (SCI); however, the involvement of SOD1, ROS, and apoptosis in their death has not been clarified. Mild compression SCI was induced in SOD1-overexpressing transgenic rats and wild-type littermates. Superoxide production, mitochondrial release of cytochrome c, and activation of caspase-9 were examined, and apoptotic DNA injury was also characterized. In the wild-type animals, increased superoxide production, mitochondrial release of cytochrome c, and cleaved caspase-9 were observed exclusively in VMN after SCI. Subsequently, a majority of VMN (75%) selectively underwent delayed apoptotic cell death. Transgenic animals showed less superoxide production, mitochondrial cytochrome c release, and caspase-9 activation, resulting in death of only 45% of the VMN. These results suggest that the ROS-initiated mitochondrial signaling pathway possibly plays a pivotal role in apoptotic VMN death after SCI and that increased levels of SOD1 in VMN reduce oxidative stress, thereby attenuating the activation of the pathway and delayed cell death.	Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Sch Med, Stanford, CA 94305 USA		Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, 1201 Welch Rd,MSLS P314, Stanford, CA 94305 USA.	phchan@leland.stanford.edu	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Yu, Fengshan/0000-0001-8620-3084			Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Buki A, 2000, J NEUROSCI, V20, P2825; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chan PH, 1996, ADV NEUROL, V71, P271; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 1997, J NEUROSCI, V17, P9172; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P1690, DOI 10.1097/00004647-200012000-00008; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Launey T, 1998, BRAIN RES, V781, P148, DOI 10.1016/S0006-8993(97)01225-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XZ, 1997, J NEUROSCI, V17, P5395; Murakami K, 1998, J NEUROSCI, V18, P205; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan WH, 1999, J NEUROSCI, V19, P3649; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RINK A, 1995, AM J PATHOL, V147, P1575; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSS IB, 1993, NEUROSURGERY, V33, P470; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; SUGAWARA T, 2002, IN PRESS J NEUROSCI; Terro F, 1998, BRAIN RES, V809, P319, DOI 10.1016/S0006-8993(98)00883-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	53	99	100	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1997	+		10.1096/fj.02-0251fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	WOS:000179167600024	12368231				2022-02-06	
J	Kobori, N; Clifton, GL; Dash, PK				Kobori, N; Clifton, GL; Dash, PK			Altered expression of novel genes in the cerebral cortex following experimental brain injury	MOLECULAR BRAIN RESEARCH			English	Article						microarray; traumatic brain injury; real-time PCR; mRNA	CORTICAL IMPACT INJURY; NERVE GROWTH-FACTOR; MESSENGER-RNA; AMYLOID-BETA; C-FOS; NEUROTROPHIC FACTOR; CELL-GROWTH; RAT-BRAIN; PROTEIN; TRANSTHYRETIN	Damage to the cerebral cortex results in neurological impairments such as motor, attention, memory and executive dysfunctions. To examine the molecular mechanisms contributing to these deficits, mRNA expression was profiled using high-density cDNA microarray hybridization after experimental cortical impact injury in mice. The mRNA levels at 2 h 6 h, 24 h, 3 days and 14 days after injury were compared with those of control animals. This revealed 86 annotated genes and 24 expression sequence tags (ESTs) as being differentially expressed with a 1.5-fold or greater change. Quantitative real-time PCR analysis was used to independently verify these results for selected genes. Seven functional classes of genes were found to be altered following injury, including transcription factors, signal transduction genes and inflammatory proteins. While a few of these genes have been previously reported to be differentially regulated following injury, the most of the genes have not been previously implicated in traumatic brain injury (TBI) pathophysiology. For example, consistent with previous reports, the transcription factor c-jun and the neurotrophic factor bdnf mRNA levels were altered as a result of TBI. Among the novel genes, the mRNA levels for the high mobility group protein I (hmg-1), the regulator of G-protein signaling 2 (rgs-2), the transforming growth factor P inducible early growth response (tieg), the inhibitor of DNA binding 3 (id3), and the heterogeneous nuclear ribonucleoprotein H (hnrnp h) were changed following injury. The functional significance of these genes in neurite outgrowth, neuronal regeneration, and plasticity following injury are discussed. (C) 2002 Published by Elsevier Science B.V.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol, Houston, TX 77255 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Anat, Houston, TX 77255 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol, POB 20708, Houston, TX 77255 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327, R01NS035457] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P050NS23327, NS35457] Funding Source: Medline		Brown AJP, 2001, EMBO J, V20, P3177, DOI 10.1093/emboj/20.12.3177; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Cavallaro S, 2001, EUR J NEUROSCI, V13, P1809, DOI 10.1046/j.0953-816x.2001.01543.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chou DKH, 2001, J NEUROCHEM, V77, P120, DOI 10.1046/j.1471-4159.2001.00209.x; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Haaland KY, 2000, BRAIN, V123, P2306, DOI 10.1093/brain/123.11.2306; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Hermsdorfer J, 2001, NEUROIMAGE, V14, P149, DOI 10.1006/nimg.2001.0796; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Ingi T, 1998, J NEUROSCI, V18, P7178; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; Klein BS, 2000, CYTOGENET CELL GENET, V88, P218, DOI 10.1159/000015554; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Merched A, 1998, FEBS LETT, V425, P225, DOI 10.1016/S0014-5793(98)00234-8; Mills JC, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e72; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Moore AN, 1999, NEUROSCIENCE, V94, P405, DOI 10.1016/S0306-4522(99)00288-2; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; Schwarzman AL, 1996, CIBA F SYMP, V199, P146; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsuzuki K, 2000, NEUROSCI LETT, V281, P171, DOI 10.1016/S0304-3940(00)00834-X; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Wolffe AP, 1999, NAT GENET, V22, P215, DOI 10.1038/10267; Yamazaki K, 2001, J NEUROL, V248, P235, DOI 10.1007/s004150170234; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41	55	99	104	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 15	2002	104	2					148	158	PII S0169-328X(02)00331-5	10.1016/S0169-328X(02)00331-5			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	602WW	WOS:000178528300007	12225869				2022-02-06	
J	Berger, C; Schabitz, WR; Georgiadis, D; Steiner, T; Aschoff, A; Schwab, S				Berger, C; Schabitz, WR; Georgiadis, D; Steiner, T; Aschoff, A; Schwab, S			Effects of hypothermia on excitatory amino acids and metabolism in stroke patients - A microdialysis study	STROKE			English	Article						cerebral metabolism; excitatory amino acids; hypothermia; microdialysis; stroke	CEREBRAL-ARTERY INFARCTION; IN-VIVO MICRODIALYSIS; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; HUMAN BRAIN; EXTRACELLULAR GLUTAMATE; MODERATE HYPOTHERMIA; INTENSIVE-CARE; HEAD-INJURY; ISCHEMIA	Background and Purpose-The objective of this study was to assess the effect of therapeutic moderate hypothermia on excitatory amino acids and metabolism by applying cerebral microdialysis in patients suffering from space-occupying middle cerebral artery infarction. Methods-This was an open, prospective, observational study of 12 patients undergoing moderate hypothermia (33 C) as rescue therapy for large, life-threatening middle cerebral artery infarction. Microdialysis probes were placed concomitantly with intracranial pressure (ICP) measuring devices in the frontal lobe of the infarcted and/or noninfarcted hemisphere. Using the CMA 600 Microdialysis Autoanalyzer, we analyzed glutamate, glycerol, pyruvate, and lactate. Results-According to follow-up cranial CT scans, 3 different compartments of microdialysis measurements could be defined. First, noninfarcted brain tissue had stable dialysate concentrations but a significant effect of hypothermia on glutamate (2.6 versus 3.6 mumol/L), lactate (1.8 versus 3 mmol/L), and pyruvate (50 versus 95.8 mumol/L). Second, measurements from peri-infarct tissue had a significant effect of hypothermia on glutamate (4.8 versus 12.6 mumol/L), glycerol (58 versus 82 mumol/L), lactate (0.7 versus 1.3 mmol/L), and pyruvate (13.3 versus 36.8 mumol/L). Third, dialysate concentrations obtained from irreversibly damaged tissue were excessive for glutamate (453 mumol/L), glycerol (1187 mumol/L), lactate (12 mumol/L), and pyruvate (4 mumol/L). In this extreme compartment, no effect of hypothermia was observed. Conclusions-Cerebral microdialysis is a safe and feasible bedside method for neurochemical monitoring indicating normal brain tissue, potentially salvageable brain tissue, and irreversibly damaged areas in stroke. We could demonstrate that hypothermia decreases glutamate, glycerol, lactate, and pyruvate in the "tissue at risk" area of the infarct but not within the infarct core. Thus, future treatment strategies for life-threatening stroke should be guided by close neurochemical monitoring.	Heidelberg Univ, Neurol Klin, Dept Neurol, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany		Berger, C (corresponding author), Heidelberg Univ, Neurol Klin, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christian_berger@med.uni-heidelberg.de	Steiner, Thorsten/A-7391-2014				Berger C, 1999, STROKE, V30, P460, DOI 10.1161/01.STR.30.2.460; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Goodman JC, 1996, ACT NEUR S, V67, P37; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HerreraMarschitz M, 1996, J NEUROCHEM, V66, P1726; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2000, NEUROSURGERY, V46, P201, DOI 10.1093/neurosurgery/46.1.201; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LARSEN M, 1994, BRAIN RES, V663, P335, DOI 10.1016/0006-8993(94)91282-3; Mendelowitsch A, 1996, ACT NEUR S, V67, P48; Mendelowitsch A, 1998, ACTA NEUROCHIR, V140, P349, DOI 10.1007/s007010050108; Mendelowitsch A, 1998, J NEUROL NEUROSUR PS, V64, P611, DOI 10.1136/jnnp.64.5.611; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nakashima K, 1996, ANESTHESIOLOGY, V85, P161, DOI 10.1097/00000542-199607000-00022; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Nilsson OG, 1996, ACT NEUR S, V67, P45; Obrenovitch TP, 1996, ACT NEUR S, V66, P50; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schwab S, 1996, NEUROLOGY, V47, P393, DOI 10.1212/WNL.47.2.393; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1998, ACT NEUR S, V71, P131; Shuaib A, 1996, ACT NEUR S, V67, P53; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	34	99	108	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2002	33	2					519	524		10.1161/hs0102.100878			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	518AX	WOS:000173644900019	11823663	Bronze			2022-02-06	
J	Dupuis, F; Johnston, KM; Lavoie, M; Lepore, F; Lassonde, M				Dupuis, F; Johnston, KM; Lavoie, M; Lepore, F; Lassonde, M			Concussions in athletes produce brain dysfunction as revealed by event-related potentials	NEUROREPORT			English	Article						electrophysiology; mild traumatic brain injury; P300; sports	HEAD-INJURY PATIENTS; P300; PLAYERS	We have used event-related potentials (ERP) to assess cerebral activity following mild traumatic brain injuries in 20 college athletes practising contact sports. Concussion victims showed a striking decrease in P300 amplitude, an effect presumed to reflect alterations in attentional-cognitive processes. Moreover, the degree of impairment was strongly related to the severity of post-concussion symptoms. Our data suggest that concussions cause objectively measurable changes in the electrophysiological markers of brain activity and hence in the functions of the structures from which they originate. ERPs may thus constitute a reliable method to accurately monitor the clinical course and recovery of head injuries in athletes. NeuroReport 11:4087-4092 (C) 2000 Lippincott Williams & Wilkins.	Univ Montreal, Grp Rech & Neuropsychol Expt, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Univ Geriatrie, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada		Lassonde, M (corresponding author), Univ Montreal, Grp Rech & Neuropsychol Expt, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Lavoie, Marc/M-4771-2019	Lavoie, Marc/0000-0002-3037-3890			[Anonymous], 1991, J CLIN NEUROPHYSIOL, V8, P200, DOI 10.1097/00004691-199104000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; COLES MGH, 1986, PSYCHOPHYSIOLOGY SYS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; ROCKSTROM J, 1989, SLOW CORTICAL POTENT; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21	17	99	99	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	DEC 18	2000	11	18					4087	4092		10.1097/00001756-200012180-00035			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	387PU	WOS:000166131600037	11192633				2022-02-06	
J	Lichtman, SW; Seliger, G; Tycko, B; Marder, K				Lichtman, SW; Seliger, G; Tycko, B; Marder, K			Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation	NEUROLOGY			English	Article							FATAL HEAD-INJURY; ALZHEIMERS-DISEASE; INDEPENDENCE MEASURE; E POLYMORPHISM; ASSOCIATION; DEPOSITION; EPSILON-4; ETIOLOGY; ALLELE	Objective: APOE epsilon4 has been associated with late-onset familial and sporadic AD and delayed recovery from head injury. The authors examined the relationship between functional recovery of patients with head injury and the APOE alleles. Methods: Thirty-one patients with head injury who had completed the Acute Neurorehabilitation Program at Helen Hayes Hospital were evaluated for presence of APOE epsilon4 and assessed for recovery based on Functional Independence Measures (FIM). Results: Analysis of covariance (using coma days as the covariate to control for differences in initial severity of injury between subjects with and without APOE epsilon4) revealed a significant difference for both total FIM and motor FIM scores between the subjects with and without APOE epsilon4. Specifically, there were lower scores for total FIM (df = 30; F = 3.341; p = 0.05) and motor FIM (df = 30; F = 4.189; p = 0.026) in APOE epsilon4 carriers, No difference was found for the cognitive portion of the FIM. Conclusions: The data suggest that the presence of the lipoprotein APOE epsilon4 adversely affects rehabilitation outcome for traumatic brain injury survivors.	Helen Hayes Hosp, Dept Internal Med, W Haverstraw, NY 10993 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Internal Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst, New York, NY 10032 USA		Lichtman, SW (corresponding author), Helen Hayes Hosp, Dept Internal Med, Route 9W, W Haverstraw, NY 10993 USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG08702] Funding Source: Medline		Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; *CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1996, ACT NEUR S, V66, P96; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P253; HIXSON JE, 1990, J LIPID RES, V31, P545; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KAMBOH MI, 1995, HUM BIOL, V67, P195; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Nicoll JAR, 1996, NEUROPATH APPL NEURO, V22, P515, DOI 10.1111/j.1365-2990.1996.tb01128.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; STOREY E, 1995, MED J AUSTRALIA, V163, P256, DOI 10.5694/j.1326-5377.1995.tb124564.x; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Zunarelli E, 1996, NEUROREPORT, V8, P45, DOI 10.1097/00001756-199612200-00010	26	99	105	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	NOV 28	2000	55	10					1536	1539		10.1212/WNL.55.10.1536			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	376DR	WOS:000165443400019	11094110				2022-02-06	
J	Diringer, MN; Yundt, K; Videen, TO; Adams, RE; Zazulia, AR; Deibert, E; Aiyagari, V; Dacey, RG; Grubb, RL; Powers, WJ				Diringer, MN; Yundt, K; Videen, TO; Adams, RE; Zazulia, AR; Deibert, E; Aiyagari, V; Dacey, RG; Grubb, RL; Powers, WJ			No reduction in cerebral metabolism as a result of early moderate hyperventilation following severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral metabolism; positron emission tomography; hyperventilation; brain injury	POSITRON EMISSION TOMOGRAPHY; BLOOD-FLOW; HEAD-INJURY; INTRAVENOUS (H2O)-O-15; O-15 RADIOTRACERS; COMATOSE PATIENTS; CARBON-DIOXIDE; ISCHEMIA; HUMANS; VOLUME	Object. Hyperventilation has been used for many years in the management of patients with traumatic brain injury (TBI). Concern has been raised that hyperventilation could lead to cerebral ischemia; these concerns have been magnified by reports of reduced cerebral blood flow (CBF) early after severe TBI. The authors tested the hypothesis that moderate hyperventilation induced early after TBI would not produce a reduction in CBF severe enough to cause cerebral energy failure (CBF that is insufficient to meet metabolic needs). Methods. Nine patients were studied a mean of 11.2 +/- 1.6 hours (range 8-14 hours) after TBI occurred. The patients' mean Glasgow Coma Scale score was 5.6 +/- 1.8 and their mean age 27 +/- 9 years; eight of the patients were male. Intracranial pressure (ICP), mean arterial blood pressure, and jugular venous oxygen content were monitored and cerebral perfusion pressure was maintained at a level higher than 70 mm Hg by using vasopressors when needed. Measurements of CBF, cerebral blood volume (CBV), cerebral metabolic rate for oxygen (CMRO2), oxygen extraction fraction (OEF), and cerebral venous oxygen content (CvO(2)) were made before and after 30 minutes of hyperventilation to a PaCO2 of 30 +/- 2 mm Hg. Ten age-matched healthy volunteers were used as normocapnic controls. Global CBF, CBV, and CvO(2) did not differ between the two groups, but in the TBI patients CMRO2 and OEF were reduced (1.59 +/- 0.44 ml/100 g/minute [p < 0.01] and 0.31 +/- 0.06 [p < 0.0001], respectively). During hyperventilation, global CBF decreased to 25.5 +/- 8.7 ml/100 g/minute (p < 0.0009), CBV fell to 2.8 +/- 0.56 ml/100 g (p < 0.001), OEF rose to 0.45 +/- 0.13 (p < 0.02), and CvO(2) fell to 8.3 +/- 3 vol% (p < 0.02); CMRO2 remained unchanged. Conclusions. The authors conclude that early, brief, moderate hyperventilation does not impair global cerebral metabolism in patients with severe TBI and, thus, is unlikely to cause further neurological injury. Additional studies are needed to assess focal changes, the effects of more severe hyperventilation, and the effects of hyperventilation in the setting of increased ICP.	Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Dept Radiol, St Louis, MO USA; Washington Univ, Sch Med, Neurol Neurosurg Intens Care Unit, St Louis, MO USA		Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966, P50NS035966] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35966] Funding Source: Medline		ALTMAN DI, 1993, PEDIATRICS, V92, P99; ALTMAN DI, 1991, J NUCL MED, V32, P1738; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; *JOINT SECT TRAUM, 1995, GUID MAN SEV HEAD IN; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTIN WRW, 1987, J CEREBR BLOOD F MET, V7, P421, DOI 10.1038/jcbfm.1987.85; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MILLER K, 1995, AKTUEL UROL, V26, P1, DOI 10.1055/s-2008-1057840; MINTUN MA, 1984, J NUCL MED, V25, P177; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; RAICHLE ME, 1983, J NUCL MED, V24, P790; SPARGO PM, 1985, ANAESTHESIA, V40, P901, DOI 10.1111/j.1365-2044.1985.tb11057.x; TEASDALE G, 1974, LANCET, V2, P81; VANRIJEN PC, 1989, MAGN RESON MED, V10, P182, DOI 10.1002/mrm.1910100204; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; WILSON DA, 1985, CIRC RES, V56, P596, DOI 10.1161/01.RES.56.4.596; YOUNG WL, 1989, ANESTH ANALG, V68, P712	33	99	102	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2000	92	1					7	13		10.3171/jns.2000.92.1.0007			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	268ZP	WOS:000084451500002	10616076				2022-02-06	
J	Snow, P; Douglas, J; Ponsford, J				Snow, P; Douglas, J; Ponsford, J			Conversational discourse abilities following severe traumatic brain injury: a follow-up study	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; BEHAVIORAL-ASSESSMENT; SOCIAL-INTERACTION; RECOVERY; DAMAGE; POPULATION; DISORDER; DEFICITS; PROFILE	The major aim of this study was to describe the conversational abilities of a group of severely injured TBI speakers, at a minimum of 2 years post-injury. The association between conversational impair ment and (a) selected measures of executive function and (b) psychosocial handicap was also examined. Twenty-four members of the group of 26 severely injured TBI speakers who had initially been assessed between 3 and 6 months post-injury were reviewed at a minimum of 2 years post-injury (mean = 2 years, 10 months). At initial assessment, TBI speakers were compared with non-TBI orthopaedic patients and with a group of university students. At follow-up, however, they were compared only with the orthopaedic patients. Conversational assessment was carried out using a modified form of Damico's Clinical Discourse Analysis. As a group, the TBI speakers' conversational abilities did not improve over time. There was, however, at subgroup (n = 8) of speakers who did improve, and these could be distinguished by greater initial severity of injury and a significantly longer period of speech-language pathology intervention than the speakers who either remained the same or worsened over time. Modest associations between conversational discourse skills and measures of executive function and a measure of psychosocial handicap were identified. These findings indicate that disruptions in conversation persist into the longer term. More assiduous efforts may need to be made to (a) identify subtle discourse changes in the early months after injury and (b) engage TBI speakers in speech-language pathology services. Such services are also required over a longer time frame, in community-based models of service provision.	La Trobe Univ, Sch Human Commun Sci, Melbourne, Vic, Australia; Bethesda Hosp, Dept Psychol, Melbourne, Vic, Australia		Snow, P (corresponding author), La Trobe Univ, Fac Hlth Sci, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ARMSTRONG EM, 1987, CLIN APHASIOLOGY, P210; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; BIELIAUSKAS LA, 1993, J CLIN EXP NEUROPSYC, V15, P119, DOI 10.1080/01688639308407223; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BOAKE C, 1996, AM J PHYSICAL MED RE, V75, P1; BODY R, 1996, INT PERSPECTIVES TRA, P221; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BOWDEN SC, 1994, AUST PSYCHOL, V29, P34, DOI 10.1080/00050069408257317; Brooks D N, 1979, Int Rehabil Med, V1, P166; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P767; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CANAVAN AGM, 1985, J NEUROL NEUROSUR PS, V48, P1049, DOI 10.1136/jnnp.48.10.1049; COEHLO CA, 1991, ARCH PHYSICAL MED RE, V72, P465; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COEHLO CA, 1991, BRAIN INJURY, V5, P381; COEHLO CA, 1993, CLIN APHASIOLOGY, V21, P183; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Damico J. S., 1985, COMMUNICATION SKILLS, P165; DAMICO JS, 1991, COMMUNICATION SKILLS, P125; DAVISON G, 1994, ABNORMAL PSYCHOL EXP; DEPOMPEI R, 1988, J HEAD TRAUMA REHAB, V3, P13; Doyle P. J., 1996, AM J SPEECH-LANG PAT, V5, P53, DOI DOI 10.1044/1058-0360.0503.53; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [10.1007/BF02214959, DOI 10.1007/BF02214959]; Grice H. P., 1975, SYNTAX SEMANTICS, P41; GURNS S, 1994, BRAIN INJURY, V8, P413, DOI 10.3109/02699059409150993; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; Hagen C, 1981, TOP LANG DIS, V1, P73; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HALL JW, 1982, LARYNGOSCOPE, V92, P883; Hannay HJ, 1996, J HEAD TRAUMA REHAB, V11, P41, DOI 10.1097/00001199-199612000-00007; HARTLEY L, 1989, J SPEECH LANGUAGE PA, V13, P51; Hartley L. L, 1995, COGNITIVE COMMUNICAT; JENNETT B, 1975, LANCET, V1, P480; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V18, P69; KEPPELL G, 1991, DESIGN ANAL RES HDB; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; MILTON SB, 1988, J HEAD TRAUMA REHAB, V3, P1; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pang D, 1985, HEAD INJURY REHABILI, P3; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; PODOSHIN L, 1975, ARCH OTOLARYNGOL, V101, P15; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO G, 1986, NEUROPSYCHOL REHABIL, P143; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Prigatano GP, 1995, PSYCHOL ASSESSMENT, V7, P396; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Ruff R, 1991, COGNITIVE REHABILITA, P23; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; SBORDONE RJ, 1991, COGNITIVE REHABILITA, P105; SCHUKNECHT HF, 1969, ANN OTO RHINOL LARYN, V78, P253, DOI 10.1177/000348946907800205; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; Snow P, 1995, TRAUMATIC BRAIN INJU, P33; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanLancker D, 1997, BRAIN LANG, V57, P1, DOI 10.1006/brln.1997.1850; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, UNPUB SCORING GUIDEL; WHITENECK GG, 1992, GUIDE USE CHART; World Health Organization, 1980, INT CLASS IMP DIS HA; Ylvisaker M., 1985, CLIN MANAGEMENT NEUR, V2nd, P243	94	99	100	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	1998	12	11					911	935		10.1080/026990598121981			25	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	143NR	WOS:000077262300002	9839026				2022-02-06	
J	Valadka, AB; Goodman, JC; Gopinath, SP; Uzura, M; Robertson, CS				Valadka, AB; Goodman, JC; Gopinath, SP; Uzura, M; Robertson, CS			Comparison of brain tissue oxygen tension to microdialysis-based measures of cerebral ischemia in fatally head-injured humans	JOURNAL OF NEUROTRAUMA			English	Article						brain tissue oxygen tension; glucose; head injury; ischemia; microdialysis; oxygen; traumatic brain injury	EXTRACELLULAR POTASSIUM; CULTURED ASTROCYTES; CELL-DAMAGE; LACTATE; RELEASE; GLUTAMATE; METABOLISM; MECHANISMS; ELEVATION; PRESSURE	This study investigated the relationship between brain tissue oxygen tension (PbtO(2)) and cerebral microdialysate concentrations of several compounds in five patients with refractory intracranial hypertension after severe head injury. The following substances were assayed: lactate and glucose; the excitatory amino acids glutamate and aspartate; and the cations potassium, calcium, and magnesium. Glucose concentrations did not correlate with PbtO(2), but lactate increased as PbtO(2) decreased. The lactate/glucose ratio exhibited a close relationship to PbtO(2), increasing sharply only when oxygen tension reached zero. Although glucose and oxygen eventually reached very low levels and zero, respectively, in these fatally head-injured patients, the terminal decrease in PbtO(2) slightly preceded that of glucose in four of the five patients. This time lag is the cause of the poor correlation between glucose and PbtO(2). Glutamate and aspartate concentrations both demonstrated a close relationship to PbtO(2), with sharp increases not occurring until PbtO(2) was zero. Concentrations of these amino acids exhibited a similar pattern in response to decreasing glucose concentrations. Potassium concentrations began increasing at a PbtO(2) of 35 mm Hg, which is not generally considered indicative of hypoxia. Sharper increases began occurring once PbtO(2) dropped below 15 mm Hg, with a slight rise in the minimum potassium concentrations recorded at these low PbtO(2) values. Calcium and magnesium concentrations did not vary in response to PbtO(2). In summary, the most robust biochemical indicators of cerebral anoxia were elevations in the lactate/glucose ratio and in the concentrations of lactate and of the excitatory amino acids glutamate and aspartate. Furthermore, the fact that glucose concentrations continue to decrease for a short period after oxygen levels reach zero suggests that cells continue to utilize glucose anaerobically for such functions as maintenance of cellular integrity, with collapse of the cell membrane as evidenced by increases of extracellular glutamate and aspartate not occurring until both oxygen and glucose concentrations reach zero.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA		Valadka, AB (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Ste 944, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; BULLOCK R, 1992, J NEUROTRAUMA S2, V9, P443; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; FLECKENSTEIN W, 1996, 1 C CER OX ROTT FEBR; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GOODMAN JC, 1997, 15 ANN NAT NEUR S NE; GOODMAN JC, 1997, ISNM 2 NEUR MON INT; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOEHNER TJ, 1987, AM J EMERG MED, V5, P19, DOI 10.1016/0735-6757(87)90283-X; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; JUURLINK BHJ, 1992, NEUROREPORT, V3, P1135, DOI 10.1097/00001756-199212000-00026; KATAYAMA Y, 1991, BRAIN RES, V567, P57, DOI 10.1016/0006-8993(91)91435-4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1995, NEUROCHEMICAL MONITO, P3; KAWAMATA T, 1995, NEUROCHEMICAL MONITO, P72; KELLEHER JA, 1995, NEUROCHEM RES, V20, P785, DOI 10.1007/BF00969690; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; Linde R, 1996, ACT NEUR S, V66, P15; LUNDGREN J, 1991, J CEREBR BLOOD F MET, V11, P587, DOI 10.1038/jcbfm.1991.108; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; SHAPIRA Y, 1989, Neurological Research, V11, P169; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; VALADKA AB, 1998, IN PRESS CRIT CARE M; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1996, J NEUROCHEM, V66, P2477; WALZ W, 1988, GLIA, V1, P366, DOI 10.1002/glia.440010603; WALZ W, 1988, NEUROSCI LETT, V86, P296, DOI 10.1016/0304-3940(88)90499-5; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; [No title captured]	41	99	102	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1998	15	7					509	519		10.1089/neu.1998.15.509			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZY374	WOS:000074614700005	9674554				2022-02-06	
J	Tate, RL; McDonald, S; Lulham, JM				Tate, RL; McDonald, S; Lulham, JM			Incidence of hospital-treated traumatic brain injury in an Australian community	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH			English	Article							HEAD; EPIDEMIOLOGY	This paper reports findings from an incidence study of head trauma in a defined population. In the North Coast Health Region of NSW, 1,259 subjects with head trauma were admitted to hospitals in a 12-month period in 1988. Direct examination of the medical records confirmed brain injury in only 413 of these cases, corresponding to an annual incidence of approximately 100/100,000 resident population. Although most injuries (62.2%) were mild, 38% were serious (either moderate, 20.3%, or severe, 13.6%; and 3.9% died after admission to hospital). Severe brain injury represented an annual incidence of 12/100,000 resident population. Road traffic accidents accounted for a higher proportion of injuries in the severe group in comparison with the other injury groups. Methodological issues involved in case ascertainment of brain injury are discussed.	Univ Sydney, Dept Psychol A16, Sydney, NSW 2006, Australia; Univ New S Wales, Kensington, NSW 2033, Australia		Tate, RL (corresponding author), Univ Sydney, Dept Psychol A16, Sydney, NSW 2006, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			CARADOCDAVIES TH, 1995, NEUROEPIDEMIOLOGY, V14, P199, DOI 10.1159/000109797; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; JENNETT J, 1981, MANAGEMENT HEAD INJU; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SELECKI BR, 1981, INJURIES HEAD SPINE; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; TEASDALE G, 1974, LANCET, V2, P81; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013	13	99	100	0	2	PUBLIC HEALTH ASSOC AUSTRALIA INC	CURTIN	PO BOX 319, CURTIN, ACT 2600, AUSTRALIA	1326-0200			AUST NZ J PUBL HEAL	Aust. N. Z. Publ. Health	JUN	1998	22	4					419	423		10.1111/j.1467-842X.1998.tb01406.x			5	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	ZX372	WOS:000074508900003	9659765				2022-02-06	
J	Hausmann, EHS; Berman, NEJ; Wang, YY; Meara, JB; Wood, GW; Klein, RM				Hausmann, EHS; Berman, NEJ; Wang, YY; Meara, JB; Wood, GW; Klein, RM			Selective chemokine mRNA expression following brain injury	BRAIN RESEARCH			English	Article						chemokine; cytokine; mRNA; brain injury; cortical lesion	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NECROSIS-FACTOR-ALPHA; INTRACEREBRAL INJECTION; INFLAMMATORY RESPONSE; CYTOKINE FAMILY; GROWTH-FACTOR; MOUSE UTERUS; GENE ENCODES	Injury in non-neuronal tissues stimulates chemokine expression leading to recruitment of inflammatory cells responsible for orchestration of repair processes. The signals involved in directing repair of damage to the brain are less well understood. We hypothesized that following brain injury, chemokines are expressed and regulate the rate and pattern of inflammatory cell accumulation. The two chemokine subfamilies are alpha(alpha)-chemokines, which primarily function as neutrophil chemoattractants, and the beta(beta)chemokines, which function primarily as monocyte chemoattractants. We assessed alpha and beta chemokine mRNA expression patterns and leukocyte accumulation following a cerebral cortical lesion. Cortical lesions were produced with and without addition of endotoxin, Escherichia coli lipopolysaccharide (LPS), which stimulates cytokine expression. We studied the expression of the beta-chemokines: monocyte chemoattractant protein (gene product JE; MCP-1/JE), macrophage inflammatory protein-1 alpha and beta (MIP-1 alpha and MIP-1 beta), and the regulated upon activation normal T expressed and secreted chemokine (RANTES) as well as the alpha-chemokines: interferon-gamma-inducible protein (IP-10) and N51/KC (KC; a murine homologue of MIP-2). Changes in gene expression were analyzed by northern analysis at different time points following injury. Leukocyte and macrophage densities were analyzed by immunohistochemistry at the same time intervals. All chemokines were elevated following cortical injury/endotoxin. MCP-1 and MIP-1 alpha were elevated at 2 h and peaked 6 h, MIP-1 beta peaked at 6 h, but declined more rapidly than MCP-1 or MIP-1 alpha, and IP-10 peaked at 6 h and showed the most rapid decline. KC was elevated at 1 h, and peaked at 6 h following LPS. RANTES was elevated at 1 h and achieved a plateau level between 6 and 18 h, then declined. In contrast, sterile injuries produced in the absence of endotoxin only induced the mRNA of the beta-chemokine MCP-1, and its expression was delayed compared to the cortical injury/endotoxin group. The presence of chemokine message as early as 1 h indicates that expression of this class of molecules is an early response in the repair process following traumatic brain injury. Macrophage/microglia accumulation occurred more rapidly, activated microglia further from the lesion border, and more cells accumulated in cortical injury/endotoxin than in cortical lesions produced under sterile conditions. Thus, there was a positive correlation between beta-chemokine expression and the number of beta-chemokine responsive cells (i.e. microglia) accumulating in injury sites. This is the first comprehensive study using a panel of chemokine probes and specific marcophage/microglial markers to study in vivo activation of the brain following injury. Our data show that the brain is capable of expression of multiple chemokine genes upon appropriate stimulation (e.g. LPS-treatment). The gradient of microglial activation is consistent with physical damage stimulating release of chemokines that diffuse from the injury site. These data strongly suggest that chemokines are instrumental in the initiation of repair processes following brain injury. (C) 1998 Elsevier Science B.V.	Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA		Klein, RM (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	rklein@kumc.edu			NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA10412] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1P60AG14635-01] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH38399] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH038399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P60AG014635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R03AA010412] Funding Source: NIH RePORTER		ALLEN RW, 1987, J BIOL CHEM, V262, P649; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; ASHWELL K, 1991, DEV BRAIN RES, V58, P1, DOI 10.1016/0165-3806(91)90231-7; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BARBUL A, 1995, OTOLARYNG CLIN N AM, V28, P955; BOZIC CR, 1995, J IMMUNOL, V154, P6048; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DE M, 1993, J REPROD FERTIL, V97, P83, DOI 10.1530/jrf.0.0970083; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Glabinski AR, 1995, BRAIN BEHAV IMMUN, V9, P315, DOI 10.1006/brbi.1995.1030; HAUSMANN EHS, 1994, INFECT IMMUN, V62, P3625, DOI 10.1128/IAI.62.9.3625-3632.1994; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; IMAMOTO K, 1977, J COMP NEUROL, V174, P255, DOI 10.1002/cne.901740205; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; KWON BS, 1987, P NATL ACAD SCI USA, V84, P2896, DOI 10.1073/pnas.84.9.2896; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; MALE D, 1990, J NEUROIMMUNOL, V30, P161, DOI 10.1016/0165-5728(90)90100-2; MATSUMOTO Y, 1992, J NEUROIMMUNOL, V37, P23, DOI 10.1016/0165-5728(92)90152-B; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; MOUMDJIAN RA, 1991, BRAIN RES, V547, P223, DOI 10.1016/0006-8993(91)90965-X; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1992, NEUROPATH APPL NEURO, V18, P454, DOI 10.1111/j.1365-2990.1992.tb00811.x; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; ROBINSON AP, 1986, IMMUNOLOGY, V57, P231; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1994, CYTOKINE HDB, P419; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Sun DM, 1997, J NEUROSCI RES, V48, P192; Tani M, 1996, J CLIN INVEST, V98, P529, DOI 10.1172/JCI118821; Taub D D, 1994, Ther Immunol, V1, P229; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; WATTS RG, 1989, NEUROSURGERY, V25, P202, DOI 10.1227/00006123-198908000-00008; WIDMER U, 1991, J IMMUNOL, V146, P4031; WOOD GW, 1992, DEV BIOL, V152, P336, DOI 10.1016/0012-1606(92)90140-C; XIE DC, 1995, J NEUROCYTOL, V24, P435, DOI 10.1007/BF01181605	56	99	100	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 30	1998	788	1-2					49	59		10.1016/S0006-8993(97)01160-8			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZM870	WOS:000073584600007	9554951				2022-02-06	
J	Hall, ED				Hall, ED			Inhibition of lipid peroxidation in central nervous system trauma and ischemia	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	Satellite Symposium on Normal and Pathological Brain Iron	SEP 17, 1994	NIAGARA FALLS, NY			antioxidant; cerebral ischemia; head injury; lipid peroxidation; subarachnoid hemorrhage; tirilazad mesylate	NONGLUCOCORTICOID 21-AMINOSTEROID U74006F; CHRONIC CEREBRAL VASOSPASM; SPINAL-CORD INJURY; SUBARACHNOID HEMORRHAGE; ARTERY OCCLUSION; PRIMATE MODEL; U-74006F; EDEMA; RATS; METHYLPREDNISOLONE	A novel group of compounds, the 21-aminosteroids (''lazaroids''), have been designed that are potent inhibitors of oxygen free radical-induced, iron-catalyzed lipid peroxidation (LP) in microvascular and nervous tissue. One of these, tirilazad mesylate (U-74006F), has been selected for clinical evaluation as a cerebroprotective agent. In vitro studies suggest that tirilazad exerts its antioxidant activity by multiple mechanisms including: increasing membrane stability, scavenging of lipid peroxyl radicals, reducing LP-induced arachidonic acid release, decreased formation or scavenging of hydroxyl radicals, and maintenance of the levels of endogenous vitamin E. The major site of action appears to be the blood-brain barrier based upon its known localization in cerebrovascular endothelium and numerous studies showing an attenuation of subarachnoid hemorrhage (SAH), injury, and ischemia-induced blood-brain barrier permeability. Tirilazad has demonstrated neuroprotective efficacy in multiple preclinical models of spinal cord and head injury, SAH, and focal cerebral ischemia, as measured by a decrease in cerebral vasospasm, blood-brain barrier compromise, post-traumatic ischemia, edema, ischemic neuronal necrosis and infarction, and improved neurological recovery. This efficacy is correlated with a reduction in markers of oxygen radical-induced LP. Phase III clinical trials are currently ongoing in spinal cord and head injury, SAH, and ischemic stroke. Initial results from a European/Australian/New Zealand trial in SAH have shown a significant decrease in mortality and an increase in the incidence of good recovery.			Hall, ED (corresponding author), UPJOHN CO, CENT NERVOUS SYST DIS RES, KALAMAZOO, MI 49001 USA.		Hall, Edward D/F-8930-2013				ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; ASANO T, 1991, CRIT REV NEUROSURG, V1, P361; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BOISVERT DP, 1991, J CEREB BLOOD FLO S2, V11, pS135; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER J M, 1989, Drugs of the Future, V14, P143; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Dimlich R V, 1990, Adv Neurol, V52, P365; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1991, STROKE, V22, P361, DOI 10.1161/01.STR.22.3.361; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Holtz A, 1991, J NEUROTRAUM, V8, P239, DOI 10.1089/neu.1991.8.239; KANAMARU K, 1991, J NEUROSURG, V74, P454, DOI 10.3171/jns.1991.74.3.0454; KANAMARU K, 1990, NEUROSURGERY, V27, P29, DOI 10.1227/00006123-199007000-00004; KARKI A, 1994, ACTA NEUROCHIR, P310; KASSELL NF, 1996, IN PRESS J NEUROSURG; MATHEWS WR, 1992, J MOL CELL CARDIO S3, V24, P517; MATSUI T, 1994, NEUROSURGERY, V34, P1035, DOI 10.1227/00006123-199406000-00012; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MORI E, 1995, CEREBROVASC DIS, V5, P342, DOI 10.1159/000107880; PARK CK, 1994, BRAIN RES, V645, P157; Raub TJ, 1993, J DRUG TARGET, V1, P269, DOI 10.3109/10611869308996085; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SILVIA RC, 1987, NEUR ABST, V13, P1499; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STEINKE DE, 1989, NEUROSURGERY, V24, P179, DOI 10.1227/00006123-198902000-00005; TAKESHIMA R, 1994, STROKE, V25, P670, DOI 10.1161/01.STR.25.3.670; VOLLMER DG, 1989, SURG NEUROL, V31, P190, DOI 10.1016/0090-3019(89)90115-8; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367; ZUCCARELLO M, 1989, J NEUROSURG, V71, P98, DOI 10.3171/jns.1989.71.1.0098	43	99	100	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	DEC	1995	134			S			79	83		10.1016/0022-510X(95)00211-J			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	TT811	WOS:A1995TT81100011	8847548				2022-02-06	
J	KIRKPATRICK, PJ; SMIELEWSKI, P; CZOSNYKA, M; MENON, DK; PICKARD, JD				KIRKPATRICK, PJ; SMIELEWSKI, P; CZOSNYKA, M; MENON, DK; PICKARD, JD			NEAR-INFRARED SPECTROSCOPY USE IN PATIENTS WITH HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article						NEAR-INFRARED SPECTROSCOPY; HEAD INJURY; MULTIMODALITY MONITORING; CEREBRAL OXYGENATION	VENOUS OXYGEN-SATURATION; CEREBRAL BLOOD-FLOW; NEWBORN-INFANTS; BRAIN INJURY; TISSUE	A multimodality recording system was used in 14 ventilated patients with closed head injury to assess the potential use of near-infrared spectroscopy (NIRS) in the neurointensive care unit. Signals of intracranial pressure, cerebral perfusion pressure, peripheral oxygen saturation, jugular venous saturation, and NIRS-derived changes in the chromophores of oxy- and deoxyhemoglobin were digitized and recorded. After a review of 886 hours of continuous monitoring, 376 hours were considered free from artifact and were entered for final analysis. In nine of the patients 38 events were recorded that demonstrated clear changes in cerebral perfusion pressure accompanied by hemodynamic changes in middle cerebral artery flow velocity (transcranial Doppler) and cortical perfusion (laser Doppler flowmetry). Near-infrared spectroscopy showed correlated changes in 37 events (97%) whereas jugular venous saturation monitoring registered only 20 (53%). There was associated peripheral oxygen desaturation in eight cases (21%), intracranial hypertension in 10 (26%), and cerebral hyperemia in eight (21%). The remaining 12 events (32%) appeared to be complex changes of uncertain origin. Iatrogenic factors were identified as causative in 14 cases (37%). The potential application of NIRS in adults and the importance of using multiple parameter recording systems in the interpretation of cerebral events are discussed.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT NEUROSURG, CAMBRIDGE, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT ANAESTHESIA, CAMBRIDGE, ENGLAND					Smielewski, Peter/0000-0001-5096-3938	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1992, J NEUROSURG, V77, P975; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; ELWELL CE, 1992, ADV EXP MED BIOL, V317, P235; ELWELL CE, 1994, ADV EXP MED BIOL, V345, P619; Ferrari M, 1986, Adv Exp Med Biol, V200, P213; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HAMPSON NB, 1990, J APPL PHYSIOL, V69, P907, DOI 10.1152/jappl.1990.69.3.907; HOSHI Y, 1993, NEUROSCI LETT, V150, P5, DOI 10.1016/0304-3940(93)90094-2; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KATO T, 1993, J CEREBR BLOOD F MET, V13, P516, DOI 10.1038/jcbfm.1993.66; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; KIRKPATRICK PJ, 1995, J NEUROSURG, V82, P756, DOI 10.3171/jns.1995.82.5.0756; KIRKPATRICK PJ, 1995, STROKE, V26, P722; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1974, LANCET, V2, P81; VANDERZEE P, 1992, ADV EXP MED BIOL, V316, P143; WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8	30	99	99	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	1995	83	6					963	970		10.3171/jns.1995.83.6.0963			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TG914	WOS:A1995TG91400002	7490639				2022-02-06	
J	ROBERTSON, CS; GOPINATH, SP; GOODMAN, JC; CONTANT, CF; VALADKA, AB; NARAYAN, RK				ROBERTSON, CS; GOPINATH, SP; GOODMAN, JC; CONTANT, CF; VALADKA, AB; NARAYAN, RK			SJVO(2) MONITORING IN HEAD-INJURED PATIENTS	JOURNAL OF NEUROTRAUMA			English	Article						HEAD INJURY; SJVO(2) MONITORING; SECONDARY INJURY	JUGULAR BULB CATHETERIZATION	Jugular venous oxygen saturation (SjvO(2)) measures the balance between cerebral oxygen delivery and cerebral oxygen consumption. Abnormalities that increase oxygen consumption (e.g., fever or seizures) or that decrease oxygen delivery (e.g., increased ICP, hypotension, hypoxia, hypocapnia, or anemia) can decrease SjvO(2). Measuring SjvO(2) continuously in the ICU in 177 patients with severe head injury, jugular venous desaturation (SjvO(2) < 50%) was identified at least once in 39% of the patients. Approximately half of the episodes of desaturation were due to intracranial hypertension and half were due to systemic causes. The occurrence of one or more episodes of desaturation was strongly associated with a poor outcome, suggesting that the reduction in oxygen delivery identified with the SjvO(2) monitoring contributed to the neurological injury. In the operating room, jugular venous desaturation was identified in 6 of 8 patients who were monitored during emergency evacuation of a traumatic intracranial hematoma. The lowest SjvO(2) observed was 28%. In all 8 cases, the SjvO(2) increased, from 47 +/- 10% to 63 +/- 5% after evacuation of the hematoma. Additional data supporting the hypothesis that these secondary insults identified with the SjvO(2) monitoring contribute to the patient's neurological injury come from measurement of the extracellular concentrations of lactate and excitatory amino acids in the brain using microdialysis. Lactate concentration increased from 0.9 +/- 0.3 to 2.4 +/- 0.5 mu mol/L and glutamate increased from 11.5 +/- 8.5 to 55.0 +/- 10.4 mu mol/L during 8 episodes of jugular venous desaturation in 7 of 22 patients monitored with microdialysis. SjvO(2) identifies global reductions in cerebral oxygenation due to a variety of causes, and is useful as a monitor for secondary insults in patients with severe head injury.			ROBERTSON, CS (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SENEFF MG, 1985, INTENS CARE MED, P16; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Stocchetti N, 1991, Minerva Anestesiol, V57, P319	9	99	108	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					891	896		10.1089/neu.1995.12.891			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600013	8594216				2022-02-06	
J	RUDGE, JS; PASNIKOWSKI, EM; HOLST, P; LINDSAY, RM				RUDGE, JS; PASNIKOWSKI, EM; HOLST, P; LINDSAY, RM			CHANGES IN NEUROTROPHIC FACTOR EXPRESSION AND RECEPTOR ACTIVATION FOLLOWING EXPOSURE OF HIPPOCAMPAL NEURON ASTROCYTE COCULTURES TO KAINIC ACID	JOURNAL OF NEUROSCIENCE			English	Article						BRAIN-DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; SIGNAL TRANSDUCTION; EPILEPSY; ISCHEMIA; EXCITOTOXICITY; RECEPTOR REGULATION	NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; ADULT-RAT BRAIN; VASOACTIVE-INTESTINAL-PEPTIDE; MOUSE ASTROGLIAL CELLS; REGIONAL DISTRIBUTION; PRIMARY CULTURES; NGF; SECRETION; SURVIVAL	Neurotrophic factor expression in the adult mammalian CNS is largely neuronal. However, upon traumatic injury reactive astrocytes express a number of neurotrophic factors including ciliary neurotrophic factor (CNTF), fibroblast growth factor (FGF), and NGF. In this study, we examined whether the upregulation of neurotrophic factors in reactive astrocytes and cultured astrocytes is a consequence of separation from their neuronal counterparts, and whether neurotrophic factor levels can be regulated by placing astrocytes into coculture with neurons. We show that reintroduction of rat hippocampal neurons to rat hippocampal astrocytes in vitro leads to a time dependent downregulation in astrocytes of the neurotrophic factors CNTF, NGF, and neurotrophin 3 (NT-3). In contrast, brain-derived neurotrophic factor (BDNF) mRNA, which is only expressed in neurons in these cultures is slightly increased. Once neurotrophic factor levels in cocultures had reached a steady state in the neuron/glia cocultures, we initiated a traumatic event with the excitotoxin kainic acid. BDNF protein was rapidly upregulated within 24 hr after lesion, whereas CNTF protein upregulation was delayed reaching maximal levels by 3 d. Despite the endogenous upregulation of both of these trophic factors, no activation of their respective receptors, as measured by tyrosine phosphorylation, was detectable following kainate administration. However, following addition of exogenous CNTF at any time point up to 24 hr after kainate administration, the beta components of the CNTF receptor (LIFR beta and gp130) could be phosphorylated. Furthermore, although activation of neuronal LIFR beta and gp130 by exogenous CNTF declined during the period of neuronal death, these receptors reappeared on astrocytes and could be activated by CNTF. in contrast, phosphorylation of TrkB by exogenous BDNF was undetectable by 24 hr and could not be reactivated after this point. These data suggest that the intimate association of astrocytes and neurons in the CNS serves to suppress astrocyte-derived neurotrophic factor expression and that neuronal loss leads to a derepression of neurotrophic factor synthesis in astrocytes. However, the upregulation of endogenous BDNF and CNTF observed after excitotoxic lesion in this culture model are insufficient to activate signal transduction and protect against neuronal loss.			RUDGE, JS (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.						ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ALTAR CA, 1992, J NEUROCHEM, V59, P2167; ASADA H, 1995, J NEUROSCI RES, V40, P22, DOI 10.1002/jnr.490400104; AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CARROLL P, 1993, GLIA, V9, P176, DOI 10.1002/glia.440090303; CONDORELLI DF, 1994, J NEUROCHEM, V63, P509; FERRARA N, 1988, BRAIN RES, V462, P223, DOI 10.1016/0006-8993(88)90550-1; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA S, 1987, BIOCHEM BIOPH RES CO, V147, P1048, DOI 10.1016/S0006-291X(87)80176-6; GASSER UE, 1990, J NEUROSCI, V10, P1276; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KNUSEL B, 1994, J NEUROSCI, V14, P1542, DOI 10.1523/JNEUROSCI.14-03-01542.1994; LASEK RJ, 1977, J CELL BIOL, V74, P501, DOI 10.1083/jcb.74.2.501; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LU B, 1991, J NEUROSCI, V11, P318; MANTHORPE M, 1986, ASTROCYTES, P315; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; NIETOSAMPEDRO M, 1983, J NEUROSCI, V3, P2219; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; Rudge J. S., 1993, ASTROCYTES PHARM FUN, P267; RUDGE JS, 1994, EUR J NEUROSCI, V6, P218, DOI 10.1111/j.1460-9568.1994.tb00264.x; RUDGE JS, 1992, EUR J NEUROSCI, V4, P459, DOI 10.1111/j.1460-9568.1992.tb00896.x; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; RUDGE JS, 1995, IBRO ABSTR, P147; SCHOOLTINK H, 1992, FEBS LETT, V314, P280, DOI 10.1016/0014-5793(92)81489-9; SHAO YP, 1994, GLIA, V11, P147, DOI 10.1002/glia.440110209; SOFRONIEW MV, 1990, SCIENCE, V247, P338, DOI 10.1126/science.1688664; SORG O, 1991, BRAIN RES, V563, P227, DOI 10.1016/0006-8993(91)91538-C; SORG O, 1992, J NEUROSCI, V12, P4923; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VARON SS, 1979, NEUROSCI RES PROG B, V17, P6; VIGE X, 1992, BRAIN RES, V591, P345, DOI 10.1016/0006-8993(92)91718-T; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YAMAKUNI T, 1987, FEBS LETT, V223, P117, DOI 10.1016/0014-5793(87)80520-3; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1992, J NEUROSCI, V12, P4793	65	99	99	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT	1995	15	10					6856	6867					12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	TB904	WOS:A1995TB90400048	7472443				2022-02-06	
J	COWEN, TD; MEYTHALER, JM; DEVIVO, MJ; IVIE, CS; LEBOW, J; NOVACK, TA				COWEN, TD; MEYTHALER, JM; DEVIVO, MJ; IVIE, CS; LEBOW, J; NOVACK, TA			INFLUENCE OF EARLY VARIABLES IN TRAUMATIC BRAIN INJURY ON FUNCTIONAL INDEPENDENCE MEASURE SCORES AND REHABILITATION LENGTH OF STAY AND CHARGES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; COMA SCALE	Objective: To determine the relationship between early variables (initial Glasgow Coma Scale [GCS] scores, computed tomography [CT] findings, presence of skeletal trauma, age, length of acute hospitalization) and outcome variables (Functional Independence Measure [FIM] scores, rehabilitation length of stay [LOS], rehabilitation charges) in traumatic brain injury (TBI). Design: Inception cohort. Setting: University tertiary care rehabilitation center. Patients: 91 patients with TBI. interventions: Inpatient rehabilitation. Main Outcome Measures: FIM, rehabilitation LOS, and rehabilitation charges. Results: Patients in the severely impaired (GCS = 3 to 7) group showed significantly lower (p = .01) mean admission and discharge motor scores (21.26, 39.83) than patients in the mildly impaired (GCS = 13 to 15) group (38.86, 55.29). Cognitive scores were also significantly lower (p < .01) in the severely impaired group on admission (26.73 vs 54.14) and discharge (42.28 vs 66.48). These findings continued to be statistically significant (p < .01) after regression analysis accounted for the other early variables previously listed. Regression analysis also illustrated that longer acute hospitalization LOS was independently associated with significantly lower admission motor (p < .01) and cognitive (p = .05) scores, and significantly higher (p = .01) rehabilitation charges. Patients with CT findings of intracranial bleed with skull fracture had longer total LOS (70.88 vs 43.08 days; p < .05), rehabilitation LOS (30.01 vs 19.68 days; p < .10), and higher rehabilitation charges ($43,346 vs $25,780; p (.05). Paradoxically, those patients in a motor vehicle crash with an extremity bone fracture had significantly higher (p = .002; p = .04 after regression analysis) FIM cognitive scores on admission (48.30 vs 27.28) and discharge (64.74 vs 45.78) than those without a fracture. Finally, data available on rehabilitation admission were used to predict discharge outcomes. The percentage of explained variance for each outcome variable is as follows: discharge FIM motor score, 69.5%; discharge FIM cognitive score, 71.2%; rehabilitation LOS, 54.1%; rehabilitation charges, 61.1%. The most powerful predictor of LOS and charges was the admission FIM motor score (p < .001), followed by CT findings (p = .02) and age (p = .04). Conclusion: Information readily available on rehabilitation admission, particularly the FIM motor score, may be useful in predicting discharge FIM scores as well as utilization of medical rehabilitation resources. Earlier transfer to rehabilitation may result in higher functional status and lower rehabilitation charges, as well as lower acute hospitalization charges. The presence of extremity fractures encountered during a motor vehicle crash is associated with a more favorable outcome in TBI as evidenced by higher discharge FIM cognitive scores. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV ALABAMA,BIRMINGHAM MED CTR,DEPT PHYS MED & REHABIL,BIRMINGHAM,AL								ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; GRANGER CV, 1986, GUIDE USE UNIFORM DA; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TEASDALE G, 1974, LANCET, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	19	99	101	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1995	76	9					797	803		10.1016/S0003-9993(95)80542-7			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	RU994	WOS:A1995RU99400001	7668948				2022-02-06	
J	ISHIGE, N; PITTS, LH; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM				ISHIGE, N; PITTS, LH; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM			EFFECT OF HYPOXIA ON TRAUMATIC BRAIN INJURY IN RATS .1. CHANGES IN NEUROLOGICAL FUNCTION, ELECTROENCEPHALOGRAMS, AND HISTOPATHOLOGY	NEUROSURGERY			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL SURG,EDITORIAL OFF,1360 9TH AVE,SUITE 210,SAN FRANCISCO,CA 94143								BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BOSE B, 1984, BRAIN RES, V311, P385, DOI 10.1016/0006-8993(84)90106-9; CHIAPPA KH, 1979, STROKE, V10, P381, DOI 10.1161/01.STR.10.4.381; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GURDJIAN E, 1940, AM J PHYSL, V156, P149; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; KATSURADA K, 1973, SURGERY, V73, P191; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; LEVINE JE, 1979, NEW ENGL J MED, V301, P109; LEVY WJ, 1980, ANESTHESIOLOGY, V53, P223, DOI 10.1097/00000542-198009000-00009; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1965, BIOPHYSIK, V2, P230; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P1; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; Miller J D, 1980, Adv Neurol, V28, P413; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NELSON LR, 1976, NEURAL TRAUMA, P297; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; RAMPIL IJ, 1983, ANESTH ANALG, V62, P186; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1982, HEAD INJURY BASIC CL, P103; SAUNDERS D, 1981, BRIT J ANAESTH, V53, P1, DOI 10.1093/bja/53.1.1; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	35	99	99	1	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1987	20	6					848	853		10.1227/00006123-198706000-00005			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	H8835	WOS:A1987H883500004	3614563				2022-02-06	
J	Ellis, MJ; Ritchie, LJ; Koltek, M; Hosain, S; Cordingley, D; Chu, S; Selci, E; Leiter, J; Russell, K				Ellis, Michael J.; Ritchie, Lesley J.; Koltek, Mark; Hosain, Shahid; Cordingley, Dean; Chu, Stephanie; Selci, Erin; Leiter, Jeff; Russell, Kelly			Psychiatric outcomes after pediatric sports-related concussion	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						psychiatric disorder; sports-related concussion; postconcussion syndrome; pediatric; depression; anxiety; suicide; trauma	TRAUMATIC BRAIN-INJURY; 1ST 6 MONTHS; PERSONALITY-CHANGE; POSTCONCUSSION SYNDROME; DEPRESSION DIAGNOSIS; ANXIETY DISORDERS; SYMPTOM SEVERITY; HIGH-SCHOOL; CHILDREN; ADOLESCENTS	OBJECT The objectives of this study were twofold: 1) to examine the prevalence of emotional symptoms among children and adolescents with a sports-related concussion (SRC) who were referred to a multidisciplinary pediatric concussion program and 2) to examine the prevalence, clinical features, risk factors, and management of postinjury psychiatric outcomes among those in this clinical population. METHODS The authors conducted a retrospective chart review of all patients with SRC referred to a multidisciplinary pediatric concussion program between September 2013 and October 2014. Clinical assessments carried out by a single neurosurgeon included clinical history, physical examination, and Post-Concussion Symptom Scale (PCSS) scoring. Postinjury psychiatric outcomes were defined as a subjective worsening of symptoms of a preinjury psychiatric disorder or new and isolated suicidal ideation or diagnosis of a novel psychiatric disorder (NPD). An NPD was defined as a newly diagnosed psychiatric disorder that occurred in a patient with or without a lifetime preinjury psychiatric disorder after a concussion. Clinical resources, therapeutic interventions, and clinical and return-to-play outcomes are summarized. RESULTS One hundred seventy-four patients (mean age 14.2 years, 61.5% male) were included in the study. At least 1 emotional symptom was reported in 49.4% of the patients, and the median emotional PCSS subscore was 4 (inter-quartile range 1-8) among those who reported at least 1 emotional symptom. Overall, 20 (11.5%) of the patients met the study criteria for a postinjury psychiatric outcome, including 14 patients with an NPD, 2 patients with isolated suicidal ideation, and 4 patients with worsening symptoms of a preinjury psychiatric disorder. Female sex, a higher initial PCSS score, a higher emotional PCSS subscore, presence of a preinjury psychiatric history, and presence of a family history of psychiatric illness were significantly associated with postinjury psychiatric outcomes. Interventions for patients with postinjury psychiatric outcomes included pharmacological therapy alone in 2 patients (10%), cognitive behavioral therapy alone in 4 (20%), multimodal therapy in 9 (45%), and no treatment in 5 (25%). Overall, 5 (25%) of the patients with postinjury psychiatric disorders were medically cleared to return to full sports participation, whereas 5 (25%) were lost to follow-up and 9 (45%) remained in treatment by the multidisciplinary concussion program at the end of the study period. One patient who was asymptomatic at the time of initial consultation committed suicide. CONCLUSIONS Emotional symptoms were commonly reported among pediatric patients with SRC referred to a multidisciplinary pediatric concussion program. In some cases, these symptoms contributed to the development of an NPD, isolated suicidal ideation, and worsening symptoms of a preexisting psychiatric disorder. Future research is needed to clarify the prevalence, pathophysiology, risk factors, and evidence-based management of postinjury psychiatric outcomes after pediatric SRC. Successful management of these patients requires prompt recognition and multidisciplinary care by experts with clinical training and experience in concussion and psychiatry.	[Ellis, Michael J.; Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; Chu, Stephanie; Selci, Erin; Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Ritchie, Lesley J.] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada; [Koltek, Mark; Hosain, Shahid] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; Koltek, Mark; Hosain, Shahid; Cordingley, Dean; Leiter, Jeff] Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.; Chu, Stephanie; Selci, Erin; Russell, Kelly] Childrens Hosp, Res Inst Manitoba, Winnipeg, MB R3A 1S1, Canada; [Ellis, Michael J.; Ritchie, Lesley J.; Koltek, Mark; Hosain, Shahid; Cordingley, Dean; Chu, Stephanie; Selci, Erin; Leiter, Jeff; Russell, Kelly] Canada North Concuss Network, Winnipeg, MB, Canada		Ellis, MJ (corresponding author), Pan Am Clin, Pan Am Concuss Program, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com	Meijer, Anna/K-5118-2016	Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation; Manitoba Health Research Council	We thank the Pan Am Clinic Foundation and the Manitoba Health Research Council for their financial support of this study.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2015, J NEUROSURG PEDIAT, V2, P1; Fletcher JM, 2008, HEALTH ECON, V17, P1215, DOI 10.1002/hec.1319; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; LEWINSOHN PM, 1993, J AM ACAD CHILD PSY, V32, P60, DOI 10.1097/00004583-199301000-00009; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P272, DOI 10.1176/appi.neuropsych.12040078; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moore E, 2014, J HEAD TRAUMA REHAB, V29, P239, DOI 10.1097/HTR.0b013e31828f9876; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Rune V, 1970, ACTA PAEDIATR SC   S, V209, P3; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	56	98	98	1	51	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2015	16	6					709	718		10.3171/2015.5.PEDS15220			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CX0FM	WOS:000365372300013	26359916	Bronze			2022-02-06	
J	Gracies, JM; Brashear, A; Jech, R; McAllister, P; Banach, M; Valkovic, P; Walker, H; Marciniak, C; Deltombe, T; Skoromets, A; Khatkova, S; Edgley, S; Gul, F; Catus, F; De Fer, BB; Vilain, C; Picaut, P				Gracies, Jean-Michel; Brashear, Allison; Jech, Robert; McAllister, Peter; Banach, Marta; Valkovic, Peter; Walker, Heather; Marciniak, Christina; Deltombe, Thierry; Skoromets, Alexander; Khatkova, Svetlana; Edgley, Steven; Gul, Fatma; Catus, France; De Fer, Beatrice Bois; Vilain, Claire; Picaut, Philippe		Int AbobotulinumtoxinA Adult Upper	Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial	LANCET NEUROLOGY			English	Article							TOXIN TYPE-A; BOTULINUM-TOXIN; REDUCING SPASTICITY; UPPER EXTREMITY; ASHWORTH SCALE; ARM SPASTICITY; TARDIEU SCALE; PLACEBO; INJECTION; NEUROTOXIN	Background Resistance from antagonistic muscle groups might be a crucial factor reducing function in chronic hemiparesis. The resistance due to spastic co-contraction might be reduced by botulinum toxin injections. We assessed the effects of abobotulinumtoxinA injection in the upper limb muscles on muscle tone, spasticity, active movement, and function. Methods In this randomised, placebo-controlled, double-blind study, we enrolled adults (aged 18-80 years) at least 6 months after stroke or brain trauma from 34 neurology or rehabilitation clinics in Europe and the USA. Eligible participants were randomly allocated in a 1: 1: 1 ratio with a computer-generated list to receive a single injection session of abobotulinumtoxinA 500 U or 1000 U or placebo into the most hypertonic muscle group among the elbow, wrist, or finger flexors (primary target muscle group [PTMG]), and into at least two additional muscle groups from the elbow, wrist, or finger flexors or shoulder extensors. Patients and investigators were masked to treatment allocation. The primary endpoint was the change in muscle tone (Modified Ashworth Scale [MAS]) in the PTMG from baseline to 4 weeks. Secondary endpoints were Physician Global Assessment (PGA) at week 4 and change from baseline to 4 weeks in the perceived function (Disability Assessment Scale [DAS]) in the principal target of treatment, selected by the patient together with physician from four functional domains (dressing, hygiene, limb position, and pain). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01313299. Findings 243 patients were randomly allocated to placebo (n=81), abobotulinumtoxinA 500 U (n=81), or abobotulinumtoxinA 1000 U (n=81). Mean change in MAS score from baseline at week 4 in the PTMG was -0.3 (SD 0.6) in the placebo group (n=79), -1.2 (1.0) in the abobotulinumtoxinA 500 U group (n=80; difference -0.9, 95% CI -1.2 to -0.6; p<0.0001 vs placebo), and -1.4 (1.1) in the abobotulinumtoxinA 1000 U group (n=79; -1.1, -1.4 to -0.8; p<0.0001 vs placebo). Mean PGA score at week 4 was 0.6 (SD 1.0) in the placebo group (n=78), 1.4 (1.1) in the abobotulinumtoxinA 500 U group (n=80; p=0.0003 vs placebo), and 1.8 (1.1) in the abobotulinumtoxinA 1000 U group (n=78; p<0.0001 vs placebo). Mean change from baseline at week 4 in DAS score for the principal target of treatment was -0.5 (0.7) in the placebo group (n=79), -0.7 (0.8) in the abobotulinumtoxinA 500 U group (n=80; p=0.2560 vs placebo), and -0.7 (0.7) in the abobotulinumtoxinA 1000 U group (n=78; p=0.0772 vs placebo). Three serious adverse events occurred in each group and none were treatment related; two resulted in death (from pulmonary oedema in the placebo group and a pre-existing unspecified cardiovascular disorder in the abobotulinumtoxinA 500 U group). Adverse events that were thought to be treatment related occurred in two (2%), six (7%), and seven (9%) patients in the placebo, abobotulinumtoxinA 500 U, and abobotulinumtoxinA 1000 U groups, respectively. The most common treatment-related adverse event was mild muscle weakness. All adverse events were mild or moderate. Interpretation AbobotulinumtoxinA at doses of 500 U or 1000 U injected into upper limb muscles provided tone reduction and clinical benefit in hemiparesis. Future research into the treatment of spastic paresis with botulinum toxin should use active movement and function as primary outcome measures.	[Gracies, Jean-Michel] Univ Paris Est Creteil, Hosp Albert Chenevier, Serv Reeduc Neurolocomotrice, EA 7377 BIOTN, F-94010 Creteil, France; [Brashear, Allison] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; [Jech, Robert] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Jech, Robert] Gen Fac Hosp, Prague, Czech Republic; [McAllister, Peter] New England Inst Neurol & Headache, Stamford, CT USA; [Banach, Marta] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland; [Valkovic, Peter] Comenius Univ, Dept Neurol 2, Bratislava, Slovakia; [Valkovic, Peter] Univ Hosp, Bratislava, Slovakia; [Walker, Heather] Univ N Carolina, Chapel Hill, NC USA; [Marciniak, Christina] Northwestern Univ, Chicago, IL 60611 USA; [Marciniak, Christina] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Deltombe, Thierry] Univ Cathol Louvain Namur, Ctr Hosp Univ Dinant Godinne, Serv Med Phys & Readaptat, Yvoir, Belgium; [Skoromets, Alexander] St Petersburg State Med Univ IP Pavlov, State Budgetary Educ Inst Higher Profess Educ, St Petersburg, Russia; [Khatkova, Svetlana] Fed State Hosp Treatments, Dept Neurol, Moscow, Russia; [Khatkova, Svetlana] Minist Hlth & Social Dev Russian Federat, Rehabil Ctr, Moscow, Russia; [Edgley, Steven] Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT USA; [Gul, Fatma] Univ Texas SW Med Ctr Dallas, Dallas, TX 75230 USA; [Catus, France] Assesoria Croissance, Santiago, Chile; [De Fer, Beatrice Bois; Vilain, Claire; Picaut, Philippe] Ipsen Innovat, Les Ulis, France		Gracies, JM (corresponding author), Univ Paris Est Creteil, Hosp Albert Chenevier, Serv Reeduc Neurolocomotrice, EA 7377 BIOTN, 51 Av Marechal Lattre Tassigny, F-94010 Creteil, France.	jean-michel.gracies@aphp.fr	Boyer, Francois Constant/P-4544-2016	Boyer, Francois Constant/0000-0003-1035-9108; Marciniak, Christina/0000-0003-3300-0050; remy-neris, olivier/0000-0001-6862-8433; Jech, Robert/0000-0002-9732-8947; Lejeune, Thierry/0000-0001-5741-7753	IpsenIpsen	The manuscript was written with editorial assistance from Martin Gilmour (ESP Bioscience, Crowthorne, UK), funded by Ipsen. The clinical research organisation responsible for the study was INC Research. We thank all the patients who participated in this study and their families; Pascale Cavillon (Ipsen) for study coordination; and the following research associates from study centres: G Stoquart and R Rak (both in Belgium), Y Angerova (Czech Republic), N Bayle and C M Loche (both in France), T Ialongo (Italy), A Botsina and A Korenko (both in Russia), J Benetin (Slovakia), M Pautler, C Dolezal, C McAllister, D Brown, G Kim, M D C Lichtenberger, A A Nmashie, R L Harvey, and Y Salem (all in the USA).	Alibiglou L, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-18; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bhakta BB, 2000, J NEUROL NEUROSUR PS, V69, P217, DOI 10.1136/jnnp.69.2.217; Bohannon R. W., 1987, PHYS THER, V67, P206; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Brashear A, 2002, ARCH PHYS MED REHAB, V83, P1349, DOI 10.1053/apmr.2002.35474; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; Demetrios M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009689.pub2; Diong J, 2013, AM J PHYS MED REHAB, V92, P565, DOI 10.1097/PHM.0b013e318274605a; Francis HP, 2004, J NEUROL NEUROSUR PS, V75, P1547, DOI 10.1136/jnnp.2003.025551; Gracies JM, 2010, EUR J PHYS REHAB MED, V46, P411; Gracies JM, 2014, ARCH PHYS MED REHAB, V95, P1303, DOI 10.1016/j.apmr.2014.03.016; Gracies JM, 2010, ARCH PHYS MED REHAB, V91, P421, DOI 10.1016/j.apmr.2009.11.017; Gracies JM, 2005, MUSCLE NERVE, V31, P535, DOI 10.1002/mus.20284; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Jost WH, 2014, J NEUROL SCI, V337, P86, DOI 10.1016/j.jns.2013.11.022; Kaji R, 2010, J NEUROL, V257, P1330, DOI 10.1007/s00415-010-5526-3; Kanovsky P, 2009, CLIN NEUROPHARMACOL, V32, P259, DOI 10.1097/WNF.0b013e3181b13308; Kinnear BZ, 2014, PHYS THER, V94, P1569, DOI 10.2522/ptj.20130408; Kinnear BZ, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-29; Lance J.W., 1980, SPASTICITY DISORDERE, P185; Leonard CT, 2006, J REHABIL MED, V38, P243, DOI 10.1080/16501970600609808; Patrick E, 2006, CLIN REHABIL, V20, P173, DOI 10.1191/0269215506cr922oa; Picelli A, 2014, CLIN REHABIL, V28, P232, DOI 10.1177/0269215513497735; Rosales RL, 2012, NEUROREHAB NEURAL RE, V26, P812, DOI 10.1177/1545968311430824; Sheean G, 2010, EUR J NEUROL, V17, P74, DOI 10.1111/j.1468-1331.2010.03129.x; Simpson DM, 2008, NEUROLOGY, V70, P1691, DOI 10.1212/01.wnl.0000311391.00944.c4; Simpson DM, 2009, J NEUROL NEUROSUR PS, V80, P380, DOI 10.1136/jnnp.2008.159657; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Smith SJ, 2000, CLIN REHABIL, V14, P5, DOI 10.1191/026921500666642221; Turner-Stokes L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002771; Ward AB, 2014, J REHABIL MED, V46, P504, DOI 10.2340/16501977-1817; Wissel J, 2009, J REHABIL MED, V41, P13, DOI 10.2340/16501977-0303; Yelnik AP, 2007, J NEUROL NEUROSUR PS, V78, P845, DOI 10.1136/jnnp.2006.103341	34	98	113	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					992	1001		10.1016/S1474-4422(15)00216-1			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2VI	WOS:000361188400010	26318836				2022-02-06	
J	Corwin, DJ; Wiebe, DJ; Zonfrillo, MR; Grady, MF; Robinson, RL; Goodman, AM; Master, CL				Corwin, Daniel J.; Wiebe, Douglas J.; Zonfrillo, Mark R.; Grady, Matthew F.; Robinson, Roni L.; Goodman, Arlene M.; Master, Christina L.			Vestibular Deficits following Youth Concussion	JOURNAL OF PEDIATRICS			English	Article							REHABILITATION; SPORT; RECOVERY; IMPACT	Objective To characterize the prevalence and recovery of pediatric patients with concussion who manifest clinical vestibular deficits and to describe the correlation of these deficits with neurocognitive function, based on computerized neurocognitive testing, in a sample of pediatric patients with concussion. Methods This was a retrospective cohort study of patients ages 5-18 years with concussion referred to a tertiary pediatric hospital-affiliated sports medicine clinic from July 1, 2010 to December 31, 2011. A random sample of all eligible patient visits was obtained, and all related visits for those patients were reviewed. Results A total of 247 patients were chosen from 3740 eligible visits for detailed review and abstraction; 81% showed a vestibular abnormality on initial clinical examination. Those patients with vestibular signs on the initial examination took a significantly longer time to return to school (median 59 days vs 6 days, P = .001) or to be fully cleared (median 106 days vs 29 days, P = .001). They additionally scored more poorly on initial computerized neurocognitive testing, and it took longer for them to recover from neurocognitive deficits. Those patients with 3 or more previous concussions had a greater prevalence of vestibular deficits, and it took longer for those deficits to resolve. Conclusion Vestibular deficits in children and adolescents with a history of concussion are highly prevalent. These deficits appear to be associated with extended recovery times and poorer performance on neurocognitive testing. Further studies evaluating the effectiveness of vestibular therapy on improving such deficits are warranted.	[Corwin, Daniel J.; Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Wiebe, Douglas J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Wiebe, Douglas J.; Zonfrillo, Mark R.; Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Robinson, Roni L.; Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Goodman, Arlene M.] St Peters Sports Med Inst, Pediat Sports Med, Somerset, NJ USA		Master, CL (corresponding author), Childrens Hosp Philadelphia, Div Pediat Orthoped, Pediat & Adolescent Sports Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu	Wiebe, Douglas J/Q-1168-2017; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Master, Christina/0000-0002-6717-4270	Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003]; Children's Hospital of Philadelphia Clinical Translational Sciences Award; research institute funding for the Comparative Effectiveness Program; National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003] Funding Source: NIH RePORTER	Supported by the Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative, the National Institutes of Health, National Center for Advancing Translational Sciences (UL1TR000003 for the University of Pennsylvania Health System), the Children's Hospital of Philadelphia Clinical Translational Sciences Award, research institute funding for the Comparative Effectiveness Program, and the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08HD073241 [to M.Z.]). The authors declare no conflicts of interest.	Aligene K, 2013, NEUROREHABILITATION, V32, P543, DOI 10.3233/NRE-130876; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Chamberlain, 1994, ADV ECONOMETRICS, V1, P171, DOI DOI 10.1017/CCOL0521444594.005; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Fukushima K, 1997, EXP BRAIN RES, V117, P1, DOI 10.1007/PL00005786; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanes DA, 2006, J VESTIBUL RES-EQUIL, V16, P75; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; Master CL, 2014, ANN INTERN MED, V160, DOI 10.7326/0003-4819-160-3-201402040-01002; Master CL, 2012, PEDIATR ANN, V41, pE174, DOI 10.3928/00904481-20120827-08; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; O'Reilly RC, 2010, OTOL NEUROTOL, V31, P1441, DOI 10.1097/MAO.0b013e3181f20673; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thiagarajan P, 2013, OPTOMETRY VISION SCI, V90, P57, DOI 10.1097/OPX.0b013e31827a233e; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	31	98	98	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAY	2015	166	5					1221	1225		10.1016/j.jpeds.2015.01.039			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CG6DW	WOS:000353387100026	25748568	Green Accepted			2022-02-06	
J	Namjoshi, DR; Cheng, WH; McInnes, KA; Martens, KM; Carr, M; Wilkinson, A; Fan, JJ; Robert, J; Hayat, A; Cripton, PA; Wellington, CL				Namjoshi, Dhananjay R.; Cheng, Wai Hang; McInnes, Kurt A.; Martens, Kris M.; Carr, Michael; Wilkinson, Anna; Fan, Jianjia; Robert, Jerome; Hayat, Arooj; Cripton, Peter A.; Wellington, Cheryl L.			Merging pathology with biomechanics using CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration): a novel, surgery-free model of traumatic brain injury	MOLECULAR NEURODEGENERATION			English	Article						Traumatic brain injury; Animal model of traumatic brain injury; Animal model of closed head injury; Diffuse axonal injury; Microglia activation; Neuroinflammation; Tau hyperphosphorylation; Head kinematics; Head injury biomechanics; Impact-acceleration traumatic brain injury model; Surgery-free animal model of traumatic brain injury; Traumatic brain injury biomechanics	DIFFUSE AXONAL INJURY; PROFESSIONAL FOOTBALL; ANGULAR-ACCELERATION; MOUSE MODEL; RAT MODEL; CONCUSSION; MICE; EPIDEMIOLOGY; MECHANISMS; PATHOPHYSIOLOGY	Background: Traumatic brain injury (TBI) is a major health care concern that currently lacks any effective treatment. Despite promising outcomes from many preclinical studies, clinical evaluations have failed to identify effective pharmacological therapies, suggesting that the translational potential of preclinical models may require improvement. Rodents continue to be the most widely used species for preclinical TBI research. As most human TBIs result from impact to an intact skull, closed head injury (CHI) models are highly relevant, however, traditional CHI models suffer from extensive experimental variability that may be due to poor control over biomechanical inputs. Here we describe a novel CHI model called CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration) that fully integrates biomechanical, behavioral, and neuropathological analyses. CHIMERA is distinct from existing neurotrauma model systems in that it uses a completely non-surgical procedure to precisely deliver impacts of prescribed dynamic characteristics to a closed skull while enabling kinematic analysis of unconstrained head movement. In this study, we characterized head kinematics as well as functional, neuropathological, and biochemical outcomes up to 14d following repeated TBI (rTBI) in adult C57BL/6 mice using CHIMERA. Results: Head kinematic analysis showed excellent repeatability over two closed head impacts separated at 24h. Injured mice showed significantly prolonged loss of righting reflex and displayed neurological, motor, and cognitive deficits along with anxiety-like behavior. Repeated TBI led to diffuse axonal injury with extensive microgliosis in white matter from 2-14d post-rTBI. Injured mouse brains also showed significantly increased levels of TNF-alpha and IL-1 beta and increased endogenous tau phosphorylation. Conclusions: Repeated TBI using CHIMERA mimics many of the functional and pathological characteristics of human TBI with a reliable biomechanical response of the head. This makes CHIMERA well suited to investigate the pathophysiology of TBI and for drug development programs.	[Namjoshi, Dhananjay R.; Cheng, Wai Hang; Martens, Kris M.; Carr, Michael; Wilkinson, Anna; Fan, Jianjia; Robert, Jerome; Hayat, Arooj; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Namjoshi, Dhananjay R.] Univ British Columbia, Grad Program Neurosci, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Mech Engn, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Orthopaed, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V5Z 1M9, Canada; [Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V5Z 1M9, Canada		Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.	wcheryl@mail.ubc.ca	Cripton, Peter Alec/AAC-8268-2020; Robert, Jerome/C-6226-2018	Cripton, Peter Alec/0000-0002-5067-0833; Robert, Jerome/0000-0002-2847-9362; Cheng, Wai Hang/0000-0002-3408-9184; McInnes, Kurt/0000-0001-5931-2963; Namjoshi, Dhananjay/0000-0003-1753-5581	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 123461]; Alzheimer Society Research Program (ASRP) Doctoral Award; ASRP Doctoral Award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao	This work was supported by an operating grant from the Canadian Institutes of Health Research to CLW (MOP 123461). DRN was supported by an Alzheimer Society Research Program (ASRP) Doctoral Award (Alzheimer Society of Canada, http://www.alzheimer.ca/en/Research/Alzheimer-Society-Research-Program). WHC is supported by an ASRP Doctoral Award and Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We are indebted to Dr. Peter Davies (Albert Einstein College of Medicine) for the kind gifts of tau antibodies.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Blumbergs PC, 1997, HEAD INJURY PATHOPHY, P39; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4; Faul M, 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Gerberding JLBS, 2003, REP C MILD TRAUM BRA; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2012, SCI TRANSL MED, V4; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McIntosh TK, 1996, LAB INVEST, V74, P315; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Nguyen U., 2011, NAT METHODS, V8, pV; O'Neill RA, 2006, P NATL ACAD SCI USA, V103, P16153, DOI 10.1073/pnas.0607973103; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Peng Y, 2014, INT J CRASHWORTHINES, V19, P105, DOI 10.1080/13588265.2013.805290; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Sevagan G, 2013, P I MECH ENG H, V227, P778, DOI 10.1177/0954411913483430; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	69	98	99	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1750-1326			MOL NEURODEGENER	Mol. Neurodegener.	DEC 1	2014	9								55	10.1186/1750-1326-9-55			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX6BH	WOS:000347008000001	25443413	Green Published, gold			2022-02-06	
J	Nordstrom, A; Nordstrom, P; Ekstrand, J				Nordstrom, Anna; Nordstrom, Peter; Ekstrand, Jan			Sports-related concussion increases the risk of subsequent injury by about 50% in elite male football players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CONSENSUS STATEMENT; EPIDEMIOLOGY; SOCCER; RECOVERY; OUTCOMES; HEAD	Background Little is known about the short-term and long-term sequelae of concussion, and about when athletes who have sustained such injuries can safely return to play. Purpose To examine whether sports-related concussion increases the risk of subsequent injury in elite male football players. Study design Prospective cohort study. Methods Injuries were registered for 46 male elite football teams in 10 European countries in the 2001/ 2002-2011/ 2102 seasons. Two survival models were used to analyse whether concussion increased the subsequent risk of an injury in the first year. Results During the follow-up period, 66 players sustained concussions and 1599 players sustained other injuries. Compared with the risk following other injuries, concussion was associated with a progressively increased risk of a subsequent injury in the first year (0 to <3 months, HR=1.56, 95% CI 1.09 to 2.23; 3 to <6 months, HR=2.78, 95% CI 1.58 to 4.89; 6-12 months, HR=4.07, 95% CI 2.14 to 7.76). In the second model, after adjustment for the number of injuries in the year preceding the concussion, this injury remained significantly associated with the risk of subsequent injury in the first year (HR=1.47, 95% CI 1.05 to 2.05). Conclusions Concussion was a risk factor for sustaining subsequent injury within the following year. In-depth medical evaluation, which includes neurological and cognitive assessment, is warranted within the concussion management and return-to-play process.	[Nordstrom, Anna] Umea Univ, Dept Surg & Perioperat Sci, S-90185 Umea, Sweden; [Nordstrom, Peter] Umea Univ, Dept Community Med & Rehabil, S-90185 Umea, Sweden; [Ekstrand, Jan] Linkoping Univ, Dept Med & Hlth Sci, Div Community Med, Football Res Grp, Linkoping, Sweden		Nordstrom, A (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, S-90185 Umea, Sweden.	anna.nordstrom@idrott.umu.se	Nordstrom, Anna/O-2504-2018; Nordstrom, Anna/F-2238-2010	Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Peter/0000-0003-2924-508X	UEFA; Swedish National Center for Research in Sports	The study was supported by grants from UEFA and the Swedish National Center for Research in Sports.	Al-Kashmiri A, 2006, TRAUMA, V8, P189, DOI 10.1177/1460408606071144; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ekstrand J, 2013, BRIT J SPORT MED, V47, P732, DOI 10.1136/bjsports-2013-092394; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nilsson M, 2013, CLIN J SPORT MED, V23, P255, DOI 10.1097/JSM.0b013e31827ee6f8; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nordstrom A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001151; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084	28	98	98	0	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2014	48	19					1447	1450		10.1136/bjsports-2013-093406			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	AP3AL	WOS:000341947200011	25082616	Green Published, Bronze			2022-02-06	
J	Pham, HP; Shaz, BH				Pham, H. P.; Shaz, B. H.			Update on massive transfusion	BRITISH JOURNAL OF ANAESTHESIA			English	Article						massive transfusion; massive transfusion protocol; paediatric transfusion protocol; transfusion management	PROTHROMBIN COMPLEX CONCENTRATE; FRESH WHOLE-BLOOD; LIFE-THREATENING HEMORRHAGE; RECOMBINANT-FACTOR-VIIA; TRAUMATIC BRAIN-INJURY; ACTIVATED FACTOR-VII; FACTOR-XIII ACTIVITY; GROUP-A PLASMA; TRANEXAMIC ACID; EARLY COAGULOPATHY	Massive haemorrhage requires massive transfusion (MT) to maintain adequate circulation and haemostasis. For optimal management of massively bleeding patients, regardless of aetiology (trauma, obstetrical, surgical), effective preparation and communication between transfusion and other laboratory services and clinical teams are essential. A well-defined MT protocol is a valuable tool to delineate how blood products are ordered, prepared, and delivered; determine laboratory algorithms to use as transfusion guidelines; and outline duties and facilitate communication between involved personnel. In MT patients, it is crucial to practice damage control resuscitation and to administer blood products early in the resuscitation. Trauma patients are often admitted with early trauma-induced coagulopathy (ETIC), which is associated with mortality; the aetiology of ETIC is likely multifactorial. Current data support that trauma patients treated with higher ratios of plasma and platelet to red blood cell transfusions have improved outcomes, but further clinical investigation is needed. Additionally, tranexamic acid has been shown to decrease the mortality in trauma patients requiring MT. Greater use of cryoprecipitate or fibrinogen concentrate might be beneficial in MT patients from obstetrical causes. The risks and benefits for other therapies (prothrombin complex concentrate, recombinant activated factor VII, or whole blood) are not clearly defined in MT patients. Throughout the resuscitation, the patient should be closely monitored and both metabolic and coagulation abnormalities corrected. Further studies are needed to clarify the optimal ratios of blood products, treatment based on underlying clinical disorder, use of alternative therapies, and integration of laboratory testing results in the management of massively bleeding patients.	[Pham, H. P.; Shaz, B. H.] New York Blood Ctr, New York, NY 10021 USA; [Pham, H. P.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA; [Shaz, B. H.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA		Shaz, BH (corresponding author), New York Blood Ctr, New York, NY 10021 USA.	bshaz@nybloodcenter.org		Pham, Huy/0000-0003-4168-3859; Shaz, Beth/0000-0002-2270-4821			Afshari A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007871.pub2; Ak K, 2009, J CARDIAC SURG, V24, P404, DOI 10.1111/j.1540-8191.2009.00840.x; [Anonymous], 2010, DEATHS MORT; Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; Blome M, 2005, THROMB HAEMOSTASIS, V93, P1101, DOI 10.1160/TH04-12-0799; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bolliger D, 2012, TRANSFUS MED REV, V26, P1, DOI 10.1016/j.tmrv.2011.07.005; Bolliger D, 2010, ANESTHESIOLOGY, V113, P1205, DOI 10.1097/ALN.0b013e3181f22b5a; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Callum JL, 2012, HEMATOL-AM SOC HEMAT, P522, DOI 10.1182/asheducation-2012.1.522; Cancio LC, 2008, J TRAUMA, V64, pS51, DOI 10.1097/TA.0b013e3181608c21; Chandler MH, 2012, SEMIN CARDIOTHORAC V, V16, P153, DOI 10.1177/1089253212452344; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Chidester SJ, 2012, J TRAUMA ACUTE CARE, V73, P1273, DOI 10.1097/TA.0b013e318265d267; Cid J, 2011, TRANSFUSION, V51, P1163, DOI 10.1111/j.1537-2995.2010.02953.x; Coakley M, 2006, J CARDIOTHOR VASC AN, V20, P548, DOI 10.1053/j.jvca.2006.01.016; Cohen B, 2013, BRIT J ANAESTH, V111, P62, DOI 10.1093/bja/aet405; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Cotton BA, 2009, J TRAUMA, V66, P41, DOI 10.1097/TA.0b013e31819313bb; Curry N, 2012, INJURY, V43, P1021, DOI 10.1016/j.injury.2012.03.014; Cushing M, 2011, MINERVA ANESTESIOL, V77, P349; Davenport R, 2011, BRIT J HAEMATOL, V155, P537, DOI 10.1111/j.1365-2141.2011.08885.x; de Moya MA, 2013, J TRAUMA ACUTE CARE, V74, P74; Dente CJ, 2009, J TRAUMA, V66, P1616, DOI 10.1097/TA.0b013e3181a59ad5; Diab YA, 2013, BRIT J HAEMATOL, V161, P15, DOI 10.1111/bjh.12247; Ducloy-Bouthors AS, 2011, CRIT CARE, V15, DOI 10.1186/cc10143; Dzik Walter H, 2004, Curr Hematol Rep, V3, P324; Dzik WH, 2011, CRIT CARE, V15, DOI 10.1186/cc10498; Fenger-Eriksen C, 2009, J THROMB HAEMOST, V7, P795, DOI 10.1111/j.1538-7836.2009.03331.x; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Friedman AJ, 2013, J CARDIOTHOR VASC AN, V27, pS44, DOI 10.1053/j.jvca.2013.05.016; Fries D, 2013, TRANSFUSION, V53, p91S, DOI 10.1111/trf.12041; Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF; Gilstad C, 2012, TRANSFUSION, V52, P930, DOI 10.1111/j.1537-2995.2011.03365.x; Girdauskas E, 2010, J THORAC CARDIOV SUR, V140, P1117, DOI 10.1016/j.jtcvs.2010.04.043; Goodnough LT, 2013, CURR OPIN ANESTHESIO, V26, P208, DOI 10.1097/ACO.0b013e32835d6f8f; Grottke O, 2011, BLOOD, V118, P1943, DOI 10.1182/blood-2011-03-343046; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Guerriero C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018987; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hendrickson JE, 2012, J PEDIAT, V160; Hendrickson JE, 2012, TRANSFUSION, V52, P1228, DOI 10.1111/j.1537-2995.2011.03458.x; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Ickx BE, 2010, EUR J ANAESTH, V27, P1031, DOI 10.1097/EJA.0b013e32833c30e3; Innerhofer P, 2013, INJURY, V44, P209, DOI 10.1016/j.injury.2012.08.047; Johansson PI, 2010, TRANSFUSION, V50, P701, DOI 10.1111/j.1537-2995.2009.02458.x; Karlsson M, 2009, THROMB HAEMOSTASIS, V102, P137, DOI 10.1160/TH08-09-0587; Kettner SC, 1998, BRIT J ANAESTH, V80, P313, DOI 10.1093/bja/80.3.313; Laverdiere Caroline, 2002, Pediatr Crit Care Med, V3, P335, DOI 10.1097/00130478-200210000-00001; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Levy JH, 2006, SEMIN HEMATOL, V43, pS59, DOI 10.1053/j.seminhematol.2005.11.019; Lier H, 2008, J TRAUMA, V65, P951, DOI 10.1097/TA.0b013e318187e15b; Lin YL, 2011, CAN MED ASSOC J, V183, pE9, DOI 10.1503/cmaj.100408; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2011, VOX SANG, V100, P231, DOI 10.1111/j.1423-0410.2010.01387.x; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; Martini WZ, 2007, ANN SURG, V246, P831, DOI 10.1097/SLA.0b013e3180cc2e94; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Mehr CR, 2013, J TRAUMA ACUTE CARE, V74, P1425, DOI 10.1097/TA.0b013e31828b813e; Mitterlechner T, 2011, J THROMB HAEMOST, V9, P729, DOI 10.1111/j.1538-7836.2011.04211.x; Molnar R, 2002, TRANSFUSION, V42, P177, DOI 10.1046/j.1537-2995.2002.00015.x; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Nunez TC, 2010, J TRAUMA, V68, P1498, DOI 10.1097/TA.0b013e3181d3cc25; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; O'Keeffe T, 2008, ARCH SURG-CHICAGO, V143, P686, DOI 10.1001/archsurg.143.7.686; Pasquali SK, 2012, J THORAC CARDIOV SUR, V143, P550, DOI 10.1016/j.jtcvs.2011.06.048; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Radwan ZA, 2013, JAMA SURG, V148, P170, DOI 10.1001/jamasurgery.2013.414; Rahe-Meyer N, 2009, BRIT J ANAESTH, V102, P785, DOI 10.1093/bja/aep089; Rahe-Meyer N, 2009, J THORAC CARDIOV SUR, V138, P694, DOI 10.1016/j.jtcvs.2008.11.065; Raymer JM, 2012, SURG CLIN N AM, V92, P221, DOI 10.1016/j.suc.2012.01.008; Reiss R F, 2000, Am J Crit Care, V9, P158; Reiss RF, 2000, AM J CRIT CARE, V9, P66; Ringer SA, 1998, PEDIATRICS, V101, P194, DOI 10.1542/peds.101.2.194; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Roberts I, 2011, LANCET, V377, P1096; Roberts I, 2011, INT J GYNECOL OBSTET, V115, P220, DOI 10.1016/j.ijgo.2011.09.001; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schreiber MA, 2007, J AM COLL SURGEONS, V205, P541, DOI 10.1016/j.jamcollsurg.2007.05.007; Seghatchian J, 2012, TRANSFUS APHER SCI, V47, P235, DOI 10.1016/j.transci.2012.06.001; Sethna NF, 2005, ANESTHESIOLOGY, V102, P727, DOI 10.1097/00000542-200504000-00006; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shaz BH, 2009, ANESTH ANALG, V108, P1760, DOI 10.1213/ane.0b013e3181a0b6c6; Sihler KC, 2010, CHEST, V137, P209, DOI 10.1378/chest.09-0252; Sorensen B, 2012, BRIT J SURG, V99, P40, DOI 10.1002/bjs.7770; Spinella PC, 2008, WORLD J SURG, V32, P2, DOI 10.1007/s00268-007-9201-5; Spinella PC, 2009, J TRAUMA, V66, pS69, DOI 10.1097/TA.0b013e31819d85fb; Stanworth SJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9394; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Tanaka KA, 2013, BRIT J ANAESTH, V111, P35, DOI 10.1093/bja/aet380; Tripodi A, 2009, BRIT J HAEMATOL, V147, P77, DOI 10.1111/j.1365-2141.2009.07833.x; Wang D, 2012, TRANSFUSION, V52, P1184, DOI 10.1111/j.1537-2995.2011.03466.x; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wikkelsoe AJ, 2011, ACTA ANAESTH SCAND, V55, P1174, DOI 10.1111/j.1399-6576.2011.02534.x; Yazer MH, 2007, TRANSFUSION, V47, P2197, DOI 10.1111/j.1537-2995.2007.01446.x; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Zielinski MD, 2013, J TRAUMA ACUTE CARE, V74, P69, DOI 10.1097/TA.0b013e3182788f8e	106	98	102	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2013	111			1			71	82		10.1093/bja/aet376			12	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	271HZ	WOS:000328383900007	24335401	Bronze			2022-02-06	
J	Huang, YY; Nagata, K; Tedford, CE; McCarthy, T; Hamblin, MR				Huang, Ying-Ying; Nagata, Kazuya; Tedford, Clark E.; McCarthy, Thomas; Hamblin, Michael R.			Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro	JOURNAL OF BIOPHOTONICS			English	Article							TRAUMATIC BRAIN-INJURY; NEAR-INFRARED LIGHT; TERM NEUROLOGICAL DEFICITS; RAT-LIVER MITOCHONDRIA; BIPHASIC DOSE-RESPONSE; CYTOCHROME-C-OXIDASE; HELIUM-NEON LASER; DIFFERENT WAVELENGTHS; DOPAMINERGIC-NEURONS; COGNITIVE DEFICITS		[Huang, Ying-Ying; Nagata, Kazuya; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China; [Nagata, Kazuya] Univ Tokyo, Grad Sch Med, Tokyo 1138654, Japan; [Tedford, Clark E.; McCarthy, Thomas] PhotoThera Inc, Carlsbad, CA USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Hamblin, Michael R/H-2758-2019; Huang, Yingying/G-3153-2011	Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Huang, Yingying/0000-0003-3066-6981	Photothera Inc; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by sponsored research funding from Photothera Inc and by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research (FA9950-04-1-0079)	Albertini R, 2007, J PHOTOCH PHOTOBIO B, V89, P50, DOI 10.1016/j.jphotobiol.2007.08.005; Ando T, 2011, PLOS ONE, V6; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bogeski I, 2006, CELL CALCIUM, V40, P1, DOI 10.1016/j.ceca.2006.03.003; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Callaghan GA, 1996, LASER SURG MED, V19, P201; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chen X, 2009, MOL CELL BIOCHEM, V332, P85, DOI 10.1007/s11010-009-0177-3; Choi K, 2009, CURR NEUROVASC RES, V6, P213, DOI 10.2174/156720209789630375; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Ciancarelli I, 2012, CURR NEUROVASC RES, V9, P266, DOI 10.2174/156720212803530717; CINI M, 1995, NEUROBIOL AGING, V16, P53, DOI 10.1016/0197-4580(95)80007-E; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eichler M, 2007, PHOTOMED LASER SURG, V25, P170, DOI 10.1089/pho.2007.2046; Freestone PS, 2009, EUR J NEUROSCI, V30, P1849, DOI 10.1111/j.1460-9568.2009.06990.x; FRIEDMANN H, 1991, J PHOTOCH PHOTOBIO B, V11, P87, DOI 10.1016/1011-1344(91)80271-I; Giuliani A, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-8; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hool LC, 2007, ANTIOXID REDOX SIGN, V9, P409, DOI 10.1089/ars.2006.1446; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Invitrogen, 2011, BIOPROBES, V64, P6; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kotake-Nara E, 2006, THESCIENTIFICWORLDJO, V6, P176, DOI 10.1100/tsw.2006.37; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lavi R, 2003, J BIOL CHEM, V278, P40917, DOI 10.1074/jbc.M303034200; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Lim WB, 2011, LASER SURG MED, V43, P344, DOI 10.1002/lsm.21038; Lin HJ, 2004, FEBS LETT, V570, P102, DOI 10.1016/j.febslet.2004.06.019; Liu XG, 2009, PHOTOMED LASER SURG, V27, P863, DOI 10.1089/pho.2008.2443; Silveira PCL, 2011, LASER MED SCI, V26, P125, DOI 10.1007/s10103-010-0839-0; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Menke T, 2003, BIOFACTORS, V18, P65, DOI 10.1002/biof.5520180208; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Moges H, 2009, LASER SURG MED, V41, P52, DOI 10.1002/lsm.20732; Moon Y, 2005, J NEUROCHEM, V93, P1199, DOI 10.1111/j.1471-4159.2005.03112.x; MOORHOUSE CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P261, DOI 10.1016/0304-4165(85)90147-3; Nicholls DG, 2008, ANN NY ACAD SCI, V1147, P53, DOI 10.1196/annals.1427.002; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pouokam E, 2009, EUR J PHARMACOL, V615, P40, DOI 10.1016/j.ejphar.2009.04.066; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Radad K, 2006, NEUROCHEM INT, V49, P379, DOI 10.1016/j.neuint.2006.02.003; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Rubio CR, 2009, PHOTOMED LASER SURG, V27, P79, DOI 10.1089/pho.2007.2232; Rochkind S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E8; Roediger B, 2003, NEUROBIOL DIS, V13, P222, DOI 10.1016/S0969-9961(03)00038-X; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Scheuer T, 2006, BIOCHEM SOC T, V34, P1299, DOI 10.1042/BST0341299; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Shefer G, 2002, J CELL SCI, V115, P1461; Silveira PCL, 2007, J PHOTOCH PHOTOBIO B, V86, P279, DOI 10.1016/j.jphotobiol.2006.10.002; Tada-Oikawa S, 2003, LIFE SCI, V73, P3277, DOI 10.1016/j.lfs.2003.06.013; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TOMARO ML, 1991, ARCH BIOCHEM BIOPHYS, V286, P610, DOI 10.1016/0003-9861(91)90088-Z; Verri M, 2012, INT J IMMUNOPATH PH, V25, P345, DOI 10.1177/039463201202500204; Wang GC, 2000, NUCLEIC ACIDS RES, V28, P2135, DOI 10.1093/nar/28.10.2135; WANG XY, 1993, ARCH BIOCHEM BIOPHYS, V306, P402, DOI 10.1006/abbi.1993.1529; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x; Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529; Zhang SQ, 2011, MOL CELL BIOCHEM, V354, P161, DOI 10.1007/s11010-011-0815-4; Zou WG, 2001, J NEUROSCI RES, V64, P646, DOI 10.1002/jnr.1118	80	98	100	0	18	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	OCT	2013	6	10			SI		829	838					10	Biochemical Research Methods; Biophysics; Optics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Optics	264NL	WOS:000327884800009	23281261	Green Accepted			2022-02-06	
J	Hannon, MJ; Crowley, RK; Behan, LA; O'Sullivan, EP; O'Brien, MMC; Sherlock, M; Rawluk, D; O'Dwyer, R; Tormey, W; Thompson, CJ				Hannon, M. J.; Crowley, R. K.; Behan, L. A.; O'Sullivan, E. P.; O'Brien, M. M. C.; Sherlock, M.; Rawluk, D.; O'Dwyer, R.; Tormey, W.; Thompson, C. J.			Acute Glucocorticoid Deficiency and Diabetes Insipidus Are Common After Acute Traumatic Brain Injury and Predict Mortality	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY INSUFFICIENCY; ANTI-DIURETIC HORMONE; INAPPROPRIATE SECRETION; FREE CORTISOL; NEUROENDOCRINE DYSFUNCTION; ANTIDIURETIC-HORMONE; SEVERE HYPONATREMIA; PLASMA-CORTISOL; SEPTIC SHOCK	Context: Published data demonstrates that hypopituitarism is common after traumatic brain injury (TBI). Hormone deficiencies are transient in many, but the natural history of the acute changes after TBI has not been documented. In addition, it is not clear whether there are any early parameters that accurately predict the development of permanent hypopituitarism. Objectives: There were 3 main objectives of this study: 1) to describe the natural history of plasma cortisol (PC) changes and sodium balance after TBI; 2) to identify whether acute hypocortisolemia or cranial diabetes insipidus (CDI) predict mortality; and 3) to identify whether the acute pituitary dysfunction predicts the development of chronic anterior hypopituitarism. Design: Each TBI patient underwent sequential measurement of PC, plasma sodium, urine osmolality, and fluid balance after TBI. All other anterior pituitary hormones were measured on day 10 after TBI. The results from 15 surgical comparisons defined a PC less than 300 nmol/L as inappropriately low for an acutely ill patient. CDI was diagnosed according to standard criteria. Surviving TBI patients underwent dynamic anterior pituitary testing at least 6 months after TBI. Setting: The patients were recruited from the Irish National Neurosurgery Centre. Patients: One hundred sequential TBI patients were recruited. Fifteen patients admitted to Intensive Therapy Unit (ITU) after major surgery were recruited as comparison patients. Main Outcome Measures: PC in TBI patients was compared with that of comparison patients. The mortality rate was compared between TBI patients with and without acute hypocortisolemia. Results of follow-up dynamic pituitary testing were compared between those with and without acute hypocortisolemia. Results: Most of the TBI patients (78%) developed inappropriately low PC after TBI. Low PC and CDI were predictive of mortality. Thirty-nine percent of the patients who had follow-up testing had at least 1 pituitary hormone deficit, all of whom had had previous acute hypocortisolemia or CDI. Conclusions: Acute hypocortisolemia and CDI are predictive of mortality and long-term pituitary deficits in TBI.	[Hannon, M. J.; Crowley, R. K.; Behan, L. A.; O'Sullivan, E. P.; O'Brien, M. M. C.; Sherlock, M.; Thompson, C. J.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Endocrinol, Dublin 9, Ireland; [Rawluk, D.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Neurosurg, Dublin 9, Ireland; [O'Dwyer, R.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Crit Care, Dublin 9, Ireland; [Tormey, W.] Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Dept Chem Pathol, Dublin 9, Ireland		Hannon, MJ (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Sch Med, Acad Dept Endocrinol, Dublin 9, Ireland.	markjhannon2002@yahoo.co.uk; christhompson@beaumont.ie		Crowley, Rachel/0000-0003-1472-4117	Novo NordiskNovo Nordisk	This work was supported by an unrestricted educational grant from Novo Nordisk.	Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Alharfi IM, 2013, PEDIATR CRIT CARE ME, V14, P203, DOI 10.1097/PCC.0b013e31827127b5; Annane D, 2005, CURR OPIN CRIT CARE, V11, P449, DOI 10.1097/01.ccx.0000176691.95562.43; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; Bendel S, 2008, ANESTH ANALG, V106, P1813, DOI 10.1213/ane.0b013e318172fdba; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cohen J, 2012, SHOCK, V37, P28, DOI 10.1097/SHK.0b013e318239b809; COOLENS JL, 1987, J STEROID BIOCHEM, V26, P197, DOI 10.1016/0022-4731(87)90071-9; Davies MJ, 1996, J ROY SOC MED, V89, pP159, DOI 10.1177/014107689608900313; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DERENDORF H, 1991, J CLIN PHARMACOL, V31, P473, DOI 10.1002/j.1552-4604.1991.tb01906.x; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; Finucane FM, 2008, CLIN ENDOCRINOL, V69, P603, DOI 10.1111/j.1365-2265.2008.03240.x; Gill G, 2006, CLIN ENDOCRINOL, V65, P246, DOI 10.1111/j.1365-2265.2006.02583.x; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HAWKER F, 1988, BRIT J HOSP MED, V39, P278; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho JT, 2006, J CLIN ENDOCR METAB, V91, P105, DOI 10.1210/jc.2005-0265; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Lanterna LA, J STROKE CEREBROVASC, DOI [10.1016/j.jstrokecerebrovasdis.2012.11.002, DOI 10.1016/J.JSTR0KECEREBR0VASDIS.2012.11.002]; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maggiore U, 2009, CRIT CARE, V13, DOI 10.1186/cc7953; Marik PE, 2009, CHEST, V135, P181, DOI 10.1378/chest.08-1149; Monson JP, 1997, CLIN ENDOCRINOL, V46, P269, DOI 10.1046/j.1365-2265.1997.87897.x; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; SECKL J, 1989, BRIT MED J, V298, P2, DOI 10.1136/bmj.298.6665.2; Sherlock M, 2009, POSTGRAD MED J, V85, P171, DOI 10.1136/pgmj.2008.072819; Smith DM, 2000, CLIN ENDOCRINOL, V52, P667, DOI 10.1046/j.1365-2265.2000.01027.x; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Stelfox HT, 2008, CRIT CARE, V12, DOI 10.1186/cc7162; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; THOMAS JP, 1971, LANCET, V1, P623; THOMPSON CJ, 1989, BAILLIERE CLIN ENDOC, V3, P473, DOI 10.1016/S0950-351X(89)80012-6; THOMPSON CJ, 1987, Q J MED, V65, P853; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; Zilberberg Marya D, 2008, BMC Pulm Med, V8, P16, DOI 10.1186/1471-2466-8-16	63	98	102	0	5	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	AUG	2013	98	8					3229	3237		10.1210/jc.2013-1555			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	196NC	WOS:000322781300039	23690314	Bronze			2022-02-06	
J	Hsieh, CL; Kim, CC; Ryba, BE; Niemi, EC; Bando, JK; Locksley, RM; Liu, JL; Nakamura, MC; Seaman, WE				Hsieh, Christine L.; Kim, Charles C.; Ryba, Bryan E.; Niemi, Erene C.; Bando, Jennifer K.; Locksley, Richard M.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.			Traumatic brain injury induces macrophage subsets in the brain	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						Alternative activation; Inflammation; Macrophage; Traumatic brain injury	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; ALTERNATIVE ACTIVATION; MICROGLIAL ACTIVATION; MICE; INFLAMMATION; RECRUITMENT; RECOVERY; HETEROGENEITY	Traumatic brain injury (TBI) elicits innate inflammatory responses that can lead to secondary brain injury. To better understand the mechanisms involved in TBI-induced inflammation, we examined the nature of macrophages responding to TBI in mice. In this model, brain macrophages were increased >20-fold the day after injury and >77-fold 4 days after injury in the ipsilateral hemisphere compared with sham controls. TBI macrophage subsets were identified by using a reporter mouse strain (YARG) that expresses eYFP from an internal ribosome entry site (IRES) inserted at the 3 end of the gene for arginase-1 (Arg1), a hallmark of alternatively activated (M2) macrophages. One day after TBI, 21 +/- 1.5% of ipsilateral brain macrophages expressed relatively high levels of Arg1 as detected by yellow fluorescent protein, and this subpopulation declined thereafter. Arg1(+) cells localized with macrophages near the TBI lesion. Gene expression analysis of sorted Arg1(+) and Arg1(-) brain macrophages revealed that both populations had profiles that included features of conventional M2 macrophages and classically activated (M1) macrophages. The Arg1(+) cells differed from Arg1(-) cells in multiple aspects, most notably in their chemokine repertoires. Thus, the macrophage response to TBI initially involves heterogeneous polarization toward at least two major subsets.	[Hsieh, Christine L.; Ryba, Bryan E.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Hsieh, Christine L.; Kim, Charles C.; Niemi, Erene C.; Bando, Jennifer K.; Locksley, Richard M.; Nakamura, Mary C.; Seaman, William E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hsieh, Christine L.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.] Northern Calif Inst Res & Educ, San Francisco, CA USA		Hsieh, CL (corresponding author), San Francisco VA Med Ctr, 4150 Clement St 111R, San Francisco, CA 94121 USA.	christine.hsieh@ucsf.edu	Liu, Jialing/A-8627-2012; Nakamura, Mary/ABI-2887-2020	Liu, Jialing/0000-0003-4420-4382; Kim, Charles/0000-0001-6474-8227; Ryba, Bryan/0000-0002-2397-9245; Bando, Jennifer/0000-0002-1331-7424; Nakamura, Mary C./0000-0001-8127-9426	NIH/NCRR UCSF-CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024131]; Department of Veterans AffairsUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK063720] Funding Source: NIH RePORTER	The authors thank Ruby Gribi of the San Francisco VA Flow Cytometry core, Dr. David Erle, Andrea Barczak, Rebecca Barbeau, and Joshua Pollack at the Sandler Asthma Basic Research (SABRE) Center Functional Genomics Core Facility (NIH/NCRR UCSF-CTSI grant number UL1 RR024131), and Ivy Hsieh of the San Francisco VA Cell Imaging core for their contributions. This work was supported by the Department of Veterans Affairs and by grants from the Department of Defense to WES and CLH, which were administered by the Northern California Institute for Research and Education.	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236; Diet A, 2007, J BIOL CHEM, V282, P36199, DOI 10.1074/jbc.M706420200; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Jin X, 2012, PLOS ONE, V7; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A., 2012, BRAIN BEHAV IMMUN; Levy A, 2009, J NEUROTRAUM, V26, P1521, DOI 10.1089/neu.2008.0746; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Manevich Y, 2005, FREE RADICAL BIO MED, V38, P1422, DOI 10.1016/j.freeradbiomed.2005.02.011; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Nair MG, 2006, J IMMUNOL, V177, P1393, DOI 10.4049/jimmunol.177.3.1393; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Nishiya T, 2011, J BIOL CHEM, V286, P9009, DOI 10.1074/jbc.M110.190678; Nussler AK, 2010, DIGEST DIS, V28, P792, DOI 10.1159/000324287; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Potts Mathew B, 2006, NeuroRx, V3, P143; Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2011, NAT NEUROSCI, V14, P1098, DOI 10.1038/nn.2917; Ransohoff RM, 2002, ANN NY ACAD SCI, V961, P346, DOI 10.1111/j.1749-6632.2002.tb03120.x; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Reinhardt RL, 2006, J IMMUNOL, V177, P1618, DOI 10.4049/jimmunol.177.3.1618; Santos CRA, 2012, IUBMB LIFE, V64, P126, DOI 10.1002/iub.585; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Vergadi E, 2011, CIRCULATION, V123, P1986, DOI 10.1161/CIRCULATIONAHA.110.978627; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; Wietecha MS, 2011, AM J PHYSIOL-HEART C, V300, pH459, DOI 10.1152/ajpheart.00244.2010; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Yang D, 2011, CRIT CARE MED, V39, P756, DOI 10.1097/CCM.0b013e318206befd; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhang JP, 2012, J INVEST DERMATOL, V132, P226, DOI 10.1038/jid.2011.268; Zhang SY, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000648; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056	53	98	101	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0014-2980	1521-4141		EUR J IMMUNOL	Eur. J. Immunol.	AUG	2013	43	8					2010	2022		10.1002/eji.201243084			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	277SN	WOS:000328839700006	23630120	Green Accepted, Bronze			2022-02-06	
J	Kuczynski, A; Crawford, S; Bodell, L; Dewey, D; Barlow, KM				Kuczynski, Andrea; Crawford, Susan; Bodell, Lisa; Dewey, Deborah; Barlow, Karen M.			Characteristics of post-traumatic headaches in children following mild traumatic brain injury and their response to treatment: a prospective cohort	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							POSTCONCUSSION SYNDROME; CHILDHOOD HEADACHES; ICHD-II; CLASSIFICATION; ADOLESCENTS; CONCUSSION; EDITION	Aim Post-traumatic headaches (PTHs) following mild traumatic brain injury (mTBI) are common; however, few studies have examined the characteristics of PTHs or their response to treatment. The aims of this study were (1) to describe the clinical characteristics of PTH in a prospective cohort of children presenting to a paediatric emergency department with mTBI, and (2) to evaluate the response of PTH to treatment. Method The emergency department cohort was obtained from a prospective longitudinal cohort study of symptoms following mTBI (n=670; 385 males, 285 females) and a comparison group of children with extracranial injury (n=120; 61 males, 59 females). A retrospective chart review of a separate cohort of children from a brain injury clinic (the treatment cohort) treated for PTH was performed (n=44; 29 females, 15 males; mean age 14y 1mo, SD 3y 1mo). The median time since injury was 6.9months (range 1-29mo). The mean follow-up interval after treatment started was 5.5weeks (SD 4.3wks). Results Among the emergency department cohort (n=39; 20 males, 19 females; mean age 11y 1mo, SD 4y 3mo) 11% of children were symptomatic with PTHs at a mean of 15.8days (SD 11.6d) post injury. Three months post injury, 7.8% of children complained of headaches; of those, 56% had pre-existing headaches and 18% had experienced migraine before the injury. Although headache type varied, 55% met the criteria for migraine. A family or past medical history of migraine was present in 82% of cases. Among the treatment cohort, medications included amitriptyline, flunarizine, topiramate, and melatonin, with an overall response rate of 64%. Conclusion This is the first prospective cohort study to describe the clinical characteristics of PTHs following mTBI in children. Migraine was the most common headache type seen; other headaches included tension-type, cervicogenic, and occipital neuralgias, and 64% responded to treatment. Referral to a headache specialist should be considered, especially when the features are not typical of one of the primary headache disorders.	[Kuczynski, Andrea; Dewey, Deborah; Barlow, Karen M.] Univ Calgary, Calgary, AB, Canada; [Crawford, Susan; Bodell, Lisa; Dewey, Deborah; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Res Inst, Calgary, AB T3B 6A8, Canada		Barlow, KM (corresponding author), Alberta Childrens Prov Gen Hosp, C1-322 4888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	karen.barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507; Dewey, Deborah/0000-0002-1323-5832	Alberta Children's Hospital Foundation [RT34396]	This research was supported by the Alberta Children's Hospital Foundation (RT34396).	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blaw M E, 1985, Pediatr Neurol, V1, P320, DOI 10.1016/0887-8994(85)90038-4; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hershey AD, 2005, HEADACHE, V45, P1288, DOI 10.1111/j.1526-4610.2005.00260.x; Hershey AD, 2002, HEADACHE, V42, P810, DOI 10.1046/j.1526-4610.2002.02185.x; Hershey AD, 2000, HEADACHE, V40, P539, DOI 10.1046/j.1526-4610.2000.00085.x; Kirk C, 2008, DEV MED CHILD NEUROL, V50, P422, DOI 10.1111/j.1469-8749.2008.02063.x; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P100; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P457; Olesen J, 2005, REV NEUROL-FRANCE, V161, P689; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Price KE, 2011, CLIN PHARMACOL THER, V89, P867, DOI 10.1038/clpt.2011.47; RADANOV B, 1986, FORTSCHR NEUROL PSYC, V54, P375, DOI 10.1055/s-2007-1001942; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003	27	98	98	0	19	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUL	2013	55	7					636	641		10.1111/dmcn.12152			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	160HO	WOS:000320109900015	23560811				2022-02-06	
J	Schatz, P; Sandel, N				Schatz, Philip; Sandel, Natalie			Sensitivity and Specificity of the Online Version of ImPACT in High School and Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neurocognitive testing; validity; ImPACT	SPORT-RELATED CONCUSSION; COUNSELING PSYCHOMETRIC ISSUES; NEUROCOGNITIVE PERFORMANCE; CLINICAL UTILITY; RECOVERY; FOOTBALL; BATTERY; INJURY	Background: The utility of postconcussion neurocognitive testing versus symptom data has been debated. The sensitivity of the desktop version of the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) tool has been documented, but psychometric properties of the recently released online version of ImPACT have yet to be fully established. Purpose: To document the sensitivity of the online ImPACT version in samples of (1) symptomatic concussed (high school and collegiate) athletes, and (2) asymptomatic concussed (high school and collegiate) athletes suspected of hiding their concussions. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 81 athletes observed to sustain a concussion by a certified athletic trainer or team physician, a finding that was confirmed with reported postconcussion symptoms, completed the ImPACT test within 3 days of injury. Data were compared with an independent sample of 81 athletes who completed preseason baseline cognitive assessments using ImPACT and who were matched (with concussed athletes) on the basis of sex, age, sport, concussion history, and absence of attention deficit hyperactivity disorder and learning disability. An independent group of 37 athletes who were also observed to sustain a concussion completed ImPACT within 3 days of injury. These athletes reported no postconcussion symptoms but were noted for suspected invalid response patterns on ImPACT (Impulse Control index >30 and Verbal Memory index <69%). The subscale data from the assessments (excluding those contributing to the aforementioned indices) were compared with a matched sample of 37 athletes who completed preseason baseline cognitive assessments in ImPACT (using the same criteria described above). Results: Data from the ImPACT online version yielded 91.4% sensitivity and 69.1% specificity. For asymptomatic athletes suspected of hiding their concussion, data from ImPACT yielded 94.6% sensitivity and 97.3% specificity. Conclusion: The online version of the ImPACT tool is a valid measure of neurocognitive performance at the acute stages of concussion, with high levels of sensitivity and specificity, even when athletes appear to be denying postconcussion symptoms.	[Schatz, Philip; Sandel, Natalie] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	One or more of the authors has declared the following potential conflict of interest or source of funding: Dr Schatz has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation, the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications Inc.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barth JT, 1989, MILD HEAD INJURY, P257; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Randolph C, 2006, J ATHL TRAINING, V41, P138; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Sandel NK, 2012, APPL NEUROPSYCHOL CH; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Stevens J.P, 2009, APPL MULTIVARIATE ST; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	29	98	98	0	33	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2013	41	2					321	326		10.1177/0363546512466038			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	081GY	WOS:000314307500015	23144368				2022-02-06	
J	Adamczak, S; Dale, G; Vaccari, JPD; Bullock, MR; Dietrich, WD; Keane, RW				Adamczak, Stephanie; Dale, Gordon; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.			Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome Clinical article	JOURNAL OF NEUROSURGERY			English	Article						biomarker; traumatic brain injury; inflammation; innate immunity; inflammasome	MOLECULAR PLATFORM; PRACTICAL SCALE; HEAD-INJURY; HYPOTHERMIA; ACTIVATION; NEUTRALIZATION; CASPASE-1; NEURONS; DISEASE; TISSUE	Object. Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1 beta. Methods. The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions. NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors. (http://thejns.org/doi/abs/10.3171/2012.9.JNS12815)	[Adamczak, Stephanie; Dale, Gordon; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Coral Gables, FL 33124 USA; [Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Coral Gables, FL 33124 USA		Keane, RW (corresponding author), 1600 NW 10th Ave,RMSB 5058, Miami, FL 33136 USA.	rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Dale, Gordon/0000-0002-4995-6017	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS032091]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER	This study was supported by NIH grant NS032091. Stephanie Adamczak, Juan Pablo de Rivero Vaccari, M. Ross Bullock, W. Dalton Dietrich, and Robert W. Keane hold a patent on inflammasome proteins as diagnostic and prognostic indicators following central nervous system trauma.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P463; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HOLM S, 1979, SCAND J STAT, V6, P65; JENNETT B, 1975, LANCET, V1, P480; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; Kumar K, 1997, METAB BRAIN DIS, V12, P21, DOI 10.1007/BF02676351; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; TEASDALE G, 1974, LANCET, V2, P81; Tomura S, 2012, J CEREB BLO IN PRESS; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46	28	98	103	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2012	117	6					1119	1125		10.3171/2012.9.JNS12815			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	042IC	WOS:000311463900019	23061392	Green Accepted			2022-02-06	
J	Washington, CW; Grubb, RL				Washington, Chad W.; Grubb, Robert L., Jr.			Are routine repeat imaging and intensive care unit admission necessary in mild traumatic brain injury?	JOURNAL OF NEUROSURGERY			English	Article						mild traumatic brain injury; head computed tomography; intensive care unit admission	HEAD COMPUTED-TOMOGRAPHY; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; CT; PROGRESSION; CLASSIFICATION; MORTALITY; TRIAL	Object. More than 1.5 million Americans suffer a traumatic brain injury (TBI) each year. Seventy-five percent of these patients have a mild TBI, with Glasgow Coma Scale (GCS) Score 13-15. At the authors' institution, the usual practice has been to admit those patients with an associated intracranial hemorrhage (ICH) to an ICU and to obtain repeat head CT scans 12-24 hours after admission. The purpose of this study was to determine if there exists a subpopulation of mild TBI patients with an abnormal head CT scan that requires neither repeat brain imaging nor admission to an ICU. This group of patients was further classified based on initial clinical factors and imaging characteristics. Methods. A retrospective review of all patients admitted to a Level I trauma center from January 2007 through December 2008 was performed using the hospital Trauma Registry Database, medical records, and imaging data. The inclusion criteria were as follows: 1) an admission GCS score >= 13; 2) an isolated head injury with no other injury requiring ICU admission; 3) an initial head CT scan positive for ICH; and 4) an initial management plan that was nonoperative. Collected data included age, etiology, initial GCS score, time of injury, duration of ICU stay, duration of hospital stay, and anticoagulation status. Primary outcomes measured were the occurrence of neurological or medical decline and the need for neurosurgical intervention. Imaging data were analyzed and classified based on the predominant blood distribution found on admission imaging. Data were further categorized based on the Marshall CT classification, Rotterdam score, and volume of intraparenchymal hemorrhage (IPH). Progression was defined as an increase in the Marshall classification, an increase in the Rotterdam score, or a 30% increase in IPH volume. Results. Three hundred twenty-one of 1101 reviewed cases met inclusion criteria for the study. Only 4 patients (1%) suffered a neurological decline and 4 (1%) required nonemergent neurosurgical intervention. There was a medical decline in 18 of the patients (6%) as a result of a combination of events such as respiratory distress, myocardial infarction, and sepsis. Both patient age and the transfusion of blood products were significant predictors of medical decline. Overall patient mortality was 1%. Based on imaging data, the rate of injury progression was 6%. The only type of ICH found to have a significant rate of progression (53%) was a subfrontal/temporal intraparenchymal contusion. Other variables found to be significant predictors of progression on head CT scans were the use of anticoagulation, an age over 65 years, and a volume of ICH > 10 ml. Conclusions. Most patients with mild TBI have a good outcome without the necessity of neurosurgical intervention. Mild TBI patients with a convexity SAH, small convexity contusion, small IPH (<= 10 ml), and/or small subdural hematoma do not require admission to an ICU or repeat imaging in the absence of a neurological decline. (DOI: 10.3171/2011.11.JNS111092)	[Washington, Chad W.; Grubb, Robert L., Jr.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA		Washington, CW (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, 660 S Euclid Ave,Campus Box 8057, St Louis, MO 63110 USA.	washingtonc@wudosis.wustl.edu					Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Egol A, 1999, CRIT CARE MED, V27, P633; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Greenberg M.S., 1997, HDB NEUROSURGERY; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	23	98	98	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2012	116	3					549	557		10.3171/2011.11.JNS111092			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	897LL	WOS:000300652100017	22196096				2022-02-06	
J	d'Avila, JC; Lam, TI; Bingham, D; Shi, J; Won, SJ; Kauppinen, TM; Massa, S; Liu, JL; Swanson, RA				d'Avila, Joana C.; Lam, Tina I.; Bingham, Deborah; Shi, Jian; Won, Seok Joon; Kauppinen, Tiina M.; Massa, Stephen; Liu, Jialing; Swanson, Raymond A.			Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor	JOURNAL OF NEUROINFLAMMATION			English	Article						Astrocyte; Behavioral; Forelimb; Inflammation; Microglia; Minocycline; Poly(ADP-ribose) polymerase; traumatic brain injury	NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; NAD(+) DEPLETION; NEURONAL DEATH; MOLECULAR-MECHANISMS; THERAPEUTIC TARGETS; CEREBRAL-ISCHEMIA; INJURY; INFLAMMATION; CNS	Background: Traumatic brain injury (TBI) induces activation of microglia. Activated microglia can in turn increase secondary injury and impair recovery. This innate immune response requires hours to days to become fully manifest, thus providing a clinically relevant window of opportunity for therapeutic intervention. Microglial activation is regulated in part by poly(ADP-ribose) polymerase-1 (PARP-1). Inhibition of PARP-1 activity suppresses NF-kB-dependent gene transcription and thereby blocks several aspects of microglial activation. Here we evaluated the efficacy of a PARP inhibitor, INO-1001, in suppressing microglial activation after cortical impact in the rat. Methods: Rats were subjected to controlled cortical impact and subsequently treated with 10 mg/kg of INO-1001 (or vehicle alone) beginning 20 - 24 hours after the TBI. Brains were harvested at several time points for histological evaluation of inflammation and neuronal survival, using markers for microglial activation (morphology and CD11b expression), astrocyte activation (GFAP), and neuronal survival (NeuN). Rats were also evaluated at 8 weeks after TBI using measures of forelimb dexterity: the sticky tape test, cylinder test, and vermicelli test. Results: Peak microglial and astrocyte activation was observed 5 to 7 days after this injury. INO-1001 significantly reduced microglial activation in the peri-lesion cortex and ipsilateral hippocampus. No rebound inflammation was observed in rats that were treated with INO-1001 or vehicle for 12 days followed by 4 days without drug. The reduced inflammation was associated with increased neuronal survival in the peri-lesion cortex and improved performance on tests of forelimb dexterity conducted 8 weeks after TBI. Conclusions: Treatment with a PARP inhibitor for 12 days after TBI, with the first dose given as long as 20 hours after injury, can reduce inflammation and improve histological and functional outcomes.	[d'Avila, Joana C.; Lam, Tina I.; Shi, Jian; Won, Seok Joon; Kauppinen, Tiina M.; Massa, Stephen; Swanson, Raymond A.] Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; [d'Avila, Joana C.; Lam, Tina I.; Shi, Jian; Won, Seok Joon; Kauppinen, Tiina M.; Massa, Stephen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; [Bingham, Deborah; Liu, Jialing] Vet Affairs Med Ctr, Dept Neurosurg, San Francisco, CA 94121 USA; [Bingham, Deborah; Liu, Jialing] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94121 USA; [d'Avila, Joana C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil		Swanson, RA (corresponding author), Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA.	raymond.swanson@ucsf.edu	d'Avila, Joana/L-8970-2013; Liu, Jialing/A-8627-2012; Kauppinen, Tiina/I-1009-2019	d'Avila, Joana/0000-0002-2045-0813; Liu, Jialing/0000-0003-4420-4382; Swanson, Raymond/0000-0002-3664-5359; Kauppinen, Tiina/0000-0001-7219-9862	U.S. Department of DefenseUnited States Department of Defense [W81XWH-05-2-0094]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS041421]; Dept. of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Defense (contract number W81XWH-05-2-0094, to RAS) National Institutes of Health (NS041421, to RAS) and by a REAP award from the Dept. of Veterans Affairs Rehabilitation Research and Development program. We thank Ms. Dongmin Wang for excellent technical assistance.	Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Carson MJ, 2007, NEUROTHERAPEUTICS, V4, P571, DOI 10.1016/j.nurt.2007.07.002; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Cubeddu LX, 2006, PHARMACOTHERAPY, V26, P1288, DOI 10.1592/phco.26.9.1288; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Fink EL, 2008, J CEREBR BLOOD F MET, V28, P1523, DOI 10.1038/jcbfm.2008.52; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Kauppinen TM, 2007, NEUROSCIENCE, V145, P1267, DOI 10.1016/j.neuroscience.2006.09.034; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen TM, 2009, J CEREBR BLOOD F MET, V29, P820, DOI 10.1038/jcbfm.2009.9; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Koh DW, 2005, CELL MOL LIFE SCI, V62, P760, DOI 10.1007/s00018-004-4508-y; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Morrow DA, 2009, J THROMB THROMBOLYS, V27, P359, DOI 10.1007/s11239-008-0230-1; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pijak MR, 2006, ARCH NEUROL-CHICAGO, V63, P300, DOI 10.1001/archneur.63.2.300-b; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; SHIN KH, 1975, CHEM PHARM BULL, V23, P1137; Stengel PW, 2007, EUR J PHARMACOL, V563, P213, DOI 10.1016/j.ejphar.2007.02.028; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	49	98	102	0	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 15	2012	9								31	10.1186/1742-2094-9-31			11	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	917II	WOS:000302166600002	22335939	Green Published, gold			2022-02-06	
J	Nunnally, ME; Jaeschke, R; Bellingan, GJ; Lacroix, J; Mourvillier, B; Rodriguez-Vega, GM; Rubertsson, S; Vassilakopoulos, T; Weinert, C; Zanotti-Cavazzoni, S; Buchman, TG				Nunnally, Mark E.; Jaeschke, Roman; Bellingan, Geoffrey J.; Lacroix, Jacques; Mourvillier, Bruno; Rodriguez-Vega, Gloria M.; Rubertsson, Sten; Vassilakopoulos, Theodoros; Weinert, Craig; Zanotti-Cavazzoni, Sergio; Buchman, Timothy G.			Targeted temperature management in critical care: A report and recommendations from five professional societies	CRITICAL CARE MEDICINE			English	Article						temperature; consensus; cardiac arrest; targeted temperature management; hypothermia	TRAUMATIC BRAIN-INJURY; MILD HYPOTHERMIA THERAPY; HOSPITAL CARDIAC-ARREST; WHOLE-BODY HYPOTHERMIA; MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CLINICAL-TRIAL; COMATOSE SURVIVORS; PERINATAL ASPHYXIA; PHASE-II	Objective: Representatives of five international critical care societies convened topic specialists and a nonexpert jury to review, assess, and report on studies of targeted temperature management and to provide clinical recommendations. Data Sources: Questions were allocated to experts who reviewed their areas, made formal presentations, and responded to questions. Jurors also performed independent searches. Sources used for consensus derived exclusively from peer-reviewed reports of human and animal studies. Study Selection: Question-specific studies were selected from literature searches; jurors independently determined the relevance of each study included in the synthesis. Conclusions and Recommendations: 1) The jury opines that the term "targeted temperature management" replace "therapeutic hypothermia." 2) The jury opines that descriptors (e. g., "mild") be replaced with explicit targeted temperature management profiles. 3) The jury opines that each report of a targeted temperature management trial enumerate the physiologic effects anticipated by the investigators and actually observed and/or measured in subjects in each arm of the trial as a strategy for increasing knowledge of the dose/duration/response characteristics of temperature management. This enumeration should be kept separate from the body of the report, be organized by body systems, and be made without assertions about the impact of any specific effect on the clinical outcome. 4) The jury STRONGLY RECOMMENDS targeted temperature management to a target of 32 degrees C-34 degrees C as the preferred treatment (vs. unstructured temperature management) of out-of-hospital adult cardiac arrest victims with a first registered electrocardiography rhythm of ventricular fibrillation or pulseless ventricular tachycardia and still unconscious after restoration of spontaneous circulation (strong recommendation, moderate quality of evidence). 5) The jury WEAKLY RECOMMENDS the use of targeted temperature management to 33 degrees C-35.5 degrees C (vs. less structured management) in the treatment of term newborns who sustained asphyxia and exhibit acidosis and/or encephalopathy (weak recommendation, moderate quality of evidence). (Crit Care Med 2011; 39:1113-1125)	[Buchman, Timothy G.] Emory Ctr Crit Care, Atlanta, GA USA; [Jaeschke, Roman] McMaster Univ, Hamilton, ON, Canada; [Bellingan, Geoffrey J.] Univ Coll London Hosp, London, England; [Lacroix, Jacques] Univ Montreal, Montreal, PQ, Canada; [Mourvillier, Bruno] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Rodriguez-Vega, Gloria M.] Univ Dist Hosp, San Juan, PR USA; [Rubertsson, Sten] Uppsala Univ, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden; [Vassilakopoulos, Theodoros] Evangelismos Med Ctr, Athens, Greece; [Weinert, Craig] Univ Minnesota, Minneapolis, MN USA; [Zanotti-Cavazzoni, Sergio] Cooper Univ Hosp, Camden, NJ USA; [Nunnally, Mark E.] Univ Chicago, Chicago, IL 60637 USA		Buchman, TG (corresponding author), Emory Ctr Crit Care, Atlanta, GA USA.	tbuchma@emory.edu		Buchman, Timothy/0000-0001-7350-5921; MOURVILLIER, BRUNO/0000-0001-5227-1468			Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; D'Cruz BJ, 2005, BRAIN RES, V1064, P108, DOI 10.1016/j.brainres.2005.09.052; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kollmar R, 2009, NEUROCRIT CARE, V10, P173, DOI 10.1007/s12028-008-9162-z; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lee SM, 2009, J CEREBR BLOOD F MET, V29, P1589, DOI 10.1038/jcbfm.2009.81; LEHOT JJ, 1992, CHEST, V102, P106, DOI 10.1378/chest.102.1.106; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Smrcka M, 2005, ACT NEUR S, V95, P273; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub4; Takaoka S, 1996, NEUROSCI LETT, V218, P25, DOI 10.1016/S0304-3940(96)13112-8; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tohyama Y, 1998, EXP BRAIN RES, V122, P333, DOI 10.1007/s002210050521; Tokutomi T, 2007, NEUROSURGERY, V61, P256, DOI [10.1227/01.NEU.00000038737.13185.C4, 10.1227/01.neu.0000279221.38257.1a]; Tomasevic G, 1999, NEUROSCIENCE, V90, P781, DOI 10.1016/S0306-4522(98)00484-9; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van Hemelrijck A, 2005, EUR J NEUROSCI, V22, P1327, DOI 10.1111/j.1460-9568.2005.04331.x; Varon J, 2008, CHEST, V133, P1267, DOI 10.1378/chest.07-2190; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner S, 2003, BRAIN RES, V984, P63, DOI 10.1016/S0006-8993(03)03088-9; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Wang Wei-ping, 2005, Chin J Traumatol, V8, P54; Whalen MJ, 1997, ACT NEUR S, V70, P260; Yenari MA, 2000, BRAIN RES, V885, P208, DOI 10.1016/S0006-8993(00)02942-5; Yenari M, 2008, STROKE, V39, P2910, DOI 10.1161/STROKEAHA.108.514471; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zhou WH, 2002, ACTA PHARMACOL SIN, V23, P64	75	98	105	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2011	39	5					1113	1125		10.1097/CCM.0b013e318206bab2			13	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	752CX	WOS:000289667000026	21187745				2022-02-06	
J	Duhaime, AC; Gean, AD; Haacke, EM; Hicks, R; Wintermark, M; Mukherjee, P; Brody, D; Latour, L; Riedy, G				Duhaime, Ann-Christine; Gean, Alisa D.; Haacke, E. Mark; Hicks, Ramona; Wintermark, Max; Mukherjee, Pratik; Brody, David; Latour, Lawrence; Riedy, Gerard		Common Data Elements Neuroimaging; Pediat Working Grp Members	Common Data Elements in Radiologic Imaging of Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Clinical research; Clinical trials; Database; Head injury; Magnetic resonance imaging; Radiology; Rehabilitation; Traumatic brain injury	DIFFUSE AXONAL INJURY; HEAD-INJURY; CLASSIFICATION; MICROBLEEDS; CHILDREN; VOLUME; MILD	Radio logic brain imaging is the most useful means of visualizing and categorizing the location, nature, and degree of damage to the central nervous system sustained by patients with traumatic brain injury (TBI). In addition to determining acute patient management and prognosis, imaging is crucial for the characterization and classification of injuries for natural history studies and clinical trials. This article is the initial result of a workshop convened by multiple national health care agencies in March 2009 to begin to make recommendations for potential data elements dealing with specific radiologic features and definitions needed to characterize injuries, as well as specific techniques and parameters needed to optimize radiologic data acquisition. The neuroimaging work group included professionals with expertise in basic imaging research and physics, clinical neuroradiology, neurosurgery, neurology, physiatry, psychiatry, TBI research, and research database formation. This article outlines the rationale and overview of their specific recommendations. In addition, we review the contributions of various imaging modalities to the understanding of TBI and the general principles needed for database flexibility and evolution over time to accommodate technical advances.	[Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Gean, Alisa D.] San Francisco Gen Hosp, Dept Radiol, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94110 USA; [Haacke, E. Mark] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA; [Hicks, Ramona] NIH, Repair & Plast Program, Bethesda, MD 20892 USA; [Wintermark, Max; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Mukherjee, Pratik] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA; [Brody, David] Washington Univ, Dept Neurol, St Louis, MO USA; [Latour, Lawrence] Natl Inst Neurol Disorders & Stroke, Stroke Diagnost & Therapeut Sect, Stroke Branch, Bethesda, MD USA; [Riedy, Gerard] Walter Reed Army Med Ctr, Dept Radiol, Washington, DC 20307 USA		Duhaime, AC (corresponding author), Massachusetts Gen Hosp, Wang 331,115 Parkman St, Boston, MA 02114 USA.	aduhaime@partners.org	Mukherjee, Pratik/A-5446-2008; Latour, Larry/AAH-5663-2021	Latour, Larry/0000-0001-6160-5263; Mukherjee, Pratik/0000-0001-7473-7409; Wintermark, Max/0000-0002-6726-3951			Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARSHALL LF, 1992, J NEUROTRAUMA S, V1, pS278; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT I NEUR DIS ST, 2010, NINDS COMM DAT EL; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale E., 1997, HEAD INJURY, P167; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x	18	98	98	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1661	1666		10.1016/j.apmr.2010.07.238			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400005	21044709				2022-02-06	
J	Jaeger, M; Dengl, M; Meixensberger, J; Schuhmann, MU				Jaeger, Matthias; Dengl, Markus; Meixensberger, Juergen; Schuhmann, Martin U.			Effects of cerebrovascular pressure reactivity-guided optimization of cerebral perfusion pressure on brain tissue oxygenation after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain injury; brain tissue oxygen; cerebrovascular pressure reactivity; cerebral perfusion pressure; neuromonitoring; cerebral autoregulation	SEVERE HEAD-INJURY; BLOOD-FLOW; TENSION; AUTOREGULATION	Objective: To evaluate the concept of a cerebrovascular pressure reactivity-guided optimal cerebral perfusion pressure after traumatic brain injury by analyzing the relationship between optimal cerebral perfusion pressure and brain tissue oxygen. Design: Prospective observational cohort study. Setting: Neurosurgical intensive care unit of a university hospital. Patients: Thirty-eight patients after head injury. Interventions: Continuous computerized monitoring of mean arterial pressure, intracranial pressure, and brain tissue oxygen for 5.3 +/- 2.6 days. The index of cerebrovascular pressure reactivity was calculated as a moving correlation coefficient between spontaneous low-frequency fluctuations of mean arterial pressure and intracranial pressure. Optimal cerebral perfusion pressure was defined as the cerebral perfusion pressure level with the lowest average index of cerebrovascular pressure reactivity. Measurements and Main Results: Optimal cerebral perfusion pressure could be identified in 32 of 38 patients. Median optimal cerebral perfusion pressure was between 70 and 75 mm Hg (range, 60-100 mm Hg). Below the level of optimal cerebral perfusion pressure, brain tissue oxygen decreased in parallel to cerebral perfusion pressure, whereas brain tissue oxygen reached a plateau above optimal cerebral perfusion pressure. Optimal cerebral perfusion pressure correlated significantly with the cerebral perfusion pressure level, where brain tissue oxygen reached its plateau (r = .79; p < .01). Average brain tissue oxygen at optimal cerebral perfusion pressure was 24.5 +/- 6.0 mm Hg. Conclusions: This study supports the concept of cerebrovascular pressure reactivity-based individual optimal cerebral perfusion pressure. Driving cerebral perfusion pressure in excess of optimal cerebral perfusion pressure does not yield improvements in brain tissue oxygen after head injury and should be avoided, whereas cerebral perfusion pressure below optimal cerebral perfusion pressure may result in secondary cerebral ischemia. (Crit Care Med 2010; 38: 1343-1347)	[Jaeger, Matthias; Dengl, Markus; Meixensberger, Juergen; Schuhmann, Martin U.] Univ Leipzig, Dept Neurosurg, Leipzig, Germany; [Jaeger, Matthias] Univ New S Wales, Liverpool Hosp, Sydney SW Area Hlth Serv, Dept Neurosurg, Liverpool, NSW, Australia; [Schuhmann, Martin U.] Univ Tubingen, Dept Neurosurg, Tubingen, Germany		Jaeger, M (corresponding author), Univ Leipzig, Dept Neurosurg, Leipzig, Germany.	Matthias.Jaeger@sswahs.nsw.gov.au					Andrews PJD, 2005, CRIT CARE, V9, P638, DOI 10.1186/cc3922; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa P, 2003, NEUROSURG FOCUS, V15, P1, DOI DOI 10.3171/foc.2003.15.6.4; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a	18	98	100	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2010	38	5					1343	1347		10.1097/CCM.0b013e3181d45530			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	593JD	WOS:000277449100015	20154598				2022-02-06	
J	Spencer, RJ; Drag, LL; Walker, SJ; Bieliauskas, LA				Spencer, Robert J.; Drag, Lauren L.; Walker, Sara J.; Bieliauskas, Linas A.			Self-reported cognitive symptoms following mild traumatic brain injury are poorly associated with neuropsychological performance in OIF/OEF veterans	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						anxiety; brain injury; cognition; depression; insight; military; neuropsychological assessment; self-report; traumatic psychometrics; veterans	OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN PATIENTS; MEMORY IMPAIRMENT; HEAD-INJURY; DEPRESSION; COMPLAINTS; DEFICITS; INDIVIDUALS; CONCUSSION	Mild traumatic brain injury (mTBI) is not uncommon among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) veterans, and many individuals within this group report lingering cognitive difficulties following their injury. For Department of Veterans Affairs clinicians, an accurate assessment of cognitive symptoms is important in providing appropriate clinical care. Although self-assessment is commonly employed to screen for difficulties in cognitive functioning, little is known about the accuracy of self-report in this population. This study collected cognitive, psychiatric, and self-report data from 105 OIF/OEF veterans with mTBI to examine the relationship between self-reported cognitive functioning and objective neuropsychological test performance. Additionally, clinicians who frequently work with OIF/OEF veterans were asked to predict the magnitude of these associations. Self-reported cognitive functioning was not significantly correlated with objective cognitive abilities, suggesting that objective neuropsychological testing should be used when cognitive weakness is suspected. Perceived cognitive deficits were associated with depression, anxiety, and posttraumatic stress disorder, illustrating the additional importance of adequate assessment and treatment of psychiatric symptoms. Clinicians tended to overestimate the association between self-report and test performance.	[Spencer, Robert J.; Walker, Sara J.; Bieliauskas, Linas A.] Dept Vet Affairs Ann Arbor Healthcare Syst, Dept Mental Hlth Serv, Ann Arbor, MI USA; [Drag, Lauren L.; Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA		Bieliauskas, LA (corresponding author), 2101 Commonwealth Blvd,Suite C, Ann Arbor, MI 48105 USA.	linas@umich.edu					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arnstein P, 1999, PAIN, V80, P483, DOI 10.1016/S0304-3959(98)00220-6; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; Burdick KE, 2005, PSYCHIAT RES, V136, P43, DOI 10.1016/j.psychres.2004.12.009; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; COMUNIAN AL, 1989, PERCEPT MOTOR SKILL, V69, P755, DOI 10.2466/pms.1989.69.3.755; Deckersbach T, 2000, J CLIN EXP NEUROPSYC, V22, P640, DOI 10.1076/1380-3395(200010)22:5;1-9;FT640; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GAGNON M, 1994, NEUROEPIDEMIOLOGY, V13, P145, DOI 10.1159/000110373; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Julian L, 2007, MULT SCLER J, V13, P81, DOI 10.1177/1352458506070255; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; LEW HL, 2007, J REHABIL RES DEV, V45, pR11; McCrea M., 2008, AM ACAD CLIN NEUROPS; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meyers JE., 1995, REY COMPLEX FIGURE T; Moore LH, 1997, J NEUROPSYCH CLIN N, V9, P37; Randolph C., 1998, REPEATABLE BATTERY A; Savage CR, 2000, NEUROPSYCHOLOGY, V14, P141, DOI 10.1037/0894-4105.14.1.141; Savage CR, 1999, BIOL PSYCHIAT, V45, P905, DOI 10.1016/S0006-3223(98)00278-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwartz CE, 1996, ANN BEHAV MED, V18, P177, DOI 10.1007/BF02883395; SOUTHWICK SM, 1991, AM J PSYCHIAT, V148, P179; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; SULLIVAN MJL, 1990, J ABNORM PSYCHOL, V99, P260, DOI 10.1037/0021-843X.99.3.260; Tanielian TL., 2008, RAND CORPORATION INV; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wechsler, 2008, WAIS 4 ADM SCORING M; Zachary, 2000, SHIPLEY I LIVING SCA; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	98	98	0	12	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	6					521	530		10.1682/JRRD.2009.11.0181			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	657FX	WOS:000282399700003	20848365	Bronze			2022-02-06	
J	Li, B; Mahmood, A; Lu, DY; Wu, HT; Xiong, Y; Qu, CS; Chopp, M				Li, Bo; Mahmood, Asim; Lu, Dunyue; Wu, Hongtao; Xiong, Ye; Qu, Changsheng; Chopp, Michael			SIMVASTATIN ATTENUATES MICROGLIAL CELLS AND ASTROCYTE ACTIVATION AND DECREASES INTERLEUKIN-1B LEVEL AFTER TRAUMATIC BRAIN INJURY	NEUROSURGERY			English	Article						Astrocyte; Interleukin-1 beta; Microglia; Simvastatin; Traumatic brain injury	NITRIC-OXIDE SYNTHASE; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; CNS INJURY; KAPPA-B; STATINS; INDUCTION; EXPRESSION; RECEPTOR; SYNAPTOGENESIS	OBJECTIVE: Our previous studies demonstrated that simvastatin promotes neurological functional recovery after traumatic brain injury (TBI) in rat; however, the underlying mechanisms remain poorly understood. The purpose of this study was to investigate the anti-inflammatory effect of simvastatin by measuring the level of cytokines and activation of glial cells. METHODS: Controlled cortical impact injury was performed in adult male Wistar rats. The rats were randomly divided into 3 groups: sham, saline control group, and simvastatin treatment group. Simvastatin was administered orally starting at day 1 after TBI until animals were killed at days 1, 3, 7, 14, and 35 after treatment. Functional outcome was measured using modified neurological severity scores. Enzyme-linked immunosorbent assay and immunohistochemical staining were used to measure the expression of interleukin (IL)-1 beta, IL-6, and tumor necrosis factor-a and to identify activated microglial cells and astrocytes. RESULTS: At days 1 and 3 after simvastatin or saline treatment, cytokine levels in the lesion boundary zone were significantly higher in the simvastatin- and saline-treated rats compared with the sham group, peaking at day 3. Simvastatin only reduced the level of IL-1 beta but not IL-6 and tumor necrosis factor-alpha, compared with the saline group. Also, simvastatin significantly reduced the number of activated microglial cells and astrocytes compared with the saline control animals. There was also a trend toward improvement of modified neurological severity score, reaching statistical significance (P = 0.003) toward the end of the trial. CONCLUSION: Our data demonstrate that TBI causes inflammatory reaction, including increased levels of IL-1 beta, IL-6, and tumor necrosis factor-alpha, as well as activated microglial cells. Simvastatin selectively reduces IL-1 beta expression and inhibits the activation of microglial cells and astrocytes after TBI, which might be one of the mechanisms underlying the therapeutic benefits of simvastatin treatment of TBI.	[Chopp, Michael] Henry Ford Hosp, Dept Neurol, Henry Ford Hlth Syst, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Li, Bo; Mahmood, Asim; Wu, Hongtao; Xiong, Ye; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Li, Bo] Harbin Med Univ, Dept Immunol, Harbin, Peoples R China; [Lu, Dunyue] SUNY Hlth Sci Ctr, Dept Psychiat, Brooklyn, NY 11203 USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, Henry Ford Hlth Syst, E&R Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Wu, Hongtao/A-8602-2011	Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS05228001A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant R01NS05228001A1. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Devaraj S, 2006, J CLIN ENDOCR METAB, V91, P4489, DOI 10.1210/jc.2006-0299; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gibson RM, 2004, VET J, V168, P230, DOI 10.1016/j.tvjl.2003.10.016; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lindberg C, 2005, J NEUROSCI RES, V82, P10, DOI 10.1002/jnr.20615; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Neuhaus O, 2004, LANCET NEUROL, V3, P369, DOI 10.1016/S1474-4422(04)00770-7; Onusko E, 2008, J FAM PRACTICE, V57, P449; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Raivich G, 2003, J NEUROSCI RES, V72, P726, DOI 10.1002/jnr.10621; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Wachtel M, 2001, J NEUROCHEM, V78, P155, DOI 10.1046/j.1471-4159.2001.00399.x; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	37	98	104	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2009	65	1					179	186		10.1227/01.NEU.0000346272.76537.DC			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	474EP	WOS:000268265600022	19574840	Green Accepted			2022-02-06	
J	Bavisetty, S; McArthur, DL; Dusick, JR; Wang, C; Cohan, P; Boscardin, WJ; Swerdloff, R; Levin, H; Chang, DJ; Muizelaar, JP; Kelly, DF				Bavisetty, Sumati; McArthur, David L.; Dusick, Joshua R.; Wang, Christina; Cohan, Pejman; Boscardin, W. John; Swerdloff, Ronald; Levin, Harvey; Chang, Dongwoo J.; Muizelaar, Jan P.; Kelly, Daniel F.			Chronic hypopituitarism after traumatic brain injury: Risk assessment and relationship to outcome	NEUROSURGERY			English	Article						endocrinopathy; growth hormone deficiency; hypopituitarism; injury severity; pituitary failure; traumatic brain injury	QUALITY-OF-LIFE; GROWTH-HORMONE DEFICIENCY; SEVERE HEAD-INJURY; GH REPLACEMENT THERAPY; PATIENT-REPORTED OUTCOMES; LONG-TERM; ADULT PATIENTS; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; SPONTANEOUS-RECOVERY	OBJECTIVE: Chronic pituitary dysfunction is increasingly recognized as a sequela of traumatic brain injury. We sought to define the incidence, risk factors, and neurobehavioral consequences of chronic hormonal deficiencies after complicated mild, moderate, or severe traumatic brain injury. METHODS: Patients aged 14 to 80 years were prospectively enrolled at the time of injury and assessed at 3 and 6 to 9 months after injury for hormonal function and neurobehavioral consequences. Major and minor (subclinical) hormonal deficiencies, including growth hormone deficiency (GHD) and growth hormone insufficiency (GHI), were identified. Acute injury characteristics, neurobehavioral, and quality of life measures were compared in patients with and without major hormonal deficits by the use of multivariate analysis. RESULTS: Out of 70 patients (mean age, 32 yr; median Glasgow Coma Scale score, 7; 19% women) tested at 6 to 9 months after injury, 15 (21 %) had at least one major hormonal deficiency, 20 (29%) had minor deficiencies, and 30 (43%) had major and/or minor deficiencies. Patients with major deficiencies included 16% with GHD or GHI, 10.5% with hypogonadism, and 1.4% with diabetes insipidus. None of the patients required adrenal or thyroid replacement. At 6 to 9 months after injury, patients with major hormonal deficits had more abnormal acute computed tomographic findings (P = 0.014), greater acute and chronic body mass index (P < 0.01), and a worse Disability Rating Scale score (multivariate P = 0.04). Compared with the 59 growth hormone-sufficient patients, the 11 patients with GHD or GHI had worse Disability Rating Scale scores (multivariate P = 0.04), greater rates of depression, (90 versus 53%; multivariate P = 0.06), and worse quality of life in the Short Form-36 domains of energy and fatigue (multivariate P = 0.03), emotional well-being (multivariate P = 0.02), and general health (multivariate P = 0.07). CONCLUSION: Chronic hypopituitarism warranting hormone replacement occurs in approximately 20% of patients after complicated mild, moderate, or severe traumatic brain injury and is associated with more severe brain injuries and increased disability. GHD and GHI are also associated with increased disability, poor quality of life, and a greater likelihood of depression. The clinical significance of minor hormonal deficits, which occur in almost 30% of patients, warrants further study. Given that major deficiencies are readily treatable, routine pituitary hormonal testing within 6 months of injury is indicated for this patient population.	[Kelly, Daniel F.] John Wayne Canc Inst, Neuroendocrine Tumor Ctr, Santa Monica, CA 90404 USA; [Bavisetty, Sumati; Wang, Christina; Swerdloff, Ronald] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [McArthur, David L.; Dusick, Joshua R.] Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; [Wang, Christina] Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Gonda Diabet Ctr, Los Angeles, CA USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Publ Hlth, Dept Med, Los Angeles, CA 90024 USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA USA; [Boscardin, W. John] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; [Levin, Harvey] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Chang, Dongwoo J.; Muizelaar, Jan P.] Univ Calif Davis, Davis Med Ctr, Dept Neurosurg, Sacramento, CA 95817 USA		Kelly, DF (corresponding author), John Wayne Canc Inst, Neuroendocrine Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwcj.org	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00865, K23 RR 1729801, MO1 RR00425, M01 RR 19975] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40777, NS30308] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000425, M01RR019975, M01RR000865, K23RR017298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS040777] Funding Source: NIH RePORTER		Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Arwert LI, 2005, NEUROENDOCRINOLOGY, V81, P31, DOI 10.1159/000084872; Arwert LI, 2005, HORM BEHAV, V47, P343, DOI 10.1016/j.yhbeh.2004.11.015; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blum WF, 2003, J CLIN ENDOCR METAB, V88, P4158, DOI 10.1210/jc.2002-021792; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DANIEL PM, 1959, LANCET, V2, P927; DANIEL PM, 1963, SCI BASIS MED ANN, V84, P83; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Giusti M, 1998, EUR J CLIN INVEST, V28, P13; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HOFFMAN DM, 1994, LANCET, V344, P482, DOI 10.1016/S0140-6736(94)91821-X; Howell S, 2001, HORM RES, V56, P86, DOI 10.1159/000048142; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KARLBERG J, 1995, ACTA OBSTET GYN SCAN, V74, P367, DOI 10.3109/00016349509024430; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kraus JF, 2003, ANN EMERG MED, V41, P18, DOI 10.1067/mem.2003.1; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mahajan T, 2004, EUR J ENDOCRINOL, V151, P325, DOI 10.1530/eje.0.1510325; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MCGAULEY GA, 1990, HORM RES, V33, P52, DOI 10.1159/000181584; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Miller KK, 2006, J CLIN ENDOCR METAB, V91, P1683, DOI 10.1210/jc.2005-2596; Mukherjee A, 2005, J CLIN ENDOCR METAB, V90, P1542, DOI 10.1210/jc.2004-0832; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Qoubaitary A, 2006, J ANDROL, V27, P853, DOI 10.2164/jandrol.106.000281; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rollero A, 1998, NEUROPSYCHOBIOLOGY, V38, P73, DOI 10.1159/000026520; Rosen T, 1997, EUR J ENDOCRINOL, V137, P240, DOI 10.1530/eje.0.1370240; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Smith, 1973, SYMBOL DIGIT MODALIT; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomei G, 1991, J Neurosurg Sci, V35, P61; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wiren L, 1998, CLIN ENDOCRINOL, V48, P613, DOI 10.1046/j.1365-2265.1998.00462.x; Zarkovic M, 1999, J CLIN ENDOCR METAB, V84, P3170, DOI 10.1210/jc.84.9.3170	96	98	100	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2008	62	5					1080	1093		10.1227/01.neu.0000325870.60129.6a			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	320FG	WOS:000257218500019	18580806				2022-02-06	
J	Nekludov, M; Bellander, BM; Blomback, M; Wallen, HN				Nekludov, Michael; Bellander, Bo-Michael; Blomback, Margareta; Wallen, Hakan N.			Platelet dysfunction in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						bleeding time; coagulopathy; platelet dysfunction; thromboelastography ( TEG); traumatic brain injury ( TBI)	HEAD-INJURY; COAGULOPATHY; THROMBOCYTOPENIA	Coagulopathy is a common phenomenon in traumatic brain injury (TBI) and a major contributor to a poor outcome. Thrombocytopenia is a strong negative prognostic factor in TBI, but bleeding tendency can be present even with a normal platelet count. We investigated platelet function in patients with TBI by means of modified thromboelastography (i.e., platelet mapping [TEG-PM]). Four groups were studied: (1) patients with severe isolated TBI (n = 20), ( 2) patients with general trauma without TBI (the ICU group, n = 10), (3) patients with chronic alcohol abuse (n = 7; as alcohol abuse is common in patients with TBI), and (4) healthy volunteers (n = 10). We measured platelet counts in venous blood (Plt), Ivy bleeding time, standard TEG parameters, and platelet responses to arachidonic acid (AA) and adenosindiphosphate (ADP), using TEG-PM. TBI patients had a lower Plt (180 +/- 68 x 10(9); mean +/- SD) and a longer bleeding time (674 +/- 230 sec) than healthy controls, (256 +/- 43 x 109, p < 0.01) and (320 +/- 95 sec, p < 0.005), respectively. TBI patients had dramatically lower platelet responses to AA (0-86%, mean 22%) compared to healthy controls (57-89%, mean 73%), the ICU group (4-75%, mean 49%), and the alcohol abusers (17-88%, mean 64%; p < 0.001). Responses to ADP did not differ significantly between the groups. Patients with low responsiveness to AA at admittance to the hospital were likely to develop bleeding complications later. Patients with TBI develop platelet dysfunction, which most likely contributes to bleeding complications. The observed platelet dysfunction appears to involve the cyclooxygenase pathway. TEG-PM analysis can be used to identify patients with a high risk of bleeding complications.	Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Div Cardiol, Stockholm, Sweden		Nekludov, M (corresponding author), Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.			Nekludov, Michael/0000-0001-9916-7086			ALEKSANDROV VN, 1984, ZH VOPR NEIROKHIR IM, V3, P19; Alstrom U, 2007, THROMB RES, V120, P353, DOI 10.1016/j.thromres.2006.10.009; BELL A, 1958, Am J Med Technol, V24, P264; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Goh KYC, 1997, J NEUROL NEUROSUR PS, V63, P334, DOI 10.1136/jnnp.63.3.334; Hansen Mads Koch, 2006, Ugeskr Laeger, V168, P3535; HARTERT H, 1951, Z GES EXP MED, V117, P189, DOI 10.1007/BF02044776; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Hobson AR, 2006, PLATELETS, V17, P509, DOI 10.1080/09537100600935259; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Maeda T, 1997, ACT NEUR S, V70, P102; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; SCHWARZMAIER S, 2006, 8 INT NEUR TRAUM SOC; Singer AJ, 2003, AM J EMERG MED, V21, P441, DOI 10.1016/S0735-6757(03)00100-1; Stein Deborah M, 2004, Curr Opin Crit Care, V10, P520, DOI 10.1097/01.ccx.0000144770.96342.65; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Tantry US, 2005, J AM COLL CARDIOL, V46, P1705, DOI 10.1016/j.jacc.2005.05.090	20	98	104	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1699	1706		10.1089/neu.2007.0322			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500003	18001200				2022-02-06	
J	Lavinio, A; Timofeev, I; Nortje, J; Outtrim, J; Smielewski, P; Gupta, A; Hutchinson, PJ; Matta, BF; Pickard, JD; Menon, D; Czosnyka, M				Lavinio, A.; Timofeev, I.; Nortje, J.; Outtrim, J.; Smielewski, P.; Gupta, A.; Hutchinson, P. J.; Matta, B. F.; Pickard, J. D.; Menon, D.; Czosnyka, M.			Cerebrovascular reactivity during hypothermia and rewarming	BRITISH JOURNAL OF ANAESTHESIA			English	Article						autoregulation; brain, injury; hypothermia; monitoring, critical care	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; INTRACRANIAL-PRESSURE; AUTOREGULATION	Background. Experimental evidence from a murine model of traumatic brain injury (TBI) suggests that hypothermia followed by fast rewarming may damage cerebral microcirculation. The effects of hypothermia and subsequent rewarming on cerebral vasoreactivity in human TBI are unknown. Methods. This is a retrospective analysis of data acquired during a prospective, observational neuromonitoring and imaging data collection project. Brain temperature, intracranial pressure (ICP), and cerebrovascular pressure reactivity index (PRx) were continuously monitored. Results. Twenty-four TBI patients with refractory intracranial hypertension were cooled from 36.0 (0.9) to 34.2 (0.5)degrees C [mean (SD), P < 0.0001] in 3.9 (3.7) h. Induction of hypothermia [average duration 40 (45) h] significantly reduced ICP from 23.1 (3.6) to 18.3 (4.8) mm Hg (P < 0.05). Hypothermia did not impair cerebral vasoreactivity as average PRx changed non-significantly from 0.00 (0.21) to -0.01 (0.21). Slow rewarming up to 37.0 degrees C [rate of rewarming, 0.2 (0.2)degrees C h(-1)] did not increase ICP [18.6 (6.2) mm Hg] or PRx [0.06 (0.18)]. However, in 17 (70. 1%) out of 24 patients, rewarming exceeded the brain temperature threshold of 37 degrees C. In these patients, the average brain temperature was allowed to increase to 37.8 (0.3)degrees C (P < 0.0001), ICP remained stable at 18.3 (8.0) mm Hg (P = 0.74), but average PRx increased to 0.32 (0.24) (P < 0.0001), indicating significant derangement in cerebrovascular reactivity. After rewarming, PRx correlated independently with brain temperature (R = 0.53; P < 0.05) and brain tissue O-2 (R=0.66; P < 0.01). Conclusions. After moderate hypothermia, rewarming exceeding the 37 degrees C threshold is associated with a significant increase in average PRx, indicating temperature-dependent hyperaemic derangement of cerebrovascular reactivity.	Addenbrookes Hosp, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge, England; Addenbrookes Hosp, Dept Anaesthesiol, Cambridge, England; Univ Brescia, Inst Anasthesiol & Intens Care Med, Brescia, Italy		Czosnyka, M (corresponding author), Addenbrookes Hosp, Dept Clin Neurosci, Acad Neurosurg Unit, Box 167, Cambridge, England.	mc141@medschl.cam.ac.uk	Lavinio, Andrea/M-1778-2016; Timofeev, Ivan/AAE-7019-2019	Outtrim, Joanne/0000-0001-8118-6430; Smielewski, Peter/0000-0001-5096-3938; Timofeev, Ivan/0000-0002-1168-0393	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0601025, G0600986] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390, G0601025] Funding Source: UKRI		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; KINCAID S, 2005, ANESTHESIOLOGY, V103, pA17; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Povoa P, 2002, INTENS CARE MED, V28, P235, DOI 10.1007/s00134-002-1209-6; Ramani R, 2006, CURR OPIN ANESTHESIO, V19, P487, DOI 10.1097/01.aco.0000245272.84539.97; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336	17	98	108	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	AUG	2007	99	2					237	244		10.1093/bja/aem118			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	199GA	WOS:000248683000014	17510046	Green Published, Bronze			2022-02-06	
J	Jensen, MP; Kuehn, CM; Amtmann, D; Cardenas, DA				Jensen, Mark P.; Kuehn, Carrie M.; Amtmann, Dagmar; Cardenas, Diane A.			Symptom burden in persons with spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						fatigue; pain; rehabilitation; signs and symptoms; spinal cord injuries	COMMUNITY INTEGRATION QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; MILD COGNITIVE IMPAIRMENT; CLOSED HEAD-INJURY; QUALITY-OF-LIFE; CHRONIC PAIN; MEMORY IMPAIRMENT; NEUROPATHIC PAIN; CASE SERIES; PREVALENCE	Objective: To determine (1) the frequency, severity, and reported course of 7 symptoms in persons with spinal cord injury (SCI) and (2) the association between these symptoms and patient functioning. Design: Postal survey. Setting: Community. Intervention: A survey that included measures of the frequency, severity, and recalled course of pain, fatigue, numbness, weakness, shortness of breath, vision loss, and memory loss, as well as a measure of community integration and psychologic functioning was mailed to a sample of persons with SCI. One hundred forty-seven usable surveys were returned (response rate, 43% of surveys mailed). Main Outcome Measures: The frequency and average severity of each symptom was computed, and the frequencies of each type of reported course were noted. Analyses estimated the associations among the symptoms, and between symptom severity and measures of patient functioning. Results: The most common symptoms were pain, weakness, fatigue, and numbness. All symptoms were reported to remain the same or to get worse more often than they were reported to improve once they began. Pain, weakness, fatigue, and memory loss were the symptoms most closely associated with patient functioning. Conclusions: Patients with SCI must deal with a number of secondary complications in addition to any disability caused by the injury itself. Of 7 symptoms studied, pain, weakness, and fatigue appeared to be most common and most closely linked to patient social and mental health functioning. Research is needed to identify the causal relationships between perceived symptoms and quality of life in patients with SCI and to identify effective treatments for those symptoms shown to impact patient functioning.	Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA; Univ Miami, Miller Sch Med, Dept Rehabil Med, Miami, FL 33152 USA		Jensen, MP (corresponding author), Univ Washington, Dept Rehabil Med, Sch Med, Box 356490, Seattle, WA 98195 USA.	mjensen@u.washington.edu		Kuehn, Carrie/0000-0001-5762-1682	NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U01 AR052171-01, U01 AR52171-01, U01 AR052171] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD033988, P01 HD033988-020001, P01 HD33988] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U01AR052171] Funding Source: NIH RePORTER		Ahn SH, 2003, SPINE, V28, P341, DOI 10.1097/00007632-200302150-00005; ANKE AGW, 1995, PARAPLEGIA, V33, P555, DOI 10.1038/sc.1995.120; Ayas N T, 1999, J Spinal Cord Med, V22, P97; Biering-Sorensen F, 2001, SPINAL CORD, V39, P505, DOI 10.1038/sj.sc.3101197; Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010; Buchholz AC, 2005, SPINAL CORD, V43, P513, DOI 10.1038/sj.sc.3101744; Budh CN, 2005, SPINAL CORD, V43, P85, DOI 10.1038/sj.sc.3101680; Caliri MHL, 2005, NURS CLIN N AM, V40, P337, DOI 10.1016/j.cnur.2004.09.009; Capel ID, 2003, SPINAL CORD, V41, P109, DOI 10.1038/sj.sc.3101401; Capoor Jaishree, 2005, Phys Med Rehabil Clin N Am, V16, P129, DOI 10.1016/j.pmr.2004.06.016; Cardenas DD, 2002, PAIN, V96, P365, DOI 10.1016/S0304-3959(01)00483-3; Castro MJ, 1999, J APPL PHYSIOL, V86, P350, DOI 10.1152/jappl.1999.86.1.350; Chen D, 2000, Phys Med Rehabil Clin N Am, V11, P45; CORIA F, 1993, J NEUROL NEUROSUR PS, V56, P973, DOI 10.1136/jnnp.56.9.973; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Donnelly C, 2005, SPINAL CORD, V43, P278, DOI 10.1038/sj.sc.3101702; Dryden DM, 2005, NEUROEPIDEMIOLOGY, V25, P55, DOI 10.1159/000086284; Ehde DM, 2004, REHABIL PSYCHOL, V49, P254, DOI 10.1037/0090-5550.49.3.254; Ehde DM, 2003, CLIN J PAIN, V19, P3, DOI 10.1097/00002508-200301000-00002; Finnerup NB, 2002, PAIN, V96, P375, DOI 10.1016/S0304-3959(01)00484-5; GERHART KA, 1997, AM REHABIL, V23, P19; Go Bette K., 1995, P21; Gordon T, 1995, ADV EXP MED BIOL, V384, P429; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Grandas NF, 2005, ARCH PHYS MED REHAB, V86, P1631, DOI 10.1016/j.apmr.2005.02.006; Haran MJ, 2005, ARCH PHYS MED REHAB, V86, P2290, DOI 10.1016/j.apmr.2005.07.293; Hicks AL, 2003, SPINAL CORD, V41, P34, DOI 10.1038/sj.sc.3101389; Jamil F, 2001, SPINAL CORD, V39, P355, DOI 10.1038/sj.sc.3101132; Jensen MP, 2005, SPINAL CORD, V43, P704, DOI 10.1038/sj.sc.3101777; Jensen MP, 2005, INT J CLIN EXP HYP, V53, P198, DOI 10.1080/00207140590927545; Jensen MP, 2004, PSYCHOLOGICA, V37, P129; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; KOIVISTO K, 1995, NEUROLOGY, V45, P741, DOI 10.1212/WNL.45.4.741; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; KREUTZER JS, 1988, ARCH PHYS MED REHAB, V69, P764; Leoni MEG, 2003, CLIN MICROBIOL INFEC, V9, P780, DOI 10.1046/j.1469-0691.2003.00643.x; Levendoglu F, 2004, SPINE, V29, P743, DOI 10.1097/01.BRS.0000112068.16108.3A; Liem NR, 2004, ARCH PHYS MED REHAB, V85, P1567, DOI 10.1016/j.apmr.2003.12.038; Linn WS, 2003, J SPINAL CORD MED, V26, P28, DOI 10.1080/10790268.2003.11753657; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879; McColl MA, 2004, ARCH PHYS MED REHAB, V85, P363, DOI 10.1016/j.apmr.2003.06.022; McColl MA, 2003, ARCH PHYS MED REHAB, V84, P1137, DOI 10.1016/S0003-9993(03)00138-2; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McComas AJ, 1995, ADV EXP MED BIOL, V384, P495; Nissen KR, 2003, OPHTHAL EPIDEMIOL, V10, P279, DOI 10.1076/opep.10.4.279.15909; Panagos A, 2004, J SPINAL CORD MED, V27, P138, DOI 10.1080/10790268.2004.11753745; Rintala DH, 2004, J REHABIL RES DEV, V41, P75, DOI 10.1682/JRRD.2004.01.0075; Rintala DH, 1998, ARCH PHYS MED REHAB, V79, P604, DOI 10.1016/S0003-9993(98)90032-6; Ritchie K, 2001, NEUROLOGY, V56, P37, DOI 10.1212/WNL.56.1.37; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Shapiro S, 2005, J NEUROSURG-SPINE, V2, P3, DOI 10.3171/spi.2005.2.1.0003; Sherman AL, 1997, ARCH PHYS MED REHAB, V78, P1012, DOI 10.1016/S0003-9993(97)90068-X; Shields RK, 2002, J ORTHOP SPORT PHYS, V32, P65, DOI 10.2519/jospt.2002.32.2.65; Song HY, 2005, DISABIL REHABIL, V27, P131, DOI 10.1080/09638280400007372; Spungen AM, 1997, SPINAL CORD, V35, P652, DOI 10.1038/sj.sc.3100489; Stein RB, 2002, PROG BRAIN RES, V137, P27; Stormer S, 1997, SPINAL CORD, V35, P446, DOI 10.1038/sj.sc.3100411; Thomas CK, 1998, J NEUROTRAUM, V15, P149, DOI 10.1089/neu.1998.15.149; Turner JA, 2002, PAIN, V98, P127, DOI 10.1016/S0304-3959(02)00045-3; Turner JA, 2001, ARCH PHYS MED REHAB, V82, P501, DOI 10.1053/apmr.2001.21855; Vaccaro AR, 1998, J SPINAL DISORD, V11, P535; Ware J., 2000, SF 36 HLTH SURVEY MA; Westgren N, 1998, ARCH PHYS MED REHAB, V79, P1433, DOI 10.1016/S0003-9993(98)90240-4; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9	67	98	98	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2007	88	5					638	645		10.1016/j.apmr.2007.02.002			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	164MN	WOS:000246238200015	17466734	Green Accepted			2022-02-06	
J	Dick, R; Hootman, JM; Agel, J; Vela, L; Marshall, SW; Messina, R				Dick, Randall; Hootman, Jennifer M.; Agel, Julie; Vela, Luzita; Marshall, Stephen W.; Messina, Renee			Descriptive epidemiology of collegiate women's field hockey injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2002-2003	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; knee injuries; ankle injuries; concussions	SPORT; PATTERNS; SEX	Objective: To review 15 years of National Collegiate Athletic Association (NCAA) injury surveillance data for women's field hockey and identify potential areas for injury prevention initiatives. Background: Field hockey is one of the most popular sports worldwide and is growing in participation in the United States, particularly among women. From 1988-1989 to 2002-2003, participation in NCAA women's field hockey increased 12%, with the largest growth among Division III programs. In 2002-2003, 253 colleges offered women's field hockey and 5385 women participated. Main Results: Game injury rates showed a significant average annual 2.5% decline over 15 years, most likely fueled by drops in ankle ligament sprain, knee internal derangement, and finger fracture injuries. Despite this, ankle ligament sprains were common (13.7% of game and 15.0% of practice injuries) and a frequent cause of severe injuries (resulting in 10+ days of time-loss activity). Concussion and head laceration injuries increased over this same time, and the risk of sustaining a concussion in a game was 6 times higher than the risk of sustaining one during practice. Overall, injury rates were twice as high in games as in practices (7.87 versus 3.70 injuries per 1000 athlete-exposures, rate ratio = 2.1, 95% confidence interval = 2.0, 2.3). Most head/neck/face (71%) and hand/finger/thumb (68%) injuries occurred when the player was near the goal or within the 25-yd line and were caused by contact with the stick or ball (greater than 77% for both body sites); for 34% of head/neck/ face injuries, a penalty was called on the play. Recommendations: Equipment (requiring helmets and padded gloves) and rule changes (to decrease field congestion near the goal) as well as evidence-based injury prevention interventions (eg, prophylactic ankle taping/bracing, neuromuscular balance exercise programs) may be viable prevention initiatives for reducing injury rates in women's collegiate field hockey players.	Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ Minnesota, Minneapolis, MN 55455 USA; W Chester Univ, W Chester, PA USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Penn State Univ, University Pk, PA 16802 USA		Hootman, JM (corresponding author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, 4770 Buford Highway NE,MSK-51, Atlanta, GA 30341 USA.	jhootman@cdc.gov		Marshall, Stephen/0000-0002-2664-9233			Beynnon BD, 2005, AM J SPORT MED, V33, P1485, DOI 10.1177/0363546505275490; Bolhuis J H, 1987, Br J Sports Med, V21, P174; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Dick R, 2007, J ATHL TRAINING, V42, P173; HANDOLL HH, 2001, COCHRANE DB SYST REV, V2; JAGDAY S, NEW OFFSIDE RULE; Junge A, 2006, AM J SPORT MED, V34, P565, DOI 10.1177/0363546505281807; MATTEI A, US OPINION GOGGLES M; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Okafor B, 1997, J BONE JOINT SURG BR, V79B, P544, DOI 10.1302/0301-620X.79B4.7432; Olmsted LC, 2004, J ATHL TRAINING, V39, P95; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rosberg HE, 2005, SCAND J PLAST RECONS, V39, P360, DOI 10.1080/02844310500340046; Stevenson MR, 2000, BRIT J SPORT MED, V34, P188, DOI 10.1136/bjsm.34.3.188; Tully MA, 2003, BRIT J SPORT MED, V37, P373, DOI 10.1136/bjsm.37.4.373; Yard EE, 2006, J ATHL TRAINING, V41, P441	17	98	99	0	28	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					211	220					10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	180RC	WOS:000247382300007	17710169				2022-02-06	
J	Gibbons, HM; Dragunow, M				Gibbons, Hannah M.; Dragunow, Mike			Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide	BRAIN RESEARCH			English	Article						microglia; nitric oxide; co-culture; microglial-neuronal interaction; hypothermia	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; INTERFERON-GAMMA; DOPAMINERGIC NEURODEGENERATION; INTERLEUKIN-10 PRODUCTION; INFLAMMATORY MECHANISMS; MODERATE HYPOTHERMIA; NEUROBLASTOMA-CELLS	Microglial cells play a major role in the pathogenesis of many neurological diseases by exacerbating neuronal and non-neuronal cell death, but the mechanisms involved are unclear. To investigate the microglial-neuronal interactions, we used the murine BV-2 microglial cell line and the human neuronal-like SK-N-SH neuroblastoma cell line in a co-culture system that enabled proximity-dependent interaction and communication, a trans-well system that allowed proximity-independent communication through diffusible molecules only, and a conditioned media system through which no proximity-dependent interactions or cell-to-cell communication is possible. Activation of BV-2 cells with lipopolysaccharide and interferon-gamma (LPS/IFN-gamma) decreased viability of the BV-2 cells alone and in co-cultures with SK-N-SH cells, but not SK-N-SH cells grown alone. In contrast, activation of BV-2 cells in the trans-well and conditioned media system did not have any effect on the viability of SK-N-SH cells, suggesting that microglia must be in close proximity to the neural cells to elicit cytotoxicity. To determine the molecules involved in proximity-dependent cell death, inhibitors of microglial activation were investigated. Only the specific inducible nitric oxide synthase (iNOS) inhibitor S-methylisothiourea, and hypothermia, which is known to suppress microglial NOS expression, prevented cell death after LPS/IFN-gamma activation. These results suggest that activated microglia release nitric oxide that is, at least partially, responsible for proximity-dependent micro glial-mediated neural toxicity. (c) 2006 Elsevier B.V. All rights reserved.	Univ Auckland, Dept Pharmacol & Clin Pharmacol, Signal Transduct Lab, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand		Dragunow, M (corresponding author), Univ Auckland, Dept Pharmacol & Clin Pharmacol, Signal Transduct Lab, Private Bag 92019, Auckland, New Zealand.	m.dragunow@auckland.ac.nz					Acarin L, 2002, J NEUROSCI RES, V68, P745, DOI 10.1002/jnr.10261; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Biagas Katherine V., 1998, Current Opinion in Pediatrics, V10, P271, DOI 10.1097/00008480-199806000-00009; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Broholm H, 2004, ACTA NEUROL SCAND, V109, P261, DOI 10.1111/j.1600-0404.2004.00207.x; Chao CC, 1997, NEUROREPORT, V8, P3163, DOI 10.1097/00001756-199709290-00031; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Choi SH, 2003, J NEUROSCI, V23, P5877; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Egger T, 2003, BIOCHEM J, V370, P459, DOI 10.1042/BJ20021358; Eskes C, 2003, J NEUROSCI RES, V71, P583, DOI 10.1002/jnr.10508; Flavin MP, 1997, NEUROSCIENCE, V80, P437, DOI 10.1016/S0306-4522(97)00078-X; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; He Y, 2003, J NEUROCHEM, V86, P1338, DOI 10.1046/j.1471-4159.2003.01938.x; Hill KE, 2004, J NEUROIMMUNOL, V151, P171, DOI 10.1016/j.jneuroim.2004.02.005; Hoozemans JJM, 2002, BRAIN RES, V951, P218, DOI 10.1016/S0006-8993(02)03164-5; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jana M, 2005, FREE RADICAL BIO MED, V38, P655, DOI 10.1016/j.freeradbiomed.2004.11.021; Jeohn GH, 2000, BRAIN RES, V880, P173, DOI 10.1016/S0006-8993(00)02737-2; Jeohn GH, 2000, MOL BRAIN RES, V79, P18, DOI 10.1016/S0169-328X(00)00081-4; Katsuse O, 2003, NEUROPATHOLOGY, V23, P9, DOI 10.1046/j.1440-1789.2003.00483.x; Klegeris A, 1999, NEUROPHARMACOLOGY, V38, P1017, DOI 10.1016/S0028-3908(99)00014-3; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; Lee P, 2003, NEUROSCI LETT, V349, P33, DOI 10.1016/S0304-3940(03)00697-9; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.00216.x; Luth HJ, 2002, BRAIN RES, V953, P135, DOI 10.1016/S0006-8993(02)03280-8; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Munch G, 2003, EXP BRAIN RES, V150, P1, DOI 10.1007/s00221-003-1389-5; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18, DOI 10.1002/jlb.67.1.18; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Saha RN, 2003, J NEUROCHEM, V86, P1057, DOI 10.1046/j.1471-4159.2003.01942.x; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Si QS, 1998, BRAIN RES, V812, P97, DOI 10.1016/S0006-8993(98)00954-8; Simpson KL, 1998, J CLIN ENDOCR METAB, V83, P4332, DOI 10.1210/jc.83.12.4332; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sugaya K, 1997, NEUROREPORT, V8, P2241, DOI 10.1097/00001756-199707070-00030; Taylor EL, 2003, CELL DEATH DIFFER, V10, P418, DOI 10.1038/sj.cdd.4401152; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Uryu S, 2002, BRAIN RES, V946, P298, DOI 10.1016/S0006-8993(02)02898-6; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Watters JJ, 2002, J BIOL CHEM, V277, P9077, DOI 10.1074/jbc.M104385200; Wong A, 2001, BRAIN RES, V920, P32, DOI 10.1016/S0006-8993(01)02872-4; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yoshikawa M, 1999, MULT SCLER J, V5, P126, DOI 10.1191/135245899678847194; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao WH, 2004, J NEUROPATH EXP NEUR, V63, P964, DOI 10.1093/jnen/63.9.964; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zujovic V, 2003, METHODS, V29, P345, DOI 10.1016/S1046-2023(02)00358-4	72	98	113	1	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 21	2006	1084						1	15		10.1016/j.brainres.2006.02.032			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	049XO	WOS:000238051300001	16564033				2022-02-06	
J	Nagdyman, N; Fleck, T; Schubert, S; Ewert, P; Peters, B; Lange, PE; Abdul-Khaliq, H				Nagdyman, N; Fleck, T; Schubert, S; Ewert, P; Peters, B; Lange, PE; Abdul-Khaliq, H			Comparison between cerebral tissue oxygenation index measured by near-infrared spectroscopy and venous jugular bulb saturation in children	INTENSIVE CARE MEDICINE			English	Article						near-infrared spectroscopy; tissue oxygenation index; cerebral oxygenation; jugular venous oxygen saturation; congenital heart defects; children	HYPOTHERMIC CIRCULATORY ARREST; CLOSED-HEAD INJURY; CARDIOPULMONARY BYPASS; OXYHEMOGLOBIN SATURATION; NIRO 300; OXIMETRY; SURGERY; NEURODEVELOPMENT; ISCHEMIA; INFANTS	Objective: To compare the cerebral tissue oxygenation index (TOI) measured by near-infrared spectroscopy (NIRS) with venous oxygen saturation in the jugular bulb (SjO(2)) during elective cardiac catheterization in children. Design and setting: Prospective observational clinical study in a catheterization laboratory for pediatric cardiology. Patients: Sixty children with congenital heart defects admitted to the catheterization laboratory. Measurements and results: TOI measured noninvasively by NIRS was compared to SjO(2) measured in the jugular bulb during cardiac catheterization. Patients were divided into two groups regarding body weight: below ( n= 29) and above 10 kg ( n= 31). Linear regression analysis and Pearson's correlation coefficient were calculated. Bland-Altman analysis, sensitivity, and specificity calculation for spatially resolved near-infrared spectroscopy with a cutoff level of 60% were performed. Simultaneously measured values for SjO(2) ( 67.3 +/- 9.8%, 40 - 84.1%) and TOI ( 65.7 +/- 7.2%, 39 - 80%) showed a significant correlation; the correlation in children weighing under 10 kg was stronger in children weighing over 10 kg. Bland-Altman analysis showed a mean bias of - 1.8% with limits of agreement between 11.7% and - 15.3% for all children. Sensitivity and specificity of the SRS method were 46% and 91%, respectively, for all children and 53% and 83% respectively in infants weighing under 10 kg. Conclusions: The results demonstrate that despite a significant correlation, sensitivity of spatially resolved spectroscopy is poor, and it is questionable whether TOI can be used reliably to detect low SjO(2).	Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects & Pediat Cardiol, D-13353 Berlin, Germany		Nagdyman, N (corresponding author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects & Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	nagdyman@dhzb.de	Fleck, Thilo Pierre Karl/H-9073-2019	Fleck, Thilo Pierre Karl/0000-0003-4531-5930			Abdul-Khaliq H, 2002, THORAC CARDIOV SURG, V50, P77, DOI 10.1055/s-2002-26698; ABDULKHALIQ H, 1998, Z HERZ THORAX GEFASS, V12, P65; Adcock LM, 1999, CLIN PERINATOL, V26, P893, DOI 10.1016/S0095-5108(18)30026-5; Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Ali MS, 2001, CAN J ANAESTH, V48, P497, DOI 10.1007/BF03028317; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BROWN R, 1993, ANAESTHESIA, V48, P697, DOI 10.1111/j.1365-2044.1993.tb07184.x; Buunk G, 1998, ANAESTHESIA, V53, P13, DOI 10.1046/j.1365-2044.1998.00263.x; Chan MTV, 1997, ANAESTHESIA, V52, P705; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Daubeney PEF, 1996, ANN THORAC SURG, V61, P930, DOI 10.1016/0003-4975(95)01186-2; Dittrich H, 2003, HEART, V89, P436, DOI 10.1136/heart.89.4.436; FALLON P, 1993, ANN THORAC SURG, V56, P1473, DOI 10.1016/0003-4975(93)90733-X; Fearn SJ, 1997, ANAESTHESIA, V52, P704; Fortune PM, 2001, INTENS CARE MED, V27, P1401, DOI 10.1007/s001340100994; GAYLE MO, 1989, CRIT CARE MED, V17, P385, DOI 10.1097/00003246-198905000-00001; GERMON TJ, 1994, BRIT J ANAESTH, V73, P503, DOI 10.1093/bja/73.4.503; GERMON TJ, 1995, J NEUROL NEUROSUR PS, V58, P477, DOI 10.1136/jnnp.58.4.477; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Jonas RA, 1998, PEDIATR CARDIOL, V19, P321, DOI 10.1007/s002469900317; Kurth CD, 1997, J THORAC CARDIOV SUR, V113, P71, DOI 10.1016/S0022-5223(97)70401-X; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MATCHER SJ, 1995, P SOC PHOTO-OPT INS, V2389, P486; Nagdyman N, 2003, BRIT J ANAESTH, V91, P438, DOI 10.1093/bja/aeg181; Nollert G, 2000, THORAC CARDIOV SURG, V48, P247, DOI 10.1055/s-2000-6895; Schulz G, 2002, INTENS CARE MED, V28, P184, DOI 10.1007/s00134-001-1182-5; SUZUKI S, 1999, P SOC PHOTO-OPT INS, V3579, P486; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Wahr JA, 1996, J CARDIOTHOR VASC AN, V10, P406, DOI 10.1016/S1053-0770(96)80107-8; WICKRAMASINGHE YABD, 1993, PEDIATR RES, V34, P15, DOI 10.1203/00006450-199307000-00004; Wypij D, 2003, J THORAC CARDIOV SUR, V126, P1397, DOI 10.1016/S0022-5223(03)00940-1	32	98	98	0	4	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2005	31	6					846	850		10.1007/s00134-005-2618-0			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932UC	WOS:000229578000015	15803294				2022-02-06	
J	Ringger, NC; O'Steen, BE; Brabham, JG; Silver, X; Pineda, J; Wang, KKW; Hayes, RL; Papa, L				Ringger, NC; O'Steen, BE; Brabham, JG; Silver, X; Pineda, J; Wang, KKW; Hayes, RL; Papa, L			A novel marker for traumatic brain injury: CSF alpha II-spectrin breakdown product levels	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; CSF; injury magnitude; lesion size; spectrin; S100 beta; tau	SEVERE HEAD-INJURY; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; SERUM S-100 PROTEIN; CEREBROSPINAL-FLUID; CALPAIN INHIBITOR; BIOCHEMICAL MARKERS; MITOCHONDRIAL DYSFUNCTION; T-2-WEIGHTED MRI; CARDIAC-SURGERY	Currently, there is no definitive diagnostic test for traumatic brain injury (TBI) to help physicians determine the seriousness of injury or the extent of cellular pathology. Calpain cleaves all-spectrin into breakdown products (SBDP) after TBI and ischemia. Mean levels of both ipsilateral cortex (IC) and cerebral spinal fluid (CSF) SBDP at 2, 6, and 24 h after two levels of controlled cortical impact (1.0 mm and 1.6 mm of cortical deformation) in rats were significantly elevated by injury. CSF and IC SBDP levels were significantly higher after severe (1.6 mm) injury than mild (1.0 mm) injury over time. The correlation between CSF SBDP levels and lesion size from T2-weighted magnetic resonance images 24 hours after TBI as well as correlation of tau and S100beta was assessed. Mean levels of CSF SBDP (r = 0.833) and tau (r = 0.693) significantly correlated with lesion size while levels of CSF S100beta did not (r = 0.188). Although levels of CSF and IC SBDP and lesion size are all significantly higher after 1.6 mm than 1.0 mm injury, the correlation between CSF SBDP and lesion size was not significant following the removal of controls from the analysis. This indicates CSF SBDP is a reliable marker of the presence or absence of injury. Furthermore, larger lesion sizes 24 h after TBI were negatively correlated with motor performance on days 1-5 after TBI (r = -0.708). Based on these data, evaluation of CSF SBDP levels as a biomarker of TBI is warranted in clinical studies.	Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injuries, Gainesville, FL 32610 USA; Univ Florida, AMRIS Facil, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Shands Hosp, Coll Med, Dept Emergency Med, Gainesville, FL USA		Ringger, NC (corresponding author), Univ Florida, McKnight Brain Inst, Dept Neurosci, 100 S Newell Dr,L1-100,POB 100244, Gainesville, FL 32610 USA.	ringger@ufbi.ufl.edu	Silver, Xeve/AAP-3398-2021; Pineda, Jose/W-2806-2019	Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40182, R01 NS39091] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER		Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Herrmann M, 1999, EUR J CARDIO-THORAC, V16, P513, DOI 10.1016/S1010-7940(99)00245-6; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Hill MD, 2000, CAN MED ASSOC J, V162, P1139; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McKeating EG, 1998, ACT NEUR S, V71, P117; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Palmer GC, 2001, ANN NY ACAD SCI, V939, P283; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wang CZ, 1998, J ASIAN NAT PROD RES, V1, P1, DOI 10.1080/10286029808039839; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	68	98	99	0	3	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2004	21	10					1443	1456		10.1089/neu.2004.21.1443			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	867BT	WOS:000224817800008	15672634				2022-02-06	
J	Farrin, L; Hull, L; Unwin, C; Wykes, T; David, A				Farrin, L; Hull, L; Unwin, C; Wykes, T; David, A			Effects of depressed mood on objective and subjective measures of attention	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							COGNITIVE FAILURES QUESTIONNAIRE; PERSIAN-GULF-WAR; MAJOR DEPRESSION; CHRONIC FATIGUE; PERFORMANCE; COMPLAINTS; DEFICITS	People with depression report frequent cognitive failures, but objective measures of cognition show mixed results. Some studies show impairment on effortful tasks. The relationship between subjective and objective cognitive failures was studied in 102 "depressed" or "nondepressed" UK servicemen, grouped by Beck Depression Inventory scores with a cutoff score of 10. Participants were administered cognitive tests including the Sustained Attention to Response Task (SART), a laboratory measure of vigilance that has revealed increased attentional lapses in traumatic brain injury patients. The depressed men made more errors on SART than the nondepressed men (P = 0.012) but reported much higher incidences objective cognitive failures on a standardized questionnaire (P = 0.0001). The depressed men's SART reaction times slowed following an error, a pattern different from that of brain-injured subjects. Nonclinical depressed subjects may respond "catastrophically" to errors, heightening the subjective sense of failure and contributing to the strong relationship between subjectively reported cognitive failures and depression.	Inst Psychiat, London SE5 8AF, England; Guys Kings & St Thomas Sch Med, Gulf War Illnesses Res Unit, London, England		David, A (corresponding author), Inst Psychiat, De Crespigny Pk, Denmark Hill, London SE5 8AF, England.		Wykes, Til/B-3812-2011; David, Anthony/O-1750-2019; Wykes, Til H M/B-7894-2008; David, Anthony S/C-1315-2011	Wykes, Til/0000-0002-5881-8003; David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X			Beck A. T., 1993, BECK DEPRESSION INVE; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROWN RG, 1994, PSYCHOL MED, V24, P829, DOI 10.1017/S0033291700028932; COPE H, 1995, BRIT J PSYCHIAT, V167, P86, DOI 10.1192/bjp.167.1.86; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; Elliott R, 1996, PSYCHOL MED, V26, P975, DOI 10.1017/S0033291700035303; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GRONWALL DMA, 1975, LANCET, V2, P1452; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; KAHN RL, 1975, ARCH GEN PSYCHIAT, V32, P1569; Mahoney AM, 1998, PSYCHOL REP, V82, P1432, DOI 10.2466/PR0.82.3.1432-1434; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Merckelbach H, 1996, PERS INDIV DIFFER, V20, P715, DOI 10.1016/0191-8869(96)00024-4; Mialet JP, 1996, PSYCHOL MED, V26, P1009, DOI 10.1017/S0033291700035339; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Purcell R, 1997, PSYCHOL MED, V27, P1277, DOI 10.1017/S0033291797005448; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Trenerry MR, 1989, PSYCHOL ASSESSMENT R; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; VANGORP WG, 1991, J CLIN EXP NEUROPSYC, V13, P812, DOI 10.1080/01688639108401091; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Wagle AC, 1999, COMPR PSYCHIAT, V40, P478, DOI 10.1016/S0010-440X(99)90093-7; WARE JE, 1993, HLTH SURVEY MANUNAL; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42	30	98	113	2	13	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2003	15	1					98	104		10.1176/appi.neuropsych.15.1.98			7	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	641RH	WOS:000180759300015	12556579				2022-02-06	
J	Levin, HS				Levin, HS			Neuroplasticity following non-penetrating traumatic brain injury	BRAIN INJURY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD-INJURY; WORKING-MEMORY; LANGUAGE-DEVELOPMENT; CORPUS-CALLOSUM; CHILDREN; APHASIA; RECOVERY; INVOLVEMENT; PLASTICITY	The primary objective of this review is to examine the methodology and evidence for neuroplasticity operating in recovery from traumatic brain injury (TBI), as compared with previous findings in patients sustaining perinatal and infantile focal vascular lesions. The evidence to date indicates that the traditional view of enhanced reorganization of function after early focal brain lesions might apply to early focal brain lesions, but does not conform with studies of early severe diffuse brain injury. In contrast to early focal vascular lesions, young age confers no advantage in the outcome of severe diffuse brain injury. Disruption of myelination could potentially alter connectivity, a suggestion which could be confirmed through diffusion tensor imaging (DTI). Initial reports of DTI in TBI patients support the possibility that this technique can demonstrate alterations in white matter connections which are not seen on conventional magnetic resonance imaging (MRI) and might change over time or with interventions. Preliminary functional MRI studies of TBI patients indicate alterations in the pattern of brain activation, suggesting recruitment of more extensive cortical regions to perform tasks which stress computational resources. Functional MRI, coupled with DTI and possibly other imaging modalities holds the promise of elucidating mechanisms of neuroplasticity and repair following TBI.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 6560 Fannin St,Box 67, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42772, NS21889] Funding Source: Medline		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; DENNIS M, 1975, BRAIN LANG, V2, P472, DOI 10.1016/S0093-934X(75)80084-8; FELDMAN HM, 1992, BRAIN LANG, V42, P89, DOI 10.1016/0093-934X(92)90058-M; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Levin HS, 1996, ARCH NEUROL-CHICAGO, V53, P88, DOI 10.1001/archneur.1996.00550010108024; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mitrushina MN, 1999, HDB NORMATIVE DATA N; Musso M, 1999, BRAIN, V122, P1781, DOI 10.1093/brain/122.9.1781; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; Rosenzweig MR, 1999, CHANGING NERVOUS SYSTEM, P25; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schallert T, 2000, CEREBRAL REORGANIZAT, P145; Stiles J, 1996, BRAIN COGNITION, V31, P46, DOI 10.1006/brcg.1996.0024; STILES J, IN PRESS J INT NEURO; Teuber H. L., 1974, NEUROSCIENCES 3 STUD, P71; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505; WOODS BT, 1980, NEUROPSYCHOLOGIA, V18, P65, DOI 10.1016/0028-3932(80)90084-6	35	98	100	0	20	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					665	674		10.1080/0269905031000107151			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500004	12850951				2022-02-06	
J	Penkowa, M; Giralt, M; Lago, N; Camats, J; Caffasco, J; Hernandez, J; Molinero, A; Campbell, IL; Hidalgo, J				Penkowa, M; Giralt, M; Lago, N; Camats, J; Caffasco, J; Hernandez, J; Molinero, A; Campbell, IL; Hidalgo, J			Astrocyte-targeted expression of IL-6 protects the CNS against a focal brain injury	EXPERIMENTAL NEUROLOGY			English	Article						neurotrauma; inflammation; neuroprotection; oxidative stress; neurodegeneration; apoptosis; wound healing	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INCREASED OXIDATIVE STRESS; TUMOR-NECROSIS-FACTOR; METALLOTHIONEIN-I; TRANSGENIC MICE; INFLAMMATORY RESPONSE; NEURODEGENERATIVE DISEASES; NEUROGLIAL ACTIVATION; IL-6-DEFICIENT MICE	The effect of CNS-targeted IL-6 gene expression has been thoroughly investigated in the otherwise nonperturbed brain but not following brain injury. Here we examined the impact of astrocyte-targeted IL-6 production in a traumatic brain injury (cryolesion) model using GFAP-IL6 transgenic mice. This study demonstrated that transgenic IL-6 production significantly increased wound healing following the cryolesion. Thus, at 20 days postlesion (dpl) the GFAP-IL6 mice showed almost complete wound healing compared to litter mate nontransgenic controls. It seems likely that a reduced inflammatory response in the long term could be responsible for this IL-6-related effect. Thus, while in the acute phase following cryolesion (1-6 dpl) the recruitment of macrophages and T lymphocytes was higher in GFAP-IL6 mice, at 10-20 dpl it was significantly reduced compared to controls. Reactive astrogliosis was also significantly increased up to but not including 20 dpl in the GFAP-IL6 mice. Oxidative stress as well as apoptotic cell death was significantly decreased throughout the time period studied in the GFAP-IL6 mice compared to controls. This could be linked to the altered inflammatory response as well as to the transgenic IL-6-induced increase of the antioxidant, neuroprotective proteins metallothionein-I + II. These results indicate that although in the brain the chronic astrocyte-targeted expression of IL-6 spontaneously induces an inflammatory response causing significant damage, during an acute neuropathological insult such as following traumatic injury, a clear neuroprotective role is evident. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Autonoma Barcelona, Fac Ciencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Bellaterra 08193, Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA		Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Bellaterra 08193, Barcelona, Spain.	Juan.Hidalgo@uab.es	Carrasco, Javier/C-9732-2011; molinero, amalia/K-2147-2014; Hidalgo, Juan/C-9082-2011; Hernandez, Joaquim/E-1298-2011; Giralt, Mercedes/K-1626-2014	Carrasco, Javier/0000-0001-6436-0863; molinero, amalia/0000-0001-8661-8570; Hidalgo, Juan/0000-0003-0921-1122; Hernandez, Joaquim/0000-0003-1409-5568; Giralt, Mercedes/0000-0002-1806-1528; Lago, Natalia/0000-0002-5631-8558			Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Aschner M, 1997, ANN NY ACAD SCI, V825, P334, DOI 10.1111/j.1749-6632.1997.tb48445.x; Aschner M, 1996, FASEB J, V10, P1129, DOI 10.1096/fasebj.10.10.8751715; Bensadoun JC, 2001, EUR J NEUROSCI, V14, P1753, DOI 10.1046/j.0953-816x.2001.01802.x; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Cai L, 2000, J BIOL CHEM, V275, P38957, DOI 10.1074/jbc.C000593200; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Crowthers KC, 2000, TOXICOL APPL PHARM, V166, P161, DOI 10.1006/taap.2000.8961; De Laurentiis A, 2000, NEUROIMMUNOMODULAT, V7, P77, DOI 10.1159/000026423; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Floyd RA, 1999, LIFE SCI, V65, P1893, DOI 10.1016/S0024-3205(99)00443-9; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563; GIJBELS K, 1995, MOL MED, V1, P795, DOI 10.1007/BF03401894; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; HIDALGO J, 1997, CURR TOPICS NEUROCHE, V1, P1; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kling PG, 2000, FREE RADICAL BIO MED, V28, P1628, DOI 10.1016/S0891-5849(00)00277-X; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Martin LJ, 2001, INT J MOL MED, V7, P455; Martiney JA, 1998, NEUROCHEM RES, V23, P349, DOI 10.1023/A:1022457500700; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Murphy PG, 1999, J NEUROSCI, V19, P3791; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; PENKOWA M, 2002, BIOMED REV, V13, P1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rana Suresh V. S., 2000, Arhiv za Higijenu Rada i Toksikologiju, V51, P279; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; Samoilova EB, 1998, J IMMUNOL, V161, P6480; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Sensi SL, 1999, NEUROREPORT, V10, P1723, DOI 10.1097/00001756-199906030-00018; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sun AY, 1998, J BIOMED SCI, V5, P401; Suzuki Y, 2000, TOXICOLOGY, V145, P51, DOI 10.1016/S0300-483X(99)00220-6; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Umegaki H, 1996, BIOCHEM PHARMACOL, V52, P911, DOI 10.1016/0006-2952(96)00422-4; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Xiao BG, 1998, J NEUROL SCI, V157, P1, DOI 10.1016/S0022-510X(98)00049-5; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; Zheng H, 1996, TOXICOL APPL PHARM, V136, P229, DOI 10.1006/taap.1996.0029	84	98	110	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2003	181	2					130	148		10.1016/S0014-4886(02)00051-1			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	687RR	WOS:000183391000002	12781987				2022-02-06	
J	Chang, EF; Wong, RJ; Vreman, HJ; Igarashi, T; Galo, E; Sharp, FR; Stevenson, DK; Noble-Haeusslein, LJ				Chang, EF; Wong, RJ; Vreman, HJ; Igarashi, T; Galo, E; Sharp, FR; Stevenson, DK; Noble-Haeusslein, LJ			Heme oxygenase-2 protects against lipid peroxidation-mediated cell loss and impaired motor recovery after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						heme oxygenase-2; traumatic brain injury; lipid peroxidation; oxidative stress; controlled cortical impact; heme-oxygenase-1	CONTROLLED CORTICAL IMPACT; CARBON-MONOXIDE; OXIDATIVE STRESS; DIFFERENTIAL EXPRESSION; CEREBRAL-ISCHEMIA; TIME-COURSE; BILIRUBIN; GENE; ANTIOXIDANT; ASTROCYTES	After traumatic brain injury (TBI), substantial extracellular heme is released from hemoproteins during hemorrhage and cell injury. Heme oxygenase (HO) isozymes are thought to detoxify the pro-oxidant heme to the potent antioxidant, bilirubin. HO-1, the inducible isozyme, is expressed in glial populations after injury and may play a protective role. However, the role of HO-2, the predominant and constitutively expressed isozyme in the brain, remains unclear after TBI. We used a controlled cortical impact injury model to determine the extent and mechanism of damage between HO-2 knock-out (KO) (-/-) and wild-type (WT) (+/+) mice. The specific cellular and temporal expressions of HO-2 and HO-1 were characterized by immunocytochemistry and Western blots. HO-2 was immunolocalized in neurons both before and after TBI, whereas HO-1 was highly upregulated in glia only after TBI. HO activity determined by gas chromatography using brain sonicates from injured HO-2 KO mice was significantly less than that of HO-2 wild types, despite the induction of HO-1 expression after TBI. Cell loss was significantly greater in KO mice in areas including the cortex, the CA3 region of hippocampus, and the lateral dorsal thalamus. Furthermore, motor recovery after injury, as measured by the rotarod assay and an inclined beam-walking task, was compromised in the KO mice. Finally, brain tissue from injured HO-2 KO mice exhibited decreased ability to reduce oxidative stress, as measured with an Fe2+/ascorbic acid-mediated carbon monoxide generation assay for lipid peroxidation susceptibility. These findings demonstrate that HO-2 expression protects neurons against TBI by reducing lipid peroxidation via the catabolism of free heme.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Program Neurosci, Cincinnati, OH 45267 USA		Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.	noblelj@itsa.ucsf.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS041256, NS 41256] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS041256] Funding Source: NIH RePORTER		Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Conti AC, 1998, J NEUROSCI, V18, P5663; Dennery PA, 2000, CURR TOP CELL REGUL, V36, P181; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dore S, 1999, ANN NY ACAD SCI, V890, P167, DOI 10.1111/j.1749-6632.1999.tb07991.x; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; EWING JF, 1993, J NEUROCHEM, V61, P1015, DOI 10.1111/j.1471-4159.1993.tb03615.x; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FOX GB, 2001, METH NE FRO NEUROSCI, P27; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GOPINATHAN V, 1994, FEBS LETT, V349, P197, DOI 10.1016/0014-5793(94)00666-0; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; IMAI K, 1990, CHEM PHARM BULL, V38, P258; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Li XQ, 2000, PAIN, V86, P75, DOI 10.1016/S0304-3959(00)00238-4; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 1996, BRAIN RES, V722, P83, DOI 10.1016/0006-8993(96)00184-9; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Patel BN, 2002, J NEUROSCI, V22, P6578; Platt JL, 1998, NAT MED, V4, P1364, DOI 10.1038/3947; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Povlishock J T, 1992, Hum Cell, V5, P345; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; Rouault TA, 2001, PEDIATR NEUROL, V25, P130, DOI 10.1016/S0887-8994(01)00260-0; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Vreman HJ, 1998, CAN J PHYSIOL PHARM, V76, P1057; VREMAN HJ, 1988, J CHROMATOGR-BIOMED, V427, P315, DOI 10.1016/0378-4347(88)80134-8; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; WONG RJ, 2000, ACTA HAEMATOL, V103, P4309; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; Zufall F, 1997, J NEUROSCI, V17, P2703	56	98	100	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAY 1	2003	23	9					3689	3696					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	675MX	WOS:000182700100016	12736340				2022-02-06	
J	Mori, T; Wang, XY; Aoki, T; Lo, EH				Mori, T; Wang, XY; Aoki, T; Lo, EH			Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; mouse; neuroprotection; proteolysis	MATRIX-METALLOPROTEINASE EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; GENE KNOCK-OUT; FOREBRAIN ISCHEMIA; TIGHT JUNCTIONS; CELL-LINE; BARRIER; INCREASE; INVOLVEMENT; PROTEOLYSIS	Emerging data suggest that matrix metalloproteinase-9 (MMP-9) plays a critical role in the pathophysiology of brain injury. However, the regulatory mechanisms involved in vivo remain unclear. In this study, we focus on a mitogen activated protein kinase (MAPK) pathway that may trigger MMP-9 after traumatic brain injury. We aim to show that inhibition of the extracellular signal regulated kinase (ERK) would attenuate MMP-9 levels, reduce blood-brain barrier damage, and attenuate edema after trauma induced by controlled cortical impact in mouse brain. Western blots showed that phospho-ERK was rapidly upregulated after trauma. Treatment with U0126, which inhibits MEK, the kinase upstream of ERK, effectively prevented the activation of ERK. After trauma, gelatin zymography showed an increase in MMP-9. U0126 significantly reduced trauma-induced MMP-9 levels. Correspondingly, U0126 ameliorated the degradation of the tight junction protein ZO-1, which is an MMP-9 substrate, and significantly attenuated tissue edema. At 7 days after trauma, traumatic lesion volumes were significantly reduced by U0126 compared with saline-treated controls. These data indicate that the ERK MAPK pathway triggers the upregulation in MMP-9 after trauma, and further suggest that targeting the upstream signaling mechanisms that regulate deleterious MMP-9 activity may reveal new therapeutic opportunities for traumatic brain injury.	Harvard Univ, MGH,Sch Med, Dept Neurol, Neuroprotect Res Lab, Boston, MA 02129 USA; Harvard Univ, MGH,Sch Med, Dept Radiol, Neuroprotect Res Lab, Boston, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02129 USA		Lo, EH (corresponding author), Harvard Univ, MGH,Sch Med, Dept Neurol, Neuroprotect Res Lab, East 149-2401, Boston, MA 02129 USA.	Lo@helix.mgh.harvard.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS38731, R01-NS37074, R01-NS40529] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037074, R01NS040529, R01NS038731] Funding Source: NIH RePORTER		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferguson TA, 2000, MOL CELL NEUROSCI, V16, P157, DOI 10.1006/mcne.2000.0859; Fini ME, 1998, BIOL EXTRAC, P299; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Genersch E, 2000, J CELL SCI, V113, P4319; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Marmarou A., 1996, NEUROTRAUMA, P413; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Nico B, 1999, DEV BRAIN RES, V114, P161, DOI 10.1016/S0165-3806(99)00008-5; Oh LYS, 1999, J NEUROSCI, V19, P8464; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SMITH DH, NEUROTRAUMA, P1445; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vu TH, 1998, BIOL EXTRAC, P115; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhang ZG, 2001, BRAIN RES, V912, P181, DOI 10.1016/S0006-8993(01)02735-4	59	98	111	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1411	1419		10.1089/089771502320914642			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500002	12490006				2022-02-06	
J	Rose, C; Michalak, A; Pannunzio, M; Chatauret, N; Rambaldi, A; Butterworth, RF				Rose, C; Michalak, A; Pannunzio, M; Chatauret, N; Rambaldi, A; Butterworth, RF			Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure	HEPATOLOGY			English	Article							ACUTE HEPATIC-FAILURE; AMINO-ACIDS; TOTAL HEPATECTOMY; CEREBRAL EDEMA; BODY-TEMPERATURE; ENCEPHALOPATHY; INJURY; AMMONIA; HYPERAMMONEMIA; MICRODIALYSIS	Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF), To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). Mild hypothermia resulted in a significant delay in the onset of severe encephalopathy and in reduction of brain water content compared with normothermic ALF rats (control [n = 8] 80.22%; ALF-37 degrees C [n = 8] 81.74%; ALF-35 degrees C [n = 8] 80.48% [P <.01 compared with ALF-37 degrees C]). This protective effect was accompanied by a significant reduction of cerebrospinal fluid (CSF) (but not plasma) ammonia concentrations (CSF ammonia: control: 0.05 mg/dL; ALF-37 degrees C: 1.01 mg/dL; ALF-35 degrees C: 0.07 mg/dL, P <.01. compared with ALF-37 degrees C). In vivo cerebral microdialysis studies revealed that mild hypothermia resulted in a significant reduction of extracellular glutamate concentrations in the brains of rats with ALF (control: 1.06 mu mol/L; ALF37 degrees C: 2.74 mu mol/L; ALF-35 degrees C: 1.49 mu mol/L [:P <.01 compared with ALF-37 degrees C]). These findings suggest that: 1) mild hypothermia is an effective approach to the prevention of the central nervous system consequences of experimental ALF; and that 2) the beneficial effect of hypothermia is mediated via mechanisms involving reduced blood-brain. transfer of ammonia and/or reduction of extracellular brain glutamate concentrations. Mild hypothermia may be an effective approach to delay the onset of brain edema in patients with ALF awaiting liver transplantation.	Univ Montreal, Ctr Hosp, Neurosci Res Unit, Montreal, PQ, Canada		Butterworth, RF (corresponding author), Hop St Luc, CHUM, Neurosci Res Unit, 1058 St Denis St, Montreal, PQ H2X 3J4, Canada.	buterwr@medclin.umontreal.ca	Rambaldi, Alessandro/M-6172-2019; Rose, Christopher F/F-1105-2010	Rambaldi, Alessandro/0000-0002-3739-7502; Rose, Christopher F/0000-0001-9854-6834			BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; BOSMAN DK, 1992, J NEUROCHEM, V59, P591, DOI 10.1111/j.1471-4159.1992.tb09410.x; BRUSILOW SW, 1985, GENETIC METABOLIC DI, P140; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUTTERWORTH RF, 1992, MOL NEUROPHARMACOL, V2, P229; Butterworth RF, 1997, HEPATOLOGY, V25, P1032, DOI 10.1002/hep.510250440; CHAN H, IN PRESS NEUROCHEM I; CHODOBSKI A, 1986, J NEUROSURG, V65, P86, DOI 10.3171/jns.1986.65.1.0086; Clemmesen JO, 1999, HEPATOLOGY, V29, P648, DOI 10.1002/hep.510290309; Cordoba J, 1996, SEMIN LIVER DIS, V16, P271, DOI 10.1055/s-2007-1007240; Cordoba J, 1999, GASTROENTEROLOGY, V116, P686, DOI 10.1016/S0016-5085(99)70191-5; DEKNEGT RJ, 1994, J HEPATOL, V20, P19, DOI 10.1016/S0168-8278(05)80462-3; DIENST SG, 1961, J LAB CLIN MED, V58, P149; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; GANZ R, 1989, METAB BRAIN DIS, V4, P213, DOI 10.1007/BF01000297; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HOLMIN T, 1983, EUR J CLIN INVEST, V13, P215, DOI 10.1111/j.1365-2362.1983.tb00090.x; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; JENKINS JG, 1987, BRIT MED J, V294, P337, DOI 10.1136/bmj.294.6568.337; KNECHT K, 1997, NEUROSCI LETT, V25, P1032; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; LEE SH, 1961, SURGERY, V50, P668; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; MANS AM, 1979, J NEUROCHEM, V32, P285, DOI 10.1111/j.1471-4159.1979.tb00350.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Michalak A, 1997, HEPATOLOGY, V25, P631, DOI 10.1002/hep.510250323; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; NORENBERG MD, 1994, ACTA NEUROCHIR, P24; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; RAO VLR, 1995, J NEUROCHEM, V65, P1221; Roberts DRD, 1999, CLIN TRANSPLANT, V13, P545, DOI 10.1034/j.1399-0012.1999.130617.x; ROZGA J, 1993, LANCET, V342, P898, DOI 10.1016/0140-6736(93)91947-K; SCHENKER S, 1962, J LAB CLIN MED, V60, P291; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; SWAIN MS, 1992, HEPATOLOGY, V16, P1028, DOI 10.1002/hep.1840160428; TAKAHASHI H, 1991, AM J PHYSIOL, V281, pH826; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Vogels BAPM, 1997, HEPATOLOGY, V25, P820, DOI 10.1002/hep.510250406	42	98	103	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	APR	2000	31	4					872	877		10.1053/he.2000.5923			6	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	299JH	WOS:000086195000009	10733542				2022-02-06	
J	Albensi, BC; Knoblach, SM; Chew, BGM; O'Reilly, MP; Faden, AI; Pekar, JJ				Albensi, BC; Knoblach, SM; Chew, BGM; O'Reilly, MP; Faden, AI; Pekar, JJ			Diffusion and high resolution MRI of traumatic brain injury in rats: Time course and correlation with histology	EXPERIMENTAL NEUROLOGY			English	Article						magnetic resonance imaging; traumatic brain injury; diffusion; fluid-percussion; edema; blood-brain barrier	CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; WATER DIFFUSION; T2-WEIGHTED MRI; FOCAL ISCHEMIA; RESONANCE; STROKE; SPECTROSCOPY; DISRUPTION; EVOLUTION	Although widely employed in studies of cerebral ischemia, the use of diffusion-weighted imaging (DWI) for traumatic brain injury (TBI) has been both limited and primarily confined to the first few hours after injury. Therefore, the present study examined the temporal evolution of magnetic resonance imaging (MRI) signal changes from hours to weeks after moderate fluid-percussion TBI in rats. We used isotropic diffusion along three directions and high resolution (HR) spin-echo pulse sequences to visualize DWI and HR MRI changes, respectively. Late changes were compared to histopathological and neurological outcome. A significant decrease (P < 0.05) in the apparent diffusion coefficients (ADC) below preinjury levels was found in the left cortex and left hippocampus (ipsilateral to injury) at 1-2 h post-TBI. At 2 weeks post-TBI, ADCs were significantly elevated (P < 0.05) above preinjury levels in both carter and hippocampus. Regions of hypo- and hyperintensity detected in HR MRI scans also showed evidence of tissue damage by histological evaluation. Neurological assessment indicated that such changes were observed at a level of injury which produced moderate impairment 2 weeks after the insult. These results indicate that alterations in DWI and HR MRI signals occur both early (hours) and late (weeks) after lateral fluid-percussion injury. Furthermore, the study showed that DWI was sensitive to MR signal change at 1-2 h post TBI (in select ROIs), whereas HR scans showed MR signal change primarily at later time points (3-4 h and later). Moreover, regions which demonstrate late changes are associated with histological damage and neurological impairment. The study demonstrates the utility of MRI to detect early changes, in some cases, that are predictive of long lasting damage verified histologically. (C) 2000 Academic Press.	Georgetown Univ, Inst Cognit & Computat Sci, Washington, DC 20007 USA		Albensi, BC (corresponding author), Warner Lambert Parke Davis, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Albensi, Benedict C/F-7304-2010; Albensi, Benedict Charles/AAJ-2359-2021	Albensi, Benedict Charles/0000-0002-7884-9261; Pekar, James/0000-0002-9830-0655			Albensi BC, 1998, INVEST RADIOL, V33, P377, DOI 10.1097/00004424-199807000-00001; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BOSE B, 1988, STROKE, V19, P28, DOI 10.1161/01.STR.19.1.28; Brown M S, 1995, J Neuroimaging, V5, P23; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVIS D, 1994, MAGNET RESON MED, V31, P454, DOI 10.1002/mrm.1910310416; GENTRY LR, 1994, RADIOLOGY, V191, P1; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOEHNBERLAGE M, 1995, MAGN RESON MED, V34, P824, DOI 10.1002/mrm.1910340607; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; KAUPPINEN RA, 1993, TRENDS NEUROSCI, V16, P88, DOI 10.1016/0166-2236(93)90129-A; LO EH, 1994, MAGN RESON IMAGING, V12, P403, DOI 10.1016/0730-725X(94)92533-X; MATSUMOTO K, 1995, AM J NEURORADIOL, V16, P1107; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; MOSELEY M, 1988, MAGNETIC RESONANCE I; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; PAN Y, 1995, J NEUROL SCI, V131, P128, DOI 10.1016/0022-510X(95)00103-9; Pierce AR, 1997, J CEREBR BLOOD F MET, V17, P183, DOI 10.1097/00004647-199702000-00008; PIERPAOLI C, 1993, RADIOLOGY, V189, P439, DOI 10.1148/radiology.189.2.8210373; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Verheul H. B., 1992, Brain Topography, V5, P171, DOI 10.1007/BF01129046; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; WARACH S, 1995, NEUROSCIENTIST, V1, P221	33	98	107	0	9	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2000	162	1					61	72		10.1006/exnr.2000.7256			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	297KX	WOS:000086083000006	10716889				2022-02-06	
J	Paradiso, S; Robinson, RG				Paradiso, S; Robinson, RG			Gender differences in poststroke depression	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	149th Annual Meeting of the American-Psychiatric-Association	MAY 04-09, 1996	NEW YORK, NEW YORK	Amer Psychiat Assoc			TRAUMATIC BRAIN INJURY; STROKE PATIENTS; MOOD DISORDERS; INTELLECTUAL IMPAIRMENT; MYOCARDIAL-INFARCTION; SEX-DIFFERENCES; REHABILITATION; LESION; FREQUENCY; COMMUNITY	In stroke and other medical illnesses, secondary depression may be associated with different factors in women than in men. The authors examined 301 consecutive admissions for acute treatment of cerebrovascular accident for gender differences in depression, psychosocial factors, physical impairment, and lesion location. Women were twice as frequently diagnosed with major depression as men. Women with major depression had a greater frequency of left hemisphere lesions than men. In men, major depression was associated with greater impairment in activities of daily living, and greater severity of depression was associated with greater impairment in daily activities and social functioning. In women, greater severity of depression was associated with prior diagnosis of psychiatric disorder and cognitive impairment. These findings suggest a different nature of poststroke depression in men and women and may have implications for its treatment.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA		Paradiso, S (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 200 Hawkins Dr,2887 JPP, Iowa City, IA 52242 USA.	sergio-paradiso@uiowa.edu	Robinson, Robert/AAF-6191-2021; Paradiso, Sergio/H-9052-2012		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH40355, MH00163] Funding Source: Medline		AGRELL B, 1994, AGING-CLIN EXP RES, V6, P49, DOI 10.1007/BF03324213; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDERSEN G, 1994, ACTA PSYCHIAT SCAND, V90, P190, DOI 10.1111/j.1600-0447.1994.tb01576.x; ANGELERI F, 1993, STROKE, V24, P1478, DOI 10.1161/01.STR.24.10.1478; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; BOLLAWILSON K, 1989, AM J PSYCHIAT, V146, P627; BOROD JC, 1992, J CONSULT CLIN PSYCH, V60, P339, DOI 10.1037/0022-006X.60.3.339; BURVILL PW, 1995, BRIT J PSYCHIAT, V166, P320, DOI 10.1192/bjp.166.3.320; CASTILLO CS, 1993, J NERV MENT DIS, V181, P100, DOI 10.1097/00005053-199302000-00005; DAM H, 1989, ACTA PSYCHIAT SCAND, V80, P118, DOI 10.1111/j.1600-0447.1989.tb01312.x; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GUR RC, 1995, SCIENCE, V267, P528, DOI 10.1126/science.7824953; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; HOUSE A, 1990, PSYCHOL MED, V20, P805, DOI 10.1017/S0033291700036497; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; MORRIS PLP, 1991, PSYCHIATRY, V54, P306; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1986, BRIT J PSYCHIAT, V148, P541, DOI 10.1192/bjp.148.5.541; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SCHWARTZ JA, 1993, BIOL PSYCHIAT, V33, P694, DOI 10.1016/0006-3223(93)90118-W; SHARPE M, 1994, BRIT J PSYCHIAT, V164, P380, DOI 10.1192/bjp.164.3.380; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TRAVELLA JI, 1994, INT J PSYCHIAT MED, V24, P357, DOI 10.2190/U8R0-A61Y-AKRP-T24V; WADE DT, 1987, BRIT J PSYCHIAT, V151, P200, DOI 10.1192/bjp.151.2.200; WEISSMAN MM, 1995, SCIENCE, V269, P799, DOI 10.1126/science.7638596; Wing J. K., 1974, MEASUREMENT CLASSIFI	36	98	103	0	8	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1998	10	1					41	47		10.1176/jnp.10.1.41			7	Clinical Neurology; Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	ZD354	WOS:000072676800006	9547465				2022-02-06	
J	Werring, DJ; Clark, CA; Barker, GJ; Miller, DH; Parker, GJM; Brammer, MJ; Bullmore, ET; Giampietro, VP; Thompson, AJ				Werring, DJ; Clark, CA; Barker, GJ; Miller, DH; Parker, GJM; Brammer, MJ; Bullmore, ET; Giampietro, VP; Thompson, AJ			The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						magnetic resonance imaging; brain mapping; motor recovery	HUMAN-BRAIN; STROKE; CORTEX; MRI	Objectives-Recovery from focal motor pathway lesions may be associated with a functional reorganisation of cortical motor areas. Previous studies of the relation between structural brain damage and the functional consequences have employed MRI and CT, which provide Limited structural information. The recent development of diffusion tensor imaging (DTI) now provides quantitative measures of fibre tract integrity and orientation. The objective was to use DTI and functional MRI (fMRI) to determine the mechanisms underlying the excellent recovery found after a penetrating injury to the right capsular region. Methods-DTI and fMRI were performed on the patient described; DTI was performed on five normal controls. Results-The injury resulted in a left hemiplegia which resolved fully over several weeks. When studied 18 months later there was no pyramidal weakness, a mild hemidystonia, and sensory disturbance. fMRI activation maps showed contralateral primary and supplementary motor cortex activation during tapping of each hand; smaller ipsilateral primary motor areas were activated by the recovered hand only. DTI disclosed preserved structural integrity and orientation in the posterior capsular limb by contrast with the disrupted structure in the anterior limb on the injured side. Conclusions-The findings suggest that the main recovery mechanism was a preservation of the integrity and orientation of pyramidal tract fibres. The fMRI studies do not suggest substantial reorganisation of the motor cortex, although ipsilateral pathways may have contributed to the recovery. The initial deficit was probably due to reversible local factors including oedema and mass effect; permanent damage to fibre tracts in the anterior capsular limb may account for the persistent sensory deficit. This study shows for the first time the potential value of combining fMRI and DTI together to investigate mechanisms of recovery and persistent deficit in an individual patient.	Neurol Inst, NMR Res Unit, London, England; Inst Psychiat, Brain Image Anal Unit, London, England		Thompson, AJ (corresponding author), Univ London, Dept Clin Neurol, Neurol Inst, Queen Sq, London WC1N 3BG, England.		Werring, David J/D-4741-2009; Giampietro, Vincent P/D-1279-2011; Werring, David/Q-8435-2019; Thompson, Alan J/C-2654-2008; Clark, Chris/C-9853-2009; Brammer, Michael J/B-7128-2012; Bullmore, Ed/C-1706-2012; Parker, Geoffrey J.M./Y-6269-2019; Barker, Gareth J/C-9616-2009	Werring, David J/0000-0003-2074-1861; Giampietro, Vincent P/0000-0002-9381-8201; Werring, David/0000-0003-2074-1861; Thompson, Alan J/0000-0002-4333-8496; Brammer, Michael J/0000-0001-9800-2052; Bullmore, Ed/0000-0002-8955-8283; Parker, Geoffrey J.M./0000-0003-2934-2234; Barker, Gareth J/0000-0002-5214-7421			Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Brammer MJ, 1997, MAGN RESON IMAGING, V15, P763, DOI 10.1016/S0730-725X(97)00135-5; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Danziger N, 1996, BRAIN, V119, P1835, DOI 10.1093/brain/119.6.1835; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; FRIES W, 1993, BRAIN, V116, P369, DOI 10.1093/brain/116.2.369; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; PIERPAOLI C, 1997, P 5 ANN M ISMRM VANC, P1741; Prichard JW, 1997, NEUROLOGY, V48, P797, DOI 10.1212/WNL.48.4.797; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; Talairach J., 1988, COPLANAR STEREOTAXIC; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; WERRING DJ, 1998, IN PRESS J NEUROLNEU	24	98	104	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	1998	65	6					863	869		10.1136/jnnp.65.6.863			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	146FK	WOS:000077418200011	9854962	Green Published, Bronze			2022-02-06	
J	Brown, M; Vandergoot, D				Brown, M; Vandergoot, D			Quality of life for individuals with traumatic brain injury: Comparison with others living in the community	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; OF-LIFE; FOLLOW-UP; SATISFACTION; DISABILITY; REHABILITATION; PREDICTORS; PEOPLE; DISABLEMENT; IMPAIRMENT	Objectives: To provide a conceptual overview of approaches to quality of life (QOL) measurement and an extensive review of research relating to QOL after TBI; to document subjective QOL of individuals with traumatic brain injury (TBI); to explore how subjective QOL differs for people with TBI in comparison to individuals with no disability (ND) and those with spinal cord injury (SCI); and to document the perceptions of unmet important needs and the relationship between such perceptions and subjective QOL. Design: Interview-based data focusing on current perceptions of QOL and unmet important needs, obtained from individuals with TBI, SCI, or ND. Covariance and partial regression analyses were used to explore group differences and to document relationships between variables. Setting: Individuals drawn from diverse communities across New York State. participants: TBI group: 430 individuals who identified themselves as having TBI; SCI group: 101 individuals with spinal cord injury; ND group: 187 people who identified themselves as having no disability. Participants were recruited through recruitment ads in general circulation newspapers and newsletters and through contacting a wide variety of community agencies. Main Outcome Measures: Two summary QOL indicators: a Global QOL Measure based on two items tapping the individual's emotion-based view of QOL, and a summary score adapted from Flanagan's Scale of Needs, reflecting the individual's perceptions of total unmet important needs. Results: Both summary QOL indicators were correlated with demographic characteristics. Unmet important needs were stronger in the TBI group than in the SCI and ND groups. Most areas of unmet important need were moderately correlated with the summary QOL indicators. Analyses of covariance showed that severity of injury was a more powerful modulator of post-TBI QOL judgments than the mere fact of TBI. For example, those with the most severe injury (ie, loss of consciousness [LOC] >1 month) rated their QOL similar to that in the ND group, whereas individuals who had experienced only a brief LOC (<20 minutes) viewed their QOL as significantly lower than that in the ND and SCI groups and lower than other TBI severity subgroups. Conclusions: This exploration of subjective QOL strengthens the argument that after TBI, the insider's reaction to injury varies greatly within the population Thus, severity of injury strongly affects perceptions of QOL. The use of a multimethod approach for exploring the reactions and perceptions of QOL has proven useful in this study.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Ctr Essential Management Serv, Jericho Turnpike, NY USA		Brown, M (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.						ALEXANDER JL, 1981, ARCH PHYS MED REHAB, V62, P261; Allison PJ, 1997, SOC SCI MED, V45, P221, DOI 10.1016/S0277-9536(96)00339-5; Andrews F. M., 1976, SOCIAL INDICATORS WE; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; BRICKMAN P, 1978, J PERS SOC PSYCHOL, V36, P917, DOI 10.1037/0022-3514.36.8.917; BROWN M, 1988, REHABIL PSYCHOL, V33, P173, DOI 10.1037//0090-5550.33.3.173; Brown M, 1983, Annu Rev Rehabil, V3, P93; BROWN M, IN PRESS MT SINAI J; BROWN M, UNPUB PREDICTORS QUA; BROWN M, 1980, REHABILITATION CLIEN; BROWN MM, 1983, DISS ABSTR INT B, V43, P2314; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; BURCKHARDT CS, 1993, J RHEUMATOL, V20, P475; CASSILETH BR, 1982, J AM ACAD DERMATOL, V7, P742, DOI 10.1016/S0190-9622(82)70155-0; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; CONDELUCI A, 1992, Brain Injury, V6, P543, DOI 10.3109/02699059209008151; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; DENNIS RE, 1993, EXCEPT CHILDREN, V59, P499, DOI 10.1177/001440299305900603; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; FUHRER MJ, 1997, ASSESSING MED REHABI; GOLEMBIEWSKI RT, 1976, J APPL BEHAV SCI, V12, P133, DOI 10.1177/002188637601200201; GORDON WA, REHABILITATION ADULT; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; IRWIN PH, 1982, SOC INDIC RES, V10, P187, DOI 10.1007/BF00302510; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LAUVER D, 1993, RES NURS HEALTH, V16, P385, DOI 10.1002/nur.4770160510; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; LEZAK MD, 1990, TRAUMATIC BRAIN INJU; MCKENNELL AC, 1983, J COMMUNITY PSYCHOL, V11, P98, DOI 10.1002/1520-6629(198304)11:2<98::AID-JCOP2290110204>3.0.CO;2-E; Millis S R, 1994, Int J Neurosci, V79, P165; MINAIRE P, 1993, VITAL HLTH STAT, V5, P9; Montgomery H, 1996, SCAND J REHABIL MED, V28, P233; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; Ormel J, 1997, SOC SCI MED, V45, P1051, DOI 10.1016/S0277-9536(97)00032-4; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAMUND B, 1988, SCAND J PSYCHOL, V29, P137, DOI 10.1111/j.1467-9450.1988.tb00783.x; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON JP, 1977, AM USE TIME SOCIAL S; ROGERSON RJ, 1995, SOC SCI MED, V41, P1373, DOI 10.1016/0277-9536(95)00122-N; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; *SAS I, 1992, SAS STAT SOFTW REL 6; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; STAMBROOK M, 1990, CAN J SURG, V33, P115; STENSMAN R, 1985, SCAND J REHABIL MED, V17, P87; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; TENNANT A, 1995, ANN RHEUM DIS, V54, P439, DOI 10.1136/ard.54.6.439; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Warren L, 1996, J REHABIL RES DEV, V33, P404; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WRIGHT B, 1960, PHYSICAL DISABILITY; [No title captured]	70	98	98	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					1	23		10.1097/00001199-199808000-00002			23	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000002	9651236				2022-02-06	
J	Lee, KS				Lee, KS			The pathogenesis and clinical significance of traumatic subdural hygroma	BRAIN INJURY			English	Article							FLUID COLLECTIONS; FINE-STRUCTURE; HEMATOMA; SPACE; NEOMEMBRANES; TOMOGRAPHY; EFFUSION; ORIGIN; BLOOD; SCANS	Subdural hygroma (SDG) is a common post-traumatic lesion. Despite its common occurrence, the pathogenesis and clinical significance are uncertain. The author reviewed the literature to clarify the present knowledge on the pathogenic, diagnostic and therapeutic aspects of this controversial lesion. A trivial trauma can cause a separation of the dura-arachnoid interface, which is the basic requirement for the development of a SDG. If the brain shrinks due to brain atrophy, excessive dehydration or decreased intracranial pressure, fluid collection may develop by a passive effusion. Most SDGs resolve when the brain is well expanded. However, a few SDGs become chronic subdural haematomas, when the necessary conditions persist over several weeks. Since the majority of patients with a SDG do not show a mass effect, surgery is rarely required. Outcome is closely related to the primary head injury not to the SDG itself. The complexity of SDG depends on Various factors including the dynamics of absorption and expansion, duration of observation, and indication and rate of surgery, besides variety of the primary head injury in types and severity. SDG is a common epiphenomenon of head injury.	Soonchunhyang Univ, Chonan Hosp, Dept Neurosurg, Chonan 330100, South Korea		Lee, KS (corresponding author), Soonchunhyang Univ, Chonan Hosp, Dept Neurosurg, Bongmyong Dong 23-20, Chonan 330100, South Korea.						AOKI N, 1994, J NEUROSURG, V81, P20, DOI 10.3171/jns.1994.81.1.0020; ARNASON O, 1983, ACTA NEUROCHIR, V67, P231, DOI 10.1007/BF01401424; BAKAY L, 1980, HEAD INJURY, P175; Borzone M, 1983, J Neurosurg Sci, V27, P161; BULLOCK R, 1990, HDB CLIN NEUROLOGY, V57, P249; Cohen I, 1927, ARCH NEURO PSYCHIATR, V18, P709, DOI 10.1001/archneurpsyc.1927.02210050041004; COOPER PR, 1993, HEAD INJURY, P275; da Costa DG, 1941, ARCH SURG-CHICAGO, V43, P559, DOI 10.1001/archsurg.1941.01210160020003; Dandy WE, 1955, PRACTICE SURG, P291; Dandy WE, 1932, PRACTICE SURG, P306; DIERCKX RA, 1989, ACTA NEUROL BELG, V89, P352; DUHAIME A, 1992, COMPLICATIONS SEQUEL, P169; ENDTZ LJ, 1978, SURG NEUROL, V10, P305; FISHER RG, 1958, JAMA-J AM MED ASSOC, V167, P176, DOI 10.1001/jama.1958.02990190030007; FRENCH BN, 1978, SURG NEUROL, V9, P145; FRIEDE RL, 1978, AM J PATHOL, V92, P69; GADE GF, 1990, NEUROLOGICAL SURG, V3, P1965; Gudeman S. K., 1989, TXB HEAD INJURY, P138; GURDJIAN ES, 1978, ACTA NEUROCHIR WIE S, V25, P36; GUTIERREZ FA, 1979, CHILD BRAIN, V5, P216; HAINES DE, 1991, ANAT RECORD, V230, P3, DOI 10.1002/ar.1092300103; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; HEYL H, 1941, J NEUROL NEUROSUR PS, V4, P270; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; HUGHES M, 1993, HEAD INJURY, P65; HYODO A, 1980, Neurological Surgery, V8, P649; Ishibashi Akira, 1994, Kurume Medical Journal, V41, P81; ITO H, 1984, ACTA NEUROCHIR, V72, P211, DOI 10.1007/BF01406871; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; KAWANO N, 1988, Neurological Surgery, V16, P747; Keller TS, 1982, CORRELATIVE NEUROSUR, P1301; KOIZUMI H, 1981, Neurologia Medico-Chirurgica, V21, P397; KOIZUMI H, 1987, SURG NEUROL, V27, P147, DOI 10.1016/0090-3019(87)90286-2; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee Kyeong-Seok, 1996, Journal of Korean Medical Science, V11, P55; LIPPER MH, 1989, TXB HEAD INJURY, P102; MASUZAWA T, 1984, NEURORADIOLOGY, V26, P245, DOI 10.1007/BF00342423; Mayo CH, 1894, NEW YORK M J, V59, P434; MCCLUNEY KW, 1992, AM J NEURORADIOL, V13, P1335; McConnell AA, 1941, J NEUROL PSYCHIATRY, V4, P237, DOI 10.1136/jnnp.4.3-4.237; McLaurin RL, 1990, NEUROLOGICAL SURG, P2149; MILLER JD, 1987, NORTHFIELDS SURG CEN, P795; Miura F, 1975, No Shinkei Geka, V3, P769; Munro D, 1936, ARCH NEURO PSYCHIATR, V35, P64, DOI 10.1001/archneurpsyc.1936.02260010074005; Murata Keiji, 1993, Neurologia Medico-Chirurgica, V33, P691, DOI 10.2176/nmc.33.691; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; NAGANUMA H, 1986, NEUROSURGERY, V19, P794, DOI 10.1227/00006123-198611000-00013; NORMAN D, 1977, RADIOLOGY, V123, P335, DOI 10.1148/123.2.335; OHNO K, 1987, J NEUROL NEUROSUR PS, V50, P1694, DOI 10.1136/jnnp.50.12.1694; OKA H, 1972, ACTA NEUROCHIR, V26, P265, DOI 10.1007/BF01407072; ORLIN JR, 1991, ANAT RECORD, V230, P22, DOI 10.1002/ar.1092300104; PARK CK, 1994, ACTA NEUROCHIR, V127, P41, DOI 10.1007/BF01808545; PARK HB, 1990, J KOREAN NEUROSURG S, V19, P126; Payr E, 1916, MED KLIN, V12, P841; POTT P, 1819, CHIRURG WORKS P POTT, P159; RABE EF, 1968, NEUROLOGY, V18, P559, DOI 10.1212/WNL.18.6.559; RABE EF, 1962, NEUROLOGY, V12, P79, DOI 10.1212/WNL.12.2.79; ROSEN HM, 1987, ANN PLAS SURG, V18, P245, DOI 10.1097/00000637-198703000-00012; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; SCHNEIDER RC, 1961, SURG CLIN N AM, V41, P1255; SCHURR PH, 1969, DEV MED CHILD NEUROL, V11, P108; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; TAGUCHI Y, 1982, Neurologia Medico-Chirurgica, V22, P276, DOI 10.2176/nmc.22.276; TAKAHASHI Y, 1982, Neurologia Medico-Chirurgica, V22, P395, DOI 10.2176/nmc.22.395; van Dongen K, 1981, Prog Neurol Surg, V10, P198, DOI 10.1159/000384770; VONKOPP W, 1988, FORTSCHRITTE GEBIETE, V148, P530; VONKOPP W, 1990, FORTSCHRITTE GEBIETE, V152, P200; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WETTERLING T, 1986, ACTA NEUROCHIR, V83, P99, DOI 10.1007/BF01402385; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; WHANG K, 1993, J KOREAN NEUROSURG S, V22, P898; WINESTOCK DP, 1975, RADIOLOGY, V115, P373, DOI 10.1148/115.2.373; Yamada H, 1979, No Shinkei Geka, V7, P55; YAMADA H, 1980, SURG NEUROL, V13, P441	77	98	106	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					595	603		10.1080/026990598122359			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200005	9653522				2022-02-06	
J	Smirnova, IV; Zhang, SX; Citron, BA; Arnold, PM; Festoff, BW				Smirnova, IV; Zhang, SX; Citron, BA; Arnold, PM; Festoff, BW			Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons	JOURNAL OF NEUROBIOLOGY			English	Article						thrombin; apoptosis; protease; motor neuron; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; CRMA-INHIBITABLE PROTEASE; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; NEURITE RETRACTION; GRANZYME-B; NEXIN-I; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ACTIN POLYMERIZATION; SYMPATHETIC NEURONS	Apoptosis, often also termed "programmed cell death," occurs in normal development in the brain and spinal cord. Important to concepts of disease and potential intervention is the exciting finding that apoptosis is also found after neurotrauma and in a number of neurodegenerative diseases. Although the precise mechanism of neuronal cell loss remains unknown, much emphasis has been placed recently on the activation of cell death protease cascades within the cell. How these cascades may be activated, especially from extracellular influences, is currently poorly understood. Thrombin, the multifunctional coagulation protease, is an early phase modulator at sites of tissue injury and has been shown to induce cell death in neurons by an apoptotic mechanism by activating its receptor, PAR-I. Using a model motor neuronal cell Line, NSC19, which me have shown undergoes apoptosis after treatment with classic apoptosis inducers such as the topoisomerase inhibitors camptothecin and etoposide, me unambiguously found that nanomolar thrombin induced characteristic signs of apoptosis, Strikingly, endonucleolysis was accompanied by an increase in caspase-3-like activity in cellular extracts, which correlated with both detection of caspase-induced signature cleavage of the cortical cytoskeleton component nonerythroid spectrin (alpha-fodrin) and identification of increased accessibility of a caspase cleavage domain, using an antibody (Ab127) made against a synthetic peptide KGDEVD. Demonstrating that thrombin activation of death proteases was linked to cell death, we were able to inhibit thrombin-induced apoptosis by using a caspase family inhibitor, benzyloxy-carbonyl-Asp-(oMe)-flouromethyl ketone (Boc-D-FMK). These novel results demonstrate that thrombin serves as an extracellular "death signal" to activate intracellular protease pathways. These pathways lead to apoptotic cell death and can be modulated by inhibiting caspase activity downstream to PAR-1. (C) 1998 John Wiley & Sons, Inc.*	Vet Affairs Med Ctr, Neurobiol Res Lab 151R, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; Univ Kansas, Med Ctr, Dept Surg Neurosurg, Kansas City, KS 66103 USA		Festoff, BW (corresponding author), Vet Affairs Med Ctr, Neurobiol Res Lab 151R, 4801 Linwood Blvd, Kansas City, MO 64128 USA.						Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; ALEXIANU ME, 1994, J NEUROCHEM, V63, P2365; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1997, J NEUROSCI, V17, P553; BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cb.09.110193.000331; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Bozyczko-Coyne D., 1996, Society for Neuroscience Abstracts, V22, P566; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; CHOU SM, 1998, IN PRESS J NEUROLOG; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Didier M, 1996, J NEUROSCI, V16, P2238; Donovan FM, 1997, J NEUROSCI, V17, P5316; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EHRENGRUBER MU, 1995, FEBS LETT, V372, P161, DOI 10.1016/0014-5793(95)00880-I; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ELLIOTT JL, 1995, NEUROREPORT, V6, P449, DOI 10.1097/00001756-199502000-00011; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FENTON JW, 1991, HAEMOSTASIS, V21, P27; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FESTOFF BW, 1980, MED HYPOTHESES, V6, P121, DOI 10.1016/0306-9877(80)90078-X; Festoff BW, 1996, J NEUROBIOL, V30, P255, DOI 10.1002/(SICI)1097-4695(199606)30:2<255::AID-NEU7>3.0.CO;2-4; Festoff BW, 1996, SEMIN THROMB HEMOST, V22, P267, DOI 10.1055/s-2007-999018; FESTOFF BW, 1990, NATO ASI SERIES A, V191, P360; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HANTAI D, 1988, REV NEUROL, V144, P680; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; INCE P, 1993, NEUROPATH APPL NEURO, V19, P291, DOI 10.1111/j.1365-2990.1993.tb00443.x; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KRUEGER BK, 1995, J NEUROSCI, V15, P3366; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Mukasa T, 1997, BIOCHEM BIOPH RES CO, V231, P770, DOI 10.1006/bbrc.1996.6002; Mundle SD, 1995, ANTICANCER RES, V15, P1895; NAKAJIMA M, 1994, BRAIN RES, V641, P350, DOI 10.1016/0006-8993(94)90165-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Smirnova IV, 1996, MOL BIOL CELL, V7, P1115; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SMIRNOVA IV, 1997, IN PRESS SPINE; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	86	98	101	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0022-3034			J NEUROBIOL	J. Neurobiol.	JUL	1998	36	1					64	80		10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.3.CO;2-4			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZW508	WOS:000074418000006	9658339				2022-02-06	
J	Bartholdi, D; Rubin, BP; Schwab, ME				Bartholdi, D; Rubin, BP; Schwab, ME			VEGF mRNA induction correlates with changes in the vascular architecture upon spinal cord damage in the rat	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						angiogenesis; CNS; lesion; X-irradiation	ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS FACTOR; RADIATION-DAMAGE; NEURITE GROWTH; OXYGEN-TENSION; TIME-COURSE; CELL-DEATH; EXPRESSION; INJURY; BRAIN	The multiple cellular and molecular processes induced by injury to the central nervous system (CNS) are still poorly understood. In the present study, we investigated the response of the vasculature and the expression of mRNA for the angiogenic vascular endothelial growth factor (VEGF) following X-irradiation of the spinal cord in the newborn and following traumatic spinal cord injury in the adult rat, Both lesion models induced changes in the density and the distribution pattern of blood vessels: while X-irradiation led to a permanent local increase in vascular density in the fibre tracts of the exposed segments, a transient local sprouting of vessels was induced upon traumatic spinal cord injury. In situ hybridization showed that an increase of VEGF mRNA anticipated and overlapped with the vascular responses in both lesion models. In addition to the temporal correlation of VEGF expression and vascular sprouting, there was a clear correlation in the spatial distribution patterns. Following X-irradiation, the expression of VEGF mRNA was restricted to the fibre tracts, precisely the areas where the changes in the vasculature were observed later on. Upon transection in the adult animal, VEGF was mainly detectable at the border of the lesion area, where the transient increase in vascular density could be observed. Interestingly, according to the type of lesion applied, astrocytes (X-irradiation) or inflammatory cells (presumably microglial cells or macrophages; traumatic lesion) are the cellular sources of VEGF mRNA, Our results strongly indicate that VEGF is crucially involved in mediating vascular changes following different types of injury in the CNS.	Univ Zurich, Brain Res Inst, CH-8029 Zurich, Switzerland		Schwab, ME (corresponding author), Univ Zurich, Brain Res Inst, August Forel Str 1, CH-8029 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016				BAKER DG, 1989, CANCER INVEST, V7, P287, DOI 10.3109/07357908909039849; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Beggs J L, 1979, Adv Neurol, V22, P179; Beggs J L, 1979, Adv Neurol, V22, P191; BLAKEMORE WF, 1982, J PATHOL, V137, P273, DOI 10.1002/path.1711370402; BREIER G, 1992, DEVELOPMENT, V114, P521; CALVO W, 1987, BRIT J RADIOL, V60, P1109, DOI 10.1259/0007-1285-60-719-1109; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CLARK RAF, 1993, DERMATOL CLIN, V11, P647, DOI 10.1016/S0733-8635(18)30218-3; DIMITRIEVICH GS, 1984, RADIAT RES, V99, P511, DOI 10.2307/3576327; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; GILMORE SA, 1963, J NEUROPATH EXP NEUR, V22, P294, DOI 10.1097/00005072-196304000-00008; HAYASHI N, 1983, J NEUROSURG, V58, P516, DOI 10.3171/jns.1983.58.4.0516; Hopewell J W, 1993, Recent Results Cancer Res, V130, P1; HOPEWELL JW, 1990, INT J RADIAT BIOL, V57, P751, DOI 10.1080/09553009014550911; HOPEWELL JW, 1979, NEUROPATH APPL NEURO, V5, P329, DOI 10.1111/j.1365-2990.1979.tb00633.x; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; IMPERATO EL, 1997, IN PRESS EXP NEUROL; Joo F, 1996, PROG NEUROBIOL, V48, P255, DOI 10.1016/0301-0082(95)00046-1; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOYANAGI I, 1993, NEUROSURGERY, V33, P277; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YQ, 1996, RADIOTHER ONCOL, V39, P35, DOI 10.1016/0167-8140(96)01705-7; LOGAN A, 1992, J NEUROSCI, V12, P3828; MASTAGLIA FL, 1976, BRAIN, V99, P101, DOI 10.1093/brain/99.1.101; MILDENBERGER M, 1990, INT J RADIAT ONCOL, V18, P1051, DOI 10.1016/0360-3016(90)90440-U; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MIYOSHI Y, 1995, EXP NEUROL, V131, P69, DOI 10.1016/0014-4886(95)90009-8; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYERS R, 1986, BRIT J CANCER, V53, P221; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PIERCE GF, 1992, AM J PATHOL, V140, P1375; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; REZVANI M, 1995, STEM CELLS, V13, P248, DOI 10.1002/stem.5530130730; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SAKLA FB, 1969, J COMP NEUROL, V136, P237, DOI 10.1002/cne.901360209; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWEGLER G, 1995, J NEUROSCI, V15, P2756; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; STURROCK RR, 1981, J ANAT, V132, P203; WALLACE MC, 1986, NEUROSURGERY, V18, P433; WHITBY DJ, 1991, DEVELOPMENT, V112, P651	57	98	101	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	1997	9	12					2549	2560		10.1111/j.1460-9568.1997.tb01684.x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZB439	WOS:000072461400006	9517460				2022-02-06	
J	Boake, C				Boake, C			Supervision rating scale: A measure of functional outcome from brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; REHABILITATION RESEARCH; CLINICAL-TRIALS; DISABILITY; RELIABILITY; COMMUNITY	Objective: To introduce a new outcome rating scale, the Supervision Rating Scale (SRS), which measures the level of supervision that a patient receives from caregivers. The SRS rates level of supervision on a 13-point ordinal scale that can optionally be grouped into five ranked categories (Independent, Overnight Supervision, Part-Time Supervision, Full-Time Indirect Supervision, and Full-Time Direct Supervision). Design: Descriptive correlational study of the scale's interrater reliability and criterion-related validity. Setting: Brain injury program of a freestanding rehabilitation hospital. Patients: Referred case series of 114 patients with moderate to severe traumatic brain injury (mean time postinjury = 3.8 years) who resided in the community or a nonhospital facility. Intervention: None. Main Outcome Measures: Functional outcome as measured by the Disability Rating Scale (DRS), Glasgow Outcome Scale (GOS), type of living arrangement, and independence in self-care and instrumental activities of daily living (ADL). Results: SRS ratings showed consistent relationships with type of living arrangement and with independence in self-care and instrumental ADL. SRS ratings were also strongly associated with ratings on the DRS and GOS. Interrater reliability of the SRS was evaluated in a subsample of 19 patients and found to be satisfactory (intraclass correlation = .86, weighted kappa = .64). Conclusions: The results suggest that the SRS should have sufficient reliability and validity to serve as a measure of functional outcome from brain injury. Because SRS ratings are based on observed behaviors, the SRS may have a smaller subjective component as compared to the DRS and GOS. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	UNIV TEXAS,SCH MED,DEPT PHYS MED & REHABIL,HOUSTON,TX; INST REHABIL RES,HOUSTON,TX								ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Boake C., 1990, COMMUNITY INTEGRATIO, P115; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Condeluci A., 1992, J HEAD TRAUMA REHAB, V7, P37; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Credner L, 1930, Z GESAMTE NEUROL PSY, V126, P721, DOI 10.1007/BF02864129; DILLER L, 1987, REHABILITATION OUTCO, P209; DODDARD D, 1988, J NEUROL NEUROSUR PS, V51, P833; Fillenbaum G., 1988, MULTIDIMENSIONAL FUN; Fleiss J, 1981, STAT METHODS RATES P, V2nd; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAFFEY W, 1989, MODELS BRAIN INJURY, P205; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; JONES ML, 1992, J INSUR MED, V4, P186; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MCDOWELL I, 1987, MEASURING HLTH GUIDE; NOSEK MA, 1987, REHABILITATION OUTCO, P71; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; OTTENBACHER KJ, 1993, AM J PHYS MED REHAB, V72, P266, DOI 10.1097/00002060-199310000-00003; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SHEIKH K, 1986, ARCH PHYS MED REHAB, V67, P245; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; WADE DT, 1993, MEASUREMENT NEUROLOG; WAGNER KA, 1986, NEUROTRAUMA TREATMEN, V1, P213; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	38	98	98	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1996	77	8					765	772		10.1016/S0003-9993(96)90254-3			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	VA965	WOS:A1996VA96500005	8702369				2022-02-06	
J	JORGE, RE; ROBINSON, RG; ARNDT, S				JORGE, RE; ROBINSON, RG; ARNDT, S			ARE THERE SYMPTOMS THAT ARE SPECIFIC FOR DEPRESSED MOOD IN PATIENTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							STROKE	This study examined the specificity of vegetative and psychological symptoms of depression among 66 patients with acute traumatic brain injury followed over 1 year. The median frequencies of vegetative and psychological symptoms among patients with depressed mood were 3 and 3. These frequencies were three times the respective rates among nondepressed patients. Although change in self-attitude and subjective anergia distinguished depressed from nondepressed patients throughout the 1-year follow-up, some symptoms, such as early awakening and difficulty concentrating, distinguished groups only after 6 months. If diagnostic criteria for major depression were modified to include only specific symptoms of depression, the standard (i.e., unmodified) DSM-III-R still had a 100% sensitivity and 94% specificity at the initial evaluation and 80% and 100%, respectively, at 1 year. There were almost no patients with depressive symptoms without a depressed mood (i.e., ''masked'' depressions). These findings suggest that DSM-III-R criteria for major depression are useful, even in an acute head-injured population, but also suggest that the nature of posttraumatic brain injury depressive disorder may change over time.			JORGE, RE (corresponding author), UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242, USA.		Robinson, Robert/AAF-6191-2021; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 000163, MH 40355] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS151178] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER		CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JORGE R, IN PRESS J AFFECTIVE; JORGE RE, IN PRESS J NEUROPSYC; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Prigatano G. P., 1991, AWARENESS DEFICIT BR; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; STARKSTEIN SE, 1990, J NEUROL NEUROSUR PS, V53, P869, DOI 10.1136/jnnp.53.10.869; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Wing J. K., 1974, MEASUREMENT CLASSIFI; [No title captured]	17	98	98	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	1993	181	2					91	99		10.1097/00005053-199302000-00004			9	Clinical Neurology; Psychiatry	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	KL710	WOS:A1993KL71000004	8426177				2022-02-06	
J	ISHIGE, N; PITTS, LH; BERRY, I; CARLSON, SG; NISHIMURA, MC; MOSELEY, ME; WEINSTEIN, PR				ISHIGE, N; PITTS, LH; BERRY, I; CARLSON, SG; NISHIMURA, MC; MOSELEY, ME; WEINSTEIN, PR			THE EFFECT OF HYPOXIA ON TRAUMATIC HEAD-INJURY IN RATS - ALTERATIONS IN NEUROLOGIC FUNCTION, BRAIN EDEMA, AND CEREBRAL BLOOD-FLOW	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT RADIOL,SAN FRANCISCO,CA 94143					BERRY, Isabelle/0000-0002-0886-3252			ASATO R, 1983, STROKE, V14, P191, DOI 10.1161/01.STR.14.2.191; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BAKER RN, 1971, J NEUROPATH EXP NEUR, V30, P668, DOI 10.1097/00005072-197110000-00010; Bazan N G, 1980, Adv Neurol, V28, P197; Blasberg R G, 1980, Adv Neurol, V28, P255; BRANTZAWADZKI M, 1984, AM J NEURORADIOL, V5, P125; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CORALES RL, 1980, INTRACRANIAL PRESSUR, V6, P280; CROCKARD A, 1980, STROKE, V11, P487; CROCKARD A, 1982, HEAD INJURY BASIC CL, P159; CRUZ J, 1985, APR ANN M AM ASS NEU, P195; CUTLER RWP, 1964, ARCH NEUROL-CHICAGO, V11, P225, DOI 10.1001/archneur.1964.00460210003001; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DICK AR, 1980, INTRACRANIAL PRESSUR, V4, P261; DUCKER TB, 1968, J NEUROSURG, V28, P112, DOI 10.3171/jns.1968.28.2.0112; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; GILDENBERG PL, 1985, TRAUMA CENTRAL NERVO, P79; GO KG, 1974, EXP NEUROL, V42, P332, DOI 10.1016/0014-4886(74)90030-2; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P840; KATSURADA K, 1973, SURGERY, V73, P191; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEVINE JE, 1979, NEW ENGL J MED, V301, P109; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1984, BRAIN EDEMA, P88; Miller J D, 1980, Adv Neurol, V28, P413; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; Pickel V.M., 1981, NEUROANATOMICAL TRAC, P483; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1980, CEREBRAL MICROVASCUL, P227; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; REULEN HJ, 1973, ACTA NEUROCHIR, V29, P29, DOI 10.1007/BF01414614; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SYMON L, 1979, STROKE, V10, P1184; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1975, EXPT MODEL HEAD INJU, P123; VANUITERT RL, 1978, STROKE, V9, P67, DOI 10.1161/01.STR.9.1.67; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Weisman SJ, 1939, SURGERY, V6, P722; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; YAMAGUCHI M, 1976, STROKE, V7, P77, DOI 10.1161/01.STR.7.1.77; [No title captured]	61	98	99	1	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	1987	7	6					759	767		10.1038/jcbfm.1987.131			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	L4589	WOS:A1987L458900012	3693431	Bronze			2022-02-06	
J	Pinto, NP; Rhinesmith, EW; Kim, TY; Ladner, PH; Pollack, MM				Pinto, Neethi P.; Rhinesmith, Elizabeth W.; Kim, Tae Yeon; Ladner, Peter H.; Pollack, Murray M.			Long-Term Function After Pediatric Critical Illness: Results From the Survivor Outcomes Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critical care outcomes; critical illness/mortality; intensive care units; morbidity; outcome assessment (health care)/methods; pediatric; survivors	QUALITY-OF-LIFE; INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; STATUS SCALE; CHILDREN; MORTALITY; ADMISSION; STAY	Objective: Knowledge of the long-term outcomes of survivors of pediatric critical illness is sparse but important. The aim of this study was to evaluate morbidity and mortality 6 months and 3 years after hospital discharge. Design: Prospective cohort study. Setting: Urban, inner city, academic PICU. Patients: Consecutive patients admitted to the PICU from June 2012 to August 2012. Interventions: None. Measurements and Main Results: We collected descriptive and demographic information and functional status assessments at baseline, admission, hospital discharge, 6 months and 3 years following discharge. Functional status was measured with the Functional Status Scale. New morbidity was defined as a change in Functional Status Scale score of greater than or equal to 3. Post-discharge assessments utilized scripted telephone surveys. Of 303 consecutive PICU patients, 253 were eligible and 129 parents consented. Follow-up outcomes were obtained for 77 patients (59.7%) at 6 months and 70 of these patients (54.2%) at 3 years. Both mortality and morbidity increased after discharge. Cumulative mortality increased from 3.9% (n = 3) at discharge to 7.8% (n = 6) at 6 months (p = 0.08) and 10.4% (n = 8) at 3 years (p = 0.03). New morbidity increased cumulatively from 5.2% (n = 4) at discharge to 6.5% (n = 5) at 6 months (p = 0.65) and 10.4% (n = 8) at 3 years (p = 0.16). Almost as many children demonstrated worsening of their functional status or died (38%) as children who survived without a change in functional status (44%). Less than 10% of children exhibited functional gains over time. Long-term functional outcome was associated with PICU variables including the need for invasive therapies and indicators of severity of illness such as use of mechanical ventilation, ventilator days, use of vasoactive medications, and PICU length of stay. The combined poor outcomes of new morbidity and mortality increased cumulatively from 9.1% (n = 7) at discharge to 14.3% (n = 11) at 6 months (p = 0.16) and 20.8% (n = 16) by 3 years (p = 0.01). Conclusions: Mortality and new morbidity appear to substantially increase after discharge. Critical illness is associated with a sustained impact on survival and functional status.	[Pinto, Neethi P.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Rhinesmith, Elizabeth W.; Pollack, Murray M.] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Kim, Tae Yeon; Ladner, Peter H.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA		Pinto, NP (corresponding author), 5841 S Maryland Ave,MC 1145, Chicago, IL 60637 USA.	npinto@peds.bsd.uchicago.edu			University of Chicago Bucksbaum Institute for Clinical Excellence; Pritzker School of Medicine	Dr. Pinto, Dr. Rhinesmith, Ms. Kim, and Mr. Ladner received grants to support this work from The University of Chicago Bucksbaum Institute for Clinical Excellence. Dr. Rhinesmith and Mr. Ladner were supported by the Pritzker School of Medicine Summer Research Program.	Ambuehl J, 2007, SWISS MED WKLY, V137, P312; Aspesberro F, 2015, INTENS CARE MED, V41, P1235, DOI 10.1007/s00134-015-3780-7; Bennett TD, 2015, PEDIATR CRIT CARE ME, V16, P377, DOI 10.1097/PCC.0000000000000380; BUTT W, 1990, CRIT CARE MED, V18, P961, DOI 10.1097/00003246-199009000-00011; Buysse CMP, 2008, CRIT CARE MED, V36, P596, DOI 10.1097/01.CCM.0000299740.65484.CA; Choong K, 2015, PEDIATR CRIT CARE ME, V16, P310, DOI 10.1097/PCC.0000000000000362; Colville GA, 2013, PEDIATR CRIT CARE ME, V14, pE85, DOI 10.1097/PCC.0b013e3182712997; Conlon NP, 2009, PEDIATR CRIT CARE ME, V10, P41, DOI 10.1097/PCC.0b013e31819371f6; Cunha F, 2013, PEDIATR CRIT CARE ME, V14, pE8, DOI 10.1097/PCC.0b013e31826012b4; de Mos N, 2006, CRIT CARE MED, V34, P1209, DOI 10.1097/01.CCM.0000208440.66756.C2; Ebrahim S, 2013, PEDIATR CRIT CARE ME, V14, P10, DOI 10.1097/PCC.0b013e31825b64b3; Epstein D, 2005, PEDIATR RES, V58, P987, DOI 10.1203/01.PDR.0000182822.16263.3D; Farris RWD, 2013, PEDIATR CRIT CARE ME, V14, P835, DOI 10.1097/PCC.0b013e3182a551c8; Jones S, 2006, PEDIATRICS, V118, P2101, DOI 10.1542/peds.2006-1455; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Knoester H, 2008, INTENS CARE MED, V34, P1076, DOI 10.1007/s00134-008-1061-4; Knoester H, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-21; Morrison Anne L, 2002, Pediatr Crit Care Med, V3, P1, DOI 10.1097/00130478-200201000-00001; Namachivayam P, 2012, PEDIATR CRIT CARE ME, V13, P520, DOI 10.1097/PCC.0b013e31824fb989; Namachivayam P, 2010, PEDIATR CRIT CARE ME, V11, P549, DOI 10.1097/PCC.0b013e3181ce7427; Namachivayam SP, 2015, CRIT CARE MED, V43, P1978, DOI 10.1097/CCM.0000000000001076; Nicholson Carol E, 2003, Pediatr Crit Care Med, V4, P196, DOI 10.1097/01.PCC.0000059728.63798.DA; Ong C, 2016, PEDIATR CRIT CARE ME, V17, pE247, DOI 10.1097/PCC.0000000000000706; Polic B, 2013, EUR J PEDIATR, V172, P85, DOI 10.1007/s00431-012-1843-0; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; Pollack MM, 2015, CRIT CARE MED, V43, P1699, DOI 10.1097/CCM.0000000000001081; Pollack MM, 2014, PEDIATR CRIT CARE ME, V15, P821, DOI 10.1097/PCC.0000000000000250; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Pollack MM, 2009, PEDIATRICS, V124, pE18, DOI 10.1542/peds.2008-1987; Quasney MW, 2015, PEDIATR CRIT CARE ME, V16, pS118, DOI 10.1097/PCC.0000000000000438; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Simpson Amelia J, 2012, Int J Crit Illn Inj Sci, V2, P149, DOI 10.4103/2229-5151.100893; Taylor A, 2003, INTENS CARE MED, V29, P795, DOI 10.1007/s00134-003-1690-6; Tilford JM, 1998, CRIT CARE MED, V26, P1737, DOI 10.1097/00003246-199810000-00032; van der Heide P, 2004, ACTA PAEDIATR, V93, P1070, DOI 10.1080/08035250410027580; Winthrop AL, 2005, J TRAUMA, V58, P468, DOI 10.1097/01.TA.0000153940.23471.B7	37	97	98	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2017	18	3					E122	E130		10.1097/PCC.0000000000001070			9	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	FH4SG	WOS:000411150600003	28107265				2022-02-06	
J	Ellis, MJ; Cordingley, D; Vis, S; Reimer, K; Leiter, J; Russell, K				Ellis, Michael J.; Cordingley, Dean; Vis, Sara; Reimer, Karen; Leiter, Jeff; Russell, Kelly			Vestibulo-ocular dysfunction in pediatric sports-related concussion	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						vestibulo-ocular dysfunction; sports-related concussion; postconcussion syndrome; pediatric; vestibular therapy; trauma	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; VESTIBULAR REHABILITATION; POSTCONCUSSION SYNDROME; SYMPTOM SEVERITY; NCAA CONCUSSION; MANAGEMENT; RECOVERY; SYSTEM; CONVERGENCE	OBJECT The objective of this study was 2-fold: 1) to examine the prevalence of vestibulo-ocular dysfunction (VOD) among children-and adolescents with acute sports-related concussion (SRC) and postconcussion syndrome (PCS) who were referred to a multidisciplinary pediatric concussion program; and 2) to determine if VOD is associated with the development of PCS in this cohort. METHODS The authors conducted a retrospective review of all patients with acute SRC (presenting 30 days or less postinjury) and PCS (3 or more symptoms for at least 1 month) referred to a multidisciplinary pediatric concussion program between September 2013 and July 2014. Initial assessment included clinical history, physical examination, and Post-Concussion Symptom Scale assessment. Patients were also assessed for VOD, which was defined as more than one subjective vestibular and oculomotor complaint (dizziness, blurred vision, and so on) and more than one objective physical examination finding (abnormal smooth pursuits, saccades, vestibulo-ocular reflex, and so on). This study was approved by the local institutional ethics review board. RESULTS A total of 101 patients (mean age 14.2 years, SD 2.3 years; 63 male and 38 female patients) participated, including 77 (76.2%) with acute SRC and 24(23.8%) with PCS. Twenty-two of the 77 patients (28.6%) with acute SRC and 15 of the 24 (62.5%) with PCS met the clinical criteria for VOD. The median duration of symptoms was 40 days (interquartile range [IQR] 28.5-54 days) for patients with acute SRC who had VOD compared with 21 days (IQR 13-32 days) for those without VOD (p = 0.0001). There was a statistically significant increase in the adjusted odds of developing PCS among patients with acute SRC who had VOD compared with those without VOD (adjusted OR 4.10; 95% CI 1.04-16.16). CONCLUSIONS Evidence of VOD was detected in a significant proportion of children and adolescents with acute SRC and PCS who were referred to a multidisciplinary pediatric concussion program. This clinical feature was a significant risk factor for the subsequent development of PCS in this pediatric acute SRC cohort.	[Ellis, Michael J.; Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada; [Ellis, Michael J.; Cordingley, Dean; Vis, Sara; Reimer, Karen; Leiter, Jeff] Pan Am Clin, Winnipeg, MB R3M 3E4, Canada; [Ellis, Michael J.; Russell, Kelly] Canada North Concuss Network, Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada		Ellis, MJ (corresponding author), Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com		Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation	We thank the Pan Am Clinic Foundation for their financial support of this study.	Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brandt T, 2005, CLIN NEUROPHYSIOL, V116, P406, DOI 10.1016/j.clinph.2004.08.009; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Eggers SDZ, 2003, SEMIN NEUROL, V23, P47; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Leddy JJ, 2014, CLIN J SPORT MED; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAbee GN, 2014, J CHILD NEUROL; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Reneker JC, 2014, J SCI MED SPORT; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Slattery EL, 2011, NEUROREHABILITATION, V29, P143, DOI 10.3233/NRE-2011-0688; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	48	97	98	2	43	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	SEP	2015	16	3					248	255		10.3171/2015.1.PEDS14524			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CP6VY	WOS:000360027500002	26031619	Bronze			2022-02-06	
J	Han, LJ; Cai, W; Mao, LL; Liu, J; Li, PY; Leak, RK; Xu, Y; Hu, XM; Chen, J				Han, Lijuan; Cai, Wei; Mao, Leilei; Liu, Jia; Li, Peiying; Leak, Rehana K.; Xu, Yun; Hu, Xiaoming; Chen, Jun			Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia	STROKE			English	Article						bromodeoxyuridine; inflammation; polarization; stroke; white matter	ACTIVATED-RECEPTOR-GAMMA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; TRAUMATIC BRAIN-INJURY; PPAR-GAMMA; OLIGODENDROCYTE DIFFERENTIATION; INTRACEREBRAL HEMORRHAGE; AGONIST ROSIGLITAZONE; NEUROPROTECTION; CELLS; PROGENITORS	Background and Purpose-Oligodendrogenesis is essential for white matter repair after stroke. Although agonists of peroxisome proliferator-activated receptors. confer neuroprotection in models of cerebral ischemia, it is not known whether this effect extends to white matter protection. This study tested the hypothesis that the peroxisome proliferator-activated receptors. agonist rosiglitazone enhances oligodendrogenesis and improves long-term white matter integrity after ischemia/reperfusion. Methods-Male adult C57/BL6 mice (25-30 g) were subjected to 60-minute middle cerebral artery occlusion and reperfusion. Rosiglitazone (3 mg/kg) was injected intraperitoneally once daily for 14 days beginning 2 hours after reperfusion. Sensorimotor and cognitive functions were evaluated <= 21 days after middle cerebral artery occlusion. Immunostaining was used to assess infarct volume, myelin loss, and microglial activation. Bromodeoxyuridine (BrdU) was injected for measurements of proliferating NG2(+) oligodendrocyte precursor cells (OPCs) and newly generated adenomatous polyposis coli(+) oligodendrocytes. Mixed glial cultures were used to confirm the effect of rosiglitazone on oligodendrocyte differentiation and microglial polarization. Results-Rosiglitazone significantly reduced brain tissue loss, ameliorated white matter injury, and improved sensorimotor and cognitive functions for at least 21 days after middle cerebral artery occlusion. Rosiglitazone enhanced OPC proliferation and increased the numbers of newly generated mature oligodendrocytes after middle cerebral artery occlusion. Rosiglitazone treatment also reduced the numbers of Iba1(+)/CD16(+) M1 microglia and increased the numbers of Iba1(+)/CD206(+) M2 microglia after stroke. Glial culture experiments confirmed that rosiglitazone promoted oligodendrocyte differentiation, perhaps by promoting microglial M2 polarization. Conclusions-Rosiglitazone treatment improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype.	[Han, Lijuan; Xu, Yun] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurol, Nanjing 21008, Jiangsu, Peoples R China; [Han, Lijuan; Cai, Wei; Mao, Leilei; Hu, Xiaoming; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA; [Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China; [Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China; [Cai, Wei] Sun Yat Sen Univ, Affiliated Hosp 3, Multiple Sclerosis Ctr, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China; [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA; [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA		Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.	xuyun20042001@aliyun.com; chenj2@upmc.edu	Leak, Rehana K/I-2607-2019	Leak, Rehana K/0000-0003-2817-7417; Li, Peiying/0000-0002-5721-9914	National institutes of Health/National Institute of neurological disorders and strokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS095671, NS045048, NS036736, NS089534, NS092618]; US Department of Veterans Affairs Research Career Scientist Award and RRD Merit ReviewUS Department of Veterans Affairs [I01RX000420]; American Heart AssociationAmerican Heart Association [13SDG14570025]; Chinese Scholarship CouncilChina Scholarship Council; China Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81230026, 81171085]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [13ZR1452200]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81400956]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095671, R01NS089534, R01NS045048, R01NS092618, R01NS036736] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000420] Funding Source: NIH RePORTER	This work was supported by the National institutes of Health/National Institute of neurological disorders and stroke grants NS095671, NS045048, NS036736, and NS089534 (to Dr Chen) and NS092618 (to Dr Hu), US Department of Veterans Affairs Research Career Scientist Award and RR&D Merit Review I01RX000420 (to Dr Chen), and grant 13SDG14570025 from the American Heart Association (to Dr Hu). Dr Han was supported by predoctoral fellowship from the Chinese Scholarship Council. Dr Xu was supported by China Natural Science Foundation grants (No. 81230026 and No. 81171085). Dr Li was supported by the Science and Technology Commission of Shanghai Municipality (13ZR1452200) and National Natural Science Foundation grant (No. 81400956).	Bernardo A, 2013, BIOL CHEM, V394, P1607, DOI 10.1515/hsz-2013-0152; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Chu Min, 2012, Front Biosci (Elite Ed), V4, P1926; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Doonan F, 2009, J NEUROCHEM, V109, P631, DOI 10.1111/j.1471-4159.2009.05995.x; Falcao AM, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00034; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Goldman SA, 2014, NAT NEUROSCI, V17, P483, DOI 10.1038/nn.3685; Gonzalez-Perez O, 2011, BRAIN RES REV, V67, P147, DOI 10.1016/j.brainresrev.2011.01.001; Ho PW, 2005, STROKE, V36, P2742, DOI 10.1161/01.STR.0000189748.52500.a7; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Kinouchi T, 2012, STROKE, V43, P478, DOI 10.1161/STROKEAHA.111.618926; Lee J, 2007, NEUROCHEM RES, V32, P635, DOI 10.1007/s11064-006-9138-3; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Maki T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00275; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; McIver SR, 2010, NEUROSCIENCE, V169, P1364, DOI 10.1016/j.neuroscience.2010.04.070; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Ortega F, 2013, NAT CELL BIOL, V15, P602, DOI 10.1038/ncb2736; Paintlia AS, 2010, GLIA, V58, P1669, DOI 10.1002/glia.21039; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; Sim FJ, 2008, GLIA, V56, P954, DOI 10.1002/glia.20669; Sozmen EG, 2009, J NEUROSCI METH, V180, P261, DOI 10.1016/j.jneumeth.2009.03.017; Wang CX, 2009, J CEREBR BLOOD F MET, V29, P1683, DOI 10.1038/jcbfm.2009.87; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x	36	97	102	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	SEP	2015	46	9					2628	2636		10.1161/STROKEAHA.115.010091			9	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	CQ9FZ	WOS:000360919700046	26243225	Green Accepted			2022-02-06	
J	Shultz, SR; Wright, DK; Zheng, P; Stuchbery, R; Liu, SJ; Sashindranath, M; Medcalf, RL; Johnston, LA; Hovens, CM; Jones, NC; O'Brien, TJ				Shultz, Sandy R.; Wright, David K.; Zheng, Ping; Stuchbery, Ryan; Liu, Shi-Jie; Sashindranath, Maithili; Medcalf, Robert L.; Johnston, Leigh A.; Hovens, Christopher M.; Jones, Nigel C.; O'Brien, Terence J.			Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury	BRAIN			English	Article						tau; MRI; DTI; protein phosphatase 2A; traumatic brain injury	PROTEIN PHOSPHATASE 2A; FLUID PERCUSSION INJURY; ABNORMALLY PHOSPHORYLATED-TAU; ALZHEIMER-DISEASE BRAIN; ANIMAL-MODEL; MOUSE-BRAIN; NEUROFIBRILLARY DEGENERATION; BEHAVIORAL DYSFUNCTION; REPEATED CONCUSSION; CELL-DEATH	Traumatic brain injury is a common and serious neurodegenerative condition that lacks a pharmaceutical intervention to improve long-term outcome. Hyperphosphorylated tau is implicated in some of the consequences of traumatic brain injury and is a potential pharmacological target. Protein phosphatase 2A is a heterotrimeric protein that regulates key signalling pathways, and protein phosphatase 2A heterotrimers consisting of the PR55 B-subunit represent the major tau phosphatase in the brain. Here we investigated whether traumatic brain injury in rats and humans would induce changes in protein phosphatase 2A and phosphorylated tau, and whether treatment with sodium selenate-a potent PR55 activator-would reduce phosphorylated tau and improve traumatic brain injury outcomes in rats. Ninety young adult male Long-Evans rats were administered either a fluid percussion injury or sham-injury. A proportion of rats were killed at 2, 24, and 72 h post-injury to assess acute changes in protein phosphatase 2A and tau. Other rats were given either sodium selenate or saline-vehicle treatment that was continuously administered via subcutaneous osmotic pump for 12 weeks. Serial magnetic resonance imaging was acquired prior to, and at 1, 4, and 12 weeks post-injury to assess evolving structural brain damage and axonal injury. Behavioural impairments were assessed at 12 weeks post-injury. The results showed that traumatic brain injury in rats acutely reduced PR55 expression and protein phosphatase 2A activity, and increased the expression of phosphorylated tau and the ratio of phosphorylated tau to total tau. Similar findings were seen in post-mortem brain samples from acute human traumatic brain injury patients, although many did not reach statistical significance. Continuous sodium selenate treatment for 12 weeks after sham or fluid percussion injury in rats increased protein phosphatase 2A activity and PR55 expression, and reduced the ratio of phosphorylated tau to total tau, attenuated brain damage, and improved behavioural outcomes in rats given a fluid percussion injury. Notably, total tau levels were decreased in rats 12 weeks after fluid percussion injury, and several other factors, including the use of anaesthetic, the length of recovery time, and that some brain injury and behavioural dysfunction still occurred in rats treated with sodium selenate must be considered in the interpretation of this study. However, taken together these data suggest protein phosphatase 2A and hyperphosphorylated tau may be involved in the neurodegenerative cascade of traumatic brain injury, and support the potential use of sodium selenate as a novel traumatic brain injury therapy.	[Shultz, Sandy R.; Zheng, Ping; Liu, Shi-Jie; Jones, Nigel C.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3050, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Stuchbery, Ryan; Hovens, Christopher M.] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3050, Australia; [Sashindranath, Maithili; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic 3010, Australia		Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr, Off 1 02, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Medcalf, Robert L/E-9632-2011; O'Brien, Terence/AAU-5525-2021; Sashindranath, Maithili/AAI-7408-2021; Johnston, Leigh A/D-7102-2014; O'Brien, Terence/L-8102-2013	Sashindranath, Maithili/0000-0002-9712-4784; Johnston, Leigh A/0000-0002-5032-4674; Jones, Nigel/0000-0002-1080-8439; Wright, David/0000-0002-7535-8651; O'Brien, Terence/0000-0002-7198-8621; Hovens, Christopher/0000-0002-0610-1289	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1006077, 1062653]; Victorian Transport Accident Commission (Victorian Neurotrauma Initiative Grant) [DNP13]; Alzheimer's Australia Dementia Research Fund; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia; Helen Macpherson Smith Trust; Parkinson's VictoriaParkinson's UK; Perpetual Philanthropic Services	This study was funded by grants to T.O., C.H., N.J., M.S. and S.S. from the National Health and Medical Research Council (NHMRC #1006077 and #1062653), the Victorian Transport Accident Commission (Victorian Neurotrauma Initiative Grant #DNP13), the Alzheimer's Australia Dementia Research Fund, the Royal Melbourne Hospital Neuroscience Foundation, and the Canadian Institute of Health Research. Human brain tissues were received from the Victorian Brain Bank Network, supported by the Mental Health Research Institute, The Alfred, Victorian Forensic Institute of Medicine, The University of Melbourne and funded by NHMRC, Helen Macpherson Smith Trust, Parkinson's Victoria and Perpetual Philanthropic Services.	Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Avants BB, 2010, NEUROIMAGE, V49, P2457, DOI 10.1016/j.neuroimage.2009.09.062; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; Bottiglieri T, 2012, J NEUROSCI, V32, P9173, DOI 10.1523/JNEUROSCI.0125-12.2012; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Dong YY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0034435, 10.1371/journal.pone.0051643, 10.1371/journal.pone.0039386]; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Koh PO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054217; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001; Li B, 2007, ACTA NEUROPATHOL, V113, P501, DOI 10.1007/s00401-007-0207-8; Liang ZH, 2009, J ALZHEIMERS DIS, V17, P531, DOI 10.3233/JAD-2009-1069; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nunbhakdi-Craig V, 2007, J NEUROCHEM, V101, P959, DOI 10.1111/j.1471-4159.2007.04503.x; Oberg EA, 2012, J BIOL CHEM, V287, P43378, DOI 10.1074/jbc.M112.420281; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2014, NEUROTHERAPEUTICS, V11, P347, DOI 10.1007/s13311-014-0258-1; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007; Sontag JM, 2008, J NEUROSCI, V28, P11477, DOI 10.1523/JNEUROSCI.2816-08.2008; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun KJ, 2013, BRAIN RES, V1506, P132, DOI 10.1016/j.brainres.2013.02.011; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.0.CO;2-6; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Yao XQ, 2012, FEBS LETT, V586, P2522, DOI 10.1016/j.febslet.2012.06.018; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9; Zhou XW, 2008, NEUROBIOL DIS, V31, P386, DOI 10.1016/j.nbd.2008.05.013	77	97	99	0	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY 1	2015	138		5				1297	1313		10.1093/brain/awv053			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH2DB	WOS:000353834100026	25771151	Green Published, Bronze			2022-02-06	
J	Sun, Q; Wu, W; Hu, YC; Li, H; Zhang, DD; Li, S; Li, W; Li, WD; Ma, B; Zhu, JH; Zhou, ML; Hang, CH				Sun, Qing; Wu, Wei; Hu, Yang-Chun; Li, Hua; Zhang, Dingding; Li, Song; Li, Wei; Li, Wei-De; Ma, Biao; Zhu, Jian-Hong; Zhou, Meng-Liang; Hang, Chun-Hua			Early release of high-mobility group box 1 (HMGB1) from neurons in experimental subarachnoid hemorrhage in vivo and in vitro	JOURNAL OF NEUROINFLAMMATION			English	Article						HMGB1; SAH; Early brain injury	GLYCATION END-PRODUCTS; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; CELL DISTRIBUTION; LIVER ISCHEMIA; RECEPTOR; EXPRESSION; PROTEIN; RAT	Background: Translocation of high-mobility group box 1 (HMGB1) from nucleus could trigger inflammation. Extracellular HMGB1 up-regulates inflammatory response in sepsis as a late mediator. However, little was known about its role in subarachnoid hemorrhage-inducible inflammation, especially in the early stage. This study aims to identify whether HMGB1 translocation occurred early after SAH and also to clarify the potential role of HMGB1 in brain injury following SAH. Methods: Sprague-Dawley (SD) rats were randomly divided into sham group and SAH groups at 2 h, 12 h and on day 1, day 2. SAH groups suffered experimental subarachnoid hemorrhage by injection of 0.3 ml autoblood into the pre-chiasmatic cistern. Rats injected by recombinant HMGB1(rHMGB1) solution were divided into four groups according to different time points. Cultured neurons were assigned into control group and four hemoglobin (Hb) incubated groups. Mixed glial cells were cultured and stimulated in medium from neurons incubated by Hb. HMGB1 expression is measured by western blot analysis, real-time polymerase chain reaction (PCR), immunohistochemistry and immunofluorescence. Downstream nuclear factor kappa B (NF-kappa B) subunit P65 and inflammatory factor Interleukin 1 beta (IL-1 beta) were measured by western blot and real-time PCR, respectively. Brain injury was evaluated by cleaved caspase-3 staining. Results: Our results demonstrated HMGB1 translocation occurred as early as 2 h after experimental SAH with mRNA and protein level increased. Immunohistochemistry and immunofluorescence results indicated cytosolic HMGB1 was mainly located in neurons while translocated HMGB1 could also be found in some microglia. After subarachnoid injection of rHMGB1, NF-kappa B, downstream inflammatory response and cleaved caspase-3 were up-regulated in the cortex compared to the saline control group. In-vitro, after Hb incubation, HMGB1 was also rapidly released from neurons to medium. Incubation with medium from neurons up-regulated IL-1 beta in mixed glial cells. This effect could be inhibited by HMGB1 specific inhibitor glycyrrhizic acid (GA) treatment. Conclusion: HMGB1 was released from neurons early after SAH onset and might trigger inflammation as an upstream inflammatory mediator. Extracellular HMGB1 contributed to the brain injury after SAH. These results might have important implications during the administration of specific HMGB1 antagonists early in order to prevent or reduce inflammatory response following SAH.	[Sun, Qing; Wu, Wei; Hu, Yang-Chun; Li, Hua; Zhang, Dingding; Li, Wei; Ma, Biao; Zhu, Jian-Hong; Zhou, Meng-Liang; Hang, Chun-Hua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Li, Song; Li, Wei-De] Southern Med Univ Guangzhou, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing, Jiangsu, Peoples R China; [Hang, Chun-Hua] Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China.	hang_neurosurgery@163.com	Li, Wei/ABE-4301-2021	Li, Hua/0000-0001-5893-535X; Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81371294]	The study was supported by the National Natural Science Foundation, China (81371294). The authors gratefully acknowledge the generous assistance of Dr Lin Zhu and Gen-Bao Feng.	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bera A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082282; Bianchi ME, 2009, SCIENCE, V323, P1683, DOI 10.1126/science.1172794; Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932; Evankovich J, 2010, J BIOL CHEM, V285, P39888, DOI 10.1074/jbc.M110.128348; Friedrich V, 2012, NEUROSCI LETT, V512, P6, DOI 10.1016/j.neulet.2012.01.036; Girard JP, 2007, CHEM BIOL, V14, P345, DOI 10.1016/j.chembiol.2007.04.001; Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557; Hanafy KA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-83; Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Jeon H, 2010, NEUROSCIENCE, V169, P1805, DOI 10.1016/j.neuroscience.2010.06.039; Jiang Y, 2012, J CLIN NEUROSCI, V19, P866, DOI 10.1016/j.jocn.2011.08.038; Kang SR, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/248592; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Krams M, 2003, STROKE, V34, P2543, DOI 10.1161/01.STR.0000092527.33910.89; Li H, 2014, BRAIN RES, V1543, P315, DOI 10.1016/j.brainres.2013.11.023; Li W, 2014, MOL NEUROBIOL, V49, P187, DOI 10.1007/s12035-013-8509-4; Li W, 2013, NEUROL SCI, V34, P847, DOI 10.1007/s10072-012-1131-9; Ma CX, 2009, CHINESE MED J-PEKING, V122, P1575, DOI 10.3760/cma.j.issn.0366-6999.2009.13.019; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Murakami K, 2011, TRANSL STROKE RES, V2, P72, DOI 10.1007/s12975-010-0052-2; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schuette AJ, 2013, WORLD NEUROSURG, V80, P264, DOI 10.1016/j.wneu.2012.10.049; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Sun Q, 2013, MED HYPOTHESES, V81, P681, DOI 10.1016/j.mehy.2013.07.026; Sun Q, 2013, BRAIN RES, V1520, P134, DOI 10.1016/j.brainres.2013.05.010; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Tsung A, 2007, J EXP MED, V204, P2913, DOI 10.1084/jem.20070247; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Kralingen C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084269; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; You WC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/786242; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhou ML, 2007, INFLAMM RES, V56, P93, DOI 10.1007/s00011-006-6035-9	41	97	100	0	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUN 12	2014	11								106	10.1186/1742-2094-11-106			16	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AL7EQ	WOS:000339296400001	24924349	Green Published, gold			2022-02-06	
J	Zhang, ZQ; Zoltewicz, JS; Mondello, S; Newsom, KJ; Yang, ZH; Yang, BX; Kobeissy, F; Guingab, J; Glushakova, O; Robicsek, S; Heaton, S; Buki, A; Hannay, J; Gold, MS; Rubenstein, R; Lu, XCM; Dave, JR; Schmid, K; Tortella, F; Robertson, CS; Wang, KKW				Zhang, Zhiqun; Zoltewicz, J. Susie; Mondello, Stefania; Newsom, Kimberly J.; Yang, Zhihui; Yang, Boxuan; Kobeissy, Firas; Guingab, Joy; Glushakova, Olena; Robicsek, Steven; Heaton, Shelley; Buki, Andras; Hannay, Julia; Gold, Mark S.; Rubenstein, Richard; Lu, Xi-chun May; Dave, Jitendra R.; Schmid, Kara; Tortella, Frank; Robertson, Claudia S.; Wang, Kevin K. W.			Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products	PLOS ONE			English	Article							SPINAL-CORD-INJURY; ALPHA-II-SPECTRIN; CENTRAL-NERVOUS-SYSTEM; GLASGOW OUTCOME SCALE; MULTIPLE-SCLEROSIS; ANTIMYELIN ANTIBODIES; ALZHEIMERS-DISEASE; ANTIPITUITARY ANTIBODIES; CEREBROSPINAL-FLUID; HEAD-INJURY	The role of systemic autoimmunity in human traumatic brain injury (TBI) and other forms of brain injuries is recognized but not well understood. In this study, a systematic investigation was performed to identify serum autoantibody responses to brain-specific proteins after TBI in humans. TBI autoantibodies showed predominant immunoreactivity against a cluster of bands from 38-50 kDa on human brain immunoblots, which were identified as GFAP and GFAP breakdown products. GFAP autoantibody levels increased by 7 days after injury, and were of the IgG subtype predominantly. Results from in vitro tests and rat TBI experiments also indicated that calpain was responsible for removing the amino and carboxyl termini of GFAP to yield a 38 kDa fragment. Additionally, TBI autoantibody staining co-localized with GFAP in injured rat brain and in primary rat astrocytes. These results suggest that GFAP breakdown products persist within degenerating astrocytes in the brain. Anti-GFAP autoantibody also can enter living astroglia cells in culture and its presence appears to compromise glial cell health. TBI patients showed an average 3.77 fold increase in anti-GFAP autoantibody levels from early (0-1 days) to late (7-10 days) times post injury. Changes in autoantibody levels were negatively correlated with outcome as measured by GOS-E score at 6 months, suggesting that TBI patients with greater anti-GFAP immune-responses had worse outcomes. Due to the long lasting nature of IgG, a test to detect anti-GFAP autoantibodies is likely to prolong the temporal window for assessment of brain damage in human patients.	[Zoltewicz, J. Susie; Newsom, Kimberly J.; Yang, Boxuan; Guingab, Joy; Glushakova, Olena] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarker Res, Gainesville, FL 32611 USA; [Zhang, Zhiqun; Yang, Zhihui; Kobeissy, Firas; Wang, Kevin K. W.] Banyan Biomarkers Inc, Alachua, FL 32615 USA; [Mondello, Stefania; Gold, Mark S.] Univ Messina, Messina, Italy; [Robicsek, Steven] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Heaton, Shelley] Univ Florida, Gainesville, FL USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Buki, Andras] Hungarian Acad Sci, Clin Neurosci Image Ctr, Pecs, Hungary; [Hannay, Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis & CNS Biomarkers, Dept Neurol, Brooklyn, NY 11203 USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis & CNS Biomarkers, Dept Physiol Pharmacol, Brooklyn, NY 11203 USA; [Lu, Xi-chun May; Dave, Jitendra R.; Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Zhang, ZQ (corresponding author), Banyan Biomarkers Inc, Alachua, FL 32615 USA.	zizizhang2012@gmail.com; susiezolt@gmail.com; kwang@ufl.edu	Glushakova, Olena/AAY-1130-2021; Kobeissy, Firas/E-7042-2017; Mondello, Stefania/A-1813-2012	Glushakova, Olena/0000-0002-2109-3651; Kobeissy, Firas/0000-0002-5008-6944; Mondello, Stefania/0000-0002-8587-3614; Hannay, H. Julia/0000-0001-7023-912X; Wang, Kevin/0000-0002-9343-6473	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01]; Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051431, R01NS052831, R01NS049175] Funding Source: NIH RePORTER	This study was supported in part by the NIH (R01 NS049175-01, R01-NS052831-01 and R01 NS051431-01), and in part by the Department of Defense (DAMD17-03-1-0772 and DAMD17-03-1-0066). The funders provide financial support and infrastructure support to this work.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Ankeny DP, 2010, TRENDS IMMUNOL, V31, P332, DOI 10.1016/j.it.2010.06.006; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Colasanti T. T., 2010, AUTOIMMUN REV, V9, P5; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; D'Andrea MR, 2005, MED HYPOTHESES, V64, P458, DOI 10.1016/j.mehy.2004.08.024; Dambinova SA, 1997, J NEUROL SCI, V152, P93, DOI 10.1016/S0022-510X(97)00150-0; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Darrah E, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00428; Deng SX, 2000, INT IMMUNOL, V12, P415, DOI 10.1093/intimm/12.4.415; Fujita K, 1998, NEUROCHEM RES, V23, P169, DOI 10.1023/A:1022476724381; Gomez-Tourino I, 2010, DIABETIC MED, V27, P247, DOI 10.1111/j.1464-5491.2009.02911.x; Gorny M, 1990, Neurol Neurochir Pol, V24, P17; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Guingab-Cagmat JD, 2012, ELECTROPHORESIS, V33, P3786, DOI 10.1002/elps.201200326; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hedegaard CJ, 2009, IMMUNOLOGY, V128, pe451, DOI 10.1111/j.1365-2567.2008.02999.x; Kamchatnov PR, 2009, ZH NEVROL PSIKHIATR, V109, P69; Kuhle J, 2007, NEW ENGL J MED, V356, P371, DOI 10.1056/NEJMoa063602; Lang B, 2003, CURR OPIN NEUROL, V16, P351, DOI 10.1097/00019052-200306000-00016; Levin EC, 2010, BRAIN RES, V1345, P221, DOI 10.1016/j.brainres.2010.05.038; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Liu MC, 2011, ASN NEURO, V3, P25, DOI 10.1042/AN20100012; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martinez JA, 2010, APOPTOSIS, V15, P1480, DOI 10.1007/s10495-010-0526-4; MECOCCI P, 1995, J NEUROIMMUNOL, V57, P165, DOI 10.1016/0165-5728(94)00180-V; MECOCCI P, 1992, BRAIN BEHAV IMMUN, V6, P286, DOI 10.1016/0889-1591(92)90049-T; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mondello S., 2011, TRANSLATIONAL STROKE, V3, P1, DOI DOI 10.3389/FNEUR.2012.00147/ABSTRACT; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Moneim I A, 1999, J Egypt Public Health Assoc, V74, P121; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelayo R, 2007, NEW ENGL J MED, V356, P426, DOI 10.1056/NEJMc062467; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Poletaev AB, 2000, AUTOIMMUNITY, V32, P33, DOI 10.3109/08916930008995985; Ponomarenko NA, 2006, IMMUNOL LETT, V103, P45, DOI 10.1016/j.imlet.2005.10.006; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Schwartz M, 2002, PROG BRAIN RES, V137, P401; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singh VK, 1997, PEDIATR NEUROL, V17, P88, DOI 10.1016/S0887-8994(97)00045-3; Sorokina EG, 2010, ZH NEVROL PSIKHIATR, V110, P30; TANAKA J, 1989, ACTA NEUROL SCAND, V80, P554, DOI 10.1111/j.1600-0404.1989.tb03926.x; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomkins O, 2011, NEUROLOGY, P1; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wei P, 2013, TUMOR BIOL, V34, P2283, DOI 10.1007/s13277-013-0770-7; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	67	97	100	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e92698	10.1371/journal.pone.0092698			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SD	WOS:000333675600065	24667434	Green Published, Green Submitted, gold			2022-02-06	
J	Eckner, JT; Oh, YK; Joshi, MS; Richardson, JK; Ashton-Miller, JA				Eckner, James T.; Oh, Youkeun K.; Joshi, Monica S.; Richardson, James K.; Ashton-Miller, James A.			Effect of Neck Muscle Strength and Anticipatory Cervical Muscle Activation on the Kinematic Response of the Head to Impulsive Loads	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussion; head kinematics; injury biomechanics; neck muscle activation; neck strength	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; ANKLE TORQUE DEVELOPMENT; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; NCAA CONCUSSION; UNITED-STATES; BIOMECHANICS	Background: Greater neck strength and activating the neck muscles to brace for impact are both thought to reduce an athlete's risk of concussion during a collision by attenuating the head's kinematic response after impact. However, the literature reporting the neck's role in controlling postimpact head kinematics is mixed. Furthermore, these relationships have not been examined in the coronal or transverse planes or in pediatric athletes. Hypotheses: In each anatomic plane, peak linear velocity (V) and peak angular velocity () of the head are inversely related to maximal isometric cervical muscle strength in the opposing direction (H1). Under impulsive loading, V and will be decreased during anticipatory cervical muscle activation compared with the baseline state (H2). Study Design: Descriptive laboratory study. Methods: Maximum isometric neck strength was measured in each anatomic plane in 46 male and female contact sport athletes aged 8 to 30 years. A loading apparatus applied impulsive test forces to athletes' heads in flexion, extension, lateral flexion, and axial rotation during baseline and anticipatory cervical muscle activation conditions. Multivariate linear mixed models were used to determine the effects of neck strength and cervical muscle activation on head V and . Results: Greater isometric neck strength and anticipatory activation were independently associated with decreased head V and after impulsive loading across all planes of motion (all P < .001). Inverse relationships between neck strength and head V and presented moderately strong effect sizes (r = 0.417 to r = 0.657), varying by direction of motion and cervical muscle activation. Conclusion: In male and female athletes across the age spectrum, greater neck strength and anticipatory cervical muscle activation (bracing for impact) can reduce the magnitude of the head's kinematic response. Future studies should determine whether neck strength contributes to the observed sex and age group differences in concussion incidence. Clinical Relevance: Neck strength and impact anticipation are 2 potentially modifiable risk factors for concussion. Interventions aimed at increasing athletes' neck strength and reducing unanticipated impacts may decrease the risk of concussion associated with sport participation.	[Eckner, James T.; Oh, Youkeun K.; Joshi, Monica S.; Richardson, James K.; Ashton-Miller, James A.] Univ Michigan, Ann Arbor, MI 48108 USA		Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			K12 Career Development Award from the Rehabilitation Medicine Scientist Training Program [5K12HD001097]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: J.T.E. has declared a potential conflict of interest as specified in the AJSM Conflict of Interest Statement. He has received funding for this study through a K12 Career Development Award from the Rehabilitation Medicine Scientist Training Program (5K12HD001097).	Beier G, 1979, DETERMINATION PHYS D; BLANPIED P, 1993, J GERONTOL, V48, pM58, DOI 10.1093/geronj/48.2.M58; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Brooks SV, 1996, J PHYSIOL-LONDON, V497, P573, DOI 10.1113/jphysiol.1996.sp021790; BURDI AR, 1969, J BIOMECH, V2, P267, DOI 10.1016/0021-9290(69)90083-9; Cohen J., 2013, STAT POWER ANAL BEHA; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dvir Z, 2008, J MANIP PHYSIOL THER, V31, P518, DOI 10.1016/j.jmpt.2008.08.008; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gregory S., 2013, TIME MAGAZINE; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton DF, 2012, BONE JOINT RES, V1, P152, DOI 10.1302/2046-3758.17.2000079; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavallee AV, 2013, J BIOMECH, V46, P527, DOI 10.1016/j.jbiomech.2012.09.029; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Newman J A, 2000, Stapp Car Crash J, V44, P215; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Patton DA, 2013, J APPL BIOMECH; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Simoneau M, 2008, J BIOMECH, V41, P2097, DOI 10.1016/j.jbiomech.2008.05.002; Staudte H W, 1994, Eur Spine J, V3, P155, DOI 10.1007/BF02190578; Thelen DG, 1996, J AM GERIATR SOC, V44, P804, DOI 10.1111/j.1532-5415.1996.tb03737.x; Thelen DG, 1996, J GERONTOL A-BIOL, V51, pM226, DOI 10.1093/gerona/51A.5.M226; Thibault LE, 1987, P 31 STAPP CAR CRASH, P267; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Vasavada AN, 1998, SPINE, V23, P412, DOI 10.1097/00007632-199802150-00002; Versace J., 1971, P 15 STAPP CAR CRASH, P771; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029	46	97	97	1	58	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2014	42	3					566	576		10.1177/0363546513517869			11	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	AH6EA	WOS:000336222300006	24488820	Green Accepted			2022-02-06	
J	Caeyenberghs, K; Leemans, A; Leunissen, I; Gooijers, J; Michiels, K; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Leemans, A.; Leunissen, I.; Gooijers, J.; Michiels, K.; Sunaert, S.; Swinnen, S. P.			Altered structural networks and executive deficits in traumatic brain injury patients	BRAIN STRUCTURE & FUNCTION			English	Article						Diffusion tensor imaging; Graph theoretical analysis; Executive functioning; Structural network; Traumatic brain injury	DIFFUSE AXONAL INJURY; WHITE-MATTER INTEGRITY; BEHAVIOR RELATIONSHIPS; RESPONSE-INHIBITION; ANATOMICAL NETWORK; FIBER ORIENTATIONS; COGNITIVE CONTROL; WORKING-MEMORY; UNITED-STATES; HEAD-INJURY	Recent research on traumatic brain injury (TBI) has shown that impairments in cognitive and executive control functions are accompanied by a disrupted neural connectivity characterized by white matter damage. We constructed binary and weighted brain structural networks in 21 patients with chronic TBI and 17 healthy young adults utilizing diffusion tensor tractography and calculated topological properties of the networks using a graph theoretical method. Executive function was assessed with the local global task and the trail making task, requiring inhibition, updating, and switching. The results revealed that TBI patients were less successful than controls on the executive tasks, as shown by the higher reaction times, higher switch costs, and lower accuracy rates. Moreover, both TBI patients and controls exhibited a small world topology in their white matter networks. More importantly, the TBI patients demonstrated increased shortest path length and decreased global efficiency of the structural network. These findings suggest that TBI patients have a weaker globally integrated structural brain network, resulting in a limited capacity to integrate information across brain regions. Furthermore, we showed that the white matter networks of both groups contained highly connected hub regions that were predominately located in the parietal cortex, frontal cortex, and basal ganglia. Finally, we showed significant correlations between switching performance and network property metrics within the TBI group. Specifically, lower scores on the switching tasks corresponded to a lower global efficiency. We conclude that analyzing the structural brain network connectivity provides new insights into understanding cognitive control changes following brain injury.	[Caeyenberghs, K.; Leunissen, I.; Gooijers, J.; Swinnen, S. P.] Katholieke Univ Leuven, Dept Kinesiol, Biomed Sci Grp, Movement Control & Neuroplast Res Grp, Louvain, Belgium; [Caeyenberghs, K.] Univ Ghent, Fac Med & Hlth Sci, Dept Phys Therapy & Motor Rehabil, B-9000 Ghent, Belgium; [Leemans, A.] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands; [Michiels, K.] Katholieke Univ Leuven Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, S.] Katholieke Univ Leuven, Biomed Sci Grp, Dept Imaging & Pathol, Louvain, Belgium		Caeyenberghs, K (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Phys Therapy & Motor Rehabil, De Pintelaan 185, B-9000 Ghent, Belgium.	Karen.Caeyenberghs@UGent.be	Gooijers, Jolien/AAH-9202-2020; Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843; Gooijers, Jolien/0000-0002-7569-7223	Research Foundation-Flanders (FWO)FWO [G.0482.010, G.A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]	This work was supported by a grant from the Research Programme of the Research Foundation-Flanders (FWO) (G.0482.010 and G.A114.11) and Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a postdoctoral fellowship of the Research Foundation-Flanders (FWO).	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bast T, 2007, REV NEUROSCIENCE, V18, P253; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Forstmann BU, 2012, NEUROIMAGE, V60, P370, DOI 10.1016/j.neuroimage.2011.12.044; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gilbert SJ, 2008, CURR BIOL, V18, pR110, DOI 10.1016/j.cub.2007.12.014; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Guilmette TJ, 1999, ASSESSMENT, V6, P33, DOI 10.1177/107319119900600104; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Ide JS, 2011, NEUROIMAGE, V54, P455, DOI 10.1016/j.neuroimage.2010.07.042; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Iturria-Medina Y, 2011, CEREB CORTEX, V21, P56, DOI 10.1093/cercor/bhq058; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubat-Silman AK, 2002, BRAIN COGNITION, V50, P178, DOI 10.1016/S0278-2626(02)00502-X; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Leemans A., 2009, 17 ANN M INT SOC MAG, DOI DOI 10.1093/OCCMED/KQR069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Leunissen I., 2012, HUM BRAIN MAPP, DOI 10.1002/hbm.21508; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Li Y, 2012, CEREB CORTEX, V12; Li YH, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000395; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Niendam TA, 2012, COGN AFFECT BEHAV NE, V12, P241, DOI 10.3758/s13415-011-0083-5; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmahmann JD, 2007, CEREBELLUM, V6, P254, DOI 10.1080/14734220701490995; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Shu N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007228; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sporns O, 2004, NEUROINFORMATICS, V2, P145, DOI 10.1385/NI:2:2:145; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Timmons SD, 2012, J NEUROSURG SCI, V56, P191; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2010, J NEUROSCI, V30, P15915, DOI 10.1523/JNEUROSCI.2874-10.2010; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011	92	97	100	1	29	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JAN	2014	219	1					193	209		10.1007/s00429-012-0494-2			17	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anatomy & Morphology; Neurosciences & Neurology	283DM	WOS:000329225400014	23232826				2022-02-06	
J	Siebenrock, KA; Behning, A; Mamisch, TC; Schwab, JM				Siebenrock, Klaus A.; Behning, Anna; Mamisch, T. Charles; Schwab, Joseph M.			Growth Plate Alteration Precedes Cam-type Deformity in Elite Basketball Players	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							FEMOROACETABULAR IMPINGEMENT; HIP; OSTEOARTHRITIS; EPIPHYSEAL; INJURIES; SALTER	Vigorous sporting activity during the growth years is associated with an increased risk of having a cam-type deformity develop. The underlying cause of this osseous deformity is unclear. One may speculate whether this is caused by reactive bone apposition in the region of the anterosuperior head-neck junction or whether sports activity alters the shape of and growth in the growth plate. If the latter is true, then one would expect athletes to show an abnormal shape of the capital growth plate (specifically, the epiphyseal extension) before and/or after physeal closure. We therefore raised three questions: (1) Do adolescent basketball players show abnormal epiphyseal extension? (2) Does the epiphyseal extension differ before and after physeal closure? (3) Is abnormal epiphyseal extension associated with high alpha angles? We performed a case-control comparative analysis of young (age range, 9-22 years) male elite basketball athletes with age-matched nonathletes, substratified by whether they had open or closed physes. We measured epiphyseal extension on radial-sequence MRI cuts throughout the cranial hemisphere from 9 o'clock (posterior) to 3 o'clock (anterior). Epiphyseal extension was correlated to alpha angle measurements at the same points. Epiphyseal extension was increased in all positions in the athletes compared with the control group. On average, athletes showed epiphyseal extension of 0.67 to 0.83 versus 0.53 to 0.71 in control subjects. In the control group epiphyseal extension was increased at all measurement points in hips after physeal closure compared with before physeal closure. In contrast, the subgroup of athletes with a closed growth plate only had increased epiphyseal extension at the 3 o'clock position compared with the athletes with a closed growth plate (0.64-0.70). We observed a correlation between an alpha angle greater than 55A degrees and greater epiphyseal extension in the anterosuperior femoral head quadrant: the corresponding Spearman r values were 0.387 (all hips) and 0.285 (alpha angle > 55A degrees) for the aggregate anterosuperior quadrant. These findings suggest that a cam-type abnormality in athletes is a consequence of an alteration of the growth plate rather than reactive bone formation. High-level sports activity during growth may be a new and distinct risk factor for a cam-type deformity.	[Siebenrock, Klaus A.; Behning, Anna; Mamisch, T. Charles; Schwab, Joseph M.] Univ Bern, Inselspital, Dept Orthopaed Surg, CH-3010 Bern, Switzerland		Siebenrock, KA (corresponding author), Univ Bern, Inselspital, Dept Orthopaed Surg, Freiburgstr, CH-3010 Bern, Switzerland.	klaus.siebenrock@insel.ch		Siebenrock, Klaus Arno/0000-0003-3627-4313; Schwab, Joseph/0000-0002-7068-5215	Maurice E. Muller Foundation of North America	One of the authors (JMS) has received fellowship funding from the Maurice E. Muller Foundation of North America. Each author certifies that he or she, or a member of his or her immediate family, has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request. Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.	ADAMS JE, 1966, CALIF MED, V105, P22; Bharam S, 2006, CLIN SPORT MED, V25, P279, DOI 10.1016/j.csm.2006.01.003; Bizzini M, 2007, AM J SPORT MED, V35, P1955, DOI 10.1177/0363546507304141; Caine D, 2006, BRIT J SPORT MED, V40, P749, DOI 10.1136/bjsm.2005.017822; Ganz R, 2003, CLIN ORTHOP RELAT R, P112, DOI 10.1097/01.blo.0000096804.78689.c2; Ganz R, 2008, CLIN ORTHOP RELAT R, V466, P264, DOI 10.1007/s11999-007-0060-z; JARAMILLO D, 1993, RADIOLOGY, V187, P171, DOI 10.1148/radiology.187.1.8451408; JARAMILLO D, 1995, RADIOLOGY, V197, P767, DOI 10.1148/radiology.197.3.7480754; Keogh MJ, 2008, SPORTS MED, V38, P863, DOI 10.2165/00007256-200838100-00005; Kienle KP, 2012, SKELETAL RADIOL, V41, P1381, DOI 10.1007/s00256-012-1358-9; Leunig M, 2009, CLIN ORTHOP RELAT R, V467, P616, DOI 10.1007/s11999-008-0646-0; MURRAY R O, 1971, Journal of Bone and Joint Surgery British Volume, V53, P406; Nanni M, 2005, SKELETAL RADIOL, V34, P405, DOI 10.1007/s00256-004-0892-5; Notzli HP, 2002, J BONE JOINT SURG BR, V84B, P556, DOI 10.1302/0301-620X.84B4.12014; Philippon M, 2007, KNEE SURG SPORT TR A, V15, P908, DOI 10.1007/s00167-007-0332-x; R Development Core Team, 2011, R LANG ENV STAT COMP; Sato T, 2002, J PEDIATR ORTHOP B, V11, P155, DOI 10.1097/00009957-200204000-00013; Siebenrock KA, 2011, CLIN ORTHOP RELAT R, V469, P3229, DOI 10.1007/s11999-011-1945-4; Siebenrock KA, 2004, CLIN ORTHOP RELAT R, P54	19	97	98	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	APR	2013	471	4					1084	1091		10.1007/s11999-012-2740-6			8	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	097YW	WOS:000315510400005	23247816	Green Published			2022-02-06	
J	Mayglothling, J; Duane, TM; Gibbs, M; McCunn, M; Legome, E; Eastman, AL; Whelan, J; Shah, KH				Mayglothling, Julie; Duane, Therese M.; Gibbs, Michael; McCunn, Maureen; Legome, Eric; Eastman, Alexander L.; Whelan, James; Shah, Kaushal H.			Emergency tracheal intubation immediately following traumatic injury: An Eastern Association for the Surgery of Trauma practice management guideline	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Guideline; endotracheal intubation; trauma; rapid sequence intubation	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; PREHOSPITAL ENDOTRACHEAL INTUBATION; CERVICAL-SPINE INJURY; POSITIVE-PRESSURE VENTILATION; NEUROMUSCULAR BLOCKING-AGENTS; IN-LINE STABILIZATION; BRAIN-INJURY; MACINTOSH LARYNGOSCOPE; AIRWAY MANAGEMENT	BACKGROUND: The ABCs of trauma resuscitation begin with the airway evaluation, and effective airway management is imperative in the care of a patient with critical injury. The Eastern Association for the Surgery of Trauma Practice Management Guidelines committee aimed to update the guidelines for emergency tracheal intubation (ETI) published in 2002. These guidelines were made to assist clinicians with decisions regarding airway management for patients immediately following traumatic injury. The goals of the work group were to develop evidence-based guidelines to (1) characterize patients in need of ETI and (2) delineate the most appropriate procedure for patients undergoing ETI. METHODS: A search of the National Library of Medicine and the National Institutes of Health MEDLINE database was performed using PubMed (www.pubmed.gov). RESULTS: The search retrieved English-language articles published from 2000 to 2012 involving patients who had sustained blunt trauma, penetrating trauma, or heat-related injury and had developed respiratory system insufficiency or required ETI in the immediate period after injury (first 2 hours after injury). Sixty-nine articles were used to construct this set of practice management guidelines. CONCLUSION: The data supported the formation of six Level 1 recommendations, four Level 2 recommendations, and two Level 3 recommendations. In summary, the decision to intubate a patient following traumatic injury is based on multiple factors, including the need for oxygenation and ventilation, the extent and mechanism of injury, predicted operative need, or progression of disease. Rapid sequence intubation with direct laryngoscopy continues to be the recommended method for ETI, although the use of airway adjuncts such as blind insertion supraglottic devices and video laryngoscopy may be useful in facilitating successful ETI and may be preferred in certain patient populations. There is no pharmacologic induction agent of choice for ETI; however, succinylcholine is the neuromuscular blockade agent recommended for rapid sequence intubation. (J Trauma Acute Care Surg. 2012;73: S333-S340. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Mayglothling, Julie; Duane, Therese M.; Whelan, James] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23298 USA; [Gibbs, Michael] Carolinas Med Ctr, Charlotte, NC 28203 USA; [McCunn, Maureen] Univ Penn, Philadelphia, PA 19104 USA; [Legome, Eric] Kings Cty Med Ctr, New York, NY USA; [Shah, Kaushal H.] Mt Sinai Med Ctr, New York, NY 10029 USA; [Eastman, Alexander L.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA		Mayglothling, J (corresponding author), Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23298 USA.	jmayglothling@mcvh-vcu.edu					Asai T, 2009, ANESTHESIOLOGY, V110, P898, DOI 10.1097/ALN.0b013e31819c45e5; Bair AE, 2002, J EMERG MED, V23, P131, DOI 10.1016/S0736-4679(02)00501-2; Baker CC, 2005, J TRAUMA, V58, P723; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Bathory I, 2009, ANAESTHESIA, V64, P1337, DOI 10.1111/j.1365-2044.2009.06075.x; Bernard Stephen, 2002, Emerg Med (Fremantle), V14, P406, DOI 10.1046/j.1442-2026.2002.00382.x; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Brown CA, 2010, ANN EMERG MED, V56, P83, DOI 10.1016/j.annemergmed.2010.01.033; Bukur M, 2011, J SURG RES, V170, pE117, DOI 10.1016/j.jss.2011.04.005; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; Bushra JS, 2004, ACAD EMERG MED, V11, P66, DOI 10.1197/S1069-6563(03)00586-4; Carassiti M, 2012, BRIT J ANAESTH, V108, P146, DOI 10.1093/bja/aer304; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christensen EF, 2003, BRIT MED J, V327, P533, DOI 10.1136/bmj.327.7414.533; Clancy M, 2001, EMERG MED J, V18, P373, DOI 10.1136/emj.18.5.373; Combes X, 2006, ACAD EMERG MED, V13, P828, DOI 10.1197/j.aem.2006.02.016; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Cotton BA, 2008, ARCH SURG-CHICAGO, V143, P62, DOI 10.1001/archsurg.143.1.62; Cudnik MT, 2007, PREHOSP EMERG CARE, V11, P224, DOI 10.1080/10903120701205208; Cudnik MT, 2010, J EMERG MED, V38, P175, DOI 10.1016/j.jemermed.2008.01.022; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2003, ANN EMERG MED, V42, P697, DOI 10.1016/S0196-0644(03)00396-2; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Domeier RM, 2005, PREHOSP EMERG CARE, V9, P114; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Ellis DY, 2007, ANN EMERG MED, V50, P653, DOI 10.1016/j.annemergmed.2007.05.006; Enomoto Y, 2008, BRIT J ANAESTH, V100, P544, DOI 10.1093/bja/aen002; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Fields AM, 2009, J TRAUMA, V67, P867, DOI 10.1097/TA.0b013e3181b021c5; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Franschman G, 2009, RESUSCITATION, V80, P1147, DOI 10.1016/j.resuscitation.2009.06.029; Guyette FX, 2007, PREHOSP EMERG CARE, V11, P473, DOI 10.1080/10903120701536958; Harris T, 2010, RESUSCITATION, V81, P810, DOI 10.1016/j.resuscitation.2010.02.023; Hassid VJ, 2008, J TRAUMA, V65, P1328, DOI 10.1097/TA.0b013e31818d07e4; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Hubble MW, 2010, PREHOSP EMERG CARE, V14, P377, DOI 10.3109/10903121003790173; Jensen JL, 2010, CAN J EMERG MED, V12, P135; Kaplan MB, 2006, J CLIN ANESTH, V18, P357, DOI 10.1016/j.jclinane.2006.01.002; KATSURADA K, 1973, SURGERY, V73, P191; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Komatsu R, 2008, BRIT J ANAESTH, V101, P863, DOI 10.1093/bja/aen288; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Koyama Y, 2011, ANAESTHESIA, V66, P895, DOI 10.1111/j.1365-2044.2011.06802.x; Kummer C, 2007, INJURY, V38, P27, DOI 10.1016/j.injury.2006.09.002; Lim HC, 2009, EUR J EMERG MED, V16, P68, DOI 10.1097/MEJ.0b013e328303e1c6; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Malik MA, 2008, BRIT J ANAESTH, V101, P723, DOI 10.1093/bja/aen231; Manoach S, 2007, ANN EMERG MED, V50, P236, DOI 10.1016/j.annemergmed.2007.01.009; Maruyama K, 2008, BRIT J ANAESTH, V101, P563, DOI 10.1093/bja/aen207; Maruyama K, 2008, BRIT J ANAESTH, V100, P120, DOI 10.1093/bja/aem313; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miraflor E, 2011, J SURG RES, V170, P117; Muakkassa FF, 2010, J TRAUMA, V68, P1305, DOI 10.1097/TA.0b013e3181dcd137; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Ollerton JE, 2006, EMERG MED J, V23, P3, DOI 10.1136/emj.2004.020552; Patterson H, 2004, EMERG MED J, V21, P302, DOI 10.1136/emj.2003.006619; Platts-Mills TF, 2009, ACAD EMERG MED, V16, P866, DOI 10.1111/j.1553-2712.2009.00492.x; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Rajani Ravi R, 2009, Am J Surg, V198, P863, DOI 10.1016/j.amjsurg.2009.08.013; Reed MJ, 2005, EMERG MED J, V22, P99, DOI 10.1136/emj.2003.008771; Russell T, 2011, ANAESTH INTENS CARE, V39, P1098, DOI 10.1177/0310057X1103900619; Russi CS, 2008, INT J EMERG MED, V1, P135, DOI 10.1007/s12245-008-0023-5; Sakles JC, J EMER MED; Salomone JP, 2005, J TRAUMA, V59, P1145; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SELLICK BA, 1961, LANCET, V2, P404; Sen A, 2005, EMERG MED J, V22, P887, DOI 10.1136/emj.2005.031716; Shafi S, 2005, J TRAUMA, V59, P1140, DOI 10.1097/01.ta.0000196434.88182.77; Sise MJ, 2009, J TRAUMA, V66, P32, DOI 10.1097/TA.0b013e318191bb0c; Stephens CT, 2009, ANESTH ANALG, V109, P866, DOI 10.1213/ane.0b013e3181ad87b0; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Stroumpoulis K, 2009, EUR J ANAESTH, V26, P218, DOI 10.1097/EJA.0b013e32831c84d1; Sun DA, 2005, BRIT J ANAESTH, V94, P381, DOI 10.1093/bja/aei041; Tallon John M, 2007, CJEM, V9, P101; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Tumpach EA, 2009, PREHOSP EMERG CARE, V13, P324, DOI 10.1080/10903120902935322; Velmahos GC, 2003, AM SURGEON, V69, P891; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2011, RESUSCITATION, V82, P378, DOI 10.1016/j.resuscitation.2010.12.014; Warner KJ, 2009, J TRAUMA, V67, P45, DOI 10.1097/TA.0b013e3181a92a70; Weitzel N, 2004, J TRAUMA, V56, P1097, DOI 10.1097/01.TA.0000071294.21893.A4; Zamora JE, 2008, BRIT J ANAESTH, V101, P723	95	97	106	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73			4			S333	S340		10.1097/TA.0b013e31827018a5			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	043VO	WOS:000311578300010	23114490	Bronze			2022-02-06	
J	Eskridge, SL; Macera, CA; Galarneau, MR; Holbrook, TL; Woodruff, SI; MacGregor, AJ; Morton, DJ; Shaffer, RA				Eskridge, Susan L.; Macera, Caroline A.; Galarneau, Michael R.; Holbrook, Troy L.; Woodruff, Susan I.; MacGregor, Andrew J.; Morton, Deborah J.; Shaffer, Richard A.			Injuries from combat explosions in Iraq: Injury type, location, and severity	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Explosions; Blasts; Blast injury; Military	TRAUMATIC BRAIN-INJURY; ENDURING FREEDOM; BLAST; POLYTRAUMA; OUTCOMES; CARE	Introduction: Explosions have caused a greater percentage of injuries in Iraq and Afghanistan than in any other large-scale conflict. Improvements in body armour and field medical care have improved survival and changed the injury profile of service personnel. This study's objective was to determine the nature, body region, and severity of injuries caused by an explosion episode in male service personnel. Materials and methods: A descriptive analysis was conducted of 4623 combat explosion episodes in Iraq between March 2004 and December 2007. The Barell matrix was used to describe the nature and body regions of injuries due to a combat explosion. Results: A total of 17,637 International Classification of Diseases, Ninth Revision (ICD-9) codes were assigned to the 4623 explosion episodes, with an average of 3.8 ICD-9 codes per episode. The most frequent single injury type was a mild traumatic brain injury (TBI; 10.8%). Other frequent injuries were open wounds in the lower extremity (8.8%) and open wounds of the face (8.2%), which includes tympanic membrane rupture. The extremities were the body regions most often injured (41.3%), followed by head and neck (37.4%) and torso (8.8%). Conclusion: The results of this study support previous observations of TBI as a pre-eminent injury of the wars in Iraq and Afghanistan, with mild TBI as the most common single injury in this large cohort of explosion episodes. The extremities had the highest frequency of injuries for any one body region. The majority of the explosion episodes resulted in more than one injury, and the variety of injuries across nearly every body region and injury type suggests a complex nature of explosion injuries. Understanding the constellation of injuries commonly caused by explosions will assist in the mitigation, treatment, and rehabilitation of the effects of these injuries. (c) 2012 Elsevier Ltd. All rights reserved.	[Eskridge, Susan L.; Galarneau, Michael R.; Holbrook, Troy L.; MacGregor, Andrew J.] USN, Dept Med Modeling & Simulat, Hlth Res Ctr, San Diego, CA 92106 USA; [Macera, Caroline A.] USN, Dept Warfighter Performance, Hlth Res Ctr, San Diego, CA 92106 USA; [Macera, Caroline A.; Shaffer, Richard A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA; [Woodruff, Susan I.] San Diego State Univ, Sch Social Work, San Diego, CA 92182 USA; [Morton, Deborah J.] Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, San Diego, CA 92103 USA; [Shaffer, Richard A.] USN, Dept Def HIV AIDS Prevent Program, Hlth Res Ctr, San Diego, CA 92106 USA		Eskridge, SL (corresponding author), USN, Dept Med Modeling & Simulat, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	susan.eskridge@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390; Eskridge, Susan/0000-0002-1817-8355	US Navy Bureau of Medicine and Surgery under the Wounded, Ill; Injured/Psychological Health/Traumatic Brain Injury Programme [60808]	This work was supported by the US Navy Bureau of Medicine and Surgery under the Wounded, Ill, and Injured/Psychological Health/Traumatic Brain Injury Programme, Work Unit No. 60808. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2009.0023).	Aharonson-Daniel L, 2003, INJURY PREV, V9, P156, DOI 10.1136/ip.9.2.156; [Anonymous], US CAS STAT; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2006, MED RES PREV MIT TRE; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; McCracken D, TRAUMATIC BRAIN INJU; Mernoff Stephen T, 2010, Med Health R I, V93, P16; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Muzaffar W, 2000, BRIT J OPHTHALMOL, V84, P626, DOI 10.1136/bjo.84.6.626; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	26	97	100	2	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2012	43	10					1678	1682		10.1016/j.injury.2012.05.027			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014OU	WOS:000309386200010	22769977				2022-02-06	
J	Yeates, KO; Kaizar, E; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M; Taylor, HG				Yeates, Keith Owen; Kaizar, Eloise; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha; Taylor, H. Gerry			Reliable Change in Postconcussive Symptoms and Its Functional Consequences Among Children With Mild Traumatic Brain Injury	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							QUALITY-OF-LIFE; FAMILY ASSESSMENT DEVICE; HEAD-INJURY; IMPROVES ACCURACY; SEVERITY SCORE; ADOLESCENTS; VALIDITY; RELIABILITY; RECOVERY; MODELS	Objective: To examine reliable change in postconcussive symptoms and its functional consequences among children with mild traumatic brain injury (TBI) over the first year postinjury as compared with children with orthopedic injuries. Design: Prospective, longitudinal cohort. Setting: Emergency departments at 2 children's hospitals. Participants: Eight-to 15-year-old children with mild TBI (n=186) or orthopedic injuries (n=99). Main Exposure: Closed-head or orthopedic trauma. Main Outcome Measures: Parents rated preinjury symptoms retrospectively shortly after injury and postconcussive symptoms at 2 weeks and 3 and 12 months postinjury. A regression-based approach was used to determine whether each child displayed reliable increases in postconcussive symptoms at each postinjury occasion. Health-related quality of life was assessed at 3 and 12 months postinjury. Information regarding children's educational programming was collected at the initial and 12-month assessments. Results: Children with mild TBI were significantly more likely than those with orthopedic injuries to show reliable increases in both cognitive and somatic symptoms. Group differences in the likelihood of reliable increases became less common with time for somatic symptoms but persisted to 12 months postinjury for cognitive symptoms. Among children with mild TBI, reliable increases in symptoms were more common among children with loss of consciousness or abnormalities on neuroimaging. Reliable increases in symptoms were associated with significant declines in health-related quality of life and an increased likelihood of educational intervention. Conclusion: Many children with mild TBI show reliable increases in postconcussive symptoms that are associated with significant functional impairment in their daily lives.	[Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Kaizar, Eloise] Ohio State Univ, Dept Stat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Bangert, Barbara] Case Western Reserve Univ, Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH 44106 USA; [Bangert, Barbara] Case Western Reserve Univ, Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Wright, Martha; Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The work was supported by grants HD44099 and HD39834 from the National Institutes of Health (Dr Yeates).	Achenbach T., 1991, INTEGRATIVE GUIDE 19; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Ashwal S., 2010, PEDIAT TRAUMATIC BRA, P68; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; Faul M, 2010, TRAUMATIC BRAIN INJU; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; L?ders H., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Landgraf JM, 1996, CHILD HLTH QUESTIONN; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Ouimet LA, 2009, J CLIN EXP NEUROPSYC, V31, P73, DOI 10.1080/13803390801992725; Palermo TM, 2008, J PEDIATR PSYCHOL, V33, P983, DOI 10.1093/jpepsy/jsn038; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Yeates KO., 2006, EXCEPTIONALITY, V14, P141, DOI DOI 10.1207/S15327035EX1403_	43	97	97	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2012	166	7					615	622		10.1001/archpediatrics.2011.1082			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	967HJ	WOS:000305897200007	22393171	Bronze, Green Accepted			2022-02-06	
J	Funk, JR; Rowson, S; Daniel, RW; Duma, SM				Funk, James R.; Rowson, Steven; Daniel, Ray W.; Duma, Stefan M.			Validation of Concussion Risk Curves for Collegiate Football Players Derived from HITS Data	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Injury criteria; Head; Brain; MTBI; Acceleration; Tolerance; Incidence; Exposure	HIGH-SCHOOL FOOTBALL; HEAD IMPACTS; PROFESSIONAL FOOTBALL; DIVISION-I; INJURY; ACCELERATION; EPIDEMIOLOGY	For several years, Virginia Tech and other schools have measured the frequency and severity of head impacts sustained by collegiate American football players in real time using the Head Impact Telemetry (HIT) System of helmet-mounted accelerometers. In this study, data from 37,128 head impacts collected at Virginia Tech during games from 2006 to 2010 were analyzed. Peak head acceleration exceeded 100 g in 516 impacts, and the Head Injury Criterion (HIC) exceeded 200 in 468 impacts. Four instrumented players in the dataset sustained a concussion. These data were used to develop risk curves for concussion as a function of peak head acceleration and HIC. The validity of this biomechanical approach was assessed using epidemiological data on concussion incidence from other sources. Two specific aspects of concussion incidence were addressed: the variation by player position, and the frequency of repeat concussions. The HIT System data indicated that linemen sustained the highest overall number of head impacts, while skill positions sustained a higher number of more severe head impacts (peak acceleration > 100 g or HIC > 200). When weighted using injury risk curves, the HIT System data predicted a higher incidence of concussion in skill positions compared to linemen at rates that were in strong agreement with the epidemiological literature (Pearson's r = 0.72-0.87). The predicted rates of repeat concussions (21-39% over one season and 33-50% over five seasons) were somewhat higher than the ranges reported in the epidemiological literature. These analyses demonstrate that simple biomechanical parameters that can be measured by the HIT System possess a high level of power for predicting concussion.	[Funk, James R.] Biodynam Res Corp, San Antonio, TX 78249 USA; [Rowson, Steven; Daniel, Ray W.; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA		Funk, JR (corresponding author), Biodynam Res Corp, 5711 Univ Hts Blvd,Suite 100, San Antonio, TX 78249 USA.	jfunk@brconline.com	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; 	National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge the National Institutes of Health (National Institute for Child Health and Human Development) R01HD048638 for sponsoring this research.	Beusenberg MC., 2000, P INT RES C BIOM IMP; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P221; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Versace J, 1971, SAE TECHNICAL PAPER; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	32	97	97	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		79	89		10.1007/s10439-011-0400-8			11	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700007	21994060				2022-02-06	
J	Spikman, JM; Timmerman, ME; Milders, MV; Veenstra, WS; van der Naalt, J				Spikman, Jacoba M.; Timmerman, Marieke E.; Milders, Maarten V.; Veenstra, Wencke S.; van der Naalt, Joukje			Social Cognition Impairments in Relation to General Cognitive Deficits, Injury Severity, and Prefrontal Lesions in Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						emotion recognition; injury severity; prefrontal lesions; social cognition; traumatic brain injury	EMOTION PERCEPTION DEFICITS; GLASGOW COMA SCALE; CLOSED-HEAD INJURY; CEREBRAL CONTUSIONS; MIND IMPAIRMENTS; FRONTAL-CORTEX; RECOGNITION; PREDICTION; NEUROBIOLOGY; ATTENTION	Impairments in social behavior are frequently found in moderate to severe traumatic brain injury (TBI) patients and are associated with an unfavorable outcome with regard to return to work and social reintegration. Neuropsychological tests measuring aspects of social cognition are thought to be sensitive to these problems. However, little is known about the effect of general cognitive problems on these tests, nor about their sensitivity to injury severity and frontal lesions. In the present study 28 chronic TBI patients with a moderate to severe TBI were assessed with tests for social cognition (emotion recognition, Theory of Mind, and empathy), and for general, non-social cognition (memory, mental speed, attention, and executive function). The patients performed significantly worse than healthy controls on all measures, with the highest effect size for the emotion recognition test, the Facial Expressions of Emotion-Stimuli and Tests (FEEST). Correlation analyses yielded no significant (partial) correlations between social and non-social cognition tests. Consequently, poor performance on social cognition tests was not due to general cognitive deficits. In addition, the emotion recognition test was the only measure that was significantly related to post-traumatic amnesia (PTA) duration, Glasgow Coma Scale (GCS) score, and the presence of prefrontal lesions. Hence, we conclude that social cognition tests are a valuable supplement to a standard neuropsychological examination, and we strongly recommend the incorporation of measurements of social cognition in clinical practice. Preferably, a broader range of social cognition tests would be applied, since our study demonstrated that each of the measures represents a unique aspect of social cognition, but if capacity is limited, at least a test for emotion recognition should be included.	[Spikman, Jacoba M.] Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Timmerman, Marieke E.] Dept Psychometr & Stat, Groningen, Netherlands; [Timmerman, Marieke E.] Univ Groningen, NL-9700 AB Groningen, Netherlands; [Spikman, Jacoba M.; Veenstra, Wencke S.; van der Naalt, Joukje] Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Milders, Maarten V.] Univ Aberdeen, Sch Psychol, Aberdeen AB9 1FX, Scotland		Spikman, JM (corresponding author), Univ Med Ctr Groningen, Dept Clin Neuropsychol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.m.spikman@rug.nl		Spikman, Jacoba/0000-0002-6477-0763; van der Naalt, Joukje/0000-0001-9873-2418			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Ahmed S, 2000, BRAIN INJURY, V14, P765; Allain P, 2005, BRAIN COGNITION, V57, P4, DOI 10.1016/j.bandc.2004.08.011; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baddeley A, 1998, CURR OPIN NEUROBIOL, V8, P234, DOI 10.1016/S0959-4388(98)80145-1; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Beer JS, 2006, BRAIN RES, V1079, P98, DOI 10.1016/j.brainres.2006.01.002; Beer JS, 2006, BRAIN RES, V1079, P1, DOI 10.1016/j.brainres.2006.02.001; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blair RJR, 2003, PHILOS T R SOC B, V358, P561, DOI 10.1098/rstb.2002.1220; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess P, 1996, BEHAV ASSESSMENT DYS; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Cohen J., 2013, STAT POWER ANAL BEHA; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Cummings JL, 1995, ANN NY ACAD SCI, V769, P1, DOI 10.1111/j.1749-6632.1995.tb38127.x; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Deelman B, 1980, NEUROPSYCHOLOGIE NED; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Enticott PG, 2008, NEUROPSYCHOLOGIA, V46, P2851, DOI 10.1016/j.neuropsychologia.2008.04.022; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Frith U, 2010, PHILOS T R SOC B, V365, P165, DOI 10.1098/rstb.2009.0160; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Howard MA, 2003, BRAIN RES PROTOC, V10, P125, DOI 10.1016/S1385-299X(02)00202-7; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Keysers C, 2006, PROG BRAIN RES, V156, P379, DOI 10.1016/S0079-6123(06)56021-2; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lichter DC, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P260; Mah LWY, 2005, J NEUROPSYCH CLIN N, V17, P66, DOI 10.1176/appi.neuropsych.17.1.66; Mathersul D, 2009, J CLIN EXP NEUROPSYC, V31, P278, DOI 10.1080/13803390802043619; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Mendez MF, 2009, CNS SPECTRUMS, V14, P608, DOI 10.1017/S1092852900023853; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Naqvi N, 2006, ORBITOFRONTAL CORTEX, P325; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Rudebeck PH, 2008, COGN AFFECT BEHAV NE, V8, P485, DOI 10.3758/CABN.8.4.485; Ruffman T, 2008, NEUROSCI BIOBEHAV R, V32, P863, DOI 10.1016/j.neubiorev.2008.01.001; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Salthouse TA, 2007, BRAIN COGNITION, V63, P279, DOI 10.1016/j.bandc.2006.09.006; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; SPSS, 2009, STAT PACK SOC SCI; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Young A., 2002, FACIAL EXPRESSIONS E	91	97	100	2	83	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					101	111		10.1089/neu.2011.2084			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300012	21933011				2022-02-06	
J	Sollman, MJ; Berry, DTR				Sollman, Myriam J.; Berry, David T. R.			Detection of Inadequate Effort on Neuropsychological Testing: A Meta-Analytic Update and Extension	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Cognitive; Effort testing; Malingering; Feigning; Review	LETTER MEMORY TEST; TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; CLASSIFICATION ACCURACY; CROSS-VALIDATION; MMPI-2; PERFORMANCE; PATTERNS; ISSUES; PAIN	The present meta-analysis provides the first meta-analysis of research on stand-alone neurocognitive feigning tests since publication of the preceding paper by Vickery, Berry, Inman, Harris & Orey (2001). Studies of dedicated neurocognitive feigning test performances in adults appearing in published or unpublished (theses and dissertations) sources through October 2010 were reviewed and subjected to stringent inclusion criteria to maximize the validity of results. Neurocognitive feigning tests were included only if at least three contrasts of criterion-supported honest patient groups and feigners were available. Tests that met criteria for review included the Victoria Symptom Validity Test, used as an anchor to compare Vickery and colleagues' results; Test of Memory Malingering, Word Memory Test, Letter Memory Test, and Medical Symptom Validity Test. Effect sizes and test parameters at published cut scores were compiled and compared. Results reflected large effect sizes for all measures (mean d = 1.55, 95% confidence interval [CI] = 1.48-1.63). Mean specificity was 0.90 (95% CI = 0.85-0.94). Mean sensitivity was 0.69 (95% CI = 0.63-0.75). Several moderators of effect size were identified, with certain manipulations resulting in a weakening of effect size. Unexpectedly, warning simulators to feign believably increased effect sizes.	[Sollman, Myriam J.; Berry, David T. R.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA		Berry, DTR (corresponding author), Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA.	dtrb85@gmail.com					Abramsky A., 2005, DISS ABSTR INT B, V66; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Berry D. T. R., 2007, ASSESSMENT MALINGERE, P226; BERRY DTR, 2002, CLIN PERSONALITY ASS, P269; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Boone K.B., 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Connell K. E., 2005, THESIS CALIFORNIA SC, V65, P5393; Covert J. H., 2010, DISS ABSTR INT B, V70, P6544; Demakis GJ, 2006, CLIN NEUROPSYCHOL, V20, P10, DOI 10.1080/13854040500203282; Farkas M. R., 2009, DISS ABSTR INT B, V69, P7136; Graue LO, 2007, CLIN NEUROPSYCHOL, V21, P929, DOI 10.1080/13854040600932137; Green P., 2003, GREENS WORD MEMORY T; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P., 2004, MED SYMPTOM VALIDITY; Greub B. L., 2005, DISS ABSTR INT, V66, P552; Greub BL, 2006, ARCH CLIN NEUROPSYCH, V21, P249, DOI 10.1016/j.acn.2005.12.006; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Harrison C., 2009, DISS ABSTR INT B, V70, P3782; Hedges L. V., 1985, STAT METHODS META AN; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Hubbard K. L., 2008, DISS ABSTR INT B, V68, P6966; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Johnson B. T., 1993, DSTAT 1 10 MANUAL; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lezak MD, 1976, NEUROPSYCHOLOGICAL A; Lindstrom WA, 2009, ARCH CLIN NEUROPSYCH, V24, P659, DOI 10.1093/arclin/acp071; Lipsey MW, 2001, PRACTICAL META ANAL; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rosenfeld B., 2010, INT J FORENSIC MENT, V9, P63, DOI DOI 10.1080/14999013.2010.499559; ROSENTHAL R, 1991, META ANAL PROCEDURES; Samra J., 2004, DISS ABSTR INT, V64, P4061; Schipper LJ, 2008, CLIN NEUROPSYCHOL, V22, P345, DOI 10.1080/13854040701218428; Shandera AL, 2010, PSYCHOL ASSESSMENT, V22, P50, DOI 10.1037/a0016585; Sharpe D, 1997, CLIN PSYCHOL REV, V17, P881, DOI 10.1016/S0272-7358(97)00056-1; Sholtz B. P., 2006, DISS ABSTR INT B, V67, P2243; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick D. J., 1996, DISS ABSTR INT, V59, P6114; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2010, PSYCHOL ASSESSMENT, V22, P325, DOI 10.1037/a0018857; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vagnini VL, 2008, J CLIN EXP NEUROPSYC, V30, P766, DOI 10.1080/13803390701754746; Vagnini VL, 2006, CLIN NEUROPSYCHOL, V20, P289, DOI 10.1080/13854040590947470; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Viglione DJ, 2001, ASSESSMENT, V8, P237, DOI 10.1177/107319110100800301; Wolfe P. L., 2004, THESIS ILLINOIS I TE, V64, P6346; Wood S. M., 2009, DISS ABSTR INT B, V70; Youngjohn JR, 1999, ARCH CLIN NEUROPSYCH, V14, P511, DOI 10.1016/S0887-6177(98)00049-3; Zapf, 2009, INT J FORENSIC MENT, V8, DOI [10.1080/14999011003635514, DOI 10.1080/14999011003635514, https://doi.org/10.1080/14999011003635514]	61	97	97	0	28	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2011	26	8					774	789		10.1093/arclin/acr066			16	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	849UX	WOS:000297151900009	22100969	Bronze			2022-02-06	
J	Cox, CS; Baumgartner, JE; Harting, MT; Worth, LL; Walker, PA; Shah, SK; Ewing-Cobbs, L; Hasan, KM; Day, MC; Lee, D; Jimenez, F; Gee, A				Cox, Charles S., Jr.; Baumgartner, James E.; Harting, Matthew T.; Worth, Laura L.; Walker, Peter A.; Shah, Shinil K.; Ewing-Cobbs, Linda; Hasan, Khader M.; Day, Mary-Clare; Lee, Dean; Jimenez, Fernando; Gee, Adrian			Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children	NEUROSURGERY			English	Article						Cellular therapy; Clinical trial; Mononuclear cell; Pediatric; Stem cell; Traumatic brain injury	STROMAL CELLS; INFLAMMATORY RESPONSE; DIFFUSION-TENSOR; HEAD-INJURY; ISCHEMIA; TRANSPLANTATION; HYPOTHERMIA; VALIDATION; DELIVERY; MODERATE	BACKGROUND: Severe traumatic brain injury (TBI) in children is associated with substantial long-term morbidity and mortality. Currently, there are no successful neuroprotective/neuroreparative treatments for TBI. Numerous preclinical studies suggest that bone marrow-derived mononuclear cells (BMMNCs), their derivative cells (marrow stromal cells), or similar cells (umbilical cord blood cells) offer neuroprotection. OBJECTIVE: To determine whether autologous BMMNCs are a safe treatment for severe TBI in children. METHODS: Ten children aged 5 to 14 years with a postresuscitation Glasgow Coma Scale of 5 to 8 were treated with 6 3 106 autologous BMMNCs/ kg body weight delivered intravenously within 48 hours after TBI. To determine the safety of the procedure, systemic and cerebral hemodynamics were monitored during bone marrow harvest; infusion-related toxicity was determined by pediatric logistic organ dysfunction (PELOD) scores, hepatic enzymes, Murray lung injury scores, and renal function. Conventional magnetic resonance imaging (cMRI) data were obtained at 1 and 6 months postinjury, as were neuropsychological and functional outcome measures. RESULTS: All patients survived. There were no episodes of harvest-related depression of systemic or cerebral hemodynamics. There was no detectable infusion-related toxicity as determined by PELOD score, hepatic enzymes, Murray lung injury scores, or renal function. cMRI imaging comparing gray matter, white matter, and CSF volumes showed no reduction from 1 to 6 months postinjury. Dichotomized Glasgow Outcome Score at 6 months showed 70% with good outcomes and 30% with moderate to severe disability. CONCLUSION: Bone marrow harvest and intravenous mononuclear cell infusion as treatment for severe TBI in children is logistically feasible and safe.	[Cox, Charles S., Jr.; Baumgartner, James E.; Harting, Matthew T.; Walker, Peter A.; Shah, Shinil K.; Ewing-Cobbs, Linda; Day, Mary-Clare; Jimenez, Fernando] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX USA; [Harting, Matthew T.; Walker, Peter A.; Shah, Shinil K.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX USA; [Hasan, Khader M.] Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, Houston, TX USA; Univ Texas Houston, Childrens Mem Hermann Hosp, Houston, TX USA; [Worth, Laura L.; Lee, Dean] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pediat, Div Cell Therapy, Houston, TX 77030 USA; [Gee, Adrian] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA		Cox, CS (corresponding author), 6431 Fannin,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu	Lee, Dean Anthony/AAK-8443-2021; Hasan, Khader M./ABB-5767-2020	Lee, Dean Anthony/0000-0001-6693-5392; Harting, Matthew/0000-0002-8929-8311	Children's Memorial Hermann Foundation, Brown Foundation, Inc., National Institute of Health [R21 HD042659-01A1, UL1 RR024148, 1T32 GM 087-92-01, R01 NS052505]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NO1-HB-37163]; CBR, Inc.; Athersys, Inc.; KCI, Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077963, R01NS052505] Funding Source: NIH RePORTER	This work was supported by Children's Memorial Hermann Foundation, Brown Foundation, Inc., National Institute of Health Grants R21 HD042659-01A1, UL1 RR024148, 1T32 GM 087-92-01, and R01 NS052505. The cell preparation was supported in part by Production Assistance for Cellular Therapies (National Heart, Lung, and Blood Institute Contract NO1-HB-37163). Dr Cox serves as a consultant and has sponsored research agreements with CBR, Inc., Athersys, Inc., and KCI, Inc. Dr Cox has stock and royalty interests in EMIT Corporation. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Boltze J, 2008, J CEREBR BLOOD F MET, V28, P1951, DOI 10.1038/jcbfm.2008.89; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fink DW, 2009, SCIENCE, V324, P1662, DOI 10.1126/science.1173712; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hasan KM, 2007, NEUROIMAGE, V34, P1497, DOI 10.1016/j.neuroimage.2006.10.029; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Walker PA, 2009, J TRAUMA, V67, pS120, DOI 10.1097/TA.0b013e3181ad323a; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willing AE, 2007, HISTOL HISTOPATHOL, V22, P697, DOI 10.14670/HH-22.697	35	97	99	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2011	68	3					588	600		10.1227/NEU.0b013e318207734c			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	719WN	WOS:000287242300021	21192274				2022-02-06	
J	Su, XF; Wang, HD; Zhao, JB; Pan, H; Mao, L				Su, Xingfen; Wang, Handong; Zhao, Jinbing; Pan, Hao; Mao, Lei			Beneficial Effects of Ethyl Pyruvate through Inhibiting High-Mobility Group Box 1 Expression and TLR4/NF-kappa B Pathway after Traumatic Brain Injury in the Rat	MEDIATORS OF INFLAMMATION			English	Article							KAPPA-B; INFLAMMATORY RESPONSE; ISCHEMIC-INJURY; HMGB1; MODEL; MICE; DYSFUNCTION; RECOVERY; RELEASE	Ethyl pyruvate (EP) has demonstrated neuroprotective effects against acute brain injury through its anti-inflammatory action. The nuclear protein high-mobility group box 1 (HMGB1) can activate inflammatory pathways when released from dying cells. This study was designed to investigate the protective effects of EP against secondary brain injury in rats after Traumatic Brain Injury (TBI). Adult male rats were randomly divided into three groups: (1) Sham + vehicle group, (2) TBI + vehicle group, and (3) TBI + EP group (n = 30 per group). Right parietal cortical contusion was made by using a weight-dropping TBI method. In TBI + EP group, EP was administered intraperitoneally at a dosage of 75mg/kg at 5min, 1 and 6 h after TBI. Brain samples were harvested at 24 h after TBI. We found that EP treatment markedly inhibited the expressions of HMGB1 and TLR4, NF-kappa B DNA binding activity and inflammatory mediators, such as IL-1 beta, TNF-alpha and IL-6. Also, EP treatment significantly ameliorated beam walking performance, brain edema, and cortical apoptotic cell death. These results suggest that the protective effects of EP may be mediated by the reduction of HMGB1/TLR4/NF-kappa B-mediated inflammatory response in the injured rat brain.	[Su, Xingfen; Wang, Handong; Zhao, Jinbing; Pan, Hao; Mao, Lei] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_nj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Jiangsu Provincial Key Subject [X4200722]	This work was supported by grants from the National Natural Science Foundation of China (no. 81070974) and the Jiangsu Provincial Key Subject (no. X4200722). The authors would like to thank Dr. Gengbao Feng for his technical assistance.	Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Cai BL, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/642462; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Genovese T, 2009, SHOCK, V32, P217, DOI 10.1097/SHK.0b013e31818d4073; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007; Kawabata H, 2010, SPINE, V35, P1109, DOI 10.1097/BRS.0b013e3181bd14b6; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; PAOLA RD, 2009, CRITICAL CARE MED, V37, P270; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roth P, 2000, Crit Care Nurs Q, V23, P14; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Wang Q, 2009, ANESTHESIOLOGY, V110, P1279, DOI 10.1097/ALN.0b013e3181a160d6; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019; Yang R, 2002, AM J PHYSIOL-GASTR L, V283, pG212, DOI 10.1152/ajpgi.00022.2002; Yang RK, 2004, CRIT CARE MED, V32, P1453, DOI 10.1097/01.CCM.0000130835.65462.06; Yu YM, 2005, STROKE, V36, P2238, DOI 10.1161/01.STR.0000181779.83472.35; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458	38	97	101	1	11	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2011	2011								807142	10.1155/2011/807142			10	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	802XD	WOS:000293543400001	21772666	Green Published, gold, Green Submitted			2022-02-06	
J	Kou, ZF; Wu, Z; Tong, KA; Holshouser, B; Benson, RR; Hu, JN; Haacke, EM				Kou, Zhifeng; Wu, Zhen; Tong, Karen A.; Holshouser, Barbara; Benson, Randall R.; Hu, Jiani; Haacke, E. Mark			The Role of Advanced MR Imaging Findings as Biomarkers of Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; diffusion tensor imaging (DTI); magnetic resonance imaging (MRI); MR spectroscopy (MRS); MR spectroscopy imaging (MRSI); neuroimaging; susceptibility-weighted imaging (SWI); traumatic brain injury (TBI)	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; WHITE-MATTER INJURY; FUNCTIONAL CONNECTIVITY; PROTON MRS; MILD; CHILDREN; TIME; MODERATE; MEMORY	Treatment of traumatic brain injury (TBI) requires proper classification of the pathophysiology. Clinical classifiers and conventional neuroimaging are limited in TBI detection, outcome prediction, and treatment guidance. Advanced magnetic resonance imaging (MRI) techniques such as susceptibility weighted imaging, diffusion tensor imaging, and magnetic resonance spectroscopic imaging are sensitive to microhemorrhages, white matter injury, and abnormal metabolic activities, respectively, in brain injury. In this article, we reviewed these 3 advanced MRI methods and their applications in TBI and report some new findings from our research. These MRI techniques have already demonstrated their potential to improve TBI detection and outcome prediction. As such, they have demonstrated the capacity of serving as a set of biomarkers to reveal the heterogeneous and complex nature of brain injury in a regional and temporal manner. Further longitudinal studies using advanced MRI in a synergistic approach are expected to provide insight in understanding TBI and imaging implications for treatment.	[Hu, Jiani; Haacke, E. Mark] Wayne State Univ, Sch Med, Dept Radiol, MR Res Facil, Detroit, MI 48201 USA; [Tong, Karen A.; Holshouser, Barbara] Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA USA; [Wu, Zhen; Haacke, E. Mark] McMaster Univ, Sch Biomed Engn, Hamilton, ON, Canada; [Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Benson, Randall R.] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA		Haacke, EM (corresponding author), Wayne State Univ, Sch Med, Dept Radiol, MR Res Facil, 3990 John R St, Detroit, MI 48201 USA.	nmrimaging@aol.com			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NIH 62983] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Alessandri B, 1999, ACT NEUR S, V75, P25; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Chastain C, 2006, J INVEST MED, V54, pS142; CHRISTMAN CW, 1980, NEUROSCI LETT, V20, P227, DOI 10.1016/0304-3940(80)90151-2; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Finkelstein E., 2006, INCIDENCE EC BURDEN; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GATTU R, 2008, P INT SOC MAGN RES M; GATTU R, 2009, P INT SOC MAGN RES M; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Grossman RI, 2003, NEURORADIOLOGY; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.3.CO;2-Y; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kou Z., 2007, P JOINT ANN M ISMRM; KOU Z, 2008, P INT SOC MAGN RES M; Kou Z., 2008, CLIN MR NEUROIMAGING; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Soher BJ, 2000, MAGN RESON IMAGING, V18, P1159, DOI 10.1016/S0730-725X(00)00212-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale E., 1997, HEAD INJURY, P167; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; WU Z, 2010, J MAGN RESO IN PRESS; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa; Zhang H, 2001, CLIN CHEM, V47, P1458; ZHEN W, 2009, THESIS MCMASTER U HA	82	97	100	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					267	282		10.1097/HTR.0b013e3181e54793			16	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900005	20611045				2022-02-06	
J	Moulaert, VRMP; Wachelder, EM; Verbunt, JA; Wade, DT; van Heugten, CM				Moulaert, Veronique R. M. P.; Wachelder, Esther M.; Verbunt, Jeanine A.; Wade, Derick T.; van Heugten, Caroline M.			DETERMINANTS OF QUALITY OF LIFE IN SURVIVORS OF CARDIAC ARREST	JOURNAL OF REHABILITATION MEDICINE			English	Article						heart arrest; quality of life; cognition disorders; hypoxia-ischaemia brain	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; LONG-TERM; CARDIOPULMONARY-RESUSCITATION; COMMUNITY INTEGRATION; EARLY DEFIBRILLATION; EVENT SCALE; VALIDATION; FATIGUE; IMPACT	Objective: To study factors related to quality of life after a hypoxic period due to cardiac arrest. Design: Retrospective cohort study. Subjects: Eighty-eight survivors of out-of-hospital cardiac arrest, admitted to a Dutch academic hospital between 2001 and 2006. Methods: Patients received a set of questionnaires at home. The main outcome measures were physical and mental quality of life (Medical Outcomes Study 36-item Short Form Health Survey; SF-36). Potential determinants were cognitive complaints, emotional problems (depression/anxiety), post-traumatic stress, fatigue, daily functioning and participation in society. Multiple linear regression analyses were performed with physical and mental quality of life as dependent variables. Results: Sixty-three (72%) patients responded. Mean time since cardiac arrest was 36 months (standard deviation (SD) 19). Backward regression analyses showed that physical quality of life was significantly (p<0.001, adjusted R(2)=0.531) related to cognitive complaints (beta=-0.378), instrumental daily life activities (beta=0.262), post-traumatic stress (beta=-0.246) and fatigue (beta=-0.226). Mental quality of life was significantly (p<0.001, adjusted R(2)=0.664) explained by anxiety/depression (beta=-0.609), fatigue (beta=-0.177) and cognitive complaints (beta=-0.175). Conclusion: Quality of life is related to cognitive complaints, fatigue, anxiety/depression, post-traumatic stress and difficulties in daily activities in survivors of out-of-hospital cardiac arrest. Rehabilitation programmes for this group should specifically address these topics.	[van Heugten, Caroline M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; [van Heugten, Caroline M.] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, NL-6200 MD Maastricht, Netherlands; [Verbunt, Jeanine A.; Wade, Derick T.] Maastricht Univ, Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands; [Wade, Derick T.] Oxford Ctr Enablement, Oxford, England; [Moulaert, Veronique R. M. P.; Wachelder, Esther M.; Verbunt, Jeanine A.] Adelante, Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands		van Heugten, CM (corresponding author), Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, POB 616, NL-6200 MD Maastricht, Netherlands.	c.vanheugten@np.unimaas.nl			Netherlands Organization for Health Research and Development (ZON/MW)Netherlands Organization for Health Research and Development; Fonds Nuts/Ohra	The study is funded by the Netherlands Organization for Health Research and Development (ZON/MW) and Fonds Nuts/Ohra.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Bekkers SCAM, 2007, AM J EMERG MED, V25, P1078, DOI 10.1016/j.ajem.2007.06.008; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Bunch TJ, 2004, RESUSCITATION, V60, P189, DOI 10.1016/j.resuscitation.2003.09.010; Bunch TJ, 2003, NEW ENGL J MED, V348, P2626, DOI 10.1056/NEJMoa023053; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; de Haan R, 1993, Ned Tijdschr Geneeskd, V137, P917; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; de Vreede-Swagemakers JJM, 1998, HEART, V79, P356, DOI 10.1136/hrt.79.4.356; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Eisenburger P, 1998, RESUSCITATION, V38, P137, DOI 10.1016/S0300-9572(98)00085-9; Gamper G, 2004, CRIT CARE MED, V32, P378, DOI 10.1097/01.CCM.0000108880.97967.C0; Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X; Hochstenbach JB, 2001, ARCH PHYS MED REHAB, V82, P1360, DOI 10.1053/apmr.2001.25970; Horsted TI, 2007, RESUSCITATION, V72, P214, DOI 10.1016/j.resuscitation.2006.06.029; Kamphuis HCM, 2002, EUROPACE, V4, P417, DOI 10.1053/eupc.2002.0258; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Lundgren-Nilsson A, 2005, RESUSCITATION, V66, P285, DOI 10.1016/j.resuscitation.2005.04.001; Moulaert Veronique R M P, 2007, BMC Cardiovasc Disord, V7, P26, DOI 10.1186/1471-2261-7-26; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Noble AJ, 2008, NEUROSURGERY, V63, P1095, DOI 10.1227/01.NEU.0000327580.91345.78; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Turnbull JC, 2000, ARCH PHYS MED REHAB, V81, P1034, DOI 10.1053/apmr.2000.7162; van Alem AP, 2004, AM J CARDIOL, V93, P131, DOI 10.1016/j.amjcard.2003.09.027; van Alem AP, 2004, AM HEART J, V148, P416, DOI 10.1016/j.ahj.2004.01.031; van de Port IGL, 2007, CEREBROVASC DIS, V23, P40, DOI 10.1159/000095757; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; Visser-Meily JMA, 2009, STROKE, V40, P1526, DOI 10.1161/STROKEAHA.108.531277; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020	34	97	99	0	6	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	JUN	2010	42	6					553	558		10.2340/16501977-0547			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	613SQ	WOS:000279001000007	20549160	Green Published, Green Submitted, gold			2022-02-06	
J	Alahmadi, H; Vachhrajani, S; Cusimano, MD				Alahmadi, Hussein; Vachhrajani, Shobhan; Cusimano, Michael D.			The natural history of brain contusion: an analysis of radiological and clinical progression - Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; brain contusion; contusion progression; natural history	SEVERE HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT-SCAN; TRAUMA; HEMORRHAGE; LESION	Object. Although brain contusions are a common neurosurgical condition, surprisingly little has been written about their natural history. The purpose of this study was to identify factors that predict radiological and clinically significant progression of this pattern of traumatic brain injury in patients who did not initially require surgery. On the basis of their results and the available literature, the authors suggest a management algorithm. Methods. The authors performed a retrospective review of clinical and radiological records of consecutive patients with brain contusions who initially underwent conservative treatment. Significant radiological progression was defined as a 30% increase in contusion size on CT scans. Statistical analysis was performed to identify clinical and radiological predictors of CT contusion progression, the significance of progression, and predictors of clinical outcome. Results. Of 98 patients identified with brain contusions who initially received conservative treatment, 44 (45%) had significant progression on CT, and 19 (19%) required surgical intervention. The initial size of the contusion and the presence of subdural hematoma were the only statistically significant predictors of CT progression in the multivariate analysis (p = 0.0212 and 0.05, respectively). Four patients required delayed contusion evacuation (3 had radiological progression on follow-up scans). Good Glasgow Coma Scale (GCS) scores on presentation and younger age were predictors of eventual discharge from the hospital (OR 1.471, CI 1.233-1.755, p < 0.001 and OR 0.949, CI 0.912-0.988, p = 0.011, respectively). No patients with an initial GCS score of 15 or an initial contusion size < 14 ml required delayed evacuation. Conclusions. Contusion progression is a common phenomenon that is seen more commonly in larger contusions. Patients with large contusions and low initial GCS scores are at risk for delayed deterioration. A proposed management algorithm for patients with contusions initially treated conservatively may help practitioners identify the best course of treatment. (DOI: 10.3171/2009.5.JNS081369)	[Alahmadi, Hussein; Vachhrajani, Shobhan; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5W 1B6, Canada		Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5W 1B6, Canada.	mountain@smh.toronto.on.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marion DW, 2006, NEUROSURGERY, V58, P655; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	26	97	102	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1139	1145		10.3171/2009.5.JNS081369			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600033	19575576				2022-02-06	
J	Hinzman, JM; Thomas, TC; Burmeister, JJ; Quintero, JE; Huettl, P; Pomerleau, F; Gerhardt, GA; Lifshitz, J				Hinzman, Jason M.; Thomas, Theresa Currier; Burmeister, Jason J.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.; Lifshitz, Jonathan			Diffuse Brain Injury Elevates Tonic Glutamate Levels and Potassium-Evoked Glutamate Release in Discrete Brain Regions at Two Days Post-Injury: An Enzyme-Based Microelectrode Array Study	JOURNAL OF NEUROTRAUMA			English	Article						amperometry; hippocampus; microdialysis; synaptic release	EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; PREFRONTAL CORTEX; MULTISITE MICROELECTRODE; EXTRACELLULAR GLUTAMATE; NEUROLOGICAL DISORDERS; MEMORY; EXCITOTOXICITY; IMPAIRMENT; EXPRESSION	Traumatic brain injury (TBI) survivors often suffer from a wide range of post-traumatic deficits, including impairments in behavioral, cognitive, and motor function. Regulation of glutamate signaling is vital for proper neuronal excitation in the central nervous system. Without proper regulation, increases in extracellular glutamate can contribute to the pathophysiology and neurological dysfunction seen in TBI. In the present studies, enzyme-based microelectrode arrays (MEAs) that selectively measure extracellular glutamate at 2Hz enabled the examination of tonic glutamate levels and potassium chloride (KCl)-evoked glutamate release in the prefrontal cortex, dentate gyrus, and striatum of adult male rats 2 days after mild or moderate midline fluid percussion brain injury. Moderate brain injury significantly increased tonic extracellular glutamate levels by 256% in the dentate gyrus and 178% in the dorsal striatum. In the dorsal striatum, mild brain injury significantly increased tonic glutamate levels by 200%. Tonic glutamate levels were significantly correlated with injury severity in the dentate gyrus and striatum. The amplitudes of KCl-evoked glutamate release were increased significantly only in the striatum after moderate injury, with a 249% increase seen in the dorsal striatum. Thus, with the MEAs, we measured discrete regional changes in both tonic and KCl-evoked glutamate signaling, which were dependent on injury severity. Future studies may reveal the specific mechanisms responsible for glutamate dysregulation in the post-traumatic period, and may provide novel therapeutic means to improve outcomes after TBI.	[Hinzman, Jason M.; Thomas, Theresa Currier; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.] Univ Kentucky, Albert B Chandler Med Ctr, Morris K Udall Parkinsons Dis Res Ctr Excellence, Lexington, KY 40536 USA; [Hinzman, Jason M.; Burmeister, Jason J.; Quintero, Jorge E.; Huettl, Peter; Pomerleau, Francois; Gerhardt, Greg A.] Univ Kentucky, Albert B Chandler Med Ctr, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, B463 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666	U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [DA017186, AG00242, NS3978, AG013494]; National Science Fund [EEC-0310723]; University of Kentucky College of Medicine; Kentucky Spinal Cord and Head Injury Research Trust [7-11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG013494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA017186] Funding Source: NIH RePORTER	The authors thank Amanda M. Lisembee and Kelley D. Hall for technical assistance with the FPI, Laura C. Crawford and Emily D. Cottrell for assistance with in vivo recordings and MEA placement, and Michelle L. Stephens for providing the coordinates for the hippocampus. Support was provided by U.S. Public Health Service grants DA017186, AG00242, NS3978, and AG013494, National Science Fund grant (ERC) EEC-0310723, and the University of Kentucky College of Medicine, and Kentucky Spinal Cord and Head Injury Research Trust Grant 7-11.	Andersen P., 2007, HIPPOCAMPUS BOOK; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Borland LM, 2005, J NEUROSCI METH, V146, P149, DOI 10.1016/j.jneumeth.2005.02.002; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Canales JJ, 2002, BRAIN, V125, P2353, DOI 10.1093/brain/awf239; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Day BK, 2006, J NEUROCHEM, V96, P1626, DOI 10.1111/j.1471-4159.2006.03673.x; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Delatour B, 2000, BEHAV BRAIN RES, V109, P113, DOI 10.1016/S0166-4328(99)00168-0; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FONNUM F, 1981, NEUROSCIENCE, V6, P863, DOI 10.1016/0306-4522(81)90168-8; FRIEDEMANN MN, 1992, NEUROBIOL AGING, V13, P325, DOI 10.1016/0197-4580(92)90046-Z; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hascup KN, 2008, J PHARMACOL EXP THER, V324, P725, DOI 10.1124/jpet.107.131698; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jaquins-Gerstl A, 2009, J NEUROSCI METH, V183, P127, DOI 10.1016/j.jneumeth.2009.06.023; Jensen JB, 2000, INT J DEV NEUROSCI, V18, P309, DOI 10.1016/S0736-5748(99)00099-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2008, ANIMAL MODELS ACUTE; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANGANO RM, 1983, BRAIN RES BULL, V10, P47, DOI 10.1016/0361-9230(83)90073-4; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McIntosh TK, 1996, LAB INVEST, V74, P315; Nickell J, 2007, NEUROBIOL AGING, V28, P1737, DOI 10.1016/j.neurobiolaging.2006.07.015; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pomerleau F, 2003, ANN NY ACAD SCI, V1003, P454, DOI 10.1196/annals.1300.051; Rao VLR, 1998, J NEUROCHEM, V70, P2020; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rutherford EC, 2007, J NEUROCHEM, V102, P712, DOI 10.1111/j.1471-4159.2007.04596.x; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Steketee JD, 2003, BRAIN RES REV, V41, P203, DOI 10.1016/S0165-0173(02)00233-3; Stephens M.L., 2009, NEUROBIOL AGING; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thomas TC, 2009, NEUROPSYCHOPHARMACOL, V34, P436, DOI 10.1038/npp.2008.74; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wu Y, 2000, NEUROSCIENCE, V96, P65, DOI 10.1016/S0306-4522(99)00539-4; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	66	97	98	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					889	899		10.1089/neu.2009.1238			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400011	20233041	Green Published			2022-02-06	
J	Twamley, EW; Allard, CB; Thorp, SR; Norman, SB; Cissell, SH; Berardi, KH; Grimes, EM; Stein, MB				Twamley, Elizabeth W.; Allard, Carolyn B.; Thorp, Steven R.; Norman, Sonya B.; Cissell, Shadha Hami; Berardi, Kelly Hughes; Grimes, Erin M.; Stein, Murray B.			Cognitive impairment and functioning in PTSD related to intimate partner violence	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Posttraumatic stress disorder; Trauma; Stress; Neuropsychological; Cognition; Domestic violence	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL FUNCTION; DISSOCIATIVE EXPERIENCES; VIETNAM VETERANS; CHILD-ABUSE; PERFORMANCE; ATTENTION; DEFICITS; IRAQ	Posttraumatic stress disorder (PTSD) has been associated with neuropsychological impairments across multiple domains, but consensus regarding the cognitive profile of PTSD has not been reached. In this Study of women with PTSD related to intimate partner violence (n = 55) and healthy, demographically similar comparison participants (NCs; n = 20), we attempted to control for many potential Confounds in PTSD samples. All participants were assessed with a comprehensive neuropsychological battery emphasizing executive functioning, including inhibition, switching, and abstraction. NCs outperformed PTSD participants on most neuropsychological measures, but the differences were significant only on speeded tasks (with and without executive functioning, components). The PTSD group's mean performance was within the average range on all neuropsychological tests. Within the PTSD group, more severe PTSD symptoms were associated with slower processing speed, and more severe dissociative symptoms were associated with poorer reasoning performance. These results Suggest that women with PTSD related to intimate partner violence demonstrate slower than normal processing speed, which is associated with the severity of psychiatric symptoms. We speculate that the cognitive slowing seen in PTSD may be attributable to reduced attention due to a need to allocate resources to cope with psychological distress Or unpleasant internal experiences. (JINS, 2009, 15, 879-887.)	[Twamley, Elizabeth W.; Allard, Carolyn B.; Thorp, Steven R.; Norman, Sonya B.; Cissell, Shadha Hami; Grimes, Erin M.; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Twamley, Elizabeth W.; Thorp, Steven R.; Norman, Sonya B.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Twamley, Elizabeth W.; Allard, Carolyn B.; Norman, Sonya B.; Berardi, Kelly Hughes] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA; [Thorp, Steven R.; Cissell, Shadha Hami; Grimes, Erin M.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Stein, Murray B.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA		Twamley, EW (corresponding author), Univ Calif San Diego, Dept Psychiat, 140 Arbor Dr 0851, San Diego, CA 92103 USA.	etwamley@ucsd.edu	Allard, Carolyn B./B-3521-2013; Thorp, Steven/AAT-7321-2020	Allard, Carolyn B./0000-0002-7803-2243; 	Veterans Affairs (VA) Merit ReviewUS Department of Veterans Affairs	This research Was Supported by a grant from the Veterans Affairs (VA) Merit Review Program to Murray B. Stein. The authors have no conflicts of interest.	American Psychiatric Association, 1980, DIAGN STAT MAN MENT; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bremner JD, 2006, ANN NY ACAD SCI, V1071, P80, DOI 10.1196/annals.1364.008; Bremner JD, 2004, BIOL PSYCHIAT, V55, P612, DOI 10.1016/j.biopsych.2003.10.001; Breslau N, 2004, PSYCHOL MED, V34, P1205, DOI 10.1017/S0033291704002594; CARREY NJ, 1995, J AM ACAD CHILD PSY, V34, P1067, DOI 10.1097/00004583-199508000-00017; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Delis D.C., 2001, D KEFS EXAMINERS MAN; DePrince AP, 2004, PSYCHOL SCI, V15, P488, DOI 10.1111/j.0956-7976.2004.00706.x; DePrince AP, 1999, AM J CLIN HYPN, V41, P281, DOI 10.1080/00029157.1999.10404221; Evans DE, 2009, ADDICT BIOL, V14, P32, DOI 10.1111/j.1369-1600.2008.00130.x; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Freyd J. J., 1996, BETRAYAL TRAUMA LOGI; Freyd Jennifer J, 2005, J Trauma Dissociation, V6, P83, DOI 10.1300/J229v06n03_04; Freyd JJ, 1998, APPL COGNITIVE PSYCH, V12, pS91, DOI 10.1002/(SICI)1099-0720(199812)12:7<S91::AID-ACP599>3.0.CO;2-Z; GARCIA E, 2004, CAL PSYCH ASS ANN M; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Golier J, 2002, PSYCHIAT CLIN N AM, V25, P295, DOI 10.1016/S0193-953X(01)00004-1; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Heaton R., 2000, WISCONSIN CARD SORTI; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Marvel CL, 2004, PSYCHIAT CLIN N AM, V27, P19, DOI 10.1016/S0193-953X(03)00106-0; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; PEREZ CM, 1994, CHILD ABUSE NEGLECT, V18, P617, DOI 10.1016/0145-2134(94)90012-4; Rey A., 1964, ARCH PSYCHOL, V28, P215; Saigh PA, 1997, BEHAV RES THER, V35, P429, DOI 10.1016/S0005-7967(96)00111-8; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scott S., 2004, SEXUALITIES, V7, P233, DOI DOI 10.1177/1363460704042166; Seedat S, 2003, J NERV MENT DIS, V191, P115, DOI 10.1097/01.NMD.0000050940.16782.6B; Sheehan D.V., 1983, ANXIETY DIS; Shucard JL, 2008, BIOL PSYCHOL, V79, P223, DOI 10.1016/j.biopsycho.2008.05.005; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Stein MB, 1999, J TRAUMA STRESS, V12, P527, DOI 10.1023/A:1024775222098; Twamley EW, 2002, AM J PSYCHIAT, V159, P2013, DOI 10.1176/appi.ajp.159.12.2013; Twamley EW, 2004, PSYCHIAT RES, V126, P265, DOI 10.1016/j.psychres.2004.01.008; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Waller NG, 1996, PSYCHOL METHODS, V1, P300, DOI 10.1037/1082-989X.1.3.300; Weathers F.W., 1993, 9 ANN C ISTSS; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029	54	97	101	1	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2009	15	6					879	887		10.1017/S135561770999049X			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	523ZV	WOS:000272114500008	19703324				2022-02-06	
J	Lotocki, G; Vaccari, JPD; Perez, ER; Sanchez-Molano, J; Furones-Alonso, O; Bramlett, HM; Dietrich, WD				Lotocki, George; Vaccari, Juan Pablo de Rivero; Perez, Enrique R.; Sanchez-Molano, Juliana; Furones-Alonso, Ofelia; Bramlett, Helen M.; Dietrich, W. Dalton			Alterations in Blood-Brain Barrier Permeability to Large and Small Molecules and Leukocyte Accumulation after Traumatic Brain Injury: Effects of Post-Traumatic Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; CD68; hypothermia; leukocytes; traumatic brain injury	NERVOUS-SYSTEM INJURY; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; RATS; TEMPERATURE; DISRUPTION; DAMAGE; BREAKDOWN	We investigated the temporal and regional profile of blood-brain barrier (BBB) permeability to both large and small molecules after moderate fluid percussion (FP) brain injury in rats and determined the effects of post-traumatic modest hypothermia (33 degrees C/4h) on these vascular perturbations. The visible tracers biotin-dextrin-amine 3000 (BDA-3K, 3 kDa) and horseradish peroxidase (HRP, 44 kDa) were injected intravenously at 4 h or 3 or 7 days post-TBI. At 30 min after the tracer infusion, both small and large molecular weight tracers were detected in the contusion area as well as remote regions adjacent to the injury epicenter in both cortical and hippocampal structures. In areas adjacent to the contusion site, increased permeability to the small molecular weight tracer (BDA-3K) was evident at 4 h post-TBI and remained visible after 7 days survival. In contrast, the larger tracer molecule (HRP) appeared in these remote areas at acute permeable sites but was not detected at later post-traumatic time periods. A regionally specific relationship was documented at 3 days between the lateoccurring permeability changes observed with BDA-3K and the accumulation of CD68-positive macrophages. Mild hypothermia initiated 30 min after TBI reduced permeability to both large and small tracers and the infiltration of CD68-positive cells. These results indicate that moderate brain injury produces temperature-sensitive acute, as well as more long-lasting vascular perturbations associated with secondary injury mechanisms.	[Lotocki, George; Vaccari, Juan Pablo de Rivero; Perez, Enrique R.; Sanchez-Molano, Juliana; Furones-Alonso, Ofelia; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miami Project Cure Paralysis, Neurotrauma Res Ctr, Dept Neurol Surg,Miller Sch Med, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miami Project Cure Paralysis, Neurotrauma Res Ctr, Dept Neurol Surg,Miller Sch Med, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu		de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	This work was supported by NIH grants (nos. NS030291 and NS42133). We wish to thank Coleen Atkins for scientific discussions, Beata Frydel for helping with 3-D reconstructions, and Jeremy Lytle for editorial assistance in manuscript preparation.	Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hartl R, 1997, ACT NEUR S, V70, P240; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Kumar K, 1997, NEUROREPORT, V8, P947, DOI 10.1097/00001756-199703030-00026; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MORGANTIKOSSMAN.MC, 2005, BLOOD BRAIN BARRIER, P457; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Raivich G, 2004, BRAIN RES REV, V46, P261, DOI 10.1016/j.brainresrev.2004.06.006; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Tannock GW, 1992, LACTIC ACID BACTERIA, V1, P21; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZILLES L, 1985, CORTEX RAT STEREOTAX	43	97	98	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1123	1134		10.1089/neu.2008.0802			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500017	19558276	Green Published			2022-02-06	
J	Simpson, DM; Gracies, JM; Yablon, SA; Barbano, R; Brashear, A; Simpson, DM; Gracies, JM; Yablon, SA; Barbano, R; Brashear, A				Simpson, D. M.; Gracies, J. M.; Yablon, S. A.; Barbano, R.; Brashear, A.; Simpson, D. M.; Gracies, J. M.; Yablon, S. A.; Barbano, R.; Brashear, A.		BoNT TZD Study Team; BoNT TZD Study Team	Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TOXIN TYPE-A; DOUBLE-BLIND; INTRAMUSCULAR INJECTION; EFFICACY; SAFETY; DYSPORT(R)	Background: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared. Methods: This study performed a randomised, double-blind, placebo-controlled trial to compare injection of BoNT-Type A into spastic upper limb muscles versus oral tizanidine (TZD), or placebo, in 60 subjects with upper-limb spasticity due to stroke or traumatic brain injury (TBI). Wrist flexors were systematically injected, while other upper limb muscles were injected as per investigator judgement. Participants were randomised into three groups: (1) intramuscular BoNT plus oral placebo; (2) oral TZD plus intramuscular placebo; (3) intramuscular placebo plus oral placebo. The primary outcome was the difference in change in wrist flexor modified Ashworth score (MAS) between groups. Other outcome measures included MAS at elbow and finger joints, Disability Assessment Scale (DAS) and adverse events (AE). Results: BoNT produced greater tone reduction than TZD or placebo in finger and wrist flexors at week 3 (p<0.001 vs TZD; p<0.02 vs placebo) and 6 (p=0.001 vs TZD; p=0.08 vs placebo), and greater improvement in the cosmesis domain of the DAS at week 6 (p<0.01). TZD was not superior to placebo in tone reduction at either time point (p>0.09). The incidence of AE related to study treatment was higher with TZD than in the BoNT (p<0.01) or placebo groups (p=0.001). Conclusions: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper-extremity spasticity, and may be considered as first-line therapy for this disorder.	[Simpson, D. M.] Mt Sinai Med Ctr, Clin Neurophysiol Labs, Box 1052, New York, NY 10029 USA; [Gracies, J. M.] CHU Henri Mondor, F-94010 Creteil, France; [Yablon, S. A.] Univ Mississippi, Sch Med, Jackson, MS 39216 USA; [Barbano, R.] Univ Rochester, New York, NY USA; [Brashear, A.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Simpson, D. M.; Gracies, J. M.] Metropolitan Hosp Ctr, New York, NY 10029 USA; [Simpson, D. M.; Gracies, J. M.] Mt Sinai Sch Med, New York, NY USA; [Gracies, J. M.] CHU Henri Mondor, F-94010 Creteil, France; [Yablon, S. A.] Univ Mississippi, Sch Med, Jackson, MS 39216 USA; [Barbano, R.] Univ Rochester, New York, NY USA; [Brashear, A.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA		Simpson, DM (corresponding author), Mt Sinai Med Ctr, Clin Neurophysiol Labs, Box 1052, New York, NY 10029 USA.	david.simpson@mssm.edu; david.simpson@mssm.edu	Brashear, Allison/G-3853-2015		Allergan, Inc.AbbVieAllergan	DMS of Mount Sinai School of Medicine is the sponsor of the study. The study was funded by an unrestricted grant by Allergan, Inc. Allergan had no influence on the design, interpretation or reporting of the study.	Adler CH, 2000, NEUROLOGY, V55, pS9; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Brans JWM, 1996, NEUROLOGY, V46, P1066, DOI 10.1212/WNL.46.4.1066; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; CHILDERS M, 2002, BOTULINUM TOXIN TYPE, P77; Chin TYP, 2005, J PEDIATR ORTHOPED, V25, P286, DOI 10.1097/01.bpo.0000150819.72608.86; Gelber DA, 2001, STROKE, V32, P1841, DOI 10.1161/01.STR.32.8.1841; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; GRACIES JM, ARCH PHYS M IN PRESS; Gracies JM, 2002, HDB BOTULINUM TOXIN, P221; GRACIES JM, 1997, MUSCLE NERVE       S, V6, P61; Hyman N, 2000, J NEUROL NEUROSUR PS, V68, P707, DOI 10.1136/jnnp.68.6.707; MATHIAS C J, 1989, Journal of Rehabilitation Research and Development, V26, P9; Montane E, 2004, NEUROLOGY, V63, P1357; NANCE PW, 1994, NEUROLOGY, V44, P44; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Sheean G, 2006, DRUG SAFETY, V29, P31, DOI 10.2165/00002018-200629010-00003; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Smith SJ, 2000, CLIN REHABIL, V14, P5, DOI 10.1191/026921500666642221; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; VANDENBERGH A, 2007, ARCH PHYS MED REHAB, V88, pE104	23	97	103	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2009	80	4					380	385		10.1136/jnnp.2008.159657			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	419SB	WOS:000264238800008	18977811	Bronze			2022-02-06	
J	Fortuna, GR; Mueller, EW; James, LE; Shutter, LA; Butler, KL				Fortuna, Gerald R.; Mueller, Eric W.; James, Laura E.; Shutter, Lori A.; Butler, Karyn L.			The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in elderly patients with hemorrhagic brain injury	SURGERY			English	Article							TRAUMATIC INTRACRANIAL HEMORRHAGE; HEAD-INJURY; OLDER-ADULTS; MORTALITY; PROPHYLAXIS; RISK; AGE; THROMBOSIS; SAFETY	Background. More elderly trauma patients are identified with preinjury use of clopidogrel, aspirin, or warfarin (CAW). The purpose of this study was to determine whether preinjury CAW use was an important predictor of mortality in patients aged >= 50 years with blunt, hemorrhagic brain injury (HBI). Methods. A retrospective review of patients with blunt, HBI aged >= 50 years with subgroup analysis for older (> 70 years) and younger (50-70 years) patients was performed. CAW use was analyzed for differences in age, gender, hospital length of stay (LOS), Injury Severity Score (ISS), Glasgow Coma Score (GCS), mechanism of injury (MOI), platelet transfusion therapy (PLT), disposition at discharge, and in-hospital mortality. Results. From January 2003 to October 2005, 416 patients were identified. The mean age was 69 +/- 1 years. No differences were found for ISS (24 +/- 0.5), GCS (12 +/- 0.2), or LOS (8 +/- 0.4 days). CAW use was present in 40% of patients and significantly higher in older patients. Mortality was not different between older and younger CAW(+) patients, but it significantly increased for older CAW(-) patients. Significant predictors of death included age, ISS, and GCS (P < .02). Conclusions. Preinjury CAW use in older blunt, HBI patients is not associated with increased mortality. Age was a significant predictor of mortality independent of CAW use.	[Fortuna, Gerald R.; James, Laura E.; Butler, Karyn L.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; [Mueller, Eric W.] Univ Cincinnati, Dept Pharm Serv, Univ Hosp, Div Pharm Practice, Cincinnati, OH USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA; [Butler, Karyn L.] Univ Cincinnati, Div Trauma Crit Care, Cincinnati, OH USA		Butler, KL (corresponding author), Hartford Hosp, 80 Seymour St, Hartford, CT 06102 USA.	kbutler@harthosp.org	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dellinger AM, 2006, J SAFETY RES, V37, P519, DOI 10.1016/j.jsr.2006.10.001; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; Hsiao G, 2005, ARTERIOSCL THROM VAS, V25, P1998, DOI 10.1161/01.ATV.0000174798.25085.d6; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; MATTOX KL, 2000, TRAUMA; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Morales D, 2006, J NEUROTRAUM, V23, P976, DOI 10.1089/neu.2006.23.976; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055	20	97	98	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2008	144	4					598	605		10.1016/j.surg.2008.06.009			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	356AL	WOS:000259751000016	18847644				2022-02-06	
J	Salim, A; Hadjizacharia, P; DuBose, J; Brown, C; Inaba, K; Chan, L; Margulies, DR				Salim, Ali; Hadjizacharia, Pantelis; DuBose, Joseph; Brown, Carlos; Inaba, Kenji; Chan, Linda; Margulies, Daniel R.			Role of anemia in traumatic brain injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; BLOOD-TRANSFUSION; SUBARACHNOID HEMORRHAGE; OXYGEN CARRIER; HEMOGLOBIN; RESUSCITATION; MANAGEMENT; MORTALITY	BACKGROUND: Few studies have investigated the effects of anemia in patients with traumatic brain injury (TBI). The objective of this study was to examine the role of anemia and blood transfusion on outcomes in TBI patients. STUDY DESIGN: We performed a retrospective review of all blunt trauma patients with TBI admitted to the ICU from July 1998 to December 2005. Admission and daily ICU blood hemoglobin (hemoglobin) levels and blood transfusions during the first week of hospitalization were measured. Anemia was defined as a hemoglobin < 9 g/dL occurring on 3 consecutive blood draws. The role of anemia and blood transfusion was investigated using logistic regression adjusting for factors, with p < 0.2 from the bivariate analysis. RESULTS: During the study period, 1, 150 TBI patients were admitted to the ICU. When both anemia and blood transfusion were included in the full model, blood transfusion was significantly associated with higher mortality (adjusted odds ratio [AOR], 2.19 [95% CI, 1.27, 3.751; p = 0.0044) and more complications (AOR, 3.67 [95% CI, 2.18, 6.171; p < 0.0001), but anemia was not. But when transfusion was not included in the full model, anemia was a significant risk factor for mortality (AOR, 1.59 (95% CI, 1.13, 2.24); p = 0.007) and for complications (AOR, 1.95 [95% CI, 1.42, 2.70]; p < 0.0001). CONCLUSIONS: Blood transfusion is associated with significantly worse outcomes in traumatic brain injured patients. Inaddition, blood transfusion is a major contributing factor to worse outcomes in TBI patients who are anemic. We caution against the liberal use of blood in TBI patients.	[Salim, Ali; Margulies, Daniel R.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hadjizacharia, Pantelis; DuBose, Joseph; Inaba, Kenji; Chan, Linda] Univ So Calif, Med Ctr, Los Angeles, CA USA; [Hadjizacharia, Pantelis; DuBose, Joseph; Inaba, Kenji; Chan, Linda] Div Trauma, Los Angeles, CA USA; [Brown, Carlos] Brackenridge Hosp, Div Trauma, Austin, TX USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Ste 8215N, Los Angeles, CA 90048 USA.						Berezina TL, 2002, J SURG RES, V102, P6, DOI 10.1006/jsre.2001.6306; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; Ely EW, 1999, NEW ENGL J MED, V340, P467, DOI 10.1056/NEJM199902113400610; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Herbert PC, 2001, CRIT CARE MED, V29, P227; JAIN R, 1992, MED CLIN N AM, V76, P727, DOI 10.1016/S0025-7125(16)30350-9; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Kuriyan M, 2004, CRIT CARE CLIN, V20, P237, DOI 10.1016/j.ccc.2003.12.001; Lane P, 2002, NAT MED, V8, P657, DOI 10.1038/nm0702-657; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; McCrossan L, 2002, BRIT J ANAESTH, V88, P6, DOI 10.1093/bja/88.1.6; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Shackford SR, 2005, J TRAUMA, V59, P560; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	26	97	99	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	2008	207	3					398	406		10.1016/j.jamcollsurg.2008.03.013			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	349FD	WOS:000259265800014	18722946				2022-02-06	
J	Fleminger, S				Fleminger, S.			Long-term psychiatric disorders after traumatic brain injury	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			brain injury; psychosis; trauma; depression; long-term effects	HEAD-INJURY; RISK-FACTOR; FOLLOW-UP; ALZHEIMERS-DISEASE; PROSPECTIVE COHORT; STRESS-DISORDER; EARLY ADULTHOOD; YOUNG-PEOPLE; AXIS-I; SCHIZOPHRENIA	In the long term after traumatic brain injury, the most disabling problems are generally related to neuropsychiatric sequelae, including personality change and cognitive impairment, rather than neurophysical sequelae. Cognitive impairment after severe injury is likely to include impaired speed of information processing, poor memory and executive problems. Personality change may include poor motivation, and a tendency to be self-centred and less aware of the needs of others. Patients may be described as lazy and thoughtless. Some become disinhibited and rude. Agitation and aggression can be very difficult to manage. Anxiety and depression symptoms are quite frequent and play a role in the development of persistent post-concussion syndrome after milder injury. Depression may be associated with a deterioration in disability over time after injury. Psychosis is not unusual though it has been difficult to confirm that traumatic brain injury is a cause of schizophrenia. Head injury may, many years later, increase the risk of Alzheimer's disease. Good rehabilitation probably minimizes the risk of psychiatric sequelae, but specific psychological and pharmacological treatments may be needed.	Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England		Fleminger, S (corresponding author), Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	s.fleminger@iop.kcl.ac.uk					Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLUMER D, 1978, PSYCHIAT ASPECTS NEU, P151; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Butler PV, 2000, AUST NZ J PSYCHIAT, V34, P684, DOI 10.1080/j.1440-1614.2000.00758.x; Cassidy John W., 1994, P43; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; Deb S, 1999, AM J PSYCHIAT, V156, P374; Eames P, 2003, NEUROPSYCHOL REHABIL, V13, P241, DOI 10.1080/09602010244000435; Feuchtwanger E., 1923, FUNKTIONEN STIRNHIRN; Fleminger S, 2003, BMJ-BRIT MED J, V327, P4, DOI 10.1136/bmj.327.7405.4; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; FLEMINGER S, 2006, COCHRANE DB SYST REV, V4; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Morris Paul Graham, 2005, BMC Fam Pract, V6, P30, DOI 10.1186/1471-2296-6-30; Mortensen PB, 2003, J AFFECT DISORDERS, V76, P79, DOI 10.1016/S0165-0327(02)00073-3; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; PILOSWKY L, 1982, BRIT J PSYCHIAT, V147, P310; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Silver JM, 2005, TXB TRAUMATIC BRAIN, P259; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P131, DOI 10.1136/jnnp.4.2.131; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	51	97	97	2	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			123	130		10.1017/S0265021507003250			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Anesthesiology	283AY	WOS:000254610100021	18289429				2022-02-06	
J	Stulemeijer, M; Vos, PE; Bleijenberg, G; van der Werf, SP				Stulemeijer, Maja; Vos, Pieter E.; Bleijenberg, Gijs; van der Werf, Sieberen P.			Cognitive complaints after mild traumatic brain injury: Things are not always what they seem	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						brain injuries; outcome assessment; cognitive functioning; distress; personality; fatigue	CHRONIC-FATIGUE-SYNDROME; POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; SELF-REPORT; NEUROPSYCHOLOGICAL DEFICITS; MEMORY COMPLAINTS; SOCIAL INHIBITION; MAJOR DEPRESSION; TEST-SCORES; PERFORMANCE	Objective: To compare nonreferred, emergency department (ED)-admitted mild traumatic brain injury (MTBI) patients with and without self-reported cognitive complaints on (1) demographic variables and injury characteristics; (2) neuropsychological test performance; (3) 12-day self-monitoring of perceived cognitive problems; and (4) emotional distress, physical functioning, and personality. Methods: (Neuro)psychological assessment was carried out 6 months post-injury in 79 patients out of a cohort of 618 consecutive MTBI patients aged 18-60, who attended the ED of our level I trauma centre. Cognitive complaints were assessed with the Rivermead Postconcussional Symptoms Questionnaire (RPSQ). In addition, patients monitored concentration problems and forgetfulness during 12 consecutive days. Results: Self-reported cognitive complaints were reported by 39% of the patients. These complaints were strongly related to lower educational levels, emotional distress, personality, and poorer physical functioning (especially fatigue) but not to injury characteristics. Severity of self-reported cognitive complaints was neither associated with the patients' daily observations of cognitive problems nor with outcome on a range of neuropsychological tests. Conclusion: Self-reported cognitive complaints were more strongly related to premorbid traits and physical and emotional state factors than to actual cognitive impairments. In line with previous work, this suggests that treatment of emotional distress and fatigue may also reduce cognitive complaints. Cognitive outcome assessment of symptomatic MTBI patients should not be restricted to checklist ratings only, but also include a (neuro) psychological screening. In addition, daily monitoring of complaints is a useful method to gather information about the frequency and pattern of cognitive problems in daily life. (c) 2007 Elsevier Inc. All rights reserved.	[Stulemeijer, Maja; van der Werf, Sieberen P.] Radboud Univ Nijmegen Med Ctr, Dept Med Psychol, Nijmegen, Netherlands; [Vos, Pieter E.] Radboud Univ Nijmegen Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Bleijenberg, Gijs] Radboud Univ Nijmegen Med Ctr, Expert Ctr Chron Fatigue, Nijmegen, Netherlands		Vos, PE (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Bleijenberg, Gijs/E-6984-2010				Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Antikainen R, 2001, EUR ARCH PSY CLIN N, V251, P6, DOI 10.1007/s004060170060; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carter SL, 2003, NEUROPSYCHOLOGY, V17, P410, DOI 10.1037/0894-4105.17.3.410; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; DEGORATIS LR, 1994, SCL90 SYNPTOM CHECKL; Delis DC, 1987, CALIFORNIA VERBAL LE; Denollet J, 2006, EUR HEART J, V27, P171, DOI 10.1093/eurheartj/ehi616; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Elixhauser A, 1999, EPILEPSY RES, V37, P13, DOI 10.1016/S0920-1211(99)00036-4; Gallo LC, 2005, J BEHAV MED, V28, P433, DOI 10.1007/s10865-005-9010-y; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; HANNINEN T, 1994, J AM GERIATR SOC, V42, P1; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kliegel MK, 2005, INT PSYCHOGERIATR, V17, P499, DOI 10.1017/S1041610205001638; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McHugh T, 2006, BRAIN COGNITION, V60, P209; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Prouteau A, 2004, SCHIZOPHR RES, V69, P85, DOI 10.1016/j.schres.2003.08.011; RABBITT P, 1990, BRIT J PSYCHOL, V81, P1, DOI 10.1111/j.2044-8295.1990.tb02342.x; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; SANDERMAN R, 1995, HET METEN PERSOONLIJ; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; Servaes P, 2002, CANCER-AM CANCER SOC, V95, P2017, DOI 10.1002/cncr.10891; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Thiele C, 2002, CLIN PSYCHOL PSYCHOT, V9, P1; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Werf SP, 2002, NEUROPSY NEUROPSY BE, V15, P2; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zimmermann P., 1996, TESTBATTERIJ AANDACH	67	97	97	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	DEC	2007	63	6					637	645		10.1016/j.jpsychores.2007.06.023			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	240XY	WOS:000251622700011	18061755				2022-02-06	
J	Son, AHPWV; Ribbers, GM; Verhagen, AP; Stam, HJ				Son, Agnes H. P. Willemse-van; Ribbers, Gerard M.; Verhagen, Arianne P.; Stam, Henk J.			Prognostic factors of long-term functioning and productivity after traumatic brain injury: a systematic review of prospective cohort studies	CLINICAL REHABILITATION			English	Article							MODERATE HEAD-INJURY; MULTICENTER ANALYSIS; ACUTE PREDICTORS; INDEPENDENCE MEASURE; EVOKED-POTENTIALS; EMPLOYMENT; OUTCOMES; RETURN; VIOLENCE; MOTOR	Objective: To systematically review prospective cohort studies that investigated prognostic factors associated with long-term activity limitations or participation restrictions and productivity after a traumatic brain injury. Data sources: PubMed and Psychinfo were searched from 1995 to April 2005, and references were checked. Review methods: Publications were selected if the study assessed prognostic factors for activity limitations or participation restrictions at least one year post injury; outcome was measured with another or additional measure besides the Glasgow Outcome Scale; the design was a prospective cohort study of adult traumatic brain injury patients; the article was a full-text article written in English, French, German or Dutch. Two reviewers independently assessed methodological quality. A study was considered as 'high quality' if it satisfied at least half of the maximum available quality score. Results: Thirty-five articles reporting on 14 cohorts were included. Due to heterogeneity in prognostic factors and outcome measures, a best-evidence synthesis was performed. All cohorts were of high quality. Strong evidence for predicting disability was found for older age, pre-injury unemployment, pre-injury substance abuse, and more disability at rehabilitation discharge. Strong prognostic factors for being non-productive were pre-injury unemployment, longer post-traumatic amnesia, more disability at rehabilitation admission, and pre-injury substance abuse. Conclusion: Older age, pre-injury unemployment, pre-injury substance abuse and more disability at rehabilitation discharge are important predictors of long-term disability. Pre-injury unemployment, longer post-traumatic amnesia, more disability at rehabilitation admission and pre-injury substance abuse are important predictors of being non-productive.	[Son, Agnes H. P. Willemse-van; Ribbers, Gerard M.; Stam, Henk J.] Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; [Ribbers, Gerard M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Verhagen, Arianne P.] Erasmus MC, Dept Gen Practice, Rotterdam, Netherlands		Son, AHPWV (corresponding author), Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanson-willemse@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; Verhagen, Arianne/0000-0002-6195-0128			Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224; Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; [Anonymous], 2006, ACTA NEUROCHIR WIEN, V148, P255; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Scholten-Peeters GGM, 2003, PAIN, V104, P303, DOI 10.1016/S0304-3959(03)00050-2; Sherer M, 1999, BRAIN INJURY, V13, P973; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stemmer B, 2000, BRAIN COGNITION, V44, P25; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHO, 2002, INT CLASS FUNCT DIS; Woischneck D, 1997, NEUROL RES, V19, P305, DOI 10.1080/01616412.1997.11740817	49	97	98	0	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	NOV	2007	21	11					1024	1037		10.1177/0269215507077603			14	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	240EW	WOS:000251571000006	17984154				2022-02-06	
J	Cavanaugh, JT; Mercer, VS; Stergiou, N				Cavanaugh, James T.; Mercer, Vicki S.; Stergiou, Nicholas			Approximate entropy detects the effect of a secondary cognitive task on postural control in healthy young adults: a methodological report	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							DUAL-TASK; CEREBRAL CONCUSSION; OLDER-ADULTS; ATTENTION; BALANCE; INTERFERENCE; PERFORMANCE; DISORDER; POSTUROGRAPHY; STABILITY	Background: Biomechanical measures of postural stability, while generally useful in neuroscience and physical rehabilitation research, may be limited in their ability to detect more subtle influences of attention on postural control. Approximate entropy (ApEn), a regularity statistic from nonlinear dynamics, recently has demonstrated relatively good measurement precision and shown promise for detecting subtle change in postural control after cerebral concussion. Our purpose was to further explore the responsiveness of ApEn by using it to evaluate the immediate, short-term effect of secondary cognitive task performance on postural control in healthy, young adults. Methods: Thirty healthy, young adults performed a modified version of the Sensory Organization Test featuring single (posture only) and dual (posture plus cognitive) task trials. ApEn values, root mean square (RMS) displacement, and equilibrium scores (ES) were calculated from anterior-posterior (AP) and medial-lateral (ML) center of pressure (COP) component time series. For each sensory condition, we compared the ability of the postural control parameters to detect an effect of cognitive task performance. Results: COP AP time series generally became more random (higher ApEn value) during dual task performance, resulting in a main effect of cognitive task (p = 0.004). In contrast, there was no significant effect of cognitive task for ApEn values of COP ML time series, RMS displacement (AP or ML) or ES. Conclusion: During dual task performance, ApEn revealed a change in the randomness of COP oscillations that occurred in a variety of sensory conditions, independent of changes in the amplitude of COP oscillations. The finding expands current support for the potential of ApEn to detect subtle changes in postural control. Implications for future studies of attention in neuroscience and physical rehabilitation are discussed.	[Cavanaugh, James T.] Univ New England, Dept Phys Therapy, Portland, ME 04103 USA; [Mercer, Vicki S.] Univ N Carolina, Dept Allied Hlth Sci, Chapel Hill, NC USA; [Stergiou, Nicholas] Univ Nebraska, HPER Biomechan Lab, Omaha, NE 68182 USA		Cavanaugh, JT (corresponding author), Univ New England, Dept Phys Therapy, Portland, ME 04103 USA.	jcavanaugh@une.edu; vmercer@med.unc.edu; nstergiou@mail.unomaha.edu	Mercer, Vicki/AAN-6669-2021	Cavanaugh, James/0000-0001-7132-6313			Allain H, 2003, PSYCHOPHARMACOLOGY, V165, P419, DOI 10.1007/s00213-002-1272-2; Andersson G, 1998, AM J OTOL, V19, P632; Barin K, 1997, Biomed Sci Instrum, V33, P388; Buatois S, 2006, GERONTOLOGY, V52, P345, DOI 10.1159/000094983; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cavanaugh JT, 2004, GAIT POSTURE S1, V20, pS55; Dault MC, 2003, COGNITIVE BRAIN RES, V16, P434, DOI 10.1016/S0926-6410(03)00058-2; Davids K, 2003, SPORTS MED, V33, P245, DOI 10.2165/00007256-200333040-00001; Di Nardo W, 1999, J DIABETES COMPLICAT, V13, P79, DOI 10.1016/S1056-8727(99)00032-X; GRASSBERGER P, 1983, PHYSICA D, V9, P189, DOI 10.1016/0167-2789(83)90298-1; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, ORTHOP PHYS THER CLI, V11, P143; Harbourne RT, 2003, DEV PSYCHOBIOL, V42, P368, DOI 10.1002/dev.10110; Hatta T, 2004, APPL NEUROPSYCHOL, V11, P153, DOI 10.1207/s15324826an1103_3; Huxhold O, 2006, BRAIN RES BULL, V69, P294, DOI 10.1016/j.brainresbull.2006.01.002; Hyndman D, 2006, DISABIL REHABIL, V28, P849, DOI 10.1080/09638280500534994; Lajoie Y, 2004, AGING CLIN EXP RES, V16, P363; Lee D.N., 1975, J HUM MOVEMENT STUD, V1, P87; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mitra S, 2004, J EXP PSYCHOL HUMAN, V30, P28, DOI 10.1037/0096-1523.30.1.28; *NEUR INT INC, 1991, NEUROCOM EQ SYST DAT; Newell K., 1998, APPL NONLINEAR DYNAM, P80; Nyberg L, 2006, CYBERPSYCHOL BEHAV, V9, P388, DOI 10.1089/cpb.2006.9.388; Perez N, 2006, EUR ARCH OTO-RHINO-L, V263, P414, DOI 10.1007/s00405-005-1027-x; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Quant S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-18; Redfern MS, 2001, GAIT POSTURE, V14, P211, DOI 10.1016/S0966-6362(01)00144-8; Roerdink M, 2006, EXP BRAIN RES, V174, P256, DOI 10.1007/s00221-006-0441-7; Schiff Steven J., 1994, Integrative Physiological and Behavioral Science, V29, P246, DOI 10.1007/BF02691329; Schneider M, 2006, EUR ARCH PSY CLIN N, V256, P32, DOI 10.1007/s00406-006-1005-3; SHUMWAYCOOK A, 2000, BIOL SCI MED SCI, V55, pM10; SHUMWAYCOOK A, 1997, BIOL SCI MED SCI, V52, pM232; Stergiou N, 2004, INNOVATIVE ANAL HUMA, P63; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stoffregen TA, 1999, J EXP PSYCHOL HUMAN, V25, P1641; TEASDALE N, 1993, EXP AGING RES, V19, P1, DOI 10.1080/03610739308253919; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Theiler J, 1996, ELECTROEN CLIN NEURO, V98, P213, DOI 10.1016/0013-4694(95)00240-5; Vaillancourt DE, 2000, CLIN NEUROPHYSIOL, V111, P2046, DOI 10.1016/S1388-2457(00)00467-3; Vuillerme N, 2000, NEUROSCI LETT, V291, P77, DOI 10.1016/S0304-3940(00)01374-4; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4; Yardley L, 1999, NEUROREPORT, V10, P215, DOI 10.1097/00001756-199902050-00003; Yardley L, 2001, J NEUROL NEUROSUR PS, V71, P48, DOI 10.1136/jnnp.71.1.48	46	97	98	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	OCT 30	2007	4								42	10.1186/1743-0003-4-42			7	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology; Rehabilitation	251YD	WOS:000252411100001	17971209	Green Published, gold			2022-02-06	
J	Boden, BP; Tacchetti, RL; Cantu, RC; Knowles, SB; Mueller, FO				Boden, Barry P.; Tacchetti, Robin L.; Cantu, Robert C.; Knowles, Sarah B.; Mueller, Frederick O.			Catastrophic head injuries in high school and college football players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						football; subdural hematoma; severe head injury	ACUTE SUBDURAL-HEMATOMA; BRAIN-INJURY; AMERICAN FOOTBALL; CONCUSSION	Background: Catastrophic head injuries in football are rare but tragic events. Purpose: To update the profile of catastrophic head injuries in high school and college football players and to describe relevant risk factors. Study Design: Case series; Level of evidence, 4. Methods: We reviewed 94 incidents of severe football head injuries reported to the National Center for Catastrophic Sports Injury Research during 13 academic years (September 1989 through June 2002). Results: In the study period there were an average of 7.23 (standard deviation = 2.05) direct high school and college catastrophic head injuries in scholastic football participants per year. There were 0.67 injuries per 100 000 (95% confidence interval: 0.54, 0.81 per 100 000) high school and 0.21 injuries per 100 000 (95% confidence interval: 0.0, 0.49 per 100 000) college participants for a risk ratio of 3.28 (95% confidence interval: 0.81, 13.3). The injuries resulted in subdural hematoma in 75 athletes, subdural hematoma with diffuse brain edema in 10 athletes, diffuse brain edema in 5 athletes, and arteriovenous malformation or aneurysm in 4 athletes. Fifty-nine percent of the contacts reported that the athlete had a history of a previous head injury, of which 71% occurred within the same season as the catastrophic event. Thirty-nine percent of the athletes (21 of 54) were playing with residual neurologic symptoms from the prior head injury. There were 8 (9%) deaths as a result of the injury, 46 (51%) permanent neurologic injuries, and 36 (40%) serious injuries with full recovery. Most players sustained a major impact to the head either from tackling or being tackled. Conclusion: The incidence of catastrophic head injuries in football has remained low since the advent of the modern day football helmet in the early 1970s. The incidence of catastrophic head injuries in football is dramatically higher at the high school level than at the college level. Although the reason for this discrepancy is unclear, an unacceptably high percentage of high school players were playing with residual symptoms from a prior head injury. Coaches, athletes, athletic trainers, and medical personnel need to adhere to the guideline that an athlete with any neurologic symptoms from a head injury should be strongly discouraged from returning to play.	Orthopaed Ctr, Med Ctr 9711, Rockville, MD 20850 USA; Emerson Hosp, Concord, MA USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA		Boden, BP (corresponding author), Orthopaed Ctr, Med Ctr 9711, Dr 201, Rockville, MD 20850 USA.	bboden@starpower.net					Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kersey RD, 1998, J ATHL TRAINING, V33, P264; Logan SM, 2001, J ATHL TRAINING, V36, P433; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; Mueller FO, 1996, CATASTROPHIC INJURIE, P1; *NAT FED STAT HIGH, 2002, PART SURV; *NCCSIR, 2005, NCCSIR 12 ANN REP; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	20	97	97	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2007	35	7					1075	1081		10.1177/0363546507299239			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	186XZ	WOS:000247813200005	17351124				2022-02-06	
J	Sonmez, U; Sonmez, A; Erbil, G; Tekmen, I; Baykara, B				Sonmez, Ulker; Sonmez, Atac; Erbil, Guven; Tekmen, Isil; Baykara, Basak			Neuroprotective effects of resveratrol against traumatic brain injury in immature rats	NEUROSCIENCE LETTERS			English	Article						immature rats; resveratrol; traumatic brain injury; hippocampus; cognition	CEREBRAL-ISCHEMIA; WINE; MECHANISMS; PROTECTS; CHILDREN; MEMORY; DAMAGE; DEFICITS	Childhood trauma resulting in traumatic brain injury (TBI) due to accidents and abuse is the major cause of death and dysfunction in the young. Since there are no approved specific pharmacological agents that block the progression of the secondary injury, the current management of TBI is mainly supportive. We aimed to determine the effect of resveratrol on hippocampal damage and behavioral deficits in 7-day-old rat pups subjected to contusion injury. Resveratrol was injected intraperitoneally at the doses of 100 mg/kg of body weight immediately after induction of traumatic injury. Hippocampal damage was examined by cresyl violet staining and behavioral alterations were evaluated using open field and novel object recognition tests 2 weeks after trauma. Histopathological evaluation showed that treatment with a single dose of 100 mg/kg resveratrol (i.p.) after the trauma significantly ameliorated the trauma induced hippocampal neuron loss at ipsilateral and contralateral hippocampal brain regions of rats. Additionally, treatment with resveratrol decreased anxiety and increased cortex/hippocampus dependent memory of animals subjected to blunt head trauma. These results show that acute treatment of resveratrol has a neuroprotective role against trauma induced hippocampal neuron loss and associated cognitive impairment in rats. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Dokuz Eylul Univ, Sch Med, Learning Resources Ctr, Res Lab, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Histol & Embryol, TR-35340 Izmir, Turkey		Sonmez, A (corresponding author), Dokuz Eylul Univ, Sch Med, Learning Resources Ctr, Res Lab, TR-35340 Izmir, Turkey.	atac.sonmez@deu.edu.tr	TEKMEN, ISIL/Q-2685-2019; Baykara, Basak/AAC-6504-2019; erbil, guven/ABB-6661-2021	TEKMEN, ISIL/0000-0003-0521-2654; Baykara, Basak/0000-0002-4178-2235; 			Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blalock EM, 2003, J NEUROSCI, V23, P3807; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock R, 2002, J NEUROTRAUM, V17, P449; Chen RS, 2002, J AGR FOOD CHEM, V50, P1665, DOI 10.1021/jf011134e; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kontinen VK, 1999, PAIN, V80, P341, DOI 10.1016/S0304-3959(98)00230-9; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Virgili M, 2000, NEUROSCI LETT, V281, P123, DOI 10.1016/S0304-3940(00)00820-X; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x	32	97	102	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 13	2007	420	2					133	137		10.1016/j.neulet.2007.04.070			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	180ZC	WOS:000247405500008	17531385				2022-02-06	
J	Lew, HL; Jerger, JF; Guillory, SB; Henry, JA				Lew, Henry L.; Jerger, James F.; Guillory, Sylvia B.; Henry, James A.			Auditory dysfunction in traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory dysfunction; blast-related injury; hearing loss; non-blast-related injury; OIF; rehabilitation; sensorineural hearing loss; TBI; tinnitus; traumatic brain injury	BLAST INJURIES; EAR; LONDON; BOMB; CARE; NEED	Effective communication is essential for successful rehabilitation, especially in patients with traumatic brain injury (TBI). The authors examined the prevalence and characteristics of auditory dysfunction in patients with TBI who were admitted to a Department of Veterans Affairs TBI inpatient unit before and after the onset of Operation Iraqi Freedom (OIF). In order to delineate the characteristics of the auditory manifestations of patients who had sustained blast-related (BR) TBI, we reviewed the medical records of 252 patients with TBI and categorized them according to admission date, either before (Group I, n = 102) or after (Group II, n = 150) the onset of OIF. We subdivided Group 11 into non-blast-related (NBR) and BR TBI; no subjects in Group I had BR TBI. We found that admissions for TBI have increased 47% since the onset of OIF. In Group I, 28% of patients with TBI complained of hearing loss and 11% reported tinnitus. In Group II-NBR (n = 108), 44% complained of hearing loss and 18% reported tinnitus. In Group II-BR (n = 42), 62% complained of hearing loss and 38% reported tinnitus. Sensorineural loss was the most prevalent type of hearing loss in Group II-BR patients. In light of the high prevalence of hearing loss and tinnitus in this growing population of returning soldiers, we need to develop and implement strategies for diagnosis and management of these conditions.	[Lew, Henry L.; Guillory, Sylvia B.] Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA; [Lew, Henry L.] Stanford Univ, Sch Med, Div Phys Med & Rehabil, Stanford, CA 94305 USA; [Jerger, James F.] Univ Texas Dallas, Sch Behav & Brain Sci, Dallas, TX 75230 USA; [Henry, James A.] VA Med Ctr, Natl Ctr Rehabil Auditory Res, VA Rehabil Res & Dev, Portland, OR USA; [Henry, James A.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA		Lew, HL (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA.	henrylew@stanford.edu					Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; BRUINS WR, 1991, J LARYNGOL OTOL, V105, P890, DOI 10.1017/S002221510011775X; *CDCP, 2003, CDC INJ PREV EXPL BL; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Davis PB, 2007, EAR HEARING, V28, P242, DOI 10.1097/AUD.0b013e3180312619; Dobie R. A. J. B., 2004, TINNITUS THEORY MANA, p1 7; Durch, 2006, NOISE MILITARY SERVI; *DVBIC, 2005, DEF VET BRAIN INJ FA; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Fausti SA, 2005, J REHABIL RES DEV, V42, P45, DOI 10.1682/JRRD.2005.02.0039; GARTH RJN, 1995, INJURY, V26, P363, DOI 10.1016/0020-1383(95)00042-8; Henry J, 1998, TINNITUS TREATMENT R, P99; Henry J., 2007, TINNITUS RETRAINING; Henry J. A. J. B., 2004, TINNITUS THEORY MANA, P220; Henry JA, 2005, J REHABIL RES DEV, V42, P95, DOI 10.1682/JRRD.2005.01.0005; HENRY JA, 2004, TINNITUS THEORY MANA, P337; Henry James A, 2005, Am J Audiol, V14, P49, DOI 10.1044/1059-0889(2005/005); Henry JA, 2006, J AM ACAD AUDIOL, V17, P104, DOI 10.3766/jaaa.17.2.4; Henry James A, 2005, Am J Audiol, V14, P21, DOI 10.1044/1059-0889(2005/004); Jastreboff P., 1998, TINNITUS TREATMENT R, V1, P201; Jastreboff PJ, 2004, TINNITUS RETRAINING; KERR AG, 1978, PRACTITIONER, V221, P677; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2004, AM J PHYS MED REHAB, V83, P210, DOI 10.1097/01.PHM.0000113402.85460.59; Martin F.N., 1986, INTRO AUDIOLOGY; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Newman C W, 1998, J Am Acad Audiol, V9, P153; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Persaud R, 2003, CLIN OTOLARYNGOL, V28, P203, DOI 10.1046/j.1365-2273.2003.00688.x; ROTH Y, 1989, Harefuah, V117, P297; Schechter Martin A, 2002, J Am Acad Audiol, V13, P545; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Singh D, 1968, J Laryngol Otol, V82, P1017, DOI 10.1017/S0022215100069802; TETER DL, 1970, LARYNGOSCOPE, V80, P1122, DOI 10.1288/00005537-197007000-00010; Tyler R.S., 2000, TINNITUS HDB, P1; Tyler RS, 2006, TINNITUS TREATMENT C; Van Campen L E, 1999, J Am Acad Audiol, V10, P231; Vernon J., 2000, TINNITUS HDB, P313; WALSH RM, 1995, J ACCID EMERG MED, V12, P194; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilson PH, 2001, PSYCHOL MANAGEMENT C; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YETISER S, 1993, MIL MED, V158, P803, DOI 10.1093/milmed/158.12.803; ZIV M, 1973, MIL MED, V138, P811, DOI 10.1093/milmed/138.12.811	46	97	104	0	11	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					921	927		10.1682/JRRD.2007.09.0140			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	253NL	WOS:000252524800005	18075949				2022-02-06	
J	Bazarian, JJ; Zemlan, FP; Mookerjee, S; Stigbrand, T				Bazarian, Jeffrey J.; Zemlan, Frank P.; Mookerjee, Sohug; Stigbrand, Torgney			Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury	BRAIN INJURY			English	Article						mild traumatic brain injury; S-100B; cleaved-tau; outcome	MINOR HEAD-INJURY; DIFFUSE AXONAL INJURY; PROTEIN MEASUREMENTS; CEREBROSPINAL-FLUID; NEURONAL DAMAGE; POSSIBLE MARKER; FOLLOW-UP; BLOOD; SYMPTOMS; QUANTIFICATION	Primary objective: To determine the relationship of serum S-100B and C-tau levels to long-term outcome after mild traumatic brain injury (mild TBI). Research design: A prospective study of 35 mild TBI subjects presenting to the emergency department. Methods and procedures: Six hour serum S-100B and C-tau levels compared to 3-month Rivermead Post Concussion Questionnaire (RPCQ) scores and post- concussive syndrome (PCS). Main outcomes and results: The linear correlation between marker levels and RPCQ scores was weak (S-100B: r = 0.071, C-tau: r = -0.21). There was no statistically significant correlation between marker levels and 3-month PCS (S-100B: AUC = 0.589, 95% CI. 038, 0.80; C-tau: AUC = 0.634, 95% CI 0.43, 0.84). The sensitivity of these markers ranged from 43.8-56.3% and the specificity from 35.7-71.4%. Conclusions: Initial serum S-100B and C-tau levels appear to be poor predictors of 3-month outcome after mild TBI.	Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY 14472 USA; Univ Cincinnati, Sch Med, Dept Psychiat, Cincinnati, OH USA; Umea Univ, Dept Immunol, Umea, Sweden		Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14472 USA.	jeff_bazarian@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS41952-04] Funding Source: Medline		Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Berger Rachel, 2003, Pediatr Crit Care Med, V4, P391, DOI 10.1097/01.PCC.0000075324.45784.8A; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mao Q, 1995, Hua Xi Yi Ke Da Xue Xue Bao, V26, P135; Marchi N, 2003, J NEUROSCI, V23, P1949; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; Mussack T, 2000, ACT NEUR S, V76, P393; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	52	97	101	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					759	765		10.1080/02699050500488207			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200010	16809208				2022-02-06	
J	Ke, Y; Chi, LY; Xu, RS; Luo, C; Gozal, D; Liu, RG				Ke, Yan; Chi, Liying; Xu, Renshi; Luo, Chun; Gozal, David; Liu, Rugao			Early response of endogenous adult neural progenitor cells to acute spinal cord injury in mice	STEM CELLS			English	Article						neural progenitor cells; neurogenesis; spinal cord injury; nestin; radial glia	CENTRAL-NERVOUS-SYSTEM; NEWLY GENERATED NEURONS; STEM-CELLS; SUBVENTRICULAR ZONE; PRECURSOR CELLS; RADIAL GLIA; HUNTINGTONS-DISEASE; COMPRESSION INJURY; BRAIN-INJURY; MOUSE MODEL	Adult neural progenitor cells (NPCs) are an attractive source for functional replacement in neurodegenerative diseases and traumatic injury to the central nervous system (CNS). It has been shown that transplantation of neural stem cells or NPCs into the lesioned region partially restores CNS function. However, the capacity of endogenous NPCs in replacement of neuronal cell loss and functional recovery of spinal cord injury (SCI) is apparently poor. Furthermore, the temporal and spatial response of endogenous adult NPCs to SCI remains largely undefined. To this end, we have analyzed the early organization, distribution, and potential function of NPCs in response to SCI, using nestin enhancer (promoter) controlled LacZ reporter transgenic mice. We showed that there was an increase of NPC proliferation, migration, and neurogenesis in adult spinal cord after traumatic compression SCI. The proliferation of NPCs detected by 5-bromodeoxyuridine incorporation and LacZ staining was restricted to the ependymal zone (EZ) of the central canal. During acute SCI, NPCs in the EZ of the central canal migrated vigorously toward the dorsal direction, where the compression lesion is generated. The optimal NPC migration occurred in the adjacent region close to the epicenter. More significantly, there was an increased de novo neurogenesis from NPCs 24 hours after SCI. The enhanced proliferation, migration, and neurogenesis of (from) endogenous NPCs in the adult spinal cord in response to SCI suggest a potential role for NPCs in attempting to restore SCI-mediated neuronal dysfunction.	Univ N Dakota, Sch Med, Dept Anat & Cell Biol, Grand Forks, ND 58202 USA; Univ Louisville, Dept Pediat, Kosair Childrens Hosp, Res Inst, Louisville, KY 40292 USA		Liu, RG (corresponding author), Univ N Dakota, Sch Med, Dept Anat & Cell Biol, Grand Forks, ND 58202 USA.	rliu@medicine.nodak.edu	Gozal, David/M-9492-2017	Xu, Renshi/0000-0003-0313-3434	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL075034, HL75034, R01 HL075034-01] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03 AG023923, R03 AG023923-01, AG23923] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045829-01, NS45829, R01 NS045829] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL075034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG023923] Funding Source: NIH RePORTER		Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Aoki Y, 2000, FASEB J, V14, P1965, DOI 10.1096/fj.00-0105com; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bedard A, 2004, DEV BRAIN RES, V151, P159, DOI 10.1016/j.devbrainres.2004.03.021; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Blight A, 1988, J Am Paraplegia Soc, V11, P26; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Clarke D, 2001, CURR OPIN GENET DEV, V11, P575, DOI 10.1016/S0959-437X(00)00235-5; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Farooque M, 2000, ACTA NEUROPATHOL, V100, P13, DOI 10.1007/s004010051187; Fujiwara Y, 2004, NEUROSCI LETT, V366, P287, DOI 10.1016/j.neulet.2004.05.080; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hasegawa K, 2005, EXP NEUROL, V193, P394, DOI 10.1016/j.expneurol.2004.12.024; Hill CE, 2004, EXP NEUROL, V190, P289, DOI 10.1016/j.expneurol.2004.05.043; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Lie DC, 2002, J NEUROSCI, V22, P6639; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Martin D, 1996, J NEUROSCI RES, V45, P588; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Roy NS, 2000, NAT MED, V6, P271; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Setoguchi T, 2004, EXP NEUROL, V189, P33, DOI 10.1016/j.expneurol.2003.12.007; Setoguchi T, 2001, BRAIN RES, V921, P219, DOI 10.1016/S0006-8993(01)03123-7; Takahashi M, 2003, J NEUROPATH EXP NEUR, V62, P185, DOI 10.1093/jnen/62.2.185; Tattersfield AS, 2004, NEUROSCIENCE, V127, P319, DOI 10.1016/j.neuroscience.2004.04.061; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Weiss S, 1996, J NEUROSCI, V16, P7599; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yaworsky PJ, 1999, DEV BIOL, V205, P309, DOI 10.1006/dbio.1998.9035	45	97	112	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	APR	2006	24	4					1011	1019		10.1634/stemcells.2005-0249			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	085WY	WOS:000240636300024	16339643	Green Accepted			2022-02-06	
J	Wall, SE; Williams, WH; Cartwright-Hatton, S; Kelly, TP; Murray, J; Murray, M; Owen, A; Turner, M				Wall, SE; Williams, WH; Cartwright-Hatton, S; Kelly, TP; Murray, J; Murray, M; Owen, A; Turner, M			Neuropsychological dysfunction following repeat concussions in jockeys	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; SPORTS; RECOVERY; SYMPTOMS; YOUNG; MRI	Background: Single and repeat concussions have a high prevalence in sport. However, there is limited research into longterm risks associated with single and repeat concussions. Objectives: To determine the effects of single and repeat historical concussions on the neuropsychological functioning and neurological reports of licensed jockeys. Methods: Six hundred and ninety eight licensed jockeys in the UK were assessed for neurological and neuropsychological symptoms of concussion at least three months after potential episodes. Results: Jockeys reporting multiple historical injuries versus a single injury showed reliable decrements on a measure of response inhibition and, to a less robust degree, on divided attention. Younger adults showed greater vulnerability. Conclusions: Repeated concussion is associated with reliable decrements in cognitive performance - even after a three month window for recent recovery.	Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England; Univ Exeter, Ctr Cognit, Washington Singer Labs, Exeter EX4 4QG, Devon, England; Univ Manchester, Div Clin Psychol, Manchester M13 9PL, Lancs, England; Newcastle Gen Hosp, Dept Neuropsychol, Reg Neurosci Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Surrey, Guildford GU2 7XL, Surrey, England; Astley Ainslie Hosp, NHS Lothian, Edinburgh EH9 2HL, Midlothian, Scotland; S Birmingham Primary Care Trust, Birmingham B13 8JL, W Midlands, England; Jockey Club, London WC2H 8AL, England		Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England.	w.h.williams@ex.ac.uk	Owen, Adrian M/B-4997-2015	TURNER, Michael/0000-0003-2323-2456; williams, huw/0000-0003-0670-2620; cartwright-hatton, sam/0000-0003-3868-3540	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G108/604] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G108/604] Funding Source: Medline		Baddeley A., 1992, SPEED CAPACITY LANGU; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BRADSHAW I, 2001, DEV DISORDERS FRONTO; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; DELIA L, 1989, COLOUR TRAILS 1 2; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Ogden JA, 1998, NEUROPSYCHOL REHABIL, V8, P413; Teasdale TW, 2003, J NEUROL NEUROSUR PS, V74, P933, DOI 10.1136/jnnp.74.7.933; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wills SM, 2001, BRAIN INJURY, V15, P645, DOI 10.1080/02699050010010502	24	97	99	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2006	77	4					518	520		10.1136/jnnp.2004.061044			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	031JT	WOS:000236701400023	16543534	Green Published			2022-02-06	
J	Hornero, R; Aboy, M; Abasolo, D; McNames, J; Goldstein, B				Hornero, R; Aboy, M; Abasolo, D; McNames, J; Goldstein, B			Interpretation of approximate entropy: Analysis of intracranial pressure approximate entropy during acute intracranial hypertension	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						approximate entropy; complex analysis; intracranial hypertension; intracranial pressure irregularity; sample entropy; traumatic brain injury (TBI)	ARTERIAL PULSE PRESSURE; TIME-SERIES; HEART-RATE; RESPIRATORY CHANGES; NEURAL-NETWORKS; QUANTIFICATION; COMPLEXITY; IRREGULARITY; PULSATILITY; REGULARITY	We studied changes in intracranial pressure (ICP) complexity, estimated by the approximate entropy (ApEn) of the ICP signal, as subjects progressed from a state of normal ICP (< 20-25 mmHg) to acutely elevated ICP (an ICP "spike" defined as ICP > 25 mmHg for < 5 m-in). We hypothesized that the measures of intracranial pressure (ICP) complexity and irregularity would decrease during acute elevations in ICP. To test this hypothesis we studied ICP spikes in pediatric subjects with severe traumatic brain injury (TBI). We conclude that decreased complexity of ICP coincides with episodes of intracranial hypertension (ICH) in TBI. This suggests that the complex regulatory mechanisms that govern intracranial pressure are disrupted during acute rises in ICP. Furthermore, we carried out a series of experiments where ApEn was used to analyze synthetic signals of different characteristics with the objective of gaining a better understanding of ApEn itself, especially its interpretation in biomedical signal analysis.	Oregon Inst Technol, Elect Engn Technol Dept, Portland, OR 97229 USA; Univ Valladolid, ETSIT, Dept Signal Theory & Commun, E-47011 Valladolid, Spain; Portland State Univ, Dept Elect & Comp Engn, Biomed Signal Proc Lab, Portland, OR 97201 USA; Portland State Univ, Dept Pediat, Complex Syst Lab, Portland, OR 97201 USA		Aboy, M (corresponding author), Oregon Inst Technol, Elect Engn Technol Dept, Portland, OR 97229 USA.	mateoaboy@ieee.org	Abasolo, Daniel/B-7322-2009; Hornero, Roberto/B-5398-2008; Hornero, Roberto/M-5313-2019; Aboy, Mateo/K-4060-2019	Abasolo, Daniel/0000-0002-4268-2885; Hornero, Roberto/0000-0001-9915-2570; Hornero, Roberto/0000-0001-9915-2570; Aboy, Mateo/0000-0002-5168-4321			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ANDELSON P, 2003, CRIT CARE MED, V31, pS417; BRADA LJ, 2001, AM J PHYSIOL-HEART C, V280, pH2674; Bruhn J, 2000, ANESTHESIOLOGY, V93, P981, DOI 10.1097/00000542-200010000-00018; Caiani EG, 2002, PHYSIOL MEAS, V23, P567, DOI 10.1088/0967-3334/23/3/308; Caiani EG, 2000, PHYSIOL MEAS, V21, P175, DOI 10.1088/0967-3334/21/1/321; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; DZEWCZYKOWSKI J, 1975, INTRACRANIAL PRESSUR, V2, P392; Engoren M, 1998, CRIT CARE MED, V26, P1817, DOI 10.1097/00003246-199811000-00021; FLEISHER LA, 1993, ANESTHESIOLOGY, V78, P683, DOI 10.1097/00000542-199304000-00011; FUSHENG Y, 2001, NONLINEAR BIOMEDICAL, V2; Goldstein B, 2003, CRIT CARE MED, V31, P433, DOI 10.1097/01.CCM.0000050285.93097.52; KAPLAN DT, 1991, BIOPHYS J, V59, P945, DOI 10.1016/S0006-3495(91)82309-8; KOLMOGOROV AN, 1958, DOKL AKAD NAUK SSSR+, V119, P861; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Larsen G Y, 1999, Pediatr Rev, V20, P234, DOI 10.1542/pir.20-7-234; Luerssen T G, 1997, Semin Pediatr Neurol, V4, P146, DOI 10.1016/S1071-9091(97)80033-2; Michard F, 1999, AM J RESP CRIT CARE, V159, P935, DOI 10.1164/ajrccm.159.3.9805077; Michard F, 2000, AM J RESP CRIT CARE, V162, P134, DOI 10.1164/ajrccm.162.1.9903035; Pincus S, 1996, P NATL ACAD SCI USA, V93, P2083, DOI 10.1073/pnas.93.5.2083; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1643, DOI 10.1152/ajpheart.1994.266.4.H1643; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1992, P NATL ACAD SCI USA, V89, P4432, DOI 10.1073/pnas.89.10.4432; PINCUS SM, 1992, AM J PHYSIOL, V262, pE741, DOI 10.1152/ajpendo.1992.262.5.E741; Pincus SM, 2001, ANN NY ACAD SCI, V954, P245; PINCUS SM, 1993, AM J PHYSIOL, V264, pR638, DOI 10.1152/ajpregu.1993.264.3.R638; Pincus SM, 1996, P NATL ACAD SCI USA, V93, P14100, DOI 10.1073/pnas.93.24.14100; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Price D, 1980, INTRACRANIAL PRESSUR, P395; Radhakrishnan N, 1998, IEEE ENG MED BIOL, V17, P89, DOI 10.1109/51.677174; Rezek IA, 1998, IEEE T BIO-MED ENG, V45, P1186, DOI 10.1109/10.709563; Swiercz M, 2000, ACTA NEUROCHIR, V142, P401, DOI 10.1007/s007010050449; Tsui F.-C., 1996, Biomedical Engineering, Applications Basis Communications, V8, P566; Tsui FC, 1996, P SOC PHOTO-OPT INS, V2762, P220, DOI 10.1117/12.236039; Turner J, 1976, INTRACRANIAL PRESSUR, P283; Veldhuis JD, 2001, AM J PHYSIOL-REG I, V281, pR1975, DOI 10.1152/ajpregu.2001.281.6.R1975; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9; Zhang XS, 2001, IEEE T BIO-MED ENG, V48, P312, DOI 10.1109/10.914794	38	97	103	0	11	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	OCT	2005	52	10					1671	1680		10.1109/TBME.2005.855722			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	967UL	WOS:000232116600006	16235653				2022-02-06	
J	Notebaert, AJ; Guskiewicz, KM				Notebaert, AJ; Guskiewicz, KM			Current trends in athletic training practice for concussion assessment and management	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; mild brain injury; evaluation	FOOTBALL PLAYERS; COLLEGIATE; INTERNET	Context: Athletic trainers surveyed in 1999 demonstrated little consensus on the use of concussion grading scales and return-to-play criteria. Most relied on clinical examination or symptom checklists to evaluate athletes with concussion. Objective: To investigate the current trends of certified athletic trainers in concussion assessment and management. Design: Subjects were invited to participate in a 32-question Internet survey. Setting: An Internet link to the survey was e-mailed to the subjects. Patients or Other Participants: A total of 2750 certified athletic trainers and members of the National Athletic Trainers' Association were randomly e-mailed and invited to participate. Main Outcome Measure(s): Survey questions addressed topics including years of certification, number of concussions evaluated each year, methods of assessing concussion, and guidelines used for return to play. Compliance with the recent position statement of the National Athletic Trainers' Association on sport-related concussion was also evaluated. Results: Certified athletic trainers averaged 9.9 +/- 7.3 years of certification and evaluated an average of 8.2 +/- 6.5 concussions per year. To assess concussion, 95% reported using the clinical examination, 85% used symptom checklists, 48% used the Standardized Assessment of Concussion, 18% used neuropsychological testing, and 16% used the Balance Error Scoring System. The most frequently used concussion grading scale and return-to-play guideline belonged to the American Academy of Neurology (30%). When deciding whether to return an athlete to play, certified athletic trainers most often used the clinical examination (95%), return-to-play guidelines (88%), symptom checklists (80%), and player self-report (62%). The most important tools for making a return-to-play decision were the clinical examination (59%), symptom checklists (13%), and return-to-play guidelines (12%). Only 3% of certified athletic trainers surveyed complied with the recent position statement, which advocated using symptom checklists, neuropsychological testing, and balance testing for managing sport-related concussion. Conclusions: Our findings suggest that only a small percentage of certified athletic trainers currently follow the guidelines proposed by the National Athletic Trainers' Association. Various assessment methods and tools are currently being used, but clinicians must continue to implement a combination of methods and tools in order to comply with the position statement.	Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Fetzer Gym CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1989, MILD HEAD INJURY, P257; Braithwaite D, 2003, FAM PRACT, V20, P545, DOI 10.1093/fampra/cmg509; BRAY C, 2004, 1982 2003 SPORTS SPO; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Durand P, 2004, J AM ACAD ORTHOP SUR, V12, P191, DOI 10.5435/00124635-200405000-00007; Ferrara Michael S., 2001, J Athl Train, V36, P145; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guskiewicz KM, 2004, AM J MED SPORTS, V6, P13; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Romanelli F, 2004, PHARMACOTHERAPY, V24, P395, DOI 10.1592/phco.24.4.395.33183; Umefjord G, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e26; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; 2001, J ATHL TRAIN, V36; 2000, CLIN J SPORT MED, V11	27	97	97	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2005	40	4					320	325					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	996MO	WOS:000234178200011	16404454				2022-02-06	
J	Yoshiyama, Y; Uryu, K; Higuchi, M; Longhi, L; Hoover, R; Fujimoto, S; McIntosh, T; Lee, VMY; Trojanowski, JQ				Yoshiyama, Y; Uryu, K; Higuchi, M; Longhi, L; Hoover, R; Fujimoto, S; McIntosh, T; Lee, VMY; Trojanowski, JQ			Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model	JOURNAL OF NEUROTRAUMA			English	Article						tau protein; transgenic mouse; repetitive head injury; neurofibrillary tangles; cerebral atrophy; cognitive deficit	CONTROLLED CORTICAL IMPACT; DEMENTIA-PUGILISTICA; ALZHEIMERS-DISEASE; TAU-PROTEIN; MICE; VULNERABILITY; IRON; RAT	Traumatic brain injury (TBI) is a risk factors for Alzheimer's disease (AD), and repetitive TBI (rTBI) may culminate in dementia pugilistica (DP), a syndrome characterized by progressive dementia, parkinsonism, and the hallmark brain lesions of AD, including neurofibrillary tangles (NFTs), formed by abnormal tau filaments and senile plaques (SPs) composed of A beta fibrils. Previous study showed that mild rTBI (mrTBI) accelerated the deposition of A beta in the brains of transgenic (Tg) mice (Tg2576) that over-express human A,6 precursor proteins with the familial AD Swedish mutations (APP695swe) and model of AD-like amyloidosis. Here, we report studies of the effects of mrTBI on AD-like tau pathologies in Tg mice expressing the shortest human tau isoform (T44) subjected to mrTBI, causing brain concussion without structural brain damage to simulate injuries linked to DP. Twelve-month-old Tg T44 (n = 18) and wild-type (WT; n = 24) mice were subjected to mrTBI (four times a day, I day per week, for 4 weeks; n = 24) or sham treatment (n = 18). Histopathological analysis of mice at 9 months after mrTBI revealed that one of the Tg T44 mice showed extensive telencephalic NFT and cerebral atrophy. Although statistical analysis of neurobehavioral tests at 6 months after mrTBI did not show any significant difference in any of groups of mice, the Tg T44 mouse with extensive NFT had an exceptionally low neurobehavioral score. The reasons for the augmentation of tau pathologies in only one T44 tau Tg mouse subjected to mrTBI remain to be elucidated.	Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Natl Chiba Higashi Hosp, Chiba, Japan; IRCCS, Osped Maggiore Policlin, Neurol Intens Care Unit, Dept Anesthesia & Crit Care Med, Milan, Italy		Trojanowski, JQ (corresponding author), Ctr Neurodegenerat Dis Res, 3600 Spruce St,HUP Maloney 3rd Fl, Philadelphia, PA 19104 USA.	trojanow@mail.med.upenn.edu	Longhi, Luca/AAF-9903-2021	Longhi, Luca/0000-0001-9894-8788	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS P50-08803, NS R0140978] Funding Source: Medline		ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; Allen B, 2002, J NEUROSCI, V22, P9340; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; Casadesus G, 2004, J ALZHEIMERS DIS, V6, P165; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Ishihara T, 2001, AM J PATHOL, V158, P555, DOI 10.1016/S0002-9440(10)63997-1; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Yamamoto A, 2002, J NEUROCHEM, V82, P1137; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	22	97	97	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1134	1141		10.1089/neu.2005.22.1134			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600009	16238489				2022-02-06	
J	Spinella, M				Spinella, M			Self-rated executive function: Development of the executive function index	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						executive; Executive Function Index; prefrontal; psychometric; self-rating	TRAUMATIC BRAIN-INJURY; EVENT-RELATED FMRI; RESPONSE-INHIBITION; PREFRONTAL CORTEX; PARKINSONS-DISEASE; WORKING-MEMORY; HEAD-INJURY; LONDON TASK; IMPULSIVITY; ATTENTION	There are several self-rating executive function (SREF) measures in existence that were developed solely in clinical populations or which sample a limited range of executive functions. The Executive Function Index (EFI) was developed here in a normal population with five subscales derived through factor analysis: Motivational Drive, Strategic Planning, Organization, Impulse Control, and Empathy. The content of three second order factors is consistent with the functions mediated by dorsolateral, orbitofrontal, and medial prefrontal circuits. Intrascale reliability and demographic relationships are reported as well as strong correlations with other SREF measures validated in clinical and neuroimaging studies. This brief measure provides a quick and efficient means of collecting data in large samples in order to test hypotheses regarding the role of prefrontal systems in various aspects of behavior and to corroborate findings of other methods, such as objective tests and functional neuroimaging.	Richard Stockton Coll New Jersey, Div Social & Behav Sci, Pomona, NJ 08240 USA		Spinella, M (corresponding author), Richard Stockton Coll New Jersey, Div Social & Behav Sci, POB 195, Pomona, NJ 08240 USA.	marcello.spinella@stockton.edu	Brennan, Kathy/D-6118-2011				Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; Beauchamp MH, 2003, NEUROIMAGE, V20, P1649, DOI 10.1016/j.neuroimage.2003.07.003; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bolla KI, 2003, NEUROIMAGE, V19, P1085, DOI 10.1016/S1053-8119(03)00113-7; BOONE KB, 1993, J CLIN PSYCHOL, V49, P54, DOI 10.1002/1097-4679(199301)49:1<54::AID-JCLP2270490108>3.0.CO;2-6; Booth JR, 2003, NEUROIMAGE, V20, P737, DOI 10.1016/S1053-8119(03)00404-X; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; CARRILLODELAPENA MT, 1993, PERCEPT MOTOR SKILL, V77, P567, DOI 10.2466/pms.1993.77.2.567; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Chow T W, 2000, Curr Psychiatry Rep, V2, P446, DOI 10.1007/s11920-000-0031-5; Colvin MK, 2001, J COGNITIVE NEUROSCI, V13, P1129, DOI 10.1162/089892901753294419; Courtney SM, 1998, PHILOS T R SOC B, V353, P1819, DOI 10.1098/rstb.1998.0334; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Curwen Tracey, 2003, Sex Abuse, V15, P347, DOI 10.1023/A:1025056312935; Davis M.H., 1980, JSAS CATALOG SELECTE, V10, P85; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; Dougherty DM, 1999, PSYCHIAT RES, V85, P315, DOI 10.1016/S0165-1781(99)00011-6; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Farrow TFD, 2001, NEUROREPORT, V12, P2433, DOI 10.1097/00001756-200108080-00029; Faw B, 2003, CONSCIOUS COGN, V12, P83, DOI 10.1016/S1053-8100(02)00030-2; Fincham JM, 2002, P NATL ACAD SCI USA, V99, P3346, DOI 10.1073/pnas.052703399; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Govern JM, 2001, CONSCIOUS COGN, V10, P366, DOI 10.1006/ccog.2001.0506; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; GRACE J, 2001, FORMAL SYSTEMS BEHAV; GUR RC, 2000, CEREB CORTEX, V12, P998; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hoptman MJ, 2002, BIOL PSYCHIAT, V52, P9, DOI 10.1016/S0006-3223(02)01311-2; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Jentsch JD, 2003, BEHAV NEUROSCI, V117, P76, DOI 10.1037/0735-7044.117.1.76; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kertesz A, 1997, CAN J NEUROL SCI, V24, P29, DOI 10.1017/S0317167100021053; Kircher TTJ, 2002, NEUROPSYCHOLOGIA, V40, P683, DOI 10.1016/S0028-3932(01)00138-5; KLINTEBERG B. A., 1987, PERCEPT MOTOR SKILL, V65, P683; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Lyke JA, 2004, INT J EAT DISORDER, V36, P229, DOI 10.1002/eat.20025; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; Martel SJ, 1999, ENVIRON ENG GEOSCI, V5, P213; Matsumoto K, 2004, CURR OPIN NEUROBIOL, V14, P178, DOI 10.1016/j.conb.2004.03.005; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MEADE ER, 1981, MERRILL PALMER QUART, V27, P271; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; Miley WM., 2003, COLL STUDENT J, V37, P545; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyakawa L, 2001, JAPANESE J PSYCHOL, V72, P435; Murphy KR, 2004, J CLIN PSYCHIAT, V65, P12; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Oswald PA, 2003, PERCEPT MOTOR SKILL, V97, P1184, DOI 10.2466/PMS.97.8.1184-1186; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Paul T, 2002, AM J PSYCHIAT, V159, P408, DOI 10.1176/appi.ajp.159.3.408; Paulsen JS, 2000, J INT NEUROPSYCH SOC, V6, P815, DOI 10.1017/S1355617700677081; Perez-Albeniz A, 2003, CHILD ABUSE NEGLECT, V27, P769, DOI 10.1016/S0145-2134(03)00111-X; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rubia K, 2000, NEUROSCI BIOBEHAV R, V24, P13, DOI 10.1016/S0149-7634(99)00055-X; Sarazin M, 2003, J NEUROL, V250, P827, DOI 10.1007/s00415-003-1087-z; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Speer NK, 2003, COGN AFFECT BEHAV NE, V3, P155, DOI 10.3758/CABN.3.3.155; Spinella M, 2004, INT J NEUROSCI, V114, P95, DOI 10.1080/00207450490249347; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; SPINELLA M, 2005, IN PRESS COLL STUDEN; SPINELLA M, 2005, IN PRESS ROLE PREFRO; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Swann AC, 2001, PSYCHIAT RES, V101, P195, DOI 10.1016/S0165-1781(00)00249-3; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; van den Heuvel OA, 2003, NEUROIMAGE, V18, P367, DOI 10.1016/S1053-8119(02)00010-1; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Zilberman ML, 2003, BMC PSYCHIATRY, V3, DOI 10.1186/1471-244X-3-1; ZWICK WR, 1986, PSYCHOL BULL, V99, P432, DOI 10.1037/0033-2909.99.3.432	82	97	100	11	38	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0020-7454			INT J NEUROSCI	Int. J. Neurosci.	MAY	2005	115	5					649	667		10.1080/00207450590524304			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	923PI	WOS:000228921400004	15823930				2022-02-06	
J	Chieregato, A; Fainardi, E; Morselli-Labate, AM; Antonelli, V; Compagnone, C; Targa, L; Kraus, J; Servadei, F				Chieregato, A; Fainardi, E; Morselli-Labate, AM; Antonelli, V; Compagnone, C; Targa, L; Kraus, J; Servadei, F			Factors associated with neurological outcome and lesion progression in traumatic subarachnoid hemorrhage patients	NEUROSURGERY			English	Article						brain contusions; head injury; lesion progression; outcome; subarachnoid hemorrhage	SEVERE HEAD-INJURY; BRAIN-INJURY; CEREBRAL VASOSPASM; MODERATE; BLOOD; SCAN; CLASSIFICATION; MANAGEMENT; HEMATOMAS; IMPACT	OBJECTIVE: Traumatic subarachnoid hemorrhage (tSAH) is a frequent finding after closed and its presence is a powerful factor associated with poor outcome. The head injuries, exact mechanism linking tSAH and an adverse outcome is poorly understood. The aim of this study was to identify the factors that may predict outcomes and changes in the computed tomographic (CT) scans of lesions in a selected population of tSAH patients. METHODS: We evaluated 141 patients admitted consecutively from January 1, 1997, to January 31, 1999, with a CT diagnosis of tSAH. The admission and 'worst" CT scans were recorded. CT scan changes were reported as "significant CT progression" (changes in the Marshall classification) or "any CT progression." The amount of subarachnoid blood was recorded using a modified Fisher classification. Outcome was assessed at 6 months after injury with the Glasgow Outcome Scale. RESULTS: Twenty-eight patients (19.9%) had an unfavorable Glasgow Outcome Scale outcome. In the univariate analysis, prognosis was significantly related to age, admission Glasgow Coma Scale score, Marshall CT classification score at admission and on the worst CT scan, amount of tSAH, and volume of the associated brain contusions. From multivariate analysis, the only factors independently related to outcome were the Glasgow Coma Scale score (P < 0.01) and size of the tSAH at admission (P < 0.001). Thirty-four patients (24.1%) had significant CT lesion progression, and 66 patients (46.8%) had some lesion progression. Patients having significant progression of the lesion had a higher risk of an unfavorable outcome (32 versus 10%; P = 0.004). Unadjusted factors predicting CT the Marshall classification progression were the Glasgow Coma Scale score at admission, the amount of subarachnoid blood, and the presence or volume of associated admission, brain contusions at admission. independent factors associated with significant CT progression were the amount of tSAH (P < 0.001) and the presence or volume of brain contusions at admission (P < 0.001). CONCLUSION: The outcome of patients with tSAH at admission is related in a logistic regression analysis to the admission Glasgow Coma Scale score and to the amount of subarachnoid blood. These patients also have a significant risk of CT progression. The amount of subarachnoid blood and the presence of associated parenchymal damage are powerful independent factors associated with CT progression, thus linking poor outcomes and CT changes.	WHO, Maurizio Bufalini Hosp, Neurotrauma Collaborating Ctr, Div Neurotraumatol, I-47023 Cesena, Italy; Maurizio Bufalini Hosp, Intens Care Unit, Cesena, Italy; St Anna Hosp, Serv Neuroradiol, Ferrara, Italy; Univ Bologna, Dept Internal Med & Gastroenterol, Alma Mater Studiorum, Bologna, Italy; Univ Calif Los Angeles, So Calif Injury Prevent Ctr, Los Angeles, CA USA		Servadei, F (corresponding author), WHO, Maurizio Bufalini Hosp, Neurotrauma Collaborating Ctr, Div Neurotraumatol, I-47023 Cesena, Italy.	fservade@ausl-cesena.emr.it		Compagnone, Christian/0000-0001-9951-5503; Morselli/Labate, Antonio Maria/0000-0001-9318-8564; Antonelli, Vincenzo/0000-0003-4231-529X; Servadei, Franco/0000-0002-3595-3464			Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chen Guangxin, 2002, Chin J Traumatol, V5, P169; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; JENNETT B, 1975, LANCET, V1, P480; KAKAIEKA A, 1997, TRAUMATIC SUBARACHNO; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TAKIZAWA T, 1984, Neurologia Medico-Chirurgica, V24, P390, DOI 10.2176/nmc.24.390; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	38	97	106	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2005	56	4					671	679		10.1227/01.NEU.0000156200.76331.7A			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	915EH	WOS:000228280200007	15792505				2022-02-06	
J	Pannu, R; Barbosa, E; Singh, AK; Singh, I				Pannu, R; Barbosa, E; Singh, AK; Singh, I			Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						atorvastatin; SCI; inflammation	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; MESSENGER-RNA; LEWIS RATS; REDUCTASE INHIBITOR; MULTIPLE-SCLEROSIS	Spinal cord injury (SCI) is a devastating and complex clinical condition involving proinflammatory cytokines and nitric oxide toxicity that produces a predictable pattern of progressive injury entailing neuronal loss, axonal destruction, and demyelination at the site of impact. The involvement of proinflammatory cytokines and inducible nitric oxide synthase (iNOS) in exacerbation of SCI pathology is well documented. We have reported previously the antiinflammatory properties and immunomodulatory activities of statins (3-hydroxy-3-methylglutaryl [HMG]-CoA reductase inhibitors) in the animal model of multiple sclerosis, experimental allergic encephalitis (EAE). The present study was undertaken to investigate the efficacy of atorvastatin (Lipitor; ILP) treatment in attenuating SCI-induced pathology. Immunohistochemical detection and real-time PCR analysis showed increased expression of iNOS, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta) after SCI. In addition, neuronal apoptosis was detected 24 hr after injury followed by a profound increase in ED1-positive inflammatory infiltrates, glial fibrillary acidic protein (GFAP)-positive reactive astrocytes, and oligodendrocyte apoptosis by 1 week after SCI relative to control. LP treatment attenuated the SCI-induced iNOS, TNFalpha, and IL-1beta expression. LP also provided protection against SCI-induced tissue necrosis, neuronal and oligodendrocyte apoptosis, demyelination, and reactive gliosis. Furthermore, rats treated with LP scored much higher on the locomotor rating scale after SCI (19.13 +/- 0.53) than did untreated rats (9.04 +/- 1.22). This study therefore reports the beneficial effect of atorvastatin for the treatment of SCI-related pathology and disability. (C) 2004 Wiley-Liss, Inc.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; Ralph H Johnson VA Med Ctr, Charleston, SC USA		Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	singhi@musc.edu	Abrams, William R/A-5782-2008				Bal-Price A, 2001, J NEUROSCI, V21, P6480; BALENTINE JD, 1978, LAB INVEST, V39, P236; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bentley David, 1994, Current Opinion in Neurobiology, V4, P43, DOI 10.1016/0959-4388(94)90030-2; Bethea JR, 1998, J NEUROSCI, V18, P3251; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Davies SJA, 1998, TRENDS NEUROSCI, V21, P515, DOI 10.1016/S0166-2236(98)01335-6; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Dergham P, 2002, J NEUROSCI, V22, P6570; Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158; Fawcett JW, 1998, SPINAL CORD, V36, P811, DOI 10.1038/sj.sc.3100769; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; HSU CY, 1985, J NEUROL SCI, V70, P275, DOI 10.1016/0022-510X(85)90169-8; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1989, ANN NY ACAD SCI, V559, P282; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jin Z, 1997, J NEUROSCI, V17, P6256; KIERNAN JA, 1990, TRENDS PHARMACOL SCI, V11, P316, DOI 10.1016/0165-6147(90)90233-X; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; LASSMANN H, 1979, ARCH NEUROL-CHICAGO, V36, P490, DOI 10.1001/archneur.1979.00500440060011; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Letourneau PC, 1996, PERSPECT DEV NEUROBI, V4, P111; Liu XZ, 1997, J NEUROSCI, V17, P5395; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pan WH, 1997, NEUROSCI BIOBEHAV R, V21, P603, DOI 10.1016/S0149-7634(96)00047-4; Pan WH, 1999, J NEUROSCI, V19, P3649; Pan WH, 2003, J NEUROIMMUNOL, V134, P111, DOI 10.1016/S0165-5728(02)00426-5; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Popovich PG, 1997, J NEUROPATH EXP NEUR, V56, P1323, DOI 10.1097/00005072-199712000-00007; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; Regan RF, 1996, NEUROSCI LETT, V213, P9, DOI 10.1016/0304-3940(96)12823-8; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Sequeira SM, 1997, NITRIC OXIDE-BIOL CH, V1, P315, DOI 10.1006/niox.1997.0144; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Taoka Y, 2000, J NEUROTRAUM, V17, P219, DOI 10.1089/neu.2000.17.219; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	77	97	104	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 1	2005	79	3					340	350		10.1002/jnr.20345			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	892FG	WOS:000226634800009	15605375				2022-02-06	
J	Chou, LS; Kaufman, KR; Walker-Rabatin, AE; Brey, RH; Basford, JR				Chou, LS; Kaufman, KR; Walker-Rabatin, AE; Brey, RH; Basford, JR			Dynamic instability during obstacle crossing following traumatic brain injury	GAIT & POSTURE			English	Article						traumatic brain injury; center of pressure; GCS	CENTER-OF-MASS; POSTURAL STABILITY; BODY BALANCE; HEAD; FALLS; SWAY; REHABILITATION; INDIVIDUALS; MODERATE; MOTION	Patients with traumatic brain injury (TBI) complain of "imbalance" or "unsteadiness" while walking, despite a normal gait on clinical examination. Thus, the purpose of this study was to determine if it was possible to quantitatively assess dynamic stability that did not have an obvious neuromuscular origin in individuals following TBI. Ten patients with documented TBI and 10 age, gender, and stature-matched healthy individuals participated in the study. All subjects were instructed to perform unobstructed level walking and to step over obstacles corresponding to 2.5%, 5%, 10%, and 15% of their height. A 13-link biomechanical model of the human body was used to compute the kinematics of the whole body center of mass (COM). Subjects with TBI walked with a significantly slower gait speed and shorter stride length than their matched controls. Furthermore, subjects with TBI displayed a significantly greater and faster medio-lateral (M-L) COM motion and maintained a significantly greater M-L separation distance between their COM and center of pressure (COP) than their matched control subjects. These measurements indicate that subjects with TBI have difficulty maintaining dynamic stability in the frontal plane and have a reduced ability to successfully arrest their sagittal momentum. These findings provide an objective measurement that reflects the complaints of instability not observable on clinical examination for individuals who have suffered a TBI. This ability to identify any functional impairment after a traumatic brain injury that may affect patient safety is critical for prevention of re-injury during the recovery period. (C) 2003 Elsevier B.V. All rights reserved.	Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Mot Anal Lab, Rochester, MN 55905 USA; Univ Oregon, Dept Exercise & Movement Sci, Eugene, OR 97403 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Vestibular Balance Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA		Kaufman, KR (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Mot Anal Lab, 200 1st St SW,Charlton N L-110L, Rochester, MN 55905 USA.	kaufman.kenton@mayo.edu		Kaufman, Kenton/0000-0002-7311-3781			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CAPLAN B, 1982, ARCH PHYS MED REHAB, V63, P362; CDC, 1999, TRAUM BRAIN INJ US R; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GOUVIER W D, 1991, Neuropsychology Review, V2, P3, DOI 10.1007/BF01108845; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HAHN ME, 2002, P 4 C BIOM CALG CAN; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JIAN YC, 1993, GAIT POSTURE, V0001, P00009, DOI DOI 10.1016/0966-6362(93)90038-3; KADABA MP, 1989, J ORTHOPAED RES, V7, P849, DOI 10.1002/jor.1100070611; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Krebs DE, 1998, ARCH PHYS MED REHAB, V79, P1489, DOI 10.1016/S0003-9993(98)90408-7; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; MACKINNON CD, 1993, J BIOMECH, V26, P633, DOI 10.1016/0021-9290(93)90027-C; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; Meglan D.A., 1991, THESIS OHIO STATE U; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; OVERSTALL PW, 1977, BRIT MED J, V1, P261, DOI 10.1136/bmj.1.6056.261; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; PRINCE F, 1994, GAIT POSTURE, V2, P19, DOI 10.1016/0966-6362(94)90013-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rimmele C T, 1987, Arch Clin Neuropsychol, V2, P353; RUBIN AM, 1995, AM J OTOL, V16, P216; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; Tucker CA, 1998, GAIT POSTURE, V8, P117, DOI 10.1016/S0966-6362(98)00030-7; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	37	97	98	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	DEC	2004	20	3					245	254		10.1016/j.gaitpost.2003.09.007			10	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	874QY	WOS:000225366100003	15531171				2022-02-06	
J	Knoblach, SM; Alroy, DA; Nikolaeva, M; Cernak, I; Stoica, BA; Faden, AI				Knoblach, SM; Alroy, DA; Nikolaeva, M; Cernak, I; Stoica, BA; Faden, AI			Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; calpain; caspase; necrosis; maitotoxin; apoptosis	CORTICAL IMPACT INJURY; SH-SY5Y NEUROBLASTOMA-CELLS; APOPTOSIS-INDUCING FACTOR; CYTOCHROME-C RELEASE; NEURONAL APOPTOSIS; DNA FRAGMENTATION; SPECTRIN PROTEOLYSIS; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE	In studies designed to evaluate the therapeutic window for treatment of traumatic brain injury, the caspase 3 inhibitor z-DEVD-fmk improved neurologic function and reduced lesion volumes when administered at I but not at 4, 8, or 24 hours after injury. Moreover, neither caspase 3 nor PARP, a caspase 3 substrate, were cleaved in injured, untreated cortex from I to 72 hours after injury. Few cortical neurons expressed active caspase 3 or were TUNEL positive from 6 to 24 hours after injury, and TUNEL staining was primarily Type I (necrotic). Nissl staining revealed extensive neuronal necrosis in the injured cortex from 6 to 24 hours after impact. Considered together, these data suggested that z-DEVD-fmk may reduce neuronal necrosis, so we used an in vitro model of necrotic cell death induced by maitotoxin to test this further and explore the potential mechanism(s) involved. Z-DEVD-fmk (1 nM-100 muM) significantly attenuated maitotoxin induced neuronal cell death and markedly reduced expression of the 145 kD calpain-mediated alpha-spectrin breakdown product after maitotoxin injury. Neither the 120 kD caspase-mediated a-spectrin cleavage product nor cathepsin B were expressed after maitotoxin injury. In a cell free assay, z-DEVD-fmk reduced hydrolysis of casein by purified calpain I. Finally, z-DEVD-fmk reduced expression of the 145 kD calpain-mediated a-spectrin cleavage fragment after traumatic brain injury in vivo. These data suggest that neuroprotection by z-DEVD-fmk may, in part, reflect inhibition of calpain-related necrotic cell death.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA		Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, EP16 New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	sknob101@georgetown.edu	Cernak, Ibolja/A-6399-2008; STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Ibolja, Cernak/0000-0003-3214-698X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036527] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS36527] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Chen J, 1998, J NEUROSCI, V18, P4914; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Inoue J, 2003, J MED CHEM, V46, P868, DOI 10.1021/jm0201924; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; KUTTY RK, 1989, TOXICOL APPL PHARM, V101, P1, DOI 10.1016/0041-008X(89)90206-8; LEGRAND AM, 1984, J MOL CELL CARDIOL, V16, P663, DOI 10.1016/S0022-2828(84)80630-6; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinnis KM, 2003, NEUROCHEM INT, V42, P517, DOI 10.1016/S0197-0186(02)00078-5; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1111/j.1365-2613.2000.00169.x; Volbracht C, 1999, MOL MED, V5, P477; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	69	97	99	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2004	24	10					1119	1132		10.1097/01.WCB.0000138664.17682.32			14	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	859YP	WOS:000224304600006	15529012	Bronze			2022-02-06	
J	Hirsch, LJ				Hirsch, LJ			Continuous EEG monitoring in the intensive care unit: An overview	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						continuous EEG monitoring; critically ill; intensive care unit; nonconvulsive seizures; seizure detection; ischemia detection	NONCONVULSIVE STATUS EPILEPTICUS; NEURON-SPECIFIC ENOLASE; CONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL; SEIZURES; HEMORRHAGE; MORBIDITY; MORTALITY; MARKER	Due to technological advances, it is now feasible to record continuous digital EEG (CEEG), with or without video, in critically ill patients and review recordings remotely. Nonconvulsive seizures (NCSzs) are more common than previously recognized and are associated with worse outcome. The majority of seizures in ICU patients are nonconvulsive and will be missed without CEEG. Factors associated with an increased risk for NCSzs include coma, prior clinical seizures, CNS infection, brain tumor, recent neurosurgery, and periodic epileptiform discharges. In addition to detecting seizures, CEEG is also useful for characterizing paroxysmal spells such as posturing or autonomic changes, detecting ischemia, assessing level of sedation, following long-term EEG trends, and prognosticating. Most NCSzs will be detected in the first 24 hours of CEEG in noncomatose patients, but longer recording periods may be required in comatose patients or in those with periodic epileptiform discharges. EEG patterns in encephalopathic or comatose patients are often equivocal. How aggressively to treat NCSzs and equivocal EEG patterns in these patients is unclear and requires further research. Real-time detection of ischemia at a reversible stage is technologically feasible with CEEG and should be developed into a practical form for prevention of in-hospital infarction in the near future.	Columbia Univ, Comprehens Epilepsy Ctr, New York, NY 10032 USA		Hirsch, LJ (corresponding author), Columbia Univ, Comprehens Epilepsy Ctr, 710 W 168th St,Box NI-135, New York, NY 10032 USA.	LJH3@columbia.edu		Hirsch, Lawrence/0000-0002-6333-832X			Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; Hirsch LJ, 2004, EPILEPSIA, V45, P109, DOI 10.1111/j.0013-9580.2004.38103.x; IVES J, IN PRESS J CLIN NEUR; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; KRUMHOLZ A, 1995, NEUROLOGY, V45, P1499, DOI 10.1212/WNL.45.8.1499; Krumholz A, 1999, J CLIN NEUROPHYSIOL, V16, P314, DOI 10.1097/00004691-199907000-00003; KULL L, IN PRESS J CLIN NEUR; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; RABINOWICZ AL, 1995, EPILEPSIA, V36, P475, DOI 10.1111/j.1528-1157.1995.tb00489.x; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Young GB, 1996, NEUROLOGY, V47, P83	27	97	98	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	SEP-OCT	2004	21	5					332	340					9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878TO	WOS:000225670000004	15592007				2022-02-06	
J	Sullivan, PG; Springer, JE; Hall, ED; Scheff, SW				Sullivan, PG; Springer, JE; Hall, ED; Scheff, SW			Mitochondrial uncoupling as a therapeutic target following neuronal injury	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article; Proceedings Paper	Mitochondria and Neuroprotection Symposium	APR 16-19, 2004	Ft Lauderdale, FL			neuronal cell death; traumatic brain injury; excitotoxicity; spinal cord injury; reactive oxygen species	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TRAUMA; AMYLOID BETA-PEPTIDE; NF-KAPPA-B; CYCLOSPORINE-A; LIPID-PEROXIDATION; OXIDATIVE STRESS; GLUTAMATE EXCITOTOXICITY; PERMEABILITY TRANSITION; IMPAIRED MITOCHONDRIAL	Mitochondrial dysfunction is a prominent feature of excitotoxic insult and mitochondria are known to play a pivotal role in neuronal cell survival and death following injury. Following neuronal injury there is a well-documented increase in cytosolic Ca2+, reactive oxygen species (ROS) production and oxidative damage. In vitro studies have demonstrated these events are dependent on mitochondrial Ca2+ cycling and that a reduction in membrane potential is sufficient to reduce excitotoxic cell death. This concept has gained additional support from experiments demonstrating that the overexpression of endogenous mitochondrial uncoupling proteins (UCP), which decrease the mitochondrial membrane potential, decreases cell death following oxidative stress. Our group has demonstrated that upregulation of UCP activity can reduce excitotoxic-mediated ROS production and cell death whereas a reduction in UCP levels increases susceptibility to neuronal injury. These findings raise the possibility that mitochondrial uncoupling could be a potential novel treatment for acute CNS injuries.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 240 HSRB, Lexington, KY 40536 USA.	patsull@uky.edu	Hall, Edward D/F-8930-2013				Argiles JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Billups B, 2002, J NEUROSCI, V22, P5840; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Choi D W, 1990, Adv Exp Med Biol, V268, P501; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Diano S, 2000, ENDOCRINOLOGY, V141, P4226, DOI 10.1210/en.141.11.4226; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Horvath TL, 1999, J NEUROSCI, V19, P10417; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Keller JN, 1997, J NEUROCHEM, V69, P273; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pivovarova NB, 2002, J NEUROSCI, V22, P10653; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zackova M, 2002, BIOSCIENCE REP, V22, P33, DOI 10.1023/A:1016009022186	63	97	100	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	AUG	2004	36	4					353	356		10.1023/B:JOBB.0000041767.30992.19			4	Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biophysics; Cell Biology	854PR	WOS:000223916300016	15377871				2022-02-06	
J	Govindaraju, V; Gauger, GE; Manley, GT; Ebel, A; Meeker, M; Maudsley, AA				Govindaraju, V; Gauger, GE; Manley, GT; Ebel, A; Meeker, M; Maudsley, AA			Volumetric proton spectroscopic imaging of mild traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; AUTOMATED SPECTRAL-ANALYSIS; DIFFUSE AXONAL INJURY; HEAD-INJURY; MR SPECTROSCOPY; H-1 MRS; METABOLITES; RELAXATION; CEREBELLUM; STEM	BACKGROUND AND PURPOSE: Poor clinical outcomes without notable neuroimaging findings after mild traumatic brain injury (MTBI) suggest diffuse tissue damage and altered metabolism not observable with conventional MR imaging and CT. In this study, MTBI-associated metabolic changes were assessed over the entire brain by using volumetric proton MR spectroscopic imaging (MRSI) and the findings related to injury and outcome assessments. METHODS: Fourteen subjects with mild closed head injury (Glasgow Coma Scale [GCS] scores of 13-15) underwent structural MR imaging and proton MRSI at 1.5 T within 1 month of injury. Distributions of N-acetylaspartate (NAA), total creatine (Cr), and total choline (Cho) were mapped over a wide region of the brain, and metabolite ratios were calculated for 25 regions without MR imaging abnormalities. Results were compared with data from 13 control subjects. RESULTS: Significant changes (P <.05) were found for some, but not all, brain regions for the average values from all MTBI subjects, with reduced NAA/Cr, increased Cho/Cr, and reduced NAA/Cho. Global NAA/Cho obtained from the sum of all sampled regions in two subjects was significantly reduced. Metabolite ratios were not significantly correlated with GCS score at admission or Glasgow Outcome Scale (GOS) score at 6 months after injury, although they were weakly correlated with GOS score at discharge. CONCLUSION. These results show evidence of widespread metabolic changes following MTBI in regions that appear normal on diagnostic MR images. Although the association with injury assessment and outcome is weak, this preliminary study demonstrates the applicability of volumetric proton MRSI for evaluating diffuse injury associated with MTBI.	Univ Calif San Francisco, No Calif Inst Res & Educ, MR Spectroscopy Unit, Vet Affairs Med Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA		Maudsley, AA (corresponding author), Univ Miami, Sch Med, Dept Radiol, MR Ctr, 1115 NW 14th St, Miami, FL 33136 USA.			Maudsley, Andrew/0000-0001-7653-3063; Govind, Varan/0000-0002-1205-5194	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038029] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB00207] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38029] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barker PB, 2000, MAGN RESON MED, V43, P348, DOI 10.1002/(SICI)1522-2594(200003)43:3<348::AID-MRM5>3.0.CO;2-M; Barker PB, 2001, ANN NEUROL, V49, P423, DOI 10.1002/ana.90; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Ebel A, 2001, MAGNET RESON MED, V46, P1072, DOI 10.1002/mrm.1301; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Graham D.I., 1996, NEUROTRAUMA, P43; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.3.CO;2-Y; Jacobs MA, 2001, MAGNET RESON MED, V46, P699, DOI 10.1002/mrm.1248; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mascalchi M, 2002, J MAGN RESON IMAGING, V16, P532, DOI 10.1002/jmri.10189; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NARUSE S, 1993, P ISMRM, P1485; Pearl GS, 1998, CLIN LAB MED, V18, P39; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rooney WD, 1996, MAGN RESON MED, V35, P688, DOI 10.1002/mrm.1910350510; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Son BC, 2000, ACT NEUR S, V76, P13; Tedeschi G, 1996, AM J NEURORADIOL, V17, P1871; vanderToorn A, 1995, NMR BIOMED, V8, P245; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	37	97	101	0	4	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2004	25	5					730	737					8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	821ZZ	WOS:000221503500010	15140711				2022-02-06	
J	Mathias, JL; Beall, JA; Bigler, ED				Mathias, JL; Beall, JA; Bigler, ED			Neuropsychological and information processing deficits following mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; information processing; diffuse brain damage; neuropsychological performance	MINOR HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; AXONAL INJURY; CORPUS-CALLOSUM; SEQUELAE; LESIONS; DAMAGE; DISCONNECTION; SPECTROSCOPY; TOPOGRAPHY	Neuroradiological and neuropathological investigations have found evidence of diffuse brain damage in the frontal and temporal lobes, corpus callosum, and fornices in patients who have sustained a mild traumatic brain injury (TBI). However, neuropsychological assessments of these patients do not typically target many of the subtle information processing deficits that may arise from diffuse damage involving the frontotemporal regions of the brain as well as white matter pathology, including the corpus callosum. Consequently, we have a limited understanding of the deficits that may be attributable to temporary or permanent disruptions to these functional pathways. This study assessed a group of mild TBI patients (N = 40) and a matched control group (N = 40) on a number of standard neuropsychological tests of selective and sustained attention, verbal and non-verbal fluency, and verbal memory. In addition, reaction time (RT) tasks, requiring both the inter- and intra-hemi spheric processing of visual and tactile information, were used to assess the functional integrity of the tracts that are likely to be affected by diffuse damage. In the 1st month after sustaining their injury, the mild TBI group demonstrated deficits in attention, non-verbal fluency, and verbal memory. They also demonstrated slower visual and tactile RTs, with the visual RTs of mild TBI patients being more affected by increased task difficulty and the need to transfer information across the corpus callosum, than did their matched controls.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA		Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	jane.mathias@psychology.adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Banich M.T., 1997, NEUROPSYCHOLOGY NEUR; Banich M.T., 1994, NEUROPSYCHOLOGY, V8, P263; Banich Marie T., 1995, P427; BANICH MT, 1992, J EXP PSYCHOL HUMAN, V18, P763, DOI 10.1037/0096-1523.18.3.763; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BENTIN S, 1984, NEUROPSYCHOLOGIA, V22, P601, DOI 10.1016/0028-3932(84)90024-1; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CLARKE JM, 1994, BEHAV BRAIN RES, V64, P185, DOI 10.1016/0166-4328(94)90131-7; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; CURRY LM, 1991, PHILADELPHIA HEAD IN; DAMASIO AR, 1980, J NEUROL NEUROSUR PS, V43, P351, DOI 10.1136/jnnp.43.4.351; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EVANS RW, 1985, PERCEPT MOTOR SKILL, V61, P699, DOI 10.2466/pms.1985.61.3.699; FOS LA, 1995, INT NEUR SOC AUSTR S; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GEFFEN G, 1985, NEUROPSYCHOLOGIA, V23, P497, DOI 10.1016/0028-3932(85)90004-1; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P161; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1974, PSYCHOL EFFECTS CONC; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; HOPTMAN MJ, 1994, PSYCHOL BULL, V116, P195, DOI 10.1037/0033-2909.116.2.195; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JONES NR, 1997, J CLIN NEUROSCI, V4, P1; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWINE JD, IN PRESS J HEAD TRAU; LEWINE JD, IN PRESS BRAIN INJUR; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NELSON HE, 1991, NATL ADULT READINT T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PANDYA DN, 1971, BRAIN RES, V32, P31, DOI 10.1016/0006-8993(71)90153-3; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robertson I., 1994, TEST EVERYDAY ATTENT; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmidt M., 1996, REY AUDITORY VERBAL; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STRICH SJ, 1961, LANCET, V2, P443; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	82	97	98	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2004	10	2					286	297		10.1017/S1355617704102117			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	780KA	WOS:000189378800015	15012849	Green Published			2022-02-06	
J	Wennersten, A; Meijer, X; Holmin, S; Wahlberg, L; Mathiesen, T				Wennersten, A; Meijer, X; Holmin, S; Wahlberg, L; Mathiesen, T			Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain injury; neurosphere; differentiation; migration; rat	INTRACEREBRAL INFLAMMATORY RESPONSE; CENTRAL-NERVOUS-SYSTEM; ADULT MAMMALIAN BRAIN; PROGENITOR CELLS; STEM-CELLS; APOPTOTIC NEURODEGENERATION; NEURONAL DIFFERENTIATION; HUMAN CNS; IN-VIVO; HIPPOCAMPUS	Object. Cultures containing human neural stem and progenitor cells (neurospheres) have the capacity to proliferate and differentiate into the major phenotypes of the adult brain. These properties make them candidates for therapeutic transplantation in cases of neurological diseases that involve cell loss. In this study, long-term cultured and cryopreserved cells were transplanted into the traumatically injured rat brain to evaluate the potential for human neural stent/progenitor cells to survive and differentiate following traumatic injury. Methods. Neural stem/progenitor cell cultures were established from 10-week-old human forebrain. Immunosuppressed adult rats received a unilateral parietal cortical contusion injury, which was delivered using the weight-drop method. Immediately following the injury, these animals received transplants of neural stem/progenitor cells, which were placed close to the site of injury. Two or 6 weeks after the procedure, these animals were killed and their brains were examined by immunohistochemical analysis. At both 2 and 6 weeks postoperatively, the transplanted human cells were found in the perilesional zone, hippocampus, corpus callosum, and ipsilateral subependymal zone of the rats. Compared with the 2-week time point, an increased number of HuN-positive cells was observed at 6 weeks. In addition, at 6 weeks post-injury/transplantation, the cells were noted to cross the midline to the contralateral corpus callosum and into the contralateral cortex. Double labeling demonstrated neuronal and astrocytic, but not oligodendrocytic differentiation. Moreover, the cortex appeared to provide an environment that was less hospitable to neuronal differentiation than the hippocampus. Conclusions. This study shows that expandable human neural stem/progenitor cells survive transplantation, and migrate, differentiate, and proliferate in the injured brain. These cells could potentially be developed for transplantation therapy in cases of traumatic brain injury.	Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden; NS Gene AS, Copenhagen, Denmark		Mathiesen, T (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.	tiit.mathiesen@ks.se	mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Barami K, 2001, J NEUROSURG, V95, P308, DOI 10.3171/jns.2001.95.2.0308; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Edwards AD, 1996, NEUROPATH APPL NEURO, V22, P494, DOI 10.1111/j.1365-2990.1996.tb01122.x; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; GrasbonFrodl EM, 1996, NEUROSCIENCE, V73, P171, DOI 10.1016/0306-4522(96)00008-5; GrasbonFrodl EM, 1997, NEUROBIOL DIS, V3, P299, DOI 10.1006/nbdi.1996.0124; Gray JA, 2000, CELL TRANSPLANT, V9, P153, DOI 10.1177/096368970000900203; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hurelbrink CB, 2002, EUR J NEUROSCI, V15, P1255, DOI 10.1046/j.1460-9568.2002.01959.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MATHIESEN T, 1989, NEUROSCI LETT, V97, P291, DOI 10.1016/0304-3940(89)90613-7; MATHIESEN T, 1989, CANCER LETT, V44, P151, DOI 10.1016/0304-3835(89)90010-4; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rosser AE, 2000, EUR J NEUROSCI, V12, P2405, DOI 10.1046/j.1460-9568.2000.00135.x; Rubio FJ, 2000, MOL CELL NEUROSCI, V16, P1, DOI 10.1006/mcne.2000.0854; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Zhou FC, 2000, EXP NEUROL, V164, P200, DOI 10.1006/exnr.2000.7425	49	97	111	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2004	100	1					88	96		10.3171/jns.2004.100.1.0088			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	761YQ	WOS:000187943400014	14743917				2022-02-06	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM			A prospective study of long-term caregiver and family adaptation following brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adaptation; brain injury; burden; family functioning; stress trauma	CLOSED-HEAD-INJURY; ASSESSMENT DEVICE; RELIABILITY; VALIDITY; PREDICTORS; RECOVERY; RELATIVES; BURDEN; HEALTH	Objective: We examined tong-term differences in family, adaptation following traumatic brain Injuries (TBI) and orthopedic injuries. Design: Families of children with severe TBI (n = 53), moderate TBI (n = 56), and orthopedic injuries (n = 80) were assessed at baseline, 6 months,and 12 months post injury and at an extended follow-up an average of 4.1 years post injury. Caregiver and family outcomes were examined using mixed model analysis. Results: Patterns of adaptation over time varied across groups but indicated long-standing injury-related stress and burden in the severe TBI group. Conclusions: Severe TBI results in persistent caregiver stress for a substantial proportion of families.	Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; Case Western Reserve Univ, Dept Pediat Psychol, Cleveland, OH 44106 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA		Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURCHINAL MR, 1994, J EARLY INTERVENTION, V18, P422; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1993, BSI BRIEF SYMPTOM IN; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1988, LANCET, V14, P480; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1994, LIFE STRESSORS SOCIA; Noller P., 1988, ICPS FAMILY FUNCTION; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; *SAS I I, 1990, STAT AN SYST VERS 6; Silverberg S. B., 1996, PARENTAL EXPERIENCE, P215; SILVERBERG SB, 1987, J YOUTH ADOLESCENCE, V16, P293, DOI 10.1007/BF02139096; SILVERBERG SB, 1990, DEV PSYCHOL, V26, P658, DOI 10.1037/0012-1649.26.4.658; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2000, NEUROPSYCHOLOGY, P14; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	47	97	99	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					96	111		10.1097/00001199-200204000-00003			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500003	11909509				2022-02-06	
J	Singleton, RH; Zhu, JP; Stone, JR; Povlishock, JT				Singleton, RH; Zhu, JP; Stone, JR; Povlishock, JT			Traumatically induced axotomy adjacent to the soma does not result in acute neuronal death	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; traumatic axonal injury; axotomy; axon reaction; rat; protein translation; TUNEL	EXPERIMENTAL BRAIN INJURY; FLUID-PERCUSSION MODEL; PIG OPTIC-NERVE; AXONAL INJURY; CORTICOSPINAL NEURONS; STRETCH INJURY; CYTOCHEMICAL EVIDENCE; HEAD-INJURY; CELL-DEATH; IN-VIVO	Traumatic axonal injury (TAI), a consequence of traumatic brain injury (TBI), results from progressive pathologic processes initiated at the time of injury. Studies attempting to characterize the pathology associated with TAI have not succeeded in following damaged and/or disconnected axonal segments back to their individual neuronal somata to determine their fate. To address this issue, 71 adult male Sprague Dawley rats were subjected to moderate central fluid percussion injury and killed between 30 min and 7 d after injury. Antibodies to the C terminus of beta-amyloid precursor protein (APP) identified TAI in continuity with individual neuronal somata in the mediodorsal neocortex, the hilus of the dentate gyrus, and the dorsolateral thalamus. These somata were followed with immunocytochemical markers of neuronal injury targeting phosphorylated 200 kDa neurofilaments (RMO-24), altered protein translation (phosphorylated eukaryotic translation initiation factor 2alpha), and cell death [terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)], with parallel electron microscopic (EM) assessment. Despite the finding of TAI within 20-50 mum of the soma, no evidence of cell death, long associated with proximal axotomy, was seen via TUNEL or routine light microscopy/ electron microscopy. Rather, there was rapid onset (<6 hr after injury) subcellular change associated with impaired protein synthesis identified by EM, immunocytochemical, and Western blot analyses. When followed 7 d after injury, these abnormalities did not reveal dramatic progression. Rather, some somata showed evidence of potential reorganization and repair. This study demonstrates a novel somatic response to TAI in the perisomatic domain and also provides insight into the multifaceted pathology associated with TBI.	Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA 23298 USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22904 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS007288, NS20193, R01 NS020193, T32NS007288] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; BARRON KD, 1979, J NEUROPATH EXP NEUR, V38, P128, DOI 10.1097/00005072-197903000-00005; Barron KD., 1983, SPINAL CORD RECONSTR, P7; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brown A, 1998, J CELL SCI, V111, P455; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CONRADI S, 1969, ACTA PHYSIOL SCAND, P53; CONRADI S, 1969, ACTA PHYSIOL SCAND, P65; Conti AC, 1998, J NEUROSCI, V18, P5663; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DENTINGER MP, 1979, J NEUROPATH EXP NEUR, V38, P551, DOI 10.1097/00005072-197909000-00008; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EGAN DA, 1977, ACTA NEUROPATHOL, V37, P13, DOI 10.1007/BF00684534; Emery DL, 2000, J COMP NEUROL, V424, P521; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; KOLIATSOS VE, 1989, BRAIN RES, V482, P205, DOI 10.1016/0006-8993(89)91183-9; Kreutzberg Georg W., 1995, P355; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.3.CO;2-R; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; MERLINE M, 1990, J COMP NEUROL, V296, P506, DOI 10.1002/cne.902960313; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RINK A, 1995, AM J PATHOL, V147, P1575; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; Shields DC, 2000, J NEUROSCI RES, V61, P146; SIEGEL SE, 1999, BASIC NEUROCHEMISTRY; SINGH LP, 1994, ENZYME PROTEIN, V48, P61, DOI 10.1159/000474972; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Teramoto N, 1998, J VIROL METHODS, V73, P89, DOI 10.1016/S0166-0934(98)00048-2; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	61	97	98	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 1	2002	22	3					791	802		10.1523/JNEUROSCI.22-03-00791.2002			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	518HB	WOS:000173660800029	11826109	Bronze, Green Published			2022-02-06	
J	Doig, E; Fleming, J; Tooth, L				Doig, E; Fleming, J; Tooth, L			Patterns of community integration 2-5 years post-discharge from brain injury rehabilitation	BRAIN INJURY			English	Article							QUALITY-OF-LIFE; CLOSED-HEAD-INJURY; QUESTIONNAIRE; DISABILITIES; IMPAIRMENTS; EMPLOYMENT; RETURN; SCALE; WORK	Outcome after traumatic brain injury (TBI) is characterized by a high degree of variability which has often been difficult to capture in traditional outcome studies. The purpose of this study was to describe patterns of community integration 2-5 years after TBI. Participants were 208 patients admitted to a Brain Injury Rehabilitation Unit between 1991-1995 in Brisbane, Australia. The design comprised retrospective data collection and questionnaire follow-up by mail. Mean follow-up was 3.5 years. Demographic, injury severity and functional status variables were retrieved from hospital records. Community integration was assessed using the Community Integration Questionnaire (CIQ), and vocational status measured by a self administered questionnaire. Data was analysed using cluster analysis which divided the data into meaningful subsets. Based on the CIQ subscale scores of home, social and productive integration, a three cluster solution was selected, with groups labelled as working (n = 78), balanced (n = 46) and poorly integrated (n = 84). Although 38% of the sample returned to a high level of productive activity and 22% achieved a balanced lifestyle, overall community integration was poor for the remainder. This poorly integrated group had more severe injury characterized by longer periods of acute care and post-traumatic amnesia (PTA) and greater functional disability on discharge. These findings have implications for service delivery prior to and during the process of reintegration after brain injury.	Princess Alexandra Hosp, Brain Injury Rehabil Unit, Brisbane, Qld, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld, Australia; Univ Queensland, Dept Social & Prevent Med, Brisbane, Qld, Australia		Doig, E (corresponding author), Princess Alexandra Hosp, Brain Injury Rehabil Unit, Brisbane, Qld, Australia.	emmahdoig@optusnet.com.au	Fleming, Jennifer M/B-4436-2011; Tooth, Leigh/F-2769-2010; Doig, Emmah/AAG-6674-2021	Doig, Emmah/0000-0002-7020-053X; Tooth, Leigh/0000-0002-1569-934X			Bickenbach JE, 1999, SOC SCI MED, V48, P1173, DOI 10.1016/S0277-9536(98)00441-9; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BODIAM C, BRIT J OCCUPATIONAL, V62, P123; BONTKE CF, 1990, COMMUNITY INTEGRATIO, P3; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fleming J, 1999, BRAIN INJURY, V13, P417; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HAIR JF, 1992, MULTIVAR DATA ANAL, P265; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Millis S R, 1994, Int J Neurosci, V79, P165; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OTTENBACHER KJ, 1988, ARCH PHYS MED REHAB, V69, P170; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stilwell P, 1998, CLIN REHABIL, V12, P521, DOI 10.1191/026921598673761855; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; TATE RL, 1988, P INT PERSP BRAIN IN, P415; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1994, BRAIN INJURY REHABIL, P355; WILLIAMS JH, 1991, GERONTOLOGIST, V31, P84, DOI 10.1093/geront/31.1.84; [No title captured]	49	97	97	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2001	15	9					747	762		10.1080/02699050110034343			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400001	11516344				2022-02-06	
J	Oishi, M; Toyama, M; Tamatani, S; Kitazawa, T; Saito, M				Oishi, M; Toyama, M; Tamatani, S; Kitazawa, T; Saito, M			Clinical factors of recurrent chronic subdural hematoma	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						chronic subdural hematoma; recurrence; clinical review; computed tomography; burr hole surgery	CLOSED-SYSTEM DRAINAGE; CRANIOSTOMY	The clinical, radiological, and operative factors of recurrent chronic subdural hematoma (CSDH) were retrospectively analyzed in 116 patients with CSDH in 134 hemispheres, treated by one burr hole surgery. The correlation of recurrence was evaluated with personal and clinical factors such as age, sex, history of head injury, and interval from onset of initial symptoms to hospitalization; laboratory findings such as bleeding tendency and liver function; computed tomography (CT) findings such as hematoma density and brain atrophy; and operative findings such as additional procedures and postoperative residual air. The recurrence group (RG) included 10 hemispheres (7.5%) in 10 patients (8.6%). The interval from onset of symptoms to hospitalization was significantly shorter in the RG than in the non-recurrence group (NRG). Headache was more frequently seen in the RG than in the NRG. Density of hematoma on CT was classified into five types: Low, iso, and high density, niveau, and mixed, and the incidence of recurrence was 0%, 2.3%, 17.2%, 12.5%, and 6.5%, respectively. Larger amounts of residual air in the postoperative hematoma cavity were associated with recurrence of CSDH. CSDH that progresses rapidly in the acute stage and appears as high density on preoperative CT is associated with a high incidence of recurrence. Intraoperative air invasion to the hematoma cavity should be avoided to prevent recurrence.	Nagaoka Red Cross Hosp, Dept Neurosurg, Nagaoka, Niigata, Japan		Oishi, M (corresponding author), Natl Nishi Niigata Chuo Hosp, Dept Neurosurg, Niigata, Japan.						ARBIT E, 1981, SURG NEUROL, V15, P175, DOI 10.1016/0090-3019(81)90133-6; Asano Y, 1992, No To Shinkei, V44, P827; CAMEL M, 1986, J NEUROSURG, V65, P183, DOI 10.3171/jns.1986.65.2.0183; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; Fukuhara T, 1996, SURG NEUROL, V45, P570, DOI 10.1016/0090-3019(95)00471-8; HAMILTON MG, 1993, NEUROSURGERY, V33, P67; ITO H, 1978, J NEUROSURG, V48, P197, DOI 10.3171/jns.1978.48.2.0197; LAUMER R, 1989, NEUROSURGERY, V25, P991, DOI 10.1227/00006123-198912000-00026; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; NAGATA K, 1989, Neurological Surgery, V17, P15; NAGATA K, 1988, Neurological Surgery, V16, P1347; OKU Y, 1984, J NEUROSURG, V61, P269, DOI 10.3171/jns.1984.61.2.0269; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; Suzuki K, 1998, SURG NEUROL, V50, P231, DOI 10.1016/S0090-3019(97)00339-X; Takahashi Yoshihiko, 1996, Neurologia Medico-Chirurgica, V36, P627, DOI 10.2176/nmc.36.627; Tsutsumi K, 1997, J NEUROSURG, V87, P870, DOI 10.3171/jns.1997.87.6.0870; WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006; YOSHII K, 1987, Neurological Surgery, V15, P1065	20	97	106	0	5	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	AUG	2001	41	8					382	386		10.2176/nmc.41.382			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	462FX	WOS:000170411000004	11561348	Bronze			2022-02-06	
J	Maier, B; Schwerdtfeger, K; Mautes, A; Holanda, M; Muller, M; Steudel, WI; Marzi, I				Maier, B; Schwerdtfeger, K; Mautes, A; Holanda, M; Muller, M; Steudel, WI; Marzi, I			Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury	SHOCK			English	Article						brain injury; cytokine; blood-brain barrier	ACUTE-PHASE RESPONSE; RAT-BRAIN; NERVOUS-SYSTEM; ORGAN FAILURE; CYTOKINES; BLOOD; INFLAMMATION; ASTROCYTES; INCREASE; BARRIER	Traumatic brain injury (TBI) is characterized by a high mortality which is largely determined by the initial cerebral trauma, secondary brain injury or indirectly during a Multiple Organ Dysfunction Syndrome (MODS). Therefore, we analyzed IL-6, IL-8, and IL-10 in cerebrospinal fluid (CSF) and in plasma with respect to blood-brain barrier (BBB) integrity in 29 patients suffering from isolated TBI. IL-6 and IL-8 were significantly increased compared to baseline levels early after trauma in CSF and plasma. In all patients CSF IL-6 and IL-8 were found to be higher than corresponding plasma levels. IL-10 in plasma was significantly increased above control plasma values, however, without a significant difference to the corresponding CSF values. BBB dysfunction was temporary present in 23 patients. Significant correlations between BBB dysfunction and cytokines were not found. Thus, alterations of the BBB seems not to influence the distribution pattern of interleukines in CSF and plasma after trauma.	Univ Saarland, Univ Hosp, Sch Med, Dept Trauma Hand & Reconstruct Surg, D-66421 Homburg, Germany; Univ Saarland, Univ Hosp, Sch Med, Dept Neurosurg, D-66421 Homburg, Germany; Univ Saarland, Univ Hosp, Sch Med, Dept Neurol, D-66421 Homburg, Germany		Marzi, I (corresponding author), Univ Frankfurt Klinikum, Dept Trauma Surg, D-60590 Frankfurt, Germany.	marzi@trauma-uni-frankfurt.de					ALOISI F, 1992, J IMMUNOL, V149, P2358; ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Aschner M, 1998, TOXICOL LETT, V103, P283, DOI 10.1016/S0378-4274(98)00324-5; BAGGIOLINI M, 1992, ADV IMMUNOL, V55, P55; BANKS WA, 1994, NEUROSCI LETT, V179, P53, DOI 10.1016/0304-3940(94)90933-4; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; BAUE AE, 1994, SHOCK, V2, P385, DOI 10.1097/00024382-199412000-00001; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bell MJ, 1997, ACT NEUR S, V70, P96; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Ertel W, 1998, UNFALLCHIRURG, V101, P520, DOI 10.1007/s001130050304; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GORIS RJA, 1990, INTENS CARE MED, V16, pS192, DOI 10.1007/BF01709699; Handa Shoichi, 1992, Kurume Medical Journal, V39, P257; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MAIER B, 1999, UNFALLCHIRURGIE, V25, P100; MCCLAIN C, 1991, J CLIN LAB MED, V118, P226; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Rose S, 1996, ZBL CHIR, V121, P896; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; TADA M, 1993, J NEURO-ONCOL, V16, P25, DOI 10.1007/BF01324831; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Woiciechowsky C, 1997, ACTA NEUROCHIR, V139, P619, DOI 10.1007/BF01411996; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	35	97	101	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2001	15	6					421	426		10.1097/00024382-200115060-00002			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	433TX	WOS:000168776800002	11386612				2022-02-06	
J	Huang, CY; Fujimura, M; Noshita, N; Chang, YY; Chan, PH				Huang, CY; Fujimura, M; Noshita, N; Chang, YY; Chan, PH			SOD1 down-regulates NF-kappa B and c-mye expression in mice after transient focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						focal cerebral ischemia; free radicals; superoxide dismutase; NF-kappa B; c-Myc; Apoptosis	CUZN-SUPEROXIDE-DISMUTASE; TRAUMATIC BRAIN INJURY; DNA-BINDING ACTIVITY; TRANSGENIC MICE; NUCLEAR-FACTOR; TRANSCRIPTION FACTOR; GLOBAL-ISCHEMIA; NITRIC-OXIDE; INDUCED APOPTOSIS; HIPPOCAMPAL-NEURONS	Reactive oxygen species (ROS) are implicated in reperfusion injury after focal cerebral ischemia (FCI). Reactive oxygen species regulate activity of transcription factors like NF-kappaB. The authors investigated the role of ROS in NF-kappaB activity after FCI using transgenic mice that overexpressed human coppcr/zinc-superoxide dismutase: (SODI) and that had reduced infarction volume after FCI. Superoxide dismutase transgenic and wild-type mice were subjected to 1 hour of middle cerebral artery occlusion (MCAO) and subsequent reperfusion. Immunohistochemistry showed SODI overexpression attenuated ischemia-induced NF-kappaB p65 immunoreactivity. Colocalization of NF-kappaB and the neuronal marker, microtubule-associated proteins (MAPs), showed that NF-kappaB was up-regulated in neurons after FCI. Electrophoretic mobility shift assays showed that SOD1 overexpression reduced ischemia-induced NF-kappaB DNA binding activity. Supershift assays showed that DNA-protein complexes contained p65 and p50 subunits. Immunoreactivity of c-myc, an NF-kappaB downstream gene, was increased in the ischemic cortex and colocalized with NF-KB. Western blotting showed that SOD1 overexpression reduced NF-KB and c-Myc protein levels in the ischemic brain. Colocalization of c-Myc and TUNEL staining was observed 24 hours after FCI. The current findings provide the first evidence that SOD 1 overexpression attenuates activation of NF-kappaB after transient FCI in mice and that preventing this early activation may block expression of downstream deleterious genes like c-myc, thereby reducing ischemic damage.	Stanford Univ, Sch Med, Dept Neurol & Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA		Chan, PH (corresponding author), Stanford Univ, Neurosci Lab, MSLS,P304,1201 Welch Rd, Stanford, CA 94305 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14534, NS25372, NS36147] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036147, R01NS025372] Funding Source: NIH RePORTER		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Asanuma M, 1998, MOL BRAIN RES, V60, P305, DOI 10.1016/S0169-328X(98)00188-0; Baichwal VR, 1997, CURR BIOL, V7, P94; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bethea JR, 1998, J NEUROSCI, V18, P3251; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; CHANDNA M, 1994, J PLANT BIOCHEM BIOT, V3, P59, DOI 10.1007/BF03321950; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foo SY, 1999, TRENDS GENET, V15, P229; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; Fujimura M, 1999, STROKE, V30, P2408, DOI 10.1161/01.STR.30.11.2408; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kamii H, 1996, J CEREBR BLOOD F MET, V16, P1153, DOI 10.1097/00004647-199611000-00009; KAMII H, 1995, CENTRAL NERVOUS SYST, V4, P425; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kondo T, 1997, J NEUROSCI, V17, P4180; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Murakami K, 1998, J NEUROSCI, V18, P205; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; Nakagomi T, 1996, NEUROL RES, V18, P559; Nakai M, 1999, MOL BRAIN RES, V64, P59, DOI 10.1016/S0169-328X(98)00310-6; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Namura S, 1998, J NEUROSCI, V18, P3659; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; Petito CK, 1997, J CEREBR BLOOD F MET, V17, P967, DOI 10.1097/00004647-199709000-00006; Qin ZH, 1999, J NEUROSCI, V19, P4023; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	61	97	103	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2001	21	2					163	173		10.1097/00004647-200102000-00008			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	399XK	WOS:000166839400008	11176282	Bronze			2022-02-06	
J	Humm, JL; Kozlowski, DA; Bland, ST; James, DC; Schallert, T				Humm, JL; Kozlowski, DA; Bland, ST; James, DC; Schallert, T			Use-dependent exaggeration of brain injury: Is glutamate involved?	EXPERIMENTAL NEUROLOGY			English	Article						use-dependent; sensorimotor cortex; MK-801; NMDA receptor; glutamate; recovery of function; forelimb use	CENTRAL-NERVOUS-SYSTEM; SENSORIMOTOR CORTEX LESIONS; TASK-SPECIFIC PRACTICE; CORTICAL CELL-CULTURE; NMDA RECEPTOR; NEUROTOXICITY INVITRO; FUNCTIONAL RECOVERY; NEOCORTICAL DAMAGE; NEURONAL INJURY; MOTOR RECOVERY	Extreme overreliance on the impaired forelimb following unilateral lesions of the forelimb representation area of the rat sensorimotor cortex (FL-SMC) leads to exaggeration of the initial cortical injury. Glutamate has repeatedly been implicated in the secondary processes leading to neuronal death following traumatic insult, chiefly because of the neuroprotective properties of excitatory amino acid antagonists in a variety of animal models of brain injury. The present study investigated the possibility that NMDA receptor-mediated processes are involved in use-dependent exaggeration of neuronal injury. Rats were fitted with one-sleeved casts that immobilized the intact forelimb for the first 7 days following FL-SMC lesion, a procedure previously shown to result in use-dependent exaggeration of injury and more severe and persistent limb-use deficits. In the present investigation, administration of MK-801 (1 mg/kg ip once daily on alternate days) during the casting period spared neural tissue surrounding the lesion and enhanced functional recovery of the impaired forelimb. These results suggest a role for NMDA receptor-mediated processes in use-dependent exaggeration of injury. (C) 1999 Academic Press.	Univ Texas, Dept Psychol, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA		Humm, JL (corresponding author), Univ Texas, Dept Psychol, Mezes 330, Austin, TX 78712 USA.	humm@mail.utexas.edu		Bland, Sondra/0000-0002-5790-089X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023964] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 23964] Funding Source: Medline		ANGEL A, 1975, J PHYSIOL-LONDON, V248, P465, DOI 10.1113/jphysiol.1975.sp010984; BARTH TM, 1990, STROKE S3, V21, P1; BIELENBERG GW, 1991, BRAIN RES, V552, P338, DOI 10.1016/0006-8993(91)90101-Z; BLAND ST, 1997, SOC NEUR ABSTR, V23; BOXER PA, 1990, STROKE, V21, P47; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P357; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAY J, 1991, PHARMACOL BIOCHEM BE, V38, P723, DOI 10.1016/0091-3057(91)90233-R; DERYCK M, 1992, BRAIN RES, V573, P44; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIMAGL U, 1990, BRAIN RES, V527, P62; FINGER S, 1982, PHYSIOL BEHAV, V29, P73, DOI 10.1016/0031-9384(82)90368-7; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; FOSTER AC, 1988, J NEUROSCI, V8, P4745; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1993, STROKE, V24, pI84; GOLDSTEIN LB, 1992, BRAIN RES, V580, P129, DOI 10.1016/0006-8993(92)90936-4; GOLDSTEIN LB, 1993, J NEUROSCI METH, V48, P35, DOI 10.1016/S0165-0270(05)80005-6; GOLDSTEIN LB, 1995, BRAIN RES, V674, P167, DOI 10.1016/0006-8993(95)00021-H; HARGREAVES EL, 1992, BEHAV BRAIN RES, V47, P23, DOI 10.1016/S0166-4328(05)80249-9; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Keefe KA, 1996, J COMP NEUROL, V367, P165, DOI 10.1002/(SICI)1096-9861(19960401)367:2<165::AID-CNE1>3.0.CO;2-3; KIRK RE, 1965, EXPT DESIGN PROCEDUR; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; Kozlowski DA, 1997, BRAIN RES, V763, P159, DOI 10.1016/S0006-8993(97)00377-6; LEVERE TE, 1980, PHYSIOL PSYCHOL, V8, P297, DOI 10.3758/BF03337462; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MICHAELS RL, 1990, J NEUROSCI, V10, P283; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Ogden R., 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; OSTENDORF CG, 1981, J AM PHYS THER ASSOC, V61, P1022; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; ROYET JP, 1991, PROG NEUROBIOL, V37, P433, DOI 10.1016/0301-0082(91)90009-P; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SAPONJIC RM, 1995, RESTOR NEUROL NEUROS, V8, P205, DOI 10.3233/RNN-1995-8406; Schallert T, 1998, RESTORATIVE NEUROLOGY, P91; SCHALLERT T, 1990, CAN J PSYCHOL, V44, P276, DOI 10.1037/h0084244; Schallert T, 1997, ADV NEUROL, V73, P229; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1997, BEHAV BRAIN RES, V89, P51, DOI 10.1016/S0166-4328(97)00049-1; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THANOS S, 1993, J NEUROSCI, V13, P455; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P19, DOI 10.1016/0165-0270(86)90111-1; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; WEBSTER HH, 1991, SOMATOSENS MOT RES, V8, P327, DOI 10.3109/08990229109144756; Whishaw IQ, 1996, BEHAV BRAIN RES, V77, P135, DOI 10.1016/0166-4328(95)00209-X; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	62	97	106	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	1999	157	2					349	358		10.1006/exnr.1999.7061			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	202LD	WOS:000080653000012	10364446				2022-02-06	
J	Rapport, LJ; Hanks, RA; Millis, SR; Deshpande, SA				Rapport, LJ; Hanks, RA; Millis, SR; Deshpande, SA			Executive functioning and predictors of falls in the rehabilitation setting	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; COMA; BIAS	Objective: To examine the incremental utility of executive function tests in the prediction of inpatient falls. Design: Evaluation of neuropsychologic and medical risk factors for fall was completed at admission. Inpatient falls were tabulated following discharge. Setting: A freestanding, urban rehabilitation hospital. Patients: Ninety consecutive admissions to traumatic brain injury, orthopedic, and spinal cord injury wards. Age of the participants ranged from 17 to 73 years old. Main Outcome Measure: Incident reports of inpatient falls. Results: Standard multiple regression analyses indicated that measures of executive functioning sensitive to self-monitoring accounted for unique variance in falls beyond that explained by age and functional motor ability as assessed by the Functional Independence Measure. Visuospatial functioning, although not directly related to falls, was a significant predictor in combination with measures of executive functioning. Together, these variables accounted for 30.3% of the variance in inpatient falls (multiple r = .55; p < .001). Conclusion: The findings suggest that the influence of motor and sensory impairments on falls are moderated, in part, by executive functioning. Patients with intact executive functioning are less likely to act in ways that could result in a fall; thus, aggressive fall prevention measures may be unnecessary. In contrast, executive dysfunction may signal the need for intervention, even among patients whose profiles are unremarkable with regard to traditional risk factors for fall. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Rehabil Inst Michigan, Dept Rehabil Psychol & Neurophychol, Detroit, MI USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.			Rapport, Lisa/0000-0001-8014-9523			Baker S P, 1985, Clin Geriatr Med, V1, P501; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benson D.F., 1986, FRONTAL LOBES; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Cummings J, 1985, CLIN NEUROPSYCHIATRY; FLETCHER KR, 1990, RN               JAN, P52; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; Grant J S, 1987, Rehabil Nurs, V12, P74; Heaton R. K., 1982, MANUAL CARD SORTING; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Luria A.R., 1973, WORKING BRAIN INTRO; Millis S R, 1994, Int J Neurosci, V79, P165; Mion L C, 1989, Rehabil Nurs, V14, P17; Moore CA, 1996, REHABIL PSYCHOL, V41, P115; MORGAN VR, 1985, AM J PUBLIC HEALTH, V75, P775, DOI 10.2105/AJPH.75.7.775; Nanna MJ, 1997, J APPL GERONTOL, V16, P120, DOI 10.1177/073346489701600107; Paolucci S, 1996, EUR NEUROL, V36, P385, DOI 10.1159/000117298; Persad C. C., 1995, J GERONTOL B-PSYCHOL, V50, P272, DOI 10.1093/geronb/50B.5.P272.; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; RAPPORT LJ, 1995, CLIN NEUROPSYCHOL, V9, P169, DOI 10.1080/13854049508401599; ROBB SS, 1986, NURS RES, V35, P113; Rubenstein LZ, 1996, CLIN GERIATR MED, V12, P881; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SEIDEL GK, 1994, ARCH PHYS MED REHAB, V75, P590; Spreen O, 1991, COMPENDIUM NEUROPSYC; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TEASDALE G, 1974, LANCET, V2, P81; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; TUFFNELL C, 1990, World Health Forum, V11, P282; *UN DAT SYST MED R, 1993, UN DAT SYST FUNC DEP; VLAHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; WEBSTER JS, 1995, ARCH PHYS MED REHAB, V76, P924, DOI 10.1016/S0003-9993(95)80068-9; WEBSTER JS, 1994, J CLIN EXP NEUROPSYC, V16, P129, DOI 10.1080/01688639408402623; Weschler D. A., 1987, WECHSLER MEMORY SCAL; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; Wolfson L I, 1985, Clin Geriatr Med, V1, P649	41	97	97	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1998	79	6					629	633		10.1016/S0003-9993(98)90035-1			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	ZT554	WOS:000074099500005	9630140				2022-02-06	
J	Hoffman, SW; Moore, S; Ellis, EF				Hoffman, SW; Moore, S; Ellis, EF			Isoprostanes: Free radical-generated prostaglandins with constrictor effects on cerebral arterioles	STROKE			English	Article						brain injuries; cerebral circulation; cerebral ischemia; lipid peroxidation; oxygen radical; rats	EXPERIMENTAL HEAD-INJURY; LOW-DENSITY-LIPOPROTEIN; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; BRAIN INJURY; F2-ISOPROSTANE; RECEPTOR; RATS; ANTAGONIST; EXISTENCE	Background and Purpose Isoprostanes are generated by cyclooxygenase-independent free radical attack of arachidonic acid and are potent constrictors of the peripheral vasculature. Traumatic brain injury stimulates oxygen radical production and is associated with cerebral blood flow reduction. However, no specific vasoconstrictor has been identified as the cause of posttraumatic blood flow reduction. The purpose of this study was to determine whether isoprostanes constrict cerebral arterioles. Methods The effects of 10(-9) to 10(-5) mol/L 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)), S-iso-prostaglandin E(2) (8-isol-PGE(2)), and prostaglandin F-2 alpha (PGF(2 alpha)) on pial arteriolar diameter were measured in anesthetized rats using a closed cranial window and in vivo microscopy. Results All prostanoids produced vasoconstriction. Of these, 8-iso-PGF(2 alpha) produced the greatest vasoconstriction (34% +/- 2), followed by 8-iso-PGE(2) (25% +/- 4) and PGF(2 alpha) (20% +/- 2). After six cerebrospinal fluid washouts of the cranial window, both 8-iso-PGF(2 alpha),- and 8-iso-PGE(2)-treated vessels remained slightly constricted, whereas the PGF(2a)-treated vessels returned to control diameter, Coapplication of the semiselective thromboxane A(2)/prostaglandin H-2 receptor antagonist SQ29548 completely blocked the vasoconstriction induced by 8-iso-PGF(2a) and 8-iso-PGE(2). Conclusions Isoprostanes are potent constrictors of cerebral arterioles and appear to act at a receptor that is similar to the thromboxane A(2)/prostaglandin H-2 receptor. Isoprostanes may play a role in the reduction of cerebral blood flow that occurs after brain injury and subsequent oxygen radical production.			Hoffman, SW (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, POB 980613, 410 N 12TH ST, RICHMOND, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214, NS-07288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		AWAD JA, 1993, J BIOL CHEM, V268, P4161; BAEZ S, 1966, J APPL PHYSIOL, V21, P229; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Caron M J, 1991, Neurosurg Clin N Am, V2, P483; CHAN KH, 1993, ACTA NEUROCHIR, P81; CLARK WM, 1995, DRUGS, V50, P971, DOI 10.2165/00003495-199550060-00005; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; FADEL MM, 1995, SURG NEUROL, V43, P52, DOI 10.1016/0090-3019(95)80038-I; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FUKUNAGA M, 1993, BIOCHEM BIOPH RES CO, V195, P507, DOI 10.1006/bbrc.1993.2075; GAETANI P, 1994, NEUROCHEM RES, V19, P839, DOI 10.1007/BF00967453; GOPAUL NK, 1994, BIOCHEM BIOPH RES CO, V200, P338, DOI 10.1006/bbrc.1994.1453; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; MAYHAN WG, 1992, AM J PHYSIOL, V262, pH539, DOI 10.1152/ajpheart.1992.262.2.H539; McIntosh TK, 1996, LAB INVEST, V74, P315; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; Mohler ER, 1996, BIOCHEM BIOPH RES CO, V225, P915, DOI 10.1006/bbrc.1996.1272; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; ROBERTS LJ, 1995, ADV PROSTAG THROMB L, V23, P219; ROSENBLUM WI, 1975, STROKE, V6, P293, DOI 10.1161/01.STR.6.3.293; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; Smith D H, 1995, New Horiz, V3, P562; SUZUKI S, 1994, ACTA NEUROCHIR, V131, P184, DOI 10.1007/BF01808610; WAGERLE LC, 1990, CIRC RES, V66, P824, DOI 10.1161/01.RES.66.3.824; WHITE RP, 1982, PHARMACOL THERAPEUT, V18, P313, DOI 10.1016/0163-7258(82)90035-3	39	97	100	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	1997	28	4					844	849		10.1161/01.STR.28.4.844			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	WR454	WOS:A1997WR45400031	9099206				2022-02-06	
J	Zafonte, RD; Hammond, FM; Mann, NR; Wood, DL; Black, KL; Millis, SR				Zafonte, RD; Hammond, FM; Mann, NR; Wood, DL; Black, KL; Millis, SR			Relationship between Glasgow Coma Scale and functional outcome	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Glasgow Coma Scaler; trauma; head injury outcome	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; PREDICTION; RECOVERY; PROGNOSIS; TRAUMA; REHABILITATION; PRESSURE	The Glasgow Coma Scale (GCS) is routinely used in the acute care setting after traumatic brain injury (TBI) to guide decisions in triage, based on its ability to predict morbidity and mortality. Although the CCS has been previously demonstrated to predict mortality, efficacy in prediction of functional outcome has not been I established, The purpose of this study was to assess the value of the acute GCS in predicting functional outcome in survivors of TBI. This study used the Multicenter National Institute on Disability and Rehabilitation Research TBI Model Systems database of 501 patients who had received acute medical care and inpatient rehabilitation within a coordinated neurotrauma program for treatment of TBI. Initial and lowest 24 hr GCS scores were correlated with the following outcome measures: the Disability Rating Scale (DRS), Rancho Los Amigos Levels of Cognitive Functioning Scale (LCFS), and cognitive and motor components of the Functional independence Measure (FIM(SM)-COG and FIM(SM)-M). Outcome data were collected at admission to and discharge from the inpatient TBI rehabilitation unit, Correlation analysis revealed only modest, but statistically significant, relationships between initial and lowest GCS scores and outcome variables. Initial and lowest GCS score comparison with outcome demonstrated the following correlation coefficients; admission DRS, -0.25 and -0.28; discharge DRS, -0.24 and -0.24; admission LCFS, 0.31 and 0.33; discharge LCFS, 0.27 and 0.25; admission FIM-COG, 0.36 and 0.37; discharge FIM-COG, 0.23 and 0.23; admission FIM-M, 0.31 and 0.31; discharge FIM-M, 0.25 and 0.21. The GCS as a single Variable may have limited value as a predictor of functional outcome.	WAYNE STATE UNIV,SCH MED,DETROIT,MI		Zafonte, RD (corresponding author), REHABIL INST MICHIGAN,PHYSICIAN SERV,261 MACK BLVD,DETROIT,MI 48201, USA.						CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FACCO E, 1986, CHILD NERV SYST, V2, P67; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; IMES C, 1983, COGNITIVE REHABILITA, V1, P11; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; *STAT U NEW YORK B, 1990, GUID US UN DAT SET M; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, ANN NY ACAD SCI, P82; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140	26	97	101	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP-OCT	1996	75	5					364	369		10.1097/00002060-199609000-00012			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	VP517	WOS:A1996VP51700009	8873704				2022-02-06	
J	Feldman, Z; Gurevitch, B; Artru, AA; Oppenheim, A; Shohami, E; Reichenthal, E; Shapira, Y				Feldman, Z; Gurevitch, B; Artru, AA; Oppenheim, A; Shohami, E; Reichenthal, E; Shapira, Y			Effect of magnesium given 1 hour after head trauma on brain edema and neurological outcome	JOURNAL OF NEUROSURGERY			English	Article						head injury; brain edema; neurological outcome; magnesium; rat	EXCITATORY AMINO-ACIDS; VOLTAGE-DEPENDENT BLOCK; NERVOUS-SYSTEM INJURY; GLUTAMATE NEUROTOXICITY; BARRIER PERMEABILITY; ACTIVATED CHANNELS; CEREBRAL EDEMA; RATS; BLOOD; NEURONS	Excitatory amino acids (EAA), mainly glutamate and aspartate, are released in excessive amounts from terminals of ischemic or traumatically injured neurons. These excessive levels of EAAs initiate a cascade of events believed to lead to secondary delayed damage to the surrounding brain. The N-methyl-D-aspartate receptor antagonists MK-801 and ketamine are reported to suppress excessive EAA release and to attenuate the development of focal brain edema following neuronal injury. Magnesium is also reported to work at the postsynaptic receptor to reduce the neurotoxic effect of glutamate. The present study was undertaken to examine the effect of postinjury treatment with Mg++ on brain edema and neurological outcome after traumatic brain injury. Sixty-nine rats that survived halothane anesthesia and closed head trauma (CHT) were randomly assigned to one of seven experimental groups: sham, CHT, and CHT with administration of Mg++ 1 hour postinjury. At 48 hours, brain tissue Mg++ concentration (calculated from optical density using a standard curve) was significantly increased compared to baseline levels (10.06 +/- 2.44 mg/g vs. 6.83 +/- 0.81 mg/g, p < 0.01 calculated by one-way analysis of variance). Also at 48 hours postinjury, brain tissue specific gravity in the contused hemisphere of Mg++-treated rats was significantly greater than that in the contused hemisphere of untreated rats, indicating attenuation of brain edema formation by Mg++. The neurological severity score (NSS) of rats treated with Mg++ improved significantly at both 18 and 48 hours, compared to baseline values obtained 1 hour after CHT but prior to administration of Mg++ (11.2 +/- 2.5 vs. 15.2 +/- 4.1, p = 0.03; and 12.3 +/- 6.1 vs. 17.3 +/- 3.6, p = 0.004, respectively). In the untreated groups, the NSS at 18 and 48 hours was not significantly different from baseline values (that is, no neurological improvement). The present study indicates that postinjury treatment with Mg++ attenuates brain edema formation and improves neurological outcome after experimental CHT.	SOROKA MED CTR,DEPT NEUROSURG,IL-84101 BEER SHEVA,ISRAEL; SOROKA MED CTR,DEPT ANESTHESIOL,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,BEER SHEVA,ISRAEL; UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98195; HADASSAH MED CTR,DEPT ANESTHESIOL,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL					Feldman, Zeev/0000-0002-9719-3894			ALEXANDER SC, 1975, BLOOD FLOW METABOLIS; ARTRU AA, 1988, J CEREBR BLOOD F MET, V8, P750, DOI 10.1038/jcbfm.1988.123; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLARK AF, 1980, J BIOL CHEM, V255, P6556; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FELDMAN Z, 1995, J NEUROSURG, V83, P1060, DOI 10.3171/jns.1995.83.6.1060; FISCHER S, 1993, EUR J PHARMACOL, V232, P121, DOI 10.1016/0014-2999(93)90736-2; FORSTER A, 1978, ANESTHESIOLOGY, V49, P26, DOI 10.1097/00000542-197807000-00008; GARFINKEL L, 1985, Magnesium, V4, P60; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GJEDDE A, 1980, J NEUROCHEM, V35, P1382, DOI 10.1111/j.1471-4159.1980.tb09013.x; GUMERLOCK MK, 1990, NEUROSURGERY, V26, P268, DOI 10.1227/00006123-199002000-00014; HANNAN CJ, 1988, 4 COLL BIOL SCI BLOO, V529, P172; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, SYNAPSE, V6, P179, DOI 10.1002/syn.890060210; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NEMOTO EM, 1978, ANESTHESIOLOGY, V49, P170, DOI 10.1097/00000542-197809000-00004; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PASHAYAN AG, 1988, ANESTHESIOLOGY REV, V15, P30; PATEL AJ, 1988, BRAIN RES, V450, P378, DOI 10.1016/0006-8993(88)91579-X; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROTHE F, 1993, NEUROREPORT, V4, P205, DOI 10.1097/00001756-199302000-00023; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SAGE JI, 1979, J NEUROCHEM, V33, P963, DOI 10.1111/j.1471-4159.1979.tb09930.x; SAIJA A, 1989, NEUROPHARMACOLOGY, V28, P997, DOI 10.1016/0028-3908(89)90202-5; SCHETTINI A, 1979, BRIT J ANAESTH, V51, P1117, DOI 10.1093/bja/51.12.1117; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1993, EUR J ANAESTH, V10, P155; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1989, PROSTAG LEUKOTR ESS, V36, P49, DOI 10.1016/0952-3278(89)90162-2; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SHOHAMI E, 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P103; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; STEWART PA, 1988, BRAIN RES, V443, P12, DOI 10.1016/0006-8993(88)91593-4; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WOLF G, 1991, NEUROSCIENCE, V43, P31, DOI 10.1016/0306-4522(91)90413-I	69	97	102	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1996	85	1					131	137		10.3171/jns.1996.85.1.0131			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UT668	WOS:A1996UT66800020	8683262				2022-02-06	
J	MOORE, AD; STAMBROOK, M				MOORE, AD; STAMBROOK, M			COGNITIVE MODERATORS OF OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY - A CONCEPTUAL-MODEL AND IMPLICATIONS FOR REHABILITATION	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; SPINAL-CORD INJURY; STAGE RENAL-DISEASE; CHRONIC ILLNESS; HEALTH LOCUS; CT SCAN; DEPRESSION; HELPLESSNESS; ATTRIBUTIONS; PREDICTORS	This paper presents a conceptual model describing the relationships between quality of life outcomes following traumatic brain injury (TBI), coping patterns, and beliefs regarding self-efficacy to assist health-care professionals in understanding the complexity of social and psychological sequelae of TBI. The model hypothesizes that long-lasting cognitive, behavioural, emotional psychiatric, and interpersonal after-effects of TBI may create a real life 'learned helplessness' with consequent deficits in coping, and altered locus of control beliefs. As a result, TBI patients are at risk for developing self-limiting belief systems about their effectiveness in altering significant events that may result in over-generalizing the effects that TBI has in their day-to-day lives. Subsequently, a feedback loop may be set up where their beliefs in not being able to influence outcomes are not tested, life chances are further restricted, outcomes are suboptimal, and quality of life is reduced. The clinical and theoretical implications of this model are discussed, and an expanded model with future research directions is suggested.	UNIV MANITOBA,HLTH SCI CLIN RES CTR,MANITOBA ADOLESCENT TREATMENT CTR,DEPT PSYCHIAT & MED,WINNIPEG,MB,CANADA		MOORE, AD (corresponding author), MANITOBA ADOLESCENT TREATMENT CTR,HLTH SCI CLIN RES CTR,SOC MANITOBANS DISABIL,WINNIPEG,MB R3A 1MS,CANADA.						ABRAMSON LY, 1989, PSYCHOL REV, V96, P358, DOI 10.1037/0033-295X.96.2.358; ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037/0021-843X.87.1.49; ALLOY LB, 1988, BRIT J CLIN PSYCHOL, V27, P5, DOI 10.1111/j.2044-8260.1988.tb00749.x; Beck A.T., 1967, DEPRESSION CLIN; Beck A.T., 1979, COGNITIVE THEORY DEP; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERROL S, 1989, MILD MODERATE HEAD I, P135; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; BUTLER RW, 1988, PROF PSYCHOL-RES PR, V19, P536, DOI 10.1037/0735-7028.19.5.536; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cooper PR, 1987, HEAD INJURY, P313; CRISSON JE, 1988, PAIN, V35, P147, DOI 10.1016/0304-3959(88)90222-9; DEVINS GM, 1981, J ABNORM PSYCHOL, V90, P531, DOI 10.1037/0021-843X.90.6.531; DEVINS GM, 1986, INT J PSYCHIAT MED, V16, P151; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FARID BT, 1988, J STUD ALCOHOL, V49, P375, DOI 10.15288/jsa.1988.49.375; FELTON BJ, 1987, PSYCHOL AGING, V2, P164, DOI 10.1037/0882-7974.2.2.164; FELTON BJ, 1984, SOC SCI MED, V10, P889; FIEFEL H, 1987, PSYCHOSOM MED, V49, P616; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; Folkman S., 1984, STRESS; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FORREST DV, 1987, AM PSYCHIATRIC PRESS, P387; FRANK RG, 1987, J CONSULT CLIN PSYCH, V55, P727; FRANK RG, 1989, PARAPLEGIA, V27, P250, DOI 10.1038/sc.1989.37; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOUVIER D, 1986, NEUROPSYCHOLOGY HDB, P278; Gronwall D, 1989, MILD HEAD INJURY, P153; HAWRYLUK GA, 1989, CANADIAN PSYCHOL, V30, P235; KASSUM DA, 1984, CAN J SURG, V27, P64; Kolb B, 1985, FUNDAMENTALS HUMAN N; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; LEFCOURT HM, 1981, RES LOCUS CONTROL CO, V2, P253; LEVENSON H, 1974, J PERS ASSESS, V38, P377, DOI 10.1080/00223891.1974.10119988; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1989, MILD MODERATE HEAD I, P153; LEVIN HS, 1990, NOV M NAT AC NEUR RE; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LOWERY BJ, 1987, NURS RES, V36, P88; LOWERY BJ, 1984, NURS RES, V34, P82; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MCGLASHAN TH, 1975, ARCH GEN PSYCHIAT, V32, P1269; MCGLASHAN TH, 1981, AM J PSYCHIAT, V138, P797; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McNair DM, 1971, EITS MANUAL PROFILE; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; Moore A D, 1994, NeuroRehabilitation, V4, P122, DOI 10.3233/NRE-1994-4208; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; Moore A. D., 1990, PSYCHOL ASSESSMENT, V2, P98, DOI [10.1037/1040-3590.2.1.98, DOI 10.1037/1040-3590.2.1.98]; MOORE AD, 1993, CANADIAN J REHABILIT, V6, P89; MOORE AD, 1989, THESIS U MANITOBA WI; NICASSIO PM, 1985, J RHEUMATOL, V12, P462; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; OHARA C, 1988, COGNITIVE REHABILITA, V6, P26; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PETERS LC, 1988, CANADIAN J REHABI S4, V1, P60; PETERSON C, 1982, COGNITIVE THER RES, V6, P287, DOI 10.1007/BF01173577; ROLLAND JS, 1987, CHANGING FAMILY LIFE, P453; ROSENBAUM M, 1977, J CLIN PSYCHOL, V33, P672, DOI 10.1002/1097-4679(197707)33:3<672::AID-JCLP2270330314>3.0.CO;2-3; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Seligman M., 1975, HELPLESSNESS; SHADISH WR, 1981, J CONSULT CLIN PSYCH, V49, P297, DOI 10.1037/0022-006X.49.2.297; SILVER JM, 1987, AM PSYCHIAT PRESS HD, P179; SOLOMON Z, 1989, BRIT J CLIN PSYCHOL, V28, P131, DOI 10.1111/j.2044-8260.1989.tb00823.x; SOSKIS DA, 1969, J NERV MENT DIS, V149, P443, DOI 10.1097/00005053-196912000-00001; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STAMBROOK M, 1990, CAN J SURG, V33, P115; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; STAMBROOK M, 1988, CANADIAN J REHABI S4, V1, P74; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; TAYLOR SE, 1984, J PERS SOC PSYCHOL, V46, P489, DOI 10.1037/0022-3514.46.3.489; TAYLOR SE, 1989, HLTH PSYCHOL; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VINEY LL, 1982, J PSYCHOSOM RES, V26, P595, DOI 10.1016/0022-3999(82)90075-7; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WARNER R, 1989, AM J ORTHOPSYCHIAT, V59, P398, DOI 10.1111/j.1939-0025.1989.tb01675.x; Wechsler, 1997, WECHSLER ADULT INTEL; WISE TN, 1988, J PSYCHOSOM RES, V26, P247; [No title captured], DOI DOI 10.1080/09602019108520164; [No title captured]; [No title captured]; [No title captured]	99	97	98	0	12	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1995	9	2					109	130		10.3109/02699059509008185			22	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QN628	WOS:A1995QN62800001	7787832				2022-02-06	
J	DAVIS, RL; MULLEN, N; MAKELA, M; TAYLOR, JA; COHEN, W; RIVARA, FP				DAVIS, RL; MULLEN, N; MAKELA, M; TAYLOR, JA; COHEN, W; RIVARA, FP			CRANIAL COMPUTED-TOMOGRAPHY SCANS IN CHILDREN AFTER MINIMAL HEAD-INJURY WITH LOSS OF CONSCIOUSNESS	ANNALS OF EMERGENCY MEDICINE			English	Article								Study objective: To assess the need for cranial computed tomography (CT) in the emergency department evaluation of children with Glasgow Coma Scale (GCS) score of 15 after mild head injury with loss of consciousness. Design: Retrospective case series of children aged 2 to 17 years with documented loss of consciousness after head injury from January 1, 1988, to July 31, 1992. All had a GCS score of 15 on initial ED evaluation and were further categorized according to physical examination findings, neurologic status, and whether the head injury was isolated or nonisolated. Recursive partitioning was used to identify variables predictive of the presence and absence of intracranial hemorrhage. Setting: ED in two settings: a regional tertiary care trauma center and a community children's hospital. Results: Of the 185 patients who met study criteria, 17 had evidence of depressed or basilar skull fractures on physical examination or had a ventriculoperitoneal shunt in place before head injury. In the remaining 168 patients, recursive partioning identified two variables (neurologic status and head injury type) associated with intracranial hemorrhage. Overall, 12 of 168 patients (7%) had intracranial bleeding. However, none of the 49 neurologically normal children with isolated head injury had intracranial hemorrhage (95% confidence interval, 0.0 to 6.0). Conclusion: The prevalence of intracranial hemorrhage in children with mild closed-head injury appears to vary with the presence of neurologic abnormalities and other noncranial injuries. After isolated head injury with loss of consciousness, children older than 2 years who are neurologically normal and without signs of depressed or basilar skull fracture may be discharged home from the ED without a cranial CT scan after careful physical examination alone.			DAVIS, RL (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,WJ-10,SEATTLE,WA 98195, USA.							0	97	97	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	OCT	1994	24	4					640	645		10.1016/S0196-0644(94)70273-X			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	PJ498	WOS:A1994PJ49800004	8092590				2022-02-06	
J	REGAN, RF; CHOI, DW				REGAN, RF; CHOI, DW			THE EFFECT OF NMDA, AMPA/KAINATE, AND CALCIUM-CHANNEL ANTAGONISTS ON TRAUMATIC CORTICAL NEURONAL INJURY IN CULTURE	BRAIN RESEARCH			English	Article						CALCIUM; CELL CULTURE; CEREBRAL CORTEX; EXCITOTOXICITY; GLUTAMATE; HEAD TRAUMA; NEUROTOXICITY	EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; BRAIN INJURY; GLUTAMATE NEUROTOXICITY; CELL-CULTURE; RECEPTOR; BLOCKADE; EXCITOTOXICITY; INVITRO	A traumatic insult was delivered to murine cortical neuronal and glial cell cultures by tearing the cell layer with a stylet in a grid pattern. Consistent with prior observations, neurons adjacent to a tear developed immediate swelling, and then went on to degenerate over the next several hours. Delivery of multiple tears produced enough cell death that measurable levels of lactate dehydrogenase accumulated in the bathing medium 24 h later, correlating well with the extent of cell death as assessed by Trypan blue exclusion and cell counts. 50-75% of this trauma-induced cell death was blocked by the NMDA receptor antagonist MK-801. 10-100 mu M CNQX also attenuated neuronal degeneration, but this neuroprotective effect was likely due to attenuation of NMDA receptor-mediated toxicity, since the more specific AMPA/kainate antagonist NBQX was ineffective. CNQX also did not augment the protective effect of MK-801. High concentrations of nimodipine or nifedipine produced modest neuroprotective effects; either dihydropyridine when combined with MK-801 reduced injury more than MK-801 alone. These results suggest that traumatic neuronal death in this in vitro model is mediated in part by excessive activation of NMDA receptors, and in part by mechanisms sensitive to high concentrations of dihydropyridines, but not by AMPA/kainate receptors.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110		REGAN, RF (corresponding author), THOMAS JEFFERSON UNIV,DEPT SURG,DIV EMERGENCY MED,1020 WALNUT ST,RM 239,THOMPSON BLDG,PHILADELPHIA,PA 19107, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26907] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026907] Funding Source: NIH RePORTER		BIRCH PJ, 1988, EUR J PHARMACOL, V156, P177, DOI 10.1016/0014-2999(88)90163-X; Cannon WB, 1901, AM J PHYSIOL, V6, P91; CARVALHO CAM, 1986, J NEUROCHEM, V47, P1774, DOI 10.1111/j.1471-4159.1986.tb13088.x; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANDSEN A, 1989, J NEUROCHEM, V53, P297, DOI 10.1111/j.1471-4159.1989.tb07327.x; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; GOLDBERG M P, 1988, Society for Neuroscience Abstracts, V14, P745; GOLDBERG M P, 1991, Neurology, V41, P390; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; JONES SW, 1990, J NEUROSCI, V10, P2261; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KOH J, 1991, BRAIN RES, V548, P318, DOI 10.1016/0006-8993(91)91140-V; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1990, J NEUROSCI, V10, P693; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; REGAN R F, 1991, Society for Neuroscience Abstracts, V17, P722; REGAN RF, 1991, ANN EMERG MED, V20, P478; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; UEMATSU D, 1991, NEUROLOGY, V41, P88, DOI 10.1212/WNL.41.1.88; WALSH MP, 1988, BIOCHEM PHARMACOL, V37, P1569, DOI 10.1016/0006-2952(88)90020-2; WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282; YAMIKAMI I, 1989, J CEREB BLOOD FLOW M, V9, P117; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; ZERNIG G, 1990, TRENDS PHARMACOL SCI, V11, P38, DOI 10.1016/0165-6147(90)90040-F	37	97	101	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 7	1994	633	1-2					236	242		10.1016/0006-8993(94)91544-X			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MQ949	WOS:A1994MQ94900030	7907934				2022-02-06	
J	ASARNOW, RF; SATZ, P; LIGHT, R; LEWIS, R; NEUMANN, E				ASARNOW, RF; SATZ, P; LIGHT, R; LEWIS, R; NEUMANN, E			BEHAVIOR PROBLEMS AND ADAPTIVE FUNCTIONING IN CHILDREN WITH MILD AND SEVERE CLOSED HEAD-INJURY	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						MILD CLOSED HEAD INJURY; SEVERE CLOSED HEAD INJURY; BEHAVIOR PROBLEMS; ADAPTIVE FUNCTIONING; CHILDREN	FOLLOW-UP; SEQUELAE		POMONA COLL, CLAREMONT, CA 91711 USA; CASA COLINA HOSP REHABIL MED, POMONA, CA USA		ASARNOW, RF (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT, DIV MENTAL RETARDAT & CHILD PSYCHIAT, LOS ANGELES, CA 90024 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0 1 NS26801] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801] Funding Source: NIH RePORTER		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ALPERN GD, 1984, DEV PROFILE, V2; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BIJUR PE, 1990, PEDIATRICS, V86, P337; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; Ciccetti D., 1984, VINELAND ADAPTIVE BE; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; HAYS WL, 1963, STATISTICS PSYCHOL; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Horowitz I, 1983, Int Rehabil Med, V5, P32; Jennett B, 1989, MILD HEAD INJURY, P23; Kaufman A. S, 1983, KAUFMAN ASSESSMENT B; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS J, IN PRESS PEDIATRICS; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWIS RS, 1989, UNPUB VERBAL MEMORY; LIGHT R, 1989, UNPUB SUSTAINED SELE; LOEBER R, 1991, J ABNORM CHILD PSYCH, V19, P75, DOI 10.1007/BF00910566; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533	25	97	97	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	OCT	1991	16	5					543	555		10.1093/jpepsy/16.5.543			13	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	GL779	WOS:A1991GL77900002	1744804				2022-02-06	
J	ERB, DE; POVLISHOCK, JT				ERB, DE; POVLISHOCK, JT			AXONAL DAMAGE IN SEVERE TRAUMATIC BRAIN INJURY - AN EXPERIMENTAL-STUDY IN CAT	ACTA NEUROPATHOLOGICA			English	Article											ERB, DE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,BOX 709,MCV STN,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587, NS-20193, NS-07288] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Berman A. L., 1968, BRAIN STEM CAT CYTOA; CAJAL SRY, 1928, DEGENERATION REGENER, P599; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRIFFIN JW, 1977, J NEUROPATH EXP NEUR, V36, P214, DOI 10.1097/00005072-197703000-00002; GROSS GW, 1983, J NEUROSCI, V3, P1979; HIGGINS ML, 1980, J NEUROSCI METH, V3, P83; MARTINEZ AJ, 1970, BRAIN RES, V19, P183, DOI 10.1016/0006-8993(70)90433-6; OCHS S, 1982, AXOPLASMIC TRANSPORT, P221; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Tomlinson B, 1970, J CLIN PATHOL S4, V23, P154	23	97	99	1	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.		1988	76	4					347	358		10.1007/BF00686971			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	P6118	WOS:A1988P611800003	2459896				2022-02-06	
J	Gardner, RC; Byers, AL; Barnes, DE; Li, YX; Boscardin, J; Yaffe, K				Gardner, Raquel C.; Byers, Amy L.; Barnes, Deborah E.; Li, Yixia; Boscardin, John; Yaffe, Kristine			Mild TBI and risk of Parkinson disease A Chronic Effects of Neurotrauma Consortium Study	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; ALPHA-SYNUCLEIN; DEMENTIA; PREVALENCE; SEQUELAE	Objective Our aim was to assess risk of Parkinson disease (PD) following traumatic brain injury (TBI), including specifically mild TBI (mTBI), among care recipients in the Veterans Health Administration. Methods In this retrospective cohort study, we identified all patients with a TBI diagnosis in Veterans Health Administration databases from October 2002 to September 2014 and age-matched 1: 1 to a random sample of patients without TBI. All patients were aged 18 years and older without PD or dementia at baseline. TBI exposure and severity were determined via detailed clinical assessments or ICD-9 codes using Department of Defense and Defense and Veterans Brain Injury Center criteria. Baseline comorbidities and incident PD more than 1 year post-TBI were identified using ICD-9 codes. Risk of PD after TBI was assessed using Cox proportional hazard models adjusted for demographics and medical/psychiatric comorbidities. Results Among 325,870 patients (half with TBI; average age 47.9 +/- 17.4 years; average follow-up 4.6 years), 1,462 were diagnosed with PD during follow-up. Compared to no TBI, those with TBI had higher incidence of PD (no TBI 0.31%, all-severity TBI 0.58%, mTBI 0.47%, moderate-severe TBI 0.75%). In adjusted models, all-severity TBI, mTBI, and moderate-severe TBI were associated with increased risk of PD (hazard ratio [95% confidence interval]: all-severity TBI 1.71 [1.53-1.92]; mTBI 1.56 [1.35-1.80]; moderate-severe TBI 1.83 [1.61-2.07]). Conclusions Among military veterans, mTBI is associated with 56% increased risk of PD, even after adjusting for demographics and medical/psychiatric comorbidities. This study highlights the importance of TBI prevention, long-term follow-up of TBI-exposed veterans, and the need to determine mechanisms and modifiable risk factors for post-TBI PD.	[Gardner, Raquel C.; Byers, Amy L.; Barnes, Deborah E.; Li, Yixia; Boscardin, John; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Byers, Amy L.; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Barnes, Deborah E.; Boscardin, John; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Boscardin, John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA		Gardner, RC (corresponding author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Gardner, RC (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	Raquel.Gardner@ucsf.edu			US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); US Department of Veterans Affairs [Chronic Effects of Neurotrauma Consortium]US Department of Veterans Affairs [W81XWH-13-2-0095, 1I01CX001246]; US Army Medical Research Acquisition Activity, Fort Detrick, MD; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Beeson K23 NS095755]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24 AG031155]; American Federation for Aging Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS095755] Funding Source: NIH RePORTER	This study was funded by the US Army Medical Research and Material Command and by the US Department of Veterans Affairs [Chronic Effects of Neurotrauma Consortium] under awards W81XWH-13-2-0095 and 1I01CX001246. The US Army Medical Research Acquisition Activity, Fort Detrick, MD, is the awarding and administering acquisition office. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the US Government, or the US Department of Veterans Affairs, and no official endorsement should be inferred. This work was also funded by the National Institute of Neurological Disorders and Stroke (Beeson K23 NS095755 to R.C.G.), National Institute on Aging (K24 AG031155 to K.Y.), and the American Federation for Aging Research (to R.C.G.).	AFHSC, TRAUM BRAIN INJ DOD; Albrecht JS, 2016, J HEAD TRAUMA REHAB, V31, pE1, DOI 10.1097/HTR.0000000000000190; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Chen H, 2010, NEUROLOGY, V74, P878, DOI 10.1212/WNL.0b013e3181d55f38; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Defense & Veterans Brain Injury Center, 2017, DOD WORLDW NUMB TBI; Department of Veterans Affairs, 2010, SCREEN EV POSS TRAUM; Formisano R, 2014, J HEAD TRAUMA REHAB, V29, P387, DOI 10.1097/HTR.0000000000000027; Gao JJ, 2015, PARKINSONISM RELAT D, V21, P292, DOI 10.1016/j.parkreldis.2014.12.033; Gardner RC, 2017, J GERONTOL A-BIOL, V72, P1233, DOI 10.1093/gerona/glw341; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Gustafsson H, 2015, NEUROLOGY, V84, P2422, DOI 10.1212/WNL.0000000000001684; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine (US) Committee, 2008, GULF WAR HLTH, V7; Jacob EL, 2010, PARKINSONISM RELAT D, V16, P576, DOI 10.1016/j.parkreldis.2010.06.014; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Kenborg L, 2015, NEUROLOGY, V84, P1098, DOI 10.1212/WNL.0000000000001362; Kotagal V, 2014, NEUROLOGY, V82, P1514, DOI 10.1212/WNL.0000000000000356; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Kuopio AM, 1999, MOVEMENT DISORD, V14, P928, DOI 10.1002/1531-8257(199911)14:6<928::AID-MDS1004>3.0.CO;2-Z; Lee PC, 2015, EUR J NEUROL, V22, P874, DOI 10.1111/ene.12585; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2017, J NEUROTRAUM, V34, P2206, DOI 10.1089/neu.2016.4434; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McHugo GJ, 2017, J HEAD TRAUMA REHAB, V32, pE65, DOI 10.1097/HTR.0000000000000249; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nelson NW, 2015, BRIT J PSYCHIAT, V206, P237, DOI 10.1192/bjp.bp.114.149096; Peran P, 2014, J NEUROTRAUM, V31, P642, DOI 10.1089/neu.2013.3103; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Ritz B, 2014, NEUROLOGY, V83, P1396, DOI 10.1212/WNL.0000000000000879; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; Spangenberg S, 2009, PARKINSONISM RELAT D, V15, P12, DOI 10.1016/j.parkreldis.2008.02.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Taylor KM, 2016, PARKINSONISM RELAT D, V23, P57, DOI 10.1016/j.parkreldis.2015.12.005; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	48	96	96	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 15	2018	90	20					E1771	E1779		10.1212/WNL.0000000000005522			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	GN6CO	WOS:000439159900005	29669907	Green Published			2022-02-06	
J	Rubenstein, R; Chang, BG; Yue, JK; Chiu, A; Winkler, EA; Puccio, A; Diaz-Arrastia, R; Yuh, EL; Mukherjee, P; Valadka, AB; Gordon, WA; Okonkwo, DO; Davies, P; Agarwal, S; Lin, F; Sarkis, G; Yadikar, H; Yang, ZH; Manley, GT; Wang, KKW				Rubenstein, Richard; Chang, Binggong; Yue, John K.; Chiu, Allen; Winkler, Ethan A.; Puccio, Avam.; Diaz-Arrastia, Ramon; Yuh, Esther L.; Mukherjee, Pratik; Valadka, Alex B.; Gordon, Wayne A.; Okonkwo, David O.; Davies, Peter; Agarwal, Sanjeev; Lin, Fan; Sarkis, George; Yadikar, Hamad; Yang, Zhihui; Manley, Geoffrey T.; Wang, Kevin K. W.		TRACK-TBI Investigators	Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers	JAMA NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; COMMON DATA ELEMENTS; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; AMYLOID-BETA; AMYLOID-BETA-1-42; ENCEPHALOPATHY	IMPORTANCE Annually in the United States, at least 3.5 million people seek medical attention for traumatic brain injury (TBI). The development of therapies for TBI is limited by the absence of diagnostic and prognostic biomarkers. Microtubule-associated protein tau is an axonal phosphoprotein. To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated. OBJECTIVE To examine the associations between plasma P-tau and total-tau (T-tau) levels and injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in acute and chronic TBI. DESIGN, SETTING, AND PARTICIPANTS In the TRACK-TBI Pilot study, plasma was collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma centers (< 24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units (mean [SD], 176.4 [44.5] days after injury). Control samples were purchased from a commercial vendor. The TRACK-TBI Pilot study was conducted from April 1, 2010, to June 30, 2012. Data analysis for the current investigation was performed from August 1, 2015, to March 13, 2017. MAIN OUTCOMES AND MEASURES Plasma samples were assayed for P-tau (using an antibody that specifically recognizes phosphothreonine-231) and T-tau using ultra-high sensitivity laser-based immunoassay multi-arrayed fiberoptics conjugated with rolling circle amplification. RESULTS In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) years. The P-tau and T-tau levels and P-tau-T-tau ratio in patients with acute TBI were higher than those in healthy controls. Receiver operating characteristic analysis for the 3 tau indices demonstrated accuracy with area under the curve (AUC) of 1.000, 0.916, and 1.000, respectively, for discriminating mild TBI (GlasgowComa Scale [GCS] score, 13-15, n = 162) from healthy controls. The P-tau level and P-tau-T-tau ratiowere higher in individuals with more severe TBI (GCS, <= 12 vs 13-15). The P-tau level and P-tau-T-tau ratio outperformed the T-tau level in distinguishing cranial computed tomography-positive from - negative cases (AUC = 0.921, 0.923, and 0.646, respectively). Acute P-tau levels and P-tau-T-tau ratioweakly distinguished patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC = 0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, <= 4 vs > 4) (AUC = 0.771 and 0.777, respectively). Plasma samples from patients with chronic TBI also showed elevated P-tau levels and a P-tau-T-tau ratio significantly higher than that of healthy controls, with both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC = 1.000 and 0.963, respectively). CONCLUSIONS AND RELEVANCE Plasma P-tau levels and P-tau-T-tau ratio outperformed T-tau level as diagnostic and prognostic biomarkers for acute TBI. Compared with T-tau levels alone, P-tau levels and P-tau-T-tau ratios show more robust and sustained elevations among patients with chronic TBI.	[Rubenstein, Richard; Chang, Binggong; Chiu, Allen] Suny Downstate Med Ctr, Dept Neurol, Lab Neurodegenerat Dis & CNS Biomarker Discovery, Brooklyn, NY 11203 USA; [Rubenstein, Richard; Chang, Binggong; Chiu, Allen] Suny Downstate Med Ctr, Dept Physiol Pharmacol, Lab Neurodegenerat Dis & CNS Biomarker Discovery, Brooklyn, NY 11203 USA; [Yue, John K.; Winkler, Ethan A.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Puccio, Avam.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Davies, Peter] Feinstein Inst Med Res, Litwin Zucker Ctr Res Alzheimers Dis, Manhasset, NY USA; [Agarwal, Sanjeev] Suny Downstate Med Ctr, Dept Orthoped Surg & Rehabil Med, Brooklyn, NY 11203 USA; [Lin, Fan; Sarkis, George; Yadikar, Hamad; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, Dept Emergency Med Psychiat & Chem, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL USA; [Sarkis, George] Alexandria Univ, Fac Sci, Dept Chem, Alexandria, Egypt; [Yadikar, Hamad] Kuwait Univ, Dept Biochem, Khadiya, Kuwait		Rubenstein, R (corresponding author), Suny Downstate Med Ctr, Dept Neurol, 450 Clarkson Ave,POB 1213, Brooklyn, NY 11203 USA.	richard.rubenstein@downstate.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Wang, Kevin/0000-0002-9343-6473	Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement [W81XWH-11-2-0069, W81XWH-14-2-0166]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS069409]; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1U01 NS086090-01, R21NS085455-01]; US DOD grant [W81XWH-14-2-0176]; US DODUnited States Department of Defense [W81XWH-13-1-04]; University of Florida McKnight Brain Institute BSCIRTF fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG022102] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001859] Funding Source: NIH RePORTER	This study was supported in part by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement under award numbers W81XWH-11-2-0069 (Dr Rubenstein) and W81XWH-14-2-0166 (Dr Rubenstein). It was also supported in part by National Institutes of Health (NIH) grant RC2 NS069409 (Dr Manley), NIH grant 1U01 NS086090-01 (Dr Manley), US DOD grant W81XWH-14-2-0176 (Dr Manley), US DOD grant W81XWH-13-1-04 (Dr Manley), NIH grant R21NS085455-01 (Dr Wang), and University of Florida McKnight Brain Institute BSCIRTF fund (DrWang).	Blennow K, 2004, NEUROLOGY, V62, P159, DOI 10.1212/WNL.62.1.159; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Dani M, 2016, EUR J NUCL MED MOL I, V43, P1139, DOI 10.1007/s00259-015-3231-2; DeKosky, 1998, Semin Clin Neuropsychiatry, V3, P176; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diniz BSO, 2008, WORLD J BIOL PSYCHIA, V9, P172, DOI 10.1080/15622970701535502; Duan YL, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-24; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Liu MC, 2011, ASN NEURO, V3, P25, DOI 10.1042/AN20100012; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Martland H., 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nonnis S, 2008, NEUROCHEM RES, V33, P518, DOI 10.1007/s11064-007-9467-x; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Park SY, 2007, NEUROSCIENCE, V144, P119, DOI 10.1016/j.neuroscience.2006.09.012; Reyes JF, 2008, NEUROBIOL DIS, V31, P198, DOI 10.1016/j.nbd.2008.04.005; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x; Toledo JB, 2015, BRAIN, V138, P2701, DOI 10.1093/brain/awv199; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zhong C, 2017, CANCER EPIDEMIOL, V46, P9, DOI 10.1016/j.canep.2016.10.007	47	96	98	3	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2017	74	9					1063	1072		10.1001/jamaneurol.2017.0655			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5LM	WOS:000410358700011	28738126	Bronze, Green Accepted, Green Published, Green Submitted			2022-02-06	
J	Kao, AW; Mckay, A; Singh, PP; Brunet, A; Huang, EJ				Kao, Aimee W.; McKay, Andrew; Singh, Param Priya; Brunet, Anne; Huang, Eric J.			Progranulin, lysosomal regulation and neurodegenerative disease	NATURE REVIEWS NEUROSCIENCE			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; HEXANUCLEOTIDE REPEAT; NEURITE OUTGROWTH; TNF RECEPTORS; HOST-DEFENSE; GENE LEADS; MUTATIONS; PROTEIN	The discovery that heterozygous and homozygous mutations in the gene encoding progranulin are causally linked to frontotemporal dementia and lysosomal storage disease, respectively, reveals previously unrecognized roles of the progranulin protein in regulating lysosome biogenesis and function. Given the importance of lysosomes in cellular homeostasis, it is not surprising that progranulin deficiency has pleiotropic effects on neural circuit development and maintenance, stress response, innate immunity and ageing. This Progress article reviews recent advances in progranulin biology emphasizing its roles in lysosomal function and brain innate immunity, and outlines future avenues of investigation that may lead to new therapeutic approaches for neurodegeneration.	[Kao, Aimee W.] Univ Calif San Francisco, Dept Neurol, 675 Nelson Rising Lane, San Francisco, CA 94158 USA; [McKay, Andrew; Singh, Param Priya; Brunet, Anne] Stanford Univ, Dept Genet, 300 Pasteur Dr, Stanford, CA 94305 USA; [Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Avenue, San Francisco, CA 94143 USA; [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, 513 Parnassus Avenue, San Francisco, CA 94143 USA		Kao, AW (corresponding author), Univ Calif San Francisco, Dept Neurol, 675 Nelson Rising Lane, San Francisco, CA 94158 USA.; Huang, EJ (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Avenue, San Francisco, CA 94143 USA.; Huang, EJ (corresponding author), San Francisco VA Med Ctr, Pathol Serv 113B, 513 Parnassus Avenue, San Francisco, CA 94143 USA.	aimee.kao@ucsf.edu; eric.huang2@ucsf.edu	Huang, Eric J./AAH-7997-2019; Singh, Param P/AAU-7841-2020	Huang, Eric J./0000-0002-5381-3801; 	US Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [NS095257, NS098516]; Tau Consortium; Consortium for Frontotemporal Dementia Research; VA Merit AwardUS Department of Veterans Affairs [BX002978]; Glenn Foundation for Medical Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS098516, R21NS082709, K08NS059604, R01NS095257] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002133, I01BX002978] Funding Source: NIH RePORTER	The authors thank W. W. Seeley, E. H. Bigio and I. R. Mackenzie for sharing the neuropathology findings in patients with frontotemporal lobar degeneration with mutations in the gene encoding progranulin. This work has been supported by US Public Health Service grants NS095257 (A.W.K.) and NS098516 (E.J.H.), the Tau Consortium (A.W.K.), the Consortium for Frontotemporal Dementia Research (E.J.H.), VA Merit Award BX002978 (E.J.H.), and the Glenn Foundation for Medical Research (A.M., P.P.S. and A.B.)	Aharon-Peretz J., NEUROLOGY, V65; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Almeida MR, 2016, NEUROBIOL AGING, V41, DOI 10.1016/j.neurobiolaging.2016.02.019; Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Bai XH, 2009, MOL CELL BIOL, V29, P4201, DOI 10.1128/MCB.00056-09; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; Belcastro V, 2011, NUCLEIC ACIDS RES, V39, P8677, DOI 10.1093/nar/gkr593; Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Carcel-Trullols J, 2015, BBA-MOL BASIS DIS, V1852, P2242, DOI 10.1016/j.bbadis.2015.04.027; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Cenik B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193433; Chen X, 2013, J NEUROSCI, V33, P9202, DOI 10.1523/JNEUROSCI.5336-12.2013; Cruts Marc, 2006, Current Alzheimer Research, V3, P485, DOI 10.2174/156720506779025251; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; De Muynck L, 2013, NEUROBIOL AGING, V34, P2541, DOI 10.1016/j.neurobiolaging.2013.04.022; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Filiano AJ, 2013, J NEUROSCI, V33, P5352, DOI 10.1523/JNEUROSCI.6103-11.2013; Finch N, 2009, BRAIN, V132, P583, DOI 10.1093/brain/awn352; Gao X, 2010, PROTEIN CELL, V1, P552, DOI 10.1007/s13238-010-0067-1; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; Gass J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-33; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; Gowrishankar S, 2015, P NATL ACAD SCI USA, V112, pE3699, DOI 10.1073/pnas.1510329112; Guerra RR, 2007, GROWTH FACTORS, V25, P280, DOI 10.1080/08977190701781222; Hassan AJ, 2004, MOL REPROD DEV, V68, P476, DOI 10.1002/mrd.20096; Herrero J, 2016, DATABASE-OXFORD, DOI [10.1093/database/bav096, 10.1093/database/baw053]; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Holler CJ, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0114-3; Hsiung GYR, 2011, J NEUROL SCI, V300, P28, DOI 10.1016/j.jns.2010.10.009; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Hulkova H, 2001, HUM MOL GENET, V10, P927, DOI 10.1093/hmg/10.9.927; Jiao J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010551; Kanazawa M, 2015, BRAIN, V138, P1932, DOI 10.1093/brain/awv079; Kao AW, 2011, P NATL ACAD SCI USA, V108, P4441, DOI 10.1073/pnas.1100650108; Kelley BJ, 2009, NEUROBIOL AGING, V30, P739, DOI 10.1016/j.neurobiolaging.2007.08.022; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Knopman DS, 2011, J MOL NEUROSCI, V45, P330, DOI 10.1007/s12031-011-9538-y; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lavergne V, 2012, CURR TOP MED CHEM, V12, P1514, DOI 10.2174/156802612802652411; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P87, DOI 10.1007/s00401-011-0838-7; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Meyer RC, 2014, BRAIN RES, V1585, P1, DOI 10.1016/j.brainres.2014.08.022; Minami SS, 2014, NAT MED, V20, P1157, DOI 10.1038/nm.3672; Mistry J, 2013, NUCLEIC ACIDS RES, V41, DOI [10.1093/nar/gkt263, 10.1093/nar/gkt1223]; Neill T, 2016, J CELL BIOL, V215, P687, DOI 10.1083/jcb.201603079; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nicholson AM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11992; Nicholson AM, 2014, NEUROLOGY, V82, P1871, DOI 10.1212/WNL.0000000000000445; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Palfree RGE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133749; Park B, 2011, IMMUNITY, V34, P505, DOI 10.1016/j.immuni.2011.01.018; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Petoukhov E, 2013, J CELL SCI, V126, P5412, DOI 10.1242/jcs.132076; Pickford F, 2011, AM J PATHOL, V178, P284, DOI 10.1016/j.ajpath.2010.11.002; Rademakers R, 2008, HUM MOL GENET, V17, P3631, DOI 10.1093/hmg/ddn257; Rademakers R, 2007, LANCET NEUROL, V6, P857, DOI 10.1016/S1474-4422(07)70221-1; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Salazar DA, 2015, J NEUROSCI, V35, P9315, DOI 10.1523/JNEUROSCI.4808-14.2015; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schuur M, 2011, NEUROBIOL AGING, V32, P1607, DOI 10.1016/j.neurobiolaging.2009.10.011; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shankaran SS, 2008, J BIOL CHEM, V283, P1744, DOI 10.1074/jbc.M705115200; Singh PP, 2012, CELL REP, V2, P1387, DOI 10.1016/j.celrep.2012.09.034; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Songsrirote K, 2010, J PROTEOMICS, V73, P1479, DOI 10.1016/j.jprot.2010.02.013; Suh HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035115; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tapia L, 2011, J NEUROSCI, V31, P11126, DOI 10.1523/JNEUROSCI.6244-10.2011; Tolkatchev D, 2008, PROTEIN SCI, V17, P711, DOI 10.1110/ps.073295308; Valenzano DR, 2015, CELL, V163, P1539, DOI 10.1016/j.cell.2015.11.008; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; van Swieten JC, 2008, LANCET NEUROL, V7, P965, DOI 10.1016/S1474-4422(08)70194-7; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang J, 2010, J NEUROCHEM, V112, P1305, DOI 10.1111/j.1471-4159.2009.06546.x; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Ward ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5642; Yin FF, 2010, FASEB J, V24, P4639, DOI 10.1096/fj.10-161471; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zeng JB, 2009, EXP CELL RES, V315, P3112, DOI 10.1016/j.yexcr.2009.08.016; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	96	96	99	1	21	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1471-003X	1471-0048		NAT REV NEUROSCI	Nat. Rev. Neurosci.	JUN	2017	18	6					325	333		10.1038/nrn.2017.36			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EV1PA	WOS:000401517300006	28435163	Green Accepted, Green Submitted			2022-02-06	
J	Kurowski, BG; Hugentobler, J; Quatman-Yates, C; Taylor, J; Gubanich, PJ; Altaye, M; Wade, SL				Kurowski, Brad G.; Hugentobler, Jason; Quatman-Yates, Catherine; Taylor, Jennifer; Gubanich, Paul J.; Altaye, Mekibib; Wade, Shari L.			Aerobic Exercise for Adolescents With Prolonged Symptoms After Mild Traumatic Brain Injury: An Exploratory Randomized Clinical Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescents; aerobic training; concussion; exercise; intervention; mild traumatic brain injury	SPORT-RELATED CONCUSSION; VESTIBULAR REHABILITATION; CEREBRAL AUTOREGULATION; POSTCONCUSSION SYNDROME; SYNAPTIC PLASTICITY; VOLUNTARY EXERCISE; DENTATE GYRUS; UP-REGULATION; CHILDREN; RECOVERY	Objective: To describe the methodology and report primary outcomes of an exploratory randomized clinical trial (RCT) of aerobic training for management of prolonged symptoms after a mild traumatic brain injury (mTBI) in adolescents. Setting: Outpatient research setting. Participants: Thirty adolescents between the ages of 12 and 17 years who sustained a mTBI and had between 4 and 16 weeks of persistent symptoms. Design: Partially blinded, pilot RCT of subsymptom exacerbation aerobic training compared with a full-body stretching program. Main Measures: The primary outcome was postinjury symptom improvement assessed by the adolescent's self-reported Post-Concussion Symptom Inventory (PCSI) repeated for at least 6 weeks of the intervention. Parent-reported PCSI and adherence are also described. Results: Twenty-two percent of eligible participants enrolled in the trial. Repeated-measures analysis of variance via mixed-models analysis demonstrated a significant group x time interaction with self-reported PCSI ratings, indicating a greater rate of improvement in the subsymptom exacerbation aerobic training group than in the full-body stretching group (F = 4.11, P = .044). Adherence to the home exercise programs was lower in the subsymptom exacerbation aerobic training group compared with the full-body stretching group (mean [SD] times per week = 4.42 [1.95] vs 5.85 [1.37], P < .0001) over the duration of the study. Conclusion: Findings from this exploratory RCT suggest subsymptom exacerbation aerobic training is potentially beneficial for adolescents with persistent symptoms after an mTBI. These findings and other recent research support the potential benefit of active rehabilitation programs for adolescents with persistent symptoms after an mTBI. Larger replication studies are needed to verify findings and improve generalizability. Future work should focus on determining the optimal type, timing, and intensity of active rehabilitation programs and characteristics of individuals most likely to benefit.	[Kurowski, Brad G.; Taylor, Jennifer; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA; [Hugentobler, Jason; Quatman-Yates, Catherine; Gubanich, Paul J.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA		Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Quatman-Yates, Catherine/U-9580-2019; Quatman-Yates, Catherine/AAK-4507-2021		Cincinnati Children's Research Foundation Trustees Grant program; Ohio Department of Public Safety; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683-01A1]; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER	Funding for this study was supported in part by the Cincinnati Children's Research Foundation Trustees Grant program, Ohio Department of Public Safety, National Institute for Child Health and Human Development K23HD074683-01A1, and grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other supporting agencies.	Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borg G., 1985, INTRO BORGS RPE SCAL; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Chin LMK, 2015, J HEAD TRAUMA REHAB, V30, P382, DOI 10.1097/HTR.0000000000000062; Churchill JD, 2002, NEUROBIOL AGING, V23, P941, DOI 10.1016/S0197-4580(02)00028-3; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cotman CW, 2002, EXERC SPORT SCI REV, V30, P75, DOI 10.1097/00003677-200204000-00006; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Davenport MH, 2012, EXERC SPORT SCI REV, V40, P153, DOI 10.1097/JES.0b013e3182553430; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; EAKIN BL, 1992, J PEDIATR-US, V120, P90, DOI 10.1016/S0022-3476(05)80608-0; Epp JR, 2007, NEUROSCIENCE, V149, P273, DOI 10.1016/j.neuroscience.2007.07.046; Eston R G, 1986, Br J Sports Med, V20, P27; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul M, 2010, TRAUMATIC BRAIN INJU; Fogelman D, 2012, PM&R, V4, P908, DOI 10.1016/j.pmrj.2012.09.028; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lemka Malgorzata, 2005, Neurol Neurochir Pol, V39, pS42; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lipsey M.W., 2001, PRACTICAL META ANAL; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P296, DOI [10.1001/archpediatrics.2012.8, 10.1001/archpediatrics.2012.79]; Moreno MA, 2011, ARCH PEDIAT ADOL MED, V165, P376, DOI 10.1001/archpediatrics.2011.31; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rooks CR, 2010, PROG NEUROBIOL, V92, P134, DOI 10.1016/j.pneurobio.2010.06.002; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2004, J NEUROSCI RES, V76, P356, DOI 10.1002/jnr.20077; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wilson DB. George Mason University, PRACTICAL METAANALYS; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Ylinen J, 2010, J REHABIL MED, V42, P344, DOI 10.2340/16501977-0527	81	96	98	1	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2017	32	2					79	89		10.1097/HTR.0000000000000238			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EN3YU	WOS:000395944700008	27120294	Green Accepted			2022-02-06	
J	Collins, MW; Kontos, AP; Okonkwo, DO; Almquist, J; Bailes, J; Barisa, M; Bazarian, J; Bloom, OJ; Brody, DL; Cantu, R; Cardenas, J; Clugston, J; Cohen, R; Echemendia, R; Elbin, RJ; Ellenbogen, R; Fonseca, J; Gioia, G; Guskiewicz, K; Heyer, R; Hotz, G; Iverson, GL; Jordan, B; Manley, G; Maroon, J; McAllister, T; McCrea, M; Mucha, A; Pieroth, E; Podell, K; Pombo, M; Shetty, T; Sills, A; Solomon, G; Thomas, DG; McLeod, TCV; Yates, T; Zafonte, R				Collins, Michael W.; Kontos, Anthony P.; Okonkwo, David O.; Almquist, Jon; Bailes, Julian; Barisa, Mark; Bazarian, Jeffrey; Bloom, O. Josh; Brody, David L.; Cantu, Robert; Cardenas, Javier; Clugston, Jay; Cohen, Randall; Echemendia, Ruben; Elbin, R. J.; Ellenbogen, Richard; Fonseca, Janna; Gioia, Gerard; Guskiewicz, Kevin; Heyer, Robert; Hotz, Gillian; Iverson, Grant L.; Jordan, Barry; Manley, Geoffrey; Maroon, Joseph; McAllister, Thomas; McCrea, Michael; Mucha, Anne; Pieroth, Elizabeth; Podell, Kenneth; Pombo, Matthew; Shetty, Teena; Sills, Allen; Solomon, Gary; Thomas, Danny G.; McLeod, Tamara C. Valovich; Yates, Tony; Zafonte, Ross			Statements of Agreement From the Targeted Evaluation and Active Management (TEAM) Approaches to Treating Concussion Meeting Held in Pittsburgh, October 15-16, 2015	NEUROSURGERY			English	Article						Concussion; mTBI; Rehabilitation; Treatment	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC MIGRAINE CHARACTERISTICS; PREDICT PROTRACTED RECOVERY; COLLEGIATE FOOTBALL PLAYERS; FEMALE HIGH-SCHOOL; LOW-BACK-PAIN; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; SEX-DIFFERENCES	BACKGROUND: Conventional management for concussion involves prescribed rest and progressive return to activity. Recent evidence challenges this notion and suggests that active approaches may be effective for some patients. Previous concussion consensus statements provide limited guidance regarding active treatment. OBJECTIVE: To describe the current landscape of treatment for concussion and to provide summary agreements related to treatment to assist clinicians in the treatment of concussion. METHODS: On October 14 to 16, 2015, the Targeted Evaluation and Active Management (TEAM) Approaches to Treating Concussion meeting was convened in Pittsburgh, Pennsylvania. Thirty-seven concussion experts from neuropsychology, neurology, neurosurgery, sports medicine, physical medicine and rehabilitation, physical therapy, athletic training, and research and 12 individuals representing sport, military, and public health organizations attended the meeting. The 37 experts indicated their agreement on a series of statements using an audience response system clicker device. RESULTS: A total of 16 statements of agreement were supported covering (1) Summary of the Current Approach to Treating Concussion, (2) Heterogeneity and Evolving Clinical Profiles of Concussion, (3) TEAM Approach to Concussion Treatment: Specific Strategies, and (4) Future Directions: A Call to Research. Support (ie, response of agree or somewhat agree) for the statements ranged from to 97% to 100%. CONCLUSION: Concussions are characterized by diverse symptoms and impairments and evolving clinical profiles; recovery varies on the basis of modifying factors, injury severity, and treatments. Active and targeted treatments may enhance recovery after concussion. Research is needed on concussion clinical profiles, biomarkers, and the effectiveness and timing of treatments.	[Collins, Michael W.; Kontos, Anthony P.; Thomas, Danny G.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Okonkwo, David O.; Maroon, Joseph] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Almquist, Jon] Fairfax Family Practice Comprehens Concuss Ctr, Fairfax, VA USA; [Bailes, Julian] NorthShore Univ Hlth Syst, Dept Neurosurg, Chicago, IL USA; [Barisa, Mark] Baylor Inst Rehabil, Frisco, TX USA; [Bazarian, Jeffrey] Univ Rochester, Dept Emergency Med, Rochester, NY USA; [Bloom, O. Josh; Fonseca, Janna] Carolina Sports Concuss Clin, Cary, NC USA; [Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO USA; [Cantu, Robert] Boston Univ, Emerson Hosp, Robert C Cantu Concuss Ctr, Concord, MA USA; [Cardenas, Javier] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA; [Clugston, Jay] Univ Florida, Community Hlth & Family Med, Gainesville, FL USA; [Cohen, Randall] Univ Arizona, Athlet Dept, Tucson, AZ USA; [Echemendia, Ruben] Psychol & Neurobehav Associates, State Coll, PA USA; [Elbin, R. J.] Univ Arkansas, Off Sports Concuss Res, Fayetteville, AR 72701 USA; [Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Gioia, Gerard] Childrens Natl Hlth Syst, Div Neuropsychol, Washington, DC USA; [Guskiewicz, Kevin] Univ N Carolina, Coll Arts & Sci, Chapel Hill, NC USA; [Heyer, Robert] Carolinas Med Ctr, Charlotte, NC 28203 USA; [Hotz, Gillian] Univ Miami, Miller Sch Med, Neurosci Ctr, Miami, FL 33136 USA; [Iverson, Grant L.] Harvard Med Sch, Brigham & Womens Hosp, Massachusetts Gen Hosp, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Boston, MA USA; [Jordan, Barry] Burke Rehabil & Res, Neurorehabilitat, White Plains, NY USA; [Manley, Geoffrey] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [McAllister, Thomas] Indiana Univ, Dept Psychiat, Bloomington, IN USA; [McCrea, Michael; Thomas, Danny G.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Mucha, Anne] Univ Pittsburgh, Med Ctr, Ctr Rehabil Serv, Pittsburgh, PA USA; [Pieroth, Elizabeth] NorthShore Univ Hlth Syst, Neurol Inst, Chicago, IL USA; [Podell, Kenneth] Houston Methodist Hosp, Houston Methodist Concuss Ctr, Houston, TX USA; [Pombo, Matthew] Emory Univ Healthcare, Dept Orthoped, Atlanta, GA USA; [Shetty, Teena] Weill Cornell Med Coll, Hosp Special Surg, Dept Neurol, New York, NY USA; [Solomon, Gary] Vanderbilt Univ, Dept Neurosurg, Vanderbilt Sports Concuss Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [Thomas, Danny G.] Childrens Hosp Wisconsin, Pediat Emergency Med, Wauwatosa, WI USA; [McLeod, Tamara C. Valovich] AT Still Univ, Dept Athlet Training, Kirksville, MO USA; [Yates, Tony] Pittsburgh Steelers, Pittsburgh, PA USA		Collins, MW (corresponding author), UPMC Rooney Sports Complex,3200 S Water St, Pittsburgh, PA 15203 USA.	collinsmw@upmc.edu	Solomon, Gary/K-9011-2019; Echemendia, Ruben/R-6939-2019; Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Iverson, Grant/0000-0001-7348-9570; Kontos, Anthony/0000-0002-3749-4310; Clugston, James/0000-0002-2103-1039; Thomas, Danny/0000-0002-7470-9835	National Football League; University of Pittsburgh Medical Center; DoDUnited States Department of Defense; NCAA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; GE-NFL; Banyan Biomarkers; Brainscope; Health South; PfizerPfizer; Arizona Super Bowl Host Committee grant; Banyan Biomarkers, Inc; NCAA-DoD CARE Consortium; Brainscope Co, Inc.; MCI; Neuro-Health Research and Rehabilitation, Inc; NeuroHealth LLC; AbbottAbbott Laboratories; Pittsburgh Steelers; GE-NFL Head Health Challenge I; CE Speakers' Bureau-American Physical Therapy Association; Medbridge Education; ImPACT Applications, Inc; Brainsteps; Inova; GE-NFL Head Initiative and Brainscope; Chembio; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services; NFL Players Association; National Operating Committee on Standards for Athletic Equipment; American Medical Society for Sports Medicine; New Jersey Commission on Brain Injury Research; NFL; USA Hockey; National Athletic Trainers' Association; NFL Benefits Association for Neurocognitive Disability Benefit; Innovative CEUs; NCAA-DoD; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	The TEAM Approaches to Treating Concussion Meeting was supported by grants from the National Football League and University of Pittsburgh Medical Center. Dr Collins is a consultant for the Pittsburgh Steelers and Pittsburgh Penguins and a developer and shareholder in ImPACT (Immediate Post Concussion Assessment and Cognitive Testing) Applications Inc. He receives research funding from the DoD, NCAA, NIH, and GE-NFL. Dr Okonkwo receives research funding from the NIH, DoD, and GE-NFL. He is a paid consultant for Lanx. J. Almquist receives an honorarium for presentations from ImPACT Applications, Inc and is owner of JLA Consulting LLC and codeveloper of BrainTrax. Dr Barisa is on the ImPACT speakers' bureau. Dr Bazarian receives grant/research support from Banyan Biomarkers and Brainscope; is a consultant for Banyan Biomarkers and a virtual shares stockholder in Black Biometrics; and is on the data safety and monitoring board for Neuren Pharmaceuticals. Dr Brody receives grant/research support from Health South and Pfizer and is a consultant for Pfizer Inc, Intellectual Ventures, Signum Nutralogix, Kypha Inc, Sage Therapeutics, iPerian Inc, and Avid Radiopharmaceuticals (Eli Lily & Co). Dr Cantu serves as vice president for the National Operating Committee on Standards for Athletic Equipment; is cofounder, chairman, and medical director for Sports Legacy (SLI, Waltham, MA); and is senior advisor to the NFL's Head, Neck and Spine Committee, providing expert witness testimony in trials. Dr Cardenas has an Arizona Super Bowl Host Committee grant for a domestic violence program, is a consultant in the NFL unaffiliated neurotrauma consultant program, and serves on the ImPACT application scientific advisory board. Dr Clugston receives grant/research support from Banyan Biomarkers, Inc and the NCAA-DoD CARE Consortium. Dr Elbin receives grant/research support from Brainscope Co, Inc. Dr Ellenbogen receives grant/research support from NIH and MCI; is an unpaid consultant for NFL-GE and a member of the NFL Head, Neck and Spine Committee; and is a scientific consultant for the VICIS helmet company. J. Fonseca is a consultant for ImPACT Applications, Inc. Dr Gioia is a test author for Psychological Assessment Resources, Inc and a consultant for the Washington Capitals and Baltimore Ravens. Dr Heyer is a consultant for the Carolina Panthers and is president of the NFL Physicians Society. Dr Hotz receives grant/research support from GE-NFL. Dr Iverson receives grant/research support from several organizations for mTBI. He is a salaried as an independent practitioner in neuropsychology, including giving expert testimony, for Neuro-Health Research and Rehabilitation, Inc, NeuroHealth LLC. He receives reimbursements from government, professional scientific bodies, and commercial organizations for discussing/presenting mTBI. Dr Manley receives grant/research support from NIH, DoD, and Abbott. Dr Maroon is employed by the University of Pittsburgh Medical Center, which has received grants from the National Football League and the Pittsburgh Steelers. He is an unpaid consultant for the Pittsburgh Steelers football club. He has been the team neurosurgeon for the Pittsburgh Steelers since 1981 and the medical director for World Wrestling Entertainment Corp since 2008 for the management of spine and brain-related injury. He also has served on the NFL's Head, Neck and Spine Committee since 2007 and is currently a consultant to the committee.; He is a founder and shareholder in ImPACT, and the World Wrestling Entertainment has partnered with ImPACT to provide concussion management. He has served as an expert witness in medical legal cases involving concussions. Dr McCrea receives grant/ research support from GE-NFL Head Health Challenge I. He is a GE Healthcare consultant and a member of the NFL Head, Neck and Spine Committee. Dr Mucha has received speaker's fees/honoraria from CE Speakers' Bureau-American Physical Therapy Association, Medbridge Education, ImPACT Applications, Inc, Brainsteps, Inova, and various healthcare and/or educational societies. Dr Podell receives grant/research support from GE-NFL Head Initiative and Brainscope. Dr Shetty receives grant/research support from GE-NFL, Chembio, and Abbott and is on the GE-NFL Medical Advisory Board. Dr Solomon receives DoD grant/research support; is a consultant for the University of Tennessee Athletics, Tennessee Tech Athletics, Tennessee Titans, and Nashville Predators; and is on the Advisory Board of ImPACT Applications, Inc. He has received speaking honoraria from the American Academy of Neurology, American Medical Society for Sports Medicine, and American Associations of Neurological Surgeons. Dr Zafonte receives grant/ research support from NIH, DoD, National Institute on Disability, Independent Living, and Rehabilitation Research, and NFL Players Association and is a consultant for Harvard football. He has relationships with Oakstone Publishing, Demos Publishing, Oxeia Biopharma, and Myomo Orthotic Devices.; The following authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr Kontos receives research funding from the NIH, NCAA, DoD, and GE-NFL. Dr Bailes is chairman for the Pop Warner Football medical advisory board. Dr Bloom is a consultant for the Carolina Hurricanes. Dr Echemendia is a consultant to the NHL, Major League Soccer, the US Soccer Federation, and Princeton University. He is principal investigator or coprincipal investigator on grants funded by National Operating Committee on Standards for Athletic Equipment, American Medical Society for Sports Medicine, and the New Jersey Commission on Brain Injury Research. Dr Guskiewicz is a member of the NCAA Health and Safety Advisory Committee for Concussion, is a member of the NFL Head, Neck and Spine Committee, has given paid expert testimonials for TBI cases, and receives research funding from NIH, NCAA, NFL, USA Hockey, and National Athletic Trainers' Association. Dr Jordan is a paid consultant for NFL Benefits Association for Neurocognitive Disability Benefit. He receives compensation from Innovative CEUs for coaching their education program and is chief medical officer of the New York State Athletic Association. Dr McAllister receives research funding from the NCAA-DoD. Dr Pieroth is a consultant for the Chicago Bears, White Sox, and Blackhawks. Dr Sills is on the Medical Board of the Federation Equestrian Internationale; is an unpaid consultant for the US Equestrian Foundation, Southeastern Conference, and the Nashville Predators; and is an unaffiliated neurotrauma consultant for the NFL. Dr Yates is the team physician for the Pittsburgh Steelers and a member of the NFL Head, Neck and Spine Committee. Drs Cohen, Pombo, Thomas, and Valovich have no funding to disclose.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Andersen LL, 2011, SCAND J WORK ENV HEA, V37, P547, DOI 10.5271/sjweh.3170; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bandelow B, 2014, DTSCH ARZTEBL INT, V111, P473, DOI 10.3238/arztebl.2014.0473; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bloom J, SIDELINE EVALUATION; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown BE, 2014, BRAIN INJURY, V28, P838; Brown HE, 2013, SPORTS MED, V43, P195, DOI 10.1007/s40279-012-0015-8; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Cacioppo JT, 2011, ANN NY ACAD SCI, V1231, P17, DOI 10.1111/j.1749-6632.2011.06028.x; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Casson IR, 2015, NEUROLOGY, V85, P110, DOI 10.1212/WNL.0000000000001700; Centers for Disease Control and Prevention, 2015, HEADS SCH SPORTS; Centers for Disease Control and Prevention, 2015, HEADS PROV; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colloca L, 2012, JAMA-J AM MED ASSOC, V307, P567, DOI 10.1001/jama.2012.115; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2014, J ATHL TRAINING, V49, P462, DOI 10.4085/1062-6059-49.2.03; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dean PJ, 2015, BRAIN INJURY, P1; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; Dias M, 2014, ARQ NEURO-PSIQUIAT, V72, P851, DOI 10.1590/0004-282X20140148; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elbin R, 2015, PERSPECT NEUROPHYSIO, V25, P4, DOI DOI 10.1044/NNSLD25.1.4; Elbin RJ, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0320-7; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2016, J HEAD TRAUMA REHAB, V31, P397, DOI 10.1097/HTR.0000000000000205; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris Poll, 2015, KNOWL AR AM CONC ASS; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Heyer GL, 2016, CEPHALALGIA, V36, P309, DOI 10.1177/0333102415590240; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kontos AP, 2016, BRIT J SPORT MED, V50, P139, DOI 10.1136/bjsports-2015-095564; Kontos Anthony P, 2015, J Trauma Acute Care Surg, V79, pS146, DOI 10.1097/TA.0000000000000667; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee Michael A, 2010, Conn Med, V74, P149; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McAvoy K, 2009, CONCUSSION RMSMICF; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Morgan CD, 2015, CHILD NERV SYST, V31, P2305, DOI 10.1007/s00381-015-2916-y; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; MURTHA S, 1990, BEHAV BRAIN RES, V39, P249, DOI 10.1016/0166-4328(90)90031-9; National Collegiate Athletic Association, 2013, CONC GUID; Nelson LD, 2016, CLIN J SPORT MED, V26, P120, DOI 10.1097/JSM.0000000000000207; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Poltavski DV, 2014, BRAIN INJURY, V28, P475, DOI 10.3109/02699052.2014.888771; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Quatman-Yates C, 2014, PHYSICIAN SPORTSMED, V42, P32, DOI 10.3810/psm.2014.09.2073; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Reynolds Erin, 2014, Neurosurgery, V75 Suppl 4, pS71, DOI 10.1227/NEU.0000000000000471; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smith A, 2011, CLIN NEUROPSYCHOL, V25, P689, DOI 10.1080/13854046.2011.586561; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; Stewart GW, 2012, INT J SPORTS PHYS TH, V7, P433; Sufrinko A, 2016, NEUROPSYCHOLOGY, V30, P484, DOI 10.1037/neu0000250; Thiagarajan P, 2014, BRAIN INJURY, V28, P930, DOI 10.3109/02699052.2014.888761; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Upchurch C, 2015, CLIN J SPORT MED, V25, P297, DOI 10.1097/JSM.0000000000000123; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Varkey E, 2011, CEPHALALGIA, V31, P1428, DOI 10.1177/0333102411419681; Wilkins SA, 2014, J NEUROSURG-PEDIATR, V13, P82, DOI 10.3171/2013.10.PEDS13241; Yang JZ, 2015, DEV NEUROPSYCHOL, V40, P18, DOI 10.1080/87565641.2014.973499; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819; Zemek R, 2014, GUIDELINES DIAGNOSIN; Zemek R, 2011, GUIDELINES CONCUSSIO; Zemek R, 2013, GUIDELINES MILD TRAU; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	175	96	97	1	20	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2016	79	6					912	929		10.1227/NEU.0000000000001447			18	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	EI6OH	WOS:000392614700043	27741219	Green Accepted, Bronze			2022-02-06	
J	McGinn, MJ; Povlishock, JT				McGinn, Melissa J.; Povlishock, John T.			Pathophysiology of Traumatic Brain Injury	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Focal and diffuse damage; Diffuse axonal injury; Neuronal circuit disruption; Altered neuronal and vascular responses; Influence of comorbid factors	CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; EXCITATORY AMINO-ACIDS; DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; GLUTAMATE TRANSPORTER GLT-1; CENTRAL-NERVOUS-SYSTEM; SPREADING DEPOLARIZATIONS; INFLAMMATORY RESPONSE; CEREBROSPINAL-FLUID	This article provides a concise overview, at the structural and functional level, of those changes evoked by traumatic brain injury across the spectrum of the disease. Using data derived from animals and humans, the pathogenesis of focal versus diffuse brain damage is presented for consideration of its overall implications for morbidity. Emphasis is placed on contusion and its potential expansion in concert with diffuse changes primarily assessed at the axonal level. Concomitant involvement of neuroexcitation and its role in global and focal metabolic changes is considered. Lastly, the influence of premorbid factors including age, genetics, and socioeconomic background is discussed.	[McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Coll Med, Dept Anat & Neurobiol, Virginia Campus 1101 East Marshall St,Room 12-048, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Coll Med, Dept Anat & Neurobiol, Virginia Campus 1101 East Marshall St,Room 12-048, Richmond, VA 23298 USA.	john.povlishock@vcuhealth.org					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alessandri B, 1999, ACT NEUR S, V75, P21; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Diamond ML, 2015, EPILEPSIA, V56, P1198, DOI 10.1111/epi.13044; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; FUJISAWA H, 1994, ACT NEUR S, V60, P193; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hinzman JM, 2016, J NEUROTRAUMA; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOVDA DA, 1990, ACT NEUR S, V51, P331; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1981, ANNU REV PHYSIOL, V43, P397, DOI 10.1146/annurev.ph.43.030181.002145; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Koura SS, 1998, ACT NEUR S, V71, P244; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MATHEW P, 1994, ACTA NEUROCHIR, P428; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Smith CJ, 2015, FRONT NEUROL, V6, DOI [10.3389/fneur.2015.00240, 10.3389/fneur.2015.00073]; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2004, BRAIN PATHOL, V14, P210, DOI 10.1111/j.1750-3639.2004.tb00055.x; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	114	96	102	1	29	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					397	+		10.1016/j.nec.2016.06.002			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800004	27637392				2022-02-06	
J	Losoi, H; Silverberg, ND; Waljas, M; Turunen, S; Rosti-Otajarvi, E; Helminen, M; Luoto, TM; Julkunen, J; Ohman, J; Iverson, GL				Losoi, Heidi; Silverberg, Noah D.; Waljas, Minna; Turunen, Senni; Rosti-Otajarvi, Eija; Helminen, Mika; Luoto, Teemu M.; Julkunen, Juhani; Ohman, Juha; Iverson, Grant L.			Recovery from Mild Traumatic Brain Injury in Previously Healthy Adults	JOURNAL OF NEUROTRAUMA			English	Article						outcome; traumatic brain injury; post-concussion syndrome; head injury; cognitive	QUALITY-OF-LIFE; POST-CONCUSSION SYMPTOMS; BNI FATIGUE SCALE; HEAD-INJURY; POSTCONCUSSION SYNDROME; RELIABILITY; METAANALYSES; IMPAIRMENT; GUIDELINES; VALIDITY	This prospective longitudinal study reports recovery from mild traumatic brain injury (MTBI) across multiple domains in a carefully selected consecutive sample of 74 previously healthy adults. The patients with MTBI and 40 orthopedic controls (i.e., ankle injuries) completed assessments at 1, 6, and 12 months after injury. Outcome measures included cognition, post-concussion symptoms, depression, traumatic stress, quality of life, satisfaction with life, resilience, and return to work. Patients with MTBI reported more post-concussion symptoms and fatigue than the controls at the beginning of recovery, but by 6 months after injury, did not differ as a group from nonhead injury trauma controls on cognition, fatigue, or mental health, and by 12 months, their level of post-concussion symptoms and quality of life was similar to that of controls. Almost all (96%) patients with MTBI returned to work/normal activities (RTW) within the follow-up of 1 year. A subgroup of those with MTBIs and controls reported mild post-concussion-like symptoms at 1 year. A large percentage of the subgroup who had persistent symptoms had a modifiable psychological risk factor at 1 month (i.e., depression, traumatic stress, and/or low resilience), and at 6 months, they had greater post-concussion symptoms, fatigue, insomnia, traumatic stress, and depression, and worse quality of life. All of the control subjects who had mild post-concussion-like symptoms at 12 months also had a mental health problem (i.e., depression, traumatic stress, or both). This illustrates the importance of providing evidence-supported treatment and rehabilitation services early in the recovery period.	[Losoi, Heidi; Waljas, Minna; Turunen, Senni; Rosti-Otajarvi, Eija; Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland; [Losoi, Heidi; Julkunen, Juhani] Univ Helsinki, Inst Behav Sci, Helsinki, Finland; [Silverberg, Noah D.] Univ British Columbia, GF Strong Rehab Ctr, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Helminen, Mika] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Helminen, Mika] Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown Navy Yard, Charlestown, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Losoi, H (corresponding author), Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland.	heidi.losoi@gmail.com	Helminen, Mika T/I-3900-2016; Luoto, Teemu/W-6468-2018	Helminen, Mika T/0000-0001-5695-2084; Luoto, Teemu/0000-0002-7329-3284; Iverson, Grant/0000-0001-7348-9570; Ohman, Juha/0000-0002-6592-1367			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Army Individual Test Battery, 1944, MAN DIR SCOR; Ashley J, 1990, Health Trends, V22, P135; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beseoglu K, 2013, BRIT J NEUROSURG, V27, P202, DOI 10.3109/02688697.2012.717984; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Halstead W.C., 1947, BRAIN INTELLIGENCE; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2012, NEUROPSYCHOLOGICAL A, P360; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman VL, 2014, ARCH PHYS MED REH S3, V95, pS266; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mistridis P, 2015, EUR ARCH PSY CLIN N, V265, P407, DOI 10.1007/s00406-014-0571-z; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Wagnild G M, 1993, J Nurs Meas, V1, P165; Waljas M, 2012, BRAIN INJURY, V26, P972, DOI 10.3109/02699052.2012.660511; Weathers F., 1993, 9 ANN C ISTSS SAN AN; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	54	96	96	0	58	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					766	776		10.1089/neu.2015.4070			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900007	26437675				2022-02-06	
J	Corrigan, JD; Cuthbert, JP; Harrison-Felix, C; Whiteneck, GG; Bell, JM; Miller, AC; Coronado, VG; Pretz, CR				Corrigan, John D.; Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.; Bell, Jeneita M.; Miller, A. Cate; Coronado, Victor G.; Pretz, Christopher R.			US Population Estimates of Health and Social Outcomes 5 Years After Rehabilitation for Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; epidemiology; outcomes; prevalence; rehabilitation; traumatic brain injury	SYSTEMS NATIONAL DATABASE; MODEL SYSTEMS; REPRESENTATIVENESS; MORTALITY; SCALE; AGE	Objective: To estimate the number of adults in the United States from 2006 to 2012 who manifest selected health and social outcomes 5 years following a traumatic brain injury (TBI) that required acute inpatient rehabilitation. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients 16 years and older receiving acute inpatient rehabilitation for a primary diagnosis of TBI. Main Outcome Measures: Mortality, functional independence, societal participation, subjective well-being, and global outcome. Results: Annually from 2001 to 2007, an average of 13 700 patients aged 16 years or older received acute inpatient rehabilitation in the United States with a primary diagnosis of TBI. Approximately 1 in 5 patients had died by the 5-year postinjury assessment. Among survivors, 12% were institutionalized and 50% had been rehospitalized at least once. Approximately one-third of patients were not independent in everyday activities. Twenty-nine percent were dissatisfied with life, with 8% reporting markedly depressed mood. Fifty-seven percent were moderately or severely disabled overall, with 39% having deteriorated from a global outcome attained 1 or 2 years postinjury. Of those employed preinjury, 55% were unemployed. Poorer medical, functional, and participation outcomes were associated with, but not limited to, older age. Younger age groups had poorer mental and emotional outcomes. Deterioration in global outcome was common and not age-related. Conclusions: Significant mortality and morbidity were evident at 5 years postinjury. The deterioration in global outcomes observed regardless of age suggests that multiple influences contribute to poorer outcomes. Public health interventions intended to reduce post-acute inpatient rehabilitation mortality and morbidity rates will need to be multifaceted and age-specific.	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.; Pretz, Christopher R.] Craig Hosp, Res Dept, Englewood, CO USA; [Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu			US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; US Department of Education, Office of Special Education and Rehabilitative Services; National Institute on Disability and Rehabilitation Research (NIDRR); NIDRR; Traumatic Brain Injury (TBI) Model Systems National Data and Statistical Center [H133A110006]; TBI Model Systems Centers grant from the NIDRR to Ohio State University [H133A120086]	This research was supported by an interagency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and the US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (NIDRR), with supplemental funding to the NIDRR-funded Traumatic Brain Injury (TBI) Model Systems National Data and Statistical Center (grant no. H133A110006). The study was also supported by a TBI Model Systems Centers grant from the NIDRR to Ohio State University (grant no. H133A120086). This article does not reflect the official policy or opinions of the CDC or HHS and does not constitute an endorsement of the individuals or their programs-by the CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. The TBI Model Systems National Database is supported by the NIDRR and created and maintained by the TBI Model Systems Centers program. This article is intended to promote the exchange of ideas among researchers and policy makers. The views expressed in it are part of ongoing research and analysis and do not necessarily reflect the position of the US Department of Education.	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Hammond FM, 2013, BRAIN INJ PROF, V10, P6; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Izrael D, 2000, P 25 ANN SAS US GROU; Kalton G., 2003, J OFF STAT, V19, P81; Kolakowsky-Hayner SA, 2012, BRAIN INJURY, V26, P1328, DOI 10.3109/02699052.2012.706353; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P468, DOI 10.1097/HTR.0b013e3181c133d2; *SUBST AB MENT HLT, 2009, HHS PUBL; Substance Abuse and Mental Health Services Administration, 2009, NSDUH SERIES H; Szklo M, 2007, EPIDEMIOLOGY BASICS; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; UDS, 2014, UN DAT SYST MED REH; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2007, INT CLASS FUNCT DIS	25	96	96	2	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					E1	E9		10.1097/HTR.0000000000000020			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800001	24495919				2022-02-06	
J	Goodrich, GL; Flyg, HM; Kirby, JE; Chang, CY; Martinsen, GL				Goodrich, Gregory L.; Flyg, Heidi M.; Kirby, Jennine E.; Chang, Chea-Yo; Martinsen, Gary L.			Mechanisms of TBI and Visual Consequences in Military and Veteran Populations	OPTOMETRY AND VISION SCIENCE			English	Article						traumatic brain injury; blast injuries; binocular vision; light sensitivity; oculomotor system	TRAUMATIC BRAIN-INJURY; POLYTRAUMA NETWORK SITE; DYSFUNCTION; IMPAIRMENT	Purpose. Blast-related (BR) traumatic brain injuries (TBIs) occur secondary to explosive blasts. Blast-related TBIs can be caused by the blast wave itself or by direct head trauma caused by events surrounding the blast. Non-blast-related (NBR) TBIs are caused by direct head trauma. Recent evidence shows that TBIs are associated with vision problems, particularly binocular system problems. The purpose of this study was to determine if similar types and amounts of vision problems are present in patients with BR TBIs and NBR TBIs. Methods. A retrospective analysis of eye examination records of 50 NBR TBI and 50 BR TBI patients was conducted. Frequencies of visual symptoms and abnormal vision function measurements were computed and compared for the two patient groups. Results. More than 65% of NRB TBI and BR TBI patients reported vision problems. Reading complaints were found in approximately 50% of the patients. Light sensitivity was reported significantly more often in BR TBI patients (67%) than in NBR TBI patients (33%) (p < 0.01). Saccadic dysfunction was measured more often in NBR TBI patients (85%) than in BR TBI patients (58%) (p < 0.01). High rates of accommodative dysfunction and convergence insufficiency were also found, but the group differences were not significant. Strabismus, pursuit abnormalities, fixation defects, and visual field defects were also common in both groups. Conclusions. For most findings, the mechanism of injury (NBR vs. BR) did not result in different frequencies or types of visual dysfunction. The reasons for finding higher frequencies of light sensitivity in the BR TBI group and saccadic dysfunction in the NBR TBI group are unknown, and further research is needed. Overall, the rates of vision complaints and oculomotor defects were high in both groups, indicating a need for a thorough eye examination for any patient with a history of TBI. (Optom Vis Sci 2013;90:105-112)	[Goodrich, Gregory L.; Flyg, Heidi M.; Kirby, Jennine E.; Chang, Chea-Yo; Martinsen, Gary L.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA		Goodrich, GL (corresponding author), Palo Alto Hlth Care Syst 124, Dept Vet Affairs, 795 Willow Rd, Menlo Pk, CA 94025 USA.	gregory.goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019		Veterans Affairs Quality Enhancement Research Initiative (QUERI) grant [RRP 11-008]	This project was supported in part by Veterans Affairs Quality Enhancement Research Initiative (QUERI) grant RRP 11-008.	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Defense and Veterans Brain Injury Center, 2012, DOD WORLDWIDE NUMB T; Doble JE, 2010, PM&R, V2, P244, DOI 10.1016/j.pmrj.2010.01.011; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Faul M, 2010, TRAUMATIC BRAIN INJU; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hofstetter, 1944, AM J OPTOM ARCH AM A, V21, P345, DOI [10.1097/00006324-194409000-00001, DOI 10.1097/00006324-194409000-00001]; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Stuhmiller JH, 2008, BLAST INJURY TRANSLA; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; United States Department of Veterans Affairs, 2011, POL TBI SYST CAR UND; Veterans Affairs Office of Research and Development Health Services Research and Development Service, 2011, POL BLAST REL INJ; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	31	96	96	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-5488			OPTOMETRY VISION SCI	Optom. Vis. Sci.	FEB	2013	90	2					105	112		10.1097/OPX.0b013e31827f15a1			8	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	082CC	WOS:000314368300007	23314131				2022-02-06	
J	McNally, KA; Bangert, B; Dietrich, A; Nuss, K; Rusin, J; Wright, M; Taylor, HG; Yeates, KO				McNally, Kelly A.; Bangert, Barbara; Dietrich, Ann; Nuss, Kathy; Rusin, Jerome; Wright, Martha; Taylor, H. Gerry; Yeates, Keith Owen			Injury Versus Noninjury Factors as Predictors of Postconcussive Symptoms Following Mild Traumatic Brain Injury in Children	NEUROPSYCHOLOGY			English	Article						concussion; pediatric; outcomes; recovery	POST-CONCUSSIVE SYMPTOMS; HEAD-INJURY; CONSEQUENCES; VALIDITY; COHORT; SCALE	Objective: To examine the relative contributions of injury characteristics and noninjury child and family factors as predictors of postconcussive symptoms (PCS) following mild traumatic brain injury (TBI) in children. Method: Participants were 8- to 15-year-old children, 186 with mild TBI and 99 with mild orthopedic injuries (OI). Parents and children rated PCS shortly after injury and at 1, 3, and 12 months postinjury. Hierarchical regression analyses were conducted to predict PCS from (1) demographic variables; (2) premorbid child factors (WASI IQ; WRAT-3 Reading; Child Behavior Checklist; ratings of preinjury PCS); (3) family factors (Family Assessment Device General Functioning Scale; Brief Symptom Inventory; and Life Stressors and Social Resources Inventory); and (4) injury group (OI, mild TBI with loss of consciousness [LOC] and associated injuries [AI], mild TBI with LOC but without AI, mild TBI without LOC but with AI, and mild TBI without LOC or AI). Results: Injury group predicted parent and child ratings of PCS but showed a decreasing contribution over time. Demographic variables consistently predicted symptom ratings across time. Premorbid child factors, especially retrospective ratings of premorbid symptoms, accounted for the most variance in symptom ratings. Family factors, particularly parent adjustment, consistently predicted parent, but not child, ratings of PCS. Conclusions: Injury characteristics predict PCS in the first months following mild TBI but show a decreasing contribution over time. In contrast, noninjury factors are more consistently related to persistent PCS.	[McNally, Kelly A.] Nationwide Childrens Hosp, Sect Pediat Psychol & Neuropsychol, Columbus, OH 43205 USA; [McNally, Kelly A.; Dietrich, Ann; Nuss, Kathy; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathy] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Wright, Martha; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Wright, Martha; Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	McNally, Kelly/0000-0001-9278-9413; Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	The work reported here was supported by grants HD44099 and HD39834 from the National Institutes of Health to Keith Owen Yeates.	Achenbach TM, 1991, MANUAL CHILD BEHAV C; Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; [Anonymous], 1999, WECHSLER ABBREVIATED; Ayr L. K., 2009, CHILD NEUROPSYCHOL, V2, P213; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MOOS R, 1988, LIFE STRESSORS SOCIA; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6; Olofsson E, 2009, ACTA PAEDIATR, V98, P17, DOI 10.1111/j.1651-2227.2008.00998.x; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TEASDALE G, 1974, LANCET, V2, P81; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	42	96	96	0	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2013	27	1					1	12		10.1037/a0031370			12	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	073QI	WOS:000313757200001	23356592	Green Accepted			2022-02-06	
J	Sharp, DJ; Ham, TE				Sharp, David J.; Ham, Timothy E.			Investigating white matter injury after mild traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						blast injury; diffusion tensor imaging; mild traumatic brain injury; susceptibility-weighted imaging	DIFFUSE AXONAL INJURY; WEIGHTED IMAGING SWI; MINOR HEAD-INJURY; WALLERIAN DEGENERATION; PROSPECTIVE COHORT; CORPUS-CALLOSUM; WATER DIFFUSION; UNITED-STATES; YOUNG-PEOPLE; DAMAGE	Purpose of review Traumatic brain injury (TBI) often results in traumatic axonal injury (TAI). This is difficult to identify using conventional neuroimaging methods. We review recent work that uses advanced imaging methods to identify TAI following mild (m)TBI. Recent findings Susceptibility-weighted imaging (SWI) is a highly sensitive way of identifying microbleeds, which are a marker of TAI. Diffusion tensor imaging (DTI) provides a more flexible way of investigating white matter injury. Recent studies largely confirm that DTI is sensitive to white matter damage after mTBI. Distinct DTI abnormalities are observed in the acute and subacute/chronic stages. DTI measurements change dynamically after an injury, reflecting the evolving pathological processes. DTI abnormalities correlate with cognitive and neuropsychiatric impairments. Importantly, DTI can contribute to the prediction of clinical outcome and has begun to be applied to the study of sports and blast injury. Summary DTI and SWI are important advances in MRI that allow more detailed investigation of white matter injury. SWI is a highly sensitive way of identifying microbleeds. DTI is a flexible way of quantifying white matter integrity, and provides a method of diagnosing clinically significant white matter injury when conventional imaging is normal.	[Sharp, David J.; Ham, Timothy E.] Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Div Expt Med, Ctr Neurosci, London W12 0NN, England		Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Div Expt Med, Ctr Neurosci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013		Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Imperial College Healthcare Charity; PfizerPfizer; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701951] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951] Funding Source: researchfish	The work was supported by The Medical Research Council (UK) (to D.J.S); D.J.S also holds grants from The Imperial College Healthcare Charity and an Investigator Led Award from Pfizer.	ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Henry LC, 2011, J NEUROTRAUMA; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Sun SW, 2008, NEUROIMAGE, V40, P1, DOI 10.1016/j.neuroimage.2007.11.049; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	60	96	100	1	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2011	24	6					558	563		10.1097/WCO.0b013e32834cd523			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	845VC	WOS:000296850900007	21986682				2022-02-06	
J	Karlin, AM				Karlin, Aaron M.			Concussion in the Pediatric and Adolescent Population: "Different Population, Different Concerns"	PM&R			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURY; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSION SYNDROME; NCAA CONCUSSION; YOUNG ATHLETE; CHILDREN	Sports-related concussions are common among pediatric and adolescent athletes, yet a scarcity of age-specific research often has meant that practitioners use guidelines developed for collegiate or adult populations. This situation is changing, as more studies are being published about this population that bears special attention because of the immaturity of the developing brain. This article describes existing knowledge about the epidemiology and etiology of concussions in youth athletes; discusses issues related to assessment, clinical management, and return to activity; examines special concerns related to the effects of concussion on the developing brain; and discusses prevention and education initiatives related to concussion in youth athletes. PM R 2011;3:S369-S379	[Karlin, Aaron M.] Ochsner Clin & Alton Ochsner Med Fdn, Div Pediat Phys Med & Rehabil, Ochsner Pediat & Adolescent Concuss Management Pr, Med Ctr,Dept Pediat, New Orleans, LA USA; [Karlin, Aaron M.] Ochsner Clin & Alton Ochsner Med Fdn, Med Ctr, Dept Phys Med & Rehabil, New Orleans, LA USA; [Karlin, Aaron M.] Ochsner Clin & Alton Ochsner Med Fdn, Med Ctr, Dept Sports Med, New Orleans, LA USA		Karlin, AM (corresponding author), Childrens Hlth Ctr, 101 Judge Tanner Dr,Suite 302, Covington, LA 70433 USA.	akarlin@ochsner.org					Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; [Anonymous], ATHL TRAIN FILL NEC; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Canadian Pediatric Society, 2006, PAEDIAT CHILD HLTH, V11, P420; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Centers for Disease Control and Prevention, WHAT TRAUM BRAIN INJ; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cook Rebecca S, 2006, J Trauma Nurs, V13, P58; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gordon Kevin E, 2006, Semin Pediatr Neurol, V13, P243, DOI 10.1016/j.spen.2006.09.005; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kieslich M, 2002, J NEUROL NEUROSUR PS, V73, P13, DOI 10.1136/jnnp.73.1.13; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee Michael A, 2009, Conn Med, V73, P171; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Center for Injury Prevention and Control, 2011, C MILD TRAUM BRAIN I; National Federation of State High School Athletic Associations, 2009 2010 HIGH SCH A; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Patel DR, 2010, PEDIATR CLIN N AM, V57, P649, DOI 10.1016/j.pcl.2010.03.006; Patel DR, 2002, PEDIATR CLIN N AM, V49, P505, DOI 10.1016/S0031-3955(02)00003-2; Patrick Kathleen, 2011, NASN Sch Nurse, V26, P15, DOI 10.1177/1942602X10390372; Pellman EJ, 2007, NEUROSURGERY, V60, P1050; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; U.S. Department of Education, 2007, FREE APPR PUBL ED ST; U.S. Department of Education, 2000, GUID IND ED PROGR; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WALLANDER J, 2003, HDB PEDIAT PSYCHOL; Washington State Department of Health, CONC MAN SCH; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	89	96	96	0	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S369	S379		10.1016/j.pmrj.2011.07.015			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	966YK	WOS:000305873100004	22035679				2022-02-06	
J	Marx, CE; Bradford, DW; Hamer, RM; Naylor, JC; Allen, TB; Lieberman, JA; Strauss, JL; Kilts, JD				Marx, C. E.; Bradford, D. W.; Hamer, R. M.; Naylor, J. C.; Allen, T. B.; Lieberman, J. A.; Strauss, J. L.; Kilts, J. D.			PREGNENOLONE AS A NOVEL THERAPEUTIC CANDIDATE IN SCHIZOPHRENIA: EMERGING PRECLINICAL AND CLINICAL EVIDENCE	NEUROSCIENCE			English	Article						neurosteroid; neuroactive steroid; pregnenolone; allopregnanolone; schizophrenia	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTORS; MICROTUBULE-ASSOCIATED PROTEIN-2; STEROID-HORMONE METABOLITES; LINKED-IMMUNOSORBENT-ASSAY; NEUROACTIVE STEROIDS; ALZHEIMERS-DISEASE; BIPOLAR DISORDER; RAT-BRAIN	Emerging preclinical and clinical evidence suggests that pregnenolone may be a promising novel therapeutic candidate in schizophrenia. Pregnenolone is a neurosteroid with pleiotropic actions in rodents that include the enhancement of learning and memory, neuritic outgrowth, and myelination. Further, pregnenolone administration results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA(A) receptor responses. In addition, pregnenolone administration elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors. There are thus multiple mechanistic possibilities for pregnenolone as a potential therapeutic agent in schizophrenia, including the amelioration of NMDA receptor hypofunction (via metabolism to pregnenolone sulfate) and the mitigation of GABA dysregulation (via metabolism to allopregnanolone). Additional evidence consistent with a therapeutic role for pregnenolone in schizophrenia includes neurosteroid changes following administration of certain antipsychotics in rodent models. For example, clozapine elevates pregnenolone levels in rat hippocampus, and these increases may potentially contribute to its superior antipsychotic efficacy [Marx et al. (2006a) Pharmacol Biochem Behav 84:598-608]. Further, pregnenolone levels appear to be altered in postmortem brain tissue from patients with schizophrenia compared to control subjects [Marx et al. (2006c) Neuropsychopharmacology 31:1249-1263], suggesting that neurosteroid changes may play a role in the neurobiology of this disorder and/or its treatment. Although clinical trial data utilizing pregnenolone as a therapeutic agent in schizophrenia are currently limited, initial findings are encouraging. Treatment with adjunctive pregnenolone significantly decreased negative symptoms in patients with schizophrenia or schizo-affective disorder in a pilot proof-of-concept randomized controlled trolled trial, and elevations in pregnenolone and allopregnanolone post-treatment with this intervention were correlated with cognitive improvements [Marx et al. (2009) Neuropsychopharmacology 34:1885-1903]. Another pilot randomized controlled trial recently presented at a scientific meeting demonstrated significant improvements in negative symptoms, verbal memory, and attention following treatment with adjunctive pregnenolone, in addition to enduring effects in a small subset of patients receiving pregnenolone longer-term [Savitz (2010) Society of Biological Psychiatry Annual Meeting New Orleans, LA]. A third pilot clinical trial reported significantly decreased positive symptoms and extrapyramidal side effects following adjunctive pregnenolone, in addition to increased attention and working memory performance [Ritsner et al. (2010) J Clin Psychiatry 71:1351-1362]. Future efforts in larger cohorts will be required to investigate pregnenolone as a possible therapeutic candidate in schizophrenia, but early efforts are promising and merit further investigation. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain. (C) 2011 Published by Elsevier Ltd on behalf of IBRO.	[Marx, C. E.; Bradford, D. W.; Naylor, J. C.; Allen, T. B.; Strauss, J. L.; Kilts, J. D.] Duke Univ, Med Ctr, Durham VA Med Ctr, Durham, NC 27705 USA; [Hamer, R. M.] Univ N Carolina, Chapel Hill, NC USA; [Lieberman, J. A.] Columbia Coll Phys & Surg, New York, NY USA		Marx, CE (corresponding author), Duke Univ, Med Ctr, Durham VA Med Ctr, 508 Fulton St,MHSL 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Lieberman, Jeffrey/AAY-8239-2020		VA Career Development Transition Award (CDTA); VA Career Development Award (CDA); VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC); VA Research Enhancement Award Program	This work was supported by the following sources: VA Career Development Transition Award (CDTA; CEM), VA Career Development Award (CDA; JLS), VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC; PI John Fairbank, PhD), and VA Research Enhancement Award Program (PI Roger Madison, PhD). Dr. Marx discloses that she is a co-applicant on pending U.S. patent applications for the use of neurosteroids and derivatives for the treatment of central nervous system disorders and for lowering cholesterol (no patents issued, no licensing in place). The remaining authors have no potential conflicts of interest related to this work to disclose. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health.	Agis-Balboa RC, 2007, P NATL ACAD SCI USA, V104, P18736, DOI 10.1073/pnas.0709419104; Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Bartzokis G, 2005, AM J PSYCHIAT, V162, P1229, DOI 10.1176/appi.ajp.162.6.1229-a; Belelli D, 2006, NEUROSCIENCE, V138, P821, DOI 10.1016/j.neuroscience.2005.07.021; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Benes FM, 2001, NEUROPSYCHOPHARMACOL, V25, P1, DOI 10.1016/S0893-133X(01)00225-1; Benes FM, 2007, P NATL ACAD SCI USA, V104, P10164, DOI 10.1073/pnas.0703806104; Benitez-King G, 2004, CNS NEUROL DISORD-DR, V3, P515, DOI 10.2174/1568007043336761; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Buchanan RW, 2008, AM J PSYCHIAT, V165, P82, DOI 10.1176/appi.ajp.2007.07050724; Buchanan RW, 2006, AM J PSYCHIAT, V163, P1867, DOI 10.1176/appi.ajp.163.11.1867; Buchanan RW, 2005, SCHIZOPHRENIA BULL, V31, P5, DOI 10.1093/schbul/sbi020; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Charlet A, 2008, PAIN, V139, P603, DOI 10.1016/j.pain.2008.06.016; CHENEY DL, 1995, NEUROREPORT, V6, P1697, DOI 10.1097/00001756-199508000-00025; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Conley RR, 2009, CLIN NEUROPHARMACOL, V32, P69, DOI 10.1097/WNF.0b013e31816f2795; CORPECHOT C, 1983, BRAIN RES, V270, P119, DOI 10.1016/0006-8993(83)90797-7; Coyle JT, 2006, CELL MOL NEUROBIOL, V26, P365, DOI 10.1007/s10571-006-9062-8; Darnaudery M, 2002, BRAIN RES, V951, P237, DOI 10.1016/S0006-8993(02)03166-9; Darnaudery M, 1998, J NEUROCHEM, V71, P2018; Davis KL, 2003, ARCH GEN PSYCHIAT, V60, P443, DOI 10.1001/archpsyc.60.5.443; Debonnel G, 1996, NEUROSCIENCE, V71, P977, DOI 10.1016/0306-4522(96)80001-7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Ebner MJ, 2006, ENDOCRINOLOGY, V147, P179, DOI 10.1210/en.2005-1065; Farb D, 2011, 44 ANN WINT C BRAIN; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; FREEMAN H, 1950, J CLIN ENDOCRINOL, V10, P1523, DOI 10.1210/jcem-10-12-1523; FRYE CA, 1994, BRAIN RES, V643, P194, DOI 10.1016/0006-8993(94)90025-6; George O, 2010, BIOL PSYCHIAT, V68, P956, DOI 10.1016/j.biopsych.2010.03.022; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Glantz LA, 2006, SCHIZOPHR RES, V81, P47, DOI 10.1016/j.schres.2005.08.014; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; Green MF, 2006, J CLIN PSYCHIAT, V67, P3, DOI 10.4088/JCP.1006e12; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Guidotti A, 2005, PSYCHOPHARMACOLOGY, V180, P191, DOI 10.1007/s00213-005-2212-8; GUO AL, 1995, GYNECOL ENDOCRINOL, V9, P1; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harvey PD, 2004, J CLIN PSYCHIAT, V65, P361; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higashi T, 2003, J PHARMACEUT BIOMED, V30, P1907, DOI 10.1016/S0731-7085(02)00534-4; Higashi T, 2003, BIOL PHARM BULL, V26, P709; Hoistad M, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.009.2009; Hsu HJ, 2006, NATURE, V439, P480, DOI 10.1038/nature04436; IRWIN RP, 1994, J PHARMACOL EXP THER, V271, P677; Jarskog LF, 2006, CURR OPIN PSYCHIATR, V19, P307, DOI 10.1097/01.yco.0000218603.25346.8f; Jarskog LF, 2004, AM J PSYCHIAT, V161, P109, DOI 10.1176/appi.ajp.161.1.109; Javitt DC, 2007, INT REV NEUROBIOL, V78, P69, DOI 10.1016/S0074-7742(06)78003-5; Javitt DC, 2004, MOL PSYCHIATR, V9, P984, DOI 10.1038/sj.mp.4001551; Jevtovic-Todorovic Vesna, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS178, DOI 10.1016/j.psyneuen.2009.06.001; Johansson T, 2008, J PHARMACOL EXP THER, V324, P759, DOI 10.1124/jpet.107.130518; KAVALIERS M, 1987, BRAIN RES, V415, P393, DOI 10.1016/0006-8993(87)90228-9; Kavaliers M, 2000, NEUROSCIENCE, V95, P807; Keefe RSE, 2008, NEUROPSYCHOPHARMACOL, V33, P1217, DOI 10.1038/sj.npp.1301499; Kelley MH, 2008, J NEUROCHEM, V107, P668, DOI 10.1111/j.1471-4159.2008.05617.x; Kilts JD, 2010, PAIN MED, V11, P1469, DOI 10.1111/j.1526-4637.2010.00927.x; Knight JG, 2007, MOL PSYCHIATR, V12, P424, DOI 10.1038/sj.mp.4001959; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Korneyev A, 1996, HORM BEHAV, V30, P37, DOI 10.1006/hbeh.1996.0006; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; Ladurelle N, 2000, BRAIN RES, V858, P371, DOI 10.1016/S0006-8993(00)01953-3; Lahti AC, 2001, NEUROPSYCHOPHARMACOL, V25, P455, DOI 10.1016/S0893-133X(01)00243-3; LAHTI AC, 1995, NEUROPSYCHOPHARMACOL, V13, P9, DOI 10.1016/0893-133X(94)00131-I; LANTHIER A, 1986, J STEROID BIOCHEM, V25, P445, DOI 10.1016/0022-4731(86)90259-1; Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Lewis DA, 2004, PSYCHOPHARMACOLOGY, V174, P143, DOI 10.1007/s00213-003-1673-x; Lewis DA, 2003, ANN NY ACAD SCI, V1003, P102, DOI 10.1196/annals.1300.007; Liao GH, 2009, BRAIN RES, V1270, P140, DOI 10.1016/j.brainres.2009.03.027; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Liu SY, 2003, ANAL CHEM, V75, P5835, DOI 10.1021/ac0346297; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MacDonald ML, 2005, BIOL PSYCHIAT, V57, P1041, DOI 10.1016/j.biopsych.2005.01.022; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Marder SR, 2004, SCHIZOPHR RES, V72, P5, DOI 10.1016/j.schres.2004.09.010; Marder SR, 2006, J CLIN PSYCHIAT, V67, P31; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; Marx CE, 2010, AM COLL NEUR ANN M M; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Marx CE, 2008, INT J NEUROPSYCHOPH, V11, P547, DOI 10.1017/S1461145708008444; MATHIS C, 1994, PSYCHOPHARMACOLOGY, V116, P201, DOI 10.1007/BF02245063; Mathis C, 1996, NEUROPHARMACOLOGY, V35, P1057, DOI 10.1016/S0028-3908(96)00041-X; Matsumoto K, 2005, STRESS, V8, P85, DOI 10.1080/10253890500159022; Mayo W, 2005, NEUROBIOL AGING, V26, P103, DOI 10.1016/j.neurobiolaging.2004.03.013; MAYO W, 1993, BRAIN RES, V607, P324, DOI 10.1016/0006-8993(93)91524-V; MCGAVACK TH, 1951, J CLIN ENDOCRINOL, V11, P559, DOI 10.1210/jcem-11-6-559; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Mendelson JH, 2005, NEUROPSYCHOPHARMACOL, V30, P1751, DOI 10.1038/sj.npp.1300753; Meyer L, 2011, PAIN, V152, P170, DOI 10.1016/j.pain.2010.10.015; Meziane H, 1996, PSYCHOPHARMACOLOGY, V126, P323, DOI 10.1007/BF02247383; Millan MJ, 2005, PSYCHOPHARMACOLOGY, V179, P30, DOI 10.1007/s00213-005-2199-1; MORROW AL, 1990, MOL PHARMACOL, V37, P263; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Mtchedlishvili Z, 2003, MOL PHARMACOL, V64, P857, DOI 10.1124/mol.64.4.857; Murakami K, 2000, P NATL ACAD SCI USA, V97, P3579, DOI 10.1073/pnas.97.7.3579; Murphy BEP, 2000, J STEROID BIOCHEM, V74, P137, DOI 10.1016/S0960-0760(00)00098-4; Naylor JC, 2008, J CLIN ENDOCR METAB, V93, P3173, DOI 10.1210/jc.2007-1229; Naylor JC, 2010, BBA-MOL CELL BIOL L, V1801, P951, DOI 10.1016/j.bbalip.2010.05.006; Pallares M, 1998, NEUROSCIENCE, V87, P551, DOI 10.1016/S0306-4522(98)00174-2; Patchev VK, 1996, NEUROPSYCHOPHARMACOL, V15, P533, DOI 10.1016/S0893-133X(96)00096-6; PATCHEV VK, 1994, NEUROSCIENCE, V62, P265, DOI 10.1016/0306-4522(94)90330-1; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pibiri F, 2008, P NATL ACAD SCI USA, V105, P5567, DOI 10.1073/pnas.0801853105; Pinna G, 2004, P NATL ACAD SCI USA, V101, P6222, DOI 10.1073/pnas.0401479101; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Pinna G, 2010, BEHAV PHARMACOL, V21, P438, DOI 10.1097/FBP.0b013e32833d8ba0; Rasmusson AM, 2006, BIOL PSYCHIAT, V60, P704, DOI 10.1016/j.biopsych.2006.03.026; Ritsner M, 2007, EUR NEUROPSYCHOPHARM, V17, P358, DOI 10.1016/j.euroneuro.2006.10.001; Ritsner MS, 2010, J CLIN PSYCHIAT, V71, P1351, DOI 10.4088/JCP.09m05031yel; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; ROMEO E, 1994, J PHARMACOL EXP THER, V270, P89; Rujescu D, 2006, BIOL PSYCHIAT, V59, P721, DOI 10.1016/j.biopsych.2005.08.029; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sadri-Vakili G, 2008, J PHARMACOL EXP THER, V327, P840, DOI 10.1124/jpet.108.143958; Savitz AJ, 2007, SCHIZOPHRENIA BULL, V33, P458; Savitz AJ, 2010, BIOL PSYCHIAT, V67, p22S; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Schumacher M, 2008, NEUROCHEM INT, V52, P522, DOI 10.1016/j.neuint.2007.08.022; Serra M, 2001, PSYCHOPHARMACOLOGY, V158, P48, DOI 10.1007/s002130100853; Sliwinski A, 2004, J NEUROSCI RES, V78, P691, DOI 10.1002/jnr.20332; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Strous RD, 2003, ARCH GEN PSYCHIAT, V60, P133, DOI 10.1001/archpsyc.60.2.133; Takahashi N, 2011, PROG NEUROBIOL, V93, P13, DOI 10.1016/j.pneurobio.2010.09.004; Tkachev D, 2003, LANCET, V362, P798, DOI 10.1016/S0140-6736(03)14289-4; Tkachev D, 2007, INT J NEUROPSYCHOPH, V10, P557, DOI 10.1017/S1461145706007334; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vallee M, 2001, EUR J NEUROSCI, V14, P2003, DOI 10.1046/j.0953-816x.2001.01817.x; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wang MD, 1997, J STEROID BIOCHEM, V62, P299, DOI 10.1016/S0960-0760(97)00041-1; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Whittaker MT, 2008, J NEUROCHEM, V107, P510, DOI 10.1111/j.1471-4159.2008.05627.x; WINFREE CJ, 1992, LIFE SCI, V50, P1007, DOI 10.1016/0024-3205(92)90095-7; WU FS, 1991, MOL PHARMACOL, V40, P333; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x	158	96	101	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP 15	2011	191				SI		78	90		10.1016/j.neuroscience.2011.06.076			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	831RR	WOS:000295749300008	21756978				2022-02-06	
J	VanGuilder, HD; Farley, JA; Yan, H; Van Kirk, CA; Mitschelen, M; Sonntag, WE; Freeman, WM				VanGuilder, Heather D.; Farley, Julie A.; Yan, Han; Van Kirk, Colleen A.; Mitschelen, Matthew; Sonntag, William E.; Freeman, Willard M.			Hippocampal dysregulation of synaptic plasticity-associated proteins with age-related cognitive decline	NEUROBIOLOGY OF DISEASE			English	Article						Nogo; CamkII; Aging; Hippocampus; Synapse; Learning and memory	LONG-TERM POTENTIATION; ACTIVATES TRYPTOPHAN 5-MONOOXYGENASE; TRAUMATIC BRAIN-INJURY; CALMODULIN KINASE-II; RAT CEREBRAL-CORTEX; NOGO-A; SPATIAL MEMORY; DREBRIN-A; TYROSINE 3-MONOOXYGENASE; OUTGROWTH INHIBITOR	Age-related cognitive decline occurs without frank neurodegeneration and is the most common cause of memory impairment in aging individuals. With increasing longevity, cognitive deficits, especially in hippocampus-dependent memory processes, are increasing in prevalence. Nevertheless, the neurobiological basis of age-related cognitive decline remains unknown. While concerted efforts have led to the identification of neurobiological changes with aging, few age-related alterations have been definitively correlated to behavioral measures of cognitive decline. In this work, adult (12 months) and aged (28 months) rats were categorized by Morris water maze performance as Adult cognitively Intact, Aged cognitively Intact or Aged cognitively Impaired, and protein expression was examined in hippocampal synaptosome preparations. Previously described differences in synaptic expression of neurotransmission-associated proteins (Dnm1, Hpca, Stx1, Syn1, Syn2, Syp, SNAP25, VAMP2 and 14-3-3 eta, gamma, and zeta) were confirmed between Adult and Aged rats, with no further dysregulation associated with cognitive impairment. Proteins related to synaptic structural stability (MAP2, drebrin, Nogo-A) and activity-dependent signaling (PSD-95, 14-3-30, CaMKII alpha) were up- and down-regulated, respectively, with cognitive impairment but were not altered with increasing age. Localization of MAP2, PSD-95, and CaMKII alpha demonstrated protein expression alterations throughout the hippocampus. The altered expression of activity- and structural stability-associated proteins suggests that impaired synaptic plasticity is a distinct phenomenon that occurs with age-related cognitive decline, and demonstrates that cognitive decline is not simply an exacerbation of the aging phenotype. (C) 2011 Elsevier Inc. All rights reserved.	[VanGuilder, Heather D.; Van Kirk, Colleen A.; Freeman, Willard M.] Penn State Coll Med, Dept Pharmacol, Hershey Ctr Appl Res, Hershey, PA 17033 USA; [Farley, Julie A.; Yan, Han; Mitschelen, Matthew; Sonntag, William E.] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK 73104 USA		Freeman, WM (corresponding author), Penn State Coll Med, Dept Pharmacol, Hershey Ctr Appl Res, 500 Univ Dr,Mc R130, Hershey, PA 17033 USA.	wfreeman@psu.edu		Freeman, Willard/0000-0001-7027-999X; sonntag, William/0000-0003-1850-2407	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026607, P01AG11370]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026607, P01AG011370] Funding Source: NIH RePORTER	This work was supported by NIA grants #R01AG026607 and #P01AG11370 to W.E.S., and generous support from the Donald W. Reynolds Foundation. We thank Robert Brucklacher and the Penn State Genome Sciences Facility for technical assistance.	Asrican B, 2007, J NEUROSCI, V27, P14007, DOI 10.1523/JNEUROSCI.3587-07.2007; Barnes CA, 1997, NATURE, V388, P272, DOI 10.1038/40859; Beique JC, 2006, P NATL ACAD SCI USA, V103, P19535, DOI 10.1073/pnas.0608492103; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Blalock EM, 2005, AGEING RES REV, V4, P481, DOI 10.1016/j.arr.2005.06.006; Blalock EM, 2003, J NEUROSCI, V23, P3807; Boric K, 2008, J NEUROSCI, V28, P8034, DOI 10.1523/JNEUROSCI.2036-08.2008; Brucklacher RM, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-26; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Butterfield DA, 2006, NEUROBIOL DIS, V22, P223, DOI 10.1016/j.nbd.2005.11.002; Carlisle HJ, 2008, J PHYSIOL-LONDON, V586, P5885, DOI 10.1113/jphysiol.2008.163469; Casadesus G, 2004, NUTR NEUROSCI, V7, P309, DOI 10.1080/10284150400020482; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Dahle CL, 2009, PSYCHOL AGING, V24, P154, DOI 10.1037/a0014283; De Camilli P, 1984, Neuroscience, V11, P817; Delint-Ramirez I, 2008, J NEUROCHEM, V106, P1658, DOI 10.1111/j.1471-4159.2008.05523.x; Dickson HM, 2010, J NEUROSCI, V30, P13319, DOI 10.1523/JNEUROSCI.1324-10.2010; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; El-Hussein AE, 2000, SCIENCE, V290, P1364; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Freeman WM, 2010, PHARMACOGENOMICS J, V10, P385, DOI 10.1038/tpj.2009.60; Freeman WM, 2009, NEUROSCIENCE, V159, P183, DOI 10.1016/j.neuroscience.2008.12.004; Freeman Willard M, 2009, J Ocul Biol Dis Infor, V2, P202; GEINISMAN Y, 1986, BRAIN RES, V398, P266, DOI 10.1016/0006-8993(86)91486-1; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Gillani RL, 2010, BEHAV BRAIN RES, V208, P415, DOI 10.1016/j.bbr.2009.12.015; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; Hayashi K, 1996, J NEUROSCI, V16, P7161; Hu FH, 2008, J NEUROSCI, V28, P1262, DOI 10.1523/JNEUROSCI.1068-07.2008; Huber AB, 2002, J NEUROSCI, V22, P3553; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; Khuchua Z, 2003, NEUROSCIENCE, V119, P101, DOI 10.1016/S0306-4522(03)00094-0; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kojima N, 2007, NEUROSCI RES, V58, P1, DOI 10.1016/j.neures.2007.02.003; Kumar A, 2007, J NEUROPHYSIOL, V98, P594, DOI 10.1152/jn.00249.2007; Lee HJ, 2008, J NEUROSCI, V28, P2753, DOI 10.1523/JNEUROSCI.5586-07.2008; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Liu P, 2008, SYNAPSE, V62, P834, DOI 10.1002/syn.20563; Lu FM, 2006, P NATL ACAD SCI USA, V103, P4264, DOI 10.1073/pnas.0508162103; Maei HR, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.004.2009; Majdi M, 2007, EUR J NEUROSCI, V26, P3583, DOI 10.1111/j.1460-9568.2007.05966.x; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Matsuo N, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.020.2009; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Mitschelen M, 2009, NEUROSCIENCE, V164, P918, DOI 10.1016/j.neuroscience.2009.08.070; Mizui T, 2005, MOL CELL NEUROSCI, V30, P630, DOI 10.1016/j.mcn.2005.06.013; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; Norris CM, 1996, J NEUROSCI, V16, P5382; O'Callaghan RM, 2009, HIPPOCAMPUS, V19, P1019, DOI 10.1002/hipo.20591; Okabe S, 2001, J NEUROSCI, V21, P6105, DOI 10.1523/JNEUROSCI.21-16-06105.2001; Okonkwo OC, 2010, CEREBROVASC DIS, V30, P362, DOI 10.1159/000319564; Park CS, 2008, NEUROSCIENCE, V151, P43, DOI 10.1016/j.neuroscience.2007.09.075; Platano D, 2008, REJUV RES, V11, P341, DOI 10.1089/rej.2008.0725; Poon HF, 2006, NEUROBIOL AGING, V27, P1020, DOI 10.1016/j.neurobiolaging.2005.05.014; Poulsen DJ, 2007, J NEUROSCI RES, V85, P735, DOI 10.1002/jnr.21163; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Raiker SJ, 2010, J NEUROSCI, V30, P12432, DOI 10.1523/JNEUROSCI.0895-10.2010; Ramsey MM, 2004, NEUROSCIENCE, V129, P119, DOI 10.1016/j.neuroscience.2004.08.001; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Rountree CB, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-61; Rowe WB, 2007, J NEUROSCI, V27, P3098, DOI 10.1523/JNEUROSCI.4163-06.2007; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; Shi L, 2005, CEREB CORTEX, V15, P571, DOI 10.1093/cercor/bhh158; SHIRAO T, 1994, EXP CELL RES, V215, P145, DOI 10.1006/excr.1994.1326; SHIRAO T, 1992, NEUROREPORT, V3, P109, DOI 10.1097/00001756-199201000-00029; Shrestha L.B., 2006, CHANGING DEMOGRAPHIC; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Small GW, 2002, BMJ-BRIT MED J, V324, P1502, DOI 10.1136/bmj.324.7352.1502; Stein V, 2003, J NEUROSCI, V23, P5503; Swofford JA, 2007, DEV NEUROBIOL, V67, P1457, DOI 10.1002/dneu.20458; Tao-Cheng JH, 2006, BRAIN CELL BIOL, V35, P117, DOI 10.1007/s11068-007-9012-5; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; TERRY AV, 2009, SPATIAL NAVIGATION; Tombaugh GC, 2002, J NEUROSCI, V22, P9932; VanGuilder HD, 2010, J NEUROCHEM, V113, P1577, DOI 10.1111/j.1471-4159.2010.06719.x; Vickers CA, 2006, BRAIN RES, V1090, P89, DOI 10.1016/j.brainres.2006.03.075; Wang YF, 2006, BRIT J PHARMACOL, V148, P147, DOI 10.1038/sj.bjp.0706720; Wang ZW, 2008, MOL NEUROBIOL, V38, P153, DOI 10.1007/s12035-008-8039-7; Wilson IA, 2003, NEUROBIOL AGING, V24, P297, DOI 10.1016/S0197-4580(02)00080-5; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; Zagrebelsky M, 2010, J NEUROSCI, V30, P13220, DOI 10.1523/JNEUROSCI.1044-10.2010; Zha XM, 2009, J NEUROSCI RES, V87, P1969, DOI 10.1002/jnr.22033	90	96	97	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUL	2011	43	1			SI		201	212		10.1016/j.nbd.2011.03.012			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	771RZ	WOS:000291179700023	21440628	Green Accepted			2022-02-06	
J	De Beaumont, L; Mongeon, D; Tremblay, S; Messier, J; Prince, F; Leclerc, S; Lassonde, M; Theoret, H				De Beaumont, Louis; Mongeon, David; Tremblay, Sebastien; Messier, Julie; Prince, Francois; Leclerc, Suzanne; Lassonde, Maryse; Theoret, Hugo			Persistent Motor System Abnormalities in Formerly Concussed Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; transcranial magnetic stimulation; clinical neurophysiology; motor control; primary motor cortex	TRANSCRANIAL MAGNETIC STIMULATION; RAPID ALTERNATING MOVEMENTS; GABA(B) RECEPTOR AGONIST; TRAUMATIC BRAIN-INJURY; CORTICAL SILENT PERIOD; CEREBRAL CONCUSSION; POSTURAL CONTROL; LONG-TERM; APPROXIMATE ENTROPY; PARKINSONS-DISEASE	Context: The known detrimental effects of sport concussions on motor system function include balance problems, slowed motor execution, and abnormal motor cortex excitability. Objective: To assess whether these concussion-related alterations of motor system function are still evident in collegiate football players who sustained concussions but returned to competition more than 9 months before testing. Design: Case-control study. Setting: University laboratory. Patients or Other Participants: A group of 21 active, university-level football players who had experienced concussions was compared with 15 university football players who had not sustained concussions. Intervention(s): A force platform was used to assess center-of-pressure (COP) displacement and COP oscillation regularity (approximate entropy) as measures of postural stability in the upright position. A rapid alternating-movement task was also used to assess motor execution speed. Transcranial magnetic stimulation over the motor cortex was used to measure long-interval intracortical inhibition and the cortical silent period, presumably reflecting gamma-aminobutyric acid subtype B receptor mediated intracortical inhibition. Main Outcome Measure(S): COP displacement and oscillation regularity, motor execution speed, long-interval intracortical inhibition, cortical silent period. Results: Relative to controls, previously concussed athletes showed persistently lower COP oscillation randomness, normal performance on a rapid alternating-movement task, and more M1 intracortical inhibition that was related to the number of previous concussions. Conclusions: Sport concussions were associated with pervasive changes in postural control and more M1 intracortical inhibition, providing neurophysiologic and behavioral evidence of lasting, subclinical changes in motor system integrity in concussed athletes.	[De Beaumont, Louis; Tremblay, Sebastien; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada; [Mongeon, David; Messier, Julie; Prince, Francois; Leclerc, Suzanne] Univ Montreal, Dept Kinesiol, Montreal, PQ H3C 3J7, Canada; [Leclerc, Suzanne] Univ Montreal, Clin Med Sport, Montreal, PQ H3C 3J7, Canada		Theoret, H (corresponding author), Univ Montreal, Ctr Rech Neuropsychol & Cognit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca	Prince, Francois/AAA-6763-2022	Theoret, Hugo/0000-0002-7458-8797			Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; Beuter A, 1999, ENVIRON RES, V80, P64, DOI 10.1006/enrs.1998.3885; Beuter A, 1999, J CLIN NEUROPHYSIOL, V16, P484, DOI 10.1097/00004691-199909000-00010; Cantello R, 2007, NEUROSCIENCE, V150, P64, DOI 10.1016/j.neuroscience.2007.08.033; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Duval C, 2001, EXP BRAIN RES, V139, P412, DOI 10.1007/s002210100780; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Geurts ACH, 2005, GAIT POSTURE, V22, P267, DOI 10.1016/j.gaitpost.2004.10.002; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kluger A, 1997, Int Psychogeriatr, V9 Suppl 1, P307, DOI 10.1017/S1041610297005048; Kluger A, 1997, J GERONTOL B-PSYCHOL, V52, pP28, DOI 10.1093/geronb/52B.1.P28; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Lang N, 2006, EPILEPSIA, V47, P813, DOI 10.1111/j.1528-1167.2006.00544.x; Laughton CA, 2003, GAIT POSTURE, V18, P101, DOI 10.1016/S0966-6362(02)00200-X; Macdonell RAL, 2001, NEUROLOGY, V57, P706, DOI 10.1212/WNL.57.4.706; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; Moller B, 2007, NEUROREPORT, V18, P1503; Mohammadi B, 2006, MUSCLE NERVE, V33, P778, DOI 10.1002/mus.20531; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nakagawa Y, 1997, BRAIN RES, V766, P101, DOI 10.1016/S0006-8993(97)00529-5; OKADA M, 1983, COMPUT BIOMED RES, V16, P59, DOI 10.1016/0010-4809(83)90007-1; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Pierantozzi M, 2004, BRAIN RES, V1028, P1, DOI 10.1016/j.brainres.2004.06.009; SHIMOYAMA I, 1990, ARCH NEUROL-CHICAGO, V47, P681, DOI 10.1001/archneur.1990.00530060095025; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M; Smith CD, 1999, NEUROLOGY, V53, P1458, DOI 10.1212/WNL.53.7.1458; Termoz N, 2008, GAIT POSTURE, V27, P463, DOI 10.1016/j.gaitpost.2007.05.015; Tinazzi M, 2005, NEUROSCI LETT, V378, P55, DOI 10.1016/j.neulet.2004.12.015; Watanabe M, 2002, INT REV CYTOL, V213, P1; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x	48	96	96	1	30	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAY-JUN	2011	46	3					234	240					7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	770YC	WOS:000291123400003	21669091				2022-02-06	
J	Rowson, S; Beckwith, JG; Chu, JJ; Leonard, DS; Greenwald, RM; Duma, SM				Rowson, Steven; Beckwith, Jonathan G.; Chu, Jeffrey J.; Leonard, Daniel S.; Greenwald, Richard M.; Duma, Stefan M.			A Six Degree of Freedom Head Acceleration Measurement Device for Use in Football	JOURNAL OF APPLIED BIOMECHANICS			English	Article						mild traumatic brain injury (MTBI); concussion; biomechanics; angular; linear; rotational	TRAUMATIC BRAIN-INJURIES; PROFESSIONAL FOOTBALL; IMPACT; ACCELEROMETERS; EPIDEMIOLOGY; CONCUSSION; LOCATION	The high incidence rate of concussions in football provides a unique opportunity to collect biomechanical data to characterize mild traumatic brain injury. The goal of this study was to validate a six degree of freedom (6DOF) measurement device with 12 single-axis accelerometers that uses a novel algorithm to compute linear and angular head accelerations for each axis of the head. The 6DOF device can be integrated into existing football helmets and is capable of wireless data transmission. A football helmet equipped with the 6DOF device was fitted to a Hybrid III head instrumented with a 9 accelerometer array. The helmet was impacted using a pneumatic linear impactor. Hybrid III head accelerations were compared with that of the 6DOF device. For all impacts, peak Hybrid III head accelerations ranged from 24 g to 176 g and 1,506 rad/s(2) to 14,431 rad/s(2). Average errors for peak linear and angular head acceleration were 1% +/- 18% and 3% +/- 24%, respectively. The average RMS error of the temporal response for each impact was 12.5 g and 907 rad/s(2).	[Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Leonard, Daniel S.; Greenwald, Richard M.] Simbex, Lebanon, NH USA		Rowson, S (corresponding author), Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA.		Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; 	National Highway Traffic Safety Administration; Toyota Central Research and Development Laboratories; National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge our sponsors for this research including the National Highway Traffic Safety Administration, Toyota Central Research and Development Laboratories, and the National Institutes of Health (National Institute for Child Health and Human Development) award R01HD048638.	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Foster J.K., 1977, P 21 STAPP CAR CRASH; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; HUBBARD RP, 1974, P 18 STAPP CAR CRASH; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Moon D W, 1971, Med Sci Sports, V3, P44; Newman J, 2000, P INT RES C BIOM IMP; Newman J.A., 1999, P INT RES C BIOM IMP; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; *NOCSAE, 2006, 08104M04 ND NOCSAE; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; RATH AL, 2005, 200520010745 SOC AUT; Reid S E, 1974, J Sports Med, V2, P86; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Walker L., 1973, P 17 STAPP CAR CRASH	28	96	96	0	18	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483			J APPL BIOMECH	J. Appl. Biomech.	FEB	2011	27	1					8	14		10.1123/jab.27.1.8			7	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	748GQ	WOS:000289378400002	21451177				2022-02-06	
J	Kim, JJ; Gean, AD				Kim, Jane J.; Gean, Alisa D.			Imaging for the Diagnosis and Management of Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						TBI; hemorrhage; subdural; epidural; contusion; traumatic shear injury	DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; WHITE-MATTER INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACEREBRAL HEMATOMA; CONSORTIUM SURVEY; CLINICAL-TRIALS; CT; LESIONS	To understand the role of imaging in traumatic brain injury (TBI), it is important to appreciate that TBI encompasses a heterogeneous group of intracranial injuries and includes both insults at the time of impact and a deleterious secondary cascade of insults that require optimal medical and surgical management. Initial imaging identifies the acute primary insult that is essential to diagnosing TBI, but serial imaging surveillance is also critical to identifying secondary injuries such as cerebral herniation and swelling that guide neurocritical management. Computed tomography (CT) is the mainstay of TBI imaging in the acute setting, but magnetic resonance tomography (MRI) has better diagnostic sensitivity for nonhemorrhagic contusions and shear-strain injuries. Both CT and MRI can be used to prognosticate clinical outcome, and there is particular interest in advanced applications of both techniques that may greatly improve the sensitivity of conventional CT and MRI for both the diagnosis and prognosis of TBI.	[Kim, Jane J.; Gean, Alisa D.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, San Francisco, CA 94143 USA		Kim, JJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave,Box 1325, San Francisco, CA 94143 USA.	jane.kim@radiology.ucsf.edu					Aiken AH, 2010, SEMIN ROENTGENOL, V45, P63, DOI 10.1053/j.ro.2009.09.007; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P597; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Centers for Disease Control and Prevention, TRAUM BRAIN INJ; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOKSEY M, 1993, BRIT J NEUROSURG, V7, P611, DOI 10.3109/02688699308995090; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Gean AD, 2010, RADIOLOGY, V257, P212, DOI 10.1148/radiol.10092075; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rauscher A, 2005, AM J NEURORADIOL, V26, P736; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	57	96	106	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2011	8	1					39	53		10.1007/s13311-010-0003-3			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	750RU	WOS:000289566500006	21274684	Green Published, Green Submitted, hybrid			2022-02-06	
J	Kabadi, SV; Hilton, GD; Stoica, BA; Zapple, DN; Faden, AI				Kabadi, Shruti V.; Hilton, Genell D.; Stoica, Bogdan A.; Zapple, David N.; Faden, Alan I.			Fluid-percussion-induced traumatic brain injury model in rats	NATURE PROTOCOLS			English	Article							MORRIS WATER MAZE; DIFFUSE AXONAL INJURY; HEAD-INJURY; COGNITIVE DEFICITS; INTRACRANIAL-PRESSURE; NEUROLOGIC DEFICITS; NEURONAL APOPTOSIS; BLAST INJURY; ADULT-RAT; MOTOR	Traumatic brain injury (TBI) is a major cause of mortality and morbidity. Various attempts have been made to replicate clinical TBI using animal models. The fluid-percussion model (FP) is one of the oldest and most commonly used models of experimentally induced TBI. Both central (CFP) and lateral (LFP) variations of the model have been used. Developed initially for use in larger species, the standard FP device was adapted more than 20 years ago to induce consistent degrees of brain injury in rodents. Recently, we developed a microprocessor-controlled, pneumatically driven instrument, micro-FP (MFP), to address operational concerns associated with the use of the standard FP device in rodents. We have characterized the MFP model with regard to injury severity according to behavioral and histological outcomes. In this protocol, we review the FP models and detail surgical procedures for LFP. The surgery involves tracheal intubation, craniotomy and fixation of Luer fittings, and induction of injury. The surgical procedure can be performed within 45-50 min.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Faden, Alan I.] Sch Med, Dept Anesthesiol, Baltimore, MD USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Faden, Alan I.] Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD USA; [Kabadi, Shruti V.; Hilton, Genell D.; Stoica, Bogdan A.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Hilton, Genell D.] San Francisco Gen Hosp, Dept Surg, Trauma Serv, San Francisco, CA 94110 USA; [Zapple, David N.] Georgetown Univ, Off Informat Serv, Washington, DC USA		Faden, AI (corresponding author), Sch Med, Dept Anesthesiol, Baltimore, MD USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health Grant no. NS052568. We would like to thank D.J. Loane for his helpful comments on the paper.; The project was conceived by A.I.F and was supported by the National Institutes of Health Grant no. NS052568 to A.I.F. The study was designed by A.I.F., B.A.S. and G.D.H. D.N.Z. originally developed the model. G.D.H. and S.V.K. equally contributed to the paper in terms of conducting the study, compiling the results and writing the paper.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANDREWS JS, 1995, PHYSIOL BEHAV, V57, P785, DOI 10.1016/0031-9384(94)00336-X; Avila MA, 2008, J CEREBR BLOOD F MET, V28, P1733, DOI 10.1038/jcbfm.2008.66; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; CAREY ME, 1995, NEUROSURG CLIN N AM, V6, P629; *CDCP, 2010, GET STATS TRAUM BRAI; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVID S, 1985, J NEUROCYTOL, V14, P1, DOI 10.1007/BF01150259; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; FINNIE JW, 1993, J COMP PATHOL, V108, P93, DOI 10.1016/S0021-9975(08)80231-9; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hoh T, 1999, J Neurosci, V19, pRC2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LIU S, 2009, J NEUROTRAUM, V11, P73; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Marmarou A, 1990, Adv Neurol, V52, P233; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; PARK HJ, 1995, ACTA OTO-LARYNGOL, V115, P273, DOI 10.3109/00016489509139307; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	84	96	100	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1754-2189	1750-2799		NAT PROTOC	Nat. Protoc.	SEP	2010	5	9					1552	1563		10.1038/nprot.2010.112			12	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	646US	WOS:000281569200006	20725070	Green Accepted			2022-02-06	
J	Covassin, T; Elbin, R; Kontos, A; Larson, E				Covassin, Tracey; Elbin, Robert; Kontos, Anthony; Larson, Elizabeth			Investigating baseline neurocognitive performance between male and female athletes with a history of multiple concussion	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; RECURRENT CONCUSSION; AGREEMENT STATEMENT; FOOTBALL PLAYERS; ESTROGEN; SPORT; SYMPTOMS; IMPACT; RISK	Objective The purpose of this study was to examine, using a dose-response model, sex differences in computerised neurocognitive performance among athletes with a history of multiple concussions. Design Retrospective with randomly selected concussion cases from four levels/numbers of previous concussion. Setting Multicentre analysis of NCAA student-athletes. Participants Subjects included a total of 100 male and 88 female NCAA athletes. Intervention Sex and four mutually exclusive groups of self-reported concussion history: (1) no history of concussion, (2) one previous concussion, (3) two previous concussions, (4) three or more previous concussions. Main outcome measurements Neurocognitive performance as measured by a computerised neurocognitive test battery (Immediate Postconcussion Assessment Cognitive Testing (ImPACT)). Results A dose-response gradient was found for two or more previous concussions and decreased neurocognitive performance. Females with a history of two and three or more concussions performed better than males with a history of two (p=0.001) and three or more concussions (p=0.012) on verbal memory. Females performed better than males with a history of three or more concussions (p=0.021) on visual memory. Finally, there was a significant difference for sex on both motor processing speed and reaction-time composite scores. Specifically, males performed worse than females on both processing speed (p=0.029) and reaction time (p=0.04). Conclusion The current study provided partial support for a dose-response model of concussion and neurocognitive performance decrements beginning at two or more previous concussions. Sex differences should be considered when examining the effects of concussion history on computerised neurocognitive performance.	[Covassin, Tracey; Elbin, Robert] Michigan State Univ, E Lansing, MI 48824 USA; [Kontos, Anthony; Larson, Elizabeth] Humboldt State Univ, Arcata, CA 95521 USA		Covassin, T (corresponding author), Michigan State Univ, 105 Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; *CDC, 2006, HEADS SPORTS CONC; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Giza CC, 2001, J ATHL TRAINING, V36, P228; Granito V.J., 2002, J SPORT BEHAV, V25, P243; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halpern DF, 1997, AM PSYCHOL, V52, P1091, DOI 10.1037/0003-066X.52.10.1091; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; JENSEN AR, 1983, PERS INDIV DIFFER, V4, P223, DOI 10.1016/0191-8869(83)90029-6; Kaufman AlanS., 1990, ASSESSING ADOLESCENT; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LOVELL M, 2005, IMMEDIATE POSTCONCUS; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SMITH SS, 1989, BRAIN RES, V503, P354, DOI 10.1016/0006-8993(89)91691-0; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	30	96	96	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2010	81	6					597	601		10.1136/jnnp.2009.193797			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	605NK	WOS:000278354100005	20522868				2022-02-06	
J	Laird, MD; Sukumari-Ramesh, S; Swift, AEB; Meiler, SE; Vender, JR; Dhandapani, KM				Laird, Melissa D.; Sukumari-Ramesh, Sangeetha; Swift, Andrew E. B.; Meiler, Steffen E.; Vender, John R.; Dhandapani, Krishnan M.			Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4?	JOURNAL OF NEUROCHEMISTRY			English	Article						cellular edema; controlled cortical impact; glia; intracranial pressure; neuroinflammation; neurotrauma	NF-KAPPA-B; SEVERE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; COMA DATA-BANK; REACTIVE ASTROCYTES; RAT-BRAIN; INTRACRANIAL HYPERTENSION; RECEPTOR ANTAGONIST; AQP4 EXPRESSION	P>Traumatic brain injury is a devastating neurological injury associated with significant morbidity and mortality. Medical therapies to limit cerebral edema, a cause of increased intracranial hypertension and poor clinical outcome, are largely ineffective, emphasizing the need for novel therapeutic approaches. In the present study, pre-treatment with curcumin (75, 150 mg/kg) or 30 min post-treatment with 300 mg/kg significantly reduced brain water content and improved neurological outcome following a moderate controlled cortical impact in mice. The protective effect of curcumin was associated with a significant attenuation in the acute pericontusional expression of interleukin-1 beta, a pro-inflammatory cytokine, after injury. Curcumin also reversed the induction of aquaporin-4, an astrocytic water channel implicated in the development of cellular edema following head trauma. Notably, curcumin blocked IL-1 beta-induced aquaporin-4 expression in cultured astrocytes, an effect mediated, at least in part, by reduced activation of the p50 and p65 subunits of nuclear factor kappa B. Consistent with this notion, curcumin preferentially attenuated phosphorylated p65 immunoreactivity in pericontusional astrocytes and decreased the expression of glial fibrillary acidic protein, a reactive astrocyte marker. As a whole, these data suggest clinically achievable concentrations of curcumin reduce glial activation and cerebral edema following neurotrauma, a finding which warrants further investigation.	[Laird, Melissa D.; Sukumari-Ramesh, Sangeetha; Vender, John R.; Dhandapani, Krishnan M.] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Swift, Andrew E. B.] Med Coll Georgia, Dept Med Illustrat, Augusta, GA 30912 USA; [Meiler, Steffen E.] Med Coll Georgia, Dept Anesthesiol & Perioperat Med, Augusta, GA 30912 USA		Dhandapani, KM (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.	kdhandapani@mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135, PRE2250690]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institute of Health (NS065172) and American Heart Association (BGIA2300135) to KMD and by a fellowship from the American Heart Association (PRE2250690) to MDL. The authors report no conflicts of interest.	Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Bae MK, 2006, BBA-MOL CELL RES, V1763, P282, DOI 10.1016/j.bbamcr.2006.01.005; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Cole GM, 2007, ADV EXP MED BIOL, V595, P197; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Di Giorgio AM, 2008, RESTOR NEUROL NEUROS, V26, P501; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FAN L, 1995, MOL BRAIN RES, V30, P125; Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029; Griebenow M, 2007, J NEUROTRAUM, V24, P1529, DOI 10.1089/neu.2007.0306; Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hewett SJ, 2006, J PHARMACOL EXP THER, V319, P1219, DOI 10.1124/jpet.106.109876; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Khan MM, 2005, ENDOCRINOLOGY, V146, P5215, DOI 10.1210/en.2005-0276; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Koch JD, 2008, J CEREBR BLOOD F MET, V28, P1294, DOI 10.1038/jcbfm.2008.15; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Lee SC, 1995, BRAIN BEHAV IMMUN, V9, P345, DOI 10.1006/brbi.1995.1032; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Lin JF, 2006, DIAM RELAT MATER, V15, P1, DOI 10.1016/j.diamond.2005.03.012; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Moynagh PN, 2005, J ANAT, V207, P265, DOI 10.1111/j.1469-7580.2005.00445.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nadjar A, 2003, J NEUROCHEM, V87, P1024, DOI 10.1046/j.1471-4159.2003.02097.x; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; Nielsen S, 1997, J NEUROSCI, V17, P171; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Richardson RM, 2009, J NEUROSURG; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vallee M, 1997, J NEUROSCI, V17, P2626; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	75	96	100	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2010	113	3					637	648		10.1111/j.1471-4159.2010.06630.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	579WD	WOS:000276406600007	20132469	Bronze, Green Accepted			2022-02-06	
J	Stein, SC; Georgoff, P; Meghan, S; Mirza, KL; El Falaky, OM				Stein, Sherman C.; Georgoff, Patrick; Meghan, Sudha; Mirza, Kasim L.; El Falaky, Omar M.			Relationship of aggressive monitoring and treatment to improved outcomes in severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; head injury; meta-analysis; intracranial pressure monitoring	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; MULTIMODALITY EVOKED-POTENTIALS; SAN-DIEGO-COUNTY; INTRACRANIAL-PRESSURE; COMPUTERIZED-TOMOGRAPHY; EARLY PREDICTION; PROGNOSTIC VALUE; MORTALITY PREDICTION; HOSPITAL ADMISSIONS	Object. Despite being common practice for decades and being recommended by national guidelines, aggressive monitoring and treatment of patients with severe traumatic brain injury (TBI) have not been supported by convincing evidence. Methods. The authors reviewed trials and case series reported after 1970 in which patients were treated for severe closed TBI, and mortality rates and favorable outcomes at 6 months after injury were analyzed. The patient groups were divided into those with and without intracranial pressure (ICP) monitoring and intensive therapy, and the authors performed a meta-analysis to assess the effects of treatment intensity on outcome. Results. Although the mortality rate fell during the years reviewed, it was consistently similar to 12% lower among patients in the intense treatment group (p < 0.001). Favorable outcomes did not change significantly over time, and were 6% higher among the aggressively treated patients (p = 0.0105). Conclusions. Aggressive ICP monitoring and treatment of patients with severe TBI is associated with a statistically significant improvement in outcome. This improvement occurs independently of temporal effects. (DOI: 10.3171/2009.8.JNS09738)	[Stein, Sherman C.; Georgoff, Patrick; Meghan, Sudha; Mirza, Kasim L.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [El Falaky, Omar M.] Cairo Univ, Dept Neurosurg, Cairo, Egypt		Stein, SC (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St,3 Silverstein, Philadelphia, PA 19104 USA.	sherman.stein@uphs.upenn.edu					Akopian G, 2007, AM SURGEON, V73, P447; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Athiappan S., 1993, Annals Academy of Medicine Singapore, V22, P452; Auer L, 1979, Acta Neurochir Suppl (Wien), V28, P171; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bang H, 2007, STAT MED, V26, P954, DOI 10.1002/sim.2663; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benzer A, 1995, Anasthesiol Intensivmed Notfallmed Schmerzther, V30, P231, DOI 10.1055/s-2007-996481; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAAKMAN R, 1992, ACTA NEUROCHIR, V116, P161, DOI 10.1007/BF01540870; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; BROWNE LA, 1977, IRISH MED J, V70, P197; BUCHMANN B, 1992, J TRAUMA, V32, P459, DOI 10.1097/00005373-199204000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BULLOCK R, 2005, NEUROTRAUMA CRIT FAL, P3; BULLOCK R, 2005, NEUROTRAUMA CRIT FAL, P6; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Cogbill TH, 2008, J TRAUMA, V65, P994, DOI 10.1097/TA.0b013e318184ce12; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; EDDY VA, 1995, AM SURGEON, V61, P24; Edwards P, 2005, LANCET, V365, P1957; Einarson TR, 1997, CLIN THER, V19, P559, DOI 10.1016/S0149-2918(97)80140-3; ESPERSEN JO, 1982, ACTA NEUROCHIR, V65, P81, DOI 10.1007/BF01405444; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Ghogawala Z, 2008, NEUROSURGERY, V62, pN9, DOI 10.1227/01.neu.0000333288.21621.a9; GIBSON RM, 1989, LANCET, V2, P369; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hsiao KY, 2008, EMERG MED J, V25, P670, DOI 10.1136/emj.2007.053405; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JENNETT B, 1979, BRIT MED J, V2, P955, DOI 10.1136/bmj.2.6196.955; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KAGAN RJ, 1994, AM SURGEON, V60, P394; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; KING JT, 1995, J NEUROSURG, V83, P403, DOI 10.3171/jns.1995.83.3.0403; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lane PL, 2000, CAN J SURG, V43, P442; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; Miller J D, 1979, Acta Neurochir Suppl (Wien), V28, P86; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; MURRAY GD, 1986, STAT MED, V5, P103, DOI 10.1002/sim.4780050202; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nathens A B, 2001, Adv Surg, V35, P61; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; Odebode TO, 2008, NIGER J CLIN PRACT, V11, P265; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Pillai SV, 2003, NEUROL INDIA, V51, P345; Ramesh VG, 2008, J CLIN NEUROSCI, V15, P1110, DOI 10.1016/j.jocn.2007.08.033; RIMEL RW, 1981, RESUSCITATION, V9, P75, DOI 10.1016/0300-9572(81)90036-8; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Rudnik A, 1992, Acta Neurochir Suppl (Wien), V55, P33; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sahuquillo J, 2008, EUR J ANAESTH, V25, P83, DOI 10.1017/S0265021507003353; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Sundbarg G, 1989, Brain Inj, V3, P283, DOI 10.3109/02699058909029641; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	150	96	102	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1105	1112		10.3171/2009.8.JNS09738			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600029	19747054				2022-02-06	
J	Williams, WH; Cordan, G; Mewse, AJ; Tonks, J; Burgess, CNW				Williams, W. Huw; Cordan, Giray; Mewse, Avril J.; Tonks, James; Burgess, Crispin N. W.			Self-reported traumatic brain injury in male young offenders: A risk factor for re-offending, poor mental health and violence?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prisoner health; Traumatic brain injury	POPULATION; PREVALENCE; DISORDERS; ADDICTION; PROFILE	Adolescence is a risk period for offending and for traumatic brain injury (TBI) and TBI is a risk factor for poor mental health and for offending. TBI has been largely neglected from guidance on managing the mental health needs of young offenders. We sought to determine the rate of self-reported TBI, of various severities, in a male, adolescent youth offending population. We also aimed to explore whether TBI was associated with number of convictions, violent offending, mental health problems and drug misuse. Young male offenders aged 11 to 19 years were recruited from a Young Offender Institute, a Youth Offending Team and a special needs school. A total of 197 participants were approached and 186 (94.4%) completed the study. They completed self-reports on TBI, crime history, mental health and drug use. TBI with loss of consciousness (LOC) was reported by 46% of the sample. LOC consistent with mild TBI was reported by 29.6%, and 16.6% reported LOC consistent with moderate to severe TBI. Possible TBI was reported by a further 19.1%. Repeat injury was common - with 32% reporting more than one LOC. Frequency of self-reported TBI was associated with more convictions. Three or more self-reported TBIs were associated with greater violence in offences. Those with self-reported TBI were also at risk of greater mental health problems and of misuse of cannabis. TBI may be associated with offending behaviour and worse mental health outcomes. Addressing TBI within adolescent offenders with neurorehabilitative input may be important for improving well-being and reducing re-offending.	[Williams, W. Huw] Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England; [Cordan, Giray] W England Forens Mental Hlth Serv, Bristol, Avon, England		Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England.	w.h.williams@exeter.ac.uk		Tonks, James/0000-0003-3930-9294; williams, huw/0000-0003-0670-2620	UK Brain Injury Forum (BIG Lottery); Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [Res-062-23-0135]; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E002692/1] Funding Source: UKRI; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E002692/1] Funding Source: researchfish	The research was supported by grants to HW from UK Brain Injury Forum (BIG Lottery) and Economic and Social Research Council (Res-062-23-0135).	[Anonymous], 2009, LANCET, V373, P603, DOI 10.1016/S0140-6736(09)60374-3; *CDC, 2009, TRAUM BRAIN INJ PRIS; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Fazel S, 2008, J AM ACAD CHILD PSY, V47, P1010, DOI [10.1097/CHI.ObO13e31817eecf3, 10.1097/CHI.0b013e31817eeef3]; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Forrest CB, 2000, PEDIATRICS, V105, P286; GOLDERBERG DWP, 1988, USERS GUIDE GEN HLTH; Hux D, 1998, BRAIN INJURY, V12, P667; Jolliffe D, 2004, AGGRESS VIOLENT BEH, V9, P441, DOI 10.1016/j.avb.2003.03.001; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Marsden J, 1998, ADDICTION, V93, P1857, DOI 10.1046/j.1360-0443.1998.9312185711.x; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Mobbs D, 2007, PLOS BIOL, V5, P693, DOI 10.1371/journal.pbio.0050103; MOORE AD, 1990, BRAIN INJURY, V4, P183; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; *PRIS POP STAT, 2009, SNSG4334 LIB HOUS CO; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; WILLIAMS WH, BRAIN INJURY IN PRES; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	28	96	96	3	33	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	6					801	812	PII 929353137	10.1080/09602011.2010.519613			12	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	684GB	WOS:000284537300001	21069616				2022-02-06	
S	Wood, WG; Eckert, GP; Igbayboa, U; Muller, WE		Andrews, RJ; Slikker, W; Trembly, B; Patterson, TA		Wood, W. Gibson; Eckert, Gunter P.; Igbayboa, Urule; Mueller, Walter E.			Statins and neuroprotection A prescription to move the field forward	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Conference on Neuroprotective Agents	SEP 07-11, 2008	Marine Biol Lab, Woods Hole, MA		Marine Biol Lab	Alzheimer's disease; cerebrovascular disease; cholesterol; HMG-CoA reductase; isoprenoids; neurodegeneration; neuroprotection; statins; stroke	COA-REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS; CULTURED CORTICAL-NEURONS; BLOOD-BRAIN-BARRIER; CELL-DEATH; ALZHEIMERS-DISEASE; IN-VITRO; GERANYLGERANYL-PYROPHOSPHATE; UP-REGULATION; CHOLESTEROL	There is growing interest in the use of statins, HMG-CoA reductase inhibitors, for treating specific neurodegenerative diseases (e.g., cerebrovascular disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis) and possibly traumatic brain injury. Neither is there a consensus on the efficacy of statins in treating the aforementioned diseases nor are the mechanisms of the purported statin-induced neuroprotection well-understood. Part of the support for statin-induced neuroprotection comes from studies using animal models and cell culture. Important information has resulted from that work but there continues to be a lack of progress on basic issues pertaining to statins and brain that impedes advancement in understanding how statins alter brain function. For example, there are scant data on the pharmacokinetics of lipophilic and hydrophilic statins in brain, statin-induced neuroprotection versus cell death, and statins and brain isoprenoids. The purpose of this mini-review will be to examine those aforementioned issues and to identify directions of future research.	[Wood, W. Gibson; Igbayboa, Urule] Univ Minnesota, Dept Pharmacol, Geriatr Res Educ & Clin Ctr, VA Med Ctr, Minneapolis, MN 55455 USA; [Eckert, Gunter P.; Mueller, Walter E.] Goethe Univ Frankfurt, Dept Pharmacol, Bioctr Niederursel, Frankfurt, Germany		Wood, WG (corresponding author), Univ Minnesota, Dept Pharmacol, Geriatr Res Educ & Clin Ctr, VA Med Ctr, 6-120 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.	woodx002@umn.edu		Muller, Werner E.G./0000-0002-8223-3689	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-23524, AG-18357]; Department of Veterans AffairsUS Department of Veterans Affairs; Hanna Bragard-Apfel Foundation; Alzheimer Forschung Initiative; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023524, P01AG018357] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institutes of Health AG-23524, AG-18357, Department of Veterans Affairs, Hanna Bragard-Apfel Foundation, and Alzheimer Forschung Initiative.	Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Bogman K, 2001, BRIT J PHARMACOL, V132, P1183, DOI 10.1038/sj.bjp.0703920; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BOTTI RE, 1991, CLIN NEUROPHARMACOL, V14, P256, DOI 10.1097/00002826-199106000-00010; Bucelli RC, 2008, J PHARMACOL EXP THER, V324, P1172, DOI 10.1124/jpet.107.132795; Chochina SV, 2001, J LIPID RES, V42, P1292; Cole SL, 2006, NEUROBIOL DIS, V22, P209, DOI 10.1016/j.nbd.2005.11.007; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Domoki F, 2009, AM J PHYSIOL-CELL PH, V296, pC97, DOI 10.1152/ajpcell.00366.2008; Eckert GP, 2005, J NEURAL TRANSM, V112, P1057, DOI 10.1007/s00702-004-0273-1; Eckert GP, 2007, FUTURE LIPIDOL, V2, P423, DOI 10.2217/17460875.2.4.423; Farooqui AA, 2007, BRAIN RES REV, V56, P443, DOI 10.1016/j.brainresrev.2007.09.004; Franke C, 2007, NEUROBIOL DIS, V25, P438, DOI 10.1016/j.nbd.2006.10.004; Hasegawa M, 2003, J PHARMACOL EXP THER, V305, P1087, DOI 10.1124/jpet.102.046847; Hirrlinger J, 2002, J NEUROCHEM, V82, P716, DOI 10.1046/j.1471-4159.2002.01082.x; Hooff GP, 2008, ANAL BIOANAL CHEM, V392, P673, DOI 10.1007/s00216-008-2306-3; Ishigami M, 2001, DRUG METAB DISPOS, V29, P282; Jacobsen W, 2000, DRUG METAB DISPOS, V28, P1369; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; Johnson-Anuna LN, 2007, J NEUROCHEM, V101, P77, DOI 10.1111/j.1471-4159.2006.04375.x; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Kantola T, 1998, CLIN PHARMACOL THER, V64, P58, DOI 10.1016/S0009-9236(98)90023-6; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; LAW MR, 2003, BRIT MED J, V326, P1; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lim JH, 2006, J NEUROCHEM, V97, P140, DOI 10.1111/j.1471-4159.2006.03715.x; Marz P, 2007, GLIA, V55, P1, DOI 10.1002/glia.20422; McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018-005-5298-6; Michikawa M, 1999, J NEUROCHEM, V72, P2278, DOI 10.1046/j.1471-4159.1999.0722278.x; Nassief A, 2008, STROKE, V39, P1042, DOI 10.1161/STROKEAHA.107.501361; Neuhaus Oliver, 2007, Expert Rev Neurother, V7, P547, DOI 10.1586/14737175.7.5.547; Orr JD, 2008, CURR ATHEROSCLER REP, V10, P11; Ostrowski SM, 2007, J BIOL CHEM, V282, P26832, DOI 10.1074/jbc.M702640200; Pai H. V., 2002, Pharmacogenomics Journal, V2, P243, DOI 10.1038/sj.tpj.6500115; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Schulz JG, 2004, J NEUROCHEM, V89, P24, DOI 10.1046/j.1471-4159.2003.02305.x; Solomon KR, 2008, TRENDS ENDOCRIN MET, V19, P113, DOI 10.1016/j.tem.2007.12.004; Stepien K, 2005, PHARMACOL REP, V57, P561; Sun HY, 2003, ADV DRUG DELIVER REV, V55, P83, DOI 10.1016/S0169-409X(02)00172-2; Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743; Takeda M, 2004, EUR J PHARMACOL, V483, P133, DOI 10.1016/j.ejphar.2003.10.017; Tanaka T, 2000, J NEUROSCI, V20, P2852; Tapia-Perez H, 2007, REV NEUROLOGIA, V45, P359, DOI 10.33588/rn.4506.2007380; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Tong H, 2008, ANAL BIOCHEM, V378, P138, DOI 10.1016/j.ab.2008.04.021; Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024; TSUJI A, 1993, J PHARMACOL EXP THER, V267, P1085; Wahner AD, 2008, NEUROLOGY, V70, P1418, DOI 10.1212/01.wnl.0000286942.14552.51; Wood W. G., 2007, HDB NEUROCHEMISTRY M, P151; Xiang ZM, 2009, EXP NEUROL, V215, P41, DOI 10.1016/j.expneurol.2008.09.010; Zacco A, 2003, J NEUROSCI, V23, P11104	56	96	101	1	12	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-777-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1199						69	76		10.1111/j.1749-6632.2009.05359.x			8	Multidisciplinary Sciences; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BRJ59	WOS:000282838900007	20633110	Green Accepted			2022-02-06	
J	Sigurdardottir, S; Andelic, N; Roe, C; Schanke, AK				Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine			Cognitive recovery and predictors of functional outcome 1 year after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Injury severity; Trauma; Neuropsychology; Fatigue; Glasgow Outcome Scale-Extended	SEVERITY SCORE; HEAD-INJURY; EMPLOYMENT; SCALE; PRODUCTIVITY; FATIGUE; POPULATION; RATES; COMA	Outcome studies on traumatic brain injury (TBI) have shown that functional status can be predicted by demographic, injury severity, and trauma-related factors. Concurrent cognitive functions as one of the determinants of functional outcome is less documented. This study evaluated the effects of concurrent neuropsychological measures on functional Outcome I year after injury. Neuropsychological data, employment status, self-reported fatigue, and the Glasgow Outcome Scale-Extended (GOSE) were collected from 115 persons with TBI (ranging from mild to severe) at 3 and 12 months postinjury. Principal components analysis was conducted with the neuropsychological measures and three components emerged. Multiple regression analysis, controlling for demographic and injury severity related factors, was used to test the effects of cognitive components at 12 months on functional outcome (GOSE). One year after injury, 64% were categorized as "good recovery" and 36% as "moderate disability" according to GOSE. Good functional recovery depended on shorter duration of posttraumatic amnesia, less fatigue, absence of intracranial pathology, higher education, and better performance on cognitive measures. The predictive values of Verbal/Reasoning and Visual/Perception components are supported; each added significantly and improved prediction of functional outcome. The Memory/Speed component showed a near-significant relationship to outcome. (JINS, 2009, 15, 740-750.)	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Univ Oslo, Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway		Sigurdardottir, S (corresponding author), Univ Oslo, Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no		Andelic, Nada/0000-0002-3719-4406	South-Eastern Norway Regional Health Authority	This study was supported by grants from the South-Eastern Norway Regional Health Authority. Special thanks to Ivar Reinvang, Professor, University of Oslo, for valuable comments; to Tone Jerstad, neuroradiologist, Department of Neuroradiology, Oslo University Hospital, Ulleval, for the CT and MRI evaluations; to Morten Hestnes and Nils Oddvar Skaga from the Oslo University Hospital's Trauma Registry, Ulleval, for the extraction of trauma scores; to Katrine Frey Froslie, The National University Hospital, for statistical assistance; and to Susan Schanche for the proof reading the English text. Competing interests: None.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL REV 19; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A., 1976, MULTILINGUAL APHASIA; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Delis D.C., 2000, CALIFORNIA VERBAL LE; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lerdal A, 2005, SCAND J PUBLIC HEALT, V33, P123, DOI 10.1080/14034940410028406; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Meyers JE., 1995, REY COMPLEX FIGURE T; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan R, 1985, HALSTEAD REITAN NEUR; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; *STAT NORW, 2008, STAT YB NORW 2008; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Taylor LA, 2003, BRAIN INJURY, V17, P295, DOI 10.1080/0269905021000038401; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	48	96	96	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2009	15	5					740	750		10.1017/S1355617709990452			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	489IZ	WOS:000269415100010	19602303				2022-02-06	
J	Swenson, DM; Yard, EE; Fields, SK; Comstock, RD				Swenson, David M.; Yard, Ellen E.; Fields, Sarah K.; Comstock, R. Dawn			Patterns of Recurrent Injuries Among US High School Athletes, 2005-2008	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						recurrent injury; reinjury; injury; high school; sports; epidemiology; surveillance	STATES HIGH-SCHOOL; UNITED-STATES; PROSPECTIVE COHORT; NORTH-CAROLINA; RISK-FACTORS; EPIDEMIOLOGY; CONCUSSION; FOOTBALL; SPORTS; COLLEGIATE	Background: High school sports participants sustain millions of injuries annually; many are recurrent injuries that can be more severe than new injuries. Hypothesis: Recurrent injury patterns differ from new injury patterns by sport and gender. Study Design: Descriptive epidemiology study. Methods: High school sports injury data for the 2005 through 2008 academic years were collected via High School Reporting Information Online (RIO) from a nationally representative sample of 100 US high schools. Results: From 2005 through 2008, certified athletic trainers reported 13 755 injuries during 5 627 921 athlete exposures (24.4 injuries per 10 000 athlete exposures). Recurrent injuries accounted for 10.5% of all injuries. Football players had the highest rate of recurrent injury (4.36 per 10 000 athlete exposures). Girls had higher rates of recurrent injuries than boys in soccer (injury rate ratio = 1.39; 95% confidence interval, 1.07-1.82). Recurrent injuries most often involved the ankle (28.3%), knee (16.8%), head/face (12.1%), and shoulder (12.0%), and were most often ligament sprains (incomplete tears) (34.9%), muscle strains (incomplete tears) (13.3%), and concussions (11.6%). A greater proportion of recurrent injuries than new injuries resulted in the student choosing to end participation (recurrent = 2.4%, new = 0.7%). Recurrent shoulder injuries were more likely to require surgery than new shoulder injuries (injury proportion ratio = 4.51; 95% confidence interval, 2.82-7.20). Conclusion: Recurrent injury rates and patterns differed by sport. Because recurrent injuries can have severe consequences on an athlete's health and future sports participation, injury prevention must be a priority. Knowledge of injury patterns can drive targeted preventive efforts.	[Swenson, David M.; Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH 43205 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Act & Educ Serv, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA		Yard, EE (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	Ellen.Yard@NationwideChildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025753]; Office of the DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD); National Institutes of Health (OD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; DonJoy Orthotics and EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025753, UL1RR025755] Funding Source: NIH RePORTER	The content of this report was funded in part by the Centers for Disease Control and Prevention (CDC) grant # R49/CE000674-01 and by the National Center for Research Resources (NCRR), award # TL1RR025753, funded by the Office of the Director, National Institutes of Health (OD) and supported by the NIH Roadmap for Medical Research. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the CDC, the NCRR, or the NIH. We would also like to acknowledge the generous research funding contributions of DonJoy Orthotics and EyeBlack.	Agel J, 2007, J ATHL TRAINING, V42, P295; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Collins CL, 2008, INJURY PREV, V14, P34, DOI 10.1136/ip.2007.017277; Collins CL, 2008, PEDIATRICS, V121, P1181, DOI 10.1542/peds.2007-2572; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Elosua R, 2005, REV ESP CARDIOL, V58, P887, DOI 10.1157/13078123; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gravlee JR, 2007, AM FAM PHYSICIAN, V75, P342; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Ingram JG, 2008, AM J SPORT MED, V36, P1116, DOI 10.1177/0363546508314400; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Kofotolis N, 2007, J ATHL TRAINING, V42, P388; Koplan JP, 2005, J AM DIET ASSOC, V105, P131, DOI 10.1016/j.jada.2004.11.023; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; *NAT FED STAT HIGH, 2005 06 HIGH SCH ATH; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rauh MJ, 2007, J ATHL TRAINING, V42, P486; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SPAKE A, 2004, LEARNING FAT TACKLIN; Tyler TF, 2006, AM J SPORT MED, V34, P471, DOI 10.1177/0363546505280429; US Census Bureau, CENS REG US; Van Tiggelen D, 2004, KNEE SURG SPORT TR A, V12, P434, DOI 10.1007/s00167-003-0479-z; Verhagen EALM, 2004, BRIT J SPORT MED, V38, P477, DOI 10.1136/bjsm.2003.005785	33	96	99	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2009	37	8					1586	1593		10.1177/0363546509332500			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	474MY	WOS:000268289400016	19372270				2022-02-06	
J	Marklund, N; Blennow, K; Zetterberg, H; Ronne-Engstrom, E; Enblad, P; Hillered, L				Marklund, Niklas; Blennow, Kaj; Zetterberg, Henrik; Ronne-Engstrom, Elisabeth; Enblad, Per; Hillered, Lars			Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						amyloid beta; diffuse axonal injury; microdialysis; tau protein; traumatic brain injury	CLOSED-HEAD INJURY; LONG-TERM ACCUMULATION; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; AXONAL INJURY; ALZHEIMERS-DISEASE; CEREBRAL MICRODIALYSIS; NEUROINTENSIVE CARE; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE	Object. Damage to axons contributes to postinjury disabilities and is commonly observed following traumatic brain injury (TBI). Traumatic brain injury is ail important environmental risk factor for the development of Alzheimer disease (AD). In the present feasibility study, the aim was to use intracerebral rnicrodialysis catheters with a high molecular Cutoff membrane (100 kD) to harvest interstitial total tau (T-tau) and amyloid beta 1-42 (A beta 42) proteins, which are important biomarkers for axonal injury and for AD, following moderate-to-severe TBI. Methods. Eight patients (5 men and 3 women) were included in the Study; 5 of the patients had a focal/mixed TBI and 3 had a diffuse axonal injury (DAI). Following the bedside analysis of the routinely measured energy metabolic markers (that is, glucose, lactate/pyrilvate ratio, glycerol, and glutaniate), the remaining dialysate was pooled and two 12-hour samples per day were used to analyze T-tau and A beta 42 by enzyme-linked immunosorbent assay from Day 1 up to 8 days postinjury. Results. The results show high levels of interstitial T-tau and A beta 42 postinjury. Patients with a predominantly focal lesion had higher interstitial T-tau levels than in the DAI group from Days 1 to 3 postinjury (p < 0.05). In contrast, patients with DAI had consistently higher A beta 42 levels when compared with patients with focal injury, Conclusions. These results suggest that monitoring of interstitial T-tau and A beta 42 by using microdialysis may be an important tool when evaluating the presence and role of axonal injury following TBI (DOI: 10.3171/2008.9.JNS08584)	[Marklund, Niklas; Ronne-Engstrom, Elisabeth; Enblad, Per; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, SE-75148 Uppsala, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Hosp Sahlgrenska, Dept Internal Med, Gothenburg, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75148 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se		Marklund, Niklas/0000-0002-9797-5626; Hillered, Lars/0000-0002-2808-9292	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Swedish Brain Foundation; Laerdahl Foundation for Acute Medicine	This work was supported by the Swedish Research Council (Drs. Marklund, Enblad, and Hillered); Uppsala University Hospital (Drs. Enblad and Hillered); the Swedish Brain Foundation (Dr. Marklund); and the Laerdahl Foundation for Acute Medicine (Drs. Marklund and Hillered).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hulstaert F, 1999, NEUROLOGY, V52, P1555, DOI 10.1212/WNL.52.8.1555; Hutchinson PJ, 2005, ACTA NEUROCHIR SUPPL, V95, P441; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Marklund N, 2006, J NEUROTRAUM, V23, P754; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; STALHAMMAR D, 1988, ACTA NEUROCHIR, V90, P73, DOI 10.1007/BF01560558; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vespa PM, 2006, CURR OPIN CRIT CARE, V12, P119, DOI 10.1097/01.ccx.0000216577.57180.bd; Wang HD, 1998, CHINESE MED J-PEKING, V111, P59; Whittle IR, 1998, NEUROREPORT, V9, P2821, DOI 10.1097/00001756-199808240-00025; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	74	96	96	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2009	110	6					1227	1237		10.3171/2008.9.JNS08584			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	451HH	WOS:000266460800018	19216653				2022-02-06	
J	O'Connell, RG; Bellgrove, MA; Dockree, PM; Lau, A; Hester, R; Garavan, H; Fitzgerald, M; Foxe, JJ; Robertson, IH				O'Connell, Redmond G.; Bellgrove, Mark A.; Dockree, Paul M.; Lau, Adam; Hester, Robert; Garavan, Hugh; Fitzgerald, Michael; Foxe, John J.; Robertson, Ian H.			The neural correlates of deficient error awareness in attention-deficit hyperactivity disorder (ADHD)	NEUROPSYCHOLOGIA			English	Article						Error awareness; ADHD; ERP; Source analysis; Anterior cingulate cortex	TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE CORTEX; EVENT-RELATED POTENTIALS; MEDIAL FRONTAL-CORTEX; DEFICIT/HYPERACTIVITY DISORDER; FUNCTIONAL-SIGNIFICANCE; ELECTRODERMAL ACTIVITY; SUSTAINED ATTENTION; CHILDREN; PERFORMANCE	The ability to detect and correct errors is critical to adaptive control of behaviour and represents a discrete neuropsychological function. A number of studies have highlighted that attention-deficit hyperactivity disorder (ADHD) is associated with abnormalities in behavioural and neural responsiveness to performance errors. One limitation of previous work has been a failure to determine the extent to which these differences are attributable to failures of conscious error awareness, a process that is dependent on the integrity of the frontal lobes. Recent advances in electrophysiological research make it possible to distinguish unconscious and conscious aspects of error processing. This study constitutes an extensive electrophysiological investigation of error awareness and error processing in ADHD. A Go/No-Go response inhibition task specifically designed to assess error awareness was administered to a group of adults diagnosed with ADHD and a group of matched control participants. The ADHD group made significantly more errors than the control group but was less likely to consciously detect these errors. An analysis of event-related potentials elicited by errors indicated that an early performance monitoring component (early positivity) was significantly attenuated in the ADHD group as was a later component that specifically reflects conscious error processing (Pe). Dipole source modelling suggested that abnormal Pe amplitudes were attributable to decreased activation of the anterior cingulate cortex. Decreased electrodermal activity in the ADHD group also suggested a motivational insensitivity to performance errors. Our data provide evidence that neuropsychological deficits associated with ADHD can be exacerbated by error processing abnormalities. Error awareness may represent an important cognitive and physiological phenotype for ADHD. (c) 2009 Elsevier Ltd. All rights reserved.	[O'Connell, Redmond G.; Dockree, Paul M.; Garavan, Hugh; Robertson, Ian H.] Trinity Coll Dublin, Sch Psychol, Dublin 2, Ireland; [O'Connell, Redmond G.; Dockree, Paul M.; Garavan, Hugh; Robertson, Ian H.] Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland; [O'Connell, Redmond G.; Dockree, Paul M.; Foxe, John J.] St Vincents Hosp, Cognit Neurophysiol Lab, Dublin 3, Ireland; [Bellgrove, Mark A.; Hester, Robert] Univ Queensland, Sch Psychol, Cognit Neurosci Lab, Brisbane, Qld, Australia; [Bellgrove, Mark A.; Hester, Robert] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Lau, Adam; Fitzgerald, Michael] Trinity Coll Dublin, Dept Psychiat, Dublin 2, Ireland; [Foxe, John J.] Nathan S Kline Inst Psychiat Res, Cognit Neurophysiol Lab, Orangeburg, NY 10962 USA; [Foxe, John J.] CUNY City Coll, Dept Psychol, Program Cognit Neurosci, New York, NY 10031 USA		O'Connell, RG (corresponding author), Trinity Coll Dublin, Sch Psychol, Lloyd Bldg, Dublin 2, Ireland.	reoconne@tcd.ie	Hester, Robert/F-2097-2011; Bellgrove, Mark/AAB-3114-2019	Hester, Robert/0000-0003-0982-8026; Bellgrove, Mark/0000-0003-0186-8349; O'Connell, Redmond/0000-0001-6949-2793; Robertson, Ian H/0000-0001-8637-561X; Foxe, John/0000-0002-4300-3098	U.S. National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65350]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065350] Funding Source: NIH RePORTER	The work reported herein was supported by the Government of Ireland Research Scholarship in the Humanities and Social Sciences to RG O'Connell and is administered by the Irish Research Council for the Humanities and Social Sciences. This work was also supported in part by a grant from the U.S. National Institute of Mental Health (MH65350 to JJF). The authors would like to thank Dr. Sherlyn Yeap and Dr. Simon Kelly for their excellent technical support and all those who participated in this study.	American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, VIV; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P184, DOI 10.1016/S1388-2457(02)00363-2; Bechara A, 1999, J NEUROSCI, V19, P5473; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; BERG P, 1994, ELECTROEN CLIN NEURO, V90, P229, DOI 10.1016/0013-4694(94)90094-9; Brazdil M, 2005, J PSYCHOPHYSIOL, V19, P244, DOI 10.1027/0269-8803.19.4.244; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Burgio-Murphy A, 2007, BIOL PSYCHOL, V75, P75, DOI 10.1016/j.biopsycho.2006.12.003; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Coles MGH, 2001, BIOL PSYCHOL, V56, P173, DOI 10.1016/S0301-0511(01)00076-X; CONNERS CK, 2003, CORNERS ADULT ADHD R; Critchley HD, 2005, NEUROIMAGE, V27, P885, DOI 10.1016/j.neuroimage.2005.05.047; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; DAWSON ME, 2000, HDB PSYCHOPHYSIOLOGY; de Bruijn ERA, 2004, PSYCHOPHARMACOLOGY, V177, P151, DOI 10.1007/s00213-004-1915-6; Debener S, 2005, J NEUROSCI, V25, P11730, DOI 10.1523/JNEUROSCI.3286-05.2005; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Falkenstein M., 2004, ERRORS CONFLICTS BRA, V1, P5; Fiehler K, 2004, EUR J NEUROSCI, V19, P3081, DOI 10.1111/j.0953-816X.2004.03414.x; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Hajcak G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hogan AM, 2005, DEVELOPMENTAL SCI, V8, P525, DOI 10.1111/j.1467-7687.2005.00444.x; HOLROYD CB, 2004, COGNITIVE NEUROSCIEN; Jonkman LM, 2007, BIOL PSYCHOL, V76, P217, DOI 10.1016/j.biopsycho.2007.08.004; Lijffijt M, 2005, J ABNORM PSYCHOL, V114, P216, DOI 10.1037/0021-843X.114.2.216; Liotti M, 2005, CORTEX, V41, P377, DOI 10.1016/S0010-9452(08)70274-0; Luu P, 2000, J EXP PSYCHOL GEN, V129, P43, DOI [10.1037/0096-3445.129.1.43, 10.1037//0096-3445.129.1.43]; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Morris SE, 2006, J ABNORM PSYCHOL, V115, P239, DOI 10.1037/0021-843X.115.2.239; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nieuwenhuis S, 2007, CEREB CORTEX, V17, P1570, DOI 10.1093/cercor/bhl068; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2004, NEUROREPORT, V15, P2535, DOI 10.1097/00001756-200411150-00021; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Overtoom CCE, 2002, BIOL PSYCHIAT, V51, P668, DOI 10.1016/S0006-3223(01)01290-2; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Ruchsow M, 2006, BIOL PSYCHOL, V72, P133, DOI 10.1016/j.biopsycho.2005.08.006; Ruchsow M, 2005, J PSYCHOPHYSIOL, V19, P298, DOI 10.1027/0269-8803.19.4.298; Schachar RJ, 2004, J ABNORM CHILD PSYCH, V32, P285, DOI 10.1023/B:JACP.0000026142.11217.f2; Seidman LJ, 2006, CLIN PSYCHOL REV, V26, P466, DOI 10.1016/j.cpr.2006.01.004; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; Sonuga-Barke EJS, 2003, NEUROSCI BIOBEHAV R, V27, P593, DOI 10.1016/j.neubiorev.2003.08.005; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Tieges Z, 2004, COGNITIVE BRAIN RES, V21, P87, DOI 10.1016/j.cogbrainres.2004.06.001; TURNER GR, 2004, COGNITIVE BEHAV REHA; van Meel CS, 2007, PSYCHIAT RES, V151, P211, DOI 10.1016/j.psychres.2006.05.011; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; Vlamings PHJM, 2008, EUR J NEUROSCI, V28, P399, DOI 10.1111/j.1460-9568.2008.06336.x; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Wiersema JR, 2005, J NEURAL TRANSM, V112, P1417, DOI 10.1007/s00702-005-0276-6; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Woods SP, 2002, CLIN NEUROPSYCHOL, V16, P12, DOI 10.1076/clin.16.1.12.8336; Zahn TP, 1999, NEUROPSYCHOLOGIA, V37, P1227, DOI 10.1016/S0028-3932(99)00020-2; Zirnheld PJ, 2004, J COGNITIVE NEUROSCI, V16, P1098, DOI 10.1162/0898929041502779	69	96	98	1	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	MAR	2009	47	4					1149	1159		10.1016/j.neuropsychologia.2009.01.011			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	423TS	WOS:000264519200022	19350709	Green Submitted, Green Published			2022-02-06	
J	Helton, WS				Helton, William S.			Impulsive responding and the sustained attention to response task	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Attention; Impulsivity; Mindlessness; Vigilance	ABBREVIATED VIGILANCE TASK; TRAUMATIC BRAIN-INJURY; PERFORMANCE; SENSITIVITY; PERCEPTION; FAILURES; WORKLOAD; SYSTEMS	Two studies investigated whether the sustained attention to response task (SART) is a better measure of impulsive responding than of sustained attention. Participants performed target detection tasks with global-local letter stimuli using one of two response formats: standard, responding to targets; and SART, withholding to targets. In the first experiment, performance in the SART changed rapidly over time, whereas performance in the standard format was stable over time. In the second experiment, performance in the SART was susceptible to global-local condensation tasks, a result previously found with highly impulsive individuals. Overall the results indicate that the SART is sensitive to impulsive responding.	Michigan Technol Univ, Dept Psychol, Houghton, MI 49931 USA		Helton, WS (corresponding author), Michigan Technol Univ, Dept Psychol, Houghton, MI 49931 USA.	Deak_Helton@yahoo.com			Department of Defense University Research Instrumentation Program (DURIP)United States Department of Defense; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA-9550-07-1-0500]	This work was supported by the Department of Defense University Research Instrumentation Program (DURIP) administered by the Air Force Office of Scientific Research (FA-9550-07-1-0500), W. S. Helton Principal Investigator. The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, Department of Defense, or the U. S. Government.	Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P843, DOI 10.1080/01688639608408307; BERCH DB, 1984, SUSTAINED ATTENTION, P143; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; DAMOS DL, 1994, J CLIN EXP NEUROPSYC, V16, P713, DOI 10.1080/01688639408402684; Davies DR., 1982, PSYCHOL VIGILANCE; DICKMAN S, 1985, J PERS SOC PSYCHOL, V48, P133, DOI 10.1037/0022-3514.48.1.133; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Gazzaniga M., 2002, COGNITIVE NEUROSCIEN; HARRINGTON DL, 1991, NEUROPSYCHOLOGIA, V29, P147, DOI 10.1016/0028-3932(91)90017-3; Hellige, 1993, HEMISPHERIC ASYMMETR; Helton W. S., 2002, P HUM FACT ERG SOC A, V46, P1546, DOI DOI 10.1177/154193120204601704; Helton WS, 2007, J CLIN EXP NEUROPSYC, V29, P545, DOI 10.1080/13803390600814757; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Helton WS, 2004, HUMAN PERFORMANCE, SITUATION AWARENESS AND AUTOMATION: CURRENT RESEARCH AND TRENDS, VOL 1, P258; Helton WS, 1999, CURR PSYCHOL, V18, P311, DOI 10.1007/s12144-999-1006-2; HOWELL WC, 1993, ANNU REV PSYCHOL, V44, P231, DOI 10.1146/annurev.ps.44.020193.001311; Kirk RE., 1995, EXPT DESIGN PROCEDUR, V3; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; MACKWORTH NH, 1950, 2680 MED RES COUNC; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MATTHEWS G, 2001, P HUMAN FACTORS ERGO, V45, P1377; Matthews Gerald, 2000, HUMAN PERFORMANCE CO; Maxwell S., 2004, DESIGNING EXPT ANAL; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parasuraman R., 1986, HDB PERCEPTION HUMAN, V2, P1; Posner, 1978, CHRONOMETRIC EXPLORA; PROCTOR RW, 1994, HUMAN FACTORS SIMPLE; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rose CL, 2002, EUR J PERSONALITY, V16, P185, DOI 10.1002/per.451; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; TUCKER DM, 1984, PSYCHOL REV, V91, P185, DOI 10.1037/0033-295X.91.2.185; Warm J. S., 1984, SUSTAINED ATTENTION, P1; Wickens C.D., 1998, INTRO HUMAN FACTORS; Wickens C. D., 1993, WORKLOAD TRANSITION, P139	45	96	96	0	25	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	1					39	47	PII 792057852	10.1080/13803390801978856			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	384IT	WOS:000261739200004	18608658				2022-02-06	
J	Tanriverdi, F; De Bellis, A; Bizzarro, A; Sinisi, AA; Bellastella, G; Pane, E; Bellastella, A; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; De Bellis, Annamaria; Bizzarro, Antonio; Sinisi, Antonio Agostino; Bellastella, Giuseppe; Pane, Elena; Bellastella, Antonio; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity?	EUROPEAN JOURNAL OF ENDOCRINOLOGY			Spanish	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; GROWTH-HORMONE DEFICIENCY; ENDOCRINE DISEASES; SECRETING CELLS; HYPOPITUITARISM; INSUFFICIENCY; HYPOPHYSITIS; PREVALENCE; CHILDREN; NEURONS	Objective: Traumatic brain injury (TBI) is a devastating public health problem that may result in hypopituitarism. However, the mechanisms responsible for hypothalamic-pituitary dysfunction due to TBI are still unclear. Although the antibodies against neurons have been demonstrated in injured animal studies, investigations regarding the occurrence of antipituitary antibodies (APAs) in patients with TBI are lacking in the literature. In order to investigate whether autoimmune mechanisms could play a role in the pituitary dysfunction after TBI, we have planned this study aimed at investigating the presence of APA at the third year of TBI and association between the TBI-induced hypopituitarism and APA. Patients and design: Twenty-nine (25 males and 4 females; age 36.5 +/- 2.3 years) patients who had completed a 3-year follow-up after TBI were included in the present study. APA and pituitary function were evaluated in all the patients 3 years after TBI; moreover, APAs were tested also in sera of 60 age-/sex-matched normal controls. The APAs were investigated by an indirect immunofluorescence method. Results: APAs were detected in 13 out of the 29 TBI patients (44.8'%), but in none of the normal controls. Pituitary dysfunction development ratio was significantly higher in APA-positive patients (46.2%) when compared with APA-negative ones (12.5%; P=0.04). There was a significant association between APA positivity and hypopituitarism due to TBI (odds ratio: 2.25, 95% confidence intervals 1.1-4.6). Moreover, there was a significant positive correlation (r = 0.74, P = 0.004) between APA titer ratio and peak GH response to GHRH+GH related peptide (GHRP)-6 test, suggesting that high APA titers were associated with low GH response to GHRH + GHRP-6 test. Conclusions: This study shows for the first time the presence of the APA in TBI patients 3 years after head trauma. Moreover, present investigation indicates preliminary evidence that APA may be associated with the development of TBI-induced pituitary dysfunction, thus suggesting that autoimmunity may contribute in the development of TBI-induced hypopituitarism. The presence of the association between APA and TBI induced hypopituitarism may provide a new point of view in this field and promote further clinical and experimental studies.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [De Bellis, Annamaria; Sinisi, Antonio Agostino; Bellastella, Giuseppe; Pane, Elena; Bellastella, Antonio] Univ Naples 2, Chair Endocrinol, I-80131 Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Chair Immunol, I-80131 Naples, Italy; [Selcuklu, Ahmet] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	kelestimur, f/ABE-9873-2021	DE BELLIS, Annamaria/0000-0002-0611-4506			Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; De Bellis A, 2005, CLIN ENDOCRINOL, V63, P45, DOI 10.1111/j.1365-2265.2005.02296.x; De Bellis A, 2005, BEST PRACT RES CL EN, V19, P67, DOI 10.1016/j.beem.2004.11.007; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 2007, J CLIN ENDOCR METAB, V92, P604, DOI 10.1210/jc.2006-1216; De Bellis A, 2006, J CLIN ENDOCR METAB, V91, P2484, DOI 10.1210/jc.2006-0040; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gionis D, 2003, J PEDIATR ENDOCR MET, V16, P49; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Manetti L, 2007, J CLIN ENDOCR METAB, V92, P2176, DOI 10.1210/jc.2006-2748; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	29	96	100	0	5	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JUL	2008	159	1					7	13		10.1530/EJE-08-0050			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	329GU	WOS:000257855800002	18463108	Bronze			2022-02-06	
J	Schoenberg, MR; Dawson, KA; Duff, K; Patton, D; Scott, JG; Adams, RL				Schoenberg, Mike R.; Dawson, Kyra A.; Duff, Kevin; Patton, Doyle; Scott, James G.; Adams, Russell L.			Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Auditory Verbal Learning Test; RAVLT; memory; positive predictive power; test scores; diagnosis	MILD COGNITIVE IMPAIRMENT; QUALITY STANDARDS SUBCOMMITTEE; ALZHEIMERS-DISEASE; DIAGNOSTIC-ACCURACY; HIPPOCAMPAL VOLUME; PRACTICE PARAMETER; TEST AVLT; SENSITIVITY; DEMENTIA; SPECIFICITY	The Rey Auditory Verbal Learning Test [RAVLT; Rey, A. (1941). L'examen psychologique dans les cas d'encephalopathie traumatique. Archives de Psychologie, 28, 21] is a commonly used neuropsychological measure that assesses verbal learning and memory. Normative data have been compiled [Schmidt, M. (1996). Rey Auditory and Verbal Learning Test: A handbook. Los Angeles, CA: Western Psychological Services]. When assessing an individual suspected of neurological dysfunction, useful comparisons include the extent that the patient deviates from healthy peers and also how closely the subject's performance matches those with known brain injury. This study provides the means and S.D.'s of 392 individuals with documented neurological dysfunction [closed head TBI (n = 68), neoplasms (n = 57), stroke (n = 47), Dementia of the Alzheimer's type (n = 158), and presurgical epilepsy left seizure focus (n = 28), presurgical epilepsy right seizure focus (n = 34)] and 122 patients with no known neurological dysfunction and psychiatric complaints. Patients were stratified into three age groups, 16-35, 36-59, and 60-88. Data were provided for trials I-V, List B, immediate recall, 30-min delayed recall, and recognition. Classification characteristics of the RAVLT using [Schmidt, M. (1996). Rey Auditory and Verbal Learning Test: A handbook. Los Angeles, CA: Western Psychological Services] meta-norms found the RAVLT to best distinguish patients suspected of Alzheimer's disease from the psychiatric comparison group. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Hosp Cleveland, Case Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Psychol, Cleveland, OH 44115 USA; Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Norman, OK 73019 USA		Schoenberg, MR (corresponding author), Univ Hosp Cleveland, Case Med Ctr, Dept Neurol, HH 5,11100 Euclid Ave, Cleveland, OH 44106 USA.	Michael.Schoenberg@uhhs.com	Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; Bolla-Wilson K, 1986, DEV NEUROPSYCHOL, V2, P203, DOI 10.1080/87565648609540342; BUTTERS N, 1985, NEUROPSYCHOLOGIA, V23, P729, DOI 10.1016/0028-3932(85)90080-6; Chen P, 2000, NEUROLOGY, V55, P1847, DOI 10.1212/WNL.55.12.1847; CROSSEN JR, 1994, J CLIN EXP NEUROPSYC, V16, P190, DOI 10.1080/01688639408402630; Davidoff G, 1990, Arch Clin Neuropsychol, V5, P77, DOI 10.1016/0887-6177(90)90009-E; Drebing CE, 1994, NEUROPSYCHOLOGY, V8, P31, DOI 10.1037/0894-4105.8.1.31; Estevez-Gonzalez A, 2003, INT J GERIATR PSYCH, V18, P1021, DOI 10.1002/gps.1010; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Gosche KM, 2002, NEUROLOGY, V58, P1476, DOI 10.1212/WNL.58.10.1476; GUILMETTE TJ, 1995, NEUROPSYCHOLOGY, V9, P338, DOI 10.1037/0894-4105.9.3.338; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Hoffmann M, 2004, ACTA NEUROL SCAND, V109, P14, DOI 10.1034/j.1600-0404.2003.00169.x; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Ivnik R.J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; Ivnik RJ, 2001, CLIN NEUROPSYCHOL, V15, P114, DOI 10.1076/clin.15.1.114.1904; IVNIK RJ, 1994, NEUROPSYCHOLOGY, V8, P203; Jack CR, 1997, NEUROLOGY, V49, P786, DOI 10.1212/WNL.49.3.786; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Kurylo M, 2001, REHABIL PSYCHOL, V46, P247, DOI 10.1037/0090-5550.46.3.247; Laakso MP, 1998, NEUROBIOL AGING, V19, P23, DOI 10.1016/S0197-4580(98)00006-2; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LUCAS JA, 1998, CLIN NEUROPSYCHOLOGY; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MUNGAS D, 1983, J CONSULT CLIN PSYCH, V51, P848, DOI 10.1037/0022-006X.51.6.848; *NEUR ASS PAN, 1996, NEUROLOGY, V34, P592; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; OBrien JT, 1997, PSYCHOL MED, V27, P1267, DOI 10.1017/S0033291797005606; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; QUERY WT, 1983, J CLIN PSYCHOL, V39, P136, DOI 10.1002/1097-4679(198301)39:1<136::AID-JCLP2270390125>3.0.CO;2-Q; RETZLAFF PD, 2001, CLIN GUIDE NEUROPSYC, P277; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Salmon DP, 2002, NEUROLOGY, V59, P1022, DOI 10.1212/WNL.59.7.1022; SAVAGE RM, 1992, ARCH CLIN NEUROPSYCH, V7, P407, DOI 10.1016/0887-6177(92)90153-E; Schmidt M., 1996, REY AUDITORY VERBAL; Simard S, 2003, BRAIN COGNITION, V53, P354, DOI 10.1016/S0278-2626(03)00142-8; SNYDER RPJ, 1998, CLIN NEUROPSYCHOLOGY; SQUIRE LR, 1986, BEHAV NEUROSCI, V100, P866, DOI 10.1037/0735-7044.100.6.866; Tangalos, 1992, CLIN NEUROPSYCHOL, V6, P83, DOI [10.1080/13854049208401880, DOI 10.1080/13854049208401880]; Taylor E.M., 1959, PSYCHOL APPRAISAL CH, P423; Tong BSK, 2002, BRAIN INJURY, V16, P987, DOI 10.1080/02699050210147202; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; UCHIYAMA CL, 1995, ARCH CLIN NEUROPSYCH, V10, P133, DOI 10.1016/0887-6177(94)E0034-M; Unkenstein A.E., 1991, CLIN NEUROPSYCHOL, V5, P24; Urbina S, 1997, PSYCHOL TESTING; Vakil E, 2000, NEUROPSYCHOLOGIA, V38, P1, DOI 10.1016/S0028-3932(99)00058-5; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Wechsler D, 1981, WESCHLER ADULT INTEL; WEINSTEIN A, 1998, CLIN NEURPSYCHOLOGY; Williamson DJG, 1996, NEUROPSYCHOLOGY CLIN; Wolfson, 1993, HALSTEAD REITAN NEUR	57	96	106	0	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	OCT	2006	21	7					693	703		10.1016/j.acn.2006.06.010			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	112JR	WOS:000242522400010	16987634	Bronze			2022-02-06	
J	Siklos, S; Kerns, KA				Siklos, Susan; Kerns, Kimberly A.			Assessing need for social support in parents of children with autism and Down syndrome	JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS			English	Article						autism spectrum disorder; social support; Down syndrome; autism; adaptation; Family Needs Questionnaire	TRAUMATIC BRAIN INJURY; FAMILY NEEDS; SCREENING QUESTIONNAIRE; BEHAVIORAL TREATMENT; SPECTRUM DISORDERS; ASPERGER-SYNDROME; STRESS; ADAPTATION; INDIVIDUALS; PERSPECTIVE	Parents of children with autism frequently turn to the service delivery system to access supports designed to help adapt to the challenges of having a child with a life-long impairment. Although studies have suggested various supports and coping strategies that are effective for adapting, few studies have examined parents' own perceptions of needs.. and whether parents felt their needs were being met. In the present study the Family Needs Questionnaire (FNQ, Waaland et al., 1993) was modified to address needs for children with developmental disorders. A sample of fifty-six parents of children with autism and a comparison group of thirty-two parents of children with Down syndrome completed the FNQ. The groups did not differ significantly on the number of important needs reported nor the number of important needs being met. However, the two groups differed in the types of supports they most frequently endorsed as Important or Unmet.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada		Kerns, KA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	kkerns@uvic.ca					Agosta J., 1989, SUPPORT CAREGIVING F; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; ARVIDSSON T, 1997, AUTISM, V1, P694; Baird G, 2000, J AM ACAD CHILD PSY, V39, P694, DOI 10.1097/00004583-200006000-00007; Berument SK, 1999, BRIT J PSYCHIAT, V175, P444, DOI 10.1192/bjp.175.5.444; Bristol M. M., 1984, EFFECTS AUTISM FAMIL, P289, DOI DOI 10.1007/978-1-4899-2293-9_17; BRISTOL MM, 1988, DEV PSYCHOL, V24, P441, DOI 10.1037/0012-1649.24.3.441; BRISTOL MM, 1987, J AUTISM DEV DISORD, V17, P469, DOI 10.1007/BF01486964; Chakrabarti S, 2001, JAMA-J AM MED ASSOC, V285, P3093, DOI 10.1001/jama.285.24.3093; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; DONENBERG G, 1993, J ABNORM CHILD PSYCH, V21, P179, DOI 10.1007/BF00911315; DONOVAN AM, 1988, AM J MENT RETARD, V92, P502; Ehlers S, 1999, J AUTISM DEV DISORD, V29, P129, DOI 10.1023/A:1023040610384; Erwin W. J., 2002, J MENTAL HLTH COUNSE, V24, P247; Filipek PA, 1999, J AUTISM DEV DISORD, V29, P439, DOI 10.1023/A:1021943802493; FISMAN S, 1991, PSYCHIAT CLIN N AM, V14, P199; Fombonne E, 2001, PEDIATRICS, V107, P411, DOI 10.1542/peds.107.2.411; Freedman RI, 2000, HEALTH SOC WORK, V25, P59, DOI 10.1093/hsw/25.1.59; HENDERSON D, 1992, PSYCHOL REP, V71, P167, DOI 10.2466/PR0.71.5.167-171; Hill R., 1949, FAMILIES STRESS; Honda H, 1996, BRIT J PSYCHIAT, V169, P228, DOI 10.1192/bjp.169.2.228; Kadesjo B, 1999, J AUTISM DEV DISORD, V29, P327, DOI 10.1023/A:1022115520317; KONSTANTAREAS MM, 1989, J CHILD PSYCHOL PSYC, V30, P459, DOI 10.1111/j.1469-7610.1989.tb00259.x; KONSTANTAREAS MM, 1991, CAN J BEHAV SCI, V23, P358, DOI 10.1037/h0079022; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KRUG DA, 1980, J CHILD PSYCHOL PSYC, V21, P221, DOI 10.1111/j.1469-7610.1980.tb01797.x; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Liwag M. E. C. D., 1989, PHILIPPINE J PSYCHOL, V22, P3; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; McCubbin H.I., 1983, MARRIAGE FAM REV, V6, P7, DOI [10.1300/J002v06n01_02, DOI 10.1300/J002V06N01_02]; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; MILGRAM NA, 1988, J AUTISM DEV DISORD, V18, P415, DOI 10.1007/BF02212196; MORGAN SB, 1988, J AUTISM DEV DISORD, V18, P263, DOI 10.1007/BF02211952; Phillips KM, 2004, PROF PSYCHOL-RES PR, V35, P281, DOI 10.1037/0735-7028.35.3.281; RODRIGUE JR, 1992, J AUTISM DEV DISORD, V22, P249, DOI 10.1007/BF01058154; Sanders JL, 1997, CHILD FAM BEHAV THER, V19, P15, DOI 10.1300/J019v19n04_02; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SIEGEL B, 1996, WORLD AUTISTIC CHILD; TUNALI B, 1993, J CHILD PSYCHOL PSYC, V34, P945, DOI 10.1111/j.1469-7610.1993.tb01100.x; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; White C, 2002, DRUG-EDUC PREV POLIC, V9, P305, DOI 10.1080/09687630110116470; Wing L, 1988, DIAGNOSIS ASSESSMENT; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; WOLF LC, 1989, J AUTISM DEV DISORD, V19, P157, DOI 10.1007/BF02212727; WORTMAN C, 1984, CANCER, V53, P339	46	96	102	1	24	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0162-3257			J AUTISM DEV DISORD	J. Autism Dev. Disord.	OCT	2006	36	7					921	933		10.1007/s10803-006-0129-7			13	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	093ME	WOS:000241171600010	16897397				2022-02-06	
J	Pellman, EJ; Viano, DC; Withnall, C; Shewchenko, N; Bir, CA; Halstead, PD				Pellman, EJ; Viano, DC; Withnall, C; Shewchenko, N; Bir, CA; Halstead, PD			Concussion in professional football: Helmet testing to assess impact performance - Part 11	NEUROSURGERY			English	Article						concussion; helmets; protective headgear; recreation and sport; sports equipment	INJURY; BIOMECHANICS; SKULL; HEAD	OBJECTIVE: National Football League (NFL) concussions occur at an impact velocity of 9.3 +/- 1.9 m/s (20.8 +/- 4.2 mph) oblique on the facemask, side, and back of the helmet. There is a need for new testing to evaluate helmet performance for impacts causing concussion. This study provides background on new testing methods that form a basis for supplemental National Operating Committee on Standards for Athletic Equipment (NOCSAE) helmet standards. METHODS: First, pendulum impacts were used to simulate 7.4 and 9.3 m/s impacts causing concussion in NFL players. An instrumented Hybrid III head was helmeted and supported on the neck, which was fixed to a sliding table for frontal and lateral impacts. Second, a linear pneumatic impactor was used to evaluate helmets at 9.3 m/s and an elite impact condition at 11.2 m/s. The upper torso of the Hybrid III dummy was used. It allowed interactions with shoulder pads and other equipment. The severity of the head responses was measured by a severity index, translational and rotational acceleration, and other biomechanical responses. High-speed videos of the helmet kinematics were also recorded. The tests were evaluated for their similarity to conditions causing NFL concussions. Finally, a new linear impactor was developed for use by NOCSAE. RESULTS: The pendulum test closely simulated the conditions causing concussion in NFL players. Newer helmet designs and padding reduced the risk of concussion in 7.4 and 9.3 m/s impacts oblique on the facemask and lateral on the helmet shell. The linear impactor provided a broader speed range for helmet testing and more interactions with safety equipment. NOCSAE has prepared a draft supplemental standard for the 7.4 and 9.3 m/s impacts using a newly designed pneumatic impactor. No helmet designs currently address the elite impact condition at 11.2 m/s, as padding bottoms out and head responses dramatically increase. CONCLUSIONS: The proposed NOCSAE standard is the first to address helmet performance in reducing concussion risks in football. Helmet performance has improved with thicker padding and fuller coverage by the she]L However, there remains a challenge for innovative designs that reduce risks in the 11.2 m/s elite impact condition.	ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; ProHLTH Care Associates LLP, Lake Success, NY USA; Biokinet & Associates Ltd, Ottawa, ON, Canada; Wayne State Univ, Ctr Bioengn, Sport Biomech Lab, Detroit, MI USA; Natl Operating Comm Stand Athlet Equipment, Overland Pk, KS USA; Univ Tennessee, Coll Engn, Impact Res Lab, Knoxville, TN USA		Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net		Bir, Cynthia/0000-0002-0777-0951			*AM SOC TEST MAT, 2001, F42901 ASTM; *AM SOC TEST MAT, 2004, F144604 ASTM; *AM SOC TEST MAT, 1989, F42901 ASTM; BACKAITIS SH, 1994, PT44 SOC AUT ENG; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; GURDJIAN E S, 1964, J Trauma, V4, P309; Gurdjian E S, 1968, Neurosci Res (N Y), V1, P333; GURDJIAN ES, 1968, GEN PRACT, V37, P78; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; HODGSON VR, 1966, J NEUROSURG, V25, P549, DOI 10.3171/jns.1966.25.5.0549; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR, 1980, P 24 STAPP CAR CRASH; HODGSON VR, 1972, P 16 STAPP CAR CRASH, P45; Hodgson VR, 1970, P 14 STAPP CAR CRASH; Mertz H J, 1978, Phys Sportsmed, V6, P95, DOI 10.1080/00913847.1978.11948406; *NAT OP COMM STAND, 1996, 00496M04A NOCSAE; *NAT OP COMM STAND, 71487 NOCSAE; *NAT OP COMM STAND, 1998, 00298M03 NOCSAE; *NAT OP COMM STAND, 1998, 02198M05 NOCSAE; *NAT OP COMM STAND, 1996, 00396M03 NOCSAE; National Operating Committee on Standards for Athletic Equipment, 2004, 00104M05 NOCSAE; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; *SOC AUT ENG, 1980, J855 SAE; *SOC AUT ENG, 1994, J1733 SAE; *SOC AUT ENG, 1995, J2111 SAE; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; VIANO DC, 1989, ACCIDENT ANAL PREV, V21, P553, DOI 10.1016/0001-4575(89)90070-5; WITHNALL C, 2005, Patent No. 6871525	34	96	96	0	35	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2006	58	1					78	95		10.1227/01.NEU.0000196265.35238.7C			18	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	000IF	WOS:000234453800017	16385332				2022-02-06	
J	Schwarzbach, E; Bonislawski, DP; Xiong, G; Cohen, AS				Schwarzbach, E.; Bonislawski, D. P.; Xiong, G.; Cohen, A. S.			Mechanisms underlying the inability to induce area CA1 LTP in the mouse after traumatic brain injury	HIPPOCAMPUS			English	Article						NMDA receptor; alpha-calmodulin kinase II (alpha-CaMKII); dendrite spine size; cognition; limbic function	LONG-TERM POTENTIATION; POST-TETANIC POTENTIATION; DENDRITIC SPINE DENSITY; SELECTIVE VULNERABILITY; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL-NEURONS; PYRAMIDAL CELLS; PROTEIN-KINASE; DENTATE GYRUS; MEMORY	Traumatic brain injury (TBI) is a significant health issue that often causes enduring cognitive deficits, in particular memory dysfunction. The hippocampus, a structure crucial in learning and memory, is frequently damaged during TBI. Since long-term potentiation (LTP) is the leading cellular model underlying learning and memory, this study was undertaken to examine how injury affects area CA1 LTP in mice using lateral fluid percussion injury (FPI). Brain slices derived from FPI animals demonstrated an inability to induce LTP in area CA1 7 days postinjury. However, area CA1 long-term depression could be induced in neurons 7 days postinjury, demonstrating that some forms of synaptic plasticity can still be elicited. Using a multidisciplined approach, potential mechanisms underlying the inability to induce and maintain area CA1 LTP were investigated. This study demonstrates that injury leads to significantly smaller N-methyl-D-aspartate potentials and glutamate-induced excitatory currents, increased dendritic spine size, and decreased expression of a-calcium calmodulin kinase II. These findings may underlie the injuryinduced lack of LTP and thus, contribute to cognitive impairments often associated with TBI. Furthermore, these results provide attractive sites for potential therapeutic intervention directed toward alleviating the devastating consequences of human TBI. (c) 2006 Wiley-Liss, Inc.	Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA		Schwarzbach, E (corresponding author), 3615 Civic Ctr Blvd,816H ARC, Philadelphia, PA 19104 USA.	eschwarz@mail.med.upenn.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD059288, R01 HD059288-07, R01 HD059288-06] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45975, R01 NS045975] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD059288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045975] Funding Source: NIH RePORTER		BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P665, DOI 10.1113/jphysiol.1972.sp010053; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cohen AS, 2000, J NEUROPHYSIOL, V84, P2465, DOI 10.1152/jn.2000.84.5.2465; Cohen AS, 1996, J NEUROPHYSIOL, V76, P953, DOI 10.1152/jn.1996.76.2.953; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V126, pP27; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Gazzaley A, 2002, NEUROSCIENCE, V111, P853, DOI 10.1016/S0306-4522(02)00021-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HANSE E, 1992, J NEUROSCI, V12, P3226, DOI 10.1523/JNEUROSCI.12-08-03226.1992; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HESS G, 1992, NEUROREPORT, V3, P361, DOI 10.1097/00001756-199204000-00018; HIRST GDS, 1981, J PHYSIOL-LONDON, V321, P97, DOI 10.1113/jphysiol.1981.sp013973; Kirov SA, 1999, NAT NEUROSCI, V2, P878, DOI 10.1038/13178; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Leuner B, 2003, J NEUROSCI, V23, P659, DOI 10.1523/JNEUROSCI.23-02-00659.2003; Li CY, 2005, J NEUROPHYSIOL, V93, P3001, DOI 10.1152/jn.00546.2004; Liu GS, 2004, NAT NEUROSCI, V7, P373, DOI 10.1038/nn1206; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MARTIN AR, 1964, J PHYSIOL-LONDON, V175, P17, DOI 10.1113/jphysiol.1964.sp007500; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Neigh GN, 2004, EUR J NEUROSCI, V20, P1865, DOI 10.1111/j.1460-9568.2004.03649.x; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Malley A, 2000, NEUROSCIENCE, V99, P229, DOI 10.1016/S0306-4522(00)00182-2; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PATEL SN, 1988, BRAIN RES, V463, P168, DOI 10.1016/0006-8993(88)90542-2; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Sabatini BL, 2002, NEURON, V33, P439, DOI 10.1016/S0896-6273(02)00573-1; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sandkuhler J, 1998, EUR J NEUROSCI, V10, P2476, DOI 10.1046/j.1460-9568.1998.00278.x; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; Segal M, 2005, NAT REV NEUROSCI, V6, P277, DOI 10.1038/nrn1649; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Toth Z, 1997, J NEUROSCI, V17, P8106; Weitlauf C, 2005, J NEUROSCI, V25, P8386, DOI 10.1523/JNEUROSCI.2388-05.2005; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wong TP, 2004, SCIENCE, V305, p1912C, DOI 10.1126/science.1102399; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547; 1999, MED PEDIAT ONCOL, V33, P357	61	96	98	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus		2006	16	6					541	550		10.1002/hipo.20183			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	049RH	WOS:000238033700003	16634077	Green Accepted			2022-02-06	
J	Newman, JA; Beusenberg, MC; Shewchenko, N; Withnall, C; Fournier, E				Newman, JA; Beusenberg, MC; Shewchenko, N; Withnall, C; Fournier, E			Verification of biomechanical methods employed in a comprehensive study of mild traumatic brain injury and the effectiveness of American football helmets	JOURNAL OF BIOMECHANICS			English	Article						concussion; mild traumatic brain injury; sports; reconstruction; validation; helmet; kinematics; video analysis; acceleration; impact; football; angular acceleration; video	PROFESSIONAL FOOTBALL; CONCUSSION; IMPACTS	Concussion, or mild traumatic brain injury, occurs in many activities, mostly as a result of the head being accelerated. A comprehensive study has been conducted to understand better the mechanics of the impacts associated with concussion in American football. This study involves a sequence of techniques to analyse and reconstruct many different head impact scenarios. It is important to understand the validity and accuracy of these techniques in order to be able to use the results of the study to improve helmets and helmet standards. Two major categories of potential errors have been investigated. The first category concerns error sources specific to the use of crash test dummy instrumentation (accelerometers) and associated data processing techniques. These are relied upon to establish both linear and angular head acceleration responses. The second category concerns the use of broadcast video data and crash test dummy head-neck-torso systems. These are used to replicate the complex head impact scenarios of whole body collisions that occur on the football field between two living human beings. All acceleration measurement and processing techniques were based on well-established practices and standards. These proved to be reliable and reproducible. Potential errors in the linear accelerations due to electrical or mechanical noise did not exceed 2% for the three different noise sources investigated. Potential errors in the angular accelerations due to noise could be as high as 6.7%, due to error accumulation of multiple linear acceleration measurements. The potential error in the relative impact velocity between colliding heads could be as high as 11%, and was found to be the largest error source in the sequence of techniques to reconstruct the game impacts. Full-scale experiments with complete crash test dummies in staged head impacts showed maximum errors of 17% for resultant linear accelerations and 25% for resultant angular accelerations. (c) 2004 Elsevier Ltd. All rights reserved.	Biokinet & Assoc Ltd, Ottawa, ON K1H 1E1, Canada		Withnall, C (corresponding author), Biokinet & Assoc Ltd, 2470 Don Reid Dr, Ottawa, ON K1H 1E1, Canada.	withnall@biokinetics.com					BACKAITIS SH, 1994, HYBRID 3 1 HUMAN LIK; BEUSENBERG M, 2001, P 2001 IRCOBI C BIOM, P295; deJager M, 1996, STAPP CAR C, VP-30, P269; DIMASI FP, 1995, HS808282 DOT NAT HIG; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; GENNARELLI TA, 1983, HEAD NECK INJ CRIT C, P20; JOHNSON AK, 1977, HS802568 DOT NAT HIG; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Newman J.A., 1999, P INT RES C BIOM I 1, P17; Newman JA, 1998, BIOM HLTH R, V21, P200; NEWMAN JA, 1993, ACCIDENTAL INJURY BI, P292; NEWMAN JA, 2000, P 2000 INT IRCOBI C, P233; NEWMAN JA, 2000, P STAPP CAR CRASH J, V44, P215; NEWMAN JA, 1982, AGARD C P 322 LIMP I; *NOCSAE, 1996, 00196 NOCSAE; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PLANK G, 1989, DOTHS807370 NAT HIGH; *SAE, 1995, SURF VEH REC PRACT 1; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; VIANO DC, 1986, P 30 STAPP CAR CRASH, P269	23	96	96	0	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL	2005	38	7					1469	1481		10.1016/j.jbiomech.2004.06.025			13	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	939WM	WOS:000230103300011	15922758				2022-02-06	
J	Skold, MK; Von Gertten, C; Sandberg-Nordqvist, AC; Mathiesen, T; Holmin, S				Skold, MK; Von Gertten, C; Sandberg-Nordqvist, AC; Mathiesen, T; Holmin, S			VEGF and VEGF receptor expression after experimental brain contusion in rat	JOURNAL OF NEUROTRAUMA			English	Article						angiogenesis; blood-brain barrier (BBB); brain; contusion; vascular endothelial growth factor (VEGF); Flt-1; Flk-1	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; FOCAL CEREBRAL-ISCHEMIA; STIMULATES AXONAL OUTGROWTH; SPINAL-CORD; INTEGRIN ALPHA(V)BETA(3); NERVOUS-SYSTEM; MESSENGER-RNA; ADULT CATS; IN-VITRO	Angiogenesis following traumatic brain injury (TBI) may be of importance not only for post-traumatic reparative processes but also for the development of secondary injuries. Vascular endothelial growth factor (VEGF) is a major regulator of endothelial cell proliferation, angiogenesis, and vascular permeability, though its possible involvement in secondary injuries after TBI is largely unknown. This study was undertaken to analyze the expression of VEGF and the VEGF receptors in experimental brain contusion in rat. Twenty-three adult female Sprague-Dawley rats were subjected to a focal cerebral contusion injury by use of a weight-drop model. Four additional rats underwent craniotomy only. The animals were sacrificed 6 h, or 1, 2, 4, 6, 8, or 16 days post-injury. Expression of VEGF and the VEGF receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1) were studied by in situ hybridization and immunohistochemistry. VEGF messenger (m)RNA and protein expression were detected in astrocytes, neutrophils, and macrophages in or adjacent to the injury from 1 day after injury, with a peak expression after 4-6 days. Flt-1 and Flk-1 mRNA and protein were detected in vessels adjacent to the lesion from I day after injury throughout day 6 after injury. It was also noted that Flt-1/Flk-1 and VEGF-positive vessels often were negative for SMI-71, a marker for vessels in areas with blood-brain barrier (BBB). In conclusion, we have demonstrated that TBI leads to an upregulation of VEGF, Flt-1, and Flk-1 mRNA and protein in and around the lesion. The data provide a foundation for future pharmacological intervention studies focusing on posttraumatic angiogenesis and possible injury repair effects of the VEGF system in TBI.	Karolinska Inst, Retzius Lab, Dept Neurosci, S-17177 Stockholm, Sweden; Karolinska Hosp, Neurosurg Sect, Dept Clin Neurosci, Stockholm, Sweden; Karolinska Inst, Swedish Natl Def Res Agcy, Dept Def Med, Stockholm, Sweden		Skold, MK (corresponding author), Karolinska Inst, Retzius Lab, Dept Neurosci, B1-5, S-17177 Stockholm, Sweden.	Mattias.Skold@neuro.ki.se	SkAld, Mattias/AAJ-8253-2020; mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; BULLOCK R, 1990, ACT NEUR S, V51, P286; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Fong GH, 1996, DEV DYNAM, V207, P1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Goldman CK, 1997, NEUROSURGERY, V40, P1269, DOI 10.1097/00006123-199706000-00029; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; ImperatoKalmar EL, 1997, EXP NEUROL, V145, P322, DOI 10.1006/exnr.1997.6449; Issa R, 1999, LAB INVEST, V79, P417; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nordqvist ACS, 1997, NEUROREPORT, V8, P455, DOI 10.1097/00001756-199701200-00016; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Okada Y, 1996, AM J PATHOL, V149, P37; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Povlishock J T, 1992, Hum Cell, V5, P345; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; RISLING M, 1989, BRAIN RES, V494, P13, DOI 10.1016/0006-8993(89)90138-8; Robinson CJ, 2001, J CELL SCI, V114, P853; SANDHU RS, 1996, IEEE COMPUT, V2, P38; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STERNBERGER NH, 1987, P NATL ACAD SCI USA, V84, P8169, DOI 10.1073/pnas.84.22.8169; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	61	96	104	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					353	367		10.1089/neu.2005.22.353			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500003	15785231				2022-02-06	
J	Chamelian, L; Feinstein, A				Chamelian, L; Feinstein, A			Outcome after mild to moderate traumatic brain injury: The role of dizziness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						dizziness; head injuries; rehabilitation; psychosocial aspects	MINOR HEAD-INJURY; BENIGN POSITIONAL VERTIGO; FOLLOW-UP; VESTIBULAR DAMAGE; ACUTE PREDICTORS; RATING-SCALE; RETURN; WORK; SEQUELAE; QUESTIONNAIRE	Objective: To assess the specific effect of dizziness on psychosocial outcome after mild to moderate traumatic brain injury (TBI). Design: Six-month cross-sectional study. Setting: An outpatient TBI clinic in a tertiary care referral center. Participants: A consecutive sample of 207 adults with mild to moderate TBI, 138 (66.7%) of whom had subjective complaint of posttraumatic dizziness. Interventions: Not applicable. Main Outcome Measures: Psychosocial indices (Glasgow Outcome Scale [GOS], General Health Questionnaire [GHQ], Rivermead Head Injury Follow-Up Questionnaire [RHFUQ], return to work status) were collected from dizzy and nondizzy patients. Results: Despite similar demographic, TBI, and global disability (GOS) profiles of both groups, psychosocial functioning (GHQ, RHFUQ, return to work) was significantly worse in dizzy subjects (P<.01 for all indices). A logistic regression analysis identified dizziness (P=.006), total GHQ (P=.001) and psychotropic and analgesic use (P=.05) as significant independent predictors of reemployment. Conclusions: Although dizziness was closely linked to psychologic distress at 6 months after head injury, it also emerged as an independent predictor of failure to return to work, suggesting that not all its adverse effects on outcome are psychologically mediated. Clinicians need to be alert to the presence of dizziness as an adverse prognostic indicator after mild to moderate TBI. (C) 2004 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Toronto, Toronto, ON, Canada		Feinstein, A (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	antfeinstein@aol.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Cohen J., 2013, STAT POWER ANAL BEHA; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAGGER S, 1992, J NEUROL NEUROSUR PS, V55, P383, DOI 10.1136/jnnp.55.5.383; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FROMMBERGER UH, 1994, ARCH INTERN MED, V154, P590; Furman JM, 2001, J ANXIETY DISORD, V15, P9, DOI 10.1016/S0887-6185(00)00040-2; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JENNETT B, 1975, LANCET, V1, P480; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KROENKE K, 1993, J GEN INTERN MED, V8, P530, DOI 10.1007/BF02599633; KROENKE K, 1994, J GEN INTERN MED, V9, P684, DOI 10.1007/BF02599010; Lemeshow S, 2000, APPL LOGISTIC REGRES; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHUTTY MS, 1991, ARCH PHYS MED REHAB, V72, P473; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; SULLIVAN M, 1993, ARCH INTERN MED, V153, P1479, DOI 10.1001/archinte.153.12.1479; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, V359, P5; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLSON GN, 1981, J LARYNGOL OTOL, V95, P1213, DOI 10.1017/S0022215100092057; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	54	96	96	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2004	85	10					1662	1666		10.1016/j.apmr.2004.02.012			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	861GS	WOS:000224404700016	15468028				2022-02-06	
J	Stein, SC; Graham, DI; Chen, XH; Smith, DH				Stein, SC; Graham, DI; Chen, XH; Smith, DH			Association between intravascular microthrombosis and cerebral ischemia in traumatic brain injury	NEUROSURGERY			English	Article						cerebral ischemia; disseminated intravascular coagulation; secondary insult; thrombosis; traumatic brain injury	ACTIVATED PROTEIN-C; SEVERE HEAD TRAUMA; BLOOD-VOLUME; MICROVASCULAR ALTERATIONS; HEMODYNAMIC DEPRESSION; CRANIOCEREBRAL TRAUMA; SEVERE SEPSIS; COAGULATION; RATS; COAGULOPATHY	OBJECTIVE: To determine the association between traumatic cerebral ischemia and intravascular thrombosis, a common finding after traumatic brain injury (TBI). METHODS: We reviewed samples of the frontal cortex and hippocampus from individuals who had sustained a fatal TBI Sections stained with hematoxylin and eosin were reviewed and rated for severity of selective neuronal necrosis (SNN). Because intravascular fibrin microthrombi may lyse within a few days of TBI, we restricted our analysis to patients who had died within 48 hours of injury. Medical records in all cases were reviewed to rule out severe or prolonged hypotension or hypoxemia. Eleven patients with severe or global SNN were compared with 11 patients in whom SNN was mild or absent. Slides adjacent to the hematoxylin and eosin sections were stained with an immunofluorescent antibody to antithrombin III and were reviewed for intravascular microthrombosis. The number of microthrombi on each slide was counted by an investigator blinded to the hematoxylin and eosin findings, and density of intravascular microthrombi was calculated. RESULTS: Intravascular microthrombi were noted in every section, excluding control (non-TBI) brain tissue. However, the density of microthrombi varied with the degree of SNN. We found a highly significant difference in the mean density of microthrombi between patients with severe SNN (7.74 +/- 3.7/cm(2)) and those with little or no SNN (2.58 +/- 1.0/cm(2)). Furthermore, a good correlation was noted between the location of intravascular microthrombi and that of SNN. CONCLUSION: These data support a strong link between intravascular microthrombosis and neuronal death after brain trauma in humans and may have important implications for new therapeutic approaches.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Glasgow, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS08803] Funding Source: Medline		Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHURLIAEV IA, 2001, ANESTEZIOL REANIMAT, V6, P27; COCCHERI S, 1977, AGGREGATION PATHOGEN, P121; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Goodnight S H Jr, 1977, Compr Ther, V3, P25; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grenander A, 2001, J NEUROSURG ANESTH, V13, P49, DOI 10.1097/00008506-200101000-00010; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; HOOTS WK, 1996, NEUROTRAUMA, P673; HUBER A, 1993, INT J LEGAL MED, V106, P152, DOI 10.1007/BF01225238; IIZUKA H, 1983, Neurological Surgery, V11, P765; IIZUKA H, 1984, Neurologia Medico-Chirurgica, V24, P696, DOI 10.2176/nmc.24.696; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Lee WL, 2000, INTENS CARE MED, V26, P1701, DOI 10.1007/s001340051349; Levi M, 2001, CRIT CARE MED, V29, pS90, DOI 10.1097/00003246-200107001-00028; Levi M, 2000, CRIT CARE MED, V28, pS20, DOI 10.1097/00003246-200009001-00005; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; Maeda T, 1997, ACT NEUR S, V70, P102; Manns BJ, 2002, NEW ENGL J MED, V347, P993, DOI 10.1056/NEJMsa020969; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1996, NEUROTRAUMA, P767; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Takahashi H, 2000, J TRAUMA, V49, P86, DOI 10.1097/00005373-200007000-00013; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; ten Cate H, 2001, CRIT CARE MED, V29, pS95, DOI 10.1097/00003246-200107001-00030; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Ungerstedt JS, 2003, J NEUROSURG ANESTH, V15, P13, DOI 10.1097/00008506-200301000-00003; Utter GH, 2002, J TRAUMA, V52, P1071, DOI 10.1097/00005373-200206000-00008; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vallet B, 2001, CRIT CARE MED, V29, pS36, DOI 10.1097/00003246-200107001-00015; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; WATTS C, 1977, SURG NEUROL, V8, P258; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; [No title captured]	64	96	102	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2004	54	3					687	691		10.1227/01.NEU.0000108641.98845.88			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500047	15028145				2022-02-06	
J	Bonne, O; Gilboa, A; Louzoun, Y; Kempf-Sherf, O; Katz, M; Fishman, Y; Ben-Nahum, Z; Krausz, Y; Bocher, M; Lester, H; Chisin, R; Lerer, B				Bonne, O; Gilboa, A; Louzoun, Y; Kempf-Sherf, O; Katz, M; Fishman, Y; Ben-Nahum, Z; Krausz, Y; Bocher, M; Lester, H; Chisin, R; Lerer, B			Cerebral blood flow in chronic symptomatic mild traumatic brain injury	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						neuropsychological testing; SPECT; statistical parametric mapping; MTBI	HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; CONTUSION INDEX; CT; ABNORMALITIES; PERFORMANCE; MRI	Patients with mild traumatic brain injury (MTBI) (journal of Head Trauma and Rehabilitation, 8, 1993, 83-84) challenge physicians' skills and test their patience. Their manifold symptomatology is often not supported by objective neurological findings. We sought to compare regional cerebral blood flow (rCBF) between symptomatic subjects with longstanding MTBI and healthy controls, and to examine the correspondence between neuropsychological deficit and rCBF compromise. Twenty-eight clinically symptomatic male subjects with MTBI and twenty matched controls underwent neuropsychological testing and Tc-99m-HMPAO brain SPECT imaging. Neuropsychological test data were used to categorize subjects into sub-groups according to the presumed location of lesions based on their neurobehavioral deficits. Image subtraction comparisons were made between controls, all MTBI subjects and sub-groups. MTBI patients demonstrated regions of hypoperfusion in frontal, pre-frontal and temporal cortices, and sub-cortical structures. Hypoperfusion in 'frontal', 'left posterior' and to a lesser extent 'sub-cortical' sub-groups was concordant with neuropsychological localization. This was not the case for the 'right posterior' group, where no concordance was found. The rCBF is reduced in symptomatic patients with longstanding MTBI and unremarkable structural brain imaging. Although group analysis is appropriate for the generation of statistically significant differences, the clinical application of brain SPECT imaging in MTBI calls for a capability to associate clinical examination, neuropsychological assessment and cerebral perfusion at the individual subject level. Such competence is still to be attained. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.	NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA; Hadassah Univ Hosp, Dept Psychiat, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Nucl Med, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Unit Treatment & Rehabil Head Trauma Victims, Jerusalem, Israel		Bonne, O (corresponding author), NIMH, Mood & Anxiety Disorders Program, 15K North Dr,Room 200, Bethesda, MD 20892 USA.	bonneo@intra.nimh.nih.gov	louzoun, yoram/F-5874-2011	louzoun, yoram/0000-0003-1714-6148			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P749; Baulieu F, 2001, J NEUROIMAGING, V11, P112, DOI 10.1111/j.1552-6569.2001.tb00020.x; BENSON DF, 1997, BEHAV NEUROLOGY NEUR, P401; Benton AL, 1974, REVISED VISUAL RETEN; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; BRADSHAW JL, 1981, BEHAV BRAIN SCI, V4, P51, DOI 10.1017/S0140525X00007548; Damasio H., 1989, LESION ANAL NEUROPSY; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; First MB, 1995, STRUCTURED CLIN INTE; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FUSTER MY, 1996, NEUROPSYCHIATRY, P407; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HOOPER HE, 1981, HOOPER VISUAL ORG TE; ICHISE M, 1994, J NUCL MED, V35, P217; Jacobs A, 1996, J NUCL MED, V37, P1605; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Mesulam MM, 2000, PRINCIPLES BEHAV COG; MEYERS J, 1995, MEYERS SCORING SYSTE; *MILD TRAUM BRAIN, 1993, J HEAD TRAUMA REHAB, V8, P83; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Osterreith P., 1993, CLIN NEUROPSYCHOL, V7, P9; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Raven J. C., 1982, REVISED MANUAL RAVEN; RICHARDSON JTE, 1999, CLIN NEUROPSYCHOLOGI; RUSSELL EW, 1984, CLIN NEUROPSYCHOLOGY; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TALAIRACH J, 1988, ATLAS ANATOMIE STERE; TEASDALE G, 1974, LANCET, V2, P81; TIFFIN J, 1968, PURDUE PEG BOARD EXA; Umile EM, 1998, BRAIN INJURY, V12, P577; Vakil E, 1997, CLIN NEUROPSYCHOL, V11, P356, DOI 10.1080/13854049708400464; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WOODS RP, 1998, J COMPUT ASSIST TOMO, V22, P141	50	96	99	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	NOV 30	2003	124	3					141	152		10.1016/S0925-4927(03)00109-4			12	Clinical Neurology; Neuroimaging; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	745VU	WOS:000186711900002	14623066				2022-02-06	
J	Petzold, A; Keir, G; Lim, D; Smith, M; Thompson, EJ				Petzold, A; Keir, G; Lim, D; Smith, M; Thompson, EJ			Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern	BRAIN RESEARCH BULLETIN			English	Article; Proceedings Paper	European Symposium on Laboratory Diagnosis of Brain Damage and Inflammation with New and Old Markers in Human Cerebrospinal Fluids and Blood	SEP, 2000	MARBURG AN DER LAHN, GERMANY			brain specific proteins; ICH; SAH; TBI; reference population	BRAIN-DAMAGE; NEUROBIOCHEMICAL MARKERS; PROTEIN; S-100; INJURY	S100B is an important brain specific protein for monitoring damage and activation of astrocytes. Using a straight forward, non-resource demanding in-house ELISA technique we measured S 10013 in cerebrospinal fluid (CSF) and serum in patients with traumatic brain injury (TBI) (serum), subarachnoid hemorrhage (SAH) (CSF, serum), intracranial hemorrhage (ICH) (CSF, serum), normal controls (NC) (serum) and a reference population (CSF, N = 409). The release and wash-out pattern found in CSF and serum are discussed in relation to the three main determinants for increased brain specific protein levels in body fluids: (i) total mass effect; (ii) pathology; and (iii) time effect. (C) 2003 Elsevier Science Inc. All rights reserved.	Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Surg Intens Care Unit, London, England		Thompson, EJ (corresponding author), Inst Neurol, Dept Neuroimmunol, Queen Sq, London WC1N 3BG, England.	e.thompson@ion.ucl.ac.uk	Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Cody R P, 1997, APPL STAT SAS PROGRA; Gao F, 2000, ANAESTHESIA, V55, P764, DOI 10.1046/j.1365-2044.2000.01466.x; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thompson EJ, 1998, MULT SCLER, V4, P5, DOI 10.1191/135245898678909169; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	11	96	100	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	AUG 15	2003	61	3					281	285		10.1016/S0361-9230(03)00091-1			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	713VZ	WOS:000184879800008	12909298				2022-02-06	
J	Bombardier, CH; Temkin, NR; Machamer, J; Dikmen, SS				Bombardier, CH; Temkin, NR; Machamer, J; Dikmen, SS			The natural history of drinking and alcohol-related problems after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcoholism; brain injuries; natural history; rehabilitation	SUBSTANCE-ABUSE; INTERVENTIONS; RECOVERY	Objective: To describe changes in drinking from before traumatic brain injury (TBI) to 1 year after TBI. Design: Inception cohort with 1-year follow-up. Setting: Level I trauma center. Participants: Adults (N=197) hospitalized with a broad range of head injury severity. Interventions: Not applicable. Main Outcome Measures: Alcohol consumption and alcohol-related problems. Results: Drinking and alcohol-related problems decreased substantially from preinjury to 1 year after TBI. However, about one quarter of the sample reported heavy drinking, significant problems, or both during the first year after TBI. Preinjury alcohol use and problems were highly predictive of heavy use and problems after TBI. Conclusion: Although drinking and alcohol-related problems decreased after TBI, there appears to be an ongoing need for prevention and intervention efforts. Screening for preinjury alcohol problems can be used to identify the vast majority of persons who will develop alcohol-related problems within 1 year after injury.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98104 USA		Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283	AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS005304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS05304] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19643] Funding Source: Medline; ODCDC CDC HHS [R49/CCR011714] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; Bombardier CH, 1997, REHABIL PSYCHOL, V42, P259; BRADLEY KA, 1993, ARCH INTERN MED, V153, P2734, DOI 10.1001/archinte.153.24.2734; BUCHOLZ KK, 1992, ALCOHOL HLTH RES WOR, V0016; Cahalan D, 1969, AM DRINKING PRACTICE, P131; Cisler RA, 1999, ALCOHOL CLIN EXP RES, V23, P263, DOI 10.1111/j.1530-0277.1999.tb04109.x; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; GRANT BF, 1991, ALCOHOL HLTH RES WOR, V0015; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HUNT WA, 1971, J CLIN PSYCHOL, V27, P455, DOI 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Marlatt GA, 1985, RELAPSE PREVENTION M; Miller WR, 1999, J CONSULT CLIN PSYCH, V67, P688, DOI 10.1037/0022-006X.67.5.688; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; TUCKER JA, 1994, J STUD ALCOHOL, V55, P401, DOI 10.15288/jsa.1994.55.401; Zweben A, 1996, SUBST USE MISUSE, V31, P1783, DOI 10.3109/10826089609064001; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	28	96	96	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					185	191		10.1053/apmr.2003.50002			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700006	12601648				2022-02-06	
J	Savva, A; Taylor, MJ; Beatty, CW				Savva, A; Taylor, MJ; Beatty, CW			Management of cerebrospinal fluid leaks involving the temporal bone: Report on 92 patients	LARYNGOSCOPE			English	Article; Proceedings Paper	104th Annual Meeting of the Triological-Society	MAY 12-16, 2001	PALM DESERT, CALIFORNIA	Triol Soc		cerebrospinal fluid; otorrhea; otorhinorrhea; retrospective study; treatment	OTORRHEA; DEFECTS; OTORHINORRHEA; MENINGITIS; DIAGNOSIS	Objective. To investigate the success of different surgical and nonsurgical techniques in the management of cerebrospinal fluid otorrhea or otorhinorrhea. Study Design: Retrospective case analysis. Methods: Ninety-two patients with confirmed diagnosis of cerebrospinal fluid otorrhea or otorhinorrhea treated at our institution between 1976 and 1998 were followed up long-term by retrospective chart review and patient interviews. Results: Conservative treatment was successful in most cases of cerebrospinal fluid otorrhea or otorhinorrhea resulting from head injury (26 of 29 patients). In contrast, surgical intervention was required in all but 1 of 53 patients with cerebrospinal fluid otorrhea or otorhinorrhea caused surgically. The primary operative success rate was 76.9%. When relapse occurred, the interval ranged from 0 days to 24 months (mean interval, 3.9 mo; median, 1.3 mo). All leaks requiring surgery eventually were closed successfully. Surgical results were chronologically dependent. Before 1989, 11 failures occurred in 37 primary procedures. After 1989, only 4 failures occurred in 28 primary procedures. Of seven patients undergoing primary dural closure alone, three (43%) had recurrence of the leak. Closure rates were highest among patients in whom a multilayer technique for leak closure was used: combining a primary graft or sealing material such as bone wax, free muscle, or fascia for closure of the defect with additional autologous free grafts or allogenic materials. This resulted in a 2-year closure rate of 100% compared with a 2-year rate of 75.4% for patients whose primary closure was supported by a single layer of autologous or allogenic material (P = .034). Fibrin glue with primary closure alone did not have additional benefit. Postoperative meningitis occurred in two patients and was treated without sequelae. Conclusions. Conservative treatment should be reserved for cerebrospinal fluid otorrhea or otorhinorrhea resulting from head injury. Postoperative and nontraumatic cerebrospinal fluid otorrhea or otorhinorrhea should have early operative intervention. A multilayer technique combining allogenic materials with free autologous grafts is recommended. Key Words: Cerebrospinal fluid, otorrhea, otorhinorrhea, retrospective study, treatment.	Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA; Univ Hannover, Dept Otorhinolaryngol, Hannover, Germany		Beatty, CW (corresponding author), Mayo Clin, Dept Otorhinolaryngol, 200 1st St SW, Rochester, MN 55905 USA.						da Cruz MJ, 1998, AM J OTOL, V19, P288; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; FERGUSON BJ, 1986, LARYNGOSCOPE, V96, P635; Gacek RR, 1999, AM J OTOL, V20, P770; GIDDINGS NA, 1994, AM J OTOL, V15, P781; HARNER SG, 1982, J NEUROSURG, V57, P258, DOI 10.3171/jns.1982.57.2.0258; Hicks G W, 1980, Laryngoscope, V90, P1, DOI 10.1288/00005537-198011001-00001; Klastersky J, 1976, Surg Neurol, V6, P111; KUHWEIDE R, 1987, Acta Oto-Rhino-Laryngologica Belgica, V41, P453; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MAY JS, 1995, AM J OTOL, V16, P765; Merchant SN, 2000, AM J OTOL, V21, P234, DOI 10.1016/S0196-0709(00)80015-0; Narayan RK, 1991, PRINCIPLES NEUROSURG, P235; NEELY JG, 1982, LARYNGOSCOPE, V92, P609; NEELY JG, 1985, OTOLARYNG HEAD NECK, V93, P625, DOI 10.1177/019459988509300511; NELSON DR, 1990, J THORAC CARDIOV SUR, V99, P977; Nuss DW, 1995, OTOLARYNGOL HEAD NEC, V8, P79; OBERASCHER G, 1988, AM J OTOL, V9, P102; OMMAYA AK, 1985, NEUROSURGERY, V2, P1637; PAPPAS DG, 1992, AM J OTOL, V13, P534; Shetty PG, 1997, AM J NEURORADIOL, V18, P478; WETMORE SJ, 1987, AM J OTOL, V8, P96; WINKLER J, 1994, ACTA NEUROL SCAND, V89, P293	23	96	103	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0023-852X			LARYNGOSCOPE	Laryngoscope	JAN	2003	113	1					50	56		10.1097/00005537-200301000-00010			7	Medicine, Research & Experimental; Otorhinolaryngology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Otorhinolaryngology	637EX	WOS:000180499500010	12514382				2022-02-06	
J	Colton, CA; Brown, CM; Cook, D; Needham, LK; Xu, Q; Czapiga, M; Saunders, AM; Schmechel, DE; Rasheed, K; Vitek, MP				Colton, CA; Brown, CM; Cook, D; Needham, LK; Xu, Q; Czapiga, M; Saunders, AM; Schmechel, DE; Rasheed, K; Vitek, MP			APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress	NEUROBIOLOGY OF AGING			English	Article; Proceedings Paper	Meeting on Brain Aging - Identifying Accelerators and Brakes	NOV, 2001	SAN DIEGO, CALIFORNIA			nitric oxide; arginine transport; apolipoprotein E; microglia; human macrophages; Alzheimer's disease	BETA-AMYLOID PROTEIN; L-ARGININE TRANSPORT; HUMAN APOLIPOPROTEIN-E; AMINO-ACID-TRANSPORT; ALZHEIMERS-DISEASE; TRANSGENIC MICE; BRAIN INJURY; PERITONEAL-MACROPHAGES; ACTIVATED MICROGLIA; INTERFERON-GAMMA	The mechanism linking the APOE4 gene with increased susceptibility for Alzheimer's disease (AD) and poorer outcomes following closed head injury and stroke is unknown. One potential link is activation of the innate immune system in the CNS. Our previously published data demonstrated that apolipoprotein E regulates production of nitric oxide, a critical cytoactive factor released by immune active macrophages. To determine if immune regulation is different in the presence of apolipoprotein E4 compared to apolipoprotein E3, we have measured NO production by peritoneal and CNS macrophages (microglia) cultured from transgenic mice that only express the human apoE4 or apoE3 protein isoform. Significantly more NO was produced in APOE4 mice compared to APOE3 transgenic mice that only express human apoE3 protein. Similarly, monocyte derived macrophages from humans carrying APOE4 gene alleles also produce significantly greater NO than those individuals with APOE3. The mechanism for this isoform-specific difference in NO production is not known and multiple sites in the NO production pathway may be affected. Expression of inducible nitric oxide synthase (iNOS) mRNA and protein are not significantly different between the APOE3 and APOE4 mice, suggesting that induction of iNOS is not a primary cause of the increased NO production in APOE4 animals. One alternative regulatory mechanism that demonstrates isoform specificity is arginine transport, which is greater in microglia from APOE4 transgenic mice compared to microglia from APOE3 mice. Increased transport is consistent with an increased production of NO and may reflect a direct or indirect effect of the APOE genotype on microglial arginine uptake and microglial activation in general. Overall, greater NO production in APOE4 carriers where characteristically high levels of oxidative/nitrosative stress are found in diseases such as AD provides a mechanism that potentially explains the genetic association between APOE4 and human diseases. (C) 2002 Elsevier Science Inc. All rights reserved.	Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA		Colton, CA (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 2900, Durham, NC 27710 USA.		Brown, Candice/AAD-4982-2019	Brown, Candice/0000-0001-5845-0221; Vitek, Michael/0000-0001-8140-8048; Colton, Carol/0000-0003-3305-370X			AKIYAMA H, 1994, TOHOKU J EXP MED, V174, P295, DOI 10.1620/tjem.174.295; ALBERTS M, 1995, LANCET, V346, P8974; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; Boschert U, 1999, NEUROBIOL DIS, V6, P508, DOI 10.1006/nbdi.1999.0251; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Breitner JCS, 1998, ALZ DIS ASSOC DIS, V12, P40, DOI 10.1097/00002093-199803000-00006; Butterfield D.A, 1996, ALZHEIMERS DIS REV, V1, P68; CHAO CC, 1992, J IMMUNOL, V149, P2736; Closs EI, 2000, MOL PHARMACOL, V57, P68; COHEN G, 1996, NEURODEGENERATIVE DI, P139; COLTON C, 1994, NEUROBIOLOGY NO OH, P54; Colton CA, 2000, ANN NY ACAD SCI, V899, P292; Colton CA, 2001, BBA-MOL BASIS DIS, V1535, P134, DOI 10.1016/S0925-4439(00)00092-2; COLTON CA, 1992, J NEUROIMMUNOL, V40, P89, DOI 10.1016/0165-5728(92)90216-8; COLTON CA, 1992, J HISTOCHEM CYTOCHEM, V40, P505, DOI 10.1177/40.4.1372634; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Dugas N, 2001, CYTOKINE, V15, P96, DOI 10.1006/cyto.2001.0896; EGENSPERGER R, 1919, MOL NEUROPATHOL, V8, P439; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GOODWIN JL, 1995, BRAIN RES, V692, P207, DOI 10.1016/0006-8993(95)00646-8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Grootendorst J, 2000, BRAIN RES, V868, P165, DOI 10.1016/S0006-8993(00)02250-2; HIBBS JB, 1987, J IMMUNOL, V138, P550; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P2143; Kakuda DK, 1999, BIOCHEM J, V340, P549, DOI 10.1042/0264-6021:3400549; Kalmar B, 2001, NEUROCHEM INT, V38, P453, DOI 10.1016/S0197-0186(00)00090-5; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; MacLeod CL, 1996, BIOCHEM SOC T, V24, P846, DOI 10.1042/bst0240846; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Maneerat Y, 2000, HISTOPATHOLOGY, V37, P269, DOI 10.1046/j.1365-2559.2000.00989.x; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Ohm TG, 1999, ACTA NEUROPATHOL, V98, P273, DOI 10.1007/s004010051080; PIANI D, 1994, NEWS PHYSIOL SCI, V9, P80; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Practico D., 2000, AM J MED, V109, P577; Praprotnik D, 1996, ACTA NEUROPATHOL, V91, P1; Roses AD, 1997, NEUROBIOL DIS, V4, P170, DOI 10.1006/nbdi.1997.0161; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SATO H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P46, DOI 10.1016/0005-2736(91)90102-E; Saunders AM, 2000, J NEUROPATH EXP NEUR, V59, P751, DOI 10.1093/jnen/59.9.751; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; SMITH M, 2001, J NEUROCHEM, V70, P2212; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Snell JC, 1997, J LEUKOCYTE BIOL, V62, P369, DOI 10.1002/jlb.62.3.369; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; STREIT WJ, 1995, SCI AM, V273, P38; Styren SD, 1998, J COMP NEUROL, V396, P511; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WEINBERG JB, 1995, BLOOD, V86, P1184; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Wink David A., 1999, P245; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	82	96	100	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580			NEUROBIOL AGING	Neurobiol. Aging	SEP-OCT	2002	23	5					777	785	PII S0197-4580(02)00016-7	10.1016/S0197-4580(02)00016-7			9	Geriatrics & Gerontology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	615EA	WOS:000179231800018	12392781				2022-02-06	
J	Guskiewicz, KM; Marshall, SW; Broglio, SP; Cantu, RC; Kirkendall, DT				Guskiewicz, KM; Marshall, SW; Broglio, SP; Cantu, RC; Kirkendall, DT			No evidence of impaired neurocognitive performance in collegiate soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; PROTECTIVE HEADGEAR; FOOTBALL PLAYERS; CONCUSSION	A high incidence of cerebral concussion has been reported among soccer players. We studied whether long-term or chronic neuropsychological dysfunction was present in collegiate soccer players. Two hundred forty subjects from a National Collegiate Athletic Association division I institution were stratified into three groups: soccer athletes (91), nonsoccer athletes (96 women's field hockey, women's lacrosse, and baseball players), and controls (53 college students). Subjects completed a concussion history questionnaire and underwent preseason baseline neuropsychological testing before the start of either the freshman or sophomore year. Data were collected on the results of six neuropsychological tests and from a concussion history questionnaire for number of previous concussions, Scholastic Aptitude Test results, and exposure to soccer and heading. Despite an average of 15.3 seasons of soccer exposure and a higher prevalence of previous concussions, the soccer athletes did not demonstrate impaired neurocognitive function or scholastic aptitude when compared with the nonsoccer athletes or the student nonathletes. Additionally, there was no significant relationship between a history of soccer-related concussion and either neurocognitive performance or scholastic aptitude. Neither participation in soccer nor a history of soccer-related concussions was associated with impaired performance of neurocognitive function in high-level United States soccer players.	Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, CB 8700, Chapel Hill, NC 27599 USA.			Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233			Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; Barth JT, 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DAILEY SW, 1992, PHYSICIAN SPORTSMED, V20, P79, DOI 10.1080/00913847.1992.11947468; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; DICK RW, 1994, HEAD NECK INJURIES S; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 2001, NEUROLOGICAL SPORTS, P123; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lovell M, 1999, SPORTS RELATED CONCU; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LUHTANEN P, 1994, HDB SPORTS MED SCI, P59; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641	23	96	99	0	17	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR-APR	2002	30	2					157	162		10.1177/03635465020300020201			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	533FV	WOS:000174519500002	11912081				2022-02-06	
J	Friedman, JA; Ebersold, MJ; Quast, LM				Friedman, JA; Ebersold, MJ; Quast, LM			Post-traumatic cerebrospinal fluid leakage	WORLD JOURNAL OF SURGERY			English	Article							TEMPORAL BONE-FRACTURES; PROPHYLACTIC ANTIBIOTICS; MANAGEMENT; RHINORRHEA; METAANALYSIS; FISTULA; REPAIR; FOSSA	Posttraumatic cerebrospinal fluid (CSF) leakage frequently complicates skull base fractures. While most CSF leaks will cease without treatment, patients with persistent CSF leaks may be at increased risk for meningitis, and many will require surgical intervention. We reviewed the medical records of 51 patients treated between 1984 and 1998, with CSF leaks that persisted for 24 hours or longer after head trauma. Twenty-eight patients (53%) had spontaneous resolution of the leakage at an average of 5 days. Twenty-three patients (47%) required surgery. Eight patients (16%) had occult leaks presenting with recurrent meningitis at an average of 6.5 years posttrauma. Forty-three (84%) patients with CSF leaks had an associated skull fracture, most commonly involving the frontal sinus, while only 18 patients (35%) had parenchymal brain injury or extra-axial hematoma. Eight patients (16%) had delayed leaks at an average of 13 days posttrauma. Among patients with clinically evident CSF leakage the frequency of meningitis was 10% with antibiotic prophylaxis, and 21% without antibiotic prophylaxis. Thus, prophylactic antibiotic administration halved risk of meningitis. A variety of surgical approaches was used, with minimal morbidity. Three of 23 surgically treated patients (13%) required additional surgery for continued leakage. Patients with CSF leaks that persist greater than 24 hours are at risk for meningitis, and many will require surgical intervention. Prophylactic antibiotics may be effective and should be considered in this group of patients. Patients with skull fractures involving the skull base or frontal sinus should be followed for delayed leakage. Surgical outcome is excellent.	Mayo Clin & Mayo Fdn, Dept Neurol Surg, Rochester, MN 55905 USA		Ebersold, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol Surg, Mayo Bldg,E6B,200 1st St SW, Rochester, MN 55905 USA.						Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; APPELBAUM E, 1960, JAMA-J AM MED ASSOC, V173, P1818, DOI 10.1001/jama.1960.03020340036010; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; Brodie HA, 1997, AM J OTOL, V18, P188; CHANDLER JR, 1983, OTOLARYNG CLIN N AM, V16, P623; Choi D, 1996, BRIT J NEUROSURG, V10, P571, DOI 10.1080/02688699646880; CLEMENZA JW, 1995, J ORAL MAXIL SURG, V53, P1004, DOI 10.1016/0278-2391(95)90114-0; Frazee RC, 1988, POSTGRAD MED, V83, P273; JEFFERSON A, 1972, BRIT J SURG, V59, P585, DOI 10.1002/bjs.1800590802; Kaufman B A, 1990, Infect Dis Clin North Am, V4, P677; Lee D, 1998, LARYNGOSCOPE, V108, P816, DOI 10.1097/00005537-199806000-00008; LEECH PJ, 1973, LANCET, V1, P1013; Lewin W, 1964, Clin Neurosurg, V12, P237; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MCGUIRT WF, 1995, LARYNGOSCOPE, V105, P359, DOI 10.1288/00005537-199504000-00003; Mendizabal G R, 1992, Rev Laryngol Otol Rhinol (Bord), V113, P423; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; Ng M, 1998, ARCH OTOLARYNGOL, V124, P1125, DOI 10.1001/archotol.124.10.1125; OKADA J, 1991, SURG NEUROL, V35, P213, DOI 10.1016/0090-3019(91)90073-I; Ommaya AK, 1996, NEUROSURGERY, P2773; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; SPETZLER RF, 1978, J NEUROSURG, V49, P393, DOI 10.3171/jns.1978.49.3.0393; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666	24	96	105	0	9	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	AUG	2001	25	8					1062	1066		10.1007/s00268-001-0059-7			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	460YF	WOS:000170337300016	11571972				2022-02-06	
J	Konrad, K; Gauggel, S; Manz, A; Scholl, M				Konrad, K; Gauggel, S; Manz, A; Scholl, M			Lack of inhibition: A motivational deficit in children with attention deficit/hyperactivity disorder and children with traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							CHOICE REACTION-TIME; HYPERACTIVITY DISORDER; MODEL; REINFORCEMENT; PERFORMANCE; ABILITY; STRESS; ADHD	Recent research has demonstrated that both brain-injured children and children with attention deficit/hyperactivity disorder (ADHD) suffer from response inhibition deficits. To investigate whether these deficits can be influenced by motivational factors, the stop-signal task was performed with and without reward contingencies for successful inhibition. Three groups of children between 8 and 12 years of age, participated in the study: 31 children with ADHD, 37 with traumatic brain injuries (TBI), and 26 normal controls. Results indicated that, although all groups showed comparable learning effects, reward contingencies had different effects on the groups. Whereas the performance of children with ADHD under reward contingencies were brought up to the performance level of normal controls, rewards were found less effective at improving response inhibition in children with TBI The results further support a motivational/energetic explanation of the inhibitory deficit in children with ADHD, and of a primary response inhibition deficit due to structural brain damage in children with TBI.	Rhein Westfal TH Aachen, Clin Child & Adolescent Psychiat, D-52074 Aachen, Germany		Konrad, K (corresponding author), Rhein Westfal TH Aachen, Clin Child & Adolescent Psychiat, Neuenhofer Weg 21, D-52074 Aachen, Germany.		Konrad, Kerstin/H-7747-2013	Konrad, Kerstin/0000-0001-9039-2615; Gauggel, Siegfried/0000-0002-2742-4917			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Baddeley, 1981, ATTENTION PERFORM, P205; Cohen J, 1977, STAT POWER ANAL BEHA; CORKUM PV, 1996, J ATTEN DISORD, V1, P114; Damasio H., 1989, LESION ANAL NEUROPSY; Dopfner M., 1998, DIAGNOSTIK SYSTEM PS; GOLDBERG E, 1987, FRONTAL LOBES REVISI, P155; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; Kahneman D., 1973, ATTENTION EFFORT; Kluger AN, 1996, PSYCHOL BULL, V119, P254, DOI 10.1037/0033-2909.119.2.254; Konrad KN, 2000, BRAIN INJURY, V14, P859; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan Gordon D., 1994, P189; Oosterlaan J, 1998, J ABNORM CHILD PSYCH, V26, P161, DOI 10.1023/A:1022650216978; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; PELHAM WE, 1986, J ABNORM PSYCHOL, V95, P319, DOI 10.1037/0021-843X.95.4.319; Rabbitt P, 1998, METHODOLOGY FRONTAL; Sagvolden T, 1998, BEHAV BRAIN RES, V94, P61, DOI 10.1016/S0166-4328(97)00170-8; Sagvolden T, 1998, BEHAV BRAIN RES, V94, P1; Sagvolden T, 1996, CONTEMPORARY PSYCHOLOGY IN EUROPE, P131; SAGVOLDEN T, 1989, ATTENTION DEFICIT DI, P369; SANDERS AF, 1983, ACTA PSYCHOL, V53, P61, DOI 10.1016/0001-6918(83)90016-1; SANDERS AF, 1970, ACTA PSYCHOL, V33, P414, DOI 10.1016/0001-6918(70)90151-4; SCHACHAR R, 1995, J ABNORM CHILD PSYCH, V23, P411, DOI 10.1007/BF01447206; SCHACHAR R, 1989, UNPUB PARENT INTERVI; Sergeant J, 2000, NEUROSCI BIOBEHAV R, V24, P7, DOI 10.1016/S0149-7634(99)00060-3; SLEATOR EK, 1981, PEDIATRICS, V67, P13; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; UNNEWEHR S, 1995, DIAGNOSTISCHES INTER; VANDERMEERE J, 1995, EUNETHYDIS EUROPEAN, P241; Wells KC, 2000, J ABNORM CHILD PSYCH, V28, P543, DOI 10.1023/A:1005131131159; [No title captured]; [No title captured]	37	96	96	0	13	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2000	6	4					286	296		10.1076/chin.6.4.286.3145			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	480DP	WOS:000171447000005	11992192				2022-02-06	
J	Leskovar, A; Moriarty, LJ; Turek, JJ; Schoenlein, IA; Borgens, RB				Leskovar, A; Moriarty, LJ; Turek, JJ; Schoenlein, IA; Borgens, RB			The macrophage in acute neural injury: Changes in cell numbers over time and levels of cytokine production in mammalian central and peripheral nervous systems	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						spinal injury; macrophage; neurotrauma; cytokine; inflammation; central nervous system; peripheral nervous system; mammal	STIMULATED HOMOLOGOUS MACROPHAGES; ISCHEMIC BRAIN-DAMAGE; NECROSIS-FACTOR-ALPHA; SPINAL-CORD INJURY; WALLERIAN DEGENERATION; RAT-BRAIN; MESSENGER-RNA; MONONUCLEAR PHAGOCYTES; INFLAMMATORY RESPONSE; BLOOD MONOCYTES	We evaluated the timing and density of ED-1-positive macrophage accumulation (ED 1 is the primary antibody for the macrophage) and measured cytokine production by macrophages in standardized compression injuries to the spinal cord and sciatic nerves of individual rats 3, 5, 10 and 21 days post-injury. The actual site of mechanical damage to the nervous tissue, and a more distant site where Wallerian degeneration had occurred, were evaluated in both the peripheral nervous system (PNS) and the central nervous system (CNS) at these time points. The initial accumulation of activated macrophages was similar at both the central and peripheral sites of damage. Subsequently, macrophage densities at all locations studied were statistically significantly higher in the spinal cord than in the sciatic nerve at every time point but one. The peak concentrations of three cytokines, tumor necrosis factor alpha (TNF alpha), interleukin-1 (IL-1) and interleukin-6 (IL-6), appeared earlier and were statistically significantly higher in injured spinal cord than in injured sciatic nerve. We discuss the meaning of these data relative to the known differences in the reparative responses of the PNS and CNS to injury.	Purdue Univ, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	rbb@vet.purdue.edu					AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AVELLINO AM, 1995, EXP NEUROL, V136, P183, DOI 10.1006/exnr.1995.1095; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Ben Zeev-Brann A, 1998, GLIA, V23, P181, DOI 10.1002/(SICI)1098-1136(199807)23:3<181::AID-GLIA1>3.0.CO;2-8; BERRY M, 1979, RECENT ADV NEUROPATH, P67; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CLARK RAF, 1995, MOL CELLULAR BIOL WO, P3; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; De Vellis Jean, 1993, P61; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; DOWNS TR, 1983, ANAL BIOCHEM, V131, P538, DOI 10.1016/0003-2697(83)90212-9; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; FAN L, 1995, MOL BRAIN RES, V30, P125; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.3.CO;2-6; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; GRIFFIN JW, 1993, LAB INVEST, V69, P257; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jacobson D R, 1991, PCR Methods Appl, V1, P146; KARAVODIN LM, 1989, EUR J IMMUNOL, V19, P1351, DOI 10.1002/eji.1830190732; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; KIRSNER RS, 1993, DERMATOL CLIN, V11, P629, DOI 10.1016/S0733-8635(18)30216-X; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LAWSON LJ, 1994, J NEUROCYTOL, V23, P729, DOI 10.1007/BF01268086; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LING EA, 1980, J COMP NEUROL, V193, P631, DOI 10.1002/cne.901930304; LING EA, 1978, J ANAT, V126, P111; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MIYAKE T, 1984, ACTA NEUROPATHOL, V62, P291, DOI 10.1007/BF00687611; MONACO S, 1992, J NEUROCYTOL, V21, P623, DOI 10.1007/BF01191724; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Perry V H, 1992, Curr Opin Neurobiol, V2, P679, DOI 10.1016/0959-4388(92)90038-M; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Ramon y Cajal, 1928, DEGENERATION REGENER; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reichert F, 1996, EUR J NEUROSCI, V8, P530, DOI 10.1111/j.1460-9568.1996.tb01237.x; Reier P., 1983, SPINAL CORD RECONSTR, P163; Reier P J, 1988, Adv Neurol, V47, P87; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; ROTSHENKER S, 1992, J NEUROIMMUNOL, V39, P75, DOI 10.1016/0165-5728(92)90176-L; SCHINDLER R, 1990, BLOOD, V75, P40; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Turek JJ, 1996, J NUTR, V126, P1541, DOI 10.1093/jn/126.6.1541; Turek JJ, 1998, J NUTR BIOCHEM, V9, P258, DOI 10.1016/S0955-2863(98)00014-X; TUREK JJ, 1991, PROSTAG LEUKOTR ESS, V43, P141, DOI 10.1016/0952-3278(91)90161-W; WAHL LM, 1991, CURRENT PROTOCOLS IM; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YOUNG W, 1995, CONT MANAGEMENT SPIN, P27	75	96	100	0	11	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	JUN	2000	203	12					1783	1795					13	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	329ZR	WOS:000087938800002	10821736				2022-02-06	
J	Schumacher, PA; Siman, RG; Fehlings, MG				Schumacher, PA; Siman, RG; Fehlings, MG			Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury	JOURNAL OF NEUROCHEMISTRY			English	Article						spinal cord injury; nerve tissue proteins; neurotrauma; calpain; neurofilament; treatment	BRAIN INJURY; NEURONAL APOPTOSIS; SECONDARY INJURY; ALPHA-SPECTRIN; IMPACT TRAUMA; BLOOD-FLOW; PROTEIN; MOTOR; RATS; PROTEOLYSIS	The pathophysiology of traumatic spinal cord injury (SCI) involves abnormal activation of the neutral cysteine protease calpain I (EC 3.4.22.17). In the present study we examined the effect of the calpain inhibitor CEP-4143 on cytoskeletal protection and neurological recovery after SCI in adult rats. Microinjection of 50 mM CEP-4143 into the T7 vertebral segment 10 min before a 35-g clip compression injury resulted in inhibition of calpain activation at 2 and 4 h postinjury, as determined by western blotting for calpain I-mediated spectrin degradation, and significantly attenuated the degradation of dephosphorylated NF200 neurofilament protein at 4 and 8 h postinjury. To examine the in vivo chronic neuroprotective effects of CEP-4143, animals underwent microinjection with saline or 50 mM CEP-4143 10 min before injury, followed by weekly blinded behavioral assessments for 6 weeks. Animals receiving CEP-4143 treatment showed significant improvement over saline-treated controls on the Basso Beattie Bresnahan locomotor rating scale (p < 0.02) and inclined plane test (p < 0.05). Counts of neurons in the red nucleus retrogradely labeled by fluorogold after introduction distal to the injury site were significantly higher in CEP-4143-treated animals. Finally, morphometric assessment of the injury site by computer-assisted image analysis revealed significant tissue preservation in CEP-4143-treated animals. We conclude that the calpain antagonist CEP-4143 exhibits biochemical, behavioral, and anatomical neuroprotection following traumatic SCI.	Toronto Western Hosp, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Cephalan, Dept Biochem, W Chester, PA USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA		Fehlings, MG (corresponding author), Toronto Western Hosp, Playfair Neurosci Unit, 399 Bathurst St,MCL 12-407, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Agrawal SK, 1996, J NEUROSCI, V16, P545; Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BALENTINE JD, 1984, J NEUROPATH EXP NEUR, V43, P500, DOI 10.1097/00005072-198409000-00005; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Barinaga M, 1996, SCIENCE, V274, P1466; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; ILDAN F, 1995, NEUROSURG REV, V18, P35, DOI 10.1007/BF00416476; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Rivlin A S, 1978, Surg Neurol, V10, P38; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WRATHALL JR, 1994, J NEUROSCI, V14, P6598	38	96	98	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	APR	2000	74	4					1646	1655		10.1046/j.1471-4159.2000.0741646.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	295DL	WOS:000085951400036	10737623				2022-02-06	
J	Ruchholtz, S				Ruchholtz, S		Arbeitsgemeinschaft Polytrauma Deu	The trauma registry of the German Society of Trauma Surgery as a basis for interclinical quality mangement. A multicenter study of the German Society of Trauma Surgery	UNFALLCHIRURG			German	Article						Trauma Registry of the German Society of; Trauma Surgery; interclinical quality management; severe trauma	INJURY SEVERITY SCORE; MULTIPLE INJURIES; CARE; IMPROVEMENT; SYSTEM; ERRORS; AUDIT; DIRECTIONS; MANAGEMENT; MORBIDITY	Based on the "Trauma Registry" of the German Society of Trauma Surgery, an interclinical quality management (QM) system was implemented. The principles of the QM system as well as the differences in the quality of outcome and treatment are presented. The analysis uses the data on 2,069 severely injured (ISS = 22 +/- 14) patients from 20 hospitals collected prospectively and anonymously between 2/93 and 12/97. Outcome quality was analyzed by the TRISS method and Z-statistics. The Z-value of the whole series was -0.24. There were three hospitals with more than 150 patients that had a Ps value calculated by the TRISS method. Clinic A had a good (-2.49), clinic B an average (-0.3) and clinic C (3.62) an adverse Z-value. The assessment of treatment quality was performed by criteria concerning both preclinical and acute clinical phases. Clinic C had a prolonged preclinical treatment time (90 min vs 62 min in clinic A) for severely injured (ISS > 15) patients. At the same time, the preclinical intubation rate for severe thoracic trauma (AIS > 3) was lower (44 %) in clinic C than in A (62 %). With 14 min clinic A had the shortest time until basic radiological and ultrasound diagnostics were completed (X-rays of chest and pelvis and abdominal ultrasound) in cases of severe blunt trauma (ISS > 15), compared to 54 min in clinic B or 31 min in clinic C. Also, cranial computed tomography for severe traumatic brain injury (GCS < 9) was applied significantly faster in clinic A (after 36 min) than in clinic C (after 62 min). Delayed diagnoses were defined as the difference between the ISS at discharge and the ISS at completion of diagnostics in the emergency department; this criterion was met best by cli nic A with an ISS difference of two patients compared to five in clinic B and four in clinic C. The hospitals participating in the Trauma Registry receive an annual analysis of their preclinical and acute clinical performance, Thus, every hospital can analyze and improve the quality of treatment based on reliable data that show which parts of the process have to be optimized. Furthermore, the data allow a com pa risen of the average and optimal results of the whole series.	Univ Essen Gesamthsch Klinikum, Abt Unfallchirurg, D-45122 Essen, Germany		Ruchholtz, S (corresponding author), Univ Essen Gesamthsch Klinikum, Abt Unfallchirurg, Hufelandstr 55, D-45122 Essen, Germany.						*AM COLL SURG COM, 1993, RES OPT CAR INJ PAT; *ARB POL DTSCH GES, 2000, IN PRESS UNFALLCHIRU; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARDENHEUE M, 1994, UNFALLCHIRURG, V97, P230; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHAMPION HR, 1988, ADV TRAUMA, V3, P241; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; COPES WS, 1995, J TRAUMA, V38, P432, DOI 10.1097/00005373-199503000-00027; DAVIS JW, 1992, J TRAUMA, V32, P660, DOI 10.1097/00005373-199205000-00020; DRAAISMA JMT, 1989, J TRAUMA, V29, P1552; Fallon WF, 1997, J TRAUMA, V42, P810, DOI 10.1097/00005373-199705000-00010; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; HOYT DB, 1994, J TRAUMA, V36, P377, DOI 10.1097/00005373-199403000-00017; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KREIS DJ, 1986, J TRAUMA, V26, P649, DOI 10.1097/00005373-198607000-00010; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; NASTKOLB D, 1992, UNFALLCHIRURG, V95, P59; OESTERN HJ, 1985, UNFALLCHIRURG, V88, P465; Petrie D, 1996, J TRAUMA, V41, P870, DOI 10.1097/00005373-199611000-00020; REGEL G, 1993, UNFALLCHIRURG, V96, P350; RUCHHOLTZ S, 1994, UNFALLCHIRURG, V97, P285; Ruchholtz S, 1997, UNFALLCHIRURG, V100, P859, DOI 10.1007/s001130050205; SCHMIDT U, 1992, J TRAUMA, V33, P548, DOI 10.1097/00005373-199210000-00010; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; TEASDALE G, 1974, LANCET, V2, P81; Trupka A, 1994, Eur J Emerg Med, V1, P1, DOI 10.1097/00063110-199403000-00002; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; YATES DW, 1994, INJURY, V25, P511, DOI 10.1016/0020-1383(94)90091-4	32	96	100	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0177-5537	1433-044X		UNFALLCHIRURG	Unfallchirurg	JAN	2000	103	1					30	37		10.1007/s001130050005			8	Emergency Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Surgery	285YW	WOS:000085416800005	10663103				2022-02-06	
J	Sabo, T; Lomnitski, L; Nyska, A; Beni, S; Maronpot, RR; Shohami, E; Roses, AD; Michaelson, DM				Sabo, T; Lomnitski, L; Nyska, A; Beni, S; Maronpot, RR; Shohami, E; Roses, AD; Michaelson, DM			Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities	NEUROSCIENCE			English	Article						Alzheimer's disease; animal models; apolipoprotein E3; apolipoprotein E4	E-DEFICIENT MICE; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; TYPE-4 ALLELE; BETA-PROTEIN; BRAIN INJURY; AMYLOID-BETA; E GENOTYPE; APOE; NEURONS	Apolipoprotein E, the major brain lipid-binding protein, is expressed in humans as three common isoforms (E2, E3 and E4). Previous studies revealed that the allele apolipoprotein E4 is a major genetic risk factor of Alzheimer's disease and that traumatic brain injury is associated with increased risk for developing this disease. Furthermore, it has been suggested that the effects of traumatic head injury and apolipoprotein E4 in Alzheimer's disease are synergistic. To test the hypothesis that the apolipoprotein E genotype affects susceptibility to brain injury, we subjected transgenic mice, expressing either human apolipoprotein E3 or human apolipoprotein E4 on a null mouse apolipoprotein E background and apolipoprotein E-deficient knockouts, to closed head injury and compared mortality, neurological recovery and the extent of brain damage of the survivors. More than 50% of the transgenic mice expressing human apolipoprotein E4 died following closed head injury, whereas only half as many of the transgenic mice expressing human apolipoprotein E3, and of the control and apolipoprotein E-deficient mice died during this period (P < 0.02). A neurological severity score used for clinical assessment of the surviving mice up to 11 days after closed head injury revealed that the four mouse groups displayed similar severity of damage at 1 h following injury. At three and 11 days post-injury, however, the neurological severity scores of the transgenic mice expressing human apolipoprotein E3 were significantly lower than those of the other three groups whose scores were similar, indicating better recovery of the transgenic mice expressing human apolipoprotein E3. Histopathological examination of the mice performed 11 days post-injury revealed, consistent with the above neurological results, that the size of the damaged brain area of the transgenic mice expressing human apolipoprotein E3 was smaller than that of the other head-injured groups. These findings show that transgenic mice expressing human apolipoprotein E4 are more susceptible than those expressing apolipoprotein E3 to closed head injury. We suggest that this effect is due to both a protective effect of apolipoprotein E3 and an apolipoprotein E4-related pathological function. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; NIEHS, Res Triangle Pk, NC 27709 USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Glaxo Wellcome Inc, Div Res, Res Triangle Pk, NC 27709 USA; Israel Inst Biol Res, IL-70450 Ness Ziona, Israel		Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.						Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Buttini M, 1999, J NEUROSCI, V19, P4867; Chapman J, 1999, ARCH NEUROL-CHICAGO, V56, P1484, DOI 10.1001/archneur.56.12.1484; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FRENCH LR, 1991, J EPIDEMIOL, V121, P414; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; LOMNITSKI L, 2000, IN PRESS EXPL TOXIC; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Metzger RE, 1996, J NEUROPATH EXP NEUR, V55, P372, DOI 10.1097/00005072-199603000-00013; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; PROPHET EB, 1994, LAB METHODS HISTOTEC, P56; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Seliger Glenn, 1997, Neurology, V48, pA213; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 2000, IN PRESS J MOL MED; SHOOTER AJC, 1997, JAMA-J AM MED ASSOC, V277, P818; Sorbi S., 1996, Neurology, V46, pA307; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Sun YL, 1998, J NEUROSCI, V18, P3261; Veinbergs I, 1998, NEUROSCI LETT, V249, P71, DOI 10.1016/S0304-3940(98)00399-1; Veinbergs I, 1999, NEUROSCI LETT, V265, P218, DOI 10.1016/S0304-3940(99)00243-8; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	54	96	96	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	101	4					879	884		10.1016/S0306-4522(00)00438-3			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	385BZ	WOS:000165982900008	11113336				2022-02-06	
J	Schneider, WN; Drew-Cates, J; Wong, TM; Dombovy, ML				Schneider, WN; Drew-Cates, J; Wong, TM; Dombovy, ML			Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study	BRAIN INJURY			English	Article							HEAD-INJURY; RECOVERY; SCALE	The objective of the current study was to determine the efficacy of amantadine in improving cognitive and behavioural performance in a traumatic brain injury (TBI) rehabilitation sample. The design was a prospective, randomized, double-blind, placebo-controlled, crossover design. Subjects were 10 adult traumatic brain injury patients in an acute brain injury rehabilitation unit. Subjects received a 2-week trail of amantadine or placebo, followed by a 2-week washout, then a 2-week trail of the alternative (placebo or amantadine). Neuropsychological outcome measures included orientation, attention, executive function, memory, orientation, behaviour, and a composite variable. Results of reheated measurer ANOVA and regression analysis of slope/change showed a main effect of rime, but no significant difference for amantadine versus placebo. In conclusion, although patients generally improved, this initial exploratory study found no differences in rate of cognitive improvement between subjects given amantadine versus those given placebo. However, the small sample size, heterogeneous population, acute time course, and large number of dependent variables limit power and generalizability. Implications are discussed for further research to better answer questions regarding efficacy of amantadine post-TBI.	St Marys Hosp, Unity Hlth Syst, Dept Phys Med & Rehabil, Rochester, NY 14611 USA; Univ Rochester, Dept Phys Med & Rehabil, Rochester, NY USA		Schneider, WN (corresponding author), St Marys Hosp, Unity Hlth Syst, Dept Phys Med & Rehabil, Rochester, NY 14611 USA.	wschneider@unityhealth.org					ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; ATKINSON WL, 1986, ARCH INTERN MED, V146, P1751, DOI 10.1001/archinte.146.9.1751; Benton AL, 1974, REVISED VISUAL RETEN; Bradley PB, 1989, INTRO NEUROPHARMACOL; Chandler M C, 1988, Brain Inj, V2, P309; CORRIGAN JD, 1995, NEUROREHABILITATION, V5, P205, DOI 10.3233/NRE-1995-5303; Diller L, 1974, REHABILITATION MONOG, V50; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; GAULTIERI CT, 1991, NEUROPSYCHIATRY BEHA, P40; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Graham D. I., 1987, HEAD INJURY, P72; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Kaplan E, 1983, BOSTON NAMING TEST; Kasamatusu T, 1981, J NEUROPHYSIOL, V45, P139; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; *MED EC CO, 1999, PHYS DESK REF, P986; *MMWR, 1987, JAMA-J AM MED ASSOC, V258, P599; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; *PURD RES FDN, 1948, EX MAN PURD PEGB; Reitan RM, 1985, HALSTEADREITAN NEURO; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VECT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792; Wechsler D, 1987, MEMORY SCALE REVISED; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Zafonte RD, 1998, BRAIN INJURY, V12, P617; ZASLER N D, 1992, Brain Injury, V6, P1, DOI 10.3109/02699059209008117	33	96	102	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	1999	13	11					863	872					10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253FZ	WOS:000083547000003	10579658				2022-02-06	
J	Hillered, L; Persson, L				Hillered, L; Persson, L			Neurochemical monitoring of the acutely injured human brain	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article; Proceedings Paper	XXVI Nordic Congress in Clinical Chemistry	JUN, 1998	TURKU, FINLAND			cerebral ischemia; free radicals; glutamate; glycerol; human microdialysis; hypoxanthine; lactate; microdialysis; neurointensive care; traumatic brain injury	IN-VIVO MICRODIALYSIS; CEREBRAL-ARTERY OCCLUSION; EXTRACELLULAR AMINO-ACIDS; ISCHEMIC HUMAN BRAIN; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; SUBSTRATE DELIVERY; INTENSIVE-CARE; HEAD TRAUMA; URIC-ACID	The main goal of modern neurointensive care (NIC) of patients with acute brain injury (traumatic brain injury, neurovascular disease) is to prevent additional loss of viable brain tissue due to secondary injury processes. It is generally held that secondary injury, mediated by, for example, cerebral hypoxia/ischemia and destructive molecular cascades on the cellular level, contributes significantly to the extent of brain damage after head injury and stroke. The basic concept is that improved knowledge of the secondary injury processes will lead to new therapeutic approaches in NIC. New methods by which secondary injury processes can be detected and monitored in NIC patients are therefore greatly needed. This paper describes intracerebral microdialysis as a novel approach to neurochemical monitoring of the human brain. The main objectives are (i) to monitor cortical energy metabolism in order to detect secondary ischemia and (ii) to monitor secondary injury processes, such as glutamate receptor overactivation and increased free radical production, in MC patients.	Univ Uppsala Hosp, Dept Med Sci, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden		Hillered, L (corresponding author), Univ Uppsala Hosp, Dept Med Sci, S-75185 Uppsala, Sweden.						AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Bachli H, 1996, NEUROL RES, V18, P370; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; DURING MJ, 1994, J NEUROCHEM, V62, P2356; DURING MJ, 1993, LANCET, V341, P1607; DURING MJ, 1992, ANN NEUROL, V32, P618, DOI 10.1002/ana.410320504; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; HAMBERGER A, 1991, EPILEPSY RES, V9, P32, DOI 10.1016/0920-1211(91)90044-G; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; HILLERED L, 1995, NEUROREPORT, V6, P1816, DOI 10.1097/00001756-199509000-00026; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HILLERED L, 1988, NEUROSCI LETT, V95, P286, DOI 10.1016/0304-3940(88)90672-6; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; KANTHAN R, 1995, J NEUROSCI METH, V60, P151, DOI 10.1016/0165-0270(95)00006-G; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; Kanthan R, 1996, NEUROCHEM RES, V21, P563, DOI 10.1007/BF02527754; Kanthan R, 1996, NEUROSCI LETT, V209, P207, DOI 10.1016/0304-3940(96)12642-2; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; KAUR H, 1990, CHEM-BIOL INTERACT, V73, P235, DOI 10.1016/0009-2797(90)90006-9; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LONNROTH P, 1987, AM J PHYSIOL, pE253; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Mendelowitsch A, 1998, NEUROL RES, V20, P142; Mendelowitsch A, 1998, J NEUROL NEUROSUR PS, V64, P611, DOI 10.1136/jnnp.64.5.611; Mendelowitsch A, 1997, NEUROL RES, V19, P66; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Persson L, 1996, J NEUROSURG, V85, P984; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robinson T. E., 1991, MICRODIALYSIS NEUROS; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; RONQUIST G, 1992, ACTA NEUROCHIR, V114, P8, DOI 10.1007/BF01401106; Runnerstam M, 1997, NEUROL RES, V19, P361, DOI 10.1080/01616412.1997.11740826; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; SCHEYER RD, 1994, NEUROLOGY, V44, P1469, DOI 10.1212/WNL.44.8.1469; SCHEYER RD, 1994, EPILEPSY RES, V18, P227, DOI 10.1016/0920-1211(94)90043-4; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	57	96	97	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0036-5513	1502-7686		SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.		1999	59			229			9	18		10.1080/00365519950185904			10	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Research & Experimental Medicine	174JY	WOS:000079032500003	10097285				2022-02-06	
J	Dixon, CE; Markgraf, CG; Angileri, F; Pike, BR; Wolfson, B; Newcomb, JK; Bismar, MM; Blanco, AJ; Clifton, GL; Hayes, RL				Dixon, CE; Markgraf, CG; Angileri, F; Pike, BR; Wolfson, B; Newcomb, JK; Bismar, MM; Blanco, AJ; Clifton, GL; Hayes, RL			Protective effects of moderate hypothermia on behavioral deficits but not necrotic cavitation following cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; traumatic brain injury; behavior; Morris water maze; rat	TRAUMATIC BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; HIPPOCAMPAL-LESIONS; DAMAGE; MEMORY; IMPAIRMENT; GLUTAMATE; MODEL; MOTOR	A number of experimental studies have reported that moderate hypothermia can produce significant protection against behavioral deficits and/or morphopathological alterations following traumatic brain injury; a Phase 3 clinical trial is currently examining the therapeutic potential for moderate hypothermia (32 degrees C) to improve outcome following severe traumatic brain injury in humans. The current study examined whether hypothermia (32 degrees C) provided behavioral protection following experimental cortical impact injury. The extent of focal cortical contusion was also examined in the same rats. A total of 30 male Sprague-Dawley rats were trained on beam balance and beam walking tasks prior to injury. Under isoflurane anesthesia, cortical impact was produced on the right parietal cortex of 20 rats. Ten rats underwent all surgical procedures but were not impacted (sham-injured rats). Ten of the injured rats were cooled to 32 degrees C (measured in temporalis muscle) beginning 5 min postinjury, maintained for 2 h and rewarmed slowly for 1 h. In the other 10 injured rats, normothermic temperatures (37.5 degrees C) were maintained for the same duration. Beam balance and beam walking performance was assessed daily for 5 days following injury. At 11 days postinjury, rats were assessed for 5 days on acquisition of the Morris water maze task. Following behavioral assessments, rats were perfused and the brain removed. Coronal sections were cut through the site of cortical impact injury and stained with hematoxylin and eosin. Hypothermic treatment resulted in significantly less beam balance and beam walking deficits than observed in normothermic rats. Hypothermia also significantly attenuated spatial memory performance deficits. Quantitative morphometric analyses failed to detect any significant differences in volumes of necrotic tissue cavitation in cortices of hypothermic and normothermic rats. Hypothermic treatment also had no effect on volumes of dorsal hippocampal tissue or numbers of cells in CA1 or CA3 regions of the hippocampus. These data suggest that hypothermia, consistent with the reports of others, can produce significant behavioral protection following cortical impact injury that is not necessarily correlated with changes in focal cortical necrosis within the first 15 days following injury.	Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Univ Pittsburgh, Div Neurosurg, Pittsburgh, PA 15260 USA		Hayes, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.		Angileri, Filippo Flavio/J-3533-2012; Angileri, Filippo/AAL-4851-2021; Angileri, Filippo/N-8556-2019	Angileri, Filippo Flavio/0000-0002-1107-4115; Angileri, Filippo/0000-0002-1107-4115			BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1996, NEUROTRAUMA; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, P SOC NEUR ANN M SOC, V21, P762; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENNARELLI TA, 1990, ENHANCEMENT AXONAL D; GENNARELLI TA, 1992, J NEUROTRAUM, V9, P60; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MEANEY DF, 1992, J NEUROTRAUMA, V9, P393; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MOSER E, 1993, J NEUROSCI, V13, P3916; Nakamura Michio, 1995, Brain and Nerve (Tokyo), V47, P484; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101	45	96	100	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1998	15	2					95	103		10.1089/neu.1998.15.95			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	YZ744	WOS:000072287300001	9512085				2022-02-06	
J	Newcomb, JK; Kampfl, A; Posmantur, RM; Zhao, XR; Pike, BR; Liu, SJ; Clifton, GL; Hayes, RL				Newcomb, JK; Kampfl, A; Posmantur, RM; Zhao, XR; Pike, BR; Liu, SJ; Clifton, GL; Hayes, RL			Immunohistochemical study of calpain-mediated breakdown products to alpha-spectrin following controlled cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						calpain; alpha-spectrin; traumatic brain injury; cytoskeleton; immunohistochemistry	MICROTUBULE-ASSOCIATED PROTEIN-2; TRAUMATIC BRAIN INJURY; TRANSIENT FOREBRAIN ISCHEMIA; CALCIUM-ACTIVATED PROTEASE; MIDDLE CEREBRAL-ARTERY; SPINAL-CORD INJURY; NEUROFILAMENT PROTEINS; GERBIL HIPPOCAMPUS; FODRIN PROTEOLYSIS; NEURONAL DAMAGE	This study examined the effect of unilateral controlled cortical impact on the appearance of calpain-mediated alpha-spectrin breakdown products (BDPs) in the rat cortex and hippocampus at various times following injury. Coronal sections were taken from animals at 15 min, 1 h, 3 h, 6 h, and 24 h after injury and immunolabeled with an antibody that recognizes calpain-mediated BDPs to alpha-spectrin (Roberts-Lewis et al., 1994). Sections from a separate group of rats were also taken at the same times and stained with hematoxylin and eosin. Analyses of early time points (15 min, 1 h, 3 h, and 6 h following injury) revealed alpha-spectrin BDPs in structurally intact neuronal soma and dendrites in cortex ipsilateral to site of injury that was not present in tissue from sham-injured control rats. By 24 h after injury labeling was not restricted to clearly defined neuronal structures in ipsilateral cortex, although there was an increased extent of diffuse labeling. BDPs to alpha-spectrin in axons were not detected until 24 h after injury, in contrast to the more rapid accumulation of BDPs observed in neuronal soma and dendrites. The presence of BDPs to alpha-spectrin in the cortex at the site of impact, and in the rostral and contralateral cortex, coincided with morphopathology detected by hematoxylin and eosin. alpha-Spectrin BDPs were also observed in the hippocampus ipsilateral to the injury in the absence of overt cell death. This investigation provides further evidence that calpain is activated after controlled cortical impact and could contribute to necrosis at the site of injury. The appearance of calpain-mediated BDPs at sites distal to the contusion site and in the hippocampus also suggests that calpain activation may precede and/or occur in the absence of extensive morphopathological changes.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,VIVIAN L SMITH CTR NEUROL RES,HOUSTON,TX 77030						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5PO1NS31998, R01NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		BANIK NL, 1987, METAB BRAIN DIS, V2, P117, DOI 10.1007/BF00999722; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BLOMGREN K, 1995, BRAIN RES, V684, P136, DOI 10.1016/0006-8993(95)00398-A; BONNEKOH P, 1990, ACTA NEUROPATHOL, V80, P18, DOI 10.1007/BF00294217; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P56; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DHERMY D, 1991, BIOL CELL, V71, P249; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GUROFF G, 1964, J BIOL CHEM, V239, P149; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KAMPFL A, 1997, IN PRESS J NEUROTRAU; KARST H, 1993, NEUROSCI LETT, V164, P154, DOI 10.1016/0304-3940(93)90880-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kleese W.C., 1990, INTRACELLULAR CALCIU, P3; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; Neumar RW, 1996, J NEUROCHEM, V66, P421; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; NILSSON P, 1993, J CEREB BLOOD FLOW M, V13, P185; NIXON RA, 1990, J NEUROCHEM, V55, P1950, DOI 10.1111/j.1471-4159.1990.tb05781.x; NIXON RA, 1986, J NEUROSCI, V6, P1264; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POSMANTUR R, 1994, J NEUROTRAUM, V533, P11; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POSMANTUR RM, 1997, IN PRESS NEUROSCIENC; POVLISHOCK JT, 1996, IN PRESS J NEUROPATH; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; SHAPIRA Y, 1989, Neurological Research, V11, P169; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WHITSON JS, 1995, BRAIN RES, V694, P213, DOI 10.1016/0006-8993(95)00745-C; WHITSON JS, 1995, NEUROSCI LETT, V197, P159, DOI 10.1016/0304-3940(95)11921-I; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Zhao X., 1996, Society for Neuroscience Abstracts, V22, P1903; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	82	96	99	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1997	14	6					369	383		10.1089/neu.1997.14.369			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	XJ836	WOS:A1997XJ83600002	9219852				2022-02-06	
J	Lewis, SB; Myburgh, JA; Thornton, EL; Reilly, PL				Lewis, SB; Myburgh, JA; Thornton, EL; Reilly, PL			Cerebral oxygenation monitoring by near-infrared spectroscopy is not clinically useful in patients with severe closed-head injury: A comparison with jugular venous bulb oximetry	CRITICAL CARE MEDICINE			English	Article						cerebral oxygenation; near-infrared spectroscopy; head injury; oxygen saturation; neurologic emergencies; brain injury; critical illness	ACUTE BRAIN INJURY; NEWBORN-INFANTS; SATURATION; TIME; DESATURATION; HEMODYNAMICS; CIRCULATION	Objective: To compare continuous jugular venous bulb oximetry and cerebral near-infrared spectroscopy in patients with severe closed head injury. Design: A prospective observational study. Setting: Intensive care unit of a major teaching hospital. Patients: Adults (n = 10) with severe closed-head injury (Glasgow Coma Scale score of less than or equal to 8). Interventions: None. Measurements and Main Results: Jugular venous bulb oximetry, cerebral near-infrared spectroscopy, and cerebral perfusion pressure were measured continuously, A total of 3,691 paired measurements of near infrared spectroscopy and jugular venous bulb oximetry were analysed, Poor correlation (r(2) =.04) between paired measurements and wide limits of agreement (-13% to +21%) were demonstrated. The mean difference between measurements was +/-4% and the standard deviation of the mean difference was +/-8.69%. The data were subsequently grouped according to three clinically significant subgroups of jugular venous bulb oxygen saturation reflecting low (<55%), normal (55% to 75%) and high (>75%) saturation values, Poor correlation and wide limits of agreement between the two methods of measurement were observed in all groups, Values recorded by near-infrared spectroscopy did not significantly change between the groups, and 14 clinically significant episodes of jugular venous bulb desaturation were not detected by near-infrared spectroscopy. Conclusions: Tissue oxygen saturation determined by near-infrared spectroscopy does not reflect significant changes in cerebral oxygenation detected by the global measurement of jugular venous bulb oximetry, This finding may be explained by inadequate signal detection and inaccuracies in the algorithm used to filter out extracranial components. Until these technical difficulties are addressed, near infrared spectroscopy, as measured by the machine assessed in this study, cannot be routinely recommended for assessment of cerebral oxygenation in patients with acute head injury.	ROYAL ADELAIDE HOSP,DEPT INTENS CARE,ADELAIDE,SA 5000,AUSTRALIA		Lewis, SB (corresponding author), ROYAL ADELAIDE HOSP,DEPT NEUROSURG,N TERR,ADELAIDE,SA 5000,AUSTRALIA.			Reilly, Peter/0000-0003-3173-0666			ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; Araki R, 1989, Adv Exp Med Biol, V248, P3; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CHANCE B, 1989, CRIT CARE MED, V17, P465, DOI 10.1097/00003246-198905000-00018; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DUJOVNY M, 1994, NEUROSURGERY, V34, P935; EDWARDS AD, 1988, LANCET, V2, P770; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOPINATH SP, 1994, NEUROSURGERY, V35, P796, DOI 10.1097/00006123-199410000-00043; HAZEKI O, 1988, J APPL PHYSIOL, V64, P799; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KURTH CD, 1993, J CLIN MONITOR, V9, P163, DOI 10.1007/BF01617023; LEWIS SB, 1995, ANAESTH INTENS CARE, V23, P307, DOI 10.1177/0310057X9502300307; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; PROUGH DS, 1995, CRIT CARE MED, V23, P1624, DOI 10.1097/00003246-199510000-00004; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SMITH DS, 1990, ANESTHESIOLOGY, V73, P12, DOI 10.1097/00000542-199007000-00003; TATEISHI A, 1995, CRIT CARE MED, V23, P1734, DOI 10.1097/00003246-199510000-00019; WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8	28	96	97	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	AUG	1996	24	8					1334	1338		10.1097/00003246-199608000-00011			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB502	WOS:A1996VB50200011	8706488				2022-02-06	
J	DASH, PK; MOORE, AN; DIXON, CE				DASH, PK; MOORE, AN; DIXON, CE			SPATIAL MEMORY DEFICITS, INCREASED PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR CREB, AND INDUCTION OF THE AP-1 COMPLEX FOLLOWING EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROSCIENCE			English	Article						CORTICAL IMPACT; SPATIAL MEMORY DEFICIT; HIPPOCAMPUS; TRANSCRIPTION FACTORS; CREB; AP-1; C-FOS	LONG-TERM POTENTIATION; CAMP RESPONSE ELEMENT; CONTROLLED CORTICAL IMPACT; II MUTANT MICE; C-FOS; NERVOUS-SYSTEM; CYCLIC-AMP; SUPRACHIASMATIC NUCLEUS; SOMATOSTATIN GENE; BINDING PROTEIN	Traumatic brain injury causes both short- and long-term neurological impairments. A cascade of biochemical changes triggered by the injury may increase the expression of several genes, which has been hypothesized to contribute to the observed cognitive deficits. The mechanism(s) of induction for these genes is not yet known. We present evidence that lateral cortical impact injury in rats that produces spatial memory deficits also increases phosphorylation of the transcription factor CREB (cAMP response element binding). Subsequent to the phosphorylation of CREB, c-Fos expression and the AP-1 complex are enhanced. The temporal and spatial activation of c-Fos is consistent with it being induced by phosphorylated CREB proteins. Thus, CREB-mediated gene activation may contribute to the observed behavioral deficits. Further elucidation of the biochemical and pathophysiological changes will be of importance for clinical therapy.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77225		DASH, PK (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,POB 20708,HOUSTON,TX 77225, USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49 CCR606659] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49962] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31998] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998] Funding Source: NIH RePORTER		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DASH PK, 1993, CELL MOL BIOL, V39, P35; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOUCET JP, 1990, MOL NEUROBIOL, V4, P27, DOI 10.1007/BF02935584; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, NATURE, V322, P519; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HAYES RL, 1992, J NEUROTRAUM, V1, pS173; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; KIM KS, 1993, J BIOL CHEM, V268, P15689; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MALEEVA NE, 1989, GENETIKA+, V25, P1119; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NIKOLAEV E, 1992, BRAIN RES B, V128, P479; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SASSONECORSI P, 1988, NATURE, V336, P646; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	96	98	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	MAR	1995	15	3	1				2030	2039		10.1523/JNEUROSCI.15-03-02030.1995			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	QM467	WOS:A1995QM46700032	7891150	Bronze, Green Published			2022-02-06	
J	RUBIN, AM; WOOLLEY, SM; DAILEY, VM; GOEBEL, JA				RUBIN, AM; WOOLLEY, SM; DAILEY, VM; GOEBEL, JA			POSTURAL STABILITY FOLLOWING MILD HEAD OR WHIPLASH INJURIES	AMERICAN JOURNAL OF OTOLOGY			English	Article							BRAIN INJURY; BALANCE; DEFICITS	Studies of the sequelae of head injury suggest that cochlear and vestibular dysfunctions comprise some of the most frequently reported delayed complications following head trauma. To date, little attention has been given to the relation between post-traumatic subjective symptoms of dizziness and the objective measures of postural stability or balance. The purpose of this study was to quantify the balance deficits in individuals who had developed symptoms of dizziness following mild head and whiplash injuries. The balance abilities of 29 patients, who developed dizziness following some type of mild head or whiplash injury, were compared to those of 51 healthy symptom-free subjects. Balance was assessed by examining the center-of-pressure movements, in the anterior-posterior and medial-lateral directions, and the total movement displacement. The isolated contributions of visual and somatosensory inputs were estimated by comparing the magnitudes of the center-of-pressure movements for the various sensory conditions. Data were collected from three 30-second trials of each combination of three visual conditions (accurate, absent, and inaccurate) and two somatosensory conditions (accurate and inaccurate), with the patient standing on a fixed-force platform. Univariate analyses of variance indicated that the group with head injury, compared to the control group, exhibited significantly greater anterior-posterior movements in four of the six sensory conditions and greater total movement displacement during the inaccurate vision/inaccurate somatosensation condition. These data suggest that patients who have sustained head or neck trauma exhibit increased reliance on accurate visual input and are unable to utilize internal vestibular orienting information to resolve conflicting information from the visual and somatosensory systems.	MED COLL OHIO,DEPT OTOLARYNGOL HEAD & NECK SURG,TOLEDO,OH 43699; MED COLL OHIO,DEPT PHYS MED & REHABIL,MOT ANAL LAB,TOLEDO,OH 43699; WASHINGTON UNIV,SCH MED,DEPT OTOLARYNGOL,ST LOUIS,MO 63110								BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROWN JJ, 1990, NEUROL CLIN, V8, P209, DOI 10.1016/S0733-8619(18)30351-7; CAVENESS WF, 1979, ADV NEUROL, P1; Droulez J., 1985, VESTIBULAR VISUAL CO, P14; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; HOUGH JVD, 1980, OTOLARYNGOLOGY, P1956; KIRTANE MV, 1982, J LARYNGOL OTOL, V96, P521, DOI 10.1017/S0022215100092793; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1987, HEAD INJURY, V2, P1; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1989, P AM PHYS THER ASS F, P5; NEWTON RA, 1990, P APTAFORUM NASHVILL, P69; PEARSON BW, 1973, ARCH OTOLARYNGOL, V97, P81; RUBIN W, 1973, ARCH OTOLARYNGOL, V97, P85; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; WARD PH, 1969, ANN OTO RHINOL LARYN, V78, P227, DOI 10.1177/000348946907800203; WILLSON GN, 1981, J LARYNGOL OTOL, V95, P1213, DOI 10.1017/S0022215100092057; WOOLLEY SM, 1993, J OTOLARYNGOL, V22, P368	25	96	98	0	5	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	MAR	1995	16	2					216	221					6	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	QK481	WOS:A1995QK48100016	8572122				2022-02-06	
J	DIXON, CE; HAMM, RJ; TAFT, WC; HAYES, RL				DIXON, CE; HAMM, RJ; TAFT, WC; HAYES, RL			INCREASED ANTICHOLINERGIC SENSITIVITY FOLLOWING CLOSED SKULL IMPACT AND CONTROLLED CORTICAL IMPACT TRAUMATIC BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; NORADRENERGIC DEPLETION; MAZE PERFORMANCE; SCOPOLAMINE; DEFICITS; MEMORY; DISRUPTION; MODEL	Evidence suggests that prolonged memory deficits in several neurodegenerative diseases are attributable to deficits in central cholinergic neurotransmission. In traumatic brain injury (TBI), such cholinergic deficits also may contribute to prolonged memory disturbances. This study determined whether moderate magnitudes of TBI produced by controlled cortical impact and mild magnitudes of experimental TBI produced by a new closed head impact technique in rats would produce an enhanced vulnerability to the memory disruptive effects of scopolamine, a muscarinic cholinergic receptor antagonist. Water maze performance was used to determine changes in cholinergic hippocampal function following TBI. In the first experiment, rats received a moderate level of TBI by means of a controlled cortical impact. A Morris water maze task assessed spatial memory function on days 30-34 postinjury. During the 5 day assessment period, statistical analyses showed a group main effect for swim latency. Subsequent post hoc analyses indicated that injured rats had significantly longer latencies on days 30 and 31 (p < 0.05, injury vs sham controls). By days 32-35, injured rats showed no statistically significant deficits in spatial memory performance. On day 35, scopolamine (1 mg/kg, IP) was injected into injured rats and sham-injured rats 15 min prior to being retested in the maze. Results showed that although the scopolamine had no effects on the performance of the sham-injured rats, the same dose significantly (p < 0.05) increased the latency to find the hidden platform in the injured group. In the second experiment, rats received a mild concussive closed head impact. Water maze performance was assessed on days 8-12 postinjury. No significant water maze performance deficits were observed. On day 13, injured and uninjured rats were pharmacologically challenged with scopolamine (1 mg/kg) and retested. Similar to the first experiment, injured rats manifested a significantly greater (p < 0.05) sensitivity to scopolamine than sham controls. The results from both experiments suggest that concussive and more severe levels of TBI can produce an enhanced vulnerability to disruption of cholinergically mediated memory function, even when memory function appears normal in the absence of secondary challenges. These data demonstrate that covert deficits can persist after the recovery of normal function. These deficits may be attributable to a decrease in the ability of cholinergic neurons to function properly. These data also provide important insights into features of receptor-coupled disturbances that could contribute to the maintenance of enduring cognitive deficits following TBI.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284		DIXON, CE (corresponding author), UNIV TEXAS,HLTH SCI CTR,DIV NEUROSURG,6431 FANNIN ST,SUITE 7147,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B80029, R49-CCR303547] Funding Source: Medline		BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349, DOI 10.1152/jn.1946.9.5.349; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; Deangelis M. M., 1992, Society for Neuroscience Abstracts, V18, P172; DECKER MW, 1987, BRAIN RES, V417, P59, DOI 10.1016/0006-8993(87)90179-X; DELAHUNTY TM, 1992, J NEUROTRAUM, V9, P58; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; Dixon C. E., 1993, Society for Neuroscience Abstracts, V19, P1486; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUBOIS B, 1987, ANN NEUROL, V22, P26, DOI 10.1002/ana.410220108; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1989, MILD HEAD INJURY, P54; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hornykiewicz O, 1986, ADV NEUROLOGY, V45, P19; HUFF FJ, 1988, DRUG DEVELOP RES, V12, P271; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SPANGLER EL, 1990, BEHAV NEUROSCI, V104, P410, DOI 10.1037/0735-7044.104.3.410; SPENCER DG, 1983, DRUG DEVELOP RES, V3, P489, DOI 10.1002/ddr.430030602; SQUIRE LR, 1981, ANN REV PHARM TOXICO, V21, P325; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1985, PSYCHOPHARMACOLOGY, V87, P247, DOI 10.1007/BF00431817; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	57	96	96	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					275	287		10.1089/neu.1994.11.275			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100004	7996582				2022-02-06	
J	RIVARA, JB; FAY, GC; JAFFE, KM; POLISSAR, NL; SHURTLEFF, HA; MARTIN, KM				RIVARA, JB; FAY, GC; JAFFE, KM; POLISSAR, NL; SHURTLEFF, HA; MARTIN, KM			PREDICTORS OF FAMILY FUNCTIONING ONE YEAR FOLLOWING TRAUMATIC BRAIN INJURY IN CHILDREN	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						FAMILY; PEDIATRIC; TRAUMATIC BRAIN INJURY	GLOBAL ASSESSMENT SCALE; SEVERE HEAD-INJURY; HANDICAPPED-CHILDREN; DISABLED-CHILDREN; SPINA-BIFIDA; MOTHERS; RELATIVES; IMPACT; ADOLESCENTS; SEQUELAE	This study examined changes in family functioning and predictors of family outcome during the year following traumatic brain injury (TBI). The families of 94 children with TBI (mild = 50, moderate = 25, severe = 19), ages six to 15, were consecutively enrolled from two regional medical centers. Family interview ratings and standard measures of family and child functioning were completed three weeks after injury (measuring preinjury status), as well as three and 12 months. Two-thirds of families had moderate to good preinjury global functioning and coping resources, but more than half exhibited high levels of stress and at-risk family relationships. No significant preinjury differences by injury severity were seen on any measure. Whereas few changes in family functioning were observed over the year in the mild or moderate groups, greater deterioration occurred in the severe group. From one third to one half noted moderate to severe strain in 13 problem areas often seen in individuals with TBI. Preinjury family global functioning, however, was more strongly predictive of 12-month family functioning (R2 = .38 to.68) than was injury severity (R2 = .05 to .09). In four out of five outcome areas assessed at 12 months, preinjury status in each area was the strongest single predictor. Preinjury coping was the best predictor of stress. Families at risk can be identified and need ongoing support for optimal functioning.	UNIV WASHINGTON,SCH SOCIAL WORK,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA; CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA					Shurtleff, Hillary/0000-0003-0959-2842			ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; BEGLEITER ML, 1976, SOC BIOL, V23, P260, DOI 10.1080/19485565.1976.9988237; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; BRESLAU N, 1982, AM J DIS CHILD, V136, P682, DOI 10.1001/archpedi.1982.03970440026007; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAIRNS NU, 1979, J PEDIATR-US, V95, P484, DOI 10.1016/S0022-3476(79)80541-7; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CLARRIDGE BR, 1989, MED CARE, V27, P352, DOI 10.1097/00005650-198904000-00003; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; FRIEDRICH WN, 1979, J CONSULT CLIN PSYCH, V47, P1140, DOI 10.1037/0022-006X.47.6.1140; GATH A, 1980, ARCH DIS CHILD, V55, P371, DOI 10.1136/adc.55.5.371; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P54; KAY T, 1988, HEAD INJURY FAMILY I; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KOSKI M, 1975, MOD PROBL PAEDIATR, V12, P348; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; KUPST MJ, 1988, J PEDIATR PSYCHOL, V13, P7, DOI 10.1093/jpepsy/13.1.7; LANSKY SB, 1978, PEDIATRICS, V62, P184; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MARTIN DA, 1988, J LEARN DISABIL, V21, P464, DOI 10.1177/002221948802100803; MCCORMICK MC, 1986, DEV MED CHILD NEUROL, V28, P53; MCCUBBIN H, 1973, STRESS FAMILY, V1, P407; MCCUBBIN H, 1979, FAMILY STRESS COPING; McCubbin H.I., 1982, FAMILY STRESS COPING; MCCUBBIN HI, 1983, SOCIAL STRESS FAMILY; McCubbin HI, 1980, FAMILY ASSESSMENT RE; MCCUBBIN MA, 1989, FAM RELAT, V38, P436, DOI 10.2307/585750; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moos RH, 1974, SOCIAL CLIMATE SCALE; MRAZEK D, 1985, 32ND P ANN M AM ACAD; ODDEY M, 1980, J NEUROL NEUROSUR PS, V43, P798; PETERSEN P, 1984, J PSYCHOSOM RES, V28, P337, DOI 10.1016/0022-3999(84)90056-4; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SCHILLING RF, 1984, FAM RELAT, V33, P47, DOI 10.2307/584589; Seligman M, 1989, ORDINARY FAMILIES SP; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; SLATER EJ, 1987, PSYCHIAT ANN, V17, P786, DOI 10.3928/0048-5713-19871201-08; TAVORMINA JB, 1981, J ABNORM CHILD PSYCH, V9, P121, DOI 10.1007/BF00917862; TEW B, 1975, BRIT J PREV SOC MED, V29, P27; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	49	96	97	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1992	73	10					899	910					12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	JU061	WOS:A1992JU06100003	1417464				2022-02-06	
J	BRAUGHLER, JM; HALL, ED				BRAUGHLER, JM; HALL, ED			INVOLVEMENT OF LIPID-PEROXIDATION IN CNS INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CAT SPINAL-CORD; METHYLPREDNISOLONE SODIUM SUCCINATE; NERVOUS-SYSTEM TRAUMA; (NA+ + K+)-ATPASE; DIETARY VITAMIN-E; RAT-BRAIN; CHEMI-LUMINESCENCE; ENERGY-METABOLISM; CEREBRAL-ISCHEMIA; DOSE-RESPONSE	The generation of oxygen radicals and the process of lipid peroxidation have become a focus of attention for investigators in the fields of central nervous system (CNS) injury and stroke (e.g., ischemia). While absolute proof for their involvement in the pathophysiology of traumatic and ischemic damage to the CNS remains to be established, numerous recent studies have provided considerable support for the occurrence of free radical and lipid peroxidation reactions in the injured or ischemic CNS. Furthermore, the use of antioxidants and free radical scavengers in the treatment of experimental and clinical CNS trauma and ischemia has provided convincing support for the involvement of oxygen radicals and lipid peroxidation in these conditions. In this report we will review some of the history behind the hypothesis for an involvement of oxygen radical-mediated lipid peroxidation in the pathophysiology of CNS injury and look at some of the more recent work conducted in this area.			BRAUGHLER, JM (corresponding author), UPJOHN CO,AQUISIT REVIEW,7223-24-3,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; Anderson D.K., 1983, NEUROCHEM PATHOL, V1, P249; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1985, J NEUROSURG, V62, P806, DOI 10.3171/jns.1985.62.6.0806; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1983, J NEUROSURG, V58, P538; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; DEMOPOULOS HB, 1972, STEROIDS BRAIN EDEMA, P29; DEMOPOULOS HB, 1980, ACTA PHYSL SCAND S, V492, P91; DZHAFAROV A I, 1985, Byulleten' Eksperimental'noi Biologii i Meditsiny, V100, P433; FOLBERGROVA J, 1981, J NEUROCHEM, V36, P1670, DOI 10.1111/j.1471-4159.1981.tb00417.x; FRANCESCO V, 1985, STROKE, V16, P14, DOI 10.1161/01.STR.16.1.14; FUJIMOTO S, 1984, SURG NEUROL, V22, P449, DOI 10.1016/0090-3019(84)90301-X; GRAFF G, 1978, J BIOL CHEM, V253, P7662; Gutteridge J M, 1986, Free Radic Res Commun, V1, P173, DOI 10.3109/10715768609083149; Hall E., 1989, J CEREB BLOOD FLO S1, V19, pS561; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HORNING EC, 1978, TOCOPHEROL OXYGEN BI, P273; IMAIZUMI S, 1984, STROKE, V15, P1061, DOI 10.1161/01.STR.15.6.1061; KONAT GW, 1985, J NEUROCHEM, V45, P1113, DOI 10.1111/j.1471-4159.1985.tb05530.x; KRAMER K, 1986, FEBS LETT, V198, P80, DOI 10.1016/0014-5793(86)81188-7; KURIHARA M, 1985, J NEUROSURG, V62, P743, DOI 10.3171/jns.1985.62.5.0743; MCGINLEY PA, 1982, J CHROMATOGR, V230, P29, DOI 10.1016/S0378-4347(00)81427-9; MEANS ED, 1981, J NEUROSURG, V55, P100; MIKEL HS, 1987, STROKE, V18, P426; Murad F, 1979, Adv Cyclic Nucleotide Res, V11, P175; NATALE JE, 1988, STROKE, V19, P1371, DOI 10.1161/01.STR.19.11.1371; OLIVER CN, 1990, FASEB J, V4, P5520; PASCOE GA, 1989, FREE RADICAL BIO MED, V6, P209, DOI 10.1016/0891-5849(89)90118-4; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1072, DOI 10.1111/j.1471-4159.1983.tb09053.x; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SELIGMAN ML, 1979, PHOTOCHEM PHOTOBIOL, V29, P549, DOI 10.1111/j.1751-1097.1979.tb07089.x; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TAPPEL AL, 1973, FED PROC, V32, P1870; TRAVIS MA, 1987, BRAIN RES, V418, P366, DOI 10.1016/0006-8993(87)90105-3; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; WILLMORE LJ, 1982, BRAIN RES, V246, P113, DOI 10.1016/0006-8993(82)90147-0; YOSHIDA S, 1985, NEUROLOGY, V35, P126, DOI 10.1212/WNL.35.1.126; YOSHIDA S, 1982, BRAIN RES, V245, P307, DOI 10.1016/0006-8993(82)90813-7; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	54	96	97	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S1	S7					7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600002	1588600				2022-02-06	
J	HADDAD, FS; HADDAD, GF; TAHA, J				HADDAD, FS; HADDAD, GF; TAHA, J			TRAUMATIC INTRACRANIAL ANEURYSMS CAUSED BY MISSILES - THEIR PRESENTATION AND MANAGEMENT	NEUROSURGERY			English	Article						BRAIN INJURIES; CEREBRAL ANEURYSMS; CEREBRAL ANGIOGRAPHY; CEREBRAL HEMORRHAGE; SPASM; SUBDURAL HEMATOMA	WOUNDS; ARTERY; BRAIN	Only 30 cases of traumatic intracranial aneurysm (TICA) secondary to missile injury have been reported to date. To these we add 15 more cases. Missile TICAs are often seen on a secondary branch of the middle cerebral artery and are usually accompanied by a intracerebral hematoma (80%) or by an acute subdural hematoma (26%). Fourteen of our cases were secondary to sharpnel injuries and only one was secondary to a bullet. None of the injuries was through-and-through. TICAs may enlarge in time and, seemingly inoffensive, may rupture and lead to death. All seven TICAs studied histologically proved to be false aneurysms. TICAs are best treated through trapping and excision. The outcome depends on the patient's status and level of consciousness before surgery. Indications for angiography are discussed.	MONTREAL NEUROL HOSP & INST,3801 UNIV ST,MONTREAL H3A 2B4,QUEBEC,CANADA; AMER UNIV BEIRUT,MED CTR,DEPT NEUROSURG,BEIRUT,LEBANON								AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; COURVILLE C B, 1960, Bull Los Angel Neuro Soc, V25, P48; CROMPTON MR, 1966, BRIT MED J, V1, P1138, DOI 10.1136/bmj.1.5496.1138; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FIELDS WS, 1965, INTRACRANIAL ANEURYS; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V3, P1453; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P423; GUIBERT, 1895, ANN OCUL, V113, P314; HADDAD FS, 1978, CAN J SURG, V21, P233; HAMBI WB, 1952, INTRACRANIAL ANEURYS, P113; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; Jackson F E, 1970, J Trauma, V10, P1158, DOI 10.1097/00005373-197012000-00008; JACKSON FE, 1974, US NAVY MED, V63, P34; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; Martin E M, 1986, J Neurosci Nurs, V18, P89; MCDONALD EJ, 1976, AM J ROENTGENOL, V126, P792, DOI 10.2214/ajr.126.4.792; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; MOORE D, 1979, SURG NEUROL, V11, P115; PAKARINEN S, 1967, ACTA NEUROL SCAND  S, V29, P1; PETTY J M, 1969, Journal of Neurosurgery, V30, P741, DOI 10.3171/jns.1969.30.6.0741; POOL JL, 1965, ANEURYSMS ARTERIOVEN, P60; RAIMONDI AJ, 1960, NEUROCHIRURGIA STUTT, V11, P219; ROBBINS JB, 1976, LARYNGOSCOPE, V86, P893, DOI 10.1288/00005537-197607000-00001; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SALAR G, 1978, J NEUROSURG, V49, P100, DOI 10.3171/jns.1978.49.1.0100; SARWAR M, 1976, RADIOLOGY, V120, P603, DOI 10.1148/120.3.603; SCHMIDT-VANDERHEYDEN W, 1971, Archiv fuer Psychiatrie und Nervenkrankheiten, V214, P10, DOI 10.1007/BF00344623; SPETZLER RF, 1979, NEUROSURGERY, V4, P334, DOI 10.1227/00006123-197904000-00011	33	96	99	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JAN	1991	28	1					1	7					7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EP137	WOS:A1991EP13700001	1994264				2022-02-06	
J	RAO, N; JELLINEK, HM; WOOLSTON, DC				RAO, N; JELLINEK, HM; WOOLSTON, DC			AGITATION IN CLOSED HEAD-INJURY - HALOPERIDOL EFFECTS ON REHABILITATION OUTCOME	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									UNIV WISCONSIN,SCH MED,DEPT REHABIL MED,MADISON,WI 53792; UNIV WISCONSIN,DEPT GEN ENGN,MADISON,WI 53706								ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GRABOWSKI SW, 1973, DIS NERV SYST, V34, P315; HAGEN C, 1979, 3RD ANN POSTGR COURS; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; HORVATH TB, 1974, J NEUROL NEUROSUR PS, V37, P416, DOI 10.1136/jnnp.37.4.416; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; LEVANN LJ, 1971, AM J MENT DEF, V75, P719; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P172; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RAO N, 1984, ARCH PHYS MED REHAB, V65, P18; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; SCHNAPER N, 1976, AM J PSYCHIAT, V133, P883; SMITH GR, 1974, PSYCHOSOMATICS, V15, P134; SNYDER SH, 1972, ARCH GEN PSYCHIAT, V27, P169; UZZELL BP, 1979, CORTEX, V15, P391, DOI 10.1016/S0010-9452(79)80066-0; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218	25	96	96	1	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.		1985	66	1					30	34					5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	AAF50	WOS:A1985AAF5000009	3966865				2022-02-06	
J	Cooper, DJ; Nichol, AD; Bailey, M; Bernard, S; Cameron, PA; Pili-Floury, S; Forbes, A; Gantner, D; Higgins, AM; Huet, O; Kasza, J; Murray, L; Newby, L; Presneill, JJ; Rashford, S; Rosenfeld, JV; Stephenson, M; Vallance, S; Varma, D; Webb, SAR; Trapani, T; McArthur, C				Cooper, D. James; Nichol, Alistair D.; Bailey, Michael; Bernard, Stephen; Cameron, Peter A.; Pili-Floury, Sebastien; Forbes, Andrew; Gantner, Dashiell; Higgins, Alisa M.; Huet, Olivier; Kasza, Jessica; Murray, Lynne; Newby, Lynette; Presneill, Jeffrey J.; Rashford, Stephen; Rosenfeld, Jeffrey V.; Stephenson, Michael; Vallance, Shirley; Varma, Dinesh; Webb, Steven A. R.; Trapani, Tony; McArthur, Colin		POLAR Trial Investigators ANZICS	Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury The POLAR Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; MANAGEMENT; PATHOPHYSIOLOGY; RESUSCITATION; GUIDELINES; SALINE	IMPORTANCE After severe traumatic brain injury, induction of prophylactic hypothermia has been suggested to be neuroprotective and improve long-term neurologic outcomes. OBJECTIVE To determine the effectiveness of early prophylactic hypothermia compared with normothermic management of patients after severe traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury-Randomized Clinical Trial (POLAR-RCT) was a multicenter randomized trial in 6 countries that recruited 511 patients both out-of-hospital and in emergency departments after severe traumatic brain injury. The first patient was enrolled on December 5. 2010, and the last on November 10.2017. The final date of follow-up was May 15, 2018. INTERVENTIONS There were 266 patients randomized to the prophylactic hypothermia group and 245 to normothermic management. Prophylactic hypothermia targeted the early induction of hypothermia (33 degrees C-35 degrees C) for at least 72 hours and up to 7 days if intracranial pressures were elevated, followed by gradual rewarming. Normothermia targeted 37 degrees C, using surface-cooling wraps when required. Temperature was managed in both groups for 7 days. All other care was at the discretion of the treating physician. MAIN OUTCOMES AND MEASURES The primary outcome was favorable neurologic outcomes or independent living (Glasgow Outcome Scale-Extended score, 5-8 [scale range, 1-8]) obtained by blinded assessors 6 months after injury. RESULTS Among 511 patients who were randomized. 500 provided ongoing consent (mean age, 34.5 years [SD. 13.4); 402 men [80.2%]) and 466 completed the primary outcome evaluation. Hypothermia was initiated rapidly after injury (median, 1.8 hours [IQR, 1.0-2.7 hours]) and rewarming occurred slowly (median, 22.5 hours [IQR, 16-27 hours)). Favorable outcomes (Glasgow Outcome Scale-Extended score, 5-8) at 6 months occurred in 117 patients (48.8%) in the hypothermia group and 111(49.1%) in the normothermia group (risk difference, 0.4% [95% CI, -9.4% to 8.7%]; relative risk with hypothermia, 0.99 [95% CI, 0.82-1.19]; P = .94). In the hypothermia and normothermia groups, the rates of pneumonia were 55.0% vs 51.3%, respectively, and rates of increased intracranial bleeding were 18.1% vs 15.4%, respectively. CONCLUSIONS AND RELEVANCE Among patients with severe traumatic brain injury, early prophylactic hypothermia compared with normothermia did not improve neurologic outcomes at 6 months. These findings do not support the use of early prophylactic hypothermia for patients with severe traumatic brain injury.	[Cooper, D. James; Nichol, Alistair D.; Bailey, Michael; Gantner, Dashiell; Higgins, Alisa M.; Huet, Olivier; Murray, Lynne; Newby, Lynette; Presneill, Jeffrey J.; Stephenson, Michael; Vallance, Shirley; Webb, Steven A. R.; Trapani, Tony; McArthur, Colin] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cooper, D. James; Nichol, Alistair D.; Bernard, Stephen; Gantner, Dashiell; Vallance, Shirley; Trapani, Tony] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Nichol, Alistair D.] St Vincents Univ Hosp, Univ Coll Dublin, Clin Res Ctr, Irish Crit Care Clin Trials Network, Dublin, Ireland; [Nichol, Alistair D.] St Vincents Univ Hosp, Dept Anaesthesia & Intens Care Med, Dublin, Ireland; [Nichol, Alistair D.] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Bernard, Stephen; Stephenson, Michael] Ambulance Victoria, Melbourne, Vic, Australia; [Cameron, Peter A.; Forbes, Andrew; Kasza, Jessica] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Cameron, Peter A.; Gantner, Dashiell] Monash Univ, Ctr Excellence Traumat Brain Injury Res, Melbourne, Vic, Australia; [Cameron, Peter A.] Hamad Med Corp, Emergency Med, Dhueta, Qatar; [Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia; [Pili-Floury, Sebastien] CHU Besancon, Serv Reanimat Chirurg, Pole Anesthesie & Reanimat, Besancon, France; [Huet, Olivier] CHRU Brest, Hop La Cavale Blanche, Dept Anaesthesia & Intens Care Med, Brest, France; [Huet, Olivier] Univ Bretagne Occidenta, UFR Med & Sci Sante, Brest, France; [Newby, Lynette; McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Presneill, Jeffrey J.] Royal Melbourne Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Presneill, Jeffrey J.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Rashford, Stephen] Queensland Ambulance Serv, Brisbane, Qld, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Neurosurg, Melbourne, Vic, Australia; [Rashford, Stephen; Varma, Dinesh] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Varma, Dinesh] Alfred Hosp, Radiol, Melbourne, Vic, Australia; [Webb, Steven A. R.] Royal Perth Hosp, Intens Care Unit, Perth, WA, Australia		Cooper, DJ (corresponding author), Monash Univ, ANZIC Res Ctr, 553 St Kilda Rd,Level 3, Melbourne, Vic 3004, Australia.	jamie.cooper@monash.edu	Haenggi, Matthias/O-2642-2019; Higgins, Alisa/AAM-8088-2020; /AAB-3060-2019; Haenggi, Matthias/A-8073-2008; Cooper, D. James/G-7961-2013	Haenggi, Matthias/0000-0001-5845-031X; Higgins, Alisa/0000-0001-8295-7559; Haenggi, Matthias/0000-0001-5845-031X; Cooper, D. James/0000-0002-5872-9051; Forbes, Andrew/0000-0003-4269-914X; Alsolamy, Sami/0000-0002-0127-0307; Nichol, Alistair/0000-0002-4689-1238	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [545901, 1121037]; Victorian Neurotrauma Initiative (VNI) [VNI D162]; Teaching Hospital of Besancon, France; Health Research Board of Ireland Clinical Trial Network Program	This trial was supported by grants from the National Health and Medical Research Council of Australia (545901 and 1121037); the Victorian Neurotrauma Initiative (VNI for the Transport Accident Commission, Victoria, Australia) (VNI D162); the Teaching Hospital of Besancon, France; and Health Research Board of Ireland Clinical Trial Network Program.	Access Economics Pty Limited for the Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bramlett HM, 2012, THER HYPOTHERMIA TEM, V2, P14, DOI 10.1089/ther.2012.0002; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Dengler B, 2015, J CRIT CARE, V30, P823, DOI 10.1016/j.jcrc.2015.03.027; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Liu YH, 2015, EXP THER MED, V9, P464, DOI 10.3892/etm.2014.2130; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Marion DW, 2014, CRIT CARE, V18, DOI 10.1186/cc13955; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichol A, 2015, CRIT CARE RESUSC, V17, P92; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Olah E, 2018, J NEUROTRAUM, V35, P2407, DOI 10.1089/neu.2018.5649; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Presneill J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2610-y; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smrcka M, 2005, ACT NEUR S, V95, P273; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tang CH, 2017, J CRIT CARE, V39, P267, DOI 10.1016/j.jcrc.2016.12.012; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhao WY, 2017, BRAIN RES, V1669, P141, DOI 10.1016/j.brainres.2017.06.006; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	33	95	101	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2018	320	21					2211	2220		10.1001/jama.2018.17075			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD4MB	WOS:000452500600012	30357266	Green Published, Bronze			2022-02-06	
J	Kon, AA; Shepard, EK; Sederstrom, NO; Swoboda, SM; Marshall, MF; Birriel, B; Rincon, F				Kon, Alexander A.; Shepard, Eric K.; Sederstrom, Nneka O.; Swoboda, Sandra M.; Marshall, Mary Faith; Birriel, Barbara; Rincon, Fred			Defining Futile and Potentially Inappropriate Interventions: A Policy Statement From the Society of Critical Care Medicine Ethics Committee	CRITICAL CARE MEDICINE			English	Article						decision making; end-of-life care; ethics; ethics consultation; medical futility	TRAUMATIC BRAIN-INJURY; LIFE-SUSTAINING THERAPY; INTENSIVE-CARE; INTRACEREBRAL HEMORRHAGE; HOSPITAL MORTALITY; CARDIAC-ARREST; UNIT PATIENTS; ILL PATIENTS; ACUTE PHYSIOLOGY; SCORE	Objectives: The Society of Critical Care Medicine and four other major critical care organizations have endorsed a seven-step process to resolve disagreements about potentially inappropriate treatments. The multiorganization statement (entitled: An official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units) provides examples of potentially inappropriate treatments; however, no clear definition is provided. This statement was developed to provide a clear definition of inappropriate interventions in the ICU environment. Design: A subcommittee of the Society of Critical Care Medicine Ethics Committee performed a systematic review of empirical research published in peer-reviewed journals as well as professional organization position statements to generate recommendations. Recommendations approved by consensus of the full Society of Critical Care Medicine Ethics Committees and the Society of Critical Care Medicine Council were included in the statement. Measurements and Main Results: ICU interventions should generally be considered inappropriate when there is no reasonable expectation that the patient will improve sufficiently to survive outside the acute care setting, or when there is no reasonable expectation that the patient's neurologic function will improve sufficiently to allow the patient to perceive the benefits of treatment. This definition should not be considered exhaustive; there will be cases in which life-prolonging interventions may reasonably be considered inappropriate even when the patient would survive outside the acute care setting with sufficient cognitive ability to perceive the benefits of treatment. When patients or surrogate decision makers demand interventions that the clinician believes are potentially inappropriate, the seven-step process presented in the multiorganization statement should be followed. Clinicians should recognize the limits of prognostication when evaluating potential neurologic outcome and terminal cases. At times, it may be appropriate to provide time-limited ICU interventions to patients if doing so furthers the patient's reasonable goals of care. If the patient is experiencing pain or suffering, treatment to relieve pain and suffering is always appropriate. Conclusions : The Society of Critical Care Medicine supports the seven-step process presented in the multiorganization statement. This statement provides added guidance to clinicians in the ICU environment.	[Kon, Alexander A.] Naval Med Ctr San Diego, Pediat Crit Care Med & Healthcare Eth, San Diego, CA 92134 USA; [Kon, Alexander A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Shepard, Eric K.] Univ Maryland, Sch Med, Anesthesiol & Crit Care Med, Baltimore, MD 21201 USA; [Sederstrom, Nneka O.] MedStar Washington Hosp Ctr, Ctr Eth, Washington, DC USA; [Swoboda, Sandra M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Swoboda, Sandra M.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; [Marshall, Mary Faith] Univ Virginia, Sch Med, Ctr Biomed Eth & Humanities, Charlottesville, VA 22908 USA; [Birriel, Barbara] Penn State Univ, Coll Nursing, Hershey, PA USA; [Rincon, Fred] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA		Kon, AA (corresponding author), Naval Med Ctr San Diego, Pediat Crit Care Med & Healthcare Eth, San Diego, CA 92134 USA.; Kon, AA (corresponding author), Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.	kon.sandiego@gmail.com	Sederstrom, Nneka/AAV-8269-2020		GenentechRoche HoldingGenentech	Dr. Kon disclosed other healthcare professional organization activities (President-elect, American Society for Bioethics and Humanities), disclosed government employment, and disclosed serving as an expert witness. Dr. Swoboda disclosed other healthcare professional organization activities (Surgical Infection Society, American Association of Critical-Care Nurses, Society for Simulation in Healthcare, International Nursing Association for Clinical Simulation and Learning member). Dr. Marshall disclosed relationships with providers of healthcare services (Consult for National Institutes of Health, and Academic Health Centers on Issues of Clinical and Research Ethics) and other healthcare professional organization activities (Consultant, National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, and American Society for Bone and Mineral Research). Dr. Rincon disclosed relationships with providers of healthcare services (Otsuka, Bard), disclosed other healthcare professional organization activities (Neurocritical Care Society, American College of Chest Physicians), and received grant support (Genentech Research Grant). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Afessa B, 2004, CHEST, V126, P1905, DOI 10.1378/chest.126.6.1905; [Anonymous], 1995, CMAJ, V153, p1652A; [Anonymous], 2011, RESP REQ NONB TREATM; Barrera R, 2001, J CRIT CARE, V16, P32, DOI 10.1053/jcrc.2001.21794; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bosslet GT, 2015, AM J RESP CRIT CARE, V191, P1318, DOI 10.1164/rccm.201505-0924ST; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; Courtwright A, 2012, HASTINGS CENT REP, V42, P41, DOI 10.1002/hast.51; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Cronberg T, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-45; Curtis JR, 2000, ARCH INTERN MED, V160, P1597, DOI 10.1001/archinte.160.11.1597; Danis M, 1997, CRIT CARE MED, V25, P887; Fanshawe M, 2002, ANAESTH INTENS CARE, V30, P628, DOI 10.1177/0310057X0203000515; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Gallo JJ, 2003, J AM GERIATR SOC, V51, P961, DOI 10.1046/j.1365-2389.2003.51309.x; Goodman D, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00162; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Ho KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003226; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Huynh TN, 2013, JAMA INTERN MED, V173, P1887, DOI 10.1001/jamainternmed.2013.10261; Ibsen LM, 2002, CRIT CARE MED, V30, pS402, DOI 10.1097/00003246-200211001-00004; Jacobs LM, 2010, J TRAUMA, V69, P1567, DOI 10.1097/TA.0b013e3181f65921; Jox RJ, 2012, J MED ETHICS, V38, P540, DOI 10.1136/medethics-2011-100479; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Karathanou A, 2011, J NEUROSURG SCI, V55, P173; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; Litton E, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.11.013; Marik PE, 1999, RESUSCITATION, V42, P197, DOI 10.1016/S0300-9572(99)00114-8; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Mulder M, 2014, CRIT CARE MED, V42, P2493, DOI 10.1097/CCM.0000000000000540; Norris WM, 2005, CHEST, V127, P2180, DOI 10.1378/chest.127.6.2180; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plows CW, 1999, JAMA-J AM MED ASSOC, V281, P937; Reisfield GM, 2006, RESUSCITATION, V71, P152, DOI 10.1016/j.resuscitation.2006.02.022; Rodriguez KL, 2006, J MED ETHICS, V32, P444, DOI 10.1136/jme.2005.014118; Rodriguez RM, 1997, CRIT CARE MED, V25, P1801, DOI 10.1097/00003246-199711000-00016; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Schneiderman LJ, 2000, CAMB Q HEALTHC ETHIC, V9, P524, DOI 10.1017/S0963180100904110; Sibbald R, 2007, CAN MED ASSOC J, V177, P1201, DOI 10.1503/cmaj.070144; Sinuff T, 2006, CRIT CARE MED, V34, P878, DOI 10.1097/01.CCM.0000201881.58644.41; SKANDALAKIS LJ, 1989, AM SURGEON, V55, P492; Smith EE, 2010, CIRCULATION, V122, P1496, DOI 10.1161/CIRCULATIONAHA.109.932822; Stein DM, 2012, J TRAUMA ACUTE CARE, V73, P419, DOI 10.1097/TA.0b013e31825ff59a; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Thenayan EAL, 2010, J CRIT CARE, V25, P300, DOI 10.1016/j.jcrc.2009.06.049; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vicente FG, 2004, INTENS CARE MED, V30, P655, DOI 10.1007/s00134-003-2139-7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Zier LS, 2009, CHEST, V136, P110, DOI 10.1378/chest.08-2753; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	60	95	97	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2016	44	9					1769	1774		10.1097/CCM.0000000000001965			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DT8CZ	WOS:000381718000017	27525995				2022-02-06	
J	Fortier, CB; Amick, MM; Grande, L; McGlynn, S; Kenna, A; Morra, L; Clark, A; Milberg, WP; McGlinchey, RE				Fortier, Catherine Brawn; Amick, Melissa M.; Grande, Laura; McGlynn, Susan; Kenna, Alexandra; Morra, Lindsay; Clark, Alexandra; Milberg, William P.; McGlinchey, Regina E.			The Boston Assessment of Traumatic Brain Injury-Lifetime (BAT-L) Semistructured Interview: Evidence of Research Utility and Validity	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; OEF/OIF; veterans; blast; traumatic brain injury (TBI)	BLAST; MECHANISMS; SEQUELAE; IRAQ	Objective: Report the prevalence of lifetime and military-related traumatic brain injuries (TBIs) in Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans and validate the Boston Assessment of TBI-Lifetime (BAT-L). Setting: The BAT-L is the first validated, postcombat, semistructured clinical interview to characterize head injuries and diagnose TBIs throughout the life span. Participants: Community-dwelling convenience sample of 131 OEF/OIF veterans. Design: TBI criteria (alteration of mental status, posttraumatic amnesia, and loss of consciousness) were evaluated for all possible TBIs, including a novel evaluation of blast exposure. Main Measures: BAT-L, Ohio State University TBI Identification Method (OSU-TBI-ID). Results: About 67% of veterans incurred a TBI in their lifetime. Almost 35% of veterans experienced at least 1 military-related TBI; all were mild in severity, 40% of them were due to blast, 50% were due to some other (ie, blunt) mechanism, and 10% were due to both types of injuries. Predeployment TBIs were frequent (45% of veterans). There was strong correspondence between the BAT-L and the OSU-TBI-ID (Cohen kappa = 0.89; Kendall tau-b = 0.95). Interrater reliability of the BAT-L was strong (kappa s >0.80). Conclusions: The BAT-L is a valid instrument with which to assess TBI across a service member's lifetime and captures the varied and complex nature of brain injuries across OEF/OIF veterans' life span.	[Fortier, Catherine Brawn; Amick, Melissa M.; Kenna, Alexandra; Morra, Lindsay; Clark, Alexandra; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders & Geriatr, Educ & Clin Ctr, Boston, MA 02130 USA; [Grande, Laura] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA; [McGlynn, Susan] VA Boston Healthcare Syst, Phys Med & Rehabil Serv, Boston, MA 02130 USA; [Fortier, Catherine Brawn; Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Amick, Melissa M.; Grande, Laura; McGlynn, Susan] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA		Fortier, CB (corresponding author), VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders & Geriatr, Educ & Clin Ctr 182, 150 S Huntington Ave, Boston, MA 02130 USA.	Catherine_Fortier@hms.harvard.edu	Fortier, Catherine/AAS-2163-2021; McGlinchey, Regina E/R-1971-2016	Fortier, Catherine/0000-0002-8953-9904; 	Translational Research Center for TBI and Stress Disorders, a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIA K01AG024898]; VA Merit Review AwardUS Department of Veterans Affairs; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG024898, K23AG034258] Funding Source: NIH RePORTER	This research was support by the Translational Research Center for TBI and Stress Disorders, a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C), NIH NIA K01AG024898, and VA Merit Review Award to Regina McGlinchey. We thank Wally Musto for his championship of our work among military personnel and his tireless recruitment efforts on our behalf. We also acknowledge the contributions of Drs Heidi Terrio and Doug Katz for their guidance in the development and analysis of the BAT-L.	Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaycox, 2008, INVISIBLE WOUNDS WAR; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461	20	95	95	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					89	98		10.1097/HTR.0b013e3182865859			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400014	23535389	Green Accepted			2022-02-06	
J	Cho, SI; Gao, SS; Xia, AP; Wang, R; Salles, FT; Raphael, PD; Abaya, H; Wachtel, J; Baek, J; Jacobs, D; Rasband, MN; Oghalai, JS				Cho, Sung-Il; Gao, Simon S.; Xia, Anping; Wang, Rosalie; Salles, Felipe T.; Raphael, Patrick D.; Abaya, Homer; Wachtel, Jacqueline; Baek, Jongmin; Jacobs, David; Rasband, Matthew N.; Oghalai, John S.			Mechanisms of Hearing Loss after Blast Injury to the Ear	PLOS ONE			English	Article							TYMPANIC-MEMBRANE PERFORATION; NERVE DEGENERATION; BRAIN-INJURY; OVERPRESSURE; EXPOSURE; MODEL; VULNERABILITY; SURVIVORS; RECOVERY; AFFERENT	Given the frequent use of improvised explosive devices (IEDs) around the world, the study of traumatic blast injuries is of increasing interest. The ear is the most common organ affected by blast injury because it is the body's most sensitive pressure transducer. We fabricated a blast chamber to re-create blast profiles similar to that of IEDs and used it to develop a reproducible mouse model to study blast-induced hearing loss. The tympanic membrane was perforated in all mice after blast exposure and found to heal spontaneously. Micro-computed tomography demonstrated no evidence for middle ear or otic capsule injuries; however, the healed tympanic membrane was thickened. Auditory brainstem response and distortion product otoacoustic emission threshold shifts were found to be correlated with blast intensity. As well, these threshold shifts were larger than those found in control mice that underwent surgical perforation of their tympanic membranes, indicating cochlear trauma. Histological studies one week and three months after the blast demonstrated no disruption or damage to the intra-cochlear membranes. However, there was loss of outer hair cells (OHCs) within the basal turn of the cochlea and decreased spiral ganglion neurons (SGNs) and afferent nerve synapses. Using our mouse model that recapitulates human IED exposure, our results identify that the mechanisms underlying blast-induced hearing loss does not include gross membranous rupture as is commonly believed. Instead, there is both OHC and SGN loss that produce auditory dysfunction.	[Cho, Sung-Il; Gao, Simon S.; Xia, Anping; Wang, Rosalie; Salles, Felipe T.; Raphael, Patrick D.; Abaya, Homer; Wachtel, Jacqueline; Oghalai, John S.] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA; [Cho, Sung-Il] Chosun Univ, Dept Otolaryngol Head & Neck Surg, Kwangju, South Korea; [Gao, Simon S.] Rice Univ, Dept Bioengn, Houston, TX USA; [Baek, Jongmin; Jacobs, David] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Rasband, Matthew N.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA		Oghalai, JS (corresponding author), Stanford Univ, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA.	joghalai@stanford.edu		Gao, Simon/0000-0002-7020-037X; Rasband, Matthew/0000-0001-8184-2477; Ryoo, Seung Mok/0000-0002-2436-3311	DoDUnited States Department of Defense [W81XWH-11-2-0004 (DM090212)]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 DC006671, P30 DC010363]; Chosun University; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K08DC006671, P30DC010363] Funding Source: NIH RePORTER	Support came from DoD W81XWH-11-2-0004 (DM090212) and NIH grants K08 DC006671 and P30 DC010363. Sungil Cho was supported by research funds from Chosun University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahroon WA, 1996, J ACOUST SOC AM, V100, P2247, DOI 10.1121/1.417934; Applegate BE, 2011, OPT LETT, V36, P4716, DOI 10.1364/OL.36.004716; Baalman KL, 2012, NEUROTRAUMA IN PRESS; Barden EK, 2012, J AM ACAD AUDIOL, V23, P332, DOI 10.3766/jaaa.23.5.4; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen ZQ, 2010, J NEUROPHYSIOL, V103, P2581, DOI 10.1152/jn.00018.2010; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Ewert DL, 2012, HEARING RES, V285, P29, DOI 10.1016/j.heares.2012.01.013; Gao SS, 2011, OPT EXPRESS, V19, P15415, DOI 10.1364/OE.19.015415; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Goldstein L.E., 2012, SCI TRANSL MED, V4; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; HAMERNIK RP, 1988, J ACOUST SOC AM, V84, P941, DOI 10.1121/1.396663; HAMERNIK RP, 1984, HEARING RES, V16, P143, DOI 10.1016/0378-5955(84)90004-2; HAMERNIK RP, 1984, HEARING RES, V13, P229, DOI 10.1016/0378-5955(84)90077-7; HAMERNIK RP, 1987, J ACOUST SOC AM, V81, P1118, DOI 10.1121/1.394632; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Horrocks C L, 2001, J R Army Med Corps, V147, P28; Ibekwe T S, 2009, J Laryngol Otol, V123, pe2, DOI 10.1017/S0022215108003800; Jeong HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013756; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Lang HN, 2006, J NEUROSCI, V26, P3541, DOI 10.1523/JNEUROSCI.2488-05.2006; Legan PK, 2000, NEURON, V28, P273, DOI 10.1016/S0896-6273(00)00102-1; Lerut B, 2012, OTOL NEUROTOL, V33, P379, DOI 10.1097/MAO.0b013e318245cea5; LIBERMAN MC, 1990, J COMP NEUROL, V301, P443, DOI 10.1002/cne.903010309; Lin HW, 2011, JARO-J ASSOC RES OTO, V12, P605, DOI 10.1007/s10162-011-0277-0; Liu CC, 2011, JARO-J ASSOC RES OTO, V12, P577, DOI 10.1007/s10162-011-0269-0; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Masel BS, 2012, J NEUROTRAUMA; Mediavilla Varas Jesus, 2011, Front Neurol, V2, P58, DOI 10.3389/fneur.2011.00058; Ohlemiller KK, 2011, HEARING RES, V272, P13, DOI 10.1016/j.heares.2010.11.006; Ohlemiller KK, 2010, JARO-J ASSOC RES OTO, V11, P605, DOI 10.1007/s10162-010-0228-1; Ohlemiller KK, 2000, HEARING RES, V149, P239, DOI 10.1016/S0378-5955(00)00191-X; PATOW CA, 1994, OTOLARYNG HEAD NECK, V110, P211, DOI 10.1177/019459989411000211; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Phillips Y., 1991, CONVENTIONAL WARFARE, V1, P271; PRICE GR, 1979, J ACOUST SOC AM, V66, P456, DOI 10.1121/1.383096; PRICE GR, 1986, J ACOUST SOC AM, V80, P1076, DOI 10.1121/1.393849; PRICE GR, 1989, J ACOUST SOC AM, V86, P2185, DOI 10.1121/1.398479; Qin ZB, 2010, HEARING RES, V263, P93, DOI 10.1016/j.heares.2009.10.002; Radford P, 2011, OTOLARYNG HEAD NECK, V145, P806, DOI 10.1177/0194599811411143; Ritzel DV, 2011, HUM FACT MED PAN S H, P1; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Saliba I, 2011, INT J PEDIATR OTORHI, V75, P527, DOI 10.1016/j.ijporl.2011.01.012; Schulz TY, 2004, TROOPS RETURN ALARMI, P18; Stuhmiller J.H., 1991, CONVENTIONAL WARFARE, P241; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; [VA Affairs DoV], 2011, VET BEN ADM ANN BEN; Viberg A, 2004, HEARING RES, V197, P1, DOI 10.1016/j.heares.2004.04.016; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; White CH, 2009, MAMM GENOME, V20, P207, DOI 10.1007/s00335-009-9178-5; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Xia AP, 2010, DIS MODEL MECH, V3, P209, DOI 10.1242/dmm.004135; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Zhang B, 2011, J TRAUMA, V71, P694, DOI 10.1097/TA.0b013e318224595f	59	95	99	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2013	8	7							e67618	10.1371/journal.pone.0067618			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175ZH	WOS:000321271900013	23840874	Green Published, gold			2022-02-06	
J	Hazrati, LN; Tartaglia, MC; Diamandis, P; Davis, KD; Green, RE; Wennberg, R; Wong, JC; Ezerins, L; Tator, CH				Hazrati, Lili-Naz; Tartaglia, Maria C.; Diamandis, Phedias; Davis, Karen D.; Green, Robin E.; Wennberg, Richard; Wong, Janice C.; Ezerins, Leo; Tator, Charles H.			Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						chronic traumatic encephalopathy; repetitive brain injury; professional athletes; dementia; neurodegenerative disease	TDP-43	Background: Chronic traumatic encephalopathy (CTE) is the term coined for the neurodegenerative disease often suspected in athletes with histories of repeated concussion and progressive dementia. Histologically, CTE is defined as a tauopathy with a distribution of tau-positive neurofibrillary tangles (NFTs) that is distinct from other tauopathies, and usually shows an absence of beta-amyloid deposits, in contrast to Alzheimer's disease (AD). Although the connection between repeated concussions and CTE-type neurodegeneration has been recently proposed, this causal relationship has not yet been firmly established. Also, the prevalence of CTE among athletes with multiple concussions is unknown. Methods: We performed a consecutive case series brain autopsy study on six retired professional football players from the Canadian Football League (CFL) with histories of multiple concussions and significant neurological decline. Results: All participants had progressive neurocognitive decline prior to death; however, only 3 cases had post-mortem neuropathological findings consistent with CTE. The other 3 participants had pathological diagnoses of AD, amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Moreover, the CTE cases showed co-morbid pathology of cancer, vascular disease, and AD. Discussion: Our case studies highlight that not all athletes with history of repeated concussions and neurological symptomology present neuropathological changes of CTE. These preliminary findings support the need for further research into the link between concussion and CTE as well as the need to expand the research to other possible causes of taupathy in athletes. They point to a critical need for prospective studies with good sampling methods to allow us to understand the relationship between multiple concussions and the development of CTE.	[Hazrati, Lili-Naz; Diamandis, Phedias; Wong, Janice C.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; [Hazrati, Lili-Naz; Tartaglia, Maria C.; Wong, Janice C.] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; [Tartaglia, Maria C.; Wennberg, Richard] Univ Toronto, Univ Hlth Network, Krembil Neurosci Ctr, Div Neurol, Toronto, ON M5S 3H2, Canada; [Davis, Karen D.; Tator, Charles H.] Univ Toronto, Univ Hlth Network, Krembil Neurosci Ctr, Div Neurosurg, Toronto, ON M5S 3H2, Canada; [Davis, Karen D.] Univ Hlth Network, Toronto Western Res Inst, Div Brain Imaging & Behav Syst Neurosci, Toronto, ON, Canada; [Davis, Karen D.] Univ Toronto, Dept Surg, Toronto, ON M5S 3H2, Canada; [Davis, Karen D.; Tator, Charles H.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 3H2, Canada; [Green, Robin E.] Univ Toronto, Toronto Rehabil Inst, Cognit Neurorehabil Sci Lab, Toronto, ON M5S 3H2, Canada; [Ezerins, Leo] Canadian Football League Alumni Assoc, Toronto, ON, Canada		Hazrati, LN (corresponding author), Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent West, Toronto, ON M5S 3H2, Canada.	lilinaz.hazrati@utoronto.ca	hazrati, lili-naz/AAE-7785-2020	hazrati, lili-naz/0000-0003-2715-1485; Green, Robin/0000-0001-9451-3963; Diamandis, Phedias/0000-0001-5291-9068	Physicians' Services Incorporated Foundation	We are grateful and would like to thank Dawn Ross, Vicky Proudfoot, Carol Conroy, Joan Toogood, Mary Kuntz, Siobhan Ribbins, Dan Slee, Bill Sokulski, and Tony Gabriel for facilitating the brain donations and for their time and contribution to the subject's histories. We are thankful to Drs. J.H. Jansen, J. Wolfe, J. Michaud, M.C. Guiot, Angela Genge, and C. Petito for their clinical expertise and help with autopsies, and to all the team members of The Canadian Sports Concussion Project. This research was funded by a generous grant from the Physicians' Services Incorporated Foundation to the Canadian Sports Concussion Project.	Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Davis K. D., 2012, J NEUROIMMUNE PHARM, DOI [10.1007/s11481-012-9386-8, DOI 10.1007/S11481-012-9386-8.[]; Dickson DW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009258; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Pickett William, 2004, Chronic Dis Can, V25, P32; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008	22	95	95	4	76	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 24	2013	7								222	10.3389/fnhum.2013.00222			9	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	152TL	WOS:000319553900001	23745112	Green Published, gold			2022-02-06	
J	Bazarian, JJ; Donnelly, K; Peterson, DR; Warner, GC; Zhu, T; Zhong, JH				Bazarian, Jeffrey J.; Donnelly, Kerry; Peterson, Derick R.; Warner, Gary C.; Zhu, Tong; Zhong, Jianhui			The Relation Between Posttraumatic Stress Disorder and Mild Traumatic Brain Injury Acquired During Operations Enduring Freedom and Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast exposure; combat intensity; diffusion tensor imaging; magnetic resonance imaging; mild traumatic brain injury; Operation Enduring Freedom; Operation Iraqi Freedom; posttraumatic stress disorder	MEDIAL PREFRONTAL CORTEX; WHITE-MATTER; INDUCED NEUROTRAUMA; PTSD; INTEGRITY; MILITARY; IDENTIFICATION; ABNORMALITIES; AFGHANISTAN; VOLUNTEERS	Objective: To understand the relations of mild traumatic brain injury (TBI), blast exposure, and brain white matter structure to severity of posttraumatic stress disorder (PTSD). Design: Nested cohort study using multivariate analyses. Participants: Fifty-two OEF/OIF veterans who served in combat areas between 2001 and 2008 were studied approximately 4 years after the last tour of duty. Main Measures: PTSD Checklist-Military; Combat Experiences Survey, interview questions concerning blast exposure and TBI symptoms; anatomical magnetic resonance imaging (MRI), and diffusion tensor imaging (DTI) scanning of the brain. Results: PTSD severity was associated with higher 1st percentile values of mean diffusivity on DTI (regression coefficient [r] = 4.2, P = .039), abnormal MRI (r = 13.3, P = .046), and the severity of exposure to combat events (r = 5.4, P = .007). Mild TBI was not significantly associated with PTSD severity. Blast exposure was associated with lower 1st percentile values of fractional anisotropy on DTI (odds ratio [OR] = 0.38 per SD; 95% confidence interval [CI], 0.15-0.92), normal MRI (OR = 0.00, 95% likelihood ratio test CI, 0.00-0.09), and the severity of exposure to traumatic events (OR = 3.64 per SD; 95% CI, 1.40-9.43). Conclusions: PTSD severity is related to both the severity of combat stress and underlying structural brain changes on MRI and DTI but not to a clinical diagnosis of mild TBI. The observed relation between blast exposure and abnormal DTI suggests that subclinical TBI may play a role in the genesis of PTSD in a combat environment.	[Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY 14642 USA; [Peterson, Derick R.] Univ Rochester, Sch Med, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Zhong, Jianhui] Univ Rochester, Sch Med, Dept Imaging Sci, Rochester, NY 14642 USA; [Donnelly, Kerry] VA Western New York Healthcare Syst Buffalo, Buffalo, NY USA; [Warner, Gary C.] Canandaigua VAMC, Canandaigua, NY USA		Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu	Peterson, Derick/W-5240-2019; Zhu, Tong/A-9402-2011; Zhong, Jianhui/AAE-6061-2020	Peterson, Derick/0000-0001-8603-660X; 	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; Health Services Research and Development [SDR 06-162]	This research was supported by a grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Health Services Research and Development (SDR 06-162). The authors thank Leslie Charles (Canandaigua VA), Samuel Z. Lewis (Canandaigua VA), and Michelle Alt (VA Western New York Healthcare System - Buffalo) for their assistance in subject recruitment and data collection and to P.-L. Westesson, MD, PhD, DDS, for magnetic resonance imaging interpretation.	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BREMNER JD, 1992, AM J PSYCHIAT, V149, P328; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Canive JM, 1997, ANN NY ACAD SCI, V821, P512, DOI 10.1111/j.1749-6632.1997.tb48318.x; CASSIDAY KL, 1992, J TRAUMA STRESS, V5, P627, DOI 10.1007/BF00979230; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cerqueira JJ, 2007, CEREB CORTEX, V17, P1998, DOI 10.1093/cercor/bhl108; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoggard N, 2009, J MED ETHICS, V35, P194, DOI 10.1136/jme.2008.025502; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; Institute of Medicine, 2009, GULF WAR HLTH, V7; Iverson GL, BRAIN INJ, V25, P1325; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Katzman GL, 1999, JAMA-J AM MED ASSOC, V282, P36, DOI 10.1001/jama.282.1.36; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lyoo IK, 2004, PSYCHIAT RES-NEUROIM, V131, P135, DOI 10.1016/j.pscychresns.2004.04.001; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Needham C, 2012, CHALLENGES MEASURING; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Radley JJ, 2008, J COMP NEUROL, V507, P1141, DOI 10.1002/cne.21588; Rutland-Brown W, 2008, J HEAD TRAUMA REHAB, V23, P84, DOI 10.1097/01.HTR.0000314527.78134.70; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Sook-Kyung CK, 2011, FRONT NEUROL, V2, P1; Talvage TM, 2011, J NEUROTRAUM, DOI [10.1089/neu.2010.1512, DOI 10.1089/NEU.2010.1512]; Tanielian T., 2008, INVISIBLE WOUNDS WAR; van Dijk EJ, 2004, HYPERTENSION, V44, P625, DOI 10.1161/01.HYP.0000145857.98904.20; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941; Zhu T, 2009, J MAGN RESON IMAGING, V29, P422, DOI 10.1002/jmri.21647	55	95	95	0	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					1	12		10.1097/HTR.0b013e318256d3d3			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400001	22647965				2022-02-06	
J	Bennett, RE; Mac Donald, CL; Brody, DL				Bennett, Rachel E.; Mac Donald, Christine L.; Brody, David L.			Diffusion tensor imaging detects axonal injury in a mouse model of repetitive closed-skull traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Diffusion tensor imaging; Traumatic brain injury; Axonal injury	AMYLOID PRECURSOR PROTEIN; HEAD TRAUMA; DEMYELINATION; DEGENERATION; WATER	Mild traumatic brain injuries (TBI) are common in athletes, military personnel, and the elderly, and increasing evidence indicates that these injuries have long-term health effects. However, the difficulty in detecting these mild injuries in vivo is a significant impediment to understanding the underlying pathology and treating mild TBI. In the following experiments, we present the results of diffusion tensor imaging (DTI) and histological analysis of a model of mild repetitive closed-skull brain injury in mouse. Histological markers used included silver staining and amyloid precursor protein (APP) immunohistochemistry to detect axonal injury, and Iba-1 immunohistochemistry to assess microglial activation. At 24 h post-injury, before silver staining or microglial abnormalities were apparent by histology, no significant changes in any of the DTI parameters were observed within white matter. At 7 days post-injury we observed a reduction in axial and mean diffusivity. Relative anisotropy at 7 days correlated strongly with the degree of silver staining. Interestingly. APP was not observed at any timepoint examined. In addition to the white matter alterations, mean diffusivity was elevated in ipsilateral cortex at 24 h but returned to sham levels by 7 days. Altogether, this demonstrates that DTI is a sensitive method for detecting axonal injury despite a lack of conventional APP pathology. Further, this reflects a need to better understand the histological basis for DTI signal changes in mild TBI. (c) 2012 Elsevier Ireland Ltd. All rights reserved.	[Bennett, Rachel E.; Mac Donald, Christine L.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020	Bennett, Rachel/0000-0001-9640-0575	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069, P30 NS057105]; Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057105, R01NS065069] Funding Source: NIH RePORTER	This work was supported by a NIH R01 NS065069 (Brody), a Burroughs Wellcome Career Award in the Biomedical Sciences (Brody), and an NIH Neuroscience Blueprint Core Grant to Washington University (P30 NS057105).	BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Le Bihan D, 2007, PHYS MED BIOL, V52, pR57, DOI 10.1088/0031-9155/52/7/R02; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	17	95	99	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	APR 4	2012	513	2					160	165		10.1016/j.neulet.2012.02.024			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	929UD	WOS:000303090300012	22343314	Green Accepted			2022-02-06	
J	Savica, R; Parisi, JE; Wold, LE; Josephs, KA; Ahlskog, JE				Savica, Rodolfo; Parisi, Joseph E.; Wold, Lester E.; Josephs, Keith A.; Ahlskog, J. Eric			High School Football and Risk of Neurodegeneration: A Community-Based Study	MAYO CLINIC PROCEEDINGS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HEAD-INJURY; DISEASE; ROCHESTER; CONCUSSION; MINNESOTA; EVOLUTION	Objective: To assess whether high school football played between 1946 and 1956, when headgear was less protective than today, was associated with development of neurodegenerative diseases later in life. Methods: All male students who played football from 1946 to 1956 in the high schools of Rochester, Minnesota, plus a non-football-playing referent group of male students in the band, glee club, or choir were identified. Using the records-linkage system of the Rochester Epidemiology Project, we reviewed (from October 31, 2010, to March 30, 2011) all available medical records to assess later development of dementia, Parkinson disease (PD), or amyotrophic lateral sclerosis (ALS). We also compared the frequency of dementia, PD, or ALS with incidence data from the general population of Olmsted County, Minnesota. Results: We found no increased risk of dementia, PD, or ALS among the 438 football players compared with the 140 non-football-playing male classmates. Parkinson disease and ALS were slightly less frequent in the football group, whereas dementia was slightly more frequent, but not significantly so. When we compared these results with the expected incidence rates in the general population, only PD was significantly increased; however, this was true for both groups, with a larger risk ratio in the non-football group. Conclusion: Our findings suggest that high school students who played American football from 1946 to 1956 did not have an increased risk of later developing dementia, PD, or ALS compared with non-football-playing high school males, despite poorer equipment and less regard for concussions compared with today and no rules prohibiting head-first tackling (spearing). (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 2012;87(4):335-340	[Savica, Rodolfo; Parisi, Joseph E.; Josephs, Keith A.; Ahlskog, J. Eric] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Parisi, Joseph E.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Wold, Lester E.] Mayo Clin Hlth Syst, Dept Pathol, Austin, MN USA		Savica, R (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	savica.rodolfo@mayo.edu			Rochester Historical Society; Lourdes High School; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AG034676]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	The authors thank all the personnel of the Rochester Historical Society and Lourdes High School for their help and support.Grant Support: The study was supported by National Institutes of Health Grant R01-AG034676, the Rochester Epidemiology Project (Principal Investigator: Walter A. Rocca, MD, MPH).	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; Bennett T, 1977, NFLS OFFICIAL ENCY H; Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; Edland SD, 2002, ARCH NEUROL-CHICAGO, V59, P1589, DOI 10.1001/archneur.59.10.1589; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; JUERGENS SM, 1980, NEUROLOGY, V30, P463, DOI 10.1212/WNL.30.5.463; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Levy ML, 2004, NEUROSURGERY, V55, P661; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482	23	95	96	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	APR	2012	87	4					335	340		10.1016/j.mayocp.2011.12.016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930OC	WOS:000303147700008	22469346	Green Published, Bronze			2022-02-06	
J	Kenne, E; Erlandsson, A; Lindbom, L; Hillered, L; Clausen, F				Kenne, Ellinor; Erlandsson, Anna; Lindbom, Lennart; Hillered, Lars; Clausen, Fredrik			Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Neutrophil; traumatic brain injury; brain edema; controlled cortical impact; neuroprotection; blood-brain-barrier; cell death; microglia; neutrophil-depletion; mouse	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; MIDDLE CEREBRAL-ARTERY; BARRIER PERMEABILITY; ISCHEMIC BRAIN; POLYMORPHONUCLEAR LEUKOCYTES; VASCULAR-PERMEABILITY; ADHESION MOLECULES; TNF-ALPHA; RATS	Background: Brain edema as a result of secondary injury following traumatic brain injury (TBI) is a major clinical concern. Neutrophils are known to cause increased vascular permeability leading to edema formation in peripheral tissue, but their role in the pathology following TBI remains unclear. Methods: In this study we used controlled cortical impact (CCI) as a model for TBI and investigated the role of neutrophils in the response to injury. The outcome of mice that were depleted of neutrophils using an anti-Gr-1 antibody was compared to that in mice with intact neutrophil count. The effect of neutrophil depletion on blood-brain barrier function was assessed by Evan's blue dye extravasation, and analysis of brain water content was used as a measurement of brain edema formation (24 and 48 hours after CCI). Lesion volume was measured 7 and 14 days after CCI. Immunohistochemistry was used to assess cell death, using a marker for cleaved caspase-3 at 24 hours after injury, and microglial/macrophage activation 7 days after CCI. Data were analyzed using Mann-Whitney test for non-parametric data. Results: Neutrophil depletion did not significantly affect Evan's blue extravasation at any time-point after CCI. However, neutrophil-depleted mice exhibited a decreased water content both at 24 and 48 hours after CCI indicating reduced edema formation. Furthermore, brain tissue loss was attenuated in neutropenic mice at 7 and 14 days after injury. Additionally, these mice had a significantly reduced number of activated microglia/macrophages 7 days after CCI, and of cleaved caspase-3 positive cells 24 h after injury. Conclusion: Our results suggest that neutrophils are involved in the edema formation, but not the extravasation of large proteins, as well as contributing to cell death and tissue loss following TBI in mice.	[Erlandsson, Anna; Hillered, Lars; Clausen, Fredrik] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Kenne, Ellinor; Lindbom, Lennart] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden		Clausen, F (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	fredrik.clausen@neuro.uu.se		Hillered, Lars/0000-0002-2808-9292; Lindbom, Lennart/0000-0001-9243-257X; Clausen, Fredrik/0000-0003-3592-4417; Kenne, Ellinor/0000-0002-2784-5244	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; Lars Hierta Memorial Fund; Swedish Brain Foundation; Selander Foundation; Ahlen Foundation; Uppsala University Hospital	This work was funded by grants from the Swedish Research Council (EK, LL, LH), the Swedish Heart-Lung Foundation (EK, LL), the Lars Hierta Memorial Fund (EK, LL), the Swedish Brain Foundation (LH, FC), the Selander Foundation (LH), the Ahlen Foundation (LH) and Uppsala University Hospital (LH).	ARFORS KE, 1987, BLOOD, V69, P338; Biber N, 2009, BRAIN INJURY, V23, P577, DOI 10.1080/02699050902926317; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2011, EUR J NEUROSCI; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Engelhardt B, 2009, SEMIN IMMUNOPATHOL, V31, P497, DOI 10.1007/s00281-009-0177-0; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ikegame Y, 2010, HYPERTENS RES, V33, P703, DOI 10.1038/hr.2010.58; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lindbom L, 2003, CHEM IMMUNOL, V83, P146; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Morancho A, 2010, ANN NY ACAD SCI, V1207, P123, DOI 10.1111/j.1749-6632.2010.05734.x; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Soares HD, 1995, J NEUROSCI, V15, P8223; Soehnlein O, 2008, EUR RESP J; Soehnlein O, 2008, BLOOD, V112, P1461, DOI 10.1182/blood-2008-02-139634; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, ACT NEUR S, V71, P212; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	47	95	97	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 23	2012	9								17	10.1186/1742-2094-9-17			11	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	917HX	WOS:000302165200001	22269349	Green Published, gold			2022-02-06	
J	Ling, J; Merideth, F; Caprihan, A; Pena, A; Teshiba, T; Mayer, AR				Ling, Josef; Merideth, Flannery; Caprihan, Arvind; Pena, Amanda; Teshiba, Terri; Mayer, Andrew R.			Head injury or head motion? Assessment and quantification of motion artifacts in diffusion tensor imaging studies	HUMAN BRAIN MAPPING			English	Article						mild TBI; DTI; diffusion tensor imaging; gradient sampling schemes; motion; simulations	TRAUMATIC BRAIN-INJURY; PRINCIPAL EIGENVECTOR MEASUREMENTS; STIMULUS-CORRELATED MOTION; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; WEIGHTED MRI; FMRI; DTI; ACQUISITION; SCHEMES	The relationship between head motion and diffusion values such as fractional anisotropy (FA) and mean diffusivity (MD) is currently not well understood. Simulation studies suggest that head motion may introduce either a positive or negative bias, but this has not been quantified in clinical studies. Moreover, alternative measures for removing bias as result of head motion, such as the removal of problematic gradients, has been suggested but not carefully evaluated. The current study examined the impact of head motion on FA and MD across three common pipelines (tract-based spatial statistics, voxelwise, and region of interest analyses) and determined the impact of removing diffusion weighted images. Our findings from a large cohort of healthy controls indicate that while head motion was associated with a positive bias for both FA and MD, the effect was greater for MD. The positive bias was observed across all three analysis pipelines and was present following established protocols for data processing, suggesting that current techniques (i.e., correction of both image and gradient table) for removing motion bias are likely insufficient. However, the removal of images with gross artifacts did not fundamentally change the relationship between motion and DTI scalar values. In addition, Monte Carlo simulations suggested that the random removal of images increases the bias and reduces the precision of both FA and MD. Finally, we provide an example of how head motion can be quantified across different neuropsychiatric populations, which should be implemented as part of any diffusion tensor imaging quality assurance protocol. Hum Brain Mapp, 2012. (C) 2011 Wiley Periodicals, Inc.	[Ling, Josef; Merideth, Flannery; Caprihan, Arvind; Pena, Amanda; Teshiba, Terri; Mayer, Andrew R.] Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-NS064464-01A1, 3R21-NS064464-01A1S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant numbers: R21-NS064464-01A1 and 3R21-NS064464-01A1S1 (to A.M.).	Aksoy M, 2008, MAGN RESON MED, V59, P1138, DOI 10.1002/mrm.21558; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Ardekani BA, 2010, HUM BRAIN M IN PRESS; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; Bullmore ET, 1999, HUM BRAIN MAPP, V7, P38, DOI 10.1002/(SICI)1097-0193(1999)7:1<38::AID-HBM4>3.3.CO;2-H; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cook PA, 2007, J MAGN RESON IMAGING, V25, P1051, DOI 10.1002/jmri.20905; Cox R, 2006, SEATTL WA INT SOC MA, P349; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Frank LR, 2010, NEUROIMAGE, V49, P1510, DOI 10.1016/j.neuroimage.2009.09.010; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; HAJNAL JV, 1994, MAGNET RESON MED, V31, P283, DOI 10.1002/mrm.1910310307; Horsfield MA, 1999, MAGN RESON IMAGING, V17, P1335, DOI 10.1016/S0730-725X(99)00077-6; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 2002, NEUROIMAGE, V17, P592, DOI 10.1006/nimg.2002.1148; Jones DK, 2002, HUM BRAIN MAPP, V15, P216, DOI 10.1002/hbm.10018; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Landman BA, 2008, MAGN RESON IMAGING, V26, P790, DOI 10.1016/j.mri.2008.01.034; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Liu CL, 2004, MAGN RESON MED, V52, P1388, DOI 10.1002/mrm.20288; Lund TE, 2005, NEUROIMAGE, V26, P960, DOI 10.1016/j.neuroimage.2005.02.021; Marenco S, 2006, PSYCHIAT RES-NEUROIM, V147, P69, DOI 10.1016/j.pscychresns.2006.01.008; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2007, J INT NEUROPSYCH SOC, V13, P839, DOI 10.1017/S1355617707071081; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Norris DG, 2001, J MAGN RESON IMAGING, V13, P486, DOI 10.1002/jmri.1072; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Roosendaal SD, 2009, NEUROIMAGE, V44, P1397, DOI 10.1016/j.neuroimage.2008.10.026; Saad ZS, 2009, NEUROIMAGE, V44, P839, DOI 10.1016/j.neuroimage.2008.09.037; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Sexton CE, 2009, BIOL PSYCHIAT, V66, P814, DOI 10.1016/j.biopsych.2009.05.024; Sijbers J, 2009, NEUROIMAGE, V46, P692; Skare S, 2000, J MAGN RESON, V147, P340, DOI 10.1006/jmre.2000.2209; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Storey P, 2007, MAGN RESON MED, V57, P614, DOI 10.1002/mrm.21132; Tijssen RHN, 2009, HUM BRAIN MAPP, V30, P2641, DOI 10.1002/hbm.20695; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; White Tonya, 2008, Top Magn Reson Imaging, V19, P97, DOI 10.1097/RMR.0b013e3181809f1e; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Yoo SS, 2005, NEUROSCI RES, V53, P84, DOI 10.1016/j.neures.2005.06.004; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zollei L, 2010, NEUROIMAGE, V51, P206, DOI 10.1016/j.neuroimage.2010.01.101	51	95	95	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1065-9471			HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2012	33	1					50	62		10.1002/hbm.21192			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	869IH	WOS:000298591100005	21391258	Green Published			2022-02-06	
J	Kanno, H; Ozawa, H; Sekiguchi, A; Yamaya, S; Itoi, E				Kanno, Haruo; Ozawa, Hiroshi; Sekiguchi, Akira; Yamaya, Seiji; Itoi, Eiji			Induction of Autophagy and Autophagic Cell Death in Damaged Neural Tissue After Acute Spinal Cord Injury in Mice	SPINE			English	Article						spinal cord injury; autophagy; LC3; apoptosis; autophagic cell death	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; UP-REGULATION; MONITORING AUTOPHAGY; APOPTOSIS; RAPAMYCIN; BECLIN-1; NEURODEGENERATION; ACTIVATION; DISEASE	Study Design. Expression of light chain 3 (LC3), a characteristic marker of autophagy, was examined by immunohistochemistry and Western blot using a spinal cord injury (SCI) model in mice. Electron microscopic analysis was also performed to examine the anatomic formation of autophagy and autophagic cell death in the injured spinal cord. Objective. To examine both biochemically and anatomically the activity of autophagy in the damaged neural tissue after SCI. Summary of Background Data. Autophagy is the bulk degradation of intracellular proteins and organelles, and it is involved in a number of diseases. Autophagy can lead to nonapoptotic programmed cell death, which is called autophagic cell death. Recent researches have revealed the increased expression of LC3 and the anatomic formation of autophagy and autophagic cell death in damaged tissues of various disease models. However, previous studies have focused on apoptotic process but not autophagic activity as mechanism of neural tissue damage after SCI. To date, there has been no study to examine the expression of LC3 and the anatomic formation of autophagy after SCI. Methods. The spinal cord was hemitransected at T10 in adult female C57BL/6J mice. The LC3 expression was examined by immunohistochemistry and Western blot. The anatomic formation of autophagic activity was investigated using electron microscopy. Results. Immunohistochemistry showed that the number of the LC3-positive cells significantly increased at the lesion site after hemisection. The increase of LC3-positive cells was observed from 4 hours and peaked at 3 days, and it lasted for at least 21 days after hemisection. The LC3-positive cells were observed in neurons, astrocytes, and oligodendrocytes. Western blot analysis demonstrated that the level of LC3-II protein expression significantly increased in the injured spinal cord. Electron microscopy showed the formation of autophagic vacuoles to increase in the damaged cells. Furthermore, the nuclei in the transferase-mediated dUTP nick end labeling-positive cells expressed LC3 were round, which is consistent with autophagic cell death, and they were neither shrunken nor fragmented as is observed in apoptotic nuclei. Conclusion. This study suggested both biochemically and anatomically that autophagy was clearly activated and autophagic cell death was induced in the damaged neural tissue after SCI.	[Kanno, Haruo] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Kanno, Haruo] Univ Miami, Miami Project Cure Paralysis, Coral Gables, FL 33124 USA		Kanno, H (corresponding author), Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kanno-h@isis.ocn.ne.jp	Kanno, Haruo/AAA-2187-2020	Kanno, Haruo/0000-0003-1985-2257	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [19591712]; Japan Orthopaedics and Traumatology Foundation, Inc. [0138]; The General insurance Association of Japan	Supported by Grant-in-Aid for Scientific Research (19591712) from Japan Society for the Promotion of Science, by Japan Orthopaedics and Traumatology Foundation, Inc. (No. 0138), and by Grant in 2007 from The General insurance Association of Japan.	Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Calle E, 1999, ACTA NEUROPATHOL, V97, P143, DOI 10.1007/s004010050967; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dong HX, 2003, J NEUROSCI, V23, P8682; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; Kanno H, 2009, AUTOPHAGY, V5, P390, DOI 10.4161/auto.5.3.7724; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0076-6879(08)01416-X, 10.1016/S0070-6879(08)01416-X]; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lee SJ, 2009, GLIA, V57, P1351, DOI 10.1002/glia.20854; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Suzuki C, 2008, BIOCHEM BIOPH RES CO, V368, P100, DOI 10.1016/j.bbrc.2008.01.059; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	42	95	105	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	OCT 15	2011	36	22					E1427	E1434		10.1097/BRS.0b013e3182028c3a			8	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	833IP	WOS:000295877800001	21304420				2022-02-06	
J	Lim, JY; Jeong, CH; Jun, JA; Kim, SM; Ryu, CH; Hou, Y; Oh, W; Chang, JW; Jeun, SS				Lim, Jung Yeon; Jeong, Chang Hyun; Jun, Jin Ae; Kim, Seong Muk; Ryu, Chung Heon; Hou, Yun; Oh, Wonil; Chang, Jong Wook; Jeun, Sin-Soo			Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia	STEM CELL RESEARCH & THERAPY			English	Article							MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; NEURAL CELLS; BONE; STROKE; TRANSPLANTATION; DIFFERENTIATION; EXPRESSION; ANGIOGENESIS; PHENOTYPES	Introduction: Stem cell transplantation is a promising therapeutic strategy for the treatment of stroke. Mesenchymal stem cells (MSCs) are a potential cell source for clinical application because they can be easily obtained and cultivated with a high proliferative capacity. The safety and efficacy of cell therapy depends on the mode of cell administration. To determine the therapeutic potential of intrathecal administration of MSCs by lumbar puncture (LP), we administrated human umbilical cord blood-derived MSCs (hUCB-MSCs) intrathecally into the lumbar spinal cord or intravenously into the tail vein in a rat model of stroke, and then investigated whether hUCB-MSCs could enter the brain, survive, and improve post-stroke neurological functional recovery. Methods: hUCB-MSCs (1.0 x 10(6)) were administrated three days after stroke induced by occlusion of the middle cerebral artery. The presence of hUCB-MSCs and their survival and differentiation in the brain tissue of the rats was examined by immunohistochemistry. Recovery of coordination of movement after administration of hUCB-MSCs was examined using a Rotarod test and adhesive-removal test on the 7th, 14th, 21st, and 28th days after ischemia. The volume of ischemic lesions seven days after the experimental procedure was evaluated using 2-3-5-triphenyltetrazolium (TTC) staining. Results: Rats receiving hUCB-MSCs intrathecally by LP had a significantly higher number of migrated cells within the ischemic area when compared with animals receiving cells intravenously. In addition, many of the cells administered intrathecally survived and a subset of them expressed mature neural-lineage markers, including the mature neuron marker NeuN and glial fibrillary acidic protein, typical of astrocytes. Animals that received hUCB-MSCs had significantly improved motor function and reduced ischemic damage when compared with untreated control animals. Regardless of the administration route, the group treated with 1 x 10(6) hUCB-MSCs showed better neurological recovery, without significant differences between the two treatment groups. Importantly, intrathecal administration of 5 x 10(5) hUCB-MSCs significantly reduced ischemic damage, but not in the intravenously treated group. Furthermore, the cells administered intrathecally survived and migrated into the ischemic area more extensively, and differentiated significantly into neurons and astrocytes. Conclusions: Together, these results indicate that intrathecal administration of MSCs by LP may be useful and feasible for MSCs treatment of brain injuries, such as stroke, or neurodegenerative disorders.	[Lim, Jung Yeon; Jeong, Chang Hyun; Jun, Jin Ae; Kim, Seong Muk; Ryu, Chung Heon; Hou, Yun; Jeun, Sin-Soo] Catholic Univ Korea, Dept Biomed Sci, Coll Med, Seoul 137701, South Korea; [Jeun, Sin-Soo] Catholic Univ Korea, Dept Neurosurg, Seoul St Marys Hosp, Seoul 137701, South Korea; [Oh, Wonil; Chang, Jong Wook] MEDIPOST Co Ltd, Medipost Biomed Res Inst, Seoul 137073, South Korea		Jeun, SS (corresponding author), Catholic Univ Korea, Dept Biomed Sci, Coll Med, Seoul 137701, South Korea.	ssjeun@catholic.ac.kr		Oh, Wonil/0000-0002-6349-738X	Ministry for Health, Welfare & Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A092258]; National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and Technology, Republic of KoreaMinistry of Education, Science and Technology, Republic of Korea [2010-0022845]; Korea Food and Drug Administration [10172KFDA993]	This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A092258) and by the Basic Science Research program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0022845), Republic of Korea, and by a grant (10172KFDA993) from Korea Food and Drug Administration in 2011.	Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brooke G, 2007, SEMIN CELL DEV BIOL, V18, P846, DOI 10.1016/j.semcdb.2007.09.012; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Goodwin HS, 2001, BIOL BLOOD MARROW TR, V7, P581, DOI 10.1053/bbmt.2001.v7.pm11760145; Jeong JA, 2005, STEM CELLS, V23, P584, DOI 10.1634/stemcells.2004-0304; Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365-3083.2003.01176.x; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lim JY, 2008, J NEUROSCI RES, V86, P2168, DOI 10.1002/jnr.21669; Lim JY, 2006, EXP NEUROL, V199, P416, DOI 10.1016/j.expneurol.2006.01.015; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Shichinohe H, 2006, J NUCL MED, V47, P486; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yang SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041; Yang WZ, 2010, J TRANSL MED, V75, P1; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	40	95	106	3	29	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1757-6512		STEM CELL RES THER	Stem Cell Res. Ther.	SEP 22	2011	2								38	10.1186/scrt79			13	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	889XL	WOS:000300108900001	21939558	gold, Green Published			2022-02-06	
J	Clausen, F; Hanell, A; Israelsson, C; Hedin, J; Ebendal, T; Mir, AK; Gram, H; Marklund, N				Clausen, Fredrik; Hanell, Anders; Israelsson, Charlotte; Hedin, Johanna; Ebendal, Ted; Mir, Anis K.; Gram, Hermann; Marklund, Niklas			Neutralization of interleukin-1 beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						behavior; cognition; edema; microglia; traumatic brain injury	CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; RECEPTOR ANTAGONIST; SUBARACHNOID HEMORRHAGE; EXPERIMENTAL STROKE; MEMORY PROCESSES	Increasing evidence suggests that interleukin-1 beta (IL-1 beta) is a key mediator of the inflammatory response following traumatic brain injury (TBI). Recently, we showed that intracerebroventricular administration of an IL-1 beta-neutralizing antibody was neuroprotective following TBI in mice. In the present study, an anti-IL-1 beta antibody or control antibody was administered intraperitoneally following controlled cortical injury (CCI) TBI or sham injury in 105 mice and we extended our histological, immunological and behavioral analysis. First, we demonstrated that the treatment antibody reached target brain regions of brain-injured animals in high concentrations (> 11 nm) remaining up to 8 days post-TBI. At 48 h post-injury, the anti-IL-1b treatment attenuated the TBI-induced hemispheric edema (P < 0.05) but not the memory deficits evaluated using the Morris water maze (MWM). Neutralization of IL-1 beta did not influence the TBI-induced increases (P < 0.05) in the gene expression of the Ccl3 and Ccr2 chemokines, IL-6 or Gfap. Up to 20 days post-injury, neutralization of IL-1 beta was associated with improved visuospatial learning in the MWM, reduced loss of hemispheric tissue and attenuation of the microglial activation caused by TBI (P < 0.05). Motor function using the rotarod and cylinder tests was not affected by the anti-IL-1 beta treatment. Our results suggest an important negative role for IL-1 beta in TBI. The improved histological and behavioral outcome following anti-IL-1 beta treatment also implies that further exploration of IL-1 beta-neutralizing compounds as a treatment option for TBI patients is warranted.	[Clausen, Fredrik; Hanell, Anders; Hedin, Johanna; Marklund, Niklas] Uppsala Univ, Univ Uppsala Hosp, Sect Neurosurg, Dept Neurosci, S-75185 Uppsala, Sweden; [Israelsson, Charlotte; Ebendal, Ted] Uppsala Univ, Sect Dev Biol, Dept Neurosci, S-75185 Uppsala, Sweden; [Mir, Anis K.; Gram, Hermann] Novartis Inst Biomed Res, Basel, Switzerland		Marklund, N (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Sect Neurosurg, Dept Neurosci, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626	Swedish Brain Foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Jeanssons Foundation; Uppsala University	The authors would like to thank Annika Kylberg for invaluable technical assistance. The work was supported by grants from the Swedish Brain Foundation, The Swedish Research Council, Uppsala University Hospital and Jeanssons Foundation, and funds from Uppsala University.	Alten R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2438; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Basu A, 2002, J NEUROSCI, V22, P6071; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; Biber K, 2002, NEUROSCIENCE, V112, P487, DOI 10.1016/S0306-4522(02)00114-8; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chapman KZ, 2009, J CEREBR BLOOD F MET, V29, P1764, DOI 10.1038/jcbfm.2009.113; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; FAN L, 1995, MOL BRAIN RES, V30, P125; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Fogal B, 2008, J NEUROCHEM, V106, P1, DOI 10.1111/j.1471-4159.2008.05315.x; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Glasper ER, 2010, HIPPOCAMPUS, V20, P706, DOI 10.1002/hipo.20672; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McIntosh TK, 1996, LAB INVEST, V74, P315; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Miller DW, 1999, J NEUROVIROL, V5, P570, DOI 10.3109/13550289909021286; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murray CA, 1998, J NEUROSCI, V18, P2974; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Price CJS, 2003, J NEUROL NEUROSUR PS, V74, P1476, DOI 10.1136/jnnp.74.11.1476; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sas A, 2008, NEUROCHEM RES, V33, P2281, DOI 10.1007/s11064-008-9715-8; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thornton P, 2008, MOL CELL NEUROSCI, V37, P135, DOI 10.1016/j.mcn.2007.09.002; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Winkler DT, 2010, BIOL PSYCHIAT, V68, P971, DOI 10.1016/j.biopsych.2010.01.030; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu HP, 2005, J IMMUNOL, V175, P6915, DOI 10.4049/jimmunol.175.10.6915; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	85	95	103	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2011	34	1					110	123		10.1111/j.1460-9568.2011.07723.x			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789NO	WOS:000292522400012	21623956				2022-02-06	
J	Berry, JG; Bloom, S; Foley, S; Palfrey, JS				Berry, Jay G.; Bloom, Sheila; Foley, Susan; Palfrey, Judith S.			Health Inequity in Children and Youth With Chronic Health Conditions	PEDIATRICS			English	Article						children; chronic disease; disability; disparity; epidemiology; incidence; prevalence; survival; special needs	TRAUMATIC BRAIN-INJURY; NUTRITION EXAMINATION SURVEY; FOLIC-ACID FORTIFICATION; UNITED-STATES; CYSTIC-FIBROSIS; CEREBRAL-PALSY; MEDICAL HOME; ETHNIC DISPARITIES; CHILDHOOD ASTHMA; CARE UTILIZATION	BACKGROUND: Over the last decades, there have been great advances in health care delivered to children with chronic conditions, but not all children have benefitted equally from them. OBJECTIVES: To describe health inequities experienced by children with chronic health conditions. METHODS: We performed a literature review of English-language studies identified from the Medline, Centers for Disease Control and Prevention, National Cancer Institute, and Cystic Fibrosis Foundation Web sites that were published between January 1985 and May 2009, included children aged 0 to 18 years, and contained the key words "incidence," "prevalence," "survival," "mortality," or "disparity" in the title or abstract for the following health conditions: acute leukemia, asthma, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders, cerebral palsy, cystic fibrosis, diabetes mellitus, Down syndrome, HIV/AIDS, major congenital heart defects, major depressive disorder, sickle cell anemia, spina bifida, and traumatic brain injury. RESULTS: Black children had higher rates of cerebral palsy and HIV/AIDS, were less likely to be diagnosed with ADHD, had more emergency department visits, hospitalizations, and had higher mortality rates associated with asthma; and survived less often with Down syndrome, type 1 diabetes, and traumatic brain injury when compared with white children. Hispanic children had higher rates of spina bifida from Mexico-born mothers, had higher rates of HIV/AIDS and depression, were less likely to be diagnosed with ADHD, had poorer glycemic control with type 1 diabetes, and survived less often with acute leukemia compared with white children. CONCLUSIONS: Serious racial and ethnic health and health care inequities persist for children with chronic health conditions. Pediatrics 2010; 126: S111-S119	[Berry, Jay G.] Harvard Univ, Program Patient Safety & Qual, Childrens Hosp Boston, Sch Med,Div Gen Pediat,Complex Care Serv, Boston, MA 02115 USA; [Bloom, Sheila] Harvard Univ, Sch Med, Ctr Child & Adolescent Hlth Policy, Mass Gen Hosp Children, Boston, MA 02115 USA; [Foley, Susan] Inst Community Inclus, Boston, MA USA; [Palfrey, Judith S.] Amer Acad Pediat, Elk Grove Village, IL USA		Berry, JG (corresponding author), Harvard Univ, Program Patient Safety & Qual, Childrens Hosp Boston, Sch Med,Div Gen Pediat,Complex Care Serv, Fegan 10,300 Longwood Ave, Boston, MA 02115 USA.	jay.berry@childrens.harvard.edu			National Institute on Disability and Rehabilitation Research [H133B060012]; HSC Foundation (Washington, DC)	This work was supported by National Institute on Disability and Rehabilitation Research grant H133B060012 and the HSC Foundation (Washington, DC). We thank James Perrin, MD, Naomi Sacks, MA, Veronica Palmer-Segal, BA, Berna Kahrama, MS, Amy Yang, and Morgan Crossman for help with the background analysis for this article.	Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; [Anonymous], 2000, TERATOLOGY, V61, P86; Barbaresi WJ, 2005, ARCH PEDIAT ADOL MED, V159, P37, DOI 10.1001/archpedi.159.1.37; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; Betancourt JR, 2009, KAOHSIUNG J MED SCI, V25, P471, DOI 10.1016/S1607-551X(09)70553-4; Bhasin TK., 2006, MMWR SURVEILL SUMM, V55, P1; Bishop J, 1997, AM J EPIDEMIOL, V145, P134; Boneva RS, 2001, CIRCULATION, V103, P2376; Botto LD, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e32; Boudreaux ED, 2003, PEDIATRICS, V111, pE615, DOI 10.1542/peds.111.5.e615; Canfield MA, 2006, BIRTH DEFECTS RES A, V76, P747, DOI 10.1002/bdra.20294; *CDCP, AUT SPECTR DIS; *CDCP, HIV AIDS AM YOUTH; *CDCP, 2008, HIV SURV REP DIAGN H, V20; *CDCP, 2005 NAT DIAB FACT S; Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P892; Centers for Disease Control and Prevention, 2007, HIV AIDS SURV REP CA; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P849; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P362; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P463; Cobanoglu A, 2002, ANN THORAC SURG, V74, P133, DOI 10.1016/S0003-4975(02)03619-6; Coker TR, 2009, ACAD PEDIATR, V9, P89, DOI 10.1016/j.acap.2008.11.007; Dabelea D, 2007, JAMA-J AM MED ASSOC, V298, P627; Dabelea D, 2007, JAMA-J AM MED ASSOC, V297, P2716; Duncan GE, 2006, ARCH PEDIAT ADOL MED, V160, P523, DOI 10.1001/archpedi.160.5.523; Dynesen H, 1978, Ugeskr Laeger, V140, P463; Flores G, 2008, PEDIATRICS, V121, pE286, DOI 10.1542/peds.2007-1243; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Forrester MB, 2002, TERATOLOGY, V65, P207, DOI 10.1002/tera.10042; Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857; Gallegos-Macias Angela R, 2003, Pediatr Diabetes, V4, P19, DOI 10.1034/j.1399-5448.2003.00020.x; Gatford A, 2001, Br J Nurs, V10, P1193; Gilman SE, 2003, PSYCHOL MED, V33, P1341, DOI 10.1017/S0033291703008377; GITHENS JH, 1990, AM J DIS CHILD, V144, P466, DOI 10.1001/archpedi.1990.02150280088018; GORTMAKER SL, 1984, PEDIATR CLIN N AM, V31, P3; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guyer B, 2000, PEDIATRICS, V106, P1307, DOI 10.1542/peds.106.6.1307; Homer CJ, 2008, PEDIATRICS, V122, pE922, DOI 10.1542/peds.2007-3762; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; Horn IB, 2004, AMBUL PEDIATR, V4, P269, DOI 10.1367/1539-4409(2004)4<269:CHDFAR>2.0.CO;2; Hoyert DL, 2001, PEDIATRICS, V108, P1241, DOI 10.1542/peds.108.6.1241; Hutton JL, 2006, CLIN PERINATOL, V33, P545, DOI 10.1016/j.clp.2006.03.016; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Kemper AR, 2006, AMBUL PEDIATR, V6, P178, DOI 10.1016/j.ambp.2006.01.001; Kessler R C, 1998, Depress Anxiety, V7, P3, DOI 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F; Kosorok MR, 1996, STAT MED, V15, P449, DOI 10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X; Lai HCJ, 2005, J PEDIATR-US, V147, pS57, DOI 10.1016/j.jpeds.2005.08.014; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P133, DOI 10.1037/0021-843X.102.1.133; Linabery AM, 2008, CANCER-AM CANCER SOC, V113, P2575, DOI 10.1002/cncr.23866; Liptak GS, 2008, J DEV BEHAV PEDIATR, V29, P152, DOI 10.1097/DBP.0b013e318165c7a0; Lipton R, 1999, PEDIATRICS, V103, P952, DOI 10.1542/peds.103.5.952; Liu SL, 2002, JAMA-J AM MED ASSOC, V287, P1561, DOI 10.1001/jama.287.12.1561; Mahle WT, 2000, CIRCULATION, V102, P136; Mandell DS, 2009, AM J PUBLIC HEALTH, V99, P493, DOI 10.2105/AJPH.2007.131243; Mandell DS, 2002, J AM ACAD CHILD PSY, V41, P1447, DOI 10.1097/00004583-200212000-00016; Mathews T J, 2002, MMWR Recomm Rep, V51, P9; Mikolajczyk RT, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-21; Milazzo AS, 2002, J NATL MED ASSOC, V94, P875; Miller TW, 2009, CLIN PSYCHOL REV, V29, P77, DOI 10.1016/j.cpr.2008.10.001; Mulvihill BA, 2007, PEDIATRICS, V119, pS107, DOI 10.1542/peds.2006-2089P; *NAT DOWN SYNDR SO, POS PAP RAC DISP; National Cancer Institute, 1975, SEER CANC STAT REV 1; Newacheck PW, 2003, ARCH PEDIAT ADOL MED, V157, P244, DOI 10.1001/archpedi.157.3.244; Newacheck PW, 2002, AMBUL PEDIATR, V2, P247, DOI 10.1367/1539-4409(2002)002<0247:RAEDIA>2.0.CO;2; Nicholas SW, 2005, AM J PUBLIC HEALTH, V95, P245, DOI 10.2105/AJPH.2004.042705; O'Connor GT, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e333; PALFREY JS, 1987, J PEDIATR-US, V111, P651, DOI 10.1016/S0022-3476(87)80238-X; PALFREY JS, 2006, CHILD HLTH AM; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Perrin JM, 2007, JAMA-J AM MED ASSOC, V297, P2755, DOI 10.1001/jama.297.24.2755; Powars DR, 2005, MEDICINE, V84, P363, DOI 10.1097/01.md.0000189089.45003.52; Prejean J., 2008, Morbidity and Mortality Weekly Report, V57, P985; PUESCHEL SM, 1995, ACTA PAEDIATR, V84, P823, DOI 10.1111/j.1651-2227.1995.tb13768.x; Raphael JL, 2009, ACAD PEDIATR, V9, P242, DOI 10.1016/j.acap.2009.05.002; Resta RG, 2005, AM J MED GENET A, V133A, P31, DOI 10.1002/ajmg.a.30553; Riolo SA, 2005, AM J PUBLIC HEALTH, V95, P998, DOI 10.2105/AJPH.2004.047225; Roberts RE, 1997, AM J COMMUN PSYCHOL, V25, P95, DOI 10.1023/A:1024649925737; ROBERTS RE, 1995, J AM ACAD CHILD PSY, V34, P1608, DOI 10.1097/00004583-199512000-00011; Rock MJ, 2005, J PEDIATR-US, V147, pS73, DOI 10.1016/j.jpeds.2005.08.004; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Schechter MS, 1998, J PEDIATR-US, V132, P260, DOI 10.1016/S0022-3476(98)70442-1; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shafer FE, 1996, J PEDIAT HEMATOL ONC, V18, P36, DOI 10.1097/00043426-199602000-00007; Shonkoff J. B., 2000, NEURONS NEIGHBORHOOD; Sia C, 2004, PEDIATRICS, V113, P1473; SIMON GE, 1995, J CLIN EPIDEMIOL, V48, P1109, DOI 10.1016/0895-4356(95)00010-2; Singh GK, 2008, ANN EPIDEMIOL, V18, P682, DOI 10.1016/j.annepidem.2008.05.001; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Sontag MK, 2005, J PEDIATR-US, V147, pS83, DOI 10.1016/j.jpeds.2005.08.005; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Szilagyi PG, 2007, AMBUL PEDIATR, V7, P10, DOI 10.1016/j.ambp.2006.09.006; Telfair J, 2003, PUBLIC HEALTH REP, V118, P27, DOI 10.1093/phr/118.1.27; *US DEP HLTH HUM R, AD YOUNG AD HIV AIDS; Velie EM, 2006, PAEDIATR PERINAT EP, V20, P219, DOI 10.1111/j.1365-3016.2006.00722.x; White House Task Force on Childhood Obesity Report to the President, SOLV PROBL CHILDH OB; Williams LJ, 2002, TERATOLOGY, V66, P33, DOI 10.1002/tera.10060; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220; Wise PH, 2007, J PEDIATR-US, V151, pS6, DOI 10.1016/j.jpeds.2007.08.013; Wong LYC, 2001, PAEDIATR PERINAT EP, V15, P374, DOI 10.1046/j.1365-3016.2001.00371.x; Wu YW, 2006, PEDIATRICS, V118, P690, DOI 10.1542/peds.2006-0278; Yeargin-Allsopp M, 2003, JAMA-J AM MED ASSOC, V289, P49, DOI 10.1001/jama.289.1.49; Yeargin-Allsopp M, 2008, PEDIATRICS, V121, P547, DOI 10.1542/peds.2007-1270	107	95	96	0	40	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2010	126			S			S111	S119		10.1542/peds.2010-1466D			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	734IV	WOS:000288328700002	21123473				2022-02-06	
J	Cantu, RC; Gean, AD				Cantu, Robert C.; Gean, Alisa D.			Second-Impact Syndrome and a Small Subdural Hematoma: An Uncommon Catastrophic Result of Repetitive Head Injury with a Characteristic Imaging Appearance	JOURNAL OF NEUROTRAUMA			English	Article						acute subdural hematoma; cerebral swelling; dysautoregulation; non-accidental head trauma; second-impact syndrome; shaken-baby syndrome; vascular brain engorgement	TRAUMATIC BRAIN-INJURY; 2ND IMPACT; SPORTS	There have been a handful of previously published cases of athletes who were still symptomatic from a prior head injury, and then suffered a second injury in which a thin, acute subdural hematoma (SDH) with unilateral hemisphere vascular engorgement was demonstrated on CT scan. In those cases, the cause of the brain swelling/dysautoregulation was ascribed to the presence of the acute SDH rather than to the acceleration/deceleration forces that caused the SDH. We believe that the brain swelling is due to "second-impact dysautoregulation," rather than due to the effect of the SDH on the underlying hemisphere. To support our hypothesis, we present 10 additional cases of acute hemispheric swelling in association with small SDHs in athletes who received a second head injury while still symptomatic from a previous head injury. The clinical history and the unique neuroimaging features of this entity on CT are described and illustrated in detail. The CT findings included an engorged cerebral hemisphere with initial preservation of grey-white matter differentiation, and abnormal mass effect and midline shift that appeared disproportionately greater than the size of the SDH. In addition, the imaging similarities between our patients and those with non-accidental head trauma (shaken-baby syndrome) will be discussed.	[Cantu, Robert C.] Boston Univ, Med Ctr, Dept Neurosurg, Boston, MA USA; [Cantu, Robert C.] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathy, Boston, MA USA; [Gean, Alisa D.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Brain & Spinal Injury Ctr, San Francisco Gen Hosp, San Francisco, CA 94143 USA		Cantu, RC (corresponding author), Boston Univ, Med Ctr, Ctr Study Traumat Eucephalopathy, Dept Neurosurg, 131 ORNAC,John Cuming Bldg,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org					BODEN B, 2000, AM J SPORTS MED, V35, P1; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 2000, NEUROLOGICAL ATHLETI, P135; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; MUELLER FO, 2009, 27 NAT CTR CAT SPORT; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider RC., 1973, HEAD NECK INJURIES F; SCHNITKER MT, 1949, J PEDIATR-US, V35, P557, DOI 10.1016/S0022-3476(49)80138-7; STREETER T, 1997, J COMMUN, V47, P128	19	95	95	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1557	1564		10.1089/neu.2010.1334			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500002	20536318	Green Published			2022-02-06	
J	Mols, F; Denollet, J				Mols, Floortje; Denollet, Johan			Type D personality among noncardiovascular patient populations: a systematic review	GENERAL HOSPITAL PSYCHIATRY			English	Article						Type D; Personality; Social inhibition; Negative affectivity; Noncardiovascular population	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; D SCALE-16; DISTRESS; ASSOCIATION; DEPRESSION; MORTALITY; CONSTRUCT	Objective: This article reviews all available literature concerning the implications of Type D personality (the conjoint effects of negative affectivity and social inhibition) among patients with noncardiovascular conditions. Methods: Published papers were included if they studied Type D personality among noncardiovascular patient populations. Twelve articles met our inclusion criteria and were subjected to a methodological quality checklist (e.g., sample size, response rate, Type D measurement). Results: The methodological quality of the selected studies was quite good. The noncardiovascular patient populations included chronic pain, asthma, tinnitus, sleep apnea, primary care patients, vulvovaginal candidiasis, mild traumatic brain injury, vertigo, melanoma and diabetic foot syndrome. Type D personality was associated with an increased number or severity of reported health complaints, heightened the perception of negative emotions (e.g., depression and anxiety), had an adverse effect on health-related behaviors, was associated with poor adherence to treatment and significantly reduced effort to perform during diagnostic testing. Conclusion: Type D is a vulnerability factor that not only affects people with cardiovascular conditions but also those with other medical conditions. Type D was associated with poor physical and mental health status and poor self-management of the disease. Consequently, including Type D in future studies seems warranted. (C) 2010 Elsevier Inc. All rights reserved.	[Mols, Floortje; Denollet, Johan] Tilburg Univ, Dept Med Psychol, CoRPS Ctr Res Psychol Somat Dis, POB 90153, NL-5000 LE Tilburg, Netherlands		Mols, F (corresponding author), Tilburg Univ, Dept Med Psychol, CoRPS Ctr Res Psychol Somat Dis, POB 90153, NL-5000 LE Tilburg, Netherlands.	F.Mols@uvt.nl			Netherlands Organization for Scientific Research (The Hague, The Netherlands)Netherlands Organization for Scientific Research (NWO)Netherlands Government [453-04-004]	The present research was supported by a VICI grant (#453-04-004) from the Netherlands Organization for Scientific Research (The Hague, The Netherlands) awarded to Johan Denollet.	Aquarius AE, 2005, AM J CARDIOL, V96, P996, DOI 10.1016/j.amjcard.2005.05.059; Barnett MD, 2009, J CLIN PSYCHOL MED S, V16, P194, DOI 10.1007/s10880-009-9152-0; Barone S, 2008, J BEHAV MED, V31, P331, DOI 10.1007/s10865-008-9164-5; BARTELS H, 2009, PSYCHOSOMAT IN PRESS; Bartels H, 2010, OTOL NEUROTOL, V31, P11, DOI 10.1097/MAO.0b013e3181bc3dd1; Brostrom A, 2007, J SLEEP RES, V16, P439, DOI 10.1111/j.1365-2869.2007.00620.x; Chapman BP, 2007, EUR J PERSONALITY, V21, P911, DOI 10.1002/per.645; De Fruyt F, 2002, PSYCHOL HEALTH, V17, P671, DOI 10.1080/08870440290025858; De Valck CFJ, 2007, AUDIOLOGICAL MED, V5, P169; Den Oudsten BL, 2007, MOVEMENT DISORD, V22, P1528, DOI 10.1002/mds.21567; DENOLLET J, 1995, PSYCHOSOM MED, V57, P582, DOI 10.1097/00006842-199511000-00011; Denollet J, 1998, ANN BEHAV MED, V20, P209, DOI 10.1007/BF02884962; Denollet J, 2000, CIRCULATION, V102, P630, DOI 10.1161/01.CIR.102.6.630; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Denollet J, 2009, PSYCHOL MED, V39, P749, DOI 10.1017/S0033291708004157; Denollet J, 1996, LANCET, V347, P417, DOI 10.1016/S0140-6736(96)90007-0; Denollet J, 1997, EUR J PERSONALITY, V11, P343, DOI 10.1002/(SICI)1099-0984(199712)11:5<343::AID-PER305>3.0.CO;2-P; Denollet J, 2008, ARCH INTERN MED, V168, P431, DOI 10.1001/archinternmed.2007.120; Denollet J, 2009, AM J CARDIOL, V103, P399, DOI 10.1016/j.amjcard.2008.09.096; Doering LV, 2004, J CARD FAIL, V10, P344, DOI 10.1016/j.cardfail.2003.10.001; Ehrstrom S, 2007, J PSYCHOSOM OBST GYN, V28, P169, DOI 10.1080/01674820601168176; KUPPER N, 2009, PSYCHOSOM M IN PRESS; MARTENS EJ, 2009, J CLIN PSYC IN PRESS; Martens EJ, 2007, J PSYCHOSOM RES, V63, P545, DOI 10.1016/j.jpsychores.2007.06.005; Molloy GJ, 2008, PSYCHOSOM MED, V70, P863, DOI 10.1097/PSY.0b013e3181842e0c; Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017; Mols F, 2010, EUR J CANCER, V46, P573, DOI 10.1016/j.ejca.2009.09.016; Pedersen SS, 2004, J PSYCHOSOM RES, V57, P265, DOI 10.1016/S0022-3999(03)00614-7; Pedersen SS, 2004, J AM COLL CARDIOL, V44, P997, DOI 10.1016/j.jacc.2004.05.064; Pedersen SS, 2003, EUR J CARDIOV PREV R, V10, P241, DOI 10.1097/00149831-200308000-00005; Pedersen SS, 2008, PSYCHOSOM MED, V70, P349, DOI 10.1097/PSY.0b013e3181656540; Pedersen SS, 2006, CURR CARDIOL REV, V2, P205, DOI 10.2174/157340306778019441; Pelle AJ, 2010, INT J CARDIOL, V142, P65, DOI 10.1016/j.ijcard.2008.12.086; Schiffer AA, 2007, HEART, V93, P814, DOI 10.1136/hrt.2006.102822; Schiffer AA, 2008, EUR J HEART FAIL, V10, P922, DOI 10.1016/j.ejheart.2008.07.010; Simson U, 2008, PSYCHOTHER PSYCH MED, V58, P44, DOI 10.1055/s-2007-971001; Spindler H, 2009, INT J BEHAV MED, V16, P98, DOI 10.1007/s12529-009-9037-5; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Thomas G, 2006, FOLIA PHONIATR LOGO, V58, P250, DOI 10.1159/000093182; Whitehead DL, 2007, J PSYCHOSOM RES, V62, P419, DOI 10.1016/j.jpsychores.2006.11.005; Williams L, 2008, J PSYCHOSOM RES, V64, P63, DOI 10.1016/j.jpsychores.2007.06.008	42	95	98	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0163-8343	1873-7714		GEN HOSP PSYCHIAT	Gen. Hosp. Psych.	JAN-FEB	2010	32	1					66	72		10.1016/j.genhosppsych.2009.09.010			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	584OE	WOS:000276761200009	20114130				2022-02-06	
J	Parvizi, J; Coburn, KL; Shillcutt, SD; Coffey, CE; Lauterbach, EC; Mendez, MF				Parvizi, Josef; Coburn, Kerry L.; Shillcutt, Samuel D.; Coffey, C. Edward; Lauterbach, Edward C.; Mendez, Mario F.			Neuroanatomy of Pathological Laughing and Crying: A Report of the American Neuropsychiatric Association Committee on Research	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							FOU RIRE PRODROMIQUE; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; POSTERIOR-FOSSA TUMORS; PSEUDOBULBAR AFFECT; MULTIPLE-SCLEROSIS; SUBTHALAMIC NUCLEUS; ELECTRICAL-STIMULATION; COGNITIVE DYSFUNCTION; PONTINE INFARCTION	Pathological laughing and crying ( PLC) is a clinical condition that occurs in patients with various neurological disorders. It is characterized by the presence of episodic and contextually inappropriate or merely exaggerated outbursts of laughter and/or crying without commensurate feelings. This review provides an in depth analysis of the neuroanatomy of lesions seen in patients with this clinical condition, discusses the relevant functional neuroimaging and electrophysiological stimulation studies in human subjects, and summarizes the current treatment options. It concludes with a presentation of the remaining questions and directions for future research.	[Parvizi, Josef] Stanford Univ, Dept Neurol, Sch Med, Stanford, CA 94305 USA; [Coburn, Kerry L.; Shillcutt, Samuel D.; Lauterbach, Edward C.] Mercer Univ, Sch Med, Dept Psychiat, Macon, GA 31207 USA; [Coffey, C. Edward] Henry Ford Hlth Syst, Dept Psychiat, Detroit, MI USA; [Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA		Parvizi, J (corresponding author), Stanford Univ, Dept Neurol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	jparvizi@stanford.edu					Abrahams S, 1997, J NEUROL NEUROSUR PS, V62, P464, DOI 10.1136/jnnp.62.5.464; ACHARI A N, 1976, Journal of the American Medical Association, V235, P1469, DOI 10.1001/jama.235.14.1469; ALLMAN P, 1989, J NEUROL NEUROSUR PS, V52, P1439, DOI 10.1136/jnnp.52.12.1439; ANDERSEN G, 1994, STROKE, V25, P1050, DOI 10.1161/01.STR.25.5.1050; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Arif H, 2005, NEUROLOGY, V64, P2154, DOI 10.1212/01.WNL.0000166033.90390.2A; BECHTEREW WV, 1909, FUNKTIONEN NERVENCEN; Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Benedetti F, 2004, BRAIN RES BULL, V63, P203, DOI 10.1016/j.brainresbull.2004.01.010; Bhatjiwale MG, 2000, NEUROSURGERY, V47, P469, DOI 10.1097/00006123-200008000-00044; Brissaud E., 1895, LECONS MALADIES NERV; Brissaud E., 1895, RIRE PLEURER SPASMOD, P446; Brooks BR, 2004, NEUROLOGY, V63, P1364; Burns A, 1999, INT J GERIATR PSYCH, V14, P681, DOI 10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.3.CO;2-Q; Carel C, 1997, STROKE, V28, P2081, DOI 10.1161/01.STR.28.10.2081; CUMMINGS JL, 2007, CNS SPECTR S5 S6, V12; DAMASIO AR, 1994, DESCARTESERROR; DAVIDSON RJ, 2003, HDB AFFECTIVE SCI; de Gelder B, 2006, NAT REV NEUROSCI, V7, P242, DOI 10.1038/nrn1872; DOORENBOS DI, 1993, NEUROLOGY, V43, P229, DOI 10.1212/WNL.43.1_Part_1.229; EKMAN P, 1992, PHILOS T ROY SOC B, V335, P63, DOI 10.1098/rstb.1992.0008; Famularo G, 2007, EUR J NEUROL, V14, P940, DOI 10.1111/j.1468-1331.2007.01784.x; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; FERE MC, 1903, REV NEUROL, P11353; Fried I, 1998, NATURE, V391, P650, DOI 10.1038/35536; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; GAVRILESCU T, 1995, CEREBROVAS BRAIN MET, V7, P218; Geday J, 2006, NEUROIMAGE, V33, P706, DOI 10.1016/j.neuroimage.2006.06.056; Ghaffar O, 2008, J NEUROL, V255, P406, DOI 10.1007/s00415-008-0685-1; Gondim FAA, 2004, REV NEUROL-FRANCE, V160, P277; Gordon B, 1996, PROG BRAIN RES, V107, P617; Gross J.J, 2007, HDB EMOTIONAL REGULA; Hargrave DR, 2006, J NEURO-ONCOL, V77, P267, DOI 10.1007/s11060-005-9034-8; HAUPT M, 1996, INT PSYCHOGERIATR S, V8, P3409; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; IRONSIDE R, 1956, BRAIN, V79, P589, DOI 10.1093/brain/79.4.589; Johnston S Claiborne, 2007, Ann Neurol, V61, p11A, DOI 10.1002/ana.21100; Kahane P, 2003, EPILEPTIC DISORD, V5, P205; Kataoka S, 1997, STROKE, V28, P809, DOI 10.1161/01.STR.28.4.809; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; KIM JS, 1995, STROKE, V26, P950, DOI 10.1161/01.STR.26.6.950; Kim JS, 1997, STROKE, V28, P2321; Kosaka H, 2006, J NEUROL NEUROSUR PS, V77, P1376, DOI 10.1136/jnnp.2005.073288; Krack P, 2001, MOVEMENT DISORD, V16, P867, DOI 10.1002/mds.1174; LAL AP, 1992, J NEUROL NEUROSUR PS, V55, P628, DOI 10.1136/jnnp.55.7.628-a; Lanteaume L, 2007, CEREB CORTEX, V17, P1307, DOI 10.1093/cercor/bhl041; Larner AJ, 1998, NEUROLOGY, V51, P916, DOI 10.1212/WNL.51.3.916; LAUTERBACH EC, 1994, BIOL PSYCHIAT, V35, P488, DOI 10.1016/0006-3223(94)90048-5; LeDoux J.E., 1998, EMOTIONAL BRAIN MYST; Levenson RW, 2003, ANN NY ACAD SCI, V1000, P348, DOI 10.1196/annals.1280.016; Low HL, 2008, ARCH NEUROL-CHICAGO, V65, P264, DOI 10.1001/archneurol.2007.53; Mallet L, 2007, P NATL ACAD SCI USA, V104, P10661, DOI 10.1073/pnas.0610849104; MATSUOKA S, 1993, J NEUROSURG, V79, P428, DOI 10.3171/jns.1993.79.3.0428; McCullagh S, 1999, J NEUROL SCI, V169, P43, DOI 10.1016/S0022-510X(99)00214-2; Meletti S, 2006, EPILEPSIA, V47, P47, DOI 10.1111/j.1528-1167.2006.00877.x; Meyer M, 2007, BEHAV BRAIN RES, V182, P245, DOI 10.1016/j.bbr.2007.04.023; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MOUTON P, 1994, REV NEUROL, V150, P302; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; Murai T, 2003, PSYCHIAT RES-NEUROIM, V123, P207, DOI 10.1016/S0925-4927(03)00065-9; Nadkarni TD, 1999, BRIT J NEUROSURG, V13, P212, DOI 10.1080/02688699944023; Niedenthal PM, 2007, SCIENCE, V316, P1002, DOI 10.1126/science.1136930; Okuda DT, 2005, MOVEMENT DISORD, V20, P1389, DOI 10.1002/mds.20607; Okun MS, 2004, J NEUROL NEUROSUR PS, V75, P921, DOI 10.1136/jnnp.2003.016485; OPPENHEIM H, 1886, MITTEILUNGEN PSEUDOB; Oppenheim H., 1911, TXB NERVOUS DIS PHYS; Panitch HS, 2006, ANN NEUROL, V59, P780, DOI 10.1002/ana.20828; Panksepp, 1998, AFFECTIVE NEUROSCIEN; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; PARVIZI J, 2003, BRAIN; Parvizi J, 2007, MOVEMENT DISORD, V22, P798, DOI 10.1002/mds.21348; Parvizi J, 2007, J NEUROPSYCH CLIN N, V19, P187, DOI 10.1176/appi.neuropsych.19.2.187; Parvizi J, 2006, MAYO CLIN PROC, V81, P1482, DOI 10.4065/81.11.1482; POECK K, 1985, CLIN NEUROPSYCHOLOGY, P219; POECK K, 1964, ARCH NEUROL PSYCHIAT, P92323; POECK K, 1985, DISORDERS HIGHER NER, P343; POLLACK IF, 1995, NEUROSURGERY, V37, P885, DOI 10.1227/00006123-199511000-00006; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; SELIGER G M, 1992, Brain Injury, V6, P267, DOI 10.3109/02699059209029668; Shafqat S, 1998, NEUROLOGY, V50, P1918, DOI 10.1212/WNL.50.6.1918; Siddiqui MS, 2006, NEUROLOGY, V66, pA369; Sperli F, 2006, EPILEPSIA, V47, P440, DOI 10.1111/j.1528-1167.2006.00442.x; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Tei H, 1997, NEURORADIOLOGY, V39, P190, DOI 10.1007/s002340050390; VANCALENBERGH F, 1995, NEUROSURGERY, V37, P894, DOI 10.1227/00006123-199511000-00007; VANHILTEN JJ, 1988, ARCH NEUROL-CHICAGO, V45, P936, DOI 10.1001/archneur.1988.00520330010001; WALI GM, 1993, J NEUROL NEUROSUR PS, V56, P209, DOI 10.1136/jnnp.56.2.209; Whitehouse PJ, 2007, NEUROTHERAPEUTICS, V4, P560, DOI 10.1016/j.nurt.2007.03.003; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Wojtecki L, 2007, MOVEMENT DISORD, V22, P1314, DOI 10.1002/mds.21266; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160	96	95	97	0	14	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2009	21	1					75	87		10.1176/jnp.2009.21.1.75			13	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	431ES	WOS:000265044700011	19359455				2022-02-06	
J	Tillou, A; Gupta, M; Baraff, LJ; Schriger, DL; Hoffman, JR; Hiatt, JR; Cryer, HM				Tillou, Areti; Gupta, Malkeet; Baraff, Larry J.; Schriger, David L.; Hoffman, Jerome R.; Hiatt, Jonathan R.; Cryer, Henry M.			Is the Use of Pan-Computed Tomography for Blunt Trauma Justified? A Prospective Evaluation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Computed tomography; Blunt injury; Trauma; Missed injuries	ABDOMINAL-TRAUMA; EMERGENCY-DEPARTMENT; INJURY; MANAGEMENT; SCAN	Objective: Many trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma. This prospective observational study was undertaken to determine whether a more selective approach could be justified. Methods: We evaluated injuries in blunt trauma victims receiving a pan-CT scan at a level 1 trauma center. The primary outcome was injury needing immediate intervention. Secondary outcome was any injury. The perceived need for each scan was independently recorded by the emergency medicine and trauma surgery service before patients went to CT. A scan was unsupported if at least one of the physicians deemed it unnecessary. Results: Between July, 1, 2007, and December, 28, 2007, 284 blunt trauma patients (average Injury Severity Score = 11) underwent a pan-CT after the survey form was completed. A total of 311 CT scans were judged to be unnecessary in 143 patients (27%), including scans of the head (62), neck (50), chest (116), and abdomen/pelvis (83). Of the 284 patients, 48 (17%) had injuries on 52 unsupported CT scans. An immediate intervention was required in 2 of the 48 patients (4%). Injuries that would have been missed included 5 of 62 unsupported head scans (8%), 2 of 50 neck scans (4%), 33 of 116 chest scans (28%), and 12 of 83 abdominal scans (14%). These missed injuries represent 5 of the 61 patients with closed head injuries (8%) in the series, 2 of the 23 with C-spine injuries (9%), 33 of the 112 with chest injuries (29%), and 12 of the 86 with abdominal injuries (14%). In 19 patients. none of the four CT scans was supported; nine of these had an injury identified, and six were admitted to the hospital (1 to the intensive care unit). Injuries that would have been missed included intraventricular and intracerebral hemorrhage (4), subarachnoid hemorrhage (2), cerebral contusion (1), C1 fracture (1), spinous and transverse process fractures (3), vertebral fracture (6), lung lacerations (1), lung contusions (14), small pneumothoraces (7), grade II-III liver and splenic lacerations (6), and perinephric or mesenteric hematomas (2). Conclusions: In this small sample, physicians were willing to omit 27% of scans. If this was done, two injuries requiring immediate actions would have been missed initially, and other potentially important injuries would have been missed in 17% of patients.	[Tillou, Areti] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Emergency Med, David Geffen Sch Med, Los Angeles, CA 90095 USA		Tillou, A (corresponding author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 10833 Conte Ave,CHS,Room 72-231, Los Angeles, CA 90095 USA.	atillou@mednet.ucla.edu		Schriger, David/0000-0003-0242-1127			BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; BRIX G, 2008, EUR J RADIOL; Broder J, 2006, EMERG RADIOL, V13, P25, DOI 10.1007/s10140-006-0493-9; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; DEMETRIADES D, 2008, ARCH SURG-CHICAGO, V133, P1084; Exadaktylos AK, 2001, J TRAUMA, V51, P1173, DOI 10.1097/00005373-200112000-00025; GLABAMAN M, HLTH PLANS STAIN CON; Goldman DP., 2005, US HLTH CARE FACTS C; Griffen MM, 2003, J TRAUMA, V55, P222, DOI 10.1097/01.TA.0000083332.93868.E2; Isenhour JL, 2007, EMERG MED CLIN N AM, V25, P713, DOI 10.1016/j.emc.2007.06.002; Kalra MK, 2004, RADIOLOGY, V230, P619, DOI 10.1148/radiol.2303021726; Livingston DH, 1998, J TRAUMA, V44, P273, DOI 10.1097/00005373-199802000-00005; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; MATSUBARA TK, 1990, J TRAUMA, V30, P410, DOI 10.1097/00005373-199030040-00006; McCarthy MC, 1998, J TRAUMA, V44, P280; PEITZMAN AB, 1986, J TRAUMA, V26, P585, DOI 10.1097/00005373-198607000-00001; PEVEC WC, 1991, SURG GYNECOL OBSTET, V173, P262; Pfeifer R, 2008, PATIENT SAF SURG, V2, DOI 10.1186/1754-9493-2-20; Poletti PA, 2004, J TRAUMA, V57, P1072, DOI 10.1097/01.TA.0000092680.73274.E1; RIZZO AG, 1995, J TRAUMA, V38, P338, DOI 10.1097/00005373-199503000-00005; Salim A, 2006, ARCH SURG-CHICAGO, V141, P468, DOI 10.1001/archsurg.141.5.468; Self ML, 2003, AM J SURG, V186, P609, DOI 10.1016/j.amjsurg.2003.08.003; Tien HC, 2007, J TRAUMA, V62, P151, DOI 10.1097/TA.0b013e31802d9700; Tyburski JG, 2006, ARCH SURG-CHICAGO, V141, P473; Vles WJ, 2003, J AM COLL SURGEONS, V197, P596, DOI 10.1016/S1072-7515(03)00601-X; WOLFMAN NT, 1992, AM J ROENTGENOL, V158, P493, DOI 10.2214/ajr.158.3.1738983	28	95	98	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					779	787		10.1097/TA.0b013e3181b5f2eb			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	506BE	WOS:000270747000018	19820586				2022-02-06	
J	Dash, PK; Zhao, J; Orsi, SA; Zhang, M; Moore, AN				Dash, Prarnod K.; Zhao, Jing; Orsi, Sara A.; Zhang, Min; Moore, Anthony N.			Sulforaphane improves cognitive function administered following traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						TBI; Nrf2; Prefrontal cortex; Hippocampus; Spatial memory	CONTROLLED CORTICAL IMPACT; OLIGONUCLEOTIDE MICROARRAY; MEMORY DEFICITS; EXPRESSION; IDENTIFICATION; NEURONS; COMPLEX; PROTEIN; STRESS; MODEL	Recent studies have shown that sulforaphane, a naturally occurring compound that is found in cruciferous vegetables, offers cellular protection in several models of brain injury. When administered following traumatic brain injury (TBI), sulforaphane has been demonstrated to attenuate blood-brain barrier permeability and reduce cerebral edema. These beneficial effects of sulforaphane have been shown to involve induction of a group of cytoprotective, Nrf2-driven genes, whose protein products include free radical scavenging and detoxifying enzymes. However, the influence of sulforaphane on post-injury cognitive deficits has not been examined. In this study, we examined if sulforaphane, when administered following cortical impact injury, can improve the performance of rats tested in hippocampal- and prefrontal cortex-dependent tasks. Our results indicate that sulforaphane treatment improves performance in the Morris water maze task (as indicated by decreased latencies during learning and platform localization during a probe trial) and reduces working memory dysfunction (tested using the delayed match-to-place task). These behavioral improvements were only observed when the treatment was initiated 1 h, but not 6 h, post-injury. These studies support the use of sulforaphane in the treatment of TBI, and extend the previously observed protective effects to include enhanced cognition. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Dash, Prarnod K.; Zhao, Jing; Orsi, Sara A.; Zhang, Min; Moore, Anthony N.] Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH072933, NS053588, NS049160]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160, R01NS053588] Funding Source: NIH RePORTER	This work was supported, in part, by grants (MH072933, NS053588, NS049160) from the National Institutes of Health to P.K.D.	CALICOS MA, 1996, BRAIN RES, V739, P111; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; SHARP FR, 1993, STROKE S, V24, P172; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	18	95	101	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 28	2009	460	2					103	107		10.1016/j.neulet.2009.04.028			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	469PD	WOS:000267911100001	19515491	Green Accepted			2022-02-06	
J	Blinman, TA; Houseknecht, E; Snyder, C; Wiebe, DJ; Nance, ML				Blinman, Thane A.; Houseknecht, Eileen; Snyder, Caitlin; Wiebe, Douglas J.; Nance, Michael L.			Postconcussive symptoms in hospitalized pediatric patients after mild traumatic brain injury	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	60th Annual Meeting of the American-Academy-of-Pediatrics	OCT 10-12, 2008	Boston, MA	Amer Acad Pediat		Closed head injury; Concussion; Symptoms; Trauma	HEAD TRAUMA; CONCUSSION; SPORT	Background: Mild traumatic brain injury (MTBI) is common in the pediatric population. The symptom complex that might be expected in children after MTBI is not well documented. We sought to clarify the frequency and severity of concussive symptoms reported by children who required hospitalization for MTBI. Methods: Pediatric blunt trauma patients (age, 11-17 years) admitted for treatment of MTBI (GCS 14-15) were prospectively enrolled over a 2-year period. Consented patients were administered a 22-question Likert-based concussion symptom scale (normal, total score 0-8). The symptom scale was repeated at the time of routine follow-up trauma clinic visit. The frequency and severity of concussive symptoms were analyzed at both time-points. Results: For the 2-year period, 116 children participated in the study including 63 who returned for clinic follow-up. The overall population had mean age of 14.1 years (median 14) and was 69.8% male. The mean symptom score (sum of Likert scores [scale 0-6] for 22 questions) was 27.9 (median, 23.5) at hospitalization and 9.2 (median, 4.0) at follow-up. An abnormal symptom score (>8) was reported in 83.6% of hospitalized patients and 38.1% at follow-up. Girls had a significantly higher mean symptom score at initial testing than boys (33.9 vs 25.3, respectively; P < .05). This difference disappeared by the time of follow-up (girls 9.2 vs boys 9.1, P = .98) The most common initial symptom was headache (71.5% of patients) and most severe (highest mean score) was fatigue (mean, 2.0; median, 2.0). At follow-up, the most common symptom was excess sleep (38.1%) and most severe symptom failing asleep (mean, 1.0; median, 0). There were no significant differences in initial scores based oil reported loss of consciousness, prior concussion history, or GCS 14 vs 15. Conclusions: Symptoms after MTBI are quite common at the time of hospitalization. Symptom scores improve to near normal for most by outpatient follow-up. The most common symptom was headache, but the most severe was fatigue, in this hospitalized pediatric population. Thoughtful assessment and follow-up of this patient Population are warranted. (C) 2009 Elsevier Inc. All rights reserved.	[Blinman, Thane A.; Houseknecht, Eileen; Snyder, Caitlin; Nance, Michael L.] Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; [Wiebe, Douglas J.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA		Blinman, TA (corresponding author), Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA.	blinman@email.chop.edu	Wiebe, Douglas J/Q-1168-2017				Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2005, J CLIN EXPER NEUROPS, V27; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Stepanski EJ, 2003, SLEEP MED REV, V7, P215, DOI 10.1053/smrv.2001.0246; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7	10	95	95	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	JUN	2009	44	6					1223	1228		10.1016/j.jpedsurg.2009.02.027			6	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics; Surgery	462HV	WOS:000267342800036	19524745				2022-02-06	
J	Reiff, DA; Haricharan, RN; Bullington, NM; Griffin, RL; McGwin, G; Rue, LW				Reiff, Donald A.; Haricharan, Ramanath N.; Bullington, Nathan M.; Griffin, Russell L.; McGwin, Gerald, Jr.; Rue, Loring W., III			Traumatic Brain Injury Is Associated With the Development of Deep Vein Thrombosis Independent of Pharmacological Prophylaxis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM PROPHYLAXIS; INTRACRANIAL HEMORRHAGIC INJURIES; MAJOR TRAUMA; ENOXAPARIN PROPHYLAXIS; 1602 EPISODES; HEAD-INJURY; DATA-BANK; SAFETY; COAGULATION	Introduction: Deep venous thrombosis (DVT) is common among trauma patients. If left untreated it may result in lethal pulmonary thromboembolism. Previous studies have suggested that intracranial hemorrhage serves as an independent risk factor for the development of DVT. These studies were not able to exclude anticoagulation therapy as a confounding variable in their analysis. Our objective was to determine the association of traumatic brain injury (TBI) to the formation of DVT irrespective of the use of anticoagulation therapy. Methods: All patients admitted to an academic level I Trauma Center between 2000 and 2007 with blunt or penetrating injuries were selected for inclusion in this study. Patients who died or who were discharged within 24 hours of admission were excluded in the analysis. TBI was defined as any intraparenchymal hemorrohage or extra-axial intracranial bleeding identified on radiographic imaging or both. Anticoagulation therapy was defined as the uninterrupted use of either subcutaneous lovenox or heparin. Risk ratios and 95% confidence intervals compared the risk of DVT among patients with and without TBI according to the initiation of anticoagulation therapy (no therapy, <24 hours, 24-48 hours, and >48 hours) adjusted for age, gender, race, injury severity, mechanism of injury, spinal injury, and lower extremity fracture. Results: Irrespective of the time of initiation of pharmacologic prophalaxis, TBI is independently associated with the formation of DVT. A threefold to fourfold increased risk of DVT formation is consistent across all prophylaxis groups among patients with TBI. Conclusion: The incidence of DVT among injured patients with TBI is significantly higher than those patients without head injury independent of anticoagulation therapy. Rigorous surveillance to detect DVT among trauma patients with TBI should be undertaken and where appropriate alternate means for pulmonary thromboembolism prevention used.	[Reiff, Donald A.; Haricharan, Ramanath N.; Bullington, Nathan M.; Griffin, Russell L.] Univ Alabama Birmingham, Dept Surg, Sect Trauma Burns & Surg Crit Care, Sch Med, Birmingham, AL 35294 USA; [Reiff, Donald A.; McGwin, Gerald, Jr.; Rue, Loring W., III] Univ Alabama Birmingham, Sch Publ Hlth, Ctr Injury Sci, Birmingham, AL 35294 USA; [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA		Reiff, DA (corresponding author), Univ Alabama Birmingham, Dept Surg, Sect Trauma Burns & Surg Crit Care, Sch Med, 1922 7th Ave S,KB 110, Birmingham, AL 35294 USA.	donald.reiff@ccc.uab.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Brandt MM, 2007, AM J SURG, V193, P383; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Macdonald RL, 2003, SURG NEUROL, V59, P363, DOI 10.1016/S0090-3019(03)00111-3; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Rogers SO, 2007, J TRAUMA, V62, P562; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Shackford SR, 2004, ANN SURG, V240, P496; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Yablon SA, 2004, NEUROLOGY, V63, P485, DOI 10.1212/01.WNL.0000133009.24727.9F; 2007, J NEUROTRAUMA S1, V24, pS32	35	95	100	5	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2009	66	5					1436	1440		10.1097/TA.0b013e31817fdf1c			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	445AJ	WOS:000266021700032	19430251				2022-02-06	
J	Dietrich, WD; Atkins, CM; Bramlett, HM				Dietrich, W. Dalton; Atkins, Coleen M.; Bramlett, Helen M.			Protection in Animal Models of Brain and Spinal Cord Injury with Mild to Moderate Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			hypothermia; regeneration; stem cells; traumatic brain injury; traumatic spinal cord injury	FOCAL CEREBRAL-ISCHEMIA; TRANSIENT GLOBAL-ISCHEMIA; DELAYED POSTISCHEMIC HYPOTHERMIA; MICROTUBULE-ASSOCIATED PROTEIN-2; COMBINATION-DRUG THERAPY; CYTOCHROME-C RELEASE; TRAUMATIC AXONAL INJURY; NITRIC-OXIDE SYNTHESIS; POSTTRAUMATIC HYPOTHERMIA; FOREBRAIN ISCHEMIA	For the past 20 years, various laboratories throughout the world have shown that mild to moderate levels of hypothermia lead to neuroprotection and improved functional outcome in various models of brain and spinal cord injury (SCI). Although the potential neuroprotective effects of profound hypothermia during and following central nervous system (CNS) injury have long been recognized, more recent studies have described clinically feasible strategies for protecting the brain and spinal cord using hypothermia following a variety of CNS insults. In some cases, only a one or two degree decrease in brain or core temperature can be effective in protecting the CNS from injury. Alternatively, raising brain temperature only a couple of degrees above normothermia levels worsens outcome in a variety of injury models. Based on these data, resurgence has occurred in the potential use of therapeutic hypothermia in experimental and clinical settings. The study of therapeutic hypothermia is now an international area of investigation with scientists and clinicians from every part of the world contributing to this important, promising therapeutic intervention. This paper reviews the experimental data obtained in animal models of brain and SCI demonstrating the benefits of mild to moderate hypothermia. These studies have provided critical data for the translation of this therapy to the clinical arena. The mechanisms underlying the beneficial effects of mild hypothermia are also summarized.	[Dietrich, W. Dalton; Atkins, Coleen M.; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,Suite 2-33, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Akaji K, 2003, BRAIN RES, V975, P149, DOI 10.1016/S0006-8993(03)02622-2; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BERGUER R, 1992, J VASC SURG, V15, P62, DOI 10.1016/0741-5214(92)70014-C; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; BUCHAN A, 1990, J NEUROSCI, V10, P311; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; BUSTO R, 1994, J NEUROCHEM, V63, P1095; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN H, 1992, ACTA NEUROPATHOL, V84, P184, DOI 10.1007/BF00311393; CHEN H, 1992, J NEUROL SCI, V107, P191, DOI 10.1016/0022-510X(92)90288-V; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Clark DL, 2008, EXP NEUROL, V212, P386, DOI 10.1016/j.expneurol.2008.04.016; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1998, BRAIN RES, V803, P69, DOI 10.1016/S0006-8993(98)00612-X; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; COLON R, 1987, ANN THORAC SURG, V43, P639, DOI 10.1016/S0003-4975(10)60238-X; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Corbett D, 1997, STROKE, V28, P2238, DOI 10.1161/01.STR.28.11.2238; DeKosky ST, 2004, J NEUROCHEM, V90, P998, DOI 10.1111/j.1471-4159.2004.02575.x; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dong H, 2001, STROKE, V32, P788, DOI 10.1161/01.STR.32.3.788; Florian B, 2008, NEUROSCI LETT, V438, P180, DOI 10.1016/j.neulet.2008.04.020; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; Fukui O, 2006, BRAIN RES, V1121, P35, DOI 10.1016/j.brainres.2006.08.121; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; GREEN EJ, 1995, BRAIN RES, V702, P145, DOI 10.1016/0006-8993(95)01034-1; Gressens P, 2008, BRAIN PATHOL, V18, P10, DOI 10.1111/j.1750-3639.2007.00095.x; Ha KY, 2008, SPINE, V33, P2059, DOI 10.1097/BRS.0b013e31818018f6; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hansebout R R, 1975, Surg Neurol, V4, P531; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; Hicks SD, 2000, NEUROSCIENCE, V98, P677, DOI 10.1016/S0306-4522(00)00169-X; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huang FP, 1998, NEUROL RES, V20, P57; Huang FP, 1998, NEUROCHEM RES, V23, P991, DOI 10.1023/A:1021088523137; Huang ZG, 1999, CAN J NEUROL SCI, V26, P298, DOI 10.1017/S0317167100000421; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Ibayashi S, 2000, NEUROCHEM RES, V25, P369, DOI 10.1023/A:1007593004806; Inamasu J, 2000, ACT NEUR S, V76, P525; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Jia XF, 2008, CRIT CARE MED, V36, P1909, DOI 10.1097/CCM.0b013e3181760eb5; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Karabiyikoglu M, 2003, J NEUROSURG, V98, P1271, DOI 10.3171/jns.2003.98.6.1271; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; Kawai N, 2002, ACT NEUR S, V81, P233; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kobayashi MS, 2008, BRAIN RES REV, V58, P171, DOI 10.1016/j.brainresrev.2008.03.001; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Kollmar R, 2004, EXP NEUROL, V190, P204, DOI 10.1016/j.expneurol.2004.07.006; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; Kuchner E F, 1976, Surg Neurol, V6, P371; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824, DOI 10.1152/ajpheart.1993.265.3.H824; Kumar K, 1996, MOL BRAIN RES, V42, P337, DOI 10.1016/S0169-328X(96)00181-7; Kumar K, 1997, METAB BRAIN DIS, V12, P21, DOI 10.1007/BF02676351; Kumura E, 1996, NEUROSCI LETT, V220, P45, DOI 10.1016/S0304-3940(96)13238-9; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Liebetrau M, 2004, NEUROSCI LETT, V357, P17, DOI 10.1016/j.neulet.2003.12.031; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LO EH, 1993, NEUROL RES, V15, P281; LO TP, 2009, J COMP NEUR IN PRESS; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; MALATOVA Z, 1995, MOL CHEM NEUROPATHOL, V25, P81, DOI 10.1007/BF02960903; Mancuso A, 2000, BRAIN RES, V887, P34, DOI 10.1016/S0006-8993(00)02963-2; Markarian GZ, 1996, NEUROSURGERY, V38, P542; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Morino T, 2008, SPINAL CORD, V46, P425, DOI 10.1038/sj.sc.3102163; Morochovic R, 2008, INT J NEUROSCI, V118, P555, DOI 10.1080/00207450601123456; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nakano H, 2007, ARQ NEURO-PSIQUIAT, V65, P810, DOI 10.1590/S0004-282X2007000500015; NASLUND TC, 1992, ANN SURG, V215, P409, DOI 10.1097/00000658-199205000-00002; Nito C, 2003, ACT NEUR S, V86, P199; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; ONESTI ST, 1991, NEUROSURGERY, V29, P369, DOI 10.1227/00006123-199109000-00005; Pabello NG, 2005, BRAIN RES, V1038, P11, DOI 10.1016/j.brainres.2004.12.047; Pabello NG, 2004, BRAIN RES, V995, P29, DOI 10.1016/j.brainres.2003.09.065; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Park CK, 1998, ACT NEUR S, V71, P225; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; PRAKASA BP, 2000, NEUROSCI LETT, V291, P196; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Shimohata T, 2007, J CEREBR BLOOD F MET, V27, P1463, DOI 10.1038/sj.jcbfm.9600450; Shimohata T, 2007, STROKE, V38, P375, DOI 10.1161/01.STR.0000254616.78387.ee; Strauch JT, 2004, EUR J CARDIO-THORAC, V25, P708, DOI 10.1016/j.ejcts.2004.01.007; SUTTON LN, 1991, STROKE, V22, P1567, DOI 10.1161/01.STR.22.12.1567; TABAYASHI K, 1993, ANN THORAC SURG, V56, P494, DOI 10.1016/0003-4975(93)90885-L; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Tetik O, 2002, EUR J VASC ENDOVASC, V24, P540, DOI 10.1053/ejvs.2002.1753; Tohyama Y, 1998, EXP BRAIN RES, V122, P333, DOI 10.1007/s002210050521; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Urrea C, 2004, ACTA NEUROPATHOL, V107, P413, DOI 10.1007/s00401-004-0827-1; Van Hemelrijck A, 2005, EUR J NEUROSCI, V22, P1327, DOI 10.1111/j.1460-9568.2005.04331.x; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wakamatsu H, 1999, ANESTH ANALG, V88, P56, DOI 10.1097/00000539-199901000-00011; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; WELLS JD, 1978, SURG NEUROL, V10, P200; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; Wu XL, 1995, NEUROREPORT, V7, P302, DOI 10.1097/00001756-199512290-00072; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yanamoto H, 2001, STROKE, V32, P232, DOI 10.1161/01.STR.32.1.232; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; Yenari MA, 2002, J CEREBR BLOOD F MET, V22, P29, DOI 10.1097/00004647-200201000-00004; Yoshitake A, 2007, J THORAC CARDIOV SUR, V134, P1220, DOI 10.1016/j.jtcvs.2007.06.015; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Zausinger S, 2003, STROKE, V34, P1526, DOI 10.1161/01.STR.0000070841.31224.29; Zhang H, 2008, NEUROL RES, V30, P332, DOI 10.1179/174313208X300279; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; Zhang Y, 2001, Acta Anaesthesiol Sin, V39, P65; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; Zhao H, 2004, STROKE, V35, P572, DOI 10.1161/01.STR.0000110787.42083.58; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2007, J NEUROSURG, V107, P636, DOI 10.3171/JNS-07/09/0636; Zhu HD, 2005, EXP NEUROL, V193, P361, DOI 10.1016/j.expneurol.2005.01.022; ZIELONKA J S, 1974, Surgical Forum (Chicago), V25, P434	175	95	109	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					301	312		10.1089/neu.2008.0806			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900003	19245308	Green Published			2022-02-06	
J	Chang, JJJ; Youn, TS; Benson, D; Mattick, H; Andrade, N; Harper, CR; Moore, CB; Madden, CJ; Diaz-Arrastia, RR				Chang, Jason J. J.; Youn, Teddy S.; Benson, Dan; Mattick, Heather; Andrade, Nicholas; Harper, Caryn R.; Moore, Carol B.; Madden, Christopher J.; Diaz-Arrastia, Ramon R.			Physiologic and functional outcome correlates of brain tissue hypoxia in traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						intracranial pressure; cerebral perfusion pressure; hemoglobin; PaCO2; traumatic brain injury; brain tissue oxygenation	SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; DISABILITY RATING-SCALE; CEREBRAL OXYGENATION; INTRACRANIAL HYPERTENSION; REGIONAL OXYGENATION; PARTIAL-PRESSURE; TENSION; MICRODIALYSIS; ISCHEMIA	Objective: Assess the prevalence of brain tissue hypoxia in patients with severe traumatic brain injuries (TBI), and to characterize the relationship between brain tissue hypoxia and functional outcome. Design: Retrospective review of severe TBI patients. Setting: Intensive care unit of a level I trauma center. Patients: Twenty-seven patients with severe TBI requiring intracranial pressure (ICP) monitoring. Median age was 22 yrs, and a majority (63%) had traumatic subarachnoid hemorrhage. Interventions: Hourly assessments of ICP, brain tissue oxygen, mean arterial pressure, fraction of inspired oxygen (FIO2), partial pressure of arterial carbon dioxide (PaCO2,), and hemoglobin concentration (hemoglobin) were recorded. Outcome was assessed 6-9 months postinjury. Measurements and Main Results: Mean (so) ICP and BTpo(2) were 13.7 (6.6) cm H2O and 30.8 (13.6) mm Hg. A total of 13.5% (379) of the BTpo(2) values recorded were <20 mm Hg, only 86 of which were associated with ICP >= 20 cm H2O. This prevalence was comparable with episodes of ICP elevations above 20 cm H2O (14.1%, 397). Hypoxic episodes were more common when cerebral perfusion pressure was below 60 mm Hg (relative risk = 3.0, p < 0.0001). We did not find an association in hypoxic risk and hemoglobin in the range of 7-12 g/dL or PaCO2 in the range of 25-40 mm Hg. Subjects with hourly episodes (epochs) of hypoxia >20% of the time had poorer scores on outcome measures compared with those with fewer hypoxic epochs. Conclusions: Hypoxic episodes are common after severe TBI, and most are independent of ICP elevations. Most episodes of hypoxia occur while cerebral perfusion pressure and mean arterial pressure are within the accepted target range. There is no clear association between PaCO2 and hemoglobin with BTpo(2),. The young age and high prevalence of traumatic subarachnoid hemorrhage in this cohort may limit its generalizability. Increased frequency of hypoxic episodes is associated with poor functional outcome. (Crit Care Med 2009; 37:283-290)	[Youn, Teddy S.; Benson, Dan; Mattick, Heather; Andrade, Nicholas; Harper, Caryn R.; Moore, Carol B.; Diaz-Arrastia, Ramon R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Chang, Jason J. J.; Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA		Chang, JJJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu	Youn, Teddy Si/N-1535-2017; Youn, Teddy/AAM-7705-2020; Youn, Teddy Si/ABH-9887-2020	Youn, Teddy Si/0000-0002-7325-1148; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); NIH-NICDHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; US Department of EducationUS Department of Education [1-1133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	Supported, in part, by the Doris Duke Charitable Foundation (to JJJC, TSY), NIH-NICDH (R01 HD48179, U01 HD42652), and US Department of Education Grant (1-1133 A020526) (to RD-A).	Ang BT, 2007, J NEUROL NEUROSUR PS, V78, P298, DOI 10.1136/jnnp.2005.082735; Artru F, 1998, NEUROL RES, V20, pS48; Bardt TF, 1998, ACT NEUR S, V71, P153; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; DITUNNO JF, 1992, J NEUROTRAUM, V9, pS301; Filippi R, 2000, NEUROSURG REV, V23, P94; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; HALSEY JH, 1968, NEUROLOGY, V18, P282; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENFELD JV, 2006, C NEUR SURG 56 ANN M; SARRAFZADEH AS, 2000, NEUROSURG FOCUS, V9, P1; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	44	95	98	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2009	37	1					283	290		10.1097/CCM.0b013e318192fbd7			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391YK	WOS:000262269900038	19050612				2022-02-06	
J	Hart, T; Seignourel, PJ; Sherer, M				Hart, Tessa; Seignourel, Paul J.; Sherer, Mark			A longitudinal study of awareness of deficit after moderate to severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Awareness of deficits; Rehabilitation	IMPAIRED SELF-AWARENESS; DISABILITY RATING-SCALE; CLOSED-HEAD INJURY; REHABILITATION; QUESTIONNAIRE; ADULTS; COMMUNITY; RECOVERY; VALIDITY; ELEMENTS	Lack of awareness of deficits is a common problem after traumatic brain injury (TBI), and is associated with worse functional outcome and poor compliance with rehabilitation. Little is known, however, about the course of awareness of deficits after TBI. Using a longitudinal design, we examined changes in self-awareness between the subacute stage (about 45 days after injury) and one-year follow-up in a sample of 123 individuals with moderate to severe TBI. Awareness of deficits was operationalised as the discrepancy between patient and family ratings on the Awareness Questionnaire (AQ) and Patient Competency Rating Scale (PCRS). Compared to baseline, awareness was improved at one year, as evidenced by smaller discrepancy scores and stronger correlations between participant and family ratings. Changes in awareness were most pronounced for the behavioural/affective domain and least pronounced for the motor/sensory domain, which showed best agreement at baseline. Even at one year, participants rated themselves as higher functioning than did their relatives. Awareness at baseline and, for the AQ, time to follow commands, significantly predicted awareness at one year. These results suggest that awareness of deficits improves between the subacute and post-acute stages after TBI, and highlight the need for effective interventions for persons with impaired awareness and for flexible timing of rehabilitation efforts.	[Hart, Tessa; Seignourel, Paul J.] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Hart, Tessa] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Seignourel, Paul J.] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 60 E Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980067, H133A980035, H133A97033] Funding Source: Medline		ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Flashman, 1998, Semin Clin Neuropsychiatry, V3, P201; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; Newman AC, 2000, BRAIN INJURY, V14, P333; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roberts CB, 2006, BRAIN INJURY, V20, P485, DOI 10.1080/02699050600664665; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977	42	95	97	0	10	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	2					161	176	PII 794669565	10.1080/09602010802188393			16	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	412HQ	WOS:000263716300001	18609008				2022-02-06	
J	Jones, NC; Cardamone, L; Williams, JP; Salzberg, MR; Myers, D; O'Brien, TJ				Jones, Nigel C.; Cardamone, Lisa; Williams, John P.; Salzberg, Michael R.; Myers, Damian; O'Brien, Terence J.			Experimental Traumatic Brain Injury Induces a Pervasive Hyperanxious Phenotype in Rats	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; behavior; depression; rat; traumatic brain injury	OF-THE-LITERATURE; PSYCHIATRIC-DISORDERS; COGNITIVE DEFICITS; AXIS-I; DEPRESSION; BEHAVIOR; ANXIETY; MODEL; ACETYLCHOLINE; RECEPTOR	Mood disturbances, including depression and anxiety disorders, are common and disabling long-term sequelae of traumatic brain injury (TBI). These psychiatric conditions have generally been considered psychosocial consequences of the trauma, but neurobiological alterations and causes have also been implicated. Using a rat model of TBI (lateral fluid-percussion injury), this longitudinal study seeks to assess anxiety and depression-like behaviors following experimental TBI. Male Wistar rats (n=20) received a severe (similar to 3.5 atmosphere) pressure pulse directed to the right sensorimotor cortex, or sham surgery (n=15). At 1, 3, and 6 months following injury, all rats underwent four assessments of anxiety and depression-like behaviors: exposure to an open field, elevated plus maze test, the forced swim test, and the sucrose preference test. Injured animals displayed increased anxiety-like behaviors throughout the study, as evidenced by reduced time spent (p=0.014) and reduced entries (p<0.001) into the center area of the open field, and reduced proportion of time in the open arms of the plus maze (p=0.015), compared to sham-injured controls. These striking changes were particularly evident 1 and 3 months after injury. No differences were observed in depression-like behaviors in the forced swim test (a measure of behavioral despair) and the sucrose preference test (a measure of anhedonia). This report provides the first evidence of persistent anxiety-like disturbances in an experimental model of TBI. This finding indicates that the common occurrence of these symptoms in human sufferers is likely to have, at least in part, a neurobiological basis. Studies in this model could provide insight into the mechanisms underlying affective disturbance in brain-injured patients.	[Jones, Nigel C.; Cardamone, Lisa; Myers, Damian; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Williams, John P.] Howard Florey Inst, Parkville, Vic, Australia; [Salzberg, Michael R.] Univ Melbourne, St Vincents Hosp, Dept Psychiat, Fitzroy, Vic 3065, Australia		Jones, NC (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia.	ncjones@unimelb.edu.au	O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021; Myers, Damian E/L-5302-2013; Jones, Nigel C/K-7773-2012	O'Brien, Terence/0000-0002-7198-8621; Jones, Nigel/0000-0002-1080-8439; Myers, Damian/0000-0002-7569-9907	Victorian Government Transport Accident Commission [DP0023]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [400088]	We wish to acknowledge the assistance of Amelia Koe for analysis of the forced swim test and the administrative support of Rosemary Paxton (Neurosciences Victoria). Funding for this project was provided by the Victorian Government Transport Accident Commission (in the form of a Victorian Neurotrauma Initiative Grant, DP0023). N.J., M.S., and T.O. wish to acknowledge the financial support of the National Health and Medical Research Council of Australia (competitive grant 400088).	American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, VIV; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Cannistraro Paul A, 2003, Psychopharmacol Bull, V37, P8; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gould TD, 2006, GENES BRAIN BEHAV, V5, P113, DOI 10.1111/j.1601-183X.2005.00186.x; GRANACHER RP, 2003, NEUROPSYCHIATRIC PSY; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JANOWSKY DS, 1994, AM J MED GENET, V54, P335, DOI 10.1002/ajmg.1320540412; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kumar G, 2007, PSYCHONEUROENDOCRINO, V32, P834, DOI 10.1016/j.psyneuen.2007.05.011; Lahmame A, 1997, BRAIN RES, V750, P285, DOI 10.1016/S0006-8993(96)01368-6; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P465, DOI 10.1016/B978-012088554-1/50039-6; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Salzberg M, 2007, EPILEPSIA, V48, P2079, DOI 10.1111/j.1528-1167.2007.01246.x; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Singh A, 2004, IDRUGS, V7, P1096; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spalletta G, 2006, MOL PSYCHIATR, V11, P984, DOI 10.1038/sj.mp.4001879; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009	45	95	97	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1367	1374		10.1089/neu.2008.0641			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900009	19061380				2022-02-06	
J	Tierney, RT; Higgins, M; Caswell, SV; Brady, J; McHardy, K; Driban, JB; Darvish, K				Tierney, Ryan T.; Higgins, Michael; Caswell, Shane V.; Brady, Jessica; McHardy, Krista; Driban, Jeffrey B.; Darvish, Kurosh			Sex Differences in Head Acceleration During Heading While Wearing Soccer Headgear	JOURNAL OF ATHLETIC TRAINING			English	Article						head impact kinematics; concussion pathomechanics; brain injuries; football players	SEGMENT DYNAMIC STABILIZATION; BRAIN-INJURY; IMPACT; PERFORMANCE; CONCUSSIONS; STRENGTH	Context: Researchers have indicated that female soccer players may be at greater risk of concussion compared with their male counterparts. Soccer headgear is marketed for reducing head acceleration and risk of concussion. Objective: To determine the effect of sex and soccer headgear on head impact kinematics and dynamic stabilization during soccer heading. Design: Cross-sectional design. Setting: Research laboratory. Patients or Other Participants: Forty-four college-aged soccer players (29 women, 15 men). Intervention(s): Using a head impact model, participants performed 4 soccer headers under 3 headgear conditions (control, Head Blast Soccer Band, and Full90 Select Performance Headguard). Main Outcome Measure(s): Dependent variables assessed before soccer heading were head-neck anthropometrics and isometric neck muscle strength, and those assessed during soccer headers were resultant linear head acceleration, Head Injury Criteria (HIC36), and superficial neck muscle electromyography. Statistical analyses included multivariate and univariate analyses of variance with repeated measures, independent-samples t tests, appropriate follow-up analyses of variance and post hoc t tests, and Pearson product moment correlations (alpha = .05). Results: Head acceleration in women was 32% and 44% greater than in men when wearing the Head Blast (21.5 g versus 16.3 g) and Full90 Select (21.8 g versus 15.2 g), respectively (P < .05). Compared with men, women exhibited 10% greater head accelerations (20.2 g versus 18.2 g) during the control condition (P = .164). Conclusions: Female soccer players exhibited greater head accelerations than their male counterparts when wearing headgear. Our results are important clinically because they indicate that soccer headgear may not be an appropriate head injury prevention tool for all athletes.	[Tierney, Ryan T.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Higgins, Michael] Towson Univ, Towson, MD USA; [Caswell, Shane V.] George Mason Univ, Manassas, VA USA		Tierney, RT (corresponding author), Temple Univ, Dept Kinesiol, 018 Pearson Hall, Philadelphia, PA 19122 USA.	rtierney@temple.edu	Driban, Jeffrey/H-3486-2019	Driban, Jeffrey/0000-0001-6098-4273; Darvish, Kurosh/0000-0002-6674-266X	Pennsylvania Athletic Trainers' Society; Eastern Athletic Trainers' Association; Mid-Atlantic Athletic Trainers' Association; Towson University	We thank the Pennsylvania Athletic Trainers' Society, Eastern Athletic Trainers' Association, Mid-Atlantic Athletic Trainers' Association, and Towson University (Faculty Research Development Grant) for funding this research.	Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; Higgins M, 2007, J ATHL TRAINING, V42, P5; HIGGINS MJ, 2007, J ATHL TRAIN S2, V42, pS28; Hrysomallis C, 2004, J SCI MED SPORT, V7, P156, DOI 10.1016/S1440-2440(04)80005-7; Mansell J, 2005, J ATHL TRAINING, V40, P310; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman J A, 2000, Stapp Car Crash J, V44, P215; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SCHANTZ P, 1983, ACTA PHYSIOL SCAND, V117, P219, DOI 10.1111/j.1748-1716.1983.tb07200.x; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; VERSACE J, 1993, BIOMECHANICS IMPACT, P309; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174	25	95	97	1	27	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2008	43	6					578	584		10.4085/1062-6050-43.6.578			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	377RN	WOS:000261268400003	19030135	Green Published			2022-02-06	
J	Levin, HS; Hanten, G; Roberson, G; Li, XQ; Ewing-Cobbs, L; Dennis, M; Chapman, S; Max, JE; Hunter, T; Schachar, R; Luerssen, TG; Swank, P				Levin, Harvey S.; Hanten, Gerri; Roberson, Garland; Li, Xiaoqi; Ewing-Cobbs, Linda; Dennis, Maureen; Chapman, Sandra; Max, Jeffrey E.; Hunter, Till; Schachar, Russell; Luerssen, Thomas G.; Swank, Paul			Prediction of cognitive sequela based on abnormal computed tomography findings in children following mild traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						computed tomography; mild traumatic brain injury; predictive factor	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; HEAD-INJURY; WORKING-MEMORY; INHIBITION; VALIDITY; PERFORMANCE; MODEL	Object. The aim of this study was to determine whether the presence of intracranial pathophysiology on computed tomography (CT) scans obtained within 24 hours of mild traumatic brain injury (MTBI) in children adversely affects neuropsychological outcome during the 1st year postinjury. Methods. A prospective longitudinal design was used to examine the neuropsychological outcomes in children (ages 5-15 years) who had been treated for MTBI, which was defined as a loss of consciousness for up to 30 minutes and a lowest Glasgow Coma Scale (GCS) score of 13-15. Exclusion criteria included any preinjury neurological disorder. Outcome assessments were performed within 2 weeks and at 3, 6, and 12 months postinjury. Outcomes were compared between patients with MTBI whose postinjury CT scans revealed complications of brain pathophysiology (32 patients, CMTBI group) and those with MTBI but without complications (48 patients, MTBI group). Results. Significant interactions confirmed that the pattern of recovery over 12 months after injury differed depending on the intracranial pathology, presence and severity of injuries to body regions other than the head, preinjury attention-deficit hyperactivity disorder (ADHD), and socioeconomic status. Children in the CMTBI group had significantly poorer episodic memory, slower cognitive processing, diminished recovery in managing cognitive interference, and poorer performance in calculating and reading than patients in the MTBI group. Among the patients with mild or no extracranial injury, visuomotor speed was slower in those in the CMTBI group; and among patients without preinjury ADHD, working memory was worse in those in the CMTBI, group. Conclusions. Neuropsychological recovery during the 1st year following MTBI is related to the presence of radiographically detectable intracranial pathology. Children with intracranial pathology on acute CT performed more poorly in several cognitive domains when compared with patients whose CT findings were normal or limited to a linear skull fracture. Depending on the presence of preinjury ADHD and concomitant extracranial injury, working memory and visuomotor speed were also diminished in patients whose CT findings revealed complications following MTBI. Computed tomography within 24 hours postinjury appears to be useful for identifying children with an elevated risk for residual neuropsychological changes.	[Levin, Harvey S.; Hanten, Gerri; Roberson, Garland; Li, Xiaoqi] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Hunter, Till] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Luerssen, Thomas G.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Ewing-Cobbs, Linda; Swank, Paul] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA; [Hunter, Till] Texas Childrens Hosp, Houston, TX 77030 USA; [Chapman, Sandra] Univ Texas Dallas, Ctr Brainhlth, Dallas, TX 75230 USA; [Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Dennis, Maureen] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Schachar, Russell] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada		Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	hlevin@bcm.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Alderson RM, 2007, J ABNORM CHILD PSYCH, V35, P745, DOI 10.1007/s10802-007-9131-6; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Delis DC., 1994, CALIFORNIA VERBAL LE; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; HOLLINGHSEAD AB, 1975, 4 FACTOR INDEX SOCIA; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Kane MJ, 2007, J EXP PSYCHOL LEARN, V33, P615, DOI 10.1037/0278-7393.33.3.615; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Littell R.C., 1996, SAS SYSTEM MIXED MOD; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Logan Gordon D., 1994, P189; Mather N., 2001, WOODCOCK JOHNSON 3 T; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wechsler D, 1991, WISC 3 MANUAL; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	46	95	96	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2008	1	6					461	470		10.3171/PED/2008/1/6/461			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	310IQ	WOS:000256522500011	18518697				2022-02-06	
J	Bermpohl, D; You, Z; Lo, EH; Kim, HH; Whalen, MJ				Bermpohl, Daniela; You, Zerong; Lo, Eng H.; Kim, Hyung-Hwan; Whalen, Michael J.			TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; genetics; knockout; neuroprotection; Fas; immature	NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; DEFICIENT MICE; UP-REGULATION; MOUSE-BRAIN; CELL-DEATH; LIGAND; RAT; NEUTRALIZATION	Tumor necrosis factor-alpha (TNF alpha) and Fas are induced after traumatic brain injury (TBI); however, their functional roles are incompletely understood. Using controlled cortical impact (CCI) and mice deficient in TNF alpha, Fas, or both (TNF alpha/ Fas -/-), we hypothesized that TNF alpha and Fas receptor mediate secondary TBI in a redundant manner. Compared with wild type (WT), TNF alpha/ Fas -/- mice had improved motor performance from 1 to 4 days (P < 0.05), improved spatial memory acquisition at 8 to 14 days (P < 0.05), and decreased brain lesion size at 2 and 6 weeks after CCI (P < 0.05). Protection in TNF alpha/Fas -/- mice from histopathological and motor deficits was reversed by reconstitution with recombinant TNF alpha before CCI, and TNF alpha -/- mice administered anti- Fas ligand antibodies had improved spatial memory acquisition versus similarly treated WT mice ( P < 0.05). Tumor necrosis factor- alpha/Fas -/- mice had decreased the numbers of cortical cells with plasmalemma damage at 6h ( P< 0.05 versus WT), and reduced matrix metalloproteinase- 9 activity in injured brain at 48 and 72 h after CCI. In immature mice subjected to CCI, genetic inhibition of TNF alpha and Fas conferred beneficial effects on histopathology and spatial memory acquisition in adulthood (both P < 0.05 versus WT), suggesting that the beneficial effects of TNF alpha/ Fas inhibition may be permanent. The data suggest that redundant signaling pathways initiated by TNF alpha and Fas play pivotal roles in the pathogenesis of TBI, and that biochemical mechanisms downstream of TNF alpha/ Fas may be novel therapeutic targets to limit neurological sequelae in children and adults with severe TBI.	Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA; Brigham & Womens Hosp, Vasc Med Res Unit, Cambridge, MA USA		Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, R01NS040529, R01NS048422] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40529, R01 NS47447, R01 NS48422] Funding Source: Medline		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Albensi BC, 2000, SYNAPSE, V35, P151; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Casha S, 2005, EXP NEUROL, V196, P390, DOI 10.1016/j.expneurol.2005.08.020; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Landau AM, 2005, J EXP MED, V202, P575, DOI 10.1084/jem.20050163; Lee RC, 1999, ANN NY ACAD SCI, V888, P266, DOI 10.1111/j.1749-6632.1999.tb07961.x; Leib SL, 2001, BRAIN, V124, P1734, DOI 10.1093/brain/124.9.1734; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Qiu JH, 2002, J NEUROSCI, V22, P3504; Sakic B, 1997, NEUROSCI BIOBEHAV R, V21, P327; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Zuliani C, 2006, CELL DEATH DIFFER, V13, P31, DOI 10.1038/sj.cdd.4401720	39	95	100	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2007	27	11					1806	1818		10.1038/sj.jcbfm.9600487			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	222ZP	WOS:000250338700004	17406655	Bronze			2022-02-06	
J	Silverberg, ND; Wertheimer, JC; Fichtenberg, NL				Silverberg, Noah D.; Wertheimer, Jeffrey C.; Fichtenberg, Norman L.			An effort index for the repeatable battery for the assessment of neuropsychological status (rbans)	CLINICAL NEUROPSYCHOLOGIST			English	Article							VERBAL-LEARNING TEST; TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; DETECTING POOR EFFORT; MILD HEAD-INJURY; SUBOPTIMAL PERFORMANCE; COGNITIVE IMPAIRMENT; MEMORY IMPAIRMENT; INCOMPLETE EFFORT; DIGIT SPAN	The present study aimed to dei,elop an internal vafidi j, indicator for a brief general purpose screening battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Two subtests of the RBANS were predicted to be relath,ely resilient to cognitive dy function on the basis of previous research. An Effort Index (EI) was created by combining them via a scaling system. The frequency of EI scores was first examined in a heterogenous clinical sample. A subsequent validation study showed good discriminability. In conclusion, the EI appears to he useful for detecting insufficient effort oil a screening battery.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Wayne State Univ, Sch Med, Inst Rehabil, Detroit, MI USA		Silverberg, ND (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	noahsilverberg@hotmail.com					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; BAYLESS JD, 1995, ARCH CLIN NEUROPSYCH, V10, P297; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carey CL, 2004, CLIN NEUROPSYCHOL, V18, P234, DOI 10.1080/13854040490501448; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Duff K, 2003, CLIN NEUROPSYCHOL, V17, P351, DOI 10.1076/clin.17.3.351.18082; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Grohman K, 2004, EXP CLIN PSYCHOPHARM, V12, P200, DOI 10.1037/1064-1297.12.3.200; Iverson G L, 2001, Appl Neuropsychol, V8, P167, DOI 10.1207/S15324826AN0803_6; IVERSON GL, 1993, CRIM JUSTICE BEHAV, V20, P347, DOI 10.1177/0093854893020004003; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; King JH, 1998, J CLIN EXP NEUROPSYC, V20, P603, DOI 10.1076/jcen.20.5.603.1124; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Lee D, 2004, REHABIL PSYCHOL, V49, P167, DOI 10.1037/0090-5550.49.2.167; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/09084280152829084; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Norris MP, 1998, LAW HUMAN BEHAV, V22, P315, DOI 10.1023/A:1025706606774; Randolph C., 1998, REPEATABLE BATTERY A; Roberts C, 2003, INT J NEUROSCI, V113, P223, DOI 10.1080/00207450390162047; Serper MR, 2002, PSYCHIAT SERV, V53, P1527, DOI 10.1176/appi.ps.53.12.1527; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Silverberg N, 2005, J CLIN EXP NEUROPSYC, V27, P907, DOI 10.1080/13803390490919326; Slick D J, 2001, Appl Neuropsychol, V8, P185, DOI 10.1207/S15324826AN0803_9; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TOMBAUGH TN, 2003, J FORENSIC NEUROPSYC, V2, P69, DOI DOI 10.1300/J151V02N03_04; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; [No title captured]	50	95	95	1	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2007	21	5					841	854		10.1080/13854040600850958			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	210KO	WOS:000249455300009	17676548				2022-02-06	
J	Klose, M; Juul, A; Poulsgaard, L; Kosteljanetz, M; Brennum, J; Feldt-Rasmussen, U				Klose, M.; Juul, A.; Poulsgaard, L.; Kosteljanetz, M.; Brennum, J.; Feldt-Rasmussen, U.			Prevalence and predictive factors of post-traumatic hypopituitarism	CLINICAL ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ANTERIOR-PITUITARY DYSFUNCTION; GROWTH-HORMONE DEFICIENCY; INSULIN-TOLERANCE-TEST; PLUS ARGININE; PROVOCATIVE TESTS; GH DEFICIENCY; LONG-TERM; FACTOR-I; DIAGNOSIS	Objective To estimate the prevalence and predictive factors of hypopituitarism following traumatic brain injury (TBI). Design A cross-sectional cohort study. Patients One hundred and four hospitalized TBI patients (26F/78M), median age 41 (range 18-64) years, body mass index (BMI) 25 (17-39) kg/m(2); severity: mild [Glasgow Coma Scale (GCS) score 13-15) n = 44, moderate (GCS 9-12) n = 20, severe (GCS < 9) n = 40]. Measurements Patients were evaluated 13 (10-27) months post-injury, with measurement of baseline (0800-1000 h) and post-stimulatory hormonal levels during an insulin tolerance test (ITT) (86%) or, if contraindicated, an arginine(arg)-GHRH test + Synacthen test (14%). Insufficiencies were confirmed by retesting. Results Hypopituitarism was found in 16 (15%) patients, affecting one axis in 10, two axes in four and more than two axes in two patients. The GH axis was most frequently affected (15%), followed by secondary hypoadrenalism (5%), hypogonadism (2%), hypothyroidism (2%) and diabetes insipidus (2%). The risk of pituitary insufficiency was increased in patients with severe TBI as opposed to mild TBI [odds ratio (OR) 10.1, 95% confidence interval (CI) 2.1-48.4, P = 0.004], and in those patients with increased intracerebral pressure [OR 6.5, 95% CI 1.0-42.2, P = 0.03]. Patients with only one affected axis were all GH deficient; 60% (n = 6) of these were overweight or obese. Conclusions The prevalence of hypopituitarism was estimated at 16%. Although high, this value was lower than previously reported, and may still be overestimated because of well-known confounding factors, such as obesity. Indicators of increased TBI severity were predictive of hypopituitarism, with a high negative predictive value. Neuroendocrine evaluation should therefore be considered in patients with severe TBI, and in particular in those with increased intracerebral pressure (ICP).	Univ Copenhagen Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Neurosurg, KAS Glostrup, DK-2100 Copenhagen, Denmark		Klose, M (corresponding author), Univ Copenhagen Hosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Juul, Anders/F-5864-2013	Juul, Anders/0000-0002-0534-4350; Brennum, Jannick/0000-0002-7961-0156			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; ANDERSSON AM, 1995, EUR J ENDOCRINOL, V132, P340, DOI 10.1530/eje.0.1320340; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bonnefont X, 2005, P NATL ACAD SCI USA, V102, P16880, DOI 10.1073/pnas.0508202102; Ceballos R, 1966, Ala J Med Sci, V3, P185; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; GRANADA ML, 1990, ACTA PAEDIATR SCAND, P63; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Karovitaki N, 2006, J NEUROL NEUROSUR PS, V77, P276, DOI 10.1136/jnnp.2005.070482; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; Schneider HJ, 2006, EUR J ENDOCRINOL, V155, P553, DOI 10.1530/eje.1.02258; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Vestergaard P, 1997, HORM METAB RES, V29, P106, DOI 10.1055/s-2007-979000	29	95	106	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	AUG	2007	67	2					193	201		10.1111/j.1365-2265.2007.02860.x			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	197BH	WOS:000248527600006	17524035				2022-02-06	
J	Chen, SF; Hung, TH; Chen, CC; Lin, KH; Huang, YN; Tsai, HC; Wang, JY				Chen, Szu-Fu; Hung, Tai-Ho; Chen, Chien-Cheng; Lin, Kuei-Han; Huang, Ya-Ni; Tsai, Hung-Chih; Wang, Jia-Yi			Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury	LIFE SCIENCES			English	Article						lovastatin; iniflammation; cytokines; traumatic brain injury	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL NITRIC-OXIDE; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; INTERCELLULAR-ADHESION MOLECULE-1; CONTROLLED CORTICAL IMPACT; COA REDUCTASE INHIBITOR; FACTOR-ALPHA; TNF-ALPHA	Traumatic brain injury (TBI) triggers a complex sequence of inflammatory responses that contribute to secondary injury. Statins have demonstrated neuroprotective effects against brain injury, but the underlying mechanisms remain unclear. This study evaluated the effects of lovastatin on a rat model of controlled cortical impact (CCI) injury. Our two hypotheses were that pre-administration of lovastatin would reduce functional deficits and extent of anatomical brain damage and that lovastatin would attenuate levels of pro-inflammatory cytokines. Rats were injected with lovastatin (4 mg/kg) or vehicle for 5 days and subjected to CCI. Neurological status was evaluated using rotarod and adhesive removal tests. Contusion volume and neuronal degeneration were examined using cresyl violet and FluoroJade B (FJB) histochemistry. Levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin- 1 beta (IL- 1 beta) mRNA and protein were assessed by real-time quantitative reverse transcriptase polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry. Lovastatin significantly improved performance on both the rotarod and adhesive removal tests before post-injury day 7. Lovastatin also significantly reduced contusion volume (20%) and number of FJB-positive degenerating neurons (35%) at 4 days. These changes were associated with a significant decrease in levels of TNF-a and IL-I beta. mRNA and protein at the contusion site at 6 It and 4 days, respectively. Our results show that pre-administration of lovastatin improved functional outcomes and reduced extent of brain damage, with a concomitant decrease in tissue levels of TNF-alpha and IL- 1 beta mRNA and protein. These findings suggest that lovastatin's protective mechanisms may be partly attributed to a dampening of the inflammatory response. (c) 2007 Elsevier Inc. All rights reserved.	Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; Chang Gung Univ, Coll Med, Taipei, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan		Wang, JY (corresponding author), Natl Def Med Ctr, Dept Physiol, 161 Sec 6,Ming Chuan E Rd, Taipei, Taiwan.	jywang@ndmctsgh.edu.tw	Hung, Tai-Ho/C-7584-2011; Chen, Szu-Fu/K-5040-2012; Hung, Tai-Ho/ABD-1800-2020	Hung, Tai-Ho/0000-0003-2354-7060; Wang, Jia-Yi/0000-0002-9106-3351			Asahi M, 2005, J CEREBR BLOOD F MET, V25, P722, DOI 10.1038/sj.jcbfm.9600070; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen JL, 2004, CHINESE PHYS LETT, V21, P12, DOI 10.1088/0256-307X/21/1/004; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CLAUDIO L, 1994, LAB INVEST, V70, P850; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Daimon M, 2004, NEUROSCI LETT, V362, P122, DOI 10.1016/j.neulet.2004.03.012; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Farmer JA, 1998, PROG CARDIOVASC DIS, V41, P71, DOI 10.1016/S0033-0620(98)80006-6; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Fox S, 1998, INFECT MED, V15, P8; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hung TH, 2006, PLACENTA, V27, P996, DOI 10.1016/j.placenta.2005.11.002; Hunter AJ, 1998, TRENDS PHARMACOL SCI, V19, P59, DOI 10.1016/S0165-6147(97)01157-7; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; LASTER SM, 1988, J IMMUNOL, V141, P2629; Li W, 2005, J PHARMACOL EXP THER, V313, P557, DOI 10.1124/jpet.104.080002; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Niwa S, 1996, INT J IMMUNOPHARMACO, V18, P669, DOI 10.1016/S0192-0561(96)00068-9; Omi H, 2003, MICROVASC RES, V65, P118, DOI 10.1016/S0026-2862(02)00033-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schmeer C, 2006, RESTOR NEUROL NEUROS, V24, P79; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Sironi L, 2005, ARTERIOSCL THROM VAS, V25, P598, DOI 10.1161/01.ATV.0000157145.98200.55; Soares HD, 1995, J NEUROSCI, V15, P8223; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; SternerKock A, 1996, IMMUNOLOGY, V87, P454; Thal SC, 2005, CURR OPIN ANESTHESIO, V18, P490, DOI 10.1097/01.aco.0000182561.32680.30; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	71	95	96	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	JUL 4	2007	81	4					288	298		10.1016/j.lfs.2007.05.023			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	199GB	WOS:000248683100004	17612572				2022-02-06	
J	Zhang, T; Yan, YN; Wang, XH; Xiong, Z; Lin, F; Wu, RD; Zhang, RJ				Zhang, Ting; Yan, Yongnian; Wang, Xiaohong; Xiong, Zhuo; Lin, Feng; Wu, Rendong; Zhang, Renj			Three-dimensional gelatin and gelatin/hyaluronan hydrogel structures for traumatic brain injury	JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS			English	Article						cell assembling; gelatin; hyaluronan; central nervous system; biocompatibility; biodegradation	HYALURONIC-ACID; SYSTEM; FABRICATION; SCAFFOLDS; DELIVERY; MATRIX; REPAIR; CELLS; RAT	Brain tissue engineering has now emerged as one of the most promising treatments for the traumatic brain injury. In this article, two groups of three-dimensional (3D) hydrogel structures composed of gelatin and gelatin/hyaluronan have been formed using our 3D cell assembly technique for in vivo study in rats, in order to investigate their effects in reparation of injury in the central nervous system (CNS). The structures were implanted into cortical defects created in rat brains, and their abilities to improve the brain tissue reconstruction were then evaluated. After 4, 8, 10, and 13 weeks of implantation, sections of brains were processed with NISSL staining for observing the immigration of host neural cells into the implanted materials and the degradation property of the materials. The results showed that simplex gelatin and gelatin/hyaluronan (20:1) with 3D structures both have good biocompatibility with brain tissue while gelatin/hyaluronan has a better contiguity with the surrounding tissue. Through our primary study, it seems that 3D gelatin/hyaluronan structures may be useful in brain tissue repair.	Tsing Hua Univ, Key Lab Adv Mfg Mat Proc Technol, Beijing 100084, Peoples R China; Tsing Hua Univ, Dept Engn Mech, Ctr Organ Mfg, Beijing 100084, Peoples R China; Tsing Hua Univ, Inst Life Sci & Med, Beijing 100084, Peoples R China		Wang, XH (corresponding author), Tsing Hua Univ, Key Lab Adv Mfg Mat Proc Technol, Beijing 100084, Peoples R China.	wangxiaohong@tsinghua.edu.cn	Wang, Zhong Lin/E-2176-2011; Lin, Feng/K-7906-2012	Wang, Zhong Lin/0000-0002-5530-0380; Lin, Feng/0000-0003-1855-504X			Choi YS, 1999, BIOMATERIALS, V20, P409, DOI 10.1016/S0142-9612(98)00180-X; CHRISTINE E, 2003, EXPT GERONTOL, V38, P79; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Landers R, 2002, BIOMATERIALS, V23, P4437, DOI 10.1016/S0142-9612(02)00139-4; Lesny P, 2002, J CHEM NEUROANAT, V23, P243, DOI 10.1016/S0891-0618(02)00011-X; Liu HX, 2006, CHINESE SCI BULL, V51, P1830, DOI 10.1007/s11434-006-2045-9; Luo Y, 2000, J CONTROL RELEASE, V69, P169, DOI 10.1016/S0168-3659(00)00300-X; Ma W, 2005, MACROMOL SYMP, V227, P327, DOI 10.1002/masy.200550933; Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7; SANES JR, 1983, ANNU REV PHYSIOL, V45, P581, DOI 10.1146/annurev.ph.45.030183.003053; SECKEL BR, 1995, J NEUROSCI RES, V40, P318, DOI 10.1002/jnr.490400305; Sun W, 2002, COMPUT METH PROG BIO, V67, P85, DOI 10.1016/S0169-2607(01)00116-X; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Wang XH, 2006, TISSUE ENG, V12, P83, DOI 10.1089/ten.2006.12.83; West JL, 1996, J REPROD MED, V41, P149; Woerly S, 1996, NEUROSCI LETT, V205, P197, DOI 10.1016/0304-3940(96)12349-1; Woerly S, 1997, MATER SCI FORUM, V250, P53, DOI 10.4028/www.scientific.net/MSF.250.53; Xiong Z, 2002, SCRIPTA MATER, V46, P771, DOI 10.1016/S1359-6462(02)00071-4; Yan YN, 2005, BIOMATERIALS, V26, P5864, DOI 10.1016/j.biomaterials.2005.02.027; Yan YN, 2005, J BIOACT COMPAT POL, V20, P259, DOI 10.1177/0883911505053658	21	95	96	6	48	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0883-9115			J BIOACT COMPAT POL	J. Bioact. Compat. Polym.	JAN	2007	22	1					19	29		10.1177/0883911506074025			11	Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Materials Science; Polymer Science	126BQ	WOS:000243487600002					2022-02-06	
J	Geva, R; Eshel, R; Leitner, Y; Fattal-Valevski, A; Harel, S				Geva, Ronny; Eshel, Rina; Leitner, Yael; Fattal-Valevski, Aviva; Harel, Shaul			Memory functions of children born with asymmetric intrauterine growth restriction	BRAIN RESEARCH			English	Article						IUGR; memory; attention; developmental outcome; digit span	FOR-GESTATIONAL-AGE; CLOSED-HEAD INJURY; SHORT-TERM-MEMORY; LOW-BIRTH-WEIGHT; HUMAN HIPPOCAMPUS; RECOGNITION MEMORY; EVOKED POTENTIALS; BRAIN-DEVELOPMENT; DENTATE GYRUS; FRONTAL-LOBE	Objective: Learning difficulties are frequently diagnosed in children born with intrauterine growth restriction (IUGR). Models of various animal species with IUGR were studied and demonstrated specific susceptibility and alterations of the hippocampal formation and its related neural structures. The main purpose was to study memory functions of children born with asymmetric IUGR in a large-scale cohort using a long-term prospective paradigm. Methods: One hundred and ten infants diagnosed with IUGR were followed-up from birth to 9 years of age. Their performance was compared with a group of 63 children with comparable gestational age and multiple socioeconomic factors. Memory functions (short-term, super-and long-term spans) for different stimuli types (verbal and visual) were evaluated using Visual Auditory Digit Span tasks (VADS), Rey Auditory Verbal Learning Test (Rey-AVLT), and Rey Osterrieth Complex Figure Test (ROCF). Results: Children with IUGR had short-term memory difficulties that hindered both serial verbal processing system and simultaneous processing of high-load visuo-spatial stimuli. The difficulties were not related to prematurity, neonatal complications or growth catch-up, but were augmented by lower maternal education. Recognition skills and benefits from reiteration, typically affected by hippocampal dysfunction, were preserved in both groups. Conclusions: Memory profile of children born with IUGR is characterized primarily by a short-term memory deficit that does not necessarily comply with a typical hippocampal deficit, but rather may reflect an executive short-term memory deficit characteristic of anterior hippocampal-prefrontal network. Implications for cognitive intervention are discussed. (c) 2006 Elsevier B.V. All rights reserved.	Bar Ilan Univ, Dev Neuropsychol Lab, Gonda Goldschmied Multidisciplinary Brain Res Ctr, Dept Psychol, IL-52900 Ramat Gan, Israel; Tel Aviv Univ, Inst Child Dev, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Pediat Neurol Unit, Div Pediat, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel		Geva, R (corresponding author), Bar Ilan Univ, Dev Neuropsychol Lab, Gonda Goldschmied Multidisciplinary Brain Res Ctr, Dept Psychol, IL-52900 Ramat Gan, Israel.	gevaro@mail.biu.ac.il		Geva, Ronny/0000-0002-5724-2153			Bachevalier J, 2005, CURR OPIN NEUROBIOL, V15, P168, DOI 10.1016/j.conb.2005.03.015; Baschat AA, 2004, OBSTET GYNECOL SURV, V59, P617, DOI 10.1097/01.OGX.0000133943.54530.76; BERGER B, 1993, HIPPOCAMPUS, V3, P279, DOI 10.1002/hipo.450030305; BLACK LS, 2004, ELECTROGRAPHIC IMAG; Camm EJ, 2000, REPROD FERT DEVELOP, V12, P165, DOI 10.1071/RD99092; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; CINTRA L, 1990, BRAIN RES, V532, P271, DOI 10.1016/0006-8993(90)91769-D; Cintra L, 1997, HIPPOCAMPUS, V7, P192, DOI 10.1002/(SICI)1098-1063(1997)7:2<192::AID-HIPO6>3.3.CO;2-G; Cohen NJ., 1993, MEMORY AMNESIA HIPPO; Cowan N, 1999, CHILD DEV, V70, P1082, DOI 10.1111/1467-8624.00080; DEADWYLER SA, 1985, BEHAV NEURAL BIOL, V44, P201, DOI 10.1016/S0163-1047(85)90198-0; deUngria M, 2000, PEDIATR RES, V48, P169, DOI 10.1203/00006450-200008000-00009; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Dieni S, 2003, J NEUROBIOL, V55, P41, DOI 10.1002/neu.10194; Ergaz Z, 2005, REPROD TOXICOL, V20, P301, DOI 10.1016/j.reprotox.2005.04.007; Fattal-Valevski A, 1999, J CHILD NEUROL, V14, P724, DOI 10.1177/088307389901401107; Frisk V, 2002, DEV NEUROPSYCHOL, V22, P565, DOI 10.1207/S15326942DN2203_2; Geva R, 2005, INFANT MENT HEALTH J, V26, P481, DOI 10.1002/imhj.20063; Geva R, 2006, PEDIATRICS, V118, P91, DOI 10.1542/peds.2005-2343; Goldenberg RL, 1998, EUR J CLIN NUTR, V52, pS54; GOTLIEB SJ, 1988, INFANT BEHAV DEV, V11, P223, DOI 10.1016/S0163-6383(88)80007-9; Gutbrod T, 2000, ARCH DIS CHILD-FETAL, V82, pF208, DOI 10.1136/fn.82.3.F208; HAREL S, 1985, BRAIN DEV-JPN, V7, P580, DOI 10.1016/S0387-7604(85)80005-X; HAREL S, 1985, BRAIN DEV-JPN, V7, P575, DOI 10.1016/S0387-7604(85)80004-8; HAWDON JM, 1990, DEV MED CHILD NEUROL, V32, P943; Hevner RF, 1996, J COMP NEUROL, V372, P384, DOI 10.1002/(SICI)1096-9861(19960826)372:3<384::AID-CNE4>3.0.CO;2-Z; Hollo O, 2002, ARCH PEDIAT ADOL MED, V156, P179, DOI 10.1001/archpedi.156.2.179; Isaacs EB, 2000, PEDIATR RES, V47, P713, DOI 10.1203/00006450-200006000-00006; Isaacs EB, 2003, P NATL ACAD SCI USA, V100, P13060, DOI 10.1073/pnas.1233825100; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; Kilpatrick C, 1997, SEIZURE, V6, P213, DOI 10.1016/S1059-1311(97)80008-8; Kohler S, 1998, NEUROPSYCHOLOGIA, V36, P901, DOI 10.1016/S0028-3932(98)00017-7; KOPPITZ EM, 1981, J LEARN DISABIL, V14, P93, DOI 10.1177/002221948101400212; KOSTOVIC I, 1989, NEUROSCIENCE, V30, P105, DOI 10.1016/0306-4522(89)90357-6; Leitner Y, 2000, J CHILD NEUROL, V15, P781, DOI 10.1177/088307380001501202; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; LOW JA, 1992, AM J OBSTET GYNECOL, V167, P1499, DOI 10.1016/0002-9378(92)91727-R; Makhoul IR, 2004, PEDIATR RES, V55, P877, DOI 10.1203/01.PDR.0000119369.21770.7A; Mallard C, 2000, NEUROSCIENCE, V100, P327, DOI 10.1016/S0306-4522(00)00271-2; Manns JR, 2003, NEURON, V37, P171, DOI 10.1016/S0896-6273(02)01147-9; Nyakas C, 1996, PROG NEUROBIOL, V49, P1; O'Keeffe MJ, 2003, PEDIATRICS, V112, P301, DOI 10.1542/peds.112.2.301; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Posner MI, 2004, CAN PSYCHOL, V45, P265, DOI 10.1037/h0086997; Sami N, 2003, CHILD NEUROPSYCHOL, V9, P237, DOI 10.1076/chin.9.4.237.23514; Schacter DL, 1999, HIPPOCAMPUS, V9, P575, DOI 10.1002/(SICI)1098-1063(1999)9:5<575::AID-HIPO11>3.0.CO;2-K; Scherjon S, 2000, PEDIATRICS, V105, P385, DOI 10.1542/peds.105.2.385; Strange BA, 2002, J NEUROSCI, V22, P523, DOI 10.1523/JNEUROSCI.22-02-00523.2002; SZATMARI P, 1990, DEV MED CHILD NEUROL, V32, P954; Talley J L, 1986, Arch Clin Neuropsychol, V1, P315, DOI 10.1016/0887-6177(86)90135-6; Tolsa CB, 2004, PEDIATR RES, V56, P132, DOI 10.1203/01.PDR.0000128983.54614.7E; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; Vakil E, 2004, CHILD NEUROPSYCHOL, V10, P57, DOI 10.1080/09297040490911078; van Wassenaer Aleid, 2005, Pediatr Endocrinol Rev, V2, P372; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	56	95	100	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 30	2006	1117						186	194		10.1016/j.brainres.2006.08.004			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	107CB	WOS:000242147200019	16962082				2022-02-06	
J	Liu, MC; Akle, V; Zheng, WR; Kitlen, J; O'Steen, B; Larner, SF; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Liu, Ming Cheng; Akle, Veronica; Zheng, Wenrong; Kitlen, Jason; O'Steen, Barbara; Larner, Stephen F.; Dave, Jitendra R.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; cell death; demyelination; protease; proteolysis; proteomic	SPINAL-CORD-INJURY; GENE KNOCK-OUT; WHITE-MATTER; BREAKDOWN PRODUCTS; ALPHA-SPECTRIN; CATHEPSIN-B; II-SPECTRIN; PROTEOLYSIS; RAT; ACTIVATION	s Axonal injury is one of the key features of traumatic brain injury (TBI), yet little is known about the integrity of the myelin sheath. We report that the 21.5 and 18.5-kDa myelin basic protein (MBP) isoforms degrade into N-terminal fragments (of 10 and 8 kDa) in the ipsilateral hippocampus and cortex between 2 h and 3 days after controlled cortical impact (in a rat model of TBI), but exhibit no degradation contralaterally. Using N-terminal microsequencing and mass spectrometry, we identified a novel in vivo MBP cleavage site between Phe114 and Lys115. A MBP C-terminal fragment-specific antibody was then raised and shown to specifically detect MBP fragments in affected brain regions following TBI. In vitro naive brain lysate and purified MBP digestion showed that MBP is sensitive to calpain, producing the characteristic MBP fragments observed in TBI. We hypothesize that TBI-mediated axonal injury causes secondary structural damage to the adjacent myelin membrane, instigating MBP degradation. This could initiate myelin sheath instability and demyelination, which might further promote axonal vulnerability.	Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarkers Res, Dept Psychiat, Gainesville, FL 32610 USA; Walter Reed Army Inst Res, Div Neurosci, Dept Neuropharmacol & Mol Biol, Silver Spring, MD USA		Liu, MC (corresponding author), Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Neurosci, L4-100F,POB 100256, Gainesville, FL 32610 USA.	liumc@mbi.ufl.edu; kwang@psychiatry.ufl.edu	Dave, Jitendra R/A-8940-2011; akle, veronica/AAD-7577-2019	Wang, Kevin/0000-0002-9343-6473; Akle, Veronica/0000-0002-2050-5511	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER		Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; BANIK NL, 1994, J NEUROSCI RES, V37, P489, DOI 10.1002/jnr.490370408; Bartholdi D, 1998, GLIA, V23, P278, DOI 10.1002/(SICI)1098-1136(199807)23:3<278::AID-GLIA10>3.0.CO;2-Q; BENUCK M, 1975, EUR J BIOCHEM, V52, P615, DOI 10.1111/j.1432-1033.1975.tb04033.x; BERLET HH, 1985, FEBS LETT, V179, P299, DOI 10.1016/0014-5793(85)80538-X; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BROSTOFF SW, 1974, J BIOL CHEM, V249, P559; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Hisahara S, 2003, NEUROSCI RES, V46, P387, DOI 10.1016/S0168-0102(03)00127-5; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; MARKS N, 1980, J NEUROSCI RES, V5, P217, DOI 10.1002/jnr.490050306; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Richter-Landsberg C, 2000, J NEUROSCI RES, V59, P11, DOI 10.1002/(SICI)1097-4547(20000101)59:1<11::AID-JNR2>3.0.CO;2-O; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668; Seyfried D, 1997, J NEUROSURG, V87, P716, DOI 10.3171/jns.1997.87.5.0716; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Sloane JA, 2003, J NEUROCHEM, V84, P157, DOI 10.1046/j.1471-4159.2003.01541.x; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; TSUBATA T, 1989, J BIOCHEM-TOKYO, V105, P23, DOI 10.1093/oxfordjournals.jbchem.a122611; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Waxman SG, 1998, NEW ENGL J MED, V338, P323, DOI 10.1056/NEJM199801293380510; WILLIAMS KR, 1986, J NEUROSCI RES, V15, P137, DOI 10.1002/jnr.490150203; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; YANAGISAWA K, 1988, J NEUROCHEM, V51, P803, DOI 10.1111/j.1471-4159.1988.tb01815.x	55	95	97	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2006	98	3					700	712		10.1111/j.1471-4159.2006.03882.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	063GV	WOS:000239007400007	16893416	Bronze			2022-02-06	
J	Erlich, S; Shohami, E; Pinkas-Kramarski, R				Erlich, Shlomit; Shohami, Esther; Pinkas-Kramarski, Ronit			Neurodegeneration induces upregulation of Beclin 1	AUTOPHAGY			English	Article						Beclin 1; autophagy; brain; traumatic brain injury; neurons; astrocytes	CLOSED-HEAD INJURY; AUTOPHAGY; NEURONS; TUMORIGENESIS; MECHANISMS; MICROGLIA; DEATH; GENE	Autophagy, a bulk degradation of subcellular constituents, is activated in normal cell growth and development, and represents the major pathway by which the cell maintains a balance between protein synthesis and protein degradation. Autophagy was documented in several neurodegenerative diseases, and under stress conditions the autophagic process can lead to cell death (type II programmed cell death). Beclin 1 is a Bcl-2 interacting protein that was previously found to promote autophagy. We have used Beclin I protein as a marker for autophagy following traumatic brain injury in mice. We demonstrated a dramatic elevation in Beclin I levels near the injury site. Interestingly Beclin I elevation starts at early stages post injury (4 h) in neurons and 3 days later in astrocytes. In both cell types it lasts for at least three weeks. Neuronal cells, but not astrocytes, that overexpress Beclin I may exhibit damaged DNA but without changes in nuclear morphology. These observations may indicate that not all the Beclin1 overexpressing cells will die. The elevation of Beclin 1 at the site of injury may represent enhanced autophagy as a mechanism to discard injured cells and reduce damage to cells by disposing of injured components.	Tel Aviv Univ, Dept Neurobiochem, Ramat Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel		Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, Ramat Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X			Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Roizin L, 1974, Trans Am Neurol Assoc, V99, P240; Selimi F, 2003, NEURON, V37, P813, DOI 10.1016/S0896-6273(03)00093-X; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Yu LY, 2003, J CELL BIOL, V163, P987, DOI 10.1083/jcb.200305083; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	28	95	95	1	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1554-8627	1554-8635		AUTOPHAGY	Autophagy	JAN-MAR	2006	2	1					49	51		10.4161/auto.2156			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	056ZP	WOS:000238564200008	16874043	Bronze			2022-02-06	
J	Wells, R; Dywan, J; Dumas, J				Wells, R; Dywan, J; Dumas, J			Life satisfaction and distress in family caregivers as related to specific behavioural changes after traumatic brain injury	BRAIN INJURY			English	Article						closed head injury; long-term care; caregiver burden; internalizing symptoms; externalizing symptoms; income change; planning; memory; impulse control; empathy; Brock Adaptive Functioning Questionnaire	BURDEN; IMPACT; PREDICTORS; MEMORY; TBI	Primary objective: To predict long-term outcome of those caring for family members who have sustained a traumatic brain injury (TBI). Methods and procedures: A multivariate approach was used to examine the effectiveness of caregiver coping strategies in the context of TBI-related behavioural change. Self-administered questionnaire packages were collected from 72 adult survivor and family-member pairs who provided information on survivors' altered executive function, behavioural control and emotional sensitivity as well as caregivers' methods of coping, attitudes toward caregiving, indices of distress, mood ratings and quality of life. Main outcomes and results: Family members generally reported higher levels of satisfaction than dissatisfaction with their caregiving role. The type of neurobehavioural deficit and the approaches taken to cope with stress had specific effects on each dimension of caregiver outcome. Conclusions: Adequate family support requires finely tuned assessment of factors relevant to successful coping.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada; Ontario Brain Injury Assoc, St Catharines, ON, Canada		Dywan, J (corresponding author), Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada.	jdywan@brocku.ca					Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; [Anonymous], 1998, REH PERS TRAUM BRAIN, P1; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; BROADBENT NJ, 2002, NEUROPSYCHOLOGY MEMO, P3; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Connell CM, 2001, J GERIATR PSYCH NEUR, V14, P179, DOI 10.1177/089198870101400403; Derogatis LR., 1983, SCL 90 R ADM SCORING; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lezak M. D., 1997, BEHAV NEUROLOGY NEUR, P43; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MCCUBBIN HI, 1982, FAMILY COPING STRATE; Minnes P, 2000, BRAIN INJURY, V14, P737; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Scheibel RS, 2004, CORTEX, V40, P218, DOI 10.1016/S0010-9452(08)70957-2; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; SCHULZ R, 1988, PSYCHOL AGING, V3, P131, DOI 10.1037/0882-7974.3.2.131; Simpson A, 2002, BRAIN INJURY, V16, P1075, DOI 10.1080/02699050210155249; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; TAYLOR S, 2004, HEAD INJURY ASS ORBI; Torner James C., 1996, P19; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; [No title captured]	37	95	96	1	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1105	1115		10.1080/02699050500150062			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000005	16286324				2022-02-06	
J	Cernak, I; Stoica, B; Byrnes, KR; Di Giovanni, S; Faden, AI				Cernak, I; Stoica, B; Byrnes, KR; Di Giovanni, S; Faden, AI			Role of the cell cycle in the pathobiology of central nervous system trauma	CELL CYCLE			English	Article						cell cycle; apoptosis; neuronal injury; traumatic brain injury; astrocyte proliferation; microglial proliferation; neuroprotection; flavopiridol	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; STIMULATED HOMOLOGOUS MACROPHAGES; KINASE INHIBITOR FLAVOPIRIDOL; IN-VITRO; ALZHEIMERS-DISEASE; DEPENDENT KINASES; MICROGLIAL ACTIVATION; NEURONAL APOPTOSIS; PARKINSONS-DISEASE	Upregulation of cell cycle proteins occurs in both mitotic and post-mitotic neural cells after central nervous system (CNS) injury in adult animals. In mitotic cells, such as astroglia and microglia, they induce proliferation, whereas in post-mitotic cells such as neurons they initiate caspase-related apoptosis. We recently reported that early central administration of the cell cycle inhibitor flavopiridol after experimental traumatic brain injury (TBI) significantly reduced lesion volume, scar formation and neuronal cell death, while promoting near complete behavioral recovery. Here we show that in primary neuronal or astrocyte cultures structurally different cell cycle inhibitors ( flavopiridol, roscovitine, and olomoucine) significantly reduce upregulation of cell cycle proteins, attenuate neuronal cell death induced by etoposide, and decrease astrocyte proliferation. Flavopiridol, in a concentration dependent manner, also attenuates proliferation/ activation of microglia. In addition, we demonstrate that central administration of flavopiridol improves functional outcome in dose-dependent manner after fluid percussion induced brain injury in rats. Moreover, delayed systemic administration of flavopiridol significantly reduces brain lesion volume and edema development after TBI. These data provide further support for the therapeutic potential of cell cycle inhibitors for the treatment of clinical CNS injury and that protective mechanisms likely include reduction of neuronal cell death, inhibition of glial proliferation and attenuation of microglial activation.	Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, Washington, DC 20057 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	fadena@georgetown.edu	STOICA, BOGDAN/H-9782-2013; Cernak, Ibolja/A-6399-2008	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Ibolja, Cernak/0000-0003-3214-698X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD4-0677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-1-2339] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [36537-03] Funding Source: Medline		ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; AKUNDI RS, 2005, IN PRESS GLIA; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161/cc.3.12.1278; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; Boonstra J, 2003, J CELL BIOCHEM, V90, P244, DOI 10.1002/jcb.10617; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; Daly J, 1998, NEUROBIOL AGING, V19, P619, DOI 10.1016/S0197-4580(98)00100-6; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GALLO V, 1995, J NEUROSCI, V15, P394; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GIULIAN D, 1988, Brain Behavior and Immunity, V2, P352, DOI 10.1016/0889-1591(88)90040-2; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Grewal RP, 1999, NEUROSCI LETT, V271, P65, DOI 10.1016/S0304-3940(99)00496-6; Hains BC, 2001, J NEUROTRAUM, V18, P409, DOI 10.1089/089771501750170994; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Harris FM, 2004, J BIOL CHEM, V279, P3862, DOI 10.1074/jbc.M309475200; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; HOEPPNER TJ, 1986, EXP NEUROL, V94, P519, DOI 10.1016/0014-4886(86)90235-9; Hunot S, 2003, ANN NEUROL, V53, pS49, DOI 10.1002/ana.10481; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; Kim HRC, 1999, CANCER RES, V59, P4148; Kim SY, 2002, MOL CELLS, V13, P429; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Moore S, 1996, PROG NEUROBIOL, V48, P441, DOI 10.1016/0301-0082(95)00051-8; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; VINK R, 1988, J BIOL CHEM, V263, P757; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Wiessner C, 1996, NEUROSCIENCE, V72, P947, DOI 10.1016/0306-4522(95)00601-X; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	84	95	97	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	SEP	2005	4	9					1286	1293		10.4161/cc.4.9.1996			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	959JB	WOS:000231512900030	16082214	Bronze			2022-02-06	
J	Davis, DP; Peay, J; Serrano, JA; Buono, C; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, DP; Peay, J; Serrano, JA; Buono, C; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB			The impact of aeromedical response to patients with moderate to severe traumatic brain injury	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Conference on Air Medical Transport	2004	Cincinnati, OH				RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; SCENE HELICOPTER TRANSPORT; BLUNT TRAUMA; ENDOTRACHEAL INTUBATION; EMERGENCY CARE; INTERHOSPITAL TRANSPORT; MULTIPLE INJURIES; AIR AMBULANCE; MORTALITY	Study objective: Aeromedical crews offer an advanced level of practice and rapid transport to definitive care; however, their efficacy remains unproven. Previous studies have used relatively small sample sizes or have been unable to adequately control for the effect of other potentially influential variables. Here we explore the impact of aeromedical response in patients, with moderate to severe traumatic brain injury. Methods: This was a retrospective analysis using our county trauma registry. All patients with head Abbreviated Injury Score of 3 or greater were included; interfacility transfers were excluded. The impact of aeromedical response was determined using logistic regression; adjusting for age, sex, mechanism; preadmission Glasgow Coma Scale score, head Abbreviated Injury Score, Injury Severity Score, and the presence of preadmission hypotension. Propensity scores were used to account for variability in selection of patients to undergo air versus ground transport: Patients with moderate and severe traumatic brain injury, as defined by head Abbreviated Injury Score and Glasgow Coma Scale score; were compared. Finally, aeromedical patients undergoing field intubation were compared with ground patients undergoing emergency department (ED) intubation. Results: A total of 10,314 patients meeting all inclusion and exclusion criteria and with complete data sets were identified and included 3,017 transported by aeromedical crews. Overall mortality was 251 in the air- and ground-transported cohorts, but outcomes were significantly better for the aeromedical patients when adjusted for age, sex, mechanism of injury, hypotension; Glasgow Coma Scale score, head Abbreviated Injury Score, and Injury Severity Score (adjusted odds ratio [OR] 1.90; 95% confidence interval [CI] 1.60 to 2.25; P < .0001). Good outcomes (discharge to home, jail, psychiatric facility, rehabilitation, or leaving against medical advice) were also higher in aeromedical patients (adjusted OR 1.36; 95% CI 1.18 to 1.58; P < .0001). The primary benefit appeared to be in more severely injured patients, as reflected by head Abbreviated Injury Score and Glasgow Coma Scale score. Improved survival was also observed for air-transported patients intubated in the field versus ground-transported patients given emergency intubation in the ED (adjusted OR 1.42; 95% CI 1.13 to 1.78; P < .001). Conclusion: Here we analyze a large database of patients with moderate to severe traumatic brain injury. Aeromedical response appears to result in improved outcomes after adjustment for multiple influential factors in patients with moderate to severe traumatic brain injury. In addition, out-of-hospital intubation among air-transported patients resulted in better outcomes,than ED intubation among ground-transported patients. Patients with more severe injuries appeared to derive the greatest benefit from aeromedical transport.	Univ Calif San Diego Emergency Med, San Diego, CA 92103 USA; Mercy Air Med Serv, San Diego, CA USA; UC San Diego, Sch Med, La Jolla, CA USA; Scripps Mercy Hosp, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Scripps La Jolla Hosp, La Jolla, CA USA; Palomar Hosp, Escondido, CA USA; UC San Diego Dept Surg, San Diego, CA USA		Davis, DP (corresponding author), Univ Calif San Diego Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Austin P N, 2000, Air Med J, V19, P90, DOI 10.1016/S1067-991X(00)90028-2; Bartolacci RA, 1998, MED J AUSTRALIA, V169, P612, DOI 10.5694/j.1326-5377.1998.tb123435.x; BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Biewener A, 2004, J TRAUMA, V56, P94, DOI 10.1097/01.TA.0000061883.92194.50; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BOYD CR, 1989, J TRAUMA, V29, P789, DOI 10.1097/00005373-198906000-00015; Brathwaite CEM, 1998, J TRAUMA, V45, P140, DOI 10.1097/00005373-199807000-00029; Brazier J, 1996, J Health Serv Res Policy, V1, P232; CAMERON PA, 1993, AUST NZ J SURG, V63, P790, DOI 10.1111/j.1445-2197.1993.tb00342.x; Celli P, 1997, Minerva Chir, V52, P1467; Chappell VL, 2002, J TRAUMA, V52, P486, DOI 10.1097/00005373-200203000-00012; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cocanour CS, 1997, J TRAUMA, V43, P83, DOI 10.1097/00005373-199707000-00019; Cunningham P, 1997, J TRAUMA, V43, P940, DOI 10.1097/00005373-199712000-00013; Dardis R, 2000, Ir Med J, V93, P50; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, 2005, IN PRESS J TRAUMA; De Wing MD, 2000, J BURN CARE REHABIL, V21, P535, DOI 10.1097/00004630-200021060-00011; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Falcone R E, 1998, Air Med J, V17, P161, DOI 10.1016/S1067-991X(98)90043-8; FISCHER RP, 1984, J TRAUMA, V24, P946, DOI 10.1097/00005373-198411000-00004; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; HAMMAN BL, 1991, J TRAUMA, V31, P490, DOI 10.1097/00005373-199104000-00007; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; Holmen CD, 2002, J TRAUMA, V53, P345, DOI 10.1097/00005373-200208000-00026; Jacobs L M, 1999, Conn Med, V63, P677; KEARNEY PA, 1991, ANN EMERG MED, V20, P882, DOI 10.1016/S0196-0644(05)81431-3; Kerr W A, 1999, Prehosp Disaster Med, V14, P159; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kurola J, 2002, ACTA ANAESTH SCAND, V46, P779, DOI 10.1034/j.1399-6576.2002.460704.x; Larson JT, 2004, J TRAUMA, V56, P89, DOI 10.1097/01.TA.0000061163.35582.A5; MALACRIDA RL, 1993, INJURY, V24, P451, DOI 10.1016/0020-1383(93)90147-X; Mann NC, 2002, ACAD EMERG MED, V9, P694, DOI 10.1111/j.1553-2712.2002.tb02147.x; Moront ML, 1996, J PEDIATR SURG, V31, P1183, DOI 10.1016/S0022-3468(96)90114-1; MOYLAN JA, 1988, ANN SURG, V207, P679, DOI 10.1097/00000658-198806000-00006; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Nardi G, 1994, Eur J Emerg Med, V1, P69; NICHOLL JP, 1995, BRIT MED J, V311, P217, DOI 10.1136/bmj.311.6999.217; Oppe S, 2001, ACCIDENT ANAL PREV, V33, P129, DOI 10.1016/S0001-4575(00)00023-3; Phillips RT, 1999, MIL MED, V164, P361, DOI 10.1093/milmed/164.5.361; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pitts L H, 1995, New Horiz, V3, P546; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; SCHILLER WR, 1988, J TRAUMA, V28, P1127, DOI 10.1097/00005373-198808000-00004; SCHMIDT U, 1992, J TRAUMA, V33, P548, DOI 10.1097/00005373-199210000-00010; Schwartz R J, 1988, Conn Med, V52, P203; Schwartz R J, 1990, Conn Med, V54, P660; SCHWARTZ RJ, 1989, J TRAUMA, V29, P1611, DOI 10.1097/00005373-198912000-00002; Shatney CH, 2002, J TRAUMA, V53, P817, DOI 10.1097/00005373-200211000-00002; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; THOMAS F, 1990, WESTERN J MED, V153, P40; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; URDANETA LF, 1987, ARCH SURG-CHICAGO, V122, P992; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wills VL, 2000, AUST NZ J SURG, V70, P506, DOI 10.1046/j.1440-1622.2000.01893.x; Wish John R, 2005, Air Med J, V24, P83, DOI 10.1016/j.amj.2004.12.007; Younge PA, 1997, J TRAUMA, V43, P511, DOI 10.1097/00005373-199709000-00021	70	95	97	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2005	46	2					115	122		10.1016/j.annemergmed.2005.01.024			8	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	950KD	WOS:000230855100004	16046940				2022-02-06	
J	Lu, KT; Wang, YW; Yang, JT; Yang, YL; Chen, HI				Lu, KT; Wang, YW; Yang, JT; Yang, YL; Chen, HI			Effect of interleukin-1 on traumatic brain injury - Induced damage to hippocampal neurons	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; IL-1; neuronal damage; rats; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; CLOSED-HEAD INJURY; RECEPTOR ANTAGONIST; MESSENGER-RNA; GLUCOCORTICOIDS MODULATE; INFLAMMATORY CYTOKINES; CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; MICE LACKING; IN-VITRO	Interleukin-1 (IL-1) has many roles in the brain in addition to mediating inflammatory processes in the glia, and has also been implicated in neurodegenerative disease. Traumatic brain injury (TBI) is one of the most prevalent causes of morbidity and mortality in young persons. We conducted a study to assess the effect of IL-1 on the TBI-induced death of hippocampal neurons. After TBI was induced in adult male Sprague-Dawley rats under anesthesia, we evaluated neuronal damage score through microscopic examination and Pulsinelli's grading system. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were used to measure the levels of IL-1 alpha and IL-1 beta in brain tissue at different points after the induction of TBI. Over a 4-day period, the specific sites of release of IL-1 alpha and IL-1 beta in the brain were elucidated by immunocytochemistry with double-labeling. TBI to the hippocampus was followed by disruption of the blood-brain barrier and severe neuronal loss. Levels of IL-1 alpha RNA and protein were significantly elevated at 3 h after TBI, peaked at 12 h, and remained elevated for 168 h. IL-1 beta RNA and protein expression were also elevated at 3 h after TBI, but remained so only for 48 h. Our findings indicate that the observed TBI-induced increases in IL-1 alpha and IL-1 beta occur largely through release of these cytokines from neurons and astrocytes, respectively. Intraventricular administration of antibodies to IL-1 alpha and IL-1 beta before TBI significantly attenuated the TBI-induced loss of hippocampal neurons. These results show that IL-1 alpha and IL-1 beta play important roles in the TBI-induced loss of hippocampal neurons.	Natl Chiayi Univ, Inst Biotechnol, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Neurosurg, Chiayi, Taiwan; Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan		Yang, YL (corresponding author), Natl Chiayi Univ, Inst Biotechnol, 300 Univ Rd, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw	Yang, Jen-Tsung/C-3187-2011				Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CALDWELL J, 1995, BLOOD, V86, P3364, DOI 10.1182/blood.V86.9.3364.bloodjournal8693364; Chen CA, 2002, MOL PHYLOGENET EVOL, V23, P137, DOI 10.1016/S1055-7903(02)00008-8; Chen YM, 2001, GLIA, V33, P343, DOI 10.1002/1098-1136(20010315)33:4<343::AID-GLIA1033>3.0.CO;2-H; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROCHEM, V64, P1351; GRAHAM DG, 1984, NEUROTOXICOLOGY, V5, P83; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hartl R, 1997, ACT NEUR S, V70, P240; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; LANDFIELD PW, 1977, J GERONTOL, V32, P3, DOI 10.1093/geronj/32.1.3; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; Lukaszevicz AC, 2002, J CEREBR BLOOD F MET, V22, P289, DOI 10.1097/00004647-200203000-00006; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 2000, NEUROTRAUMA, V17, P143; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Reichert SA, 2001, J NEUROSCI, V21, P6608, DOI 10.1523/JNEUROSCI.21-17-06608.2001; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; TOWER DB, 1973, J NEUROCHEM, V20, P269, DOI 10.1111/j.1471-4159.1973.tb12126.x; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com	51	95	100	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					885	895		10.1089/neu.2005.22.885			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900004	16083355				2022-02-06	
J	Chiaretti, A; Genovese, O; Aloe, L; Antonelli, A; Piastra, M; Polidori, G; Di Rocco, C				Chiaretti, A; Genovese, O; Aloe, L; Antonelli, A; Piastra, M; Polidori, G; Di Rocco, C			Interleukin 1 beta and interleukin 6 relationship with paediatric head trauma severity and outcome	CHILDS NERVOUS SYSTEM			English	Article						interleukin 1 beta; interleukin 6; traumatic brain injury; Glasgow Coma Scale; Glasgow Outcome Score	INDUCED NEUTROPHIL CHEMOATTRACTANT; NECROSIS-FACTOR-ALPHA; BRAIN-INJURY; CEREBROSPINAL-FLUID; RAT-BRAIN; IL-6; CYTOKINES; ISCHEMIA; INCREASE; ACCUMULATION	Background: Based on the known inflammatory role of interleukins (IL), we evaluated IL-1beta and IL-6 expressions and their association with the severity of traumatic brain injury (TBI; Glasgow Coma Scale [GCS]) and the outcome (Glasgow Outcome Score [GOS]) recorded in a paediatric population. Design: The design was a perspective observational clinical study carried out in the paediatric intensive care unit of the University Hospital. Methods: We measured the IL-1beta and IL-6 levels in 14 children with severe TBI (patients) and in 12 children with obstructive hydrocephalus (control group). Cerebrospinal fluid (CSF) and plasma samples were collected 2 h (T1) and 24 h (T2) after TBI. Interleukins were assayed using the immunoenzymatic method. Results: The IL-1beta mean level was significantly lower than the IL-6 mean level both in the CSF and plasma of TBI children. In the CSF, the IL-1beta level increased from 55.71+/-72.79 pg/ml at T1 to 106.10+/-142.12 pg/ml at T2 and the IL-6 level increased from 405.43+/-280.28 pg/ml at T1 to 631.57+/-385.35 pg/ml at T2; a similar trend was observed in plasma. We found a statistically significant correlation between the increase in CSF and plasma interleukin levels between T1 and T2 and head injury severity (GCSless than or equal to5) as well as poor outcome (GOSless than or equal to3). Conclusions: The increases in IL-1beta and IL-6 expression were correlated with head injury severity and were indicative of poor clinical outcome, reflecting an endogenous neuroinflammatory response after TBI.	Policlin A Gemelli, I-00168 Rome, Italy; CNR, Inst Neurobiol, Rome, Italy; Univ Cattolica Sacro Cuore, Sch Med, Paediat Neurosurg Dept, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Sch Med, Paediat Intens Care Unit, I-00168 Rome, Italy		Chiaretti, A (corresponding author), Policlin A Gemelli, Largo A Gemelli 1, I-00168 Rome, Italy.	achiaretti@yahoo.it		GENOVESE, Orazio/0000-0002-1989-1363			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BELL M, 1998, CRIT CARE MED, V26, pA86; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fassbender K, 1997, J NEUROIMMUNOL, V74, P130, DOI 10.1016/S0165-5728(96)00214-7; GILLES FH, 1977, ANN NEUROL, V2, P49, DOI 10.1002/ana.410020108; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HACK CE, 1992, INFECT IMMUN, V60, P2835, DOI 10.1128/IAI.60.7.2835-2842.1992; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HANGBERG H, 1999, PEDIATR RES, V40, P603; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hodge CJ, 2001, NEUROSURGERY, V48, P2, DOI 10.1097/00006123-200101000-00002; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; Matsumoto T, 1997, LAB INVEST, V77, P119; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Oygur N, 1998, ARCH DIS CHILD-FETAL, V79, pF190, DOI 10.1136/fn.79.3.F190; PETTILA V, 2002, INTENS CARE MED, V21, P94; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; Savman K, 1998, PEDIATR RES, V43, P746; Seekamp A, 2002, EUR J TRAUMA, V3, P183; Shalak LF, 2002, PEDIATRICS, V110, P673, DOI 10.1542/peds.110.4.673; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Strecker W, 2002, EUR J TRAUMA, V28, P75; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; YOSHIDA S, 1989, NEUROSURGERY, V25, P373, DOI 10.1227/00006123-198909000-00009; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6	56	95	101	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2005	21	3					185	193		10.1007/s00381-004-1032-1			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	902OY	WOS:000227367600003	15455248				2022-02-06	
J	Hlatky, R; Valadka, AB; Goodman, JC; Contant, CF; Robertson, CS				Hlatky, R; Valadka, AB; Goodman, JC; Contant, CF; Robertson, CS			Patterns of energy substrates during ischemia measured in the brain by microdialysis	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; glucose; lactate; microdialysis; traumatic brain injury	CEREBRAL MICRODIALYSIS; TISSUE PO-2; HEAD-INJURY; OXYGEN	The purpose of this study was to examine the patterns of change in microdialysate concentrations of glucose, lactate, pyruvate, and glutamate in the brain during periods of hypoxia/ischemia identified by monitoring brain tissue pO(2) (PbtO(2)). Of particular interest was a better understanding of what additional information could be obtained by the microdialysis parameters that was not available from the PbtO(2). Fifty-seven patients admitted with severe traumatic brain injury who had placement of both a brain tissue pO(2) (PbtO(2)) and microdialysis probe were studied. The microdialysis probe was perfused with Ringer's solution at 0.3 muL/min and dialysate was collected at 1-h intervals. The concentration of glucose, pyruvate, lactate, and glutamate were measured in each dialysate sample. Changes in the microdialysis parameters were examined during episodes where the PbtO(2) decreased to below 10 mm Hg. Ten episodes of tissue hypoxia/ischemia identified by a decrease in PbtO(2) below 10 mm Hg were observed during the period of monitoring. The concentration of the dialysate glucose closely followed the PbtO(2). The dialysate pyruvate concentration was more variable and in some patients transiently increased as the PbtO(2) dropped below 10 mm Hg. The dialysate concentration of lactate was significantly increased as the PbtO(2) decreased to less than 10 mm Hg. Dialysate glutamate was significantly elevated only when PbtO(2) decreased to very low levels. Although changes in the PbtO(2) provided the earliest sign of hypoxia/ischemia, the microdialysis assays provided additional information about the consequences that the reduced tissue pO(2) has on brain metabolism, which may be helpful in managing these critically ill patients.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Charles Univ Prague, Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin,Ste 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; GOODMAN JC, 1999, CRIT CARE MED, V27, P2337; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; Kett-White R, 2002, ACT NEUR S, V81, P363; Kett-White R, 2002, ACT NEUR S, V81, P327; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; RASBASH J, 2002, MLWIN VERSION 1 20 M; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299	22	95	101	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					894	906		10.1089/0897715041526195			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800007	15307902				2022-02-06	
J	Whiteneck, GG; Gerhart, KA; Cusick, CP				Whiteneck, GG; Gerhart, KA; Cusick, CP			Identifying environmental factors that influence the outcomes of people with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; environment; environment design; social environment	SPINAL-CORD-INJURY; MODEL SYSTEMS; FOLLOW-UP; MEDICAL COMPLICATIONS; LIFE SCALE; SATISFACTION; PREDICTION; EMPLOYMENT; DISABILITY; COMMUNITY	Objectives: To determine the types of environmental barriers reported by persons with traumatic brain injury (TBI) and to identify the relations between environmental barriers and such components of societal participation as employment, community mobility, social integration, and life satisfaction. Design: Seventy-three persons with TBI who were participating in the TBI Model Systems program at Craig Hospital were surveyed at 1 year, using a new measure of the environment, the Craig Hospital Inventory of Environmental Factors (CHIEF), which rates frequency and impact of 25 barriers. Results: Transportation, the surroundings, government policies, attitudes, and the natural environment were the environmental barriers with the greatest reported impact. Those who were married, older, and unemployed or not in school reported the most barriers overall. Additionally, those reporting a greater impact from environmental barriers also reported lower levels of participation and life satisfaction. Conclusions: Although environmental barriers affect TBI survivors and play a role in their outcomes, their interplay with other, perhaps as yet unidentified, factors requires continued research. CHIEF may be a valuable tool for understanding the environment's role in the lives of people with TBI, and identifying the general environmental domains where interventions are needed to reduce their negative impact.	Craig Hosp, Res Dept, Englewood, CO 80113 USA		Whiteneck, GG (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craighospital.org					Brandt EN, 1997, ENABLING AM ASSESSIN; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; Consortium for Spinal Cord Medicine, 1999, OUTC FOLL TRAUM SPIN; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; Creek G., 1987, PERSONAL SOCIAL IMPL; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1982, ARCH PHYS MED REHAB, V65, P66; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; ELGHATIT AZ, 1976, ARCH PHYS MED REHAB, V57, P470; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; ELGHATIT AZ, 1978, J CHRON DIS, V31, P363, DOI 10.1016/0021-9681(78)90053-X; Fougeyrollas P., 2002, TOP SPINAL CORD INJ, V7, P1, DOI DOI 10.1310/QDNN-8FN0-NJMG-TVWB; FUHRER M, 1997, RIMA 8 8 WORLD C INT; Gerhart KA, 1999, SPINAL CORD, V37, P183, DOI 10.1038/sj.sc.3100804; GERHART KA, 1993, ARCH PHYS MED REHAB, V74, P1030, DOI 10.1016/0003-9993(93)90057-H; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; GRANGER CV, 1997, ASSESSING MED REHABI; Gray DB, 2003, J ARCHIT PLAN RES, V20, P29; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; KEMP BJ, 1971, J CHRON DIS, V24, P259, DOI 10.1016/0021-9681(71)90078-6; KRAUSE JS, 1990, PARAPLEGIA, V28, P186, DOI 10.1038/sc.1990.24; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; NOREAU I, 2002, TOP SPINAL CORD INJ, V7, P56; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Rintala D. H., 1997, WOMEN PHYS DISABILIT, P223; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; *US DEP ED OFF SPE, 2000, LONG RANG PLAN 1999; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, PARAPLEGIA, V30, P616; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS; World Health Organization, 1992, INT CLASS DIS ICD 10; YARDLEY JK, 1991, SOC INDIC RES, V24, P101, DOI 10.1007/BF00292653	46	95	97	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					191	204		10.1097/00001199-200405000-00001			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300001	15247842				2022-02-06	
J	Rekling, JC				Rekling, JC			Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation	NEUROSCIENCE LETTERS			English	Article						hippocampal slice cultures; oxygen/glucose deprivation; anticonvulsants; neuroprotection	IN-VITRO ISCHEMIA; GLUCOSE DEPRIVATION; DAMAGE; INHIBITION; OXYGEN; DRUGS	Some anticonvulsants show neuroprotective effects, and may be of use in reducing neuronal death resulting from stroke or traumatic brain injury. Here I report that a broad range of anticonvulsants protect cells in hippocampal slice cultures from death induced by oxygen/glucose deprivation (OGD). Hippocampal slice cultures were submitted to 1 h OGD and the resulting cell death was quantified 24 h later using a novel automated fluorescent scanning method. The classical anticonvulsants phenobarbital, phenytoin, ethosuximide, chlordiazepoxide and midazolam all significantly and dose-dependently reduced cell death induced by OGD. The newer anticonvulsants carbamazepine, felbamate, lamotrigine, tiagabine, and oxcarbazepine also had significant neuroprotective effects, but gabapentin, valproic acid (10 mM), levetiracetam and retigabine were not neuroprotective at a concentration up to 300 muM. In conclusion, several classical and newer anticonvulsants have neuroprotective properties in an in vitro model that simulates cerebral ischemia. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	H Lundbeck & Co AS, Biol Res, Dept 828, DK-2500 Valby, Denmark		Rekling, JC (corresponding author), H Lundbeck & Co AS, Biol Res, Dept 828, Ottiliavej 9, DK-2500 Valby, Denmark.			Rekling, Jens C./0000-0002-8568-2332			Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Hetka R, 1999, EUR J PHARMACOL, V386, P165, DOI 10.1016/S0014-2999(99)00786-4; Margineanu DG, 2000, PHARMACOL RES, V42, P281; Nicolson A, 2001, CNS DRUGS, V15, P955, DOI 10.2165/00023210-200115120-00005; Obrenovitch TP, 1997, INT REV NEUROBIOL, V40, P109; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; REKLING JC, 1993, J NEUROSCI, V13, P1954; RENKAWEK K, 1989, Neuropatologia Polska, V27, P323; Sills GJ, 2001, EPILEPTIC DISORD, V3, P165; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; Taylor CP, 1999, J NEUROSCI, V19, P619; Thompson SM, 1996, J COMP NEUROL, V372, P515; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; WEBER ML, 1994, BRAIN RES, V664, P167, DOI 10.1016/0006-8993(94)91967-4	17	95	95	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 2	2003	335	3					167	170	PII S0304-3940(02)01193-X	10.1016/S0304-3940(02)01193-X			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	635QT	WOS:000180410900005	12531459				2022-02-06	
J	Biswas, AK; Bruce, DA; Sklar, FH; Bokovoy, JL; Sommerauer, JF				Biswas, AK; Bruce, DA; Sklar, FH; Bokovoy, JL; Sommerauer, JF			Treatment of acute traumatic brain injury in children with moderate hypothermia improves intracranial hypertension	CRITICAL CARE MEDICINE			English	Article						moderate hypothermia; traumatic brain injury; cerebral ischemia; intracranial hypertension; pediatric intensive care unit	SEVERE HEAD-INJURIES; CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; SYSTEMIC HYPOTHERMIA; METABOLISM; PRESSURE; DAMAGE		Univ Texas, SW Med Ctr, Dept Pediat, Div Pediat Crit Care Med, Dallas, TX USA; Childrens Med Ctr, Dallas, TX 75235 USA		Biswas, AK (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Div Pediat Crit Care Med, 5323 Harry Hines Blvd, Dallas, TX USA.						ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1975, LANCET, V1, P480; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mathew P., 1995, Journal of Neurotrauma, V12, P430; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Munro D, 1928, J AMER MED ASSOC, V90, P1688, DOI 10.1001/jama.1928.02690480010004; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070	46	95	98	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2742	2751		10.1097/00003246-200212000-00020			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	633AP	WOS:000180257300020	12483067				2022-02-06	
J	Winter, CD; Iannotti, F; Pringle, AK; Trikkas, C; Clough, GF; Church, MK				Winter, CD; Iannotti, F; Pringle, AK; Trikkas, C; Clough, GF; Church, MK			A microdialysis method for the recovery of IL-1 beta, IL-6 and nerve growth factor from human brain in vivo	JOURNAL OF NEUROSCIENCE METHODS			English	Article						microdialysis; human; traumatic brain injury (TBI); extracellular fluid (ECF); interleukin-1 beta; interleukin-6; nerve growth factor	TUMOR-NECROSIS-FACTOR; HEAD-INJURY; HUMAN SKIN; TNF-ALPHA; IN-VIVO; CYTOKINES; TISSUE; INFLAMMATION; HISTAMINE; PLASMA	Intracerebral microdialysis is used extensively as a research tool in the investigation of the neurochemical and metabolic,changes that occur following acute brain injury. Microdialysis has enabled elucidation of intra-cerebral levels of substances such as lactate, pyruvate and glycerol but, as yet, has not been used effectively to recover macromolecules from the human brain. Traumatic brain injury is known to result in the generation of cytokines and neurotrophins into extracellular fluid compartment of the brain, with effects on neuronal damage and repair. We have developed a technique of in vivo sampling of the interstitial fluid of the brain of patients with severe head injuries which has allowed the measurement of IL-1beta, IL-6 and nerve growth factor. This report confirms the safety and effectiveness of this modified microdialysis method in the clinical setting of a neurological intensive care unit. The technique provides a timely addition to the armamentarium of the clinical scientist and will potentially lead to a greater understanding of neuroinflammation following acute traumatic brain injury. (C) 2002 Elsevier Science B.V. All rights reserved.	Southampton Gen Hosp, Wessex Neurol Ctr, Dept Neurosurg, Southampton SO16 6YD, Hants, England; Univ Southampton, Sch Med, Southampton SO16 7PX, Hants, England; Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England		Winter, CD (corresponding author), Southampton Gen Hosp, Wessex Neurol Ctr, Dept Neurosurg, Southampton SO16 6YD, Hants, England.	mkc@soton.ac.uk		WINTER, Craig/0000-0003-4626-7280; Pringle, Ashley/0000-0003-2421-4380			Anderson C, 1995, Curr Probl Dermatol, V23, P121; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; BETZ AL, 1992, NEUROSURGERY SCI BAS, P353; Clapp-Lilly KL, 1999, J NEUROSCI METH, V90, P129, DOI 10.1016/S0165-0270(99)00064-3; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; HAMBERGER A, 1983, GLUTAMINE GLUTAMATE, P473; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Landolt H, 1996, ACT NEUR S, V67, P31; LONNROTH P, 1990, J INTERN MED, V227, P295; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Petersen LJ, 1997, CLIN EXP ALLERGY, V27, P284; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Rukwied R, 2000, BRIT J DERMATOL, V142, P1114, DOI 10.1046/j.1365-2133.2000.03535.x; Schmelz M, 1997, NEUROSCI LETT, V230, P117, DOI 10.1016/S0304-3940(97)00494-1; Schmelz M, 1999, CLIN EXP ALLERGY, V29, P695; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TRIKKAS C, 2001, J VASC RES, V38, P199; Westerink BHC, 2001, J NEUROSCI METH, V109, P53, DOI 10.1016/S0165-0270(01)00401-0; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	26	95	96	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	SEP 15	2002	119	1					45	50	PII S0165-0270(02)00153-X	10.1016/S0165-0270(02)00153-X			6	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	597DK	WOS:000178206700006	12234634				2022-02-06	
J	Cervantes, M; Gonzalez-Vidal, MD; Ruelas, R; Escobar, A; Morali, G				Cervantes, M; Gonzalez-Vidal, MD; Ruelas, R; Escobar, A; Morali, G			Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus	ARCHIVES OF MEDICAL RESEARCH			English	Article						global cerebral ischemia; neuroprotection; caudate nucleus; progesterone; cat	TRANSIENT FOREBRAIN ISCHEMIA; GAMMA-AMINOBUTYRIC-ACID; SUBSTANTIA-NIGRA-RETICULATA; TRAUMATIC BRAIN-INJURY; SELECTIVE VULNERABILITY; CARDIAC-ARREST; ARTERY OCCLUSION; GENE-EXPRESSION; ANIMAL-MODEL; GABA	Background. In addition to the hippocampus, the dorsolateral caudate nucleus (CN) and the pars reticularis of the substantia nigra (SNr) are among the most vulnerable brain areas to ischemia. A possible association of the neuronal injury in these two subcortical nuclei has been proposed, the primary damage affecting the CN GABAergic neurons innervating the SNr, and secondarily the SNr neurons as a result of an imbalance of GABAergic and glutamatergic input to the SNr. Progesterone (P-4) exerts a GABAergic action on the central nervous system (CNS) and is known to protect neurons in the cat hippocampus from the damaging effect of acute global cerebral ischemia (AGCI). The effects of AGCI on the neuronal populations of the CN and SNr, in addition to the possible neuroprotective effects Of P-4, were assessed in cats in the present study. Methods. Ovariectomized adult cats were treated subcutaneously (s.c.) with either P-4 (10 mg/kg/day) or corn oil during the 7 days before and 7 days after being subjected to a period of AGCI by 15 min of cardiorespiratory arrest followed by 4 min of reanimation. After 14 days of survival, animals were sacrificed and their brains perfused in situ with phosphate-buffered 10% formaldehyde for histologic examination. Results. ACGI resulted in an intense glial reaction in the CN and a significant loss (43%) of medium-sized neurons of the CN, but no difference was found in the densities of SNr neurons between controls and ischemic oil- and P-4-treated cats. Progesterone treatment completely prevented CN neuronal loss. Conclusions. The overall results point to the higher vulnerability of CN neurons to ischemia as compared to neuron, in the SNr and show the protective effects of P-4 upon CN neuronal damage after ischemia. (C) 2002 IMSS. Published by Elsevier Science Inc.	IMSS, Ctr Med Nacl Siglo 21, Unidad Invest Med Farmacol, Mexico City 03020, DF, Mexico; IMSS, Ctr Invest Biomed Michoacan, Lab Neurofarmacol, Morelia, Michoacan, Mexico; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Fisiol, Mexico City 04510, DF, Mexico		Morali, G (corresponding author), IMSS, Ctr Med Nacl Siglo 21, Unidad Invest Med Farmacol, Apdo Postal 73-032, Mexico City 03020, DF, Mexico.	gmorali@hotmail.com	Morali, Gabriela/AAH-8014-2020				Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; BARNEA A, 1990, ENDOCRINOLOGY, V127, P500, DOI 10.1210/endo-127-1-500; BARRON KD, 1977, BRAIN RES, V130, P469, DOI 10.1016/0006-8993(77)90109-3; BITRAN D, 1993, PHARMACOL BIOCHEM BE, V45, P423, DOI 10.1016/0091-3057(93)90260-Z; Cervantes M, 1995, Arch Med Res, V26, P385; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CRAIN BJ, 1988, NEUROSCIENCE, V27, P387; Crumrine RC, 1997, STROKE, V28, P2230, DOI 10.1161/01.STR.28.11.2230; DEARDEN NM, 1985, LANCET, V2, P255; DOWNIE MM, 1983, BASIC STAT METHODS; FISHER RS, 1986, BRAIN RES, V398, P148, DOI 10.1016/0006-8993(86)91260-6; Friess E, 1997, AM J PHYSIOL-ENDOC M, V272, pE885, DOI 10.1152/ajpendo.1997.272.5.E885; FRIESS E, 1997, AM J PHYSL, V272; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; FRYE CA, 1995, BRAIN RES, V696, P113, DOI 10.1016/0006-8993(95)00793-P; GEE KW, 1988, J PHARMACOL EXP THER, V246, P803; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GONZALES C, 1992, NEUROSCI LETT, V135, P53, DOI 10.1016/0304-3940(92)90134-S; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; Hall ED, 1997, J CEREBR BLOOD F MET, V17, P875, DOI 10.1097/00004647-199708000-00006; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; HASHIMOTO N, 1994, BRAIN RES BULL, V33, P281, DOI 10.1016/0361-9230(94)90195-3; HAWKINSON JE, 1994, EUR J PHARM-MOLEC PH, V269, P157, DOI 10.1016/0922-4106(94)90082-5; HOSSMANN KA, 1985, PROG BRAIN RES, V63, P3; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JOHANSEN FF, 1991, ACTA NEUROL SCAND, V84, P1; KAPLAN J, 1987, RESUSCITATION, V15, P149, DOI 10.1016/0300-9572(87)90012-8; KAWAI K, 1992, J CEREBR BLOOD F MET, V12, P238, DOI 10.1038/jcbfm.1992.34; KIRINO T, 1985, PROG BRAIN RES, V63, P39; KIRKNESS EF, 1989, TRENDS PHARMACOL SCI, V10, P6, DOI 10.1016/0165-6147(89)90091-6; KOGURE K, 1988, NEUROCHEM PATHOL, V9, P145; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; KORNEYEV A, 1993, J NEUROCHEM, V61, P2041, DOI 10.1111/j.1471-4159.1993.tb07440.x; KRAUSE GS, 1988, CRIT CARE MED, V16, P714, DOI 10.1097/00003246-198807000-00015; KUBLIGARFIAS C, 1976, BRAIN RES, V114, P71, DOI 10.1016/0006-8993(76)91008-8; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; LEPEILLET E, 1992, BRAIN RES, V571, P115; LI H, 1993, J CEREBR BLOOD F MET, V13, P933, DOI 10.1038/jcbfm.1993.116; LUNA LG, 1960, MANUAL HISTOLOGIC ST, P185; LYDEN PD, 1994, STROKE, V25, P189, DOI 10.1161/01.STR.25.1.189; Lyden PD, 1997, INT REV NEUROBIOL, V40, P233; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MAKER HS, 1986, NEUROPHARMACOLOGY, V25, P25, DOI 10.1016/0028-3908(86)90054-7; MCGEER PL, 1975, BRAIN RES, V91, P331, DOI 10.1016/0006-8993(75)90558-2; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MORDECAI Y-T, 1991, Stroke, V22, P128; NITSCH C, 1988, BRAIN RES, V461, P127, DOI 10.1016/0006-8993(88)90731-7; POIRIER LJ, 1983, BRAIN RES BULL, V11, P371, DOI 10.1016/0361-9230(83)90173-9; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAICHLE ME, 1983, ANN NEUROL, V13, P2, DOI 10.1002/ana.410130103; RIBAK CE, 1979, J COMP NEUROL, V187, P261, DOI 10.1002/cne.901870203; Roine R.O., 1997, CURRENT REV CEREBROV, P159; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SAJI M, 1993, NEUROSCI LETT, V155, P47, DOI 10.1016/0304-3940(93)90670-G; SAJI M, 1994, BRAIN RES, V643, P234, DOI 10.1016/0006-8993(94)90030-2; Sarraf-Yazdi S, 1999, NEUROL DIS, V48, P243; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; SHUAIB A, 1992, BRAIN RES, V590, P13, DOI 10.1016/0006-8993(92)91076-Q; SHUAIB A, 1993, EXP NEUROL, V123, P284, DOI 10.1006/exnr.1993.1160; SHUAIB A, 1995, NEUROSCI LETT, V197, P109, DOI 10.1016/0304-3940(95)11934-O; Siegel S., 1956, NONPARAMETRIC STAT B, pXVII, 312; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SLIVKA A, 1988, J NEUROCHEM, V50, P1714, DOI 10.1111/j.1471-4159.1988.tb02468.x; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Snider RS, 1961, STEREOTAXIC ATLAS CA; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; TATEISHI A, 1989, STROKE, V20, P1044, DOI 10.1161/01.STR.20.8.1044; TODD MM, 1982, ANESTHESIOLOGY, V57, P76, DOI 10.1097/00000542-198208000-00003; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; VONLUBITZ DKEJ, 1989, NEUROSCIENCE, V30, P451, DOI 10.1016/0306-4522(89)90265-0; WHITE BC, 1993, NEUROLOGY, V43, P1656, DOI 10.1212/WNL.43.9.1656; WIELOCH T, 1985, PROG BRAIN RES, V63, P69; Yamada K, 1996, BRAIN RES, V743, P233, DOI 10.1016/S0006-8993(96)01052-9	90	95	98	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0188-4409	1873-5487		ARCH MED RES	Arch. Med. Res.	JAN-FEB	2002	33	1					6	14	PII S0188-4409(01)00347-2	10.1016/S0188-4409(01)00347-2			9	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	524DQ	WOS:000173997200002	11825624				2022-02-06	
J	Anderson, VA; Catroppa, C; Haritou, F; Morse, S; Pentland, L; Rosenfeld, J; Stargatt, R				Anderson, VA; Catroppa, C; Haritou, F; Morse, S; Pentland, L; Rosenfeld, J; Stargatt, R			Predictors of acute child and family outcome following traumatic brain injury in children	PEDIATRIC NEUROSURGERY			English	Article						traumatic brain injury; childhood; functional outcome	PEDIATRIC HEAD-INJURY; RECOVERY; SEQUELAE	Objective: To examine the relative contributions of injury severity, level of physical and cognitive disability, child behavior and family function to short-term outcome 6 months following traumatic brain injury (TBI) in children. Design: Prospective, longitudinal, between-group design, comparing preinjury and postinjury measures of functional outcome across three levels of injury severity. Subjects: One hundred and twelve children, aged 2-12 years admitted to the Royal Children's Hospital, Melbourne, with a diagnosis of TBI. The sample was divided into three groups, according to injury severity: mild TBI (n = 31), moderate TBI (n = 52) and severe TBI (n = 29). Children with a history of neurologic, developmental and psychiatric disorder were excluded from participation. Main Outcome Measures: Levels of postinjury functioning in the following domains: physical function, cognitive ability (incorporating intellect, memory and attention), behavioral and family functioning, and level of family burden. Results: A clear dose-response relation ship for physical and cognitive outcomes was found, with severe TBI associated with greater impairment of physical, intellectual, memory and attentional function. For psychosocial outcome, results were less clearly linked to injury severity. Preinjury behavioral and family functioning were closely related to postinjury function in these domains, with an interaction identified between family function and child behavior at 6 months postinjury. Family functioning remained unchanged postinjury, although level of burden was high, and predicted by injury severity, functional impairment and postinjury behavioral disturbance. Conclusions: These results suggest ongoing functional problems for the child and significant family burden 6 months following TBI. The nature and severity of physical and cognitive problems are most closely related to injury severity, with family functioning and child behavior better predicted by psychosocial and premorbid factors. Copyright (C) 2001 S. Karger AG, Basel.	Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Nurdoch Childrens Res Inst, Melbourne, Vic, Australia		Anderson, VA (corresponding author), Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia.	v.anderson@psych.unimelb.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			ADAMS W, 1989, MANUAL WIDE RANGE AS; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 1995, NEUROPSYCHOLOGICAL A; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROOKS N, 1985, CLOSED HEAD INJURY P; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DANIEL A, 1983, PRIVILEGE PRESTIGE O; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; Kaufman, 1979, INTELLIGENT TESTING; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P165; Lachar D., 1992, PERSONALITY INVENTOR; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LHERMITTE J, 1972, REV NEUROL, V74, P20; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Noller P., 1988, ICPS FAMILY FUNCTION; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROWE KJ, 1992, J AM ACAD CHILD PSY, V31, P357, DOI 10.1097/00004583-199203000-00026; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TAYLOR HG, IN PRESS NEUROPSYCHO; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D., 1987, MANUAL PRESCHOOL PRI; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; [No title captured]	46	95	96	2	14	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	MAR	2001	34	3					138	148		10.1159/000056009			11	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	432YC	WOS:000168722900006	11359102				2022-02-06	
J	Otto, M; Holthusen, S; Bahn, E; Sohnchen, N; Wiltfang, I; Geese, R; Fischer, A; Reimers, CD				Otto, M; Holthusen, S; Bahn, E; Sohnchen, N; Wiltfang, I; Geese, R; Fischer, A; Reimers, CD			Boxing and running lead to a rise in serum levels of S-100B protein	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						boxing; jogging; sports medicine; neurotrauma; S-100B protein	CHRONIC BRAIN-DAMAGE; MINOR HEAD-INJURY; APOLIPOPROTEIN-E EPSILON-4; NEURON-SPECIFIC ENOLASE; CREATINE-KINASE; S100 PROTEIN; STROKE; BLOOD; BOXERS; MRI	Permanent neurological dysfunction is the primary medical concern of boxing. Recently it was reported that patients presenting elevated levels of the glial protein S-100B in serum after minor head injuries are more prone to develop neuropsychological deficits than patients with lower levels of S-100B protein. We assessed this protein before and after amateur boxing competitions (n =10)and sparring bouts (n = 15). In several control groups, we investigated S-100B levels of participants before and after a 25 km race (n=11), jogging (10 km, n=12), shortterm running (n = 12), and heading footballs (n =12). There was an increase in S-100B protein after boxing and the running disciplines but not after ergometer cycling or soft heading of footballs. The increase in S-100B protein concentrations due to competitive boxing and after the 25 km race was significantly higher than that after performing other disciplines (p<0.001). There was no significant difference between the increases caused by sparring and the running disciplines (p = 0.21). The number and severity of the strikes to the head correlated significantly with the increase in the S-100B protein levels. Levels of S-100B protein known to be associated with neuropsychological deficits were not reached in our study. In professional boxing, much higher levels are to be expected and would be worthy of investigation.	Univ Hosp Gottingen, Dept Neurol, Gottingen, Germany; Univ Hosp Gottingen, Dept Clin Neurophysiol, Gottingen, Germany; Univ Hosp Gottingen, Dept Psychiat, Gottingen, Germany; Univ Gottingen, Inst Sport Sci, Gottingen, Germany		Otto, M (corresponding author), Univ Gottingen, Neurol Klin & Poliklin, Robert-Koch-Str 40, D-37075 Gottingen, Germany.		Otto, Markus/F-4304-2015	Otto, Markus/0000-0003-4273-4267			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Barzo P, 1997, ACT NEUR S, V70, P243; BORTZ JJ, 1985, STAT SOZIALWISSENSCH, P259; BRAYNE CEG, 1982, LANCET, V2, P1308; Brayne H, 1998, BRIT MED J, V316, P1813, DOI 10.1136/bmj.316.7147.1813; Fiore DC, 1996, JAMA-J AM MED ASSOC, V276, P954; Gillon R, 1998, J MED ETHICS, V24, P3, DOI 10.1136/jme.24.1.3; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HAIMOTO H, 1987, LAB INVEST, V57, P489; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; HORNER E, 1993, CLIN J SPORT MED, V3, P144; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; JORDAN B, 1989, SPORTS NEUROLOGY, P219; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Nygaard O, 1997, CLIN CHEM, V43, P541; Otto M, 1998, BRIT MED J, V316, P577, DOI 10.1136/bmj.316.7131.577; Pisa EK, 1999, STROKE, V30, P1153; RICKMANN M, 1995, NEUROSCIENCE, V67, P977, DOI 10.1016/0306-4522(94)00615-C; Ryan AJ, 1998, CLIN SPORT MED, V17, P155, DOI 10.1016/S0278-5919(05)70070-3; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Unterharnscheidt F, 1995, Rev Neurol, V23, P1013; Unterharnscheidt F, 1995, Rev Neurol, V23, P833; USUI A, 1989, CLIN CHEM, V35, P1942; Warburton N, 1998, J MED ETHICS, V24, P56, DOI 10.1136/jme.24.1.56; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1998, CLIN CHEM, V44, P1056; WOERTGEN C, 1998, 1 INT C BIOCH MARK B, pA43; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; ZIMMER DB, 1987, AM J PHYSIOL, V252, P285; 1997, ASS INT MARATHON JUL, P46	37	95	98	1	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622			INT J SPORTS MED	Int. J. Sports Med.	NOV	2000	21	8					551	555		10.1055/s-2000-8480			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	383TQ	WOS:000165899300002	11156273				2022-02-06	
J	Ferguson, RJ; Mittenberg, W; Barone, DF; Schneider, B				Ferguson, RJ; Mittenberg, W; Barone, DF; Schneider, B			Postconcussion syndrome following sports-related head injury: Expectation as etiology	NEUROPSYCHOLOGY			English	Article							SYMPTOMS; TRAUMA; CONCUSSION	Mild head trauma is often complicated by a persistent set of symptoms known as postconcussion syndrome (PCS). Past research has suggested that an expectancy-guided, retrospective-recall bias may account for much of the variance in PCS symptom reporting. The present study examined the influence of symptom expectations on mild head trauma symptom reports among participants in contact sports. Head-injured athletes reported symptom rates that did not differ from those of uninjured athletes but consistently underestimated the preinjury incidence of symptoms. Athletes with no head trauma history overestimated the expected degree of pre- to postinjury change in symptom status. Results suggest that individuals with mild head injury tend to overestimate postconcussion symptom change in a manner consistent with their symptom expectations. A cognitive-behavioral model that explains the persistence of PCS is proposed.	Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Behav Med Sect, Dept Psychiat, Lebanon, NH 03756 USA; Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA		Ferguson, RJ (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Behav Med Sect, Dept Psychiat, Lebanon, NH 03756 USA.						Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Barth JT, 1989, MILD HEAD INJURY, P257; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CONWAY M, 1984, J PERS SOC PSYCHOL, V47, P738, DOI 10.1037/0022-3514.47.4.738; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Cook J. B, 1969, LATE EFFECTS HEAD IN, P408; Davis CH, 1999, ARCH CLIN NEUROPSYCH, V14, P28, DOI 10.1093/arclin/14.1.28a; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Farber M, 1994, SPORTS ILLUSTRATED, p[38, 39, 46]; Ferguson RJ, 1996, SOURCEBOOK PSYCHOL T, P615; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; HIRT ER, 1990, J PERS SOC PSYCHOL, V58, P937, DOI 10.1037/0022-3514.58.6.937; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LINTON SJ, 1982, PAIN, V13, P281, DOI 10.1016/0304-3959(82)90017-3; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MCFARLAND C, 1989, J PERS SOC PSYCHOL, V57, P522, DOI 10.1037/0022-3514.57.3.522; MCFARLAND C, 1992, J PERS SOC PSYCHOL, V5, P837; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; WILLIAMS CW, 1993, J SOC BEHAV PERS, V8, P489; World Health Organization, 1992, ICD 10 CLASSIFICATIO; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253; [No title captured]	45	95	98	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	1999	13	4					582	589		10.1037/0894-4105.13.4.582			8	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	244DC	WOS:000083035700013	10527067				2022-02-06	
J	Neufeld, MY; Vishne, T; Chistik, V; Korczyn, AD				Neufeld, MY; Vishne, T; Chistik, V; Korczyn, AD			Life-long history of injuries related to seizures	EPILEPSY RESEARCH			English	Article						seizure; trauma; seizure-related injury; epilepsy	EPILEPSY; RISK	There is meager information in the literature regarding the characteristics and risk factors for injuries caused during epileptic seizures in adults. Previous studies focused mainly on specific types of injuries incurred, and only few explored associated risk factors. A questionnaire regarding lifetime seizures and their traumatic consequences was administered to 298 consecutive epileptic patients and their caretakers or relatives. Ninety-one of them (30%) have reported trauma: 185 events (age 39.8 +/- 18 years, 54 males), of which 61 were severe. This translates to one seizure-related injury every 21 patient-years, and a serious injury once every 64 patient-years. The most common site of injury was the head (55% of the events). Blunt injuries occurred most frequently (40%), followed by cuts (28%). Severe injuries included fractures and dislocations (17%), burns (6%), brain concussion (6%), subdural hematoma (3%) and intracerebral hematoma (1%). Most injuries occurred at home. The 91 patients with traumatic events were compared with the 207 epileptic patients without previous trauma (age 37.8 +/- 14.7 years, 112 males). Patients with seizure-related trauma had significantly earlier onset age of epilepsy. They more commonly had generalized from onset tonic-clonic, complex partial, myoclonic or absence seizures but fewer had partial seizures with secondary generalization. The risk of trauma was mostly related to seizure type (generalized tonic-clonic from onset and myoclonic seizures). This information may be helpful for better management of epileptic patients. (C) 1999 Elsevier Science B.V. All rights reserved.	Tel Aviv Univ, Tel Aviv Elias Sourasky Med Ctr, Dept Neurol, IL-64239 Tel Aviv, Israel		Neufeld, MY (corresponding author), Tel Aviv Univ, Tel Aviv Elias Sourasky Med Ctr, Dept Neurol, 6 Weizman St, IL-64239 Tel Aviv, Israel.		Korczyn, Amos D/C-3461-2017	Korczyn, Amos D/0000-0003-0125-2579			ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; FINELLI PF, 1989, NEUROLOGY, V39, P858, DOI 10.1212/WNL.39.6.858; HAMPTON KK, 1988, BRIT MED J, V296, P1659, DOI 10.1136/bmj.296.6637.1659; KIRBY S, 1995, EPILEPSIA, V36, P25, DOI 10.1111/j.1528-1157.1995.tb01660.x; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; SPITZ MC, 1994, EPILEPSIA, V35, P764, DOI 10.1111/j.1528-1157.1994.tb02508.x	8	95	98	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	APR	1999	34	2-3					123	127		10.1016/S0920-1211(98)00105-3			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	194MC	WOS:000080196600005	10210026				2022-02-06	
J	Kujawa, SG; Liberman, MC				Kujawa, SG; Liberman, MC			Conditioning-related protection from acoustic injury: Effects of chronic deefferentation and sham surgery	JOURNAL OF NEUROPHYSIOLOGY			English	Article							CROSSED OLIVOCOCHLEAR BUNDLE; MIDDLE-EAR MUSCLES; COCHLEAR DE-EFFERENTATION; SUPERIOR OLIVARY COMPLEX; AUDITORY-NERVE RESPONSE; INDUCED HEARING-LOSS; OUTER HAIR-CELLS; GUINEA-PIG; THRESHOLD SHIFT; NOISE EXPOSURE	The inner ear can be made less vulnerable to acoustic injury by a "conditioning" treatment involving exposure to a moderate-level acoustic stimulus before the acoustic overexposure. The present study was designed to explore the role of the olivocochlear (OC) system in this "protection" Guinea pigs were divided into a number of groups: some (trauma-only) were exposed to a traumatic noise for 4 h at 109 dB SPL; others (condition/trauma) were conditioned by daily exposure to the same noise at 85 dB SPL before the traumatic exposure. In OC-intact animals, the condition/trauma group showed significantly less permanent threshold shift (PTS) than the trauma-only group as measured via compound action potentials and distortion-product otoacoustic-emissions (DPOAEs). Other animals with identical noise-exposure regimens underwent deefferentation surgery before the start of conditioning: the OC bundle (OCB) was cut in the brain stem, either at the midline (cutting the crossed OCB to both ears) or at the sulcus limitans (cutting all OC fibers to 1 side). Lesion success was quantified by measuring OC fascicles to the outer hair cell region in each ear. The results from the surgical groups showed that total loss of the OCB significantly increased the noise-induced PTS, whereas loss of the COCB only did not; that the conditioning exposure in deefferented animals increased, rather than decreased, the PTS from the traumatic exposure; and that animals undergoing sham surgery (brain stem cuts that failed to transect the OCB) appeared protected whether or not they received the conditioning noise exposure. The latter result suggests that conditioning-related protection may arise from a generalized stress response, which can be elicited by noise exposure, brain surgery, or a variety of other means. The former results make an OC role in the conditioning process, per se, difficult to assess, given the large effects of OC activity on general acoustic vulnerability.	Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA		Liberman, MC (corresponding author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000188, F32DC000180] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC-000188, F32 DC-00180] Funding Source: Medline		ARNESEN AR, 1984, ACTA OTOLARYNGOL STO, V98, P225; AVAN P, 1992, HEARING RES, V59, P59, DOI 10.1016/0378-5955(92)90102-S; BOETTCHER FA, 1992, HEARING RES, V62, P217, DOI 10.1016/0378-5955(92)90189-T; BROWN MC, 1989, HEARING RES, V40, P93, DOI 10.1016/0378-5955(89)90103-2; BROWN MC, IN PRESS J NEUROPHYS; CANLON B, 1993, NEUROSCI LETT, V150, P103, DOI 10.1016/0304-3940(93)90118-5; Canlon B, 1996, AUDITORY SYSTEM PLASTICITY AND REGENERATION, P118; CANLON B, 1988, HEARING RES, V34, P197, DOI 10.1016/0378-5955(88)90107-4; CANLON B, 1995, HEARING RES, V84, P112, DOI 10.1016/0378-5955(95)00020-5; CANLON B, 1991, NOISE INDUCED HEARIN, P489; GUINAN JJ, 1984, J COMP NEUROL, V226, P21, DOI 10.1002/cne.902260103; GUINAN JJ, 1983, J COMP NEUROL, V221, P358, DOI 10.1002/cne.902210310; HANDROCK M, 1982, ARCH OTO-RHINO-LARYN, V234, P191, DOI 10.1007/BF00453630; HENDERSON D, 1994, HEARING RES, V74, P22, DOI 10.1016/0378-5955(94)90172-4; KIANG NYS, 1965, MIT RES MONOGRAPH, V35; KUJAWA SG, 1996, ABSTR ASS RES OT, V19, P34; LIBERMAN MC, 1990, J COMP NEUROL, V301, P443, DOI 10.1002/cne.903010309; LIBERMAN MC, 1990, HEARING RES, V49, P209, DOI 10.1016/0378-5955(90)90105-X; LIBERMAN MC, 1979, ACTA OTO-LARYNGOL, V88, P161, DOI 10.3109/00016487909137156; LIBERMAN MC, 1988, J NEUROPHYSIOL, V60, P1779, DOI 10.1152/jn.1988.60.5.1779; LIBERMAN MC, 1995, HEARING RES, V90, P158, DOI 10.1016/0378-5955(95)00160-2; LIBERMAN MC, 1978, ACTA OTOLARYNGOL S, V358, P5; LIM HH, 1993, HEARING RES, V69, P146; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MOUNTAIN DC, 1980, SCIENCE, V210, P71, DOI 10.1126/science.7414321; MUCHNIK C, 1992, HEARING RES, V58, P101, DOI 10.1016/0378-5955(92)90013-D; OSEN KK, 1969, BRAIN RES, V16, P165, DOI 10.1016/0006-8993(69)90092-4; PUEL JL, 1988, HEARING RES, V37, P65, DOI 10.1016/0378-5955(88)90078-0; RAJAN R, 1988, J NEUROPHYSIOL, V60, P569, DOI 10.1152/jn.1988.60.2.569; RAJAN R, 1995, J NEUROPHYSIOL, V74, P582, DOI 10.1152/jn.1995.74.2.582; RAJAN R, 1991, NOISE INDUCED HEARIN, P429; RAREY KE, 1995, HEARING RES, V82, P135, DOI 10.1016/0378-5955(94)00171-L; REITER ER, 1995, J NEUROPHYSIOL, V73, P506, DOI 10.1152/jn.1995.73.2.506; REITER ER, 1991, ARO MIDW M, V14, P157; ROBERTSON D, 1987, EXP BRAIN RES, V66, P449, DOI 10.1007/BF00270677; RYAN AF, 1994, HEARING RES, V72, P23, DOI 10.1016/0378-5955(94)90201-1; SCHMIEDT RA, 1984, J ACOUST SOC AM, V76, P1293, DOI 10.1121/1.391446; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303, DOI 10.1152/jn.1982.47.2.303; SMITH CA, 1961, ANN OTO RHINOL LARYN, V70, P504, DOI 10.1177/000348946107000216; SMITH CA, 1963, ANN OTO RHINOL LARYN, V72, P489, DOI 10.1177/000348946307200218; SRIDHAR TS, 1995, J NEUROSCI, V15, P3667; Sridhar TS, 1997, J NEUROSCI, V17, P428, DOI 10.1523/JNEUROSCI.17-01-00428.1997; Subramaniam M, 1996, AUDITORY SYSTEM PLASTICITY AND REGENERATION, P128; SUBRAMANIAM M, 1991, HEARING RES, V52, P181, DOI 10.1016/0378-5955(91)90197-H; SUBRAMANIAM M, 1991, HEARING RES, V56, P65, DOI 10.1016/0378-5955(91)90154-2; TERAYAMA Y, 1969, ANN OTO RHINOL LARYN, V78, P1254, DOI 10.1177/000348946907800612; TRAHIOTIS C, 1970, J ACOUST SOC AM, V47, P592, DOI 10.1121/1.1911934; Tsuji J, 1997, J COMP NEUROL, V381, P188; WARREN EH, 1989, HEARING RES, V37, P89, DOI 10.1016/0378-5955(89)90032-4; Zheng XY, 1997, HEARING RES, V107, P147, DOI 10.1016/S0378-5955(97)00031-2; Zheng XY, 1997, HEARING RES, V104, P191, DOI 10.1016/S0378-5955(96)00187-6	51	95	98	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	DEC	1997	78	6					3095	3106		10.1152/jn.1997.78.6.3095			12	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	YP840	WOS:000071320900027	9405529				2022-02-06	
J	Bleiberg, J; Garmoe, WS; Halpern, EL; Reeves, DL; Nadler, JD				Bleiberg, J; Garmoe, WS; Halpern, EL; Reeves, DL; Nadler, JD			Consistency of within-day and across-day performance after mild brain injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						mild TBI; variability; ANAM; sustained performance	REACTION-TIME; HEAD-INJURY	The objective of this study was to determine whether inconsistent and erratic within-day and across-day performance is a symptom of mild to moderate traumatic brain injury (TBI), and to determine whether impaired consistency of performance can coexist, in the same patient, with intact or ''normal'' performance on single administrations of neuropsychological and other cognitive tests. The design was a matched-pair study in which a computerized cognitive test battery was administered 30 times over 4 days to all subjects. Performance patterns between TBI and control subjects were compared. Subjects also received traditional neuropsychological testing. The setting was a rehabilitation hospital outpatient department. The subjects were 12 adult volunteers, six with documented TBI and six with no history of TBI, neurologic illness, or injury. Control subjects showed consistent improvement of performance over days 1 to 4, whereas subjects with TBI showed erratic and inconsistent performance across days. In addition to inconsistent performance, some subjects with TBI showed worsening performance across days. The main outcome measures were performance on the Automated Neuropsychological Assessment Metrics (ANAM) battery and performance on traditional neuropsychological tests. Some patients with TBI in the study who have normal initial performance on traditional clinical neuropsychological tests and newly developed computerized cognitive tests show abnormalities of sustained performance. Such abnormalities are most apparent when performance is observed over multiple days, and are characterized by erratic and inconsistent across-day performance. Inconsistent performance was observed even in those subjects with TBI whose initial performance was equal to or better than that of the control subjects. Deficits in dynamic performance may explain why some patients with TBI who have excellent neuropsychological test performance nonetheless complain of functional decrement from premorbid ability.	MEDLANT RES INST, WASHINGTON, DC USA; USN, MED CTR, SAN DIEGO, CA 92152 USA; FLORIDA HOSP MED CTR, ORLANDO, FL 32803 USA		Bleiberg, J (corresponding author), NATL REHABIL HOSP, PSYCHOL SERV, MEDLANT RES INST, 102 IRVING ST NW, WASHINGTON, DC 20010 USA.						Benton A., 1978, MULTILINGUAL APHASIA; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; CULLUM CM, 1991, FORENSIC NEUROPSYCHO; DELIS C, 1987, CALIFORNIA VERBAL LE; Golden CJ, 1978, STROOP COLOR WORD TE; GRONWALL D, 1974, LANCET, V2, P1452; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Head H., 1926, APHASIA KINDRED DISO; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KAY T, 1992, REHABILITATION POST, P109; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Pritchard, 1996, DETECTING MALINGERIN; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; REEVES D, 1989, UNITED TRISERVICE CO; Reitan R, 1985, HALSTEAD REITAN NEUR; RUFF RM, 1987, NEUROBEHAVIORAL RECO, P176; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; THORNE DR, 1991, THROUGHPUT SIMPLE RA; VANZOMEREN AH, 1989, NEUROBEHAVIORAL RECO, P398; Wechsler, 1997, WECHSLER ADULT INTEL; Wilkinson, 1984, WIDE RANGE ACHIEVEME	24	95	95	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	OCT	1997	10	4					247	253					7	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	YD472	WOS:A1997YD47200005	9359122				2022-02-06	
J	Geddes, JF; Vowles, GH; Beer, TW; Ellison, DW				Geddes, JF; Vowles, GH; Beer, TW; Ellison, DW			The diagnosis of diffuse axonal injury: implications for forensic practice	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						head injuries; diffuse axonal injury; beta-amyloid precursor protein; forensic medicine	MILD HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; BRAIN; DAMAGE; HUMANS; TRAUMA	The diagnosis of diffuse axonal injury (DAI), which may be of considerable importance in forensic medicine, necessitates widespread sampling of the brain for histology, Because a limited sampling method for screening brains for axonal damage would be of value for medico-legal work, the authors have tested the findings of an earlier study which suggested that a standard set of three blocks from above and below the tentorium could reliably be used in routine practice as a basis for the diagnosis of DAI, A series of 22 previously diagnosed cases of DAI, with a range of survival times, was studied using immunohistochemistry with antibodies to beta-amyloid precursor protein (beta APP), the microglial-associated antigen CD68 (PG-MI) and for GFAP. Strict histological criteria were used to assess traumatic damage, and the evolution of the histological changes with increasing survival is described, In four cases, the sampling scheme employed yielded evidence of axonal damage in only one block, and a diagnosis of DAI could have been made in only 13/22 cases, In six of the shortest surviving cases, beta APP positivity in the corpus callosum and brainstem outlined areas of early ischaemia, as well as of traumatic damage, so that interpretation of immunolabelling was not always clear-cut. The findings suggest that DAI cannot be reliably diagnosed on a restricted number of blocks from vulnerable areas, and that the use of beta APP and PG-M1 immunocytochemistry may bring interpretative problems that can only be resolved by taking a larger series of tissue samples for histology.	SOUTHAMPTON GEN HOSP,DEPT HISTOPATHOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND		Geddes, JF (corresponding author), ROYAL LONDON HOSP,DEPT MORBID ANAT,LONDON E1 1BB,ENGLAND.		Ellison, David/N-4806-2018	Beer, Trevor/0000-0002-3096-3030			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BAZZAZ AA, 1995, NEUROPATHOL APPL NEU, V21, P446; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; GEAN AD, 1994, IMAGING HEAD TRAUMA, P220; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1993, J EMERG MED, V1, P5; Gennarelli TA, 1996, NEUROPATHOL APPL S1, V22, P44; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1989, MILD MODERATE HEAD I, P63; MAXSWELL WL, IN PRESS J NEUROTRAU; MCKENZIE KJ, 1996, NEUROPATHOL APPL NEU, V22, P160; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526	29	95	99	0	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	AUG	1997	23	4					339	347		10.1046/j.1365-2990.1997.4498044.x			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	XW008	WOS:A1997XW00800010	9292874				2022-02-06	
J	Kraus, MF; Maki, PM				Kraus, MF; Maki, PM			Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ALZHEIMERS-DISEASE; CEREBRAL-CORTEX; FLUENCY TEST; DEMENTIA; THERAPY; EPILEPSY; PROFILE; PATIENT; MILD; PET	Symptoms consistent with dysfunction of the frontal lobes can occur following traumatic brain injury (TBI) or other types of acquired brain injury (stroke, aneurysm). These symptoms can include problems with short-term memory, attention, planning, problem solving, impulsivity, disinhibition, poor motivation, and other behavioral and cognitive deficits (''frontal lobe syndrome''). These symptoms may respond to certain drugs, such as dopaminergic agents. This case series describes results of using amantadine in 7 patients with this type of symptom profile (6 with TBI, 1 with meningitis following sinus surgery). Patients received neuropsychiatric examinations and serial neuropsychological testing. All patients showed some degree of positive response. One had side effects that resolved upon discontinuation of drug. The rationale for using dopaminergics is discussed, and pertinent literature is reviewed.	JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA				Maki, Pauline/AAF-1554-2021	Maki, Pauline/0000-0002-8443-3430	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00149] Funding Source: Medline		ALBERT M, 1992, J AM GERIATR SOC, V40, P449, DOI 10.1111/j.1532-5415.1992.tb02009.x; ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; DRAKE ME, 1991, ACTA NEUROL BELG, V91, P159; ERKULWATER S, 1989, SOUTHERN MED J, V82, P550, DOI 10.1097/00007611-198905000-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625, DOI 10.3181/00379727-103-25617; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MORYL E, 1993, PHARMACOL TOXICOL, V72, P394, DOI 10.1111/j.1600-0773.1993.tb01351.x; MULLER HF, 1979, J AM GERIATR SOC, V27, P9; MURRAY TJ, 1985, CAN J NEUROL SCI, V12, P251, DOI 10.1017/S0317167100047107; *NATL I NEUR DIS S, 1989, INT HEAD INJ TASK FO; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; Reitan RM, 1985, HALSTEADREITAN NEURO; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; Schretlen D., 1989, BRIEF TEST ATTENTION; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; SEMLITSCH HV, 1992, J NEURAL TRANSM-PARK, V4, P319, DOI 10.1007/BF02260080; SHAHAR EM, 1992, J PEDIATR-US, V121, P819, DOI 10.1016/S0022-3476(05)81922-5; Suitsu N, 1992, Seishin Shinkeigaku Zasshi, V94, P238; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; WARKENTIN S, 1993, DEMENTIA, V4, P188, DOI 10.1159/000107322; Wechsler D, 1987, MEMORY SCALE REVISED; WELLER M, 1992, MED HYPOTHESES, V38, P329, DOI 10.1016/0306-9877(92)90027-A; WOLFE N, 1990, J NEUROL NEUROSUR PS, V53, P915, DOI 10.1136/jnnp.53.10.915	39	95	99	0	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	1997	9	2					222	230					9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	WX311	WOS:A1997WX31100004	9144101				2022-02-06	
J	Togher, L; Hand, L; Code, C				Togher, L; Hand, L; Code, C			Analysing discourse in the traumatic brain injury population: Telephone interactions with different communication partners	BRAIN INJURY			English	Article							HEAD-INJURY; ADULTS; LANGUAGE; DEFICITS; SKILLS	A range of discourse analyses are effective in identifying features which are aberrant following traumatic brain injury (TBI). We examined the exchanges of five traumatically brain-injured subjects and five matched controls across four speaking situations which included speaking to a therapist, to the bus timetable information service, to the police, and to their mothers on the telephone. Transcripts were analysed using the exchange structure analysis of systemic functional grammar. This analysis provided an indication of information giving (K1 moves per minute), information requesting and receiving (K2 moves per minute) and the amount of negotiation that was needed for the messages to be conveyed (dynamic moves per minute). Results indicated that the TBI subjects performed differently across the four conditions, and were differentiated from the matched controls on a number of measures. The role of different communication partners is also addressed. Communication partners were noted to interact differently with TBI subjects when compared with controls. This included increased information-giving to control subjects; more requests for information by police from TBI subjects and a greater use of dynamic moves by therapists with controls. The potential of exchange structure analysis is discussed as a useful way of examining the discourse of TBT subjects and their communication partners. Exchange structure analysis highlighted the dynamic nature of information exchange and the subtle ways speakers responded to familiarity and power imbalance in social interaction. This study has implications for family and community education regarding communication with people with TBI.	LIVERPOOL AREA HLTH SERV,BRAIN INJURY UNIT,SYDNEY,NSW,AUSTRALIA; UNIV SYDNEY,FAC HLTH SCI,SCH COMMUNICAT DISORDERS,SYDNEY,NSW 2006,AUSTRALIA		Togher, L (corresponding author), UNIV SYDNEY,FAC HLTH SCI,BRAIN DAMAGE & COMMUNICAT RES,POB 170,LIDCOMBE,NSW 2141,AUSTRALIA.		Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010				ADAMOVITCH BLB, AM J SPEECH LANGUAGE, P39; BERRY M, 1981, STUDIES DISCOURSE AN, P120; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Cameron Deborah, 1989, WOMEN THEIR SPEECH C, P74; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Fairclough N., 1992, DISCOURSE SOCIAL CHA; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; Glosser G., 1990, BRAIN LANG, V40, P67; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY LL, 1990, NEUROPSYCHOLOGY EVER, P135; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MILTON SB, 1988, J HEAD TRAUMA REHAB, V3, P1; OBARR WM, 1987, LANG COMMUN, P205; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; POYNTON C, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rimel RW, 1990, REHABILITATION ADULT, P8; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; SILVAST M, 1991, APHASIOLOGY, V5, P383, DOI 10.1080/02687039108248540; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THWAITES A, THESIS U SYDNEY SYDN; VENTOLA E, STRUCTURE SOCIAL INT	40	95	98	1	14	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1997	11	3					169	189		10.1080/026990597123629			21	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	WL158	WOS:A1997WL15800002	9057999				2022-02-06	
J	Marion, DW; Leonov, Y; Ginsberg, M; Katz, LM; Kochanek, PM; Lechleuthner, A; Nemoto, EM; Obrist, W; Safar, P; Sterz, F; Tisherman, SA; White, RJ; Xiao, F; Zar, H				Marion, DW; Leonov, Y; Ginsberg, M; Katz, LM; Kochanek, PM; Lechleuthner, A; Nemoto, EM; Obrist, W; Safar, P; Sterz, F; Tisherman, SA; White, RJ; Xiao, F; Zar, H			Resuscitative hypothermia	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	International Resuscitation Research Conference (IRRC 94)	MAY 07-09, 1994	PITTSBURGH, PA			cardiac arrest; brain trauma; cardiopulmonary resuscitation; resuscitation; hypothermia; free radicals, cooling; cerebral resuscitation; cerebral ischemia; cerebral protection	PROLONGED CARDIAC-ARREST; D-ASPARTATE ANTAGONIST; GLOBAL BRAIN ISCHEMIA; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; CEREBRAL-ISCHEMIA; FOREBRAIN ISCHEMIA; HEAD-INJURY; DEEP HYPOTHERMIA; NEURONAL DAMAGE	Resuscitative (postinsult) hypothermia is less well studied than protective-preservative (pre and intra-arrest) hypothermia. The latter is in wide clinical use, particularly for protecting the brain during cardiac surgery. Resuscitative hypothermia was explored in the 1950s and then lay dormant until the 1980s when it was revived. This change occurred through the discoveries of brain damage mitigating effects after cardiac arrest in dogs, and after forebrain ischemia in rats, of mild (34 degrees C) hypothermia (which is safe), and of benefits derived from moderate hypothermia (30 degrees C) after traumatic brain injury or focal brain ischemia in various species. The idea that protection-preservation or resuscitation by hypothermia is mainly explained by its ability to reduce cerebral oxygen demand has been replaced by an increasingly documented synergism of many beneficial mechanisms. Deleterious chemical cascades during and after these insults are suppressed even by mild hypothermia. Prolonged moderate hypothermia carries some risks, e.g., arrhythmias, infection and coagulopathies. These side effects need further study. In global brain ischemia, protective-preservative mild hypothermia provides lasting mitigation of brain damage. Resuscitative mild hypothermia, however, may be beneficial in terms of long-term outcome or may merely delay the inevitable loss of selectively vulnerable neurons. Even if the latter is true, mild hypothermia may extend the therapeutic window for other interventions. This extension of the therapeutic window requires further documentation. After normothermic cardiac arrest of 11 mins in dogs, mild resuscitative hypothermia from 15 mins to 12 hrs after reperfusion plus cerebral blood flow promotion normalized functional recovery with the least histologic damage seen thus far. Optimal duration of, and rewarming methods from, resuscitative hypothermia need clarification. The earliest possible induction of mild hypothermia after cardiac arrest seems desirable. Head-neck surface cooling alone is too slow. Among many clinically feasible rapid cooling methods, carotid cold flush and peritoneal cooling look promising. After traumatic brain injury or focal brain ischemia, which seem to still benefit from even later cooling, surface cooling methods may be adequate. Resuscitative hypothermia after cardiac arrest, traumatic brain injury, or focal brain ischemia should be considered for clinical trials.	ASSAF HAROFE MED CTR, ICU DEPT, IL-70300 YAAKOV, ISRAEL; UNIV MIAMI, SCH MED, DEPT NEUROL D45, MIAMI, FL 33101 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV MIAMI, JACKSON MEM HOSP, DEPT EMERGENCY MED, MIAMI, FL 33136 USA; MERHEIM HOSP, DEPT SURG, W-5000 COLOGNE, GERMANY; UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL, CCM, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, MED CTR, DEPT NEUROL SURG, PITTSBURGH, PA 15261 USA; STADT WIEN UNIV KLIN, ALLGEMEINES KRANKENHAUS, ABT NOTFALLMED, A-1090 VIENNA, AUSTRIA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44109 USA; METROHLTH MED CTR, CLEVELAND, OH 44109 USA; LOUISIANA STATE UNIV, CTR MED, DEPT EMERGENCY MED, SHREVEPORT, LA 71130 USA		Marion, DW (corresponding author), UNIV PITTSBURGH, PRESBYTERIAN HOSP, MED CTR, DEPT NEUROL SURG, B400, PITTSBURGH, PA 15213 USA.		Tisherman, Samuel A./AAK-9377-2020; Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Tisherman, Samuel A./0000-0003-3810-3729; Kochanek, Patrick M/0000-0002-2627-913X			Benson DW, 1958, ANESTH ANALG, V38, P423; BORISMOLLER F, 1989, NEUROSCI RES COMMUN, V5, P87; BOVERIS A, 1980, P NATL ACAD SCI-BIOL, V77, P347, DOI 10.1073/pnas.77.1.347; BRADER E, 1985, Annals of Emergency Medicine, V14, P510, DOI 10.1016/S0196-0644(85)80398-X; BUCHAN A, 1991, J NEUROSCI, V11, P1049; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DRIPPS RD, 1956, PHYSL INDUCED HYPOTH; EBMEYER U, 1994, RESUSCITATION, V28, pS13; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; FAY T, 1945, TRAUMA CENTRAL NERVO, P611; GINSBERG MD, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P255; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GLOBUS MYT, IN PRESS J NEUROCHEM; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HOSSMANN KA, 1988, CRIT CARE MED, V16, P964, DOI 10.1097/00003246-198810000-00007; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KATZ L, 1994, RESUSCITATION, V28, pS10; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; KUBOYAMA K, 1994, RESUSCITATION, V27, P231, DOI 10.1016/0300-9572(94)90037-X; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; LIN B, 1994, STROKE, V25, P254; MANSFIELD RT, IN PRESS J CEREB BLO; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARION DW, IN PRESS J NEUROTRAU; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; NEMOTO EM, 1977, STROKE, V8, P558, DOI 10.1161/01.STR.8.5.558; NEMOTO EM, IN PRESS J NEUROSURG; OKU K, 1993, STROKE, V24, P1590, DOI 10.1161/01.STR.24.10.1590; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PARADIS NA, 1995, CARDIAC ARREST, pCH49; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; RAVITCH MM, 1961, NEW ENGL J MED, V264, P36, DOI 10.1056/NEJM196101052640109; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; SAFAR P, 1988, CRIT CARE MED, V16, P919; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STERNAU L, 1991, J CEREB BLOOD FLO S2, V11, pS123; STERZ F, 1989, ANESTHESIOLOGY, V71, P907, DOI 10.1097/00000542-198912000-00014; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; TISHERMAN S, 1991, PREHOSP DISASTER MED, V6, P207; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WHITE RJ, 1978, MAYO CLIN PROC, V53, P450; WOLFSON SK, 1973, J SURG RES, V14, P449, DOI 10.1016/0022-4804(73)90053-X; XIAO F, 1995, RESUSCITATION, V30, P51, DOI 10.1016/0300-9572(94)00858-D; XIAO F, 1994, RESUSCITATION, V28, pS21; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAR H, 1994, FASEB J, V8, pA128	67	95	97	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	1996	24	2		S			S81	S89					9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TW260	WOS:A1996TW26000008	8608709				2022-02-06	
J	Massaro, F; Lanotte, M; Faccani, G; Triolo, C				Massaro, F; Lanotte, M; Faccani, G; Triolo, C			One hundred and twenty-seven cases of acute subdural haematoma operated on - Correlation between CT scan findings and outcome	ACTA NEUROCHIRURGICA			English	Article						acute subdural haematoma; head injury; outcome	COMATOSE PATIENTS; HEAD-INJURY; HEMATOMA; MORTALITY	Traumatic acute subdural haematoma is one of the most lethal of all head injuries: the mortality rate is reported to be between 50 and 90%. We reviewed the clinical records of 1688 head injured patients admitted to the Department of Neurosurgery at C.T.O. hospital between 1982 and 1992. In 127 cases (7,5%) CTscan on admission showed acute subdural haematoma requiring surgery because the midline shift was greater than 5 mm. The overall mortality rate was 57% and 23% had functional recovery. The following variables were assessed with regard to morbidity and mortality: mechanism of injury, age, neurological presentation, time delay from injury to intervention, CTscan finding on admission. GCS and CTscan findings were found to be the most important prognostic variable. Timing of operative intervention for clot removal with regard to outcome was not statistically significant. But no conclusions regarding the importance of early haematoma evacuation can be drawn from such an oversimplifying statement, because it does not take into account factors like rapidity of haematoma development and related brain decompensation as well as additional direct brain lesions. The results of this study suggest that the extent of primary brain injury underlying the subdural haematoma is the most important factor affecting outcome.	CTO HOSP,DEPT NEUROSURG,TURIN,ITALY				Lanotte, Michele M./I-2647-2012	Lanotte, Michele M./0000-0002-4184-028X			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adams JH, 1982, RECENT ADV NEUROPATH, P165; CANTORE GP, 1987, ACTA NEUROCHIR WIEN, V41, P349; Cooper P R, 1976, Surg Neurol, V5, P25; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JENNETT B, 1975, LANCET, V1, P480; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOEW F, 1960, ACTA NEUROCHIR WIE S, V3; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCKISSOCK W, 1960, LANCET, V1, P1365; SCHISANO G, 1964, Acta Chir Scand, V128, P471; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TALALLA A, 1971, J TRAUM, V11, P771, DOI 10.1097/00005373-197109000-00008; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WINTZEN AR, 1980, BRAIN, V103, P855, DOI 10.1093/brain/103.4.855; YUE CP, 1983, INJURY, V14, P489, DOI 10.1016/0020-1383(83)90051-7	25	95	96	0	4	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1996	138	2					185	191		10.1007/BF01411359			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TX189	WOS:A1996TX18900012	8686543				2022-02-06	
J	WAXWEILER, RJ; THURMAN, D; SNIEZEK, J; SOSIN, D; ONEIL, J				WAXWEILER, RJ; THURMAN, D; SNIEZEK, J; SOSIN, D; ONEIL, J			MONITORING THE IMPACT OF TRAUMATIC BRAIN INJURY - A REVIEW AND UPDATE	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		EPIDEMIOLOGY; BRAIN INJURY; ETIOLOGY; INCIDENCE	HEAD-INJURY; POPULATION; COUNTY; DEATHS		CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT PROGRAMMING & GRAPH,ATLANTA,GA 30341		WAXWEILER, RJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.			Thurman, David/0000-0002-0533-7062			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1991, NEUROEPIDEMIOLOGY TR, P333; LAND G, 1994, MISSOURI HEAD SPINAL; LEMIER M, 1994, ASSESSMENT HEAD SPIN; MALLONEE S, 1993, SUMMARY REPORTABLE I; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; Thurman DJ., 1995, GUIDELINES SURVEILLA; THURMAN DJ, 1993, HEAD INJURIES AM IND; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1989, INT CLASSIFICATION D; 1977, INT CLASSIFICATION D	20	95	102	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					509	516		10.1089/neu.1995.12.509			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000002	8683602				2022-02-06	
J	HEINEMANN, AW; HAMILTON, B; LINACRE, JM; WRIGHT, BD; GRANGER, C				HEINEMANN, AW; HAMILTON, B; LINACRE, JM; WRIGHT, BD; GRANGER, C			FUNCTIONAL STATUS AND THERAPEUTIC INTENSITY DURING INPATIENT REHABILITATION	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						TRAUMATIC BRAIN INJURY; SPINAL CORD INJURY; FUNCTIONAL STATUS; THERAPY INTENSITY; MEDICAL REHABILITATION	CONTROLLED TRIAL; STROKE REHABILITATION; RHEUMATOID-ARTHRITIS; INDEPENDENCE MEASURE; PERFORMANCE; TEAM	The objective of this study was to describe the relationships between functional status at discharge and intensity of therapies received during inpatient medical rehabilitation. The sample was comprised of 140 patients with traumatic brain injury and 106 patients with spinal cord injury at eight hospitals that subscribe to the Uniform Data System for Medical Rehabilitation. Data included linear measures of motor and cognitive ability derived from the Functional Independence Measure at admission to and discharge from rehabilitation. Multiple regression was used to predict intensity of therapies, discharge motor and cognitive function, the extent to which potential functional gains were achieved, and the efficiency of gains. Intensities of occupational, physical, and speech therapies were not significant predictors of outcomes for either group, controlling linearly for admission function, psychology intensity, length of stay, onset to admission interval, age, and interrupted stays. Only intensity of psychology services seemed to have any relation to functional gain (in cognition for patients with traumatic brain injury). The apparent lack of benefit related to intensity of therapies may be due to factors such as spontaneous recovery, goals not measured by the Functional Independence Measure, limited modulation of therapy intensity according to likely patient responsiveness, or therapies focused on impairment or other goals rather than disability. We suggest that efficiently staged rehabilitation should vary the intensity and nature of services according to patients' functional status, impairments, comorbid conditions, and other clinical factors.	REHABIL INST CHICAGO,CHICAGO,IL 60611; UNIV CHICAGO,CHICAGO,IL 60637; VET AFFAIRS MED CTR,DURHAM,NC 27705; SUNY BUFFALO,BUFFALO,NY				Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR503609] Funding Source: Medline		AHLMEN M, 1988, ARTHRITIS RHEUM, V31, P471, DOI 10.1002/art.1780310403; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BACHYRITA P, 1989, TRAUMATIC BRAIN INJU, P81; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1992, REHABILITATION EFFIC; JOHNSTON MV, 1986, ARCH PHYS MED REHAB, V67, P581; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KEITH RA, 1991, ARCH PHYS MED REHAB, V72, P269; KENNEDY OG, 1972, ARCH PHYS MED REHAB, V53, P461; LIANG MH, 1987, MED CARE, V25, P276, DOI 10.1097/00005650-198704000-00002; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; NORUSIS MJ, 1993, SPSS WINDOWS BASE SY; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; SMITH ME, 1982, ARCH PHYS MED REHAB, V63, P21; SPIEGEL JS, 1986, ARTHRITIS RHEUM-US, V29, P628, DOI 10.1002/art.1780290507; Stolov W., 1981, HDB SEVERE DISABILIT; Wehman P., 1989, J HEAD TRAUMA REHAB, V4, P66, DOI [10.1097/00001199-198909000-00010, DOI 10.1097/00001199-198909000-00010]	27	95	96	0	11	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1995	74	4					315	326		10.1097/00002060-199507000-00011			12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	RP735	WOS:A1995RP73500011	7632391				2022-02-06	
J	STEIN, SC; SPETTELL, C				STEIN, SC; SPETTELL, C			THE HEAD-INJURY SEVERITY SCALE (HISS) - A PRACTICAL CLASSIFICATION OF CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							GLASGOW COMA SCALE; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; DATA-BANK; MANAGEMENT; PREDICTION; DISABILITY; TRAUMA; CONSCIOUSNESS; PRESSURE	The authors introduce a two-dimensional scale for rating closed-head injury, the Head Injury Severity Scale (HISS). This system is based on a five-interval severity classification (minimal through critical), determined primarily by the initial post-resuscitation Glasgow Coma Scale score. The second dimension is predicated on the presence or absence of complications, appropriate for each severity interval. The outcomes of almost 25 000 patients with head injury encountered at our institution over a 7-year period were evaluated. We discovered that adding a complication dimension to each seventy category resulted in significant outcome differences and effectively divided patients into groups with very different risks, prognosis and treatment requirements. The HISS is proposed as a framework on which further research can be done to guide care to predict outcome and to perform audits on head-injured patients.	UNIV MED & DENT NEW JERSEY, COOPER HOSP UNIV MED CTR, ROBERT WOOD JOHNSON MED SCH, DEPT SURG, CAMDEN, NJ 08103 USA; MEDIPLEX REHAB, CAMDEN, NJ 08103 USA								BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BARROW DL, 1983, PHARMACOLOGICAL APPR, P76; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BECKER DP, 1982, NEUROLOGICAL SURGERY, V4, P1938; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BRAAKMAN R, 1986, ACTA NEUROCHIRUR S36, P112; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CROSBY L, 1989, HEART LUNG, V18, P121; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIBSON RM, 1989, LANCET, V2, P369; HOLMGREN E, 1981, ACTA NEUROCHIR, V56, P141; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; LANGFITT T, 1989, MILD MODERATE HEAD I, P235; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LINDGREN S, 1986, ACTA NEUROCHIRUR S36, P70; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; PRICE DJ, 1986, ACTA NEUROCHIRUR S36, P67; RANSOHOFF J, 1975, JAMA-J AM MED ASSOC, V234, P861, DOI 10.1001/jama.234.8.861; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Safar P, 1981, BRAIN FAILURE RESUSC, P155; SALCMAN M, 1981, NEUROSURGERY, V8, P15; SEGATORE M, 1992, HEART LUNG, V21, P548; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1989, MILD MODERATE HEAD I, P227; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; YEN JK, 1978, J NEUROL NEUROSUR PS, V41, P1125, DOI 10.1136/jnnp.41.12.1125; 1993, INT CLASSIFICATION D, P77; 1990, ABBERIVATED INJURY S, P15; 1993, INT CLASSIFICATION D, P213	53	95	95	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1995	9	5					437	444		10.3109/02699059509008203			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100002	7550215				2022-02-06	
J	GOODMAN, JC; CHERIAN, L; BRYAN, RM; ROBERTSON, CS				GOODMAN, JC; CHERIAN, L; BRYAN, RM; ROBERTSON, CS			LATERAL CORTICAL IMPACT INJURY IN RATS - PATHOLOGICAL EFFECTS OF VARYING CORTICAL COMPRESSION AND IMPACT VELOCITY	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; DIFFUSE AXONAL INJURY; HEAD-INJURY; NEUROFILAMENT SUBUNITS; VASCULAR DISRUPTION; DAMAGE; INDEX; CAT	Direct lateral cortical impact through the intact leptomeninges using a pneumatically driven piston produces increasingly severe pathophysiologic derangements with increasing cortical deformation. We studied the histopathologic correlates of cortical impact injury produced by 2 mm, 2.5 mm, and 3 mm deformation in the rat at 5 m/sec. Additionally, the effect of impact velocity at a 2.5 mm deformation was assessed at 1 m/sec, 3 m/sec, and 5 m/sec. The brains were examined 14 days after injury. Cortical contusion maximum cross-sectional area, volume, and the percentage CA1 and CA3 hippocampal neuronal loss correlate with cortical deformation and impactor velocity. Contusion volume increased with increasing cortical deformation. Deformations of 2, 2.5, and 3 mm at 5 m/sec produced contusion volumes of 4.59, 8.9, and 21.68 mm(3), respectively. At a fixed cortical deformation of 2.5 mm, contusion volume increased with increasing impact velocity. Impact velocities of 1, 3, and 5 m/sec produced contusion volumes of 5.79, 7.42, and 8.9 mm(3), respectively. Hippocampal CA3 neuronal loss increased with increasing cortical deformation. Deformations of 2, 2.5, and 3 mm at 5 m/sec produced neuronal loss of 29%, 48.3%, and 79.5%, respectively. At a fixed cortical deformation of 2.5 mm, hippocampal CA3 neuronal loss increased with increasing impact velocity. Impact velocities of 1, 3, and 5 m/sec produced neuronal loss of 18.25%, 33.75%, and 48.3%, respectively. Hippocampal CA1 neuronal loss was also seen and paralleled cortical deformation and impact velocity. Cortical deformation and impact velocity are critical parameters in producing cortical contusion and must be considered when comparing results using this model.	BAYLOR COLL MED, DEPT NEUROSURG, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT ANESTHESIOL, HOUSTON, TX 77030 USA		GOODMAN, JC (corresponding author), BAYLOR COLL MED, DEPT PATHOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [LB14960] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BRYAN RM, 1994, IN PRESS ANESTH ANAL; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Faden AI., 1994, NEUROBIOLOGY CENTRAL, P3; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1993, J EMERG MED, V1, P5; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marmarou A, 1990, Adv Neurol, V52, P233; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	45	95	99	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					587	597		10.1089/neu.1994.11.587			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700011	7861450				2022-02-06	
J	PAPADOPOULOS, SM; DICKMAN, CA; SONNTAG, VKH; REKATE, HL; SPETZLER, RF				PAPADOPOULOS, SM; DICKMAN, CA; SONNTAG, VKH; REKATE, HL; SPETZLER, RF			TRAUMATIC ATLANTOOCCIPITAL DISLOCATION WITH SURVIVAL	NEUROSURGERY			English	Article						ATLANTOOCCIPITAL DISLOCATION; OCCIPITAL ATLANTOAXIAL FUSION; SPINAL CORD INJURY	ATLANTO-OCCIPITAL DISLOCATION; JUNCTION; FRACTURES; SPINE	Survival after traumatic atlantooccipital dislocation is rare. Only long-term survivors have been reported in the literature; however, improved prehospital care is likely responsible for the increase in the number of these patients seen at neurotrauma centers over the last decade. Associated severe and persistent neurological dificits are common in the few survivors. We report the case of a 10-year-old boy with traumatic atlantooccipital dislocation and a severe neurological injury. Low-field magnetic resonance imaging provided the additional diagnosis of an associated cervicomedullary epidural hematoma. The patient underwent emergency operative evacuation of the hematoma and an occipital-cervical fusion with internal fixation. He had a remarkable recovery in neurological function and achieved stable bony fusion 3 months postoperatively. With early recognition of this entity, improved neuroradiological imaging techniques, and aggressive treatment, patients may survive with significant neurological recovery.	BARROW NEUROL INST,DIV NEUROL SURG,350 W THOMAS RD,PHOENIX,AZ 85013								ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; COLLALTO PM, 1986, J BONE JOINT SURG AM, V68A, P1106, DOI 10.2106/00004623-198668070-00024; DUBLIN AB, 1980, J NEUROSURG, V52, P541, DOI 10.3171/jns.1980.52.4.0541; DUCKER TB, 1978, SURG NEUROL, V10, P71; EISMONT FJ, 1978, J BONE JOINT SURG AM, V60, P397, DOI 10.2106/00004623-197860030-00024; EVARTS CM, 1970, J BONE JOINT SURG AM, VA 52, P1653, DOI 10.2106/00004623-197052080-00017; FARTHING J W, 1948, N C Med J, V9, P34; FINNEY HL, 1978, J NEUROSURG, V48, P636, DOI 10.3171/jns.1978.48.4.0636; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; GABRIELS.TO, 1966, AMER J ROENTGENOL RA, V97, P624, DOI 10.2214/ajr.97.3.624; GERLOCK AJ, 1983, NEUROSURGERY, V13, P316, DOI 10.1227/00006123-198309000-00019; KAUFMAN RA, 1987, AM J NEURORADIOL, V8, P995; KAUFMAN RA, 1982, AM J NEURORADIOL, V3, P415; LEE C, 1984, AM J NEURORADIOL, V5, P775; LEE C, 1987, AM J NEURORADIOL, V8, P19; LEVINE AM, 1989, CLIN ORTHOP RELAT R, V239, P53; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PANG D, 1980, NEUROSURGERY, V7, P503, DOI 10.1227/00006123-198011000-00017; POWERS B, 1979, NEUROSURGERY, V4, P12, DOI 10.1097/00006123-197901000-00004; ROCKSWOLD GL, 1979, MINN MED, V62, P151; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; VANDENBOUT AH, 1986, SPINE, V11, P174, DOI 10.1097/00007632-198603000-00017; WATRIDGE CB, 1985, NEUROSURGERY, V17, P345, DOI 10.1227/00006123-198508000-00021; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHITE AA, 1978, ORTHOP CLIN N AM, V9, P867; WOODRING JH, 1981, AM J ROENTGENOL, V137, P21, DOI 10.2214/ajr.137.1.21; 1908, ANN SURG, V47, P654	29	95	104	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1991	28	4					574	579		10.1227/00006123-199104000-00015			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FC831	WOS:A1991FC83100015	2034353				2022-02-06	
J	LEVIN, HS; WILLIAMS, D; CROFFORD, MJ; HIGH, WM; EISENBERG, HM; AMPARO, EG; GUINTO, FC; KALISKY, Z; HANDEL, SF; GOLDMAN, AM				LEVIN, HS; WILLIAMS, D; CROFFORD, MJ; HIGH, WM; EISENBERG, HM; AMPARO, EG; GUINTO, FC; KALISKY, Z; HANDEL, SF; GOLDMAN, AM			RELATIONSHIP OF DEPTH OF BRAIN-LESIONS TO CONSCIOUSNESS AND OUTCOME AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article									UNIV TEXAS,MED BRANCH,DEPT RADIOL,GALVESTON,TX 77550; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT RADIOL,HOUSTON,TX 77030; MED CTR DEL ORO,DEPT REHABIL MED,HOUSTON,TX		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D-73,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SARPEL G, 1987, ARCH NEUROL-CHICAGO, V44, P725, DOI 10.1001/archneur.1987.00520190035014; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TEASDALE G, 1974, LANCET, V2, P81	11	95	96	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1988	69	6					861	866		10.3171/jns.1988.69.6.0861			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	R0342	WOS:A1988R034200008	3193191				2022-02-06	
J	Gao, XF; Zheng, P; Kasani, S; Wu, S; Yang, F; Lewis, S; Nayeem, S; Engler-Chiurazzi, EB; Wigginton, JG; Simpkins, JW; Wu, NQ				Gao, Xuefei; Zheng, Peng; Kasani, Sujan; Wu, Steven; Yang, Feng; Lewis, Sara; Nayeem, Sara; Engler-Chiurazzi, Elizabeth B.; Wigginton, Jane G.; Simpkins, James W.; Wu, Nianqiang			Paper-Based Surface-Enhanced Raman Scattering Lateral Flow Strip for Detection of Neuron-Specific Enolase in Blood Plasma	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; LABEL-FREE DETECTION; SENSITIVE DETECTION; ENZYME-IMMUNOASSAY; BIOMARKER; IMMUNOSENSOR; NANOPARTICLES; BIOSENSOR; MARKERS; PROTEIN	An inexpensive and disposable paper-based lateral flow strip (PLFS) has been developed as an immunoassay, in which surface-enhanced Raman scattering (SERS) is utilized for sensing signal transduction. The Au nanostar@Raman Reporter@silica sandwich nanoparticles are developed as the SERS probes, which is the key to the high sensitivity of the device. Compared with a colorimetric PLFS, the SERS-PLFS exhibits superior performance in terms of sensitivity and limit of detection (LOD) in a blood plasma-containing sample matrix. In addition, the SERS-PLFS has been successfully used for detection of neuron-specific enolase (NSE), a traumatic brain injury (TBI) protein biomarker, in diluted blood plasma samples, achieving a LOD of 0.86 ng/mL. Moreover, the SERS-PLFS was successfully employed to measure the NSE level in clinical blood plasma samples taken from deidentified TBI patients. This work demonstrates that the SERS-PLFS has great potential in assisting screening of TBI patients in the point-of-care setting.	[Gao, Xuefei; Zheng, Peng; Wu, Steven; Wu, Nianqiang] West Virginia Univ, Dept Mech & Aerosp Engn, Morgantown, WV 26506 USA; [Kasani, Sujan] West Virginia Univ, Lane Dept Comp Sci & Elect Engn, Morgantown, WV 26506 USA; [Yang, Feng] West Virginia Univ, Ind & Management Syst Engn Dept, Morgantown, WV 26506 USA; [Lewis, Sara; Nayeem, Sara; Engler-Chiurazzi, Elizabeth B.; Simpkins, James W.] Ctr Neurosci, Ctr Basic & Translat Stroke Res, Physiol & Pharmacol, Morgantown, WV 26505 USA; [Wigginton, Jane G.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA		Wu, NQ (corresponding author), West Virginia Univ, Dept Mech & Aerosp Engn, Morgantown, WV 26506 USA.	nick.wu@mail.wvu.edu	Wu, Nianqiang/B-9798-2015; Kasani, Sujan Phani Kumar/K-2869-2019; Kasani, Sujan/AAG-9345-2019; Gao, Xuefei/G-4028-2015	Wu, Nianqiang/0000-0002-8888-2444; Kasani, Sujan Phani Kumar/0000-0003-1458-9509; Gao, Xuefei/0000-0003-0641-2244	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS087515]; UT Southwestern High Impact/High Risk Grant; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001105]; National Heart, Lung and Blood Institute in partnershipUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077887]; U.S. Army Medical Research & Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); American Heart AssociationAmerican Heart Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001105] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077887, U01HL077863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS087515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (R15NS087515). The resources provided by the Byars-Tarnay Endowment in the WVU Foundation are also appreciated. The characterization was performed at WVU Shared Facility. In addition, J.G.W. was involved in the RESCUE study in this manuscript that was funded in part by the UT Southwestern High Impact/High Risk Grant, the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1TR001105, and the Resuscitation Outcomes Consortium cooperative agreements (5U01 HL077863-University of Washington Data Coordinating Center, HL077887-University of Texas Southwestern Medical Center in Dallas) from the National Heart, Lung and Blood Institute in partnership with the U.S. Army Medical Research & Material Command and the American Heart Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Al-Ogaidi I, 2014, CHEM COMMUN, V50, P1344, DOI 10.1039/c3cc47701k; Centers for Disease Control and Prevention, 2017, TBI GET THE FACTS; Centers for Disease Control and Prevention, 2017, SEV TBI; Cheng SS, 2015, SENSOR ACTUAT B-CHEM, V212, P329, DOI 10.1016/j.snb.2015.02.038; Fu XH, 2014, ANAL METHODS-UK, V6, P2233, DOI 10.1039/c3ay42075b; Fu XL, 2012, ANAL CHIM ACTA, V722, P114, DOI 10.1016/j.aca.2012.02.007; Fu X, 2016, BIOSENS BIOELECTRON, V78, P530, DOI 10.1016/j.bios.2015.11.099; Gao XF, 2016, TALANTA, V146, P648, DOI 10.1016/j.talanta.2015.06.060; Gao XF, 2014, BIOSENS BIOELECTRON, V54, P578, DOI 10.1016/j.bios.2013.10.055; Han J, 2012, BIOSENS BIOELECTRON, V31, P399, DOI 10.1016/j.bios.2011.10.055; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Lee Bruce, 2005, NeuroRx, V2, P372; Li M, 2015, ANALYST, V140, P386, DOI 10.1039/c4an01079e; Li M, 2013, ACS NANO, V7, P4967, DOI 10.1021/nn4018284; Li M, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/11/115501; Li ZH, 2010, ANAL CHEM, V82, P7008, DOI 10.1021/ac101405a; Liang JJ, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/49/495501; Lin YY, 2008, BIOSENS BIOELECTRON, V23, P1659, DOI 10.1016/j.bios.2008.01.037; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Ngom B, 2010, ANAL BIOANAL CHEM, V397, P1113, DOI 10.1007/s00216-010-3661-4; North S., 2013, NRL REV, V13, P164; Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2; Wang X, 2017, ANAL CHEM, V89, P1163, DOI 10.1021/acs.analchem.6b03536; Yu TX, 2012, TALANTA, V93, P433, DOI 10.1016/j.talanta.2012.02.047; Yu XY, 2015, ANAL CHEM, V87, P4237, DOI 10.1021/ac504456w; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep22234	28	94	96	11	220	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	SEP 19	2017	89	18					10104	10110		10.1021/acs.analchem.7b03015			7	Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	FH9RJ	WOS:000411549100068	28817769	Green Accepted			2022-02-06	
J	Otero-Ortega, L; Laso-Garcia, F; Gomez-de Frutos, MD; Rodriguez-Frutos, B; Pascual-Guerra, J; Fuentes, B; Diez-Tejedor, E; Gutierrez-Fernandez, M				Otero-Ortega, Laura; Laso-Garcia, Fernando; del Carmen Gomez-de Frutos, Maria; Rodriguez-Frutos, Berta; Pascual-Guerra, Jorge; Fuentes, Blanca; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria			White Matter Repair After Extracellular Vesicles Administration in an Experimental Animal Model of Subcortical Stroke	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; NEUROVASCULAR PLASTICITY; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; STROMAL CELLS; EXOSOMES; RATS; THERAPY; TOOL	Mesenchymal stem cells have previously been shown to mediate brain repair after stroke; they secrete 50-100 nm complexes called extracellular vesicles (EVs), which could be responsible for provoking neurovascular repair and functional recovery. EVs have been observed by electron microscopy and NanoSight, and they contain associated proteins such as CD81 and Alix. This purified, homogeneous population of EVs was administered intravenously after subcortical stroke in rats. To evaluate the EVs effects, we studied the biodistribution, proteomics analysis, functional evaluation, lesion size, fiber tract integrity, axonal sprouting and white matter repair markers. We found that a single administration of EVs improved functional recovery, fiber tract integrity, axonal sprouting and white matter repair markers in an experimental animal model of subcortical stroke. EVs were found in the animals' brain and peripheral organs after euthanasia. White matter integrity was in part restored by EVs administration mediated by molecular repair factors implicated in axonal sprouting, tract connectivity, remyelination and oligodendrogenesis. These findings are associated with improved functional recovery. This novel role for EVs presents a new perspective in the development of biologics for brain repair.	[Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria] Autonomous Univ Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Neurosci & Cerebrovasc Res Lab,Dept Neurol,Neuros, Madrid, Spain; Autonomous Univ Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Stroke Ctr,Neurosci Area, Madrid, Spain		Diez-Tejedor, E; Gutierrez-Fernandez, M (corresponding author), Autonomous Univ Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Neurosci & Cerebrovasc Res Lab,Dept Neurol,Neuros, Madrid, Spain.	exuperio.diez@salud.madrid.org; mgutierrezfernandez@salud.madrid.org	Laso Garcia, Fernando/F-2259-2018; Fuentes, Blanca/I-2114-2019	Laso Garcia, Fernando/0000-0002-5481-0514; Fuentes, Blanca/0000-0002-0363-862X; Pascual Guerra, Jorge/0000-0001-6667-3310; Otero Ortega, Laura/0000-0001-8765-6341	INVICTUS (Spanish Neurovascular Network) [RD12/0014]; Miguel Servet [CP15/00069]; Sara Borrell postdoctoral fellowship from Research Institute Carlos III [CD12/00706]; Ministry of Science and Innovation of SpainSpanish Government; European Regional Development FundEuropean Commission;  [PS15/01318]	This study has been partially supported by grants from PS15/01318 and INVICTUS (RD12/0014) (Spanish Neurovascular Network), Miguel Servet (CP15/00069 to Maria Gutierrez-Fernandez) and a Sara Borrell postdoctoral fellowship (CD12/00706, to Laura Otero-Ortega) from Research Institute Carlos III, Ministry of Science and Innovation of Spain and European Regional Development Fund. We greatly appreciate the support of ServingMed.com for editing assistance. Also greatly thanked is Prof. Carmichael for his supervision of the Laura Otero-Ortega's stay at his laboratory regarding experiments of neuronal tracers.	Back SA, 2007, STROKE, V38, P724, DOI 10.1161/01.STR.0000254729.27386.05; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Barratt HE, 2014, J CEREBR BLOOD F MET, V34, P1463, DOI 10.1038/jcbfm.2014.107; Beer L., 2016, APOPTOSIS IN PRESS; Chen T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33862; Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078; Eckert MA, 2013, J CEREBR BLOOD F MET, V33, P1322, DOI 10.1038/jcbfm.2013.91; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Ellwanger JH, 2016, MED HYPOTHESES, V95, P67, DOI 10.1016/j.mehy.2016.09.005; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054; Gutierrez-Fernandez M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0406-3; Hu L, 2016, SCI REP IN PRESS; Kalani A, 2016, INT J BIOCHEM CELL B, V79, P360, DOI 10.1016/j.biocel.2016.09.002; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Lee M, 2016, BIOCH BIOPH IN PRESS; Leu S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-63; Li GH, 2016, NEURAL REGEN RES, V11, P1015, DOI 10.4103/1673-5374.184506; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; Navarro P, 2014, J PROTEOME RES, V13, P1234, DOI 10.1021/pr4006958; Otero-Ortega L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0111-4; Ramos-Cejudo J, 2015, STROKE, V46, P221, DOI 10.1161/STROKEAHA.114.006692; Rodriguez-Frutos B, 2016, BIOMATERIALS, V100, P41, DOI 10.1016/j.biomaterials.2016.05.028; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sozmen EG, 2012, NEUROTHERAPEUTICS, V9, P349, DOI 10.1007/s13311-012-0106-0; Sozmen EG, 2009, J NEUROSCI METH, V180, P261, DOI 10.1016/j.jneumeth.2009.03.017; Suzuki E, 2016, WORLD J STEM CELLS, V8, P297, DOI 10.4252/wjsc.v8.i9.297; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xu WT, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0429-5; Zhang Y, 2016, NEUROCHEM I IN PRESS; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770	36	94	96	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 16	2017	7								44433	10.1038/srep44433			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EO3CN	WOS:000396572600001	28300134	gold, Green Published, Green Submitted			2022-02-06	
J	Kumar, A; Barrett, JP; Alvarez-Croda, DM; Stoica, BA; Faden, AI; Loane, DJ				Kumar, Alok; Barrett, James P.; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.			NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						NADPH oxidase; NOX2; Traumatic brain injury; Microglia; Macrophage; Neuroinflammation; M1-/M2-like; Neurodegeneration	SPINAL-CORD-INJURY; NADPH OXIDASE; MICROGLIAL ACTIVATION; OXIDATIVE STRESS; WHITE-MATTER; ALTERNATIVE ACTIVATION; INFLAMMATORY RESPONSE; THERAPEUTIC TARGETS; REDOX REGULATION; MOUSE MODEL	Following traumatic brain injury (TBI), activation of microglia and peripherally derived inflammatory macrophages occurs in association with tissue damage. This neuroinflammatory response may have beneficial or detrimental effects on neuronal survival, depending on the functional polarization of these cells along a continuum from M1-like to M2-like activation states. The mechanisms that regulate M1-like and M2-like activation after TBI are not well understood, but appear in part to reflect the redox state of the lesion microenvironment. NADPH oxidase (NOX2) is a critical enzyme system that generates reactive oxygen species in microglia/macrophages. After TBI, NOX2 is strongly up-regulated in Ml-like, but not in M2-like polarized cells. Therefore, we hypothesized that NOX2 drives M1-like neuroinflammation and contributes to neurodegeneration and loss of neurological function after TBI. In the present studies we inhibited NOX2 activity using NOX2-knockout mice or the selective peptide inhibitor gp91ds-tat. We show that NOX2 is highly up-regulated in infiltrating macrophages after injury, and that NOX2 deficiency reduces markers of M1-like activation, limits tissue loss and neurodegeneration, and improves motor recovery after moderate-level control cortical injury (CCI). NOX2 deficiency also promotes M2-like activation after CCI, through increased IL-4R alpha signaling in infiltrating macrophages, suggesting that NOX2 acts as a critical switch between M1- and M2-like activation states after TBI. Administration of gp91ds-tat to wild-type CCI mice starting at 24 h post-injury reduces deficits in cognitive function and increased M2-like activation in the hippocampus. Collectively, our data indicate that increased NOX2 activity after TBI drives Ml-like activation that contributes to inflammatory-mediated neurodegeneration, and that inhibiting this pathway provides neuroprotection, in part by altering M1-/M2-like balance towards the M2-like neuroinflammatory response. (C) 2016 Elsevier Inc. All rights reserved.	[Kumar, Alok; Barrett, James P.; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Kumar, Alok; Barrett, James P.; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Alvarez-Croda, Dulce-Mariely] Univ Veracruzana, Posgrad Neuroetol, Xalapa, Veracruz, Mexico; [Alvarez-Croda, Dulce-Mariely] Univ Veracruzana, Ctr Invest Cerebrales, Xalapa, Veracruz, Mexico		Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Barrett, James/0000-0002-0924-9449; Faden, Alan I./0000-0003-0128-2348	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313]; National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]; CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [249772/389071]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS082308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We thank Ashley Singh for expert technical assistance. This work was supported by NIH grant R01NS082308 (D.J. Loane), R01NS037313 (A.I. Faden), The National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747 (D.J. Loane), and a CONACYT Scholarship 249772/389071 (DM Alvarez-Croda).	Abais JM, 2013, ANTIOXID REDOX SIGN, V18, P1537, DOI 10.1089/ars.2012.4666; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Averaimo S, 2010, FEBS LETT, V584, P2076, DOI 10.1016/j.febslet.2010.02.073; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Csanyi G, 2011, FREE RADICAL BIO MED, V51, P1116, DOI 10.1016/j.freeradbiomed.2011.04.025; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hsieh C. L., 2014, J NEUROTRAUMA; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khayrullina G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0391-8; Kumar A., 2015, J NEUROTRAUMA; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Liu XR, 2016, STROKE, V47, P498, DOI 10.1161/STROKEAHA.115.012079; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Mander P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-20; Matsubara K, 2015, J NEUROSCI, V35, P2452, DOI 10.1523/JNEUROSCI.4088-14.2015; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Qin LY, 2013, GLIA, V61, P855, DOI 10.1002/glia.22479; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Tang XN, 2011, ANN NEUROL, V70, P606, DOI 10.1002/ana.22476; van Horssen J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-156; von Leden R. E., 2016, J NEUROTRAUM; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Wu DC, 2006, P NATL ACAD SCI USA, V103, P12132, DOI 10.1073/pnas.0603670103; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	70	94	94	2	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2016	58						291	309		10.1016/j.bbi.2016.07.158			19	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	DZ5MG	WOS:000385905600034	27477920	Green Accepted			2022-02-06	
J	Olivera, A; Lejbman, N; Jeromin, A; French, LM; Kim, HS; Cashion, A; Mysliwiec, V; Diaz-Arrastia, R; Gill, J				Olivera, Anlys; Lejbman, Natasha; Jeromin, Andreas; French, Louis M.; Kim, Hyung-Suk; Cashion, Ann; Mysliwiec, Vincent; Diaz-Arrastia, Ramon; Gill, Jessica			Peripheral Total Tau in Military Personnel Who Sustain Traumatic Brain Injuries During Deployment	JAMA NEUROLOGY			English	Article							MILD COGNITIVE IMPAIRMENT; HEAD-INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; RISK; ENCEPHALOPATHY; BIOMARKERS; ASSOCIATION; CONCUSSION; ACTIVATION	IMPORTANCE Approximately one-third of military personnel who deploy for combat operations sustain 1 or more traumatic brain injuries (TBIs), which increases the risk for chronic symptoms of postconcussive disorder, posttraumatic stress disorder, and depression and for the development of chronic traumatic encephalopathy. Elevated concentrations of tau are observed in blood shortly following a TBI, but, to our knowledge, the role of tau elevations in blood in the onset and maintenance of chronic symptoms after TBI has not been investigated. OBJECTIVES To assess peripheral tau levels in military personnel exposed to TBI and to examine the relationship between chronic neurological symptoms and tau elevations. DESIGN, SETTING, AND PARTICIPANTS Observational assessment from September 2012 to August 2014 of US military personnel at the Madigan Army Medical Center who had been deployed within the previous 18 months. Plasma total tau concentrations were measured using a novel ultrasensitive single-molecule enzyme-linked immunosorbent assay. Classification of participants with and without self-reported TBI was made using the Warrior Administered Retrospective Casualty Assessment Tool. Self-reported symptoms of postconcussive disorder, posttraumatic stress disorder, and depression were determined by the Neurobehavioral Symptom Inventory, the Posttraumatic Stress Disorder Checklist Military Version, and the Quick Inventory of Depressive Symptomatology, respectively. Group differences in tau concentrations were determined through analysis of variance models, and area under the receiver operating characteristic curve determined the sensitivity and specificity of tau concentrations in predicting TBI and chronic symptoms. Seventy participants with self-reported TBI on theWarrior Administered Retrospective Casualty Assessment Tool and 28 control participants with no TBI exposure were included. MAIN OUTCOMES AND MEASURES Concentration of total tau in peripheral blood. RESULTS Concentrations of plasma tau were significantly elevated in the 70 participants with self-reported TBI compared with the 28 controls (mean [SD], 1.13 [0.78] vs 0.63 [0.48] pg/mL, respectively; F-1,F-97 = 4.97; P = .03). Within the self-reported TBI cases, plasma total tau concentrations were significantly associated with having a medical record of TBI compared with self-reported TBI only (mean [SD], 1.57 [0.92] vs 0.85 [0.52] pg/mL, respectively; F1,69 = 6.15; P = .02) as well as reporting the occurrence of 3 of more TBIs during deployment compared with fewer than 3 TBIs (mean [SD], 1.52 [0.82] vs 0.82 [0.60] pg/mL, respectively; F1,69 = 8.57; P = .008). The severity of total postconcussive symptoms correlated with total tau concentrations in the self-reported TBI group (r = 0.37; P = .003). CONCLUSIONS AND RELEVANCE Military personnel who report multiple TBIs have long-term elevations in total tau concentration. The total tau concentration relates to symptoms of postconcussive disorder.	[Olivera, Anlys; Lejbman, Natasha; Kim, Hyung-Suk; Cashion, Ann; Gill, Jessica] NINR, NIH, Bethesda, MD 20814 USA; [Jeromin, Andreas] Quantenx Corp, Lexington, MA USA; [French, Louis M.] Natl Intrepid Ctr Excellence, Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [French, Louis M.; Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Mysliwiec, Vincent] Madigan Army Med Ctr, Tacoma, WA 98431 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Gill, J (corresponding author), NINR, NIH, One Cloister Court,Room 256, Bethesda, MD 20814 USA.	gillj@mail.nih.gov	french, louis/AAB-2083-2020; Gill, Gill M/Q-2020-2017	french, louis/0000-0002-9451-0604; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Intramural Research Program of the National Institutes of Nursing Research; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000015, ZIANR000027, ZIANR000030] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Program of the National Institutes of Nursing Research and in part by grant 60855 from the Center for Neuroscience and Regenerative Medicine.	Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brickell TA, 2014, MIL MED, V179, P827, DOI 10.7205/MILMED-D-13-00506; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Han DH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6633; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morales I, 2013, J ALZHEIMERS DIS, V37, P849, DOI 10.3233/JAD-131843; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Quanterix, SIM SCI; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	48	94	98	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	OCT	2015	72	10					1109	1116		10.1001/jamaneurol.2015.1383			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT6ZQ	WOS:000362963000005	26237304	Bronze			2022-02-06	
J	Cantu, D; Walker, K; Andresen, L; Taylor-Weiner, A; Hampton, D; Tesco, G; Dulla, CG				Cantu, David; Walker, Kendall; Andresen, Lauren; Taylor-Weiner, Amaro; Hampton, David; Tesco, Giuseppina; Dulla, Chris G.			Traumatic Brain Injury Increases Cortical Glutamate Network Activity by Compromising GABAergic Control	CEREBRAL CORTEX			English	Article						cortical hyperexcitability; epilepsy; glutamate signaling; network reorganization; traumatic brain injury	CALCIUM-BINDING PROTEINS; GAMMA-AMINOBUTYRIC-ACID; HEAD-INJURY; POSTTRAUMATIC EPILEPSY; MITOCHONDRIAL DYSFUNCTION; EPILEPTIFORM DISCHARGES; SYNAPTIC INPUT; VISUAL-CORTEX; DENTATE GYRUS; IMPACT INJURY	Traumatic brain injury (TBI) is a major risk factor for developing pharmaco-resistant epilepsy. Although disruptions in brain circuitry are associated with TBI, the precise mechanisms by which brain injury leads to epileptiform network activity is unknown. Using controlled cortical impact (CCI) as a model of TBI, we examined how cortical excitability and glutamatergic signaling was altered following injury. We optically mapped cortical glutamate signaling using FRET-based glutamate biosensors, while simultaneously recording cortical field potentials in acute brain slices 2-4 weeks following CCI. Cortical electrical stimulation evoked polyphasic, epileptiform field potentials and disrupted the input-output relationship in deep layers of CCI-injured cortex. High-speed glutamate biosensor imaging showed that glutamate signaling was significantly increased in the injured cortex. Elevated glutamate responses correlated with epileptiform activity, were highest directly adjacent to the injury, and spread via deep cortical layers. Immunoreactivity for markers of GABAergic inter-neurons were significantly decreased throughout CCI cortex. Lastly, spontaneous inhibitory postsynaptic current frequency decreased and spontaneous excitatory postsynaptic current increased after CCI injury. Our results suggest that specific cortical neuronal microcircuits may initiate and facilitate the spread of epileptiform activity following TBI. Increased glutamatergic signaling due to loss of GABAergic control may provide a mechanism by which TBI can give rise to post-traumatic epilepsy.	[Cantu, David; Andresen, Lauren; Taylor-Weiner, Amaro; Hampton, David; Dulla, Chris G.] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; [Walker, Kendall; Tesco, Giuseppina] Tufts Univ, Sch Med, Alzheimers Dis Res Lab, Dept Neurosci, Boston, MA 02111 USA; [Andresen, Lauren] Tufts Univ, Sackler Sch Biomed Sci, Program Neurosci, Boston, MA 02111 USA		Dulla, CG (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave,SC203, Boston, MA 02111 USA.	chris.dulla@tufts.edu		Lau, Lauren/0000-0003-3312-183X	Epilepsy Foundation; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS076885]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12GM074869]; National Institute On AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033016]; Cure Alzheimer's Fund; Tufts Center for Neuroscience Research [P30 NS047243]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K12GM074869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047243, R01NS076885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033016] Funding Source: NIH RePORTER	This work was supported by the Epilepsy Foundation (C.D.), National Institute of Neurological Disorders and Stroke (R01-NS076885) (C.D.), the NIH (K12GM074869) (D.C.), National Institute On Aging (R01AG033016) (G.T.), Cure Alzheimer's Fund (G.T.), and Tufts Center for Neuroscience Research (P30 NS047243).	Anderson CM, 2000, GLIA, V32, P1; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brill J, 2010, CEREB CORTEX, V20, P2926, DOI 10.1093/cercor/bhq040; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Buritica E, 2009, J NEUROTRAUM, V26, P2145, DOI 10.1089/neu.2009.0894; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; Cavus I, 2005, ANN NEUROL, V57, P226, DOI 10.1002/ana.20380; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cline H, 2008, J PHYSIOL-LONDON, V586, P1509, DOI 10.1113/jphysiol.2007.150029; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; COWAN RL, 1990, J COMP NEUROL, V302, P197, DOI 10.1002/cne.903020202; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Dulla CG, 2013, NEUROBIOL DIS, V49, P232, DOI 10.1016/j.nbd.2012.09.001; Dulla C, 2008, J NEUROSCI METH, V168, P306, DOI 10.1016/j.jneumeth.2007.10.017; FAN L, 1995, MOL BRAIN RES, V30, P125; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; GLEZER II, 1993, CEREB CORTEX, V3, P249, DOI 10.1093/cercor/3.3.249; Goldshmit Y, 2010, NEUROSCIENCE, V166, P886, DOI 10.1016/j.neuroscience.2009.12.039; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hof PR, 1999, J CHEM NEUROANAT, V16, P77, DOI 10.1016/S0891-0618(98)00065-9; Holmseth S, 2009, NEUROSCIENCE, V162, P1055, DOI 10.1016/j.neuroscience.2009.03.048; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; Kwon HB, 2011, NATURE, V474, P100, DOI 10.1038/nature09986; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Li HF, 2012, NEUROBIOL DIS, V48, P429, DOI 10.1016/j.nbd.2012.06.019; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Ma YY, 2012, NEUROBIOL DIS, V47, P102, DOI 10.1016/j.nbd.2012.03.027; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MIENVILLE JM, 1987, NEUROPHARMACOLOGY, V26, P779, DOI 10.1016/0028-3908(87)90242-5; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Pan JW, 2008, EPILEPSIA, V49, P31, DOI 10.1111/j.1528-1167.2008.01508.x; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Rudy B, 2011, DEV NEUROBIOL, V71, P45, DOI 10.1002/dneu.20853; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Scimemi A, 2009, J NEUROSCI, V29, P14581, DOI 10.1523/JNEUROSCI.4845-09.2009; Stafstrom CE, 2008, EPILEPSIA, V49, P97, DOI 10.1111/j.1528-1167.2008.01848.x; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Tani H, 2010, J NEUROSCI, V30, P1288, DOI 10.1523/JNEUROSCI.0106-09.2010; Telfeian AE, 1998, EPILEPSIA, V39, P700, DOI 10.1111/j.1528-1157.1998.tb01154.x; VANBREDERODE JFM, 1990, J COMP NEUROL, V298, P1, DOI 10.1002/cne.902980102; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Walker KR, 2012, J NEUROSCI, V32, P10423, DOI 10.1523/JNEUROSCI.5491-11.2012; Ward JL, 2011, J TRAUMA, V70, P1471, DOI 10.1097/TA.0b013e31821c38bd; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yokobori S, 2013, CNS NEUROL DISORD-DR, V12, P1; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	75	94	96	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	AUG	2015	25	8					2306	2320		10.1093/cercor/bhu041			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CO7DU	WOS:000359320000026	24610117	Green Published, Bronze			2022-02-06	
J	Vanderploeg, RD; Cooper, DB; Belanger, HG; Donnell, AJ; Kennedy, JE; Hopewell, CA; Scott, SG				Vanderploeg, Rodney D.; Cooper, Douglas B.; Belanger, Heather G.; Donnell, Alison J.; Kennedy, Jan E.; Hopewell, Clifford A.; Scott, Steven G.			Screening for Postdeployment Conditions: Development and Cross-Validation of an Embedded Validity Scale in the Neurobehavioral Symptom Inventory	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						veterans; assessment; postconcussion syndrome; neuropsychology; concussions; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; VETERANS; ASSOCIATIONS; PERFORMANCE; UTILITY	Objective: To develop and cross-validate internal validity scales for the Neurobehavioral Symptom Inventory (NSI). Participants: Four existing data sets were used: (1) outpatient clinical traumatic brain injury (TBI)/neurorehabilitation database from a military site (n = 403), (2) National Department of Veterans Affairs TBI evaluation database (n = 48 175), (3) Florida National Guard nonclinical TBI survey database (n = 3098), and (4) a cross-validation outpatient clinical TBI/neurorehabilitation database combined across 2 military medical centers (n = 206). Research Design: Secondary analysis of existing cohort data to develop (study 1) and cross-validate (study 2) internal validity scales for the NSI. Main Measures: The NSI, Mild Brain Injury Atypical Symptoms, and Personality Assessment Inventory scores. Results: Study 1: Three NSI validity scales were developed, composed of 5 unusual items (Negative Impression Management [NIM5]), 6 low-frequency items (LOW6), and the combination of 10 nonoverlapping items (Validity-10). Cut scores maximizing sensitivity and specificity on these measures were determined, using a Mild Brain Injury Atypical Symptoms score of 8 or more as the criterion for invalidity. Study 2: The same validity scale cut scores again resulted in the highest classification accuracy and optimal balance between sensitivity and specificity in the cross-validation sample, using a Personality Assessment Inventory Negative Impression Management scale with a T score of 75 or higher as the criterion for invalidity. Conclusions: The NSI is widely used in the Department of Defense and Veterans Affairs as a symptom-severity assessment following TBI, but is subject to symptom overreporting or exaggeration. This study developed embedded NSI validity scales to facilitate the detection of invalid response styles. The NSI Validity-10 scale appears to hold considerable promise for validity assessment when the NSI is used as a population-screening tool.	[Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.] Univ S Florida, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Scott, Steven G.] Univ S Florida, Dept Phys Med & Rehabil, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] Univ S Florida, HSR&D, Rehabil Res & Dev RR&D Ctr Excellence Maximizing, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.] Univ S Florida, James A Haley Vet Hosp, Def & Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Tampa, FL USA; [Cooper, Douglas B.; Kennedy, Jan E.] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA; [Cooper, Douglas B.; Kennedy, Jan E.] San Antonio Mil Med Ctr, Neurol Serv, Dept Med, San Antonio, TX USA; [Hopewell, Clifford A.] Darnall Army Med Ctr, Traumat Brain Injury Clin, Killeen, TX USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.vanderploeg@va.gov			Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Department of Veterans Affairs Health Service Research DevelopmentUS Department of Veterans Affairs [CCN 06-164]; James A. Haley Veterans' Hospital and its HSR&D/RR&D center of excellence	This research was supported by the Department of Veterans Affairs, Veterans Health Administration, and Defense and Veterans Brain Injury Center and by a Department of Veterans Affairs Health Service Research & Development grant CCN 06-164 to Steven G. Scott, DO. Further support was provided by the James A. Haley Veterans' Hospital and its HSR&D/RR&D center of excellence.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; Butcher J.N., 2001, MINNESOTA MULTIPHASI; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Interian A, 2004, PSYCHOSOM MED, V66, P141, DOI 10.1097/01.PSY.0000107883.14385.EC; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Morey L.C., 2007, PERSONALITY ASSESSME; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	17	94	95	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					1	10		10.1097/HTR.0b013e318281966e			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400001	23474880				2022-02-06	
J	Maas, AIR; Murray, GD; Roozenbeek, B; Lingsma, HF; Butcher, I; McHugh, GS; Weir, J; Lu, J; Steyerberg, EW				Maas, Andrew I. R.; Murray, Gordon D.; Roozenbeek, Bob; Lingsma, Hester F.; Butcher, Isabella; McHugh, Gillian S.; Weir, James; Lu, Juan; Steyerberg, Ewout W.		Int Mission Prognosis Anal Clinica	Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research	LANCET NEUROLOGY			English	Article							RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; HEAD-INJURY; COVARIATE ADJUSTMENT; EXTERNAL VALIDATION; ACUTE STROKE; INTERNATIONAL MISSION; STATISTICAL-ANALYSIS; PROGNOSTIC ANALYSIS; OUTCOME PREDICTION	Research in traumatic brain injury (TBI) is challenging for several reasons; in particular, the heterogeneity between patients regarding causes, pathophysiology, treatment, and outcome. Advances in basic science have failed to translate into successful clinical treatments, and the evidence underpinning guideline recommendations is weak. Because clinical research has been hampered by non-standardised data collection, restricted multidisciplinary collaboration, and the lack of sensitivity of classification and efficacy analyses, multidisciplinary collaborations are now being fostered. Approaches to deal with heterogeneity have been developed by the IMPACT study group. These approaches can increase statistical power in clinical trials by up to 50% and are also relevant to other heterogeneous neurological diseases, such as stroke and subarachnoid haemorrhage. Rather than trying to limit heterogeneity, we might also be able to exploit it by analysing differences in treatment and outcome between countries and centres in comparative effectiveness research. This approach has great potential to advance care in patients with TBI.	[Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, B-2650 Edegem, Belgium; [Murray, Gordon D.; Butcher, Isabella; McHugh, Gillian S.; Weir, James] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Roozenbeek, Bob] Univ Med Ctr Rotterdam, Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Lu, Juan] Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, Richmond, VA USA		Maas, AIR (corresponding author), Univ Antwerp Hosp, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Steyerberg, Ewout W/C-1509-2018	Steyerberg, Ewout W/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This work was supported by NIH-NINDS (NS-042691). AIM, HFL, and EWS are participants in CENTER-TBI, a large collaborative project funded by the European Commission 7th Framework program (602150). We have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Adams HP, 2008, STROKE, V39, P3277, DOI 10.1161/STROKEAHA.107.508853; Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Annane D, 2009, CRIT CARE MED, V37, pS117, DOI 10.1097/CCM.0b013e318192078b; [Anonymous], 2012, LANCET NEUROL, V11, P651, DOI 10.1016/S1474-4422(12)70166-7; Bath P, 2009, STROKE, V40, P888, DOI 10.1161/STROKEAHA.108.519207; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Edwards P, 2005, LANCET, V365, P1957; European Commission, RES INN PART PORT FP; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Harrell FE Jr, 2017, REGRESSION MODELING; Hebert PC, 2002, CHEST, V121, P1290, DOI 10.1378/chest.121.4.1290; Hernandez AV, 2006, ANN EPIDEMIOL, V16, P41, DOI 10.1016/j.annepidem.2005.09.007; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1975, LANCET, V1, P480; Kidwell CS, 2001, STROKE, V32, P1349, DOI 10.1161/01.STR.32.6.1349; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Li BY, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-77; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-201; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Macdonald RL, 2013, WORLD NEUROSURG, V79, P418, DOI 10.1016/j.wneu.2013.01.006; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease, 2011, PREC MED; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Roozenbeek B, 2009, J NEUROTRAUM, V26, P1069, DOI 10.1089/neu.2008.0569; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Steyerberg, 2019, CLIN PREDICTION MODE; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Turner EL, 2012, J CLIN EPIDEMIOL, V65, P474, DOI 10.1016/j.jclinepi.2011.08.012; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Yue JK, 2013, J NEUROTRAUM, DOI DOI 10.1089/NEU.2013.2970	82	94	95	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1200	1210		10.1016/S1474-4422(13)70234-5			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	265BG	WOS:000327924100015	24139680	Green Accepted			2022-02-06	
J	Urban, JE; Davenport, EM; Golman, AJ; Maldjian, JA; Whitlow, CT; Powers, AK; Stitzel, JD				Urban, Jillian E.; Davenport, Elizabeth M.; Golman, Adam J.; Maldjian, Joseph A.; Whitlow, Christopher T.; Powers, Alexander K.; Stitzel, Joel D.			Head Impact Exposure in Youth Football: High School Ages 14 to 18 Years and Cumulative Impact Analysis	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Brain injury; Concussion; Football; Pediatric; Youth; Helmet; Risk; High school	STATES HIGH-SCHOOL; UNITED-STATES; COLLEGIATE; PLAYERS; CONCUSSION; INJURY; ACCELERATION; EPIDEMIOLOGY; MAGNITUDE; LOCATION	Sports-related concussion is the most common athletic head injury with football having the highest rate among high school athletes. Traditionally, research on the biomechanics of football-related head impact has been focused at the collegiate level. Less research has been performed at the high school level, despite the incidence of concussion among high school football players. The objective of this study is to twofold: to quantify the head impact exposure in high school football, and to develop a cumulative impact analysis method. Head impact exposure was measured by instrumenting the helmets of 40 high school football players with helmet mounted accelerometer arrays to measure linear and rotational acceleration. A total of 16,502 head impacts were collected over the course of the season. Biomechanical data were analyzed by team and by player. The median impact for each player ranged from 15.2 to 27.0 g with an average value of 21.7 (+/- 2.4) g. The 95th percentile impact for each player ranged from 38.8 to 72.9 g with an average value of 56.4 (+/- 10.5) g. Next, an impact exposure metric utilizing concussion injury risk curves was created to quantify cumulative exposure for each participating player over the course of the season. Impacts were weighted according to the associated risk due to linear acceleration and rotational acceleration alone, as well as the combined probability (CP) of injury associated with both. These risks were summed over the course of a season to generate risk weighted cumulative exposure. The impact frequency was found to be greater during games compared to practices with an average number of impacts per session of 15.5 and 9.4, respectively. However, the median cumulative risk weighted exposure based on combined probability was found to be greater for practices vs. games. These data will provide a metric that may be used to better understand the cumulative effects of repetitive head impacts, injury mechanisms, and head impact exposure of athletes in football.	[Urban, Jillian E.; Davenport, Elizabeth M.; Golman, Adam J.; Stitzel, Joel D.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Winston Salem, NC 27157 USA; [Urban, Jillian E.; Davenport, Elizabeth M.; Golman, Adam J.; Maldjian, Joseph A.; Whitlow, Christopher T.; Powers, Alexander K.; Stitzel, Joel D.] Wake Forest Sch Med, Winston Salem, NC 27157 USA; [Maldjian, Joseph A.; Whitlow, Christopher T.] Wake Forest Sch Med, Dept Radiol Neuroradiol, Winston Salem, NC 27157 USA; [Powers, Alexander K.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Translat Sci Inst, Winston Salem, NC 27157 USA; [Powers, Alexander K.; Stitzel, Joel D.] Wake Forest Sch Med, Childress Inst Pediat Trauma, Winston Salem, NC 27157 USA		Stitzel, JD (corresponding author), Wake Forest Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Maldjian, Joseph/0000-0002-6384-1072	Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082453] Funding Source: NIH RePORTER	The authors would like to thank the Reagan High School, especially Ashley Lake, ATC (Reagan High School), Corbin Ratcliffe, Lauren Smith and the football program. Thank you to Elizabeth Lillie and all those who contributed to the study development. Special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center for providing support for this study.	[Anonymous], 2012, 2011 2012 HIGH SCH A; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Dick R, 2009, J ATHL TRAINING, V42, P173; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hodgson V., 1983, P 27 STAPP CAR CRASH; Irick E., 2011, NCAA SPORTS SPONSORS; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0	35	94	94	3	38	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2013	41	12					2474	2487		10.1007/s10439-013-0861-z			14	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	249UN	WOS:000326803700002	23864337	Green Accepted			2022-02-06	
J	Piao, CS; Stoica, BA; Wu, JF; Sabirzhanov, B; Zhao, ZR; Cabatbat, R; Loane, DJ; Faden, AI				Piao, Chun-Shu; Stoica, Bogdan A.; Wu, Junfang; Sabirzhanov, Boris; Zhao, Zaorui; Cabatbat, Rainier; Loane, David J.; Faden, Alan I.			Late exercise reduces neuroinflammation and cognitive dysfunction after traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Exercise; Neurodegeneration; Inflammation; Neurogenesis	FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; VOLUNTARY EXERCISE; GENE-EXPRESSION; UP-REGULATION; ENVIRONMENTAL ENRICHMENT; LIMITS NEUROINFLAMMATION; MICROGLIAL ACTIVATION; MOTOR CORTEX; MOUSE-BRAIN	Delayed secondary biochemical and cellular changes after traumatic brain injury continue for months to years, and are associated with chronic neuroinflammation and progressive neurodegeneration. Physical activity can reduce inflammation and facilitate recovery after brain injury. Here, we investigated the time-dependent effects, and underlying mechanisms of post-traumatic exercise initiation on outcome after moderate traumatic brain injury using a well-characterized mouse controlled cortical impact model. Late exercise initiation beginning at 5 weeks after trauma, but not early initiation of exercise at 1 week, significantly reduced working and retention memory impairment at 3 months, and decreased lesion volume compared to non-exercise injury controls. Cognitive recovery was associated with attenuation of classical inflammatory pathways, activation of alternative inflammatory responses and enhancement of neurogenesis. In contrast, early initiation of exercise failed to alter behavioral recovery or lesion size, while increasing the neurotoxic pro-inflammatory responses. These data underscore the critical importance of timing of exercise initiation after trauma and its relation to neuroinflammation, and challenge the widely held view that effective neuroprotection requires early intervention. (C) 2013 Elsevier Inc. All rights reserved.	[Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Loane, David/ABD-5177-2021	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	Maryland Exercise and Robotics Center of Excellence (MERCE) Pilot Project Award [7RO1NS061839-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We thank Titilola Akintola, Katherine Cardiff, Jeremy Bengson and Domenick Giordano for expert technical assistance. This work is supported by the Maryland Exercise and Robotics Center of Excellence (MERCE) Pilot Project Award and 7RO1NS061839-02, "Mechanisms and modulation of cell death in traumatic brain injury" to AIF.	Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Bland ST, 2001, BEHAV BRAIN RES, V126, P33, DOI 10.1016/S0166-4328(01)00243-1; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Clark RE, 2000, J NEUROSCI, V20, P8853; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; Funk JA, 2011, BRAIN BEHAV IMMUN, V25, P1063, DOI 10.1016/j.bbi.2011.03.012; Galea I, 2005, GLIA, V49, P375, DOI 10.1002/glia.20124; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; JONES TA, 1994, J NEUROSCI, V14, P2140; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kelley MS, 1997, REV NEUROSCIENCE, V8, P147; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kobilo T, 2011, LEARN MEMORY, V18, P605, DOI 10.1101/lm.2283011; Komitova M, 2002, J CEREBR BLOOD F MET, V22, P852, DOI 10.1097/00004647-200207000-00010; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lalancette-Hebert M, 2012, J NEUROSCI, V32, P10383, DOI 10.1523/JNEUROSCI.1498-12.2012; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Pajoohesh-Ganji A, 2012, BRAIN RES, V1475, P96, DOI 10.1016/j.brainres.2012.07.058; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; Petersen AMW, 2005, J APPL PHYSIOL, V98, P1154, DOI 10.1152/japplphysiol.00164.2004; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Qu M, 1998, NEUROSCIENCE, V85, P29, DOI 10.1016/S0306-4522(97)00656-8; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2002, J NEUROCHEM, V83, P1072, DOI 10.1046/j.1471-4159.2002.01208.x; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; Van Keuren KR, 1998, BRAIN RES, V780, P56, DOI 10.1016/S0006-8993(97)01184-0; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; VANDERWOLF CH, 1994, BRAIN RES REV, V19, P264, DOI 10.1016/0165-0173(94)90015-9; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Witte OW, 1997, ADV NEUROL, V73, P207; Woods JA, 2005, BRAIN BEHAV IMMUN, V19, P369, DOI 10.1016/j.bbi.2005.04.007; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	67	94	98	1	35	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2013	54						252	263		10.1016/j.nbd.2012.12.017			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	132EZ	WOS:000318052000024	23313314	Green Accepted			2022-02-06	
J	Boden, BP; Breit, I; Beachler, JA; Williams, A; Mueller, FO				Boden, Barry P.; Breit, Ilan; Beachler, Jason A.; Williams, Aaron; Mueller, Frederick O.			Fatalities in High School and College Football Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						football; fatalities; cardiac; brain	SICKLE-CELL TRAIT; SUDDEN-DEATH; AMERICAN FOOTBALL; CERVICAL-SPINE; INJURIES; SPORTS; YOUNG; CONCUSSION; STATEMENT; ASTHMA	Background: Fatalities in football are rare but tragic events. Purpose: The purpose was to describe the causes of fatalities in high school and college football players and potentially provide preventive strategies. Study Design: Descriptive epidemiology study. Methods: We reviewed the 243 football fatalities reported to the National Center for Catastrophic Sports Injury Research from July 1990 through June 2010. Results: Football fatalities averaged 12.2 per year, or 1 per 100,000 participants. There were 164 indirect (systemic) fatalities (average, 8.2 annually [or 0.7 per 100,000 participants]) and 79 direct (traumatic) fatalities (average, 4.0 annually [or 0.3 per 100,000 participants]). Indirect fatalities were 2.1 times more common than direct fatalities. The risk of a fatality in college compared with high school football players was 2.8 (95% CI, 0.7-8.2) times higher for all fatalities, 3.6 (95% CI, 2.5-5.3) times higher for indirect events, 1.4 (95% CI, 0.6-3.0) times higher for direct injuries, 3.8 (95% CI, 1.8-8.3) times higher for heat illness, and 66 (95% CI, 14.4-308) times higher for sickle cell trait (SCT) fatalities. Most indirect events occurred in practice sessions; preseason practices and intense conditioning sessions were vulnerable periods for athletes to develop heat illness or SCT fatalities, respectively. In contrast, most brain fatalities occurred during games. The odds of a fatality during the second decade, compared with the first decade of the study, were 9.7 (95% CI, 1.2-75.9) for SCT, 1.5 (95% CI, 0.8-2.9) for heat illness, 1.1 (95% CI, 0.8-1.7) for cardiac fatalities, and 0.7 (95% CI, 0.4-1.2) for brain fatalities. The most common causes of fatalities were cardiac failure (n = 100, 41.2%), brain injury (n = 62, 25.5%), heat illness (n = 38, 15.6%), SCT (n = 11, 4.5%), asthma and commotio cordis (n = 7 each, 2.9% each), embolism/blood clot (n = 5, 2.1%), cervical fracture (n = 4, 1.7%), and intra-abdominal injury, infection, and lightning (n = 3, 1.2% each). Conclusion: High school and college football have approximately 12 fatalities annually with indirect systemic causes being twice as common as direct blunt trauma. The most common causes are cardiac failure, brain injury, and heat illness. The incidence of fatalities is much higher at the college level for most injuries other than brain injuries, which were only slightly more common at the college level. The risk of SCT, heat-related, and cardiac deaths increased during the second decade of the study, indicating these conditions require a greater emphasis on diagnosis, treatment, and prevention.	[Boden, Barry P.; Breit, Ilan; Beachler, Jason A.; Williams, Aaron; Mueller, Frederick O.] Orthopaed Ctr, Rockville, MD 20850 USA		Boden, BP (corresponding author), Orthopaed Ctr, 9420 Key West Ave,300, Rockville, MD 20850 USA.	bboden@starpower.net					[Anonymous], 1987, Med Sci Sports Exerc, V19, P529; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Carlsen KH, 2011, BRIT J SPORT MED, V45, P1266, DOI 10.1136/bjsports-2011-090591; Eichner ER, 2010, CURR SPORT MED REP, V9, P347, DOI 10.1249/JSR.0b013e3181fc73d7; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Howe AS, 2007, AM J SPORT MED, V35, P1384, DOI 10.1177/0363546507305013; Janda DH., 1992, CLIN J SPORT MED, V2, P172; Maron BJ, 2010, NEW ENGL J MED, V362, P917, DOI 10.1056/NEJMra0910111; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; Mitchell BL, 2007, J NATL MED ASSOC, V99, P300; Moffatt K, 2007, MED SCI SPORT EXER, V39, P899, DOI 10.1249/01.mss.0b013e31803d35e7; Mueller FO, 2010, FALL 1982 SPRING 201; Mueller FO, 1996, CATASTROPHIC INJURIE, P1; National Climatic Data Center, NOAA SAT INF SERV; National Collegiate Athletic Association, RESOURCES; National Federation of State High School Associations, PART DAT; Oller AR, 2010, J ATHL TRAINING, V45, P222, DOI 10.4085/1062-6050-45.3.222; Tao K, 2010, J EMERG MED, V38, P351, DOI 10.1016/j.jemermed.2008.07.030; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Torg J S, 1979, Am J Sports Med, V7, P127; Torg JS, 2002, J BONE JOINT SURG AM, V84A, P112, DOI 10.2106/00004623-200201000-00017; United States Census Bureau, CENS REG DIV US; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; Walsh KM, 2000, J ATHL TRAINING, V35, P471; Weather Underground Inc, WEATH UND	30	94	96	3	41	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2013	41	5					1108	1116		10.1177/0363546513478572			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	135OQ	WOS:000318298300024	23477766				2022-02-06	
J	Juhra, C; Wieskotter, B; Chu, K; Trost, L; Weiss, U; Messerschmidt, M; Malczyk, A; Heckwolf, M; Raschke, M				Juhra, C.; Wieskoetter, B.; Chu, K.; Trost, L.; Weiss, U.; Messerschmidt, M.; Malczyk, A.; Heckwolf, M.; Raschke, M.			Bicycle accidents - Do we only see the tip of the iceberg? A prospective multi-centre study in a large German city combining medical and police data	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Bicycle accidents; Traumatic brain injury; Helmet; Economic impact; Fracture	HELMET LEGISLATION; ROAD	Introduction: Bicycles are becoming increasingly popular. In Munster, a German town with a population of 273,000, bicycles were the main method of transportation in 2009, used more often (37.8%) than cars (36.4%). Each day in Munster, bicycles are used around 450,000 times. In 1982, they were only used around 270,000 times a day. However, the increased use of bicycles has also led to an increased number of bicycle accidents. Methods: Between February 2009 and January 2010, data on bicycle-accidents leading to injuries were collected by the Police of Munster and in all emergency units of the six hospitals in Munster. A systematic acquisition of technical data from the police and the medical data from the hospitals were combined anonymously. None of the forms contained personal data of patients involved, except for patient age and sex as well as time and place of bicycle accidents to match the questionnaires. The data were entered into a central database (MS Access for input/MySQL for data retrieval). Results: 2250 patients were included in this study. For each of these patients either a patient record or a hospital record or a police record or a combination of any of these different records existed in our database. In total, 1767 patients received medical treatment at a hospital and 484 people included in the study did not go to a hospital. Three fatalities occurred as a result of bicycle accidents. Considering reasons for hospital admission, traumatic brain injuries were the leading cause (25.7%). However, the largest resource consumption was attributed to fractures of the upper extremities (36.8%) and lower extremities (29.9%) with major surgery. Discussion: Bicycle accidents occur more frequently than indicated by police records. The results of the Munster Bicycle Study have shown that the actual number of bicycle accidents exceeds the officially reported number by nearly two times. Since bicycle helmets cannot prevent accidents it is recommended not only to focus on helmet use as the only injury prevention method. Other factors, such as weather, pavement and default of traffic, roadworthiness of the bicycles or alcohol/drug abuse also affect the accident rates. (C) 2011 Elsevier Ltd. All rights reserved.	[Juhra, C.; Wieskoetter, B.; Chu, K.; Trost, L.; Raschke, M.] Univ Hosp Munster, Dept Trauma Hand & Reconstruct Surg, D-48149 Munster, Germany; [Weiss, U.; Messerschmidt, M.] Police Munster, Munster, Germany		Juhra, C (corresponding author), Univ Hosp Munster, Dept Trauma Hand & Reconstruct Surg, Waldeyerstr 1, D-48149 Munster, Germany.	juhra@ukmuenster.de	Juhra, Christian/W-4888-2019; Laumann, Marion/AAX-3607-2021		German Insurance Association/German Insurers Accident Research; German Insurers Accident Research	This study was funded by the German Insurance Association/German Insurers Accident Research. The German Insurers Accident Research supported the scientific study design, analysis and interpretation of data from a technical perspective. The funding source was not involved in the collection and analysis of the data or in the interpretation of the data from a medical perspective. The joint authors' decision to submit this paper was supported by the funding source.	Andersen LB, 2000, ARCH INTERNAL MED, V160; [Anonymous], 70 MILL DRAHT WERD D; [Anonymous], BAU STADT FAHRR; ECMT, 2000, SAF TRAFF VULN US; Guttler Martina, 2009, FAKTEN FAHRRADHAUPTS; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; Hautzinger H, 1993, DUNKELZIFFER UNFALLE; Karkhaneh M, 2006, INJURY PREV, V12, P76, DOI 10.1136/ip.2005.010942; Macpherson A, 2009, BICYCLE HELMET LEGIS; Naci H, 2009, INJURY PREV, V15, P55, DOI 10.1136/ip.2008.018721; Osberg J.S., 1998, TRANSPORT Q, V52, P61; Richter M, 2001, UNFALLCHIRURG, V104, P733, DOI 10.1007/s001130170075; Richter M, 2005, Z ORTHOPADIE, V146, P604, DOI [10.1055/s-2005-923493, DOI 10.1055/S-2005-923493]; Rivara FP, 2015, INJURY PREV, V21, P47, DOI 10.1136/injprev-00002-0038rep; Robinson DL, 2007, ACCIDENT ANAL PREV, V39, P86, DOI 10.1016/j.aap.2006.06.007; Thompson DC, 2005, COCHRANE DATABASE SY, V4; Towner E, 2002, 30 ROAD SAF DFT; Wardlaw MJ, 2000, BRIT MED J, V321, P1582, DOI 10.1136/bmj.321.7276.1582; World Health Organization, TRANSP HLTH HLTH EC	19	94	94	2	35	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	DEC	2012	43	12					2026	2034		10.1016/j.injury.2011.10.016			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	028XM	WOS:000310458600011	22105099				2022-02-06	
J	Zafonte, RD; Bagiella, E; Ansel, BM; Novack, TA; Friedewald, WT; Hesdorffer, DC; Timmons, SD; Jallo, J; Eisenberg, H; Hart, T; Ricker, JH; Diaz-Arrastia, R; Merchant, RE; Temkin, NR; Melton, S; Dikmen, SS				Zafonte, Ross D.; Bagiella, Emilia; Ansel, Beth M.; Novack, Thomas A.; Friedewald, William T.; Hesdorffer, Dale C.; Timmons, Shelly D.; Jallo, Jack; Eisenberg, Howard; Hart, Tessa; Ricker, Joseph H.; Diaz-Arrastia, Ramon; Merchant, Randall E.; Temkin, Nancy R.; Melton, Sherry; Dikmen, Sureyya S.			Effect of Citicoline on Functional and Cognitive Status Among Patients With Traumatic Brain Injury Citicoline Brain Injury Treatment Trial (COBRIT)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; CDP-CHOLINE; CLINICAL-TRIALS; MULTIPLE OUTCOMES; HIPPOCAMPAL; SYMPTOMS; RECOVERY; TBI	Context Traumatic brain injury (TBI) is a serious public health problem in the United States, yet no treatment is currently available to improve outcome after TBI. Approved for use in TBI in 59 countries, citicoline is an endogenous substance offering potential neuroprotective properties as well as facilitated neurorepair post injury. Objective To determine the ability of citicoline to positively affect functional and cognitive status in persons with complicated mild, moderate, and severe TBI. Design, Setting, and Patients The Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, double-blind randomized clinical trial conducted between July 20, 2007, and February 4, 2011, among 1213 patients at 8 US level 1 trauma centers to investigate effects of citicoline vs placebo in patients with TBI classified as complicated mild, moderate, or severe. Intervention Ninety-day regimen of daily enteral or oral citicoline (2000 mg) or placebo. Main Outcome Measures Functional and cognitive status, assessed at 90 days using the TBI-Clinical Trials Network Core Battery. A global statistical test was used to analyze the 9 scales of the core battery. Secondary outcomes were functional and cognitive improvement, assessed at 30, 90, and 180 days, and examination of the long-term maintenance of treatment effects. Results Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicoline group and 35.6% in the placebo group. For all other scales the rate of improvement ranged from 37.3% to 86.5% in the citicoline group and from 42.7% to 84.0% in the placebo group. The citicoline and placebo groups did not differ significantly at the 90-day evaluation (global odds ratio [OR], 0.98 [95% CI, 0.83-1.15]); in addition, there was no significant treatment effect in the 2 severity subgroups (global OR, 1.14 [95% CI, 0.88-1.49] and 0.89 [95% CI, 0.72-1.49] for moderate/severe and complicated mild TBI, respectively). At the 180-day evaluation, the citicoline and placebo groups did not differ significantly with respect to the primary outcome (global OR, 0.87 [95% CI, 0.72-1.04]). Conclusion Among patients with traumatic brain injury, the use of citicoline compared with placebo for 90 days did not result in improvement in functional and cognitive status.	[Zafonte, Ross D.] Harvard Univ, Spaulding Rehabil Hosp Network, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bagiella, Emilia] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA; [Ansel, Beth M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Novack, Thomas A.; Melton, Sherry] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Friedewald, William T.] Columbia Univ, Dept Biostat, New York, NY USA; [Hesdorffer, Dale C.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Timmons, Shelly D.] Geisinger Med Ctr, Dept Neurosurg, Danville, PA 17822 USA; [Jallo, Jack] Thomas Jefferson Univ, Div Neurotrauma & Crit Care, Philadelphia, PA 19107 USA; [Eisenberg, Howard] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Hart, Tessa] Moss Rehabil Res Inst, Philadelphia, PA USA; [Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA; [Merchant, Randall E.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		Zafonte, RD (corresponding author), Harvard Univ, Spaulding Rehabil Hosp Network, Sch Med, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	rzafonte@partners.org		Jallo, Jack/0000-0002-5512-1729; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Ricker, Joseph/0000-0003-3415-991X	National Institute of Child Health and Human Development at Temple University [U01HD042738]; National Institute of Child Health and Human Development at University of Alabama at Birmingham [U01HD042687]; National Institute of Child Health and Human Development at University of Maryland [U01HD042736]; National Institute of Child Health and Human Development at University of Pittsburgh [U01HD042678]; National Institute of Child Health and Human Development at University of Tennessee Health Sciences Center [U01HD042686]; National Institute of Child Health and Human Development at University of Texas Southwestern [U01HD042652]; National Institute of Child Health and Human Development grants at University of Washington [U01HD042653]; National Institute of Child Health and Human Development grants at Virginia Commonwealth University [U01HD042689]; National Institute of Child Health and Human Development grants at Columbia University [Columbia University (U01HD042823]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042687, U01HD042653, U01HD042678, U01HD042738, U01HD042823, U01HD042689, U01HD042686, U01HD042736] Funding Source: NIH RePORTER	This study was supported by National Institute of Child Health and Human Development grants at the following institutions: Temple University (U01HD042738); University of Alabama at Birmingham (U01HD042687); University of Maryland (U01HD042736); University of Pittsburgh (U01HD042678); University of Tennessee Health Sciences Center (U01HD042686); University of Texas Southwestern (U01HD042652); University of Washington (U01HD042653); Virginia Commonwealth University (U01HD042689); and Columbia University (U01HD042823). Ferrer Grupo provided the citicoline and identical placebo used in the study.	Adibhatla RM, 2002, J NEUROSCI RES, V70, P133, DOI 10.1002/jnr.10403; Alexandrov A V, 2001, Curr Opin Investig Drugs, V2, P1757; Arenth PM, 2011, PM&R, V3, pS123, DOI 10.1016/j.pmrj.2011.03.012; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Benton A., 1994, CONTRIBUTIONS NEUROP; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; COHADON F, 1982, NEUROCHIRURGIE, V28, P287; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hernandez AV, 2005, NEUROSURGERY, V57, P1244, DOI 10.1227/01.NEU.0000186039.57548.96; Kelso ML, 2011, PROG MOL BIOL TRANSL, V98, P85, DOI 10.1016/B978-0-12-385506-0.00003-X; KENNEDY EP, 1956, J BIOL CHEM, V222, P185; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Little RJA., 1987, STAT ANAL MISSING DA; LoBello S, 2003, ARCH PHYS MED REHAB, V84, pA9; LOZANO R, 1991, J NEUROL SCI, V103, pS43; MALDONADO VC, 1991, J NEUROL SCI, V103, pS15; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Pocock SJ, 1997, CONTROL CLIN TRIALS, V18, P530, DOI 10.1016/S0197-2456(97)00008-1; Reitan RM, 1992, TRAIL MAKING TEST MA; REITAN RM, 1993, HALSTEAD REITH NEURO; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rubin D.B., 1997, MULTIPLE IMPUTATION; Secades JJ, 2011, REV NEUROLOGIA, V52, pS1, DOI 10.33588/rn.52S02.2010787; Team RDC, 2008, R LANG ENV STAT COMP; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	40	94	97	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2012	308	19					1993	2000		10.1001/jama.2012.13256			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	040AQ	WOS:000311291400023	23168823	Bronze			2022-02-06	
J	Lucas, S; Hoffman, JM; Bell, KR; Walker, W; Dikmen, S				Lucas, Sylvia; Hoffman, Jeanne M.; Bell, Kathleen R.; Walker, William; Dikmen, Sureyya			Characterization of headache after traumatic brain injury	CEPHALALGIA			English	Article						Headache; traumatic brain injury; TBI; post-traumatic headache; PTH; migraine; probable migraine; tension-type headache; cervicogenic headache; secondary headaches	POSTTRAUMATIC HEADACHE; MIGRAINE; PATHOGENESIS; SOLDIERS; RATES	Background: Headache is a common and persistent symptom following traumatic brain injury (TBI). Headaches following TBI are defined primarily by their temporal association to injury, but have no defining clinical features. To provide a framework for treatment, primary headache symptoms were used to characterize headache. Methods: Three hundred and seventy-eight participants were prospectively enrolled during acute in-patient rehabilitation for TBI. Headaches were classified into migraine/probable migraine, tension-type, or cervicogenic headache at baseline and 3, 6, and 12 months following TBI. Results: Migraine was the most frequent headache type occurring in up to 38% of participants who reported headaches. Probable migraine occurred in up to 25%, tension-type headache in up to 21%, then cervicogenic headache in up to 10%. Females were more likely to have endorsed pre-injury migraine than males, and had migraine or probable migraine at all time points after injury. Those classified with migraine were more likely to have frequent headaches. Conclusions: Our data show that most headache after TBI may be classified using primary headache criteria. Migraine/probable migraine described the majority of headache after TBI across one year post-injury. Using symptom-based criteria for headache following TBI can serve as a framework from which to provide evidence-based treatment for these frequent, severe, and persistent headaches.	[Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Hoffman, Jeanne M.; Bell, Kathleen R.; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Walker, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA		Lucas, S (corresponding author), Univ Washington, Dept Neurol, Box 356097, Seattle, WA 98195 USA.	lucass@uw.edu		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research; TBI Model Systems: University of Washington Traumatic Brain Injury Model System [H133A070032]; Virginia Commonwealth Traumatic Brain Injury Model System [H133A070036]; NIDRR; Wadsworth Foundation; MerckMerck & Company; GSKGlaxoSmithKline; Map; Nupathe; St. Jude MedicalSt. Jude Medical; BiogenIdecBiogen; Sanofi-AventisSanofi-Aventis; John L. Locke Foundation; National Headache Foundation; EMD Serono-PfizerPfizer; Zogenix; NovartisNovartis; Allozyne	This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, TBI Model Systems: University of Washington Traumatic Brain Injury Model System H133A070032, Virginia Commonwealth Traumatic Brain Injury Model System H133A070036. Dr Lucas received funding from NIDRR and Wadsworth Foundation for this study. Other research funding has been from Merck, GSK, Map, Nupathe, St. Jude Medical (formerly AGA), BiogenIdec, Sanofi-Aventis, John L. Locke Foundation and the National Headache Foundation. Honoraria, advisory or consulting fees have been received from Merck, GSK, BiogenIdec, EMD Serono-Pfizer, Zogenix, Map, Novartis and Allozyne. Dr Hoffman receives research funding from NIDRR. Dr Bell receives research funding from NIDRR. Dr Walker receives research funding from NIDRR. Dr Dikmen receives research funding from NIDRR.	Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Faul M, TRAUMATIC BRAIN INJU; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Jaycox, 2008, INVISIBLE WOUNDS WAR, P3; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; STEWART WF, 1991, AM J EPIDEMIOL, V134, P1111, DOI 10.1093/oxfordjournals.aje.a116014; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; [No title captured]	18	94	94	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	JUN	2012	32	8					600	606		10.1177/0333102412445224			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	959XS	WOS:000305352100004	22623761				2022-02-06	
J	Reger, ML; Poulos, AM; Buen, F; Giza, CC; Hovda, DA; Fanselow, MS				Reger, Maxine L.; Poulos, Andrew M.; Buen, Floyd; Giza, Christopher C.; Hovda, David A.; Fanselow, Michael S.			Concussive Brain Injury Enhances Fear Learning and Excitatory Processes in the Amygdala	BIOLOGICAL PSYCHIATRY			English	Article						Concussion; fear conditioning; GAD-67; NMDA; PTSD; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; LATERAL FLUID PERCUSSION; RIGHT PARIETAL CORTEX; CONDITIONED FREEZING DEFICIT; MILD TRAUMATIC LESION; BASOLATERAL AMYGDALA; POTENTIATED STARTLE; COGNITIVE FUNCTION; GABA(A) RECEPTOR; DELTA-SUBUNIT	Background: Mild traumatic brain injury (cerebral concussion) results in cognitive and emotional dysfunction. These injuries are a significant risk factor for the development of anxiety disorders, including posttraumatic stress disorder. However, because physically traumatic events typically occur in a highly emotional context, it is unknown whether traumatic brain injury itself is a cause of augmented fear and anxiety. Methods: Rats were trained with one of five fear-conditioning procedures (n = 105) 2 days after concussive brain trauma. Fear learning was assessed over subsequent days and chronic changes in fear learning and memory circuitry were assessed by measuring N-methyl-D-aspartate receptor subunits and glutamic acid decarboxylase, 67 kDa isoform protein levels in the hippocampus and basolateral amygdala complex (BLA). Results: Injured rats exhibited an overall increase in fear conditioning, regardless of whether fear was retrieved via discrete or contextual-spatial stimuli. Moreover, injured rats appeared to overgeneralize learned fear to both conditioned and novel stimuli. Although no gross histopathology was evident, injury resulted in a significant upregulation of excitatory N-methyl-D-aspartate receptors in the BLA. There was a trend toward decreased gamma-aminobutyric acid-related inhibition (glutamic acid decarboxylase, 67 kDa isoform) in the BLA and hippocampus. Conclusions: These results suggest that mild traumatic brain injury predisposes the brain toward heightened fear learning during stressful postinjury events and provides a potential molecular mechanism by which this occurs. Furthermore, these data represent a novel rodent model that can help advance the neurobiological and therapeutic understanding of the comorbidity of posttraumatic stress disorder and traumatic brain injury.	[Reger, Maxine L.; Poulos, Andrew M.; Fanselow, Michael S.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Reger, Maxine L.; Giza, Christopher C.; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Univ Calif Los Angeles Neurotrauma Lab, Los Angeles, CA 90095 USA; [Fanselow, Michael S.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; [Buen, Floyd] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA		Fanselow, MS (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	fanselow@ucla.edu			University of California at Los Angeles Brain Injury Research Center; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1PO1NS058489, 1RO1NS27544, RC1MH088184, KO2NS057420]; Department of DefenseUnited States Department of Defense [DR080372]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1MH088184, R01MH062122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, R01NS027544, K02NS057420] Funding Source: NIH RePORTER	This research was supported by the University of California at Los Angeles Brain Injury Research Center, National Institutes of Health Grants 1PO1NS058489 (DAH), 1RO1NS27544 (DAH), RC1MH088184 (MSF), and KO2NS057420 (CCG) and the Department of Defense Grant DR080372 (CCG).	Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Centers for Disease Control and Prevention, TRAUM BRAIN INJ; Cordero MI, 1998, BEHAV NEUROSCI, V112, P885, DOI 10.1037/0735-7044.112.4.885; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; Crestani F, 2002, P NATL ACAD SCI USA, V99, P8980, DOI 10.1073/pnas.142288699; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; FANSELOW MS, 1979, B PSYCHONOMIC SOC, V14, P88; FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P210, DOI 10.1037/0735-7044.108.1.210; Fendt M, 1999, NEUROSCI BIOBEHAV R, V23, P743, DOI 10.1016/S0149-7634(99)00016-0; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Foa E. B., 2006, PATHOLOGICAL ANXIETY; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gale GD, 2004, J NEUROSCI, V24, P3810, DOI 10.1523/JNEUROSCI.4100-03.2004; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Godsil BP, 1997, ANN M SOC NEUR OCT 2, P1612; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jacobs NS, 2010, J NEUROSCI METH, V190, P235, DOI 10.1016/j.jneumeth.2010.04.029; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim JJ, 2006, NEUROSCI BIOBEHAV R, V30, P188, DOI 10.1016/j.neubiorev.2005.06.005; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Liu GS, 2004, NAT NEUROSCI, V7, P373, DOI 10.1038/nn1206; Makkar SR, 2010, NEUROPSYCHOPHARMACOL, V35, P1625, DOI 10.1038/npp.2010.53; Maren S, 1998, J NEUROSCI, V18, P3088; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAND Corporation Center for Military Health Policy Research, 2008, MG720CCF RAND CORP C; Rau V, 2005, NEUROSCI BIOBEHAV R, V29, P1207, DOI 10.1016/j.neubiorev.2005.04.010; Rodrigues SM, 2001, J NEUROSCI, V21, P6889, DOI 10.1523/JNEUROSCI.21-17-06889.2001; Rothbaum BO, 2001, J TRAUMA STRESS, V14, P283, DOI 10.1023/A:1011160800958; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shin RM, 2006, NEURON, V52, P883, DOI 10.1016/j.neuron.2006.10.010; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P558, DOI 10.1016/j.neubiorev.2007.01.001; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Walker DL, 2008, LEARN MEMORY, V15, P67, DOI 10.1101/lm.798908; Wiltgen BJ, 2005, LEARN MEMORY, V12, P327, DOI 10.1101/lm.89705; Wiltgen BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.037.2009; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	57	94	96	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	FEB 15	2012	71	4					335	343		10.1016/j.biopsych.2011.11.007			9	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	879FJ	WOS:000299314800012	22169439	Green Accepted			2022-02-06	
J	Kim, Y; Kent, RD; Weismer, G				Kim, Yunjung; Kent, Raymond D.; Weismer, Gary			An Acoustic Study of the Relationships Among Neurologic Disease, Dysarthria Type, and Severity of Dysarthria	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						acoustic measures; dysarthria; classification	VOICE ONSET TIME; SPEECH-INTELLIGIBILITY; SPEAKING RATE; BRAIN-INJURY; PARKINSONS; IDENTIFICATION; SLOPE	Purpose: This study examined acoustic predictors of speech intelligibility in speakers with several types of dysarthria secondary to different diseases and conducted classification analysis solely by acoustic measures according to 3 variables (disease, speech severity, and dysarthria type). Method: Speech recordings from 107 speakers with dysarthria due to Parkinson's disease, stroke, traumatic brain injury, and multiple system atrophy were used for acoustic analysis and for perceptual judgment of speech intelligibility. Acoustic analysis included 8 segmental/suprasegmental features: 2nd formant frequency slope, articulation rate, voiceless interval duration, 1st moment analysis for fricatives, vowel space, F0, intensity range, and Pairwise Variability Index. Results: The results showed that (a) acoustic predictors of speech intelligibility differed slightly across diseases and (b) classification accuracy by dysarthria type was typically worse than by disease type or severity. Conclusions: These findings were discussed with respect to (a) the relationship between acoustic characteristics and speech intelligibility and (b) dysarthria classification.	[Kim, Yunjung] Louisiana State Univ, Baton Rouge, LA 70803 USA; [Kent, Raymond D.; Weismer, Gary] Univ Wisconsin, Madison, WI 53706 USA		Kim, Y (corresponding author), Louisiana State Univ, Baton Rouge, LA 70803 USA.	ykim6@lsu.edu	Kent, Raymond D/AAI-1928-2020		NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC00319] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER		ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; Ackermann H, 1997, BRAIN LANG, V56, P321, DOI 10.1006/brln.1997.1740; ANSEL BM, 1992, J SPEECH HEAR RES, V35, P296, DOI 10.1044/jshr.3502.296; Auzou P, 2000, CLIN LINGUIST PHONET, V14, P131; Brown J.R., 1975, MOTOR SPEECH DISORDE; CANTER GJ, 1963, J SPEECH HEAR DISORD, V28, P221, DOI 10.1044/jshd.2803.221; CARMICHAEL JN, 2007, THESIS U SHEFFIELD U; *CDCP, 2003, TRAUM BRAIN INJ; CHIU MJ, 1996, EUR NEUROL, V46, P310; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; De Bodt MS, 2002, J COMMUN DISORD, V35, P283, DOI 10.1016/S0021-9924(02)00065-5; Duffy, 2005, MOTOR SPEECH DISORDE; Duffy J. R., 2006, MOTOR SPEECH DISORDE, P7; Fonville S, 2008, J NEUROL, V255, P1545, DOI 10.1007/s00415-008-0978-4; FORREST K, 1989, J ACOUST SOC AM, V85, P2608, DOI 10.1121/1.397755; Gescheider G.A, 1976, PSYCHOPHYSICS METHOD; Goberman AM, 2005, J MED SPEECH-LANG PA, V13, P51; Guerra EC, 2003, LECT NOTES COMPUT SC, V2905, P314; HERTRICH I, 1994, BRAIN LANG, V47, P182, DOI 10.1006/brln.1994.1048; KENT JF, 1992, J SPEECH HEAR RES, V35, P723, DOI 10.1044/jshr.3504.723; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; KENT RD, 1989, CLIN LINGUIST PHONET, V3, P347, DOI 10.3109/02699208908985295; Kent RD., 2008, HDB CLIN LINGUISTICS, P360; Kim Y, 2009, FOLIA PHONIATR LOGO, V61, P329, DOI 10.1159/000252849; Liss JM, 2009, J SPEECH LANG HEAR R, V52, P1334, DOI 10.1044/1092-4388(2009/08-0208); Liu HM, 2000, CLIN LINGUIST PHONET, V14, P447; Low E., 2000, LANG SPEECH, V43, P377, DOI DOI 10.1177/00238309000430040301; LUDLOW CL, 1987, BRAIN LANG, V32, P195, DOI 10.1016/0093-934X(87)90124-6; McRae PA, 2002, J SPEECH LANG HEAR R, V45, P35, DOI 10.1044/1092-4388(2002/003); MILENKOVIC P, 2001, TF 32 COMPUTER PROGR; MONSEN RB, 1983, J SPEECH HEAR DISORD, V48, P286, DOI 10.1044/jshd.4803.286; MORRIS RJ, 1989, J COMMUN DISORD, V22, P23, DOI 10.1016/0021-9924(89)90004-X; MULLIGAN M, 1994, J SPEECH HEAR RES, V37, P496, DOI 10.1044/jshr.3703.496; *NAT I NEUR DIS ST, 2001, HUNT DIS HOP RES; *NAT STROK ASS, 2002, ALL STROK; Nishio M, 2001, CLIN LINGUIST PHONET, V15, P309; Ozawa Y, 2001, FOLIA PHONIATR LOGO, V53, P67, DOI 10.1159/000052656; Ozsancak C, 2001, FOLIA PHONIATR LOGO, V53, P48, DOI 10.1159/000052653; Rosenbek, 1984, DYSARTHRIAS PHYSL AC, P101; SOLOMON NP, 1993, J SPEECH HEAR RES, V36, P294, DOI 10.1044/jshr.3602.294; STUNTEBECK S, 2002, THESIS U WISCONSIN M; Tjaden K, 2004, J SPEECH LANG HEAR R, V47, P766, DOI 10.1044/1092-4388(2004/058); TURNER GS, 1993, J SPEECH HEAR RES, V36, P1134, DOI 10.1044/jshr.3606.1134; Van der Graaff M, 2009, EUR NEUROL, V61, P295, DOI 10.1159/000206855; Van Nuffelen G, 2010, FOLIA PHONIATR LOGO, V62, P110, DOI 10.1159/000287209; Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; WEISMER G, 1992, J ACOUST SOC AM, V91, P1085, DOI 10.1121/1.402635; WEISMER G, 1988, J ACOUST SOC AM, V84, P1281, DOI 10.1121/1.396627; Weismer G, 2001, FOLIA PHONIATR LOGO, V53, P1, DOI 10.1159/000052649; Weismer G., 2010, SPEECH MOTOR CONTROL, P229; WEISMER G, 1991, NIDCD MONOGRAPH, V1, P83; Weismer G, 2006, CLIN LINGUIST PHONET, V20, P315, DOI 10.1080/02699200400024806; Weismer Gary., 1983, VOCAL FOLD PHYSL CON, P317; White L, 2007, J PHONETICS, V35, P501, DOI 10.1016/j.wocn.2007.02.003; Zeplin J., 1996, DISORDERS MOTOR SPEE, P145; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZYSKI BJ, 1987, J COMMUN DISORD, V20, P367, DOI 10.1016/0021-9924(87)90025-6; [No title captured]; [No title captured]; [No title captured]	61	94	96	2	32	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	APR 1	2011	54	2					417	429		10.1044/1092-4388(2010/10-0020)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	744BM	WOS:000289067600001	20884780				2022-02-06	
J	High, WM; Briones-Galang, M; Clark, JA; Gilkison, C; Mossberg, KA; Zgaljardic, DJ; Masel, BE; Urban, RJ				High, Walter M. Jrl; Briones-Galang, Maria; Clark, Jessica A.; Gilkison, Charles; Mossberg, Kurt A.; Zgaljardic, Dennis J.; Masel, Brent E.; Urban, Randall J.			Effect of Growth Hormone Replacement Therapy on Cognition after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; hypopituitarism; traumatic brain injury	QUALITY-OF-LIFE; FACTOR-I; POSTACUTE REHABILITATION; PITUITARY INSUFFICIENCY; GH DEFICIENCY; HYPOPITUITARISM; ADULTS; PERFORMANCE; DYSFUNCTION; MODERATE	Traumatic brain injury (TBI) is a major public health issue, and yet medical science has little to offer for the persistent symptoms that prevent many of these individuals from fully re-entering society. Post-traumatic hypopituitarism, and specifically growth hormone deficiency (GHD), has been found in a large percentage of individuals with chronic moderate to severe TBI. Presently, there are no published treatment studies of hormone replacement in this population. In this study, 83 subjects with chronic TBI were screened for hypopituitarism. Forty-two subjects were found to have either GHD or GH insufficiency (GHI), of which 23 agreed to be randomized to either a year of GH replacement or placebo. All subjects completed the study with no untoward side effects from treatment. A battery of neuropsychological tests and functional measures were administered before and after treatment. Improvement was seen on the following tests: Dominant Hand Finger Tapping Test, Wechsler Adult Intelligence Scale III-Information Processing Speed Index, California Verbal Learning Test II, and the Wisconsin Card Sorting Test (executive functioning). The findings of this pilot study provide preliminary evidence suggesting that some of the cognitive impairments observed in persons who are GHD/GHI after TBI may be partially reversible with appropriate GH replacement therapy.	[High, Walter M. Jrl; Clark, Jessica A.] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY 40504 USA; [High, Walter M. Jrl] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY 40504 USA; [High, Walter M. Jrl; Clark, Jessica A.] Univ Kentucky, Coll Med, Dept Psychol, Lexington, KY 40504 USA; [High, Walter M. Jrl] Univ Kentucky, Coll Med, SCoBIRC, Lexington, KY 40504 USA; [Briones-Galang, Maria] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Gilkison, Charles; Urban, Randall J.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA; [Mossberg, Kurt A.] Univ Texas Med Branch, Dept Phys Therapy, Galveston, TX USA; [Zgaljardic, Dennis J.] Univ Texas Med Branch, Dept Rehabil Sci, Galveston, TX USA; [Zgaljardic, Dennis J.; Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA		High, WM (corresponding author), Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Cardinal Hill Rehabil Hosp,SCoBIRC, 2050 Versailles Rd, Lexington, KY 40504 USA.	walter.high@uky.edu			Moody Endowment; Pfizer, Inc.Pfizer; National Center for Research Resources, National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00073, M01RR00188]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000188, M01RR000073] Funding Source: NIH RePORTER	This work was partially funded by the generous support of the Moody Endowment and Pfizer, Inc. Recombinant growth hormone was supplied by Pfizer, Inc. This study was conducted in the General Clinical Research Center (GCRC) at the University of Texas Medical Branch at Galveston, funded by grant M01RR00073, and on the GCRC at Baylor University, Houston, Texas, funded by grant M01RR00188 from the National Center for Research Resources, National Institutes of Health, U.S. Public Health Service.	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ALMQVIST O, 1986, PSYCHONEUROENDOCRINO, V11, P347, DOI 10.1016/0306-4530(86)90020-X; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P416, DOI 10.1016/j.ghir.2005.09.001; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Beca S. G., 2008, PITUITARY; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; BINNERTS A, 1992, CLIN ENDOCRINOL, V37, P79, DOI 10.1111/j.1365-2265.1992.tb02287.x; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dusick JR, 2012, PITUITARY, V15, P2, DOI 10.1007/s11102-008-0130-6; EDWARDS OM, 1986, MEDICINE, V65, P281; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Hatton J, 2006, J NEUROSURG, V105, P843, DOI 10.3171/jns.2006.105.6.843; High Jr WM, 2005, REHABILITATION TRAUM; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Landis J, 2006, ARCH PHYS MED REHAB, V87, P799, DOI 10.1016/j.apmr.2006.02.017; LE GREVES M, 2006, EXP BRAIN RES, V173, P267; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lichtenwalner RJ, 2006, J NEUROSCI RES, V83, P199, DOI 10.1002/jnr.20719; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lijffijt M, 2003, NEUROSCI LETT, V353, P123, DOI 10.1016/j.neulet.2003.09.028; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P527, DOI 10.1111/j.1365-2265.1989.tb01276.x; Mahmoud GS, 2006, J NEUROPHYSIOL, V95, P2962, DOI 10.1152/jn.00947.2005; Maruff P, 2005, HORM RES, V64, P100, DOI 10.1159/000089325; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Peace KA, 1998, CLIN ENDOCRINOL, V49, P391; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Poole NA, 2008, BRAIN INJURY, V22, P519, DOI 10.1080/02699050802132495; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; SARTORIO A, 1995, HORM RES, V44, P6, DOI 10.1159/000184582; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; VAN DAM PS, 2005, PSYCHONEUROENDOCRINO, V30, P357; Wolf SL, 2007, RESTOR NEUROL NEUROS, V25, P549; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	60	94	99	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1565	1575		10.1089/neu.2009.1253			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500003	20578825	Green Published			2022-02-06	
J	Singleton, RH; Yan, HQ; Fellows-Mayle, W; Dixon, CE				Singleton, Richard H.; Yan, Hong Q.; Fellows-Mayle, Wendy; Dixon, C. Edward			Resveratrol Attenuates Behavioral Impairments and Reduces Cortical and Hippocampal Loss in a Rat Controlled Cortical Impact Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; contusion; neuroprotection; resveratrol (3,5,4 '-trihydroxystilbene); traumatic brain injury	RED WINE POLYPHENOL; MORRIS WATER MAZE; NF-KAPPA-B; SPINAL-CORD; TRANS-RESVERATROL; COGNITIVE DEFICITS; OXIDATIVE STRESS; INDUCED SEIZURES; PROTECTS; ACTIVATION	Resveratrol (3,5,4'-trihydroxystilbene) is a plant-derived small molecule that is protective against multiple neurological and systemic insults. To date, no studies have explored the potential for resveratrol to provide behavioral protection in adult animals in the setting of traumatic brain injury (TBI). Using 50 male Sprague-Dawley rats, we employed the controlled cortical impact (CCI) model to ascertain whether post-injury administration of resveratrol would reduce the severity of the well-described cognitive and motor deficits associated with the model. Contusion volumes and hippocampal neuronal numbers were also measured to characterize the tissue and neuronal-sparing properties, respectively, of resveratrol. We found that 100 mg/kg, but not 10 mg/kg, of intraperitoneal resveratrol administered after injury provides significant behavioral protection in rats sustaining CCI. Specifically, rodents treated with 100 mg/kg of resveratrol showed improvements in motor performance (beam balance and beam walking) and testing of visuospatial memory (Morris water maze). Behavioral protection was correlated with significantly reduced contusion volumes, preservation of CA1 and CA3 hippocampal neurons, and protection from overt hippocampal loss as a result of incorporation into the overlying cortical contusion in resveratrol-treated animals. Although the mechanisms by which resveratrol mediates its neuroprotection is unclear, the current study adds to the growing literature identifying resveratrol as a potential therapy for human brain injury.	[Singleton, Richard H.; Yan, Hong Q.; Fellows-Mayle, Wendy; Dixon, C. Edward] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	dixoec@upmc.edu			National Institutes of Health-National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS030318, NS060672]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R01NS060672, P50NS030318, P01NS030318] Funding Source: NIH RePORTER	The authors would like to thank Xiecheng Ma for her help with animal preparation and injury, Sherman Culver and Kristin Macfarlane for their help with animal behavioral testing, and Yue-Fang Chang, Ph.D., for her assistance with statistical analyses. This work was supported by National Institutes of Health-National Institute of Neurological Disorders and Stroke grants NS030318 and NS060672.	[Anonymous], 1996, GUIDE CARE USE LAB A; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Ates O, 2006, ACTA PHARMACOL SIN, V27, P1317, DOI 10.1111/j.1745-7254.2006.00416.x; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Buryanovskyy L, 2004, BIOCHEMISTRY-US, V43, P11417, DOI 10.1021/bi049162o; Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152; Ciolino HP, 1998, CANCER RES, V58, P5707; Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dong WP, 2008, J VASC SURG, V48, P709, DOI 10.1016/j.jvs.2008.04.007; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Floreani M, 2003, LIFE SCI, V72, P2741, DOI 10.1016/S0024-3205(03)00179-6; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Freyberger A, 2005, TOXICOL LETT, V155, P1, DOI 10.1016/j.toxlet.2004.06.014; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gupta YK, 2002, PHARMACOLOGY, V65, P170, DOI 10.1159/000058044; Gupta YK, 2002, PHARMACOL BIOCHEM BE, V71, P245, DOI 10.1016/S0091-3057(01)00663-3; Gupta YK, 2001, METHOD FIND EXP CLIN, V23, P241, DOI 10.1358/mf.2001.23.5.662120; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaga S, 2005, J MOL CELL CARDIOL, V39, P813, DOI 10.1016/j.yjmcc.2005.08.003; Kaplan S, 2005, ANN THORAC SURG, V80, P2242, DOI 10.1016/j.athoracsur.2005.05.016; Karlsson J, 2000, J NEUROCHEM, V75, P141, DOI 10.1046/j.1471-4159.2000.0750141.x; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Kline AE, 2001, HEAD TRAUMA, P65; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Li C, 2010, NEUROCHEM INT, V56, P495, DOI 10.1016/j.neuint.2009.12.009; Liu BQ, 2010, BIOCHEM BIOPH RES CO, V391, P778, DOI 10.1016/j.bbrc.2009.11.137; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouton P. R., 2002, PRINCIPLES PRACTICES; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Piver B, 2001, TOXICOL LETT, V125, P83, DOI 10.1016/S0378-4274(01)00418-0; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; West T, 2007, DEV NEUROSCI-BASEL, V29, P363, DOI 10.1159/000105477; Wu Z, 2009, NEUROCHEM RES, V34, P1393, DOI 10.1007/s11064-009-9920-0; Yang YB, 2003, ACTA PHARMACOL SIN, V24, P703; Yu C, 2003, RAPID COMMUN MASS SP, V17, P307, DOI 10.1002/rcm.918	59	94	102	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1091	1099		10.1089/neu.2010.1291			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300012	20560755	Green Published			2022-02-06	
J	Ventura, T; Harrison-Felix, C; Carlson, N; DiGuiseppi, C; Gabella, B; Brown, A; DeVivo, M; Whiteneck, G				Ventura, Thomedi; Harrison-Felix, Cynthia; Carlson, Nichole; DiGuiseppi, Carolyn; Gabella, Barbara; Brown, Allen; DeVivo, Michael; Whiteneck, Gale			Mortality After Discharge From Acute Care Hospitalization With Traumatic Brain Injury: A Population-Based Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Comorbidity; Mortality; Population surveillance; Rehabilitation	LONG-TERM SURVIVAL; DEATH	Ventura T, Harrison-Felix C, Carlson N, DiGuiseppi C, Gabella B, Brown A, De Vivo M, Whiteneck G. Mortality after discharge from acute care hospitalization with traumatic brain injury: a population-based study. Arch Phys Med Rehabil 2010;91:20-9. Objective: To characterize mortality after acute hospitalization with traumatic brain injury (TBI) in a socioeconomically diverse population. Design: Population-based retrospective cohort study. Setting: Statewide TBI surveillance program. Participants: Colorado residents with TBI discharged alive from acute hospitalization between 1998 and 2003 (N=18,998). Interventions: Not applicable. Main Outcome Measures: Vital status at the end of the study period (December 31, 2005) and statewide population mortality rates were used to calculate all-cause and cause-specific standardized mortality ratios (SMRs) and life expectancy compared with population mortality rates. The influence of demographics, injury severity, and comorbid conditions on time until death was investigated using age-stratified Cox proportional hazards modeling. Results: Patients with TBI carried about 2.5 times the risk of death compared with the general population (SMR=2.47; 95% confidence interval [Cl], 2.31-2.65). Life expectancy reduction averaged 6 years. SMRs were largest for deaths caused by mental/behavioral (SMR=3.84; 95% Cl. 2.67-5.51) and neurologic conditions (SMR=2.79; 95% Cl, 2.07-3.77) and were smaller but significantly higher than 1.0 for an array of other causes. Injury severity and older age increased mortality among young people (age <20y). However, risk factors for mortality among adults age 20 and older involved multiple domains of demographics (eg, metropolitan residence), injury-related measures (eg, falls versus vehicular incidents), and comorbidity (eg, >= 3 comorbid health conditions versus none). Conclusions: TBI confers an increased risk of mortality in the months and years after hospital discharge. Although life expectancy is reduced across the population, the excess in mortality lessens as time since injury increases. Specific risk factors (eg, high injury severity, poor general health) pose an especially high threat to survival and should prompt an increased vigilance of health status, especially among younger patients.	[Harrison-Felix, Cynthia; Whiteneck, Gale] Craig Hosp, Englewood, CO 80113 USA; [Carlson, Nichole] Univ Colorado, Dept Biostat & Informat, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [DiGuiseppi, Carolyn] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [Ventura, Thomedi] Univ Colorado, MSPH MPH Program, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [Harrison-Felix, Cynthia] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [DiGuiseppi, Carolyn; Whiteneck, Gale] Colorado State Univ, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA; [Gabella, Barbara] Colorado Dept Publ Hlth & Environm, Denver, CO USA; [DeVivo, Michael] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Brown, Allen] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA		Harrison-Felix, C (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org	DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817; Brown, Allen W./0000-0001-7228-3351	Colorado Traumatic Brain Injury Trust; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR811509]	Supported by the Colorado Traumatic Brain Injury Trust Fund Research Program (Colorado Department of Human Services). DiGuiseppi was supported in part by the Centers for Disease Control and Prevention (grant no. R49/CCR811509). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.	Anderson R N, 2001, Natl Vital Stat Rep, V49, P1; *ASS ADV AUT MED, 1998, ABBR INJ SCAL AIS 19; Baguley I, 2000, BRAIN INJURY, V14, P505; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Collett D., 2003, MODELLING SURVIVAL D, V2nd; *CTR MED MED SERV, MED ENR STAT AG GROU; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Lai DJ, 1996, AM J EPIDEMIOL, V143, P832; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marr A., 2004, CENTRAL NERVOUS SYST; *MON CTR HLTH POL, 2008, CONC COMPL COM; National Center for Health Statistics, INT CLASS DIS; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SHAVELLE RM, 2006, BRAIN INJURY MED PRI, P247; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; *US BUR CENS, 2008, METR MICR STAT AR; World Health Organisation, 2006, INT STAT CLASS DIS R	30	94	94	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2010	91	1					20	29		10.1016/j.apmr.2009.08.151			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	592YG	WOS:000277417300004	20103393				2022-02-06	
J	Oddo, M; Levine, JM; Frangos, S; Carrera, E; Maloney-Wilensky, E; Pascual, JL; Kofke, WA; Mayer, SA; LeRoux, PD				Oddo, M.; Levine, J. M.; Frangos, S.; Carrera, E.; Maloney-Wilensky, E.; Pascual, J. L.; Kofke, W. A.; Mayer, S. A.; LeRoux, P. D.			Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; BLOOD-FLOW; SODIUM-CHLORIDE; FLUID RESUSCITATION; 20-PERCENT MANNITOL; CUSHING RESPONSE; PRESSURE; SHOCK; 7.2-PERCENT	Background: The impact of osmotic therapies on brain oxygen has not been extensively studied in humans. We examined the effects on brain tissue oxygen tension (PbtO(2)) of mannitol and hypertonic saline (HTS) in patients with severe traumatic brain injury (TBI) and refractory intracranial hypertension. Methods: 12 consecutive patients with severe TBI who underwent intracranial pressure (ICP) and PbtO(2) monitoring were studied. Patients were treated with mannitol (25%, 0.75 g/kg) for episodes of elevated ICP (> 20 mm Hg) or HTS (7.5%, 250 ml) if ICP was not controlled with mannitol. PbtO2, ICP, mean arterial pressure, cerebral perfusion pressure (CPP), central venous pressure and cardiac output were monitored continuously. Results: 42 episodes of intracranial hypertension, treated with mannitol (n = 28 boluses) or HTS (n = 14 boluses), were analysed. HTS treatment was associated with an increase in PbtO2 (from baseline 28.3 (13.8) mm Hg to 34.9 (18.2) mm Hg at 30 min, 37.0 (17.6) mm Hg at 60 min and 41.4 (17.7) mm Hg at 120 min; all p < 0.01) while mannitol did not affect PbtO2 (baseline 30.4 (11.4) vs 28.7 (13.5) vs 28.4 (10.6) vs 27.5 (9.9) mm Hg; all p > 0.1). Compared with mannitol, HTS was associated with lower ICP and higher CPP and cardiac output. Conclusions: In patients with severe TBI and elevated ICP refractory to previous mannitol treatment, 7.5% hypertonic saline administered as second tier therapy is associated with a significant increase in brain oxygenation, and improved cerebral and systemic haemodynamics.	[LeRoux, P. D.] Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, Philadelphia, PA 19104 USA; [Pascual, J. L.] Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA; [Levine, J. M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, J. M.; Kofke, W. A.] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Carrera, E.; Mayer, S. A.] Columbia Univ, Med Ctr, Dept Neurol, Crit Care Div, New York, NY USA		LeRoux, PD (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, Philadelphia, PA 19104 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525; Carrera, Emmanuel/0000-0003-0045-5382	SICPA Foundation, Switzerland; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBLAB-119620]; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	Supported by Research Grants from the SICPA Foundation, Switzerland (to MO and EC), the Swiss National Science Foundation, Grant PBLAB-119620 (EC), the Integra Foundation (PDL) and the Mary Elisabeth Groff Surgical and Medical Research Trust (PDL).	Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bermueller C, 2006, J NEUROL SCI, V241, P73, DOI 10.1016/j.jns.2005.10.016; Chen CH, 2007, NEUROCRIT CARE, V7, P92, DOI 10.1007/s12028-007-0033-9; Chen Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1051, DOI 10.1152/ajpcell.00216.2005; DAUTERMANN C, 1992, ADV EXP MED BIOL, V317, P731; DEFELIPPE J, 1980, LANCET, V2, P1002; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Hartl R, 1997, ACT NEUR S, V70, P40; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Schmidt EA, 2005, ACTA NEUROCHIR SUPPL, V95, P253; SCHRADER H, 1985, ACTA NEUROL SCAND, V72, P283; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; STEENBERGEN JM, 1993, AM J PHYSIOL, V265, pH323, DOI 10.1152/ajpheart.1993.265.1.H323; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; Toung TJK, 2007, CRIT CARE MED, V35, P526, DOI 10.1097/01.CCM.0000253309.44567.A6; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Zausinger S, 2004, NEUROSURGERY, V55, P679, DOI 10.1227/01.NEU.0000134558.28977.EE	36	94	101	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2009	80	8					916	920		10.1136/jnnp.2008.156596			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	471JT	WOS:000268054300019	19293171				2022-02-06	
J	Hemphill, JC; White, DB				Hemphill, J. Claude, III; White, Douglas B.			Clinical Nihilism in Neuroemergencies	EMERGENCY MEDICINE CLINICS OF NORTH AMERICA			English	Article						Prognosis; Do-not-resuscitate; Withdrawal of support; Intracerebral hemorrhage; Traumatic brain injury	INTENSIVE-CARE-UNIT; NOT-RESUSCITATE ORDERS; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; SEVERE HEAD-INJURY; OF-LIFE CARE; COMATOSE SURVIVORS; AMERICAN-ACADEMY; CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; TREATMENT PREFERENCES	Mortality and morbidity remain high from neurologic emergencies, such as acute stroke, traumatic brain injury, and hypoxic-ischemic encephalopathy after cardiac arrest. Decisions regarding initial aggressiveness of care must be made at the time of presentation, and perceived prognosis is often used as part of this decision-making process. These decisions are predicated on the accuracy of early outcome prediction, however. Decisions to limit treatment early after neuroemergencies must be balanced with avoidance of self-fulfilling prophecies of poor outcome attributable to clinical nihilism. This article examines the role of prognostication early after neuroemergencies, the potential impact of early treatment limitations, and how these may relate to communication with patients and surrogate decision makers in the context of these acute neurologic events.	[Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Neurocrit Care Program, San Francisco Gen Hosp, San Francisco, CA 94110 USA; [White, Douglas B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; [White, Douglas B.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94110 USA; [White, Douglas B.] Univ Calif San Francisco, San Francisco, CA 94143 USA		Hemphill, JC (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco Gen Hosp, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.	chemphill@sfgh.ucsf.edu	Demchuk, Andrew M/E-1103-2012; Hemphill, Claude/AAY-5630-2021	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS41240, U10NS058931, KL2RR024130]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041240, U10NS058931] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grants K23NS41240 and U10NS058931 (JCH) and grant KL2RR024130 from the National Center for Research Resources, a component of the NIH and NIH Roadmap for Medical Research (DBW).	Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Danis M, 1997, CRIT CARE MED, V25, P887; Danis M, 1998, NEW HORIZ-SCI PRACT, V6, P110; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Gregson BA, 2003, STROKE, V34, P2593, DOI 10.1161/01.STR.0000097491.82104.F3; Hemphill JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5687; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Holzer M, 2002, NEW ENGL J MED, V346, P549; Johnston SC, 2000, MUSCLE NERVE, V23, P839, DOI 10.1002/(SICI)1097-4598(200006)23:6<839::AID-MUS1>3.3.CO;2-M; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Levy MM, 2006, CRIT CARE MED, V34, pS306, DOI 10.1097/01.CCM.0000246096.18214.79; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; Lloyd CB, 2004, CRIT CARE MED, V32, P649, DOI 10.1097/01.CCM.0000115636.29294.2F; Luce JM, 2002, AM J RESP CRIT CARE, V165, P750, DOI 10.1164/ajrccm.165.6.2109045; Lyden PD, 2007, STROKE, V38, P2262, DOI 10.1161/STROKEAHA.106.472746; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mendelow AD, 2005, LANCET, V365, P387; Merton Robert K., 1968, SOCIAL THEORY SOCIAL, P477; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; Rocker G, 2004, CRIT CARE MED, V32, P1149, DOI 10.1097/01.CCM.0000126402.51524.52; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; Shepardson LB, 1999, J GEN INTERN MED, V14, P15, DOI 10.1046/j.1525-1497.1999.00275.x; Shepardson LB, 1997, ARCH INTERN MED, V157, P1841, DOI 10.1001/archinte.157.16.1841; TERES D, 1993, CRIT CARE MED, V21, P598, DOI 10.1097/00003246-199304000-00022; THOMAS W.I., 1928, CHILD AM, P572; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; Vetsch G, 2002, SWISS MED WKLY, V132, P190; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72; Zier LS, 2008, CRIT CARE MED, V36, P2341, DOI 10.1097/CCM.0b013e318180ddf9; Zurasky JA, 2005, NEUROLOGY, V64, P725, DOI 10.1212/01.WNL.0000152045.56837.58; [No title captured]	50	94	95	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8627			EMERG MED CLIN N AM	Emerg. Med. Clin. N. Am.	FEB	2009	27	1					27	+		10.1016/j.emc.2008.08.009			13	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	420MC	WOS:000264292900005	19218017	Green Accepted			2022-02-06	
J	Loetscher, PD; Rossaint, J; Rossaint, R; Weis, J; Fries, M; Fahlenkamp, A; Ryang, YM; Grottke, O; Coburn, M				Loetscher, Philip D.; Rossaint, Jan; Rossaint, Rolf; Weis, Joachim; Fries, Michael; Fahlenkamp, Astrid; Ryang, Yu-Mi; Grottke, Oliver; Coburn, Mark			Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury	CRITICAL CARE			English	Article							ORGANOTYPIC HIPPOCAMPAL CULTURES; NEURONAL CELL-DEATH; SLICE CULTURES; RECEPTOR ANTAGONISTS; GLUCOSE DEPRIVATION; UNITED-STATES; NOBLE-GASES; XENON; DAMAGE; NMDA	Introduction Recently, it has been shown in several experimental settings that the noble gases xenon and helium have neuroprotective properties. In this study we tested the hypothesis that the noble gas argon has a neuroprotective potential as well. Since traumatic brain injury and stroke are widespread and generate an enormous economic and social burden, we investigated the possible neuroprotective effect in in vitro models of traumatic brain injury and cerebral ischemia. Methods Organotypic hippocampal slice cultures from mice pups were subjected to either oxygen-glucose deprivation or to a focal mechanical trauma and subsequently treated with three different concentrations (25, 50 and 74%) of argon immediately after trauma or with a two-or-three-hour delay. After 72 hours of incubation tissue injury assessment was performed using propidium iodide, a staining agent that becomes fluorescent when it diffuses into damaged cells via disintegrated cell membranes. Results We could show argon's neuroprotective effects at different concentrations when applied directly after oxygen-glucose deprivation or trauma. Even three hours after application, argon was still neuroprotective. Conclusions Argon showed a neuroprotective effect in both in vitro models of oxygen-glucose deprivation and traumatic brain injury. Our promising results justify further in vivo animal research.	[Loetscher, Philip D.; Rossaint, Jan; Rossaint, Rolf; Fahlenkamp, Astrid; Ryang, Yu-Mi; Grottke, Oliver; Coburn, Mark] Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany; [Weis, Joachim] Rhein Westfal TH Aachen, Univ Hosp, Dept Neuropathol, D-52074 Aachen, Germany; [Fries, Michael] Rhein Westfal TH Aachen, Univ Hosp, Dept Surg Intens Care, D-52074 Aachen, Germany; [Ryang, Yu-Mi] Rhein Westfal TH Aachen, Univ Hosp, Dept Neurosurg, D-52074 Aachen, Germany		Coburn, M (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mcoburn@ukaachen.de	Grottke, Oliver/F-1508-2018; Weis, Joachim/G-1984-2014; Ryang, Yu-Mi/Q-8373-2016	Weis, Joachim/0000-0003-3280-6773; Ryang, Yu-Mi/0000-0002-9045-5038; Coburn, Mark/0000-0002-7930-0270; Grottke, Oliver/0000-0002-0722-3122	START program of the Medical Faculty of the RWTH Aachen	This research was conducted with funding by the START program of the Medical Faculty of the RWTH Aachen.; We thank Rosemarie Blaumeiser-Debarry for her help with data acquisition and the teams at the Departments of Neuropathology, Pathology and Animal Research at the University Hospital Aachen for expert laboratory advice, assistance and help.	AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Abraini JH, 2003, ANESTH ANALG, V96, P746, DOI 10.1213/01.ANE.0000050282.14291.38; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; [Anonymous], IMAGEJ IMAGE PROCESS; ASCHER P, 1987, TRENDS NEUROL SCI, V10, P8; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Behnke AR, 1939, AM J PHYSIOL, V126, P409, DOI 10.1152/ajplegacy.1939.126.2.409; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Galeffi F, 2000, J NEUROCHEM, V75, P1242, DOI 10.1046/j.1471-4159.2000.0751242.x; Goldberg MP, 1997, INT REV NEUROBIOL, V40, P69, DOI 10.1037/10225-004; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; KENNEDY RR, 1992, ANAESTH INTENS CARE, V20, P66, DOI 10.1177/0310057X9202000113; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Petzelt C, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-55; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; Preckel B, 2000, ANESTH ANALG, V91, P1327, DOI 10.1097/00000539-200012000-00003; Pringle AK, 1996, NEUROSCI LETT, V211, P203, DOI 10.1016/0304-3940(96)12745-2; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Scartabelli T, 2008, NEUROPHARMACOLOGY, V55, P509, DOI 10.1016/j.neuropharm.2008.06.019; Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011; Schwartz-Bloom RD, 2000, NEUROSCIENCE, V98, P471, DOI 10.1016/S0306-4522(00)00144-5; Soldatov P E, 1998, Aviakosm Ekolog Med, V32, P33; Sosin DM, 1996, BRAIN INJURY, V10, P47; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRASSER U, 1995, BRAIN RES, V687, P167, DOI 10.1016/0006-8993(95)00519-V; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trudell JR, 1998, ANESTH ANALG, V87, P411, DOI 10.1097/00000539-199808000-00034; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; Wise-Faberowski L, 2003, J NEUROSURG ANESTH, V15, P193, DOI 10.1097/00008506-200307000-00006; Xu J, 2008, NEUROPHARMACOLOGY, V54, P1029, DOI 10.1016/j.neuropharm.2008.01.014; Yarin YM, 2005, HEARING RES, V201, P1, DOI 10.1016/j.heares.2004.09.015; Zhang F, 2007, NEUROSCIENCE, V150, P938, DOI 10.1016/j.neuroscience.2007.09.070	57	94	101	0	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	6							R206	10.1186/cc8214			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	556DF	WOS:000274567900035	20017934	Green Published, gold			2022-02-06	
J	Berlac, P; Hyldmo, PK; Kongstad, P; Kurola, J; Nakstad, AR; Sandberg, M				Berlac, P.; Hyldmo, P. K.; Kongstad, P.; Kurola, J.; Nakstad, A. R.; Sandberg, M.			Pre-hospital airway management: guidelines from a task force from the Scandinavian Society for Anaesthesiology and Intensive Care Medicine	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						pre-hospital; airway management; endotracheal intubation; laryngeal mask airway; laryngeal tube airway; combitube; emergency medical systems	LARYNGEAL MASK AIRWAY; RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; ADVANCED LIFE-SUPPORT; BAG-VALVE-MASK; RESUSCITATION-COUNCIL GUIDELINES; ESOPHAGEAL-TRACHEAL COMBITUBE; CARDIOPULMONARY-RESUSCITATION; ENDOTRACHEAL INTUBATION; ANESTHETIZED PATIENTS	This article is intended as a generic guide to evidence-based airway management for all categories of pre-hospital personnel. It is based on a review of relevant literature but the majority of the studies have not been performed under realistic, pre-hospital conditions and the recommendations are therefore based on a low level of evidence (D). The advice given depends on the qualifications of the personnel available in a given emergency medical service (EMS). Anaesthetic training and routine in anaesthesia and neuromuscular blockade is necessary for the use of most techniques in the treatment of patients with airway reflexes. For anaesthesiologists, the Task Force commissioned by the Scandinavian Society of Anaesthesia and Intensive Care Medicine recommends endotracheal intubation (ETI) following rapid sequence induction when securing the pre-hospital airway, although repeated unsuccessful intubation attempts should be avoided independent of formal qualifications. Other physicians, as well as paramedics and other EMS personnel, are recommended the lateral trauma recovery position as a basic intervention combined with assisted mask-ventilation in trauma patients. When performing advanced cardiopulmonary resuscitation, we recommend that non-anaesthesiologists primarily use a supraglottic airway device. A supraglottic device such as the laryngeal tube or the intubation laryngeal mask should also be available as a backup device for anaesthesiologists in failed ETI.	[Berlac, P.] Capital Reg Denmark, Rigshosp, Copenhagen Mobile Intens Care Unit, Copenhagen, Denmark; [Hyldmo, P. K.] Sorlandet Hosp, Div Anaesthesia & Emergency Med, Kristiansand, Norway; [Kurola, J.] Kuopio Univ Hosp, Dept Anaesthesia & Intens Care, SF-70210 Kuopio, Finland; [Nakstad, A. R.] Ullevaal Univ Hosp, Dept Anaesthesiol, Oslo, Norway; [Sandberg, M.] Ullevaal Univ Hosp, Air Ambulance Dept, Lorenskog, Norway		Sandberg, M (corresponding author), Ullevaal Univ Hosp, Air Ambulance Dept, Sykehusveien 19, N-1474 Nordbyhagen, Norway.	marten.sandberg@gmail.com	Hyldmo, Per Kristian/AAF-4896-2020	Sandberg, Marten/0000-0002-4812-0103			Adnet F, 1998, ANN EMERG MED, V32, P454, DOI 10.1016/S0196-0644(98)70175-1; ALEXANDER R, 1993, ANAESTHESIA, V48, P231, DOI 10.1111/j.1365-2044.1993.tb06909.x; Ali J, 1997, J TRAUMA, V42, P786, DOI 10.1097/00005373-199705000-00006; Asai T, 2002, BRIT J ANAESTH, V89, P729, DOI 10.1093/bja/aef241; Blake WED, 2002, RESUSCITATION, V53, P289, DOI 10.1016/S0300-9572(02)00037-0; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Cook TM, 2006, RESUSCITATION, V69, P371, DOI 10.1016/j.resuscitation.2005.10.015; Cook TM, 2003, BRIT J ANAESTH, V91, P678, DOI 10.1093/bja/aeg239; Cook TM, 2003, ANAESTHESIA, V58, P191; Cook TM, 2001, ANAESTHESIA, V56, P660, DOI 10.1046/j.1365-2044.2001.01969.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; DAVIES PRF, 1990, LANCET, V336, P977, DOI 10.1016/0140-6736(90)92429-L; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Dickinson E T, 1999, Prehosp Emerg Care, V3, P191, DOI 10.1080/10903129908958935; DiRusso SM, 2005, J TRAUMA, V59, P84, DOI 10.1097/01.TA.0000171462.28379.F3; Doerges V, 1999, RESUSCITATION, V41, P63, DOI 10.1016/S0300-9572(99)00036-2; Donald MJ, 2006, EMERG MED J, V23, P728, DOI 10.1136/emj.2006.037184; Dorph E, 2004, RESUSCITATION, V61, P23, DOI 10.1016/j.resuscitation.2003.12.017; Driscoll P, 2005, EMERG MED J, V22, P2, DOI 10.1136/emj.2004.021212; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; FRASS M, 1988, CHEST, V93, P781, DOI 10.1378/chest.93.4.781; Gatward JJ, 2008, BRIT J ANAESTH, V100, P351, DOI 10.1093/bja/aem364; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Hadorn DC, 1996, J CLIN EPIDEMIOL, V49, P749, DOI 10.1016/0895-4356(96)00019-4; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Hein C, 2005, ANAESTH INTENS CARE, V33, P756, DOI 10.1177/0310057X0503300609; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Kette F, 2005, RESUSCITATION, V66, P21, DOI 10.1016/j.resuscitation.2004.12.023; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Kober A, 2004, ANESTH ANALG, V98, P206, DOI 10.1213/01.ANE.0000090145.73834.2F; KOKKINIS K, 1994, RESUSCITATION, V27, P9, DOI 10.1016/0300-9572(94)90015-9; Konrad C, 1998, ANESTH ANALG, V86, P635; Krafft P, 1998, ANESTH ANALG, V87, P1457, DOI 10.1097/00000539-199812000-00059; Kurola J, 2006, ACTA ANAESTH SCAND, V50, P40, DOI 10.1111/j.1399-6576.2005.00852.x; Kurola JO, 2005, ANESTH ANALG, V101, P1477, DOI 10.1213/01.ANE.0000182330.54814.70; Langhelle A, 2004, RESUSCITATION, V61, P9, DOI 10.1016/j.resuscitation.2003.12.008; LEACH A, 1993, RESUSCITATION, V25, P245, DOI 10.1016/0300-9572(93)90121-6; Lefrancois DP, 2002, RESUSCITATION, V52, P77, DOI 10.1016/S0300-9572(01)00441-5; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; MARTIN PD, 1993, ANAESTHESIA, V48, P33; McGlinch BP, 2004, ANN EMERG MED, V44, P320, DOI 10.1016/j.annemergmed.2004.05.022; Meyer PG, 2000, PAEDIATR ANAESTH, V10, P253, DOI 10.1046/j.1460-9592.2000.00496.x; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Nolan J D, 2001, Curr Opin Crit Care, V7, P413, DOI 10.1097/00075198-200112000-00008; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Ochs M, 2000, Prehosp Emerg Care, V4, P333, DOI 10.1080/10903120090941065; Ocker H, 2002, ANESTH ANALG, V95, P1094, DOI 10.1097/00000539-200210000-00057; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; Pelucio M, 1997, ACAD EMERG MED, V4, P563, DOI 10.1111/j.1553-2712.1997.tb03579.x; PENNANT JH, 1992, ANESTH ANALG, V75, P1074, DOI 10.1213/00000539-199212000-00046; PENNANT JH, 1992, ANESTH ANALG, V74, P531; Puntervoll SA, 2002, ACTA ANAESTH SCAND, V46, P455, DOI 10.1034/j.1399-6576.2002.460422.x; Rabitsch W, 2004, AM J EMERG MED, V22, P4, DOI 10.1016/j.ajem.2003.09.008; REINHART DJ, 1994, ANN EMERG MED, V24, P260, DOI 10.1016/S0196-0644(94)70139-3; Richards Christopher F., 1998, Journal of Emergency Medicine, V16, P37, DOI 10.1016/S0736-4679(97)00239-4; Rocca B, 2000, Prehosp Emerg Care, V4, P164, DOI 10.1080/10903120090941443; SAMARKANDI AH, 1994, RESUSCITATION, V28, P103, DOI 10.1016/0300-9572(94)90080-9; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stone BJ, 1998, RESUSCITATION, V38, P3, DOI 10.1016/S0300-9572(98)00068-9; Stoppacher R, 2004, J FORENSIC SCI, V49, P586; Tanigawa K, 1998, Prehosp Emerg Care, V2, P96, DOI 10.1080/10903129808958850; Vadeboncoeur TF, 2006, J EMERG MED, V30, P131, DOI 10.1016/j.jemermed.2005.04.019; Vaida SJ, 2004, ANESTH ANALG, V99, P124, DOI 10.1213/01.ANE.0000123492.26499.63; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916	70	94	94	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	AUG	2008	52	7					897	907		10.1111/j.1399-6576.2008.01673.x			11	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	323VB	WOS:000257475400004	18702752	Bronze			2022-02-06	
J	Sesma, HW; Slomine, BS; Ding, R; McCarthy, ML				Sesma, Heather Whitney; Slomine, Beth S.; Ding, Ru; McCarthy, Melissa L.		CHAT Study Grp	Executive functioning in the first year after pediatric traumatic brain injury	PEDIATRICS			English	Article						executive function/dysfunction; traumatic brain injury; cognitive function	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; QUALITY-OF-LIFE; BEHAVIOR PROBLEMS; WORKING-MEMORY; SHORT-TERM; CHILDREN; CHILDHOOD; ATTENTION; RECOVERY	BACKGROUND AND OBJECTIVE. Children with traumatic brain injuries often show impaired executive function (the ability to carry out goal-directed behavior). The Behavior Rating Inventory of Executive Function, a caregiver-report questionnaire, measures executive function in everyday activities. In this study, our goal was to use the Behavior Rating Inventory of Executive Function to document changes in children's executive function in the first year after traumatic brain injury and identify child, family, and injury variables associated with greater dysfunction. We predicted that children with traumatic brain injury would have more executive dysfunction than children hospitalized for orthopedic fractures and that more severe traumatic brain injury would predict greater dysfunction. Children's premorbid functioning and family characteristics were expected to moderate their executive function. PATIENTS AND METHODS. Caregivers of children aged 5 to 15 years (330 mild-to-severe traumatic brain injury, 103 control orthopedic fractures) enrolled onto a longitudinal study of executive function. Caregivers completed the Behavior Rating Inventory of Executive Function by telephone at baseline (obtained retrospectively) and 3 months and 1 year after the injury. RESULTS. Traumatic brain injury groups and controls showed no baseline differences in Behavior Rating Inventory of Executive Function scores. Three months after the injury, children with traumatic brain injury had more dysfunction than controls on the Global Executive Composite. One year after injury, all traumatic brain injury groups differed from the controls on the Behavioral Regulation Index, Metacognition Index, and Global Executive Composite. The working memory scale was the only scale to discriminate between the control group and all 3 traumatic brain injury severity groups at both 3 and 12 months after injury. Executive-function ratings remained stable from 3 to 12 months after injury. Across time points, preexisting learning/behavior problems, lower respondent education, and poor family functioning predicted greater Global Executive Composite dysfunction. CONCLUSIONS. Between 18% and 38% of the children with traumatic brain injury had significant executive dysfunction in the first year after injury, with greater dysfunction reported for children with more severe traumatic brain injury. Our findings support previous reports that preinjury learning and behavior problems, limited family resources, and poor family functioning adversely affect executive function. These results suggest a need for more systematic screening for executive dysfunction after traumatic brain injury to increase recognition of cognitive disability and improve access to appropriate services.	[Sesma, Heather Whitney] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Ding, Ru; McCarthy, Melissa L.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA		Sesma, HW (corresponding author), Univ Minnesota, Dept Pediat, Mayo Mail Code 486,420 Delaware St, Minneapolis, MN 55455 USA.	hwsesma@umn.edu	ding, ru/B-1615-2009	Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR319701] Funding Source: Medline		Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P842; *COMM INJ SCAL, 1990, ABBR INJ SCAL; CONKLIN H, 2006, 34 ANN M INT NEUR SO; Denckla MB., 1989, INT PEDIAT, V4, P155; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA IP, 2000, BEHAV RATING INVENTO; Glang A, 2004, NEUROREHABILITATION, V19, P219; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009	49	94	95	1	52	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2008	121	6					E1686	E1695		10.1542/peds.2007-2461			10	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	307IX	WOS:000256313700031	18519472				2022-02-06	
J	Qiu, W; Zhang, Y; Sheng, H; Zhang, JM; Wang, WM; Liu, WG; Chen, KY; Zhou, JF; Xu, ZF				Qiu, Wusi; Zhang, Ying; Sheng, Hong; Zhang, Jianmin; Wang, Weiming; Liu, Weiguo; Chen, Keyong; Zhou, Junfu; Xu, Zefeng			Effects of therapeutic mild hypothermia on patients with severe traumatic brain injury after craniotomy	JOURNAL OF CRITICAL CARE			English	Article						traumatic brain injury; hypothermia; craniotomy; intracranial pressure; superoxide dismutase; prognosis	SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; CLINICAL-TRIAL; CRITICAL-CARE; MANAGEMENT; CHILDREN; RODENTS	Purpose: We investigated the effects of therapeutic mild hypothermia on patients with severe traumatic brain injury after craniotomy (TBI). Methods: Eighty patients with severe TBI after unilateral craniotomy were randomized into a therapeutic hypothermia group with the brain temperature maintained at 33 degrees C to 35 degrees C for 4 days, and a normothermia control group in the intensive care unit. Vital signs, intracranial pressure, serum superoxide dismutase level, Glasgow Outcome Scale scores, and complications were prospectively analyzed. Results: The mean intracranial pressure values of the therapeutic hypothermia group at 24, 48, and 72 hours after injury were much lower than those of the control group (23.49 +/- 2.38, 24.68 +/- 1.71, and 22.51 +/- 2.44 vs 25.87 +/- 2.18, 25.90 +/- 1.86, and 24.57 +/- 3.95 mm Hg; P = .000, .000, and .003, respectively). The mean serum superoxide dismutase levels of the therapeutic hypothermia group at days 3 and 7 were much higher than those of the control group at the same time point (533.0 +/- 103.4 and 600.5 +/- 82.9 vs 458.7 +/- 68.1 and 497.0 +/- 57.3 mu g/L, respectively; P = .000). The percentage of favorable neurologic outcome 1 year after injury was 70.0% and 47.5%, respectively (P = .041). Complications, including pulmonary infections (57.5% in the therapeutic hypothermia group vs 32.5% in the control group; P = .025) were managed without severe sequelae. Conclusions: Therapeutic mild hypothermia provides a promising way in the intensive care unit for patients with severe TBI after craniotomy. (C) 2007 Elsevier Inc. All rights reserved.	[Qiu, Wusi; Zhang, Ying; Wang, Weiming] Hangzhou Hosp 2, Dept Neurosurg, Sch Med, Hangzhou Normal Coll, Hangzhou 310012, Peoples R China; [Qiu, Wusi; Sheng, Hong; Zhang, Jianmin; Liu, Weiguo; Zhou, Junfu; Xu, Zefeng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Brain Ctr, Hangzhou 310009, Peoples R China		Qiu, W (corresponding author), Hangzhou Hosp 2, Dept Neurosurg, Sch Med, Hangzhou Normal Coll, Hangzhou 310012, Peoples R China.	shihai954@163.com; sh_2nd@163.com					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2005, CRIT CARE MED, V33, P1890, DOI 10.1097/01.CCM.0000174103.99462.1E; Akinci OI, 2005, J CRIT CARE, V20, P66, DOI 10.1016/j.jcrc.2004.11.001; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Brooks AJ, 2005, INJURY, V36, P310, DOI 10.1016/j.injury.2004.09.023; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Hovland A, 2006, RESUSCITATION, V68, P143, DOI 10.1016/j.resuscitation.2005.05.019; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kinoshita K, 2003, ACTA NEUROCHIR SUPPL, V86, P373; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6; Zhou JF, 2002, BIOMED ENVIRON SCI, V15, P233	32	94	99	1	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	SEP	2007	22	3					229	235		10.1016/j.jcrc.2006.06.011			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256HO	WOS:000252719200008	17869973				2022-02-06	
J	Solomon, J; Raymont, V; Braun, A; Butman, JA; Grafman, J				Solomon, Jeffrey; Raymont, Vanessa; Braun, Allen; Butman, John A.; Grafman, Jordan			User-friendly software for the analysis of brain lesions (ABLe)	COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE			English	Article						brain lesion; cytoarchitecture; Brodmann areas; computer software; prefrontal cortex	IMAGE REGISTRATION; ATTENTION; INJURY	We previously developed a software package called ABLe (analysis of brain lesions) which characterizes brain lesions in terms of lesion volume and intersection with cytoarchitecture (e.g. Brodmann areas). Since our previous publication, there have been significant improvements to this software package which utilize methods standard to the neuroimaging community. These features include spatial normalization to the MNI template brain (standard of the international consortium for brain mapping), and use of the volume occupancy Talairach labels (VOTL) and automated anatomical labeling (AAL) atlases for full brain quantification of structures impacted by the lesion. Methods for multi-subject studies including lesion-symptom mapping proposed by Bates et al. have been extended in ABLe to produce an exploratory analysis summarizing correlations between subjects with overlapping lesions and behavioral deficit. A subset of data from an ongoing traumatic head injury study correlating deficit with brain anatomy is used to demonstrate the power of this software package. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Med Numer Inc, Germantown, MD USA; Henry M Jackson Fdn, Vietnam Head Injury Study, Bethesda, MD USA; NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; NIDCD, Language Sect, NIH, Bethesda, MD USA; NIH, Ctr Clin, Dept Diagnost Radiol, Bethesda, MD 20892 USA		Solomon, J (corresponding author), 20410 Observ Dr,Suite 210, Germantown, MD 20876 USA.	jsolomon@cc.nih.gov	Butman, John/J-2780-2013; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [Z01DC000031] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z99 CL999999, 001-0512-948] Funding Source: Medline		Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Cuadra MB, 2004, IEEE T MED IMAGING, V23, P1301, DOI 10.1109/TMI.2004.834618; Damasio H., 1989, LESION ANAL NEUROPSY; Delis DC., 2001, DELIS KAPLAN EXECUTI; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Frackowiak R.S.J., 2003, HUMAN BRAIN FUNCTION; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hill DLG, 2001, PHYS MED BIOL, V46, pR1, DOI 10.1088/0031-9155/46/3/201; Howell DC, 2001, STAT METHODS PSYCHOL; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Mah L, 2004, AM J PSYCHIAT, V161, P1247, DOI 10.1176/appi.ajp.161.7.1247; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rorden C, 2004, NAT REV NEUROSCI, V5, P813, DOI 10.1038/nrn1521; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sylvester CYC, 2003, NEUROPSYCHOLOGIA, V41, P357, DOI 10.1016/S0028-3932(02)00167-7; Talairach J., 1988, COPLANAR STEREOTAXIC; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wood JN, 2005, CORTEX, V41, P796, DOI 10.1016/S0010-9452(08)70298-3; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028	21	94	94	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-2607			COMPUT METH PROG BIO	Comput. Meth. Programs Biomed.	JUN	2007	86	3					245	254		10.1016/j.cmpb.2007.02.006			10	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Medical Informatics	170KV	WOS:000246663200006	17408802	Green Accepted			2022-02-06	
J	Diringer, MN; Aiyagari, V; Zazulia, AR; Videen, TO; Powers, WJ				Diringer, Michael N.; Aiyagari, Venkatesh; Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.			Effect of hyperoxia on cerebral metabolic rate for oxygen measured using positron emission tomography in patients with acute severe head injury	JOURNAL OF NEUROSURGERY			English	Article						severe head injury; cerebral metabolism; hyperoxia; oxygen	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; O-15 RADIOTRACERS; INSPIRED OXYGEN; MICRODIALYSIS; HYPERVENTILATION; REDUCTION; THERAPY; LACTATE	Object. Recent observations indicate that traumatic brain injury (TBI) may be associated with mitochondrial dysfunction. This, along with growing use of brain tissue PO, monitors, has led to considerable interest in the potential use of ventilation with 100% oxygen to treat patients who have suffered a TBI. To date, the impact of normobaric hyperoxia has only been evaluated using indirect measures of its impact on brain metabolism. To determine if normobaric hyperoxia improves brain oxygen metabolism following acute TBI, the authors directly measured the cerebral metabolic rate for oxygen (CMRO2) with positron emission tomography before and after ventilation with 100% oxygen. Methods. Baseline measurements of arterial and jugular venous blood gases, mean arterial blood pressure, intracranial pressure, cerebral blood flow (CBF), cerebral blood volume, oxygen extraction fraction, and CNIRO2 were made at baseline while the patients underwent ventilation with a fraction of inspired oxygen (FiO(2)) of 0.3 to 0.5. The FiO(2) was then increased to 1.0, and 1 hour later all measurements were repeated. Five patients were studied a mean of 17.9 +/- 5.8 hours (range 12-23 hours) after trauma. The median admission Glasgow Coma Scale score was 7 (range 3-9). During ventilation with 100% oxygen, there was a marked rise in PaO2 (from 117 +/- 31 to 371 +/- 99 mm Hg, p < 0.0001) and a small rise in arterial oxygen content (12.7 +/- 4.0 to 13.3 +/- 4.6 vol % = 0.03). There were no significant changes in systemic hemodynamic or other blood gas measurements. At the baseline evaluation, bihemispheric CBF was 39 +/- 12 ml/100 g/min and bihemispheric CMRO2 was 1.9 +/- 0.6 ml/100 g/min. During hyperoxia there was no significant change in either of these measurements. (Values are given as the mean +/- standard deviation throughout.) Conclusions. Normobaric hyperoxia did not improve brain oxygen metabolism. In the absence of outcome data from clinical trials, these preliminary data do not support the use of 100% oxygen in patients with acute TBI, although larger confirmatory studies are needed.	Washington Univ, Dept Neurol, St Louis, MO 63130 USA		Diringer, MN (corresponding author), Washington Univ, Dept Neurol, Campus Box 8111,600 S Euclid Ave, St Louis, MO 63130 USA.	diringerm@neuro.wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Aiyagari, Venkatesh/0000-0001-8139-3819	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS044885] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS044885] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [N535966] Funding Source: Medline		[Anonymous], 2000, J NEUROTRAUMA, V17, P463; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Cruz J, 2003, J NEUROSURG, V99, P1110; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Longhi Luca, 2004, Curr Opin Crit Care, V10, P105, DOI 10.1097/00075198-200404000-00005; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MINTUN MA, 1984, J NUCL MED, V25, P177; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; RAICHLE ME, 1983, J NUCL MED, V24, P790; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	26	94	96	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	APR	2007	106	4					526	529		10.3171/jns.2007.106.4.526			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	155OJ	WOS:000245586900003	17432700				2022-02-06	
J	Pickelsimer, EE; Selassie, AW; Sample, PL; Heinemann, AW; Gu, JK; Veldheer, LC				Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.; Sample, Pat L.; Heinemann, Allen W.; Gu, Ja K.; Veldheer, Linda C.			Unmet service needs of persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						barriers to receiving services; traumatic brain injury; unmet service needs	SUBSTANCE-ABUSE; MENTAL-HEALTH; LIFE SATISFACTION; HEAD-INJURY; ALCOHOL-USE; CARE; INDIVIDUALS; DISABILITY; AWARENESS; REHABILITATION	Objectives: Assess unmet needs of persons with traumatic brain injury (TBI) 1 year after hospital discharge; compare perceived need with needs based on deficits (unrecognized need); determine major barriers to services; evaluate association of needs with satisfaction with life. Participants: Representative sample of 1830 community-dwelling persons with TBI aged 15 years and older. Measures: Perceived and unrecognized unmet needs, barriers to receiving services, and satisfaction with life as a function of met service needs. Results: 35.2% of participants reported at least 1 unmet need, 51.5% had unrecognized needs, 47% reported at least 1 barrier to receiving help. Receipt of services significantly increased satisfaction with life. Conclusions: Many persons experiencing TBI report having unmet service needs 1 year after hospital discharge.	Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Colorado State Univ, Dept Occupat Therapy, Ft Collins, CO USA; Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA; Northwestern Univ, Dept Phys Med & Rehabil, Evanston, IL 60208 USA; Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL USA; S Carolina Dept Disabil & Special Needs, Columbia, SC USA		Pickelsimer, EE (corresponding author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, POB 250835,135 Cannon Str, Charleston, SC 29425 USA.	pickelse@musc.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BARRERA M, 1983, J COMMUNITY PSYCHOL, V11, P133, DOI 10.1002/1520-6629(198304)11:2<133::AID-JCOP2290110207>3.0.CO;2-L; Batavia AI, 2001, ARCH PHYS MED REHAB, V82, P546, DOI 10.1053/apmr.2001.20829; BERK ML, 1995, HEALTH AFFAIR, V14, P139, DOI 10.1377/hlthaff.14.3.139; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; CORRIGAN JD, 2006, PROBLEMATIC SUBSTANC; Craske MG, 2005, PSYCHIAT SERV, V56, P988, DOI 10.1176/appi.ps.56.8.988; DAMIANO AM, 1996, SIP USERS MANUAL; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; *INT CLASS DIS, 1996, CLIN MOD; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kraus J, 2000, HEAD INJURY, P1; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; LaPlante MP, 2004, J GERONTOL B-PSYCHOL, V59, pS98, DOI 10.1093/geronb/59.2.S98; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; *NAT CTR HLTH STAT, 1995, NAT HLTH INT SURV CU; Parslow RA, 2001, AUST NZ J PSYCHIAT, V35, P455, DOI 10.1046/j.1440-1614.2001.00924.x; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; Roy CW, 2002, BRAIN INJURY, V16, P1057, DOI 10.1080/02699050210154231; Sample PL, 2004, BRAIN INJURY, V18, P1177, DOI 10.1080/02699050410001719925; *SAS I INC, 2004, STAT AN SOFTW; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Schatz P, 1996, ARCH CLIN NEUROPSYCH, V11, P444; Schootman M, 1999, BRAIN INJURY, V13, P995; Smith J E, 2000, Care Manag J, V2, P27; SOKOL K, 1999, ARCH PHYS MED REHAB, V80, P974; Sturm R, 2001, J BEHAV HEALTH SER R, V28, P81, DOI 10.1007/BF02287236; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; *TRIAN INC, 1997, ICDMAP 90 SOFTW; US Department of Health and Human Service, 1999, TRAUM BRAIN INJ US R; *US GAO, 2001, GAOHEHS9855; WARE JE, 2000, SF36 HLTH SURVEY MAN; Woods J., 2002, LINKING PEOPLE TRAUM; YEATTS DE, 1992, GERONTOLOGIST, V32, P24, DOI 10.1093/geront/32.1.24	63	94	95	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2007	22	1					1	13		10.1097/00001199-200701000-00001			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	130SX	WOS:000243820400001	17235226				2022-02-06	
J	Van Landeghem, FKH; Weiss, T; Oehmichen, M; Von Deimling, A				Van Landeghem, Frank K. H.; Weiss, Thorsten; Oehmichen, Manfred; Von Deimling, Andreas			Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; glutamate; glutamate transporter; human; traumatic brain injury	AMINO-ACID RELEASE; MICROGLIA; ISCHEMIA; PROTEINS; PATTERNS; REVERSAL; GLT-1; EAAT2	The primary mechanism for eliminating synaptically released glutamate is uptake by astrocytes. In the present study, we examined whether traumatic brain injury (TBI) affects the cellular expression of glutamate transporters EAAT1 and EAAT2. Morphometrical immunohistochemical analysis demonstrated a predominant expression of EAAT1 and EAAT2 in astrocytes of normal human neocortex (n = 10). Following traumatic injury of human brain (n = 55), the number of EAAT2-positive cells was decreased for a prolonged survival period within the traumatized neocortex and the pericontusional region. GFAP-positive astrocytes decreased in number within the first 24 h. Thereafter, the number of GFAP-positive astrocytes increased again, indicating formation of reactive gliosis. Double immunofluorescence examinations revealed a reduction in absolute numbers of GFAP-positive astrocytes coexpressing EAAT1 or EAAT2 at survival times up to 7 days. In addition, the relative fractions of astrocytes coexpressing glutamate transporters decreased following TBI. We conclude that the posttraumatic reduction in cellular EAAT 1 and EAAT2 expression is predominantly due to degeneration of astrocytes and to down-regulation in surviving astrocytes. Our results support the view that reduced glutamate uptake by astrocytes contributes to posttraumatic elevation of extracellular glutamate in humans.	Charite Univ Med Berlin, Inst Neuropathol, D-13353 Berlin, Germany; Univ Kiel, Klinikum Schleswig Holstein, Inst Legal Med, Kiel, Germany		Van Landeghem, FKH (corresponding author), Charite Univ Med Berlin, Inst Neuropathol, Campus Virchow Klinikum,Augustenburger Platz 1, D-13353 Berlin, Germany.	frank.van_landeghem@charite.de	von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; van Landeghem, Frank/0000-0002-9404-7031			Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Domercq M, 1999, EUR J NEUROSCI, V11, P2226, DOI 10.1046/j.1460-9568.1999.00639.x; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Ikematsu K, 2002, FORENSIC SCI INT, V130, P83, DOI 10.1016/S0379-0738(02)00344-4; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; Li S, 1999, J Neurosci, V19, pRC16; LONGUEMARE MC, 1995, J NEUROSCI RES, V40, P379, DOI 10.1002/jnr.490400312; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Milton ID, 1997, MOL BRAIN RES, V52, P17, DOI 10.1016/S0169-328X(97)00233-7; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Privat Alain, 1995, P3; Rao VLR, 1998, J NEUROCHEM, V70, P2020; REYNOLDS R, 1986, BRAIN RES, V371, P253, DOI 10.1016/0006-8993(86)90361-6; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; RUTLEDGE EM, 1999, AM J PHYSIOL, V271, pC1511; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Suchak SK, 2003, J NEUROCHEM, V84, P522, DOI 10.1046/j.1471-4159.2003.01553.x; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takahashi M, 1997, J EXP BIOL, V200, P401; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Vermeiren C, 2005, J NEUROCHEM, V94, P405, DOI 10.1111/j.1471-4159.2005.03216.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; [No title captured]	42	94	95	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1518	1528		10.1089/neu.2006.23.1518			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500011	17020486				2022-02-06	
J	Berger, RP; Dulani, T; Adelson, PD; Leventhal, JM; Richichi, R; Kochanek, PM				Berger, RP; Dulani, T; Adelson, PD; Leventhal, JM; Richichi, R; Kochanek, PM			Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: A possible screening tool	PEDIATRICS			English	Article						biomarker; blood and CSF; neuron-specific enolase; child abuse; inflicted traumatic brain injury	COMPUTED-TOMOGRAPHY; PROTEIN S100B; CHILD-ABUSE; HEAD-INJURY; DAMAGE	OBJECTIVE. Inflicted traumatic brain injury (iTBI) is the leading cause of death from TBI in infants. Misdiagnosis of iTBI is common and results in increased morbidity and mortality. Biomarkers may be able to assist in screening infants who are at high risk for iTBI and whose injury might otherwise be missed. We investigated whether serum and/or cerebrospinal fluid (CSF) concentrations of neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP) are sensitive and specific for iTBI in high-risk infants. METHODS. A prospective case-control study was conducted of 98 well-appearing infants who presented with nonspecific symptoms and no history of trauma. Serum or CSF was collected. NSE, S100B, and MBP concentrations were measured by enzyme-linked immunosorbent assay. Abnormal marker concentrations were defined a priori. Patients were followed for 12 months to assess for subsequent abuse. RESULTS. Fourteen patients received a clinical diagnosis of iTBI. Using preestablished cutoffs, NSE was 77% sensitive and 66% specific and MBP was 36% sensitive and 100% specific for iTBI. S100B was neither sensitive nor specific for iTBI. Five patients who were not identified with iTBI at enrollment were identified at follow-up as being possible victims of abuse; 4 had an increased NSE concentration at enrollment. CONCLUSIONS. Serum and/or CSF concentrations of NSE and MBP may be useful as a screening test to identify infants who are at increased risk for iTBI and may benefit from additional evaluation with a head computed tomography scan. S100B is neither sensitive nor specific for iTBI in this study population. The ability to identify iTBI that might otherwise be missed has important implications for decreasing the morbidity and the mortality from iTBI.	Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, Pittsburgh, PA 15217 USA; Childrens Hosp Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15217 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Stat Anal & Measurement Consultants Inc, Lanexa, VA USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15217 USA.	rberger@pitt.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD43843-01] Funding Source: Medline; ODCDC CDC HHS [R49/CCR323155-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER		Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Benz MG, 2004, PEDIATRICS, V114, P205, DOI 10.1542/peds.114.1.205; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2002, NEUROSURG CLIN N AM, V13, P149, DOI 10.1016/S1042-3680(02)00002-5; Ellaway BA, 2004, ARCH DIS CHILD, V89, P845, DOI 10.1136/adc.2003.035493; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Motin VG, 2002, B EXP BIOL MED+, V133, P110, DOI 10.1023/A:1015518015515; Nikitin V P, 2002, Neurosci Behav Physiol, V32, P25, DOI 10.1023/A:1012992124052; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Pitetti RD, 2002, PEDIATRICS, V110, P557, DOI 10.1542/peds.110.3.557; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; *US DEP HHS, 1986, 872905 NIH; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9	26	94	104	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2006	117	2					325	332		10.1542/peds.2005-0711			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	014PC	WOS:000235491100009	16452350				2022-02-06	
J	Struve, J; Maher, PC; Li, YQ; Kinney, S; Fehlings, MG; Kuntz, C; Sherman, LS				Struve, J; Maher, PC; Li, YQ; Kinney, S; Fehlings, MG; Kuntz, C; Sherman, LS			Disruption of the hyaluronan-based extracellular matrix in spinal cord promotes astrocyte proliferation	GLIA			English	Article						gliosis; spinal cord; astrocyte; trauma; CD44; hyaluronan	CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER; RAT-BRAIN; REACTIVE ASTROCYTES; CHONDROITINASE ABC; NEURITE OUTGROWTH; BINDING PROTEIN; CARCINOMA-CELLS; ADULT-RAT; IN-VIVO	Astrocyte proliferation is tightly controlled during development and in the adult nervous system. In the present study, we find that a high-molecular-weight (MW) form of the glycosaminoglycan hyaluronan (HA) is found in rat spinal cord tissue and becomes degraded soon after traumatic spinal cord injury. Newly synthesized HA accumulates in injured spinal cord as gliosis proceeds, such that high-MW HA becomes overabundant in the extracellular matrix surrounding glial scars after 1 month. Injection of hyaluronidase, which degrades HA, into normal spinal cord tissue results in increased numbers of glial fibrillary acidic protein (GFAP)-positive cells that also express the nuclear proliferation marker Ki-67, suggesting that HA degradation Promotes astrocyte proliferation. In agreement with this observation, adding high- but not low-MW HA to proliferating astrocytes in vitro inhibits cell growth, while treating confluent, quiescent astrocyte cultures with hyaluronidase induces astrocyte proliferation. Collectively, these data indicate that high-MW HA maintains astrocytes in a state of quiescence, and that degradation of HA following CNS injury relieves growth inhibition, resulting in increased astrocyte proliferation. (c) 2005 Wiley-Liss, Inc.	Univ Cincinnati, Inst Neurosci, Dept Neurosurg, Cincinnati, OH 45221 USA; Mayfield Clin, Cincinnati, OH USA; Spine Inst, Cincinnati, OH USA; Hyaluron Inc, Burlington, MA USA; Univ Toronto, Div Neurosurg, Div Cell & Mol Biol, Toronto Western Res Inst,Krembil Neurosci Ctr, Toronto, ON, Canada		Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu		Fehlings, Michael/0000-0002-5722-6364	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00163] Funding Source: Medline		ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BIGNAMI A, 1992, INT J DEV NEUROSCI, V10, P45, DOI 10.1016/0736-5748(92)90006-L; BIGNAMI A, 1992, EXP NEUROL, V117, P90, DOI 10.1016/0014-4886(92)90115-7; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Cole R, 2001, PROTOCOLS NEURAL CEL, P117, DOI [10.1385/1-59259-207-4:117, DOI 10.1385/1-59259-207-4:117]; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; EGGLI PS, 1992, NEUROSCIENCE, V48, P737, DOI 10.1016/0306-4522(92)90417-Z; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Fitch MT, 2001, GLIAL CELL DEV, P263; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; GREENWALD RA, 1980, ARTHRITIS RHEUM-US, V23, P455, DOI 10.1002/art.1780230408; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; Jones LL, 1997, EUR J NEUROSCI, V9, P1854, DOI 10.1111/j.1460-9568.1997.tb00752.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Little AR, 2001, NEUROTOXICOLOGY, V22, P607, DOI 10.1016/S0161-813X(01)00032-8; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Liu Y, 2002, GLIA, V40, P25, DOI 10.1002/glia.10111; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Moon LDF, 2003, J NEUROSCI RES, V71, P23, DOI 10.1002/jnr.10449; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Rivlin A S, 1978, Surg Neurol, V10, P38; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Sherman LS, 2002, GLIA, V38, P93, DOI 10.1002/glia.10053; Sleeman JP, 1996, CANCER RES, V56, P3134; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; Tokita Y, 2001, J NEUROSCI, V21, P1257; TONA A, 1993, J NEUROSCI RES, V36, P191, DOI 10.1002/jnr.490360209; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tuohy TMF, 2004, GLIA, V47, P335, DOI 10.1002/glia.20042; VOGEL H, 1992, J NEUROCYTOL, V21, P363, DOI 10.1007/BF01191704; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3	47	94	96	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	OCT	2005	52	1					16	24		10.1002/glia.20215			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	964GJ	WOS:000231866800002	15892130				2022-02-06	
J	Bayir, H; Kagan, VE; Borisenko, GG; Tyurina, YY; Janesko, KL; Vagni, VA; Billar, TR; Williams, DL; Kochanek, PM				Bayir, H; Kagan, VE; Borisenko, GG; Tyurina, YY; Janesko, KL; Vagni, VA; Billar, TR; Williams, DL; Kochanek, PM			Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ascorbate; DAF-2; head injury; nitric oxide; nitrosative stress; oxidative stress	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CEREBROSPINAL-FLUID; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; S-NITROSYLATION; L-ARGININE; SELECTIVE-INHIBITION; SUPEROXIDE-DISMUTASE; PROTEIN NITRATION	Studies in experimental traumatic brain injury (TBI) suggests both deleterious and protective effects of inducible nitric oxide synthase (iNOS). Early after injury, iNOS may be detrimental via formation of peroxynitrite and iNOS inhibitors are protective. In contrast, we reported impaired long-term functional outcome after TBI in iNOS knockout (ko) versus wild-type (wt) mice. To elucidate potential neuroprotective and neurotoxic mechanisms for iNOS we studied nitric oxide formation by electron paramagnetic resonance (EPR) spectroscopy using diethyldithiocarbamate-iron (DETC-Fe) as a spin trap and markers of nitrosative (S-nitrosothiol (RSNO, Fluorescent assay); nitrotyrosine (3NT, ELISA )) and oxidative stress (ascorbate, HPLC) at 72 h after controlled cortical impact (CCI) in iNOS ko and wt and in uninjured iNOS ko and wt mice. 3NT immunostaining with macrophage and myeloperoxidase (MPO) dual labelling was also assessed in brain sections. Brain DETC-Fe-NO low-temperature EPR signal intensity was similar to 2-fold greater in wt versus iNOS ko at 72h after CCI. Ascorbate levels decreased in injured hemisphere in wt and iNOS ko versus uninjured -this decrease was more pronounced in NOS ko. In wt mice, RSNO and 3NT levels were increased after CCI versus uninjured (50% and 400%, respectively, P < 0.05). RSNO levels were not increased in iNOS ko after CCI. Nitrotyrosine levels increased after CCI in wt and ko versus respective uninjured -this increase was more pronounced in wt (2.34 +/- 0.95 versus 1.27 +/- 0.49 pmol/mg protein, P < 0.05). Increased 3NT immunoreactivity was detected in wt versus iNOS ko at 72 h after CCI, and colocalized with macrophage marker and Ill Our data support a role for iNOS-derived NO as an endogenous antioxidant after CCI. iNOS also contributes protein nitrosylation and nitration. Colocalization of 3NT with macrophages and MPO suggests generation of nitrating agents by macrophages and/or phagocytosis of nitrated proteins.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth & Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA		Bayir, H (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bavihx@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Tyurina, Yulia/0000-0003-0287-2091	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL64145] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER		Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003; Bolan EA, 2000, J NEUROSCI, V20, P4798; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BRAU RH, 1984, NEUROSURGERY, V14, P142, DOI 10.1227/00006123-198402000-00004; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Johnson MA, 2001, J BIOL CHEM, V276, P39872, DOI 10.1074/jbc.M102781200; Kagan VE, 2001, ANTIOXID REDOX SIGN, V3, P189, DOI 10.1089/152308601300185160; Kahl KG, 2004, NEUROSCI LETT, V358, P58, DOI 10.1016/j.neulet.2003.12.095; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1998, J IMMUNOL, V161, P4122; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kojima H, 1998, NEUROREPORT, V9, P3345, DOI 10.1097/00001756-199810260-00001; KUBRINA LN, 1992, BIOCHIM BIOPHYS ACTA, V1099, P233, DOI 10.1016/0005-2728(92)90032-W; Levy D, 2001, J NEUROPATH EXP NEUR, V60, P411, DOI 10.1093/jnen/60.5.411; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Okamoto H, 1998, STROKE, V29, P1209, DOI 10.1161/01.STR.29.6.1209; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sahrbacher UC, 1998, EUR J IMMUNOL, V28, P1332, DOI 10.1002/(SICI)1521-4141(199804)28:04<1332::AID-IMMU1332>3.0.CO;2-G; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Schulz JB, 1995, J NEUROSCI, V15, P8419; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sjakste N, 1999, BIOCHEM PHARMACOL, V58, P1955, DOI 10.1016/S0006-2952(99)00281-6; SPECTOR R, 1984, FED PROC, V43, P196; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Strong MJ, 1998, BIOCHEM BIOPH RES CO, V248, P157, DOI 10.1006/bbrc.1998.8930; TOMINAGA T, 1994, J CEREBR BLOOD F MET, V14, P715, DOI 10.1038/jcbfm.1994.92; Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu AM, 2000, HYPERTENSION, V36, P291, DOI 10.1161/01.HYP.36.2.291; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Zhao XR, 2000, BRAIN RES, V872, P215, DOI 10.1016/S0006-8993(00)02459-8; Zhu DY, 2003, J NEUROSCI, V23, P223	71	94	99	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2005	25	6					673	684		10.1038/sj.jcbfm.9600068			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	928BK	WOS:000229245900002	15716856	Bronze			2022-02-06	
J	Channon, S; Pellijeff, A; Rule, A				Channon, S; Pellijeff, A; Rule, A			Social cognition after head injury: Sarcasm and theory of mind	BRAIN AND LANGUAGE			English	Article						social cognition; frontal lobes; theory of mind; mentalising; pragmatic; sarcasm	BRAIN-DAMAGED PATIENTS; VERBAL IRONY; CHILDREN; LANGUAGE; IMPAIRMENTS; DYSFUNCTION; DECEPTION; INFERENCE; MEANINGS; DEFICITS	Closed head injury (CHI) is associated with communication difficulties in everyday social interactions. Previous work has reported impaired comprehension of sarcasm, using sarcastic remarks where the intended meaning is the opposite of the sincere or literal meaning. Participants with CHI in the present study were assessed using two types of sarcastic items, those with a directly opposite meaning and those with an indirect, non-literal but not directly opposite meaning. The CHI group was differentially poorer at comprehending sarcastic versus sincere remarks, although type of sarcastic materials did not influence performance. Errors involved not only literal interpretations, but also incorrect non-literal interpretations. Theory of mind (mentalising) was also assessed by comparing comprehension of human actions with control physical events. The CHI group was selectively impaired on the mentalising component of this task, and mentalising scores correlated with sarcasm comprehension. The implications of the findings for our understanding of impaired sarcastic comprehension after acquired brain injury are discussed. (c) 2004 Elsevier Inc. All rights reserved.	UCL, Dept Psychol, London, ON, Canada		Channon, S (corresponding author), UCL, Dept Psychol, London, ON, Canada.	s.channon@ucl.ac.uk	Channon, Shelley/C-1754-2008				Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bishop D. V., 1989, TEST RECEPTION GRAMM; BODY R, 1999, COMMUNICATION DISORD; BOSCO F, 2004, 26 ANN M COGN SCI SO; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Channon S, 2004, ACTA PSYCHOL, V115, P235, DOI 10.1016/j.actpsy.2003.12.008; CHANNON S, UNPUB COMPREHENSION; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Creusere MA, 1999, DEV REV, V19, P213, DOI 10.1006/drev.1998.0474; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J AUTISM DEV DISORD, V31, P47, DOI 10.1023/A:1005661613288; Dews S, 1996, CHILD DEV, V67, P3071, DOI 10.2307/1131767; DEWS S, 1995, METAPHOR SYMB ACT, V10, P3, DOI 10.1207/s15327868ms1001_2; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gibbs RW, 2002, J PRAGMATICS, V34, P457, DOI 10.1016/S0378-2166(01)00046-7; Gibbs RW., 2000, METAPHOR SYMBOL, V15, P5, DOI [10.1080/10926488.2000.9678862, DOI 10.1080/10926488.2000.9678862]; Giora R, 1999, J PRAGMATICS, V31, P919, DOI 10.1016/S0378-2166(98)00100-3; Grice H. P., 1975, SYNTAX SEMANTICS; Grice P., 1989, STUDIES WAY WORDS; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Jennett B, 1981, MANAGEMENT HEAD INJU; Jorgensen J, 1996, J PRAGMATICS, V26, P613, DOI 10.1016/0378-2166(95)00067-4; KATZ AN, 2000, METAPHOR SYMBOL, V15, P1; KREUZ RJ, 1989, J EXP PSYCHOL GEN, V118, P374, DOI 10.1037/0096-3445.118.4.374; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Mitchley N.J., 1998, COGNITIVE NEUROPSYCH, V3, P127, DOI [10.1080/135468098396206, DOI 10.1080/135468098396206]; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Ozonoff S, 1996, BRAIN LANG, V52, P411, DOI 10.1006/brln.1996.0022; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Shamay SG, 2002, BRAIN COGNITION, V48, P558, DOI 10.1006/brcg.2001.1417; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Sullivan K, 2003, DEV NEUROPSYCHOL, V23, P85, DOI 10.1207/S15326942DN231&2_5; WechslerD, 2001, WECHSLER TEST ADULT; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x	48	94	97	2	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	MAY	2005	93	2					123	134		10.1016/j.bandl.2004.09.002			12	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	913ZX	WOS:000228195300001	15781300				2022-02-06	
J	Vespa, P				Vespa, P			Continuous EEG monitoring for the detection of seizures in traumatic brain injury, infarction, and intracerebral hemorrhage: "To detect and protect"	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						seizures; brain injury; intracerebral hemorrhage; coma; stroke; continuous electroencephalography	INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL PERFUSION-PRESSURE; VENOUS OXYGEN-SATURATION; EXCITATORY AMINO-ACIDS; HEAD TRAUMA; MICRODIALYSIS; STROKE; EPILEPSY; INCREASE	Brain injury results in a primary pathophysiologic response that enables the brain to have seizures. Seizures occur frequently after traumatic and nontraumatic intracerebral bleeding. These seizures can be nonconvulsive, and if one does not monitor for seizures, one will not know they are occurring. The use of continuous EEG monitoring (cEEG) to detect brain arrhythmias after a primary insult, much in way that cardiac arrhythmias are detected after myocardial infarction, can influence treatment decisions and mitigate some of the pathophysiologic natural history of brain injuries. Seizures after brain injury worsen clinical outcome and need to be treated. In summary, cEEG is a valuable clinical instrument "to detect and protect," i.e., to detect seizures and protect the brain from seizure-related injury in critically ill patients, whose brains are often in a particularly vulnerable state.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, Los Angeles, CA 90095 USA		Vespa, P (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, 10833 Le Conte Ave,CHS 18-218, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu					ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Black P, 1975, CIBA F S, V34, P215; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DAVALOS A, 1992, CEREBROVASC DIS, V2, P327, DOI 10.1159/000109039; Drislane FW, 2000, EPILEPSY BEHAV, V1, P301, DOI 10.1006/ebeh.2000.0100; Enblad P, 1997, J NEUROL NEUROSUR PS, V62, P512, DOI 10.1136/jnnp.62.5.512; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; Kollevold T, 1976, J Oslo City Hosp, V26, P99; LANCMAN ME, 1993, EPILEPSIA, V34, P141, DOI 10.1111/j.1528-1157.1993.tb02386.x; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Litt Brian, 1994, Epilepsia, V35, P10; Miller J D, 1994, Neurosurg Clin N Am, V5, P661; OLSEN TS, 1987, NEUROLOGY, V37, P1209, DOI 10.1212/WNL.37.7.1209; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; Scholtes FB, 1996, J NEUROL NEUROSUR PS, V61, P93, DOI 10.1136/jnnp.61.1.93; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHIELDS D, 2004, ANN M AM ASS NEUR SU; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; Si Y, 1998, ELECTROEN CLIN NEURO, V106, P488, DOI 10.1016/S0013-4694(97)00154-5; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Young GB, 1996, NEUROLOGY, V47, P83	35	94	98	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	APR	2005	22	2					99	106		10.1097/01.WNP.0000154919.54202.E0			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	914CH	WOS:000228201800003	15805809				2022-02-06	
J	Jaeger, M; Soehle, M; Schuhmann, MU; Winkler, D; Meixensberger, J				Jaeger, M; Soehle, M; Schuhmann, MU; Winkler, D; Meixensberger, J			Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen	ACTA NEUROCHIRURGICA			English	Article						brain tissue oxygen; cerebral blood flow; thermal diffusion flowmetry; neuromonitoring	AUTOREGULATION; INJURY; PO2	Background. The purpose of this study was to investigate the relationship between continuously monitored regional cerebral blood flow (CBF) and brain tissue oxygen (PtiO2). Methods. Continuous advanced multimodal neuromonitoring including monitoring of PtiO2 (Licox, GMS) and CBF (QFlow, Hemedex) was performed in eight patients after severe subarachnoid haemorrhage (n = 5) and traumatic brain injury (n = 3) for an average of 9.6 days. Parameters were measured using a flexible polarographic PtiO2-probe and a thermal diffusion CBF-microprobe. Findings. Regarding the whole monitoring period in all patients, the data indicated a significant correlation between CBF and PtiO2 (r = 0.36). In 72% of 400 analysed intervals of 30 minutes duration with PtiO2 changes larger than 5 mmHg, a strong correlation between CBF and PtiO2 existed (r > 0.6). In 19% of intervals a still statistically significant correlation was observed (0.3 < r < 0.6). During the remaining 9% no correlation was found (r < 0.3). Regarding the clinical stability of the monitoring devices, the CBF monitoring system allowed monitoring of CBF in 64% of the time when PtiO2 monitoring was possible only. Phases of non-monitoring were mostly due to fever of the patient, when the system does not allow monitoring to avoid overheating of the cerebral tissue. Conclusions. This study suggests a correlation between CBF and PtiO2. The level of PtiO2 seems to be predominately determined by regional CBF, since changes in PtiO2 were correlated in 90% of episodes to simultaneous changes of CBF.	Univ Leipzig, Dept Neurosurg, D-7010 Leipzig, Germany; Univ Bonn, Dept Anaesthesiol & Intens Care Med, D-5300 Bonn, Germany		Jaeger, M (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Neurochirurgie, Liebigstr 20, D-04103 Leipzig, Germany.	jaem@medizin.uni-leipzig.de					Bardt TF, 1998, ACT NEUR S, V71, P153; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1996, ZBL NEUROCHIR, V57, P177; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	15	94	94	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2005	147	1					51	56		10.1007/s00701-004-0408-z			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	888JL	WOS:000226370100015	15565486				2022-02-06	
J	Brown, CVR; Weng, J; Oh, D; Salim, A; Kasotakis, G; Demetriades, D; Velmahos, GC; Rhee, P				Brown, CVR; Weng, J; Oh, D; Salim, A; Kasotakis, G; Demetriades, D; Velmahos, GC; Rhee, P			Does routine serial computed tomography of the head influence management of traumatic brain injury? - A prospective evaluation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blunt trauma; head injury; traumatic brain injury; computed tomography	CRITICALLY-ILL PATIENTS; INTRAHOSPITAL TRANSPORT; ADMISSION; NEED	Background. Computed tomography (CT) of the head is the current standard for diagnosing intracranial pathology following blunt head trauma. It is common practice to repeat the head CT to evaluate any progression of injury. Recent retrospective reviews have challenged the need for serial head CT after traumatic brain injury (TBI). This study intends to prospectively examine the value of routine serial head CT after TBI. Methods. consecutive adult blunt trauma patients with an abnormal head CT admitted to an urban, Level I trauma center from January 2003 to September 2003 were prospectively studied. Variables collected included: initial head CT results, indication for repeat head CT (routine versus neurologic change), number and results of repeat head CT scans, and clinical interventions following repeat head CT. Results: Over the 9-month period, there were 128 patients admitted with an abnormal head CT after sustaining blunt trauma. The 16 patients who died within 24 hours and the 12 patients who went directly to craniotomy were excluded. The remaining 100 patients make up the study population. Abnormal head CT findings were subarachnoid hemorrhage (47%), intraparenchymal hemorrhage (37%), subdural hematoma (28%), contusion (14%), epidural hematoma (11%), intraventricular hemorrhage (3%), and diffuse axonal injury (2%). Overall, 32 patients (32%) had only the admission head CT, while 68 patients (68%) underwent 90 repeat CT scans. Of the repeat head CT scans, 81 (90%) were performed on a routine basis without neurologic change. The remaining 9 (10%) were performed for a change in Glasgow Coma Scale (n = 5), change in intracranial pressure (n = 1), change in Glasgow Coma Scale and intracranial pressure (n = 1), change in pupil size (n = 1), or sudden appearance of a headache (n = 1). Three patients had their care altered after repeat head CT: two underwent craniotomy and one was started on barbiturate therapy. All three patients had their repeat head CT after neurologic change (decrease in Glasgow Coma Scale in 2 and increase in intracranial pressure in 1). Conclusions. Serial head CT is common after TBI. Most repeat head CT scans are performed on a routine basis without neurologic change. Few patients with TBI have their management altered after repeat head CT, and these patients have neurologic deterioration before the repeat head CT. The use of routine serial head CT in patients without neurologic deterioration is not supported by the findings of this study.	Los Angeles Cty, Div Trauma & Crit Care, Dept Surg, Los Angeles, CA USA; Univ So Calif, Med Ctr, Los Angeles, CA USA		Brown, CVR (corresponding author), 1200 N State St,Room 9900, Los Angeles, CA 90033 USA.	carlosbr@usc.edu		Oh, Daniel/0000-0002-2843-8077; Kasotakis, George/0000-0002-7630-0742			ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; KAUPS KL, 2003, ANN M AM ASS SURG TR; Nakamura T, 2003, CHEST, V123, P159, DOI 10.1378/chest.123.1.159; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Stearley H E, 1998, Am J Crit Care, V7, P282; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; VALADKA AB, 2000, TRAUMA, P385; WADDELL G, 1975, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.5968.417	16	94	96	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2004	57	5					939	943		10.1097/01.TA.0000149492.92558.03			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	878QD	WOS:000225660600003	15580014				2022-02-06	
J	Grossman, KJ; Goss, CW; Stein, DG				Grossman, KJ; Goss, CW; Stein, DG			Effects of progesterone on the inflammatory response to brain injury in the rat	BRAIN RESEARCH			English	Article						progesterone; traumatic brain injury; microglia; astrocyte; edema; neuronal survival	CEREBRAL-ARTERY OCCLUSION; FIBRILLARY ACIDIC PROTEIN; NITRIC-OXIDE SYNTHASE; CONTUSION INJURY; SPINAL-CORD; CORTICAL CONTUSION; REACTIVE GLIOSIS; CORTEX ABLATION; MICROGLIA; CNS	The effects of progesterone on the cellular inflammatory response to frontal cortex in jury were examined on Postsurgical days 1, 3 5, 7 and 9 in male rats treated with progesterone (4 mg/kg) and/or vehicle. Rats with bilateral contusions showed increased levels of edema on days I, 3 and 5, more reactive astrocytes on days 3, 5, 7 and 9, and more macrophages/activated microglia on days 1, 3, 5 and 9 compared to shams. The number of neurons in the medial dorsal nucleus (MDN) of the thalamus reduced on days 5 and 9 after injury compared to shams. Progesterone reduced edema levels and increased the accumulation of macrophages/activated microglia compared to vehicle controls (p<0.025); however, these changes in the inflammatory response were not related to MDN neuronal Survival. Our results Confirm the possibility that one way progesterone mediates its neuroprotective effects following injury is through its actions on the inflammatory response. (C) 2004 Elsevier B.V. All rights reserved.	Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA		Grossman, KJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	kgrossm@uchicago.edu	Stein, Donald/AAJ-5139-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS3866401A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664] Funding Source: NIH RePORTER		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BOLOVENTA B, 1992, PROG BRAIN RES, V94, P367; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HE J, 2001, J NEUROTRAUM, V18, P1140; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Keppel G., 1991, DESIGN ANAL RES HDB, P169; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kuebler JF, 2003, ARCH SURG-CHICAGO, V138, P727, DOI 10.1001/archsurg.138.7.727; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; MANNEL DN, 1990, IMMUNOL LETT, V26, P89, DOI 10.1016/0165-2478(90)90181-O; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; MORALI G, 2002, ABSTR SOC NEUR; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V86, P361, DOI 10.1016/0304-3940(88)90511-3; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Paxinos G., 1982, RAT BRAIN; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Ramos-Remus C, 2002, J INVEST MED, V50, P458, DOI 10.1136/jim-50-06-06; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; SMITH JS, 1998, J NEUROTRAUM, V15, P905; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	64	94	99	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 15	2004	1008	1					29	39		10.1016/j.brainres.2004.02.022			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817YD	WOS:000221211900004	15081379				2022-02-06	
J	Petersen, MA; Dailey, ME				Petersen, MA; Dailey, ME			Diverse microglial motility behaviors during clearance of dead cells in hippocampal slices	GLIA			English	Article						microglia; cell death; phagocytosis; brain slice; time-lapse imaging; cell motility	IN-VITRO MODEL; ADHESION MOLECULE EXPRESSION; COLONY-STIMULATING FACTOR; RAT FACIAL NUCLEUS; NERVOUS-SYSTEM; CULTURED MICROGLIA; RAMIFIED MICROGLIA; BRAIN MACROPHAGES; PROPIDIUM IODIDE; PHAGOCYTOSIS	We used two-channel three-dimensional time-lapse fluorescence confocal imaging in live rat hippocampal slice cultures (1-7 days in vitro) to determine the motility behaviors of activated microglia as they engage dead and dying cells following traumatic brain tissue injury. Live microglia were labeled with a fluorescently conjugated lectin (IB4), and dead neurons were labeled with a membrane-impermeant fluorescent DNA-binding dye (Sytox Orange or To-Pro-3). Tissue injury during the slicing procedure induced neuronal death and microglial activation, but the density of dead cells diminished similar to 10-fold by 7 days in vitro as resident microglia cleared dead cells. In time-lapse movies (4-20 h long), activated microglia exhibited varying levels of motile and locomotory activity. The motility of microglia could change abruptly following contact by other microglia or death of nearby cells. When neighboring cells died, some microglia rapidly moved toward or extended a process to engulf the dead cell, consistent with a chemotactic signaling response. Dead cell nuclei usually were engulfed and carried along by highly motile and locomoting microglia. The mean time to engulfment was similar to 5 times faster for newly deceased cells (33 min) than for extant dead cells (160 min), suggesting that the efficacy of microglial phagocytosis in situ might vary with time after cell death or mode of cell death. These observations demonstrate that activated microglia are heterogeneous with respect to motile activity following traumatic tissue injury and further indicate that cell motility in situ is temporally regulated at the single cell level, possibly by direct cell-cell contact and by diffusible substances emanating from nearby dead cells. (C) 2004 Wiley-Liss, Inc.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA		Dailey, ME (corresponding author), Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA.	michael-e-dailey@uiowa.edu	Petersen, Mark/AAN-5634-2020		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR017941] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43468, R01 NS043468] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER		ABDELBASSET EM, 1994, ACTA NEUROPATHOL, V88, P527, DOI 10.1007/BF00296489; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Bohatschek M, 2001, J NEUROSCI RES, V64, P508, DOI 10.1002/jnr.1103; BOOTH PL, 1991, CELL TISSUE RES, V266, P541, DOI 10.1007/BF00318596; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Calvo CF, 1996, EUR J NEUROSCI, V8, P1725, DOI 10.1111/j.1460-9568.1996.tb01316.x; Chan A, 2001, GLIA, V33, P87, DOI 10.1002/1098-1136(20010101)33:1<87::AID-GLIA1008>3.0.CO;2-S; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Grossmann R, 2002, GLIA, V37, P229, DOI 10.1002/glia.10031; HAAPANIEMI H, 1995, NEUROSCI LETT, V193, P121, DOI 10.1016/0304-3940(95)11683-N; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Hartlage-Rubsamen M, 2001, BRAIN RES, V897, P20, DOI 10.1016/S0006-8993(01)02093-5; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; MAJNO G, 1995, AM J PATHOL, V146, P3; MCGLADEMCCULLOH E, 1989, P NATL ACAD SCI USA, V86, P1093, DOI 10.1073/pnas.86.3.1093; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002; Moller T, 1997, J NEUROSCI, V17, P615; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Nolte C, 1997, EUR J NEUROSCI, V9, P1690, DOI 10.1111/j.1460-9568.1997.tb01526.x; Ohsawa K, 2000, J CELL SCI, V113, P3073; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SIEVERS J, 1994, GLIA, V12, P245, DOI 10.1002/glia.440120402; Skibo GG, 2000, NEUROSCIENCE, V96, P427, DOI 10.1016/S0306-4522(99)00562-X; Smith ME, 2000, J NEUROIMMUNOL, V102, P154, DOI 10.1016/S0165-5728(99)00218-0; SMITH SJ, 1990, 23 S MED HOECHST BIO, P49; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Takeda H, 1998, NEUROSCI LETT, V240, P5, DOI 10.1016/S0304-3940(97)00917-8; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Tomia Minoru, 1996, Keio Journal of Medicine, V45, P213; von Zahn J, 1997, NEUROREPORT, V8, P3851, DOI 10.1097/00001756-199712220-00003; WARD SA, 1991, J NEUROSCI RES, V29, P13, DOI 10.1002/jnr.490290103; Witting A, 2000, J NEUROCHEM, V75, P1060, DOI 10.1046/j.1471-4159.2000.0751060.x; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	58	94	97	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR 15	2004	46	2					195	206		10.1002/glia.10362			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	812RO	WOS:000220856800008	15042586				2022-02-06	
J	Lavoie, ME; Dupuis, F; Johnston, KM; Leclerc, S; Lassonde, M				Lavoie, ME; Dupuis, F; Johnston, KM; Leclerc, S; Lassonde, M			Visual P300 effects beyond symptoms in concussed college athletes	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; CEREBRAL CONCUSSION; LATENCY; COMPONENT; ATTENTION; FOOTBALL; PERFORMANCE; DYSFUNCTION	In order to assess whether cerebral anomalies may be observed in the absence of clinical symptoms, the current study compared the effects of concussions on attentional capacities (reaction times, accuracy) and Event-Related Potentials (ERPs) in concussed athletes with (n = 10) or without (n = 10) symptoms as well as in athletes who never had a concussion (n = 10). The P300 response was recorded from 28 electrodes during a modified visual oddball paradigm. Participants were instructed to press a key upon the appearance of the frequent stimuli as well as when a rare nontarget stimulus followed the frequent one. The other key was to be pressed when the subsequent rare stimuli (rare target) appeared until a frequent one reappeared. The symptomatic athletes displayed longer reaction times than the other two groups of athletes. The P300 amplitude to the rare target stimuli was significantly more attenuated in the symptomatic athletes than in the other two groups. Moreover, the P300 amplitude varied inversely with the severity of postconcussion symptoms but was not influenced by time elapsed since injury. Although the clinical significance of the P300 differences shown by the symptomatic athletes is still uncertain, the results do indicate that symptom severity may be a crucial indicator of functional impairments following mild traumatic brain injury.	Univ Montreal, Grp Rech Neuropsychol Expt, Canada Res Chair Dev Neuropsychol, Dept Psychol, Montreal, PQ H3W 1W5, Canada; McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ, Canada; Univ Montreal, Hop Louis H Lafontaine, Ctr Rech Fernand Seguin, Dept Psychiat, Montreal, PQ, Canada		Lassonde, M (corresponding author), Univ Montreal, Grp Rech Neuropsychol Expt, Canada Res Chair Dev Neuropsychol, Dept Psychol, CP 6128,Succ Centreville, Montreal, PQ H3W 1W5, Canada.	marc.lavoie@crfs.umontreal.ca; Maryse.Lassonde@umontreal.ca	Lavoie, Marc/M-4771-2019; Lavoie, Marc/G-2941-2013	Lavoie, Marc/0000-0002-3037-3890; Lavoie, Marc/0000-0002-3037-3890			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; BEGLEITER H, 1983, PSYCHOPHYSIOLOGY, V20, P95, DOI 10.1111/j.1469-8986.1983.tb00909.x; Blackwood DHR, 1996, BRIT J PSYCHIAT, V168, P85; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BRETON F, 1990, BIOL PSYCHOL, V31, P57, DOI 10.1016/0301-0511(90)90078-B; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Coles M. G. H., 1990, PRINCIPLES PSYCHOPHY, P413; Coles M. G. H., 1994, OX PSYCH S, P86; Coles MGH, 1996, OX PSYCH S, P1; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GEETS W, 1985, ACTA NEUROL BELG, V85, P277; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Greenham SL, 2000, BIOL PSYCHOL, V55, P79, DOI 10.1016/S0301-0511(00)00070-3; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; JOHNSON R, 1978, ELECTROEN CLIN NEURO, V44, P424, DOI 10.1016/0013-4694(78)90027-5; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; Katayama J, 1996, INT J PSYCHOPHYSIOL, V23, P33, DOI 10.1016/0167-8760(96)00030-X; Kaustio O, 2002, J AFFECT DISORDERS, V71, P43, DOI 10.1016/S0165-0327(01)00410-4; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KRAIUHIN C, 1990, BIOL PSYCHIAT, V28, P372, DOI 10.1016/0006-3223(90)90406-R; Kramer A., 1991, HDB COGNITIVE PSYCHO, P179; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LEVIT RA, 1973, PSYCHOL MED, V3, P487, DOI 10.1017/S0033291700054295; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MANDEL S, 1989, POSTGRAD MED, V85, P213; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; NAATANEN R, 1991, PSYCHOPHYSIOLOGY, V28, P478, DOI 10.1111/j.1469-8986.1991.tb00735.x; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; Parkinson D, 1996, SURG NEUROL, V45, P459, DOI 10.1016/0090-3019(95)00210-3; PATTERSON JV, 1988, ELECTROEN CLIN NEURO, V71, P450, DOI 10.1016/0168-5597(88)90049-4; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SARA G, 1994, J AFFECT DISORDERS, V31, P29, DOI 10.1016/0165-0327(94)90124-4; SHAGASS C, 1992, INT J PSYCHOPHYSIOL, V13, P255, DOI 10.1016/0167-8760(92)90075-M; Solbakk AK, 2002, CLIN ELECTROENCEPHAL, V33, P102, DOI 10.1177/155005940203300306; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Sullivan T E, 1994, J Neurosci Nurs, V26, P24; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; Weir N, 1998, SCHIZOPHR RES, V31, P151, DOI 10.1016/S0920-9964(98)00017-6; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	64	94	94	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2004	26	1					55	73		10.1076/jcen.26.1.55.23936			19	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	769TH	WOS:000188665500006	14972694				2022-02-06	
J	Nabors, N; Seacat, J; Rosenthal, M				Nabors, N; Seacat, J; Rosenthal, M			Predictors of caregiver burden following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; SOCIAL SUPPORT; FAMILY NEEDS; HEALTH; INDIVIDUALS; DIMENSIONS; STRESS; IMPACT	Primary objective: To investigate the relationship of demographic characteristics of the caregiver (i.e. race, age, household income, education) to caregiver burden, family needs, family functioning and social support to assess the predictors of caregiver burden. Research design: Information was obtained through mailed surveys and follow-up phone interviews. Methods and procedures: Participants were 24 African American and 21 White caregivers of individuals with traumatic brain injury who were at least 1-year post-injury. Measures administered included the Head Injury Family Interview, Family Needs Questionnaire, Family Assessment Device and the NON, a measure of social support. Main outcomes and results: Regression analyses revealed that importance of needs and percentage of needs met accounted for a significant amount of the variance in predicting affective/behavioural, cognitive and physical/dependency burden. Conclusions: Rehabilitation professionals need to provide support that includes ongoing assessment of needs and provides a resource for steering caregivers to potential sources for meeting those needs.	Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA		Nabors, N (corresponding author), Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA.						BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; HORWITZ AV, 1995, J HEALTH SOC BEHAV, V36, P138, DOI 10.2307/2137221; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KOSCIULEK JF, 1994, REHABIL COUNS BULL, V37, P244; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martin CD, 2000, J FAM ISSUES, V21, P986, DOI 10.1177/019251300021008003; MILLER B, 1991, J GERONTOL, V46, pS9, DOI 10.1093/geronj/46.1.S9; MILLER IW, 1983, J MARITAL FAMILY THE, V9, P171; Morey, 1991, PERSONALITY ASSESSME; Moules S, 1999, BRAIN INJURY, V13, P983; Panting A, 1972, REHABILITATION, V38, P33; PERRY CM, 1994, INT J AGING HUM DEV, V38, P41, DOI 10.2190/UQKB-EL57-TN8R-3W1A; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TURNER WL, 1994, J NATL MED ASSOC, V86, P915; Walker A E, 1972, Scand J Rehabil Med, V4, P5; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WITOL AS, 1996, MOD SYST BRAIN INJ C; YOUNG JB, 1995, ABNF J           MAY, P68	40	94	96	1	13	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2002	16	12					1039	1050		10.1080/02699050210155285			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	617KK	WOS:000179360700002	12487718				2022-02-06	
J	Kupina, NC; Nath, R; Bernath, EE; Inoue, J; Mitsuyoshi, A; Yuen, PW; Wang, KKW; Hall, ED				Kupina, NC; Nath, R; Bernath, EE; Inoue, J; Mitsuyoshi, A; Yuen, PW; Wang, KKW; Hall, ED			The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						calpain activation; calpain-mediated spectrin proteolysis; neuroprotection; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD INJURY; CLOSED-HEAD INJURY; AXONAL INJURY; SPECTRIN PROTEOLYSIS; RAT; NEURONS; CALCIUM; DEGRADATION	A principal mechanism of calcium-mediated neuronal injury is the activation of neutral proteases known as calpains. Proteolytic substrates for calpain include receptor and cytoskeletal proteins, signal transduction enzymes and transcription factors. Recently, calpain inhibitors have been shown to provide benefit in rat models of focal head injury and focal cerebral ischemia. The present study sought to investigate, in experiment 1, the time course of calpain-mediated cytoskeletal injury in a mouse model of diffuse head injury by measuring the 150- and 145-kDa alpha -spectrin breakdown products (SBDP). Secondly, in experiment 2, we examined the effect of early (20 min postinjury) administration of the novel calpain inhibitor SJA6017 on functional outcome measured 24 h following injury and its effect on posttraumatic ce-spectrin degradation. Lastly, in experiment 3, we examined the effect of delayed (4 or 6 h postinjury) administration of SJA6017 on 24-h postinjury functional outcome. In experiment 1, isoflurane-anesthetized male CF-1 mice (18-22 g) were subjected to a 750 g-cm weight drop-induced injury and were sacrificed for SBDP analysis at postinjury times of 30 min, and 1, 2, 6, 24 and 48 h (plus sham). In experiments 2 and 3, mice were injured as described, and delivered a single tail vein injection of either SJA6017 (0.3, 1, or 3 mg/kg) or vehicle (administered immediately, 4 or 6 h postinjury [3 mg/kg]). Functional outcome was evaluated in both studies, and, in experiment 2, 24-h postinjury assessment of SBDPs was determined. Following injury, the level of SBDP 145 was significantly different from sham at 24 and 48 h in cortical and at 24 h in the hippocampal tissues and at 48 h in the striatum. Immediate postinjury administration of SJA6017 resulted in a dose-related improvement in 24-h functional outcome (p < 0.05 at 3 mg/kg). Significance was maintained after a 4-h delay of the 3 mg/kg, but was lost after a 6-h delay. Despite improvement in functional outcome at 24 h, SJA6017 did not reduce spectrin breakdown in cortical or hippocampal tissues. These results support a role for calpain-mediated neuronal injury and the potential for a practical therapeutic window for calpain inhibition following traumatic brain injury. However, measurements of regional spectrin degradation may not be the most sensitive marker for determining the effects of calpain inhibition.	Pfizer Global Res & Dev, Ann Arbor Labs, Neurosci Therapeut, Ann Arbor, MI 48015 USA; Senju Pharmaceut Co Ltd, Kobe Creat Ctr, Kobe, Hyogo, Japan; Pfizer Global Res & Dev, Ann Arbor Labs, Neurosci Chem, Ann Arbor, MI 48015 USA		Hall, ED (corresponding author), Pfizer Global Res & Dev, Ann Arbor Labs, Neurosci Therapeut, 2800 Plymouth Rd, Ann Arbor, MI 48015 USA.	edward.hall@pfizer.com	Hall, Edward D/F-8930-2013	Wang, Kevin/0000-0002-9343-6473			Aronowski J, 1999, J CEREBR BLOOD F MET, V19, P652, DOI 10.1097/00004647-199906000-00008; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; HALL ED, 1998, CEREBROVASC DIS, P710; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Li PA, 1998, NEUROSCI LETT, V247, P17, DOI 10.1016/S0304-3940(98)00266-3; Liebetrau M, 1999, NEUROREPORT, V10, P529, DOI 10.1097/00001756-199902250-00016; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NIXON RA, 1989, ANN NY ACAD SCI, V568, P198; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur R, 1997, J NEUROCHEM, V68, P2328; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock JT, 1999, ACT NEUR S, V73, P15; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SHAPIRA Y, 1989, Neurological Research, V11, P169; Shields DC, 1999, J NEUROSCI RES, V55, P533, DOI 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Yuen Po-Wai, 1998, Drugs of the Future, V23, P741, DOI 10.1358/dof.1998.023.07.858362; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291	61	94	96	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2001	18	11					1229	1240		10.1089/089771501317095269			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	491KC	WOS:000172106700004	11721741	Green Submitted			2022-02-06	
J	Rao, VLR; Dogan, A; Todd, KG; Bowen, KK; Dempsey, RJ				Rao, VLR; Dogan, A; Todd, KG; Bowen, KK; Dempsey, RJ			Neuroprotection by memantine, a non-competitive antagonist after traumatic brain injury NMDA receptor in rats	BRAIN RESEARCH			English	Article						excitotoxicity; glutamate antagonist; memantine; neuroprotection; secondary neuronal death; traumatic brain injury	CHANNEL BLOCKER MEMANTINE; GLUTAMATE; ISCHEMIA; HYPOTHERMIA; ACTIVATION; EXPRESSION; SYMPTOMS; DEATH	This study investigated whether memantine, a non-competitive NMDA receptor antagonist is neuroprotective after traumatic brain injury (TBI) induced in adult rats with a controlled cortical impact device. TBI led to significant neuronal death in the hippocampal CA2 and CA3 regions (by 50 and 59%, respectively), by 7 days after the injury. Treatment of rats with memantine (10 and 20 mg/Kg, i.p.) immediately after the injury significantly prevented the neuronal loss in both CA2 and CA3 regions. This is the first study showing the neuroprotective potential of memantine to prevent the TBI-induced neuronal damage. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA; Univ Alberta, Dept Psychiat, Edmonton, AB, Canada		Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, H4-336 CSC,600 Highland Ave, Madison, WI 53792 USA.	dempsey@neurosurg.wisc.edu	Dogan, Aclan/AAF-8305-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220, NS28000] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER		Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dogan A, 1999, ACTA NEUROCHIR, V141, P1107, DOI 10.1007/s007010050491; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Ehrlich M, 1999, J THORAC CARDIOV SUR, V117, P285, DOI 10.1016/S0022-5223(99)70424-1; ERDO SL, 1991, EUR J PHARMACOL, V198, P215, DOI 10.1016/0014-2999(91)90625-Z; Heidrich A, 1997, FORTSCHR NEUROL PSYC, V65, P108, DOI 10.1055/s-2007-996315; Hesselink MB, 1999, PHARMACEUT RES, V16, P637, DOI 10.1023/A:1018856020583; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Krieglstein J, 1997, EUR J PHARM SCI, V5, P71, DOI 10.1016/S0928-0987(96)00257-6; LODGE D, 1991, TRENDS PHARMACOL SCI, P1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Mukhin A, 1996, J NEUROSCI, V16, P6012; Myseros JS, 1995, ANN NY ACAD SCI, V765, P262, DOI 10.1111/j.1749-6632.1995.tb16583.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Osborne NN, 1999, VISUAL NEUROSCI, V16, P45, DOI 10.1017/S0952523899161017; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; SCHNEIDER E, 1984, DEUT MED WOCHENSCHR, V109, P987, DOI 10.1055/s-2008-1069311; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Stieg PE, 1999, EUR J PHARMACOL, V375, P115, DOI 10.1016/S0014-2999(99)00214-9; WESEMANN W, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1243	30	94	99	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 17	2001	911	1					96	100					5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	468JC	WOS:000170753500012	11489449				2022-02-06	
J	Shavelle, RM; Strauss, D; Whyte, J; Day, SM; Yu, YL				Shavelle, RM; Strauss, D; Whyte, J; Day, SM; Yu, YL			Long-term causes of death after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						cause of death; life expectancy; maladaptive behavior; mortality; standardized mortality ratio	LIFE EXPECTANCY; PHYSICAL-ACTIVITY; CEREBRAL-PALSY; COLLEGE ALUMNI; MORTALITY; CHILDREN; MEN	Objective: To determine which causes of death are more frequent in persons with traumatic brain injury (TBI), and by how much, compared with the general population. Our focus was the period beginning 1 yr after injury. Design: Subjects were 2320 Californians with long-term mental disability after a TBI at age 10 yr or more, followed up between 1988 and 1997. The units of study were person-years, each linked to the subject's age, gender, level of ambulation, time since injury, and cause of death (if any) for the specific year. Observed numbers of cause-specific deaths were compared with numbers expected according to general population mortality rates. Results: Mortality was higher between 1.0 and 5.0 yr postinjury than after 5.0 yr and was strongly related to reduced mobility. Death rates were elevated for circulatory diseases, respiratory diseases, choking/suffocation, and seizures, with seizure deaths being relatively frequent, even among the most ambulatory. Conclusions: Death rates for several causes are elevated in persons with long-term sequelae of TBI, The increased risk of choking/suffocation should be of interest to caregivers. Life expectancy seems to be reduced, even for patients who are fully ambulatory.	Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Univ Hong Kong, Dept Med, Div Neurol, Hong Kong, Hong Kong, Peoples R China		Shavelle, RM (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.		Day, Steven/P-1002-2019	Day, Steven/0000-0001-8305-5813; Day, Marc/0000-0002-1711-3963; Whyte, John/0000-0002-4381-1474			ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; *CAL DEP DEV SERV, 1978, CLIENT DEV ED REP; *CONT SOFTW SYST I, 1995, INT CLASS DIS; DEVIVO DJ, 1995, SPINAL CORD INJURY C; HARRIS CW, 1982, INTERRATER RELIABILI; HUTTON JL, 1994, BRIT MED J, V309, P431, DOI 10.1136/bmj.309.6952.431; Kahn HA, 1989, STAT METHODS EPIDEMI; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lilienfeld A.M., 1980, FDN EPIDEMIOLOGY; MacKenzie E J, 1989, Md Med J, V38, P725; NEWMAN SC, 1991, CAN J PSYCHIAT, V36, P239, DOI 10.1177/070674379103600401; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; SHAVELLE RM, 1998, J INSURANCE MED, V30, P240; SINGER RB, 1992, MED SELECTION LIFE R, P58; *STAT CAL DEP FIN, 1988, RAC ETHN POP AG SEX; Strauss D, 1998, DEV MED CHILD NEUROL, V40, P369; Strauss D, 1999, J INSUR MED, V31, P104; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strauss DJ, 2000, J INSURANCE MED, V32, P11; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WIDAMAN DF, 1984, 92 ANN M AM PSYCH AS; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; CALIFORNIA WELFARE I; [No title captured]	28	94	94	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2001	80	7					510	516		10.1097/00002060-200107000-00009			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	442ZC	WOS:000169314000006	11421519				2022-02-06	
J	McCrory, PR; Ariens, M; Berkovic, SF				McCrory, PR; Ariens, M; Berkovic, SF			The nature and duration of acute concussive symptoms in Australian football	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; football; Australian; brain; wounds and injuries	RULES FOOTBALLERS	Objective: The purpose of this pilot study was to document the nature and temporal profile of the clinical symptoms of acute sport-related concussion. Design: Prospective cohort study Patient Population: A total of 303 elite Australian football players participating in a national competition during a single season. Outcome Measures: Number and duration of symptoms, digit symbol substitution test (DSST) scores, time of return to play post injury. Results: A total of 23 concussions were recorded over the course of the 20-week football season. No catastrophic head injuries occurred. Headache was the most common symptom and the most persistent, with 40% of players reporting headache symptoms lasting more than 15 minutes. Ten of the players (43%) returned to sport on the day of the injury with the remainder resuming play within 2 weeks. A low likelihood of return to play on the day of injury was found where 3 or more symptoms were present or where the symptoms lasted more than 15 minutes. These findings were significantly correlated with poor DSST performance. Conclusions: This pilot study suggests that both the number of postconcussive symptoms and their duration may be used as a measure of injury severity and a guide for return to play.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med Neurol, Heidelberg, Vic, Australia; Oakleigh Chargers Football Club, Oakleigh, Vic, Australia; Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia		McCrory, PR (corresponding author), 31 Grosvenor Rd, Balwyn, Vic 3004, Australia.		McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			Barth JT, 1989, MILD HEAD INJURY, P257; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; ORCHARD J, 1997, AFL INJURIES SEASON; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; WESCHLER D, 1981, WESCHLER ADULT INTEL	14	94	95	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	OCT	2000	10	4					235	238		10.1097/00042752-200010000-00002			4	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	389HK	WOS:000166232400002	11086747				2022-02-06	
J	Bernal-Sprekelsen, M; Bleda-Vazquez, C; Carrau, RL				Bernal-Sprekelsen, M; Bleda-Vazquez, C; Carrau, RL			Ascending meningitis secondary to traumatic cerebrospinal fluid leaks	AMERICAN JOURNAL OF RHINOLOGY			English	Article							FRONTAL SKULL BASE; MANAGEMENT; RHINORRHEA; DIAGNOSIS; LESIONS	Cerebrospinal fluid (CSF) leakage may cause immediate or delayed complications, such as ascending meningitis and brain abscess, potentially lethal complications that may appear years or decades after the trauma. Thus, the initial treatment of a CSF fistula may decisively influence long-term outcome. In a retrospective study including 1036 consecutive patients presenting with severe cranial trauma from May 1990 to March 1996, we identified 27 patients (2.6%) with CSF fistulas. Patients with a post-traumatic CSF leak were most commonly males between 15 and 40 years involved in a motor vehicle accident. The most common sites of injury were the frontal area and anterior skull base for those patients with rhinorrhea and the temporal bone for those patients with otorrhea. A transcranial repair was used for large cranial base defects (n = 10), while conservative treatment, comprised of bedrest, lumbar drainage, and medications, was used for smaller fistulas (n = 17). Four patients (40%) initially treated with a transcranial repair, and five patients (29%) initially treated conservatively, developed a meningitis. Therefore, neither the conservative approach nor the transcranial repair was able to prevent this considerable incidence of ascending meningitis. We believe that the high incidence of meningitis is not acceptable; thus, we are now evaluating early intervention using endoscopic techniques for the identification and/or repair of post-traumatic fistulas.	Hosp Clin Barcelona, Dept Otolaryngol, Barcelona, Spain		Bernal-Sprekelsen, M (corresponding author), Hosp Clin Barcelona, Serv ORL, C Villarroel 170, E-08036 Barcelona, Spain.		Bernal-Sprekelsen, Manuel/AAG-4299-2021; Bernal-Sprekelsen, Manuel/AAJ-7568-2021	Bernal-Sprekelsen, Manuel/0000-0001-8191-9833; 			Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; BERNAL M, 1994, CIRUGIA ENDOSCOPICA, P212; Choi D, 1996, BRIT J NEUROSURG, V10, P571, DOI 10.1080/02688699646880; Elverland Hans H., 1996, Tidsskrift for den Norske Laegeforening, V116, P3098; Gjuric M, 1998, HNO, V46, P205, DOI 10.1007/s001060050228; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; Kelley TF, 1996, NEUROSURGERY, V39, P743, DOI 10.1097/00006123-199610000-00019; KESSLER L, 1983, VERLETZUNGEN GESICHT; MESSERKLINGER W, 1972, HNO-WEGW FACHARZT PR, V20, P268; Moura-Ribeiro M V, 1992, Arq Neuropsiquiatr, V50, P199; Oberascher G, 1998, HNO, V46, P197, DOI 10.1007/s001060050225; Schick B, 1998, LARYNGO RHINO OTOL, V77, P144, DOI 10.1055/s-2007-996949; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; Simmen D, 1998, LARYNGO RHINO OTOL, V77, P264, DOI 10.1055/s-2007-996972; SIMON H, 1970, LARYN RHINOL OTOL, V59, P54; Spangenberg P, 1997, ANASTH INTENSIV NOTF, V32, P105, DOI 10.1055/s-2007-995018; Wax MK, 1997, OTOLARYNG HEAD NECK, V116, P442, DOI 10.1016/S0194-5998(97)70292-4	17	94	98	0	3	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1050-6586			AM J RHINOL	Am. J. Rhinol.	JUL-AUG	2000	14	4					257	259		10.2500/105065800779954473			3	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	347VG	WOS:000088949400009	10979500				2022-02-06	
J	Weise, J; Isenmann, S; Klocker, N; Kugler, S; Hirsch, S; Gravel, C; Bahr, M				Weise, J; Isenmann, S; Klocker, N; Kugler, S; Hirsch, S; Gravel, C; Bahr, M			Adenovirus-mediated expression of ciliary neurotrophic factor (CNTF) rescues axotomized rat retinal ganglion cells but does not support axonal regeneration in vivo	NEUROBIOLOGY OF DISEASE			English	Article							CENTRAL-NERVOUS-SYSTEM; IN-VIVO; GENE-TRANSFER; FACTOR PREVENTS; ADULT-RATS; OPTIC-NERVE; REGIONAL DISTRIBUTION; NEURONAL DEATH; MOTOR-NEURONS; MESSENGER-RNA	Rat optic nerve (ON) transection leads to mainly apoptotic cell death of about 85% of the retinal ganglion cell (RGC) population within 14 days after lesion. in the present study, we tested the effect of adenovirally delivered CNTF (Ad-CNTF) on survival and regeneration of axotomized adult RGCs in vivo. Single intravitreal Ad-CNTF injection led to stable CNTF mRNA and protein expression for at least 18 days and significantly enhanced RGC survival by 155% when compared to control animals 14 days after ON transection. ON stump application of Ad-CNTF also resulted in an increased number of surviving RGCs. Ad-CNTF injection led to better preservation of intraretinal RGC axons but did not support regeneration of axotomized RGCs into a peripheral nerve graft. Thus, adenovirus-mediated neurotrophic factor supply is a suitable approach for reducing axotomy-induced RGC death in vivo and may constitute a relevant strategy for clinical treatment of traumatic brain injury. (C) 2000 Academic Press.	Univ Tubingen, Sch Med, Dept Neurol, D-72076 Tubingen, Germany; Univ Laval, Ctr Rech, Quebec City, PQ, Canada		Weise, J (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, D-72076 Tubingen, Germany.		Baehr, Mathias/K-2188-2014; Isenmann, Stefan/AAJ-3788-2020				BAHR M, 1994, TRENDS NEUROSCI, V17, P473, DOI 10.1016/0166-2236(94)90136-8; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BUDENZ DL, 1995, INVEST OPHTH VIS SCI, V36, P2211; Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328; CARTER DA, 1989, J NEUROSCI, V9, P4042; Cayouette M, 1996, INVEST OPHTH VIS SCI, V37, P2022; Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423; Cayouette M, 1998, J NEUROSCI, V18, P9282; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; Clatterbuck RE, 1996, J COMP NEUROL, V369, P543, DOI 10.1002/(SICI)1096-9861(19960610)369:4<543::AID-CNE5>3.0.CO;2-4; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; ESCHWEILER GW, 1993, J NEUROL SCI, V116, P34, DOI 10.1016/0022-510X(93)90086-E; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Jo SA, 1999, NEUROSCIENCE, V89, P579, DOI 10.1016/S0306-4522(98)00546-6; KAHN MA, 1995, BRAIN RES, V685, P55, DOI 10.1016/0006-8993(95)00411-I; Kahn MA, 1997, DEV BRAIN RES, V98, P221, DOI 10.1016/S0165-3806(96)00180-0; Kermer P, 1998, J NEUROSCI, V18, P4656; KIRSCH M, 1994, NEUROSCI LETT, V180, P163, DOI 10.1016/0304-3940(94)90512-6; Kirsch M, 1997, J NEUROCHEM, V68, P979; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Kugler S, 1999, GENE THER, V6, P1759, DOI 10.1038/sj.gt.3301000; LE GLS, 1993, SCIENCE, V259, P988; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Lisovoski F, 1997, J NEUROSCI, V17, P7228; MAYER M, 1994, DEVELOPMENT, V120, P143; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; RAMON PP, 1996, INVEST OPHTH VIS SCI, V37, P489; Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691; ROBAEY SM, 1994, P NATL ACAD SCI USA, V91, P10319; Sakamoto T, 1998, HUM GENE THER, V9, P789, DOI 10.1089/hum.1998.9.6-789; Sawai H, 1996, J NEUROSCI, V16, P3887; SENDTNER M, 1994, J NEUROBIOL, V25, P1436, DOI 10.1002/neu.480251110; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VALENZUELA EG, 1994, J NEUROBIOL, V25, P431; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; Weise J, 2000, MICROSC RES TECHNIQ, V48, P55; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865	52	94	105	0	5	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUN	2000	7	3					212	223		10.1006/nbdi.2000.0285			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	329GW	WOS:000087899900007	10860786				2022-02-06	
J	Van den Heuvel, C; Blumbergs, PC; Finnie, JW; Manavis, J; Jones, NR; Reilly, PL; Pereira, RA				Van den Heuvel, C; Blumbergs, PC; Finnie, JW; Manavis, J; Jones, NR; Reilly, PL; Pereira, RA			Upregulation of amyloid precursor protein messenger RNA in response to traumatic brain injury: an ovine head impact model	EXPERIMENTAL NEUROLOGY			English	Article						amyloid precursor protein; head injury; experimental animal model; sheep; neuronal cell body; messenger RNA; in situ hybridization; immunocytochemistry	ALZHEIMERS-DISEASE; BETA-PROTEIN; RAT-BRAIN; NERVOUS-SYSTEM; TRANSCRIPTIONAL ACTIVATION; NEUROTROPHIC ACTIVITY; NEURITE OUTGROWTH; SECRETED FORMS; GENE; LOCALIZATION	There is evidence that the amyloid precursor protein (APP) plays an important role in neuronal growth and synaptic plasticity and that its increased expression following traumatic brain injury represents an acute phase response to trauma. We hypothesized that the previously described increased APP expression in response to injury (Van den Heuvel et al., Acta Neurochir. Suppl. 71., 209-211) is due to increased mRNA expression and addressed this by examining the expression of APP mRNA and APP within neuronal cell bodies over time in an ovine head impact model. Twenty-five anesthetized and ventilated 2-year-old Merino ewes sustained a left temporal head impact using a humane stunner and 9 normal sheep were used as nonimpact controls. Following postimpact survival periods of 15, 30, 45, 60, and 120 min, brains were perfusion fixed in 4% paraformaldehyde and examined according to standard neuropathological protocol. APP mRNA and antigen expression were examined in 5-mu m sections by nonisotopic in situ hybridization and APP immunocytochemistry. The percentage of brain area with APP immunoreactivity within neuronal cell bodies in the impacted animals increased with time from a mean of 7.5% at 15 min to 54.5% at 2 h. Control brains showed only very small numbers of weakly APP-positive neuronal cell bodies ranging from 2 to 14% (mean 7%). Increased expression of APP mRNA was first evident in impacted hemispheres at 30 min after impact and progressively increased over time to involve neurons in all sampled regions of the brain, suggesting increased transcription of APP. In contrast, APP mRNA was undetectable in tissue from nonimpacted sheep. These data show that APP mRNA and antigen expression are sensitive early indicators of neuronal injury with widespread upregulation occurring as early as 30 min after head impact. (C) 1999 Academic Press.	Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; Inst Med & Vet Sci, Dept Neuropathol, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Vet Div, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Infect Dis Lab, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA 5000, Australia		Van den Heuvel, C (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA, Australia.			, Corinna/0000-0003-0664-8935; Reilly, Peter/0000-0003-3173-0666			ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; ARTHUR J, 1993, J GEN VIROL, V74, P1363, DOI 10.1099/0022-1317-74-7-1363; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; BENDOTTI C, 1988, P NATL ACAD SCI USA, V85, P3628, DOI 10.1073/pnas.85.10.3628; Beyreuther K, 1996, ANN NY ACAD SCI, V777, P74, DOI 10.1111/j.1749-6632.1996.tb34403.x; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARD JP, 1988, NEURON, V1, P835, DOI 10.1016/0896-6273(88)90131-6; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; DEWJI NN, 1995, MOL BRAIN RES, V33, P245, DOI 10.1016/0169-328X(95)00131-B; Dewji NN, 1996, MOL BRAIN RES, V35, P325, DOI 10.1016/0169-328X(95)00214-D; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FARBER SA, 1995, J NEUROSCI, V15, P7442; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Griffin WST, 1998, BRAIN PATHOL, V8, P65; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAJIMOHAMMADREZA I, 1994, BRAIN RES, V640, P25, DOI 10.1016/0006-8993(94)91853-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Lin L, 1998, NEUROREPORT, V9, P547, DOI 10.1097/00001756-199802160-00030; LOWE J, 1990, NEUROPATH APPL NEURO, V16, P281, DOI 10.1111/j.1365-2990.1990.tb01263.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; Panegyres PK, 1998, J NEUROL SCI, V154, P123, DOI 10.1016/S0022-510X(97)00214-1; PEREIRA RA, 1994, J EXP MED, V180, P841, DOI 10.1084/jem.180.3.841; Pierce JES, 1996, J NEUROSCI, V16, P1083; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROCH JM, 1993, ANN NY ACAD SCI, V695, P149, DOI 10.1111/j.1749-6632.1993.tb23044.x; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANDYSWINSCH DC, 1994, BIOCONTROL SCI TECHN, V4, P269, DOI 10.1080/09583159409355335; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SCOTT JN, 1991, MOL BRAIN RES, V10, P315, DOI 10.1016/0169-328X(91)90090-K; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMALL DH, 1994, J NEUROSCI, V14, P2117; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Storey E, 1996, BRAIN RES, V735, P217, DOI 10.1016/0006-8993(96)00608-7; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TREJO J, 1994, J BIOL CHEM, V269, P21682; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; Wallace WC, 1997, MOL BRAIN RES, V52, P213, DOI 10.1016/S0169-328X(97)00259-3; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	64	94	96	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	1999	159	2					441	450		10.1006/exnr.1999.7150			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	246ED	WOS:000083150700010	10506515				2022-02-06	
J	Gale, SD; Hopkins, RO; Weaver, LK; Bigler, ED; Booth, EJ; Blatter, DD				Gale, SD; Hopkins, RO; Weaver, LK; Bigler, ED; Booth, EJ; Blatter, DD			MRI, quantitative MRI, SPECT, and neuropsychological findings following carbon monoxide poisoning	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; TOMOGRAPHY; DEPRESSION; ENCEPHALOPATHY; INTOXICATION; INTELLIGENCE; SEQUELAE; DEATHS; SLEEP; COPD	Carbon monoxide (CO) poisoning has been shown to result in neuropathologic changes and cognitive impairments due to anoxia and other related biochemical mechanisms. The present study investigated brain-behaviour relationships between neuropsychological outcome and SPECT, MRI, and Quantitative magnetic resonance imaging (QMRI) in 21 patients with CO poisoning. Ninety-three per cent of the patients exhibited a variety of cognitive impairments, including impaired attention, memory, executive function, and mental processing speed. Ninety-five per cent of the patients experienced affective changes including depression and anxiety. The results from the imaging studies revealed that 38% of the patients had abnormal clinical MRI scans, 67% had abnormal SPECT scans, and 67% had QMRI findings including hippocampal atrophy and/or diffuse cortical atrophy evidenced by an enlarged ventricle-to-brain ratio (VBI). Hippocampal atrophy was also found on QMRI. SPECT and QMRI appear to be sensitive tools which can be used to identify the neuropathological changes and cerebral perfusion defects which occur following CO poisoning. Cerebral perfusion defects include frontal and temporal lobe hypoperfusion. Significant relationships existed between the various imaging techniques and neuropsychological impairments. The data from this study indicate that a multi-faceted approach to clinical evaluation of the neuropathological and neurobehavioural changes following CO poisoning may provide comprehensive information regarding the neuroanatomical and neurobehavioural effects of CO poisoning.	Latter Day St Hosp, Dept Med, Crit Care Div, Salt Lake City, UT 84143 USA; Brigham Young Univ, Provo, UT 84602 USA; Univ Virginia, Charlottesville, VA 22903 USA		Hopkins, RO (corresponding author), Latter Day St Hosp, Dept Med, Crit Care Div, 8th Ave & C St, Salt Lake City, UT 84143 USA.		Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BARGER SD, 1991, UNDERSEA BIOMEDICA S, V18, P33; Beck AT, 1993, BECK ANXIETY INVENTO; Beck AT, 1987, BECK DEPRESSION INVE; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; CHANG KH, 1992, RADIOLOGY, V184, P117, DOI 10.1148/radiology.184.1.1609067; CHAPEL JL, 1978, PSYCHIAT OPINION MAR, P33; CHOI J, 1992, J KOREAN MED SCI, V7, P11; CHOI S, 1993, J KOREAN MED SCI, V8, P78; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; DEREUCK J, 1993, J NEUROL, V240, P430; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; FASCHINGBAUER TR, 1974, J CONSULT CLIN PSYCH, V42, P645, DOI 10.1037/h0037049; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GARLAND H, 1967, Q J MED, V36, P445; GIFT AG, 1993, HEART LUNG, V22, P289; GRAY BG, 1996, J NUCL MED, V37, P1605; GROLLKNAPP E, 1982, NEUROBEH TOXICOL TER, V4, P709; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAMPSON NB, 1997, UNDERSEA HYPERBARI S, V24, P21; Heaton RK, 1991, COMPREHENSIVE NORMS; Hopkins R O, 1995, J Int Neuropsychol Soc, V1, P501; Hopkins R. O., 1993, UNDERSEA HYPERBAR M, V20, P15; HOPKINS RO, 1991, UNDERSEA BIOMED RES, V18, P34; HOPKINS RO, 1997, UNDERSEA HYPERBAR M, V24, P20; HOPKINS RO, 1994, J INT NEUROPSYCH SOC, V2, P454; JACOB H, 1939, NEUROLOGIE PSYCHIAT, V139, P161; JAECKLE RS, 1985, J NERV MENT DIS, V173, P503, DOI 10.1097/00005053-198508000-00009; JAIN KK, 1990, CARBON MONOXIDE POIS; JARRARD LE, 1993, NEUROPATH APPL NEURO, V19, P381, DOI 10.1111/j.1365-2990.1993.tb00458.x; JEFFERSON JW, 1976, AM J PSYCHIAT, V133, P961; KALES A, 1985, J CHRON DIS, V38, P427, DOI 10.1016/0021-9681(85)90138-9; KELLY D A, 1990, Neuropsychology Review, V1, P323, DOI 10.1007/BF01109028; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LIGHT RW, 1985, CHEST, V87, P35, DOI 10.1378/chest.87.1.35; Mathieu D, 1996, UNDERSEA HYPERB MED, V23, P7; *MAY FDN, 1993, BIOM IM RES ANALYZE; MYERS RAM, 1985, ANN EMERG MED, V14, P1163, DOI 10.1016/S0196-0644(85)81022-2; NABESHIMA T, 1991, J PHARMACOL EXP THER, V256, P378; NAUGLE RI, 1998, INTRO CLIN NEUROPSYC; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; OKEDA R, 1981, ACTA NEUROPATHOL, V54, P1, DOI 10.1007/BF00691327; PIANTADOSI CA, 1987, J HYPERBARIC MED, V2, P27; Piantidosi CA, 1995, UNDERSEA HYPERBAR M, V22, P15; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; PRIGATANO GP, 1983, J CONSULT CLIN PSYCH, V51, P108, DOI 10.1037/0022-006X.51.1.108; RAPHAEL JC, 1989, LANCET          0819, P414; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; SMITH JS, 1973, BRIT MED J, V1, P318, DOI 10.1136/bmj.1.5849.318; THOM SR, 1993, TOXICOL APPL PHARM, V123, P234, DOI 10.1006/taap.1993.1242; THOM SR, 1990, J APPL PHYSIOL, V68, P997, DOI 10.1152/jappl.1990.68.3.997; THOM SR, ANN EMERGENCY MED, V23, P3; Tom T, 1996, J NEUROIMAGING, V6, P161, DOI 10.1111/jon199663161; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wilson J, 1996, J NUCL MED, V37, P1256; YELLOWLEES PM, 1987, MED J AUSTRALIA, V146, P305, DOI 10.5694/j.1326-5377.1987.tb120267.x; Yoon SS, 1998, JAMA-J AM MED ASSOC, V279, P685, DOI 10.1001/jama.279.9.685	66	94	97	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					229	243		10.1080/026990599121601			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400002	10230524				2022-02-06	
J	Gentleman, SM; Greenberg, BD; Savage, MJ; Noori, M; Newman, SJ; Roberts, GW; Griffin, WST; Graham, DI				Gentleman, SM; Greenberg, BD; Savage, MJ; Noori, M; Newman, SJ; Roberts, GW; Griffin, WST; Graham, DI			A beta(42) is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury	NEUROREPORT			English	Article						Alzheimer's disease; amyloid beta-protein; head injury; human; immunocytochemistry; vascular	FAMILIAL ALZHEIMERS-DISEASE; DEPOSITION; PRECURSOR; MUTATION; PEPTIDE	Fatal head injury results in the formation of diffuse parenchymal deposits of amyloid beta-protein (A beta) in the brains of approximately 30% of individuals. We used carboxyl terminal-specific antisera to examine the exact nature of these deposits in paraffin sections of neocortex from seven head-injured patients. Immunostaining for A beta(42) was observed in all parenchymal deposits whereas staining for A beta(40), the form of the protein which predominates in serum and cerebrospinal fluid, was seen in only a small proportion of deposits. The relative paucity of A beta(40) suggests that post-traumatic deposits do not arise as a result of passive leakage from damaged cerebral blood vessels but are similar to the early A beta(42) parenchymal deposits seen in Down's syndrome and Alzheimer's disease.	CEPHALON INC,W CHESTER,PA 19380; SMITHKLINE BEECHAM PHARMACEUT,MOL NEUROPATHOL RES,HARLOW CM19 5AW,ESSEX,ENGLAND; MCLELLAN VET AFFAIRS MED CTR,LITTLE ROCK,AR 72205; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,LANARK,SCOTLAND		Gentleman, SM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,ST DUNSTANS RD,LONDON W6 8RP,ENGLAND.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG012411] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12411] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GREENBERG BD, 1995, AMYLOID, V2, P195, DOI 10.3109/13506129509036927; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAUNDERS AM, 1993, P NATL ACAD SCI USA, V90, P8098; Savage MJ, 1995, AMYLOID, V2, P234, DOI 10.3109/13506129508999005; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEKOE DJ, 1994, ANN REV NEUROSCI, V17, P489; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290	18	94	95	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	APR 14	1997	8	6					1519	1522		10.1097/00001756-199704140-00039			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XB174	WOS:A1997XB17400041	9172166				2022-02-06	
J	Kitchen, P; Salman, MM; Halsey, AM; Clarke-Bland, C; MacDonald, JA; Ishida, H; Vogel, HJ; Almutiri, S; Logan, A; Kreida, S; Al-Jubair, T; Missel, JW; Gourdon, P; Tomroth-Horsefield, S; Conner, MT; Ahmed, Z; Conner, AC; Bill, RM				Kitchen, Philip; Salman, Mootaz M.; Halsey, Andrea M.; Clarke-Bland, Charlotte; MacDonald, Justin A.; Ishida, Hiroaki; Vogel, Hans J.; Almutiri, Sharif; Logan, Ann; Kreida, Stefan; Al-Jubair, Tamim; Missel, Julie Winkel; Gourdon, Pontus; Tomroth-Horsefield, Susanna; Conner, Matthew T.; Ahmed, Zubair; Conner, Alex C.; Bill, Roslyn M.			Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema	CELL			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; X-RAY-STRUCTURE; WATER PERMEABILITY; BARRIER PERMEABILITY; CORTICAL ASTROCYTES; CALMODULIN-BINDING; CEREBRAL EDEMA; CELL-VOLUME; CHANNEL	Swelling of the brain or spinal cord (CNS edema) affects millions of people every year. All potential pharmacological interventions have failed in clinical trials, meaning that symptom management is the only treatment option. The water channel protein aquaporin-4 (AQP4) is expressed in astrocytes and mediates water flux across the blood-brain and blood-spinal cord barriers. Here we show that AQP4 cell-surface abundance increases in response to hypoxia-induced cell swelling in a calmodulin-dependent manner. Calmodulin directly binds the AQP4 carboxyl terminus, causing a specific conformational change and driving AQP4 cell-surface localization. Inhibition of calmodulin in a rat spinal cord injury model with the licensed drug trifluoperazine inhibited AQP4 localization to the blood-spinal cord barrier, ablated CNS edema, and led to accelerated functional recovery compared with untreated animals. We propose that targeting the mechanism of calmodulin-mediated cell-surface localization of AQP4 is a viable strategy for development of CNS edema therapies.	[Kitchen, Philip; Clarke-Bland, Charlotte; Bill, Roslyn M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Salman, Mootaz M.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Salman, Mootaz M.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA; [Salman, Mootaz M.] Univ Mosul, Coll Pharm, Dept Pharmacol, Mosul 41002, Iraq; [Halsey, Andrea M.; Almutiri, Sharif; Logan, Ann; Ahmed, Zubair] Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Neurosci & Ophthalmol, Birmingham B15 2TT, W Midlands, England; [MacDonald, Justin A.; Vogel, Hans J.] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4Z6, Canada; [Ishida, Hiroaki; Vogel, Hans J.] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 4N1, Canada; [Almutiri, Sharif] Shaqra Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Shaqra, Saudi Arabia; [Kreida, Stefan; Al-Jubair, Tamim; Tomroth-Horsefield, Susanna] Lund Univ, Dept Biochem & Struct Biol, POB 124, S-22100 Lund, Sweden; [Missel, Julie Winkel; Gourdon, Pontus] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen, Denmark; [Gourdon, Pontus] Lund Univ, Dept Expt Med Sci, POB 118, S-22100 Lund, Sweden; [Conner, Matthew T.] Univ Wolverhampton, Sch Sci, Res Inst Healthcare Sci, Wolverhampton WV1 1LY, England; [Conner, Alex C.] Univ Birmingham, Coll Med & Dent Sci, Inst Clin Sci, Birmingham B15 2TT, W Midlands, England		Bill, RM (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.; Ahmed, Z (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Neurosci & Ophthalmol, Birmingham B15 2TT, W Midlands, England.; Conner, AC (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Clin Sci, Birmingham B15 2TT, W Midlands, England.	z.ahmed.1@bham.ac.uk; a.c.conner@bham.ac.uk; r.m.bill@aston.ac.uk	Salman, Mootaz M./J-3111-2019; Ahmed, Zubair/AAN-1869-2021; Bill, Roslyn M/D-4554-2012; Kitchen, Philip/J-6936-2019; Jubair, Tamim Al/P-8642-2016	Salman, Mootaz M./0000-0002-5683-1706; Bill, Roslyn M/0000-0003-1331-0852; Kitchen, Philip/0000-0002-1558-4673; Jubair, Tamim Al/0000-0001-6954-5293; Missel, Julie Winkel/0000-0002-9727-1274	Biotechnology & Biosciences Research Council [BB/P025927/1]; Aston University; BiogenBiogen; International Spinal Research Trust [NRB116]; Saudi Education Ministry in London [SHU11]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2013-05945]; Crafoord Foundation [20140811, 20180916]; Magnus Bergvall Foundation [2015-01534]; Knut and Alice Wallenburg FoundationKnut & Alice Wallenberg Foundation; Lundbeck FoundationLundbeckfonden; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/P025927/1] Funding Source: UKRI	We acknowledge grants from the Biotechnology & Biosciences Research Council (to R.M.B., A.C.C., and P.K. through BB/P025927/1); Aston University (to P.K. through a 50th Anniversary Prize Fellowship); Biogen (to M.M.S. through funding to Prof. Tomas Kirchhausen); the International Spinal Research Trust (to A.H., A.L., and Z.A. through NRB116); the Saudi Education Ministry in London (to Z.A. and S.A. through SHU11); the Swedish Research Council (to S.T.-H. through 2013-05945); the Crafoord Foundation (to S.T.-H. through 20140811 and 20180916); the Magnus Bergvall Foundation (to S.T.-H. through 2015-01534); the Knut and Alice Wallenburg Foundation (to P.G.); the Lundbeck Foundation (to P.G.); and the Natural Sciences and Engineering Research Council of Canada (to H.J.V. and J.A.M.). We thank Prof. Sara Linse (Lund University), for recombinantly expressed human CaM and Prof. Tomas Kirchhausen, Dr. Florian Winau, and Prof. John Flanagan (Harvard Medical School) for constructive discussions regarding our study.	Abir-Awan M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071589; Allahyari R.V., 2015, JOVE-J VIS EXP, V100; Almutiri S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29124-z; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Chu HL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081249; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Creese I, 1996, J NEUROPSYCH CLIN N, V8, P223; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Esmaeili M, 2014, NEURAL REGEN RES, V9, P1653, DOI 10.4103/1673-5374.141797; Fagoe ND, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150141; Farr GW, 2019, NEUROSCIENCE, V404, P484, DOI 10.1016/j.neuroscience.2019.01.034; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Frick A, 2014, P NATL ACAD SCI USA, V111, P6305, DOI 10.1073/pnas.1321406111; Gonen T, 2004, NATURE, V429, P193, DOI 10.1038/nature02503; GOODMAN JH, 1976, J NEUROSURG, V44, P418, DOI 10.3171/jns.1976.44.4.0418; Gopalakrishnan MS, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00977; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108; Harries WEC, 2004, P NATL ACAD SCI USA, V101, P14045, DOI 10.1073/pnas.0405274101; Heller Stefan, 2007, P113; Hiroaki Y, 2006, J MOL BIOL, V355, P628, DOI 10.1016/j.jmb.2005.10.081; Ho JD, 2009, P NATL ACAD SCI USA, V106, P7437, DOI 10.1073/pnas.0902725106; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; Horsefield R, 2008, P NATL ACAD SCI USA, V105, P13327, DOI 10.1073/pnas.0801466105; Hoshi Y, 2018, J NEUROSCI, V38, P5700, DOI 10.1523/JNEUROSCI.2888-17.2018; HUERTABAHENA J, 1983, MOL PHARMACOL, V23, P67; Jha RM, 2019, NEUROPHARMACOLOGY, V145, P230, DOI 10.1016/j.neuropharm.2018.08.004; Jo AO, 2015, J NEUROSCI, V35, P13525, DOI 10.1523/JNEUROSCI.1987-15.2015; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Kitchen P, 2015, J BIOL CHEM, V290, P16873, DOI 10.1074/jbc.M115.646034; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kreida S, 2015, CURR OPIN STRUC BIOL, V33, P126, DOI 10.1016/j.sbi.2015.08.004; Kuppers E, 2008, EUR J NEUROSCI, V28, P2173, DOI 10.1111/j.1460-9568.2008.06531.x; Lafrenaye AD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020330; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Li S, 1999, SPINAL CORD, V37, P820, DOI 10.1038/sj.sc.3100941; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Luan Q, 2018, MED SCI MONITOR, V24, P5391, DOI 10.12659/MSM.910191; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MCKEON TA, 1991, ANAL BIOCHEM, V193, P125, DOI 10.1016/0003-2697(91)90051-T; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; National Institute for Health and Care Excellence (NICE), 2019, BRIT NATL FORMULARY; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; O'Connell DJ, 2010, MOL CELL PROTEOMICS, V9, P1118, DOI 10.1074/mcp.M900324-MCP200; Oberg F, 2011, MOL MEMBR BIOL, V28, P398, DOI 10.3109/09687688.2011.602219; Offringa R, 2013, J INTEGR PLANT BIOL, V55, P789, DOI 10.1111/jipb.12096; Oklinski MK, 2014, J HISTOCHEM CYTOCHEM, V62, P598, DOI 10.1369/0022155414537495; Orellana JA, 2010, GLIA, V58, P329, DOI 10.1002/glia.20926; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Bordone MP, 2019, J NEUROCHEM, V151, P139, DOI 10.1111/jnc.14829; Qin J, 2009, PFLUG ARCH EUR J PHY, V458, P643, DOI 10.1007/s00424-009-0658-y; Rabaud NE, 2009, BIOCHEM BIOPH RES CO, V383, P54, DOI 10.1016/j.bbrc.2009.03.128; Raslan Ahmed, 2007, Neurosurg Focus, V22, pE12; Reichow SL, 2008, STRUCTURE, V16, P1389, DOI 10.1016/j.str.2008.06.011; Reichow SL, 2013, NAT STRUCT MOL BIOL, V20, P1085, DOI 10.1038/nsmb.2630; Rosenberg GA, 1999, PROG CARDIOVASC DIS, V42, P209, DOI 10.1016/S0033-0620(99)70003-4; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Salman MM, 2017, EUR J NEUROSCI, V46, P2542, DOI 10.1111/ejn.13723; Salman MM, 2017, EUR J NEUROSCI, V46, P2121, DOI 10.1111/ejn.13652; Sanabra C, 2011, J CHEM NEUROANAT, V41, P43, DOI 10.1016/j.jchemneu.2010.11.001; Sansing LH, 2011, NEUROCRIT CARE, V14, P395, DOI 10.1007/s12028-010-9498-z; Sato T, 2003, J PHARMACOL EXP THER, V304, P1042, DOI 10.1124/jpet.102.045039; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Slovinska L., 2016, IN VITRO MODELS SPIN, DOI [10.5772/63459, DOI 10.5772/63459]; Stefanetti Renae J, 2018, F1000Res, V7, DOI 10.12688/f1000research.15258.1; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stokum JA, 2015, NEUROCHEM RES, V40, P317, DOI 10.1007/s11064-014-1374-3; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Surey S, 2014, NEUROSCIENCE, V275, P62, DOI 10.1016/j.neuroscience.2014.06.003; Tang GH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101413; Tani K, 2009, J MOL BIOL, V389, P694, DOI 10.1016/j.jmb.2009.04.049; TANOKURA M, 1986, J BIOL CHEM, V261, P749; Tidow H, 2013, FEBS J, V280, P5551, DOI 10.1111/febs.12296; Tong JH, 2012, BIOPHYS J, V103, P1899, DOI 10.1016/j.bpj.2012.09.025; Torre-Healy A, 2012, NEUROCRIT CARE, V17, P117, DOI 10.1007/s12028-011-9649-x; Tseng WC, 2008, ANAL BIOCHEM, V375, P376, DOI 10.1016/j.ab.2007.12.013; Ullah S, 2016, SCI REP-UK, V6, DOI 10.1038/srep23534; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Vella J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00108; Verkman AS, 2017, EXPERT OPIN THER TAR, V21, P1161, DOI 10.1080/14728222.2017.1398236; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Werten PJL, 2001, FEBS LETT, V504, P200, DOI 10.1016/S0014-5793(01)02703-X; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Yang BX, 1997, BIOCHEMISTRY-US, V36, P7625, DOI 10.1021/bi970231r; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	104	93	93	28	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2020	181	4					784	+		10.1016/j.cell.2020.03.037			35	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LO4UD	WOS:000533623900007	32413299	Green Published, hybrid, Green Accepted	Y	N	2022-02-06	
J	Chen, CK; Wu, YT; Chang, YC				Chen, Chang-Kai; Wu, Yung-Tsan; Chang, Yu-Chao			Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study	ALZHEIMERS RESEARCH & THERAPY			English	Article						Alzheimer's disease; Periodontitis; Risk factors; Nationwide population; Cohort study	SUGGESTS INCREASED RISK; COGNITIVE DECLINE; TOOTH LOSS; DEMENTIA; INFLAMMATION; ATHEROSCLEROSIS; THERAPY; LINK	Background: Although recent short-term cross-sectional studies have revealed that chronic periodontitis (CP) may be a risk factor for increased cognitive impairment in patients with Alzheimer's disease (AD), systematic reviews and long-term longitudinal studies have provided less clear evidence regarding the relationship between CP and AD. Therefore, we conducted a retrospective cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan to determine whether patients with CP are at increased risk of developing AD. Methods: We conducted a retrospective matched-cohort study using the NHIRD of Taiwan. We identified 9291 patients newly diagnosed with CP between 1997 and 2004. A total of 18,672 patients without CP were matched to the patient cohort according to sex, age, index year, co-morbidity and urbanisation level. Cox proportional hazards regression analyses were performed to evaluate the subsequent risk of AD. Results: Patients with CP had a higher prevalence of hyperlipidaemia, depression, traumatic brain injury and co-morbidities, as well as higher urbanisation levels, than those in the unexposed cohort (all p < 0.01). At the final follow-up, totals of 115 (1.24%) and 208 (1.11%) individuals in the CP exposed and unexposed groups, respectively, had developed AD. Patients with 10 years of CP exposure exhibited a higher risk of developing AD than unexposed groups (adjusted HR 1.707, 95% CI 1.152-2.528, p = 0.0077). Conclusions: Our findings demonstrate that 10-year CP exposure was associated with a 1.707-fold increase in the risk of developing AD. These findings highlight the need to prevent progression of periodontal disease and promote healthcare service at the national level.	[Chen, Chang-Kai; Chang, Yu-Chao] Chung Shan Med Univ, Sch Dent, 110,Sect 1,Jianguo N Rd, Taichung 40201, Taiwan; [Chen, Chang-Kai] Kaohsiung Armed Forces Gen Hosp, Sect Dent, Zuoying Branch, Kaohsiung, Taiwan; [Wu, Yung-Tsan] Triserv Gen Hosp, Natl Def Med Ctr, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, Yu-Chao] Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan		Chang, YC (corresponding author), Chung Shan Med Univ, Sch Dent, 110,Sect 1,Jianguo N Rd, Taichung 40201, Taiwan.; Chang, YC (corresponding author), Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan.	cyc@csmu.edu.tw					Abbayya K, 2015, N AM J MED SCI, V7, P241, DOI 10.4103/1947-2714.159325; Al-Shammari KF, 2005, J PERIODONTOL, V76, P1910, DOI 10.1902/jop.2005.76.11.1910; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Burke SL, 2016, INT PSYCHOGERIATR, V28, P1409, DOI 10.1017/S1041610216000405; Campos CH, 2017, J ORAL REHABIL, V44, P178, DOI 10.1111/joor.12476; Campos CH, 2017, CLIN ORAL INVEST, V21, P573, DOI 10.1007/s00784-016-1923-z; Chan WSH, 2010, EPMA J, V1, P563, DOI 10.1007/s13167-010-0056-8; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; D'Aiuto F, 2005, Int J Immunopathol Pharmacol, V18, P1; Gaur S, 2015, GERIATR GERONTOL INT, V15, P391, DOI 10.1111/ggi.12425; Gil-Montoya JA, 2015, J PERIODONTOL, V86, P244, DOI 10.1902/jop.2014.140340; Helmer C, 2011, NEUROLOGY, V77, P2043, DOI 10.1212/WNL.0b013e31823b4765; Honig LS, 2005, NEUROLOGY, V64, P494, DOI 10.1212/01.WNL.0000150886.50187.30; Hsu CC, 2011, J ALZHEIMERS DIS, V24, P485, DOI 10.3233/JAD-2011-101524; Huang CY, 2015, CURR ALZHEIMER RES, V12, P287, DOI 10.2174/1567205012666150302155536; Huang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087095; Ide M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151081; Kamer AR, 2008, ALZHEIMERS DEMENT, V4, P242, DOI 10.1016/j.jalz.2007.08.004; Lakschevitz F, 2011, CURR DIABETES REV, V7, P433, DOI 10.2174/157339911797579205; Lee YT, 2017, J AM GERIATR SOC, V65, P301, DOI 10.1111/jgs.14449; Lin RT, 1998, J NEUROL SCI, V160, P67, DOI 10.1016/S0022-510X(98)00225-1; Liu CY, 2006, J HEALTHC MANAG, V4, P1, DOI DOI 10.29805/JHM.200606.0001; Liu TC, 2013, MOVEMENT DISORD, V28, P1307, DOI 10.1002/mds.25359; Llibre R., 2008, LANCET, V372, P464, DOI DOI 10.1016/S0140-6736(08)61002-8; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Martande SS, 2014, AM J ALZHEIMERS DIS, V29, P498, DOI 10.1177/1533317514549650; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Cervantes CM, 2017, NEUROLOGIA, V32, P309, DOI 10.1016/j.nrl.2015.12.006; Paraskevas S, 2008, J CLIN PERIODONTOL, V35, P277, DOI 10.1111/j.1600-051X.2007.01173.x; Passoja A, 2010, J CLIN PERIODONTOL, V37, P881, DOI 10.1111/j.1600-051X.2010.01602.x; Peng DT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003727; Roher AE, 2003, ARTERIOSCL THROM VAS, V23, P2055, DOI 10.1161/01.ATV.0000095973.42032.44; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Teles R, 2011, ORAL DIS, V17, P450, DOI 10.1111/j.1601-0825.2010.01784.x; Tonsekar PP, 2017, GERODONTOLOGY, V34, P151, DOI 10.1111/ger.12261; Tzeng NS, ARE CHRONIC PERIODON; Uppoor AS, 2013, GERODONTOLOGY, V30, P239, DOI 10.1111/j.1741-2358.2012.00660.x; Vanhanen M, 2006, NEUROLOGY, V67, P843, DOI 10.1212/01.wnl.0000234037.91185.99; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Watts Amber, 2008, Neuropsychiatr Dis Treat, V4, P865; Wen BW, 2014, QJM-INT J MED, V107, P283, DOI 10.1093/qjmed/hct248; WONG CS, 2016, MEDICINE, V95; Yan Q, 2003, J NEUROSCI, V23, P7504	44	93	99	3	43	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.	AUG 8	2017	9								56	10.1186/s13195-017-0282-6			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FD1KQ	WOS:000407296600001	28784164	Green Published, gold			2022-02-06	
J	Ashayeri, K; Jackson, EM; Huang, J; Brem, H; Gordon, CR				Ashayeri, Kimberly; Jackson, Eric M.; Huang, Judy; Brem, Henry; Gordon, Chad R.			Syndrome of the Trephined: A Systematic Review	NEUROSURGERY			English	Article						Craniofacial reconstruction; Cranioplasty; Decompressive craniectomy; Neurosurgery; Rehabilitation; Syndrome of the trephined; Systematic review	SINKING SKIN-FLAP; DECOMPRESSIVE CRANIECTOMY; PARADOXICAL HERNIATION; CRANIOPLASTY; SECONDARY; COMPLICATIONS; RECOVERY; BRAIN; IMPROVEMENT; HEMICRANIECTOMY	BACKGROUND: Syndrome of the trephined (SoT) is a rare, important complication of a craniectomy characterized by neurological dysfunction that improves with cranioplasty. Its varied symptoms include motor, cognitive, and language deficits. Its exact characterization appears suboptimal, with differing approaches of evaluation. Accordingly, this topic is in great need of further investigation. OBJECTIVE: To accurately describe SoT and explore methods of an objective diagnosis/evaluation. METHODS: Electronic searches of PubMed, MEDLINE, Web of Knowledge, and Psy-cINFO databases used the key words "syndrome of the trephined" and "sinking skin flap." Non-English-language and duplicate articles were eliminated. Title and abstract reviews were selected for relevance. Full-text reviews were selected for articles providing individual characteristics of SoT patients. RESULTS: This review identified that SoT most often occurs in male patients (60%) at 5.1 +/- 10.8 months after craniectomy for neurotrauma (38%). The average reported craniectomy is 88.3 +/- 34.4 cm(2) and usually exists with a "sunken skin flap" (93%). Symptoms most commonly include motor, cognitive, and language deficits (57%, 41%, 28%, respectively), with improvement after cranioplasty within 3.8 +/- 3.9 days. Functional independence with activities of daily living is achieved by 54.9% of patients after 2.9 +/- 3.4 months of rehabilitation. However, evaluation of SoT is inconsistent, with only 53% of reports documenting objective studies. DISCUSSION: SoT is a variable phenomenon associated with a prolonged time to cranioplasty. Due to current weaknesses in objectivity, we hypothesize that SoT is often underdiagnosed and recommend a multifaceted approach for consistent evaluation. CONCLUSION: SoT is a serious complication that lacks exact characterization and deserves future investigation. Improved understanding and recognition have important implications for early intervention and patient outcomes.	[Ashayeri, Kimberly] Albert Einstein Coll Med, New York, NY USA; [Jackson, Eric M.; Huang, Judy; Brem, Henry; Gordon, Chad R.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD USA; [Gordon, Chad R.] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD USA		Gordon, CR (corresponding author), Johns Hopkins Sch Med, Multidisciplinary Adult Cranioplasty Ctr, Dept Plast Surg & Neurosurg, 601 N Caroline St,8th Floor, Baltimore, MD 21287 USA.	cgordon@jhmi.edu		Huang, Judy/0000-0002-0675-1935			Abdou A, 2015, ANN PHYS REHABIL MED, V58, P183, DOI 10.1016/j.rehab.2014.11.003; Alibhai MK, 2013, INT J ORAL MAX SURG, V42, P559, DOI 10.1016/j.ijom.2013.01.001; Annan Mariam, 2014, Pract Neurol, V14, P266, DOI 10.1136/practneurol-2013-000704; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Calvi AR, 2015, J HEAD TRAUMA REHAB, V30, pE111; Carota A, 2011, EUR NEUROL, V66, P227, DOI 10.1159/000331939; Cecchi PC, 2008, ACTA NEUROCHIR, V150, P409, DOI 10.1007/s00701-007-1459-8; Chalouhi N, 2012, NEUROLOGIST, V18, P423, DOI 10.1097/NRL.0b013e318272f7be; Chamilos C, 2012, BRAIN INJURY, V26, P617; Chieregato A, 2006, INTENS CARE MED, V32, P1668, DOI 10.1007/s00134-006-0302-7; Coelho F, 2014, NEUROPSYCH DIS TREAT, V10, P695, DOI 10.2147/NDT.S52875; Corallo F, 2014, FUNCT NEUROL, V29, P273, DOI 10.11138/FNeur/2014.29.4.273; Corallo F, 2015, TURK NEUROSURG, V25, P193, DOI 10.5137/1019-5149.JTN.10618-14.2; de Araujo AS, 2013, ARQ NEURO-PSIQUIAT, V71, P963, DOI 10.1590/0004-282X20130176; de Quintana-Schmidt C, 2011, REV NEUROLOGIA, V52, P661, DOI 10.33588/rn.5211.2010732; Delaunois E, 2015, ANN PHYS REHABIL MED, V58, P186, DOI 10.1016/j.rehab.2015.04.006; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; dos Santos JFA, 2011, J NEUROL, V258, P131; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Francel P C, 1992, J Craniofac Surg, V3, P145, DOI 10.1097/00001665-199211000-00006; Gadde Judith, 2012, Del Med J, V84, P213; Gordon CR, 2014, OPER NEUROSURG, V10, P179, DOI 10.1227/NEU.0000000000000296; Gottlob Irene, 2002, Strabismus, V10, P271, DOI 10.1076/stra.10.4.271.13830; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; GRANTHAM EG, 1948, J NEUROSURG, V5, P19, DOI 10.3171/jns.1948.5.1.0019; Han PY, 2008, J KOREAN NEUROSURG S, V43, P51, DOI 10.3340/jkns.2008.43.1.51; Higgins JPT, COCHRANE HDB SYSTEMA; Hodozuka A, 2000, NEUROL SURG TOKYO, V28, P245; Honeybul S, 2013, BRAIN INJURY, V27, P1732, DOI 10.3109/02699052.2013.830194; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Ibrahim Z, 2016, J CRANIOFAC SURG, V27, P229, DOI 10.1097/SCS.0000000000002289; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Janzen C, 2012, BRAIN INJURY, V26, P101, DOI 10.3109/02699052.2011.635357; Jeyaraj P, 2015, J MAXILLOFAC ORAL SU, V14, P666, DOI 10.1007/s12663-014-0673-1; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kamiya-Matsuoka C, 2014, BMJ CASE REP, V2014; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Krishnan P, 2015, J NEUROSCI RURAL PRA, V6, P225, DOI 10.4103/0976-3147.150281; Kumar GSS, 2004, NEUROL INDIA, V52, P504; Lim J, 2014, INT J STROKE, V9, P244; Lopez J, 2016, PLAST RECONSTR SURG, V137, p394E, DOI 10.1097/01.prs.0000475770.14396.1e; Narro-Donate JM, 2015, NEUROCIRUGIA, V26, P95, DOI 10.1016/j.neucir.2014.09.006; Ng D, 1997, J CLIN NEUROSCI, V4, P346, DOI 10.1016/S0967-5868(97)90103-X; Paredes I, 2015, NEUROCIRUGIA, V26, P115, DOI 10.1016/j.neucir.2014.10.001; Picard N, 2015, J NEUROSCI RURAL PRA, V6, P298, DOI 10.4103/0976-3147.154583; Picard NA, 2013, ACTA NEUROCHIR, V155, P2149, DOI 10.1007/s00701-013-1838-2; Romero FR, 2013, INT J SURG CASE REP, V4, P1007, DOI 10.1016/j.ijscr.2013.08.013; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sankey EW, 2016, PLAST RECONSTR SURG, V137, P595, DOI 10.1097/01.prs.0000475773.99148.ba; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schorl M, 2008, AKTUEL NEUROL, V35, P340, DOI 10.1055/s-2008-1067463; Sedney CL, 2015, J NEUROSCI RURAL PRA, V6, P438, DOI 10.4103/0976-3147.158778; Silva M, 2012, ARCH CLIN NEUROPSYCH, V27, P628; SNOW RB, 1991, NEUROSURGERY, V28, P880, DOI 10.1227/00006123-199106000-00016; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Voss HU, 2011, CLIN IMAG, V35, P253, DOI 10.1016/j.clinimag.2010.07.008; Wee HY, 2014, INT MED CASE REP J, V7, P67, DOI 10.2147/IMCRJ.S59410; Winkler PA., 2000, NEUROSURG FOCUS, V8, DOI [10.3171/foc.2000.8.1.1920, DOI 10.3171/FOC.2000.8.1.1920, DOI 10.3171/INS.2000.93.1.0053]; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zhao JC, 2015, CLIN NEUROL NEUROSUR, V133, P6, DOI 10.1016/j.clineuro.2015.03.010	66	93	104	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2016	79	4					525	533		10.1227/NEU.0000000000001366			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DX5RK	WOS:000384439200026	27489166	Bronze			2022-02-06	
J	Elbin, RJ; Sufrinko, A; Schatz, P; French, J; Henry, L; Burkhart, S; Collins, MW; Kontos, AP				Elbin, R. J.; Sufrinko, Alicia; Schatz, Philip; French, Jon; Henry, Luke; Burkhart, Scott; Collins, Michael W.; Kontos, Anthony P.			Removal From Play After Concussion and Recovery Time	PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; SCHOOL FOOTBALL PLAYERS; 2ND IMPACT SYNDROME; VOLUNTARY EXERCISE; ONLINE VERSION; SYMPTOMS; PRESSURE; WINDOW	OBJECTIVE: Despite increases in education and awareness, many athletes continue to play with signs and symptoms of a sport-related concussion (SRC). The impact that continuing to play has on recovery is unknown. This study compared recovery time and related outcomes between athletes who were immediately removed from play and athletes who continued to play with an SRC. METHODS: A prospective, repeated measures design was used to compare neurocognitive performance, symptoms, and recovery time between 35 athletes (mean +/- SD age, 15.61 +/- 1.65 years) immediately removed after an SRC (REMOVED group) compared with 34 athletes (mean +/- SD age, 15.35 +/- 1.73 years) who continued to play (PLAYED group) with SRC. Neurocognitive and symptom data were obtained at baseline and at 1 to 7 days and 8 to 30 days after an SRC. RESULTS: The PLAYED group took longer to recover than the REMOVED group (44.4 +/- 36.0 vs 22.0 +/- 18.7 days; P = .003) and were 8.80 times more likely to demonstrate protracted recovery (= 21 days) (P < .001). Removal from play status was associated with the greatest risk of protracted recovery (adjusted odds ratio, 14.27; P = .001) compared with other predictors (eg, sex). The PLAYED group exhibited significantly worse neurocognitive and greater symptoms than the REMOVED group. CONCLUSIONS: SRC recovery time may be reduced if athletes are removed from participation. Immediate removal from play is the first step in mitigating prolonged SRC recovery, and these data support current consensus statements and management guidelines.	[Elbin, R. J.] Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA; [Sufrinko, Alicia; French, Jon; Henry, Luke; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Burkhart, Scott] Florida State Univ, Dept Human Sci, Tallahassee Orthoped Clin, Tallahassee, FL 32306 USA		Elbin, RJ (corresponding author), Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA.	rjelbin@uark.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos. Funded by the National Institutes of Health (NIH).	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Centers for Disease Control and Prevention, HEADS; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham R., 2014, SPORTS RELATED CONCU; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; IBM Corp, 2012, IBM SPSS STAT WINDOW, V21st; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kroshus E, 2015, J ATHL TRAINING, V50, P944, DOI 10.4085/1062-6050-50.6.03; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kurowski BG, 2015, J TRAUMA ACUTE CARE, V79, pS21, DOI 10.1097/TA.0000000000000675; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Vagnozzi R, 2013, BRAIN 11, V136, pi1; Vagnozzi R, 2013, BRAIN, V136, DOI 10.1093/brain/awt121; Weinstein E, 2013, J NEUROSURG-PEDIATR, V11, P331, DOI 10.3171/2012.11.PEDS12343; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	42	93	92	1	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2016	138	3							e20160910	10.1542/peds.2016-0910			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DW9SE	WOS:000384002100039	27573089	Green Published, Bronze			2022-02-06	
J	Russo, RM; Williams, TK; Grayson, JK; Lamb, CM; Cannon, JW; Clement, NF; Galante, JM; Neff, LP				Russo, Rachel M.; Williams, Timothy K.; Grayson, John Kevin; Lamb, Christopher M.; Cannon, Jeremy W.; Clement, Nathan F.; Galante, Joseph M.; Neff, Lucas P.			Extending the golden hour: Partial resuscitative endovascular balloon occlusion of the aorta in a highly lethal swine liver injury model	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	74th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 09-12, 2015	Las Vegas, NV	Amer Assoc Surg Trauma		Trauma; endovascular; resuscitation; intra-aortic balloon; swine	NONCOMPRESSIBLE TORSO HEMORRHAGE; TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION; ISCHEMIC-STROKE; PORCINE MODEL; BLOOD-FLOW; SHOCK; MORTALITY; HYPERTENSION; SURVIVAL	BACKGROUND Combat-injured patients may require rapid and sustained support during transport; however, the prolonged aortic occlusion produced by conventional resuscitative endovascular balloon occlusion of the aorta (REBOA) may lead to substantial morbidity. Partial REBOA (P-REBOA) may permit longer periods of occlusion by allowing some degree of distal perfusion. However, the ability of this procedure to limit exsanguination is unclear. We evaluated the impact of P-REBOA on immediate survival and ongoing hemorrhage in a highly lethal swine liver injury model. METHODS Fifteen Yorkshire-cross swine were anesthetized, instrumented, splenectomized, and subjected to rapid 10% total blood loss followed by 30% liver amputation. Coagulopathy was created through colloid hemodilution. Randomized swine received no intervention (control), P-REBOA, or complete REBOA (C-REBOA). Central mean arterial pressure (cMAP), carotid blood flow, and blood loss were recorded. Balloons remained inflated in the P-REBOA and C-REBOA groups for 90 minutes followed by graded deflation. The study ended at 180 minutes from onset of hemorrhage or death of the animal. Survival analysis was performed, and data were analyzed using repeated-measures analysis of variance with post hoc pairwise comparisons. RESULTS Mean survival times in the control, P-REBOA, and C-REBOA groups were, 25 21, 86 +/- 40, and 163 +/- 20 minutes, respectively (p < 0.001). Blood loss was greater in the P-REBOA group than the C-REBOA or control groups, but this difference was not significant (4,722 +/- 224, 3,834 +/- 319, 3,818 +/- 37 mL, respectively, p = 0.10). P-REBOA resulted in maintenance of near-baseline carotid blood flow and cMAP, while C-REBOA generated extreme cMAP and prolonged supraphysiologic carotid blood flow. Both experimental groups experienced profound decreases in cMAP following balloon deflation. CONCLUSION In the setting of severe ongoing hemorrhage, P-REBOA increased survival time beyond the golden hour while maintaining cMAP and carotid flow at physiologic levels.	[Russo, Rachel M.; Williams, Timothy K.; Galante, Joseph M.; Neff, Lucas P.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA; [Russo, Rachel M.; Williams, Timothy K.; Grayson, John Kevin; Lamb, Christopher M.; Neff, Lucas P.] David Grant USAF Med Ctr, Clin Invest Facil, Fairfield, CA USA; [Williams, Timothy K.; Lamb, Christopher M.] David Grant USAF Med Ctr, Dept Vasc & Endovasc Surg, Fairfield, CA USA; [Clement, Nathan F.] David Grant USAF Med Ctr, Dept Pathol, Fairfield, CA USA; [Neff, Lucas P.] David Grant USAF Med Ctr, Dept Gen Surg, Fairfield, CA 94535 USA; [Cannon, Jeremy W.] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA; [Lamb, Christopher M.] Royal Ctr Def Med, Acad Dept Mil Surg & Trauma, Birmingham, W Midlands, England		Neff, LP (corresponding author), David Grant USAF Med Ctr, Dept Gen Surg, Fairfield, CA 94535 USA.	lucas.neff.2@us.af.mil	Cannon, Jeremy/T-3875-2019	Cannon, Jeremy/0000-0002-2969-9316			Annecke T, 2008, ACTA ANAESTH SCAND, V52, P977, DOI 10.1111/j.1399-6576.2008.01665.x; Avaro JP, 2011, J TRAUMA, V71, P720, DOI 10.1097/TA.0b013e318221a94a; Barmparas G, 2014, J TRAUMA ACUTE CARE, V77, P592, DOI 10.1097/TA.0000000000000382; Biffl WL, 2015, J TRAUMA ACUTE CARE, V78, P1054, DOI 10.1097/TA.0000000000000609; Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; CoAxia, 2005, NEUROFLO PERF AUGM I; DUNN E, 1977, J SURG RES, V22, P463, DOI 10.1016/0022-4804(77)90028-2; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; Emery DJ, 2011, STROKE, V42, P1135, DOI 10.1161/STROKEAHA.110.607846; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; GOLDEN MA, 1991, J VASC SURG, V13, P792, DOI 10.1016/0741-5214(91)90043-T; Hammer M, 2009, CEREBROVASC DIS, V28, P406, DOI 10.1159/000235628; Kotwal RS, 2015, JAMA SURG, V30, P1; Lylyk P, 2005, NEUROL RES, V27, pS129, DOI 10.1179/016164105X35512; Markov NP, 2013, SURGERY, V153, P848, DOI 10.1016/j.surg.2012.12.001; Morrison JJ, 2014, J SURG RES, V191, P423, DOI 10.1016/j.jss.2014.04.012; Morrison JJ, 2014, SHOCK, V41, P130, DOI 10.1097/SHK.0000000000000085; Morrison JJ, 2013, J TRAUMA ACUTE CARE, V75, pS263, DOI 10.1097/TA.0b013e318299da0a; Mundasad S, 2015, BBC NEWS; Norii T, 2015, J TRAUMA ACUTE CARE, V78, P721, DOI 10.1097/TA.0000000000000578; Rasmussen TE, 2015, ARMY AL T MAGAZINE, P80; Saito N, 2015, J TRAUMA ACUTE CARE, V78, P897, DOI 10.1097/TA.0000000000000614; Sellmann T, 2012, DTSCH ARZTEBL INT, V109, P849, DOI 10.3238/arztebl.2012.0849; Shuaib A, 2011, STROKE, V42, P1680, DOI 10.1161/STROKEAHA.110.609933; Stannard A, 2013, J TRAUMA ACUTE CARE, V74, P830, DOI 10.1097/TA.0b013e31827a3704; Stannard A, 2011, J TRAUMA, V71, P1869, DOI 10.1097/TA.0b013e31823fe90c; STOKLAND O, 1980, AM J PHYSIOL, V238, pH423, DOI 10.1152/ajpheart.1980.238.4.H423; Trauma and Injury Subcommittee, 2015, COMB TRAUM LESS LEAR; White JM, 2011, SURGERY, V150, P400, DOI 10.1016/j.surg.2011.06.010; Winship IR, 2014, J CEREBR BLOOD F MET, V34, P61, DOI 10.1038/jcbfm.2013.162	32	93	97	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2016	80	3					372	378		10.1097/TA.0000000000000940			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	DF7XT	WOS:000371571900005	26670114				2022-02-06	
J	Sweet, JJ; Benson, LM; Nelson, NW; Moberg, PJ				Sweet, Jerry J.; Benson, Laura M.; Nelson, Nathaniel W.; Moberg, Paul J.			The American Academy of Clinical Neuropsychology, National Academy of Neuropsychology, and Society for Clinical Neuropsychology (APA Division 40) 2015 TCN Professional Practice and 'Salary Survey': Professional Practices, Beliefs, and Incomes of U.S. Neuropsychologists	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychology.; Salary; Professional Practice; Survey; Income	FOLLOW-UP SURVEY; CAREER SATISFACTION; PSYCHOLOGY; LIFE	Objective: The current survey updated professional practice and income information pertaining to clinical neuropsychology. Methods: Doctoral-level members of the American Academy of Clinical Neuropsychology, Division 40 (Clinical Neuropsychology) of the American Psychological Association, and the National Academy of Neuropsychology and other neuropsychologists, as well as postdoctoral trainees in the Association of Postdoctoral Programs in Clinical Neuropsychology and at other training sites were invited to participate in a web-based survey in early 2015. The sample of 1777 respondents, of whom 1579 were doctoral-level practitioners and 198 were postdoctoral trainees, was larger than the prior 2010 income and practice survey. Results: The substantial proportional change in gender has continued, with women now a clear majority in the postdoctoral trainee sample as well as in the practitioner sample. Dissimilar from the median age trajectory of American Psychological Association members, the median age of clinical neuropsychologists remains essentially unchanged since 1989, indicating a substantial annual influx of young neuropsychologists. The question of whether the Houston Conference training model has become an important influence in the specialty can now be considered settled in the affirmative among postdoctoral trainees and practitioners. Testing assistant usage remains commonplace, and continues to be more common in institutions. The vast majority of clinical neuropsychologists work full-time and very few are unemployed and seeking employment. The numbers of neuropsychologists planning to retire in the coming 5-10years do not suggest a "baby boomer" effect or an unexpected bolus of planned retirements in the next 10 years that would be large enough to be worrisome. Average length of time reported for evaluations appears to be increasing across time. The most common factors affecting evaluation length were identified, with the top three being: (1) goal of evaluation, (2) stamina/health of examinee, and (3) age of examinee. Pediatric specialists remain more likely than others to work part-time, more likely to work in institutions, report lower incomes than respondents with a lifespan professional identity, and are far more likely to be women. Incomes continue to vary considerably by years of clinical practice, work setting, amount of forensic practice, state, and region of country. Neurologists are the number one referral source in institutions and in private practice, as well as for pediatric, adult, and lifespan practitioners. Learning disability is no longer among the top five conditions seen by pediatric neuropsychologists; traumatic brain injury and seizure disorder are common reasons for clinical evaluations at all age ranges. There is a continued increase in forensic practice and a clear consensus on the use of validity testing. There is a substantial interest in subspecialization board certification, with the greatest interest evident among postdoctoral trainees. Income satisfaction, job satisfaction, and work-life balance satisfaction are higher for men. Job satisfaction varies across general work setting and across age range of practice. Work-life balance satisfaction is moderately correlated with income satisfaction and job satisfaction. Again in this five-year interval survey, a substantial majority of respondents reported increased incomes, despite experiencing substantial negative practice effects related to changes in the US health care system. Numerous breakdowns related to income and professional activities are provided. Conclusions: Professional practice survey information continues to provide valuable perspectives regarding consistency and change in the activities, beliefs, and incomes of US clinical neuropsychologists.	[Sweet, Jerry J.; Benson, Laura M.] NorthShore Univ HealthSyst, Evanston, IL USA; [Sweet, Jerry J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Nelson, Nathaniel W.] Univ St Thomas, Minneapolis, MN USA; [Moberg, Paul J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA		Sweet, JJ (corresponding author), NorthShore Univ HealthSyst, Pritzker Sch Med, 909 Davis St,Suite 160, Evanston, IL 60201 USA.; Sweet, JJ (corresponding author), Univ Chicago, Evanston, IL 60201 USA.	jerrysweet@uchicago.edu					American Psychological Association, 2005, APA MEMB PROF DEM CH; American Psychological Association, 2000, APA MEMB PROF DEM CH; American Psychological Association, 2014, APA MEMB PROF DEM CH; American Psychological Association, 2010, APA MEMB PROF DEM CH; Baron IS, 2011, CLIN NEUROPSYCHOL, V25, P1075, DOI 10.1080/13854046.2011.594455; Cox DR, 2010, CLIN NEUROPSYCHOL, V24, P493, DOI 10.1080/13854040902802947; Cummins R. A., 2000, J HAPPINESS STUD, V1, P133; Diener E, 2009, SOC INDIC RES SER, V37, P201, DOI 10.1007/978-90-481-2350-6_9; Hannay HJ, 1998, ARCH CLIN NEUROPSYCH, V13, P157, DOI 10.1016/S0887-6177(98)00003-1; HOWARD A, 1986, AM PSYCHOL, V41, P1311, DOI 10.1037/0003-066X.41.12.1311; Judge TA, 2010, J VOCAT BEHAV, V77, P157, DOI 10.1016/j.jvb.2010.04.002; Kahneman D, 2010, P NATL ACAD SCI USA, V107, P16489, DOI 10.1073/pnas.1011492107; Khanna C., 2010, IND ORG PSYCHOL, V48, P23; Khanna C., 2013, IND ORG PSYCHOL, V51, P18; Leigh JP, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-166; Lin L., 2015, MONITOR PSYCHOL  JUL, P17; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Mindt MR, 2010, CLIN NEUROPSYCHOL, V24, P429, DOI 10.1080/13854040903058960; OSTERTAG PA, 1991, PSYCHOL WOMEN QUART, V15, P349, DOI 10.1111/j.1471-6402.1991.tb00413.x; Putnam S., 1989, CLIN NEUROPSYCHOL, V3, P97; Romero HR, 2009, CLIN NEUROPSYCHOL, V23, P761, DOI 10.1080/13854040902881958; Rupert PA, 2012, PROF PSYCHOL-RES PR, V43, P495, DOI 10.1037/a0029420; Shanafelt TD, 2015, MAYO CLIN PROC, V90, P1600, DOI 10.1016/j.mayocp.2015.08.023; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; Sweet JJ, 2000, CLIN NEUROPSYCHOL, V14, P18, DOI 10.1076/1385-4046(200002)14:1;1-8;FT018; Sweet JJ, 2000, CLIN NEUROPSYCHOL, V14, P479, DOI 10.1076/clin.14.4.479.7201; SWEET JJ, 1990, CLIN NEUROPSYCHOL, V4, P101, DOI DOI 10.1080/13854049008401504; The Physicians Foundation, 2014, 2014 SURV AM PHYS PR	29	93	93	0	18	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2015	29	8					1069	1162		10.1080/13854046.2016.1140228			94	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	DF0DC	WOS:000371008200001	26878229	Bronze			2022-02-06	
J	Comstock, RD; Currie, DW; Pierpoint, LA; Grubenhoff, JA; Fields, SK				Comstock, R. Dawn; Currie, Dustin W.; Pierpoint, Lauren A.; Grubenhoff, Joseph A.; Fields, Sarah K.			An Evidence-Based Discussion of Heading the Ball and Concussions in High School Soccer	JAMA PEDIATRICS			English	Article							NEUROPSYCHOLOGICAL CONSEQUENCE; NEUROCOGNITIVE PERFORMANCE; POSTURAL CONTROL; SEX-DIFFERENCES; INJURIES; FEMALE; BRAIN; ACCELERATION; EPIDEMIOLOGY; IMPAIRMENT	IMPORTANCE Soccer, originally introduced as a safer sport for children and adolescents, has seen a rapid increase in popularity in the United States over the past 3 decades. Recently, concerns have been raised regarding the safety of soccer ball heading (when an athlete attempts to play the ball in the air with his or her head) given the rise in concussion rates, with some calling for a ban on heading among soccer players younger than 14 years. OBJECTIVES To evaluate trends over time in boys' and girls' soccer concussions, to identify injury mechanisms commonly leading to concussions, to delineate soccer-specific activities during which most concussions occur, to detail heading-related soccer concussion mechanisms, and to compare concussion symptom patterns by injury mechanism. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of longitudinal surveillance data collected from 2005-2006 through 2013-2014 in a large, nationally representative sample of US high schools. Participants were boys and girls who were high school soccer players. EXPOSURES Concussions sustained during high school-sanctioned soccer games and practices. MAIN OUTCOMES AND MEASURES Mechanism and sport-specific activity of concussion. RESULTS Overall, 627 concussions were sustained during 1 393 753 athlete exposures (AEs) among girls (4.50 concussions per 10 000 AEs), and 442 concussions were sustained during 1 592 238 AEs among boys (2.78 concussions per 10 000 AEs). For boys (68.8%) and girls (51.3%), contact with another player was the most common concussion mechanism. Heading was the most common soccer-specific activity, responsible for 30.6% of boys' concussions and 25.3% of girls' concussions. Contact with another player was the most common mechanism of injury in heading-related concussions among boys (78.1%) and girls (61.9%). There were few differences in concussion symptom patterns by injury mechanism. CONCLUSIONS AND RELEVANCE Although heading is the most common activity associated with concussions, the most frequent mechanism was athlete-athlete contact. Such information is needed to drive evidence-based, targeted prevention efforts to effectively reduce soccer-related concussions. Although banning heading from youth soccer would likely prevent some concussions, reducing athlete-athlete contact across all phases of play would likely be a more effective way to prevent concussions as well as other injuries.	[Comstock, R. Dawn; Currie, Dustin W.; Pierpoint, Lauren A.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA; [Comstock, R. Dawn; Grubenhoff, Joseph A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Fields, Sarah K.] Univ Colorado, Dept Commun, Denver, CO 80202 USA		Comstock, RD (corresponding author), Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Mail Stop B119,13001E 17th Pl, Aurora, CO 80045 USA.	dawn.comstock@ucdenver.edu	Grubenhoff, Joseph A/H-9994-2019	Grubenhoff, Joseph A/0000-0001-5072-4064	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment; EyeBlack; DonJoy Orthotics; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER	This study was funded in part by grants R49/CE000674-01 and R49/CE001172-01 from the Centers for Disease Control and Prevention. Research funding was also provided by the National Federation of State High School Associations, National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack.	Adams AL, 2006, ACAD EMERG MED, V13, P571, DOI 10.1197/j.aem.2005.12.015; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; [Anonymous], 2013 14 HIGH SCH ATH; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Brown S., 2007, Soccer and Society, V8, P366, DOI 10.1080/14660970701224640; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Current comment from the American College of Sports Medicine, 1993, MED SCI SPORTS EXERC, V25, P1; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Fields SK, 2011, FEMALE GLADIATORS GE; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Halloran JD, 2013, RISE RISE US WOMENS; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Sports Legacy Institute, SAF SOCC IN; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Teymouri M, 2012, ARCH TRAUMA RES, V1, P44, DOI [10.5812/atr.5399, 10.5812/atr.5307]; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; U.S. Census Bureau, 2014, CENS REG DIV US CENS REG DIV US; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047	40	93	93	0	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	SEP	2015	169	9					830	837		10.1001/jamapediatrics.2015.1062			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CR0CT	WOS:000360986500014	26168306	Bronze			2022-02-06	
J	Fazel, S; Wolf, A; Pillas, D; Lichtenstein, P; Langstrom, N				Fazel, Seena; Wolf, Achim; Pillas, Demetris; Lichtenstein, Paul; Langstrom, Niklas			Suicide, Fatal Injuries, and Other Causes of Premature Mortality in Patients With Traumatic Brain Injury A 41-Year Swedish Population Study	JAMA PSYCHIATRY			English	Article							UNITED-STATES; HEAD-INJURY; RISK; SCHIZOPHRENIA; DIAGNOSES; DISCHARGE; REGISTER; HEALTH; DISORDERS; VALIDITY	IMPORTANCE Longer-term mortality in individuals who have survived a traumatic brain injury (TBI) is not known. OBJECTIVES To examine the relationship between TBI and premature mortality, particularly by external causes, and determine the role of psychiatric comorbidity. DESIGN, SETTING, AND PATIENTS We studied all persons born in 1954 or later in Sweden who received inpatient and outpatient International Classification of Diseases-based diagnoses of TBI from 1969 to 2009 (n = 218 300). We compared mortality rates 6 months or more after TBI to general population controls matched on age and sex (n = 2 163 190) and to unaffected siblings of patients with TBI (n = 150 513). Furthermore, we specifically examined external causes of death (suicide, injury, or assault). We conducted sensitivity analyses to investigate whether mortality rates differed by sex, age at death, severity (including concussion), and different follow-up times after diagnosis. MAIN OUTCOMES AND MEASURES Adjusted odds ratios (AORs) of premature death by external causes in patients with TBI compared with general population controls. RESULTS Among those who survived 6 months after TBI, we found a 3-fold increased odds of mortality (AOR, 3.2; 95% CI, 3.0-3.4) compared with general population controls and an adjusted increased odds of mortality of 2.6 (95% CI, 2.3-2.8) compared with unaffected siblings. Risks of mortality from external causes were elevated, including for suicide (AOR, 3.3; 95% CI, 2.9-3.7), injuries (AOR, 4.3; 95% CI, 3.8-4.8), and assault (AOR, 3.9; 95% CI, 2.7-5.7). Among those with TBI, absolute rates of death were high in those with any psychiatric or substance abuse comorbidity (3.8% died prematurely) and those with solely substance abuse (6.2%) compared with those without comorbidity (0.5%). CONCLUSIONS AND RELEVANCE Traumatic brain injury is associated with substantially elevated risks of premature mortality, particularly for suicide, injuries, and assaults, even after adjustment for sociodemographic and familial factors. Current clinical guidelines may need revision to reduce mortality risks beyond the first few months after injury and address high rates of psychiatric comorbidity and substance abuse.	[Fazel, Seena; Wolf, Achim] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Pillas, Demetris] UCL, Dept Epidemiol & Publ Hlth, London, England; [Lichtenstein, Paul; Langstrom, Niklas] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden		Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008; Langstrom, Niklas/C-5615-2009	Fazel, Seena/0000-0002-5383-5365; Langstrom, Niklas/0000-0002-2686-6799; lichtenstein, paul/0000-0003-3037-5287	Wellcome TrustWellcome TrustEuropean Commission [095806]; Swedish Prison and Probation Service; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study was funded by grant 095806 from the Wellcome Trust (Dr Fazel and Mr Wolf), the Swedish Prison and Probation Service (Dr Langstrom), and the Swedish Research Council (Drs Lichtenstein and Langstrom).	ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown AW, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318280d3e6; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Coronado V. G., 2011, SURVEILLANCE FOR TRA; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Ekholm B, 2005, NORD J PSYCHIAT, V59, P457, DOI 10.1080/08039480500360906; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fazel S, 2013, LANCET, V382, P1646, DOI 10.1016/S0140-6736(13)60899-5; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Fazel S, 2009, JAMA-J AM MED ASSOC, V301, P2016, DOI 10.1001/jama.2009.675; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horton R, 2013, LANCET, V381, P509, DOI 10.1016/S0140-6736(13)60100-2; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JIANG GX, 1995, ACTA NEUROL SCAND, V91, P109; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Klein-Geltink JE, 2007, J CLIN EPIDEMIOL, V60, P766, DOI 10.1016/j.jclinepi.2006.11.008; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MATHERS C, 2008, THE GLOBAL BURDEN OF; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; National Board of Health and Welfare, CAUSE OF DEATH REGIS; National Institute for Health and Clinical Excellence, 2004, SELF HARM THE SHORT; Neeleman J, 1997, PSYCHOL MED, V27, P467, DOI 10.1017/S0033291796004631; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Redelmeier DA, 2003, LANCET, V361, P2177, DOI 10.1016/S0140-6736(03)13770-1; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Runeson B, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3222; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Sellgren C, 2011, ACTA PSYCHIAT SCAND, V124, P447, DOI 10.1111/j.1600-0447.2011.01747.x; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; Statistics Sweden, 2005, FLERGENERATIONSREGIS; Swedish National Board of Health and Welfare, PATIENTREGISTRET; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Volavka J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001148; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	50	93	94	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	MAR	2014	71	3					326	333		10.1001/jamapsychiatry.2013.3935			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AC8FU	WOS:000332769700015	24430827	Green Accepted, Bronze			2022-02-06	
J	Wang, S; Cheng, HB; Dai, GH; Wang, XD; Hua, RR; Liu, XB; Wang, PS; Chen, GM; Yue, W; An, YH				Wang, Sen; Cheng, Hongbin; Dai, Guanghui; Wang, Xiaodong; Hua, Rongrong; Liu, Xuebin; Wang, Peishen; Chen, Guangming; Yue, Wu; An, Yihua			Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury	BRAIN RESEARCH			English	Article						Umbilical cord mesenchymal stem cells; Traumatic brain injury; Stem cell transplantation; Rehabilitation	QUALITY-OF-LIFE; THERAPY; STROKE; OUTCOMES	The aim of this study was to investigate the effects of transplantation with umbilical cord mesenchymal stem cells in patients with sequelae of traumatic brain injury (TBI). The study hypothesis was that umbilical cord mesenchymal stem cell transplantation could safely and effectively improve neurological function in patients with sequelae of traumatic brain injury. Forty patients with sequelae of TBI were randomly assigned to the stem cell treatment group or the control group. The patients in the stem cell treatment group underwent 4 stem cell transplantations via lumbar puncture. All patients of the group were also evaluated using Fugl-Meyer Assessments (FMA) and Functional Independence Measures (FIM) before and at 6 months after the stem cell transplantation. The patients in the control group did not receive any medical treatment (i.e., neither surgery nor medical intervention), and their FMA and FIM scores were determined on the day of the visit to the clinic and at 6 months after that clinical observation. The FMA results demonstrated an improvement in upper extremity motor sub-score, lower extremity motor sub-score, sensation sub-score and balance sub-score in the stem cell transplantation group at 6 months after the transplantation (P<0.05). The FIM results also exhibited significant improvement (P<0.05) in the patient self-care sub-score, sphincter control sub-score, mobility sub-score, locomotion sub-score, communication sub-score and social cognition sub-score. The control group exhibited no improvements after 6 months (P>0.05). All in all, the study results confirmed that the umbilical cord mesenchymal stem cell transplantation improved the neurological function and self-care in patients with TBI sequels. Umbilical cord mesenchymal stem cell transplantation may be a potential treatment for patients with sequelae of TBI. Further research, including a multicenter and large sample size prospective randomized clinical trial, will be required to define definitively the role of umbilical cord mesenchymal stem cell transplantation on sequelae of TBI. (c) 2013 Elsevier B.V. All rights reserved.	[Wang, Sen; Dai, Guanghui; Wang, Xiaodong; Liu, Xuebin; Wang, Peishen; Chen, Guangming; An, Yihua] Gen Hosp Chinese Peoples Armed Police Forces, Dept Cell Transplantat, Beijing 100039, Peoples R China; [Cheng, Hongbin; Yue, Wu; An, Yihua] Harbin Med Univ, Affiliated Hosp 4, Dept Neurosurg, Harbin 150001, Peoples R China		Yue, W (corresponding author), Harbin Med Univ, Affiliated Hosp 4, Dept Neurosurg, Harbin 150001, Peoples R China.	yuewu@vip.163.com; riveran@163.com		An, Yihua/0000-0003-0033-2999; Hua, Rongrong/0000-0001-5102-115X	Department of Science and Technology, Guangdong Province, China [2011A08401003]	This research was supported by a Grant from the Department of Science and Technology, Guangdong Province, China (2011A08401003).	Al-Jarrah MD, 2009, NEUROSCIENCES, V14, P41; Ali H, 2012, STEM CELL REV REP, V8, P210, DOI 10.1007/s12015-011-9287-x; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Carrade DD, 2011, CYTOTHERAPY, V13, P1180, DOI 10.3109/14653249.2011.602338; Cheng JL, 2010, CHIN J TRAUMATOL, V13, P173, DOI 10.3760/cma.j.issn.1008-1275.2010.03.008; Chernykh ER, 2011, B EXP BIOL MED+, V151, P512, DOI 10.1007/s10517-011-1369-x; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Connell LA, 2012, CLIN REHABIL, V26, P68, DOI 10.1177/0269215511412982; Cui YF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017126; Dasari VR, 2009, J NEUROTRAUM, V26, P2057, DOI [10.1089/neu.2008.0725, 10.1089/neu.2008-0725]; Deuse T, 2011, CELL TRANSPLANT, V20, P655, DOI 10.3727/096368910X536473; Fan CG, 2011, STEM CELL REV REP, V7, P195, DOI 10.1007/s12015-010-9168-8; Feng M, 2011, J NUCL MED, V52, P90, DOI 10.2967/jnumed.110.080325; Fugl-Meyer AR., 1975, SCAND J REHABIL MED, V7, P13; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Granger CV, 1984, FUNCTIONAL ASSESSMEN; Hsieh YW, 2009, STROKE, V40, P1386, DOI 10.1161/STROKEAHA.108.530584; Hu XB, 2012, BRAIN INJURY, V26, P183, DOI 10.3109/02699052.2011.648707; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Jackson EL, 2008, CELLS TISSUES ORGANS, V188, P212, DOI 10.1159/000114541; Jaracz K, 2008, NEUROL NEUROCHIR POL, V42, P525; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Li JM, 2010, BRAIN RES, V1334, P65, DOI 10.1016/j.brainres.2010.03.080; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lu LL, 2006, HAEMATOLOGICA, V91, P1017; Lu ZJ, 2012, CURR NEUROVASC RES, V9, P250, DOI 10.2174/156720212803530708; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Palmgren B, 2012, EXP NEUROL, V235, P599, DOI 10.1016/j.expneurol.2012.03.014; Pardal R, 2012, ADV EXP MED BIOL, V741, P206, DOI 10.1007/978-1-4614-2098-9_14; Park JH, 2012, DIABETES RES CLIN PR, V98, P465, DOI 10.1016/j.diabres.2012.09.034; Qiu J, 1998, CHINESE J REHABILITA, V13, P54; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Secco M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; Wang Y, 2011, STEM CELLS DEV, V21, P1401; Wu KH, 2007, J CELL BIOCHEM, V100, P608, DOI 10.1002/jcb.21078; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiong N, 2011, GENE THER, V18, P394, DOI 10.1038/gt.2010.152; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang HT, 2010, DIFFERENTIATION, V79, P15, DOI 10.1016/j.diff.2009.09.002; Zhao YD, 2001, WORLD J SURG, V25, P1202	48	93	102	2	32	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 26	2013	1532						76	84		10.1016/j.brainres.2013.08.001			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	228NS	WOS:000325194100008	23942181				2022-02-06	
J	Kerr, ZY; Casa, DJ; Marshall, SW; Comstock, RD				Kerr, Zachary Y.; Casa, Douglas J.; Marshall, Stephen W.; Comstock, R. Dawn			Epidemiology of Exertional Heat Illness Among U.S. High School Athletes	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							CONCUSSION; INJURIES	Background: It is estimated that more than 9000 high school athletes are treated for exertional heat illness annually. Risk factors include being obese and beginning practice during hot and humid weather, when athletes are not yet acclimated to physical exertion in heat. Purpose: To describe the epidemiology of exertional heat illness in high school athletes. Methods: National High School Sports-Related Injury Surveillance System data (2005/2006-2010/2011) were analyzed in 2012 to calculate rates and describe circumstances of exertional heat illness. Results: Exertional heat illness occurred at a rate of 1.20 per 100,000 athlete exposures (95% CI = 1.12, 1.28). Exertional heat illnesses were widely distributed geographically, and most occurred in August (60.3%). Of the exertional heat illnesses reported during practice, almost one third (32.0%) occurred more than 2 hours into the practice session. The exertional heat illness rate in football (4.42 per 100,000 athlete exposures) was 11.4 times that in all other sports combined (95% CI = 8.3, 15.5, p < 0.001). In addition, approximately one third (33.6%) of exertional heat illnesses occurred when a medical professional was not onsite at the time of onset. Conclusions: Although most exertional heat illnesses occurred in football, athletes in all sports and all geographic areas are at risk. Because exertional heat illness frequently occurs when medical professionals are not present, it is imperative that high school athletes, coaches, administrators, and parents are trained to identify and respond to it. Implementing effective preventive measures depends on increasing awareness of exertional heat illness and relevant preventive and therapeutic countermeasures. (Am J Prev Med 2013;44(1):8-14) (C) 2013 American Journal of Preventive Medicine	[Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Casa, Douglas J.] Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, Storrs, CT USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA		Comstock, RD (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	dawn.comstock@nationwidechildrens.org		Kerr, Zachary/0000-0003-1423-1259; Marshall, Stephen/0000-0002-2664-9233	Society for Public Health Education (SOPHE)/CDC Student Fellowship in Injury/Violence Prevention and Control; CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; DonJoy Orthotics; EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674, R49CE001172] Funding Source: NIH RePORTER	ZYK was funded by The Society for Public Health Education (SOPHE)/CDC Student 2012 Fellowship in Injury/Violence Prevention and Control.; The content of this report was also funded in part by the CDC Grant Nos. R49/CE000674-01 and R49/CE001172-01. The authors also acknowledge the generous research funding contributions of the National Federation of State High School Associations, DonJoy Orthotics, and EyeBlack.	Anderson SJ, 2000, PEDIATRICS, V106, P158; Armstrong L. E., 1996, MED SCI SPORTS EXERC, V28, P139; Armstrong LE, 2007, MED SCI SPORT EXER, V39, P556, DOI 10.1249/MSS.0b013e31802fa199; Binkley HM, 2002, J ATHL TRAINING, V37, P329; Brady Erik, 2011, US TODAY; Casa DJ, 2003, NATA NEWS, P24; Casa Douglas J, 2005, Curr Sports Med Rep, V4, P309; Casa DJ, 2012, CURR SPORT MED REP, V11, P115, DOI 10.1249/JSR.0b013e31825615cc; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; CDC, 2012, YOUTH RISK BEH SURV; Centers for Disease Control, 2000, CDC GROWTH CHARTS US; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Council Sports Med, 2011, PEDIATRICS, V128, pE741, DOI 10.1542/peds.2011-1664; Howe AS, 2007, AM J SPORT MED, V35, P1384, DOI 10.1177/0363546507305013; Huffman EA, 2008, J ATHL TRAINING, V43, P624, DOI 10.4085/1062-6050-43.6.624; Kerr ZY, 2013, AM J LIFESTYLE MED, V7, P138, DOI 10.1177/1559827612450683; Luke AC, 2007, CLIN J SPORT MED, V17, P488, DOI 10.1097/JSM.0b013e31815889f2; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Mueller F, 2011, ANN SURVEY FOOTBALL; Mueller FO, 2009, ANN SURVEY FOOTBALL; Mueller FO, 2010, 28 U N CAR CHAP HILL; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; National High School Federation, 2011, HIGH SCH SPORTS PART; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Sports Medicine Advisory Committee, 2012, HEAT ACCL HEAT ILLN; United States Census Bureau, 2009, CENS REG US; Yard EE, 2010, J SAFETY RES, V41, P471, DOI 10.1016/j.jsr.2010.09.001; Youth Football Coaches Associaton, 2012, HYDR	29	93	95	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	JAN	2013	44	1					8	14		10.1016/j.amepre.2012.09.058			7	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; General & Internal Medicine	071FQ	WOS:000313574700002	23253644				2022-02-06	
J	Zhuang, L; Yang, T; Zhao, HL; Fidalgo, AR; Vizcaychipi, MP; Sanders, RD; Yu, BW; Takata, M; Johnson, MR; Ma, DQ				Zhuang, Lei; Yang, Ting; Zhao, Hailin; Fidalgo, Antonio Rei; Vizcaychipi, Marcela P.; Sanders, Robert D.; Yu, Buwei; Takata, Masao; Johnson, Mark R.; Ma, Daqing			The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats	CRITICAL CARE MEDICINE			English	Article						argon; helium; hypoxia-ischemia; neuroprotection; noble gas; xenon	HYPOXIC-ISCHEMIC ENCEPHALOPATHY; TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; CELL-DEATH; MODERATE HYPOTHERMIA; POTASSIUM CHANNELS; CEREBRAL-ISCHEMIA; NITROUS-OXIDE; CYTOCHROME-C; NOBLE-GASES	Objective: Xenon provides neuroprotection in multiple animal models; however, little is known about the other noble gases. The aim of the current study was to compare xenon, argon, and helium neuroprotection in a neonatal asphyxia model in rats. Design: Randomized controlled trial. Setting: Laboratory. Subjects: Seven-day-old postnatal Sprague-Dawley rats. Interventions: Seventy percent argon, helium, xenon, or nitrogen balanced with oxygen after hypoxic-ischemic brain injury. Measurements and Main Results: Control animals undergoing moderate hypoxic-ischemia endured reduced neuronal survival at 7 days with impaired neurologic function at the juvenile age compared with naive animals. Severe hypoxic-ischemic damage produced a large cerebral infarction in controls. After moderate hypoxic-ischemia, all three noble gases improved cell survival, brain structural integrity, and neurologic function on postnatal day 40 compared with nitrogen. Interestingly, argon improved cell survival to naive levels, whereas xenon and helium did not. When tested against more severe hypoxic-ischemic injury only, argon and xenon reduced infarct volume. Furthermore, postinjury body weight in moderate insult was lower in the helium-treated group compared with the naive, control, and other noble gas treatment groups, whereas in the severe injurious setting, it is lower in both control and helium-treated groups than other groups. In the nondirectly injured hemisphere, argon, helium, and xenon increased the expression of Bcl-2, whereas helium and xenon increased Bcl-xL. In addition, Bax expression was enhanced in the control and helium groups. Conclusions: These studies indicate that argon and xenon provide neuroprotection against both moderate and severe hypoxia-ischemic brain injury likely through prosurvival proteins synthesis. (Crit Care Med 2012; 40:1724-1730)	[Zhuang, Lei; Yang, Ting; Zhao, Hailin; Fidalgo, Antonio Rei; Vizcaychipi, Marcela P.; Sanders, Robert D.; Takata, Masao; Ma, Daqing] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Anaesthet Intens Care & Pain Med, London, England; [Zhuang, Lei; Yu, Buwei] Shanghai Jiao Tong Univ, Sch Med, Dept Anesthesiol, Rui Jin Hosp, Shanghai 200030, Peoples R China; [Johnson, Mark R.] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Surg & Canc, London, England		Ma, DQ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Anaesthet Intens Care & Pain Med, London, England.	d.ma@imperial.ac.uk	Fidalgo, Antonio R/A-7402-2010; Vizcaychipi, Marcela/H-5487-2011; Sanders, Robert/A-7844-2012	Fidalgo, Antonio R/0000-0003-3384-0017; Vizcaychipi, Marcela/0000-0001-7894-873X; Sanders, Robert/0000-0003-0113-0328; Ma, Daqing/0000-0003-1235-0537; Ma, Daqing/0000-0002-0688-2097	SPARKS, London, UK [10IMP01]; Chinese Society of Anesthesiology, Beijing, China; Sparks Charity [10IMP01] Funding Source: researchfish	This work was supported partially by a grant (10IMP01) from SPARKS, London, UK. Drs. Zhuang and Yang were supported by a scholarship from Chinese Society of Anesthesiology, Beijing, China.	Abraini JH, 2003, ANESTH ANALG, V96, P746, DOI 10.1213/01.ANE.0000050282.14291.38; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bantel C, 2009, ANESTHESIOLOGY, V110, P986, DOI 10.1097/ALN.0b013e31819dadc7; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Heinen A, 2008, ANESTHESIOLOGY, V109, P830, DOI 10.1097/ALN.0b013e3181895aa0; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Johnson SA, 2008, J NEUROSURG ANESTH, V20, P21, DOI 10.1097/ANA.0b013e3181271850; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2007, ANESTHESIOLOGY, V106, P746, DOI 10.1097/01.anes.0000264762.48920.80; Ma DQ, 2009, J AM SOC NEPHROL, V20, P713, DOI 10.1681/ASN.2008070712; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017; MAJNO G, 1995, AM J PATHOL, V146, P3; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Pagel PS, 2008, J CARDIOTHOR VASC AN, V22, P554, DOI 10.1053/j.jvca.2008.04.005; Pagel PS, 2007, ANESTH ANALG, V105, P562, DOI 10.1213/01.ane.0000278083.31991.36; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Ryang YM, 2011, CRIT CARE MED, V39, P1448, DOI 10.1097/CCM.0b013e31821209be; Sanders RD, 2010, ANESTHESIOLOGY, V113, P233, DOI 10.1097/ALN.0b013e3181dc1b84; Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shindler KS, 1997, J NEUROSCI, V17, P3112; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004	39	93	96	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1724	1730		10.1097/CCM.0b013e3182452164			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946EZ	WOS:000304335600005	22610177				2022-02-06	
J	Schoeler, M; Loetscher, PD; Rossaint, R; Fahlenkamp, AV; Eberhardt, G; Rex, S; Weis, J; Coburn, M				Schoeler, Marc; Loetscher, Philip D.; Rossaint, Rolf; Fahlenkamp, Astrid V.; Eberhardt, Georg; Rex, Steffen; Weis, Joachim; Coburn, Mark			Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury	BMC NEUROLOGY			English	Article						Neuroprotection; Traumatic brain injury; Dexmedetomidine	HIPPOCAMPAL ORGANOTYPIC CULTURES; INCOMPLETE CEREBRAL-ISCHEMIA; ALPHA(2A)-ADRENOCEPTOR SUBTYPE; SIGNALING PATHWAY; SLICE CULTURES; UNITED-STATES; HYPOTHERMIA; NEURONS; MILD; RATS	Background: The alpha(2)-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro model for traumatic brain injury. Methods: Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway inhibitors were examined. Results: Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum effect at a dosage of 1 mu M. This effect was partially reversed by the simultaneous administration of the ERK inhibitor PD98059. Conclusion: In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that activation of ERK might be involved in mediating this effect.	[Schoeler, Marc; Loetscher, Philip D.; Rossaint, Rolf; Fahlenkamp, Astrid V.; Eberhardt, Georg; Rex, Steffen; Coburn, Mark] Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany; [Weis, Joachim] Rhein Westfal TH Aachen, Univ Hosp, Inst Neuropathol, D-52074 Aachen, Germany; [Rex, Steffen] Katholieke Univ Leuven, Univ Hosp, Dept Anesthesiol, B-3000 Louvain, Belgium		Coburn, M (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Anesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mcoburn@ukaachen.de	Weis, Joachim/G-1984-2014	Weis, Joachim/0000-0003-3280-6773; Rex, Steffen/0000-0002-3536-9321; Coburn, Mark/0000-0002-7930-0270	Orion Corporation, Espoo, Finland; Orion Corporation	This study was supported by Orion Corporation, Espoo, Finland. RR received consultant fees from Orion Corporation, a company producing and marketing pharmaceuticals such as dexmedetomidine. All other authors declare that they have no competing interests.	Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dahmani S, 2008, ANESTHESIOLOGY, V108, P457, DOI 10.1097/ALN.0b013e318164ca81; Dahmani S, 2010, ANESTHESIOLOGY, V112, P373, DOI 10.1097/ALN.0b013e3181ca6982; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; HOFFMAN WE, 1991, ANESTHESIOLOGY, V75, P328, DOI 10.1097/00000542-199108000-00022; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hua Y, 2010, J ANESTH, V24, P726, DOI 10.1007/s00540-010-0999-x; Laudenbach V, 2002, ANESTHESIOLOGY, V96, P134, DOI 10.1097/00000542-200201000-00026; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; MULLER D, 1993, DEV BRAIN RES, V71, P93, DOI 10.1016/0165-3806(93)90109-N; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Paris A, 2006, ANESTH ANALG, V102, P456, DOI 10.1213/01.ane.0000194301.79118.e9; Roehl AB, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-97; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Sanders RD, 2010, ACTA ANAESTH SCAND, V54, P710, DOI 10.1111/j.1399-6576.2009.02177.x; Sato K, 2010, ACTA ANAESTH SCAND, V54, P377, DOI 10.1111/j.1399-6576.2009.02139.x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TASKER RC, 1992, J NEUROSCI, V12, P4298; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toborek M, 2007, J CELL BIOCHEM, V100, P279, DOI 10.1002/jcb.21013; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043	29	93	110	0	23	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	APR 11	2012	12								20	10.1186/1471-2377-12-20			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	943BJ	WOS:000304095100001	22494498	gold, Green Published			2022-02-06	
J	Kim, S; Endres, NK; Johnson, RJ; Ettlinger, CF; Shealy, JE				Kim, Suezie; Endres, Nathan K.; Johnson, Robert J.; Ettlinger, Carl F.; Shealy, Jasper E.			Snowboarding Injuries Trends Over Time and Comparisons With Alpine Skiing Injuries	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						snowboard; skiing; injuries	UPPER-EXTREMITY INJURIES; SPINAL-INJURIES; WRIST; SKIERS; RISK; SEVERITY	Background: Participation in snowboarding as a winter sport is comparable to alpine skiing concerning the demographics of the participants, risk of injury, and variation in types of injuries sustained. Purpose: To examine the types of snowboarding injuries and changes in injury patterns over time. We also sought to highlight important differences in injury patterns between snowboarders and alpine skiers as affected by age, experience, and sex. Study Design: Case control; Level of evidence, 3. Methods: Data were collected on injured snowboarders and skiers in a base-lodge clinic of a ski resort in Vermont over 18 seasons (1988-2006) and included extensive information about injury patterns, demographics, and experience. Control data were also obtained during this time period to provide information about the population at risk. Results: The injury rates were assessed as mean days between injuries (MDBI). The average MDBI for all injuries among snowboarders was 345 as compared with 400 for skiers (the lower the number, the higher the injury rate). The most common type of injury for snowboarders was a wrist injury (MDBI, 1258), while for skiers, it was an anterior cruciate ligament (ACL) sprain (MDBI, 2332). Wrist injuries accounted for 27.6% of all snowboard injuries and 2.8% of skiing injuries, and ACL injuries composed 1.7% of all snowboard injuries and 17.2% of skiing injuries. Among snowboarders, more wrist injuries, shoulder soft tissue injuries, ankle injuries, concussions, and clavicle fractures were seen, while skiers had more ACL sprains, medial collateral ligament (MCL) sprains of the knee, lateral collateral ligament (LCL) sprains of the knee, lower extremity contusions, and tibia fractures. The trend analysis revealed an increased incidence of clavicle fractures (P < .01) and a decrease in MCL injuries (P < .01) and ankle injuries (P < .025) among snowboarders over time. Skiers had a decrease in thumb metacarpophalangeal-ulnar collateral ligament (MCP-UCL) injuries (P < .001) and MCL injuries of the knee (P < .001) over time. We found the highest rate of injury among young, inexperienced, female snowboarders. When examining the location of injury, 21.8% of snowboard injuries occurred in the terrain park compared with 6.5% of ski injuries. Conclusion: Injury rates in snowboarders have fluctuated over time but currently remain higher than in skiers. Wrist, shoulder, and ankle injuries are more common among snowboarders, while knee ligament injuries are more common in skiers. Injured snowboarders were significantly younger, less experienced, and more likely to be female than injured skiers or snowboard control participants. We did not find any evidence that those who spend time in terrain parks are overrepresented in the injury population.	[Kim, Suezie; Endres, Nathan K.; Johnson, Robert J.] Univ Vermont, Coll Med, Dept Orthopaed & Rehabil, Burlington, VT USA; [Ettlinger, Carl F.] Vermont Ski Safety Equipment Corp, Underhill, VT USA		Kim, S (corresponding author), NYU, Hosp Joint Dis, Dept Orthopaed Surg, 301 E 17th St,Room 1402, New York, NY 10003 USA.	suezie.kim@nyumc.org					ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Bissell BT, 2008, AM J SPORT MED, V36, P1880, DOI 10.1177/0363546508318195; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Davidson TM, 1996, WESTERN J MED, V164, P231; Davies H, 2009, KNEE SURG SPORT TR A, V17, P1048, DOI 10.1007/s00167-008-0695-7; DeMorat G, 2004, AM J SPORT MED, V32, P477, DOI 10.1177/0363546503258928; Dohjima T, 2001, ACTA ORTHOP SCAND, V72, P657, DOI 10.1080/000164701317269111; Domire ZJ, 2011, J BIOMECH, V44, P1630, DOI 10.1016/j.jbiomech.2011.03.001; Franz T, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.038166; Greenwald RM, 1998, AM J SPORT MED, V26, P825, DOI 10.1177/03635465980260061501; Hagel B, 2005, ACCIDENT ANAL PREV, V37, P103, DOI 10.1016/j.aap.2004.04.003; Hagel B, 2005, AM J EPIDEMIOL, V162, P149, DOI 10.1093/aje/kwi181; Hagel BE, 2004, EPIDEMIOLOGY, V15, P279, DOI 10.1097/01.ede.0000120044.62029.b4; Hagel BE, 1999, CLIN J SPORT MED, V9, P9, DOI 10.1097/00042752-199901000-00003; Hayes JR, 2008, J PEDIATR SURG, V43, P928, DOI 10.1016/j.jpedsurg.2007.12.041; Idzikowski JR, 2000, AM J SPORT MED, V28, P825, DOI 10.1177/03635465000280061001; Janes PC, 1999, AM SOC TEST MATER, V1345, P141, DOI 10.1520/STP12364S; Johnson RJ, 1989, ASTM STP, P25; Johnson RJ, 2009, AM SOC TEST MATER, V1510, P11, DOI 10.1520/STP47461S; Kary JM, 2008, CURR SPORT MED REP, V7, P35, DOI 10.1097/01.CSMR.0000308670.07441.4f; Kirkpatrick DP, 1998, AM J SPORT MED, V26, P271, DOI 10.1177/03635465980260021901; Langran M, 2004, AM J SPORT MED, V32, P96, DOI 10.1177/0095399703258684; Langran M, 2002, BRIT J SPORT MED, V36, P135, DOI 10.1136/bjsm.36.2.135; Machold W, 2002, J TRAUMA, V52, P517, DOI 10.1097/00005373-200203000-00016; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Matsumoto K, 2002, CLIN J SPORT MED, V12, P354, DOI 10.1097/00042752-200211000-00006; O'Neill DF, 1999, AM J SPORT MED, V27, P94; O'Neill DF, 2003, CLIN ORTHOP RELAT R, P91, DOI 10.1097/01.blo.0000057785.10364.dc; Ogawa H, 2010, AM J SPORT MED, V38, P532, DOI 10.1177/0363546509348763; Ronning R, 2000, AM J SPORT MED, V28, P506, DOI 10.1177/03635465000280041001; Ronning R, 2001, AM J SPORT MED, V29, P581, DOI 10.1177/03635465010290051001; Russell K, 2007, CLIN J SPORT MED, V17, P145, DOI 10.1097/JSM.0b013e31803f901b; Sakamoto Y, 2008, AM J SPORT MED, V36, P943, DOI 10.1177/0363546507313573; Sasaki K, 1999, J TRAUMA, V46, P1059, DOI 10.1097/00005373-199906000-00015; Shealy JE, 1989, SKIING TRAUMA SAFETY, P75; Snowsports Industries America, SNOW SPORTS FACT SHE; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; Wasden CC, 2009, J TRAUMA, V67, P1022, DOI 10.1097/TA.0b013e3181b0d559; Yamakawa H, 2001, J TRAUMA, V50, P1101, DOI 10.1097/00005373-200106000-00020; Yamauchi K, 2010, AM J SPORT MED, V38, P1468, DOI 10.1177/0363546509361190	41	93	95	2	32	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2012	40	4					770	776		10.1177/0363546511433279			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	918XO	WOS:000302285100005	22268231				2022-02-06	
J	Wu, QH; Xuan, WJ; Ando, T; Xu, T; Huang, LY; Huang, YY; Dai, TH; Dhital, S; Sharma, SK; Whalen, MJ; Hamblin, MR				Wu, Qiuhe; Xuan, Weijun; Ando, Takahiro; Xu, Tao; Huang, Liyi; Huang, Ying-Ying; Dai, Tianghong; Dhital, Saphala; Sharma, Sulbha K.; Whalen, Michael J.; Hamblin, Michael R.			Low-Level Laser Therapy for Closed-Head Traumatic Brain Injury in Mice: Effect of Different Wavelengths	LASERS IN SURGERY AND MEDICINE			English	Article						photobiomodulation; low-level laser therapy; traumatic brain injury; mouse model; Neurological Severity Score	CEREBRAL-ISCHEMIA; TRANSCRANIAL LASER; UNITED-STATES; STROKE; PHOTOTHERAPY; MECHANISMS; LIGHT; RATS; PATHOPHYSIOLOGY; REGENERATION	Background and Objectives Traumatic brain injury (TBI) affects millions worldwide and is without effective treatment. One area that is attracting growing interest is the use of transcranial low-level laser therapy (LLLT) to treat TBI. The fact that near-infrared light can penetrate into the brain would allow non-invasive treatment to be carried out with a low likelihood of treatment-related adverse events. LLLT may treat TBI by increasing respiration in the mitochondria, causing activation of transcription factors, reducing inflammatory mediators and oxidative stress, and inhibiting apoptosis. Study Design/Materials and Methods: We tested LLLT in a mouse model of closed-head TBI produced by a controlled weight drop onto the skull. Mice received a single treatment with continuous-wave 665, 730, 810, or 980 nm lasers (36 J/cm(2) delivered at 150 mW/cm(2)) 4-hour post-TBI and were followed up by neurological performance testing for 4 weeks. Results: Mice with moderate-to-severe TBI treated with 665 and 810 nm laser (but not with 730 or 980 nm) had a significant improvement in Neurological Severity Score that increased over the course of the follow-up compared to sham-treated controls. Morphometry of brain sections showed a reduction in small deficits in 665 and 810 nm laser treated mouse brains at 28 days. Conclusions: The effectiveness of 810 nm agrees with previous publications, and together with the effectiveness of 660 nm and non-effectiveness of 730 and 980 nm can be explained by the absorption spectrum of cytochrome oxidase, the candidate mitochondrial chromophore in transcranial LLLT. Lasers Surg. Med. 44: 218-226, 2012. (C) 2012 Wiley Periodicals, Inc.	[Wu, Qiuhe; Xuan, Weijun; Ando, Takahiro; Xu, Tao; Huang, Liyi; Huang, Ying-Ying; Dai, Tianghong; Dhital, Saphala; Sharma, Sulbha K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Wu, Qiuhe; Xuan, Weijun; Xu, Tao; Huang, Liyi; Huang, Ying-Ying; Dai, Tianghong; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Wu, Qiuhe] Shandong Univ, Dept Burns & Plast Surg, Jinan Cent Hosp, Jinan 250100, Peoples R China; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Ando, Takahiro] Keio Univ, Dept Elect & Elect Engn, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai, Peoples R China; [Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Dhital, Saphala] Univ Tokyo, Dept Microbiol, Tokyo, Japan; [Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Dai, Tianhong/P-5961-2018; Huang, yingying/J-7329-2012; Ando, Takahiro/H-5209-2019; Huang, Ying-ying/G-3153-2011; Ando, Takahiro/R-8374-2019; Hamblin, Michael R/H-2758-2019	Dai, Tianhong/0000-0001-8960-8896; Huang, yingying/0000-0002-4038-0277; Huang, Ying-ying/0000-0003-3066-6981; Hamblin, Michael R/0000-0001-6431-4605; Dhital, Saphala/0000-0001-5566-0733; Xu, Tao/0000-0001-5868-4079	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J04881] Funding Source: KAKEN; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI050875, R01AI050875] Funding Source: Medline		Al-Watban FAH, 2007, PHOTOMED LASER SURG, V25, P72, DOI 10.1089/pho.2006.1094; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Davis PJ, 2007, METHODS NUMERICAL IN, p[xii, 612]; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Demir O, 2009, ANAT REC, V292, P1953, DOI 10.1002/ar.20980; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Hamblin M.R., 2006, P SOC PHOTO-OPT INS, V6140, P1, DOI DOI 10.1117/12.646294; Huang YY, 2010, SER MED PHYS BIOMED, P687; Huang YY, 2010, SER MED PHYS BIOMED, P717; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Park JJ, 2012, LASER MED SCI, V27, P223, DOI 10.1007/s10103-011-0944-8; Protheroe RT, 2011, ANAESTHESIA, V66, P1035, DOI 10.1111/j.1365-2044.2011.06874.x; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P137, DOI 10.1089/pho.2007.2076; Rovegno M, 2012, MED INTENSIVA, V36, P37, DOI 10.1016/j.medin.2011.06.008; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Skopin MD, 2009, PHOTODERMATOL PHOTO, V25, P75, DOI 10.1111/j.1600-0781.2009.00406.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zhang H, 2012, CELL SIGNAL, V24, P224, DOI 10.1016/j.cellsig.2011.09.004; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	49	93	98	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0196-8092	1096-9101		LASER SURG MED	Lasers Surg. Med.	MAR	2012	44	3					218	226		10.1002/lsm.22003			9	Dermatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Dermatology; Surgery	909NZ	WOS:000301572700005	22275301	Green Accepted			2022-02-06	
J	[Anonymous]				[Anonymous]			Concussion (Mild Traumatic Brain Injury) and the Team Physician: A Consensus Statement-2011 Update	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							COLLEGIATE FOOTBALL PLAYERS; SPORT; MANAGEMENT; RISK; RELIABILITY							Guskiewicz, Kevin/0000-0002-8682-2130			[Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; [Anonymous], NCAA REQ CONC MAN PL; [Anonymous], CLIN TEAM PHYS CONS; [Anonymous], 2009, BRIT J SPORT MED, V43, pi85; [Anonymous], 2009, 2009 NFHS CONC BROCH; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broglio SP, 2007, J ATHL TRAINING, V42, P509; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Meeham WP, 2010, CONCUSSION SPORTS CL; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Randolph C, 2005, J ATHL TRAINING, V40, P139; Van Kampen D., 2006, AM J SPORTS MED, V34, P1	34	93	93	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2011	43	12					2412	2422		10.1249/MSS.0b013e3182342e64			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	851EL	WOS:000297251100024	22089299				2022-02-06	
J	Steinsapir, KD; Goldberg, RA				Steinsapir, Kenneth D.; Goldberg, Robert A.			Traumatic Optic Neuropathy: An Evolving Understanding	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							SPINAL-CORD-INJURY; NERVE TRAUMA; CONTROLLED-TRIAL; METHYLPREDNISOLONE; CORTICOSTEROIDS; DECOMPRESSION; MANAGEMENT	PURPOSE: To critically review the treatment of traumatic optic neuropathy. DESIGN: A perspective of clinical and basic science studies related to traumatic optic neuropathy and its treatment. METHODS: Published clinical and basic science studies on traumatic optic neuropathy were critically reviewed and interpreted. RESULTS: Clinical progress in the treatment of traumatic optic neuropathy is limited by small clinical studies lacking appropriate control groups. The Corticosteroid Randomization for Acute Head Trauma (CRASH) trial found an increased rate of death among patients with acute head trauma treated with high-dose corticosteroids compared to placebo-treated patients (21% vs 18%, P = .0001). Recent animal studies also suggest that high-dose corticosteroids are toxic to the injured optic nerve. CONCLUSIONS: The Corticosteroid Randomization for Acute Head Trauma study is immediately relevant to the treatment of traumatic optic neuropathy as individuals with traumatic optic neuropathy often have concomitant head trauma. High-dose corticosteroids for traumatic optic neuropathy will result in a measurable loss of life in patients who also have a brain injury. Death has never been an endpoint for traumatic optic neuropathy studies. Given human and animal data suggesting that treatment is harmful and the lack of demonstrated clinical efficacy, corticosteroids should not be used to treat traumatic optic neuropathy. The benefit of optic canal decompression is also unclear. There is a need to identify traumatic optic neuropathy soon after injury to further define the natural history of this injury. This information will provide a basis for assessing potential future treatments for traumatic optic neuropathy. (Am J Ophthalmol 2011;151: 928-933. (C) 2011 by Elsevier Inc. All rights reserved.)	[Steinsapir, Kenneth D.; Goldberg, Robert A.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Div Orbital & Ophthalm Plast Surg, Los Angeles, CA 90095 USA		Steinsapir, KD (corresponding author), 11645 Wilshire Blvd,Suite 750, Los Angeles, CA 90025 USA.	kenstein@ix.netcom.com	Goldberg, Robert/AAE-3046-2019				Alford MA, 2001, OPHTHAL PLAST RECONS, V17, P323, DOI 10.1097/00002341-200109000-00005; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; Bracken MB, 2005, NEUROSURGERY, V57, P1300, DOI 10.1227/01.NEU.0000187320.71967.59; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Chou PI, 1996, NEURO-OPHTHALMOLOGY, V16, P325, DOI 10.3109/01658109609044636; Cirovic S, 2006, BRIT J OPHTHALMOL, V90, P778, DOI 10.1136/bjo.2005.086538; Cook MW, 1996, ARCH OTOLARYNGOL, V122, P389; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Fukado Y, 1975, Mod Probl Ophthalmol, V14, P474; Holmes MD, 2004, OPHTHAL PLAST RECONS, V20, P342, DOI 10.1097/01.IOP.0000134272.55294.4C; HOOPER RS, 1951, BRIT J SURG, V39, P126, DOI 10.1002/bjs.18003915406; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jamal BT, 2009, J ORAL MAXIL SURG, V67, P986, DOI 10.1016/j.joms.2008.12.035; JOSEPH MP, 1990, ARCH OPHTHALMOL-CHIC, V108, P1091, DOI 10.1001/archopht.1990.01070100047032; Lee V, 2010, EYE, V24, P240, DOI 10.1038/eye.2009.79; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Lubben B, 2001, LARYNGOSCOPE, V111, P320; MILLER NR, 1990, ARCH OPHTHALMOL-CHIC, V108, P1086, DOI 10.1001/archopht.1990.01070100042030; MILLESI W, 1988, ACTA NEUROCHIR, V93, P50, DOI 10.1007/BF01409902; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; NAU HE, 1987, ACTA NEUROCHIR, V89, P16, DOI 10.1007/BF01406662; Rajiniganth MG, 2003, ARCH OTOLARYNGOL, V129, P1203, DOI 10.1001/archotol.129.11.1203; Simon GJB, 2006, J NEUROTRAUM, V23, P1072, DOI 10.1089/neu.2006.23.1072; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Steinsapir KD, 2006, J NEURO-OPHTHALMOL, V26, P65, DOI 10.1097/01.wno.0000204646.94991.68; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; STEINSAPIR KD, 2005, COMP OPHTHALMOL UPDA, V6, P11; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; Wang BH, 2001, PLAST RECONSTR SURG, V107, P1655, DOI 10.1097/00006534-200106000-00003; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033	35	93	105	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	JUN	2011	151	6					928	933		10.1016/j.ajo.2011.02.007			6	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	773GQ	WOS:000291295400004	21529765				2022-02-06	
J	Chen, G; Fang, Q; Zhang, J; Zhou, D; Wang, Z				Chen, Gang; Fang, Qi; Zhang, Jian; Zhou, Dai; Wang, Zhong			Role of the Nrf2-ARE Pathway in Early Brain Injury After Experimental Subarachnoid Hemorrhage	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						early brain injury; subarachnoid hemorrhage; Nrf2	CEREBRAL-ISCHEMIA; RATS; SIMVASTATIN; EXPRESSION	The nuclear factor erythroid 2-related factor 2 and antioxidant-response element (Nrf2-ARE) pathway is a key regulator for modulating inflammation and oxidative damage, which are involved in the pathogenesis of early brain injury (EBI) after subarachnoid hemorrhage (SAH). Previous studies have demonstrated that Nrf2-ARE pathway play neural protective roles in traumatic brain injury, cerebral ischemia, and intracerebral hemorrhage models; however, it has not been investigated whether, and to what degree, the Nrf2-ARE pathway is induced by SAH, and the role of the Nrf2-ARE pathway in development of EBI following SAH remains unknown. Experiment 1 sought to investigate the time course of Nrf2-ARE activation in the cortex in the early stage of SAH. In experiment 2, we assessed the effect of sulforaphane (SUL; a specific Nrf2 activator) on regulation of the Nrf2-ARE pathway in the SAH model and evaluated the impact of SUL on EBI after SAH. The rat SAH model was used injection of 0.3 ml fresh arterial, nonheparinized blood into the prechiasmatic cistern over 20 sec. As a result, Nrf2 and its target gene product, heme oxygenase-1 (HO-1), were up-regulated in the cortex after SAH and peaked at 24 hr post-SAH. After intraperitoneal SUL administration, the elevated expression of Nrf2-ARE-related factors such as Nrf2, HO-1, NAD(P)H:quinone oxidoreductase 1 (NQO1), and glutathione S-transferase-alpha 1 (GST-alpha 1) was detected in the cortex at 48 hr following blood injection. In the SUL-treated group, early brain damage such as brain edema, blood brain barrier (BBB) impairment, cortical apoptosis, and motor deficits was significantly ameliorated compared with vehicle-treated SAH rats. Our results suggest that the Nrf2-ARE pathway is activated in the brain after SAH, playing a beneficial role in EBI development, possibly through inhibiting cerebral oxidative stress by inducing antioxidant and detoxifying enzymes. (C) 2011 Wiley-Liss, Inc.	[Chen, Gang; Zhang, Jian; Zhou, Dai; Wang, Zhong] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu Prov, Peoples R China; [Fang, Qi] Soochow Univ, Affiliated Hosp 1, Dept Neurol, Suzhou 215006, Jiangsu Prov, Peoples R China		Wang, Z (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu Prov, Peoples R China.	dr.daizhou@gmail.com; dr.zhongwang@gmail.com		Chen, Gang/0000-0002-0758-1907	Health Department of Jiangsu Province [RC2007081]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [20090460085]	Contract grant sponsor: 135 Grant from Health Department of Jiangsu Province; Contract grant number: RC2007081; Contract grant sponsor: China Postdoctoral Science Foundation; Contract grant number: 20090460085.	Ayer RE, 2008, ACTA NEUROCHIR SUPPL, V104, P33; Cahill J, 2009, STROKE, V40, pS86, DOI 10.1161/STROKEAHA.108.533315; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kong L, 2009, NEUROCHEM INT, V54, P172, DOI 10.1016/j.neuint.2008.08.013; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; Naga KK, 2007, NEUROL RES, V29, P877, DOI 10.1179/016164107X181842; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; Prunell GF, 2005, NEUROSURGERY, V56, P1082, DOI 10.1227/01.NEU.0000157966.76590.39; Prunell GF, 2002, NEUROREPORT, V13, P2553, DOI 10.1097/00001756-200212200-00034; Prunell GF, 2004, NEUROSURGERY, V54, P426, DOI 10.1227/01.NEU.0000103670.09687.7A; Reddy PVB, 2010, NEUROCHEM INT, V56, P780, DOI 10.1016/j.neuint.2010.02.017; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; SHILL AY, 2003, J NEUROSCI, V23, P3394; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smeyne M, 2007, P NATL ACAD SCI USA, V104, P1977, DOI 10.1073/pnas.0610978104; Stringer JL, 2004, J COMP NEUROL, V471, P289, DOI 10.1002/cne.20048; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang Z, 2010, ANN CLIN LAB SCI, V40, P32; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	23	93	104	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2011	89	4					515	523		10.1002/jnr.22577			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	731WX	WOS:000288142200005	21259333				2022-02-06	
J	Cheng, D; Jenner, AM; Shui, GH; Cheong, WF; Mitchell, TW; Nealon, JR; Kim, WS; McCann, H; Wenk, MR; Halliday, GM; Garner, B				Cheng, Danni; Jenner, Andrew M.; Shui, Guanghou; Cheong, Wei Fun; Mitchell, Todd W.; Nealon, Jessica R.; Kim, Woojin S.; McCann, Heather; Wenk, Markus R.; Halliday, Glenda M.; Garner, Brett			Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex	PLOS ONE			English	Article							LEWY BODY DISEASE; APOLIPOPROTEIN-D EXPRESSION; TANDEM MASS-SPECTROMETRY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; LIVER X RECEPTORS; ALPHA-SYNUCLEIN; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA	Background: We present a lipidomics analysis of human Parkinson's disease tissues. We have focused on the primary visual cortex, a region that is devoid of pathological changes and Lewy bodies; and two additional regions, the amygdala and anterior cingulate cortex which contain Lewy bodies at different disease stages but do not have as severe degeneration as the substantia nigra. Methodology/Principal Findings: Using liquid chromatography mass spectrometry lipidomics techniques for an initial screen of 200 lipid species, significant changes in 79 sphingolipid, glycerophospholipid and cholesterol species were detected in the visual cortex of Parkinson's disease patients (n = 10) compared to controls (n = 10) as assessed by two-sided unpaired t-test (p-value <0.05). False discovery rate analysis confirmed that 73 of these 79 lipid species were significantly changed in the visual cortex (q-value < 0.05). By contrast, changes in 17 and 12 lipid species were identified in the Parkinson's disease amygdala and anterior cingulate cortex, respectively, compared to controls; none of which remained significant after false discovery rate analysis. Using gas chromatography mass spectrometry techniques, 6 out of 7 oxysterols analysed from both non-enzymatic and enzymatic pathways were also selectively increased in the Parkinson's disease visual cortex. Many of these changes in visual cortex lipids were correlated with relevant changes in the expression of genes involved in lipid metabolism and an oxidative stress response as determined by quantitative polymerase chain reaction techniques. Conclusions/Significance: The data indicate that changes in lipid metabolism occur in the Parkinson's disease visual cortex in the absence of obvious pathology. This suggests that normalization of lipid metabolism and/or oxidative stress status in the visual cortex may represent a novel route for treatment of non-motor symptoms, such as visual hallucinations, that are experienced by a majority of Parkinson's disease patients.	[Cheng, Danni; Kim, Woojin S.; McCann, Heather; Halliday, Glenda M.; Garner, Brett] Neurosci Res Australia, Sydney, NSW, Australia; [Jenner, Andrew M.; Shui, Guanghou; Cheong, Wei Fun; Wenk, Markus R.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Shui, Guanghou] Natl Univ Singapore, Inst Life Sci, Singapore 117548, Singapore; [Mitchell, Todd W.] Univ Wollongong, Sch Hlth Sci, Wollongong, NSW, Australia; [Mitchell, Todd W.; Garner, Brett] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Nealon, Jessica R.] Univ Wollongong, Sch Chem, Wollongong, NSW, Australia; [Kim, Woojin S.; Halliday, Glenda M.] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Wenk, Markus R.] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Garner, Brett] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia		Cheng, D (corresponding author), Neurosci Res Australia, Sydney, NSW, Australia.	brettg@uow.edu.au	McCann, Heather/I-3815-2012; Wenk, Markus Rene/D-1441-2014; Halliday, Glenda M/E-8555-2011; Mitchell, Todd/G-7044-2012; jenner, andrew M/H-4791-2016	McCann, Heather/0000-0002-8474-8969; Halliday, Glenda M/0000-0003-0422-8398; Mitchell, Todd/0000-0002-1372-9963; jenner, andrew M/0000-0003-1767-2033; Shui, Guanghou/0000-0002-1621-9643	Australian Brain Foundation; Australian Research CouncilAustralian Research Council; Singapore National Research FoundationNational Research Foundation, Singapore [2007-04]; Biomedical Research Council of SingaporeAgency for Science Technology & Research (ASTAR) [R-183-000-211-305]; National Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [R-183-000-224-213]; SystemsX.ch RTD project LipidX; Neuroscience Research Australia; University of New South Wales; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia; University of SydneyUniversity of Sydney; Schizophrenia Research Institute; National Institute of Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	DC is supported by a PhD scholarship from the Australian Brain Foundation. GH and BG are Fellows of the NHMRC. BG holds an Australian Research Council Future Fellowship. Work at the NUS lipidomics laboratory (MRW) is supported by grants from the Singapore National Research Foundation under CRP Award No. 2007-04, the Biomedical Research Council of Singapore (R-183-000-211-305), the National Medical Research Council (R-183-000-224-213) and the SystemsX.ch RTD project LipidX. The Sydney Brain Bank is supported by Neuroscience Research Australia, the University of New South Wales and the National Health and Medical Research Council of Australia (NHMRC). The NSW Tissue Resource Centre is supported by the University of Sydney, the NHMRC, the Schizophrenia Research Institute and the National Institute of Alcohol Abuse and Alcoholism. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bar-On P, 2008, J NEUROCHEM, V105, P1656, DOI 10.1111/j.1471-4159.2008.05254.x; Barcelo-Coblijn G, 2007, J NEUROCHEM, V101, P132, DOI 10.1111/j.1471-4159.2006.04348.x; Barnes J, 2001, J NEUROL NEUROSUR PS, V70, P727, DOI 10.1136/jnnp.70.6.727; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bosco DA, 2006, NAT CHEM BIOL, V2, P249, DOI 10.1038/nchembio782; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Bras J, 2008, FEBS J, V275, P5767, DOI 10.1111/j.1742-4658.2008.06709.x; Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Burke RE, 2008, ANN NEUROL, V64, P485, DOI 10.1002/ana.21541; Caesar R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011525; Cartagena CM, 2010, BRAIN RES, V1319, P1, DOI 10.1016/j.brainres.2009.12.080; Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08; Cheng D, 2008, NEUROREPORT, V19, P1685, DOI 10.1097/WNR.0b013e32831578b2; DAMIER P, 1993, NEUROSCIENCE, V52, P1, DOI 10.1016/0306-4522(93)90175-F; De Haan EH, 2007, NEUROREPORT, V18, P1177, DOI 10.1097/WNR.0b013e32820049d3; Deeley JM, 2008, BBA-MOL CELL BIOL L, V1781, P288, DOI 10.1016/j.bbalip.2008.04.002; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; Dickson DW, 2009, PARKINSONISM RELAT D, V15, pS1, DOI 10.1016/S1353-8020(09)70769-2; Diederich NJ, 2009, NAT REV NEUROL, V5, P331, DOI 10.1038/nrneurol.2009.62; EBERLING JL, 1994, NEUROBIOL AGING, V15, P329, DOI 10.1016/0197-4580(94)90028-0; Elliott DA, 2011, NEUROBIOL AGING, V32, P257, DOI 10.1016/j.neurobiolaging.2009.02.006; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268; Fasano C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000612; Fedorow H, 2005, J NEUROCHEM, V92, P990, DOI 10.1111/j.1471-4159.2004.02975.x; Forsaa EB, 2010, ARCH NEUROL-CHICAGO, V67, P996, DOI 10.1001/archneurol.2010.166; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Graessler J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006261; Guerrera IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007735; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Halliday G, 2002, ACTA NEUROPATHOL, V104, P72, DOI 10.1007/s00401-002-0529-5; Halliday GM, 2010, ANN NY ACAD SCI, V1184, P188, DOI 10.1111/j.1749-6632.2009.05118.x; Halliday GM, 2005, BRAIN, V128, P2654, DOI 10.1093/brain/awh584; Han XL, 2010, BBA-MOL CELL BIOL L, V1801, P774, DOI 10.1016/j.bbalip.2010.01.010; Han XL, 2002, ANAL BIOCHEM, V302, P199, DOI 10.1006/abio.2001.5536; Harding AJ, 2002, BRAIN, V125, P2431, DOI 10.1093/brain/awf251; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Henchcliffe C, 2008, NAT CLIN PRACT NEURO, V4, P600, DOI 10.1038/ncpneuro0924; Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200; Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200; Holroyd S, 2006, J NEUROPSYCH CLIN N, V18, P402, DOI 10.1176/appi.neuropsych.18.3.402; Hu CX, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0015542, 10.1371/journal.pone.0013318]; Huang Q, 2006, CANCER RES, V66, P5807, DOI 10.1158/0008-5472.CAN-06-0077; Ibarretxe-Bilbao N, 2009, MOVEMENT DISORD, V24, pS748, DOI 10.1002/mds.22670; Jellinger KA, 2008, ACTA NEUROPATHOL, V116, P1, DOI 10.1007/s00401-008-0406-y; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; Kim HJ, 2008, P NATL ACAD SCI USA, V105, P2094, DOI 10.1073/pnas.0711599105; Kim WS, 2009, J NEUROCHEM, V109, P1053, DOI 10.1111/j.1471-4159.2009.06031.x; Kolsch H, 1999, BRAIN RES, V818, P171, DOI 10.1016/S0006-8993(98)01274-8; Kolsch H, 2000, NEUROCHEM INT, V36, P507, DOI 10.1016/S0197-0186(99)00157-6; Le Lay S, 2009, J LIPID RES, V50, P1609, DOI 10.1194/jlr.M800601-JLR200; Lee CYJ, 2009, ANTIOXID REDOX SIGN, V11, P407, DOI [10.1089/ars.2008.2179, 10.1089/ARS.2008.2179]; Lwin A, 2004, MOL GENET METAB, V81, P70, DOI 10.1016/j.ymgme.2003.11.004; Meppelink AM, 2009, BRAIN, V132, P2980, DOI 10.1093/brain/awp223; Mosconi L, 2008, ANN NY ACAD SCI, V1147, P180, DOI 10.1196/annals.1427.007; Neumann J, 2009, BRAIN, V132, P1783, DOI 10.1093/brain/awp044; Obeso JA, 2010, NAT MED, V16, P653, DOI 10.1038/nm.2165; Ordonez C, 2006, HISTOL HISTOPATHOL, V21, P361, DOI 10.14670/HH-21.361; Owen AD, 1996, ANN NY ACAD SCI, V786, P217, DOI 10.1111/j.1749-6632.1996.tb39064.x; Power JHT, 2009, ACTA NEUROPATHOL, V117, P63, DOI 10.1007/s00401-008-0438-3; Prabhakara JPR, 2008, J NEUROCHEM, V107, P1722, DOI 10.1111/j.1471-4159.2008.05736.x; Ramirez-Ruiz B, 2007, EUR J NEUROL, V14, P750, DOI 10.1111/j.1468-1331.2007.01768.x; Ramirez-Ruiz B, 2008, MOVEMENT DISORD, V23, P2335, DOI 10.1002/mds.22258; Rappley I, 2009, J NEUROCHEM, V111, P15, DOI 10.1111/j.1471-4159.2009.06290.x; Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823-07.2007; RUIPEREZ V, 2010, PROG LIPID RES; Sacchetti P, 2009, CELL STEM CELL, V5, P409, DOI 10.1016/j.stem.2009.08.019; Sanchez-Castaneda C, 2010, MOVEMENT DISORD, V25, P615, DOI 10.1002/mds.22873; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Scholpp J, 2004, J NEUROTRAUM, V21, P667, DOI 10.1089/0897715041269632; Schwab U, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002630; Seet RCS, 2010, FREE RADICAL BIO MED, V48, P560, DOI 10.1016/j.freeradbiomed.2009.11.026; Shui G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011956; Shui GH, 2010, MOL BIOSYST, V6, P1008, DOI 10.1039/b913353d; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; STALLBER.S, 1965, J LIPID RES, V6, P146; STOMMEL A, 1989, MECH AGEING DEV, V48, P1, DOI 10.1016/0047-6374(89)90021-3; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802; Tong JC, 2010, BRAIN, V133, P172, DOI 10.1093/brain/awp282; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Williams DR, 2008, J NEUROL NEUROSUR PS, V79, P652, DOI 10.1136/jnnp.2007.124677; Williams DR, 2005, LANCET NEUROL, V4, P605, DOI 10.1016/S1474-4422(05)70146-0; Wilson RS, 2000, J NEUROL NEUROSUR PS, V69, P172, DOI 10.1136/jnnp.69.2.172; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	88	93	93	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2011	6	2							e17299	10.1371/journal.pone.0017299			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729EM	WOS:000287931400051	21387008	Green Published, gold, Green Submitted, Green Accepted			2022-02-06	
J	Tollard, E; Galanaud, D; Perlbarg, V; Sanchez-Pena, P; Le Fur, Y; Abdennour, L; Cozzone, P; Lehericy, S; Chiras, J; Puybasset, L				Tollard, Eleonore; Galanaud, Damien; Perlbarg, Vincent; Sanchez-Pena, Paola; Le Fur, Yann; Abdennour, Lamine; Cozzone, Patrick; Lehericy, Stephane; Chiras, Jacques; Puybasset, Louis			Experience of diffusion tensor imaging and H-1 spectroscopy for outcome prediction in severe traumatic brain injury: Preliminary results	CRITICAL CARE MEDICINE			English	Article						diffusion tensor imaging; spectroscopy; traumatic brain injury; coma; outcome; fractional anisotropy	MAGNETIC-RESONANCE-SPECTROSCOPY; CLOSED-HEAD INJURY; MINIMALLY CONSCIOUS STATE; PROTON MR SPECTROSCOPY; AXONAL INJURY; VEGETATIVE STATE; IN-VIVO; COMATOSE PATIENTS; PROGNOSTIC VALUE; RECOVERY	Objective: The objective of the study is to test whether multimodal magnetic resonance imaging can provide a reliable outcome prediction of the clinical status, focusing on consciousness at 1 year after severe traumatic brain injury (TBI). Design: Single center prospective cohort with consecutive inclusions. Setting. Critical Care Neurosurgical Unit of a university hospital. Patients: Forty-three TBI patients not responding to simple orders after sedation cessation and 15 healthy controls. Interventions. A multimodal magnetic resonance imaging combining morphologic sequences, diffusion tensor imaging (DTI), and H-1 proton magnetic resonance spectroscopy (MRS) was performed 24 +/- 11 days after severe TBI. The ability of DTI and MRS to predict 1-year outcome was assessed by linear discriminant analysis (LDA). Robustness of the classification was tested using a bootstrap procedure. Measurements and Main Results: Fractional anisotropy (FA) was computed as the mean of values at discrete brain sites in the infratentorial and supratentorial regions. The N-acetyl aspartate/creatine (NAA/Cr) ratio was measured in the thalamus, lenticular nucleus, insular cortex, occipital periventricular white matter, and pons. After 1 year, 19 (44%) patients had unfavorable outcomes (death, persistent vegetative state, or minimally conscious state) and 24 (56%) favorable outcomes (normal consciousness with or without functional impairments). Analysis of variance was performed to compare FA and NAA/Cr in the two outcome groups and controls. FA and MRS findings showed highly significant differences between the outcome groups, with significant variables by LDA being supratentorial FA, NAA/Cr (pons), NAA/Cr (thalamus), NAA/Cr (insula), and infratentorial FA. LDA of combined FA and MRS data clearly separated the unfavorable outcome, favorable outcome, and control groups, with no overlap. Unfavorable outcome was predicted with up to 86% sensitivity and 97% specificity; these values were better than those obtained with DTI or MRS alone. Conclusion: FA and NAA/Cr hold potential as quantitative outcome-prediction tools at the subacute phase of TBI. (Crit Care Med 2009; 37:1448-1455)	[Tollard, Eleonore] Univ Hosp, Dept Neuroradiol, Rouen, France; [Galanaud, Damien] Hop La Pitie Salpetriere, CR ICM, CNRS, UMR 7225, Paris, France; [Tollard, Eleonore; Galanaud, Damien; Chiras, Jacques] Hop La Pitie Salpetriere, Dept Neuroradiol, Paris, France; [Perlbarg, Vincent] Univ Paris 06, INSERM, U678, F-75252 Paris 05, France; [Sanchez-Pena, Paola] Univ Paris 06, Lab Funct Imaging, F-75252 Paris 05, France; [Sanchez-Pena, Paola] Univ Paris 06, Dept Anesthesiol & Crit Care, F-75252 Paris 05, France; [Le Fur, Yann; Cozzone, Patrick] Univ Mediterranee Aix Marseille II, Ctr Magnet Resonance Med Biol, Ctr Natl Rech Sci, Marseille, France; [Abdennour, Lamine] Univ Mediterranee Aix Marseille II, Dept Anesthesiol & Crit Care, Marseille, France; [Lehericy, Stephane] Univ Paris 06, Dept Neuroradiol, Paris, France; [Lehericy, Stephane] Univ Paris 06, Ctr Neuroimaging Res CENIR, Paris, France; [Puybasset, Louis] Hop La Pitie Salpetriere, Dept Anesthesiol, Paris, France; [Puybasset, Louis] Hop La Pitie Salpetriere, Crit Care & Intens Care Neurosurg Unit, Paris, France		Galanaud, D (corresponding author), Univ Hosp, Dept Neuroradiol, Rouen, France.	galanaud@dat.org			Assistance Publique-Hopitaux de Paris; French Health Ministry [ADM 05 101]	This study was funded solely by departmental sources (Assistance Publique-Hopitaux de Paris) and French Health Ministry (ADM 05 101 to LP).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Galanaud D, 2007, CURR OPIN NEUROL, V20, P627, DOI 10.1097/WCO.0b013e3282f169ec; Galanaud D, 2006, MAGN RESON MED, V55, P1236, DOI 10.1002/mrm.20886; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Thierry AGM, 2006, EUR RADIOL, V16, P1651, DOI 10.1007/s00330-006-0175-8; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Karantanas A, 2000, J NEUROSURG, V92, P896; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Robinson Lawrence R, 2004, Phys Med Rehabil Clin N Am, V15, P43, DOI 10.1016/S1047-9651(03)00102-5; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Weiss FU, 2008, BEST PRACT RES CL GA, V22, P3, DOI 10.1016/j.bpg.2007.10.017	43	93	101	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2009	37	4					1448	1455		10.1097/CCM.0b013e31819cf050			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	426HQ	WOS:000264699000038	19242330				2022-02-06	
J	Jha, A; Weintraub, A; Allshouse, A; Morey, C; Cusick, C; Kittelson, J; Harrison-Felix, C; Whiteneck, G; Gerber, D				Jha, Amitabh; Weintraub, Alan; Allshouse, Amanda; Morey, Clare; Cusick, Chris; Kittelson, John; Harrison-Felix, Cynthia; Whiteneck, Gale; Gerber, Don			A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; fatigue; modafinil; randomized clinical trial	BECK DEPRESSION INVENTORY; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; HEALTH SURVEY; HEAD-INJURY; PLACEBO; RELIABILITY; SCALE; SPECIFICITY; SENSITIVITY	Background: This study examines the efficacy of modafinil in treating fatigue and excessive daytime sleepiness in individuals with traumatic brain Injury (TBI). Methods: A single-center, double-blind, placebo-controlled cross-over trial, where 53 participants with TBI were randomly assigned to receive up to 400 mg of modafinil, or equal number of inactive placebo tablets. Main eligibility criteria were being at least 1 year post-TBI severe enough to require inpatient rehabilitation. The primary outcome measures were fatigue (Fatigue Severity Scale, FSS) and daytime sleepiness (Epworth Sleepiness Scale, ESS). Results: After adjusting for baseline scores and period effects, there were no statistically siginficant differences between improvements seen with modafinil and placebo in the FSS at week 4 (-0.5 +/- 1.88; P = .80) or week 10 (-1.4 +/- 2.75; P = .61). For ESS, average changes were significantly greater with modafinil than placebo at week 4 (-1.2 +/- 0.49; P = .02) but not at week 10 (-0.5 +/- 0.87; P = .56). Modafinil was safe and well tolerated, although insomnia was reported significantly more often with modafinil than placebo (P = .03). Conclusions: While there were sporadic statistically significant differences identified, a clear beneficial pattern from modafinil was not seen at either week 4 or week 10 for any of the 12 outcomes. There was no consistent and persistent clinically significant difference between treatment with modafinil and placebo.	[Jha, Amitabh; Weintraub, Alan; Morey, Clare; Cusick, Chris; Kittelson, John; Harrison-Felix, Cynthia; Whiteneck, Gale; Gerber, Don] Craig Hosp, Res Dept, Englewood, CO 80110 USA; [Jha, Amitabh; Harrison-Felix, Cynthia; Whiteneck, Gale] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Allshouse, Amanda; Kittelson, John] Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80202 USA		Jha, A (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80110 USA.	ajha@craighospital.org		Allshouse, Amanda/0000-0003-0109-7193			[Anonymous], 1998, Ann Neurol, V43, P88; Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406; Beck A., 1996, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Beusterien KM, 1999, SLEEP, V22, P757, DOI 10.1093/sleep/22.6.757; Black JE, 2005, SLEEP, V28, P464, DOI 10.1093/sleep/28.4.464; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Carter Gregory T, 2006, Am J Hosp Palliat Care, V23, P412, DOI 10.1177/1049909106292169; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chan KM, 2006, MUSCLE NERVE, V33, P138, DOI 10.1002/mus.20437; CHRISTENSEN L, 1995, J CONSULT CLIN PSYCH, V63, P495; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COLLINS M, 2002, MED SCI SPORTS EXE S, V34; COLLINS M, 2002, J ATHLETIC TRAIN S, V37; CONNERS CK, 2000, CONNERS CPT, V2; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; DeBattista C, 2003, J CLIN PSYCHIAT, V64, P1057, DOI 10.4088/JCP.v64n0911; ERICKSEN J, 2001, BRAIN INJ SOURCE, V5, P32; Fava M, 2005, J CLIN PSYCHIAT, V66, P85, DOI 10.4088/JCP.v66n0112; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; HAMMOND F, 1997, PHYS MED REH CLIN N, V8, P801; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HAWN K, 2002, J ATHLETIC TRAIN S, V37; Homack Susan, 2006, J Atten Disord, V9, P556, DOI 10.1177/1087054705283578; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Jones DEJ, 2007, ALIMENT PHARM THER, V25, P471, DOI 10.1111/j.1365-2036.2006.03223.x; KJERULFF KH, 1995, MED CARE, V33, pAS156; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lee K A, 1994, Image J Nurs Sch, V26, P149; LOVELL M, 2002, MED SCI SPORTS EXE S, V34; LOVELL M, 2002, J ATHLETIC TRAIN S, V37; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Newton JL, 2006, HEPATOLOGY, V44, P91, DOI 10.1002/hep.21230; Ninan PT, 2004, J CLIN PSYCHIAT, V65, P414; Okuyama T, 2000, J PAIN SYMPTOM MANAG, V19, P5, DOI 10.1016/S0885-3924(99)00138-4; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pack AI, 2001, AM J RESP CRIT CARE, V164, P1675, DOI 10.1164/ajrccm.164.9.2103032; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PEPPER CM, 1993, J NEUROPSYCH CLIN N, V5, P200; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Roth T, 1996, CLIN THER, V18, P562, DOI 10.1016/S0149-2918(96)80207-4; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sevy S, 2005, J CLIN PSYCHIAT, V66, P839, DOI 10.4088/JCP.v66n0705; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMITH S, 2007, SLEEP MED       0517; Stankoff B, 2005, NEUROLOGY, V64, P1139, DOI 10.1212/01.WNL.0000158272.27070.6A; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Taylor RR, 2000, PSYCHOL MED, V30, P849, DOI 10.1017/S0033291799002500; Teitelman E, 2001, AM J PSYCHIAT, V158, P1341, DOI 10.1176/ajp.158.8.1341; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WALKER EA, 1993, J GEN INTERN MED, V8, P436, DOI 10.1007/BF02599621; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Warden DL, 2000, J HEAD TRAUMA REHAB, V15, P1092, DOI 10.1097/00001199-200010000-00003; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; Wolman RL, 1994, CLIN REHABIL, V8, P253; Zifko UA, 2002, J NEUROL, V249, P983, DOI 10.1007/s00415-002-0765-6; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; 2000, NEUROL, V54, P1166	78	93	95	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					52	63		10.1097/01.HTR.0000308721.77911.ea			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800009	18219235				2022-02-06	
J	Brown, CVR; Zada, G; Salim, A; Inaba, K; Kasotakis, G; Hadjizacharia, P; Demetriades, D; Rhee, P				Brown, Carlos V. R.; Zada, Gabriel; Salim, Ali; Inaba, Kenji; Kasotakis, Georgios; Hadjizacharia, Pantelis; Demetriades, Demetrios; Rhee, Peter			Indications for routine repeat head computed tomography (CT) stratified by severity of traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		blunt; trauma; head injury; traumatic brain injury; computed tomography	MANAGEMENT	Background: controversy exists as to the role of a routine repeat head computed tomography (CT) for patients with traumatic brain injury and an initially abnormal head CT. The specific aim of this study is to identify patients with head injuries who would benefit from a routine repeat head CT. Methods: This was a 2-year (2003 and 2004) prospective study of all patients with blunt trauma admitted to an urban, Level I trauma center that presented with an abnormal head CT. Results of initial head CT and indications for repeat head CT (routine vs. neurologic change) were recorded. Interventions were both medical (diuresis, hyperventilation, barbiturates) and surgical (intracranial pressure monitor placement or craniotomy). Patients were categorized by Glasgow Coma Scale (GCS) score as having mild (GCS 13-15), moderate (GCS 9-12), or severe (GCS <= 8) head injury. Results: There were 354 patients admitted with an initially abnormal head CT. The 37 (10%) patients who went directly to craniotomy and the 43 (12%) patients who died within 24 hours of admission were excluded from analysis. The remaining 274 patients (44 years old, 70% male, mean injury severity score = 19, mean GCS = 10) are the focus of this analysis. After admission, 163 patients underwent a total of 241 repeat CT scans. Of the repeat scans obtained, 102 scans (43%) were unchanged, 54 scans (22%) were better, and 85 scans (35%) were worse. Neurologic deterioration prompted 45 repeat scans (19%), and 196 repeat scans (81%) were obtained routinely after admission without change in neurologic status. The 45 CT scans obtained for neurologic change led to medical or surgical intervention in 38% (n = 17) of cases, whereas scans obtained led to an intervention in only two patients (1%). Both patients who underwent an intervention after a routine scan had a GCS score <= 8 at admission and at the time of routine repeat head CT. One patient had an intracranial pressure monitor placed and the other was taken for craniotomy. No patient with a mild or moderate traumatic brain injury underwent an intervention after a routine repeat head CT. Conclusions: Patients with any head injury (mild, moderate, or severe) should undergo a repeat head CT after neurologic deterioration, because it leads to intervention in over one-third of patients. Routine repeat head CT is indicated for patients with a GCS score :58, as results might lead to intervention without neurologic change.	Univ So Calif, Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA		Brown, CVR (corresponding author), 1200 N State St,Room 6341, Los Angeles, CA 90033 USA.	carlosbr@usc.edu	INABA, KENJI/AAC-8532-2020	Kasotakis, George/0000-0002-7630-0742			Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	7	93	101	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2007	62	6					1339	1344		10.1097/TA.0b013e318054e25a			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	179YM	WOS:000247326600004	17563645				2022-02-06	
J	Pandya, JD; Pauly, JR; Nukala, VN; Sebastian, AH; Day, KM; Korde, AS; Maragos, WF; Hall, ED; Sullivan, PG				Pandya, Jignesh D.; Pauly, James R.; Nukala, Vidya N.; Sebastian, Andrea H.; Day, Kristen M.; Korde, Amit S.; Maragos, William F.; Hall, Edward D.; Sullivan, Patrick G.			Post-injury administration of mitochondrial uncouplers increases tissue sparing and improves Behavioral outcome following traumatic brain injury in rodents	JOURNAL OF NEUROTRAUMA			English	Article						carbonyl cyanide 4-trifluoromethoxy phenylhydrazone; cortical contusion; 2,4-dinitrophenol; mitochondrial bioenergetics; mitochondrial uncoupling; reactive oxygen species	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; HIPPOCAMPAL-NEURONS; CORTICAL IMPACT; CALCIUM-UPTAKE; NMDA RECEPTOR; CELL-DEATH; DAMAGE; RAT; DYSFUNCTION	Following experimental traumatic brain injury (TBI), a rapid and significant necrosis occurs at the site of injury which coincides with significant mitochondrial dysfunction. The present study is driven by the hypothesis that TBI-induced glutamate release increases mitochondrial Call cycling/overload, ultimately leading to mitochondrial dysfunction. Based on this premise, mitochondrial uncoupling during the acute phases of TBI-induced excitotoxicity should reduce mitochondrial Ca2+ uptake (cycling) and reactive oxygen species (ROS) production since both are mitochondrial membrane potential dependent. In the present study, we utilized a cortical impact model of TBI to assess the potential use of mitochondrial uncouplers (2,4-DNP, FCCP) as a neuroprotective therapy. Young adult male rats were intraperitoneally administered vehicle (DMSO), 2,4-DNP (5 mg/kg), or FCCP (2.5 mg/kg) at 5 min post-injury. All animals treated with the uncouplers demonstrated a significant reduction in the amount of cortical damage and behavioral improvement following TBI. In addition, mitochondria isolated from the injured cortex at 3 or 6 h post-injury demonstrated that treatment with the uncouplers significantly improved several parameters of mitochondrial bioenergetics. These results demonstrate that post-injury treatment with mitochondrial uncouplers significantly (p < 0.01) increases cortical tissue sparing (similar to 12%) and significantly (p < 0.01) improves behavioral outcome following TBI. The mechanism of neuroprotection most likely involves the maintenance of mitochondrial homeostasis by reducing mitochondrial Call loading and subsequent mitochondrial dysfunction. These results further implicate mitochondrial dysfunction as an early event in the pathophysiology of TBI and that targeting acute mitochondrial events can result in long-term neuroprotection and improve behavioral outcome following brain injury.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 375 BBSRB, Lexington, KY 40536 USA.	PatSullivan@uky.edu	Hall, Edward D/F-8930-2013	Korde, Amit/0000-0003-0702-290X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196, R01NS048191] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42196, NS48191] Funding Source: Medline		Amaral David G., 1995, P443; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Billups B, 2002, J NEUROSCI, V22, P5840; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HALL ED, 2004, NEUROSCIENCE MOL MED, P35; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Korde AS, 2005, J NEUROTRAUM, V22, P1142, DOI 10.1089/neu.2005.22.1142; Korde AS, 2005, J NEUROCHEM, V94, P1676, DOI 10.1111/j.1471-4159.2005.03328.x; KURT TL, 1986, VET HUM TOXICOL, V28, P574; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Pivovarova NB, 2002, J NEUROSCI, V22, P10653; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	59	93	96	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					798	811		10.1089/neu.2006.3673			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300005	17518535				2022-02-06	
J	Flaada, JT; Leibson, CL; Mandrekar, JN; Diehl, N; Perkins, PK; Brown, AW; Malec, JF				Flaada, Julie Testa; Leibson, Cynthia L.; Mandrekar, Jayawant N.; Diehl, Nancy; Perkins, Patricia K.; Brown, Allen W.; Malec, James F.			Relative risk of mortality after traumatic brain injury: A population-based study of the role of age and injury severity	JOURNAL OF NEUROTRAUMA			English	Article						aging; mortality; TBI	HEAD-INJURIES; TRENDS; EPIDEMIOLOGY; SURVIVAL; SEIZURES	To test if observed vs. expected mortality differs by age among traumatic brain injury (TBI) cases, a population-based, historical cohort study was conducted in Olmsted County, Minnesota. From all residents with any diagnosis suggestive of TBI 1985-1999, we randomly sampled 7,800 and reviewed their medical records to confirm the event. Confirmed incident cases were categorized by age in years (< 16 = pediatric, 16-65 = adult, > 65 = elderly) and severity (moderate/severe vs. mild) and followed for vital status through 6/30/2004. We compared observed 6-month and 10-year mortality with expected and tested if the differences varied by age. Of 1,433 confirmed incident cases, 35% were pediatric; 55% were adult; only 9% were elderly; 11.2% of all cases were moderate/severe; the proportions by increasing age group were 11.4%, 8.5%, 26.7%. The proportions who died within 6 months increased with increasing age group, both for moderate/severe (10.3%, 40.3%, 50.0%) and mild cases (0%, 0%, 9.1%); mortality for moderate/severe cases was nearly 40 times that for mild cases, independent of age. Among 6-month survivors, 10-year mortality differed from expected only for adult cases. For all cases, after adjusting for sex, year of TBI, and severity, the difference between observed and expected 10-year mortality was greater for adult cases than for pediatric cases and similar for adult and elderly cases. Elderly individuals account for < 10% of TBI cases and > 50% of 10-year mortality, yet much of this discrepancy reflects age-associated mortality in general. Findings have implications for (1) reducing the number of excess deaths following TBI and (2) caring for survivors.	Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA		Malec, JF (corresponding author), Mayo Clin, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA.	malec.james@mayo.edu		Brown, Allen W./0000-0001-7228-3351	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HI33A020507] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-07447] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R56HD007447, R01HD007447] Funding Source: NIH RePORTER		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Goleburn CR, 2001, J CLIN GEROPSYCHOL, V7, P161; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NATL CTR INJ PREV, 2003, REPORT CONGRESS MILD; Ogungbo B, 2004, J AM COLL SURGEONS, V198, P852, DOI 10.1016/j.jamcollsurg.2004.02.003; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE GM, 1979, ACTA NEUROCHIR S, V75, pS37; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA	25	93	94	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2007	24	3					435	445		10.1089/neu.2006.0119			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	152RQ	WOS:000245379900001	17402850				2022-02-06	
J	Bonislawski, DP; Schwarzbach, EP; Cohen, AS				Bonislawski, David P.; Schwarzbach, Elizabeth P.; Cohen, Akiva S.			Brain injury impairs dentate gyrus inhibitory efficacy	NEUROBIOLOGY OF DISEASE			English	Article						head injury; hippocampus; dentate gyrus; GABA; KCC2; gramacidin; perforated patch; chloride fluorescence	ENDURING MEMORY IMPAIRMENT; KCC2 EXPRESSION; HIPPOCAMPUS; NEURONS; COTRANSPORTER; NEOCORTEX; SEIZURES; SOMA; RAT; CA1	Every 23 s, a person sustains a traumatic brain injury in the United States leaving many patients with substantial cognitive impairment and epilepsy. Injury-induced alterations in the hippocampus underpin many of these disturbances of neurological function. Abnormalities in the dentate gyrus are likely to play a major role in the observed pathophysiology because this subregion functions as a filter impeding excessive or aberrant activity from propagating further into the circuit and following experimental brain injury, the dentate gyrus becomes more excitable. Although alteration in excitation or inhibition could mediate this effect in the dentate gyrus, we show a key role played by an impairment of GABA(A)ergic inhibition. The efficacy of GABA(A)-mediated inhibition depends on a low [CI-](i) that is maintained by neuronal K-Cl co-transporter 2 (KCC2). Using fluid percussion injury (FPI) in the mouse, we demonstrate significant reductions in KCC2 protein and mRNA expression in the dentate gyrus that causes a depolarizing shift in GABA(A) reversal potential, due to impaired chloride clearance, resulting in reduced inhibitory efficiency. This study elucidates a novel mechanism underlying diminished dentate gyrus inhibitory efficacy and provides an innovative target for the development of potential therapeutics to restore the severe pathological consequences of traumatic brain injury. (c) 2006 Elsevier Inc. All rights reserved.	Univ Penn, Childrens Hosp, Sch Med, Div Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA		Cohen, AS (corresponding author), Abramson Res Ctr 3516, Room 816H,Civic Ctr Blvd, Philadelphia, PA 19104 USA.	cohena@email.chop.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45975, R01 NS045975] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045975] Funding Source: NIH RePORTER		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; *BIAUSA, 2004, TBI STAT; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Cohen AS, 2003, EUR J NEUROSCI, V17, P1607, DOI 10.1046/j.1460-9568.2003.02597.x; Eldridge LL, 2005, J NEUROSCI, V25, P3280, DOI 10.1523/JNEUROSCI.3420-04.2005; GRADY MS, 1995, ANESTHETIC MANAGEMEN, P87; HEINEMANN U, 1992, EPILEPSY RES, P273; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; LOTHMAN EW, 1992, EPILEPSY RES, P301; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Plotkin MD, 1997, J NEUROBIOL, V33, P781, DOI 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Sun MK, 2001, J NEUROPHYSIOL, V85, P269, DOI 10.1152/jn.2001.85.1.269; Toth Z, 1997, J NEUROSCI, V17, P8106; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Zhu L, 2005, J NEUROPHYSIOL, V93, P1557, DOI 10.1152/jn.00616.2004; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	28	93	95	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JAN	2007	25	1					163	169		10.1016/j.nbd.2006.09.002			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	114KN	WOS:000242665200017	17045484	Green Accepted			2022-02-06	
J	Chen, Y; Samal, B; Hamelink, CR; Xiang, CC; Chen, Y; Chen, M; Vaudry, D; Brownstein, MJ; Hallenbeck, JM; Eiden, LE				Chen, Yun; Samal, Babru; Hamelink, Carol R.; Xiang, Charlie C.; Chen, Yong; Chen, Mei; Vaudry, David; Brownstein, Michael J.; Hallenbeck, John M.; Eiden, Lee E.			Neuroprotection by endogenous and exogenous PACAP following stroke	REGULATORY PEPTIDES			English	Article; Proceedings Paper	Workshop on Signalling Mechanisms of VIP, PACAP and Related Peptides - Contribution of Genomics, Proteomics and Bioinformatics	SEP, 2005	Rouen, FRANCE			pituitary adenylate cyclase activating polypeptide; PACAP; PACAP-deficient mouse; middle cerebral artery occlusion; MCAO; neurological severity score; NSS; cerebral ischerma; infarct volume; cDNA microarray; PACAP responsive gene; neuroprotection; neurotrauma	CYCLASE-ACTIVATING POLYPEPTIDE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; VASOACTIVE-INTESTINAL-PEPTIDE; HIPPOCAMPAL GENE-EXPRESSION; CEREBELLAR GRANULE CELLS; MICROARRAY ANALYSIS; LIGAND/RECEPTOR SYSTEM; PROENKEPHALIN GENE; GENOMIC RESPONSE	We investigated the effects of PACAP treatment, and endogenous PACAP deficiency, on infarct volume, neurological function, and the cerebrocortical transcriptional response in a mouse model of stroke, middle cerebral artery occlusion (MCAO). PACAP-38 administered i.v. or i.e. v. 1 h after MCAO significantly reduced infarct volume, and ameliorated functional motor deficits measured 24 h later in wild-type mice. Infarct volumes and neurological deficits (walking faults) were both greater in PACAP-deficient than in wild-type mice, but treatment with PACAP reduced lesion volume and neurological deficits in PACAP-deficient mice to the same level of improvement as in wild-type mice. A 35,546-clone mouse cDNA microarray was used to investigate cortical transcriptional changes associated with cerebral ischemia in wild-type and PACAP-deficient mice, and with PACAP treatment after MCAO in wild-type mice. 229 known (named) transcripts were increased (228) or decreased (1) in abundance at least 50% following cerebral ischemia, in wild-type mice. 49 transcripts were significantly up-regulated only at 1 h post-MCAO (acute response transcripts), 142 were up-regulated only at 24 h post-MCAO (delayed response transcripts) and 37 transcripts were upregulated at both times (sustained response transcripts). More than half of these are transcripts not previously reported to be altered in ischemia. A larger percentage of genes up-regulated at 24 hr than at 1 hr required endogenous PACAP, suggesting a more prominent role for PACAP in later response to injury than in the initial response. This is consistent with a neuroprotective role for PACAP in late response to injury, i.e., even when administered 1 hr or more after MCAO. Putative injury effector transcripts regulated by PACAP include beta-actin, rnidline 2, and metallothionein 1. Potential neuroprotective transcripts include several demonstrated to be PACAP-regulated in other contexts. Prominent among these were transcripts encoding the PACAP-regulated gene ler3, and the neuropeptides enkephalin, substance P (tachykinin 1), and neurotensin. (c) 2006 Elsevier B.V. All rights reserved.	NIH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA; NIMH, Genet Lab, NIH, Bethesda, MD 20892 USA; NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA		Eiden, LE (corresponding author), NIH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bldg 10, Bethesda, MD 20892 USA.	eidenl@mail.nih.gov	Samal, Babru/ABE-5931-2020; VAUDRY, David/M-1454-2018; Samal, Babru B/C-5563-2008	VAUDRY, David/0000-0003-3567-7452; Eiden, Lee/0000-0001-7524-944X	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 MH002386-21, Z01 MH002386-22] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002924, Z01NS002856] Funding Source: NIH RePORTER		ALLEN GV, 1995, NEUROSCIENCE, V68, P1037, DOI 10.1016/0306-4522(95)00198-R; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Bernaudin M, 2002, J BIOL CHEM, V277, P39728, DOI 10.1074/jbc.M204619200; Bowler RP, 2002, FREE RADICAL BIO MED, V33, P1141, DOI 10.1016/S0891-5849(02)01008-0; Campagne MV, 1998, J NEUROSCI RES, V53, P279; Canonico PL, 1996, ANN NY ACAD SCI, V805, P470; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Chen Y, 2004, PROCEEDINGS OF THE 2004 INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND CYBERNETICS, VOLS 1-7, P267; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chuquet J, 2002, J CEREBR BLOOD F MET, V22, P1165, DOI 10.1097/01.wcb.0000037987.07114.7c; Dawson DA, 1999, J CEREBR BLOOD F MET, V19, P616, DOI 10.1097/00004647-199906000-00004; del Rio G, 2001, FEBS LETT, V509, P230, DOI 10.1016/S0014-5793(01)03165-9; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1200; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DeWitt D S, 1995, New Horiz, V3, P376; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Dicicco-Bloom E, 1998, ANN NY ACAD SCI, V865, P274, DOI 10.1111/j.1749-6632.1998.tb11188.x; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; FISCHERCOLBRIE R, 1992, J NEUROCHEM, V59, P780, DOI 10.1111/j.1471-4159.1992.tb09440.x; FISCHERCOLBRIE R, 1988, P NATL ACAD SCI USA, V85, P3240, DOI 10.1073/pnas.85.9.3240; Fox S, 1998, INFECT MED, V15, P8; Georg B, 2000, MOL BRAIN RES, V79, P67, DOI 10.1016/S0169-328X(00)00101-7; Gozes I, 2004, J ALZHEIMERS DIS, V6, pS37; Hamelink C, 2002, P NATL ACAD SCI USA, V99, P461, DOI 10.1073/pnas.012608999; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; Jin K, 2002, NEUROCHEM RES, V27, P1105, DOI 10.1023/A:1020913123054; Jin KL, 2001, ANN NEUROL, V50, P93, DOI 10.1002/ana.1073; Just L, 1998, J MOL NEUROSCI, V11, P57, DOI 10.1385/JMN:11:1:57; Just L, 2000, GLIA, V30, P242, DOI 10.1002/(SICI)1098-1136(200005)30:3<242::AID-GLIA4>3.0.CO;2-V; Kim YD, 2002, BRAIN RES BULL, V58, P491, DOI 10.1016/S0361-9230(02)00823-7; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koistinaho J, 1997, NEUROREPORT, V8, pR1; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LOW KG, 1992, ENDOCRINOLOGY, V131, P1908, DOI 10.1210/en.131.4.1908; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marciano PG, 2001, RESTOR NEUROL NEUROS, V18, P105; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mizushima H, 1999, PEPTIDES, V20, P1337, DOI 10.1016/S0196-9781(99)00143-6; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Onoue S, 2002, REGUL PEPTIDES, V107, P43, DOI 10.1016/S0167-0115(02)00065-4; Pan W, 2002, BIOINFORMATICS, V18, P546, DOI 10.1093/bioinformatics/18.4.546; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Ravni A, 2006, J NEUROCHEM, V98, P1229, DOI 10.1111/j.1471-4159.2006.03962.x; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Read SJ, 2001, J CEREBR BLOOD F MET, V21, P755, DOI 10.1097/00004647-200107000-00001; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Rickhag M, 2006, J NEUROCHEM, V96, P14, DOI 10.1111/j.1471-4159.2005.03508.x; Riera M, 2001, TRANSPLANTATION, V72, P1217, DOI 10.1097/00007890-200110150-00006; Sano H, 2002, REGUL PEPTIDES, V109, P107, DOI 10.1016/S0167-0115(02)00193-3; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shioda Seiji, 2004, Nihon Yakurigaku Zasshi, V123, P243; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Takei N, 1998, J NEUROSCI RES, V54, P698, DOI 10.1002/(SICI)1097-4547(19981201)54:5<698::AID-JNR15>3.0.CO;2-5; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; Tateishi N, 2002, J CEREBR BLOOD F MET, V22, P723, DOI 10.1097/00004647-200206000-00011; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Xiang CC, 2002, NAT BIOTECHNOL, V20, P738, DOI 10.1038/nb0702-738; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Zhou CJ, 1999, NEUROSCIENCE, V93, P375, DOI 10.1016/S0306-4522(99)00108-6	78	93	94	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-0115	1873-1686		REGUL PEPTIDES	Regul. Pept.	NOV 15	2006	137	1-2					4	19		10.1016/j.regpep.2006.06.016			16	Endocrinology & Metabolism; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Endocrinology & Metabolism; Physiology	117OD	WOS:000242881700002	17027094	Green Accepted			2022-02-06	
J	Wu, YL; Tang, Z; Fang, HQ; Gao, SL; Chen, J; Wang, Y; Yan, HC				Wu, Yulian; Tang, Zhe; Fang, Heqing; Gao, Shunliang; Chen, Jian; Wang, Yong; Yan, Haichao			High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer	JOURNAL OF SURGICAL ONCOLOGY			English	Article						pancreatic cancer; radiofrequency ablation (RFA); complication; mortality	BLOOD-FLOW; OCCLUSION; RESECTION; SURVIVAL; LESIONS; TIME	Background and Objectives: To report and discuss the effect, complications and mortality of cool-tip radiofrequency ablation (RFA) for unresectable pancreatic cancer. Methods: During October 2003 to July 2004, sixteen patients with unresectable pancreatic cancer were treated by open cool-tip RFA. One-half of the 16 patients had tumors located in the pancreatic head. A 5-mm minimum safe distance between RFA site and major peripancreatic vessels was kept to avoid injury to the vessels. Results: Six of twelve patients with back pain got pain relief postoperatively. Pancreatic fistula occurred in three patients (18.8%) and healed smoothly in 7-10 days with routine abdominal drainage. The mortality was 25% (4/16). In the four death cases, tumors were all located in the pancreatic head; three patients with tumor close to portal vein died suddenly of massive gastrointestinal hemorrhage on the 4th, 30th, 40th postoperative day respectively and a 79-year-old patient died of acute renal failure on the 2nd postoperative day. Conclusions: Standard use of cool-tip RFA was dangerous for pancreatic head cancer close to portal vein, in which a 5-mm minimum safe distance between RFA site and major peripancreatic vessels might not be enough to avoid injury to the vessels.	Zhejiang Univ, Coll Med, Dept Surg, Affiliated Hosp 2, Hangzhou 310009, Peoples R China		Wu, YL (corresponding author), Zhejiang Univ, Coll Med, Dept Surg, Affiliated Hosp 2, 88 Jiefan Rd, Hangzhou 310009, Peoples R China.	wuyulian@medmail.com.cn					Andren-Sandberg A, 2002, PANCREATOLOGY, V2, P431, DOI 10.1159/000064710; BRAMHALL S, 1998, PANCREAS, P889; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Chen KX, 2003, WORLD J GASTROENTERO, V9, P2557; Elias D, 2004, EJSO, V30, P85, DOI 10.1016/j.ejso.2003.10.013; Friedman M, 2004, CARDIOVASC INTER RAD, V27, P427, DOI 10.1007/s00270-004-0062-0; Heisterkamp J, 1997, BRIT J SURG, V84, P1245; Lowenfels AB, 2004, JPN J CLIN ONCOL, V34, P238, DOI 10.1093/jjco/hyh045; Lu DSK, 2002, AM J ROENTGENOL, V178, P47, DOI 10.2214/ajr.178.1.1780047; Matsui Y, 2000, PANCREAS, V20, P14, DOI 10.1097/00006676-200001000-00002; Mirza AN, 2001, CANCER J, V7, P95; Morrison CP, 2003, MED SCI MONITOR, V9, pBR43; Neoptolemos JP, 1997, BRIT J SURG, V84, P1370; Ng Kelvin Kwok-Chai, 2003, Asian J Surg, V26, P50, DOI 10.1016/S1015-9584(09)60218-9; Ng KKC, 2004, BRIT J SURG, V91, P632, DOI 10.1002/bjs.4500; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Patterson EJ, 1998, ANN SURG, V227, P559, DOI 10.1097/00000658-199804000-00018; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Shore S, 2004, SURG ONCOL, V13, P201, DOI 10.1016/j.suronc.2004.11.001; Wiersinga WJ, 2003, BRIT J SURG, V90, P306, DOI 10.1002/bjs.4040; Yamasaki T, 2002, CANCER-AM CANCER SOC, V95, P2353, DOI 10.1002/cncr.10966	21	93	100	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4790	1096-9098		J SURG ONCOL	J. Surg. Oncol.	OCT 1	2006	94	5					392	395		10.1002/jso.20580			4	Oncology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Surgery	089AQ	WOS:000240852700008	16967436				2022-02-06	
J	Harwin, WS; Patton, JL; Edgerton, VR				Harwin, William S.; Patton, James L.; Edgerton, V. Reggie			Challenges and opportunities for robot-mediated neurorehabilitation	PROCEEDINGS OF THE IEEE			English	Article						haptic interfaces; neurological injury; neurorehabilitation; rehabilitation; robot; spinal cord injury; stroke; traumatic brain injury; virtual reality	REHABILITATION THERAPY; CASE-FATALITY; STROKE; DESIGN; ENVIRONMENT; ADAPTATION; FORCE	Robot-mediated neurorehabilitation is a rapidly advancing field that seeks to use advances in robotics, virtual realities, and haptic interfaces, coupled with theories in neuroscience and rehabilitation to define new methods for treating neurological injuries such as stroke, spinal cord injury, and traumatic brain injury. The field is nascent and much work is needed to identify efficient hardware, software, and control system designs alongside the most effective methods for delivering treatment in home and hospital settings. This paper identifies the need for robots in neurorehabilitation and identifies important goals that will allow this field to advance.	Univ Reading, Sch Syst Engn, Cybernet Grp, Reading RG6 6AY, Berks, England; Rehabil Inst Chicago, Chicago, IL 60611 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA		Harwin, WS (corresponding author), Univ Reading, Sch Syst Engn, Cybernet Grp, Reading RG6 6AY, Berks, England.	W.S.Harwin@readihg.ac.uk; j-patton@northwestern.edu; vre@ucla.edu	Harwin, William S/N-1148-2014	Harwin, William S/0000-0002-3928-3381			Amirabdollahian F, 2002, 2002 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS I-IV, PROCEEDINGS, P3380, DOI 10.1109/ROBOT.2002.1014233; AMIRABODOLLAHIA.F, 2003, THSIS U READING READ; Arbib MA, 1995, HDB BRAIN THEORY NEU; BAVELIER D, 2000, NATURE REV NEUROSCI, V3, P443; Brewer B. R., 2003, P 8 INT C REH ROB DA, P258; Brewer BR, 2005, IEEE T NEUR SYS REH, V13, P1, DOI 10.1109/TNSRE.2005.843443; Brewer BR, 2004, IEEE INT CONF ROBOT, P2080, DOI 10.1109/ROBOT.2004.1308130; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; Cai LL, 2005, INT C REHAB ROBOT, P575; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Colombo G, 2005, INT C REHAB ROBOT, P227; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; DUNNETT S, 2004, ACAD MED SCI      MA, P47; Emken JL, 2005, IEEE T NEUR SYS REH, V13, P33, DOI 10.1109/TNSRE.2004.843173; ERLANDSON RF, 1995, IEEE T REHABIL ENG, V3, P22, DOI 10.1109/86.372889; EYRE J, 2004, RESTORING NEUROLOGIC, P35; Fasoli SE, 2004, ARCH PHYS MED REHAB, V85, P1106, DOI 10.1016/j.apmr.2003.11.028; FLANAGAN JR, 1995, J NEUROPHYSIOL, V74, P2174, DOI 10.1152/jn.1995.74.5.2174; Galvez JA, 2005, INT C REHAB ROBOT, P231; GALVEZ JA, 2005, TECHNOL STRATEG ENHA, V0011, P00018, DOI DOI 10.1310/DAMJ-G43A-16EH-1BDK; Goldstein A, 1993, WE AM ELDERLY; Goodbody SJ, 1998, J NEUROPHYSIOL, V79, P1825, DOI 10.1152/jn.1998.79.4.1825; HARWIN WS, 1995, IEEE T REHABIL ENG, V3, P3, DOI 10.1109/86.372887; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HOGAN N, 1992, P SPIE C TEL TECHN, P28; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; Johnson MJ, 2003, ROBOTICA, V21, P13, DOI 10.1017/S0263574702004599; KANADE T, 2004, NSF INT ADV ROB PROG; Kearney RE, 1997, IEEE T BIO-MED ENG, V44, P493, DOI 10.1109/10.581944; Kording KP, 2004, P NATL ACAD SCI USA, V101, P9839, DOI 10.1073/pnas.0308394101; Kording KP, 2004, NATURE, V427, P244, DOI 10.1038/nature02169; Kujala T, 2000, TRENDS NEUROSCI, V23, P115, DOI 10.1016/S0166-2236(99)01504-0; Liu J, 2005, INT C REHAB ROBOT, P37; Loureiro R, 2003, AUTON ROBOT, V15, P35, DOI 10.1023/A:1024436732030; *MERCK RES LAB, 1997, MARCK MAN GER WHITH; Miall RC, 1996, NEURAL NETWORKS, V9, P1265, DOI 10.1016/S0893-6080(96)00035-4; Mirbagheri MM, 2005, INT C REHAB ROBOT, P561; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; Patton JL, 2004, IEEE T BIO-MED ENG, V51, P636, DOI 10.1109/TBME.2003.821035; PATTON JL, 2005, EXPT BRAIN RES; Penfield W., 1950, CEREBRAL CORTEX MAN; REINKENSMEYER D, 1999, BIOMECHANTRONICS, P61; Robles-De-La-Torre G, 2001, NATURE, V412, P445, DOI 10.1038/35086588; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; SANDERCOCK P, 2002, HLTH TECHNOL ASSESS, V6; SRINIVASAN MA, 1995, J NEUROPHYSIOL, V73, P88, DOI 10.1152/jn.1995.73.1.88; Stewart JA, 1999, BRIT MED J, V318, P967, DOI 10.1136/bmj.318.7189.967; *STROK ASS, 2006, STROK STAT FACT SHEE; Taub E, 1999, J REHABIL RES DEV, V36, P237; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Timoszyk WK, 2003, ROBOTICA, V21, P25, DOI 10.1017/S0263574702004605; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8; WEI Y, 2005, P IEEE INT C ROB AUT; WING A, 2004, RESTORING NEUROLOGIC, P58; Winstein CJ, 1999, NEUROPSYCHOLOGIA, V37, P975, DOI 10.1016/S0028-3932(98)00145-6; Wolfe CDA, 2002, J NEUROL NEUROSUR PS, V72, P211, DOI 10.1136/jnnp.72.2.211	57	93	95	1	13	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9219	1558-2256		P IEEE	Proc. IEEE	SEP	2006	94	9					1717	1726		10.1109/JPROC.2006.880671			10	Engineering, Electrical & Electronic	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	101ZK	WOS:000241780000008					2022-02-06	
J	McCarthy, ML; MacKenzie, EJ; Durbin, DR; Aitken, ME; Jaffe, KM; Paidas, CN; Slomine, BS; Dorsch, AM; Christensen, JR; Ding, R				McCarthy, ML; MacKenzie, EJ; Durbin, DR; Aitken, ME; Jaffe, KM; Paidas, CN; Slomine, BS; Dorsch, AM; Christensen, JR; Ding, R		Children's Hlth After Trauma Stdy	Health-related quality of life during the first year after traumatic brain injury	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							GENERIC CORE SCALES; CLOSED-HEAD-INJURY; FAMILY ASSESSMENT DEVICE; LONG-TERM OUTCOMES; CHILD-HEALTH; INTELLECTUAL ABILITY; BEHAVIOR PROBLEMS; FOLLOW-UP; RELIABILITY; VALIDITY	Objectives: To document health-related quality of life (HRQOL) of children with traumatic brain injury (TBI) and to examine the relationship between TBI severity and HRQOL during the first year after injury. Design: Prospective cohort study. Setting: Four pediatric level I trauma centers. Patients: Children with TBI (n=330). Main Exposure: Traumatic brain injury. Main Outcome Measures: A primary caregiver completed telephone interviews at baseline, 3 months, and 12 months to measure the child's HRQOL using the Pediatric Quality of Life Inventory. The HRQOL outcomes were modeled as a function of injury, patient characteristics, and family characteristics using longitudinal, multivariable regression. Results: A considerable proportion of children had impaired HRQOL at 3 months (42% of children) and 12 months (40% of children) after injury. Multiple dimensions of HRQOL were negatively affected among children with moderate or severe TBI (decrease of 3.7 to 17.6) (P < .05) and did not improve significantly over time. Concomitant lower extremity fractures and spinal injuries resulted in large declines in overall HRQOL, particularly at 3 months after injury (decrease of 12.9 and 8.1, respectively) (P < .05). The HRQOL scores were also reduced by preexisting psychosocial conditions (decrease of 2.9 to 12.3), impaired family functioning (decrease of 5.1 to 6.8), having Medicaid coverage or being uninsured (decrease of 3.1 to 5.5), and single-parent households (decrease of 3.2 to 3.4) (P < .05). Conclusions: Moderate or severe TBI resulted in measurable declines in children's HRQOL after injury. Injury-related factors impacted HRQOL more compared with patient and family characteristics during the first year after injury.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Rehabil Psychol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA; Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; Kennedy Krieger Inst, Dept Pediat Rehabil Med, Baltimore, MD USA		McCarthy, ML (corresponding author), 5802 Smith Ave,Davis Bldg,Room 220, Baltimore, MD 21209 USA.	mmccarth@jhmi.edu	Durbin, Dennis/AAD-7829-2022; ding, ru/B-1615-2009; Aitken, Mary/ABG-6119-2021	Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR319701] Funding Source: Medline		Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bastiaansen D, 2004, QUAL LIFE RES, V13, P489, DOI 10.1023/B:QURE.0000018483.01526.ab; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Broman S. H., 1995, TRAUMATIC HEAD INJUR; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; Daltroy LH, 1998, J PEDIATR ORTHOPED, V18, P561, DOI 10.1097/00004694-199809000-00001; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DING R, IN PRESS J PEDIAT OR; Eiser C, 2003, CHILD CARE HLTH DEV, V29, P95, DOI 10.1046/j.1365-2214.2003.00318.x; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Friefeld S, 2004, CNS SPECTRUMS, V9, P465; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; HALEY SM, 1992, PEDIAT EVALUATION DI; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAPLAN RM, 1989, MED CARE, V27, P27; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; KRAUS JF, 1987, PEDIATRICS, V79, P501; Laffel LMB, 2003, DIABETES CARE, V26, P3067, DOI 10.2337/diacare.26.11.3067; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MCCARTHY ML, 1995, J TRAUMA, V39, P828, DOI 10.1097/00005373-199511000-00005; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Pollak AN, 2003, J BONE JOINT SURG AM, V85A, P1893, DOI 10.2106/00004623-200310000-00005; Powers SW, 2004, CEPHALALGIA, V24, P120, DOI 10.1111/j.1468-2982.2004.00652.x; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STARFIELD B, 1993, PEDIATRICS, V91, P430; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Varni JW, 2002, ARTHRITIS RHEUM, V46, P714, DOI 10.1002/art.10095; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2003, DIABETES CARE, V26, P631, DOI 10.2337/diacare.26.3.631; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c; Ware JE, 2003, ARCH PHYS MED REHAB, V84, pS43, DOI 10.1053/apmr.2003.50246; Ware JE., 1996, CHQ USERS MANUAL; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	62	93	94	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	2006	160	3					252	260		10.1001/archpedi.160.3.252			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	019XK	WOS:000235871300003	16520444	Bronze			2022-02-06	
J	Vlodavsky, E; Palzur, E; Soustiel, JF				Vlodavsky, E; Palzur, E; Soustiel, JF			Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						hyperbaric oxygen; neuroinflammation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; CELL-DEATH; EXTRACELLULAR PROTEOLYSIS; PLASMINOGEN ACTIVATORS; INFLAMMATORY RESPONSE; BARRIER PERMEABILITY; TISSUE INHIBITOR	The acute inflammatory response plays an important role in secondary brain damage after traumatic brain injury (TBI). Neutrophils provide the main source of matrix metalloproteinases (MMPs) which also play a deleterious role in TBI. Numerous preclinical studies have suggested that hyperbaric oxygen therapy (HBOT) may by beneficial in various noncerebral and cerebral inflammatory diseases. The goal of this study was to evaluate the effects of HBOT on inflammatory infiltration and the expression of MMPs in correlation with secondary cell death in the rat model of dynamic cortical deformation (DCD). Twenty animals underwent DCD with subsequent HBOT (2.8 ATA, two sessions of 45 min each); 10 animals: DCD and normobaric oxygenation (1 ATA), 10 animals: not treated after DCD. Cell death was evaluated by TUNEL. Neutrophils were revealed by myeloperoxidase staining. Immunohistochemical staining for MMP-2 and -9 and tissue inhibitors of MMP-1 (TIMP-1) and -2 was also performed and the results were quantitatively evaluated by image analysis. In the animals treated by HBOT, a significant decrease in the number of TUNEL-positive cells and neutrophilic inflammatory infiltration was seen in comparison with nontreated animals and those treated by normobaric oxygen. The expression of MMP-9 was also significantly lower in the treated group. Staining for MMP-2 and TIMP-2 did not change significantly. Our results demonstrate that HBOT decreased the extent of secondary cell death and reactive neuroinflammation in the TBI model. The decline of MMP-9 expression after HBOT may also contribute to protection of brain tissue in the perilesional area. Further research should be centred on the evaluation of long-term functional and morphological results of HBOT.	Rambam Med Ctr, Inst Pathol, IL-31096 Haifa, Israel; Rambam Med Ctr, Div Neurosurg, IL-31096 Haifa, Israel; Rambam Med Ctr, Acute Brain Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Haifa, Israel		Vlodavsky, E (corresponding author), Rambam Med Ctr, Inst Pathol, IL-31096 Haifa, Israel.	e_vlodavsky@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Akin ML, 2002, UNDERSEA HYPERBAR M, V29, P279; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buras J, 2000, INT ANESTHESIOL CLIN, V38, P91, DOI 10.1097/00004311-200001000-00007; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Crocker SJ, 2004, J NEUROSCI RES, V75, P1, DOI 10.1002/jnr.10836; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Demchenko IT, 2000, NITRIC OXIDE-BIOL CH, V4, P597, DOI 10.1006/niox.2000.0313; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Garrity MM, 2003, MODERN PATHOL, V16, P389, DOI 10.1097/01.MP.0000062657.30170.92; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hjelde A, 2002, EUR J APPL PHYSIOL, V86, P401, DOI 10.1007/s00421-001-0573-1; Juttner B, 2003, UNDERSEA HYPERBAR M, V30, P305; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kochanek PM, 2001, CRIT CARE MED, V29, P906, DOI 10.1097/00003246-200104000-00050; Kubes P, 2000, BRAIN PATHOL, V10, P127; Larson JL, 2000, PLAST RECONSTR SURG, V105, P1375, DOI 10.1097/00006534-200004040-00017; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Maier CM, 2004, STROKE, V35, P1169, DOI 10.1161/01.STR.0000125861.55804.f2; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mun-Bryce S, 2004, BRAIN RES, V1026, P227, DOI 10.1016/j.brainres.2004.08.024; NEWCOMB JK, EXP NEUROL, V999, P76; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; REN H, 2000, CHIN J TRAUMATOL, V4, P239; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Shibayama M, 1997, ACT NEUR S, V70, P220; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Sumen G, 2001, EUR J PHARMACOL, V431, P265, DOI 10.1016/S0014-2999(01)01446-7; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	65	93	113	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	2006	32	1					40	50		10.1111/j.1365-2990.2005.00698.x			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	999TN	WOS:000234413500005	16409552				2022-02-06	
J	Yao, XL; Liu, J; Lee, E; Ling, GSF; McCabe, JT				Yao, XL; Liu, J; Lee, E; Ling, GSF; McCabe, JT			Progesterone differentially regulates pro- and anti-apoptotic gene expression in cerebral cortex following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; Bcl-2; brain injury; neuroprotection; neurotrauma; progesterone	CENTRAL-NERVOUS-SYSTEM; BCL-2 MESSENGER-RNA; CELL-DEATH; IN-VIVO; ALTERED EXPRESSION; DNA FRAGMENTATION; ARTERY OCCLUSION; CONTUSION INJURY; UNITED-STATES; ADULT BRAIN	Although the administration of progesterone has been shown to be neuroprotective in experimental models of traumatic brain injury (TBI), the mechanisms for this beneficial effect are still poorly understood. The present study examined the effects of progesterone on mRNA and protein levels of the Bcl-2 apoptosis regulatory genes, bax, bad, bcl-2, and bcl-x(L), in cerebral cortex after TBI. Male Sprague-Dawley rats were subjected to either sham surgery or lateral fluid percussion brain injury of moderate severity (2.4-2.6 atm). Within 1 h post-surgery, progesterone (4 mg/kg) or vehicle (corn oil) administration was initiated for 1-7 days postoperatively. Our results indicate that bax and bad mRNA levels and Bax and Bad protein expression in the ipsilateral, injured cerebral cortex were significantly elevated post-TBI, while mRNA levels of bcl-2 and bcl-XL or Bcl-2 and Bcl-x(L) protein expression were not changed. Under the sham-treated condition, progesterone significantly increased mRNA levels of the anti-apoptotic gene, bcl-2, but down-regulated pro-apoptotic gene expression (bax and bad) in cerebral cortex. After TBI, progesterone treatment reduced bax and bad mRNA levels in the ipsilateral cerebral cortex of TBI rats, and decreased Bax and Bad protein levels. In addition, bcl-2 and bcl-x(L) mRNA levels, as well as Bcl-2 and Bcl-x(L) protein expression, were increased by progesterone in TBI injured cortex. These data indicate that one of the neuroprotective mechanisms of progesterone may be related to its differential regulation of apoptotic signals.	Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Yao, XL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		McCabe, Joseph T/J-6293-2014	McCabe, Joseph T/0000-0002-1159-7442			Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Ceremuga TE, 2001, ENDOCR RES, V27, P433, DOI 10.1081/ERC-100107867; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen J, 1996, J NEUROCHEM, V67, P64; Clark RSB, 1997, J NEUROSCI, V17, P9172; *CTR DIS CONTR, 2001, TRAUM BRAIN INJ US; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Dubal DB, 1999, J NEUROSCI, V19, P6385; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GOTSCHALL CS, 1995, J NEUROTRAUM, V12, P611, DOI 10.1089/neu.1995.12.611; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Luo Chun, 2002, Chin J Traumatol, V5, P299; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; Viegas LR, 2004, J BIOL CHEM, V279, P9831, DOI 10.1074/jbc.M312402200; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Ye X, 2001, BIOCHEM BIOPH RES CO, V286, P401, DOI 10.1006/bbrc.2001.5396; Zhang SM, 1999, CHINESE MED J-PEKING, V112, P608	51	93	103	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					656	668		10.1089/neu.2005.22.656			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400005	15941375				2022-02-06	
J	Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A				Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A			Mortality following rehabilitation in the Traumatic Brain Injury Model Systems of Care	NEUROREHABILITATION			English	Article						traumatic brain injury; mortality; life expectancy	NATIONAL-DEATH-INDEX; SEVERE HEAD-INJURY; LIFE EXPECTANCY; EMPLOYMENT STATUS; LONGITUDINAL-MORTALITY; EARLY PREDICTORS; VITAL STATUS; SURVIVAL; POPULATION; COMA	While many outcomes after traumatic brain injury (TBI) have been systematically investigated, the most basic of all outcomes - survival - has been neglected. The purpose of this study was to investigate mortality in a cohort of 2,178 individuals with TBI completing inpatient rehabilitation in one of 15 National Institute on Disability and Rehabilitation Research-funded TBI Model Systems of care. The study hypotheses were: (1) relative to the general population, TBI increases mortality and decreases life expectancy in individuals with TBI completing inpatient rehabilitation and surviving to one-year post-injury; and (2) within the TBI population, the risk of death is greater in certain TBI subgroups. Results indicate that individuals with TBI were twice as likely to die compared to individuals in the general population of similar age, gender and race, resulting in an estimated average life expectancy reduction of seven years for individuals with TBI. Within the TBI population, the strongest independent risk factors for death after one-year post-injury were older age and not being employed at injury, and greater disability at rehabilitation discharge. This information is important to guide decision-making for treatment, utilization of limited medical resources, and planning for ongoing health care needs and lifetime planning.	Craig Hosp, Res Dept, Englewood, CO 80113 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; Charlotte Inst Rehabil, Charlotte, NC USA; Univ Colorado, Denver Hlth Med Ctr, Dept Rehabil Med, Denver, CO 80202 USA		Harrison-Felix, C (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org					ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Baguley I, 2000, BRAIN INJURY, V14, P505; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; Gordis L, 2000, EPIDEMIOLOGY; GOTSCH K, 2001, BRAIN INJ ASS ANN M; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; MININO A, 2002, NATL VITAL STAT REPO, V50; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NAT I DIS REH RES, 1996, J HEAD TRAUMA REHAB, V11, P1; *NAT I OCC SAF HLT, 2000, BRIEF REP RES GRANT; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; ROGOT E, 1992, PUBLIC HEALTH REP, V107, P457; Rosner B, 2000, FUNDAMENTALS BIOSTAT; Schnorr TM, 1997, EPIDEMIOLOGY, V8, P321, DOI 10.1097/00001648-199705000-00017; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Sesso HD, 2000, AM J EPIDEMIOL, V152, P107, DOI 10.1093/aje/152.2.107; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SINGH GK, 1996, MONTHLY VITAL STAT S, V45; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; SORLIE PD, 1990, AM J EPIDEMIOL, V132, P983, DOI 10.1093/oxfordjournals.aje.a115741; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; STEENLAND K, 1991, EPIDEMIOLOGY, V2, P418, DOI 10.1097/00001648-199111000-00005; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; THURMAN D, 2001, HEAD TRAUMA BASIC PR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *TRAUM BRAIN INJ M, 2001, TRAUM BRAIN INJ MOD; *TRAUM BRAIN INJ M, 1993, J HEAD TRAUMA REHAB, V8, P1; *TRAUM BRAIN INJ M, ANN REP TRAUM BRAIN; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; Whiteneck G, 2001, COLORADO TRAUMATIC B; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	62	93	95	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2004	19	1					45	54					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	777KA	WOS:000189176500006	14988587				2022-02-06	
J	Piland, SG; Motl, RW; Ferrara, MS; Peterson, CL				Piland, SG; Motl, RW; Ferrara, MS; Peterson, CL			Evidence for the factorial and construct validity of a self-report concussion symptoms scale	JOURNAL OF ATHLETIC TRAINING			English	Article						confirmatory factor analysis; symptoms	COVARIANCE STRUCTURE-ANALYSIS; MILD HEAD-INJURY; TEST STATISTICS; NEUROPSYCHOLOGICAL ASSESSMENT; PERFORMANCE; RECOVERY; CRITERIA; FIT	Objective: To evaluate the factorial and construct validity of the Head Injury Scale (HIS) among a sample of male and female collegiate athletes. Design and Setting: Using a cross-sectional design, we established the factorial validity of the HIS scale with confirmatory factor analysis and the construct validity of the HIS with Pearson product moment correlation analyses. Using an experimental design, we compared scores on the HIS between concussed and nonconcussed groups with a 2 (groups) x 5 (time) mixed-model analysis of variance. Subjects: Participants (N = 279) in the cross-sectional analyses were predominately male (n = 223) collegiate athletes with a mean age of 19.49 +/- 1.63 years. Participants (N = 33) in the experimental analyses were concussed (n = 17) and nonconcussed control (n = 16) collegiate athletes with a mean age of 19.76 +/- 1.49 years. Measurements: All participants completed baseline measures for the 16-item HIS, neuropsychological testing battery, and posturography. Concussed individuals and paired controls were evaluated on days 1, 2, 3, and 10 postinjury on the same testing battery. Results: Confirmatory factor analysis indicated that a theoretically derived, 3-factor model provided a good but not excellent fit to the 16-item HIS. Hence, the 16-item HIS was modified on the basis of substantive arguments about item-content validity. The subsequent analysis indicated that the 3-factor model provided an excellent fit to the modified 9-item HIS. The 3 factors were best described by a single second-order factor: concussion symptoms. Scores from the 16-item HIS and 9-item HIS were strongly correlated, but there were few significant correlations between HIS scores and scores from the neuropsychological and balance measures. A significant group-by-day interaction was noted on both the 9-item HIS and 16-item HIS, with significant differences seen between groups on days 1 and 2 postconcussion. Conclusions: We provide evidence for the factorial and construct validity of the HIS among collegiate athletes. This scale might aid in return-to-play decisions by physicians and athletic trainers.	Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA; James Madison Univ, Harrisonburg, VA 22807 USA		Piland, SG (corresponding author), Univ Georgia, Dept Exercise Sci, 300 River Rd, Athens, GA 30602 USA.	spiland@coe.uga.edu	, scott/ABB-2057-2021				Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ALVES WM, 1987, CLIN SPORT MED, V6, P211; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barth JT, 1989, MILD HEAD INJURY; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179; BROWNE MW, 2002, TESTING STRUCTURAL E, P136; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CHOU CP, 1991, BRIT J MATH STAT PSY, V44, P347, DOI 10.1111/j.2044-8317.1991.tb00966.x; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DIKMEN SS, 1998, RECOVERY, V9, P10; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ferrara Michael S., 2001, J Athl Train, V36, P145; Fouladi RT, 2000, STRUCT EQU MODELING, V7, P356, DOI 10.1207/S15328007SEM0703_2; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; GUSKIEWICZ KM, 1998, J ATHL TRAIN S, V33, pS22; GUSKIEWICZ KM, 1998, J ATHL TRAIN S, V33, pS8; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; HU LT, 1992, PSYCHOL BULL, V112, P351, DOI 10.1037//0033-2909.112.2.351; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Joreskog K., 1993, TESTING STRUCTURAL E; Joreskog K, 1996, LISREL 8 USERS REFER; Kelly JP, 1997, NEUROLOGY, V48, P581; LARRABEE GJ, 1998, RECOVERY, V9, P12; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; MARDIA KV, 1970, BIOMETRIKA, V57, P519, DOI 10.2307/2334770; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MARUISH ME, 1997, CLIN NEUROPSYCHOLOGY, P132; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Motl RW, 2000, MED SCI SPORT EXER, V32, P1007; Motl RW, 2000, MEASUREMENT PHYS ED, V4, P13; MUTHEN B, 1985, BR J MATH STAT PSYCH, V38, P347; Paulhus D.L., 1991, MEASURES PERSONALITY, P17, DOI 10.1016/B978-0-12-590241-0.50006-X; Riemann BL, 1999, J SPORT REHABIL, V8, P171, DOI 10.1123/jsr.8.3.171; Riemann BL, 1998, J ATHL TRAIN S, V33, pS18; ROOS R, 1996, PHYSICIAN SPORTSMED, V24, P31; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SATORRA A, 1989, PSYCHOMETRIKA, V54, P131, DOI 10.1007/BF02294453; SATORRA A, 1988, P BUS EC STAT SECT P; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	52	93	93	1	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2003	38	2					104	112					9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	738JW	WOS:000186284300001	12937520				2022-02-06	
J	Borgaro, SR; Prigatano, GP; Kwasnica, C; Rexer, JL				Borgaro, SR; Prigatano, GP; Kwasnica, C; Rexer, JL			Cognitive and affective sequelae in complicated and uncomplicated mild traumatic brain injury	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; IMPAIRED AWARENESS; STEM RESPONSES; CONCUSSION; SYMPTOMS; DYSFUNCTION	This study examined cognitive and affective disturbances in patients with complicated (presence of space occupying lesion) vs uncomplicated (absence of space occupying lesion) mild traumatic brain injury (TBI). It was predicted that the complicated group would perform worse in both domains compared to the uncomplicated group. Participants were 28 patients admitted to an inpatient neurorehabilitation unit with mild TBI and assessed within 40 days of their injury. The complicated group (n = 14) was matched to the uncomplicated group (n = 14) on Glasgow Coma Scale score and compared to 14 normal controls on the BNI Screen for Higher Cerebral Functions (BNIS). The complicated group showed greater cognitive disturbances than the uncomplicated and control groups, while both TBI groups performed worse on affective measures. These findings document the role of affective disturbances in mild TBI. They also highlight the importance of early intervention strategies for improving affective communication in patients with mild TBI.	Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA		Borgaro, SR (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BORGARO S, 2002, BNI Q, V17, P14; BORGARO SR, IN PRESS J HEAD TRAU; CARLIDGE NEF, 1977, SCOTTISH MED J, V23, P103; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, 1975, LANCET, V2, P995; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENNETT B, 1974, MANAGEMENT HEAD INJU; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVINE MJ, 1988, COGNITIVE REHABILITA, V6, P14; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Prigatano G. P., 1995, BNI Q, V9, P2; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenstein LD, 1997, NEUROPSY NEUROPSY BE, V10, P113; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	31	93	95	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	3					189	198		10.1080/0269905021000013183			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	645CB	WOS:000180957700001	12623495				2022-02-06	
J	Marion, DW; Puccio, A; Wisniewski, SR; Kochanek, P; Dixon, CE; Bullian, L; Carlier, P				Marion, DW; Puccio, A; Wisniewski, SR; Kochanek, P; Dixon, CE; Bullian, L; Carlier, P			Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						severe traumatic brain injury; hyperventilation; microdialysis; local cerebral blood flow; glutamate; lactate	SEVERE HEAD-INJURY; OXYGEN-SATURATION; MICRODIALYSIS; METABOLISM; HYPOCAPNIA; CARE	Objective., To determine the potential adverse effects of brief periods of hyperventilation commonly used for acute neurologic deterioration. Design: Prospective clinical trial. Setting: University medical school. Patients: Twenty patients with severe traumatic brain injury. Interventions: The effect of 30 mins of hyperventilation (mean PaCO2, 24.6 mm Hg) on the extracellular metabolites associated with ischemia, and on local cerebral blood flow was studied by using microdialysis and local cerebral blood flow techniques. Normal appearing brain adjacent to evacuated hemorrhagic contusions or underlying evacuated subdural hematomas was studied. Hyperventilation trials were done 24-36 hrs after injury and again at 3-4 days after injury. Dialysate concentrations of glutamate, lactate, and pyruvate were measured before and for 4 hrs after the hyperventilation trials. Measurements and Main Results., At 24-36 hrs, hyperventilation led to a greater than or equal to10% increase in the extracellular concentrations of glutamate in 14 of 20 patients, with concentrations in those 14 patients 13.7-395% above baseline; a greater than or equal to10% increase in lactate in 7 of 20 patients (11.6-211% above baseline); and a greater than or equal to10% increase in the lactate/pyruvate ratio in eight of 20 patients (10.8-227% above baseline). At 3-4 days after injury, ten of 13 patients had an increase in glutamate of greater than or equal to10%, while only three of 13 patients had an increase in extracellular lactate and two of 13 patients had an increase in the lactate/pyruvate ratio of this magnitude. The hyperventilation associated increases in extracellular glutamate and lactate concentrations were significant (P <.05; one-sample Student's t-test) at both time points after injury, as was the lactate/pyruvate ratio at 24-36 hrs. A greater than or equal to10% decline in local cerebral blood flow was observed with hyperventilation in five of 20 patients at 24-36 hrs (range, 10.2-18.7% below baseline), and in ten of 13 patients studied at 3-4 days (11.3-54% below baseline). There was no correlation with the presence or absence of local CO2 vasoresponsivity and increases in the extracellular metabolites at either the early or late time points. Conclusions: In brain tissue adjacent to cerebral contusions or underlying subdural hematomas, even brief periods of hyperventilation can significantly increase extracellular concentrations of mediators of secondary brain injury. These hyperventilation-induced changes are much more common during the first 24-36 hrs after injury than at 3-4 days.	Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA		Marion, DW (corresponding author), Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B400, Pittsburgh, PA 15213 USA.	dmarion@neuronet.pitt.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Ausina A, 1998, ACT NEUR S, V71, P1; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Dexter F, 1997, J NEUROSURG ANESTH, V9, P217, DOI 10.1097/00008506-199707000-00003; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; Kerr ME, 1997, NURS RES, V46, P195, DOI 10.1097/00006199-199707000-00003; LANGFITT TW, 1966, J NEUROSURG, V24, P975, DOI 10.3171/jns.1966.24.6.0975; Letarte PB, 1999, ACT NEUR S, V75, P45; Lundberg N., 1959, ACTA PSYCHIAT SCAND, V34, P4; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHNEIDER GH, 1995, ACTA NEUROCHIR, V134, P71, DOI 10.1007/BF01428507; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212	24	93	100	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2619	2625		10.1097/00003246-200212000-00001			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	633AP	WOS:000180257300001	12483048				2022-02-06	
J	Leon-Carrion, J; Van Eeckhout, P; Dominguez-Morales, MD; Perez-Santamaria, FJ				Leon-Carrion, J; Van Eeckhout, P; Dominguez-Morales, MD; Perez-Santamaria, FJ			The locked-in syndrome: a syndrome looking for a therapy	BRAIN INJURY			English	Article							MULTI-INFARCT DEMENTIA; ALZHEIMER TYPE	The locked-in syndrome (LIS) is a very severe condition caused by a primary vascular or traumatic injury to the brainstem, normally corresponding to a ventral pons lesion due to an obstruction of the basilar artery, and characterized by upper motor neuron quadriplegia, paralysis of lower cranial nerves, bilateral paresis of horizontal gaze and anarthria, and with preserved consciousness. Patients who have suffered this pontine lesion generally have preserved vertical eye movements and movement of the eyelids (blinking), this being their only means of responding to the outside world. A survey was conducted of 44 people diagnosed with LIS, all of them belonging to the Association of Locked-in Syndrome (ALIS) of France. Results of this survey showed that LIS was equally frequent in men and women (51.2% vs. 48.1%) and had occurred at any age between 22-77 years of age (normally between 41-52 years, the mean age being 46.79 years). The average time that transpired post-insult was 71.35 months. The principal cause of LIS was stroke (86.4%), with traumatic brain injury (TBI) being a distant second cause with an incidence of only 13.6%. The diagnosis of LIS was usually made around the middle of the second month after onset (mean of 78.76 days). The principal treatments, when present, were pharmacological and physiotherapy. However, 47.1% of the patients were not receiving treatment of any kind at the time of the survey. Neuropsychologically, 86% had a good attentional level, 97.6% were temporally oriented and 76.7% could read; 18.6% reported memory problems and 24% showed visual deficit (found mainly in patients with LIS originated by TBI); 47.5% reported a good mood state and 12.5% reported feeling depressed; 61.1% reported having sexual desire, but only 30% maintained sexual relations; 78% were capable of emitting sounds and 65.8% could communicate without technical aid; 73.2% enjoyed going out and 81% met with friends at least twice a month. Only 14.3% participated in social activities and 23.8% watched television regularly. Nearly 100% of the patients reported being sensitive to touch to any part of their bodies. This survey suggests diagnostics and rehabilitation procedures.	Univ Seville, Seville 41018, Spain; Federat Neurol La Pitie Salpetriere, Paris, France; CRECER, Ctr Brain Injury Rehabil, Seville, Spain		Leon-Carrion, J (corresponding author), Univ Seville, San Francisco Javier S-N, Seville 41018, Spain.		Odom, James V/A-1344-2013	Odom, James V/0000-0001-5874-1707			Allain P, 1998, CORTEX, V34, P629, DOI 10.1016/S0010-9452(08)70520-3; ALONI R, 1993, SEX DISABIL, V11, P121; ARBOIX S, 1990, NEUROLOGIA, V5, P137; BOLDRINI P, 1991, ARCH PHYS MED REHAB, V72, P202; BUCHT G, 1984, J AM GERIATR SOC, V32, P491, DOI 10.1111/j.1532-5415.1984.tb02233.x; CUMMINGS JL, 1987, ARCH NEUROL-CHICAGO, V44, P389, DOI 10.1001/archneur.1987.00520160031010; DELACOUR J L, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P433, DOI 10.1016/S0750-7658(88)80065-0; GALLO UE, 1989, AM J EMERG MED, V7, P581, DOI 10.1016/0735-6757(89)90278-7; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Griffith ER, 1993, SEXUALITY PERSON TRA; HAIG AJ, 1987, ARCH PHYS MED REHAB, V68, P24; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; Markus E, 1992, Rehabilitation (Stuttg), V31, P85; MOINGA TN, 1986, ARCH PHYSICAL MED RE, V67, P19; PLUM F, 1982, DIAGNOSIS STUPOR COM, P9; PROSIEGEL M, 1980, FORTSCHR MED, V98, P1489; SJOGREN K, 1981, INT REHABILITATION M, V15, P55; STARKSTEIN SE, 1991, NEUROBEHAVIORAL ASPE, P150	18	93	97	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2002	16	7					571	582		10.1080/02699050110119781			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	569RN	WOS:000176616100002	12119076				2022-02-06	
J	Lang, EW; Mehdorn, HM; Dorsch, NWC; Czosnyka, M				Lang, EW; Mehdorn, HM; Dorsch, NWC; Czosnyka, M			Continuous monitoring of cerebrovascular autoregulation: a validation study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DYNAMIC CEREBRAL AUTOREGULATION; TRANSCRANIAL DOPPLER; BLOOD-FLOW; HUMANS; INJURY	Background: Continuous monitoring of dynamic cerebral autoregulation, using a moving correlation index of cerebral perfusion pressure and mean middle cerebral artery flow velocity, may be useful in patients with severe traumatic brain injury to guide treatment, and has been shown to be of prognostic value. Objective: To compare an index of dynamic cerebral autoregulation (Mx) with an index of static cerebral autoregulation (sRoR) Methods: Mx was validated in a prospective comparative study against sRoR, using 83 testing sessions in 17 patients with traumatic brain injury. sRoR and Mx were calculated simultaneously during pharmacologically induced blood pressure variations. Results: Mx was significantly correlated with sRoR (R = -0.78, p < 0.05). Nine patients were found to have failure of cerebral autoregulation, with an sRoR value < 50%. If an Mx value of 0.3 was used as the cut off point for failure of cerebral autoregulation, this index had 100% sensitivity and 90% specificity for demonstrating failure of autoregulation compared with the sRoR. An increase in cerebral blood flow velocity correlated significantly with Mx (R = 0.73, p < 0.05) but not with cerebral perfusion pressure (R = 0,41). Conclusions: Dynamic and static cerebral autoregulation are significantly correlated in traumatic 21 brain injury. Cerebral autoregulation can be monitored continuously, graded, and reliably assessed using a moving correlation analysis of cerebral perfusion pressure and cerebral blood flow velocity (Mx). The Mx index can be used to monitor cerebral blood flow regulation. It is useful in traumatic brain. injury because it does not require any external stimulus.	Univ Kiel, Dept Neurosurg, D-24106 Kiel, Germany; Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Sydney, Westmead Hosp, Dept Neurosurg, Westmead, NSW 2145, Australia		Lang, EW (corresponding author), Westmead Hosp, Dept Neurosurg, Level 5, Sydney, NSW 2145, Australia.		Mehdorn, Maximilian/D-2495-2010				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1996, STROKE, V27, P829; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Heckmann JG, 1999, NEUROL RES, V21, P457, DOI 10.1080/01616412.1999.11740959; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; STEINMEIER R, 1999, J NEUROSURG, V90, P427; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Tiecks FP, 1996, STROKE, V27, P1177, DOI 10.1161/01.STR.27.7.1177; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014	17	93	93	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2002	72	5					583	586		10.1136/jnnp.72.5.583			4	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	547QX	WOS:000175344200009	11971041	Bronze, Green Published			2022-02-06	
J	Qiu, JH; Whalen, MJ; Lowenstein, P; Fiskum, G; Fahy, B; Darwish, R; Aarabi, B; Yuan, JY; Moskowitz, MA				Qiu, JH; Whalen, MJ; Lowenstein, P; Fiskum, G; Fahy, B; Darwish, R; Aarabi, B; Yuan, JY; Moskowitz, MA			Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; Fas; death-inducing signaling complex; caspases; human; adenoviral vectors	NEURONAL CELL-DEATH; PC12 CELLS; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; CORTICAL IMPACT; TRANSGENIC MICE; CD95; EXPRESSION; CASPASE-3; PROTEIN	Recent studies have implicated Fas in the pathogenesis of inflammatory, ischemic, and traumatic brain injury (TBI); however, a direct link between Fas activation and caspase-mediated cell death has not been established in injured brain. We detected Fas-Fas ligand binding and assembly of death-inducing signaling complexes (DISCs) [Fas, Fas-associated protein with death domain, and procaspase-8 or procaspase-10; receptor interacting protein (RIP)-RIP-associated interleukin-1beta converting enzyme and CED-3 homolog-1/Ced 3 homologous protein with a death domain-procaspase-2] by immunoprecipitation and immunoblotting within mouse parietal cortex after controlled cortical impact. At the time of DISC assembly, procaspase-8 was cleaved and the cleavage product appeared at 48 hr in terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling-positive neurons. Cleavage of caspase-8 was accompanied by caspase-3 processing detected at 48 hr by immunohistochemistry, and by caspase-specific cleavage of poly( ADP-ribose) polymerase at 12 hr. Fas pathways were also stimulated by TBI in human brain, because Fas expression plus Fas-procaspase-8 interaction were robust in contused cortical tissue samples surgically removed between 2 and 30 hr after injury. To address whether Fas functions as a death receptor in brain cells, cultured embryonic day 17 cortical neurons were transfected with an adenoviral vector containing the gene encoding Fas ligand. After 48 hr in culture, Fas ligand expression and Fas-procaspase-8 DISC assembly increased, and by 72 hr, cell death was pronounced. Cell death was decreased by similar to50% after pan-caspase inhibition (Z-Val-ALa-Asp(Ome)-fluoromethylketone). These data suggest that Fas-associated DISCs assemble in neurons overexpressing Fas ligand as well as within mouse and human contused brain after TBI. Therefore, Fas may function as a death receptor after brain injury.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Charlestown, MA 02129 USA; Cedars Sinai Med Ctr, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90048 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA		Moskowitz, MA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, 149 13th St,Room 6403, Charlestown, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011	Darwish, Ribal/0000-0003-0727-0401	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152, K08NS041969] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS041969, R01 NS034152, P50 NS010828, 2 RO1 NS34152, KO8 NS41969-01, 2 R01 NS34152] Funding Source: Medline		Aquaro S, 2000, J LEUKOCYTE BIOL, V68, P429; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Cheema ZF, 1999, J NEUROSCI, V19, P1754; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Holland GN, 2000, OCUL IMMUNOL INFLAMM, V8, P1, DOI 10.1076/0927-3948(200003)8:1;1-S;FT001; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morelli AE, 1999, J GEN VIROL, V80, P571, DOI 10.1099/0022-1317-80-3-571; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Rose S, 2000, AM J GASTROENTEROL, V95, P1; Saas P, 1999, J IMMUNOL, V162, P2326; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stefanis L, 1997, J NEUROCHEM, V69, P1425; Troy CM, 1997, J NEUROSCI, V17, P1911; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wang J, 2000, J CELL SCI, V113, P753; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	52	93	100	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	2002	22	9					3504	3511					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	546VN	WOS:000175296200028	11978827				2022-02-06	
J	Stone, JR; Singleton, RH; Povlishock, JT				Stone, JR; Singleton, RH; Povlishock, JT			Intra-axonal neurofilament compaction does not evoke local axonal swelling in all traumatically injured axons	EXPERIMENTAL NEUROLOGY			English	Article						axonal injury; cytoskeleton; axoplasmic transport; ultrastructure; rats	AMYLOID PRECURSOR PROTEIN; DIFFUSE BRAIN INJURY; HEAD-INJURY; AXOLEMMAL PERMEABILITY; RETROGRADE CONVERSION; TRANSPORTED VESICLES; CYTOSKELETAL CHANGES; BETA-APP; DAMAGE; MARKER	Traumatic axonal injury (TAI) contributes to morbidity and mortality following traumatic brain injury (TBI). Single-label immunocytochemical studies employing antibodies to neurofilament compaction (NFC), RM014, and antibodies to APP, a marker of impaired axonal transport (AxT), have shown that TAI involves both NFC and disruption of AxT. Although it may be hypothesized that both events occur within the same injured axon, this has not been confirmed. To determine the relationship between NFC and impaired AxT, dual-label immunofluorescence was employed. To compare and contrast specific changes associated with these two markers of TAI, single-label electron microscopy was also used. Rats were subjected to an impact acceleration injury (30 min-6 h survival), and their brains were prepared for dual-label immunofluorescence and single-label electron microscopy. APP and RM014 were consistently found in two distinct classes of TAL One, which showed only RM014 immunoreactivity, was thin and elongate, was sometimes vacuolated, and revealed little progressive change over time. The second was distinguished by focal axonal swellings containing APP immunoreactivity alone in small-caliber axons or in combination with RM014 immunoreactivity in large-caliber axons. These swellings were localized to either nodal or internodal loci and underwent progressive swelling over time, ultimately leading to secondary axotomy. Ultrastructural examination of these two classes of TAI revealed NFC together with mitochondrial dilation without organelle pooling in the RM014 single-labeled axons. However, the APP single-labeled small-caliber axons and APP/RM014 dual-labeled large-caliber axons revealed a progressive accumulation of organelles associated with increased axonal swelling over time. In contrast to previous thought, it now appears that NFC may occur independent of impaired AxT in TAL This finding underscores the complexity of TAI, suggesting the need for multiple immunocytochemical approaches to fully assess the overall axonal response to TBI. (C) 2001 Elsevier Science.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA		Stone, JR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Campus Virginia Commonwelth Univ, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; MALBOUISSON AMB, 1985, ANAT EMBRYOL, V171, P339, DOI 10.1007/BF00347022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; MAXWELL ML, 1998, J NEUROCYTOL, V23, P379; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	46	93	100	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	2001	172	2					320	331		10.1006/exnr.2001.7818			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	510QK	WOS:000173218600007	11716556				2022-02-06	
J	Steiner, T; Ringleb, P; Hacke, W				Steiner, T; Ringleb, P; Hacke, W			Treatment options for large hemispheric stroke	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; CEREBRAL-ARTERY OCCLUSION; INCREASED INTRACRANIAL-PRESSURE; TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; TRANSTENTORIAL HERNIATION; DECOMPRESSIVE CRANIECTOMY; FUNCTIONAL RECOVERY; MILD HYPOTHERMIA; BARBITURATE COMA	Some stroke patients suffering acute middle cerebral artery (MCA) infarction develop massive brain edema and herniation, a condition known as malignant MCA infarction. Severe swelling increases intracranial pressure (ICP) and leads to progressive brainstem dysfunction. Once ICP reaches critical values (> 30 mm Hg) herniation occurs, usually within 2 to 5 days. Patients rarely survive (80% mortality) with standard treatment, and those who do are often severely disabled. Malignant MCA infarction is often missed by neurologists, despite well-defined clinical and neuroimaging (CT scan) diagnostic criteria. After diagnosis, conventional treatments such as osmotherapy, barbiturates, buffers, and hyperventilation center on reducing ICP. The goal of hyperosmolar therapy is to increase the serum osmolarity to approximately 315-320 mOsm/L. Enteric glycerol is used routinely to reduce ICP. In more severe cases and when glycerol fails, mannitol may be administered. Other therapies are also available, including hypertonic saline solution, THAM (Tris-hydroxy-methyl-aminomethane) buffer, and high-dose barbiturates. Hyperventilation also helps reduce ICP. All measures work effectively for a short time only. Other approaches to control elevated ICP, including decompression surgery and hypothermia, have shown promising results. In the Heidelberg decompression surgery trial, mortality in surgically treated patients was significantly lower (32%) than in non-treated patients (76%) despite conventional treatment. Importantly, of the surviving treated patients, 66% were rated independent with only mild to moderate disability. Moderate hypothermia (33-36 degreesC) has recently been shown to be effective in severe MCA infarction. Hypothermia induction within 14 hours of ischemic injury and maintained for 72 hours significantly reduced ICP and mortality (44%).	Univ Klinikum Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany		Hacke, W (corresponding author), Univ Klinikum Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Hacke, Werner/ABE-8661-2020; Steiner, Thorsten/L-2868-2018; Steiner, Thorsten/A-7391-2014	Steiner, Thorsten/0000-0002-5080-8222; 			AKIOKA T, 1976, INTRACRANIAL PRESSUR, P219; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BELL BA, 1987, LANCET, V1, P66; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHIARA O, 1987, CRIT CARE MED, V15, P995, DOI 10.1097/00003246-198711000-00001; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; DORFLER A, 1996, J NEUROSURG, V85, P853; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; GARCIASOLA R, 1991, ACTA NEUROCHIR, V109, P114, DOI 10.1007/BF01403005; GRECO T, 1935, ARCH ITAL CHIR, V39, P757; GREENWOOD J, 1968, JOHNS HOPKINS MED J, V122, P254; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; IVAMOTO HS, 1974, STROKE, V5, P365, DOI 10.1161/01.STR.5.3.365; JENNETT B, 1975, LANCET, V1, P480; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KING AB, 1951, J NEUROSURG, V8, P536, DOI 10.3171/jns.1951.8.5.0536; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAU R, 1992, EUR J CLIN PHARMACOL, V42, P181, DOI 10.1007/BF00278481; NUSSBAUM ES, 1991, NEUROSURGERY, V29, P62, DOI 10.1227/00006123-199107000-00010; Ojemann RG., 1988, SURG MANAGEMENT CERE; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; Reid WL, 1940, SURGERY, V8, P756; RENGACHARY S, 1985, NEUROSURGERY, P1267; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SAITO I, 1987, STROKE, V18, P863, DOI 10.1161/01.STR.18.5.863; SCARCELLA G, 1956, J NEUROSURG, V13, P366; SCHNEIDER RC, 1952, J NEUROSURG, V9, P495, DOI 10.3171/jns.1952.9.5.0495; Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHAW CM, 1959, ARCH NEUROL-CHICAGO, V1, P161; STEIGER HJ, 1991, ACTA NEUROCHIR, V111, P73, DOI 10.1007/BF01400491; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; Tsuruno Takashi, 1993, Neurological Surgery, V21, P823; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; YOUNG PH, 1982, SOUTHERN MED J, V75, P473, DOI 10.1097/00007611-198204000-00025; [No title captured]	54	93	102	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP 11	2001	57	5		2			S61	S68		10.1212/WNL.57.suppl_2.S61			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	471PP	WOS:000170938000013	11552058				2022-02-06	
J	Barth, JT; Freeman, JR; Broshek, DK; Varney, RN				Barth, JT; Freeman, JR; Broshek, DK; Varney, RN			Acceleration-deceleration sport-related concussion: The gravity of it all	JOURNAL OF ATHLETIC TRAINING			English	Article						mild head injury; physics; athletic injury; axonal injury; whiplash	HEAD-INJURY; RECOVERY	Objective: To discuss a newtonian physics model for understanding and calculating acceleration-deceleration forces found in sport-related cerebral concussions and to describe potential applications of this formula, including (1) an attempt to measure the forces applied to the brain during acceleration-deceleration injuries, (2) a method of accruing objective data regarding these forces, and (3) use of these data to predict functional outcome, such as neurocognitive status, recovery curves, and return to play. Background: Mild concussion in sports has gained considerable attention in the last decade. Athletic trainers and team physicians have attempted to limit negative outcomes by gaining a better understanding of the mechanisms and severity of mild head injuries and by developing meaningful return-to-play criteria. Mild head injury in sports has become an even greater area of focus and concern, given the negative neurobehavioral outcomes experienced by several recent high-profile professional athletes who sustained repeated concussions, Applying the principles of physics to characterize injury types, injury severity, and outcomes may further our development of better concussion management techniques and prevention strategies. Description: We describe the search for models to explain neuronal injury secondary to concussion and provide an exploratory method for quantifying acceleration-deceleration forces and their relationship to severity of mild head injury. Implications for injury prevention and reduction of morbidity are also considered.	Univ Virginia, Sch Med, Neuropsychol Lab, Dept Psychiat Med, Charlottesville, VA 22908 USA		Barth, JT (corresponding author), Univ Virginia, Sch Med, Neuropsychol Lab, Dept Psychiat Med, 800203 HSC, Charlottesville, VA 22908 USA.	jtb4y@virginia.edu	Broshek, Donna/ABA-4208-2021	Broshek, Donna/0000-0002-7175-7815			BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P81; Barth JT, 1989, MILD HEAD INJURY, P257; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GENNARELLI TA, 1981, ACTA NEUROPATHOL B S, V1, P23; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1989, MILD HEAD INJURY, P176; Varney RN, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P39; Winters JE, 2001, J ATHL TRAINING, V36, P339	16	93	93	0	17	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					253	256					4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	557NC	WOS:000175913800007	12937493				2022-02-06	
J	Grant, SA; Bettencourt, K; Krulevitch, P; Hamilton, J; Glass, R				Grant, SA; Bettencourt, K; Krulevitch, P; Hamilton, J; Glass, R			In vitro and in vivo measurements of fiber optic and electrochemical sensors to monitor brain tissue pH	SENSORS AND ACTUATORS B-CHEMICAL			English	Article						sol-gel method; optoelectronics; stroke; brain injury; iridium oxide	OXYGEN; BIOSENSOR; STROKE; INJURY	We report herein the development of fiber optic and electrochemical pH sensors that could become part of an arsenal to quickly and aggressively treat people undergoing a stroke as well as people who have suffered traumatic brain injury. The fiber optic pH sensor design consists of the immobilization of a pH sensitive dye, seminaphthorhodamine-1 carboxylate (SNARF-1C) within a silica sol-gel matrix. A miniature optoelectronics package was developed to acquire data from the fiber optic sensor. The electrochemical sensor consists of a thin film multilayer coating sputtered on a kapton substrate. The sensors were tested in vitro and in vivo. For both sensors, the in vitro results show linear and reproducible responses in human blood in the pH range 6.8-8.0. The results of the in vivo studies which were performed in Spraque-Dawley rats indicate that both the fiber optic and electrochemical sensors monitor pH with very little drift. It was concluded that both types of sensors would be useful in tracking brain tissue pH. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Calif Lawrence Livermore Natl Lab, Chem & Mat Sci Directorate, Livermore, CA 94550 USA		Grant, SA (corresponding author), Michigan Technol Univ, Ctr Biomed Engn, 1400 Townsend Dr, Houghton, MI 49931 USA.						BRONK KS, 1995, ANAL CHEM, V67, P2750, DOI 10.1021/ac00113a005; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; GOLDEN JP, 1994, IEEE T BIO-MED ENG, V41, P585, DOI 10.1109/10.293246; Grant SA, 1997, SENSOR ACTUAT B-CHEM, V45, P35, DOI 10.1016/S0925-4005(97)00263-3; Grant SA, 1999, IEEE T BIO-MED ENG, V46, P1207, DOI 10.1109/10.790497; Johnson G., 1998, TRAUMATIC BRAIN INJU; LEVINE SR, 1992, PROG CARDIOVASC DIS, V34, P235, DOI 10.1016/0033-0620(92)90020-Z; Matchar D. B., 1994, STROKE CLIN UPDATES, V5, P9; McKinley BA, 1996, CRIT CARE MED, V24, P1858, DOI 10.1097/00003246-199611000-00016; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Muller P, 1998, Biomed Instrum Technol, V32, P656; RATNER BD, BIOMATERIALS SCI INT, P105; SOLLER BR, 1994, IEEE ENG MED BIOL, V6, P327; VENKATESH B, 1994, CRIT CARE MED, V22, P588, DOI 10.1097/00003246-199404000-00013; Watson JC, 1997, STROKE, V28, P1624, DOI 10.1161/01.STR.28.8.1624; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Xu Z, 1998, J BIOMED MATER RES, V39, P9, DOI 10.1002/(SICI)1097-4636(199801)39:1<9::AID-JBM2>3.0.CO;2-U; YANG L, 1995, ANAL CHEM, V67, P1307, DOI 10.1021/ac00104a002; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; ZAUNER A, 1995, NEUROSURGERY, V37, P1176	20	93	94	2	43	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0925-4005			SENSOR ACTUAT B-CHEM	Sens. Actuator B-Chem.	JAN 25	2001	72	2					174	179		10.1016/S0925-4005(00)00650-X			6	Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Electrochemistry; Instruments & Instrumentation	397HW	WOS:000166688100011					2022-02-06	
J	Madigan, NK; DeLuca, J; Diamond, BJ; Tramontano, G; Averill, A				Madigan, NK; DeLuca, J; Diamond, BJ; Tramontano, G; Averill, A			Speed of information processing in traumatic brain injury: Modality-specific factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	10th Annual Meeting of the American-Psychological-Society	MAY 21-24, 1998	WASHINGTON, D.C.	Amer Psychol Soc			CLOSED-HEAD-INJURY; MULTIPLE-SCLEROSIS; SERIAL-ADDITION; WORKING-MEMORY; REACTION-TIME; ATTENTION; DEFICITS; FATIGUE; TASK	Objective: To assess speed of information processing by two serial addition tests (one visual, one auditory) in individuals with moderate-to-severe traumatic brain injuries (TBIs) and in a healthy, normal control group (NC). The tasks were designed to equate and control for accuracy of performance across the TBI and NC groups, thus allowing for quantification of information processing speed. Design: Performance across groups and tasks were compared using 2 x 2 repeated measure analyses of variance (AOVAs). In addition, each individual's processing speed was used to adjust rate of stimulus presentation on a subsequent "rehabilitation" trial to determine further whether this adjustment equated accuracy of performance. setting: Rehabilitation hospital. Patients: 22 outpatients with moderate-to-severe TBI (6 women, 16 men; mean age = 34.6 years; duration of loss of consciousness = 22.6 days) and 20 age- and education-matched healthy controls. Results: Processing speed was slower in TBI subjects, relative to controls and was significantly related to measures of executive functioning for those with TBI. Relative to controls, speed of processing in the TBI group was disproportionately slower when information was presented in the auditor relative to the visual, modality. Conclusions: Speed of information processing is a major impairment in those with TBI when unconfounded by performance accuracy. The modality-specific impairment observed in the TBI group may, in part, be due to a greater within-modality interference effect created by the auditory version of the task. By manipulating information at a pace customized for an individual through compensatory strategies and environmental environmental modifications, information-processing performance of TBI participants can be enhanced significantly.	Kessler Med Rehabil Res & Educ Ctr, Dept Phys Med & Rehabil, Dept Res, W Orange, NJ 07052 USA; Ctr Res Alternat & Complementary Med, W Orange, NJ USA; Kessler Inst Rehabil, Welkin Facil, Dept Neuropsychol & Cognit Remediat, Chester, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Res, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA		DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	delucajo@umdnj.edu					Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Baddeley A.D., 1986, WORKING MEMORY; Beck AT, 1987, BECK DEPRESSION INVE; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; DEARY IJ, 1991, PERS INDIV DIFFER, V12, P983, DOI 10.1016/0191-8869(91)90027-9; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gathercole S., 1994, NEUROPSYCHOLOGY, V8, P494, DOI DOI 10.1037/0894-4105.8.4.494; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; Heaton R.K., 1981, WISCONSIN CARD SORTI; Hiscock M, 1998, J CLIN EXP NEUROPSYC, V20, P463, DOI 10.1076/jcen.20.4.463.1466; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Johnson SK, 1996, PERCEPT MOTOR SKILL, V83, P51, DOI 10.2466/pms.1996.83.1.51; Kewman D G, 1988, Brain Inj, V2, P131, DOI 10.3109/02699058809150937; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, SCAND J REHABIL MED, P33; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEOD P, 1984, ATTENTION PERFORM, V10, P55; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; ODDY M, 1987, J NEUORL NEUROSURG P, V48, P564; PAPO I, 1982, ACTA NEUROCHIR, V62, P47, DOI 10.1007/BF01402210; PIKE R, 1974, ACTA PSYCHOL, V38, P379, DOI 10.1016/0001-6918(74)90042-0; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Spielberger CD., 1983, STATE TRAIT ANXIETY; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Wechsler D., 1981, WAIS R MANUAL	44	93	95	2	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2000	15	3					943	956		10.1097/00001199-200006000-00007			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	321FL	WOS:000087445400007	10785624				2022-02-06	
J	Kline, AE; Yan, HQ; Bao, JL; Marion, DW; Dixon, E				Kline, AE; Yan, HQ; Bao, JL; Marion, DW; Dixon, E			Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						brain injury; methylphenidate; dopamine; rat; cortical impact	DOUBLE-BLIND; HEAD-INJURY; RECOVERY; AMPHETAMINE; EXPERIENCE; ABLATION; MODERATE	Methylphenidate (MPH), a central nervous system stimulant with dopaminergic activity, facilitates neurobehavioral outcome following cortical suction ablation injury, but its potential efficacy following experimental traumatic brain injury (TBI) is unknown. Thus, beginning 24 h after controlled cortical impact injury or sham surgery, male Sprague-Dawley rats were injected (i.p.) once daily for 18 days with either MPH (5 mg/kg) or saline vehicle (VEH) and motor function assessed on post-operative days 1-4, followed by Morris water maze training to find a hidden platform on days 14-18. The MPH treatment regimen was ineffective in accelerating beam-balance or beam-walk recovery, but did significantly decrease swim latencies when compared to VEH-treated controls. The results are consistent with published studies showing improved outcome with MPH therapy. Furthermore, this positive finding with delayed treatment suggests that strategies that enhance catecholamine neurotransmission during the chronic post injury phase may be a useful adjunct in ameliorating some of the neurobehavioral sequelae following TBI in humans. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Dixon, E (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318, R01NS033150] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS30318] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR/312296] Funding Source: Medline		Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Zeiner P, 1999, ACTA PAEDIATR, V88, P298, DOI 10.1080/08035259950170060	20	93	94	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 25	2000	280	3					163	166		10.1016/S0304-3940(00)00797-7			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	290VG	WOS:000085698100003	10675786				2022-02-06	
J	O'Dell, MW; Barr, K; Spanier, D; Warnick, RE				O'Dell, MW; Barr, K; Spanier, D; Warnick, RE			Functional outcome of inpatient rehabilitation in persons with brain tumors	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	American-Academy-of-Physical-Medicine-and-Rehabilitation Annual Assembly	SEP 11-12, 1996	CHICAGO, ILLINOIS	Amer Acad Phys Med & Rehabil			MALIGNANT CEREBRAL GLIOMA; QUALITY-OF-LIFE; INDEPENDENCE MEASURE; CANCER REHABILITATION; STROKE; RADIOTHERAPY; DISABILITY; SURVIVAL; SURGERY	Objective: To document functional outcome in persons with brain tumors undergoing inpatient rehabilitation and to compare outcomes with a group of traumatically brain injured patients. Design: Retrospective, descriptive, and case-matched. Setting: A free-standing inpatient brain injury rehabilitation unit. Participants: Forty consecutive patients with a variety of tumor types (40% were either glioblastoma multiforme or meningioma) and a mean age of 53.1 (SD 15.4) years. Sixty percent were men, 25% had recurrent tumors, and 15% had metastatic disease. Also, 40 patients with traumatic brain injury (TBI) matched for age, gender, and admission functional status. Main Outcome Measures: Change in Functional Independence Measure (FIM) scores, length of rehabilitation stay (LOS) and discharge disposition. Results: The mean LOS for the tumor group was 17.8 (SD 9.9) days, mean FIM gain was 25.4 (SD 20.1) points, and 82.5% were discharged home. No demographic or tumor characteristic was statistically significant in predicting functional outcome at discharge, but greater gains were seen for persons with the diagnosis of meningioma, those with left-sided cerebral lesions, and those not receiving radiation therapy. TBI patients made statistically significant greater gains in total FIM change (34.6 vs 25.4), self-care (12.3 vs 8.5), and social cognition (5.2 vs 3.6). However, FIM efficiency and LOS were not statistically different between the TBI and tumor groups (1.9 vs 1.5 FIM points/day and 22.1 vs 17.8 days, respectively). Conclusions: Daily functional gains made by persons with brain tumor undergoing rehabilitation were similar to those made by a group of persons with TBI matched by age, gender, and admission functional status. Further research should use larger samples and address the impact of psychosocial and team factors on LOS and discharge disposition. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine aad Rehabilitation.	Univ Cincinnati, Coll Med, Dept Phys Med & Rehabil, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Mayfield Clin, Cincinnati, OH USA		O'Dell, MW (corresponding author), Southside Hosp, Brain Injury Rehabil Program, 2440 Brackett Bldg,301 E Main St, Bay Shore, NY 11706 USA.						ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; Batchelor T, 1996, NEUROSURG CLIN N AM, V7, P435; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS37, DOI 10.1016/S0003-9993(98)90120-4; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; Chae J, 1996, AM J PHYS MED REHAB, V75, P177, DOI 10.1097/00002060-199605000-00004; Clinchot DM, 1997, ARCH PHYS MED REHAB, V78, P346, DOI 10.1016/S0003-9993(97)90223-9; Culver KW, 1996, BONE MARROW TRANSPL, V18, pS6; Davies E, 1996, BRIT MED J, V313, P1507, DOI 10.1136/bmj.313.7071.1507; Davies E, 1996, BMJ-BRIT MED J, V313, P1512, DOI 10.1136/bmj.313.7071.1512; ELOVIC E, 1996, MED REHABILITATION T, P1; Fernandez-Vicioso E, 1997, Radiat Oncol Investig, V5, P31, DOI 10.1002/(SICI)1520-6823(1997)5:1<31::AID-ROI5>3.0.CO;2-L; GANZ PA, 1990, CANCER, V65, P742, DOI 10.1002/1097-0142(19900201)65:3+<742::AID-CNCR2820651319>3.0.CO;2-P; GARDEN FH, 1996, TXB PHYSICAL MED REH, P1199; Gerber Lynn, 1997, P2925; GREENBURG MS, 1997, HDB NEUROSURGERY; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HUANG ME, 1997, ARCH PHYS MED REHAB, V78, P1054; LEHMANN JF, 1978, ARCH PHYS MED REHAB, V59, P410; Levinson SF, 1993, REHABILITATION MED P, P916; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; MELLETTE SJ, 1994, SEMIN ONCOL, V21, P779; Meyers C A, 1990, Oncology (Williston Park), V4, P115; Meyers Christina A., 1993, Cancer Bulletin (Houston), V45, P362; Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U; Poduri KR, 1996, INT J REHABIL RES, V19, P327, DOI 10.1097/00004356-199612000-00005; REIS LA, 1991, CANC STAT REV 1973 1; Ring H, 1997, ARCH PHYS MED REHAB, V78, P630, DOI 10.1016/S0003-9993(97)90429-9; Scheibel RS, 1996, J NEURO-ONCOL, V30, P61; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; SIPOS EP, 1995, NEUROL CLIN, V13, P813, DOI 10.1016/S0733-8619(18)30019-7; *STAT, 1992, AN SOFTW 4 0; Stewart-Amidei C, 1995, Crit Care Nurs Clin North Am, V7, P125; Takakura K, 1982, METASTATIC TUMORS CE; Weitzner MA, 1996, J NEUROSURG, V84, P29, DOI 10.3171/jns.1996.84.1.0029; Weitzner MA, 1996, BAILLIERE CLIN NEUR, V5, P425; WEN PY, 1995, NEUROL CLIN, V13, P875, DOI 10.1016/S0733-8619(18)30023-9; Whitton AC, 1997, CANCER, V80, P258, DOI 10.1002/(SICI)1097-0142(19970715)80:2<258::AID-CNCR14>3.0.CO;2-T	39	93	93	1	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1998	79	12					1530	1534		10.1016/S0003-9993(98)90414-2			5	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	146GW	WOS:000077421800007	9862294				2022-02-06	
J	Max, JE; Koele, SL; Smith, WL; Sato, Y; Lindgren, SD; Robin, DA; Arndt, S				Max, JE; Koele, SL; Smith, WL; Sato, Y; Lindgren, SD; Robin, DA; Arndt, S			Psychiatric disorders in children and adolescents after severe traumatic brain injury: A controlled study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; pediatrics; psychopathology	HEAD-INJURY; DEPRESSION	Objective: To study psychiatric and behavioral morbidity associated with severe traumatic brain injury (TBI). Method: A consecutive series (n = 24) of children aged 5 through 14 years whet suffered a severe TBI were matched to subjects who sustained a mild TBI and to a second matched group who sustained an orthopedic injury with no evidence of TBI. Standardized psychiatric, behavioral, and neuroimaging assessments were conducted on average 2 years after injury. Results: Severe TBI was associated with a significantly higher rate of current."novel" psychiatric disorders (15/24; 63%) compared with children with mild TBI (5/24; 21%) and orthopedic injury (1/24; 4%). Higher effect sizes were evident for child and adolescent self-report of internalizing symptoms rather than externalizing symptoms, for parents' report of overall behavior and internalizing symptoms rather than externalizing symptoms, and for teachers' reports of overall behavior and externalizing symptoms rather than internalizing symptoms. Conclusions: Severe TBI is a profound risk factor for the development of a psychiatric disorder. Survivors should be assessed for organic personality syndrome, which is the most common psychiatric disorder after this type of injury.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA		Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MHCRC43271, MH31593, MH40856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040856, R01MH031593, P50MH043271, P30MH043271, R37MH031593] Funding Source: NIH RePORTER		Achenbach, 1991, MANUAL TEACHERS REPO; Achenbach T.M., 1991, MANUAL YOUTH SELF RE; Achenbach TM, 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cohen J., 2013, STAT POWER ANAL BEHA; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KAY T, 1988, HEAD INJURY FAMILY I; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; McCubbin HI, 1980, FAMILY ASSESSMENT RE; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Shaffer D, 1975, Ciba Found Symp, P191; TEASDALE G, 1974, LANCET, V2, P81	22	93	98	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	AUG	1998	37	8					832	840		10.1097/00004583-199808000-00013			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	103ZY	WOS:000074988800013	9695445				2022-02-06	
J	Satz, P; Forney, DL; Zaucha, K; Asarnow, RR; Light, R; McCleary, C; Levin, H; Kelly, D; Bergsneider, M; Hovda, D; Martin, N; Namerow, N; Becker, D				Satz, P; Forney, DL; Zaucha, K; Asarnow, RR; Light, R; McCleary, C; Levin, H; Kelly, D; Bergsneider, M; Hovda, D; Martin, N; Namerow, N; Becker, D			Depression, cognition, and functional correlates of recovery outcome after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; MAJOR DEPRESSION; SELF-REPORT; PERFORMANCE; INDIVIDUALS; DISORDERS; DIAGNOSIS; MOOD	The present study investigated the prevalence and magnitude of depressive symptomatology in a sample of patients who had sustained traumatic brain injury (TBI) six months earlier. Depression was examined as a function of recovery outcome status, and its association with neuropsychological functioning, personal competency, and employability was also explored. Subjects were 100 patients who had previously sustained moderate-to-severe TBI who were enrolled as research subjects in the UCLA Brain Injury Research Center, and 30 matched control subjects who had sustained traumatic injuries other than to the head six months prior to evaluation. The results showed a significant association between depression and recovery status as measured by the Glasgow Outcome Scale (GOS). A significant majority of depressed subjects were found in the poorer dos outcome groups (severe and moderate disability), compared to TBI subjects who had good GOS outcomes, and control subjects. This association was also reflected in the magnitude of the mean depression scores on two self-report measures of depression. However, no association was found between depression status and performance on the neuropsychological measures. Effects of depression were found only on an examiner-rated Patient Competency scale, and a metacognition measure based on self-report. These results are discussed in terms of brain injury severity, recovery status, and metacognition issues in TBI and other disorders.	Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Daniel Freeman Mem Hosp, Los Angeles, CA USA; USC, Sch Med, Dept Neurol, Los Angeles, CA USA; Univ Texas, Med Ctr, Houston, TX USA		Satz, P (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, NPI Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.			Martin, Neil/0000-0002-6565-4131			ALOIA MS, 1995, ANN M INT NEUR SOC S; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS N, 1984, CLOSED HEAD INJURY; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; BURTON LA, 1994, J NEUROLOGICAL REHAB, V8, P63, DOI DOI 10.1177/136140969400800202; Christensen B, 1994, ADV MED PSYCHOTHERAP, V7, P23; DELIA LF, 1996, COLOR TRAILS TEST AD; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GASS CS, 1990, PSYCHOL ASSESSMENT J, V2, P175, DOI DOI 10.1037//1040-3590.2.2.175; HAMMELL K, 1992, INT J REHABILITATION, V17, P319; HARKER JO, UNPUB MEASURING DEPR; HINKIN C, 1996, J CLIN EXPT NEUROPSY, V18, P1; HINKIN CH, 1992, J CLIN EXP NEUROPSYC, V14, P289, DOI 10.1080/01688639208402829; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MOORE L, IN PRESS J NEUROPSYC; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1984, CLOSED HEAD INJURY; PIRGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; RUSSO A, 1996, C NAT AC NEUR NOV; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; SWEET JJ, 1992, CLIN PSYCHOL REV, V12, P21, DOI 10.1016/0272-7358(92)90090-U; VANGORP WG, 1991, J CLIN EXP NEUROPSYC, V13, P812, DOI 10.1080/01688639108401091; WETZLER S, 1993, J PERS ASSESS, V60, P1, DOI 10.1207/s15327752jpa6001_1; WETZLER S, 1989, J PERS ASSESS, V53, P22, DOI 10.1207/s15327752jpa5301_3; Wing J. K., 1974, MEASUREMENT CLASSIFI; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; ZEFF K, 1987, MIL MED, V152, P529; [No title captured]; [No title captured]	50	93	93	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					537	553		10.1080/026990598122313			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200001	9653518				2022-02-06	
J	Lindner, MD; Plone, MA; Cain, CK; Frydel, B; Francis, JM; Emerich, DF; Sutton, RL				Lindner, MD; Plone, MA; Cain, CK; Frydel, B; Francis, JM; Emerich, DF; Sutton, RL			Dissociable long-term cognitive deficits after frontal versus sensorimotor cortical contusions	JOURNAL OF NEUROTRAUMA			English	Article						attention; cognitive deficits; recovery of function; spatial learning; traumatic brain injury	TRAUMATIC BRAIN INJURY; IMPROVES SPATIAL MEMORY; SEVERE HEAD-INJURY; WATER MAZE; AGED RATS; BEHAVIORAL DEFICITS; NEGLECT; LESIONS; ATTENTION; RECOVERY	Cognitive deficits are the most enduring and disabling sequelae of human traumatic brain injury (TBI), but quantifying the magnitude, duration, and pattern of cognitive deficits produced by different types of TBI has received little emphasis in preclinical animal models. The objective of the present study was to use a battery of behavioral tests to determine if different impact sites produce different patterns of behavioral deficits and to determine how long behavioral deficits can be detected after TBI. Prior to surgery, rats were trained to criteria on delayed nonmatching to position, radial arm maze, and rotarod tasks. Rats received sham surgery (controls), midline frontal contusions (frontal TBI, 2.25 m/sec impact), or unilateral sensorimotor cortex contusions (lateral TBI, 3.22 m/sec impact) at 12 months of age and were tested throughout the next 12 months. Cognitive deficits were more robust and more enduring than sensorimotor deficits for both lateral TBI and frontal TBI groups. Lateral TBI rats exhibited transient deficits in the forelimb placing and in the rotarod test of motor/ambulatory function, but cognitive deficits were apparent throughout the 12-month postsurgery period on tests of spatial learning and memory including: (1)reacquisition of a working memory version of the radial arm maze 6-7 months post-TBI, (2) performance in water maze probe trials 8 months post-TBI, and (3) repeated acquisition of the Morris mater maze 8 and 11 months post-TBI. Frontal TBI rats exhibited a different pattern of deficits, with the most robust deficits in tests of attention/orientation such as: (1) the delayed nonmatching to position task (even with no delays) 1-11 weeks post-TBI, (2) the repeated acquisition version of the water maze--especially on the first "information" trial 8 months post-TBI, (3) a test of sensorimotor neglect or inattention 8.5 months post-TBI, and (4) a DRL20 test of timing and/or sustained attention 11 months after surgery. These results suggest that long-term behavioral deficits can be detected in rodent models of TBI, that cognitive deficits seem to be more robust than sensorimotor deficits, and that different TBI impact sites produce dissociable patterns of cognitive deficits in rats.	CytoTherapeut Inc, Lincoln, RI 02865 USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA		Lindner, MD (corresponding author), CytoTherapeut Inc, 701 George Washington Highway, Lincoln, RI 02865 USA.			Lindner, Mark/0000-0002-8646-2980; Cain, Christopher/0000-0002-3929-6094			AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DENOBLE VJ, 1979, PHARMACOL BIOCHEM BE, V10, P393, DOI 10.1016/0091-3057(79)90203-X; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1979, BRAIN RES, V178, P329, DOI 10.1016/0006-8993(79)90697-8; GAGE FH, 1984, SCIENCE, V225, P533, DOI 10.1126/science.6539949; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, P86; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1972, NEUROLOGY, V22, P660, DOI 10.1212/WNL.22.6.660; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOYMAN L, 1979, PHYSIOL BEHAV, V22, P139, DOI 10.1016/0031-9384(79)90415-3; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZMAN R, 1991, J AM GERIATR SOC, V39, P516, DOI 10.1111/j.1532-5415.1991.tb02500.x; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LINDNER MD, 1992, BEHAV NEURAL BIOL, V58, P94, DOI 10.1016/0163-1047(92)90303-L; Lindner MD, 1997, NEUROBIOL LEARN MEM, V68, P203, DOI 10.1006/nlme.1997.3782; Lindner MD, 1996, CELL TRANSPLANT, V5, P205, DOI 10.1016/0963-6897(95)02029-2; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARKOWSKA AL, 1993, BEHAV NEUROSCI, V107, P627; MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MECK WH, 1987, J NEUROSCI, V7, P3505; Meck WH, 1996, COGNITIVE BRAIN RES, V3, P227, DOI 10.1016/0926-6410(96)00009-2; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MITCHELL DE, 1973, LANCET, V2, P215; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Morris RGM., 1983, NEUROBIOLOGY HIPPOCA, P405; OLTON DS, 1988, NEUROPSYCHOLOGIA, V26, P307, DOI 10.1016/0028-3932(88)90083-8; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; READING PJ, 1995, EXP BRAIN RES, V105, P76; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; *SAS I INC, 1989, SAS STAT US GUID VER, V1; SCHENK F, 1990, EXP BRAIN RES, V82, P641; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SOKOLOWSKI JD, 1994, BRAIN RES, V642, P20, DOI 10.1016/0006-8993(94)90901-6; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SUTTON RL, 1995, CENTRAL NERVOUS SYST, P497; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Teuber HL, 1955, ANNU REV PSYCHOL, V6, P267, DOI 10.1146/annurev.ps.06.020155.001411; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; [No title captured]	83	93	94	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					199	216		10.1089/neu.1998.15.199			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500005	9528920				2022-02-06	
J	Asikainen, I; Kaste, M; Sarna, S				Asikainen, I; Kaste, M; Sarna, S			Predicting late outcome for patients with traumatic brain injury referred to a rehabilitation programme: a study of 508 Finnish patients 5 years or more after injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; CHILDREN; POPULATION; PROGNOSIS; SEQUELAE; SEVERITY; COHORT; COMA	Variables were studied which predict at the acute stage the functional and occupational long-term outcome for patients with traumatic brain injury (TBI). Glasgow Coma Scale (GCS) score on hospital admission, length of coma (LOG) and duration of post-traumatic amnesia (PTA) were studied in a group of 508 TBI rehabilitation patients, age 0.8-71, mean age 19, followed up between five and over 20 years, mean of 12 years. information from hospital charts and all data available before and after the injury were gathered and reviewed. The study was carried out among a consecutive sample of Finnish patients with TBI referred to a rehabilitation programme at the out-patient neurological clinic of Kauniala Hospital, which specializes in brain injuries in Finland. The patients came from Various hospital districts in the country for an evaluation of their educational and vocational problems. Main outcome measures were functional outcome, as measured by the Glasgow Outcome scale (GOS) at the end of follow-up, and post-injury occupational outcome. The patients' reemployment on the open job marklet, subsidized employment or inability to work war noted. The GCS score on hospital admission correlated clearly with the functional outcome of the patients at the end of follow-up. Length of coma and duration of post-traumatic amnesia correlated specifically with the patient's work history after the brain injury and with functional outcome measured by the GOS. Outcomes varied among age groups and seemed to be affected by age at injury. Accordingly, the extent of recovery and quality of life for rehabilitation patients with TBI can be estimated early on by prognostic factor reflecting injury severity in the acute phase. The results suggest that the GCS score, LOC and duration of PTA all have a strong predictive Value in assessing functional or occupational outcome for TBI patients.	Kauniala Hosp, Dept Neurol, Kauniainen 02700, Finland; Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland		Asikainen, I (corresponding author), Kauniala Hosp, Dept Neurol, Kylpylantie 19, Kauniainen 02700, Finland.			Kaste, Markku/0000-0001-6557-6412; Sarna, Seppo/0000-0003-3458-1627			AMACHER AL, 1987, NEUROSURGERY, V20, P954; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DOUGLAS I, 1994, ARCH NEUROL-CHICAGO, V51, P661; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GIBSON RM, 1989, LANCET, V2, P369; GUATIERI CT, 1988, BRAIN INJURY, V2, P101; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HORN S, 1992, Brain Injury, V6, P321, DOI 10.3109/02699059209034946; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; KIRKPATRICK JB, 1987, J AM GERIATR SOC, V26, P489; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; Marshall LF, 1991, J NEUROSURG S, V75, P14; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAULINE P, 1993, BRAIN INJURY, V4, P283; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RUCKERT RF, 1985, UNFALLCHIRURG, V88, P99; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	47	93	95	0	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1998	12	2					95	107		10.1080/026990598122737			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	YV073	WOS:000071786900001	9492958				2022-02-06	
J	Burleigh, SA; Farber, RS; Gillard, M				Burleigh, SA; Farber, RS; Gillard, M			Community integration and life satisfaction after traumatic brain injury: Long-term findings	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	APR   13, 1997	ORLANDO, FLORIDA	Amer Occupat Therapy Assoc		head injuries; quality of life; social adjustment	HEAD-INJURY; IMPAIRMENT; REHABILITATION; REINTEGRATION; DISABILITY; HANDICAP; INDEX	Objective. This study examines the relationship of the degree of community integration to the life satisfaction of persons with traumatic brain injury (TBI). Method. The responses to two self-administered questionnaires measuring aspects of community integration and life satisfaction were studied for 30 persons with TBI who were 26 to 60 years of age. Results. A significant relationship (rho = .37, p < .05) was found between life satisfaction and social integration (a component of community integration), No significant association was found between the total community integration score and life satisfaction. Conclusion. The results suggest the need for rehabilitation programs to provide long-term assistance with community-based social integration as well as more effective treatment strategies to develop these skills in persons with TBI.	ReMed Recovery Care Ctr, Bryn Mawr, PA 19010 USA; Temple Univ, Coll Allied Hlth Profess, Dept Occupat Therapy, Philadelphia, PA 19122 USA		Burleigh, SA (corresponding author), ReMed Recovery Care Ctr, 780 W Lancaster Ave,Suite 103, Bryn Mawr, PA 19010 USA.						ADAMS DL, 1969, J GERONTOL, V24, P470, DOI 10.1093/geronj/24.4.470; Andrews F. M., 1976, SOCIAL INDICATORS WE; Condeluci A., 1992, J HEAD TRAUMA REHAB, V7, P37; Di Donato B A, 1994, Rehabil Nurs, V19, P219; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JACKSON JD, 1994, AM J OCCUP THER, V48, P251, DOI 10.5014/ajot.48.3.251; JENNETT B, 1976, LANCET, V1, P1031; JOHNSTON MV, 1994, ARCH PHYSICAL MED RE, V75, P2; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LARSON RJ, 1974, J GERONTOL, V28, P109; LOHMANN N, 1977, J GERONTOL, V32, P73, DOI 10.1093/geronj/32.1.73; MATTINGLY C, 1991, AM J OCCUP THER, V45, P979, DOI 10.5014/ajot.45.11.979; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCDOWELL I, 1987, MEASURING HLTH GUIDE, P204; *NAT HEAD INJ FDN, 1995, BAS QUEST BRAIN INJ; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; *NIH, 1990, NAT I NEUR DIS STROK; OAKLEY F, 1982, THESIS VIRGINIA COMM; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OKUN MA, 1984, INT J AGING HUM DEV, V19, P111, DOI 10.2190/QGJN-0N81-5957-HAQD; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; REILLY M, 1969, AM J OCCUP THER, V23, P299; SCHAAF SV, 1992, NEWSLETTER NATL HEAD, V11, P9; STRAX TE, 1994, ARCH PHYSICAL MED RE, V75, P1; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1994, ARCH PHYSICAL MED RE, V73, P1073; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; World Health Organization, 1980, INT CLASS IMP DIS HA; [No title captured]	38	93	93	1	4	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JAN	1998	52	1					45	52		10.5014/ajot.52.1.45			8	Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Rehabilitation	YL778	WOS:000070991900006	9426858				2022-02-06	
J	GomezHernandez, R; Max, JE; Kosier, T; Paradiso, S; Robinson, RG				GomezHernandez, R; Max, JE; Kosier, T; Paradiso, S; Robinson, RG			Social impairment and depression after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP	Objective: Previous studies have shown that social impairment is associated with major depression throughout the first year after traumatic brain injury (TBI). This study examined the specific social factors that were associated with post-TBI depression. Method: A consecutive series of 65 patients with closed head injuries were cross-sectionally and longitudinally examined using a semistructured psychiatric interview, the Hamilton Depression Rating Scale, and the Social Functioning Exam during in-hospital care and at 3-, 6-, 9-, and 12-month follow-ups. Results: Depressed subjects showed poorer social functioning at the initial evaluation, and at 6, 9, and 12 months. Measures of preinjury job dissatisfaction and fear of job loss were significantly associated with depression at the initial evaluation. Concurrent impaired close personal relationships as well as continued fear of job loss were associated with depression at 6, 9, and 12 months after TBI. Conclusions: These findings suggest that two of the psychosocial factors associated with depression during the acute TBI period (patient's satisfaction with work and fear of job loss) are the same as those operant during the chronic period, but an additional psychosocial factor (close interpersonal relationships) is also operant during the chronic period. These findings support the need for early targeted social intervention in cases of TBI. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	HOSP CLIN, DEPT PSYCHIAT, ZARAGOZA, SPAIN; UNIV IOWA, COLL MED, DEPT PSYCHIAT, IOWA CITY, IA 52242 USA				Paradiso, Sergio/H-9052-2012		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH53592] Funding Source: Medline		BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hathaway S.R., 1951, MINNESOTA MULTIPHASI; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KARPMAN T, 1985, J APPL REHABILITATIO, V0017, P00028; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KRAUS J, 1985, HEAD INJURY, P1; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1984, CLOSED HEAD INJURY, P109; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Silver JM., 1994, NEUROPSYCHIATRY TRAU; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TRIESCHMANN RB, 1990, J HEAD TRAUMA REHAB, V5, P57; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1990, VOCATIONAL REHABILIT; Wing J. K., 1974, MEASUREMENT CLASSIFI	28	93	95	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1997	78	12					1321	1326		10.1016/S0003-9993(97)90304-X			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	YK894	WOS:A1997YK89400007	9421985				2022-02-06	
J	Kinsella, G; Murtagh, D; Landry, A; Homfray, K; Hammond, M; OBeirne, L; Dwyer, L; Lamont, M; Ponsford, J				Kinsella, G; Murtagh, D; Landry, A; Homfray, K; Hammond, M; OBeirne, L; Dwyer, L; Lamont, M; Ponsford, J			Everyday memory following traumatic brain injury	BRAIN INJURY			English	Article							FUNCTIONING QUESTIONNAIRE; TEST-PERFORMANCE; IMPAIRMENT; COMPLAINT; DEFICITS	Residual memory deficits may represent a problem to the everyday functioning of a large number of people, including those who have sustained traumatic brain injury (TBI). The present exploratory study sought to investigate the interrelationships between subjective memory reports, performance on traditional memory tests, and performance on tests of prospective memory. These interrelationships were contrasted between a group of 24 adults who had sustained TBI and a group of 24 matched control subjects. Prospective memory was hypothesized to be indicative of everyday memory functioning. The results provided preliminary evidence that prospective memory tests are sensitive to TBI-related neurological impairment and, in comparison to traditional tests, may be better indicators of functional memory capacity. This pattern was particularly true for control subjects, possibly because TBI subjects had difficulties in evaluating their memory functioning.	ALBURY BASE HOSP,COGNIT REHABIL PROGRAMME,ALBURY,NSW,AUSTRALIA; BETHESDA HOSP,DEPT PSYCHOL,RICHMOND,VIC,AUSTRALIA		Kinsella, G (corresponding author), LA TROBE UNIV,SCH PSYCHOL,BUNDOORA,VIC 3083,AUSTRALIA.		Kinsella, Glynda/O-6347-2017; Murtagh, Donal/F-8694-2011	Kinsella, Glynda/0000-0002-5859-0934; Murtagh, Donal/0000-0003-1539-3559			[Anonymous], 1992, NEUROPSYCHOLOGICAL R, DOI [10.1080/09602019208401416, DOI 10.1080/09602019208401416]; BADDELEY A, 1982, ALZHEIMERS DISEASE R, P141; BARBA GD, 1993, HDB NEUROPSYCHOLOGY, V8, P239; Benson D.F., 1986, FRONTAL LOBES; BROWN FH, 1991, J CLIN PSYCHOL, V47, P772, DOI 10.1002/1097-4679(199111)47:6<772::AID-JCLP2270470607>3.0.CO;2-P; CROSSEN JR, 1988, CLIN NEUROPSYCHOL, V2, P393; DOBBS AR, 1987, CAN J PSYCHOL, V41, P209, DOI 10.1037/h0084152; Gilewski M.J., 1986, CLIN MEMORY ASSESSME, P93, DOI [10.1037/10057-008, DOI 10.1037/10057-008]; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; KAHN RL, 1975, ARCH GEN PSYCHIAT, V32, P1569; LARRABEE GJ, 1991, J CLIN EXP NEUROPSYC, V13, P466, DOI 10.1080/01688639108401064; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Rey A., 1964, EXAMEN CLIN PSYCHOL; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wechsler D, 1987, MEMORY SCALE REVISED; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; ZELINSKI EM, 1990, PSYCHOL AGING, V5, P388, DOI 10.1037/0882-7974.5.3.388; Zelinski EM, 1980, NEW DIRECTIONS MEMOR, P519	26	93	94	0	25	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1996	10	7					499	507		10.1080/026990596124214			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UU819	WOS:A1996UU81900003	8806010				2022-02-06	
J	Gross, H; Kling, A; Henry, G; Herndon, C; Lavretsky, H				Gross, H; Kling, A; Henry, G; Herndon, C; Lavretsky, H			Local cerebral glucose metabolism in patients with long-term behavioral and cognitive deficits following mild traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POSITRON EMISSION TOMOGRAPHY; CLOSED HEAD-INJURY; PREFRONTAL CORTEX; RHESUS-MONKEY; BLOOD-FLOW; ATTENTION; LOCALIZATION; SEQUELAE; ANATOMY; SYSTEM	A retrospective study of 20 patients with mild traumatic brain injury (MTBI) examined brain regions of interest by comparing [F-18]-2-deoxyglucose PET, neuropsychological test results, and continuing behavioral dysfunction. Abnormal local cerebral metabolic rates (rLCMs) were most prominent in midtemporal, anterior cingulate, precuneus, anterior temporal, frontal white, and corpus callosum brain regions. Abnormal rLCMs were significantly correlated statistically with 1) overall clinical complaints, most specifically with inconsistent attention/concentration and 2) overall neuropsychological test results. The authors conclude that 1) even mild TBI may result in continuing brain behavioral deficits; 2) PET can help elucidate dysfunctional brain circuitry in neurobehavioral disorders; and 3) specific brain areas may correlate with deficits in daily neurobehavioral functioning and neuropsychological test findings.	VET ADM MED CTR, PSYCHIAT SERV, SEPULVEDA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT & BEHAV SCI, LOS ANGELES, CA 90024 USA; CHARLES R DREW UNIV MED & SCI, DEPT BEHAV RES, LOS ANGELES, CA 90059 USA				Lavretsky, Helen/M-5711-2015	Lavretsky, Helen/0000-0001-9990-5085			BENCH CJ, 1993, NEUROPSYCHOLOGIA, V31, P907, DOI 10.1016/0028-3932(93)90147-R; Benson D.F., 1986, FRONTAL LOBES; BEYER WH, 1985, HDB TABLES PROBABILI; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BUCHSBAUM MS, 1984, ARCH GEN PSYCHIAT, V41, P1159; CUMMINGS JL, 1993, FRONTAL SUBCORTICAL, P873; Damasio A., 1994, DESCARTES ERROR EMOT; DEUTSCH G, 1987, INT J NEUROSCI, V36, P23, DOI 10.3109/00207458709002136; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; GRONWALL D, 1974, LANCET, V2, P605; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HAXBY J, 1993, NEUROPSYCHOLOGIA, V29, P539; Heaton R.K., 1981, WISCONSIN CARD SORTI; Hooper H., 1958, HOOPER VISUAL ORG TE; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Kaplan E, 1983, BOSTON NAMING TEST; KLING A, 1981, AMYGDALOID COMPLEX, P271; KLING AS, 1987, BEHAV NEURAL BIOL, V47, P54, DOI 10.1016/S0163-1047(87)90156-7; KLING AS, 1993, BEHAV BRAIN RES, V56, P161, DOI 10.1016/0166-4328(93)90034-N; Laberge D, 1990, J Cogn Neurosci, V2, P358, DOI 10.1162/jocn.1990.2.4.358; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEZAK MD, 1989, FRONTIERS CLIN NEURO; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Milner B, 1972, Clin Neurosurg, V19, P421; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; Reitan R, 1969, MANUAL ADM NEUROPSYC; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RETSBERG J, 1977, NEUROPSYCHOLOGIA, V15, P793; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; ROLAND PE, 1989, WENNER-GR C, V53, P141; ROLAND PE, 1985, J NEUROPHYSIOL, V53, P1219, DOI 10.1152/jn.1985.53.5.1219; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SELEMON LD, 1988, J NEUROSCI, V8, P4049; SELEMON LD, 1995, AM J PSYCHIAT, V152, P5, DOI 10.1176/ajp.152.1.5; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SPERRY R, 1884, NEUROPSYCHOLOGIA, V22, P6; Spreen O., 1969, NEUROSENSORY CTR COM; Taylor E., 1959, PSYCHOL APPRAISAL CH; UZZELL BP, 1991, INT NEUR SOC SAN ANT; UZZELL BP, 1990, INT NEUR SOC INNSBR; Van Hoesen G., 1981, AMYGDALOID COMPLEX, P77; VOGT BA, 1987, ENCY NEUROSCIENCE, P244; Wechsler D, 1987, MEMORY SCALE REVISED; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Wilcoxon F., 1949, SOME RAPID APPROXIMA; Yaremko R.M., 1986, HDB RES QUANTITATIVE; [No title captured]; [No title captured]	65	93	94	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	1996	8	3					324	334					11	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	VB219	WOS:A1996VB21900011	8854305				2022-02-06	
J	LANG, DA; TEASDALE, GM; MACPHERSON, P; LAWRENCE, A				LANG, DA; TEASDALE, GM; MACPHERSON, P; LAWRENCE, A			DIFFUSE BRAIN-SWELLING AFTER HEAD-INJURY - MORE OFTEN MALIGNANT IN ADULTS THAN CHILDREN	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; BRAIN SWELLING; OUTCOME; CHILDREN	COMPUTED-TOMOGRAPHY; NEUROSURGICAL UNIT; COMA; MILD	A series of 118 patients with diffuse traumatic brain swelling was studied retrospectively in order to compare the clinical findings in children with those in adults, and to determine the occurrence of neurological deterioration and outcome. The computerized tomography (CT) picture of absent third ventricle and basal cisterns was used to identify the cases. Although this condition has been associated with children, we found the same number of children and adults (59 cases each). Secondary deterioration (decline in consciousness, the development of new focal neurological signs, or an increase in intracranial pressure) occurred in 40% of cases and was more common in adults than children. Features that were significantly associated with deterioration were the presence of prolonged coma (> 1 hour) after the injury, CT signs of diffuse axonal injury or subarachnoid hemorrhage, or a recorded episode of hypotension. A moderate or good recovery at 6 months was achieved by 70 patients (59%), but 45 patients had a poor outcome (severe disability in nine, vegetative state in three, and death in 33) and this was often a consequence of secondary deterioration. In three patients, the outcome was not known. The combination of a severe initial injury, secondary insult, and diffuse swelling is associated with a poor outlook, particularly in adults. The CT appearance of diffuse swelling may develop more readily in children because of the lack of cerebrospinal fluid available for displacement. In children, diffuse swelling may have a relatively benign course unless there is a severe primary injury or a secondary hypotensive insult.	SO GEN HOSP, INST NEUROL SCI, GLASGOW G51 4TF, SCOTLAND								ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BRIGGS M, 1984, BRIT MED J, V288, P983; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DEARDEN NM, 1989, INTRACRANIAL PRESSUR, V7, P474; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GRANT R, 1987, MAGN RESON IMAGING, V5, P465, DOI 10.1016/0730-725X(87)90380-8; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; MARMAROU A, 1990, ACT NEUR S, V51, P123; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MENDELOW AD, 1983, INTRACRANIAL PRESSUR, V5, P495; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, IN PRESS J NEUROL NE; TEASDALE GM, 1989, INTRACRANIAL PRESSUR, V7, P560; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	28	93	98	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	1994	80	4					675	680		10.3171/jns.1994.80.4.0675			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	NC826	WOS:A1994NC82600011	8151346				2022-02-06	
J	CRUZ, J				CRUZ, J			ONLINE MONITORING OF GLOBAL CEREBRAL HYPOXIA IN ACUTE BRAIN INJURY - RELATIONSHIP TO INTRACRANIAL HYPERTENSION	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; INTRACRANIAL PRESSURE; CEREBRAL OXYGENATION; CEREBRAL HYPOXIA; COMA; FIBEROPTIC MONITORING	SEVERE HEAD-INJURY; BLOOD-FLOW; HEMODYNAMIC RESERVE; OXYGENATION; METABOLISM; COMA; HYPERVENTILATION; PRESSURE; TRAUMA	Global cerebral oxygenation, perfusion pressure, and expired CO2 tension were continuously monitored in 69 adults with acute severe closed brain trauma. Cerebral oxygenation was assessed by continuous fiberoptic monitoring of jugular bulb oxyhemoglobin saturation, in conjunction with continuous monitoring of arterial oxyhemoglobin saturation. Jugular desaturation associated with arterial desaturation (hypoxemic cerebral hypoxia) was evaluated and managed. A total of 121 episodes of combined arterial and jugular desaturation were documented, 76 in the presence of gross abnormalities identified on chest roentgenograms. Prolonged episodes that did not respond promptly to treatment occurred 32 times in 12 patients, usually after the initial 72 hours posttrauma. The remaining 89 episodes promptly responded to treatment and occurred predominantly within the initial 72 hours. Profound but brief desaturation was not associated with neurological deterioration, while profound and prolonged desaturation was accompanied by significant decreases in Glasgow Coma Scale scores, even though intracranial pressure levels were not significantly different in these two groups. Global cerebral hypoxia that does not respond promptly to treatment appears to be independently deleterious to neurological function in severely head-injured patients.	HOSP UNIV PENN,CTR HEAD INJURY,PHILADELPHIA,PA 19104		CRUZ, J (corresponding author), HOSP UNIV PENN,DIV NEUROSURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303697-04] Funding Source: Medline		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; CRUZ J, 1992, J TRAUMA, V33, P304, DOI 10.1097/00005373-199208000-00022; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1992, J TRAUMA, V32, P401, DOI 10.1097/00005373-199203000-00020; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; CRUZ J, 1993, IN PRESS CRIT CARE M; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	23	93	95	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1993	79	2					228	233		10.3171/jns.1993.79.2.0228			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LP276	WOS:A1993LP27600010	8331405				2022-02-06	
J	UNTERBERG, A; KIENING, K; SCHMIEDEK, P; LANKSCH, W				UNTERBERG, A; KIENING, K; SCHMIEDEK, P; LANKSCH, W			LONG-TERM OBSERVATIONS OF INTRACRANIAL-PRESSURE AFTER SEVERE HEAD-INJURY - THE PHENOMENON OF SECONDARY RISE OF INTRACRANIAL-PRESSURE	NEUROSURGERY			English	Article						HEAD INJURY; INTRACRANIAL PRESSURE; LEUKOCYTOSIS; SECONDARY RISE OF INTRACRANIAL PRESSURE	AGGRESSIVE TREATMENT; HYPONATREMIA; MANAGEMENT; COMA	THE LONG-TERM COURSE of intracranial pressure (ICP) was studied in 53 patients from a group of 90 patients with severe head injury treated over a 3-year period. In 49 of these, ICP was significantly elevated during the observation period. The maximum in ICP was usually observed 24 to 96 hours posttrauma. A subgroup of patients developed a second rise of ICP. Such a course was observed in 15 (31%) of the 49 patients with intracranial hypertension. In these cases, ICP increased initially to 20 to 30 mm Hg but could be controlled. Thereafter, ICP was decreased again for at least 12 hours. The secondary ICP rise occurred 3 to 10 days after trauma. In six patients, intracranial hypertension became uncontrollable and eventually caused brain death. The outcome of patients with a secondary rise of ICP was worse when compared with that of patients without this complication. A cause of the secondary ICP rise could only be identified in some cases. Delayed traumatic intracerebral hemorrhage, traumatic vasospasm, hypoxia, and hyponatremia were diagnosed in seven cases. In seven other patients, the secondary ICP rise coincided with a pronounced leukocytosis, which was not associated with apparent infections. Because the occurrence and degree of a secondary rise of ICP after severe head injury are important factors affecting outcome, monitoring of ICP after severe head injury should be prolonged.	UNIV MUNICH, KLINIKUM GROSSHADERN, DEPT NEUROSURG, W-8000 MUNICH 70, GERMANY		UNTERBERG, A (corresponding author), FREE UNIV BERLIN, RUDOLF VIRCHOW MED CTR, AUGUSTENBURGER PL 1, W-1000 BERLIN 65, GERMANY.						AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; BAETHMANN A, 1987, MECHANISM SECONDARY; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; COOPER PR, 1982, HEAD INJURY, P212; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FREIDENFELT H, 1963, ACTA RADIOL DIAGN, V1, P278, DOI 10.1177/028418516300100221; GAMACHE FW, 1982, NEUROSURGERY, V10, P468, DOI 10.1227/00006123-198204000-00009; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; JOHNSTON I H, 1970, Lancet, V2, P433; LUNDBERG N, 1960, ACTA PSYCHIATR NEU S, V149, P7; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P549; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1987, MECHANISM SECONDARY, P323; MIZUKAMI M, 1983, HYPERTENSIVE INTRACE, P239; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Pappius H.M., 1974, HDB CLIN NEUROLOGY 1, V16, P167; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; Turner H B, 1988, J Neurosci Nurs, V20, P236; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	34	93	94	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	1993	32	1					17	24		10.1227/00006123-199301000-00003			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	KF376	WOS:A1993KF37600003	8421552				2022-02-06	
J	KIRGIS, A; ALBRECHT, S				KIRGIS, A; ALBRECHT, S			PALSY OF THE DEEP PERONEAL NERVE AFTER PROXIMAL TIBIAL OSTEOTOMY - AN ANATOMICAL STUDY	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article								Iatrogenic, isolated weakness or paralysis of the extensor hallucis longus muscle is a common complication in patients who have had a proximal tibial and fibular osteotomy. To investigate why this complication occurs, we dissected the deep peroneal nerve and neighboring structures, such as the tibia and fibula and the muscles of the leg, in twenty-nine specimens from cadavera, paying special attention to the motor branches supplying the extensor hallucis longus. Of forty-six motor nerves that were identified, eight entered the muscle from the lateral side in an area seventy to 150 millimeters distal to the fibular head; all of them ran close to the fibular periosteum. We suggest that, in some patients, the nerve supply to the extensor hallucis longus is at high risk for injury during a tibial osteotomy because of the proximity of the bone to the motor branches.			KIRGIS, A (corresponding author), FREE UNIV BERLIN,TEACHING HOSP,EV WALDKRANKENHAUS SPANDAU,SCH MED,DEPT ANAT,STADTRANDSTR 55,W-1000 BERLIN 20,GERMANY.						BLAUTH W, 1976, ORTHOP PRAXIIS, V12, P176; LANG J, 1972, PRAKTISCHE ANATOMI 4, V1, P83; LEGAL H, 1987, ORTHOP PRAX, V23, P53; MAQUET P, 1985, CLIN ORTHOP RELAT R, V192, P108; NAUMANN T, 1984, ORTHOP PRAX, V20, P914; NAUMANN T, 1987, ORTHOP PRAX, V23, P466; STURZ H, 1979, Z ORTHOP GRENZGEB, V117, P31; WASMER G, 1987, ORTHOP PRAX, V23, P453; WEINGARDEN SI, 1979, JAMA-J AM MED ASSOC, V241, P1248, DOI 10.1001/jama.241.12.1248	9	93	101	0	2	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	SEP	1992	74A	8					1180	1185		10.2106/00004623-199274080-00007			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	JV595	WOS:A1992JV59500007	1400546				2022-02-06	
J	KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA				KOTAPKA, MJ; GRAHAM, DI; ADAMS, JH; GENNARELLI, TA			HIPPOCAMPAL PATHOLOGY IN FATAL NONMISSILE HUMAN HEAD-INJURY	ACTA NEUROPATHOLOGICA			English	Article						HIPPOCAMPUS; HEAD INJURY; SELECTIVE VULNERABILITY	RAISED INTRACRANIAL-PRESSURE; ISCHEMIC BRAIN-DAMAGE; VULNERABILITY; SECONDARY; COMMON	The hippocampus has been known to be involved in fatal non-missile human head injury, although detailed histopathology of this lesion has yet to be described. This report documents the frequency and distribution of hippocampal damage in a consecutive series of 112 fatal human non-missile head injuries. Damage to the hippocampus was noted in 94 cases (84%). Lesions always involved the CA1 subfield and were bilateral in 70 cases. Other subfields of the hippocampus were involved less frequently. Lesions were focal in the majority of cases (58%). Pathological evidence of high intracranial pressure was present in 86% of the cases. Hypoxic brain damage in other regions of the brain was present in 74% of cases. Thus, the hippocampus is frequently damaged in fatal non-missile human head injury. The pattern of this damage is similar to that observed in experimental head injury. Hypoxia and high intracranial pressure are likely to contribute to the occurrence of human traumatic hippocampal damage but other mechanisms. such as excitotoxicity, are likely to be operative.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV GLASGOW,DEPT NEUROPATHOL,GLASGOW G12 8QQ,SCOTLAND								ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brierly J, 1984, GREENFIELDS NEUROPAT, P125; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; BULLOCK R, 1990, ACT NEUR S, V51, P274; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; DUHAIME AC, 1990, BRAIN RES, V512, P169, DOI 10.1016/0006-8993(90)91188-M; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; INGLIS FM, 1990, ACT NEUR S, V51, P277; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1991, INTRACRANIAL PRESSUR, V8; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29	23	93	96	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1992	83	5					530	534		10.1007/BF00310031			5	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	HQ511	WOS:A1992HQ51100012	1621508				2022-02-06	
J	ZORNOW, MH; SCHELLER, MS; SHACKFORD, SR				ZORNOW, MH; SCHELLER, MS; SHACKFORD, SR			EFFECT OF A HYPERTONIC LACTATED RINGERS SOLUTION ON INTRACRANIAL-PRESSURE AND CEREBRAL WATER-CONTENT IN A MODEL OF TRAUMATIC BRAIN INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article									UNIV CALIF SAN DIEGO, DEPT SURG, LA JOLLA, CA 92093 USA		ZORNOW, MH (corresponding author), UNIV CALIF SAN DIEGO, DEPT ANESTHESIOL, M-029, LA JOLLA, CA 92093 USA.						CLASEN RA, 1962, J NEUROPATH EXP NEUR, V21, P579, DOI 10.1097/00005072-196210000-00006; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; DEFELIPPE J, 1980, LANCET, V2, P1002; FENSTERMACHER JD, 1984, EDEMA, P393; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; LEVIN AB, 1979, NEUROSURGERY, V5, P570, DOI 10.1227/00006123-197911000-00005; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARSHALL LF, 1985, CLIN NEUROSURG, V29, P312; MESSMER K, 1969, BRIT J SURG, V56, P626; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; TROUT JJ, 1986, LAB INVEST, V55, P622; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; 1977, DISEASE DISABILITY S, P483	16	93	94	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	1989	29	4					484	488		10.1097/00005373-198904000-00011			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	U4679	WOS:A1989U467900011	2709456				2022-02-06	
J	KLONOFF, PS; COSTA, LD; SNOW, WG				KLONOFF, PS; COSTA, LD; SNOW, WG			PREDICTORS AND INDICATORS OF QUALITY-OF-LIFE IN PATIENTS WITH CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV VICTORIA, VICTORIA V8W 2Y2, BC, CANADA; SUNNYBROOK MED CTR, TORONTO M4N 3M5, ONTARIO, CANADA		KLONOFF, PS (corresponding author), ST JOSEPHS HOSP & MED CTR, BARROW NEUROL INST, DEPT NEUROL, NEUROPSYCHOL SECT, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BLACK FW, 1973, J CLIN PSYCHOL, V29, P441; Bond M R, 1975, Ciba Found Symp, P141; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; ESSON ME, 1979, ALBANY DEV ASSESSMEN; Fidell L.S., 1983, USING MULTIVARIATE S; Field, 1976, EPIDEMIOLOGY HEAD IN; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRONWALL DMA, 1974, LANCET          1122, P995; Harris A. J., 1958, HARRIS TESTS LATERAL; Hathaway SR, 1967, MINNESOTA MULTIPHASI; Holbourn AHS, 1943, LANCET, V2, P438; HPAY H, 1971, P INT S HEAD INJURIE, P110; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1975, CIBA F S, V34; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KERR TA, 1971, BRIT J PREV SOC MED, V25, P179; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF PS, NEUROSURGERY; KLONOFF PS, 1984, THESIS U VICTORIA VI; LEIGH D, 1979, PSYCHIATRY DIGES AUG, P21; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1980, FEB M INT NEUR SOC S; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; MACK JL, MMPI CURRENT CLIN RE; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MINDERHOUD JM, 1982, CLIN NEUROL NEUROSUR, V84, P15, DOI 10.1016/0303-8467(82)90106-8; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Panting A, 1972, REHABILITATION, V38, P33; Porteus SD., 1950, PORTEUS MAZE TEST IN; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Spellacy F. J., 1969, CORTEX, V5, P390, DOI [10.1016/S0010-9452(69)80015-8, DOI 10.1016/S0010-9452(69)80015-8]; Spreen O., 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VIOLON A, 1978, HEAD INJURIES, P105; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WECHLSER D, 1945, MANUAL WECHSLER MEMO; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZAZULA T, 1981, UNPUB VERY EARLY BED; [No title captured]	70	93	94	1	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1986	8	5					469	485		10.1080/01688638608405171			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	E9205	WOS:A1986E920500001	3805248				2022-02-06	
J	Hawryluk, GWJ; Aguilera, S; Buki, A; Bulger, E; Citerio, G; Cooper, DJ; Arrastia, RD; Diringer, M; Figaji, A; Gao, GY; Geocadin, R; Ghajar, J; Harris, O; Hoffer, A; Hutchinson, P; Joseph, M; Kitagawa, R; Manley, G; Mayer, S; Menon, DK; Meyfroidt, G; Michael, DB; Oddo, M; Okonkwo, D; Patel, M; Robertson, C; Rosenfeld, JV; Rubiano, AM; Sahuquillo, J; Servadei, F; Shutter, L; Stein, D; Stocchetti, N; Taccone, FS; Timmons, S; Tsai, E; Ullman, JS; Vespa, P; Videtta, W; Wright, DW; Zammit, C; Chesnut, RM				Hawryluk, Gregory W. J.; Aguilera, Sergio; Buki, Andras; Bulger, Eileen; Citerio, Giuseppe; Cooper, D. Jamie; Arrastia, Ramon Diaz; Diringer, Michael; Figaji, Anthony; Gao, Guoyi; Geocadin, Romergryko; Ghajar, Jamshid; Harris, Odette; Hoffer, Alan; Hutchinson, Peter; Joseph, Mathew; Kitagawa, Ryan; Manley, Geoffrey; Mayer, Stephan; Menon, David K.; Meyfroidt, Geert; Michael, Daniel B.; Oddo, Mauro; Okonkwo, David; Patel, Mayur; Robertson, Claudia; Rosenfeld, Jeffrey V.; Rubiano, Andres M.; Sahuquillo, Juan; Servadei, Franco; Shutter, Lori; Stein, Deborah; Stocchetti, Nino; Taccone, Fabio Silvio; Timmons, Shelly; Tsai, Eve; Ullman, Jamie S.; Vespa, Paul; Videtta, Walter; Wright, David W.; Zammit, Christopher; Chesnut, Randall M.			A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)	INTENSIVE CARE MEDICINE			English	Article						Brain injury; Head trauma; Algorithm; Protocol; Consensus; Intracranial pressure; Tiers; Seattle; SIBICC	DECOMPRESSIVE CRANIECTOMY; AUTOREGULATION; TRIAL	Background Management algorithms for adult severe traumatic brain injury (sTBI) were omitted in later editions of the Brain Trauma Foundation's sTBI Management Guidelines, as they were not evidence-based. Methods We used a Delphi-method-based consensus approach to address management of sTBI patients undergoing intracranial pressure (ICP) monitoring. Forty-two experienced, clinically active sTBI specialists from six continents comprised the panel. Eight surveys iterated queries and comments. An in-person meeting included whole- and small-group discussions and blinded voting. Consensus required 80% agreement. We developed heatmaps based on a traffic-light model where panelists' decision tendencies were the focus of recommendations. Results We provide comprehensive algorithms for ICP-monitor-based adult sTBI management. Consensus established 18 interventions as fundamental and ten treatments not to be used. We provide a three-tier algorithm for treating elevated ICP. Treatments within a tier are considered empirically equivalent. Higher tiers involve higher risk therapies. Tiers 1, 2, and 3 include 10, 4, and 3 interventions, respectively. We include inter-tier considerations, and recommendations for critical neuroworsening to assist the recognition and treatment of declining patients. Novel elements include guidance for autoregulation-based ICP treatment based on MAP Challenge results, and two heatmaps to guide (1) ICP-monitor removal and (2) consideration of sedation holidays for neurological examination. Conclusions Our modern and comprehensive sTBI-management protocol is designed to assist clinicians managing sTBI patients monitored with ICP-monitors alone. Consensus-based (class III evidence), it provides management recommendations based on combined expert opinion. It reflects neither a standard-of-care nor a substitute for thoughtful individualized management.	[Hawryluk, Gregory W. J.] Univ Manitoba, Sect Neurosurg, GB1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada; [Aguilera, Sergio] Valparaiso Univ, Almirante Nef Naval Hosp, Vina Del Mar, Chile; [Aguilera, Sergio] Univ Valparaiso, Valparaiso, Chile; [Buki, Andras] Med Sch, Dept Neurosurg, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Szentagothai Res Ctr, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Univ Pecs, Pecs, Hungary; [Bulger, Eileen] Univ Washington, Harborview Med Ctr, Dept Surg, 325 Ninth Ave, Seattle, WA 98104 USA; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] ASST Monza, Anaesthesia & Intens Care, San Gerardo & Desio Hosp, Monza, Italy; [Cooper, D. Jamie] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Intens Care Med, Melbourne, Vic, Australia; [Cooper, D. Jamie] Alfred Hosp, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Arrastia, Ramon Diaz] Univ Penn, Perelman Sch Med, Penn Presbyterian Med Ctr, Dept Neurol, 51 North 39th St, Philadelphia, PA 19104 USA; [Diringer, Michael] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Diringer, Michael] Barnes Jewish Hosp, Dept Neurol, 1 Barnes Jewish Hosp Plaza Suite 10400, St Louis, MO 63110 USA; [Figaji, Anthony] Univ Cape Town, Groote Schuur Hosp, Div Neurosurg, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Figaji, Anthony] Univ Cape Town, Groote Schuur Hosp, Neurosci Inst, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Gao, Guoyi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Head Trauma, Dept Neurosurg,Renji Hosp, 1630 Dongfang Rd, Shanghai 200127, Peoples R China; [Geocadin, Romergryko] Johns Hopkins Univ, Sch Med, Dept Neurol, 600 N Wolfe St,Phipps 455, Baltimore, MD 21287 USA; [Ghajar, Jamshid] Stanford Neurosci Hlth Ctr, Dept Neurosurg, 213 Quarry Rd 4th Fl,MC 5958, Palo Alto, CA 94304 USA; [Harris, Odette] Dept Neurosurg, 300 Pasteur Dr,Room R205,Edwards Bldg,MC 5327, Stanford, CA 94305 USA; [Hoffer, Alan] Case Western Reserve Univ, Sch Med, Dept Neurol Surg, 11100 Euclid Ave,5042, Cleveland, OH 44106 USA; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB20QQ, England; [Hutchinson, Peter] Cambridge Biomed Campus, Cambridge CB20QQ, England; [Joseph, Mathew] Christian Med Coll & Hosp, Dept Neurol Sci, Ida Scudder Rd, Vellore, Tamil Nadu, India; [Kitagawa, Ryan] UTHealth, McGovern Med Sch, Vivian L Smith Dept Neurosurg, 6400 Fannin St,Suite 2800, Houston, TX 77030 USA; [Manley, Geoffrey] San Francisco Gen Hosp, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Manley, Geoffrey] Univ Calif San Francisco, Ctr Trauma, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Mayer, Stephan] Henry Ford Hosp, Dept Neurol, Neurol, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Menon, David K.] Addenbrookes Hosp, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Meyfroidt, Geert] Univ Hosp Leuven, Dept & Lab Intens Care Med, Herestr 49,Box 7003 63, B-3000 Leuven, Belgium; [Meyfroidt, Geert] Katholieke Univ Leuven, Herestr 49,Box 7003 63, B-3000 Leuven, Belgium; [Michael, Daniel B.] Oakland Univ, William Beaumont Sch Med, Michigan Head & Spine Inst, Dept Neurosurg,Beaumont Hlth, Southfield, MI USA; [Oddo, Mauro] Univ Lausanne, CHUV Lausanne Univ Hosp, Fac Biol & Med, Dept Intens Care Med, Lausanne, Switzerland; [Okonkwo, David] Univ Pittsburgh, Presbyterian Med Ctr, Dept Neurosurg, Suite B-400 200 Lothrop St, Pittsburgh, PA 15213 USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr, Dept Surg, 1211 21st Ave South,404 MAB, Nashville, TN 37212 USA; [Robertson, Claudia] Baylor Coll Med, Dept Neurosurg, One Baylor Plaza, Houston, TX 77030 USA; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] El Bosque Univ, Neurosci Inst, INUB MEDITECH Res Grp, Bogota, Colombia; [Rubiano, Andres M.] MEDITECH Fdn, Clin Res, Calle 7-A 44-95, Cali 760036, Colombia; [Sahuquillo, Juan] Univ Hosp Vall dHebron, Dept Neurosurg, Barcelona, Spain; [Servadei, Franco] Humanitas Univ & Res Hosp, Dept Neurosurg, Milan, Italy; [Shutter, Lori] Univ Pittsburgh, Med Ctr, Dept Crit Care Med Neurol & Neurosurg, 3550 Terrace St,Room 646, Pittsburgh, PA 15261 USA; [Stein, Deborah] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Surg, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stein, Deborah] Univ Calif San Francisco, Ctr Trauma, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci Intens Care Unit, Milan, Italy; [Taccone, Fabio Silvio] ULB, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Timmons, Shelly] Dept Neurol Surg, GH 5100 SNEU, Indianapolis, IN 46202 USA; [Tsai, Eve] Univ Ottawa, Suruchi Bhargava Chair Spinal Cord & Brain Regene, Ottawa Hosp, Dept Surg,Div Neurosurg, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada; [Ullman, Jamie S.] North Shore Univ Hosp, Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Neurosurg, 300 Community Dr,9 Tower, Manhasset, NY USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Gary L Brinderson Family Chair Neurocrit Care, Los Angeles, CA USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Crit Care Med Res, Santa Monica, CA USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Neurosurg & Neurol, Santa Monica, CA USA; [Vespa, Paul] Ronald Reagan UCLA Med Ctr, Neurocrit Care, Santa Monica, CA USA; [Videtta, Walter] Posadas Hosp, Intens Care, Buenos Aires, DF, Argentina; [Wright, David W.] Emory Univ, Sch Med, Dept Emergency Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA; [Zammit, Christopher] Univ Rochester, Med Ctr, Dept Emergency Med, 265 Crittenden Blvd,Suite 2100,Box 655C, Rochester, NY 14642 USA; [Chesnut, Randall M.] Univ Washington, Dept Neurol Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Dept Orthopaed Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Sch Global Hlth, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Harborview Med Ctr, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98104 USA		Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98104 USA.	ghawryluk@hsc.mb.ca; chesnutr@uw.edu	RUBIANO, ANDRES M/K-6704-2012; Cooper, D. James/G-7961-2013; Sahuquillo, Juan/B-3577-2008; Tsai, Eve/ABE-6056-2021; Ullman, Jamie/AAP-5983-2020; Shutter, Lori A/G-2957-2013; Tsai, Eve/D-7007-2014	RUBIANO, ANDRES M/0000-0001-8931-3254; Cooper, D. James/0000-0002-5872-9051; Sahuquillo, Juan/0000-0003-0713-5875; Figaji, Anthony/0000-0002-3357-6490; Tsai, Eve/0000-0002-8152-349X; Chesnut, Randall/0000-0001-6377-3666; Shutter, Lori/0000-0002-1390-0628; Hawryluk, Gregory/0000-0002-5604-7057	NIHRNational Institute for Health Research (NIHR); American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Neurotrauma and Critical Care, Bard; Brain Trauma Foundation; DePuy; Hemedex; Integra; Neurointensive Care Section of the European Society of Intensive Care Medicine; Neurosurgical Society of Australasia; MedtronicMedtronic; Moberg Research; NatusNational University of Singapore; Neuroptics; Raumedic; Sophysa; Stryker; Zoll; NIHR (Cambridge BRC); NIHR (Global Health Research Group on Neurotrauma)	We thank our moderators Kevin Dunne and Theodore Michalke, Jone Howard for our audience response system, Kelley Chaddock for extensive administrative support, Peter Hendrickson, PhD for managing our web-based surveys, PJH is supported by the NIHR (Research Professorship, Cambridge BRC and Global Health Research Group on Neurotrauma), and DKM is an Emeritus Senior Investigator of the National Institute of Health Research (UK). We thank our financial supporters who include Adler/Geirsch Attorney at Law, the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Neurotrauma and Critical Care, Bard, the Brain Trauma Foundation, DePuy, Hemedex, Integra, the Neurointensive Care Section of the European Society of Intensive Care Medicine, Neurosurgical Society of Australasia, Medtronic, Moberg Research, Natus, Neuroptics, Raumedic, Sophysa, Stryker, and Zoll.	[Anonymous], 2007, J NEUROTRAUM, V24, pS1, DOI 10.1089/neu.2007.9997; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2018, JAMA-J AM MED ASSOC, V320, P2211, DOI 10.1001/jama.2018.17075; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Hendrickson P, 2018, WORLD NEUROSURG, V110, pE952, DOI 10.1016/j.wneu.2017.11.142; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; Trauma ACoSCo, 2015, BOOK BEST PRACT MAN	20	92	92	1	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2019	45	12								10.1007/s00134-019-05805-9		OCT 2019	12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW5BG	WOS:000492941700002	31659383	Green Published, hybrid, Green Accepted	Y	N	2022-02-06	
J	Bolos, M; Llorens-Martin, M; Jurado-Arjona, J; Hernandez, F; Rabano, A; Avila, J				Bolos, Marta; Llorens-Martin, Maria; Jurado-Arjona, Jeronimo; Hernandez, Felix; Rabano, Alberto; Avila, Jesus			Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; clearance; microglia; tau protein; tauopathies	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; TRANSGENIC MICE; EXTRACELLULAR TAU; PATHOLOGICAL TAU; ACTIVATION; TAUOPATHY; PROPAGATION; PROTEIN; CLEARANCE	The microtubule-associated protein (MAP) tau plays a critical role in the pathogenesis of tauopathies. Excess tau can be released into the extracellular medium in a physiological or pathological manner to be internalized by surrounding neurons-a process that contributes to the spread of this protein throughout the brain. Such spreading may correlate with the progression of the abovementioned diseases. In addition to neurons, tau can be internalized into other cells. Here we demonstrate that microglia take up tau in vitro and in vivo. In this regard, microglia from primary cultures internalized soluble (human recombinant tau42) and insoluble (homogenates derived from human AD brain) tau in vitro. Furthermore, using stereotaxic injection of tau in mice in vivo, we show that murine microglia internalize human tau. In addition, we demonstrate, for the first time, that microglia colocalize with various forms of tau in postmortem brain tissue of patients with Alzheimer's disease and non-demented control subjects. Our data reveal a potential role of microglia in the internalization of tau that might be relevant for the design of strategies to enhance the clearance of extracellular tau in neurodegenerative diseases characterized by the accumulation of this protein.	[Bolos, Marta; Llorens-Martin, Maria; Jurado-Arjona, Jeronimo; Hernandez, Felix; Avila, Jesus] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Bolos, Marta; Llorens-Martin, Maria; Jurado-Arjona, Jeronimo; Hernandez, Felix; Avila, Jesus] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid, Spain; [Rabano, Alberto] CIEN Fdn, Dept Neuropathol, Madrid, Spain		Avila, J (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, C Nicolas Cabrera 1, E-28049 Madrid, Spain.	jesus.avila@csic.es	Hernandez, Felix/L-2114-2015; Llorens-Martin, Maria/R-4613-2017; Avila, Jesus/I-2610-2015; Bolos, Marta/J-7620-2014	Hernandez, Felix/0000-0001-8753-8249; Llorens-Martin, Maria/0000-0001-9129-5198; Avila, Jesus/0000-0002-6288-0571; Bolos, Marta/0000-0003-2652-8607	Spanish Ministry of HealthInstituto de Salud Carlos IIISpanish Government; Comunidad de MadridComunidad de Madrid; Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII); Alzheimer's AssociationAlzheimer's Association	This study was funded by grants from the Spanish Ministry of Health, the Comunidad de Madrid, the Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII), and the Alzheimer's Association.	[Anonymous], 2012, BIOPRESERV BIOBANK, V10, P79, DOI DOI 10.1089/BIO.2012.1022; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Bellucci A, 2011, NEURODEGENER DIS, V8, P221, DOI 10.1159/000322228; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bradshaw EM, 2013, NAT NEUROSCI, V16, P848, DOI 10.1038/nn.3435; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Dujardin S, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-14; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Funk KE, 2015, J BIOL CHEM, V290, P21652, DOI 10.1074/jbc.M115.657924; Gebicke-Haerter PJ, 2001, MICROSC RES TECHNIQ, V54, P47, DOI 10.1002/jemt.1120; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Gomez-Ramos A, 2006, FEBS LETT, V580, P4842, DOI 10.1016/j.febslet.2006.07.078; Gomez-Ramos A, 2009, EUR NEUROPSYCHOPHARM, V19, P708, DOI 10.1016/j.euroneuro.2009.04.006; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Guillot-Sestier MV, 2013, CNS NEUROL DISORD-DR, V12, P593; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Herber DL, 2007, J NEUROIMMUNE PHARM, V2, P222, DOI 10.1007/s11481-007-9069-z; Holmes BB, 2014, P NATL ACAD SCI USA, V111, pE4376, DOI 10.1073/pnas.1411649111; Holmes BB, 2013, P NATL ACAD SCI USA, V110, pE3138, DOI 10.1073/pnas.1301440110; Iba M, 2015, ACTA NEUROPATHOL, V130, P349, DOI 10.1007/s00401-015-1458-4; Ikeda M, 2005, AM J PATHOL, V166, P521, DOI 10.1016/S0002-9440(10)62274-2; Ishizawa K, 2001, J NEUROPATH EXP NEUR, V60, P647, DOI 10.1093/jnen/60.6.647; Jiang T, 2014, MOL NEUROBIOL, V49, P529, DOI 10.1007/s12035-013-8536-1; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kanmert D, 2015, J NEUROSCI, V35, P10851, DOI 10.1523/JNEUROSCI.0387-15.2015; Karch CM, 2012, J BIOL CHEM, V287, P42751, DOI 10.1074/jbc.M112.380642; Kfoury N, 2012, J BIOL CHEM, V287, P19440, DOI 10.1074/jbc.M112.346072; Kim W, 2010, FEBS LETT, V584, P3085, DOI 10.1016/j.febslet.2010.05.042; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Llorens-Martin M, 2013, MOL PSYCHIATR, V18, P451, DOI 10.1038/mp.2013.4; Luo WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11161; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Maphis N, 2015, BRAIN, V138, P1738, DOI 10.1093/brain/awv081; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Perez M, 1996, J NEUROCHEM, V67, P1183; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Sasaki A, 2008, BRAIN RES, V1214, P159, DOI 10.1016/j.brainres.2008.02.084; Simon D, 2012, FEBS LETT, V586, P47, DOI 10.1016/j.febslet.2011.11.022; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Yamada K, 2011, J NEUROSCI, V31, P13110, DOI 10.1523/JNEUROSCI.2569-11.2011; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Yu Y, 2015, CELL MOL NEUROBIOL, V35, P71, DOI 10.1007/s10571-014-0101-6; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013	45	92	94	1	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	50	1					77	87		10.3233/JAD-150704			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA8VS	WOS:000368085200010	26638867				2022-02-06	
J	Takeda, YS; Xu, QB				Takeda, Yuji S.; Xu, Qiaobing			Neuronal Differentiation of Human Mesenchymal Stem Cells Using Exosomes Derived from Differentiating Neuronal Cells	PLOS ONE			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; SCIATIC-NERVE INJURY; BONE-MARROW; MICRORNA EXPRESSION; MEDIATED TRANSFER; PROGENITOR CELLS; STROMAL CELLS; PROLIFERATION; REGENERATION	Exosomes deliver functional proteins and genetic materials to neighboring cells, and have potential applications for tissue regeneration. One possible mechanism of exosome-promoted tissue regeneration is through the delivery of microRNA (miRNA). In this study, we hypothesized that exosomes derived from neuronal progenitor cells contain miRNAs that promote neuronal differentiation. We treated mesenchymal stem cells (MSCs) daily with exosomes derived from PC12 cells, a neuronal cell line, for 1 week. After the treatment with PC12-derived exosomes, MSCs developed neuron-like morphology, and gene and protein expressions of neuronal markers were upregulated. Microarray analysis showed that the expression of miR-125b, which is known to play a role in neuronal differentiation of stem cells, was much higher in PC12-derived exosomes than in exosomes from B16-F10 melanoma cells. These results suggest that the delivery of miRNAs contained in PC12-derived exosomes is a possible mechanism explaining the neuronal differentiation of MSC.	[Takeda, Yuji S.; Xu, Qiaobing] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA		Xu, QB (corresponding author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.	qiaobing.xu@tufts.edu			Pew Charitable Trusts	QX received a grant from The Pew Charitable Trusts (http://www.pewtrusts.org/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberti KA, 2014, BIOMATERIALS, V35, P3551, DOI 10.1016/j.biomaterials.2013.12.082; Aldrich BT, 2009, NEUROSCIENCE, V164, P711, DOI 10.1016/j.neuroscience.2009.08.033; Lopez-Verrilli MA, 2013, GLIA, V61, P1795, DOI 10.1002/glia.22558; Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje; Bell JHA, 2012, TISSUE ENG PART B-RE, V18, P116, DOI [10.1089/ten.teb.2011.0498, 10.1089/ten.TEB.2011.0498]; Cantaluppi V, 2012, CELL TRANSPLANT, V21, P1305, DOI 10.3727/096368911X627534; Chen XP, 2014, CANCER LETT, V353, P201, DOI 10.1016/j.canlet.2014.07.026; Cvjetkovic A, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23111; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Harrop JS, 2012, J NEUROSURG-SPINE, V17, P230, DOI 10.3171/2012.5.AOSPINE12115; Kennea NL, 2009, CELL CYCLE, V8, P1069, DOI 10.4161/cc.8.7.8121; Kim BM, 2012, BIOCHEM BIOPH RES CO, V426, P183, DOI 10.1016/j.bbrc.2012.08.058; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Kim SY, 2012, BIOCHEM BIOPH RES CO, V429, P173, DOI 10.1016/j.bbrc.2012.10.117; Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Lai CPK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00228; Lattanzi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067411; Le MTN, 2009, MOL CELL BIOL, V29, P5290, DOI 10.1128/MCB.01694-08; Li WG, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-55; Liu DZ, 2012, GENE, V495, P120, DOI 10.1016/j.gene.2011.12.041; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loohuis NFMO, 2012, CELL MOL LIFE SCI, V69, P89, DOI 10.1007/s00018-011-0788-1; Prabhakaran MP, 2009, BIOMATERIALS, V30, P4996, DOI 10.1016/j.biomaterials.2009.05.057; Rau CS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-181; Rehfeld F, 2015, CELL TISSUE RES, V359, P145, DOI 10.1007/s00441-014-1872-2; Saba R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003652; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sharma A, 2012, CELL TRANSPLANT, V21, pS79, DOI 10.3727/096368912X633798; Shelke GV, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24783; Straley KS, 2010, J NEUROTRAUM, V27, P1, DOI 10.1089/neu.2009.0948; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Tabesh H, 2009, NEUROCHEM INT, V54, P73, DOI 10.1016/j.neuint.2008.11.002; Takeda YS, 2015, NEURAL REGEN RES, V10, P689, DOI 10.4103/1673-5374.156946; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang R, 2012, CELL PHYSIOL BIOCHEM, V29, P381, DOI 10.1159/000338493; Willerth SM, 2007, ADV DRUG DELIVER REV, V59, P325, DOI 10.1016/j.addr.2007.03.014; Williams AH, 2009, SCIENCE, V326, P1549, DOI 10.1126/science.1181046; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Wu D, 2011, NEUROSCIENCE, V190, P386, DOI 10.1016/j.neuroscience.2011.06.017; Wu R, 2013, CELL BIOL INT, V37, P812, DOI 10.1002/cbin.10103; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xu JA, 2011, NUCLEIC ACIDS RES, V39, P825, DOI 10.1093/nar/gkq832; Xu WY, 2013, INT J ONCOL, V42, P757, DOI 10.3892/ijo.2012.1742; Yau WWY, 2012, BIOMATERIALS, V33, P2608, DOI 10.1016/j.biomaterials.2011.12.021; Yu B, 2012, NUCLEIC ACIDS RES, V40, P10356, DOI 10.1093/nar/gks750; Yu B, 2012, J CELL SCI, V125, P2675, DOI 10.1242/jcs.098996; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhou SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044768; Zhou SL, 2011, NEUROSCI LETT, V494, P89, DOI 10.1016/j.neulet.2011.02.064	56	92	101	2	83	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0135111	10.1371/journal.pone.0135111			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MQ	WOS:000359062300101	26248331	gold, Green Published, Green Submitted			2022-02-06	
J	Fagerholm, ED; Hellyer, PJ; Scott, G; Leech, R; Sharp, DJ				Fagerholm, Erik D.; Hellyer, Peter J.; Scott, Gregory; Leech, Robert; Sharp, David J.			Disconnection of network hubs and cognitive impairment after traumatic brain injury	BRAIN			English	Article						traumatic brain injury; diffusion tensor imaging; betweenness centrality; network hubs; graph theory	FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; TRACTOGRAPHY; ARCHITECTURE; DYSFUNCTION; SELECTION; ANATOMY; CORTEX	Traumatic brain injury affects brain connectivity by producing traumatic axonal injury. This disrupts the function of large-scale networks that support cognition. The best way to describe this relationship is unclear, but one elegant approach is to view networks as graphs. Brain regions become nodes in the graph, and white matter tracts the connections. The overall effect of an injury can then be estimated by calculating graph metrics of network structure and function. Here we test which graph metrics best predict the presence of traumatic axonal injury, as well as which are most highly associated with cognitive impairment. A comprehensive range of graph metrics was calculated from structural connectivity measures for 52 patients with traumatic brain injury, 21 of whom had microbleed evidence of traumatic axonal injury, and 25 age-matched controls. White matter connections between 165 grey matter brain regions were defined using tractography, and structural connectivity matrices calculated from skeletonized diffusion tensor imaging data. This technique estimates injury at the centre of tract, but is insensitive to damage at tract edges. Graph metrics were calculated from the resulting connectivity matrices and machine-learning techniques used to select the metrics that best predicted the presence of traumatic brain injury. In addition, we used regularization and variable selection via the elastic net to predict patient behaviour on tests of information processing speed, executive function and associative memory. Support vector machines trained with graph metrics of white matter connectivity matrices from the microbleed group were able to identify patients with a history of traumatic brain injury with 93.4% accuracy, a result robust to different ways of sampling the data. Graph metrics were significantly associated with cognitive performance: information processing speed (R-2 = 0.64), executive function (R-2 = 0.56) and associative memory (R-2 = 0.25). These results were then replicated in a separate group of patients without microbleeds. The most influential graph metrics were betweenness centrality and eigenvector centrality, which provide measures of the extent to which a given brain region connects other regions in the network. Reductions in betweenness centrality and eigenvector centrality were particularly evident within hub regions including the cingulate cortex and caudate. Our results demonstrate that betweenness centrality and eigenvector centrality are reduced within network hubs, due to the impact of traumatic axonal injury on network connections. The dominance of betweenness centrality and eigenvector centrality suggests that cognitive impairment after traumatic brain injury results from the disconnection of network hubs by traumatic axonal injury.	[Fagerholm, Erik D.; Hellyer, Peter J.; Scott, Gregory; Leech, Robert; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp Campus, Fac Med, Div Brain Sci,Computat Cognit & Clin Neuroimaging, London, England		Fagerholm, ED (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Hellyer, Peter J/F-7112-2013; Sharp, David J/A-2119-2013; Leech, Robert/AAE-8254-2019	Hellyer, Peter J/0000-0002-5139-3401; Leech, Robert/0000-0002-5801-6318; Scott, Gregory/0000-0001-8063-5871	MRC (UK) Clinician Scientist FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute of Health Research Professorship [RP-011-048]; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; MRC DTA studentshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	The work has been supported by an MRC (UK) Clinician Scientist Fellowship (D.J.S.) and a National Institute of Health Research Professorship - RP-011-048 (D.J.S.). The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. This work is also supported by an MRC DTA studentship (E.D.F.).	Andersson JLR, 2007, NONLINEAR REGISTRATI; Baddeley AD, 1994, DOORS PEOPLE TEST VI; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Cawley GC, 2006, IEEE IJCNN, P1661; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Crossley NA, 2014, BRAIN, V137, P2382, DOI 10.1093/brain/awu132; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Gottlich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077336; Goni J, 2014, P NATL ACAD SCI USA, V111, P833, DOI 10.1073/pnas.1315529111; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hwang K, 2013, CEREB CORTEX, V23, P2380, DOI 10.1093/cercor/bhs227; Jan HT, 2013, IEEE ENG MED BIO, P523, DOI 10.1109/EMBC.2013.6609552; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Li YC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058272, 10.1371/journal.pone.0073186]; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Platt JC, 2000, ADV NEUR IN, P61; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; van den Heuvel MP, 2013, J NEUROSCI, V33, P14489, DOI 10.1523/JNEUROSCI.2128-13.2013; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Vives-Gilabert Y, 2013, PSYCHIAT RES-NEUROIM, V214, P322, DOI 10.1016/j.pscychresns.2013.09.009; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Xue KQ, 2014, EPILEPSY RES, V108, P125, DOI 10.1016/j.eplepsyres.2013.10.002; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	43	92	94	1	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN 1	2015	138		6				1696	1709		10.1093/brain/awv075			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM9BD	WOS:000357999300031	25808370	Green Published, hybrid			2022-02-06	
J	Davis, PK; Musunuru, H; Walsh, M; Cassady, R; Yount, R; Losiniecki, A; Moore, EE; Wohlauer, MV; Howard, J; Ploplis, VA; Castellino, FJ; Thomas, SG				Davis, Patrick K.; Musunuru, Harsha; Walsh, Mark; Cassady, Robert; Yount, Robert; Losiniecki, Andrew; Moore, Ernest E.; Wohlauer, Max V.; Howard, Janet; Ploplis, Victoria A.; Castellino, Francis J.; Thomas, Scott G.			Platelet Dysfunction is an Early Marker for Traumatic Brain Injury-Induced Coagulopathy	NEUROCRITICAL CARE			English	Article						Traumatic Brain Injury (TBI); Platelet function in TBI; Thromboelastography (TEG); Thromboelastography modified platelet mapping (TEG/PM); Coagulation; Coagulopathy of trauma	SEVERE HEAD-INJURY; INTRAVASCULAR COAGULATION; INTRACEREBRAL HEMORRHAGE; CARE; THROMBELASTOGRAPHY; CONSEQUENCES; ASSOCIATION; MANAGEMENT; SEVERITY; PATIENT	The goal of this study is to determine the presence of platelet dysfunction in patients with traumatic brain injury (TBI). The mechanisms underlying the coagulopathy associated with TBI remain elusive. The question of platelet dysfunction in TBI is unclear. This was a prospective observational study conducted at Memorial Hospital of South Bend, IN, and Denver Health Medical Center, CO. A total of 50 patients sustaining TBI, and not under treatment with anticoagulants or platelet inhibitors, were analyzed utilizing modified thromboelastography (TEG) with platelet mapping (TEG/PM), along with standard coagulation tests. Compared to normal controls, patients with severe TBI had a significantly increased percentage of platelet ADP and arachidonic acid (AA) receptor inhibition. Furthermore, the percentage of ADP inhibition distinguished between survivors and non-survivors in patients with TBI (Mann-Whitney test, P = 0.035). ADP inhibition correlates strongly with severity of TBI (Mann-Whitney test, P = 0.014), while AA inhibition did not. These data indicate that early platelet dysfunction is prevalent after severe TBI, can be measured in a point-of-care setting using TEG/PM, and correlates with mortality. The mechanism responsible for this platelet dysfunction and associated implications for TBI management remains to be defined.	[Davis, Patrick K.; Musunuru, Harsha; Walsh, Mark; Cassady, Robert; Ploplis, Victoria A.; Castellino, Francis J.] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; [Walsh, Mark; Cassady, Robert; Yount, Robert; Losiniecki, Andrew; Howard, Janet; Thomas, Scott G.] Mem Hosp South Bend, Emergency Trauma Ctr, South Bend, IN 46601 USA; [Walsh, Mark] Indiana Univ Sch Med, South Bend, IN 46617 USA; [Moore, Ernest E.] Univ Colorado, Denver, CO 80045 USA; [Wohlauer, Max V.] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA		Walsh, M (corresponding author), Mem Hosp South Bend, Emergency Trauma Ctr, South Bend, IN 46601 USA.	markwalshmd@gmail.com		Walsh, Mark/0000-0002-5795-1144	CSL Behring; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL013423] Funding Source: NIH RePORTER	Dr. Walsh received consulting fees from CSL Behring.	Akins PT, 2010, NEUROCRIT CARE, V12, P375, DOI 10.1007/s12028-010-9336-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bartal C, 2009, CURR OPIN ANESTHESIO, V22, P281, DOI 10.1097/ACO.0b013e328325a6be; Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Carroll RC, 2009, TRANSL RES, V154, P34, DOI 10.1016/j.trsl.2009.04.001; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; CIAVARELLA D, 1987, BRIT J HAEMATOL, V67, P365, DOI 10.1111/j.1365-2141.1987.tb02359.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Creutzfeldt CJ, 2009, STROKE, V40, pE645, DOI 10.1161/STROKEAHA.109.561191; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maeda T, 1997, ACT NEUR S, V70, P102; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; SCHOCHL H, 2011, NEUROTRAUMA, V28, P2033, DOI DOI 10.1089/NEU.2010.1744; Shore-Lesserson L., 2009, BRIT J ANAESTHESI S1, V103, pI14, DOI 10.1093/bja/aep318; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P1; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Ziai Wendy C, 2003, J Stroke Cerebrovasc Dis, V12, P201, DOI 10.1016/S1052-3057(03)00075-2	47	92	100	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2013	18	2					201	208		10.1007/s12028-012-9745-6			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	105PR	WOS:000316084700007	22847397				2022-02-06	
J	Maegele, M				Maegele, Marc			Coagulopathy after traumatic brain injury: incidence, pathogenesis, and treatment options	TRANSFUSION			English	Article							RECOMBINANT FACTOR VIIA; HEAD-INJURY; INTRAVASCULAR COAGULATION; PLATELET TRANSFUSION; HYPERFIBRINOLYSIS; MICROPARTICLES; PROGRESSION; HEMORRHAGE; MORTALITY; RATIOS	Coagulopathy after traumatic brain injury (TBI) is frequent and represents a powerful predictor related to outcome and prognosis. The complex pathophysiological mechanisms of the coagulopathy of TBI are multifactorial and remain still undefined. The nature of the coagulation abnormalities differs between severe TBI and non-TBI with somatic injuries. The current hypothesis for the development of coagulopathy after TBI includes combinations of both hypo- and hypercoagulable states promoted by the magnitude and the extent of the injury resulting in a variable degree of secondary injury via subsequent ischemic and hemorrhagic lesioning. The proposed underlying mechanisms may comprise the release of tissue factor (TF), hyperfibrinolysis, shock, and hypoperfusion thus triggering the protein C pathway, disseminated intravascular coagulation, and platelet dysfunction. Hemocoagulative disorders after TBI may be amenable to treatment, and adequate and timely management may protect from secondary injury and poor outcomes. Functional assays such as viscoelastic tests may be supportive in early detection, diagnosis, and guidance of treatment. This review summarizes the current understanding with regard to frequency, pathogenesis, diagnosis, and treatment of the coagulopathy after TBI.	[Maegele, Marc] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Maegele, Marc] Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med IFOM, D-51109 Cologne, Germany		Maegele, M (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de					Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Borgman MA, 2011, VOX SANG, V101, P44, DOI 10.1111/j.1423-0410.2011.01466.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; Giesen PLA, 2000, SEMIN THROMB HEMOST, V26, P379, DOI 10.1055/s-2000-8456; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Letarte PB, 2008, J TRAUMA, V64, P627; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pathak A, 2005, Neurol India, V53, P178; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schochl H, 2012, HAMOSTASEOLOGIE, V32, P22, DOI 10.5482/ha-1178; Schochl H, 2011, J NEUROTRAUM, V28, P2033, DOI 10.1089/neu.2010.1744; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Swanson CA, 2010, J TRAUMA, V68, P1072, DOI 10.1097/TA.0b013e3181d7a6f2; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	43	92	99	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	JAN	2013	53			1	SI		28S	37S		10.1111/trf.12033			10	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	071SR	WOS:000313615000006	23301970				2022-02-06	
J	Failli, V; Kopp, MA; Gericke, C; Martus, P; Klingbeil, S; Brommer, B; Laginha, I; Chen, YY; DeVivo, MJ; Dirnagl, U; Schwab, JM				Failli, Vieri; Kopp, Marcel A.; Gericke, Christine; Martus, Peter; Klingbeil, Susann; Brommer, Benedikt; Laginha, Ines; Chen, Yuying; DeVivo, Michael J.; Dirnagl, Ulrich; Schwab, Jan M.			Functional neurological recovery after spinal cord injury is impaired in patients with infections	BRAIN			English	Article						intrinsic/endogenous recovery potential; poor outcome; neurological recovery	CLINICAL-TRIALS; NEURODEGENERATIVE DISEASE; SYSTEMIC INFLAMMATION; EXPERIMENTAL STROKE; ISCHEMIC-STROKE; ICCP PANEL; BRAIN; MOTOR; REHABILITATION; PLASTICITY	Infections are a common threat to patients after spinal cord injury. Furthermore, infections might propagate neuronal death, and consequently contribute to the restriction of neurological recovery. We investigated the association of infections (i.e. pneumonia and/or postoperative wound infections) with functional neurological outcome after acute severe traumatic spinal cord injury. We screened data sets of 24 762 patients enrolled in a prospective cohort study (National Spinal Cord Injury Database, Birmingham, AL, USA). Patients were assessed according to the ASIA classification. ASIA impairment scale-classified A and B patients recruited within 24 h post-trauma (n = 1436) were selected as being a major recruitment population for interventional trials. Patients with documented pneumonia and/or postoperative wound infections (n = 581) were compared with control subjects (non-documented infections, n = 855). The functional neurological outcome parameters (i) upward ASIA impairment scale conversions; (ii) gain of ASIA motor scores; and (iii) gain of motor and sensory levels were consecutively analysed over time up to 1 year after spinal cord injury. The group with pneumonia and/or postoperative wound infections revealed less ASIA impairment scale upward conversions after 1 year than the control group (ASIA impairment scale A: 17.2 versus 23.9%, P = 0.03; ASIA impairment scale B: 57.1 versus 74.7%, P = 0.009). ASIA motor score gain [median (interquartile range)] was lower in patients with infections [ASIA impairment scale A: 8 (4-12) versus 10 (5-17), P = 0.01; ASIA impairment scale B: 19.5 (8-53.5) versus 42 (20.5-64), P = 0.03)]. Analysis of acquired motor/sensory levels supported these findings. In ASIA impairment scale A patients, the gain in motor levels (21.7 versus 33.3%, P = 0.04) and sensory levels (24.4 versus 38 of 102, 37.3%, P = 0.03) was significantly lower in the group with pneumonia and/or postoperative wound infections than in the control group. Multiple regression analysis identified pneumonia and/or postoperative wound infections as independent risk factors for impaired ASIA impairment scale upward conversion (odds ratio: 1.89, 95% confidence interval: 1.36-2.63, P < 0.0005) or lower gain in ASIA motor score (regression coefficient: -8.21, 95% confidence interval: -12.29 to -4.14, P < 0.0005). Infections associated with spinal cord injury, such as pneumonia and/or postoperative wound infections, qualify as independent risk factors for poor neurological outcome after motor complete spinal cord injury. Infections constitute a clinically relevant target for protecting the limited endogenous functional regeneration capacity. Upcoming interventional trials might gain in efficacy with improved patient stratification and might benefit from complementary protection of the intrinsic recovery potential after spinal cord injury.	[Dirnagl, Ulrich; Schwab, Jan M.] Charite, Dept Neurol & Expt Neurol, Ctr Stroke Res Berlin, D-10117 Berlin, Germany; [Gericke, Christine; Martus, Peter] Charite, Inst Biostat & Clin Epidemiol, D-12203 Berlin, Germany; [Martus, Peter] Univ Tubingen, Dept Clin Epidemiol & Appl Biostat, D-72070 Tubingen, Germany; [Klingbeil, Susann] Univ Hosp Cologne, Dept Neurol, D-50937 Cologne, Germany; [Chen, Yuying; DeVivo, Michael J.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Natl Spinal Cord Injury Stat Ctr, Birmingham, AL 35233 USA		Schwab, JM (corresponding author), Charite, Dept Neurol & Expt Neurol, Ctr Stroke Res Berlin, Charite Pl 1, D-10117 Berlin, Germany.	jan.schwab@charite.de	Kopp, Marcel/AAX-3960-2020	Kopp, Marcel/0000-0001-6832-9599; Dirnagl, Ulrich/0000-0003-0755-6119; Schwab, Jan/0000-0001-6784-4919	German Research Council (DFG, Research Training School, Neuroinflammation)German Research Foundation (DFG) [1258]; Berlin-Brandenburg Centre for Regenerative Therapies (BCRT) [81717034]; International Foundation for Research in Paraplegia, Switzerland (IFP) [P102]; Wings for Life Spinal Cord Research Foundation, Austria [WfL-DE-006/12]; National Institute on Disability and Rehabilitation Research (NIDRR), U.S. Department of Education, USA [H133A060039]	This work was supported by the German Research Council (DFG, Research Training School, Neuroinflammation, Grant number 1258); the Berlin-Brandenburg Centre for Regenerative Therapies (BCRT, Grant number 81717034); the International Foundation for Research in Paraplegia, Switzerland (IFP, Grant number P102); and Wings for Life Spinal Cord Research Foundation, Austria (Grant Number WfL-DE-006/12). The NSCID is funded by the National Institute on Disability and Rehabilitation Research (NIDRR, Grant number H133A060039), U.S. Department of Education, USA.	Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Burns AS, 2003, J NEUROTRAUM, V20, P477, DOI 10.1089/089771503765355540; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; DeVivo Michael J, 2002, J Spinal Cord Med, V25, P335; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Dobkin BH, 2007, DEV NEUROBIOL, V67, P1133, DOI 10.1002/dneu.20514; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Dobkin BH, 2007, NEUROREHAB NEURAL RE, V21, P3, DOI 10.1177/1545968306297329; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1; Fouad K, 2011, BRAIN RES BULL, V84, P337, DOI 10.1016/j.brainresbull.2010.04.017; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; Furlan JC, 2008, J NEUROTRAUM, V25, P1273, DOI 10.1089/neu.2008.0617; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Held KS, 2010, EXP NEUROL, V226, P242, DOI 10.1016/j.expneurol.2010.08.036; Koennecke HC, 2011, NEUROLOGY, V77, P965, DOI 10.1212/WNL.0b013e31822dc795; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Marino RJ, 2003, J SPINAL CORD MED S1, V26, pS50; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Moreno B, 2011, ANN NEUROL, V70, P932, DOI 10.1002/ana.22550; Oropallo MA, 2012, J IMMUNOL, V188, P5257, DOI 10.4049/jimmunol.1101934; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Popovich P, 2009, NAT MED, V15, P736, DOI 10.1038/nm0709-736; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Richards J. Scott, 1995, P10; Riegger T, 2003, ACTA NEUROPATHOL, V106, P392; Riegger T, 2009, NEUROSCIENCE, V158, P1194, DOI 10.1016/j.neuroscience.2008.08.021; Riegger T, 2007, EUR J NEUROSCI, V25, P1743, DOI 10.1111/j.1460-9568.2007.05447.x; Schnell L, 1997, EUR J NEUROSCI, V9, P1000, DOI 10.1111/j.1460-9568.1997.tb01450.x; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Steeves JD, 2007, SPINAL CORD, V45, P206, DOI 10.1038/sj.sc.3102008; Steeves JD, 2011, SPINAL CORD, V49, P257, DOI 10.1038/sc.2010.99; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; Urra X, 2009, J CEREBR BLOOD F MET, V29, P994, DOI 10.1038/jcbfm.2009.25; Vega JL, 2003, J NEUROPATH EXP NEUR, V62, P848, DOI 10.1093/jnen/62.8.848; Vermeij FH, 2009, CEREBROVASC DIS, V27, P465, DOI 10.1159/000210093; Westendorp WF, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-110; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Zariffa J, 2011, SPINAL CORD, V49, P463, DOI 10.1038/sc.2010.140; Zorner B, 2010, J NEUROTRAUM, V27, P241, DOI 10.1089/neu.2009.0901	44	92	92	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2012	135		11				3238	3250		10.1093/brain/aws267			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044SV	WOS:000311644800012	23100450	Bronze			2022-02-06	
J	Lester, P; Saltzman, WR; Woodward, K; Glover, D; Leskin, GA; Bursch, B; Pynoos, R; Beardslee, W				Lester, Patricia; Saltzman, William R.; Woodward, Kirsten; Glover, Dorie; Leskin, Gregory A.; Bursch, Brenda; Pynoos, Robert; Beardslee, William			Evaluation of a Family-Centered Prevention Intervention for Military Children and Families Facing Wartime Deployments	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH; SOLDIERS; IRAQ; MALTREATMENT; CHECKLIST; PARENTS; RISK; CARE; WAR	Objectives. We evaluated the Families Over Coming Under Stress program, which provides resiliency training designed to enhance family psychological health in US military families affected by combat- and deployment-related stress. Methods. We performed a secondary analysis of Families Over Coming Under Stress program evaluation data that was collected between July 2008 and February 2010 at 11 military installations in the United States and Japan. We present data at baseline for 488 unique families (742 parents and 873 children) and pre-post outcomes for 331 families. Results. Family members reported high levels of satisfaction with the program and positive impact on parent child indicators. Psychological distress levels were elevated for service members, civilian parents, and children at program entry compared with community norms. Change scores showed significant improvements across all measures for service member and civilian parents and their children (P<.001). Conclusions. Evaluation data provided preliminary support for a strength-based, trauma-informed military family prevention program to promote resiliency and mitigate the impact of wartime deployment stress. (Am J Public Health. 2012;102:S48-S54. doi:10.2105/AJPH.2010.300088)	[Lester, Patricia; Saltzman, William R.; Glover, Dorie; Leskin, Gregory A.; Bursch, Brenda; Pynoos, Robert] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA; [Woodward, Kirsten] US Bur Navy Med & Surg, Washington, DC USA; [Beardslee, William] Childrens Hosp, Boston, MA 02115 USA; [Beardslee, William] Harvard Univ, Sch Med, Boston, MA USA		Lester, P (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,A8-159, Los Angeles, CA 90024 USA.	plester@mednet.ucla.edu			US Department of the Navy, Bureau of Medicine and Surgery [N00189-09-C-Z057]; Frederick R. Weisman Philanthropic Foundation and Discretionary Trust	The US Department of the Navy, Bureau of Medicine and Surgery (contract No. N00189-09-C-Z057) and the Frederick R. Weisman Philanthropic Foundation and Discretionary Trust supported Families OverComing Under Stress.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Baker DG, 2009, MIL MED, V174, P773; Beardslee WR, 2003, PEDIATRICS, V112, pE119, DOI 10.1542/peds.112.2.e119; Beardslee WR, 2009, ZERO 3, V29, P34; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; CHANDRA A, 2008, UNDERSTANDING IMPACT; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chartrand MM, 2008, ARCH PEDIAT ADOL MED, V162, P1009, DOI 10.1001/archpedi.162.11.1009; Compas BE, 1989, PRIMARY PREVENTION P, P60; Cozza SJ, 2005, PSYCHIAT QUART, V76, P371, DOI 10.1007/s11126-005-4973-y; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Derogatis L.R., 2001, BRIEF SYMPTOM INVENT; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Gewirtz A, 2008, J MARITAL FAM THER, V34, P177, DOI 10.1111/j.1752-0606.2008.00063.x; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; Greeno CG, 2002, PSYCHIATR SERV, V53, P624, DOI 10.1176/appi.ps.53.5.624; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huebner AJ, 2007, FAM RELAT, V56, P112, DOI 10.1111/j.1741-3729.2007.00445.x; Layne CM, 2008, J AM ACAD CHILD PSY, V47, P1048, DOI 10.1097/CHI.0b013e31817eecae; Lester P., 2008, EVIDENCE BASED TREAT, P170; Lester P, 2011, MIL MED, V176, P19, DOI 10.7205/MILMED-D-10-00122; Lester P, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P149, DOI 10.1007/978-1-4419-7064-0_8; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lincoln A, 2008, J CLIN PSYCHOL, V64, P984, DOI 10.1002/jclp.20520; MacDermid S. M., 2008, UNDERSTANDING PROMOT; McCarroll JE, 2008, CHILD ABUSE REV, V17, P108, DOI 10.1002/car.986; Nash W, 2009, COMBAT OPERATIONAL S; Nash WP, 2011, COMBAT OPERATIONAL B, P107; National Research Council and Institute of Medicine, 2009, DEPR PAR PAR CHILDR; National Research Council Institute of Medicine, 1994, PREV MENT EM BEH DIS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Palmer C, 2008, MIL PSYCHOL, V20, P205, DOI 10.1080/08995600802118858; PATTERSON JM, 1987, J ADOLESCENCE, V10, P163, DOI 10.1016/S0140-1971(87)80086-6; Rentz ED, 2007, AM J EPIDEMIOL, V165, P1199, DOI 10.1093/aje/kwm008; ROSEN LN, 1993, MIL MED, V158, P465, DOI 10.1093/milmed/158.7.465; Rotheram-Borus MJ, 2001, AM J PUBLIC HEALTH, V91, P1294, DOI 10.2105/AJPH.91.8.1294; RUTTER M, 1984, PSYCHOL MED, V14, P853, DOI 10.1017/S0033291700019838; Ryan CE., 2005, EVALUATION TREATING; Saltzman WR, 2009, FOCUS MILITARY UNPUB; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; SPIRITO A, 1988, J PEDIATR PSYCHOL, V13, P555, DOI 10.1093/jpepsy/13.4.555; Spoth Richard L, 2002, Prev Sci, V3, P145, DOI 10.1023/A:1019924615322; Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Waldrep DA, 2004, IRAQ WAR CLIN GUIDE, P83; Walker EA, 2002, GEN HOSP PSYCHIAT, V24, P375, DOI 10.1016/S0163-8343(02)00203-7; Walsh F, 2002, FAM RELAT, V51, P130, DOI 10.1111/j.1741-3729.2002.00130.x; Walsh F., 2006, STRENGTHENING FAMILY; Weathers FW, 1993, 9 ANN M ISTSS OCT SA	54	92	94	1	26	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health		2012	102			1			S48	S54		10.2105/AJPH.2010.300088			7	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	893EO	WOS:000300338600018	22033756	Green Published, Green Submitted			2022-02-06	
J	Donnelly, KT; Donnelly, JP; Dunnam, M; Warner, GC; Kittleson, CJ; Constance, JE; Bradshaw, CB; Alt, M				Donnelly, Kerry T.; Donnelly, James P.; Dunnam, Mina; Warner, Gary C.; Kittleson, C. J.; Constance, Janet E.; Bradshaw, Charles B.; Alt, Michelle			Reliability, Sensitivity, and Specificity of the VA Traumatic Brain Injury Screening Tool	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; mass screening; posttraumatic; stress disorders; sensitivity and specificity; veterans		Objective: To provide item analyses, estimates of temporal reliability and internal consistency, and examination of the sensitivity and specificity of a traumatic brain injury-screening tool. Participants: Five hundred veterans of the wars in Iraq and Afghanistan enrolled in the study, approximately half of whom (248) volunteered. The remaining 252 participants were referred to Veteran Affairs (VA) neuropsychology or polytrauma clinics. Design: This psychometric study constitutes part of a larger 4-year, multisite prospective cohort study of veterans returning from Iraq and Afghanistan. Setting: Five VA medical centers and one VA outpatient clinic. Main Measures: Veteran traumatic brain injury screening tool (VATBIST), a structured diagnostic interview for traumatic brain injury; a military-oriented posttraumatic stress disorder checklist. Results: The VATBIST appeared to have high-internal consistency (0.77) and test-retest reliability (0.80), high sensitivity (0.94) and moderate specificity (0.59). Diagnostic odds ratios for the screening tool ranged from 12.6 for the total sample to 24, when veterans with probable posttraumatic stress disorder were excluded from analysis. Conclusions: The VATBIST appears to be a reliable and valid instrument. The presence of significant posttraumatic stress disorder symptoms, however, reduces the accuracy of the measure and highlights the need for careful clinical follow-up of persons who screen positive.	[Donnelly, Kerry T.] VA WNY Healthcare Syst, Buffalo, NY 14215 USA; [Donnelly, James P.] SUNY Buffalo, Dept Counseling, Sch & Educ Psychol, Albany, NY USA; [Warner, Gary C.] Canandaigua VA Med Ctr, Canandaigua, NY USA; [Kittleson, C. J.] Bath VA Med Ctr, Bath, NY USA; [Constance, Janet E.; Bradshaw, Charles B.] Syracuse VA Med Ctr, Syracuse, NY USA; [Alt, Michelle] VA Western New York Healthcare Syst Buffalo, Buffalo, NY USA		Donnelly, KT (corresponding author), VA WNY Healthcare Syst, 3495 BaileyAve 116B, Buffalo, NY 14215 USA.	Kerry.Donnelly@va.gov	Donnelly, James/AAI-4840-2020		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development, Health Services Research and Development	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development.	Barth, 2009, MANAGEMENT CONCUSSIO; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Donnelly K, 2008, AM J ALZHEIMERS DIS, V23, P218, DOI 10.1177/1533317508315932; Flahault A, 2005, J CLIN EPIDEMIOL, V58, P859, DOI 10.1016/j.jclinepi.2004.12.009; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jablensky A, 2002, AUST NZ J PSYCHIAT, V36, P297, DOI 10.1046/j.1440-1614.2002.01035.x; Mackinnon A, 2000, COMPUT BIOL MED, V30, P127, DOI 10.1016/S0010-4825(00)00006-8; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Pascrell W, 2007, REPORT C BRAIN INJUR; Pascrell WJ, 2009, CLIN NEUROPSYCHOL, V23, P1281, DOI 10.1080/13854040902939319; Petzel R, 2009, SCREENING EVALUATION; Rutherford GB, 2008, LONG TERMCONSEQUENCE; Schwab KA, 2006, NEUROLOGY, V66, pA235; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003; [No title captured]	23	92	92	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2011	26	6					439	453		10.1097/HTR.0b013e3182005de3			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	859AC	WOS:000297845000001	21386716				2022-02-06	
J	Alford, PW; Dabiri, BE; Goss, JA; Hemphill, MA; Brigham, MD; Parker, KK				Alford, Patrick W.; Dabiri, Borna E.; Goss, Josue A.; Hemphill, Matthew A.; Brigham, Mark D.; Parker, Kevin Kit			Blast-induced phenotypic switching in cerebral vasospasm	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						neurotrauma; mechanotransduction; tissue engineering; vascular mechanics	SMOOTH-MUSCLE-CELLS; MYOSIN LIGHT-CHAIN; EXTRACELLULAR-MATRIX; SUBARACHNOID HEMORRHAGE; GROWTH; MODEL; MODULATION; INJURY; MECHANOTRANSDUCTION; PHOSPHORYLATION	Vasospasm of the cerebrovasculature is a common manifestation of blast-induced traumatic brain injury (bTBI) reported among combat casualties in the conflicts in Afghanistan and Iraq. Cerebral vasospasm occurs more frequently, and with earlier onset, in bTBI patients than in patients with other TBI injury modes, such as blunt force trauma. Though vasospasm is usually associated with the presence of subarachnoid hemorrhage (SAH), SAH is not required for vasospasm in bTBI, which suggests that the unique mechanics of blast injury could potentiate vasospasm onset, accounting for the increased incidence. Here, using theoretical and in vitro models, we show that a single rapid mechanical insult can induce vascular hypercontractility and remodeling, indicative of vasospasm initiation. We employed high-velocity stretching of engineered arterial lamellae to simulate the mechanical forces of a blast pulse on the vasculature. An hour after a simulated blast, injured tissues displayed altered intracellular calcium dynamics leading to hypersensitivity to contractile stimulus with endothelin-1. One day after simulated blast, tissues exhibited blast force dependent prolonged hypercontraction and vascular smooth muscle phenotype switching, indicative of remodeling. These results suggest that an acute, blast-like injury is sufficient to induce a hypercontraction-induced genetic switch that potentiates vascular remodeling, and cerebral vasospasm, in bTBI patients.	[Alford, Patrick W.; Dabiri, Borna E.; Goss, Josue A.; Hemphill, Matthew A.; Brigham, Mark D.; Parker, Kevin Kit] Harvard Univ, Wyss Inst Biologically Inspired Engn, Dis Biophys Grp, Sch Engn & Appl Sci, Cambridge, MA 02138 USA		Parker, KK (corresponding author), Harvard Univ, Wyss Inst Biologically Inspired Engn, Dis Biophys Grp, Sch Engn & Appl Sci, Pierce Hall 321,29 Oxford St, Cambridge, MA 02138 USA.	kkparker@seas.harvard.edu		Brigham, Mark/0000-0002-7196-2261	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-08-C-2036]; Harvard School of Engineering and Applied Sciences	The authors gratefully acknowledge the use of facilities at the Harvard Center for Nanoscale Systems. This work was funded by the Defense Advanced Research Projects Agency Preventing Violent Explosive Neurologic Trauma (PREVENT) N66001-08-C-2036 (K. K. P.) and Harvard School of Engineering and Applied Sciences.	Alford PW, 2008, COMPUT METHOD BIOMEC, V11, P525, DOI 10.1080/10255840801930710; Alford PW, 2008, BIOMECH MODEL MECHAN, V7, P245, DOI 10.1007/s10237-007-0101-2; Alford PW, 2010, BIOMATERIALS, V31, P3613, DOI 10.1016/j.biomaterials.2010.01.079; Alford PW, 2003, J BIOMECH, V36, P1135, DOI 10.1016/S0021-9290(03)00089-7; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Balasubramanian L, 2007, AM J PHYSIOL-REG I, V293, pR1586, DOI 10.1152/ajpregu.00025.2007; Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chesler NC, 1999, AM J PHYSIOL-HEART C, V277, pH2002, DOI 10.1152/ajpheart.1999.277.5.H2002; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; COX RH, 1978, AM J PHYSIOL, V234, pH533, DOI 10.1152/ajpheart.1978.234.5.H533; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Feinberg AW, 2007, SCIENCE, V317, P1366, DOI 10.1126/science.1146885; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Humphrey JD, 2007, ANN BIOMED ENG, V35, P1485, DOI 10.1007/s10439-007-9321-y; Humphrey JD, 2003, BIOMECH MODEL MECHAN, V2, P109, DOI [10.1007/s10237-003-0033-4, 10.1007/S10237-003-0033-4]; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Intengan HD, 2001, HYPERTENSION, V38, P581, DOI 10.1161/hy09t1.096249; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; MASAOKA H, 1989, LANCET, V2, P1402; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Polte TR, 2004, AM J PHYSIOL-CELL PH, V286, pC518, DOI 10.1152/ajpcell.00280.2003; Qin H, 2000, EXP MOL PATHOL, V69, P79, DOI 10.1006/exmp.2000.2321; Ramasubramanian A, 2008, T ASME, V130; RODRIGUEZ EK, 1994, J BIOMECH, V27, P455, DOI 10.1016/0021-9290(94)90021-3; Sato M, 2000, CIRC RES, V87, P195, DOI 10.1161/01.RES.87.3.195; Stegemann JP, 2005, J APPL PHYSIOL, V98, P2321, DOI 10.1152/japplphysiol.01114.2004; Taber LA, 1998, J BIOMECH ENG-T ASME, V120, P348, DOI 10.1115/1.2798001; Taber LA, 1998, J THEOR BIOL, V193, P201, DOI 10.1006/jtbi.1997.0618; Tachibana E, 1999, ACTA NEUROCHIR, V141, P13, DOI 10.1007/s007010050260; Warden DL, 2005, NEW ENGL J MED, V353, P633; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Yamaguchi-Okada M, 2009, CEREBROVASC DIS, V28, P135, DOI 10.1159/000223439; YAMAMOTO M, 1993, EXP CELL RES, V204, P121, DOI 10.1006/excr.1993.1016; Zhang W, 2007, AM J PHYSIOL-HEART C, V293, pH2355, DOI 10.1152/ajpheart.00423.2007; Zhang ZD, 2006, NEUROL RES, V28, P713, DOI 10.1179/016164106X151990	49	92	92	0	9	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 2	2011	108	31					12705	12710		10.1073/pnas.1105860108			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	800SC	WOS:000293385700038	21765001	Green Published, Bronze, Green Submitted			2022-02-06	
J	Martini, DN; Sabin, MJ; DePesa, SA; Leal, EW; Negrete, TN; Sosnoff, JJ; Broglio, SP				Martini, Douglas N.; Sabin, Matthew J.; DePesa, Sarah A.; Leal, Elisa W.; Negrete, Tabitha N.; Sosnoff, Jacob J.; Broglio, Steven P.			The Chronic Effects of Concussion on Gait	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Cognitive function; Dual task; Motor control; Rehabilitation; Traumatic brain injuries (TBIs)	POSTURAL-CONTROL; INTERNATIONAL-CONFERENCE; RECURRENT CONCUSSION; MOTOR FUNCTION; SPORT; STABILITY; STATEMENT	Martini DN, Sabin MJ, DePesa SA, Leal EW, Negrete TN, Sosnoff JJ, Broglio SP. The chronic effects of concussion on gait. Arch Phys Med Rehabil 2011;92:585-9. Objective: To examine the effects of concussion on gait patterns of young adults with and without a history of concussion during single- and dual-task paradigms. Design: Cross-sectional evaluation. Setting: A research laboratory. Participants: Persons with (n=28; mean, 6.32y postinjury) and without (n=40) a concussion history. Intervention: Not applicable. Main Outcome Measures: A battery of gait analyses during single- and dual-task conditions. Normalized velocity, step length, stride width, number correct from cognitive task, time in single-leg stance, and time in double-leg stance were the variables of interest. Gait was analyzed using an electronic walkway system, and the Brooks visuospatial cognitive task was used to index cognition. Results: Data analyses using multiple 2-way repeated-measures analyses of variance and correlations indicated that participants with a history of concussion spent significantly more time in a double-leg stance and significantly decreased time in a single-leg stance and had slower gait velocity. There also was a significant negative correlation between number of concussions and time in single-leg stance and positive correlations between number of concussions and time in double-leg stance and double-stance percent. Conclusion: These findings suggest that persons with a history of concussion adopt a more conservative gait strategy.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, Urbana, IL 61801 USA; [Sosnoff, Jacob J.] Univ Illinois, Motor Control Lab, Urbana, IL 61801 USA		Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, 906 Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207			Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; BROOKS LR, 1967, Q J EXP PSYCHOL, V19, P289, DOI 10.1080/14640746708400105; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; *GAITRITE I, 2006, GAITRITE EL WALKW ME, P9; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Montero-Odasso M, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-35; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Paterson KL, 2008, ARCH PHYS MED REHAB, V89, P2360, DOI 10.1016/j.apmr.2008.06.018; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Siu KC, 2007, GAIT POSTURE, V25, P121, DOI 10.1016/j.gaitpost.2006.02.002; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Voisin T, 2009, DRUG AGING, V26, P135, DOI 10.2165/0002512-200926020-00005; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Webster KE, 2005, GAIT POSTURE, V22, P317, DOI 10.1016/j.gaitpost.2004.10.005	31	92	93	0	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					585	589		10.1016/j.apmr.2010.11.029			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	743VT	WOS:000289047500009	21440703	Green Submitted			2022-02-06	
J	Carroll, E; Coetzer, R				Carroll, Emma; Coetzer, Rudi			Identity, grief and self-awareness after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Identity; Traumatic brain injury; Psychotherapy	HOSPITAL ANXIETY; HEAD-INJURY; DEPRESSION; DISORDERS; ESTEEM; NARRATIVES; DISTRESS; DEFICITS; THERAPY	The objective of this study was to investigate perceived identity change in adults with traumatic brain injury (TBI) and explore associations between identity change, grief, depression, self-esteem and self-awareness. The participants were 29 adults with TBI who were being followed up by a community brain injury rehabilitation service. Participants were longer post-injury than those more commonly studied. Time since injury ranged from 2.25 to 40 years (mean = 11.17 years, SD = 11.4 years). Participants completed a battery of questionnaires. Significant others and clinicians completed a parallel version of one of these measures. Questionnaires included the Head Injury Semantic Differential Scale (HISDS-III), Brain Injury Grief Inventory (BIGI), Hospital Anxiety and Depression Scale - Depression, Rosenberg Self-Esteem Scale (RSES) and the Awareness Questionnaire (Self/Significant other/Clinician versions). The main findings were that participants reported significant changes in self-concept with current self being viewed negatively in comparison to pre-injury self. Perceived identity change was positively associated with depression and grief and negatively associated with self-esteem and awareness. Awareness was negatively associated with self-esteem and positively associated with depression. These findings were consistent with previous research, revealing changes in identity following TBI. Further research is needed to increase our understanding of the psychological factors involved in emotional adjustment after TBI and to inform brain injury rehabilitation interventions, including psychotherapy approaches.	[Carroll, Emma] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Belfast, Antrim, North Ireland		Coetzer, R (corresponding author), Betsi Cadwaladr Univ, N Wales Brain Injury Serv, Hlth Board NHS Wales, Colwyn Bay Hosp, Hesketh Rd, Colwyn Bay LL29 8AY, England.	Rudi.Coetzer@wales.nhs.uk		Coetzer, Rudi/0000-0003-4505-7230			ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Cloute K, 2008, NEUROPSYCHOL REHABIL, V18, P651, DOI 10.1080/09602010701306989; Coetzer B. R., 2003, J COGNITIVE REHABILI, V21, P4; Coetzer B. R., 2003, BRAIN INJURY G UNPUB; Coetzer BR, 2001, J COGN REHABIL, V19, P8; Coetzer R., 2010, ANXIETY MOOD DISORDE; Coetzer R, 2008, NEUROPSYCHOL REHABIL, V18, P766, DOI 10.1080/09602010701860266; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FLEMING JS, 1980, J PERS SOC PSYCHOL, V39, P921, DOI 10.1037/0022-3514.39.5.921; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Gracey F, 2007, NEUROPSYCHOL REHABIL, V17, P106, DOI 10.1080/09602010500505260; Guindon MH, 2002, J COUNS DEV, V80, P204, DOI 10.1002/j.1556-6678.2002.tb00184.x; HAYNES SD, 1994, ARCH CLIN NEUROPSYCH, V9, P323, DOI 10.1016/0887-6177(94)90020-5; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Judd D. P., 1999, COUNSELLING PSYCHOL, V14, P4; Keppel CC, 2000, NEUROPSYCHOL REHABIL, V10, P15, DOI 10.1080/096020100389273; Leon-Carrion J, 1997, NEUROPSYCHOL REHABIL, P301; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; McBrinn J, 2008, BRAIN INJURY, V22, P765, DOI 10.1080/02699050802372208; Meredith K., 1999, J COGNITIVE REHABILI, V17, P10; Myles SM, 2004, INT J PSYCHOL PSYCHO, V4, P487; Naylor E, 2008, NEUROPSYCHOL REHABIL, V18, P590, DOI 10.1080/09602010701608681; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Roberts CB, 2006, BRAIN INJURY, V20, P485, DOI 10.1080/02699050600664665; Rosenberg M., 1965, SOC ADOLESCENT SELF; Ruddle JA., 2005, ILLNESS, V13, P235; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stonnington CM, 2001, BRAIN INJURY, V15, P561, DOI 10.1080/02699050110034316; STREIN W, 1993, SCHOOL PSYCHOL REV, V22, P273; Tasker SL., 2003, ILLN CRISES LOSS, V11, P337, DOI DOI 10.1177/1054137303256585; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	92	92	0	42	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	3					289	305	PII 934339402	10.1080/09602011.2011.555972			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	761ND	WOS:000290403800001	21391119				2022-02-06	
J	Kovesdi, E; Gyorgy, AB; Kwon, SKC; Wingo, DL; Kamnaksh, A; Long, JB; Kasper, CE; Agoston, DV				Kovesdi, Erzsebet; Gyorgy, Andrea B.; Kwon, Sook-Kyung C.; Wingo, Daniel L.; Kamnaksh, Alaa; Long, Joseph B.; Kasper, Christine E.; Agoston, Denes V.			The effect of enriched environment on the outcome of traumatic brain injury; a behavioral, proteomics, and histological study	FRONTIERS IN NEUROSCIENCE			English	Article						neurogenesis; enriched environment; traumatic brain injury; memory; anxiety; hippocampus; histology; proteomics		De novo hippocampal neurogenesis contributes to functional recovery following traumatic brain injury (TBI). Enriched environment (EEN) can improve the outcome of TBI by positively affecting neurogenesis. Blast induced traumatic brain injury (bTBI) characterized by memory impairment and increased anxiety levels, is a leading cause of chronic disability among soldiers. Using a rodent model of bTBI we asked: (a) whether long-term exposure to EEN after injury can ameliorate behavioral abnormalities and (b) what the effects of EEN are at the molecular and cellular levels and on de novo neurogenesis. We found that housing injured animals in EEN resulted in significantly improved spatial memory while animals in normal housing (NH) showed persistent memory impairment. VEGF and Tau protein but not Interleukin-6 (IL-6) levels were normalized in the dorsal hippocampus (DHC) of EEN rats while all three markers remained elevated in NH rats. Interestingly, after peaking at 6 weeks post-injury, anxiety returned to normal levels at 2 months independent of housing conditions. Housing animals in EEN had no significant effect on VEGF and Tau protein levels in the ventral hippocampus (VHC) and the amygdala (AD). We also found that EEN reduced IL-6 and IFN gamma levels in the VHC; these markers remained elevated following NH. We observed an increase in GFAP and DCX immunoreactivities in the VHC of NH animals at 2 months post-injury. Conversely, injured animals housed in EEN showed no increase in GFAP or DCX immunoreactivity in their VHC. In summary, long-term exposure of injured animals to EEN appears to play a positive role in the restoration of memory functions but not on anxiety, which returned to normal levels after a significant period of time. Cellular and molecular changes in response to EEN appear to be a part of neurogenesis-independent as well as dependent recovery processes triggered by bTBI.	[Kovesdi, Erzsebet; Kasper, Christine E.] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Gyorgy, Andrea B.; Kwon, Sook-Kyung C.; Wingo, Daniel L.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Long, Joseph B.] Walter Reed Army Inst Res, Div Mil Casualty Res, Silver Spring, MD USA		Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu	Kasper, Christine/AAF-2347-2021	Kasper, Christine/0000-0002-7784-2519	VA grant [B5044R]	We thank the Neurotrauma Team (WRAIR) for their technical help during the blast exposures; Dr. David Jacobowitz (USU) for his help in brain micropunch dissections; Ms. Cara Olsen (USU) for her help in statistical analysis; Drs. Neil Grunberg and John Wu (USU) for their input in designing and interpreting the behavioral experiments. The work was supported by VA grant # B5044R.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Aimone JB, 2010, TRENDS COGN SCI, V14, P325, DOI 10.1016/j.tics.2010.04.003; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Barkho BZ, 2006, STEM CELLS DEV, V15, P407, DOI 10.1089/scd.2006.15.407; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Barron KD, 1995, J NEUROL SCI, V134, P57, DOI 10.1016/0022-510X(95)00209-K; Berrocal Y, 2007, J NEUROTRAUM, V24, P1761, DOI 10.1089/neu.2007.0327; Bremner J Douglas, 2007, Expert Rev Neurother, V7, P393, DOI 10.1586/14737175.7.4.393; Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cacci E, 2005, J NEUROSCI RES, V80, P789, DOI 10.1002/jnr.20531; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dahlqvist P, 2004, EUR J NEUROSCI, V19, P2288, DOI 10.1111/j.0953-816X.2004.03248.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dhanushkodi A, 2007, BEHAV NEUROSCI, V121, P491, DOI 10.1037/0735-7044.121.3.491; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Ehninger D, 2003, CEREB CORTEX, V13, P845, DOI 10.1093/cercor/13.8.845; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fischer FR, 2007, J SPINAL CORD MED, V30, P147, DOI 10.1080/10790268.2007.11753926; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gross C, 2004, NEUROTOX RES, V6, P493, DOI 10.1007/BF03033286; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Harrison FE, 2009, BEHAV BRAIN RES, V198, P247, DOI 10.1016/j.bbr.2008.10.015; Hebb, 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; HENKE PG, 1990, BRAIN RES BULL, V25, P691, DOI 10.1016/0361-9230(90)90044-Z; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; JURASKA JM, 1985, BRAIN RES, V333, P73, DOI 10.1016/0006-8993(85)90125-8; JURASKA JM, 1988, BRAIN RES, V450, P1, DOI 10.1016/0006-8993(88)91538-7; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kempermann G., 2000, NOVART FDN SYMP, V231, P302; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kozorovitskiy Y, 2003, J CLIN EXP NEUROPSYC, V25, P721, DOI 10.1076/jcen.25.5.721.14580; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu QO, 2011, J AFFECT DISORDERS, V128, P309, DOI 10.1016/j.jad.2010.07.007; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mora F, 2007, BRAIN RES REV, V55, P78, DOI 10.1016/j.brainresrev.2007.03.011; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; Mueller FJ, 2005, E SCHERING RES FDN W, V53, P83; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Paxinos, 1999, CHEMOARCHITECTONIC A; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Puurunen K, 2002, REV NEUROSCIENCE, V13, P347; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Salzberg M, 2007, EPILEPSIA, V48, P2079, DOI 10.1111/j.1528-1167.2007.01246.x; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Shum FWF, 2007, LEARN MEMORY, V14, P304, DOI 10.1101/lm.530607; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashiro A, 2007, J NEUROSCI, V27, P3252, DOI 10.1523/JNEUROSCI.4941-06.2007; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Tischler L, 2006, ANN NY ACAD SCI, V1071, P405, DOI 10.1196/annals.1364.031; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, NEW ENGL J MED, V353, P633; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016; Wright RL, 2008, BEHAV BRAIN RES, V187, P41, DOI 10.1016/j.bbr.2007.08.025; Yasuhara T, 2004, EUR J NEUROSCI, V19, P1494, DOI 10.1111/j.1460-9568.2004.03254.x; Yehuda R, 2007, NEURON, V56, P19, DOI 10.1016/j.neuron.2007.09.006; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	124	92	94	5	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.		2011	5								42	10.3389/fnins.2011.00042			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V36GI	WOS:000209200600038	21503146	gold, Green Published			2022-02-06	
J	Raymont, V; Salazar, AM; Lipsky, R; Goldman, D; Tasick, G; Grafman, J				Raymont, V.; Salazar, A. M.; Lipsky, R.; Goldman, D.; Tasick, G.; Grafman, J.			Correlates of posttraumatic epilepsy 35 years following combat brain injury	NEUROLOGY			English	Article							PENETRATING HEAD-INJURY; POST-TRAUMATIC EPILEPSY; MECHANICAL INJURY; SEIZURES; SOFTWARE; GENETICS; GENES; RISK	Background: The Vietnam Head Injury Study (VHIS) is a prospective, longitudinal follow-up of 1,221 Vietnam War veterans with mostly penetrating head injuries (PHIs). The high prevalence (45%-53%) of posttraumatic epilepsy (PTE) in this unique cohort makes it valuable for study. Methods: A standardized multidisciplinary neurologic, cognitive, behavioral, and brain imaging evaluation was conducted on 199 VHIS veterans plus uninjured controls, some 30 to 35 years after injury, as part of phase 3 of this study. Results: The prevalence of seizures (87 patients, 43.7%) was similar to that found during phase 2 evaluations 20 years earlier, but 11 of 87 (12.6%) reported very late onset of PTE after phase 2 (more than 14 years after injury). Those patients were not different from patients with earlier-onset PTE in any of the measures studied. Within the phase 3 cohort, the most common seizure type last experienced was complex partial seizures (31.0%), with increasing frequency after injury. Of subjects with PTE, 88% were receiving anticonvulsants. Left parietal lobe lesions and retained ferric metal fragments were associated with PTE in a logistic regression model. Total brain volume loss predicted seizure frequency. Conclusions: Patients with PHI carry a high risk of PTE decades after their injury, and so require long-term medical follow-up. Lesion location, lesion size, and lesion type were predictors of PTE. Neurology (R) 2010;75:224-229	[Raymont, V.; Salazar, A. M.; Grafman, J.] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Raymont, V.; Tasick, G.] Henry M Jackson Fdn, Natl Naval Med Ctr, Vietnam Head Injury Study, Bethesda, MD USA; [Raymont, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Lipsky, R.] Inova Fairfax Hosp, Inova Hlth Syst, Dept Neurosci, Falls Church, VA USA; [Goldman, D.] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA		Grafman, J (corresponding author), Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bldg 10,Room 7D43,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov	Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Lipsky, Robert/0000-0001-7753-1473; Grafman, Jordan H./0000-0001-8645-4457	United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); National Institute on Alcohol Abuse and Alcoholism intramural research programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); UD Department of Defense; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); National Institute of Neurological Disorders and Stroke intramural research programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	Dr. Raymont was supported by a project grant from the United States Army Medical Research and Material Command and administered by the Henry M. Jackson Foundation (DAMD17-01-1-0675). Dr. Salazar is CEO and Chairman of Oncovir, Inc., in which he owns stock; serves on the editorial board of the Journal of Neurology Neurosurgery & Psychiatry; and may accrue revenue on a patent re: Method for Preparation of large batches of Poly-ICLC. Dr. Lipsky serves as a field editor for Amino Acids and on the editorial board of CNS and Neurological Disorders-Drug Targets; may accrue revenue on a patents re: A Missense Variant (P10L) of the Melanopsin (OPN4) Gene in Seasonal Affective Disorder and re: Methods for detecting nucleic acid sequence variation; was supported by the National Institute on Alcohol Abuse and Alcoholism intramural research program; and receives research support from the UD Department of Defense. Dr. Goldman is supported by the National Institute on Alcohol Abuse and Alcoholism intramural research program. Ms. Tasick was supported by a project grant from the US Army Medical Research and Material Command and administered by the Henry M. Jackson Foundation (DAMD17-01-1-0675). Dr. Grafman is supported by the National Institute of Neurological Disorders and Stroke intramural research program; and serves as Coeditor of Cortex.	Aarabi B, 2000, Neurosurg Focus, V8, pe1; ADELOYE A, 1971, Clinical Radiology, V22, P312, DOI 10.1016/S0009-9260(71)80079-X; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1960, AFQT7A DEP DEF; Bazan N G, 1999, Adv Neurol, V79, P659; Benarroch EE, 2007, NEUROLOGY, V68, P612, DOI 10.1212/01.wnl.0000255669.83468.dd; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Crino PB, 2007, EPILEPSIA, V48, P42, DOI 10.1111/j.1528-1167.2007.01066.x; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Grafman J, 1992, Adv Neurol, V57, P369; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gurnett CA, 2007, ARCH NEUROL-CHICAGO, V64, P324, DOI 10.1001/archneur.64.3.324; Helmstaedter C, 2001, CURR OPIN NEUROL, V14, P211, DOI 10.1097/00019052-200104000-00013; Jennett B, 1975, J R Coll Physicians Lond, V9, P231; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; Pagni Carlo Alberto, 2006, Expert Rev Neurother, V6, P1223, DOI 10.1586/14737175.6.8.1223; PANTER SS, 1984, T ASSOC AM PHYSICIAN, V97, P56; Prince D A, 1999, Adv Neurol, V79, P665; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; RUSSELL WR, 1951, J NEUROL NEUROSUR PS, V14, P35, DOI 10.1136/jnnp.14.1.35; Salazar A, 1987, ADV EPILEPTOL, P267; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1999, AM ASS NEUROLOGICAL, P281; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Talairach J., 1988, COPLANAR STEREOTAXIC; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	40	92	96	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUL 20	2010	75	3					224	229		10.1212/WNL.0b013e3181e8e6d0			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	628ES	WOS:000280097900007	20644150	Green Published			2022-02-06	
J	Hoffer, ME; Balaban, C; Gottshall, K; Balough, BJ; Maddox, MR; Penta, JR				Hoffer, Michael E.; Balaban, Carey; Gottshall, Kim; Balough, Ben J.; Maddox, Michael R.; Penta, Joseph R.			Blast Exposure: Vestibular Consequences and Associated Characteristics	OTOLOGY & NEUROTOLOGY			English	Article; Proceedings Paper	Spring Meeting of the American-Neurotology-Society	MAY 29-30, 2009	Phoenix, AZ	Amer Neurotol Soc		Headaches; Hearing loss; Mild traumatic brain injury; Posttraumatic stress disorders; Traumatic brain injury; Vestibular disorders; Vestibular function tests	TRAUMATIC BRAIN-INJURY; DIZZINESS; IMPAIRMENT; DISORDER; STRESS; IRAQ; WAR	Objective: To characterize vestibular and related symptoms seen after blast exposure. Study Design: Prospective single-subject design. Settings: Tertiary care facility and military field hospital. Patients: Active-duty US Military personnel exposed to blast(s) in Iraq and/or Afghanistan. Interventions: Vestibular function tests, auditory tests, and a structured history and physical examination. Results: Blast exposure induced vestibular disorders, and related symptoms are significantly different than those seen in blunt head trauma. The vestibular characteristics and objective tests of vestibular function significantly worsen in blast-exposed patients as a function of time between injury and presentation. Conclusion: Blast exposure produces a unique set of vestibular disorders and associated symptoms that progress over time. Understanding the characteristics of these symptoms as they vary over time may be critical in designing treatment strategies that modify long-term outcome.	[Hoffer, Michael E.; Balaban, Carey; Gottshall, Kim; Balough, Ben J.] USN, Spatial Orientat Ctr, Dept Otolaryngol, San Diego Med Ctr, San Diego, CA 92134 USA; [Maddox, Michael R.] 1st Marine Expeditionary Grp, Camp Pendleton, CA USA; [Penta, Joseph R.] 1st Marine Logist Grp, Camp Pendleton, CA USA; [Balaban, Carey] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA		Hoffer, ME (corresponding author), USN, Spatial Orientat Ctr, Dept Otolaryngol, San Diego Med Ctr, 34800 Bob Wilson Dive, San Diego, CA 92134 USA.	Michael.hoffer@med.navy.mil	Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844			*ASS SECR DEF, 2007, MEM TRAUM BRAIN INJ; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Engelhard IM, 2007, BRIT J PSYCHIAT, V191, P140, DOI 10.1192/bjp.bp.106.034884; Furman JM, 2005, J NEUROL NEUROSUR PS, V76, P1, DOI 10.1136/jnnp.2004.048926; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Newman-Toker DE, 2008, ACTA OTO-LARYNGOL, V128, P601, DOI 10.1080/00016480701596096; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Solomon Z, 2005, J CLIN PSYCHIAT, V66, P1031, DOI 10.4088/JCP.v66n0811; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980	12	92	95	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1531-7129			OTOL NEUROTOL	Otol. Neurotol.	FEB	2010	31	2					232	236		10.1097/MAO.0b013e3181c993c3			5	Clinical Neurology; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Otorhinolaryngology	581VX	WOS:000276554400010	20009782				2022-02-06	
J	Williams, C; Wood, RL				Williams, Claire; Wood, Rodger Ll.			Alexithymia and emotional empathy following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						20-Item Toronto Alexithymia Scale; Balanced Emotional Empathy Scale; Traumatic brain injury; Emotional perception; Emotion recognition; Injury severity	HEAD-INJURY; IMPAIRED RECOGNITION; POSTTRAUMATIC AMNESIA; BEHAVIORAL-CHANGES; BILATERAL DAMAGE; DECISION-MAKING; MIND; SCALE; PAIN; FMRI	The frequency of alexithymia and the proportion of cases reporting low emotional empathy after traumatic brain injury (TBI) were compared with a control group. The study also examined the relationship between alexithymia and emotional empathy, controlling for the influence of cognitive ability, severity of head injury, and time since injury. A total of 64 TBI patients and matched controls completed the 20-Item Toronto Alexithymia Scale (TAS-20) and Balanced Emotional Empathy Scale (BEES). The TBI group exhibited a significantly higher frequency of alexithymia (60.9%) and low emotional empathy (64.4%) than did the control group (10.9% and 34.4%). Significant moderate negative correlations were found between TAS-20 and BEES scores, with TAS-20 total scores accounting for a significant amount of variance in BEES scores. However, no significant correlation was obtained between Subscale 1 of the TAS-20 (difficulty identifying feelings) and BEES scores in the TBI group. Additionally, there were no significant relationships between alexithymia, emotional empathy, injury severity, and time since injury. The results suggest an inverse relationship between alexithymia and emotional empathy.	[Williams, Claire; Wood, Rodger Ll.] Swansea Univ, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales		Williams, C (corresponding author), Swansea Univ, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	200528@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X	Brain Injury Rehabilitation Trust, UK	Funding for this research was obtained, in part, from the Brain Injury Rehabilitation Trust, UK.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Allerdings MD, 2001, BRAIN COGNITION, V47, P304; Bagby R. M., 1993, ANN M AM PSYCH SOC C; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Burba B, 2006, CAN J PSYCHIAT, V51, P468, DOI 10.1177/070674370605100709; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Danziger N, 2006, BRAIN, V129, P2494, DOI 10.1093/brain/awl155; Davies M, 1998, J PERS SOC PSYCHOL, V75, P989, DOI 10.1037/0022-3514.75.4.989; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Dougherty DD, 2004, ARCH GEN PSYCHIAT, V61, P795, DOI 10.1001/archpsyc.61.8.795; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Guttman H, 2002, COMPR PSYCHIAT, V43, P448, DOI 10.1053/comp.2002.35905; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Heberlein AS, 2008, J COGNITIVE NEUROSCI, V20, P721, DOI 10.1162/jocn.2008.20049; Heberlein AS, 2005, NEUROIMAGE, V28, P770, DOI 10.1016/j.neuroimage.2005.06.064; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Houtveen JH, 1997, J PSYCHOPHYSIOL, V11, P147; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; KRYSTAL H, 1979, AM J PSYCHOTHER, V33, P17, DOI 10.1176/appi.psychotherapy.1979.33.1.17; LAMBERTY GJ, 1995, J NEUROPSYCH CLIN N, V7, P320; Lane RD, 1996, PSYCHOSOM MED, V58, P203, DOI 10.1097/00006842-199605000-00002; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Luminet O, 2001, PSYCHOTHER PSYCHOSOM, V70, P254, DOI 10.1159/000056263; Mah LWY, 2005, J NEUROPSYCH CLIN N, V17, P66, DOI 10.1176/appi.neuropsych.17.1.66; Mandal MK, 1999, J NERV MENT DIS, V187, P603, DOI 10.1097/00005053-199910000-00003; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McDougall J., 1989, THEATRES BODY PSYCHO; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; Mehrabian A, 1997, J PSYCHOL, V131, P101, DOI 10.1080/00223989709603508; Mehrabian A., 2000, MANUAL BALANCED EMOT; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Moriguchi Y, 2007, CEREB CORTEX, V17, P2223, DOI 10.1093/cercor/bhl130; Nummenmaa L, 2008, NEUROIMAGE, V43, P571, DOI 10.1016/j.neuroimage.2008.08.014; PARKER JDA, 1993, EUR J PERSONALITY, V7, P221, DOI 10.1002/per.2410070403; Parker JDA, 2001, PERS INDIV DIFFER, V30, P107, DOI 10.1016/S0191-8869(00)00014-3; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Rastam M, 1997, ACTA PSYCHIAT SCAND, V95, P385, DOI 10.1111/j.1600-0447.1997.tb09650.x; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, BRAIN, V130, P1663, DOI 10.1093/brain/awm093; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shuren JE, 2002, ARCH NEUROL-CHICAGO, V59, P916, DOI 10.1001/archneur.59.6.916; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1987, PSYCHOSOMATIC MED CO; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wood RL, 2001, NEUROBEHAVIOURAL DIS, P1; WOOD RL, 2006, BRAIN INJURY, V20, P1; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Worthington A. D., 2008, PSYCHOL APPROACHES R; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	80	92	93	2	36	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	3					259	267		10.1080/13803390902976940			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	572XY	WOS:000275871900005	19548166				2022-02-06	
J	Williams, WH; Mewse, AJ; Tonks, J; Mills, S; Burgess, CNW; Cordan, G				Williams, W. Huw; Mewse, Avril J.; Tonks, James; Mills, Sarah; Burgess, Crispin N. W.; Cordan, Giray			Traumatic brain injury in a prison population: Prevalence and risk for re-offending	BRAIN INJURY			English	Article						Prisoner health; traumatic brain injury; neuroepidemiology; head injury; behavioural disorder; epidemiology; neuropsychology	CRIMINAL BEHAVIOR; HEAD-INJURY; VIOLENT; ASSOCIATION; DYSFUNCTION; DISORDERS	Background: TBI can lead to cognitive, behavioural and emotional difficulties. Previous studies suggest that TBI is relatively elevated in offender populations. In this study the aims were to establish the rate of TBI of various severities in a representative sample of adult offenders and patterns of custody associated with TBI. Methods: A self-report survey of adult, male offenders within a prison. Of 453 offenders, 196 (43%) responded. Results: Over 60% reported 'Head Injuries'. Reports consistent with TBI of various severities were given by 65%. Of the overall sample, 16% had experienced moderate-to-severe TBI and 48% mild TBI. Adults with TBI were younger at entry into custodial systems and reported higher rates of repeat offending. They also reported greater time, in the past 5 years, spent in prison. Conclusions: These findings indicate that there is a need to account for TBI in the assessment and management of offenders.	[Williams, W. Huw] Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England		Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter EX4 4QG, Devon, England.	w.h.williams@exeter.ac.uk		williams, huw/0000-0003-0670-2620; Tonks, James/0000-0003-3930-9294	UK Acquired Brain Injury Forum; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [Res-062-23-0135]	Research supported by grants to HW from: UK Acquired Brain Injury Forum and Economic and Social Research Council (Res-062-23-0135).	Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Birbaumer N, 2005, ARCH GEN PSYCHIAT, V62, P799, DOI 10.1001/archpsyc.62.7.799; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; BRADLEY L, REV PEOPLE MENTAL HL; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; *CDC, REP CTR DIS CONTR TR; DESOUZA C, 2003, BRAIN INJURY, V17, P39; Farrell M, 2002, BRIT J PSYCHIAT, V181, P393, DOI 10.1192/bjp.181.5.393; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Loza W, 2007, J INTERPERS VIOLENCE, V22, P1144, DOI 10.1177/0886260507303730; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Mobbs D, 2007, PLOS BIOL, V5, P693, DOI 10.1371/journal.pbio.0050103; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; *NEW S WAL CHIEF H, REP NEW S WAL CHIEF; RAINE A, 1994, BIOL PSYCHIAT, V36, P365, DOI 10.1016/0006-3223(94)91211-4; Raine A, 1998, PSYCHOL CRIME LAW, V4, P107, DOI 10.1080/10683169808401752; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	27	92	92	0	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	10					1184	1188		10.3109/02699052.2010.495697			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100004	20642322				2022-02-06	
J	Bar-Joseph, G; Guilburd, Y; Tamir, A; Guilburd, JN				Bar-Joseph, Gad; Guilburd, Yoav; Tamir, Ada; Guilburd, Joseph N.			Effectiveness of ketamine in decreasing intracranial pressure in children with intracranial hypertension Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article; Proceedings Paper	5th World Congress of Pediatric Critical Care	JUN, 2007	Geneva, SWITZERLAND			ketamine; sedation; intracranial pressure; child; intracranial hypertension; traumatic brain injury; cerebral perfusion pressure	CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID PRESSURE; INJURY PATIENTS; METABOLISM; ANESTHESIA; MIDAZOLAM; BRAIN; SEDATION; PIG	Object. Deepening sedation is often needed in patients with intracranial hypertension. All widely used sedative and anesthetic agents (opioids, benzodiazepines, propofol, and barbiturates) decrease blood pressure and may therefore decrease cerebral perfusion pressure (CPP). Ketamine is a potent, safe, rapid-onset anesthetic agent that does not decrease blood pressure. However, ketamine's use in patients with traumatic brain injury and intracranial hypertension is precluded because it is widely stated that it increases intracranial pressure (ICP). Based on anecdotal clinical experience, the authors hypothesized that ketamine does not increase-but may rather decrease-ICP. Methods. The authors conducted a prospective, controlled, clinical trial of data obtained in a pediatric intensive care unit of a regional trauma center. All patients were sedated and mechanically ventilated prior to inclusion in the study. Children with sustained, elevated ICP (> 18 mm Hg) resistant to first-tier therapies received a single ketamine dose (1-1.5 mg/kg) either to prevent further ICP increase during a potentially distressing intervention (Group 1) or as an additional measure to lower ICP (Group 2). Hemodynamic, ICP, and CPP values were recorded before ketamine administration, and repeated-measures analysis of variance was used to compare these values with those recorded every minute for 10 minutes following ketamine administration. Results. The results of 82 ketamine administrations in 30 patients were analyzed. Overall, following ketamine administration, ICP decreased by 30% (from 25.8 +/- 8.4 to 18.0 +/- 8.5 mm Hg) (p < 0.001) and CPP increased from 54.4 +/- 11.7 to 58.3 +/- 13.4 mm Hg (p < 0.005). In Group 1, ICP decreased significantly following ketamine administration and increased by > 2 mm Hg during the distressing intervention in only 1 of 17 events. In Group 2, when ketamine was administered to lower persistent intracranial hypertension, ICP decreased by 33% (from 26.0 +/- 9.1 to 17.5 +/- 9.1 mm Hg) (p < 0.0001) following ketamine administration. Conclusions. In ventilation-treated patients with intracranial hypertension, ketamine effectively decreased ICP and prevented untoward ICP elevations during potentially distressing interventions, without lowering blood pressure and CPP. These results refute the notion that ketamine increases ICP. Ketamine is a safe and effective drug for patients with traumatic brain injury and intracranial hypertension, and it can possibly be used safely in trauma emergency situations. (DOI: 10.3171/2009.1.PEDS08319)	[Bar-Joseph, Gad; Guilburd, Yoav; Tamir, Ada; Guilburd, Joseph N.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; [Bar-Joseph, Gad; Guilburd, Joseph N.] Rambam Med Ctr, Meyer Childrens Hosp, Haifa, Israel		Bar-Joseph, G (corresponding author), Rambam Med Ctr, Meyer Childrens Hosp, POB 9602, Haifa, Israel.	g_barjoseph@rambam.health.gov.il					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; AKESON J, 1993, ACTA ANAESTH SCAND, V37, P525, DOI 10.1111/j.1399-6576.1993.tb03759.x; AKESON J, 1993, ACTA ANAESTH SCAND, V37, P211, DOI 10.1111/j.1399-6576.1993.tb03703.x; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; BJORKMAN S, 1992, J PHARMACOKINET BIOP, V20, P637, DOI 10.1007/BF01064423; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS71; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; CRUMRINE RS, 1975, ANESTHESIOLOGY, V42, P758, DOI 10.1097/00000542-197506000-00026; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; Dershwitz M., 2008, ANESTHESIOLOGY, P849; DUKE JC, 2003, TRAUMA, P329; EVANS J, 1971, LANCET, V1, P40; Evers AS, 2006, GOODMAN GILMANS PHAR, P341; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; Heard CMB, 2006, PEDIAT CRITICAL CARE, P1748; Holcomb HH, 2001, NEUROPSYCHOPHARMACOL, V25, P165, DOI 10.1016/S0893-133X(01)00229-9; JOHNSTON MN, 2003, EMERGENCY MED COMPRE, P858; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; LEE TS, 2002, CURRENT CRITICAL CAR, P104; LIST WF, 1972, ANESTHESIOLOGY, V36, P98, DOI 10.1097/00000542-197201000-00023; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; Miller, 2005, MILLERS ANESTHESIA, P317; OREN RE, 1987, STROKE, V18, P441, DOI 10.1161/01.STR.18.2.441; Ralston CS, 1999, PEDIAT NEUROSURGERY, P1; Schulte am Esch J, 1978, ACTA NEUROCHIR, V45, P15; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; SHERWOOD ER, 2008, SABISTON TXB SURG, P401; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; TREVOR AJ, 2006, BASIC CLIN PHARM, P395; Vishteh AG, 2004, YOUMANS NEUROLOGICAL, P1503; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021; ZIMMER GD, 2003, EMERGEN MED, P257	39	92	93	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUL	2009	4	1					40	46		10.3171/2009.1.PEDS08319			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pediatrics; Surgery	462VB	WOS:000267384000014	19569909				2022-02-06	
J	Summers, CR; Ivins, B; Schwab, KA				Summers, Carl R.; Ivins, Brian; Schwab, Karen A.			Traumatic Brain Injury in the United States: An Epidemiologic Overview	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						epidemiology; head injury; traumatic brain injury	MILD	A basic description of severity and frequency is needed for planning healthcare delivery for any disease process. In the case of trumatic brain injury, severity is typically categorized into mild, moderate, and severe with information from a combination of clinical observation and self-report methodologies. Recent US civilian epidemiological findings measuring the frequency of mortality and morbidity of traumatic brain injury are presented, including demographic and etiological breakdowns of the data. Falls, motor vehicle accidents, and being struck by objects are the major etiologies of traumatic brain injury. US civilian and Army hospitalization trends are discussed and compared. Features of traumatic brain injuries form Operation Iraqi Freedom and Operation Enduring Freedom are discussed. Mt Sinai J Med 76:105-110, 2009 (C) 2009 Mount Sinai School of Medicine	[Summers, Carl R.; Ivins, Brian; Schwab, Karen A.] Def & Vet Brain Injury Ctr, Washington, DC USA		Summers, CR (corresponding author), Def & Vet Brain Injury Ctr, Washington, DC USA.	Carl.Summers@amedd.army.mil					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL 2005; Brundage JF, 1998, MIL MED, V163, P272, DOI 10.1093/milmed/163.5.272; CAMEY N, 2007, GUIDELINES PREHOSPIT; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2006, NEUROEPIDEMIOLOGY, V27, P154, DOI 10.1159/000096127; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; NAPAOLITANO E, 2007, BRAIN INJURY MED, P57; *NAT CTR INJ PREV, 2006, REP C MILD TRAUM BRA; *NAT CTR INJ PREV, 2006, TRAUM BRAIN INJ US E; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sosin DM, 1996, BRAIN INJURY, V10, P47; TEASDALE G, 1974, LANCET, V2, P81; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 2007, BRAIN INJURY MED; *US ARM PUBL AFF, 1997, ARMY ACHIEVES SAFEST; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	25	92	95	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					105	110		10.1002/msj.20100			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	427OE	WOS:000264787800003	19306375				2022-02-06	
J	Ishrat, T; Sayeed, I; Atif, F; Stein, DG				Ishrat, Tauheed; Sayeed, Iqbal; Atif, Fahim; Stein, Donald G.			Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats	BRAIN RESEARCH			English	Article						Progesterone; Brain damage; Permanent MCAO; Functional recovery; Infarct volume	TRAUMATIC BRAIN-INJURY; ARTERY OCCLUSION; COGNITIVE DEFICITS; CELL-DEATH; STROKE; ALLOPREGNANOLONE; NEUROSTEROIDS; MICE; HYPERTHERMIA; MECHANISMS	Recent experimental evidence indicates that progesterone (PROG) protects against various models of brain injury, including ischemic stroke. Most human studies of pharmacologic treatments for acute cerebral stroke have failed despite initial success in animal models. To simulate better the typical human stroke without reperfusion, the present study was conducted to examine the efficacy of PROG on infarct volume and functional outcome in a permanent model of stroke, using direct cauterization of the middle cerebral artery (MCA). Twenty-four male adult Sprague-Dawley rats underwent pMCAO by electro-coagulation and sham operation. After induction of permanent MCA occlusion (pMCAO), the rats received an initial intraperitoneal injection of PROG (8 mg/kg) or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 24 and 48 h. Functional deficits were tested on the rotarod and grip-strength meter at 24, 48 and 72 h after pMCAO. The rats were killed 72 h after surgery and isolated brain was sectioned into coronal slices and stained with 2, 3, 5-triphenyltetrazolium chloride (TTC). PROG-treated rats showed a substantial reduction (54.05%) in the volume of the infarct (% contralateral hemisphere) compared to vehicle controls. In addition there was a significant improvement in ability to remain on an accelerating rotarod and increased grip strength observed in the pMCAO rats treated with PROG compared to vehicle. Taken together, these data indicate that PROG is beneficial in one of the best-characterized models of stroke, and may warrant further testing in future clinical trials for human stroke. (C) 2008 Elsevier B.V. All rights reserved.	[Ishrat, Tauheed; Sayeed, Iqbal; Atif, Fahim; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, 1365B Clifton Rd NE, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS04851]; Rooms to Go Scholar award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER	This work was supported by NIH grants R01 NS04851 and Rooms to Go Scholar award. We acknowledge Leslie McCann for her help in manuscript preparation.	AGGARWAL R, 2008, PHARM PHARM, V60, P731; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1999, BRAIN RES, V833, P181, DOI 10.1016/S0006-8993(99)01528-0; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; BIXO M, 1990, PSYCHONEUROENDOCRINO, V15, P159, DOI 10.1016/0306-4530(90)90025-5; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; DELCKER A, 1993, EUR ARCH PSY CLIN N, V242, P179, DOI 10.1007/BF02189960; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Feigin VL, 2005, LANCET, V365, P2160, DOI 10.1016/S0140-6736(05)66755-4; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gilmer LK, 2008, J NEUROTRAUM, V25, P593, DOI 10.1089/neu.2007.0477; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hankey GJ, 1999, ARCH NEUROL-CHICAGO, V56, P748, DOI 10.1001/archneur.56.6.748; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hunter AJ, 1998, TRENDS PHARMACOL SCI, V19, P59, DOI 10.1016/S0165-6147(97)01157-7; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kassem-Moussa H, 2002, ARCH NEUROL-CHICAGO, V59, P1870, DOI 10.1001/archneur.59.12.1870; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Luconi M, 1998, J CLIN ENDOCR METAB, V83, P877, DOI 10.1210/jc.83.3.877; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; Mergenthaler P, 2004, METAB BRAIN DIS, V19, P151, DOI 10.1023/B:MEBR.0000043966.46964.e6; MERRYMAN W, 1954, J CLIN ENDOCR METAB, V14, P1567, DOI 10.1210/jcem-14-12-1567; Muntner P, 2002, STROKE, V33, P1209, DOI 10.1161/01.STR.0000015031.57955.D1; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Reglodi D, 2003, BRAIN RES BULL, V59, P459, DOI 10.1016/S0361-9230(02)00962-0; Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Smith Sheryl S, 2004, Cleve Clin J Med, V71 Suppl 2, pS4; STEIN DG, HORMONES BR IN PRESS, V4; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	63	92	101	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 27	2009	1257						94	101		10.1016/j.brainres.2008.12.048			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	420SI	WOS:000264309100011	19135987	Green Accepted			2022-02-06	
J	Stein, SC; Fabbri, A; Servadei, F; Glick, HA				Stein, Sherman C.; Fabbri, Andrea; Servadei, Franco; Glick, Henry A.			A Critical Comparison of Clinical Decision Instruments for Computed Tomographic Scanning in Mild Closed Traumatic Brain Injury in Adolescents and Adults	ANNALS OF EMERGENCY MEDICINE			English	Article							MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; INTRACRANIAL INJURIES; EMERGENCY-DEPARTMENT; NICE GUIDELINES; CT; RULE; MANAGEMENT; METHODOLOGY; PROPOSAL	Study objective: A number of clinical decision aids have been introduced to limit unnecessary computed tomographic scans in patients with mild traumatic brain injury. These aids differ in the risk factors they use to recommend a scan. We compare the instruments according to their sensitivity and specificity and recommend ones based on incremental benefit of correctly classifying patients as having surgical, nonsurgical, or no intracranial lesions. Methods: We performed a secondary analysis of prospectively collected database from 7,955 patients aged 10 years or older with mild traumatic brain injury to compare sensitivity and specificity of 6 common clinical decision strategies: the Canadian CT Head Rule, the Neurotraumatology Committee of the World Federation of Neurosurgical Societies, the New Orleans, the National Emergency X-Radiography Utilization Study II (NEXUS-II), the National Institute of Clinical Excellence guideline, and the Scandinavian Neurotrauma Committee guideline. Excluded from the database were patients for whom the history of trauma was unclear, the initial Glasgow Coma Scale score was less than 14, the injury was penetrating, vital signs were unstable, or who refused diagnostic tests. Patients revisiting the emergency department within 7 days were counted only once. Results: The percentage of scans that would have been required by applying each of the 6 aids were Canadian CT head rule (high risk only) 53%, Canadian (medium & high risk) 56%, the Neurotraumatology Committee of the World Federation of Neurosurgical Societies 56%, New Orleans 69%, NEXUS-II 56%, National Institute of Clinical Excellence 71%, and the Scandinavian 50%. The 6 decision aids' sensitivities for surgical hematomas could not be distinguished statistically (P>.05). Sensitivity was 100% (95% confidence interval [CI] 96% to 100%) for NEXUS-II, 98.1% (95% Cl 93% to 100%) for National Institute of Clinical Excellence, and 99.1% (95% CI 94% to 100%) for the other 4 clinical decision instruments. Sensitivity for any intracranial lesion ranged from 95.7% (95% CI 93% to 97%) (Scandinavian) to 100% (95% Cl 98% to 100%) (National Institute of Clinical Excellence). In contrast, specificities varied between 30.9% (95% CI 30% to 32%) (National Institute of Clinical Excellence) and 52.9% (95% CI 52% to 54) (Scandinavian). Conclusion: NEXUS-II and the Scandinavian clinical decision aids displayed the best combination of sensitivity and specificity in this patient population. However, we cannot demonstrate that the higher sensitivity of NEXUS-II for surgical hematomas is statistically significant. Therefore, choosing which of the 2 clinical decision instruments to use must be based on decisionmakers' attitudes toward risk. [Ann Emerg Med. 2009;53: 180-188.]	[Stein, Sherman C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19106 USA; [Fabbri, Andrea] Osped Morgagni Pierantoni, Dept Emergency Med, Forli, Italy; [Servadei, Franco] Osped Maggiore Parma, Dept Neurosurg, Parma, Italy; [Glick, Henry A.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA		Stein, SC (corresponding author), Hosp Univ Penn, Dept Neurosurg, 310 Spruce St, Philadelphia, PA 19106 USA.	sherman.stein@uphs.upenn.edu	Fabbri, Andrea/K-9994-2016	Fabbri, Andrea/0000-0002-9837-4638; Servadei, Franco/0000-0002-3595-3464	Manuscript Submission Agreement	Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.	Atzema C, 2004, ANN EMERG MED, V44, P47, DOI 10.1016/j.annemergmed.2004.02.032; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boyle A, 2004, EMERG MED J, V21, P426, DOI 10.1136/emj.2002.002063; Bramley R, 2002, CLIN RADIOL, V57, P151, DOI 10.1053/crad.2001.0868; Clement CM, 2006, ANN EMERG MED, V48, P245, DOI 10.1016/j.annemergmed.2006.04.008; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Dunning J, 2004, EMERG MED J, V21, P404, DOI 10.1136/emj.2004.014944; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; Fleiss JL, 1981, STAT METHODS RATES P, V2nd, P14; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Hollander JE, 2003, ACAD EMERG MED, V10, P830, DOI 10.1197/aemj.10.8.830; Huda W, 2007, AM J ROENTGENOL, V188, P540, DOI 10.2214/AJR.06.0101; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lee JB, 2004, EMERG MED J, V21, P125; Linden A, 2006, J EVAL CLIN PRACT, V12, P132, DOI 10.1111/j.1365-2753.2005.00598.x; Macgregor DM, 2005, EMERG MED J, V22, P541, DOI 10.1136/emj.2004.017160; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; Maharaj I, 2001, LANCET, V358, P1013, DOI 10.1016/S0140-6736(01)06139-6; MAHARAJ I, 2001, LANCET, V358, P1014; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Miller L, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-7; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Mower WR, 2002, ANN EMERG MED, V40, P505, DOI 10.1067/mem.2002.129245; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; National Institute for Clinical Excellence, 2007, CLIN GUID; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Qushmaq Ismael, 2006, ACP J Club, V144, P53; REILLY PL, 1975, LANCET, V2, P375; Schwam E, 2006, JAMA-J AM MED ASSOC, V295, P497, DOI 10.1001/jama.295.5.497-a; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; Smits M, 2006, JAMA-J AM MED ASSOC, V295, P497, DOI 10.1001/jama.295.5.497-b; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; SOX HC, 1988, MED DECIS MAKING, P135; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2000, CAN MED ASSOC J, V163, P1465; Stiell IG, 2006, JAMA-J AM MED ASSOC, V295, P498, DOI 10.1001/jama.295.5.498-a; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STIELL IG, 2001, LANCET, V358, P1013; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; TEASDALE G, 1974, LANCET, V2, P81; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395	54	92	98	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	FEB	2009	53	2					180	188		10.1016/j.annemergmed.2008.01.002			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	405LI	WOS:000263225900006	18339447				2022-02-06	
J	Jayakumar, AR; Liu, ML; Moriyama, M; Ramakrishnan, R; Forbush, B; Reddy, PVB; Norenberg, MD				Jayakumar, Arumugam R.; Liu, Mingli; Moriyama, Mitsuaki; Ramakrishnan, Ramugounder; Forbush, Bliss, III; Reddy, Pichili V. B.; Norenberg, Michael D.			Na-K-Cl Cotransporter-1 in the Mechanism of Ammonia-induced Astrocyte Swelling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; ION-TRANSPORT; NA+-K+-2CL(-) COTRANSPORTER; HEPATIC-ENCEPHALOPATHY; PRIMARY CULTURES; BENZODIAZEPINE-RECEPTOR; GLUTAMATE TRANSPORTER; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; TYROSINE KINASE	Brain edema and the consequent increase in intracranial pressure and brain herniation are major complications of acute liver failure (fulminant hepatic failure) and a major cause of death in this condition. Ammonia has been strongly implicated as an important factor, and astrocyte swelling appears to be primarily responsible for the edema. Ammonia is known to cause cell swelling in cultured astrocytes, although the means by which this occurs has not been fully elucidated. A disturbance in one or more of these systems may result in loss of ion homeostasis and cell swelling. In particular, activation of the Na-K-Cl cotransporter (NKCC1) has been shown to be involved in cell swelling in several neurological disorders. We therefore examined the effect of ammonia on NKCC activity and its potential role in the swelling of astrocytes. Cultured astrocytes were exposed to ammonia (NH4Cl; 5 mM), and NKCC activity was measured. Ammonia increased NKCC activity at 24 h. Inhibition of this activity by bumetanide diminished ammonia-induced astrocyte swelling. Ammonia also increased total as well as phosphorylated NKCC1. Treatment with cyclohexamide, a potent inhibitor of protein synthesis, diminished NKCC1 protein expression and NKCC activity. Since ammonia is known to induce oxidative/nitrosative stress, and antioxidants and nitric-oxide synthase inhibition diminish astrocyte swelling, we also examined whether ammonia caused oxidation and/or nitration of NKCC1. Cultures exposed to ammonia increased the state of oxidation and nitration of NKCC1, whereas the antioxidants N-nitro-L-arginine methyl ester and uric acid all significantly diminished NKCC activity. These agents also reduced phosphorylated NKCC1 expression. These results suggest that activation of NKCC1 is an important factor in the mediation of astrocyte swelling by ammonia and that such activation appears to be mediated by NKCC1 abundance as well as by its oxidation/nitration and phosphorylation.	[Jayakumar, Arumugam R.; Liu, Mingli; Moriyama, Mitsuaki; Ramakrishnan, Ramugounder; Reddy, Pichili V. B.; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; [Norenberg, Michael D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Norenberg, Michael D.] Vet Affairs Med Ctr, Miami, FL 33101 USA; [Moriyama, Mitsuaki] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka 5998531, Japan; [Forbush, Bliss, III] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK063311]; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK063311] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant DK063311. This work was also supported by a Merit Review from the Department of Veterans Affairs. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Abbruscato TJ, 2004, J PHARMACOL EXP THER, V310, P459, DOI 10.1124/jpet.104.066274; Albrecht J, 1999, J NEUROL SCI, V170, P138, DOI 10.1016/S0022-510X(99)00169-0; Albrecht J, 2006, HEPATOLOGY, V44, P788, DOI 10.1002/hep.21357; Bender AS, 1996, NEUROCHEM RES, V21, P567, DOI 10.1007/BF02527755; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.0.CO;2-P; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chin SS, 1999, CURR EYE RES, V18, P254, DOI 10.1076/ceyr.18.4.254.5359; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; ELLIOTT SJ, 1992, AM J PHYSIOL, V263, pH96, DOI 10.1152/ajpheart.1992.263.1.H96; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P404, DOI 10.1097/00005072-198507000-00004; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P397, DOI 10.1097/00005072-198507000-00003; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; HANSSON E, 1986, NEUROCHEM RES, V11, P759, DOI 10.1007/BF00965202; Hazell AS, 1999, P SOC EXP BIOL MED, V222, P99, DOI 10.1046/j.1525-1373.1999.d01-120.x; Hertz L, 1994, HDB NEUROCHEMISTRY, P603; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Isaacks RE, 1999, NEUROCHEM RES, V24, P51, DOI 10.1023/A:1020928029845; ITZHAK Y, 1994, NEUROSCI LETT, V177, P35, DOI 10.1016/0304-3940(94)90038-8; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Juncos R, 2005, AM J PHYSIOL-RENAL, V288, pF982, DOI 10.1152/ajprenal.00348.2004; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; KIMELBERG HK, 1983, CELL MOL NEUROBIOL, V3, P1, DOI 10.1007/BF00734994; KIMELBERG HK, 1985, BRAIN RES, V361, P125, DOI 10.1016/0006-8993(85)91282-X; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; Kintner DB, 2007, AM J PHYSIOL-CELL PH, V292, pC1113, DOI 10.1152/ajpcell.00412.2006; Kintner DB, 2007, FRONT BIOSCI-LANDMRK, V12, P762, DOI 10.2741/2099; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Lenart B, 2004, J NEUROSCI, V24, P9585, DOI 10.1523/JNEUROSCI.2569-04.2004; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MacVicar BA, 2002, GLIA, V37, P114, DOI 10.1002/glia.10023; Mallozzi C, 2001, FEBS LETT, V503, P189, DOI 10.1016/S0014-5793(01)02726-0; MARTINEZ A, 1968, ACTA NEUROPATHOL, V11, P82, DOI 10.1007/BF00692797; Mobasheri A, 1998, HISTOL HISTOPATHOL, V13, P893, DOI 10.14670/HH-13.893; Murthy CRK, 2001, J NEUROSCI RES, V66, P282, DOI 10.1002/jnr.1222; Nagaraja TN, 1998, AM J PHYSIOL-CELL PH, V274, pC883, DOI 10.1152/ajpcell.1998.274.4.C883; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; NORENBERG MD, 1990, J NEUROPATH EXP NEUR, V49, P399, DOI 10.1097/00005072-199007000-00004; Norenberg MD, 1996, SEMIN LIVER DIS, V16, P245, DOI 10.1055/s-2007-1007237; Norenberg MD, 2004, METAB BRAIN DIS, V19, P313, DOI 10.1023/B:MEBR.0000043978.91675.79; Norenberg MD, 1997, GLIA, V21, P124; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; Norenberg MD, 2003, HEPATOLOGY, V37, P245, DOI 10.1053/jhep.2003.50087; Norenberg MD, 1998, METAB BRAIN DIS, V13, P319, DOI 10.1023/A:1020688925901; NORENBERG MD, 1977, LAB INVEST, V36, P618; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; NORENBERG MD, 1987, NEUROCHEM PATHOL, V6, P13, DOI 10.1007/BF02833599; NORENBERG MD, 2001, ASTROCYTES AGING BRA, P477; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Pichili VBR, 2007, GLIA, V55, P801, DOI 10.1002/glia.20499; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Rao KVR, 2003, J NEUROSCI RES, V74, P891, DOI 10.1002/jnr.10755; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Rose CR, 1998, J NEUROSCI, V18, P3554; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schomberg SL, 2003, J NEUROPHYSIOL, V89, P159, DOI 10.1152/jn.00229.2002; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; STAUB F, 1994, J NEUROTRAUM, V11, P679, DOI 10.1089/neu.1994.11.679; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Su G, 2000, AM J PHYSIOL-CELL PH, V279, pC1710; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939, DOI 10.1152/jn.1999.81.4.1939; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; TAS PWL, 1987, BIOCHIM BIOPHYS ACTA, V903, P411, DOI 10.1016/0005-2736(87)90047-2; TAS PWL, 1986, NEUROSCI LETT, V70, P369, DOI 10.1016/0304-3940(86)90581-1; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Vaquero Javier, 2003, Ann Hepatol, V2, P12; WALZ W, 1992, CAN J PHYSIOL PHARM, V70, pS260, DOI 10.1139/y92-270; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Yan YP, 2001, BRAIN RES, V911, P43, DOI 10.1016/S0006-8993(01)02649-X; Zhou BG, 1999, NEUROSCI LETT, V276, P145, DOI 10.1016/S0304-3940(99)00816-2	84	92	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2008	283	49					33874	33882		10.1074/jbc.M804016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	377UY	WOS:000261277700012	18849345	Green Published, hybrid			2022-02-06	
J	Gallagher, S; Phillips, AC; Oliver, C; Carroll, D				Gallagher, Stephen; Phillips, Anna C.; Oliver, Christopher; Carroll, Douglas			Predictors of Psychological Morbidity in Parents of Children with Intellectual Disabilities	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						anxiety; caregiving; depression; parents of children with intellectual disability	ZARIT-BURDEN-INTERVIEW; TRAUMATIC BRAIN-INJURY; SCHOOL-AGE-CHILDREN; BEHAVIOR PROBLEMS; DIFFICULTIES QUESTIONNAIRE; FAMILY CAREGIVERS; HOSPITAL ANXIETY; SOCIAL SUPPORT; DOWNS-SYNDROME; STRESS	Objective This study examined predictors of excess psychological morbidity in parents of children with intellectual disabilities. Methods Thirty-two parents of children with intellectual disabilities and 29 parents of typically developing children completed the Hospital Depression and Anxiety Scale, and measures of social support, child problem behaviors, sleep quality, and perceived caregiver burden. Results Parents of children with intellectual disabilities registered high depression and anxiety scores, and the majority met the criteria for possible clinical depression and/or anxiety. The strongest predictor of psychological morbidity was caregiver burden. Analyses of its component dimensions indicated that feelings of guilt held the greatest consequence for depression and anxiety. Conclusions Caregiver burden, in general, and its guilt component, in particular, predicted symptoms of depression and anxiety in parents of children with intellectual disabilities. Assisting such parents to resolve their feelings of guilt should benefit their psychological status.	[Gallagher, Stephen; Phillips, Anna C.; Carroll, Douglas] Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England; [Oliver, Christopher] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England		Gallagher, S (corresponding author), Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England.	sxg598@bham.ac.uk	Whittaker, Anna C./A-3577-2013; Oliver, Christopher/A-7519-2008	Whittaker, Anna C./0000-0002-5461-0598; , Stephen/0000-0002-5471-7774; Oliver, Christopher/0000-0001-5217-6209			Achenbach TM, 1991, MANUAL CHILD BEHAV C; AMAN MG, 1987, AM J MENT RETARD, V91, P570; Ankri J, 2005, INT J GERIATR PSYCH, V20, P254, DOI 10.1002/gps.1275; Bailey D., 1994, J SOCIOL SOC WELFARE, V21, P127; Baker BL, 2003, J INTELL DISABIL RES, V47, P217, DOI 10.1046/j.1365-2788.2003.00484.x; Benderix Y, 2006, AUTISM, V10, P629, DOI 10.1177/1362361307070902; Blacher J, 2006, J INTELL DISABIL RES, V50, P184, DOI 10.1111/j.1365-2788.2005.00768.x; BRAMLEY PN, 1988, ACTA PSYCHIAT SCAND, V77, P133, DOI 10.1111/j.1600-0447.1988.tb05089.x; Brummett BH, 2006, HEALTH PSYCHOL, V25, P220, DOI 10.1037/0278-6133.25.2.220; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carter PA, 2006, CANCER NURS, V29, P95, DOI 10.1097/00002820-200603000-00003; Clyburn LD, 2000, J GERONTOL B-PSYCHOL, V55, pS2, DOI 10.1093/geronb/55.1.s2; Dunn ME, 2001, COMMUNITY MENT HLT J, V37, P39, DOI 10.1023/A:1026592305436; DUNST CJ, 1988, ENABLING EMPOWERING; DYSON LL, 1993, AM J MENT RETARD, V98, P207; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Floyd FJ, 1997, FAM RELAT, V46, P359, DOI 10.2307/585096; GALLAGHER D, 1985, 38 ANN SCI M GER SOC; Glidden LM, 2003, J INTELL DISABIL RES, V47, P250, DOI 10.1046/j.1365-2788.2003.00487.x; Goodman R, 1998, EUR CHILD ADOLES PSY, V7, P125, DOI 10.1007/s007870050057; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; Grandner Michael A, 2006, Sleep Biol Rhythms, V4, P129, DOI 10.1111/j.1479-8425.2006.00207.x; Graungaard AH, 2007, CHILD CARE HLTH DEV, V33, P296, DOI 10.1111/j.1365-2214.2006.00666.x; GRAY DE, 1992, J INTELLECT DEV DIS, V18, P83, DOI DOI 10.1080/07263869200034841; Hastings RP, 2006, AM J MENT RETARD, V111, P48, DOI 10.1352/0895-8017(2006)111[48:MDAEEC]2.0.CO;2; Hastings RP, 2005, AUTISM, V9, P377, DOI 10.1177/1362361305056078; Hastings RP, 2002, AM J MENT RETARD, V107, P222, DOI 10.1352/0895-8017(2002)107<0222:BPOCWA>2.0.CO;2; Hebert R, 2000, CAN J AGING, V19, P494, DOI 10.1017/S0714980800012484; Hedov G, 2002, SCAND J CARING SCI, V16, P424, DOI 10.1046/j.1471-6712.2002.00109.x; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Lenhard W, 2005, AM J MED GENET A, V133A, P170, DOI 10.1002/ajmg.a.30571; Maes B, 2003, J INTELL DISABIL RES, V47, P447, DOI 10.1046/j.1365-2788.2003.00513.x; Magana SM, 2007, PSYCHIAT SERV, V58, P378, DOI 10.1176/appi.ps.58.3.378; McCubbin H. I., 1981, SYSTEMATIC ASSESSMEN, P67; McCurry SM, 2007, SLEEP MED REV, V11, P143, DOI 10.1016/j.smrv.2006.09.002; MCGUBBIN HI, 1983, SOCIAL STRESS FAMILY, P7; Meltzer LJ, 2008, J PEDIATR PSYCHOL, V33, P279, DOI 10.1093/jpepsy/jsm118; Meltzer LJ, 2006, ARCH INTERN MED, V166, P1749, DOI 10.1001/archinte.166.16.1749; Nikcevic AV, 2007, J PSYCHOSOM RES, V63, P283, DOI 10.1016/j.jpsychores.2007.04.004; Ostwald SK, 1999, GERONTOLOGIST, V39, P299, DOI 10.1093/geront/39.3.299; Phipps S, 2005, J PEDIATR PSYCHOL, V30, P139, DOI 10.1093/jpepsy/jsi002; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; Shearn J, 2000, J APPL RES INTELLECT, V13, P109, DOI 10.1046/j.1468-3148.2000.00021.x; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Stores R, 1998, J INTELL DISABIL RES, V42, P228, DOI 10.1046/j.1365-2788.1998.00123.x; THOMPSON A, INT J GERIA IN PRESS; TRIVETTE C, 1985, PERSONAL WELL UNPUB; Vedhara K, 2002, J PSYCHOSOM RES, V53, P1153, DOI 10.1016/S0022-3999(02)00343-4; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Weiss MJ, 2002, AUTISM, V6, P115, DOI 10.1177/1362361302006001009; White N, 2004, J APPL RES INTELLECT, V17, P181, DOI 10.1111/j.1468-3148.2004.00197.x; Wilcox S, 1999, J GERONTOL B-PSYCHOL, V54, pP189, DOI 10.1093/geronb/54B.3.P189; Wright Marilyn, 2006, Phys Occup Ther Pediatr, V26, P55, DOI 10.1300/J006v26n03_05; Yirmiya N, 2005, J CHILD PSYCHOL PSYC, V46, P69, DOI 10.1111/j.1469-7610.2004.00334.x; Zammit GK, 1999, SLEEP, V22, pS379; Zarit S.H., 1990, MEMORY BEHAV PROBLEM; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	59	92	98	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	NOV-DEC	2008	33	10					1129	1136		10.1093/jpepsy/jsn040			8	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	367NB	WOS:000260557600007	18430761	Green Published, Green Submitted, Bronze			2022-02-06	
J	Fischer, C; Dailler, F; Morlet, D				Fischer, Catherine; Dailler, Frederic; Morlet, Dominique			Novelty P3 elicited by the subject's own name in comatose patients	CLINICAL NEUROPHYSIOLOGY			English	Article						P3; MMN; Novelty; Coma; Consciousness; Own name	MINIMALLY CONSCIOUS STATE; SOMATOSENSORY-EVOKED POTENTIALS; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; INVOLUNTARY ATTENTION; MISMATCH NEGATIVITY; NONTRAUMATIC COMA; ODDBALL PARADIGM; PREDICTIVE-VALUE; RESPONSES	Objective: To assess patterns of novelty P3 elicited by the subject's own name (SON) in comatose patients and to compare SON novelty P3 prognostic value with that of mismatch negativity (MMN). Methods: A passive oddball paradigm, previously validated in healthy subjects, including duration deviants and SON presented as a novel was applied in 50 severe comatose patients on average 20 days after coma onset. The outcome was assessed 3 months after coma onset. Results: MMN to deviants was found in 14/50 patients and a central-parietal P3 to SON was found in 21/50 patients. In 12 patients, a parietal component (P3b) was also clearly present in the late part of P3. Four patients showed an MMN but no P3. Eleven patients had a novelty P3. with a late parietal component for 5 of them, but no MMN. The presence of a P3 was highly correlated with awakening. Compared to MMN, P3 showed as large a specificity for awakening (0.85). It showed a much higher sensitivity (0.71 versus 0.42). All but one patient with P3b woke up. Conclusions: The use of novelty P3 elicited by SON increases the prognostic value of MMN alone and improves the assessment of comatose patients by demonstrating the activation of higher-level cognitive functions in some of them. It shows that unconsciously perceived stimuli are processed and activate brain areas similarly to consciously perceived stimuli. Significance: SON as a novel in an MMN design can be used to increase the prognostic value of ERPs in comatose patients and to assess unconscious cognitive processes in uncommunicative patients. (c) 2008 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Fischer, Catherine] Neurol Hosp Lyon, Hosp Civils Lyon, Clin Neurophysiol Unit, F-69677 Bron, France; [Fischer, Catherine; Morlet, Dominique] INSERM, U Brain Dynam & Cognit 821, F-69500 Bron, France; [Fischer, Catherine; Morlet, Dominique] Univ Lyon 1, F-69000 Lyon, France; [Dailler, Frederic] Neurol Hosp, Hosp Civils Lyon, Dept Intens Care, Lyon, France		Fischer, C (corresponding author), Neurol Hosp Lyon, Hosp Civils Lyon, Clin Neurophysiol Unit, 59 Blvd Pinel, F-69677 Bron, France.	catherine.fischer@chu-lyon.fr					Alho K, 1998, PSYCHOPHYSIOLOGY, V35, P211, DOI 10.1111/1469-8986.3520211; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; BASTUJI H, 1995, J CLIN NEUROPHYSIOL, V12, P155, DOI 10.1097/00004691-199503000-00006; BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Bernat E, 2001, CLIN NEUROPHYSIOL, V112, P159, DOI 10.1016/S1388-2457(00)00445-4; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Escera C, 2000, AUDIOL NEURO-OTOL, V5, P151, DOI 10.1159/000013877; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer C, 2006, CRIT CARE MED, V34, P1520, DOI 10.1097/01.CCM.0000215823.36344.99; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; Folmer RL, 1997, BRAIN LANG, V56, P306, DOI 10.1006/brln.1997.1828; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; GUTHRIE D, 1991, PSYCHOPHYSIOLOGY, V28, P240, DOI 10.1111/j.1469-8986.1991.tb00417.x; Holeckova I, 2006, BRAIN RES, V1082, P142, DOI 10.1016/j.brainres.2006.01.089; Holeckova I, 2008, BRAIN RES, V1189, P152, DOI 10.1016/j.brainres.2007.10.091; JENNETT B, 1975, LANCET, V1, P480; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Melloni L, 2007, J NEUROSCI, V27, P2858, DOI 10.1523/JNEUROSCI.4623-06.2007; Muller HM, 1996, NEUROREPORT, V8, P221; Naccache L, 2005, CLIN NEUROPHYSIOL, V116, P988, DOI 10.1016/j.clinph.2004.10.009; Ofek E, 2005, CLIN NEUROPHYSIOL, V116, P2354, DOI 10.1016/j.clinph.2005.05.021; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Perrin F, 1999, CLIN NEUROPHYSIOL, V110, P2153, DOI 10.1016/S1388-2457(99)00177-7; PLOURDE G, 1991, ANESTH ANALG, V72, P342; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Reuter B M, 1989, Arch Psychol (Frankf), V141, P155; ROLLS ET, 1982, BRAIN, V105, P611, DOI 10.1093/brain/105.4.611; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; SQUIRES KC, 1976, SCIENCE, V193, P1142, DOI 10.1126/science.959831; WOOD N, 1995, J EXP PSYCHOL LEARN, V21, P255, DOI 10.1037/0278-7393.21.1.255; WOODS DL, 1980, SCIENCE, V207, P655, DOI 10.1126/science.7352278; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	44	92	100	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	OCT	2008	119	10					2224	2230		10.1016/j.clinph.2008.03.035			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	373LW	WOS:000260974400013	18760663				2022-02-06	
J	Jones, KE; Puccio, AM; Harshman, KJ; Falcione, B; Benedict, N; Jankowitz, BT; Stippler, M; Fischer, M; Sauber-Schatz, EK; Fabio, A; Darby, JM; Okonkwo, DO				Jones, Kristen E.; Puccio, Ava M.; Harshman, Kathy J.; Falcione, Bonnie; Benedict, Neal; Jankowitz, Brian T.; Stippler, Martina; Fischer, Michael; Sauber-Schatz, Erin K.; Fabio, Anthony; Darby, Joseph M.; Okonkwo, David O.			Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						antiepileptic drug; posttraumatic seizure; seizure prophylaxis; traumatic brain injury	POSTTRAUMATIC SEIZURES; PREVENTION	Object. Current standard of care for patients with severe traumatic brain injury (TBI) is prophylactic treatment with phenytoin for 7 days to decrease the risk of early posttraumatic seizures. Phenytoin alters drug metabolism, induces fever, and requires therapeutic-level monitoring. Alternatively, levetiracetam (Keppra) does not require serum monitoring or have significant pharmacokinetic interactions. In the current study, the authors compare the EEG findings in patients receiving phenytoin with those receiving levetiracetam monotherapy for seizure prophylaxis following severe TBI. Methods. Data were prospectively collected in 32 cases in which patients received levetiracetam for the first 7 days after severe TBI and compared with data from a historical cohort of 41 cases in which patients received phenytoin monotherapy. Patients underwent 1-hour electroencephalographic (EEG) monitoring if they displayed persistent coma, decreased mental status, or clinical signs of seizures. The EEG results were grouped into normal and abnormal findings, with abnormal EEG findings further categorized as seizure activity or seizure tendency. Results. Fifteen of 32 patients in the levetiracetam group warranted EEG monitoring. In 7 of these 15 cases the results were normal and in 8 abnormal; 1 patient had seizure activity, whereas 7 had seizure tendency. Twelve of 41 patients in the phenytoin group received EEG monitoring, with all results being normal. Patients treated with levetiracetam and phenytoin had equivalent incidence of seizure activity (p = 0.556). Patients receiving levetiracetam had a higher incidence of abnormal EEG findings (p = 0.003). Conclusions. Levetiracetam is as effective as phenytoin in preventing early posttraumatic seizures but is associated with an increased seizure tendency on EEG analysis.	[Jones, Kristen E.; Puccio, Ava M.; Harshman, Kathy J.; Jankowitz, Brian T.; Stippler, Martina; Fischer, Michael; Sauber-Schatz, Erin K.; Fabio, Anthony; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA; [Falcione, Bonnie; Benedict, Neal] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; [Darby, Joseph M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA		Okonkwo, DO (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu		Fabio, Anthony/0000-0002-6808-4939; Jones, Kristen/0000-0002-2007-028X	University of Pittsburgh Brain Trauma Research CenterUniversity of Pittsburgh [NIH P50NS30318]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER	This research was performed at the University of Pittsburgh Medical Center and was supported by the University of Pittsburgh Brain Trauma Research Center (NIH P50NS30318).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; JONES GL, 1983, MED RES REV, V3, P383, DOI 10.1002/med.2610030403; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahin S, 2008, CLIN NEUROPHARMACOL, V31, P93, DOI 10.1097/WNF.0b013e31806ad6cb; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC	15	92	95	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E3	10.3171/FOC.2008.25.10.E3			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100003	18828701	Bronze, Green Accepted			2022-02-06	
J	Kilinc, D; Gallo, G; Barbee, KA				Kilinc, Devrim; Gallo, Gianluca; Barbee, Kenneth A.			Mechanically-induced membrane poration causes axonal beading and localized cytoskeletal damage	EXPERIMENTAL NEUROLOGY			English	Article						diffuse axonal injury; mechanoporation; neuroprotection; Poloxamer 188; axonal bead formation; fluid shear stress injury; plasma membrane	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; NEURONAL INJURY; STRETCH-INJURY; POLOXAMER 188; NERVE-FIBERS; OPTIC-NERVE; HEAD-INJURY; TRANSPORT; CALCIUM	Diffuse axonal injury (DAI), a major component of traumatic brain injury, is a manifestation of microstructural cellular trauma and various ensuing neurochemical reactions that leads to secondary neuronal death. DAI is suggested to result from the initial increase in the membrane permeability caused by the mechanical forces acting on the axons. Permeability increases disturb ion balance and lead to cytoskeletal disruption resulting in the impairment of axonal transport. We present an in vitro model that reproduces important features of in vivo DAI such as membrane permeability changes, focal disruption of microtubules, impaired axonal transport, and focal accumulation of organelles. We induced fluid shear stress injury (FSSI) on Cultured primary chick forebrain neurons and characterized the resulting structural and morphological changes. In addition, we tested the effect of Poloxamer 188 (P188), a tri-block co-polymer that is known to Promote resealing membrane pores. We found that FSSI induces mechanoporation that leads to axonal bead formation, the "hallmark" morphology of DAI. Beads contained accumulated mitochondria and co-localized with focal microtubule disruptions, also a characteristic of DAI. Post-injury P188 treatment prevented FSSI-induced membrane permeability changes and reduced axonal beading to control levels. These results indicate that acute mechanoporation of axons in response to injury is a necessary condition for subsequent axonal pathology, suggesting that membrane integrity is a potential target for therapeutic interventions. P188 provides neuroprotection Via resealing the plasma membrane following injury and prevents focal disruption of microtubules and axonal bead formation. (C) 2008 Published by Elsevier Inc.	[Kilinc, Devrim; Barbee, Kenneth A.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Gallo, Gianluca] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA		Barbee, KA (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu	Barbee, Kenneth/F-4333-2014; Kilinc, Devrim/E-8733-2011; Kilinc, Devrim/I-4180-2019	Kilinc, Devrim/0000-0003-3321-5203; Kilinc, Devrim/0000-0003-3321-5203	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS048090, R01NS048090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048090] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Baekmark TR, 1997, BIOPHYS J, V73, P1479, DOI 10.1016/S0006-3495(97)78180-3; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gallo G, 1999, J NEUROSCI, V19, P3860; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hannig J, 2000, IEEE T PLASMA SCI, V28, P97, DOI 10.1109/27.842873; Heidemann SR, 2003, METHOD CELL BIOL, V71, P51, DOI 10.1016/S0091-679X(03)01004-5; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; KILINC D, 2007, EMBC07, P5395; KOENIG E, 1985, J NEUROSCI, V5, P715; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2005, ANN NY ACAD SCI, V1066, P310, DOI 10.1196/annals.1363.018; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McIntosh TK, 1996, LAB INVEST, V74, P315; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Sharma V, 1996, BIOPHYS J, V71, P3229, DOI 10.1016/S0006-3495(96)79516-4; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	55	92	98	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2008	212	2					422	430		10.1016/j.expneurol.2008.04.025			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	334WL	WOS:000258252000025	18572167				2022-02-06	
J	Stiver, SI; Wintermark, M; Manley, GT				Stiver, Shirley I.; Wintermark, Max; Manley, Geoffrey T.			Reversible monoparesis following decompressive hemicraniectomy for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebrospinal fluid; cerebrovascular circulation; cranioplasty; craniotomy; neurological deficit; trephine	ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURIES; COMMUNICATING HYDROCEPHALUS; BLOOD-FLOW; CRANIECTOMY; CRANIOPLASTY; MANAGEMENT; DEFECTS; METABOLISM; DYNAMICS	Object. The "syndrome of the trephined" is an uncommon and poorly understood disorder of delayed neurological deficit following craniectomy. From the authors' extensive experience with decompressive hemicraniectomy for traumatic brain injury (TBI), they have encountered a number of patients who developed delayed motor deficits, also called "motor trephine syndrome," and reversal of the weakness following cranioplasty repair. The authors set out to study motor function systematically in this patient population to define the incidence, contributing factors, and outcome of patients with motor trephine syndrome. Methods. The authors evaluated patient demographics, injury characteristics, detailed motor examinations, and CT scans in 38 patients with long-term follow-up after decompressive hemicraniectomy for TBI. Results. Ten patients (26%) experienced delayed contralateral upper-extremity weakness, beginning 4.9 +/- 0.4 months (mean standard error) after decompressive hemicraniectomy. Motor deficits improved markedly within 72 hours of cranioplasty repair, and all patients recovered full motor function. The CT perfusion scans, performed in 2 patients, demonstrated improvements in cerebral blood flow commensurate with resolution of cerebrospinal fluid flow disturbances on CT scanning and return of motor strength. Comparisons between 10 patients with and 20 patients (53%) without delayed motor deficits identified 3 factors - ipsilateral contusions, abnormal cerebrospinal fluid circulation, and longer intervals to cranioplasty repair-to be strongly associated with delayed, reversible monoparesis following decompressive hemicraniectomy. Conclusions. Delayed, reversible monoparesis, also called motor trephine syndrome, is common following decompressive hemicraniectomy for TBI. The results of this study suggest that close follow-up of motor strength with early cranioplasty repair may prevent delayed motor complications of decompressive hemicraniectomy.	[Stiver, Shirley I.; Manley, Geoffrey T.] Univ Calif San Francisco, Sch Med, Dept Neurosurg, San Francisco, CA 94110 USA; [Wintermark, Max] Univ Calif San Francisco, Sch Med, Dept Radiol, San Francisco, CA 94110 USA		Stiver, SI (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurosurg, 1001 Potrero Ave,Roomm 101, San Francisco, CA 94110 USA.	sstiver@neurosurg.ucsf.edu		Wintermark, Max/0000-0002-6726-3951			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Carmelo A, 2002, ACT NEUR S, V81, P109; Cohen JE, 2004, NEUROL RES, V26, P763, DOI 10.1179/016164104225015930; Colohan Austin R T, 2005, Clin Neurosurg, V52, P19; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; DUJOVNY M, 1998, CALVARIAL DURAL RECO, P77; Falconer MA, 1944, J NEUROSURG, V1, P182, DOI 10.3171/jns.1944.1.3.0182; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; GARDNER WJ, 1945, SURG GYNECOL OBSTET, V80, P303; GEORGE AE, 1974, RADIOLOGY, V111, P627; GOTTLOB L, 2002, STRABISMUS, V10, P271; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; JAMES AE, 1974, RADIOLOGY, V111, P143, DOI 10.1148/111.1.143; JAMES AE, 1975, J NEUROL SCI, V24, P151, DOI 10.1016/0022-510X(75)90231-2; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maeshima S, 2005, EUR NEUROL, V53, P164, DOI 10.1159/000086129; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; Marion DW, 2006, NEUROSURGERY, V58, P655; Matsuno A, 2003, SURG NEUROL, V60, P23, DOI 10.1016/S0090-3019(03)00023-5; Meier U, 2005, ACT NEUR S, V95, P55; MORI K, 1977, SURG NEUROL, V8, P337; NAU HE, 1981, NEUROCHIRURGIA, V24, P192; RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183; RINALDI A, 1990, ACT NEUR S, V51, P394; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; STULA D, 1985, NEUROCHIRURGIA, V28, P164; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yamaura A, 1977, No Shinkei Geka, V5, P345; YOSHIDA K, 1994, AM J NEURORADIOL, V15, P1681	44	92	98	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2008	109	2					245	254		10.3171/JNS/2008/109/8/0245			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	330QR	WOS:000257958400012	18671636				2022-02-06	
J	Sherer, M; Struchen, MA; Yablon, SA; Wang, Y; Nick, TG				Sherer, M.; Struchen, M. A.; Yablon, S. A.; Wang, Y.; Nick, T. G.			Comparison of indices of traumatic brain injury severity: Glasgow Coma Scale, length of coma and post-traumatic amnesia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; OUTCOMES; PROGRAM; PREDICTION; MANAGEMENT; VARIABLES; RECOVERY; MODERATE; MODEL; TREE	Background: Classification of traumatic brain injury (TBI) severity guides management and contributes to determination of prognosis. Common indicators of TBI severity include Glasgow Coma Scale (GCS) scores, length of coma (LOC) and duration of post-traumatic amnesia (PTA). Objective: To compare GCS, LOC and PTA by examining distributions and intercorrelations and develop multivariable linear regression models for estimating LOC and PTA duration. Methods: Prospective study of 519 of 614 consecutive patients with TBI. Indices of TBI severity studied were GCS, LOC, PTA and PTA-LOC (the interval from return of command-following to return of orientation). Candidate predictor variables for estimation of LOC, PTA and PTA LOC intervals were age, years of education, year of injury (before 1997 vs 1997 or later), GCS, LOC (for PTA and PTA-LOC), pupillary responsiveness, type of injury, CT pathology and intracranial operations. Results: Although there was a severity/response relationship between GCS and LOC, PTA and PTA-LOC intervals, there was overlap in these intervals between GCS severity categories. Age, year of injury, GCS, pupillary responsiveness and CT pathology were predictive of LOC. Age, years of education, year of injury, GCS, LOC, pupillary responsiveness and intracranial operations were predictive of PTA duration. Age, years of education, year of injury, GCS, LOC and pupillary responsiveness were predictive of PTA-LOC. GCS and LOC effects were influenced by age. Conclusions: Predictors for estimating LOC, PTA and PTA-LOC intervals were determined and simple equations were developed. These equations will be helpful to clinicians, researchers and those counselling family members of patients with TBI.	[Sherer, M.; Struchen, M. A.] Mem Hermann TIRR, Dept Res, Houston, TX 77030 USA; [Sherer, M.; Struchen, M. A.] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, S. A.] Methodist Rehabil Ctr, Jackson, MS USA; [Yablon, S. A.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Wang, Y.; Nick, T. G.] Cincinnati Childrens Hosp, Ctr Med, Ctr Biostat & Epidemiol, Cincinnati, OH USA; [Nick, T. G.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Sherer, M (corresponding author), Mem Hermann TIRR, Dept Res, 1333 Moursund, Houston, TX 77030 USA.	Sherer@memorialhermann.org					Alex BV, 1996, NEUROTRAUMA, P119; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; [Anonymous], 2000, J Neurotrauma, V17, P563; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bland JM, 1998, BRIT MED J, V317, P1572, DOI 10.1136/bmj.317.7172.1572; Bullock R, 1995, GUIDELINES MANAGEMEN; Capruso D. X., 2000, HEAD INJURY, P525; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELANEY KA, 2000, HEAD INJURY, P41; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Huang L, 2007, COMPUT METH PROG BIO, V86, P45, DOI 10.1016/j.cmpb.2006.12.005; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LAWLESS JF, 1978, BIOMETRICS, V34, P318, DOI 10.2307/2530022; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SMITH PJ, 2004, INT J RELIABILITY QU, V11, P163; Stare J, 2001, COMPUT METH PROG BIO, V64, P45, DOI 10.1016/S0169-2607(00)00083-3; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	40	92	92	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2008	79	6					678	685		10.1136/jnnp.2006.111187			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	302FS	WOS:000255954800016	17928328				2022-02-06	
J	Inaba, K; Teixeira, PG; David, JS; Chan, LS; Salim, A; Brown, C; Browder, T; Beale, E; Rhee, P; Demetriades, D				Inaba, Kenji; Teixeira, Pedro Gr; David, Jean-Stephane; Chan, Linda S.; Salim, Ali; Brown, Carlos; Browder, Timothy; Beale, Elizabeth; Rhee, Peter; Demetriades, Demetrios			Beta-blockers in isolated blunt head injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMATIC BRAIN-INJURY; ADULT BURN PATIENTS; IMPROVED OUTCOMES; MYOCARDIAL DAMAGE; IMPROVED SURVIVAL; NERVOUS-SYSTEM; BLOCKADE; CATECHOLAMINES; HEMORRHAGE; PROPRANOLOL	BACKGROUND: The purpose of this study was to evaluate the effect of beta-blockers on patients sustaining acute traumatic brain injury. Our hypothesis was that beta-blocker exposure is associated with improved survival. STUDY DESIGN: The trauma registry and the surgical ICU databases of an academic Level I trauma center were used to identify all patients sustaining blunt head injury requiring ICU admission from July 1998 to December 2005. Patients sustaining major associated injuries (Abbreviated Injury Score >= 4 in any body region other than the head) were excluded. Patient demographics, injury profile, Injury Severity Score, and beta-blocker exposure were abstracted. The primary outcomes measure evaluated was in-hospital mortality. RESULTS: During the 90-month study period, 1, 156 patients with isolated head injury were admitted to the ICU. Of these, 203 (18%) received beta-blockers and 953 (82%) did not. Patients receiving beta-blockers were older (50 +/- 21 years versus 38 +/- 20 years, p < 0.001), had more frequent severe (Abbreviated Injury Score 4) head injury (54% versus 43%, p < 0.01), Glasgow Coma Scale <= 8 less often (37% versus 47%, P=0.01), more skull fractures (20% versus 12%, p < 0.01), and underwent craniectomy more frequently (23% versus 4%, p < 0.001). Stepwise logistic regression identified beta-blocker use as an independent protective factor for mortality (adjusted odds ratio: 0.54; 95% CI, 0.33 to 0.91; p=0.01). On subgroup analysis, elderly patients (55 years or older) with severe head injury (Abbreviated Injury Score >= 4) had a mortality of 28% on beta-blockers as compared with 60% when they did not receive them (odds ratio: 0.3; 96% CI, 0.1 to 0.6; p=0.001). CONCLUSIONS: Beta-blockade in patients with traumatic brain injury was independently associated with improved survival. Older patients with severe head injuries demonstrated the largest reduction in mortality with beta-blockade.	[Inaba, Kenji; Teixeira, Pedro Gr; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Dept Surg, Div Trauma Surg & Surg Crit Care, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Keck Sch Med, Dept Emergency Med, Los Angeles, CA 90033 USA; [Beale, Elizabeth] Univ So Calif, Keck Sch Med, Div Endocrinol, Dept Med, Los Angeles, CA 90033 USA; [David, Jean-Stephane] Univ Lyon 1, Dept Anesthesia & Crit Care, F-69365 Lyon, France; [Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Brown, Carlos] Univ Texas Austin, Med Branch, Dept Surg, Brackenridge Hosp, Austin, TX USA; [Browder, Timothy] Univ Nevada, Sch Med, Div Trauma & Surg Crit Care, Las Vegas, NV 89154 USA; Univ Arizona, Div Trauma Surg Crit Care & Emergency Surg, Tucson, AZ USA		Inaba, K (corresponding author), Univ So Calif, Div Trauma Surg & Surg Crit Care, LAC Med Ctr, 1200 N State St,Room 10-750, Los Angeles, CA 90033 USA.		David, Jean Stephane/H-9399-2019; Teixeira, Pedro/H-2239-2011; INABA, KENJI/AAC-8532-2020	David, Jean Stephane/0000-0001-6274-7044; Teixeira, Pedro/0000-0002-7258-7977; 			ALEXANDER RW, 1975, NATURE, V258, P437, DOI 10.1038/258437a0; Amory DW, 2002, J CARDIOTHOR VASC AN, V16, P270, DOI 10.1053/jcan.2002.124132; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; *CDC, 2003, MMWR-MORBID MORTAL W, V56, P167; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Enderson BL, 2007, J TRAUMA, V62, P33; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P115, DOI 10.1007/BF00571658; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAWKINS WE, 1971, CARDIOVASC RES, V5, P524, DOI 10.1093/cvr/5.4.524; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489, DOI 10.1152/ajplegacy.1976.231.2.489; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Martin M, 2005, J TRAUMA, V59, P1086, DOI 10.1097/01.ta.0000190249.19668.37; MEYR JS, 1976, STROKE, V7, P145; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; Pryor JP, 2007, J TRAUMA, V62, P61; Simon RJ, 2004, J TRAUMA, V56, P269; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	28	92	93	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2008	206	3					432	438		10.1016/j.jamcollsurg.2007.10.005			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	271LR	WOS:000253790400005	18308212				2022-02-06	
B	Gaertner, DJ; Hallman, TM; Hankenson, FC; Batchelder, MA		Fish, RE; Brown, MJ; Danneman, PJ; Karas, AZ		Gaertner, Diane J.; Hallman, Troy M.; Hankenson, F. Claire; Batchelder, Margaret A.			Anesthesia and Analgesia for Laboratory Rodents	ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS, 2ND EDITION	American College of Laboratory Animal Medicine Series		English	Article; Book Chapter							MORPHINE-INDUCED ANALGESIA; ADULT MALE-RATS; KETAMINE-XYLAZINE ANESTHESIA; FENTANYL-DROPERIDOL DROPERIDOL; SPRAGUE-DAWLEY RATS; MU-OPIOID-RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LIPOSOME-ENCAPSULATED OXYMORPHONE; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE		[Gaertner, Diane J.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; [Hallman, Troy M.] Sch Vet Med, Univ Lab Anim Resources, Philadelphia, PA 19104 USA; [Hankenson, F. Claire] Univ Penn, Sch Vet Med, Univ Lab Anim Resources, Dept Pathobiol, Philadelphia, PA 19104 USA; [Batchelder, Margaret A.] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA		Gaertner, DJ (corresponding author), Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA.						Abbott FV, 1997, VET REC, V140, P553, DOI 10.1136/vr.140.21.553; Abbott FV, 2000, BEHAV BRAIN RES, V112, P177, DOI 10.1016/S0166-4328(00)00179-0; Abram SE, 1997, ANESTHESIOLOGY, V87, P127, DOI 10.1097/00000542-199707000-00017; Adachi YU, 2005, BRIT J ANAESTH, V95, P485, DOI 10.1093/bja/aei213; AKERMAN SBA, 1985, BRIT J ANAESTH, V57, P329, DOI 10.1093/bja/57.3.329; Alexander M, 2005, J SURG RES, V129, P161, DOI 10.1016/j.jss.2005.04.028; Alkire MT, 2005, ANESTHESIOLOGY, V103, P1167, DOI 10.1097/00000542-200512010-00010; Altholtz LY, 2006, J AM ASSOC LAB ANIM, V45, P17; AMOUZADEH HR, 1989, VET HUM TOXICOL, V31, P532; Antunes LM, 2003, EUR J ANAESTH, V20, P800, DOI 10.1097/00003643-200310000-00005; Antunes LM, 2003, VET ANAESTH ANALG, V30, P15, DOI 10.1046/j.1467-2995.2003.00085.x; Arevalo MI, 2004, ANESTH ANALG, V98, P1407, DOI 10.1213/01.ANE.0000107936.69436.5B; Arras M, 2001, COMPARATIVE MED, V51, P443; Asai T, 1998, BRIT J ANAESTH, V80, P814, DOI 10.1093/bja/80.6.814; Attia MA, 2004, INT J PHARM, V276, P11, DOI 10.1016/j.ijpharm.2004.01.041; BACKONJA MM, 1995, NEUROSCI LETT, V196, P61, DOI 10.1016/0304-3940(95)11844-M; Bagis H, 2004, LAB ANIM-UK, V38, P50, DOI 10.1258/00236770460734399; Barr GA, 1999, PAIN, V81, P155, DOI 10.1016/S0304-3959(99)00003-2; Barrett AC, 2002, EUR J PHARMACOL, V452, P163, DOI 10.1016/S0014-2999(02)02274-4; Bartok RE, 1997, J PHARMACOL EXP THER, V282, P769; BARZAGO MM, 1994, LAB ANIM SCI, V44, P648; Bauer DJ, 2003, CONTEMP TOP LAB ANIM, V42, P20; Beagles K, 2004, MOL PHARMACOL, V65, P437, DOI 10.1124/mol.65.2.437; Beiglbock C, 2003, J WILDLIFE DIS, V39, P665, DOI 10.7589/0090-3558-39.3.665; Beirith A, 1998, EUR J PHARMACOL, V345, P233, DOI 10.1016/S0014-2999(98)00026-0; Bekker A, 2006, ANESTH ANALG, V102, P1134, DOI 10.1213/01.ane.0000198637.36539.c1; Ben-Nathan D, 2000, ANN NY ACAD SCI, V917, P944; Benesova O, 2001, EUR NEUROPSYCHOPHARM, V11, P367, DOI 10.1016/S0924-977X(01)00102-X; Bickler PE, 2006, ANESTH ANALG, V103, P419, DOI 10.1213/01.ane.0000223671.49376.b2; Blais V, 2002, ENDOCRINOLOGY, V143, P4820, DOI 10.1210/en.2002-220598; BOHRER H, 1994, LAB ANIM SCI, V44, P326; Bolan EA, 2002, J PHARMACOL EXP THER, V303, P557, DOI 10.1124/jpet.102.035881; Borchard R.E., 1992, INTRO DRUG DOSAGE LA, pix; BRAMMER A, 1993, LAB ANIM, V27, P250, DOI 10.1258/002367793780745354; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P213; BRIGGS SL, 1995, PHARMACOL BIOCHEM BE, V52, P561, DOI 10.1016/0091-3057(95)00140-R; Brown ET, 2005, VISUAL NEUROSCI, V22, P615, DOI 10.1017/S0952523805225105; BROWN JN, 1989, LAB ANIM SCI, V39, P142; Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623-200401000-00017; Brown RH, 1999, J APPL PHYSIOL, V87, P2362, DOI 10.1152/jappl.1999.87.6.2362; Brown-Woodman PDC, 2004, TOXICOL IN VITRO, V18, P719, DOI 10.1016/j.tiv.2003.12.002; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; BRUGUEROLLE B, 1991, CHRONOBIOL INT, V8, P277, DOI 10.3109/07420529109063932; Brunson D.B., 1997, ANESTHESIA ANALGESIA; BUELKESAM J, 1978, LAB ANIM SCI, V28, P157; Buetow BS, 1999, CONTEMP TOP LAB ANIM, V38, P47; Buzaleh AM, 1996, GEN PHARMACOL, V27, P1009, DOI 10.1016/0306-3623(95)02137-X; CADRANEL JF, 1993, J CLIN GASTROENTEROL, V17, P52, DOI 10.1097/00004836-199307000-00015; CALCAGNETTI DJ, 1990, PHARMACOL BIOCHEM BE, V37, P193, DOI 10.1016/0091-3057(90)90061-L; CALDERONE L, 1986, EXP EYE RES, V42, P331, DOI 10.1016/0014-4835(86)90026-6; Campos AR, 2006, BIOL PHARM BULL, V29, P86, DOI 10.1248/bpb.29.86; Camprodon RAM, 2006, TRANSPLANT P, V38, P1857, DOI 10.1016/j.transproceed.2006.05.005; Cantwell Shauna L., 2001, Veterinary Clinics of North America Exotic Animal Practice, V4, P169; CAPETOLA RJ, 1983, J CLIN PHARMACOL, V23, P545, DOI 10.1002/j.1552-4604.1983.tb01802.x; Castonguay A, 1998, EXP LUNG RES, V24, P605, DOI 10.3109/01902149809087389; Ceccarelli I, 2006, NEUROSCIENCE, V140, P929, DOI 10.1016/j.neuroscience.2006.02.044; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Cetin N, 2005, LAB ANIM-UK, V39, P100, DOI 10.1258/0023677052886510; CHAU TT, 1989, J PHARMACOL EXP THER, V248, P907; Chen Kuan-Ting, 2002, Acta Anaesthesiol Sin, V40, P191; Chen NN, 2002, PROSTAG OTH LIPID M, V67, P143, DOI 10.1016/S0090-6980(01)00185-X; CHILD KJ, 1971, BRIT J ANAESTH, V43, P2, DOI 10.1093/bja/43.1.2-a; Choi SS, 2001, BRAIN RES, V921, P233, DOI 10.1016/S0006-8993(01)03126-2; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Chu DK, 2006, J AM ASSOC LAB ANIM, V45, P8; Cicero TJ, 2002, J PHARMACOL EXP THER, V300, P695, DOI 10.1124/jpet.300.2.695; Clark JA, 1997, LAB ANIM SCI, V47, P300; Clark MD, 2004, COMPARATIVE MED, V54, P558; Clifford D. H., 1984, Laboratory animal medicine, P527; Clowry GJ, 2000, LAB ANIM, V34, P260, DOI 10.1258/002367700780384771; COLE DJ, 1990, LAB ANIM SCI, V40, P506; COLPAERT FC, 1987, PAIN, V28, P201, DOI 10.1016/0304-3959(87)90117-5; COLPAERT FC, 1982, LIFE SCI, V31, P67, DOI 10.1016/0024-3205(82)90402-7; Colpaert FC, 2001, PAIN, V91, P33, DOI 10.1016/S0304-3959(00)00413-9; Craft RM, 2003, CLIN J PAIN, V19, P175, DOI 10.1097/00002508-200305000-00005; Craft RM, 2003, PHARMACOL BIOCHEM BE, V75, P235, DOI 10.1016/S0091-3057(03)00076-5; Craft RM, 2001, DRUG ALCOHOL DEPEN, V63, P215, DOI 10.1016/S0376-8716(00)00209-X; Crain SM, 2001, BRAIN RES, V888, P75, DOI 10.1016/S0006-8993(00)03010-9; CRIFO S, 1975, ORL J OTO-RHINO-LARY, V37, P27, DOI 10.1159/000275201; Cruz JI, 1998, LAB ANIM-UK, V32, P18, DOI 10.1258/002367798780559383; CUNNINGHAM MG, 1993, J NEUROSCI METH, V47, P105, DOI 10.1016/0165-0270(93)90026-N; CURL JL, 1983, LAB ANIM, V17, P290, DOI 10.1258/002367783781062361; CURL JL, 1988, LAB ANIM, V22, P309, DOI 10.1258/002367788780746269; D'Amato FR, 1998, BEHAV PHARMACOL, V9, P369; D'Elia M, 2003, CLIN IMMUNOL, V109, P179, DOI 10.1016/S1521-6616(03)00177-3; DADA MO, 1992, LIFE SCI, V51, P29; DALKARA T, 1995, J CEREBR BLOOD F MET, V15, P631, DOI 10.1038/jcbfm.1995.78; DALLEINNE CP, 1982, VET HUM TOXICOL, V24, P410; Danneman PJ, 1997, LAB ANIM SCI, V47, P386; DAVIS A, 1993, AGENTS ACTIONS, V38, pC10, DOI 10.1007/BF01991121; DELMONTE M, 1990, BRIT J PHARMACOL, V99, P582; DeSouza AC, 1997, PHARMACOL BIOCHEM BE, V56, P481, DOI 10.1016/S0091-3057(96)00246-8; Diaz-Reval MI, 2001, ARCH MED RES, V32, P13, DOI 10.1016/S0188-4409(00)00268-X; Dimaculangan D, 2006, J NEUROSURG ANESTH, V18, P78, DOI 10.1097/01.ana.0000194705.67834.09; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Dittmar MS, 2004, COMPARATIVE MED, V54, P652; Doretto MC, 1998, NEUROREPORT, V9, P2415, DOI 10.1097/00001756-199807130-00048; DRETCHEN K, 1971, ANESTHESIOLOGY, V34, P463, DOI 10.1097/00000542-197105000-00024; Drobac E, 2004, PHYSIOL BEHAV, V82, P279, DOI 10.1016/j.physbeh.2004.03.013; DUBOIS M A, 1981, Journal of Microsurgery, V3, P107; DWYER RC, 1994, ANESTHESIOLOGY, V81, P403, DOI 10.1097/00000542-199408000-00019; Easterly ME, 2001, LAB ANIMAL, V30, P46; EBERT B, 1995, NEUROSCI LETT, V187, P165, DOI 10.1016/0304-3940(95)11364-3; Efstathiou JA, 2005, FERTIL STERIL, V83, P171, DOI 10.1016/j.fertnstert.2004.06.058; EGER RP, 1995, CAN J ANAESTH, V42, P173, DOI 10.1007/BF03028273; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; Elena G, 2003, LAB ANIM-UK, V37, P193, DOI 10.1258/002367703766453038; Elena G, 1997, INT J IMMUNOPHARMACO, V19, P699; Engelhard K, 1999, BRIT J ANAESTH, V83, P415, DOI 10.1093/bja/83.3.415; ENGELHARDT G, 1995, INFLAMM RES, V44, P423, DOI 10.1007/BF01757699; Epemolu O, 2003, ANESTHESIOLOGY, V99, P632, DOI 10.1097/00000542-200309000-00018; Erbil Y, 1998, ACTA CHIR BELG, V98, P245; Erhan E, 2005, METHOD FIND EXP CLIN, V27, P629, DOI 10.1358/mf.2005.27.9.939337; Erichsen HK, 2005, PAIN, V116, P347, DOI 10.1016/j.pain.2005.05.004; FAGIOLI S, 1990, BRAIN RES, V510, P150, DOI 10.1016/0006-8993(90)90743-U; Fang ZX, 1997, ANESTH ANALG, V84, P852, DOI 10.1097/00000539-199704000-00028; Ferrari L, 2005, COMPARATIVE MED, V55, P256; Field K.J., 1988, THESIS LAB ANIMAL ME, P104; FIELD KJ, 1988, LAB ANIM, V22, P255, DOI 10.1258/002367788780746331; FIELD KJ, 1993, LAB ANIM, V27, P258, DOI 10.1258/002367793780745471; Filaretov A A, 1996, Neurosci Behav Physiol, V26, P572, DOI 10.1007/BF02359502; FILE SE, 1988, J PHARM PHARMACOL, V40, P57, DOI 10.1111/j.2042-7158.1988.tb05152.x; FINSTER M, 1972, ANESTHESIOLOGY, V36, P159, DOI 10.1097/00000542-197202000-00017; Fitzpatrick LR, 1999, ALIMENT PHARM THER, V13, P1553; Flecknell P. A., 1996, LAB ANIMAL ANAESTHES; FLECKNELL PA, 1991, LAB ANIM, V25, P50, DOI 10.1258/002367791780808239; FLECKNELL PA, 1990, LAB ANIM-UK, V24, P142, DOI 10.1258/002367790780890121; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; Flecknell PA, 1999, LAB ANIM, V33, P169, DOI 10.1258/002367799780578381; FLECKNELL PA, 1993, METHOD ENZYMOL, V225, P16; FLECKNELL PA, 1993, BRIT J ANAESTH, V71, P885, DOI 10.1093/bja/71.6.885; Flecknell PA, 1999, VET REC, V144, P65, DOI 10.1136/vr.144.3.65; FLECKNELL PA, 1984, LAB ANIM, V18, P147, DOI 10.1258/002367784780891226; Flecknell PA., 1987, J ASS VET ANAESTHETI, V17, P111; FLECKNELL PA, 1987, LAB ANIMAL ANAESTHES; FLEISCHMAN RW, 1977, LAB ANIM SCI, V27, P238; Flood P, 2002, ANESTHESIOLOGY, V97, P192, DOI 10.1097/00000542-200207000-00027; FORSYTHE DB, 1992, LAB ANIM SCI, V42, P497; FRASE BA, 1989, J WILDLIFE DIS, V25, P444, DOI 10.7589/0090-3558-25.3.444; FU ES, 1995, REGION ANESTH, V20, P291; Furukawa S, 1998, LAB ANIM SCI, V48, P357; Gades NM, 2000, CONTEMP TOP LAB ANIM, V39, P8; GAERTNER DJ, 1987, LAB ANIM SCI, V37, P80; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; Gaveriaux-Ruff C, 1998, P NATL ACAD SCI USA, V95, P6326, DOI 10.1073/pnas.95.11.6326; GAWRISCH E, 1990, CRIT CARE MED, V18, P1034, DOI 10.1097/00003246-199009000-00022; Genedani S, 1999, EUR J PHARMACOL, V367, P13, DOI 10.1016/S0014-2999(98)00966-2; GIBBS NM, 1989, ANESTHESIOLOGY, V71, P214; Gillingham MB, 2001, CONTEMP TOP LAB ANIM, V40, P21; GILROY BA, 1980, VET MED SM ANIM CLIN, V75, P508; Giraud O, 2000, AM J RESP CRIT CARE, V162, P2278, DOI 10.1164/ajrccm.162.6.9807113; Giraud O, 2003, ANESTHESIOLOGY, V98, P74, DOI 10.1097/00000542-200301000-00015; GLEN JB, 1980, BRIT J ANAESTH, V52, P731, DOI 10.1093/bja/52.8.731; Goecke JC, 2005, COMPARATIVE MED, V55, P37; Gong DH, 1998, ANESTH ANALG, V86, P198, DOI 10.1097/00000539-199801000-00038; Gonzalez MI, 2000, PAIN, V88, P79, DOI 10.1016/S0304-3959(00)00309-2; Gopalan C, 2005, CONTEMP TOP LAB ANIM, V44, P7; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; Goto T, 1996, BRIT J ANAESTH, V76, P702, DOI 10.1093/bja/76.5.702; Gotoh H, 2004, EXP ANIM TOKYO, V53, P63, DOI 10.1538/expanim.53.63; Gourine AV, 2003, J PHYSIOL-LONDON, V552, P197, DOI 10.1113/jphysiol.2003.045294; Graham MD, 2004, BIOPHYS J, V86, p48A; GRANADOSSOTO V, 1995, METHOD FIND EXP CLIN, V17, P535; GREEN C J, 1975, Laboratory Animals (London), V9, P161, DOI 10.1258/002367775780994574; GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; GREEN CJ, 1978, LAB ANIM, V12, P85, DOI 10.1258/002367778780953206; Greenwood-Van Meerveld B, 2004, NEUROGASTROENT MOTIL, V16, P46, DOI 10.1111/j.1743-3150.2004.00555.x; Gringauz M, 2001, J Anesth, V15, P204, DOI 10.1007/s005400170004; Groeben H, 2003, BRIT J ANAESTH, V91, P541, DOI 10.1093/bja/aeg222; Gross M. E., 2001, Veterinary pharmacology and therapeutics, P299; Gultekin H, 2006, ADV THER, V23, P39, DOI 10.1007/BF02850345; Gupta A, 2001, PHARMACOL BIOCHEM BE, V68, P635, DOI 10.1016/S0091-3057(00)00475-5; Gupta SK, 2002, SKIN PHARMACOL APPL, V15, P105, DOI 10.1159/000049397; GURTU S, 1994, NEUROREPORT, V5, P715, DOI 10.1097/00001756-199402000-00014; Haberham ZL, 1999, LAB ANIM, V33, P47, DOI 10.1258/002367799780578570; Hacker SO, 2005, CONTEMP TOP LAB ANIM, V44, P7; Haelewyn B, 2004, BRIT J ANAESTH, V92, P552, DOI 10.1093/bja/aeh100; Hahn N, 2005, LAB ANIMAL, V34, P48, DOI 10.1038/laban0205-48; Hall L. W., 2001, VET ANAESTHESIA, P113; Hall TJ, 1996, INFLAMM RES, V45, P299, DOI 10.1007/BF02280995; Hamura H, 2000, JPN J PHARMACOL, V83, P286, DOI 10.1254/jjp.83.286; Hanson CE, 2001, COMPARATIVE MED, V51, P224; Haque SF, 2004, J REPROD DEVELOP, V50, P185, DOI 10.1262/jrd.50.185; HARKNESS JE, 1995, BIOL MED RABBITS ROD; HART MV, 1984, AM J VET RES, V45, P2328; Haseneder R, 2004, ANESTH ANALG, V98, P1718, DOI 10.1213/01.ANE.0000112309.80017.3F; Hasirci V, 2003, LIFE SCI, V73, P3323, DOI 10.1016/S0024-3205(03)00615-5; HASSAN HG, 1989, REGION ANESTH, V14, P138; HASSAN HG, 1993, ACTA ANAESTH SCAND, V37, P70, DOI 10.1111/j.1399-6576.1993.tb03601.x; Hawk CT., 2005, FORMULARY LAB ANIMAL, V3rd ed; Hayashi H, 2002, PAEDIATR ANAESTH, V12, P770, DOI 10.1046/j.1460-9592.2002.00883.x; Hayes JH, 1999, LAB ANIM-UK, V33, P16, DOI 10.1258/002367799780578534; Hayes KE, 2000, CONTEMP TOP LAB ANIM, V39, P18; Hayton SM, 1999, LAB ANIM-UK, V33, P243, DOI 10.1258/002367799780578219; Heard D.J., 2004, ANESTHESIA ANALGESIA; Heavner J.E., 1997, AM COLL LAB ANIMAL M; Heavner JE, 2001, COMPARATIVE MED, V51, P500; Hedenqvist P, 2000, LAB ANIM-UK, V34, P244, DOI 10.1258/002367700780384762; Hedenqvist P, 2000, LAB ANIM, V34, P207, DOI 10.1258/002367700780457536; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; HENNING RH, 1993, BRIT J PHARMACOL, V108, P717, DOI 10.1111/j.1476-5381.1993.tb12867.x; Hernandez-Delgadillo GP, 2006, EUR J PHARMACOL, V546, P54, DOI 10.1016/j.ejphar.2006.07.027; Hernandez-Delgadillo GP, 2004, EUR J PHARMACOL, V502, P67, DOI 10.1016/j.ejphar.2004.08.032; Hernandez-Delgadillo GP, 2003, EUR J PHARMACOL, V469, P71, DOI 10.1016/S0014-2999(03)01727-8; Hernandez-Delgadillo GP, 2002, EUR J PHARMACOL, V441, P177, DOI 10.1016/S0014-2999(02)01344-4; Herrero JF, 1996, BRIT J PHARMACOL, V118, P968, DOI 10.1111/j.1476-5381.1996.tb15494.x; Hertl MC, 1998, REGION ANESTH PAIN M, V23, P152, DOI 10.1136/rapm-00115550-199823020-00007; Hildebrand S.V., 1997, PARALYTIC AGENTS; HIRST M, 1984, CAN J PHYSIOL PHARM, V62, P1102, DOI 10.1139/y84-184; HOAR RM, 1969, FED PROC, V28, P1517; Hockertz S, 1996, ARZNEIMITTEL-FORSCH, V46, P1012; Hoff JB, 2006, J AM ASSOC LAB ANIM, V45, P57; HRAPKIEWICZ KL, 1989, LAB ANIM SCI, V39, P338; HSU WH, 1986, J AM VET MED ASSOC, V189, P1040; HSU WH, 1982, EUR J PHARMACOL, V83, P55, DOI 10.1016/0014-2999(82)90285-0; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Hu GC, 2003, ANESTHESIOLOGY, V98, P712, DOI 10.1097/00000542-200303000-00020; Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X; Huang C, 2002, BRAIN RES, V945, P20, DOI 10.1016/S0006-8993(02)02503-9; Huang Y, 2005, ACTA ANAESTH SCAND, V49, P1544, DOI 10.1111/j.1399-6576.2005.00760.x; HUGHES EW, 1982, CLIN EXP PHARMACOL P, V9, P119, DOI 10.1111/j.1440-1681.1982.tb00788.x; Iltis I, 2005, J MAGN RESON IMAGING, V22, P242, DOI 10.1002/jmri.20352; Imai T, 1998, CAN J ANAESTH, V45, P360, DOI 10.1007/BF03012029; Ingalls CP, 1996, J APPL PHYSIOL, V80, P332, DOI 10.1152/jappl.1996.80.1.332; Institute for Laboratory Animal Research (U.S. ) (ILAR). Commission on Life Sciences N. R. C. U. S., 1996, GUID CAR US LAB AN; Institute for Laboratory Animal Research (U. S. ) (ILAR). Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research and N. R. Council, 2003, GUID CAR US MAMM NEU; Institute for LaboratoryAnimal Research (U.S. ) (ILAR). Committee on Pain and Distress in Laboratory Animals N. R. C., 1992, REC ALL PAIN DISTR L; IRAC,, 1985, US GOV PRINC UT CAR US GOV PRINC UT CAR; Jablonski P, 2002, LAB ANIM-UK, V36, P134, DOI 10.1258/0023677021912415; Jablonski P, 2001, LAB ANIM-UK, V35, P213, DOI 10.1258/0023677011911651; Jacobsen KO, 2004, CONTEMP TOP LAB ANIM, V43, P8; Jacobson C, 2000, LAB ANIM, V34, P202, DOI 10.1258/002367700780457509; Jacobson C, 2001, LAB ANIM-UK, V35, P271, DOI 10.1258/0023677011911598; Jain NK, 2002, LIFE SCI, V70, P2857, DOI 10.1016/S0024-3205(02)01549-7; Jain Subheet, 2005, Current Drug Delivery, V2, P223, DOI 10.2174/1567201054368020; Jang S, 2006, ARCH PHARM RES, V29, P677, DOI 10.1007/BF02968252; Janicki PK, 1996, LIFE SCI, V59, pPL269, DOI 10.1016/0024-3205(96)00477-8; Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003; Jaquenod M, 1998, ANESTH ANALG, V86, P1090, DOI 10.1097/00000539-199805000-00036; JAUCHEM JR, 1991, LAB ANIM SCI, V41, P70; Javan M, 2006, BRAIN RES, V1104, P73, DOI 10.1016/j.brainres.2006.05.088; Ji YP, 2006, AM J PHYSIOL-REG I, V291, pR307, DOI 10.1152/ajpregu.00824.2005; Jobin N, 2000, CELL IMMUNOL, V200, P65, DOI 10.1006/cimm.2000.1619; JOHANSEN O, 1994, LAB ANIM, V28, P244, DOI 10.1258/002367794780681723; Jong WMC, 2002, CONTEMP TOP LAB ANIM, V41, P28; Joshi SK, 2006, NEUROSCIENCE, V143, P587, DOI 10.1016/j.neuroscience.2006.08.005; Jou IM, 2000, J APPL PHYSIOL, V89, P1766, DOI 10.1152/jappl.2000.89.5.1766; Jungwirth B, 2006, ANESTHESIOLOGY, V104, P770, DOI 10.1097/00000542-200604000-00022; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Kalinichev M, 2001, PSYCHOPHARMACOLOGY, V157, P305, DOI 10.1007/s002130100806; Kanaan SA, 1997, PHARMACOLOGY, V54, P285, DOI 10.1159/000139498; Kanarek RB, 1997, PHARMACOL BIOCHEM BE, V58, P43, DOI 10.1016/S0091-3057(96)00470-4; Kandatsu N, 2005, ANESTHESIOLOGY, V102, P1182, DOI 10.1097/00000542-200506000-00018; KANUI TI, 1990, COMP BIOCHEM PHYS C, V96, P131, DOI 10.1016/0742-8413(90)90057-G; Karas AZ, 2002, LAB ANIMAL, V31, P49; Karuri AR, 1998, BRAIN RES BULL, V47, P205, DOI 10.1016/S0361-9230(98)00072-0; Kashimoto S, 1997, EUR J ANAESTH, V14, P359, DOI 10.1046/j.1365-2346.1997.00092.x; Kastl S, 2004, ADV PHYSIOL EDUC, V28, P29, DOI 10.1152/advan.00008.2003; Katz Y, 2002, J MED VIROL, V66, P576, DOI 10.1002/jmv.2184; Kavaliers M, 1997, BRAIN RES, V766, P11, DOI 10.1016/S0006-8993(97)00521-0; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; KAYSER V, 1991, EUR J PHARMACOL, V195, P37, DOI 10.1016/0014-2999(91)90379-5; Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476; Kennedy BW, 2002, LAB ANIMAL, V31, P34; Kest B, 1999, J PHARMACOL EXP THER, V289, P1370; Kharasch ED, 2006, TOXICOL SCI, V90, P419, DOI 10.1093/toxsci/kfj088; Kharasch ED, 1999, ANESTHESIOLOGY, V91, P1267, DOI 10.1097/00000542-199911000-00017; Kiatchoosakun S, 2001, COMPARATIVE MED, V51, P26; Kilgore JL, 2003, TEX J SCI, V55, P149; Kim H, 2006, TOXICOLOGY, V220, P169, DOI 10.1016/j.tox.2005.12.010; Kim T, 1996, ANESTHESIOLOGY, V85, P331, DOI 10.1097/00000542-199608000-00015; KIPP DE, 1989, INT J VITAM NUTR RES, V59, P172; Kirsch JH, 2002, CONTEMP TOP LAB ANIM, V41, P9; Kissin I, 1996, ANESTH ANALG, V83, P600, DOI 10.1097/00000539-199609000-00029; KLIDE AM, 1967, J PHARMACOL EXP THER, V158, P28; KOBAYASHI K, 1985, EXP ANIM TOKYO, V34, P379, DOI 10.1538/expanim1978.34.4_379; Koblin DD, 1998, ANESTH ANALG, V87, P419, DOI 10.1097/00000539-199808000-00035; Koch VW, 2006, LAB ANIMAL, V35, P27, DOI 10.1038/laban0506-27; Kohler I, 1999, LAB ANIM, V33, P155, DOI 10.1258/002367799780578390; Kolesnikov Y, 1999, J PHARMACOL EXP THER, V290, P247; Kolesnikov YA, 2000, J PHARMACOL EXP THER, V295, P546; Kolesnikov YA, 2003, ANESTH ANALG, V97, P1721, DOI 10.1213/01.ANE.0000087801.20395.97; Komatsu H, 1998, ANESTHESIOLOGY, V89, P1184, DOI 10.1097/00000542-199811000-00019; KOMULAINEN A, 1991, AM J VET RES, V52, P585; Konat GW, 2003, METAB BRAIN DIS, V18, P11, DOI 10.1023/A:1021922500998; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; Koo ST, 2002, PAIN, V99, P423, DOI 10.1016/S0304-3959(02)00164-1; Kopjas NN, 2006, EPILEPSY RES, V69, P87, DOI 10.1016/j.eplepsyres.2005.12.001; Krugner-Higby L, 2003, COMPARATIVE MED, V53, P270; Kubota T, 1999, BRAIN RES, V840, P175, DOI 10.1016/S0006-8993(99)01793-X; KUFOY EA, 1989, EXP EYE RES, V49, P861, DOI 10.1016/S0014-4835(89)80045-4; Kumar SGV, 2006, METHOD FIND EXP CLIN, V28, P419, DOI 10.1358/mf.2006.28.7.1003549; KUPERS R, 1995, PAIN, V60, P137, DOI 10.1016/0304-3959(94)00106-O; Kuratani N, 1996, ANESTH ANALG, V83, P798, DOI 10.1097/00000539-199610000-00025; Laber-Laird K, 1996, HDB RODENT RABBIT ME; Laird JMA, 1996, INFLAMM RES, V45, P150, DOI 10.1007/BF02265170; Laird JMA, 1997, INFLAMM RES, V46, P203, DOI 10.1007/s000110050174; Laird JMA, 1998, INFLAMM RES, V47, P389, DOI 10.1007/s000110050349; Langford DJ, 2006, SCIENCE, V312, P1967, DOI 10.1126/science.1128322; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Lawson DM, 2001, CONTEMP TOP LAB ANIM, V40, P18; Leach MC, 2002, VET REC, V150, P808, DOI 10.1136/vr.150.26.808; Leach MC, 2002, COMPARATIVE MED, V52, P249; LEASH AM, 1973, LAB ANIM SCI, V23, P720; Lee SC, 1997, ANESTH ANALG, V84, P810, DOI 10.1097/00000539-199704000-00021; LEEUWIN RS, 1984, BRIT J PHARMACOL, V82, P339, DOI 10.1111/j.1476-5381.1984.tb10768.x; LEGROS J, 1984, ARCH INT PHARMACOD T, V271, P11; Lemke KA, 1996, J AM VET MED ASSOC, V209, P776; Lerche P, 2000, J AM VET MED ASSOC, V217, P485, DOI 10.2460/javma.2000.217.485; LEVIN LL, 1986, ANESTH ANALG, V65, P330; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; Liang DY, 2006, PAIN, V121, P232, DOI 10.1016/j.pain.2005.12.026; Lieggi CC, 2005, CONTEMP TOP LAB ANIM, V44, P11; Lieggi CC, 2005, CONTEMP TOP LAB ANIM, V44, P17; LIGHTFOOTE WE, 1978, AM J VET RES, V39, P1061; LILES JH, 1994, J VET PHARMACOL THER, V17, P284, DOI 10.1111/j.1365-2885.1994.tb00247.x; Liles JH, 1998, LAB ANIM, V32, P149, DOI 10.1258/002367798780600025; LIN MT, 1978, CAN J PHYSIOL PHARM, V56, P963, DOI 10.1139/y78-153; LIND RC, 1987, ANESTH ANALG, V66, P222; LIND RC, 1989, ANESTHESIOLOGY, V71, P878, DOI 10.1097/00000542-198912000-00011; Linden RD, 2000, CONTEMP TOP LAB ANIM, V39, P40; Lindsay DS, 2005, J PARASITOL, V91, P1488, DOI 10.1645/GE-732R.1; LIPMAN NS, 1987, LAB ANIM SCI, V37, P474; Liu KS, 2004, BRIT J ANAESTH, V92, P712, DOI 10.1093/bja/aeh126; Loepke AW, 2006, ANESTH ANALG, V102, P75, DOI 10.1213/01.ANE.0000181102.92729.B8; LOOMIS CW, 1989, ANESTHESIOLOGY, V71, P704, DOI 10.1097/00000542-198911000-00013; Lorenz JN, 2002, AM J PHYSIOL-REG I, V282, pR1565, DOI 10.1152/ajpregu.00759.2001; LUCIANO L, 1992, ARCH HISTOL CYTOL, V55, P131, DOI 10.1679/aohc.55.Suppl_131; Lumb W.V., 1984, LUMB JONES VET ANEST; LUNAM CA, 1985, J PHARMACOL EXP THER, V232, P802; Lutz M, 2006, ANESTH ANALG, V102, P984, DOI 10.1213/01.ane.0000198568.79079.4c; MACDONALD E, 1989, ACTA VET SCAND, P77; MAHELOVA O, 1991, PHYSIOL RES, V40, P355; Malik AA, 2002, J ENDOUROL, V16, P605, DOI 10.1089/089277902320913314; MARIANI L, 1978, TOXICOL APPL PHARM, V45, P637, DOI 10.1016/0041-008X(78)90126-6; Martin LBE, 2001, COMPARATIVE MED, V51, P43; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; Matson DJ, 2007, J PHARMACOL EXP THER, V320, P194, DOI 10.1124/jpet.106.109736; Matsuura S, 2006, ANESTH ANALG, V102, P1703, DOI 10.1213/01.ane.0000216001.36932.a3; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCLAUGHLIN CR, 1994, PHARMACOL BIOCHEM BE, V49, P1017, DOI 10.1016/0091-3057(94)90258-5; McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P1241, DOI 10.1038/sj.npp.1300872; Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7; Lopez JRM, 2006, EUR J PHARMACOL, V544, P31, DOI 10.1016/j.ejphar.2006.06.041; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Mellon RD, 2001, DRUG ALCOHOL DEPEN, V62, P141, DOI 10.1016/S0376-8716(00)00184-8; MERTENS J, 1991, EUR ARCH OTO-RHINO-L, V248, P402, DOI 10.1007/BF01463563; MESSIHA FS, 1991, NEUROTOXICOLOGY, V12, P571; Mets B, 1997, ACTA ANAESTH SCAND, V41, P252, DOI 10.1111/j.1399-6576.1997.tb04675.x; Metten P, 2007, BEHAV GENET, V37, P160, DOI 10.1007/s10519-006-9094-3; Meyer RE, 2005, LAB ANIMAL, V34, P47, DOI 10.1038/laban1105-47; Mickley GA, 2006, J AM ASSOC LAB ANIM, V45, P48; MILANES MV, 1984, GEN PHARMACOL, V15, P357, DOI 10.1016/0306-3623(84)90015-6; Millecamps M, 2005, ARTHRITIS RHEUM-US, V52, P3470, DOI 10.1002/art.21403; MIMURA M, 1990, PSYCHOPHARMACOLOGY, V102, P399, DOI 10.1007/BF02244110; MIMURA M, 1992, ACTA ANAESTH SCAND, V36, P460, DOI 10.1111/j.1399-6576.1992.tb03497.x; MISHRA Y, 1992, CAN J ANAESTH, V39, P370, DOI 10.1007/BF03009048; MISHRA Y, 1993, ANESTH ANALG, V77, P780; MISHRA Y, 1992, CLIN EXP PHARMACOL P, V19, P803, DOI 10.1111/j.1440-1681.1992.tb00418.x; MISHRA Y, 1993, CAN J ANAESTH, V40, P32, DOI 10.1007/BF03009315; MISHRA Y, 1993, ANESTH ANALG, V76, P627; MOLINA VA, 1994, PSYCHOPHARMACOLOGY, V114, P433, DOI 10.1007/BF02249333; Molthen RC, 2006, J AM ASSOC LAB ANIM, V45, P88; MORCH ET, 1956, J PHARMACOL EXP THER, V117, P184; Morimoto K, 2001, J VET MED A, V48, P303, DOI 10.1046/j.1439-0442.2001.00360.x; MUIR WA, 1989, HDB VET ANESTHESIA; MULDER JB, 1978, LAB ANIM SCI, V28, P70; MULDER JB, 1978, J AM VET MED ASSOC, V173, P1252; MULDER KJ, 1979, VET MED SM ANIM CLIN, V74, P569; Nadeson R, 2000, PAIN, V88, P31, DOI 10.1016/S0304-3959(00)00300-6; National Institute for Occupational Safety and Health, 1977, CRIT REC STAND OCC E; Nelson CJ, 1997, ANESTH ANALG, V85, P620, DOI 10.1097/00000539-199709000-00024; NEMETH S, 1985, ENDOCRINOL EXP, V19, P91; NEUGEBAUER V, 1994, AGENTS ACTIONS, V41, P62, DOI 10.1007/BF01986396; NEVALAINEN T, 1989, ACTA VET SCAND, P139; NEWTON WM, 1975, LAB ANIM SCI, V25, P597; Nielsen AN, 2004, EUR J PHARMACOL, V487, P93, DOI 10.1016/j.ejphar.2004.01.017; NIELSEN GD, 1985, ACTA PHARMACOL TOX, V56, P165; Nikfar S, 1997, GEN PHARMACOL-VASC S, V29, P583, DOI 10.1016/S0306-3623(96)00575-7; Nishiyama T, 2006, ACTA ANAESTH SCAND, V50, P228, DOI 10.1111/j.1399-6576.2006.00921.x; Njoku D, 1997, ANESTH ANALG, V84, P173, DOI 10.1097/00000539-199701000-00031; Noguchi M, 2005, EUR J PHARMACOL, V513, P229, DOI 10.1016/j.ejphar.2005.01.058; NORRIS ML, 1983, LAB ANIM, V17, P324, DOI 10.1258/002367783781062370; Noseworthy MD, 1997, J BIOCHEM BIOPH METH, V34, P107, DOI 10.1016/S0165-022X(97)01207-4; NOTARNICOLA A, 1983, LIFE SCI, V33, P481, DOI 10.1016/0024-3205(83)90546-5; Obal D, 2003, CAN J ANAESTH, V50, P940, DOI 10.1007/BF03018744; Obal D, 2001, BRIT J ANAESTH, V87, P905, DOI 10.1093/bja/87.6.905; Office of Laboratory Animal Welfar, 2002, PUBL HLTH SERV POL H; Ogawa A, 2003, NEUROSCIENCE, V120, P1081, DOI 10.1016/S0306-4522(03)00214-8; OLSON ME, 1988, LAB ANIM SCI, V38, P299; OLSON ME, 1986, J AM VET MED ASSOC, V189, P1035; Omisore NOA, 2004, J ETHNOPHARMACOL, V95, P7, DOI 10.1016/j.jep.2004.05.022; Ordodi VL, 2005, LAB ANIMAL, V34, P37, DOI 10.1038/laban0905-37; Oropeza-Hernandez LF, 2002, PHARMACOL BIOCHEM BE, V72, P937, DOI 10.1016/S0091-3057(02)00767-0; Ortiz MI, 2002, EUR J PHARMACOL, V438, P85, DOI 10.1016/S0014-2999(02)01288-8; OSTROWSKI NL, 1979, PHARMACOL BIOCHEM BE, V11, P673, DOI 10.1016/0091-3057(79)90261-2; Ozdogan UK, 2006, EUR J PHARMACOL, V529, P105, DOI 10.1016/j.ejphar.2005.10.029; Ozdogan UK, 2004, EUR J PHARMACOL, V497, P161, DOI 10.1016/j.ejphar.2004.06.051; Paddleford R R, 1986, Semin Vet Med Surg Small Anim, V1, P249; Padi SSV, 2004, EUR J PHARMACOL, V491, P69, DOI 10.1016/j.ejphar.2004.03.013; Page GG, 2002, J PAIN, V3, P301, DOI 10.1054/jpai.2002.125184; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Pape M, 2006, ANESTH ANALG, V103, P173, DOI 10.1213/01.ane.0000222634.51192.a4; Paris A, 2005, ANESTH ANALG, V100, P102, DOI 10.1213/01.ANE.0000139355.86522.D1; Park KW, 1998, ANESTH ANALG, V86, P646, DOI 10.1097/00000539-199803000-00039; Park WK, 1996, ANESTHESIOLOGY, V84, P1166, DOI 10.1097/00000542-199605000-00019; Parkhill AL, 2006, INT IMMUNOPHARMACOL, V6, P1013, DOI 10.1016/j.intimp.2006.01.012; PAVONE F, 1989, DEV BRAIN RES, V49, P156, DOI 10.1016/0165-3806(89)90071-0; Payne RS, 2005, BRAIN RES, V1034, P147, DOI 10.1016/j.brainres.2004.12.006; PAYTON AJ, 1993, CORNELL VET, V83, P153; Penderis J, 2005, VET ANAESTH ANALG, V32, P256, DOI 10.1111/j.1467-2995.2005.00183.x; Perez-Garcia CC, 2003, LAB ANIM-UK, V37, P68, DOI 10.1258/002367703762226719; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; PHIFER CB, 1986, PHYSIOL BEHAV, V38, P887, DOI 10.1016/0031-9384(86)90058-2; Pick CG, 1996, EUR NEUROPSYCHOPHARM, V6, P201, DOI 10.1016/0924-977X(96)00021-1; PICK CG, 1991, BRAIN RES, V566, P295, DOI 10.1016/0006-8993(91)91712-A; Piersma FE, 1999, LAB ANIM-UK, V33, P328, DOI 10.1258/002367799780487887; Pinardi G, 2005, PHARMACOL BIOCHEM BE, V82, P120, DOI 10.1016/j.pbb.2005.07.017; Plachinta RV, 2003, ANESTHESIOLOGY, V98, P89, DOI 10.1097/00000542-200301000-00017; Planas E, 2003, EUR J PHARMACOL, V482, P223, DOI 10.1016/j.ejphar.2003.09.048; Plate AYA, 2005, ANESTH ANALG, V101, P1063, DOI 10.1213/01.ane.0000166791.30963.ef; Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008; POOLE T. B., 1987, UFAW HDB CARE MANAGE, V18a; Poonawala T, 2005, WOUND REPAIR REGEN, V13, P165, DOI 10.1111/j.1067-1927.2005.130207.x; Poveda R, 2003, EUR J PAIN, V7, P439, DOI 10.1016/S1090-3801(03)00003-X; Poyhia R, 1999, ANESTH ANALG, V89, P428, DOI 10.1097/00000539-199908000-00033; Prado WA, 2002, BRAZ J MED BIOL RES, V35, P111, DOI 10.1590/S0100-879X2002000100016; Prechel MM, 2000, NEUROCHEM RES, V25, P357, DOI 10.1023/A:1007588903897; Public Health Service (PHS), 2002, POL HUM CAR US LAB A; Puig NR, 1999, REPROD TOXICOL, V13, P361, DOI 10.1016/S0890-6238(99)00031-3; Radde GR, 1996, LAB ANIM-UK, V30, P220, DOI 10.1258/002367796780684935; Rampil IJ, 2006, ANESTH ANALG, V102, P1431, DOI 10.1213/01.ane.0000202384.96269.51; Rampil IJ, 1996, ANESTHESIOLOGY, V85, P129, DOI 10.1097/00000542-199607000-00018; Rana J, 1995, In Vivo, V9, P163; Randolph B C, 1997, Anesth Prog, V44, P11; Rank J., 1989, Scandinavian Journal of Laboratory Animal Science, V16, P115; RAO SB, 1990, INDIAN VET J, V67, P339; Reboucas ECC, 2005, PSYCHOPHARMACOLOGY, V179, P349, DOI 10.1007/s00213-004-2045-x; Redwine KE, 2003, PHARMACOL BIOCHEM BE, V76, P361, DOI 10.1016/j.pbb.2003.08.009; REID WD, 1989, LAB ANIM, V23, P156, DOI 10.1258/002367789780863592; Rembert MS, 2004, LAB ANIM-UK, V38, P55, DOI 10.1258/00236770460734407; Rhodes J, 2001, COMPARATIVE MED, V51, P457; Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rieg T, 2004, N-S ARCH PHARMACOL, V370, P320, DOI 10.1007/s00210-004-0982-x; Robertson Sheilah A., 2001, Veterinary Clinics of North America Exotic Animal Practice, V4, P1; Rodrigues SF, 2006, LIFE SCI, V79, P1630, DOI 10.1016/j.lfs.2006.05.019; Rofael HZ, 2003, TOXICOLOGY, V188, P101, DOI 10.1016/S0300-483X(03)00081-7; Rogers B, 1986, AAOHN J, V34, P574; Roughan JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002; Roughan JV, 1999, LAB ANIM-UK, V33, P234, DOI 10.1258/002367799780578183; Roughan JV, 2003, EUR J PAIN, V7, P397, DOI 10.1016/S1090-3801(02)00140-4; Roughan JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423; Roughan JV, 2001, PAIN, V90, P65, DOI 10.1016/S0304-3959(00)00387-0; Roy S, 2005, J NEUROSCI, V25, P3229, DOI 10.1523/JNEUROSCI.0332-05.2005; RUSSELL GB, 1995, PHARMACOLOGY, V50, P162, DOI 10.1159/000139278; Russell W. M. S., 1959, PRINCIPLES HUMANE EX; Sabetkasaie M, 2004, EUR J PHARMACOL, V501, P95, DOI 10.1016/j.ejphar.2004.08.010; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; SAGE MD, 1985, LAB ANIM SCI, V35, P153; Saito Osamu, 2005, J Anesth, V19, P218, DOI 10.1007/s00540-005-0323-3; Santos ARS, 1998, INFLAMM RES, V47, P302, DOI 10.1007/s000110050333; SARLIS N J, 1991, Middle East Journal of Anesthesiology, V11, P271; Sarraf-Yazdi S, 1999, J NEUROSURG ANESTH, V11, P31, DOI 10.1097/00008506-199901000-00006; Saurer TB, 2006, J NEUROIMMUNOL, V173, P3, DOI 10.1016/j.jneuroim.2005.11.009; SCHAEFER CF, 1984, J APPL PHYSIOL, V56, P533, DOI 10.1152/jappl.1984.56.2.533; SCHMIDT WK, 1985, DRUG ALCOHOL DEPEN, V14, P339, DOI 10.1016/0376-8716(85)90066-3; SCHOLER DW, 1986, AM J MED, V80, P34, DOI 10.1016/0002-9343(86)90077-X; SCHULTZ VL, 1995, J BONE MINER RES, V10, P1298; Schwenke DO, 2004, COMPARATIVE MED, V54, P77; Segato FN, 1997, BRAZ J MED BIOL RES, V30, P981, DOI 10.1590/S0100-879X1997000800011; Sendil D, 2003, BIOMATERIALS, V24, P1969, DOI 10.1016/S0142-9612(02)00567-7; Serita R, 2002, BRIT J ANAESTH, V89, P896, DOI 10.1093/bja/aef282; SEVERS WB, 1981, PHARMACOLOGY, V22, P209, DOI 10.1159/000137493; Sharma Sameer, 2005, Indian Journal of Experimental Biology, V43, P498; Sharp J, 2003, CONTEMP TOP LAB ANIM, V42, P22; Sheffels P, 2004, CHEM RES TOXICOL, V17, P1177, DOI 10.1021/tx049899e; Shin Y S, 1992, J Anesth, V6, P1; Shuey DL, 2007, TOXICOL SCI, V96, P162, DOI 10.1093/toxsci/kfl178; SILVERMAN J, 1993, LAB ANIM SCI, V43, P210; SILVERMAN J, 1986, LAB ANIM SCI, V36, P539; Silverman J, 2003, LAB ANIMAL, V32, P19, DOI 10.1038/laban1103-19a; SILVERMAN J, 1983, LAB ANIM SCI, V33, P457; Simpson DP, 1997, LAB ANIM SCI, V47, P519; Sintov AC, 2004, J CONTROL RELEASE, V95, P173, DOI 10.1016/j.jconrel.2003.11.004; Skeehan TM, 1995, J CARDIOTHOR VASC AN, V9, P706, DOI 10.1016/S1053-0770(05)80233-2; SKORNIK WA, 1990, J APPL PHYSIOL, V68, P2536, DOI 10.1152/jappl.1990.68.6.2536; Sluka KA, 2002, PAIN, V100, P183, DOI 10.1016/S0304-3959(02)00294-4; SMILER KL, 1990, LAB ANIM SCI, V40, P60; SMITH JA, 1993, SEMIN VET MED SURG, V8, P90; Smith JC, 2004, LAB ANIM-UK, V38, P38, DOI 10.1258/00236770460734371; Smith JC, 2003, CONTEMP TOP LAB ANIM, V42, P10; Smith LJ, 2006, COMPARATIVE MED, V56, P487; Smith LJ, 2003, COMPARATIVE MED, V53, P280; Smith MA, 2002, PSYCHOPHARMACOLOGY, V162, P255, DOI 10.1007/s00213-002-1102-6; Smith MA, 2001, PSYCHOPHARMACOLOGY, V156, P445, DOI 10.1007/s002130100750; Smith DE, 1999, CONTEMP TOP LAB ANIM, V38, P84; Smith LJ, 2002, PAIN, V97, P267, DOI 10.1016/S0304-3959(02)00028-3; Smith MA, 2003, PSYCHOPHARMACOLOGY, V168, P426, DOI 10.1007/s00213-003-1471-5; Sonner JM, 1999, ANESTH ANALG, V89, P1030, DOI 10.1097/00000539-199910000-00039; Sonner JM, 2000, ANESTH ANALG, V91, P720, DOI 10.1213/00000539-200009000-00042; SORAHAN T, 1993, BRIT J IND MED, V50, P528; STACKMAN RW, 1992, BEHAV NEURAL BIOL, V57, P233, DOI 10.1016/0163-1047(92)90206-J; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Steffey MA, 2003, AM J VET RES, V64, P470, DOI 10.2460/ajvr.2003.64.470; Sternberg WF, 2005, PAIN, V113, P347, DOI 10.1016/j.pain.2004.11.013; Sternberg WF, 2004, NEUROSCI LETT, V363, P178, DOI 10.1016/j.neulet.2004.04.004; STERNBERG WF, 1995, EUR J ANAESTH, V12, P14; Sternberg WF, 2003, PHYSIOL BEHAV, V78, P375, DOI 10.1016/S0031-9384(03)00015-5; Stevenson GW, 2006, J PAIN, V7, P408, DOI 10.1016/j.jpain.2006.01.447; Stewart LSA, 2003, COMPARATIVE MED, V53, P29; Stewart LSA, 2003, CONTEMP TOP LAB ANIM, V42, P28; Stringer SK, 1996, LAB ANIM SCI, V46, P430; Suganuma T, 1998, BIOL PHARM BULL, V21, P756; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; Sunaga H, 2006, ANESTH ANALG, V103, P601, DOI 10.1213/01.ane.0000229720.13815.73; Szczesny G, 2004, LAB ANIM-UK, V38, P64, DOI 10.1258/00236770460734416; Taira Y, 2000, BRIT J ANAESTH, V85, P881, DOI 10.1093/bja/85.6.881; Takada K, 2002, ANESTHESIOLOGY, V96, P1420, DOI 10.1097/00000542-200206000-00022; Takahashi K, 1997, ANESTH ANALG, V85, P347, DOI 10.1097/00000539-199708000-00019; Takahashi M, 2005, REGION ANESTH PAIN M, V30, P351, DOI 10.1016/j.rapm.2005.04.010; Tanaka T, 1993, J Anesth, V7, P75, DOI 10.1007/s0054030070075; TATSUO MAKF, 1994, INFLAMMATION, V18, P399, DOI 10.1007/BF01534437; Taylor J, 1998, EUR J PHARMACOL, V351, P39, DOI 10.1016/S0014-2999(98)00298-2; Taylor R, 2000, CONTEMP TOP LAB ANIM, V39, P14; Terner JM, 2002, PSYCHOPHARMACOLOGY, V163, P183, DOI 10.1007/s00213-002-1143-x; Themistocleous A, 2007, J PAIN, V8, P208, DOI 10.1016/j.jpain.2006.07.003; Thompson AC, 2004, COMPARATIVE MED, V54, P293; Thompson AC, 2006, J AM ASSOC LAB ANIM, V45, P13; Thompson JS, 2002, COMPARATIVE MED, V52, P63; Thornton SR, 1998, DEV BRAIN RES, V105, P269, DOI 10.1016/S0165-3806(97)00185-5; Thurmon J. C., 1996, LUMB JONES VET ANEST, P183; Tokuyama S, 1998, LIFE SCI, V62, P1677, DOI 10.1016/S0024-3205(98)00127-1; Torjman MC, 2005, INT J PHARM, V294, P65, DOI 10.1016/j.ijpharm.2004.12.028; Torres-Lopez JE, 2002, LIFE SCI, V70, P1669, DOI 10.1016/S0024-3205(02)01491-1; Tortorici V, 1996, BRAIN RES, V725, P106, DOI 10.1016/S0006-8993(96)00196-5; TORTORICI V, 1994, PAIN, V57, P197, DOI 10.1016/0304-3959(94)90224-0; TOWETT PK, 1993, PHARMACOL BIOCHEM BE, V45, P153, DOI 10.1016/0091-3057(93)90099-F; Tsutsumi YM, 2006, AM J PHYSIOL-HEART C, V291, pH979, DOI 10.1152/ajpheart.00266.2006; Tsutsumi YM, 2006, ANESTHESIOLOGY, V104, P495, DOI 10.1097/00000542-200603000-00017; Turner PV, 2005, COMPARATIVE MED, V55, P175; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; VACCARINO AL, 1988, NEUROSCI LETT, V84, P103, DOI 10.1016/0304-3940(88)90345-X; Vahl TP, 2005, AM J PHYSIOL-ENDOC M, V289, pE823, DOI 10.1152/ajpendo.00122.2005; Vaillancourt C, 1999, EXP NEUROL, V160, P142, DOI 10.1006/exnr.1999.7201; Vanegas H, 2002, CELL MOL NEUROBIOL, V22, P655, DOI 10.1023/A:1021896622089; VANLOVEREN H, 1994, LAB ANIM-UK, V28, P355, DOI 10.1258/002367794780745119; VANPELT LF, 1977, J AM VET MED ASSOC, V171, P842; Veiga APC, 2004, LIFE SCI, V75, P2807, DOI 10.1016/j.lfs.2004.05.028; Vella ET, 2004, COMPARATIVE MED, V54, P202; Vergari A, 2004, Eur Rev Med Pharmacol Sci, V8, P103; Vergari A, 2003, LAB ANIM-UK, V37, P204, DOI 10.1258/002367703766453047; Verma-Gandhu M, 2006, GASTROENTEROLOGY, V130, P1721, DOI 10.1053/j.gastro.2006.01.045; VICKERY B, 1979, PROSTAG LEUKOTR ESS, V2, P325, DOI 10.1016/0161-4630(79)90105-8; VIRTANEN R, 1989, ACTA VET SCAND, P29; Volker D, 2000, LAB ANIM-UK, V34, P423, DOI 10.1258/002367700780387732; Wakeno-Takahashi M, 2005, AM J PHYSIOL-HEART C, V289, pH2585, DOI 10.1152/ajpheart.00400.2005; Walker JS, 2003, ADV EXP MED BIOL, V521, P148; Walker JS, 1996, INFLAMM RES, V45, P557, DOI 10.1007/BF02342227; Wang JJ, 2006, J CONTROL RELEASE, V115, P140, DOI 10.1016/j.jconrel.2006.07.023; WARD GS, 1974, LAB ANIM SCI, V24, P737; Watkins JC, 2006, BRIT J PHARMACOL, V147, pS100, DOI 10.1038/sj.bjp.0706444; Weber NC, 2005, BRIT J PHARMACOL, V144, P123, DOI 10.1038/sj.bjp.0706063; WEICHBROD RH, 1988, LAB ANIM SCI, V38, P296; Weinandy R, 2005, LAB ANIM-UK, V39, P200, DOI 10.1258/0023677053739828; WEINGER MB, 1995, BRIT J ANAESTH, V74, P455, DOI 10.1093/bja/74.4.455; Weiss J, 1999, LAB ANIM, V33, P192, DOI 10.1258/002367799780578417; WEKSLER B, 1994, J APPL PHYSIOL, V76, P1823, DOI 10.1152/jappl.1994.76.4.1823; Welberg LAM, 2006, J AM ASSOC LAB ANIM, V45, P13; WEST CD, 1987, LAB ANIM, V21, P143, DOI 10.1177/002367728702100211; West JP, 1998, DRUG ALCOHOL DEPEN, V53, P31, DOI 10.1016/S0376-8716(98)00109-4; WHITE WJ, 1987, VET CLIN N AM-SMALL, V17, P989, DOI 10.1016/S0195-5616(87)50102-4; Whiteside GT, 2004, BRIT J PHARMACOL, V141, P85, DOI 10.1038/sj.bjp.0705568; Whittington RA, 2006, ANESTH ANALG, V103, P92, DOI 10.1213/01.ane.0000221488.48352.61; Wiesmann F, 2000, AM J PHYSIOL-HEART C, V278, pH652, DOI 10.1152/ajpheart.2000.278.2.H652; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Williams Jon L., 2005, Psychological Record, V55, P3; Wilson AW, 2006, EUR J PAIN, V10, P537, DOI 10.1016/j.ejpain.2005.08.003; WILSON RP, 1992, PHARMACOL BIOCHEM BE, V43, P1129, DOI 10.1016/0091-3057(92)90492-X; Wilson SG, 2003, J PHARMACOL EXP THER, V304, P547, DOI 10.1124/jpet.102.041889; Wixson S.K., 1997, ANESTHESIA ANALGESIA, P166; WIXSON SK, 1987, LAB ANIM SCI, V37, P726; WIXSON SK, 1987, LAB ANIM SCI, V37, P731; WIXSON SK, 1987, LAB ANIM SCI, V37, P736; WIXSON SK, 1987, LAB ANIM SCI, V37, P743; Wood AKW, 2001, ACAD RADIOL, V8, P1136, DOI 10.1016/S1076-6332(03)80727-4; WOOLFOLK DR, 1995, PHARMACOL BIOCHEM BE, V51, P699, DOI 10.1016/0091-3057(94)00440-T; Wright-Williams SL, 2007, PAIN, V130, P108, DOI 10.1016/j.pain.2006.11.003; Yamakage M, 2002, CAN J ANAESTH, V49, P62, DOI 10.1007/BF03020420; Yamasaki A, 2001, BIOCHEM PHARMACOL, V62, P375, DOI 10.1016/S0006-2952(01)00664-5; Yamasaki K, 2003, EXP ANIM TOKYO, V52, P349, DOI 10.1538/expanim.52.349; Yang J, 2006, NEUROSCI RES, V54, P49, DOI 10.1016/j.neures.2005.10.006; Yokoro CM, 2003, BRAZ J MED BIOL RES, V36, P77, DOI 10.1590/S0100-879X2003000100011; Yu JG, 2004, CAN J ANAESTH, V51, P979, DOI 10.1007/BF03018483; Zagon IS, 1998, PHARMACOL BIOCHEM BE, V59, P201, DOI 10.1016/S0091-3057(97)00419-X; Zambricki EA, 2004, COMPARATIVE MED, V54, P49; ZATZMAN ML, 1988, CRYOBIOLOGY, V25, P212, DOI 10.1016/0011-2240(88)90028-4; Zelcer S, 2005, BRAIN RES, V1040, P151, DOI 10.1016/j.brainres.2005.01.070; Zeller W, 1998, LAB ANIM, V32, P407, DOI 10.1258/002367798780599811; Zhan XH, 2006, ANESTHESIOLOGY, V104, P995, DOI 10.1097/00000542-200605000-00016; Zhang RX, 2004, PHARMACOL BIOCHEM BE, V78, P793, DOI 10.1016/j.pbb.2004.05.010; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044; Zhao CS, 2004, J PAIN, V5, P104, DOI 10.1016/j.jpain.2003.12.001; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018; Zhou JX, 2006, ANESTH ANALG, V102, P129, DOI 10.1213/01.ane.0000189612.24147.07; ZHU CB, 1995, ACTA PHARM SINIC, V16, P311; Zuurbier CJ, 2002, AM J PHYSIOL-HEART C, V282, pH2099, DOI 10.1152/ajpheart.01002.2001; Zvara DA, 2006, ANESTH ANALG, V102, P1341, DOI 10.1213/01.ane.0000204357.06219.8c	612	92	93	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS			978-0-12-373898-1; 978-0-12-373898-1	AM COLL LAB			2008							239	297		10.1016/B978-012373898-1.50014-0			59	Veterinary Sciences	Book Citation Index – Science (BKCI-S)	Veterinary Sciences	BED52	WOS:000316210000011					2022-02-06	
J	Ponsford, J; Whelan-Goodinson, R; Bahar-Fuchs, A				Ponsford, Jennie; Whelan-Goodinson, Rochelle; Bahar-Fuchs, Alex			Alcohol and drug use following traumatic brain injury: A prospective study	BRAIN INJURY			English	Article						alcohol; drug use; traumatic brain injury	SUBSTANCE-ABUSE; DISORDERS; REHABILITATION; VALIDITY; MISUSE; LEVEL	Primary objectives: To establish pre-morbid alcohol and drug use in persons with TBI, relative to controls, investigate how patterns of substance use change over time following TBI and identify factors associated with heavy post-injury substance use. Methods and procedures: The Alcohol Use Disorders Identification test (AUDIT) and Drug Abuse Screening Test (DAST) was completed by 121 hospital inpatients with TBI, documenting pre-injury alcohol and drug use, and 133 demographically similar controls. Participants with TBI completed these measures and the Hospital Anxiety and Depression Scale (HADS) again 1 and 2 years post-injury and 76 also completed them at 3 years. Results: Participants with TBI showed similar levels of drug and alcohol use to controls pre-injury, with 31.4% of the TBI group and 29.3% of controls drinking at hazardous levels. Alcohol and drug use declined in the first year post-injury, but increased by 2 years post-injury, with only 21.4% of participants with TBI reporting abstinence from alcohol and 25.4% drinking at hazardous levels. Only 9% showed a drug problem, but 24% had returned to some drug use. Those showing heavy alcohol use post-injury were young, male and heavy drinkers pre-injury. Drug and alcohol use was similar at 3 years post-injury. Conclusions: More active intervention is needed to reduce alcohol and drug use following TBI.	[Ponsford, Jennie; Whelan-Goodinson, Rochelle; Bahar-Fuchs, Alex] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Dept Psychol, Richmond, Vic 3121, Australia; [Ponsford, Jennie; Whelan-Goodinson, Rochelle; Bahar-Fuchs, Alex] Monash Univ, Clayton, Vic 3168, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Dept Psychol, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au		Bahar-Fuchs, Alex/0000-0002-9248-6057			Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SKINNER HA, 1982, DRUG ABUSE SCREENING; Snaith R., 1994, HOSP ANXIETY DEPRESS; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336	30	92	92	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1385	1392		10.1080/02699050701796960			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200006	18066940				2022-02-06	
J	Zlotnik, A; Gurevich, B; Tkachov, S; Maoz, I; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Gurevich, Boris; Tkachov, Sergei; Maoz, Ilana; Shapira, Yoram; Teichberg, Vivian I.			Brain neuroprotection by scavenging blood glutamate	EXPERIMENTAL NEUROLOGY			English	Article						acute brain neurodegeneration; closed head injury; brain glutamate levels; blood glutamate scavenging; oxaloacetate; glutamate-oxaloacetate transaminase; neuroprotection; neurological severity score; spontaneous recovery	EXCITATORY AMINO-ACIDS; HUMAN HEAD-INJURY; RAT CEREBRAL-CORTEX; CEREBROSPINAL-FLUID; ISCHEMIC STROKE; MOUSE-BRAIN; BARRIER; RELEASE; MICRODIALYSIS; RECEPTORS	Excess glutamate in brain fluids characterizes acute brain insults such as traumatic brain injury and stroke. Its removal could prevent the glutamate excitotoxicity that causes long-lasting neurological deficits. As blood glutamate scavenging has been demonstrated to increase the efflux of excess glutamate from brain into blood, we tested the prediction that oxaloacetate-mediated blood glutamate scavenging causes neuroprotection in a pathological situation such as closed head injury (CHI), in which there is a well established deleterious increase of glutamate in brain fluids. We observed highly significant improvements of the neurological status of rats submitted to CHI following an intravenous treatment with 1 mmol oxaloacetate/100 g rat weight which decreases blood glutamate levels by 40%. No detectable therapeutic effect was obtained when rats were treated IV with 1 mmol oxaloacetate together with 1 mmol glutamate/100 g rat. The treatment with 0.005 mmol/100 g rat oxaloacetate was no more effective than saline but when it was combined with the intravenous administration of 0.14 nmol/100 g of recombinant glutamate-oxaloacetate transaminase, recovery was almost complete. Oxaloacetate provided neuroprotection when administered before CHI or at 60 min post CHI but not at 120 min post CHI. Since neurological recovery from CHI was highly correlated with the decrease of blood glutamate levels (r=0.89, P=0.001), we conclude that blood glutamate scavenging affords brain neuroprotection Blood glutamate scavenging may open now new therapeutic options. (c) 2006 Elsevier Inc. All rights reserved.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel		Teichberg, VI (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	vivian.teichberg@weizmann.ac.il					Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burckhardt BC, 2005, AM J PHYSIOL-RENAL, V288, pF792, DOI 10.1152/ajprenal.00360.2004; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Desagher S, 1997, J NEUROSCI, V17, P9060; Engstrom ER, 2005, NEUROSCI LETT, V384, P7, DOI [10.1016/j.neurlet.2005.04.030, 10.1016/j.neulet.2005.04.030]; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Ferrarese C, 2001, NEUROLOGY, V57, P671, DOI 10.1212/WNL.57.4.671; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hosoya K, 1999, J NEUROCHEM, V73, P1206, DOI 10.1046/j.1471-4159.1999.0731206.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Koura SS, 1998, ACT NEUR S, V71, P244; Margaill I, 1996, J CEREBR BLOOD F MET, V16, P107, DOI 10.1097/00004647-199601000-00013; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215, DOI 10.1152/ajpcell.2001.280.5.C1215; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Phillis JW, 1996, NEUROCHEM INT, V29, P115, DOI 10.1016/0197-0186(95)00154-9; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Serena J, 2001, STROKE, V32, P1154, DOI 10.1161/01.STR.32.5.1154; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; SINGH IN, 2006, J CEREB BLOOD FLOW M; Smith QR, 2000, J NUTR, V130, p1016S, DOI 10.1093/jn/130.4.1016S; Spranger M, 1996, J NEUROL SCI, V143, P126, DOI 10.1016/S0022-510X(96)00197-9; Spreux-Varoquaux O, 2002, J NEUROL SCI, V193, P73, DOI 10.1016/S0022-510X(01)00661-X; Stoffel M, 2002, J NEUROTRAUM, V19, P467, DOI 10.1089/08977150252932415; Takamatsu H, 1998, EUR J PHARMACOL, V352, P165, DOI 10.1016/S0014-2999(98)00353-7; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WESTERGREN I, 1992, BRAIN RES, V573, P324, DOI 10.1016/0006-8993(92)90781-4; WESTERGREN I, 1993, J CEREBR BLOOD F MET, V13, P603, DOI 10.1038/jcbfm.1993.78; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458	48	92	94	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2007	203	1					213	220		10.1016/j.expneurol.2006.08.021			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	123NU	WOS:000243303400023	17014847				2022-02-06	
J	Vardy, J; Wong, K; Yi, QL; Park, A; Maruff, P; Wagner, L; Tannock, IF				Vardy, Janette; Wong, Karen; Yi, Qi-long; Park, Alison; Maruff, Paul; Wagner, Lynne; Tannock, Ian F.			Assessing cognitive function in cancer patients	SUPPORTIVE CARE IN CANCER			English	Article						cognitive impairment; neuropsychological assessment; adjuvant chemotherapy	RECEIVING ADJUVANT CHEMOTHERAPY; BREAST-CANCER; NEUROPSYCHOLOGICAL ASSESSMENT; MENOPAUSAL SYMPTOMS; VALIDATION; TESTS; WOMEN; IMPAIRMENT; CONCUSSION; WORKSHOP	Goals of work: Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments. Materials and methods: Cancer patients (n=31) who had received adjuvant chemotherapy within 2 years underwent cognitive evaluation on three occasions. Fluent English speakers (n=20) completed the High Sensitivity Cognitive Screen (HSCS), the computer-based Headminder and CogHealth, and the Functional Assessment of Cancer Therapy-cognitive function (FACT-COG) questionnaire. Patients not fluent in English (NESB) (n=11) performed CogHealth and Headminder. Results: The patients were aged 31-65 years, and 94% were women with breast cancer. At baseline, 6 of 20 (30%) had moderate-severe cognitive impairment on HSCS, 17 of 31 (55%) had scores greater than one standard deviation (SD) below the mean for normative data in one to two of three domains on Headminder, and on CogHealth, 8 of 31 (26%) were greater than one SD below the mean in at least two of six domains. A large practice effect was seen for the HSCS, with moderate-severe cognitive impairment decreasing from 30 to 5% between the first and second assessment. On FACT-COG, 9 of 19 patients (47%) rated their cognition as greater than one SD below that of a pre-chemotherapy breast cancer control group, with impact on quality of life greater than one SD below for 10 of 19 (53%) patients. No correlation was seen between objective cognitive testing and the FACT-COG. Conclusions: CogHealth and Headminder were suitable for NESB patients. The HSCS is not recommended for longitudinal studies with short intervals between testing due to practice effect. There is poor correlation between the patients' perception of their cognitive impairment and the objective tests.	Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; CogState Ltd, Melbourne, Vic 3000, Australia; Northwestern Univ, Sch Med, Evanston NW Healthcare, Evanston, IL 60201 USA		Vardy, J (corresponding author), Princess Margaret Hosp, Dept Med Oncol & Hematol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	janette.vardy@uhn.on.ca	Maruff, Paul/ABA-1673-2020; Maruff, Paul/AAD-2454-2021	Maruff, Paul/0000-0002-6947-9537; Vardy, Janette/0000-0002-5739-5790			Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bornstein R. A., 1994, NEUROPSYCHOLOGY HIV, P146; Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; Brezden CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695; BUTTERS N, 1990, J CLIN EXP NEUROPSYC, V12, P963, DOI 10.1080/01688639008401035; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; FALLETI MG, 2006, IN PRESS J CLIN EXP; Fan HGM, 2005, J CLIN ONCOL, V23, P8025, DOI 10.1200/JCO.2005.01.6550; FAUST D, 1989, J NERV MENT DIS, V177, P25, DOI 10.1097/00005053-198901000-00004; Fogel B S, 1991, Int Psychogeriatr, V3, P273, DOI 10.1017/S1041610291000728; Gonzalez R, 2003, J INT NEUROPSYCH SOC, V9, P64, DOI 10.1017/S1355617703910071; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; MILLER EN, 1994, NEUROPSYCHOLOGY HIV, P161; Phillips KA, 2003, JNCI-J NATL CANCER I, V95, P190, DOI 10.1093/jnci/95.3.190; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Silbert BS, 2004, BRIT J ANAESTH, V92, P814, DOI 10.1093/bja/aeh157; Symes E, 2000, AUST NZ J PSYCHIAT, V34, P770, DOI 10.1046/j.1440-1614.2000.00808.x; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Wagner L, 2003, ANN BEHAV MED, V25; White D A, 1995, J Int Neuropsychol Soc, V1, P304; WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/pon.2960040108; Woods SP, 2003, J CLIN EXP NEUROPSYC, V25, P431, DOI 10.1076/jcen.25.3.431.13800	34	92	93	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	NOV	2006	14	11					1111	1118		10.1007/s00520-006-0037-6			8	Oncology; Health Care Sciences & Services; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology; Health Care Sciences & Services; Rehabilitation	111PA	WOS:000242464300006	16538498				2022-02-06	
J	Xu, Z; Wang, BR; Wang, X; Kuang, F; Duan, XL; Jiao, XY; Ju, G				Xu, Zhen; Wang, Bai-Ren; Wang, Xi; Kuang, Fang; Duan, Xiao-Li; Jiao, Xi-Ying; Ju, Gong			ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury	LIFE SCIENCES			English	Article						spinal cord injury; microglia; macrophages; inducible nitric oxide synthase; mitogen-activated protein kinase; neuron; rat	NITRIC-OXIDE SYNTHASE; TRANSIENT FOREBRAIN ISCHEMIA; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; MICROGLIAL ACTIVATION; BRAIN-INJURY; EXPRESSION; APOPTOSIS; PATHOPHYSIOLOGY; EXCITOTOXICITY	The enhanced production of nitric oxide (NO) via inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesis of neuronal apoptosis after acute traumatic spinal cord injury (SCI). In the present study, to further characterize the pathways mediating the synthesis and release of NO, we examined activation of extracellular signal regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinases (p38 MAPK) in microglia/macrophages in the injured area of adult rats subjected to a complete transection at the T 10 vertebrae level and assessed their role in NO production and survival of neurons by using immunohistochemistry, Western blot, RT-PCR and pharmacological interventions. Results showed activation of microglia/macrophages featured by morphological changes, as visualized immunohistochemically with the marker OX-42, in the areas adjacent to the lesion epicenter 1 h after surgery. Concomitantly, iNOS mRNA and its protein in the activated microglia/macrophages were also significantly upregulated at early hours after surgery. Their levels were maximal at 6 It, persisted for at least 24 It, and returned to basal level 72 h after SCI. Furthermore, phosphorylated ERK 1/2 and p38 MAPK were activated as well in microglia/macrophages in injured area with a similar time course as iNOS. With administration Of L-NAME, a NOS inhibitor, the number of apoptotic neurons was clearly decreased, as assessed with TUNEL method at 24 h after SCI. In parallel, loss of neurons induced by SCI, assessed with NeuN immumohistochemistry, was also diminished. Moreover, the effect of inhibition of phosphorylation ERK1/2 and p38 MAPK by corresponding inhibitors PD98059 and SB203580 administered before and after SCI was also investigated. Inhibition of p38 effectively reduced iNOS mRNA expression and rescued neurons from apoptosis and death in the area adjacent to the lesion epicenter; whereas the inhibition of ERK 1/2 had a smaller effect on decrease of iNOS mRNA and no long-term protective effect on cell loss. These results indicate the ERK1/2 and p38 MAPK signaling pathway, especially the latter, play an important role in NO-mediated degeneration of neuron in the spinal cord following SCI. Strategies directed to blocking the initiation of this cascade prove to be beneficial for the treatment of acute SCI. (c) 2006 Elsevier Inc. All rights reserved.	Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China		Wang, BR (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.	wbrnim@fmmu.edu.cn					Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bhat NR, 1998, J NEUROSCI, V18, P1633; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; CHAO CC, 1992, J IMMUNOL, V149, P2736; Choi SH, 2003, J NEUROSCI, V23, P5877; Combs CK, 2001, J NEUROSCI, V21, P1179; Dawson VL, 1996, J NEUROSCI, V16, P2479; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kwak EK, 2005, J KOREAN MED SCI, V20, P663, DOI 10.3346/jkms.2005.20.4.663; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang MJ, 2004, J NEUROIMMUNOL, V146, P50, DOI 10.1016/j.jneuroim.2003.10.034; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	37	92	100	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	OCT 12	2006	79	20					1895	1905		10.1016/j.lfs.2006.06.023			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	097TP	WOS:000241472000002	16978658				2022-02-06	
J	Pagulayan, KF; Temkin, NR; Machamer, J; Dikmen, SS				Pagulayan, KF; Temkin, NR; Machamer, J; Dikmen, SS			A longitudinal study of health-related quality of life after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; longitudinal studies; quality of life; rehabilitation	CLOSED-HEAD-INJURY; SICKNESS IMPACT PROFILE; FOLLOW-UP; RANDOMIZED-TRIAL; NEUROPSYCHOLOGICAL RECOVERY; DISABILITY; MODERATE; SCALE; MILD; REHABILITATION	Objective: To examine the longitudinal course of health-related quality of life from 1 month to 3 to 5 years after traumatic brain injury (TBI). Design: Longitudinal cohort study with 4 evaluation points. Setting: Level 1 trauma center. Participants: Consecutive hospital admissions of 133 adolescents and adults with complicated mild to severe TBI who completed the Outcome measure at all 4 time points, 111 general trauma patients, and 87 healthy friend controls. Interventions: Not applicable. Main Outcome Measure: Sickness Impact Profile. Results: TBI patients reported significant limitations at I month postinjury, with substantial improvement occurring by 6 months. especially in the physical domain. Psychosocial improvement was smaller, and perceived cognitive, emotional, and communication difficulties did not change over the time period assessed. Persons with TBI had clear difficulties relative to healthy peers, but their reported level of difficulties was very similar to that of the persons who had sustained a general trauma by 1 year postinjury. Conclusions: In this sample, TBI was associated with significant early limitations in most aspects of everyday life. Considerable improvement was noted over the first 6 months postinjury, especially in physical domains. Some aspects of psychosocial functioning also improved, although reported limitations in communication, cognitive, and emotional domains remained constant over time. These findings highlight the persistence of injury-related difficulties that compromise quality of life.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Pagulayan, KF (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	farkat@u.washington.edu	Pagulayan, Kati/AAR-9225-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD048030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD048030] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643, R01 NS019643] Funding Source: Medline		Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Brooks D N, 1979, Int Rehabil Med, V1, P166; CARTER WB, 1976, HEALTH SERV RES, V11, P516; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P157; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1999, MILD HEAD INJURY	45	92	94	1	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2006	87	5					611	618		10.1016/j.apmr.2006.01.018			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	039UW	WOS:000237333900002	16635622				2022-02-06	
J	Wang, Y; Chan, RCK; Deng, YY				Wang, Ya; Chan, Raymond C. K.; Deng, Yongyu			Examination of postconcussion-like symptoms in healthy university students: Relationships to subjective and objective neuropsychological function performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						postconcussion; base rate; neuropsychological performance; brain injury	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; BASE RATES; ATTENTIONAL DEFICITS; WORKING-MEMORY; COMPLAINTS; STRESS; QUESTIONNAIRE; DEPRESSION; DISORDER	This study examined postconcussion-like symptoms in a group of university students and explored their relationships to neuropsychological function performance. A sample of 124 students was recruited. All of the participants received the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and completed a comprehensive set of neuropsychological tests. They reported a relatively high base rate of postconcussion-like symptoms. The most frequently endorsed items were "fatigue" (76.9%), "longer time to think" (60.3%), "poor concentration" (58.7%), "sleep disturbance" (50.4%), and "frustration" (46.3%). There were no significant differences between low symptom reporters and high symptom reporters, except for self-reported dysexecutive problems. A comparison of the healthy high symptom reporters and a convenient sample of traumatic brain injury patients revealed that the patients performed significantly worse on neuropsychological functions than the high symptom reporters, despite non-significant differences between symptom endorsement. Our findings demonstrate that: (a) the base rate of postconcussion-like symptoms in a group of healthy university students is relatively high and (b) postconcussion symptom (PCS) is not related to neuropsychological functions in normal people. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Guangdong, Peoples R China; Chinese Acad Sci, Inst Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Beijing 100080, Peoples R China; Zhongkai Univ Agr & Technol, Guangzhou, Guangdong, Peoples R China		Chan, RCK (corresponding author), Sun Yat Sen Univ, Dept Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Guangzhou 510275, Guangdong, Peoples R China.	edschchq@zsu.edu.cn	Chan, Raymond CK/B-6717-2009; Wang, Ya/C-7374-2009	Chan, Raymond CK/0000-0002-3414-450X; Wang, Ya/0000-0001-5764-6740			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; Beck A.T., 1967, DEPRESSION CAUSES TR; BOHNEN NI, 1995, J NEUROSURG, V70, P509; BOHNEN NI, 1992, NEUROPSYCHOLOGY, V15, P170; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Callicott JH, 1998, NEUROPSYCHOPHARMACOL, V18, P186, DOI 10.1016/S0893-133X(97)00096-1; CHAN CM, 1984, COGNITIVE THER RES, V8, P501, DOI 10.1007/BF01173287; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P735, DOI 10.1016/S0887-6177(99)80228-5; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050150209156; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GANGADHAR BN, 1985, NIMHANS J, V3, P147; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GASQUOINE PG, 2000, APPL NEUROPSYCHOL, V2, P83; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gronwall D, 1974, PSYCHOL EFFECTS CONC; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Piland SG, 2003, J ATHL TRAINING, V38, P104; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Varney N R, 1995, Appl Neuropsychol, V2, P47, DOI 10.1207/s15324826an0202_1; Wechsler D, 1987, MEMORY SCALE REVISED; WONG J. L., 2000, INT J REHABILITATION, V5, P85; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; [No title captured]	52	92	95	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2006	21	4					339	347		10.1016/j.acn.2006.03.006			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	067GI	WOS:000239289500011	16765018	Bronze			2022-02-06	
J	Bakshi, A; Shimizu, S; Keck, CA; Cho, S; LeBold, DG; Morales, D; Arenas, E; Snyder, EY; Watson, DJ; McIntosh, TK				Bakshi, A; Shimizu, S; Keck, CA; Cho, S; LeBold, DG; Morales, D; Arenas, E; Snyder, EY; Watson, DJ; McIntosh, TK			Neural progenitor cells engineered to secrete GDNF show enhanced survival, neuronal differentiation and improve cognitive function following traumatic brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cognition; glial cell line-derived neurotrophic factor; neural progenitor cells; rats; traumatic brain injury	NERVE GROWTH-FACTOR; FLUID-PERCUSSION MODEL; STEM-CELLS; NEUROTROPHIC FACTOR; SPINAL-CORD; C-RET; NEUROLOGICAL MOTOR; NESTIN EXPRESSION; TYROSINE KINASE; AXONAL GROWTH	We sought to evaluate the potential of C17.2 neural progenitor cells (NPCs) engineered to secrete glial cell line-derived neurotrophic factor (GDNF) to survive, differentiate and promote functional recovery following engraftment into the brains of adult male Sprague-Dawley rats subjected to lateral fluid percussion brain injury. First, we demonstrated continued cortical expression of GDNF receptor components (GFR alpha-1, c-Ret), suggesting that GDNF could have a physiological effect in the immediate post-traumatic period. Second, we demonstrated that GDNF over-expression reduced apoptotic NPC death in vitro. Finally, we demonstrated that GDNF over-expression improved survival, promoted neuronal differentiation of GDNF-NPCs at 6 weeks, as compared with untransduced (MT) C17.2 cells, following transplantation into the perilesional cortex of rats at 24 h post-injury, and that brain-injured animals receiving GDNF-C17.2 transplants showed improved learning compared with those receiving vehicle or MT-C17.2 cells. Our results suggest that transplantation of GDNF-expressing NPCs in the acute post-traumatic period promotes graft survival, migration, neuronal differentiation and improves cognitive outcome following traumatic brain injury.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, Stockholm, Sweden; Burnham Inst, Program Dev & Regenerat Cell Biol, La Jolla, CA 92037 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Watson, DJ (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, 371A Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	djw3@mail.med.upenn.edu	Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577; Morales, Diego/0000-0001-6672-9046	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40978] Funding Source: Medline		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Blesch A, 2001, J COMP NEUROL, V436, P399, DOI 10.1002/cne.1076; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Burazin TCD, 1999, MOL BRAIN RES, V73, P151, DOI 10.1016/S0169-328X(99)00217-X; Ceccatelli S, 2004, TOXICOL LETT, V149, P59, DOI 10.1016/j.toxlet.2003.12.060; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fink JS, 2000, CELL TRANSPLANT, V9, P273, DOI 10.1177/096368970000900212; Fujiwara Y, 2004, NEUROSCI LETT, V366, P287, DOI 10.1016/j.neulet.2004.05.080; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Heuckeroth RO, 1998, DEV BIOL, V200, P116, DOI 10.1006/dbio.1998.8955; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Hurelbrink CB, 2001, EXP NEUROL, V171, P46, DOI 10.1006/exnr.2001.7749; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Ito H, 2003, J NEUROSCI RES, V71, P648, DOI 10.1002/jnr.10532; Iwai M, 2001, Hum Cell, V14, P27; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larsson LC, 2001, EXP NEUROL, V172, P100, DOI 10.1006/exnr.2001.7738; Lee CS, 2005, EXP NEUROL, V191, P65, DOI 10.1016/j.expneurol.2004.08.025; Liu WG, 2004, NEUROCHEM RES, V29, P2207, DOI 10.1007/s11064-004-7027-1; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lynch WP, 1999, J VIROL, V73, P6841, DOI 10.1128/JVI.73.8.6841-6851.1999; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mellodew K, 2004, DEV BRAIN RES, V151, P13, DOI 10.1016/j.devbrainres.2004.03.018; Miyazaki H, 1999, NEUROSCIENCE, V89, P643, DOI 10.1016/S0306-4522(98)00592-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; National Research Council, 1996, GUID CAR US LAB AN; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; RINK A, 1995, AM J PATHOL, V147, P1575; Rosario CM, 1997, DEVELOPMENT, V124, P4213; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sarabi A, 2003, NEUROSCIENCE, V116, P261, DOI 10.1016/S0306-4522(02)00559-6; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Tamm C, 2004, EUR J NEUROSCI, V19, P2613, DOI 10.1111/j.0953-816X.2004.03391.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; Tuszynski MH, 1996, NEUROSCIENCE, V71, P761, DOI 10.1016/0306-4522(95)00440-8; Ugarte SD, 2003, J NEUROSCI RES, V73, P105, DOI 10.1002/jnr.10632; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	81	92	103	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	APR	2006	23	8					2119	2134		10.1111/j.1460-9568.2006.04743.x			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	034PQ	WOS:000236943500016	16630059				2022-02-06	
J	Kaufman, KR; Brey, RH; Chou, LS; Rabatin, A; Brown, AW; Basford, JR				Kaufman, KR; Brey, RH; Chou, LS; Rabatin, A; Brown, AW; Basford, JR			Comparison of subjective and objective measurements of balance disorders following traumatic brain injury	MEDICAL ENGINEERING & PHYSICS			English	Article						traumatic brain injury; center of mass; dizziness handicap inventory; gait; balance	CENTER-OF-MASS; DYNAMIC POSTUROGRAPHY; DIZZINESS; GAIT; DEFICITS; SUPPORT; MOTION; HEAD	Patients with mild traumatic brain injury (TBI) often complain of dizziness. However, these problems may be undetected by a clinical exam. Therefore, the purpose of this study was to evaluate the relationships between the subjective and objective measures of balance impairment. Ten patients with TBI (6 men and 4 women) and 10 matched controls participated in this study. Average duration since the TBI was 2.8 years (range 0.4-14.4). Six of the 10 subjects with TBI had abnormal imaging studies. All subjects and controls had a normal neuromuscular exam. Tinetti Balance Assessments were obtained and the TBI group was not significantly different from the control group. The Dizziness Handicap Inventory (DHI) score supported their complaints of "unsteadiness" and "imbalance" from the subjects with TBI. The DHI score was 32 +/- 23 (range 4-68) out of a maximum possible score of 100. Balance was tested using computerized dynamic posturography. The Sensory Organization Test score was significantly lower for subjects who had a TBI (70 +/- 12) compared to the control subjects (80 +/- 8), which indicated that the subjects with TBI had poorer balance than the control subjects. A 13-link biomechanical model of the human body was used to compute the kinematics of the whole body center of mass (COM) while walking on a level surface. The subjects with TBI had significantly less displacement in the anterior/posterior direction, walked significantly slower, had significantly greater medial/lateral sway and velocity than the normal controls, and had significantly greater medial/lateral imbalance. There was a significant relationship between the physical aspects of the DHI and posturography. There was also significant relationship between the physical, functional, and total DHI and the motion of the COM. Overall, the motion of the COM predicted between 42 and 69% of the DHI score. The present study has demonstrated that objective measurements can quantify the patient's functional deficits. Therefore, these objective measurement techniques should be used to assess the clinical complaints of imbalance from patients with TBI. (c) 2005 IPEM. Published by Elsevier Ltd. All rights reserved.	Mayo Clin & Mayo Fdn, Dept Orthopaed Surg, Biomech Motion Analysis Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol, Vestibular Balance Lab, Rochester, MN 55905 USA; Univ Oregon, Dept Exercise & Movement Sci, Eugene, OR 97403 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA		Kaufman, KR (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthopaed Surg, Biomech Motion Analysis Lab, 200 1st St SW, Rochester, MN 55905 USA.	kaufman.kenton@mayo.edu		Kaufman, Kenton/0000-0002-7311-3781; Brown, Allen W./0000-0001-7228-3351			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; *CDC, 1999, TRAUM BRAIN INJ; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; Dobie RA, 1997, AM J OTOL, V18, P108; *EQUITEST, 1992, SYST OP MAN VERS 4 0; Evans MK, 1999, OTOLARYNG HEAD NECK, V120, P164, DOI 10.1016/S0194-5998(99)70401-8; FREGLY AR, 1968, AEROSPACE MED, V39, P277; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P501; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hillier SL, 1997, BRAIN INJURY, V11, P649; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JENNETT B, 1975, LANCET, V1, P480; JIAN YC, 1993, GAIT POSTURE, V0001, P00009, DOI DOI 10.1016/0966-6362(93)90038-3; KADABA MP, 1989, J ORTHOPAED RES, V7, P849, DOI 10.1002/jor.1100070611; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Meglan D.A., 1991, THESIS OHIO STATE U; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NASHNER LM, 1982, J NEUROSCI, V2, P536; O'Neill DE, 1998, AM J OTOL, V19, P797; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Palliyath S, 1998, MOVEMENT DISORD, V13, P958, DOI 10.1002/mds.870130616; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROMBERG MH, 1853, MANUAL NERVOUS DIS M, P395; RUBIN AM, 1995, AM J OTOL, V16, P216; Seidel B, 2002, J REHABIL MED, V34, P288, DOI 10.1080/165019702760390392; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	34	92	93	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533	1873-4030		MED ENG PHYS	Med. Eng. Phys.	APR	2006	28	3					234	239		10.1016/j.medengphy.2005.05.005			6	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	013WK	WOS:000235440500004	16043377				2022-02-06	
J	Geddes-Klein, DM; Schiffman, KB; Meaney, DF				Geddes-Klein, DM; Schiffman, KB; Meaney, DF			Mechanisms and consequences of neuronal stretch injury in vitro differ with the model of trauma	JOURNAL OF NEUROTRAUMA			English	Article						cytosolic calcium; in vitro models; NMDA receptors; permeability	DIFFUSE AXONAL INJURY; BRAIN-INJURY; CORTICAL-NEURONS; QUANTITATIVE-DETERMINATION; MEMBRANE-PERMEABILITY; GLUTAMATE-RECEPTOR; CALCIUM RESPONSE; MEDIATED CURRENT; NEURAL TRAUMA; STRAIN-RATE	The deformation to the brain that occurs during traumatic brain injury (TBI) results in a complex strain distribution throughout the brain tissue. Recently, many in vitro models of neuronal injury have been developed to simplify the mechanics which occur during TBI. We hypothesized that the type of mechanical insult imparted onto neurons would significantly alter both the mechanism and severity of the neuronal response to injury. In this study, primary cortical neurons were cultured on an elastic substrate and subjected to graded levels (0%, 10%, 30%, 50%) of either uniaxial (cells stretched in one direction only) or biaxial (cells simultaneously stretched in two directions) stretch. We found that neurons stretched in either injury paradigm exhibited immediate increases in intracellular free calcium ([Ca2+](i)), but the magnitude of the [Ca2+](i) rise was nearly an order of magnitude higher in biaxially stretched neurons compared to uniaxially stretched neurons. Moreover, while the [Ca2+](i) transient after uniaxial stretch was blocked with specific channel antagonists (APV, CNQX, nimodipine, TTX), a substantial [Ca2+], transient persisted in biaxially stretched neurons. We theorized that the additional calcium influx after biaxial stretch entered through nonspecific pores/tears formed in the membrane, since biaxially stretched neurons exhibited significant uptake of carboxyfluorescein, a molecule typically impermeant to cell membranes. Despite the large [Ca2+](i) transients, neither injury profile resulted in death within 24 h of injury. Interestingly, though, uniaxially stretched neurons exhibited enhanced [Ca+2](i) influx following NMDA stimulation 24 h after trauma, compared to both control and biaxially stretched neurons. These data point out that the type of mechanical insult will influence the acute mechanisms of injury in vitro, can cause differences in the response to potential secondary excitotoxic injury mechanisms, and emphasizes the need to further study how these mechanical conditions can separately affect cell fate following mechanical injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Geddes-Klein, DM (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,120 Hayden Hall, Philadelphia, PA 19104 USA.	dmgeddes@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35712] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NICHD 41699] Funding Source: Medline		Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Furukawa Y, 2000, NEUROSCIENCE, V96, P385, DOI 10.1016/S0306-4522(99)00553-9; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gift EA, 2000, CYTOMETRY, V39, P243; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Holbourn AHS, 1943, LANCET, V2, P438; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; OMMAYA AK, 1967, 13 STAPP CAR CRASH C; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; SHREIBER DI, 1997, 41 STAPP CAR CRASH C; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	42	92	95	1	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					193	204		10.1089/neu.2006.23.193			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600008	16503803				2022-02-06	
J	Frankel, JE; Marwitz, JH; Cifu, DX; Kreutzer, JS; Englander, J; Rosenthal, M				Frankel, JE; Marwitz, JH; Cifu, DX; Kreutzer, JS; Englander, J; Rosenthal, M			A follow-up study of older adults with traumatic brain injury: Taking into account decreasing length of stay	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	65th Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	OCT, 2004	Phoenix, AZ	Amer Acad Phys Med & Rehabil		age; brain injuries; geriatrics; rehabilitation; treatment outcome	DISABILITY RATING-SCALE; FUNCTIONAL OUTCOMES; REHABILITATION; AGE; PATIENT	Objective: To examine age-related differences in rehabilitation outcomes following traumatic brain injury (TBI). Design: Retrospective collaborative study. Setting: Patients received acute neurotrauma and inpatient rehabilitation services at 1 of the 17 National Institute on Disability and Rehabilitation Research-designated Traumatic Brain Injury Model Systems (TBIMS) centers. Participants: A sample of 273 older patients (>= 55 y) admitted for TBI were taken from the TBIMS National Database. Older patients were matched with subjects 44 years of age or younger, based on severity of injury (Glasgow Coma Scale score, length of coma, intracranial pressure elevations). Due to decreasing length of stay (LOS), only patients admitted from 1996 through 2002 were included. Intervention: Inpatient interdisciplinary brain injury rehabilitation. Main Outcome Measures: Acute care LOS, inpatient rehabilitation LOS, admission and discharge FIM instrument and Disability Rating Scale (DRS) scores, FIM and DRS efficiency, acute and rehabilitative charges, and discharge disposition. Results: One-way analyses of variance demonstrated a statistically significant difference between older and younger patients with respect to LOS in rehabilitation but not for acute care. Total rehabilitative charges, and admission and discharge DRS and FIM scores also showed statistically significant differences between groups. Older patients progressed with significantly less efficiency on both the DRS and FIM scales. Significantly more charges were generated per unit for older patients to improve on the DRS scale, but not the FIM scale. Using chi-square analysis, a statistically significant difference in rate of discharge to home was identified between older (80.5%) and younger (94.4%) patients. Conclusions: Results in this study are similar to those in earlier studies with smaller sample sizes. Major differences observed include significantly slower and more costly progress in inpatient rehabilitation for older patients with TBI, as well as a significantly lower rate of discharge to community for older patients. However, even with decreasing LOS in both settings, community discharge rate is still encouraging for older patients with TBI.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr Traumat Brain Injury & Spinal Cor, Santa Clara, CA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA		Cifu, DX (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980677,Med Coll Virginia Campus, Richmond, VA 23298 USA.	dcifu@mail2.vcu.edu		Cifu, David/0000-0003-1600-9387			Bagg S, 2002, STROKE, V33, P179, DOI 10.1161/hs0102.101224; Bodenheimer CF, 2004, ARCH PHYS MED REHAB, V85, pS23, DOI 10.1016/j.apmr.2004.03.009; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Ergeletzis D, 2002, AM J PHYS MED REHAB, V81, P881, DOI 10.1097/00002060-200212000-00001; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1997, ASSESSING MED REHABI, P103; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt SM, 2002, ARCH PHYS MED REHAB, V83, P894, DOI 10.1053/apmr.2002.33219; *STAT U NY, 1996, GUID UN DAT SET MED; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Worsowicz GM, 2004, ARCH PHYS MED REHAB, V85, pS3, DOI 10.1016/j.apmr.2004.03.005	26	92	93	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2006	87	1					57	62		10.1016/j.apmr.2005.07.309			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	003GT	WOS:000234670500010	16401439				2022-02-06	
J	Lee, SH; Chun, W; Kong, PJ; Han, JA; Cho, BP; Kwon, OY; Lee, HJ; Kim, SS				Lee, SH; Chun, W; Kong, PJ; Han, JA; Cho, BP; Kwon, OY; Lee, HJ; Kim, SS			Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus	JOURNAL OF PINEAL RESEARCH			English	Article						Akt; excitotoxicity; glial cell line-derived neurotrophic factor; inducible nitric oxide synthase; kainic acid; melatonin	MESSENGER-RNA EXPRESSION; NEUROTROPHIC FACTOR; IN-VIVO; ANTIBODY-RESPONSE; INDUCED APOPTOSIS; PINEAL-GLAND; BRAIN-DAMAGE; NITRIC-OXIDE; RAT; RECEPTORS	In the present study, the underlying protective mechanism of melatonin on kainic acid (KA)-induced excitotoxicity was examined in the hippocampus of mice. KA, administered intracerebroventricularly (i.c.v.), induced marked neuronal cell death with concurrent microglial activation and subsequent induction of inducible nitric oxide synthase (iNOS) in the hippocampus. Histopathological analysis demonstrated that melatonin (10 mg/kg), administered 1 hr prior to KA, attenuated KA-induced death of pyramidal neurons in the CA3 region. Melatonin obviously suppressed KA-induced microglial activation and consequent iNOS expression that were determined by increased immunoreactivities of microglial marker OX-6 and iNOS, respectively. Increased phosphorylation of Akt in pyramidal neurons was observed as early as 2 hr after administration of melatonin. Further, melatonin resulted in increased expression of astroglial glial cell line-derived neurotrophic factor (GDNF), which started to appear approximately 6 hr after administration of melatonin. The results of the present study demonstrate that melatonin exerts its neuroprotective action against KA-induced excitotoxicity both through the activation of neuronal Akt and via the direct action on hippocampal neurons and through the increased expression of astroglial GDNF, which subsequently activates neuronal PI3K/Akt pathway. Therefore, the present study suggests that melatonin, pineal secretory product, is potentially useful in the treatment of acute brain pathologies associated with excitotoxic neuronal damage such as epilepsy, stroke, and traumatic brain injury.	Kangweon Natl Univ, Coll Med, Dept Pharmacol, Chunchon 200701, South Korea; Kangweon Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chunchon 200701, South Korea; Yonsei Univ, Wonju Coll Med, Dept Anat, Wonju, Kangwon, South Korea		Kim, SS (corresponding author), Kangweon Natl Univ, Coll Med, Dept Pharmacol, Hyoja 2 Chunchon, Chunchon 200701, South Korea.	ksslsy@kangwon.ac.kr		Min, Jeong-Ki/0000-0003-4924-8739; LEE, HEE JAE/0000-0002-7816-6444; Lee, Sang-Hyun/0000-0002-9682-1473			Anhe GF, 2004, J NEUROCHEM, V90, P559, DOI 10.1111/j.1471-4159.2004.02514.x; Armstrong KJ, 2002, NEUROREPORT, V13, P473, DOI 10.1097/00001756-200203250-00023; BAKER H, 1993, NEUROSCIENCE, V52, P115, DOI 10.1016/0306-4522(93)90187-K; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Conti A, 1995, J PINEAL RES, V19, P103, DOI 10.1111/j.1600-079X.1995.tb00177.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franceschini D, 1999, ADV EXP MED BIOL, V467, P207; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; Henshall DC, 2002, J NEUROSCI, V22, P8458; Izquierdo LA, 2000, BEHAV BRAIN RES, V111, P93, DOI 10.1016/S0166-4328(00)00137-6; Joo JY, 1998, RESTOR NEUROL NEUROS, V13, P185; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lezoualch F, 1996, NEUROREPORT, V7, P2071, DOI 10.1097/00001756-199609020-00003; MAESTRONI GJM, 1987, CLIN EXP IMMUNOL, V68, P384; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Musshoff U, 2002, HIPPOCAMPUS, V12, P165, DOI 10.1002/hipo.1105; Pong K, 1998, J NEUROCHEM, V71, P1912; Pyo H, 2003, NEUROSCI LETT, V346, P141, DOI 10.1016/S0304-3940(03)00505-6; Reppert SM, 1996, TRENDS PHARMACOL SCI, V17, P100, DOI 10.1016/0165-6147(96)10005-5; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Sarabi A, 2000, BRAIN RES, V877, P262, DOI 10.1016/S0006-8993(00)02682-2; Skaper SD, 1998, FASEB J, V12, P725, DOI 10.1096/fasebj.12.9.725; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Stewart LS, 2005, EPILEPSIA, V46, P473, DOI 10.1111/j.0013-9580.2005.30204.x; Tan DX, 1998, J NEUROSCI RES, V54, P382, DOI 10.1002/(SICI)1097-4547(19981101)54:3<382::AID-JNR9>3.0.CO;2-Y; Tang YP, 1998, J NEUROSCI RES, V53, P593; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1996, NATURE, V381, P789; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Zagulska-Szymczak S, 2001, NEUROCHEM INT, V38, P485, DOI 10.1016/S0197-0186(00)00101-7	40	92	100	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	JAN	2006	40	1					79	85		10.1111/j.1600-079X.2005.00283.x			7	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	987PO	WOS:000233530000011	16313502				2022-02-06	
J	Wang, HE; Kupas, DF; Hostler, D; Cooney, R; Yealy, DM; Lave, JR				Wang, HE; Kupas, DF; Hostler, D; Cooney, R; Yealy, DM; Lave, JR			Procedural experience with out-of-hospital endotracheal intubation	CRITICAL CARE MEDICINE			English	Article						intubation (intratracheal); emergency medical services; clinical competence; resuscitation	RAPID-SEQUENCE INTUBATION; MEDICAL-SERVICES SYSTEM; TRAUMATIC BRAIN-INJURY; SUCCESS RATES; PARAMEDICS	Objective. Out-of-hospital rescuers likely need regular clinical experience to perform endotracheal intubation (ETI) in a safe and effective manner. We sought to determine the frequency of ETI performed by individual out-of-hospital rescuers. Design. Analysis of an administrative database of all emergency medical services (EMS) patient care reports in Pennsylvania. Setting: Commonwealth of Pennsylvania from January I to December 31, 2003. Subjects: EMS advanced life support rescuers (paramedics, prehospital nurses, and EMS physicians) who reported at least one patient contact during the study period. Interventions. None. Measurements. We calculated individual rescuer ETI frequency and opportunity. We evaluated relationships between ETI frequency and the number of patient contacts. We also examined the relationship with practice setting (air medical vs. ground rescuers and urban vs. rural rescuers). Main Results: In 1,544,791 patient care reports, 11,484 ETIs were reported by 5,245 out-of-hospital rescuers. The median ETI frequency was one (interquartile range, 0-3; range, 0-23). Of 5,245 rescuers, > 67% (3,551) performed two or fewer ETIs, and > 39% (2,054) rescuers did not perform any ETIs. The median number of ETI opportunities was three (interquartile range, 0-6; range, 0-76). ETI frequency was associated with patient volume (Spearman's rho = 0.67) and was higher for air medical (p = .006) and urban (p < .0001) rescuers. ETI frequency was not associated with response (Spearman's rho = -0.01) or transport (Spearman's rho = -0.06) times. Conclusions. Out-of-hospital ETI, an important and difficult resuscitation intervention, is an uncommon event for most rescuers.	Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15260 USA; Geisinger Hlth Syst, Dept Emergency Med, Danville, PA USA; Univ Pittsburgh, Off Emergency Med Serv, Dept Hlth, Harrisburg, PA USA; Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA		Wang, HE (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15260 USA.			Kupas, Douglas/0000-0002-2183-4018; Hostler, David/0000-0002-7711-4001	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08-HS13628] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS013628] Funding Source: NIH RePORTER		*ACCR COUNC GRAD M, EM MED GUID PROC RES; Burton John H, 2003, Prehosp Emerg Care, V7, P352, DOI 10.1080/10903120390936554; Charuluxananan Somrat, 2001, Journal of the Medical Association of Thailand, V84, pS251; *COUNC ACCR NURS A, 2004, ED PROGR STAND ACCR; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; FILHO GR, 2002, ANESTH ANALG, V95, P411; Gabrielli Andrea, 2002, Curr Opin Crit Care, V8, P199, DOI 10.1097/00075198-200206000-00002; JACOBS LM, 1983, JAMA-J AM MED ASSOC, V250, P2175, DOI 10.1001/jama.250.16.2175; Jaeger K, 2000, RESUSCITATION, V43, P147, DOI 10.1016/S0300-9572(99)00124-0; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Luft HS, 1990, HOSP VOLUME PHYS VOL; Mizelle H Leland, 2002, Prehosp Emerg Care, V6, P472, DOI 10.1080/10903120290938184; National Highway Traffic Safety Administration, EM MED TECHN PAR NAT; O'Malley RN, 2001, ANN EMERG MED, V38, P441, DOI 10.1067/mem.2001.118018; Persse DE, 2003, RESUSCITATION, V59, P97, DOI 10.1016/S0300-9572(03)00178-3; Pollock M J, 1997, Prehosp Emerg Care, V1, P263; Ricketts TC, 1998, DEFINITIONS RURAL HD; Sakles JC, 1998, ANN EMERG MED, V31, P325, DOI 10.1016/S0196-0644(98)70342-7; STEWART RD, 1984, CHEST, V85, P341, DOI 10.1378/chest.85.3.341; STEWART RD, 1984, ANN EMERG MED, V13, P1032, DOI 10.1016/S0196-0644(84)80064-5; STRATTON SJ, 1991, ANN EMERG MED, V20, P1314, DOI 10.1016/S0196-0644(05)81073-X; *USDHHS, MED PRIC NAT STANS P; Wang H E, 2001, Prehosp Emerg Care, V5, P10, DOI 10.1080/10903120190940254; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2003, RESUSCITATION, V58, P49, DOI 10.1016/S0300-9572(03)00058-3; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916	27	92	93	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2005	33	8					1718	1721		10.1097/01.CCM.0000171208.07895.2A			4	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958ZS	WOS:000231487300006	16096447				2022-02-06	
J	Mi, WQ; Beirowski, B; Gillingwater, TH; Adalbert, R; Wagner, D; Grumme, D; Osaka, H; Conforti, L; Arnhold, S; Addicks, K; Wada, K; Ribchester, RR; Coleman, MP				Mi, WQ; Beirowski, B; Gillingwater, TH; Adalbert, R; Wagner, D; Grumme, D; Osaka, H; Conforti, L; Arnhold, S; Addicks, K; Wada, K; Ribchester, RR; Coleman, MP			The slow Wallerian degeneration gene, Wld(S), inhibits axonal spheroid pathology in gracile axonal dystrophy mice	BRAIN			English	Article						axon; axonal spheroid; gracile axonal dystrophy; ubiquitin; Wallerian degeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID PRECURSOR PROTEIN; UBIQUITIN-PROTEASOME SYSTEM; CARBOXY-TERMINAL HYDROLASE; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; CYTOSKELETAL PATHOLOGY; NERVE-TERMINALS; HIV-INFECTION; ANIMAL-MODEL	Axonal dystrophy is the hallmark of axon pathology in many neurodegenerative disorders of the CNS, including Alzheimer's disease, Parkinson's disease and stroke. Axons can also form larger swellings, or spheroids, as in multiple sclerosis and traumatic brain injury. Some spheroids are terminal endbulbs of axon stumps, but swellings may also occur on unbroken axons and their role in axon loss remains uncertain. Similarly, it is not known whether spheroids and axonal dystrophy in so many different CNS disorders arise by a common mechanism. These surprising gaps in current knowledge result largely from the lack of experimental methods to manipulate axon pathology. The slow Wallerian degeneration gene, Wld(S), delays Wallerian degeneration after injury, and also delays 'dying-back' in peripheral nervous system disorders, revealing a mechanistic link between two forms of axon degeneration traditionally considered distinct. We now report that Wld(S) also inhibits axonal spheroid pathology in gracile axonal dystrophy (gad) mice. Both gracile nucleus (P < 0.001) and cervical gracile fascicle (P = 0.001) contained significantly fewer spheroids in gad/Wld(S) mice, and secondary signs of axon pathology such as myelin loss were also reduced. Motor nerve terminals at neuromuscular junctions continued to degenerate in gad/Wld(S) mice, consistent with previous observations that Wld(S) has a weaker effect on synapses than on axons, and probably contributing to the fact that Wld(S) did not alleviate gad symptoms. Wld(S) acts downstream of the initial pathogenic events to block gad pathology, suggesting that its effect on axonal swelling need not be specific to this disease. We conclude that axon degeneration mechanisms are more closely related than previously thought and that a link exists in gad between spheroid pathology and Wallerian degeneration that could hold for other disorders.	Babraham Inst, Cambridge CB2 4AT, England; Univ Cologne, ZMMK, Cologne, Germany; Univ Cologne, Inst Genet, D-5000 Cologne, Germany; Univ Cologne, Dept Anat 1, Cologne, Germany; Univ Edinburgh, Div Neurosci, Edinburgh, Midlothian, Scotland; Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo, Japan; Kanagawa Childrens Med Ctr, Clin Res Inst, Yokohama, Kanagawa, Japan		Coleman, MP (corresponding author), Babraham Inst, Cambridge CB2 4AT, England.	michael.coleman@bbsrc.ac.uk	Gillingwater, Thomas/G-2880-2011	Gillingwater, Thomas/0000-0002-0306-5577; Adalbert, Robert/0000-0003-0782-1402; Ribchester, Richard/0000-0003-2670-6995			ADELBERT R, IN PRESS EUR J NEURO; Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; Brendza RP, 2003, J COMP NEUROL, V456, P375, DOI 10.1002/cne.10536; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bu BT, 2002, J NEUROSCI, V22, P6515; BUCKMASTER EA, 1995, EUR J NEUROSCI, V7, P1596, DOI 10.1111/j.1460-9568.1995.tb01155.x; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Edgar JM, 2004, J CELL BIOL, V166, P121, DOI 10.1083/jcb.200312012; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GEORGE R, 1994, J NEUROCYTOL, V23, P657, DOI 10.1007/BF01181641; Gillingwater TH, 2004, J CEREBR BLOOD F MET, V24, P62, DOI 10.1097/01.WCB.0000095798.98378.34; Gillingwater TH, 2002, J PHYSIOL-LONDON, V543, P739, DOI 10.1113/jphysiol.2002.022343; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Hughes PM, 2003, J NEUROPATH EXP NEUR, V62, P1276, DOI 10.1093/jnen/62.12.1276; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; KIKUCHI T, 1990, ACTA NEUROPATHOL, V80, P145, DOI 10.1007/BF00308917; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kornek B, 2001, BRAIN, V124, P1114, DOI 10.1093/brain/124.6.1114; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kurihara LJ, 2001, HUM MOL GENET, V10, P1963, DOI 10.1093/hmg/10.18.1963; Laser H, 2003, J NEUROSCI RES, V74, P906, DOI 10.1002/jnr.10806; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Liberski PP, 1999, ACTA NEUROPATHOL, V97, P329, DOI 10.1007/s004010050995; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mi WQ, 2003, MUTAT RES-FUND MOL M, V526, P33, DOI 10.1016/S0027-5107(03)00011-3; Mi WQ, 2002, J NEUROSCI METH, V113, P215, DOI 10.1016/S0165-0270(01)00501-5; MIIKE T, 1986, ACTA NEUROPATHOL, V69, P117, DOI 10.1007/BF00687047; MIURA H, 1993, NEUROPATH APPL NEURO, V19, P41, DOI 10.1111/j.1365-2990.1993.tb00403.x; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; Norreel JC, 2001, EUR J NEUROSCI, V13, P1625, DOI 10.1046/j.0953-816x.2001.01535.x; ODA K, 1992, NEUROPATH APPL NEURO, V18, P265, DOI 10.1111/j.1365-2990.1992.tb00789.x; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Pan YA, 2003, J NEUROSCI, V23, P11479; Pierce ET., 1971, ATLAS MOUSE BRAIN SP; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Samsam M, 2003, J NEUROSCI, V23, P2833; SUNG JH, 1981, J NEUROPATH EXP NEUR, V40, P37; Takahashi T, 1997, ACTA NEUROPATHOL, V94, P294, DOI 10.1007/s004010050707; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Wilson SM, 2002, NAT GENET, V32, P420, DOI 10.1038/ng1006; WUJEK JR, 1983, J NEUROSCI, V3, P243; YAMAZAKI K, 1988, P SOC EXP BIOL MED, V187, P209; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	74	92	94	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2005	128		2				405	416		10.1093/brain/awh368			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	891UF	WOS:000226605800020	15644421	Bronze			2022-02-06	
J	Sun, D; Colello, RJ; Daugherty, WP; Kwon, TH; McGinn, MJ; Harvey, HB; Bullock, MR				Sun, D; Colello, RJ; Daugherty, WP; Kwon, TH; McGinn, MJ; Harvey, HB; Bullock, MR			Cell proliferation and neuronal differentiation in the dentate gyrus in juvenile and adult rats following traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						BrdU; dentate gyrus; fluid percussion injury; hippocampus; neurogenesis; proliferation	FIBROBLAST-GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; FLUID-PERCUSSION MODEL; SUBVENTRICULAR ZONE; HIPPOCAMPAL NEUROGENESIS; GRANULE CELLS; FRONTAL LESIONS; NERVOUS-SYSTEM; IN-VIVO; AGE	It is well known that the cognitive functions of juveniles recover to a greater extent than adult patients following traumatic brain injury (TBI). The exact mechanisms underlying this age-related disparity are unknown; however, we speculate that this improved recovery in juveniles following TBI may be associated with an endogenous neurogenic response in the hippocampus. We, therefore, examined the effects of TBI on cellular proliferation and differentiation in the dentate gyrus (DG) of the hippocampus in juvenile and adult rats following lateral fluid percussion injury (FPI). The temporal profile of the injury-induced proliferative response was determined using BrdU labeling at varying survival times. The differentiation of these newly generated cells was investigated using cell-type specific markers. We found that, following injury, there was a significant increase in cell proliferation in the DG in both injured juveniles and adults at 2 days post injury when compared to shams. When comparing the extent of cell proliferation between juveniles and adults following TBI, the absolute number of cells generated in the subgranular zone (SGZ) was far greater in the juveniles. Moreover, the percentage of newly generated cells in the SGZ that differentiated into neurons was nearly two times higher in the juveniles as compared to adults. Conversely, more glial differentiation was observed in the DG of adult rats. These findings provide compelling evidence that age-related differences in the neurogenic response to injury may underlie the differences observed in cognitive recovery in juvenile mammals as compared to adults following TBI.	Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia, Richmond, VA 23298 USA		Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia, POB 980631, Richmond, VA 23298 USA.	dsun@hsc.vcu.edu					ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dong HX, 2003, J NEUROSCI, V23, P1742; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Gray WP, 2002, NEUROSCI LETT, V330, P235, DOI 10.1016/S0304-3940(02)00810-8; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Jiang W, 2003, BRAIN RES, V977, P141, DOI 10.1016/S0006-8993(03)02438-7; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2002, J NEUROSCI, V22, P5365; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kirn JR, 1999, J COMP NEUROL, V411, P487; KOLB B, 1991, BEHAV BRAIN RES, V43, P51, DOI 10.1016/S0166-4328(05)80051-8; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Markakis EA, 1999, J COMP NEUROL, V406, P449; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	54	92	98	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					95	105		10.1089/neu.2005.22.95			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600006	15665605				2022-02-06	
J	Pelsers, MMAL; Hanhoff, T; Van Der Voort, D; Arts, B; Peters, M; Ponds, R; Honig, A; Rudzinski, W; Spener, F; De Kruijk, JR; Twijnstra, A; Hermens, WT; Menheere, PPCA; Glatz, JFC				Pelsers, MMAL; Hanhoff, T; Van Der Voort, D; Arts, B; Peters, M; Ponds, R; Honig, A; Rudzinski, W; Spener, F; De Kruijk, JR; Twijnstra, A; Hermens, WT; Menheere, PPCA; Glatz, JFC			Brain- and heart-type fatty acid-binding proteins in the brain: Tissue distribution and clinical utility	CLINICAL CHEMISTRY			English	Article							NEURON-SPECIFIC ENOLASE; ACUTE MYOCARDIAL-INFARCTION; MYELIN BASIC-PROTEIN; SKELETAL-MUSCLE INJURY; CEREBROSPINAL-FLUID; S-100 PROTEIN; MOUSE-BRAIN; SERUM CONCENTRATIONS; CARDIAC-SURGERY; EARLY MARKER	Background: Detection of brain injury by serum markers is not a standard procedure in clinical practice, although several proteins, such as S100B, neuron-specific enolase (NSE), myelin basic protein, and glial fibrillary acidic protein, show promising results. We investigated the tissue distribution of brain- and heart-type fatty acid-binding proteins (B-FABP and H-FABP) in segments of the human brain and the potential of either protein to serve as plasma marker for diagnosis of brain injury. Methods: B-FABP and H-FABP were measured immunochemically in autopsy samples of the brain (n = 6) and in serum samples from (a) patients with mild traumatic brain injury (MTBI; n = 130) and (b) depressed patients undergoing bilateral electroconvulsive therapy (ECT; n = 14). The protein markers S100B and NSE were measured for comparison. Reference values of B-FABP and H-FABP were established in healthy individuals (n = 92). Results: The frontal, temporal, and occipital lobes, the striatum, the pons, and the cerebellum had different tissue concentrations of B-FABP and of H-FABP. B-FABP ranged from 0.8 mug/g wet weight in striatum tissue to 3.1 mug/g in frontal lobe. H-FABP was markedly higher, ranging from 16.2 mug/g wet weight in cerebellum tissue to 39.5 mug/g in pons. No B-FABP was detected in serum from healthy donors. H-FABP serum reference value was 6 mug/L. In the MTBI study, serum B-FABP was increased in 68% and H-FABP in 70% of patients compared with S100B (increased in 45%) and NSE (increased in 51% of patients). In ECT, serum B-FABP was increased in 6% of all samples (2 of 14 patients), whereas H-FABP was above its upper reference limit (6 mug/L) in 17% of all samples (8 of 14 patients), and S100B was above its upper reference limit (0.3 mug/L) in 0.4% of all samples. Conclusions: B-FABP and H-FABP patterns differ among brain tissues, with the highest concentrations in the frontal lobe and pons, respectively. However, in each part of the brain, the H-FABP concentration was at least 10 times higher than that of B-FABP. Patient studies indicate that B-FABP and H-FABP are more sensitive markers for minor brain injury than the currently used markers S100B and NSE. (C) 2004 American Association for Clinical Chemistry.	Maastricht Univ, Dept Mol Genet, CARIM, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Biophys, CARIM, NL-6200 MD Maastricht, Netherlands; Univ Munster, Dept Biochem, D-4400 Munster, Germany; Med Acad Bialystok, Dept Surg, Bialystok, Poland; Univ Hosp Maastricht, Dept Psychiat, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Clin Chem, Maastricht, Netherlands		Pelsers, MMAL (corresponding author), Maastricht Univ, Dept Mol Genet, CARIM, POB 616, NL-6200 MD Maastricht, Netherlands.	maurice.pelsers@gen.unimaas.nl		ponds, rudolf/0000-0002-9748-4659			AURREL A, 1991, STROKE, V22, P1254; Balendiran GK, 2000, J BIOL CHEM, V275, P27045; BAUDIER J, 1984, BIOCHIM BIOPHYS ACTA, V790, P164, DOI 10.1016/0167-4838(84)90220-6; Broderick JP, 2002, CIRCULATION, V106, P1563, DOI 10.1161/01.CIR.0000030406.47365.26; Carney S, 2003, LANCET, V361, P799; de Groot MJM, 1999, CARDIOVASC RES, V44, P315, DOI 10.1016/S0008-6363(99)00199-6; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DEVANAND DP, 1994, AM J PSYCHIAT, V151, P957; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Glatz JFC, 2002, J CLIN LIGAND ASSAY, V25, P167; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Guillaume E, 2003, PROTEOMICS, V3, P1495, DOI 10.1002/pmic.200300478; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ishii J, 1997, CLIN CHEM, V43, P1372; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; JONSSON H, 2000, VASC ANESTH, V6, P698; Key G, 1999, CLIN BIOCHEM, V32, P229, DOI 10.1016/S0009-9120(98)00108-8; Kilminster S, 1999, STROKE, V30, P1869, DOI 10.1161/01.STR.30.9.1869; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; MyersPayne SC, 1996, J NEUROCHEM, V66, P1648; NAKAGAWA H, 1994, NEUROSURGERY, V34, P825, DOI 10.1227/00006123-199405000-00006; Nooijen PTGA, 1997, DEMENT GERIATR COGN, V8, P169, DOI 10.1159/000106627; Owada Y, 1996, MOL BRAIN RES, V42, P156, DOI 10.1016/S0169-328X(96)00182-9; Pelsers MMAL, 1999, CLIN CHEM, V45, P441; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Pu LX, 1999, MOL CELL BIOCHEM, V198, P69, DOI 10.1023/A:1006946027619; Robers M, 1998, CLIN CHEM, V44, P1564; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; ROOS W, 1995, J IMMUNOL METHODS, V183, P149, DOI 10.1016/0022-1759(95)00043-A; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; SELLNER PA, 1995, DEV BRAIN RES, V89, P33, DOI 10.1016/0165-3806(95)00099-Y; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Sorichter S, 1998, BRIT J SPORT MED, V32, P121, DOI 10.1136/bjsm.32.2.121; van der Voort D, 2003, BIOSENS BIOELECTRON, V19, P465, DOI 10.1016/S0956-5663(03)00205-7; VANNIEUWENHOVEN FA, 1995, CIRCULATION, V92, P2848, DOI 10.1161/01.CIR.92.10.2848; Verbeek MM, 2003, ANN CLIN BIOCHEM, V40, P25, DOI 10.1258/000456303321016141; Watanabe T, 2001, CLIN BIOCHEM, V34, P257, DOI 10.1016/S0009-9120(01)00200-4; Wodzig KWH, 1997, ANN CLIN BIOCHEM, V34, P263, DOI 10.1177/000456329703400307	45	92	102	0	8	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147			CLIN CHEM	Clin. Chem.	SEP	2004	50	9					1568	1575		10.1373/clinchem.2003.030361			8	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	848YJ	WOS:000223503800014	15217991	Green Published, Bronze			2022-02-06	
J	Susco, TM; McLeod, TCV; Gansneder, BM; Shultz, SJ				Susco, TM; McLeod, TCV; Gansneder, BM; Shultz, SJ			Balance recovers within 20 minutes after exertion as measured by the balance error scoring system	JOURNAL OF ATHLETIC TRAINING			English	Article						postural stability; fatigue; recuperation; concussion	MILD HEAD-INJURY; MOTONEURON FIRING RATES; POSTURAL STABILITY; TREADMILL EXERCISE; MUSCLE FATIGUE; CONCUSSION; CONTRACTIONS; PERFORMANCE; COLLEGIATE; MANAGEMENT	Objective: To determine a balance recovery timeline after a functional exertion protocol using the Balance Error Scoring System (BESS). Design and Setting: Five subject groups (4 test, 1 control) were tested 3 times during 1 session: once before the exertion protocol (pretest) and twice after the exertion protocol (posttest I and posttest II). Posttest I occurred at staggered intervals of 0, 5, 10, and 15 minutes, depending on experimental group assignment, and posttest II occurred at 20 minutes. Subjects: One hundred subjects (80 test, 20 control) volunteered to participate in this study. None of the subjects had a balance disorder, mild head injury, or lower extremity injury in the 6 months before testing. Measurements: We assessed balance using the BESS, assigning a score for each stance-surface condition. Results: We found a significant decrease in BESS performance after the exertion protocol in all test groups, with exertion having the greatest effect on the tandem and single-leg stance conditions. All subjects recovered by posttest II, which was administered 20 minutes after cessation of the exertion protocol. Conclusions: Athletic trainers need to be aware of the effect of exertion when administering the BESS after physical activity. Athletic trainers can expect the BESS performance of healthy athletes to return to baseline levels within 20 minutes of rest.	Arizona Sch Hlth Sci, Dept Sports Hlth Care, Mesa, AZ 85206 USA; Washington Univ, St Louis, MO USA; Univ Virginia, Charlottesville, VA USA; Univ N Carolina, Greensboro, NC 27412 USA		McLeod, TCV (corresponding author), Arizona Sch Hlth Sci, Dept Sports Hlth Care, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722			Adlerton AK, 1996, SCAND J MED SCI SPOR, V6, P211; BAKER AJ, 1993, J APPL PHYSIOL, V74, P2294, DOI 10.1152/jappl.1993.74.5.2294; Barr WB, 2001, J ATHL TRAINING, V36, P297; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; Borg G., 1998, BORGS PERCEIVED EXER; BYUNG YJ, 1991, ARCH PHYS MED REHAB, V72, P642; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1992, PHYSICAN SPORTSMED, V20, P66; Crowell DH, 2001, J ATHL TRAINING, V36, pS; Derave W, 2002, INT J SPORTS MED, V23, P44, DOI 10.1055/s-2002-19374; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; DIENER HC, 1988, PROG BRAIN RES, V76, P253; Fulco CS, 1999, ACTA PHYSIOL SCAND, V167, P233; FUNDERBURK CF, 1974, J APPL PHYSIOL, V37, P392, DOI 10.1152/jappl.1974.37.3.392; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAKKINEN K, 1993, INT J SPORTS MED, V14, P53, DOI 10.1055/s-2007-1021146; HAKKINEN K, 1983, ELECTROEN CLIN NEURO, V55, P436, DOI 10.1016/0013-4694(83)90132-3; HORAK FB, 1990, EXP BRAIN RES, V82, P167; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; MARKS R, 1993, PERCEPT MOTOR SKILL, V77, P1195, DOI 10.2466/pms.1993.77.3f.1195; McCrea M, 2001, J ATHL TRAINING, V36, P274; Moyna NM, 2001, MED SCI SPORT EXER, V33, P1404, DOI 10.1097/00005768-200108000-00025; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Nardone A, 1998, ARCH PHYS MED REHAB, V79, P920, DOI 10.1016/S0003-9993(98)90088-0; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robertson RJ, 2000, MED SCI SPORT EXER, V32, P2120, DOI 10.1097/00005768-200012000-00024; SELIGA R, 1991, AM IND HYG ASSOC J, V52, P417, DOI 10.1202/0002-8894(1991)052<0417:EOWLAR>2.0.CO;2; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; THOMAS JR, 1975, MED SCI SPORT EXER, V7, P203; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; WOODS JJ, 1987, J NEUROPHYSIOL, V58, P125, DOI 10.1152/jn.1987.58.1.125; Yaggie J. A., 1999, Medicine and Science in Sports and Exercise, V31, pS284, DOI 10.1097/00005768-199905001-01399; YATES JW, 1987, EUR J APPL PHYSIOL, V56, P662, DOI 10.1007/BF00424807	43	92	93	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2004	39	3					241	246					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	858UF	WOS:000224216800005	15496993				2022-02-06	
J	Zhu, S; Li, MW; Figueroa, BE; Liu, AJ; Stavrovskaya, IG; Pasinelli, P; Beal, MF; Brown, RH; Kristal, BS; Ferrante, RJ; Friedlander, RM				Zhu, S; Li, MW; Figueroa, BE; Liu, AJ; Stavrovskaya, IG; Pasinelli, P; Beal, MF; Brown, RH; Kristal, BS; Ferrante, RJ; Friedlander, RM			Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice	JOURNAL OF NEUROSCIENCE			English	Article						creatine; ischemia; caspase; cytochrome c; neuroprotection; bioenergetics	NEURONAL CELL-DEATH; MOUSE MODEL; INJURY; MITOCHONDRIA; ATTENUATION; MINOCYCLINE; PROTECTS; MUTANT; BCL-2	Creatine mediates remarkable neuroprotection in experimental models of amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and traumatic brain injury. Because caspase-mediated pathways are shared functional mechanistic components in these diseases, as well as in ischemia, we evaluated the effect of creatine supplementation on an experimental stroke model. Oral creatine administration resulted in a remarkable reduction in ischemic brain infarction and neuroprotection after cerebral ischemia in mice. Postischemic caspase-3 activation and cytochrome c release were significantly reduced in creatine-treated mice. Creatine administration buffered ischemia-mediated cerebral ATP depletion. These data provide the first direct correlation between the preservation of bioenergetic cellular status and the inhibition of activation of caspase cell-death pathways in vivo. An alternative explanation to our findings is that creatine is neuroprotective through other mechanisms that are independent of mitochondrial cell-death pathways, and therefore postischemic ATP preservation is the result of tissue spearing. Given its safety record, creatine might be considered as a novel therapeutic agent for inhibition of ischemic brain injury in humans. Prophylactic creatine supplementation, similar to what is recommended for an agent such as aspirin, may be considered for patients in high stroke-risk categories.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Nuerosurg,Neuroapoptosis Lab, Boston, MA 02115 USA; Bedford Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Burke Med Res Inst, White Plains, NY 10605 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY 10021 USA; Massachusetts Gen Hosp E, Dept Neurol, Day Neuromuscular Res Lab, Charlestown, MA 02129 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA		Friedlander, RM (corresponding author), Harvard Univ, Sch Med, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu	Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219; Pasinelli, Piera/0000-0002-3385-2707			Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Dedeoglu A, 2003, J NEUROCHEM, V85, P1359, DOI 10.1046/j.1471-4159.2003.01706.x; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kristal BS, 1999, ANN NY ACAD SCI, V893, P321, DOI 10.1111/j.1749-6632.1999.tb07846.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tatsumi T, 2003, CARDIOVASC RES, V59, P428, DOI 10.1016/S0008-6363(03)00391-2; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zoghbi HY, 2002, TRENDS GENET, V18, P463, DOI 10.1016/S0168-9525(02)02729-4	27	92	100	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 30	2004	24	26					5909	5912		10.1523/JNEUROSCI.1278-04.2004			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	833PZ	WOS:000222351900007	15229238	Bronze, Green Published			2022-02-06	
J	Suuronen, T; Huuskonen, J; Pihlaja, R; Kyrylenko, S; Salminen, A				Suuronen, T; Huuskonen, J; Pihlaja, R; Kyrylenko, S; Salminen, A			Regulation of microglial inflammatory response by histone deacetylase inhibitors	JOURNAL OF NEUROCHEMISTRY			English	Article						acetylation; Alzheimer; epigenetics; histone deacetylase; neurodegeneration; nuclear factor kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; IMMUNE-SYSTEM; CHROMATIN STRUCTURE; GENE-REGULATION; UP-REGULATION; ACETYLATION; ACTIVATION; CYTOKINES	The activation of microglial cells is involved in the pathogenesis of a variety of neurodegenerative diseases, stroke and traumatic brain injuries. Recent studies suggest that protein acetylation can affect the extent of inflammatory responses. Our aim was to elucidate whether histone deacetylase inhibitors, inducers of protein hyperacetylation, regulate the inflammatory response in neural models of inflammation in vitro and whether neurone - glia interactions affect this regulation. Interestingly, we observed that histone deacetylase inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid, strongly potentiated the lipopolysaccharide (LPS)-induced inflammatory response in murine N9 and rat primary microglial cells as well in neural co-cultures and hippocampal slice cultures. TSA clearly potentiated the LPS-induced expression of interleukin (IL)-6 and inducible nitric oxide synthase mRNAs, as well as the secretion of cytokines IL-6, tumour necrosis factor-alpha and macrophage inflammatory protein (MIP)-2, and nitric oxide (NO). Co-culture and slice culture experiments showed that the presence of astrocytes and neurones did not stimulate or prevent the pro-inflammatory potentiation induced by histone deacetylase inhibitor in microglial cells. The potentiation of cytokine and NO responses was blocked by the nuclear factor kappa B (NF-kappaB) inhibitors caffeic acid phenethyl ester and helenalin, demonstrating that the NF-kappaB signalling pathway is involved. The DNA-binding activity of the NF-kappaB complex was strongly increased by LPS treatment but not enhanced by TSA. This suggests that potentiation of the inflammatory response is not dependent on the level of cytoplasmic NF-kappaB activation or DNA-binding activity but that site of action may be at the level of transcriptional regulation. Our results suggest that environmental stresses, ageing, diet and diseases that regulate protein acetylation status may also affect the inflammatory response.	Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Salminen, A (corresponding author), Univ Kuopio, Dept Neurol & Neurosci, Pob 1627, FIN-70211 Kuopio, Finland.	antero.salminen@uku.fi					Ajamian F, 2003, NEUROSCI LETT, V346, P57, DOI 10.1016/S0304-3940(03)00545-7; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Chang KT, 2002, AGEING RES REV, V1, P313, DOI 10.1016/S1568-1637(02)00003-X; Chang RCC, 2000, BRAIN RES, V853, P236, DOI 10.1016/S0006-8993(99)02255-6; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Helenius M, 1999, EXP CELL RES, V248, P194, DOI 10.1006/excr.1999.4393; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; Helenius M, 2001, ANTIOXID REDOX SIGN, V3, P147, DOI 10.1089/152308601750100669; Holloway AF, 2002, MOL IMMUNOL, V38, P567, DOI 10.1016/S0161-5890(01)00094-3; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jung M, 2001, CURR MED CHEM, V8, P1505, DOI 10.2174/0929867013372058; Kaltschmidt B, 2000, EXP BRAIN RES, V130, P100, DOI 10.1007/s002210050011; Kerokoski P, 2001, NEUROCHEM INT, V38, P127, DOI 10.1016/S0197-0186(00)00071-1; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nakamura Y, 2002, BIOL PHARM BULL, V25, P945, DOI 10.1248/bpb.25.945; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Polevoda B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-5-reviews0006; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	47	92	95	2	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					407	416		10.1046/j.1471-4159.2003.02004.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100014	14511118	Bronze			2022-02-06	
J	Timonen, M; Miettunen, J; Hakko, H; Zitting, P; Veijola, J; von Wendt, L; Rasanen, P				Timonen, M; Miettunen, J; Hakko, H; Zitting, P; Veijola, J; von Wendt, L; Rasanen, P			The association of preceding traumatic brain injury with mental disorders, alcoholism and criminality: the Northern Finland 1966 Birth Cohort Study	PSYCHIATRY RESEARCH			English	Article						psychiatric disorders; alcohol abuse; alcohol dependence; criminal	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PSYCHIATRIC-DISORDERS; NERVOUS-SYSTEM; HEAD-INJURY; SUBSTANCE-ABUSE; UNITED-STATES; FOLLOW-UP; SCHIZOPHRENIA; COMORBIDITY	The purpose of this study was to test the hypothesis that traumatic brain injury (TBI) during childhood and adolescence is associated with psychiatric disorders, heavy alcohol use and criminal offenses in adulthood. We made use of an unselected, general population birth cohort (n=12058) in Northern Finland, which was followed up prospectively up to the age of 31. The data on TBIs of the cohort members were collected from the hospital case notes of the outpatient clinics of the hospitals in the region and from the Finnish Hospital Discharge Registers (FHDR). The data on mental disorders including alcohol diagnoses were also collected from the FHDR after a careful validation process. The Ministry of Justice provided information on criminal offenses for all subjects. The final number of subjects in our study was 5589 males and 5345 females. We found that after controlling for confounders, TBI during childhood or adolescence increased the risk of developing mental disorders two-fold (OR 2.1, 95% CI 1.1-3.6) and TBI was significantly related to later mental disorder with coexisting criminality in male cohort members (OR 4.1, 95% CI 1.2-13.6). The results support the TBI's association with psychiatric morbidity, which should not be overlooked when treating psychiatric patients, especially those with comorbid criminality. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Oulu, Dept Psychiat, FIN-90014 Oulu, Finland; Oulu Hlth Ctr, FIN-90015 Oulu, Finland; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, FIN-90220 Oulu, Finland; HUCH Hosp Children & Adolescents, Dept Child Neurol, FIN-00029 Helsinki, HYKS, Finland		Timonen, M (corresponding author), Univ Oulu, Dept Psychiat, POB 5000, FIN-90014 Oulu, Finland.		Miettunen, Jouko/AAC-4334-2019	Miettunen, Jouko/0000-0003-0575-2669			BARNFIELD TV, 1988, BRAIN INJURYU, V12, P455; BIEDERMAN J, 1995, AM J PSYCHIAT, V152, P1652; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; CLONINGER CR, 1995, EUR ARCH PSY CLIN N, V245, P239, DOI 10.1007/BF02191803; Deb S, 1999, AM J PSYCHIAT, V156, P374; Diaz F G, 1995, Med Law, V14, P131; Eyestone L L, 1994, Bull Am Acad Psychiatry Law, V22, P181; Faraone SV, 2000, BIOL PSYCHIAT, V48, P9, DOI 10.1016/S0006-3223(00)00889-1; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HILL AB, 1965, P ROY SOC MED, V58, P293; Isohanni M, 1997, SOC PSYCH PSYCH EPID, V32, P303, DOI 10.1007/BF00789044; JOUKAMAA M, 1991, M10791; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KONDRAD K, 2000, BRAIN INJURY, V14, P859; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEWIS DO, 1982, J ADOLESCENT HEALTH, V3, P160, DOI 10.1016/S0197-0070(82)80119-8; LEWIS DO, 1979, CHILD PSYCHIAT HUM D, V9, P210, DOI 10.1007/BF01433696; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; McAllister, 1998, Semin Clin Neuropsychiatry, V3, P211; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MILBERGER S, 1995, AM J PSYCHIAT, V152, P1793; Pliszka SR, 2000, CHILD ADOL PSYCH CL, V9, P525; POIKOLAINEN K, 1983, DRUG ALCOHOL DEPEN, V12, P315, DOI 10.1016/0376-8716(83)90002-9; RANTAKALLIO P, 1979, SOC SCI MED-MED SOC, V13, P423, DOI 10.1016/0160-7979(79)90131-0; RANTAKALLIO P, 1995, SOC PSYCH PSYCH EPID, V30, P113, DOI 10.1007/BF00802039; RANTAKALLIO P, 1992, INT J EPIDEMIOL, V21, P1106, DOI 10.1093/ije/21.6.1106; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; RANTAKALLIO P, 1985, J EPIDEMIOL COMMUN H, V39, P353, DOI 10.1136/jech.39.4.353; RANTAKALLIO P, 1969, ACTA PAEDIAT SC S193, V0193; Rantakallio P, 1997, INT J EPIDEMIOL, V26, P837, DOI 10.1093/ije/26.4.837; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SHANOK SS, 1981, ARCH GEN PSYCHIAT, V38, P211; *STAT FINL CRIM NO, 1996, HANDBOOKS, V27; Taylor, 1998, Semin Clin Neuropsychiatry, V3, P224; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	46	92	92	0	20	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	DEC 30	2002	113	3					217	226	PII S0165-1781(02)00269-X	10.1016/S0165-1781(02)00269-X			10	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	643VL	WOS:000180881900001	12559478				2022-02-06	
J	Sun, FY; Lin, X; Mao, LZ; Ge, WH; Zhang, LM; Huang, YL; Gu, J				Sun, FY; Lin, X; Mao, LZ; Ge, WH; Zhang, LM; Huang, YL; Gu, J			Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia	JOURNAL OF PINEAL RESEARCH			English	Article						antioxidant; apoptosis; brain; DNA repair; injury; ischemia; neuronal death	TRAUMATIC BRAIN INJURY; CELL-DEATH; FOREBRAIN ISCHEMIA; OXIDATIVE DAMAGE; EXCISION-REPAIR; REPERFUSION; PROTECTS; EXPRESSION; BCL-2; REDUCTION	In the present study, double fluorescence staining combined with confocal laser scanning microscopy analysis were used to examine the effects of melatonin on ischemia-induced neuronal DNA strand breaks and its possible mechanisms in a transient middle cerebral artery (MCA) occlusion model. Results showed that melatonin dose-dependently reduced infarct areas and decreased both DNA double and single strand breaks (DSB and SSB) and enhanced cell viability in the peri-ischemic brain regions. Furthermore, Bcl-2 induction in the ischemic brain was further enhanced by melatonin treatment. Double staining analysis indicated that the cells costained for Bcl-2 and TdT-mediated-deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL), a DSB marker, displayed a relative regular morphology compared with the cells only stained with TUNEL. Transient ischemia induced an expression of excision repair cross-complementing factor 6 (ERCC6) mRNA, a gene essential for the preferential repair of nuclear excision repair, in the injured neurons. Double labeling showed that ERCC6 only co-localized with proliferating cell nuclear antigen (PCNA), a member of the nuclear excision repair complex, but not with TUNEL. Melatonin further and statistical significantly up-regulated ERCC6 mRNA expression in the peri-ischemic region of rat brains. The results suggest that neuroprotection by melatonin against ischemic injury may be related to modulation of apoptosis and DNA repair capacity.	Fudan Univ, Med Ctr, Natl Key Lab Med Neurobiol, Shanghai 200032, Peoples R China		Sun, FY (corresponding author), Fudan Univ, Med Ctr, Natl Key Lab Med Neurobiol, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.						Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; Cazevieille C, 1997, BRAIN RES, V755, P91, DOI 10.1016/S0006-8993(97)00090-5; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chang YY, 1999, NEUROSCI LETT, V277, P61, DOI 10.1016/S0304-3940(99)00799-5; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; Chen J, 1997, J NEUROCHEM, V69, P232; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; Li XJ, 2002, J PINEAL RES, V32, P47, DOI 10.1034/j.1600-079x.2002.10831.x; Li XJ, 1999, ACTA PHARMACOL SIN, V20, P201; Li XJ, 1997, ACTA PHARMACOL SIN, V18, P394; Lin LH, 2000, J NEUROCHEM, V74, P1098; Ling X, 1999, ACTA PHARMACOL SIN, V20, P15; Ling X, 1999, ACTA PHARMACOL SIN, V20, P409; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu PK, 1996, J NEUROSCI, V16, P6795; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Love S, 1999, BRAIN PATHOL, V9, P119; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Murakami K, 1997, BRAIN RES, V751, P160, DOI 10.1016/S0006-8993(97)00029-2; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; Pierre C., 1994, LIFE SCI, V55, P271; Reiter, 2000, CURR TOP BIOPHYS, V24, P171; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, P W PHARMACOL SOC, V41, P229; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Reiter RJ, 1999, BIOL SIGNAL RECEPT, V8, P56; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Tang L, 1998, MOL CELL BIOCHEM, V178, P299, DOI 10.1023/A:1006815530519; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Wakatsuki A, 2001, J PINEAL RES, V31, P167, DOI 10.1034/j.1600-079x.2001.310211.x; Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yin KJ, 1999, BRAIN RES, V815, P29, DOI 10.1016/S0006-8993(98)01071-3; [No title captured]; [No title captured]	45	92	94	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0742-3098			J PINEAL RES	J. Pineal Res.	AUG	2002	33	1					48	56		10.1034/j.1600-079X.2002.01891.x			9	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	573MF	WOS:000176833300007	12121485				2022-02-06	
J	Servadei, F; Murray, GD; Teasdale, GM; Dearden, M; Iannotti, F; Lapierre, F; Maas, AJR; Karimi, A; Ohman, J; Persson, L; Stocchetti, N; Trojanowski, T; Unterberg, A				Servadei, F; Murray, GD; Teasdale, GM; Dearden, M; Iannotti, F; Lapierre, F; Maas, AJR; Karimi, A; Ohman, J; Persson, L; Stocchetti, N; Trojanowski, T; Unterberg, A			Traumatic subarachnoid hemorrhage: Demographic and clinical study of 750 patients from the European Brain Injury Consortium survey of head injuries	NEUROSURGERY			English	Article						computed tomographic classification; moderate and severe head injury; outcome; subarachnoid hemorrhage	TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL BLOOD-FLOW; SUBDURAL HEMATOMAS; VASOSPASM; DAMAGE; SPASM; SCAN; COMA	OBJECTIVE: Previous reports identified the presence of traumatic subarachnoid hemorrhage (tSAH) on admission computed tomographic (CT) scans as an independent prognostic factor in worsening outcomes. The mechanism underlying the link between tSAH and prognosis has not been clarified. The aim of this study was to investigate the association between CT evidence of tSAH and outcomes after moderate or severe head injuries. METHODS: In a survey organized by the European Brain Injury Consortium, data on initial severity, treatment, and subsequent outcomes were prospectively collected for 1005 patients with moderate or severe head injuries who were admitted to one of the 67 European neurosurgical units during a 3-month period in 1995. The CT findings were classified according to the Traumatic Coma Data Bank classification system, and the presence or absence of tSAH was recorded separately in the initial CT scan forms. RESULTS: Complete data on early clinical features, CT findings, and outcomes at 6 months were available for 750 patients, of whom 41% exhibited evidence of tSAH on admission CT scans. There was a strong, highly statistically significant association between the presence of tSAH and poor outcomes. In fact, 41% of patients without tSAH achieved the level of good recovery, whereas only 15% of patients with tSAH achieved this outcome. Patients with tSAH were significantly older (median age, 43 yr; standard deviation, 21.1 yr) than those without tSAH (median age, 32 yr; standard deviation, 19.5 yr), and there was a significant tendency for patients with tSAH to exhibit lower Glasgow Coma Scale scores at the time of admission. A logistic regression analysis of favorable/unfavorable outcomes demonstrated that there was still a very strong association between tSAH and outcomes after simultaneous adjustment for age, Glasgow Coma Scale Motor Scores, and admission CT findings (odds ratio, 2.49; 95% confidence interval, 1.74-3.55; P < 0.001). Comparison of the time courses for 164 patients with early (within 14 d after injury) deaths demonstrated very similar patterns, with an early peak and a subsequent decline; there was no evidence of a delayed increase in mortality rates for either group of patients (with or without tSAH). CONCLUSION: These findings for an unselected series of patients confirm previous reports of the adverse prognostic significance of tSAH. The data support the view that death among patients with tSAH is related to the severity of the initial mechanical damage, rather than to the effects of delayed vasospasm and secondary ischemic brain damage.	Osped Maurizio Bufalini, WHO, Neurotrauma Collaborating Ctr, Div Neurochirurg Traumatol, I-47023 Cesena, Italy; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Inst Neurol Sci, Glasgow, Lanark, Scotland; Leeds Gen Infirmary, Dept Anaesthet, Leeds, W Yorkshire, England; Southampton Gen Hosp, Dept Clin Neurosci, Southampton SO9 4XY, Hants, England; Ctr Hosp Univ Poitiers, Serv Neurochirurg, Poitiers, France; Univ Rotterdam Hosp, Dept Neurosurg, Rotterdam, Netherlands; Univ Cologne, Neurochirurg Klin, Cologne, Germany; Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; Akad Hosp, Dept Neurosurg, Uppsala, Sweden; Osped Maggiore Policlin, Ist Ricovero & Cura Carattere Sci Milano, Terapia Intens Neurochirug Serv Anestesia & Riani, Milan, Italy; Tech Univ Lublin, Sch Med, Dept Neurosurg, PL-20618 Lublin, Poland; Humboldt Univ, Fak Med, Klinikum Rudolf Virchow, Dept Neurosurg, Berlin, Germany		Servadei, F (corresponding author), Osped Maurizio Bufalini, WHO, Neurotrauma Collaborating Ctr, Div Neurochirurg Traumatol, I-47023 Cesena, Italy.	fservade@ausl-cesena.emr.it	Stocchetti, Nino/O-7444-2017; Maas, Andrew IR/C-5584-2013	Stocchetti, Nino/0000-0003-3250-6834; Maas, Andrew IR/0000-0003-1612-1264; Ohman, Juha/0000-0002-6592-1367; Murray, Gordon/0000-0001-9866-4734; Servadei, Franco/0000-0002-3595-3464; Trojanowski, Tomasz/0000-0002-4914-1838			BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; Domenicucci M, 1998, NEUROSURGERY, V42, P51, DOI 10.1097/00006123-199801000-00010; DORSCH NW, 1993, CAN J NEUROL SCI S1, V20, P28; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; HALEY EC, 1992, STROKE, V23, P205, DOI 10.1161/01.STR.23.2.205; HALEY EC, 1993, J NEUROSURG, V78, P548, DOI 10.3171/jns.1993.78.4.0548; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Kakarieka A, 1997, TRAUMATIC SUBARACHNO, P1; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; PERRONE P, 1985, ITAL J NEUROL SCI, V6, P43, DOI 10.1007/BF02229216; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SHIGEMORI M, 1990, Neurologia Medico-Chirurgica, V30, P396, DOI 10.2176/nmc.30.396; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699943277; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Zubkov ZY, 2000, SURG NEUROL, V53, P126	34	92	100	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2002	50	2					261	267		10.1097/00006123-200202000-00006			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	514FE	WOS:000173427300007	11844260				2022-02-06	
J	Lynch, JR; Pineda, JA; Morgan, D; Zhang, L; Warner, DS; Benveniste, H; Laskowitz, DT				Lynch, JR; Pineda, JA; Morgan, D; Zhang, L; Warner, DS; Benveniste, H; Laskowitz, DT			Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema	ANNALS OF NEUROLOGY			English	Article							CLOSED-HEAD INJURY; TRAUMATIC BRAIN INJURY; COGNITIVE DEFICITS; TNF-ALPHA; ACTIVATION; MICE	Apolipoprotein E has been implicated in modifying neurological outcome after traumatic brain injury, although the mechanisms by which this occurs remain poorly defined. To investigate the role of endogenous apolipoprotein E following acute brain injury, noninvasive magnetic resonance imaging was performed on anesthetized mice following closed head injury. Effacement of the lateral ventricle was used as a radiographic surrogate for cerebral edema. At 24 hours following injury, apolipoprotein E-deficient animals had a greater degree of cerebral edema as compared to matched controls. In addition, the brains of apolipoprotein E-deficient animals had a significantly greater upregulation of tissue necrosis factor alpha messenger ribonuclcic acid as compared to controls as early as 1-hr post injury. Thus, modulation of the endogenous central nervous system inflammatory response may be one mechanism by which apolipoprotein E affects outcome following acute brain injury.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Lab, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.		Pineda, Jose/W-2806-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR05959] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM08600] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37235, 1K08NS01949] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR005959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001949, R01NS037235] Funding Source: NIH RePORTER		Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Hu JR, 1998, J NEUROCHEM, V71, P1626; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pineda JA, 2001, J NEUROTRAUM, V18, P625, DOI 10.1089/089771501750291864; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	17	92	98	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0364-5134			ANN NEUROL	Ann. Neurol.	JAN	2002	51	1					113	117		10.1002/ana.10098			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	508JK	WOS:000173084800015	11782990				2022-02-06	
J	Morganti-Kossmann, MC; Hans, VHJ; Lenzlinger, PM; Dubs, R; Ludwig, E; Trentz, O; Kossmann, T				Morganti-Kossmann, MC; Hans, VHJ; Lenzlinger, PM; Dubs, R; Ludwig, E; Trentz, O; Kossmann, T			TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function	JOURNAL OF NEUROTRAUMA			English	Article						antiinflammatory; blood-brain barrier; interleukin-6; lung; lymphocytes; outcome; transforming growth factor-beta; traumatic brain injury	GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; VENTRICULAR CEREBROSPINAL-FLUID; RAT-BRAIN; LUNG INJURY; IN-VITRO; CEREBRAL INJURY; TNF-ALPHA; EXPRESSION	Traumatic brain injury (TBI) induces local and systemic immunologic changes, release of cytokines, and cell activation. Perpetuation of these cascades may contribute to secondary damage to the brain. Therefore, the ability of the antiinflammatory mediator transforming growth factor-beta (TGF-beta) to downregulate intrathecal immunoactivation may be of fundamental value for diminishing the incidence and extent of secondary insults. In this study, the release of TGF-beta into cerebrospinal fluid (CSF) and serum of 22 patients with severe TBI was analyzed with respect to the function of the blood-brain barrier (BBB) for 21 days. Levels of TGF-beta in CSF increased to their maximum on the first day (median, 1.26 ng/mL), thereafter decreasing gradually over time. Median TGF-beta values in serum always remained within the reference interval (6.5 to 71.5 ng/mL). Daily assessment of the CSF-serum albumin quotient (Q(A)) and of the CSF-serum TGF-beta quotient (Q(TGF-beta)) showed a strong correlation between maximal Q(TGF-beta) and Q(A), indicating a passage of this cytokine from the periphery to the intrathecal compartment across the BBB. However, calculation of the TGF-beta index (Q(TGF-beta 0)/Q(A)) suggested a cerebral production of TGF-beta in 9 of 22 patients. Levels of TGF-beta could not be correlated with extent of initial injury by computed tomography (CT), CD4/CD8 ratios, acute lung injury, or clinical outcome as rated by the Glasgow Outcome Scale (GOS). Although increased levels of TGF-beta in CSF seem to parallel BBB function, a partial intrathecal production is suggested, possibly modulated by elevation of interleukin-6 (IL-6). Thus, TGF-beta may function as a factor in the complex cytokine network following TBI, acting as an antiinflammatory and neuroprotective mediator.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Hosp Bonn, Inst Neuropathol, Bonn, Germany; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Internal Med, Div Clin Immunol, Zurich, Switzerland		Morganti-Kossmann, MC (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, Raemistr 100, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			AYALA A, 1993, IMMUNOLOGY, V79, P479; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CAMPBELL LL, 1998, ANN NY ACAD SCI, V840, P83; CHAO CC, 1995, CLIN IMMUNOL IMMUNOP, V77, P358, DOI 10.1006/clin.1995.1163; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; DELPECH B, 1972, CLIN CHIM ACTA, V37, P15, DOI 10.1016/0009-8981(72)90410-X; deLuca A, 1996, J NEUROSCI, V16, P4174; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; FREI K, 1993, INT REV EXP PATHOL, V34, P183; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOODING R, 1995, BRIT J CANCER, V72, P452, DOI 10.1038/bjc.1995.354; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; HENRICHNOACK P, 1994, J NEURAL TRANSM-SUPP, P33; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNS LD, 1993, J NEUROIMMUNOL, V47, P1, DOI 10.1016/0165-5728(93)90278-7; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KITAZAWA K, 1994, STROKE, V25, P1400, DOI 10.1161/01.STR.25.7.1400; Kossik J, 1997, GENET ENG NEWS, V17, P28; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Marshall LF, 1991, J NEUROSURG S, V75, P14; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; RICOU B, 1996, YB INTENSIVE CARE EM, P375; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, V95, P417; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Rollnik JD, 1997, ACTA NEUROL SCAND, V96, P101; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHENKAR R, 1994, AM J RESP CELL MOL, V11, P351, DOI 10.1165/ajrcmb.11.3.8086171; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Specht H., 1997, Society for Neuroscience Abstracts, V23, P1149; STOCKER R, 1995, INTEGRATED APPROACH, P197; SUZUKI Y, 1994, J APPL PHYSIOL, V77, P1281, DOI 10.1152/jappl.1994.77.3.1281; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vawter MP, 1996, EXP NEUROL, V142, P313, DOI 10.1006/exnr.1996.0200; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Winkler MK, 1998, GLIA, V22, P171, DOI 10.1002/(SICI)1098-1136(199802)22:2<171::AID-GLIA8>3.0.CO;2-A; ZHOU DH, 1991, FASEB J, V5, P2582, DOI 10.1096/fasebj.5.11.1868982	66	92	95	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					617	628		10.1089/neu.1999.16.617			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700006	10447073				2022-02-06	
J	Shum, D; Valentine, M; Cutmore, T				Shum, D; Valentine, M; Cutmore, T			Performance of individuals with severe long-term traumatic brain injury on time-, event-, and activity-based prospective memory tasks	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								This study investigated the effect of traumatic brain injury (TBI) on time-, event-, and activity-based prospective memory using a laboratory paradigm developed in the literature on ageing (Einstein, McDaniel, Richardson, Guynn, & Cunfer, 1995). The participants were 12 individuals with severe longterm TBI and 12 community controls. Participants were asked to answer general-knowledge questions on a computer for two sessions. The time- and event-based tasks were embedded in this filler activity. Participants were also required to carry out activity-based actions at the end of the two sessions. Participants with TBI performed significantly worse than did controls on all three prospective-memory tasks, indicating that TBI affects not only retrospective but also prospective memory. Implications of these results for the assessment and rehabilitation of memory problems in individuals with TBI are discussed.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Neuropsychol Unit, Brisbane, Qld 4111, Australia		Shum, D (corresponding author), Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; DALLABARBA G, 1993, HDB NEUROPSYCHOLOGY, V8, P239; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; LEVIN HS, 1991, HDB NEUROPSYCOLOGY, V6, P183; MAPOU RL, 1992, HDB HEAD TRAUMA ACUT, P75; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; TEASDALE G, 1974, LANCET, V2, P81	15	92	94	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1999	21	1					49	58		10.1076/jcen.21.1.49.943			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	214VN	WOS:000081348400006	10421001				2022-02-06	
J	Giometto, B; An, SF; Groves, M; Scaravilli, T; Geddes, JF; Miller, R; Tavolato, B; Beckett, AAJ; Scaravilli, F				Giometto, B; An, SF; Groves, M; Scaravilli, T; Geddes, JF; Miller, R; Tavolato, B; Beckett, AAJ; Scaravilli, F			Accumulation of beta-amyloid precursor	ANNALS OF NEUROLOGY			English	Article							AIDS DEMENTIA COMPLEX; DEFICIENCY SYNDROME AIDS; TRAUMATIC BRAIN INJURY; FRONTAL-CORTEX; HIV-INFECTION; AXONAL INJURY; HEAD-INJURY; PROTEIN; DAMAGE; CELLS	The pathogenesis of neuropsychological abnormalities in patients with human immunodeficiency virus type 1 (HN-B) encephalitis is obscure because neurons are nor the target of infection and severe neuronal loss occurs only late during the disease. Moreover, there is evidence indicating that HIV dementia is not a homogeneous entity and could partially reverse after treatment with zidovudine, The finding that impaired axonal flow, evidenced by beta-amyloid precursor protein immunoreactivity, could contribute to the neuropsychological deficits prompted the present study. Brains of patients with full-blown acquired immunodeficiency syndrome (AIDS) were studied and findings compared with those of normal and abnormal control subjects. The presence of HIV-1 DNA was investigated by nested polymerase chain reaction; axonal abnormalities were detected by beta-amyloid precursor protein, ubiquitin immunohistochemistry, and silver staining. Accumulation of beta-amyloid precursor protein was observed in all the HIV encephalitis brains studied; the appearance of the immunostaining varied from globular structures to bundles of parallel formations. In 2 AIDS brains without pathological abnormalities, only the latter pattern was detected. The brains with trauma mere strongly reactive with beta-amyloid precursor protein antibody and the different reactivity within them correlated with posttrauma survival, only globular structures being detected in the older cases. No correlation was found between the different pattern of beta-amyloid precursor protein reactivity and dementia in AIDS patients. These results shaw that widespread axonal injury is a constant feature in AIDS brains and suggest that it could play a role in the pathogenesis of the neuropsychological abnormalities of these patients.	UNIV LONDON,INST NEUROL,DEPT NEUROPATHOL,NATL HOSP NEUROL & NEUROSURG,LONDON WC1N 3BG,ENGLAND; UNIV PADUA,DEPT PSYCHIAT & NEUROL,NEUROL CLIN,PADUA,ITALY; UNIV LONDON,DEPT MORBID ANAT & HISTOPATHOL,LONDON,ENGLAND; UNIV LONDON,DEPT SEXUALLY TRANSMITTED DIS,LONDON,ENGLAND				Giometto, Bruno/AAG-3236-2019	giometto, bruno/0000-0003-2311-9752; Miller, Robert/0000-0003-2067-4291			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; AN SF, 1994, J CLIN PATHOL, V47, P990, DOI 10.1136/jcp.47.11.990; An SF, 1996, ACTA NEUROPATHOL, V91, P494, DOI 10.1007/s004010050457; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BUDKA H, 1986, ACTA NEUROPATHOL, V69, P253, DOI 10.1007/BF00688301; BUDKA H, 1993, NEUROPATHOLOGY HIV I, P171; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; CIECHANOVER A, 1993, BRAIN PATHOL, V3, P67, DOI 10.1111/j.1750-3639.1993.tb00727.x; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRIFFIN JW, 1987, J NEUROPATHOL EXP NE, V36, P214; JANSSEN RS, 1991, NEUROLOGY, V41, P778; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLEIHUES P, 1985, ACTA NEUROPATHOL, V68, P333, DOI 10.1007/BF00690837; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PETITO CK, 1995, AM J PATHOL, V146, P1121; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Price RW, 1991, BRAIN PATHOL, V1, P155, DOI 10.1111/j.1750-3639.1991.tb00655.x; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613	33	92	93	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0364-5134			ANN NEUROL	Ann. Neurol.	JUL	1997	42	1					34	40		10.1002/ana.410420108			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XK106	WOS:A1997XK10600006	9225683				2022-02-06	
J	Marklund, N; Salci, K; Lewen, A; Hillered, L				Marklund, N; Salci, K; Lewen, A; Hillered, L			Glycerol as a marker for post-traumatic membrane phospholipid degradation in rat brain	NEUROREPORT			English	Article						degradation; glycerol; membrane function; microdialysis; phospholipid; rat; traumatic brain injury	FREE FATTY-ACIDS; AMINO-ACIDS; INJURY; ISCHEMIA	Degradation of membrane phospholipids (PLs) is a well known phenomenon in acute brain injuries and is thought to underlie the disturbance of vital cellular membrane functions. In the present study glycerol, an end product of PL degradation, was examined in brain interstitial fluid as a marker of PL breakdown following experimental traumatic brain injury (TBI) using microdialysis. TBI was induced in artificially ventilated rats using the weight-drop technique. The trauma caused a significant, eight-fold increase of dialysate glycerol in the injured cortex, with the peak concentration in the second 10 min fraction after trauma. Glycerol then levelled off but remained significantly above sham-operated controls for the entire 4 h observation period in the perimeter of the injury region where scattered neuronal death is seen. The results support the concept that PL degradation occurs early after TBI and that interstitial glycerol, harvested by microdialysis, may be useful as a marker allowing in vivo monitoring of PL breakdown.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN				Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Marklund, Niklas/0000-0002-9797-5626			ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; AGARDH CD, 1981, J NEUROCHEM, V36, P490, DOI 10.1111/j.1471-4159.1981.tb01619.x; Agranoff Bernard W., 1994, P97; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FAROOQUI AA, 1994, INT REV NEUROBIOL, V36, P267, DOI 10.1016/S0074-7742(08)60306-2; FELLANDER G, 1994, J CLIN ENDOCR METAB, V78, P150, DOI 10.1210/jc.78.1.150; FOSTER KJ, 1978, CLIN CHEM, V24, P1568; GARDINER M, 1981, J NEUROCHEM, V36, P1500, DOI 10.1111/j.1471-4159.1981.tb00592.x; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; GERCKEN G, 1969, J NEUROCHEM, V16, P761, DOI 10.1111/j.1471-4159.1969.tb06454.x; HINZEN DH, 1970, PFLUG ARCH EUR J PHY, V318, P117, DOI 10.1007/BF00586491; LLOYD B, 1978, CLIN CHEM, V24, P1724; MARKLUND N, 1996, J NEUROTRAUMA, V13, P600; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NILSSON P, 1994, BRAIN RES, V37, P227; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SLESJO B, 1992, NEUROBIOLOGY ESSENTI, P41; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WESTERGREN I, 1994, J NEUROCHEM, V62, P159	30	92	95	0	1	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	APR 14	1997	8	6					1457	1461		10.1097/00001756-199704140-00026			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XB174	WOS:A1997XB17400028	9172153				2022-02-06	
J	DeWitt, DS; Smith, TG; Deyo, DJ; Miller, KR; Uchida, T; Prough, DS				DeWitt, DS; Smith, TG; Deyo, DJ; Miller, KR; Uchida, T; Prough, DS			L-arginine and superoxide dismutase prevent or reverse cerebral hypoperfusion after fluid-percussion traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; free radicals; head trauma; ischemia; L-arginine; laser Doppler; nitric oxide	BLOOD-FLOW; NITRIC-OXIDE; RELAXING FACTOR; HEAD-INJURY; ARTERY OCCLUSION; RAT; INHIBITION; ISCHEMIA; DAMAGE; MICROCIRCULATION	To determine whether treatment with L-arginine or superoxide dismutase (SOD) would prove effective in reducing cerebral hypoperfusion after traumatic brain injury (TBI), we measured cerebral blood flow (CBF) using laser Doppler flowmetry (LDF) in rats treated before or after moderate (2.2 atm) fluid-percussion (FP) TBI. Rats were anesthetized with isoflurane and prepared for midline FP TBI and then for LDF by thinning the calvaria using an air-cooled drill. Rats were then randomly assigned to receive sham injury, sham injury plus L-arginine (100 mg/kg, 5 min after sham TBI), TBI plus 0.9 % NaCl, TBI plus L-arginine (100 mg/kg, 5 min post-TBI), TBI plus SOD (24,000 U/kg pre-TBI + 1600 units/kg/min for 15 min after TBI), or TBI plus SOD and L-arginine. A second group of rats received TBI plus saline, L-, or D-arginine (100 mg/kg, 5 min after-TBI). After treatment and TBI or sham injury, CBF was measured continuously using LDF for 2 h and CBF was expressed as a percent of the preinjury baseline for 2 h after TBI. Rats treated with saline or D-arginine exhibited significant reductions in CBF that persisted throughout the monitoring period. Rats treated with L-arginine alone or in combination with SOD exhibited no decreases in CBF after TBI. CBF in the SOD-treated group decreased significantly within 15 min after TBI but returned to baseline levels by 45 min after TBI. These studies indicate that L-arginine but not D-arginine administered after TBI prevents posttraumatic hypoperfusion and that pretreatment with SOD will restore CBF after a brief period of hypoperfusion.	UNIV TEXAS, MED BRANCH, DEPT PREVENT MED & COMMUNITY HLTH, GALVESTON, TX 77555 USA		DeWitt, DS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, CHARLES R ALLEN RES LABS, GALVESTON, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [19355] Funding Source: Medline		ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1991, J CEREB BLOOD FLO S2, V11, pS629; BONVENTO G, 1994, J CEREBR BLOOD F MET, V14, P699, DOI 10.1038/jcbfm.1994.90; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Crow J P, 1995, Adv Pharmacol, V34, P17; DEWITT D S, 1992, Anesthesiology (Hagerstown), V77, pA689, DOI 10.1097/00000542-199209001-00689; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; FARACI FM, 1991, AM J PHYSIOL, V261, pH1038, DOI 10.1152/ajpheart.1991.261.4.H1038; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247, DOI 10.1152/ajpheart.1989.256.4.H1247; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KOZNIEWSKA E, 1992, J CEREBR BLOOD F MET, V12, P311; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MILLER JD, 1990, BRIT J SURG, V77, P241, DOI 10.1002/bjs.1800770302; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Morita K, 1996, ANN THORAC SURG, V61, P1775, DOI 10.1016/0003-4975(96)00146-4; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ODLIND B, 1988, PHARMACOL TOXICOL, V62, P95, DOI 10.1111/j.1600-0773.1988.tb01853.x; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Prado R, 1996, J CEREBR BLOOD F MET, V16, P612, DOI 10.1097/00004647-199607000-00011; REYES AA, 1994, AM J PHYSIOL, V267, pF331, DOI 10.1152/ajprenal.1994.267.3.F331; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SZABO C, 1994, CIRC SHOCK, V44, P104; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; YUAN XQ, 1989, J NEUROTRAUMA, V6, P211; ZHANG ZG, 1995, J NEUROL SCI, V128, P22, DOI 10.1016/0022-510X(94)00216-B	50	92	93	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1997	14	4					223	233		10.1089/neu.1997.14.223			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WY593	WOS:A1997WY59300005	9151771				2022-02-06	
J	Steinmeier, R; Bauhuf, C; Hubner, U; Bauer, RD; Fahlbusch, R; Laumer, R; Bondar, I				Steinmeier, R; Bauhuf, C; Hubner, U; Bauer, RD; Fahlbusch, R; Laumer, R; Bondar, I			Slow rhythmic oscillations of blood pressure, intracranial pressure, microcirculation, and cerebral oxygenation - Dynamic interrelation and time course in humans	STROKE			English	Article						autoregulation; blood pressure; cerebral blood flow; intracranial pressure	LASER-DOPPLER FLOWMETRY; WAVE-FORM ANALYSIS; FLOW VELOCITY; B-WAVES; AUTOREGULATION; MODEL	Background and Purpose Various biological signals show nonpulsatile, slow rhythmic oscillations. These include arterial blood pressure (aBP), blood flow velocity in cerebral arteries, intracranial pressure (ICP), cerebral microflow, and cerebral tissue Po-2. Generation and interrelations between these rhythmic fluctuations remained unclear. The aim of this study was to analyze whether stable dynamic interrelations in the low-frequency range exist between these different variables, and if they do, to analyze their exact time delay. Methods In a clinical study, 16 comatose patients with either higher-grade subarachnoid hemorrhage or severe traumatic brain injury were examined. A multimodal digital data acquisition system was used to simultaneously monitor aBP, flow velocity in the middle cerebral artery (FVMCA), ICP, cerebral microflow, and oxygen saturation in the jugular bulb (Sjo(2)). Cross-correlation as a means to analyze time delay and correlation between two periodic signals was applied to a time series of 30 minutes' duration divided into four segments of 2048 data points (approximate to 436 seconds) each. This resulted in four cross-correlations for each 30-minute time series. If the four cross-correlations were consistent and reproducible, averaging of the original cross-correlations was performed, resulting in a representative time delay and correlation for the complete 30-minute interval. Results Reproducible cross-correlations and stable dynamic interrelations were found between aBP, FVMCA, ICP, and Sjo(2). The mean time delay between aBP and ICP was 6.89 +/- 1.90 sec ends, with a negative correlation in 81%. A mean time delay of 1.50 +/- 1.29 seconds (median, 0.85 seconds) was found between FVMCA and ICP, with a positive correlation in 94%. The mean delay between ICP and Sjo(2) was 9.47 +/- 2.21 seconds, with a positive correlation in 77%. Mean values of aBP and ICP did not influence the time delay and dynamic interrelation between the different parameters. Conclusions These results strongly support Rosner's theory that ICP B-waves are the autoregulatory response of spontaneous fluctuations of cerebral perfusion pressure. There is casuistic evidence that failure of autoregulation significantly modifies time delay and the correlation between aBP and ICP.	UNIV ERLANGEN NURNBERG, INST PHYSIOL & CARDIOL, D-91054 ERLANGEN, GERMANY; UNIV HEIDELBERG, DEPT MED INFORMAT, FACHHSCH HEILBRONN, HEILBRONN, GERMANY		Steinmeier, R (corresponding author), UNIV ERLANGEN NURNBERG, NEUROCHIRURG KLIN, DEPT NEUROSURG, SCHWABACHANLAGE 6, D-91054 ERLANGEN, GERMANY.						AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AUER LM, 1981, EUR NEUROL, V20, P448, DOI 10.1159/000115278; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; BUSSE R, 1982, KREISLAUFPHYSIOLOGIE; CHALLIS RE, 1990, MED BIOL ENG COMPUT, V28, P509, DOI 10.1007/BF02442601; CLARK LC, 1958, J APPL PHYSIOL, V13, P85, DOI 10.1152/jappl.1958.13.1.85; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DALEY ML, 1995, IEEE T BIO-MED ENG, V42, P420, DOI 10.1109/10.376137; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; DEOUGEMENT J, 1972, INTRACRANIAL PRESSUR, V1, P232; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; DORA E, 1981, ACTA PHYSIOL HUNG, V57, P261; EINHAUPL KM, 1986, INTRACRANIAL PRESSUR, V6, P290; FLORENCE G, 1992, J CEREBR BLOOD F MET, V12, P674, DOI 10.1038/jcbfm.1992.92; FRIESEN WO, 1984, AM J PHYSIOL, V246, pR847, DOI 10.1152/ajpregu.1984.246.6.R847; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Gretchin V B, 1969, Electroencephalogr Clin Neurophysiol, V26, P546; HALSEY J H JR, 1974, Stroke, V5, P219; HAXHIU MA, 1989, AM J PHYSIOL, V257, pR804, DOI 10.1152/ajpregu.1989.257.4.R804; HUNDLEY WG, 1988, AM J PHYSIOL, V254, pH67, DOI 10.1152/ajpheart.1988.254.1.H67; JONES SC, 1995, AM J PHYSIOL-HEART C, V268, pH569, DOI 10.1152/ajpheart.1995.268.2.H569; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; LUNDAR T, 1990, ACTA NEUROCHIR, V102, P85, DOI 10.1007/BF01405419; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MAUTNER-HUPPERT D, 1989, Neurological Research, V11, P194; MAYEVSKY A, 1991, Neurological Research, V13, P39; MORITATSUZUKI Y, 1992, ACTA PHYSIOL SCAND, V146, P431, DOI 10.1111/j.1748-1716.1992.tb09444.x; NELSON RJ, 1992, NEUROSURGERY, V31, P705; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; OKAWARA SH, 1974, J NEUROSURG, V41, P415, DOI 10.3171/jns.1974.41.4.0415; PETTOROSSI VE, 1978, EUR NEUROL, V17, P216, DOI 10.1159/000114948; PIPER IR, 1993, NEUROSURGERY, V32, P805, DOI 10.1227/00006123-199305000-00014; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Press W.H., 1988, NUMERICAL RECIPES C; Rosner M., 1986, INTRACRANIAL PRESSUR, P137, DOI [10.1007/978-3-642-70971-5_25, DOI 10.1007/978-3-642-70971-5_25]; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROSNER MJ, 1983, INTRACRANIAL PRESSUR, V5, P301; STEARNS SD, 1988, SIGNAL PROCESSDING A; Symon L, 1973, STROKE, V4, P139, DOI 10.1161/01.STR.4.2.139; VENES JL, 1979, CHILD BRAIN, V5, P352; VERN BA, 1988, J CEREBR BLOOD F MET, V8, P215, DOI 10.1038/jcbfm.1988.52; YAMAMOTO S, 1983, INTRACRANIAL PRESSUR, V5, P333	44	92	92	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	1996	27	12					2236	2243		10.1161/01.STR.27.12.2236			8	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	VY009	WOS:A1996VY00900015	8969787				2022-02-06	
J	Haas, DC				Haas, DC			Chronic post-traumatic headaches classified and compared with natural headaches	CEPHALALGIA			English	Article						post-traumatic headache; whiplash headache	CHRONIC POSTTRAUMATIC HEADACHE; WHIPLASH INJURY; CLUSTER HEADACHE; BRAIN INJURY; MINOR HEAD; SYMPTOMS; NECK; CONCUSSION; FEATURES	This study sought to determine whether chronic post-traumatic headaches are different from or identical to the naturally occurring headaches. The chronic post-traumatic headaches of 48 patients were classified, as if they were natural headaches, by the diagnostic criteria of the International Headache Society. Thirty-six patients' headaches (75%) were chronic tension-type headache, 10 (21%) were migraine without aura, and 2 (4%) were unclassifiable. The characteristics and accompaniments of the headaches within each diagnostic group were then compared to those in a control group with natural headaches of the same type. Nc notable differences between the post-traumatic and control groups were found. Hence, chronic post-traumatic headaches have no special features, but are symptomatically identical to either chronic tension-type headache or migraine without aura (in this series of patients). This identity suggests that post-traumatic headaches are generated by the same processes causing the natural headaches, not by intracranial derangement from head blows or jolts.	SUNY HLTH SCI CTR,DEPT NEUROL,SYRACUSE,NY 13210								ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BEHRMAN S, 1977, INJURY, V9, P74, DOI 10.1016/0020-1383(77)90059-6; BENOLIEL R, 1994, J ORAL MAXIL SURG, V52, P1138, DOI 10.1016/0278-2391(94)90530-4; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; CARTLIDGE NEF, 1981, HEAD INJURY, P106; CARTLIDGE NEF, 1981, HEAD INJURY, P110; CARTLIDGE NEF, 1981, HEAD INJURY, P145; CARTLIDGE NEF, 1981, HEAD INJURY, P107; Cook J. B, 1969, LATE EFFECTS HEAD IN, P408; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DUCKRO PN, 1995, HEADACHE Q-CURR TREA, V6, P34; DUCKRO PN, 1992, HEADACHE Q-CURR TREA, V3, P295; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; FOLETTI G, 1995, PRESSE MED, V24, P1121; Haas DC, 1994, HEADACHE CLASSIFICAT, P155; International Headache Society, 1988, CEPHALALGIA S7, V8, P9; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Lidvall HF, 1974, ACTA NEUROLOGICA S56, V50, P7; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore KL, 1996, HEADACHE Q-CURR TREA, V7, P21; PACKARD RC, 1993, HEADACHE Q-CURR TREA, V4, P42; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; RADANOV BP, 1993, BRIT MED J, V307, P652, DOI 10.1136/bmj.307.6905.652; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; REIK L, 1987, HEADACHE, V27, P509, DOI 10.1111/j.1526-4610.1987.hed2709509.x; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SOLOMON S, 1992, CEPHALALGIA, V12, P365, DOI 10.1111/j.1468-2982.1992.00365.x; TURKEWITZ LJ, 1992, HEADACHE, V32, P504, DOI 10.1111/j.1526-4610.1992.hed3210504.x; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; Young WB, 1996, NEUROLOGY, V46, P1488, DOI 10.1212/WNL.46.5.1488	32	92	93	0	4	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0333-1024			CEPHALALGIA	Cephalalgia	NOV	1996	16	7					486	493		10.1046/j.1468-2982.1996.1607486.x			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VR956	WOS:A1996VR95600007	8933993				2022-02-06	
J	Rosenthal, M; Dijkers, M; HarrisonFelix, C; Nabors, N; Witol, AD; Young, ME; Englander, JS				Rosenthal, M; Dijkers, M; HarrisonFelix, C; Nabors, N; Witol, AD; Young, ME; Englander, JS			Impact of minority status on functional outcome and community integration following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; etiology; functional outcome; minority status	HEAD TRAUMA; REHABILITATION; SEVERITY; BLACKS; STROKE; CALIFORNIA; HISPANICS; LESIONS; WHITES; SCALE	Objective: To determine whether minority status affected short-term and 1-year functional outcome and community integration for patients with traumatic brain injury (TBI) in the TBI Model Systems National Data Base. Design: Prospective study, consecutive sample. Setting: Four tertiary care rehabilitation centers. Patients: Five hundred and eighty-six patients with TBI admitted to one of four TBI Model Systems programs from February 1989 through June 1995. Inclusion criteria for the study included evidence of a TBI, admission to the system hospital emergency department within 8 hours of injury, 19 years of age or older, and acute care and inpatient rehabilitation within the system hospitals. Information was collected for demographics such as race, age, gender, education, employment status, marital status, and data related to the injury such as injury severity, etiology of injury, and payer source. Over half of the sample was white (53.4%) with the 46.6% of minorities composed of blacks (37.2%). Hispanics (7.3%), and Asians (2.0%). Main Outcome Measures: Functional outcome was measured with the Functional Independence Measure (FIM). Disability Rating Scale (DRS), and Community Integration Questionnaire (CIQ). The FIM and DRS were measured at inpatient rehabilitation admission, discharge, and 1 year post injury. The CIQ total score and subscale scores for Home Integration, Social integration, and Productivity were obtained at 1-year post injury, It was hypothesized that minority status would not predict functional outcome after acute rehabilitation but would predict functional outcome and community integration at 1 year post injury. Results: There were no significant differences between whites and minorities for DRS and FM scores at acute rehabilitation discharge. There were also no significant differences between whites and minorities on FIM scores 1 year post injury, but there were significant differences between whites and minorities on the Social Integration and Productivity subscales and total score of the CIQ. Multiple regression indicated that minority status predicted functional outcome for CIQ total score (r=-.28) and two subscales, Social Integration (r=-.28) and Productivity (r=-.23) even after controlling for etiology, severity of injury, age, gender, and functional status a rehabilitation discharge. Conclusions: Although minority status does not negatively impact recovery of basic mobility and daily living skills, it may impact long-term outcome related to community integration as measured by productivity and social integration. Greater outreach and access to postdischarge services and support may be needed to optimize community integration outcomes. Further studies are needed to determine how best to serve the needs of this segment of the population with TBI.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA; INST REHABIL & RES,HOUSTON,TX; SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128		Rosenthal, M (corresponding author), WAYNE STATE UNIV,DEPT PHYS MED & REHABIL,261 MACK BLVD,DETROIT,MI 48201, USA.			Dijkers, Marcel/0000-0002-8362-5596			BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FOULKES MA, 1991, J NEUROSURG S, V75, pS9; FRANKOWSKI RF, 1986, CENTRAL NERVOUS SYST; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; HAGEN C, 1977, LEVELS COGNITIVE FUN; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HOWARD G, 1994, STROKE, V25, P2120, DOI 10.1161/01.STR.25.11.2120; JENNETT B, 1992, PROGNOSIS NEUROLOGIC; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; JOHNSTON MV, 1996, MED REHABILITATION T; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keith RA, 1987, ADV CLIN REHABILITAT; KENTON EJ, 1991, ARCH NEUROL-CHICAGO, V48, P480, DOI 10.1001/archneur.1991.00530170040018; KLATSKY AL, 1991, AM J PUBLIC HEALTH, V81, P1423, DOI 10.2105/AJPH.81.11.1423; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KUHLEMEIER KV, 1994, STROKE, V25, P2126, DOI 10.1161/01.STR.25.11.2126; LILLIEBLANTON M, 1995, NATIONS INTEREST EQU; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; SAAB PG, 1991, J HYPERTENS, V9, P249, DOI 10.1097/00004872-199103000-00009; SACCO RL, 1991, STROKE, V22, P305, DOI 10.1161/01.STR.22.3.305; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SKORD KG, 1994, BRAIN INJURY, V8, P383, DOI 10.3109/02699059409150989; Stover S. L., 1995, SPINAL CORD INJURY C; TEASDALE G, 1974, LANCET, V2, P81; WATERS RL, 1995, ORTHOP CLIN N AM, V26, P117; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WRIGHT TJ, 1988, J APPLIED REHABILITA, V19, P4; ZWEIFLER RM, 1995, STROKE, V26, P245, DOI 10.1161/01.STR.26.2.245; 1994, NIH GUIDE, V23, P2; 1994, FED REG         0603, V59, P29139	40	92	92	0	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					40	57		10.1097/00001199-199610000-00005			18	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300005					2022-02-06	
J	Young, B; Ott, L; Kasarskis, E; Rapp, R; Moles, K; Dempsey, RJ; Tibbs, PA; Kryscio, R; McClain, C				Young, B; Ott, L; Kasarskis, E; Rapp, R; Moles, K; Dempsey, RJ; Tibbs, PA; Kryscio, R; McClain, C			Zinc supplementation is associated with improved neurologic recovery rate and visceral protein levels of patients with severe closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						zinc supplementation; head injury; neurologic outcome; nutritional/metabolic status	COMA DATA-BANK; METHYL-D-ASPARTATE; SERUM-ZINC; CORTICAL-NEURONS; DEFICIENCY; BINDING; TRANSCRIPTION; IONS	Sixty-eight patients were entered into a randomized, prospective, double-blinded controlled trial of supplemental zinc versus standard zinc therapy to study the effects of zinc supplementation on neurologic recovery and nutritional/metabolic status after severe closed head injury. One month after injury, the mortality rates in the standard zinc group and the zinc-supplemented group were 26 and 12%, respectively. Glasgow Coma Scale (GCS) scores of the zinc-supplemented group exceeded the adjusted mean GCS score of the standard group at day 28 (p = 0.03). Mean motor GCS score levels of the zinc-supplemented group were significantly higher on days 15 and 21 than those of the control group (p = 0.005, p = 0.02). This trend continued on day 28 of the study (p = 0.09). The groups did not differ in serum zinc concentration, weight, energy expenditure, or total urinary nitrogen excretion after hospital admission. Mean 24-h urine zinc levels were significantly higher in the zinc-supplemented group at days 2 (p = 0.0001) and 10 (p = 0.01) after injury. Mean serum prealbumin concentrations were significantly higher in the zinc-supplemented group (p = 0.003) at 3 weeks after injury. A similar pattern was found for mean serum retinol binding protein level (p = 0.01). A significantly larger number of patients in the standard zinc group had craniotomies for evacuation of hematoma; thus a bias may have been present. The results of this study indicate that zinc supplementation during the immediate postinjury period is associated with improved rate of neurologic recovery and visceral protein concentrations for patients with severe closed head injury.	UNIV KENTUCKY, MED CTR, DEPT NEUROL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT STAT, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT NUTR SCI, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT PHARM, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT TOXICOL, LEXINGTON, KY 40536 USA; VET ADM MED CTR, LEXINGTON, KY 40511 USA		Young, B (corresponding author), UNIV KENTUCKY, MED CTR, DEPT SURG, 800 ROSE ST, LEXINGTON, KY 40536 USA.				NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR2602-04] Funding Source: Medline		BATES J, 1981, AM J CLIN NUTR, V34, P1655, DOI 10.1093/ajcn/34.9.1655; BAUDIER J, 1983, BIOCHEM BIOPH RES CO, V114, P1138, DOI 10.1016/0006-291X(83)90681-2; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; DAMASK MC, 1987, CRIT CARE CLIN, V3, P71, DOI 10.1016/S0749-0704(18)30562-1; DRUMMOND RW, 1985, J PARENT ENTER NUTR, V9, P196; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FAURE H, 1991, BIOL TRACE ELEM RES, V30, P37, DOI 10.1007/BF02990340; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; HALLBOOK T, 1972, LANCET, V2, P780; HENNIG B, 1993, J NUTR, V123, P1003; HENNIG B, 1992, J NUTR, V122, P1242, DOI 10.1093/jn/122.6.1242; HESKETH JE, 1982, INT J BIOCHEM, V14, P983, DOI 10.1016/0020-711X(82)90059-3; HULME EC, 1983, EUR J PHARMACOL, V94, P59, DOI 10.1016/0014-2999(83)90442-9; JIANG ZM, 1985, JPEN-PARENTER ENTER, V9, P196, DOI 10.1177/0148607185009002196; KAY RG, 1983, SURGICAL NUTRITION, P283; KOH JY, 1988, J NEUROSCI, V8, P2164; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LO MMS, 1983, J NEUROSCI, V3, P2270; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MCCLAIN CJ, 1985, PROG FOOD NUTR SCI, V9, P185; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; POWANDA MC, 1973, AM J PHYSIOL, V225, P399, DOI 10.1152/ajplegacy.1973.225.2.399; POWANDA MC, 1980, P SOC EXP BIOL MED, V163, P296; SLEVIN JT, 1985, BRAIN RES, V334, P281, DOI 10.1016/0006-8993(85)90219-7; SLOMIANKA L, 1992, NEUROSCIENCE, V48, P325, DOI 10.1016/0306-4522(92)90494-M; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; WANNEMACHER RW, 1972, J INFECT DIS, V126, P77, DOI 10.1093/infdis/126.1.77; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; 1984, USP DI, V2, P1394	37	92	95	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	1996	13	1					25	34		10.1089/neu.1996.13.25			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TW167	WOS:A1996TW16700004	8714860				2022-02-06	
J	COELHO, CA; LILES, BZ; DUFFY, RJ				COELHO, CA; LILES, BZ; DUFFY, RJ			IMPAIRMENTS OF DISCOURSE ABILITIES AND EXECUTIVE FUNCTIONS IN TRAUMATICALLY BRAIN-INJURED ADULTS	BRAIN INJURY			English	Article							HEAD	Preliminary findings from an ongoing investigation of the potential relationship between narrative discourse performance and executive functions in adults with traumatic brain injuries (TBI) are reported. Narrative stories were elicited from 32 adults with TBI. Stories were analysed at three levels: sentence production, intersentential cohesive adequacy, and story episode structure. These measures were then correlated with scores from the Wisconsin Card Sorting Test (WCST), the primary measure of executive function. A significant correlation was noted between a factor score from the WCST and the measure of story structure, but not sentence production or cohesive adequacy. These results suggest that executive functions may be a promising avenue to pursue in the search for underlying causal factors of narrative discourse dysfunction and, therefore to better delineate the nature of communicative deficits secondary to TBI.	GAYLORD HOSP,WALLINGFORD,CT; UNIV CONNECTICUT,STORRS,CT		COELHO, CA (corresponding author), SO CONNECTICUT STATE UNIV,DEPT COMMUN DISORDERS,501 CRESCENT ST,NEW HAVEN,CT 06515, USA.						BLANK M, 1978, PRESCHOOL LANGUAGE A; Coelho C.A., 1993, CLIN APHASIOLOGY, V21, P183; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Grant D. A., 1948, WISCONSIN CARD SORTI; HAGAN C, 1980, REHABILITATION HEAD; Halliday M. A. K., 1989, LANGUAGE CONTEXT TEX; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton R.K., 1981, WISCONSIN CARD SORTI; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V23, P123; MATTIS S, 1976, GERIATRIC PSYCHIAT, P148; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stein NL., 1979, NEW DIRECTIONS DISCO; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005	20	92	94	0	10	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					471	477		10.3109/02699059509008206			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100005	7550218				2022-02-06	
J	BRODKEY, JA; LAYWELL, ED; OBRIEN, TF; FAISSNER, A; STEFANSSON, K; DORRIES, HU; SCHACHNER, M; STEINDLER, DA				BRODKEY, JA; LAYWELL, ED; OBRIEN, TF; FAISSNER, A; STEFANSSON, K; DORRIES, HU; SCHACHNER, M; STEINDLER, DA			FOCAL BRAIN INJURY AND UP-REGULATION OF A DEVELOPMENTALLY-REGULATED EXTRACELLULAR-MATRIX PROTEIN	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; WOUND HEALING; CEREBRAL CORTEX; ASTROCYTES; TENASCIN; IMMUNOCYTOCHEMISTRY	MASSIVE CORTICAL REORGANIZATION; NEURAL CREST CELLS; NEURITE OUTGROWTH; ENHANCED EXPRESSION; RAT-BRAIN; TENASCIN; GROWTH; MOLECULES; GLYCOPROTEINS; FIBRONECTIN	Tenascin is an extracellular matrix glycoprotein expressed during both normal development and neoplastic growth in both neural and nonneural tissues. During development of the central nervous system (CNS), tenascin is synthesized by glial cells, in particular by immature astrocytes, and is concentrated in transient boundaries around emerging groups of functionally distinct neurons. In the mature CNS, only low levels of the glycoprotein can be detected. The present study demonstrates that following trauma to the adult human cerebral cortex, discrete populations of reactive astrocytes upregulate their expression of tenascin and dramatically increase their transcription of the tenascin gene. The enhanced expression of tenascin may be involved in CNS wound healing, and may also affect neurite growth within and around a brain lesion.	UNIV TENNESSEE,COLL MED,DEPT ANAT & NEUROBIOL,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT NEUROSURG,MEMPHIS,TN; UNIV HEIDELBERG,DEPT NEUROBIOL,W-6900 HEIDELBERG,GERMANY; HARVARD UNIV,DEPT NEUROL,BOSTON,MA; ETH ZURICH,ZURICH,SWITZERLAND				Stefansson, Kari/AAE-7187-2019; Faissner, Andreas/A-5314-2008; Steindler, Dennis/AAJ-5811-2020	Faissner, Andreas/0000-0002-2211-8259; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020856] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20856] Funding Source: Medline		BARTSCH S, 1992, J NEUROSCI, V12, P736; BOURDON MA, 1983, CANCER RES, V43, P2796; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; CHUONG CM, 1991, AM J PATHOL, V138, P427; DACUNHA A, 1993, BRAIN RES, V600, P161, DOI 10.1016/0006-8993(93)90415-J; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1988, DIFFERENTIATION, V37, P104, DOI 10.1111/j.1432-0436.1988.tb00802.x; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HALFTER W, 1989, DEV BIOL, V132, P14, DOI 10.1016/0012-1606(89)90200-5; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; NIETOSAMPEDRO M, 1988, PHARM APPROACHES TRE, P331; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; PROBSTMEIER R, 1990, J NEUROCHEM, V54, P1016, DOI 10.1111/j.1471-4159.1990.tb02351.x; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; Ramon y Cajal, 1928, DEGENERATION REGENER; Reier P., 1983, SPINAL CORD RECONSTR, P163; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Steindler D., 1992, Society for Neuroscience Abstracts, V18, P1042; STEINDLER DA, 1993, ANNU REV NEUROSCI, V16, P445, DOI 10.1146/annurev.ne.16.030193.002305; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TERVO K, 1991, INVEST OPHTH VIS SCI, V32, P2912; TUCKER RP, 1991, DEVELOPMENT, V112, P1031; Waller, 1850, PHILOS T R SOC LOND, VI, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021]	35	92	93	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	1995	82	1					106	112		10.3171/jns.1995.82.1.0106			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	PZ080	WOS:A1995PZ08000017	7529300				2022-02-06	
J	ORRISON, WW; GENTRY, LR; STIMAC, GK; TARREL, RM; ESPINOSA, MC; COBB, LC				ORRISON, WW; GENTRY, LR; STIMAC, GK; TARREL, RM; ESPINOSA, MC; COBB, LC			BLINDED COMPARISON OF CRANIAL CT AND MR IN CLOSED-HEAD INJURY EVALUATION	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article						HEAD, INJURIES; HEAD, COMPUTED TOMOGRAPHY; HEAD, MAGNETIC RESONANCE; MAGNETIC RESONANCE, COMPARATIVE STUDIES; COMPUTED TOMOGRAPHY, COMPARATIVE STUDIES; EFFICACY STUDIES	MAGNETIC-RESONANCE; COMPUTERIZED-TOMOGRAPHY; FIELD MR; TRAUMA; HEMATOMA; MANAGEMENT; MORTALITY; FEATURES; LESIONS	PURPOSE: To compare CT and MR in the evaluation of acute head injury. METHODS: One hundred seven consecutive patients who were referred to the emergency department and underwent both MR and CT cranial examinations within 48 hours were retrospectively reviewed. The films were interpreted by two neuroradiologists blinded to all patient information. RESULTS: The sensitivity of MR was significantly higher than that of CT for the detection of contusion, shearing injury, subdural and epidural hematoma, and sinus involvement. The sensitivity of CT was significantly higher than that of MR for the evaluation of fracture. The sensitivities of MR and CT were statistically equivalent for the detection of superficial soft-tissue injury. The overall sensitivity of MR for the detection of abnormalities in acute head trauma was 96.4%, and for CT was 63.4%. CONCLUSIONS: CT and MR are complementary studies in the evaluation of acute head trauma. MR is necessary to define or exclude contusions, deep shearing injury, and extraaxial fluid collections in acute head trauma.	UNIV NEW MEXICO,SCH MED,DEPT COMMUNITY MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT NEUROL,ALBUQUERQUE,NM 87131; UNIV WISCONSIN,CTR CLIN SCI,DEPT RADIOL,MADISON,WI; FIRST HILL DIAGNOST CTR,SEATTLE,WA		ORRISON, WW (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT RADIOL,ALBUQUERQUE,NM 87131, USA.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adams JH, 1982, RECENT ADV NEUROPATH, P165; BAKER SP, 1989, JAMA-J AM MED ASSOC, V262, P2284, DOI 10.1001/jama.262.16.2284; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; CHANEY RK, 1992, NEUROIMAG CLIN N AM, V2, P25; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; FRENCH BN, 1977, SURG NEUROL, V7, P171; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HESSELINK JR, 1988, AM J NEURORADIOL, V9, P269; JANOUSEK A, 1991, NEURORADIOLOGY S, V33, P616; JENKINS A, 1986, LANCET, V2, P445; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANKSCH W, 1978, ADV NEUROSURG, V5, P27; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; MOON KL, 1984, AM J NEURORADIOL, V5, P319; MOSELEY IF, 1976, J NEURORADIOLOGY, V3, P277; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; YOON HC, 1988, AM J NEURORADIOL, V9, P404; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757; ZIMMERMAN RD, 1982, RADIOL CLIN N AM, V20, P105	27	92	98	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	1994	15	2					351	356					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	MX594	WOS:A1994MX59400025	8192085				2022-02-06	
J	LeCount, ER; Apfelbach, CW				LeCount, ER; Apfelbach, CW			Pathologic anatomy of traumatic fractures of cranial bones and concomitant brain injuries	JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																	AUVRAY M, 1909, MALADIES CRANE ENCEP; GREENACRE, 1917, B J HOPKINS HOSP, V28, P312; TILMANN, 1902, ARCH KLIN CHIR, V66, P750; TILMANN, 1899, ARCH KLIN CHIR, V59, P236	4	92	92	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0002-9955			J AMER MED ASSOC	J. Am. Med. Assoc.	JAN-MAR	1920	74						501	511		10.1001/jama.1920.02620080003002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V24KL	WOS:000201649500152		Green Submitted			2022-02-06	
J	Willis, EF; MacDonald, KPA; Nguyen, QH; Garrido, AL; Gillespie, ER; Harley, SBR; Bartlett, PF; Schroder, WA; Yates, AG; Anthony, DC; Rose-John, S; Ruitenberg, MJ; Vukovic, J				Willis, Emily F.; MacDonald, Kelli P. A.; Nguyen, Quan H.; Garrido, Adahir Labrador; Gillespie, Ellen R.; Harley, Samuel B. R.; Bartlett, Perry F.; Schroder, Wayne A.; Yates, Abi G.; Anthony, Daniel C.; Rose-John, Stefan; Ruitenberg, Marc J.; Vukovic, Jana			Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner	CELL			English	Article							PROGENITOR-CELL; STEM-CELLS; IN-VIVO; INTERLEUKIN-6; NEURONS; INFLAMMATION; INJURY; DEGENERATION; REVEALS; DOUBLECORTIN	Cognitive dysfunction and reactive microglia are hallmarks of traumatic brain injury (TBI), yet whether these cells contribute to cognitive deficits and secondary inflammatory pathology remains poorly understood. Here, we show that removal of microglia from the mouse brain has little effect on the outcome of TBI, but inducing the turnover of these cells through either pharmacologic or genetic approaches can yield a neuroprotective microglial phenotype that profoundly aids recovery. The beneficial effects of these repopulating microglia are critically dependent on interleukin-6 (IL-6) trans-signaling via the soluble IL-6 receptor (IL-6R) and robustly support adult neurogenesis, specifically by augmenting the survival of newborn neurons that directly support cognitive function. We conclude that microglia in the mammalian brain can be manipulated to adopt a neuroprotective and pro-regenerative phenotype that can aid repair and alleviate the cognitive deficits arising from brain injury.	[Willis, Emily F.; Garrido, Adahir Labrador; Gillespie, Ellen R.; Harley, Samuel B. R.; Ruitenberg, Marc J.; Vukovic, Jana] Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld, Australia; [Willis, Emily F.; Harley, Samuel B. R.; Bartlett, Perry F.; Vukovic, Jana] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [MacDonald, Kelli P. A.; Schroder, Wayne A.] QIMR Berghofer Med Res Inst, Dept Immunol, Brisbane, Qld, Australia; [Nguyen, Quan H.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Yates, Abi G.; Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Lab Expt Neuropathol, Oxford OX1 3QT, England; [Rose-John, Stefan] Christian Albrechts Univ Kiel, Biochem Inst, Kiel, Germany; [Schroder, Wayne A.] Griffith Univ, Sch Environm & Sci, Brisbane, Qld, Australia		Vukovic, J (corresponding author), Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld, Australia.; Vukovic, J (corresponding author), Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia.	j.vukovic@uq.edu.au	Willis, Emily/ABF-7570-2020; Anthony, Daniel C/F-7765-2010; MacDonald, Kelli/AAV-5365-2020; MacDonald, Kelli/O-2722-2016	Anthony, Daniel C/0000-0003-1380-6655; MacDonald, Kelli/0000-0003-3451-4221; Willis, Emily/0000-0002-3756-5318	Australian Research Council Discovery Early Career Research AwardAustralian Research Council [DE150101578]; National Health and Medical Research Council (NHMRC) projectNational Health and Medical Research Council of Australia [1124503]; Herdsman Fellowship in Medical Science (UQ); SpinalCure Australia; Wings for Life Spinal Cord Research Foundation; NHMRCNational Health and Medical Research Council of Australia [1060538, 1163835]; UQ-StemCARE funding	We thank J. Yu, K.C. Leong, R. Adams, and N. Kurniawan for experimental assistance; the staff of UQ's Biological Resources Facility for breeding and maintaining the animals in this study; G.R. Hill for vavcre x IL6R mouse line, Alan Ho for statistical assistance; T. Bruxner for RNA-seq assistance; V. Nink for flow cytometry assistance; R. Tweedale for editorial assistance; N. Valmas for graphic design; and S. Millard, S. Thor, J. Goetz, and B. Key for critical reading and comments on the manuscript. Imaging was performed at the School of Biomedical Sciences and the Queensland Brain Institute (QBI)'s Advanced Microscopy Facilities. Behavioral tests were performed at the QBI's Behavior and Surgical Facility. FACS was performed at the QBI's Flow Cytometry Facility. RNA-seq library preparation and sequencing was performed at the Institute for Molecular Bioscience Sequencing Facility (UQ). We acknowledge QIMR Berghofer scientific services, the Genome Informatics Group and Medical Genomics Groups for their support in the RNA-seq analysis, and A. Lam and D. Pham for assisting with generating and analyzing the spatial transcriptomics data. J.V. is the recipient of an Australian Research Council Discovery Early Career Research Award (DE150101578) and National Health and Medical Research Council (NHMRC) project grant (1124503). E.F.W. is supported by the Herdsman Fellowship in Medical Science (UQ). M.J.R. is supported by SpinalCure Australia, the Wings for Life Spinal Cord Research Foundation, and the NHMRC (1060538 and 1163835). A.L.G. was supported by UQ-StemCARE funding.	Bellver-Landete V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08446-0; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Biber K, 2008, NEUROPSYCHOPHARMACOL, V33, P2237, DOI 10.1038/sj.npp.1301612; Bradley CK, 2007, GENESIS, V45, P145, DOI 10.1002/dvg.20274; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585; Campbell IL, 2014, J NEUROSCI, V34, P2503, DOI 10.1523/JNEUROSCI.2830-13.2014; Cheng XW, 2011, CELL RES, V21, P338, DOI 10.1038/cr.2010.141; Codeluppi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092649; Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Elmore MRP, 2018, AGING CELL, V17, DOI 10.1111/acel.12832; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Garbers C, 2018, METHODS MOL BIOL, V1725, P127, DOI 10.1007/978-1-4939-7568-6_11; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Godwin JW, 2013, P NATL ACAD SCI USA, V110, P9415, DOI 10.1073/pnas.1300290110; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Haage V, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0665-y; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hickman S, 2018, NAT NEUROSCI, V21, P1359, DOI 10.1038/s41593-018-0242-x; Hilla AM, 2017, J NEUROSCI, V37, P6113, DOI 10.1523/JNEUROSCI.0584-17.2017; Hodge RD, 2012, J NEUROSCI, V32, P6275, DOI 10.1523/JNEUROSCI.0532-12.2012; Hoeffel G, 2018, CELL IMMUNOL, V330, P5, DOI 10.1016/j.cellimm.2018.01.001; Hong H, 2016, INT NEUROUROL J, V20, pS2, DOI 10.5213/inj.1632604.302; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Ma SH, 2015, CELL CALCIUM, V58, P286, DOI 10.1016/j.ceca.2015.06.006; Martin M., 2011, EMBNET J, V17, P200; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Ngwenya LB, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01014; Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285; Ogilvy S, 1999, BLOOD, V94, P1855; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rice RA, 2017, GLIA, V65, P931, DOI 10.1002/glia.23135; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Scott G, 2018, BRAIN, V141, P459, DOI 10.1093/brain/awx339; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101; Timper K, 2017, CELL REP, V19, P267, DOI 10.1016/j.celrep.2017.03.043; Vukovic J, 2013, J NEUROSCI, V33, P6603, DOI 10.1523/JNEUROSCI.3064-12.2013; Vukovic J, 2012, J NEUROSCI, V32, P6435, DOI 10.1523/JNEUROSCI.5925-11.2012; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; Weber MD, 2019, BIOL PSYCHIAT, V85, P667, DOI 10.1016/j.biopsych.2018.10.009; Willis EF, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00197; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; Yang P, 2012, EXP NEUROL, V236, P19, DOI 10.1016/j.expneurol.2012.03.019; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	67	91	95	18	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2020	180	5					833	+		10.1016/j.cell.2020.02.013			30	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KT7JN	WOS:000519189800006	32142677	Bronze	Y	N	2022-02-06	
J	Guo, SW; Perets, N; Betzer, O; Ben-Shaul, S; Sheinin, A; Michaelevski, I; Popovtzer, R; Offen, D; Levenberg, S				Guo, Shaowei; Perets, Nisim; Betzer, Oshra; Ben-Shaul, Shahar; Sheinin, Anton; Michaelevski, Izhak; Popovtzer, Rachela; Offen, Daniel; Levenberg, Shulamit			Intranasal Delivery of Mesenchymal Stem Cell Derived Exosomes Loaded with Phosphatase and Tensin Homolog siRNA Repairs Complete Spinal Cord Injury	ACS NANO			English	Article						intranasal; exosome; PTEN siRNA; targeted delivery; functional recovery; complete spinal cord injury	PROMOTE FUNCTIONAL RECOVERY; STROMAL CELLS; NEUROVASCULAR PLASTICITY; REGENERATIVE GROWTH; MEDIATED DELIVERY; LOCAL TRANSLATION; RNA INTERFERENCE; TRAUMATIC BRAIN; MOTOR FUNCTION; AXON GROWTH	Individuals with spinal cord injury (SCI) usually suffer from permanent neurological deficits, while spontaneous recovery and therapeutic efficacy are limited. Here, we demonstrate that when given intranasally, exosomes derived from mesenchymal stem cells (MSC-Exo) could pass the blood brain barrier and migrate to the injured spinal cord area. Furthermore, MSC-Exo loaded with phosphatase and tensin homolog small interfering RNA (ExoPTEN) could attenuate the expression of PTEN in the injured spinal cord region following intranasal administrations. In addition, the loaded MSC-Exo considerably enhanced axonal growth and neovascularization, while reducing microgliosis and astrogliosis. The intranasal ExoPTEN therapy could also partly improve structural and electrophysiological function and, most importantly, significantly elicited functional recovery in rats with complete SCI. The results imply that intranasal ExoPTEN may be used clinically to promote recovery for SCI individuals.	[Guo, Shaowei; Ben-Shaul, Shahar; Levenberg, Shulamit] Technion Israel Inst Technol, Dept Biomed Engn, IL-3200003 Haifa, Israel; [Guo, Shaowei] Shantou Univ, Affiliated Hosp 1, Med Coll, Shantou 515041, Peoples R China; [Perets, Nisim; Sheinin, Anton; Offen, Daniel] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Offen, Daniel] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Betzer, Oshra; Popovtzer, Rachela] Bar Ilan Univ, Fac Engn, IL-5290002 Ramat Gan, Israel; [Betzer, Oshra; Popovtzer, Rachela] Bar Ilan Univ, Inst Nanotechnol & Adv Mat, IL-5290002 Ramat Gan, Israel; [Michaelevski, Izhak] Ariel Univ, Dept Mol Biol, IL-40700 Ariel, Israel		Levenberg, S (corresponding author), Technion Israel Inst Technol, Dept Biomed Engn, IL-3200003 Haifa, Israel.	shulamit@bm.technion.ac.il	Michaelevski, Izhak/G-8940-2018	Michaelevski, Izhak/0000-0002-0783-1443; Guo, Shaowei/0000-0002-3662-0290; Popovtzer, Rachela/0000-0002-3585-348X; Levenberg, Shulamit/0000-0001-5471-7339; Betzer, Oshra/0000-0002-4429-7024	J&J Shervington Fund; Israel Foundation for Spinal Cord Injury; Israel Science Foundation ISFIsrael Science Foundation [749/14]; Brainboost project; Council for Higher Education; Ministry of Science, Technology Space Israel	This work was supported by the J&J Shervington Fund (SL), the Israel Foundation for Spinal Cord Injury (SL), and the Israel Science Foundation ISF 749/14. We would like to thank the Brainboost project for supporting N.P. with a scholarship. We would like to thank the Council for Higher Education and the Ministry of Science, Technology & Space Israel, for supporting O.B. with scholarships. We wish to thank the Technion's Preclinical Research Authority and M. Tendler for their professional animal care. We thank the Technion's BCF MRI team. We thank A. Yvgi and S. Finkel for BBB scoring. We also thank J. Zavin for the cryosections, S. Landau for writing the MATLAB code, N. Cohen and T. Bronshtein for the Nanosight assistance, M. Poley and J. Shainsky for the ICP test, and Dr. Y. Posen for proofreading the article.	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Anwar MA, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00098; Aung Wint Yan, 2013, Imaging Med, V5, P427; Baglio SR, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0116-z; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Betzer O., 2018, P SOC PHOTO-OPT INS, V44; Betzer O., 2017, P SOC PHOTO-OPT INS, P10077; Betzer O, 2017, ACS NANO, V11, P10883, DOI 10.1021/acsnano.7b04495; Betzer O, 2017, NANOMEDICINE-UK, V12, P1533, DOI 10.2217/nnm-2017-0022; Betzer O, 2015, SCI REP-UK, V5, DOI 10.1038/srep15400; Boudreau RL, 2011, HUM MOL GENET, V20, pR21, DOI 10.1093/hmg/ddr137; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Butts JC, 2017, P NATL ACAD SCI USA, V114, P4969, DOI 10.1073/pnas.1608254114; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73; Didiot MC, 2016, MOL THER, V24, P1836, DOI 10.1038/mt.2016.126; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Ferguson SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19581-x; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fleming JC, 2009, J NEUROSURG-SPINE, V11, P575, DOI 10.3171/2009.6.SPINE08915; Fleming JC, 2008, EXP NEUROL, V214, P147, DOI 10.1016/j.expneurol.2008.04.024; Gao ZB, 2013, NANOMED-NANOTECHNOL, V9, P174, DOI 10.1016/j.nano.2012.06.003; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Geremia NM, 2012, J NEUROTRAUM, V29, P539, DOI 10.1089/neu.2011.1976; Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633; Gong M, 2017, ONCOTARGET, V8, P45200, DOI 10.18632/oncotarget.16778; Haney MJ, 2015, J CONTROL RELEASE, V207, P18, DOI 10.1016/j.jconrel.2015.03.033; Haraszti RA, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32570; Hengst U, 2006, J NEUROSCI, V26, P5727, DOI 10.1523/JNEUROSCI.5229-05.2006; Hengst U, 2009, NAT CELL BIOL, V11, P1024, DOI 10.1038/ncb1916; Hiebert GW, 2002, J NEUROSCI RES, V69, P160, DOI 10.1002/jnr.10275; Hong SW, 2014, NUCLEIC ACID THER, V24, P192, DOI 10.1089/nat.2013.0466; Hu YL, 2010, J CONTROL RELEASE, V147, P154, DOI 10.1016/j.jconrel.2010.05.015; Kar AN, 2013, J NEUROSCI, V33, P7165, DOI 10.1523/JNEUROSCI.2040-12.2013; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim HS, 2012, J PROTEOME RES, V11, P839, DOI 10.1021/pr200682z; Kjell J, 2016, DIS MODEL MECH, V9, P1125, DOI 10.1242/dmm.025833; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lewandowski G, 2014, J NEUROSCI, V34, P9951, DOI 10.1523/JNEUROSCI.1996-14.2014; Li YQ, 2017, NAT MED, V23, P733, DOI 10.1038/nm.4331; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Locht C, 2011, FEBS J, V278, P4668, DOI 10.1111/j.1742-4658.2011.08237.x; Long Q, 2017, P NATL ACAD SCI USA, V114, pE3536, DOI 10.1073/pnas.1703920114; M'Dahoma S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102027; Mahar M, 2018, NAT REV NEUROSCI, V19, P323, DOI 10.1038/s41583-018-0001-8; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; McCall J, 2012, CELL TISSUE RES, V349, P27, DOI 10.1007/s00441-012-1388-6; McKerracher L, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00051; Meng ZJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00331; Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014; Ni HQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00014; Nitzsche F, 2017, STEM CELLS, V35, P1446, DOI 10.1002/stem.2614; Ohtake Y, 2014, BIOMATERIALS, V35, P4610, DOI 10.1016/j.biomaterials.2014.02.037; Okada S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0026-1; Otero-Ortega L, 2018, J CEREBR BLOOD F MET, V38, P767, DOI 10.1177/0271678X17708917; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Perets N, 2019, NANO LETT, V19, P3422, DOI 10.1021/acs.nanolett.8b04148; Perets N, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0240-6; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Qu MK, 2018, J CONTROL RELEASE, V287, P156, DOI 10.1016/j.jconrel.2018.08.035; Ramachandran PS, 2013, NEUROTHERAPEUTICS, V10, P473, DOI 10.1007/s13311-013-0183-8; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rauch MF, 2009, EUR J NEUROSCI, V29, P132, DOI 10.1111/j.1460-9568.2008.06567.x; Reza-Zaldivar EE, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00317; Rocha LA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00164; Satkunendrarajah K, 2018, NATURE, V562, P419, DOI 10.1038/s41586-018-0595-z; Segal-Gavish H, 2016, AUTISM RES, V9, P17, DOI 10.1002/aur.1530; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Song JR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05827-9; Sun GD, 2018, MAT SCI ENG C-MATER, V89, P194, DOI 10.1016/j.msec.2018.04.006; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Terenzio M, 2018, SCIENCE, V359, P1416, DOI 10.1126/science.aan1053; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Walker CL, 2014, NEUROSCI LETT, V573, P64, DOI 10.1016/j.neulet.2014.02.039; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wang L, 2018, CELL PHYSIOL BIOCHEM, V50, P1535, DOI 10.1159/000494652; Warren PM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06937-0; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Williams RR, 2015, CELL TRANSPLANT, V24, P115, DOI 10.3727/096368913X674657; Xin HQ, 2017, STROKE, V48, P747, DOI 10.1161/STROKEAHA.116.015204; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yang JL, 2017, MOL THER-NUCL ACIDS, V7, P278, DOI 10.1016/j.omtn.2017.04.010; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001; Yu SK, 2016, SCI REP-UK, V6, DOI 10.1038/srep33428; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZG, 2019, NAT REV NEUROL, V15, P193, DOI 10.1038/s41582-018-0126-4; Zholudeva LV, 2018, TRENDS NEUROSCI, V41, P625, DOI 10.1016/j.tins.2018.06.004; Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164; Zukor K, 2013, J NEUROSCI, V33, P15350, DOI 10.1523/JNEUROSCI.2510-13.2013	97	91	95	13	84	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	SEP	2019	13	9					10015	10028		10.1021/acsnano.9b01892			14	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	JA5BZ	WOS:000487859600024	31454225				2022-02-06	
J	DiFazio, M; Silverberg, ND; Kirkwood, MW; Bernier, R; Iverson, GL				DiFazio, Marc; Silverberg, Noah D.; Kirkwood, Michael W.; Bernier, Raquel; Iverson, Grant L.			Prolonged Activity Restriction After Concussion: Are We Worsening Outcomes?	CLINICAL PEDIATRICS			English	Article						concussion; mTBI; activity restriction; rest; rehabilitation; treatment	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; QUALITY-OF-LIFE; BED REST; DEPRESSED AFFECT; TEMPORAL WINDOW; UP-REGULATION; CHILDREN	The current treatment of concussion or mild traumatic brain injury (mTBI) is primarily based on expert consensus. Most clinical practice guidelines advise cognitive and physical rest after injury including withdrawal from normal life activities such as school attendance, sports participation, and technology use until symptoms resolve. Some individuals who sustain an mTBI experience persistent physical, cognitive, and mental health problems. Activity restriction itself may contribute to protracted recovery and other complications. Williamson's Activity Restriction Model of Depression, formulated more than 20 years ago, is central to this hypothesis. We review research evidence for potential harms of prolonged activity restriction and report an mTBI case as an example of how an activity restriction cascade can unfold. According to this model, psychological consequences of removal from validating life activities, combined with physical deconditioning, contribute to the development and persistence of postconcussive symptoms after mTBI in some youth. A modification to mTBI guidelines that emphasizes prompt reengagement in life activities as tolerated is encouraged.	[DiFazio, Marc; Bernier, Raquel] Childrens Natl Hlth Syst, Washington, DC USA; [Silverberg, Noah D.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Aurora, CO USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Boston, MA USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA		DiFazio, M (corresponding author), 9850 Key West Ave, Rockville, MD 20850 USA.	mdifazio@childrensnational.org		Iverson, Grant/0000-0001-7348-9570	Mooney-Reed Charitable Foundation; Vancouver Coastal Health Research Institute	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GLI acknowledges funding support from the Mooney-Reed Charitable Foundation. NDS receives salary support from the Vancouver Coastal Health Research Institute.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDREASSEN J, 1957, ACTA MED SCAND, V158, P239; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bass P, 2014, CONT PEDIAT; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Clayton RB, 2015, J COMPUT-MEDIAT COMM, V20, P119, DOI 10.1111/jcc4.12109; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; Fainaru S, 2003, ESPN OUTSIDE LINES; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Fortney SM, 2011, COMPR PHYSIOL, P889; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hartman-Maeir A, 2007, DISABIL REHABIL, V29, P559, DOI 10.1080/09638280600924996; Hernandez SE, 2015, J ALTERN COMPLEM MED, V21, P175, DOI 10.1089/acm.2013.0450; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kirkwood MW, 2012, CLIN J SPORT MED, V22, P383, DOI 10.1097/JSM.0b013e31826396fc; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lewinsohn P.M., 1985, THEORETICAL ISSUES B, P313; Lewinsohn PM, 1997, J ABNORM PSYCHOL, V106, P365, DOI 10.1037/0021-843X.106.3.365; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; MEERLOO AM, 1949, J NERV MENT DIS, V110, P347, DOI 10.1097/00005053-194911040-00005; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Molton IR, 2014, J HEALTH PSYCHOL, V19, P1025, DOI 10.1177/1359105313483156; Morrissey D, 2014, J TRAUMA ACUTE CARE, V77, pS8, DOI 10.1097/TA.0000000000000331; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peterson RL, 2015, J NEUROPSYCH CLIN N, V27, P280, DOI 10.1176/appi.neuropsych.14120373; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Short EB, 2010, EVID-BASED COMPL ALT, V7, P121, DOI 10.1093/ecam/nem163; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smorawinski J, 2001, J APPL PHYSIOL, V91, P249, DOI 10.1152/jappl.2001.91.1.249; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Turner AP, 2009, ARCH PHYS MED REHAB, V90, P420, DOI 10.1016/j.apmr.2008.09.558; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2014, PSYCHOL INJ LAW, V7, P245, DOI 10.1007/s12207-014-9201-3; VORIS HC, 1950, AM J SURG, V80, P707, DOI 10.1016/0002-9610(50)90595-2; Walters AS, 1999, CHILD HEALTH CARE, V28, P33, DOI 10.1207/s15326888chc2801_3; Watt J., 1938, AM J SURG, V41, P272; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WILLIAMSON GM, 1995, PSYCHOL AGING, V10, P369, DOI 10.1037/0882-7974.10.3.369; Williamson GM, 2000, HEALTH PSYCHOL, V19, P339, DOI 10.1037//0278-6133.19.4.339; Wilson TD, 2014, SCIENCE, V345, P75, DOI 10.1126/science.1250830; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	88	91	92	1	25	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAY	2016	55	5					443	451		10.1177/0009922815589914			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DJ5FM	WOS:000374232200007	26130391				2022-02-06	
J	Gagnon, I; Grilli, L; Friedman, D; Iverson, GL				Gagnon, I.; Grilli, L.; Friedman, D.; Iverson, G. L.			A pilot study of active rehabilitation for adolescents who are slow to recover from sport-related concussion	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Pediatric; mild traumatic brain injury; children; physiotherapy; sports; post-concussion symptoms; aerobics	TRAUMATIC BRAIN-INJURY; VOLUNTARY EXERCISE; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; NEUROTROPHIC FACTOR; PHYSICAL-EXERCISE; CONTUSION INJURY; TEMPORAL WINDOW; DEPRESSION; SYMPTOMS	The purpose of this study was to examine the effectiveness of an active rehabilitation intervention for adolescents who are slow-to-recover after a sport-related concussion. Ten adolescents (three girls and seven boys) seen at the Montreal Children's Hospital Concussion Clinic participated in this case series. Adolescents who were symptomatic more than 4 weeks after the injury were provided with an active rehabilitation intervention (M=7.9 weeks following injury; range=3.7 to 26.2 weeks). The rehabilitation program includes gradual, closely monitored light aerobic exercise, general coordination exercises, mental imagery, as well as reassurance, normalization of recovery, and stress/anxiety reduction strategies. The program continued until complete symptom resolution and readiness to begin stepwise return to activities. The primary outcome of the study was evolution of post-concussion symptoms. Secondary outcomes included mood, energy, balance, and cognition. After the intervention, post-concussion symptoms significantly decreased for the group of participants. They also had decreased fatigue and improved mood after 6 weeks of initiating the rehabilitation intervention. This case series shows that postconcussive symptoms and functioning in adolescents following sports-related concussion can be improved after participation in an active rehabilitation intervention. The introduction of graded light intensity exercise in the post-acute period following concussion is safe, feasible and appears to have a positive impact on adolescents' functioning.	[Gagnon, I.] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Gagnon, I.; Grilli, L.; Friedman, D.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Trauma Ctr, Montreal, PQ, Canada; [Gagnon, I.; Friedman, D.] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; [Friedman, D.] Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada; [Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, G. L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, G. L.] Mass Gen Hosp, Children Sports Concuss Program, Boston, MA USA; [Iverson, G. L.] Red Sox Fdn, Boston, MA USA; [Iverson, G. L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Gagnon, I (corresponding author), Montreal Childrens Hosp, Trauma Programs C 833, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	Isabelle.gagnon8@mcgill.ca	Meijer, Anna/K-5118-2016	Iverson, Grant/0000-0001-7348-9570; Gagnon, Isabelle/0000-0003-2043-1644	Research Institute of the McGill University Health Center; The Montreal Children's Hospital Trauma Programs	We would like to thank the children and their families for participating in this study and The Montreal Children's Hospital Trauma Programs professionals for their support. As well, we wish to thank the Research Institute of the McGill University Health Center for its support of this research.	Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barbour KA, 2007, J CARDIOPULM REHABIL, V27, P359, DOI 10.1097/01.HCR.0000300262.69645.95; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Bruininks BD, 2006, BRUININKS OSERETSKY; Canadian Pediatric Society, 2006, PAEDIAT CHILD HLTH, V11, P420; CHAOULOFF F, 1989, ACTA PHYSIOL SCAND, V137, P1, DOI 10.1111/j.1748-1716.1989.tb08715.x; Cohen J., 2013, STAT POWER ANAL BEHA; Daley A, 2008, J CLIN PSYCHOL MED S, V15, P140, DOI 10.1007/s10880-008-9105-z; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greenwood BN, 2008, NEUROMOL MED, V10, P81, DOI 10.1007/s12017-008-8029-y; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herring MP, 2010, ARCH INTERN MED, V170, P321, DOI 10.1001/archinternmed.2009.530; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lojovich JM, 2010, J HEAD TRAUMA REHAB, V25, P184, DOI 10.1097/HTR.0b013e3181dc78cd; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Merom D, 2008, J ANXIETY DISORD, V22, P959, DOI 10.1016/j.janxdis.2007.09.010; Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004; Rimer J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub5; Roemmich JN, 2006, MED SCI SPORT EXER, V38, P1014, DOI 10.1249/01.mss.0000218123.81079.49; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smits JAJ, 2008, DEPRESS ANXIETY, V25, P689, DOI 10.1002/da.20411; Spielberger C.D., 1980, TEST ANXIETY INVENTO; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003	60	91	92	2	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	MAR	2016	26	3					299	306		10.1111/sms.12441			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DF3MB	WOS:000371247200007	25735821				2022-02-06	
J	McCuen, E; Svaldi, D; Breedlove, K; Kraz, N; Cummiskey, B; Breedlove, EL; Traver, J; Desmond, KF; Hannemann, RE; Zanath, E; Guerra, A; Leverenz, L; Talavage, TM; Nauman, EA				McCuen, Emily; Svaldi, Diana; Breedlove, Katherine; Kraz, Nicole; Cummiskey, Brian; Breedlove, Evan L.; Traver, Jessica; Desmond, Katherine F.; Hannemann, Robert E.; Zanath, Erica; Guerra, Alexandra; Leverenz, Larry; Talavage, Thomas M.; Nauman, Eric A.			Collegiate women's soccer players suffer greater cumulative head impacts than their high school counterparts	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain Injury; TBI; Subconcussive head impacts	DEFAULT MODE NETWORK; FOOTBALL PLAYERS; BRAIN-INJURY; CONCUSSIONS; FMRI; IMPAIRMENT; DEFICITS; ATHLETE; BALL	Soccer is the source of the highest concussion rates among female athletes and is associated with neurological deficits at many levels of play. Despite its importance to our understanding of head trauma in female athletes, little is known about the number and magnitude of head impacts experienced by female soccer players. Head impacts experienced by high school and collegiate athletes were quantified using xPatch sensors (X2 Biosystems) affixed behind the right ear of each player. The average peak translational acceleration (PTA) sustained by players at th high school level was significantly lower than that of the collegiate players, but the average peak angular accelerations (PAA) were not significantly different. Given that the collegiate players took many more impacts throughout the season, their mean cumulative exposure to translational (cPTA) and angular accelerations (cPAA) were significantly higher than those of the high school players. Additional research is required to determine whether the differences in cumulative exposure are responsible for the elevated risk of concussion in collegiate soccer players or if there are additional risk factors. (C) 2015 Elsevier Ltd. All rights reserved.	[McCuen, Emily; Svaldi, Diana; Hannemann, Robert E.; Zanath, Erica; Guerra, Alexandra; Talavage, Thomas M.; Nauman, Eric A.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Breedlove, Katherine; Leverenz, Larry] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Kraz, Nicole] Purdue Univ, Dept Athlet, W Lafayette, IN 47907 USA; [Cummiskey, Brian; Breedlove, Evan L.; Traver, Jessica; Desmond, Katherine F.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Hannemann, Robert E.] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA		Nauman, EA (corresponding author), 585 Purdue Mall West, W Lafayette, IN 47907 USA.	enauman@purdue.edu		Talavage, Thomas/0000-0003-4977-6398	Indiana State Department of Health Spinal Cord and Brain Injury Research Fund; Indiana Clinical and Translational Sciences Institute; Purdue's Office of the Vice President for Research	The authors would like to thank Dr. Gregory G. Tamer, Jr., for assistance in data collection. This work was supported in part by grants from the Indiana State Department of Health Spinal Cord and Brain Injury Research Fund, a Core Facility Grant from the Indiana Clinical and Translational Sciences Institute, and Purdue's Office of the Vice President for Research.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Higgins M.J., 2009, SPORTS ENG TECHNOL, V223, P117; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	28	91	91	1	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	OCT 15	2015	48	13					3720	3723		10.1016/j.jbiomech.2015.08.003			4	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	CX0DS	WOS:000365367700022	26329462				2022-02-06	
J	Hennessy, E; Griffin, EW; Cunningham, C				Hennessy, Edel; Griffin, Eadaoin W.; Cunningham, Colm			Astrocytes Are Primed by Chronic Neurodegeneration to Produce Exaggerated Chemokine and Cell Infiltration Responses to Acute Stimulation with the Cytokines IL-1 beta and TNF-alpha	JOURNAL OF NEUROSCIENCE			English	Article						astrocyte; chemokine; cytokine; microglia; neurodegeneration; neuroinflammation	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; SPINAL-CORD; INFLAMMATORY RESPONSE; BRAIN; EXPRESSION; INDUCTION; MODEL; RECRUITMENT; ACTIVATION	Microgliosis and astrogliosis are standard pathological features of neurodegenerative disease. Microglia are primed by chronic neurodegeneration such that toll-like receptor agonists, such as LPS, drive exaggerated cytokine responses on this background. However, sterile inflammatory insults are more common than direct CNS infection in the degenerating brain and these insults drive robust IL-1 beta and TNF-alpha responses. It is unclear whether these pro-inflammatory cytokines can directly induce exaggerated responses in the degenerating brain. We hypothesized that glial cells in the hippocampus of animals with chronic neurodegenerative disease (ME7 prion disease) would display exaggerated responses to central cytokine challenges. TNF-alpha or IL-1 beta were administered intrahippocampally to ME7-inoculated mice and normal brain homogenate-injected (NBH) controls. Both IL-1 beta and TNF-alpha produced much more robust IL-1 beta synthesis in ME7 than in NBH animals and this occurred exclusively in microglia. However, there was strong nuclear localization of the NF kappa B subunit p65 in the astrocyte population, associated with marked astrocytic synthesis of the chemokines CXCL1 and CCL2 in response to both cytokine challenges in ME7 animals. Conversely, very limited expression of these chemokines was apparent in NBH animals similarly challenged. Thus, astrocytes are primed in the degenerating brain to produce exaggerated chemokine responses to acute stimulation with pro-inflammatory cytokines. Furthermore, this results in markedly increased neutrophil, T-cell, and monocyte infiltration in the diseased brain. These data have significant implications for acute sterile inflammatory insults such as stroke and traumatic brain injury occurring on a background of aging or neurodegeneration.	[Hennessy, Edel; Griffin, Eadaoin W.; Cunningham, Colm] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Inst Neurosci, Dublin 2, Ireland		Cunningham, C (corresponding author), Univ Dublin Trinity Coll, Sch Biochem & Immunol, Inst Neurosci, Dublin 2, Ireland.	colm.cunningham@tcd.ie	Hennessy, Edel/H-4438-2019; Cunningham, Colm/A-1743-2010	Hennessy, Edel/0000-0003-4024-0802; Griffin, Eadaoin/0000-0002-2017-453X; Cunningham, Colm/0000-0003-1423-5209	Wellcome TrustWellcome TrustEuropean Commission; Trinity College Dublin Research Studentship	This work was supported by The Wellcome Trust and E.H. was supported by a Trinity College Dublin Research Studentship. We acknowledge the gift of the Mc21 anti CCR2 antibody from Steffen Jung, Weizmann Institute of Science, Israel, and the MBS-1 neutrophil antibody from Daniel Anthony, Oxford, UK. We thank Hugh Perry and Diego Gomez-Nicola for helpful discussions and Gavin MacManus for technical assistance with confocal microscopy.	An Y, 2011, J INFLAMM RES, V4, P11, DOI 10.2147/JIR.S15357; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2014, GLIA, V62, P452, DOI 10.1002/glia.22616; Bruhl H, 2007, ARTHRITIS RHEUM, V56, P2975, DOI 10.1002/art.22854; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Choi K, 2011, J NEUROCHEM, V116, P438, DOI 10.1111/j.1471-4159.2010.07124.x; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Fouillet A, 2012, BRAIN RES, V1437, P115, DOI 10.1016/j.brainres.2011.11.049; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Henn A, 2011, J IMMUNOL, V186, P3237, DOI 10.4049/jimmunol.1002787; Hughes MM, 2010, GLIA, V58, P2017, DOI 10.1002/glia.21070; Jing T, 2010, BIOCHEM BIOPH RES CO, V402, P241, DOI 10.1016/j.bbrc.2010.10.006; Khorooshi R, 2008, J IMMUNOL, V181, P7284, DOI 10.4049/jimmunol.181.10.7284; Kim JM, 2005, CLIN EXP IMMUNOL, V140, P450, DOI 10.1111/j.1365-2249.2005.02804.x; Lee YH, 2012, INT IMMUNOPHARMACOL, V12, P547, DOI 10.1016/j.intimp.2012.01.011; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McKimmie CS, 2010, BIOCHEM BIOPH RES CO, V394, P1006, DOI 10.1016/j.bbrc.2010.03.111; Moreno M, 2014, J NEUROSCI, V34, P8175, DOI 10.1523/JNEUROSCI.1137-14.2014; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Murray C, 2012, NEUROBIOL AGING, V33, P603, DOI 10.1016/j.neurobiolaging.2010.04.002; PACE JL, 1983, J IMMUNOL, V130, P2011; Godoy MCP, 2008, BRAIN, V131, P1880, DOI 10.1093/brain/awn101; Ritter L, 2011, MICROCIRCULATION, V18, P552, DOI 10.1111/j.1549-8719.2011.00115.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Sly LM, 2001, BRAIN RES BULL, V56, P581, DOI 10.1016/S0361-9230(01)00730-4; Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; Wang YF, 2007, J NEUROCHEM, V103, P814, DOI 10.1111/j.1471-4159.2007.04803.x; Yao Y, 2011, J CELL SCI, V124, P1486, DOI 10.1242/jcs.082834; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang ZJ, 2013, PAIN, V154, P2185, DOI 10.1016/j.pain.2013.07.002	41	91	92	0	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 3	2015	35	22					8411	8422		10.1523/JNEUROSCI.2745-14.2015			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN2JV	WOS:000358247900005	26041910	Green Published, hybrid			2022-02-06	
J	George, MS; Raman, R; Benedek, DM; Pelic, CG; Grammer, GG; Stokes, KT; Schmidt, M; Spiegel, C; DeAlmeida, N; Beaver, KL; Borckardt, JJ; Sun, XY; Jain, S; Stein, MB				George, Mark S.; Raman, Rema; Benedek, David M.; Pelic, Christopher G.; Grammer, Geoffrey G.; Stokes, Karen T.; Schmidt, Matthew; Spiegel, Chad; DeAlmeida, Nancy; Beaver, Kathryn L.; Borckardt, Jeffrey J.; Sun, Xiaoying; Jain, Sonia; Stein, Murray B.			A Two-site Pilot Randomized 3 Day Trial of High Dose Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Suicidal Inpatients	BRAIN STIMULATION			English	Article						TMS; Transcranial; Suicide; Prefrontal; Magnetic	LEARNED HELPLESSNESS; MOTOR THRESHOLD; DEPRESSION; CORTEX; PAIN; LITHIUM; PREVENTION; DISORDER; THERAPY; PLACEBO	Background: Suicide attempts and completed suicides are common, yet there are no proven acute medication or device treatments for treating a suicidal crisis. Repeated daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 4-6 weeks is a new FDA-approved treatment for acute depression. Some open-label rTMS studies have found rapid reductions in suicidality. Design: This study tests whether a high dose of rTMS to suicidal inpatients is feasible and safe, and also whether this higher dosing might rapidly improve suicidal thinking. This prospective, 2-site, randomized, active sham-controlled (1: 1 randomization) design incorporated 9 sessions of rTMS over 3 days as adjunctive to usual inpatient suicidality treatment. The setting was two inpatient military hospital wards (one VA, the other DOD). Patients: Research staff screened approximately 377 inpatients, yielding 41 adults admitted for suicidal crisis. Because of the funding source, all patients also had either post-traumatic stress disorder, mild traumatic brain injury, or both. TMS methods: Repetitive TMS (rTMS) was delivered to the left prefrontal cortex with a figure-eight solid core coil at 120% motor threshold, 10 Hertz (Hz), 5 second (s) train duration, 10 s intertrain interval for 30 minutes (6000 pulses) 3 times daily for 3 days (total 9 sessions; 54,000 stimuli). Sham rTMS used a similar coil that contained a metal insert blocking the magnetic field and utilized electrodes on the scalp, which delivered a matched somatosensory sensation. Main outcome measure: Primary outcomes were the daily change in severity of suicidal thinking as measured by the Beck Scale of Suicidal Ideation (SSI) administered at baseline and then daily, as well as subjective visual analog scale measures before and after each TMS session. Mixed model repeated measures (MMRM) analysis was performed on modified intent to treat (mITT) and completer populations. Results: This intense schedule of rTMS with suicidal inpatients was feasible and safe. Minimal side effects occurred, none differing by arm, and the 3-day retention rate was 88%. No one died of suicide within the 6 month followup. From the mITT analyses, SSI scores declined rapidly over the 3 days for both groups (sham change -15.3 points, active change -15.4 points), with a trend for more rapid decline on the first day with active rTMS (sham change -6.4 points, active -10.7 points, P = 0.12). This decline was more pronounced in the completers subgroup [sham change -5.9 (95% CI: -10.1, -1.7), active -13 points (95% CI: -18.7, -7.4); P = 0.054]. Subjective ratings of 'being bothered by thoughts of suicide' declined non- significantly more with active rTMS than with sham at the end of 9 sessions of treatment in the mITT analysis [sham change 31.9 (95% CI: 41.7, 22.0), active change 42.5 (95% CI: 53.8, 31.2); P = 0.17]. There was a significant decrease in the completers sample [sham change -24.9 (95% CI: -34.4, -15.3), active change -43.8 (95% CI: -57.2, -30.3); P = 0.028]. Conclusions: Delivering high doses of left prefrontal rTMS over three days (54,000 stimuli) to suicidal inpatients is possible and safe, with few side effects and no worsening of suicidal thinking. The suggestions of a rapid anti-suicide effect (day 1 SSI data, Visual Analogue Scale data over the 3 days) need to be tested for replication in a larger sample. (C) 2014 Elsevier Inc. All rights reserved.	[George, Mark S.; Pelic, Christopher G.; Schmidt, Matthew; Beaver, Kathryn L.; Borckardt, Jeffrey J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [George, Mark S.; Pelic, Christopher G.; Schmidt, Matthew; Beaver, Kathryn L.; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA; [Benedek, David M.; Grammer, Geoffrey G.; Spiegel, Chad; DeAlmeida, Nancy] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20889 USA; [Raman, Rema; Stokes, Karen T.; Sun, Xiaoying; Jain, Sonia; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA		George, MS (corresponding author), MUSC, IOP, 502 N,67 President St, Charleston, SC 29425 USA.	georgem@musc.edu		George, Mark/0000-0003-1767-1815	U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC); DOD INTRuST [W81XWH-08-2-0159]	Funded by U.S. Army Medical Research and Materiel Command (USAMRMC).; Funding mechanism: Contract # W81XWH-08-2-0159, DOD INTRuST.	Amat J, 2008, NEUROSCIENCE, V154, P1178, DOI 10.1016/j.neuroscience.2008.04.005; Anderson B, 2006, J ECT, V22, P49, DOI 10.1097/00124509-200603000-00011; [Anonymous], 2012, MSMR, V19, P2; [Anonymous], 2012, MSMR, V19, P5; Arana AB, 2008, BRAIN STIMUL, V1, P44, DOI 10.1016/j.brs.2007.08.006; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Baratta MV, 2007, NEUROSCIENCE, V146, P1495, DOI 10.1016/j.neuroscience.2007.03.042; Baratta MV, 2008, LEARN MEMORY, V15, P84, DOI 10.1101/lm.800308; Barth Kelly S, 2011, Front Psychiatry, V2, P9, DOI 10.3389/fpsyt.2011.00009; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; Bluml V, 2013, J PSYCHIATR RES, V47, P407, DOI 10.1016/j.jpsychires.2012.12.002; Borckardt JJ, 2007, PAIN RES MANAG, V12, P287, DOI 10.1155/2007/741897; Borckardt JJ, 2008, BRAIN STIMUL, V1, P52, DOI 10.1016/j.brs.2007.09.003; Borckardt JJ, 2006, ANESTHESIOLOGY, V105, P557, DOI 10.1097/00000542-200609000-00020; Borckardt JJ, 2011, CLIN J PAIN, V27, P486, DOI 10.1097/AJP.0b013e31820d2733; Borckardt JJ, 2011, PAIN, V152, P182, DOI 10.1016/j.pain.2010.10.018; Borckardt JJ, 2009, PAIN MED, V10, P840, DOI 10.1111/j.1526-4637.2009.00657.x; Borckardt JJ, 2006, J ECT, V22, P169, DOI 10.1097/01.yct.0000235923.52741.72; Borckardt JJ, 2009, J ECT, V25, P91, DOI 10.1097/YCT.0b013e318183c6a4; Borckardt JJ, 2008, BRAIN STIMUL, V1, P122, DOI 10.1016/j.brs.2008.04.002; Borckardt JJ, 2013, BRAIN STIMUL; Centers for Disease Control and Prevention (CDC), 1800, MMWR Morb Mortal Wkly Rep, V62, P321; Christianson JP, 2008, STRESS, P1; Cipriani A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3646; Fawcett J, 2013, DEPRESS ANXIETY, V30, P898, DOI 10.1002/da.22058; Fink M, 2013, J ECT; George M.S., 1994, DEPRESSION, V2, P59, DOI [10.1002/depr.3050020202, DOI 10.1002/DEPR.3050020202]; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; George MS, 2011, AM J PSYCHIAT, V168, P356, DOI 10.1176/appi.ajp.2010.10060864; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; GEORGE MS, 1994, CONVULSIVE THER, V10, P251; Gold KJ, 2013, GEN HOSP PSYCHIAT, V35, P45, DOI 10.1016/j.genhosppsych.2012.08.005; Hadley D, 2011, J ECT, V27, P18, DOI 10.1097/YCT.0b013e3181ce1a8c; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Holtzheimer PE, 2010, DEPRESS ANXIETY, V27, P960, DOI 10.1002/da.20731; Jollant F, 2011, WORLD J BIOL PSYCHIA, V12, P319, DOI 10.3109/15622975.2011.556200; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp J, 2012, SUICIDE DATA REPORT; Larkin GL, 2011, INT J NEUROPSYCHOPH, V14, P1127, DOI 10.1017/S1461145711000629; Madsen T, 2012, J CLIN PSYCHIAT, V73, P144, DOI 10.4088/JCP.10m06473; Martin L, 2013, PAIN MED, V14, P999, DOI 10.1111/pme.12129; MILLER WR, 1975, J ABNORM PSYCHOL, V84, P228, DOI 10.1037/h0076720; Mishory A, 2004, J ECT, V20, P160, DOI 10.1097/00124509-200409000-00007; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Olfson M, 2005, ARCH GEN PSYCHIAT, V62, P1122, DOI 10.1001/archpsyc.62.10.1122; Oquendo MA, 2011, AM J PSYCHIAT, V168, P1050, DOI 10.1176/appi.ajp.2011.11010163; Perlis RH, 2011, AM J PSYCHIAT, V168, P1009, DOI 10.1176/appi.ajp.2011.11081250; Pridmore S, 1998, J ECT, V14, P25; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Roy-Byrne P, 2013, DEPRESS ANXIETY, V30, P893, DOI 10.1002/da.22181; SELIGMAN MEP, 1975, J COMP PHYSIOL PSYCH, V88, P542, DOI 10.1037/h0076431; Stein MB, 2013, DEPRESS ANXIETY, V30, P896, DOI 10.1002/da.22196; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1189, DOI 10.1038/npp.2013.13; Taylor JJ, 2012, PAIN, V153, P1219, DOI 10.1016/j.pain.2012.02.030; Troister Talia, 2008, Curr Psychiatry Rep, V10, P60, DOI 10.1007/s11920-008-0011-8; Vollmayr B, 2001, MOL PSYCHIATR, V6, P471, DOI 10.1038/sj.mp.4000907; Young AH, 2013, EVID-BASED MENT HEAL, V16, P112, DOI 10.1136/eb-2013-101493	58	91	95	2	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	MAY-JUN	2014	7	3					421	431		10.1016/j.brs.2014.03.006			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG9KZ	WOS:000335739400012	24731434				2022-02-06	
J	Helmer, KG; Pasternak, O; Fredman, E; Preciado, RI; Koerte, IK; Sasaki, T; Mayinger, M; Johnson, AM; Holmes, JD; Forwell, LA; Skopelja, EN; Shenton, ME; Echlin, PS				Helmer, Karl G.; Pasternak, Ofer; Fredman, Eli; Preciado, Ronny I.; Koerte, Inga K.; Sasaki, Takeshi; Mayinger, Michael; Johnson, Andrew M.; Holmes, Jeffrey D.; Forwell, Lorie A.; Skopelja, Elaine N.; Shenton, Martha E.; Echlin, Paul S.			Hockey Concussion Education Project, Part 1. Susceptibility-weighted imaging study in male and female ice hockey players over a single season	JOURNAL OF NEUROSURGERY			English	Article						susceptibility-weighted imaging; ice hockey; sex-based difference; concussion; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; PHYSICIAN-OBSERVED CONCUSSION; WHITE-MATTER INTEGRITY; DIFFUSE AXONAL INJURY; PROFESSIONAL BOXERS; MICROSTRUCTURAL DAMAGE; COGNITIVE DYSFUNCTION; SPORTS CONCUSSION; FOOTBALL PLAYERS; ANISOTROPY	Object. Concussion, or mild traumatic brain injury (mTBI), is a commonly occurring sports-related injury, especially in contact sports such as hockey. Cerebral microbleeds (CMBs), which appear as small, hypointense lesions on T-2*-weighted images, can result from TBI. The authors use susceptibility-weighted imaging (SWI) to automatically detect small hypointensities that may be subtle signs of chronic and acute damage due to both subconcussive and concussive injury. The goal was to investigate how the burden of these hypointensities changes over time, over a playing season, and postconcussion, in comparison with subjects who did not suffer a medically observed and diagnosed concussion. Methods. Images were obtained in 45 university-level adult male and female ice hockey players before and after a single Canadian Interuniversity Sports season. In addition, 11 subjects (5 men and 6 women) underwent imaging at 72 hours, 2 weeks, and 2 months after concussion. To identify subtle changes in brain tissue and potential CMBs, nonvessel clusters of hypointensities on SWI were automatically identified, and a hypointensity burden index was calculated for all subjects at the beginning of the season (BUS), the end of the season (EOS), and at postconcussion time points (where applicable). Results. A statistically significant increase in the hypointensity burden, relative to the BOS, was observed for male subjects with concussions at the 2-week postconcussion time point. A smaller, nonsignificant rise in the burden for female subjects with concussions was also observed within the same time period. There were no significant changes in burden for nonconcussed subjects of either sex between the BUS and BUS time points. However, there was a statistically significant difference in the burden between male and female subjects in the nonconcussed group at both the BUS and BUS time points, with males having a higher burden. Conclusions. This method extends the utility of SWI from the enhancement and detection of larger (> 5 mm) CMBs, which are often observed in more severe cases of TBI, to cases involving smaller lesions in which visual detection of injury is difficult. The hypointensity burden metric proposed here shows statistically significant changes over time in the male subjects. A smaller, nonsignificant increase in the burden metric was observed in the female subjects.	[Helmer, Karl G.] Massachusetts Gen Hosp Massachusetts Inst Technol, Charlestown, MA USA; [Preciado, Ronny I.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Pasternak, Ofer; Fredman, Eli; Koerte, Inga K.; Sasaki, Takeshi; Mayinger, Michael; Shenton, Martha E.; Echlin, Paul S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA; [Koerte, Inga K.; Mayinger, Michael] Univ Munich, Inst Clin Radiol, Munich, Germany; [Sasaki, Takeshi] Tokyo Med & Dent Univ, Grad Sch, Dept Psychiat & Behav Sci, Tokyo, Japan; [Johnson, Andrew M.] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada; [Holmes, Jeffrey D.] Univ Western Ontario, Sch Occupat Therapy, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Fowler Kennedy Sport Med Clin, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Sch Phys Therapy, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Ruth Lilly Med Lib, Indianapolis, IN 46204 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA; [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON L7N 2G3, Canada		Echlin, PS (corresponding author), Elliott Sports Med Clin, 1100 Walkers Line,Ste 2, Burlington, ON L7N 2G3, Canada.	psechlin@gmail.com	Koerte, Inga Katharina/AAW-3031-2021; Holmes, Jeffrey/M-6484-2015; Shenton, Martha/V-8780-2019; Johnson, Andrew M/B-2048-2012	Holmes, Jeffrey/0000-0002-5744-8338; Johnson, Andrew M./0000-0002-7269-3016; Skopelja, Elaine/0000-0002-2847-8909	Ontario Trillium Foundation; Dave Irwin Foundation for Brain Injury; Ontario Neurotrauma Foundation; Air Canada; The Ontario Ministry of Health and Long-Term Care; The Ontario Ministry of Tourism, Culture and Sport; The Ontario Ministry of Education; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [S2301]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41RR013218, P41EB015902, R01MH074794]; Department of DefenseUnited States Department of Defense [X81XWH-07-CC-CSDoD]; NARSAD (National Alliance for Research on Schizophrenia and Depression)NARSAD; Brain & Behavior Research FoundationNARSAD; Else Kroner-Fresenius Foundation, Germany; Petraeic Legate Foundation; Henry Jackson Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER	Funding for this work was provided to the HCEP and Dr. Echlin by the Ontario Trillium Foundation, the Dave Irwin Foundation for Brain Injury, the Ontario Neurotrauma Foundation, Air Canada, The Ontario Ministry of Health and Long-Term Care, The Ontario Ministry of Tourism, Culture and Sport, and The Ontario Ministry of Education. Dr. Sasaki is supported by Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from the Japan Society for the Promotion of Science (S2301). This work was partially funded by grants from the NIH (Grant Nos. P41RR013218, P41EB015902, and R01MH074794), the Department of Defense (No. X81XWH-07-CC-CSDoD), and a VA merit grant. Dr. Pasternak was partially supported by a NARSAD (National Alliance for Research on Schizophrenia and Depression) Young Investigator grant from the Brain & Behavior Research Foundation. Dr. Koerte is supported by the Else Kroner-Fresenius Foundation, Germany. Mr. Mayinger is supported by the Petraeic Legate Foundation. This work was part of Mr. Mayinger's doctoral thesis. Dr. Shenton is a consultant on an NIH grant to the State University of New York on velocardiofascial syndrome and on a grant supported by the Henry Jackson Foundation.	Agel J, 2010, CAN J SURG, V53, P319; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chappell MH, 2008, MAGN RESON IMAGING, V26, P1398, DOI 10.1016/j.mri.2008.04.004; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12287; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Faul M, 2010, TRAUMATIC BRAIN INJU; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pasternak O, 2014, J NEUROSURG, DOI [10.3171/2013.12.JNS132090, DOI 10.3171/2013.12.JNS132090]]; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	52	91	91	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					864	890		10.3171/2013.12.JNS132093			27	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800011	24490785	Green Accepted, Bronze			2022-02-06	
J	Twamley, EW; Jak, AJ; Delis, DC; Bondi, MW; Lohr, JB				Twamley, Elizabeth W.; Jak, Amy J.; Delis, Dean C.; Bondi, Mark W.; Lohr, James B.			Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) for Veterans with traumatic brain injury: Pilot randomized controlled trial	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						attention; brain injury; cognitive rehabilitation; cognitive training; depression; employment; executive functioning; memory; postconcussive symptoms; posttraumatic stress disorder; rehabilitation; unemployment	MILD HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; EMPLOYMENT; METAANALYSIS; REMEDIATION; RETURN; COSTS; WORK	Traumatic brain injury (TBI) can result in cognitive impairments and persistent postconcussive symptoms that limit functional recovery, including return to work. We evaluated a 12 wk compensatory cognitive training intervention(Cognitive Symptom Management and Rehabilitation Therapy[CogSMART]) in the context of supported employment for Veterans with mild to moderate TBI. Participants were randomly assigned to receive 12 wk of supported employment plus CogSMART or enhanced supported employment that controlled for therapist attention (control). CogSMART sessions were delivered by the employment specialist and included psychoeducation regarding TBI; strategies to improve sleep, fatigue, headaches, and tension; and compensatory cognitive strategies in thedomains of prospective memory, attention, learning and memory, and executive functioning. Compared with controls, those assigned to supported employment plus CogSMART demonstrated significant reductions in postconcussive symptoms (Cohen d = 0.97) and improvements in prospective memory functioning (Cohen d = 0.72). Effect sizes favoring CogSMART for posttraumatic stress disorder symptom severity, depressive symptom severity, and attainment of competitive work within 14 wk were in the small to medium range (Cohen d = 0.35-0.49). Those who received CogSMART rated the intervention highly. Results suggest that adding CogSMART to supported employment may improve postconcussive symptoms and prospective memory. These effects, as well as smaller effects on psychiatric symptoms and ability to return to work, warrant replication in a larger trial.	[Twamley, Elizabeth W.; Jak, Amy J.; Delis, Dean C.; Lohr, James B.] Dept Vet Affairs VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Twamley, Elizabeth W.; Jak, Amy J.; Bondi, Mark W.; Lohr, James B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA		Twamley, EW (corresponding author), VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr 116A, San Diego, CA 92161 USA.	etwamley@ucsd.edu			DODUnited States Department of Defense [W81XWH-08-2-0193]	Funding/Support: This material was based on work supported by the DOD (award W81XWH-08-2-0193).	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CVLT 3 CALIFORNIA VE; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Fischer H., 2007, US MILITARY CASUALTY; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; James W., 1890, PRINCIPLES PSYCHOL; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Koehler R, 2011, COGNITIVE REHABILITATION THERAPY FOR TRAUMATIC BRAIN INJURY: EVALUATING THE EVIDENCE, P1; Kongs S. K., 2000, WCST 64 WISCONSIN CA; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEHMAN AF, 1988, EVAL PROGRAM PLANN, V11, P51, DOI 10.1016/0149-7189(88)90033-X; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 2012, NEUROPSYCHOL REHABIL, V22, P40, DOI 10.1080/09602011.2011.632908; Sitzer DI, 2006, ACTA PSYCHIAT SCAND, V114, P75, DOI 10.1111/j.1600-0447.2006.00789.x; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wilkinson G. S, 1993, WRAT 3 WIDE RANGE AC; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855	44	91	93	0	33	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	1					59	69		10.1682/JRRD.2013.01.0020			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	AF8GB	WOS:000334952600006	24805894	Bronze			2022-02-06	
J	Kalin, JH; Bergman, JA				Kalin, Jay H.; Bergman, Joel A.			Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; CONTAINING HYDROXAMIC ACIDS; TRAUMATIC BRAIN-INJURY; 2 CATALYTIC DOMAINS; HDAC INHIBITORS; CELL-MIGRATION; CANCER CELLS; HISTONE/PROTEIN DEACETYLASES; STRUCTURAL REQUIREMENTS; CYTOPLASMIC DEACETYLASE	This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein-protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.	[Kalin, Jay H.; Bergman, Joel A.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA		Kalin, JH (corresponding author), Johns Hopkins Univ, Dept Pharmacol, 725 N Wolfe St, Baltimore, MD 21205 USA.	jkalin1@jhmi.edu		Kalin, Jay/0000-0002-8747-6022			Abe T, 2008, CURR OPIN PHARMACOL, V8, P57, DOI 10.1016/j.coph.2007.12.002; Akimova T, 2012, BLOOD, V119, P2443, DOI 10.1182/blood-2011-10-292003; Aldana-Masangkay GI, 2011, LEUKEMIA LYMPHOMA, V52, P1544, DOI 10.3109/10428194.2011.570821; Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; [Anonymous], 2010, J Natl Cancer Inst, V102, P219, DOI 10.1093/jnci/djq030; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bardai FH, 2011, J NEUROSCI, V31, P1746, DOI 10.1523/JNEUROSCI.5704-10.2011; Bazzaro M, 2008, CLIN CANCER RES, V14, P7340, DOI 10.1158/1078-0432.CCR-08-0642; Beier UH, 2011, CURR OPIN IMMUNOL, V23, P670, DOI 10.1016/j.coi.2011.07.002; Bergman JA, 2012, J MED CHEM, V55, P9891, DOI 10.1021/jm301098e; Berry JM, 2008, EXPERT OPIN DRUG SAF, V7, P53, DOI [10.1517/14740338.7.1.53, 10.1517/14740338.7.1.53 ]; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Best JD, 2010, DRUG DISCOV TODAY, V15, P1008, DOI 10.1016/j.drudis.2010.10.006; Bieliauskas AV, 2008, CHEM SOC REV, V37, P1402, DOI 10.1039/b703830p; Bieliauskas AV, 2007, BIOORG MED CHEM LETT, V17, P2216, DOI 10.1016/j.bmcl.2007.01.117; Blair LP, 2012, DNA CELL BIOL, V31, pS49, DOI 10.1089/dna.2012.1654; Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bush EW, 2010, CIRC RES, V106, P272, DOI 10.1161/CIRCRESAHA.109.209338; Butler KV, 2008, CURR PHARM DESIGN, V14, P505; Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v; Calkins MJ, 2011, BBA-MOL BASIS DIS, V1812, P507, DOI 10.1016/j.bbadis.2011.01.007; Castro-Castro A, 2012, EUR J CELL BIOL, V91, P950, DOI 10.1016/j.ejcb.2012.07.001; Cecarini V, 2012, BBA-MOL BASIS DIS, V1822, P1741, DOI 10.1016/j.bbadis.2012.07.015; Chen SG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010848; Chen YT, 2012, CLIN EXP PHARMACOL P, V39, P751, DOI 10.1111/j.1440-1681.2012.05729.x; Chen Y, 2008, J MED CHEM, V51, P3437, DOI 10.1021/jm701606b; Chen YF, 2009, CHEMMEDCHEM, V4, P842, DOI 10.1002/cmdc.200800461; Choi SE, 2011, BIOORG MED CHEM LETT, V21, P6139, DOI 10.1016/j.bmcl.2011.08.027; Chuang DM, 2009, TRENDS NEUROSCI, V32, P591, DOI 10.1016/j.tins.2009.06.002; Cook C, 2012, HUM MOL GENET, V21, P2936, DOI 10.1093/hmg/dds125; d'Ydewalle C, 2012, INT J BIOCHEM CELL B, V44, P1299, DOI 10.1016/j.biocel.2012.04.020; d'Ydewalle C, 2012, TRAFFIC, V13, P771, DOI 10.1111/j.1600-0854.2012.01347.x; d'Ydewalle C, 2011, NAT MED, V17, P968, DOI 10.1038/nm.2396; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; de Zoeten EF, 2011, MOL CELL BIOL, V31, P2066, DOI 10.1128/MCB.05155-11; Decker H, 2010, J NEUROSCI, V30, P9166, DOI 10.1523/JNEUROSCI.1074-10.2010; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Dickson DW, 1999, BRAIN PATHOL, V9, P657; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Du H, 2010, P NATL ACAD SCI USA, V107, P18670, DOI 10.1073/pnas.1006586107; Fukushima N, 2009, J NEUROCHEM, V109, P683, DOI 10.1111/j.1471-4159.2009.06013.x; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073/pnas.0908908106; Granger A, 2008, FASEB J, V22, P3549, DOI 10.1096/fj.08-108548; Greer JM, 2012, BIOL-TARGETS THER, V6, P307, DOI 10.2147/BTT.S24067; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hackanson B, 2012, LEUKEMIA RES, V36, P1055, DOI 10.1016/j.leukres.2012.02.026; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hammond JW, 2008, CURR OPIN CELL BIOL, V20, P71, DOI 10.1016/j.ceb.2007.11.010; Hammond JW, 2010, MOL BIOL CELL, V21, P572, DOI 10.1091/mbc.E09-01-0044; Hancock WW, 2012, ANN RHEUM DIS, V71, P46, DOI 10.1136/annrheumdis-2011-200593; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Heltweg B, 2004, J MED CHEM, V47, P5235, DOI 10.1021/jm0497592; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hsieh TH, 2012, TOXICOL SCI, V128, P365, DOI 10.1093/toxsci/kfs163; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inks ES, 2012, ACS CHEM BIOL, V7, P330, DOI 10.1021/cb200134p; Iyer A, 2010, BRIT J PHARMACOL, V159, P1408, DOI 10.1111/j.1476-5381.2010.00637.x; Jones P, 2008, BIOORG MED CHEM LETT, V18, P3456, DOI 10.1016/j.bmcl.2008.02.026; Jung KH, 2012, HEPATOLOGY, V56, P644, DOI 10.1002/hep.25699; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Kalin JH, 2012, CHEMMEDCHEM, V7, P425, DOI 10.1002/cmdc.201100522; Kalin JH, 2012, J MED CHEM, V55, P639, DOI 10.1021/jm200773h; Kaluza D, 2011, EMBO J, V30, P4142, DOI 10.1038/emboj.2011.298; Kamemura K, 2008, BIOCHEM BIOPH RES CO, V374, P84, DOI 10.1016/j.bbrc.2008.06.092; Kamemura K, 2012, FEBS LETT, V586, P1379, DOI 10.1016/j.febslet.2012.03.060; Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898; Kawada J, 2009, J BIOL CHEM, V284, P17102, DOI 10.1074/jbc.M809090200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kerr E, 2012, CELL DEATH DIFFER, V19, P1317, DOI 10.1038/cdd.2012.8; Kim C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042983; Kim D, 2008, NEURON, V60, P803, DOI 10.1016/j.neuron.2008.10.015; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Konsoula R, 2008, INT J PHARM, V361, P19, DOI 10.1016/j.ijpharm.2008.05.001; Konsoula Z, 2011, INT J RADIAT ONCOL, V79, P1541, DOI 10.1016/j.ijrobp.2010.11.057; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kozikowski AP, 2008, J MED CHEM, V51, P4370, DOI 10.1021/jm8002894; Kozikowski AP, 2007, J MED CHEM, V50, P3054, DOI 10.1021/jm070178x; Kozikowski AR, 2008, CHEMMEDCHEM, V3, P487, DOI 10.1002/cmdc.200700314; Lafarga V, 2012, EMBO J, V31, P856, DOI 10.1038/emboj.2011.466; Langley B, 2008, J NEUROSCI, V28, P163, DOI 10.1523/JNEUROSCI.3200-07.2008; Lee JY, 2010, J CELL BIOL, V189, P671, DOI 10.1083/jcb.201001039; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Lemon DD, 2011, J MOL CELL CARDIOL, V51, P41, DOI 10.1016/j.yjmcc.2011.04.005; Li GY, 2011, J NEUROL SCI, V304, P1, DOI 10.1016/j.jns.2011.02.017; Luxton GWG, 2007, DEV CELL, V13, P161, DOI 10.1016/j.devcel.2007.07.014; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Murphy PJM, 2005, J BIOL CHEM, V280, P33792, DOI 10.1074/jbc.M506997200; Myzak MC, 2007, EXP BIOL MED, V232, P227; Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Ontoria JM, 2009, J MED CHEM, V52, P6782, DOI 10.1021/jm900555u; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Pan F, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003364; Parmigiani RB, 2008, P NATL ACAD SCI USA, V105, P9633, DOI 10.1073/pnas.0803749105; Penela P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003098; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Rao R, 2008, BLOOD, V112, P1886, DOI 10.1182/blood-2008-03-143644; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Rey M, 2011, EUR J CELL BIOL, V90, P128, DOI 10.1016/j.ejcb.2010.09.004; Rivieccio MA, 2009, P NATL ACAD SCI USA, V106, P19599, DOI 10.1073/pnas.0907935106; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Schafer S, 2008, BIOORGAN MED CHEM, V16, P2011, DOI 10.1016/j.bmc.2007.10.092; Schaefer S, 2009, CHEMMEDCHEM, V4, P283, DOI 10.1002/cmdc.200800196; Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Sigala R, 2007, CURR BIOL, V17, pR18, DOI 10.1016/j.cub.2006.11.036; Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008-5472.CAN-08-3502; Smil DV, 2009, BIOORG MED CHEM LETT, V19, P688, DOI 10.1016/j.bmcl.2008.12.045; Sternson SM, 2001, ORG LETT, V3, P4239, DOI 10.1021/ol016915f; Sung YM, 2013, EXP NEUROL, V239, P192, DOI 10.1016/j.expneurol.2012.10.005; Suzuki T, 2005, BIOORG MED CHEM LETT, V15, P331, DOI 10.1016/j.bmcl.2004.10.074; Suzuki T, 2004, BIOORG MED CHEM LETT, V14, P3313, DOI 10.1016/j.bmcl.2004.03.063; Suzuki T, 2003, BIOORG MED CHEM LETT, V13, P4321, DOI 10.1016/j.bmcl.2003.09.048; Suzuki T, 2006, J MED CHEM, V49, P4809, DOI 10.1021/jm060554y; Tapadar S, 2009, BIOORG MED CHEM LETT, V19, P3023, DOI 10.1016/j.bmcl.2009.04.058; Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431; True O, 2012, IMMUNOL CELL BIOL, V90, P78, DOI 10.1038/icb.2011.103; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033160; Welberg L, 2009, NAT REV DRUG DISCOV, V8, DOI 10.1038/nrd2934; Wickstrom SA, 2010, EMBO J, V29, P131, DOI 10.1038/emboj.2009.317; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Wittich S, 2002, J MED CHEM, V45, P3296, DOI 10.1021/jm0208119; Xia WL, 2010, CLIN EXP PHARMACOL P, V37, P253, DOI 10.1111/j.1440-1681.2009.05279.x; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Yao Tso-Pang, 2010, Genes Cancer, V1, P779; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang LX, 2010, AM J PHYSIOL-HEART C, V298, pH2154, DOI 10.1152/ajpheart.01015.2009; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zhang XH, 2011, CNS NEUROSCI THER, V17, P590, DOI 10.1111/j.1755-5949.2011.00271.x; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06; Zhao TC, 2007, CARDIOVASC RES, V76, P473, DOI 10.1016/j.cardiores.2007.08.010; Zhao TC, 2010, BBA-MOL CELL RES, V1803, P872, DOI 10.1016/j.bbamcr.2010.04.007; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813; Zou H, 2006, BIOCHEM BIOPH RES CO, V341, P45, DOI 10.1016/j.bbrc.2005.12.144; Zuo QQ, 2012, ONCOL REP, V27, P819, DOI 10.3892/or.2011.1553	154	91	94	2	54	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	AUG 22	2013	56	16					6297	6313		10.1021/jm4001659			17	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	207IZ	WOS:000323593400002	23627282				2022-02-06	
J	Hawkins, BE; Krishnamurthy, S; Castillo-Carranza, DL; Sengupta, U; Prough, DS; Jackson, GR; DeWitt, DS; Kayed, R				Hawkins, Bridget E.; Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Prough, Donald S.; Jackson, George R.; DeWitt, Douglas S.; Kayed, Rakez			Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; POSTTRAUMATIC EPILEPSY; PHOSPHORYLATION SITES; NEURONAL LOSS; MOUSE MODEL; HEAD-INJURY; IN-VITRO; TAUOPATHY	Traumatic brain injury (TBI) is a serious problem that affects millions of people in the United States alone. Multiple concussions or even a single moderate to severe TBI can also predispose individuals to develop a pathologically distinct form of tauopathy- related dementia at an early age. No effective treatments are currently available for TBI or TBI-related dementia; moreover, only recently has insight been gained regarding the mechanisms behind their connection. Here, we used antibodies to detect oligomeric and phosphorylated Tau proteins in a non-transgenic rodent model of parasagittal fluid percussion injury. Oligomeric and phosphorylated Tau proteins were detected 4 and 24 h and 2 weeks post-TBI in injured, but not sham control rats. These findings suggest that diagnostic tools and therapeutics that target only toxic forms of Tau may provide earlier detection and safe, more effective treatments for tauopathies associated with repetitive neurotrauma.	[Hawkins, Bridget E.; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; [Hawkins, Bridget E.; Prough, Donald S.; DeWitt, Douglas S.] Univ Texas Med Branch, Moody Ctr Traumat Brain & Spinal Cord Injury Res, Galveston, TX 77555 USA; [Hawkins, Bridget E.; Prough, Donald S.; DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA; [Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Krishnamurthy, Shashirekha; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, George & Cynthia Mitchell Ctr Neurodegenerat Dis, Galveston, TX 77555 USA		Kayed, R (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	rakayed@utmb.edu	Prough, Donald S/G-5793-2013; Hawkins, Bridget/H-4933-2015	Prough, Donald S/0000-0001-7994-532X; Hawkins, Bridget/0000-0002-1887-3657; Castillo-Carranza, Diana/0000-0003-2511-949X	Cullen Family Trust for Health Care, the Mitchell Center for Neurodegenerative Diseases; Moody Center for Traumatic Brain & Spinal Cord Injury Research/Mission Connect	This work was supported by the Cullen Family Trust for Health Care, the Mitchell Center for Neurodegenerative Diseases, and the Moody Center for Traumatic Brain & Spinal Cord Injury Research/Mission Connect. R.K. has patent applications on the compositions and methods related to Tau oligomers and antibodies.	Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Castillo-Carranza D. L., 2010, SOC NEUROSCI; Castillo-Carranza Diana L, 2013, Front Biosci (Schol Ed), V5, P426; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cowan CM, 2012, BIOCHEM SOC T, V40, P693, DOI 10.1042/BST20120135; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Goldstein L.E., 2012, SCI TRANSL MED, V4; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Hall GF, 2012, PRION, V6, P223, DOI 10.4161/pri.19912; Haroutunian V, 2007, NEUROBIOL AGING, V28, P1, DOI 10.1016/j.neurobiolaging.2005.11.001; Hawkins BE, 2012, BRAIN RES, V1432, P28, DOI 10.1016/j.brainres.2011.11.009; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Henkins KM, 2012, BRAIN PATHOL, V22, P826, DOI 10.1111/j.1750-3639.2012.00598.x; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kril JJ, 2002, ACTA NEUROPATHOL, V103, P370, DOI 10.1007/s00401-001-0477-5; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lasagna-Reeves CA, 2011, J BIOL CHEM, V286, P22122, DOI 10.1074/jbc.M111.236257; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Le Meghan N, 2012, Am J Neurodegener Dis, V1, P316; Li Y, 2010, BRAIN RES, V1330, P131, DOI 10.1016/j.brainres.2010.03.034; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pooler AM, 2013, EMBO REP, V14, P389, DOI 10.1038/embor.2013.15; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Schneider A, 2008, NEUROTHERAPEUTICS, V5, P443, DOI 10.1016/j.nurt.2008.05.006; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Tai HC, 2012, AM J PATHOL, V181, P1426, DOI 10.1016/j.ajpath.2012.06.033; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Ubhi K, 2011, EXP NEUROL, V230, P157, DOI 10.1016/j.expneurol.2010.10.007; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528	63	91	93	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2013	288	23					17042	17050		10.1074/jbc.M113.472746			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163ZU	WOS:000320378900075	23632019	Green Published, hybrid			2022-02-06	
J	Faubert, J; Sidebottom, L				Faubert, Jocelyn; Sidebottom, Lee			Perceptual-Cognitive Training of Athletes	JOURNAL OF CLINICAL SPORT PSYCHOLOGY			English	Article						perceptual-cognitive training; sport; athlete; concussion; injury		This present article discusses an approach to training high-level athletes' perceptual-cognitive skills. The intention herein is to (a) introduce concepts in regard to what may be required by athletes to optimally process sports-related visual scenes at the perceptual-cognitive level; (b) present an experimental method of how it may be possible to train this capacity in athletes while discussing the necessary features for a successful perceptual-cognitive training outcome; and (c) propose that this capacity may be trainable even among the highest-level athletes. An important suggestion is that a simple difference between sitting and standing testing conditions may strongly influence speed thresholds with this task, which is analogous to game movement dynamics in sports, indicating shared resources between such high-level perceptual-cognitive demands and mechanisms involved in posture control. A discussion follows emphasizing how a perceptual-cognitive training approach may be useful as an integral component of athletic training. The article concludes with possible future directions.	[Faubert, Jocelyn] Univ Montreal, Visual Psychophys & Percept Lab, Montreal, PQ, Canada; [Sidebottom, Lee] CogniSens Athlet Inc, Montreal, PQ, Canada		Faubert, J (corresponding author), Univ Montreal, Visual Psychophys & Percept Lab, Montreal, PQ, Canada.		Faubert, Jocelyn/E-2207-2011		Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	The authors would like to thank Felix Rehnberg and Adam Lorton for help with editing and data compilation for the manuscript. Jocelyn Faubert would like to acknowledge research grant support from the Natural Sciences and Engineering Research Council of Canada discovery grant program.	Barris S, 2008, SPORTS MED, V38, P1025, DOI 10.2165/00007256-200838120-00006; Bennett PJ, 2007, VISION RES, V47, P799, DOI 10.1016/j.visres.2007.01.001; Biderman D, 2010, WALL STREET J; Blaser E, 2008, PERCEPTION, V37, P624, DOI 10.1068/p5812; Bridge H, 2008, BRAIN, V131, P1433, DOI 10.1093/brain/awn063; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Carling C, 2010, J SPORT SCI, V28, P319, DOI 10.1080/02640410903473851; Cavanagh P, 2005, TRENDS COGN SCI, V9, P349, DOI 10.1016/j.tics.2005.05.009; CRUZNEIRA C, 1992, COMMUN ACM, V35, P64, DOI 10.1145/129888.129892; Draganski B, 2008, BEHAV BRAIN RES, V192, P137, DOI 10.1016/j.bbr.2008.02.015; Faubert J, 2002, CAN J EXP PSYCHOL, V56, P164, DOI 10.1037/h0087394; Faubert J., P SPIE, P168, DOI [10.1117/12.419794, DOI 10.1117/12.419794]; Faubert J., 2009, 19 IAGG WORLD C GER; Fougnie D, 2006, PSYCHOL SCI, V17, P526, DOI 10.1111/j.1467-9280.2006.01739.x; GARLAND DJ, 1990, PERCEPT MOTOR SKILL, V70, P1299, DOI 10.2466/PMS.70.4.1299-1314; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Greenwald HS, 2005, VISION RES, V45, P1975, DOI 10.1016/j.visres.2005.01.025; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Hagemann N, 2006, J SPORT EXERCISE PSY, V28, P143, DOI 10.1123/jsep.28.2.143; Haywood KM, 1984, J SPORT SCI, V2, P139, DOI 10.1080/02640418408729709; Intriligator J, 2001, COGNITIVE PSYCHOL, V43, P171, DOI 10.1006/cogp.2001.0755; Iordanescu L, 2009, J VISION, V9, DOI 10.1167/9.4.1; Julesz B., 1971, FDN CYCLOPEAN PERCEP; Knudson D., 1997, J PHYS ED RECREATION, V68, P17, DOI [DOI 10.1080/07303084.1997.10604922, 10.1080/07303084.1997.10604922]; Kraemer WJ, 2007, OPTIMIZING STRENGTH; Kupers R, 2010, P NATL ACAD SCI USA, V107, P12716, DOI 10.1073/pnas.1006199107; LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375; Ma LS, 2010, BRAIN RES, V1318, P64, DOI 10.1016/j.brainres.2009.12.073; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; Mann DTY, 2007, J SPORT EXERCISE PSY, V29, P457, DOI 10.1123/jsep.29.4.457; May A, 2007, CEREB CORTEX, V17, P205, DOI 10.1093/cercor/bhj138; Mori S, 2002, HUM MOVEMENT SCI, V21, P213, DOI 10.1016/S0167-9457(02)00103-3; Nagano T, 2006, PERCEPT MOTOR SKILL, V102, P147, DOI 10.2466/PMS.102.1.147-156; Novack TA, 1998, J INT NEUROPSYCH SOC, V4, P409, DOI 10.1017/S1355617798004093; O'Hearn K, 2005, PSYCHOL SCI, V16, P905, DOI 10.1111/j.1467-9280.2005.01635.x; PYLYSHYN Z, 1994, COGNITION, V50, P363, DOI 10.1016/0010-0277(94)90036-1; PYLYSHYN Z W, 1988, Spatial Vision, V3, P179, DOI 10.1163/156856888X00122; Richards E, 2006, VISION RES, V46, P4217, DOI 10.1016/j.visres.2006.08.011; Rogers TJ, 2005, J SPORT EXERCISE PSY, V27, P271, DOI 10.1123/jsep.27.3.271; Sacks O., 2006, NEW YORKER, P64; Savelsbergh GJP, 2005, ERGONOMICS, V48, P1686, DOI 10.1080/00140130500101346; Sears CR, 2000, CAN J EXP PSYCHOL, V54, P1, DOI 10.1037/h0087326; Sekuler R, 2008, PERCEPTION, V37, P867, DOI 10.1068/p5923; SHEEDY JE, 1986, AM J OPTOM PHYS OPT, V63, P839; Smeeton NJ, 2005, J EXP PSYCHOL-APPL, V11, P98, DOI 10.1037/1076-898X.11.2.98; Starkes J., 2003, EXPERT PERFORMANCE S, P220; Stone MH, 2000, STRENGTH COND J, V22, P65; Tang Y, 2009, J VISION, V9, DOI 10.1167/9.7.18; Tinjust D., 2010, J VISION CHARLOTTESV, V8, P509, DOI [10.1167/8.6.509, DOI 10.1167/8.6.509]; Trick LM, 2005, J GERONTOL B-PSYCHOL, V60, pP102, DOI 10.1093/geronb/60.2.P102; Vaeyens R, 2007, J SPORT EXERCISE PSY, V29, P147, DOI 10.1123/jsep.29.2.147; VanLehn K., 1991, ARCHITECTURES INTELL, P189; WILLIAMS AM, 1994, RES Q EXERCISE SPORT, V65, P127, DOI 10.1080/02701367.1994.10607607; Williams AM, 2000, J SPORT SCI, V18, P737, DOI 10.1080/02640410050120113; Williams AM, 2006, PERCEPTION, V35, P317, DOI 10.1068/p5310; Williams JM, 1997, BEHAV MED, V22, P160, DOI 10.1080/08964289.1997.10543549; Williams M, 2002, PSYCHOLOGIST, V15, P416; WILLIAMS M, 1995, J SPORT EXERCISE PSY, V17, P259, DOI 10.1123/jsep.17.3.259; Williams Mark A., 1999, VISUAL PERCEPTION AC; Wood JM, 1997, OPTOMETRY VISION SCI, V74, P646, DOI 10.1097/00006324-199708000-00026; Zelinsky GJ, 2010, J VISION, V10, DOI 10.1167/10.14.29; Zhang H, 2010, VIS COGN, V18, P617, DOI 10.1080/13506280903211142	63	91	94	1	2	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1932-9261	1932-927X		J CLIN SPORT PSYCHOL	J. Clin. Sport Psychol.	MAR	2012	6	1					85	102		10.1123/jcsp.6.1.85			18	Psychology, Applied	Emerging Sources Citation Index (ESCI)	Psychology	V22SD	WOS:000215040600006					2022-02-06	
J	Bauer, RM; Iverson, GL; Cernich, AN; Binder, LM; Ruff, RM; Naugle, RI				Bauer, Russell M.; Iverson, Grant L.; Cernich, Alison N.; Binder, Laurence M.; Ruff, Ronald M.; Naugle, Richard I.			Computerized Neuropsychological Assessment Devices: Joint Position Paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology	CLINICAL NEUROPSYCHOLOGIST			English	Article						Computerized testing; neurocognition; neuropsychological test validity	MILD COGNITIVE IMPAIRMENT; TEST-RETEST RELIABILITY; BRAIN-INJURY; PSYCHOLOGICAL-ASSESSMENT; MOOD DISORDERS; CATEGORY TEST; TEST-SCORES; IRAQ-WAR; CONCUSSION; BATTERY	This joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology sets forth our position on appropriate standards and conventions for computerized neuropsychological assessment devices (CNADs). In this paper, we first define CNADs and distinguish them from examiner-administered neuropsychological instruments. We then set forth position statements on eight key issues relevant to the development and use of CNADs in the healthcare setting. These statements address (a) device marketing and performance claims made by developers of CNADs; (b) issues involved in appropriate end-users for administration and interpretation of CNADs; (c) technical (hardware/software/firmware) issues; (d) privacy, data security, identity verification, and testing environment; (e) psychometric development issues, especially reliability and validity; (f) cultural, experiential, and disability factors affecting examinee interaction with CNADs; (g) use of computerized testing and reporting services; and (h) the need for checks on response validity and effort in the CNAD environment. This paper is intended to provide guidance for test developers and users of CNADs that will promote accurate and appropriate use of computerized tests in a way that maximizes clinical utility and minimizes risks of misuse. The positions taken in this paper are put forth with an eye toward balancing the need to make validated CNADs accessible to otherwise underserved patients with the need to ensure that such tests are developed and utilized competently, appropriately, and with due concern for patient welfare and quality of care.	[Bauer, Russell M.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Cernich, Alison N.] VA Maryland Hlth Care Syst, Baltimore, MD USA; [Binder, Laurence M.] Oregon Hlth & Sci Univ, Portland, OR USA; [Ruff, Ronald M.] San Francisco Clin Neurosci, San Francisco, CA USA; [Naugle, Richard I.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Bauer, Russell M.; Cernich, Alison N.; Naugle, Richard I.] Amer Acad Clin Neuropsychol, Ann Arbor, MI USA; [Iverson, Grant L.; Binder, Laurence M.; Ruff, Ronald M.] Natl Acad Neuropsychol, Ann Arbor, MI USA		Bauer, RM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, POB 100165 HSC, Gainesville, FL 32610 USA.	rbauer@phhp.ufl.edu		Iverson, Grant/0000-0001-7348-9570	University of FloridaUniversity of Florida [UL1 RR029890]; Canadian government; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029890] Funding Source: NIH RePORTER	Russell M. Bauer, Ph.D. is supported in part by grants UL1 RR029890 to the University of Florida. Grant Iverson has led or been a member of research teams that have received grant funding from test publishing companies, the pharmaceutical industry, and the Canadian government to study the psychometrics of computerized and traditional neuropsychological tests. These companies include AstraZeneca Canada, Lundbeck Canada, Pfizer Canada, ImPACT Applications, Inc., CNS Vital Signs, Psychological Assessment Resources (PAR, Inc.), and the Canadian Institute of Health Research. He is also a co-author on a test published by PAR, Inc. Alison Cernich's views are her own and do not necessarily represent the views of the Department of Veteran's Affairs (VA). The VA had no role in the writing of the article or the decision to submit it for publication. Ronald Ruff has published four tests with Psychological Assessment Resources, Inc. Laurence Binder is the author and publisher of the Portland Digit Recognition Test.	*AM PSYCH ASS, 1986, GUID COMP BAS TESTS; American Psychological Association, 1999, STAND ED PSYCH TEST; American Psychological Association [APA], 2010, ETH PRINC PSYCH COD; Anger WK, 1999, J INT NEUROPSYCH SOC, V5, P203, DOI 10.1017/S1355617799533031; [Anonymous], 2007, AM PSYCHOL, V62, P993, DOI 10.1037/0003-066X.62.9.993; Berger SG, 1997, J CLIN PSYCHOL, V53, P723; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bolfer C, 2010, ARQ NEURO-PSIQUIAT, V68, P282, DOI 10.1590/S0004-282X2010000200025; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Campbell KA, 1999, ASSESSMENT, V6, P21, DOI 10.1177/107319119900600103; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Chamberlain SR, 2011, BIOL PSYCHIAT, V69, P1192, DOI 10.1016/j.biopsych.2010.08.019; Choca J., 1992, CLIN NEUROPSYCHOL, V6, P9, DOI [10.1080/13854049208404112, DOI 10.1080/13854049208404112]; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; CREEGER CP, 1990, BEHAV RES METH INSTR, V22, P34, DOI 10.3758/BF03203120; Crook T. H., 2009, NEUROPSYCHOLOGICAL A, P84; Doniger Glen M., 2005, Current Alzheimer Research, V2, P117; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; Dorion AA, 2002, NEUROPSYCHOLOGIA, V40, P946, DOI 10.1016/S0028-3932(01)00150-6; Dwolatzky T, 2004, J MOL NEUROSCI, V24, P33, DOI 10.1385/JMN:24:1:033; Feldstein SN, 1999, CLIN NEUROPSYCHOL, V13, P303, DOI 10.1076/clin.13.3.303.1744; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; Franzen M. D., 1989, RELIABILITY VALIDITY; Franzen M. D., 2000, RELIABILITY VALIDITY; Gaver W. W., 1991, CHI 1991 P SIGCHI C; Gofen A, 1997, SPATIAL VISION, V10, P361, DOI 10.1163/156856897X00285; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Gualtieri C Thomas, 2006, J Atten Disord, V9, P534, DOI 10.1177/1087054705283758; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Haladyna T.M., 2006, HDB TEST DEV; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hitchcock E, 2006, TOP STROKE REHABIL, V13, P22, DOI 10.1310/0HWA-DJN8-JUPC-GET1; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2011, J AFFECT DISORDERS, V132, P360, DOI 10.1016/j.jad.2011.03.001; Iverson GL, 2009, J CLIN EXP NEUROPSYC, V31, P594, DOI 10.1080/13803390802372125; KRAMER JJ, 1987, AM PSYCHOL, V42, P889, DOI 10.1037/0003-066X.42.9.889.b; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Matarazzo J. D., 1985, Computers in Human Behaviour, V1, P235, DOI 10.1016/0747-5632(85)90015-9; MATARAZZO JD, 1986, AM PSYCHOL, V41, P96; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; MCINNES WJ, 2001, BEHAV RES METH INSTR, V31, P129; Mclay R, 2010, MIL MED, V175, P945, DOI 10.7205/MILMED-D-09-00237; Messick S., 1989, ED MEASUREMENT, V3, P13; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Moore JL, 2002, EPILEPSY BEHAV, V3, P92, DOI 10.1006/ebeh.2001.0313; Myors B, 1999, BEHAV RES METH INS C, V31, P322, DOI 10.3758/BF03207727; Naglieri JA, 2004, AM PSYCHOL, V59, P150, DOI 10.1037/0003-066X.59.3.150; Newman TB, 2009, EVIDENCE-BASED DIAGNOSIS, P1, DOI 10.1017/CBO9780511759512; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; OZONOFF D, 1995, LANCET, V346, P860, DOI 10.1016/S0140-6736(95)92706-9; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Plant RR, 2009, BEHAV RES METHODS, V41, P598, DOI 10.3758/BRM.41.3.598; Plant RR, 2004, BEHAV RES METH INS C, V36, P291, DOI 10.3758/BF03195575; Polderman TJC, 2011, CHILD NEUROPSYCHOL, V17, P138, DOI 10.1080/09297049.2010.518142; Raymond PD, 2006, EUR J CARDIO-THORAC, V29, P82, DOI 10.1016/j.ejcts.2005.10.016; Reise SP, 2009, ANNU REV CLIN PSYCHO, V5, P27, DOI 10.1146/annurev.clinpsy.032408.153553; Retzlaff P. D., 2000, CLIN GUIDE NEUROPSYC, P277; Retzlaff PD, 1999, MIL MED, V164, P514, DOI 10.1093/milmed/164.7.514; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Sweeney JA, 2000, BIOL PSYCHIAT, V48, P674, DOI 10.1016/S0006-3223(00)00910-0; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Thomas ML, 2011, ASSESSMENT, V18, P291, DOI 10.1177/1073191110374797; Thorndike, 1971, ED MEASUREMENT, P443, DOI DOI 10.1037/14353-009; Tien Allen Y., 1996, Kaohsiung Journal of Medical Sciences, V12, P479; Tornatore JB, 2005, J NEUROPSYCH CLIN N, V17, P98, DOI 10.1176/appi.neuropsych.17.1.98; URBINA S, 2004, ESSENTIALS PSYCHOL T; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Wild K, 2008, ALZHEIMERS DEMENT, V4, P428, DOI 10.1016/j.jalz.2008.07.003; Wouters H, 2009, DEMENT GERIATR COGN, V28, P486, DOI 10.1159/000250593; Wouters H, 2009, INT J METH PSYCH RES, V18, P118, DOI 10.1002/mpr.283; [No title captured]	86	91	93	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	2					177	196		10.1080/13854046.2012.663001			20	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	936EO	WOS:000303573900001	22394228	Green Accepted			2022-02-06	
J	Fevang, E; Lockey, D; Thompson, J; Lossius, HM				Fevang, Espen; Lockey, David; Thompson, Julian; Lossius, Hans Morten		Torpo Res Collaboration	The top five research priorities in physician-provided pre-hospital critical care: a consensus report from a European research collaboration	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							EMERGENCY MEDICAL-SERVICES; ADVANCED LIFE-SUPPORT; INTERNATIONAL EMS SYSTEMS; TRAUMATIC BRAIN-INJURY; GOLDEN-HOUR; RESPONSE-TIME; PATIENT; SURVIVAL; PROGRAM; IMPACT	Background: Physician-manned emergency medical teams supplement other emergency medical services in some countries. These teams are often selectively deployed to patients who are considered likely to require critical care treatment in the pre-hospital phase. The evidence base for guidelines for pre-hospital triage and immediate medical care is often poor. We used a recognised consensus methodology to define key priority areas for research within the subfield of physician-provided pre-hospital critical care. Methods: A European expert panel participated in a consensus process based upon a four-stage modified nominal group technique that included a consensus meeting. Results: The expert panel concluded that the five most important areas for further research in the field of physician-based pre-hospital critical care were the following: Appropriate staffing and training in pre-hospital critical care and the effect on outcomes, advanced airway management in pre-hospital care, definition of time windows for key critical interventions which are indicated in the pre-hospital phase of care, the role of pre-hospital ultrasound and dispatch criteria for pre-hospital critical care services. Conclusion: A modified nominal group technique was successfully used by a European expert group to reach consensus on the most important research priorities in physician-provided pre-hospital critical care.	[Fevang, Espen; Lossius, Hans Morten] Norwegian Air Ambulance Fdn, Dept Res & Dev, Drobak, Norway; [Fevang, Espen] Stavanger Univ Hosp, Dept Anaesthesiol & Intens Care, Stavanger, Norway; [Lockey, David; Thompson, Julian] Royal London Hosp, London HEMS, London E1 1BB, England; [Lockey, David] Univ Bristol, Sch Clin Sci, Bristol, Avon, England; [Lossius, Hans Morten] Univ Bergen, Dept Surg Sci, Bergen, Norway		Fevang, E (corresponding author), Norwegian Air Ambulance Fdn, Dept Res & Dev, Drobak, Norway.	espen.fevang@norskluftambulanse.no	Di Bartolomeo, Stefano/K-1695-2016; Wisborg, Torben/H-5126-2011	Di Bartolomeo, Stefano/0000-0002-3468-9358; Wisborg, Torben/0000-0002-7213-8012; Sandberg, Marten/0000-0002-4812-0103; Fredriksen, Knut/0000-0002-9281-8007	Norwegian Air Ambulance Foundation (SNLA); SNLA	The entirety of this project and the consensus meeting were financed by the Norwegian Air Ambulance Foundation (SNLA), and the main author is on a research scholarship from SNLA. The authors would like to thank all members and involved staff from SNLA for making this study possible.	Ali J, 1997, J TRAUMA, V42, P1018, DOI 10.1097/00005373-199706000-00005; Ali J, 1998, WORLD J SURG, V22, P1192, DOI 10.1007/s002689900543; Ali J, 1998, J TRAUMA, V44, P588, DOI 10.1097/00005373-199804000-00005; Berger E, 2010, ANN EMERG MED, V56, p17A, DOI 10.1016/j.annemergmed.2010.09.012; Berlot G, 2006, CRIT CARE CLIN, V22, P457, DOI 10.1016/j.ccc.2006.03.009; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Blackwell TH, 2002, ACAD EMERG MED, V9, P288, DOI 10.1111/j.1553-2712.2002.tb01321.x; Botker MT, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-12; Breitkreutz R, 2010, RESUSCITATION, V81, P1527, DOI 10.1016/j.resuscitation.2010.07.013; Busch M, 2006, ACTA ANAESTH SCAND, V50, P754, DOI 10.1111/j.1399-6576.2006.01030.x; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; Carley S, 2001, RESUSCITATION, V48, P47, DOI 10.1016/S0300-9572(00)00317-8; Carmont MR, 2005, POSTGRAD MED J, V81, P87, DOI 10.1136/pgmj.2004.021543; Chun Rosaleen, 2004, Prehosp Disaster Med, V19, P366; Davis DP, 2011, CRIT CARE, V15, DOI 10.1186/cc10039; DELBECQ AL, 1971, J APPL BEHAV SCI, V7, P466, DOI 10.1177/002188637100700404; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Dissmann PD, 2007, EMERG MED J, V24, P59, DOI 10.1136/emj.2006.038844; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Frederiksen CA, 2011, ACTA ANAESTH SCAND, V55, P126, DOI 10.1111/j.1399-6576.2010.02330.x; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Garner Alan A, 2004, Emerg Med Australas, V16, P318, DOI 10.1111/j.1742-6723.2004.00636.x; Gillman LM, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-34; GOLD CR, 1987, ANN EMERG MED, V16, P797, DOI 10.1016/S0196-0644(87)80578-4; GOODMAN CM, 1987, J ADV NURS, V12, P729, DOI 10.1111/j.1365-2648.1987.tb01376.x; GUSS DA, 1989, ANN EMERG MED, V18, P1141, DOI 10.1016/S0196-0644(89)80048-4; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Iirola TT, 2006, EUR J EMERG MED, V13, P335, DOI 10.1097/01.mej.0000224429.51623.fb; Isenberg DL, 2005, PREHOSPITAL DISASTER, V20, P265, DOI 10.1017/S1049023X0000265X; JANTZEN JPA, 1993, TXB TRAUMA ANESTHESI; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; JONES SE, 1991, ANN EMERG MED, V20, P857, DOI 10.1016/S0196-0644(05)81427-1; Jorgensen H, 2010, EUR J EMERG MED, V17, P249, DOI 10.1097/MEJ.0b013e328336adce; Knudsen L, 2011, ACTA ANAESTH SCAND, V55, P377, DOI 10.1111/j.1399-6576.2011.02400.x; Kruger AJ, 2010, RESUSCITATION, V81, P427, DOI 10.1016/j.resuscitation.2009.12.019; Kugler G, 2002, ADACOPTER AUFZEICHNU; Kwan I, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002245; Langhelle A, 2004, RESUSCITATION, V61, P9, DOI 10.1016/j.resuscitation.2003.12.008; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lockey D, 2009, RESUSCITATION, V80, P722, DOI 10.1016/j.resuscitation.2009.04.006; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; Lossius HM, 2011, CRIT CARE, V15, DOI 10.1186/cc9973; Lossius HM, 2002, ACTA ANAESTH SCAND, V46, P771, DOI 10.1034/j.1399-6576.2002.460703.x; Lyon RM, 2010, EMERG MED J, V27, P637, DOI 10.1136/emj.2009.087395; McManus John G, 2008, Am J Disaster Med, V3, P241; Meisler Rikke, 2009, Ugeskr Laeger, V171, P2548; Morrison CA, 2009, J SURG RES, V157, P115, DOI 10.1016/j.jss.2009.03.051; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Osterwalder JJ, 2003, J TRAUMA, V55, P355, DOI 10.1097/01.TA.0000034231.94460.1F; Pepe PE, 2009, CRIT CARE MED, V37, pS91, DOI 10.1097/CCM.0b013e318192154d; PEPE PE, 1993, ANN EMERG MED, V22, P17, DOI 10.1016/S0196-0644(05)80244-6; Polk JD, 2001, AVIAT SPACE ENVIR MD, V72, P432; Pons PT, 2005, ACAD EMERG MED, V12, P594, DOI 10.1197/j.aem.2005.02.013; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Price S, 2010, CURR OPIN CRIT CARE, V16, P211, DOI 10.1097/MCC.0b013e3283399d4c; RENNIE D, 1981, NEW ENGL J MED, V304, P665, DOI 10.1056/NEJM198103123041110; Ringburg A, 2009, PREHOSP EMERG CARE, V13, P28, DOI 10.1080/10903120802472012; Ringdal KG, 2008, SCAND J TRAUMA RESUS, V16, DOI 10.1186/1757-7241-16-7; Ryynanen OP, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-62; Sackman H., 1974, DELPHI CRITIQUE EXPE; Salomone JP, 2005, J TRAUMA, V58, P509, DOI 10.1097/01.TA.0000152807.63559.2E; Santora TA, 1996, AM J EMERG MED, V14, P564, DOI 10.1016/S0735-6757(96)90100-X; Schou J, 1997, Eur J Emerg Med, V4, P174, DOI 10.1097/00063110-199709000-00013; Seamon MJ, 2007, J TRAUMA, V63, P113, DOI 10.1097/TA.0b013e31806842a1; Simons R, 1999, J TRAUMA, V46, P811, DOI 10.1097/00005373-199905000-00008; Smith RM, 2009, INJURY, V40, pS23, DOI 10.1016/j.injury.2009.10.033; Snooks H, 2009, EMERG MED J, V26, P549, DOI 10.1136/emj.2008.065862; Sollid SJM, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-58; Taylor DM, 2008, PREHOSP EMERG CARE, V12, P42, DOI 10.1080/10903120701710389; Tazarourte K, 2011, ACTA ANAESTH SCAND, V55, P422, DOI 10.1111/j.1399-6576.2010.02372.x; Timmermann A, 2008, CURR OPIN ANESTHESIO, V21, P222, DOI 10.1097/ACO.0b013e3282f5f4f7; van der Velden MWA, 2008, EMERG MED J, V25, P444, DOI 10.1136/emj.2007.052662; VANDEVEN AH, 1972, AM J PUBLIC HEALTH N, V62, P337, DOI 10.2105/AJPH.62.3.337; Wang HE, 2007, ANN EMERG MED, V50, P643, DOI 10.1016/j.annemergmed.2007.08.004; Wang Henry E, 2004, Prehosp Emerg Care, V8, P366; Wigman LD, 2010, INJURY, V41, P1022, DOI DOI 10.1016/J.INJURY.2010.03.015; Williams MJ, 1997, J ACCID EMERG MED, V14, P81; Zalstein S, 1997, AUST NZ J SURG, V67, P593, DOI 10.1111/j.1445-2197.1997.tb04604.x	81	91	92	2	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	OCT 13	2011	19								57	10.1186/1757-7241-19-57			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	844GB	WOS:000296734600001	21996444	Green Published, gold			2022-02-06	
J	Capaldi, VF; Guerrero, ML; Killgore, WDS				Capaldi, Vincent F., II; Guerrero, Melanie L.; Killgore, William D. S.			Sleep Disruptors Among Returning Combat Veterans From Iraq and Afghanistan	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; POOR SLEEP; DAYTIME SLEEPINESS; PREVALENCE; SYMPTOMS; INSOMNIA; QUALITY; ASSOCIATIONS; EXPERIENCES	Background: Post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) are common injuries among returning combat veterans from the wars in Iraq and Afghanistan. Although these combat injuries have been associated with increased sleep disruption, little is known about the nature and specificity of sleep problems within these common injury categories. Method: A retrospective chart review of 69 consecutive referrals to the Walter Reed Army Medical Center sleep clinic was conducted. All cases were active duty soldiers who had recently returned from combat deployment in Iraq or Afghanistan. Data from polysomnographically (PSG) recorded sleep stages, sleepiness scales, and documented medical diagnoses were extracted from medical records. Sleep data were compared across diagnoses of PTSD, TBI, and other clinical conditions. Results: As expected, clinical sleep disturbances, including rates of obstructive sleep apnea, excessive awakenings, daytime sleepiness, and hypoxia, were high for the sample as a whole. However, no differences across diagnostic groups were found. Differences were observed, however, on PSG measures of sleep quality, suggesting more frequent arousals from sleep among patients with PTSD and greater slow wave sleep among those with TBI. Except for REM latency, medication status had virtually no effect on sleep variables. Conclusions: Among recently redeployed combat veterans, clinically significant sleep disturbances and problems with sleep-disordered breathing are common but nonspecific findings across primary diagnoses of PTSD, TBI, major depression, and anxiety disorder, whereas more subtle differences in sleep architecture and arousals as measured by overnight PSG recordings were modestly, but significantly, effective at distinguishing among the diagnostic groups.	[Capaldi, Vincent F., II] Walter Reed Army Med Ctr, Washington, DC 20307 USA; [Guerrero, Melanie L.; Killgore, William D. S.] Walter Reed Army Inst Res, Silver Spring, MD 20910 USA; [Killgore, William D. S.] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA		Capaldi, VF (corresponding author), Walter Reed Army Med Ctr, 6900 Georgia Ave NW, Washington, DC 20307 USA.			Killgore, William/0000-0002-5328-0208			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Amin MM, 2010, MIL MED, V175, P155; Anderer P, 2007, P ANN INT IEEE EMBS, P3994, DOI 10.1109/IEMBS.2007.4353209; Caldwell Barbara A, 2005, Issues Ment Health Nurs, V26, P721, DOI 10.1080/01612840591008294; Carlson KF, J HEAD TRAU IN PRESS; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Dezee KJ, 2005, J CLIN SLEEP MED, V1, P136; Flemons WW, 2002, NEW ENGL J MED, V347, P498, DOI 10.1056/NEJMcp012849; Germain A, 2004, J TRAUMA STRESS, V17, P477, DOI 10.1007/s10960-004-5796-6; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hukins Craig A, 2006, Neuropsychiatr Dis Treat, V2, P309, DOI 10.2147/nedt.2006.2.3.309; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Krakow B, 2004, J TRAUMA STRESS, V17, P257, DOI 10.1023/B:JOTS.0000029269.29098.67; Krakow B, 2001, BIOL PSYCHIAT, V49, P948, DOI 10.1016/S0006-3223(00)01087-8; Krakow B, 2006, J NERV MENT DIS, V194, P433, DOI 10.1097/01.nmd.0000221286.65021.e0; Krakow Barry, 2002, Sleep Breath, V6, P189; Kristo DA, 2005, CHEST, V127, P1654, DOI 10.1378/chest.127.5.1654; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Loube DI, 1999, CHEST, V115, P1333, DOI 10.1378/chest.115.5.1333; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; O'Donnell T, 2004, NEUROPSYCHOBIOLOGY, V50, P273, DOI 10.1159/000080952; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Orr SP, 2002, PSYCHIAT CLIN N AM, V25, P271, DOI 10.1016/S0193-953X(01)00007-7; Pace-Schott EF, 2009, SLEEP, V32, P19; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Pole N, 2009, BIOL PSYCHIAT, V65, P235, DOI 10.1016/j.biopsych.2008.07.015; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Spoormaker VI, J PSYCHIAT IN PRESS; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wahner-Roedler DL, 2007, GENDER MED, V4, P329, DOI 10.1016/S1550-8579(07)80062-3; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wessa M, 2007, AM J PSYCHIAT, V164, P1684, DOI 10.1176/appi.ajp.2007.07030525; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	44	91	92	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2011	176	8					879	888		10.7205/MILMED-D-10-00440			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	804TB	WOS:000293675800007	21882777	Bronze			2022-02-06	
J	Hankin, JA; Farias, SE; Barkley, R; Heidenreich, K; Frey, LC; Hamazaki, K; Kim, HY; Murphy, RC				Hankin, Joseph A.; Farias, Santiago E.; Barkley, Robert M.; Heidenreich, Kim; Frey, Lauren C.; Hamazaki, Kei; Kim, Hee-Yong; Murphy, Robert C.			MALDI Mass Spectrometric Imaging of Lipids in Rat Brain Injury Models	JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY			English	Article						MALDI; IMS; Imaging mass spectrometry; Sublimation; Brain; Phosphatidylcholine; Ceramide; Traumatic brain injury; Ischemia reperfusion; Brain injury; Alkali metal adduct images; CA1; Hippocampus damage	GERBIL HIPPOCAMPUS; FOREBRAIN ISCHEMIA; MATRIX; PHOSPHOLIPIDS; TISSUE; DAMAGE; IMS	Matrix-assisted laser desorption ionization/ionization imaging mass spectrometry (MALDI IMS) with a time-of-flight analyzer was used to characterize the distribution of lipid molecular species in the brain of rats in two injury models. Ischemia/reperfusion injury of the rat brain after bilateral occlusion of the carotid artery altered appearance of the phospholipids present in the hippocampal region, specifically the CA1 region. These brain regions also had a large increase in the ion abundance at m/z 548.5 and collisional activation supported identification of this ion as arising from ceramide (d18:1/18:0), a lipid known to be associated with cellular apoptosis. Traumatic brain injury model in the rat was examined by MALDI IMS and the area of damage also showed an increase in ceramide (d18:1/18:0) and a remarkable loss of signal for the potassium adduct of the most abundant phosphocholine molecular species 16:0/18:1 (PC) with a corresponding increase in the sodium adduct ion. This change in PC alkali attachment ion was suggested to be a result of edema and influx of extracellular fluid likely through a loss of Na/K-ATPase caused by the injury. These studies reveal the value of MALDI IMS to examine tissues for changes in lipid biochemistry and will provide data needed to eventually understand the biochemical mechanisms relevant to tissue injury.	[Hankin, Joseph A.; Farias, Santiago E.; Barkley, Robert M.; Heidenreich, Kim; Murphy, Robert C.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA; [Hamazaki, Kei; Kim, Hee-Yong] NIAAA, Lab Mol Signaling, NIH, Bethesda, MD USA; [Frey, Lauren C.] Univ Colorado Denver, Dept Neurol, Aurora, CO USA		Murphy, RC (corresponding author), Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA.	Robert.Murphy@ucdenver.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	General Medical Sciences Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM069338]; Colorado TBI Trust; NIAAA, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM069338] Funding Source: NIH RePORTER	The authors acknowledge that this work was supported, in part, by a grant from the LipidMAPS Large Scale Collaborative grant from General Medical Sciences Institute (GM069338) of the National Institutes of Health and Colorado TBI Trust Fund. A part of this research (Kei H. and H.Y.K.) was supported by the intramural program of NIAAA, NIH. The authors thank Erin Genova (UC Denver Pathology Department) for assistance in preparation of FPI tissue sections.	Astigarraga E, 2008, ANAL CHEM, V80, P9105, DOI 10.1021/ac801662n; Burnum KE, 2009, J LIPID RES, V50, P2290, DOI 10.1194/jlr.M900100-JLR200; Chen YF, 2008, ANAL CHEM, V80, P2780, DOI 10.1021/ac702350g; Cornett DS, 2007, NAT METHODS, V4, P828, DOI 10.1038/NMETH1094; Deeley JM, 2010, J LIPID RES, V51, P2753, DOI 10.1194/jlr.M007716; Drexler Dieter M., 2007, Journal of Pharmacological and Toxicological Methods, V55, P279, DOI 10.1016/j.vascn.2006.11.004; Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415; Farias S, 2009, J NEUROTRAUM, V26, P1977, DOI 10.1089/neu.2009.0877; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Grey AC, 2010, ANAT REC, V293, P821, DOI 10.1002/ar.21103; Hankin JA, 2007, J AM SOC MASS SPECTR, V18, P1646, DOI 10.1016/j.jasms.2007.06.010; Hankin JA, 2010, ANAL CHEM, V82, P8476, DOI 10.1021/ac101079v; Jackson SN, 2007, J AM SOC MASS SPECTR, V18, P17, DOI 10.1016/j.jasms.2006.08.015; Jackson SN, 2008, J AM SOC MASS SPECTR, V19, P1655, DOI 10.1016/j.jasms.2008.07.005; Jurchen JC, 2005, J AM SOC MASS SPECTR, V16, P1654, DOI 10.1016/j.jasms.2005.06.006; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Koizumi S, 2010, NEUROSCIENCE, V168, P219, DOI 10.1016/j.neuroscience.2010.03.056; Kubota M, 1996, NEUROL RES, V18, P337; MURPHY RC, 2010, MASS SPECTR IN PRESS; Murphy RC, 2009, J LIPID RES, V50, pS317, DOI 10.1194/jlr.R800051-JLR200; Nakane M, 2000, NEUROSCI LETT, V296, P89, DOI 10.1016/S0304-3940(00)01655-4; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Schwamborn K, 2010, NAT REV CANCER, V10, P639, DOI 10.1038/nrc2917; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spencer SJ, 2006, J CEREBR BLOOD F MET, V26, P456, DOI 10.1038/sj.jcbfm.9600206; Sugiura Y, 2009, J LIPID RES, V50, P1776, DOI 10.1194/jlr.M900047-JLR200; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Vestal ML, 2009, J MASS SPECTROM, V44, P303, DOI 10.1002/jms.1537; Wisztorski M, 2008, DEV NEUROBIOL, V68, P845, DOI 10.1002/dneu.20623; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	32	91	92	2	54	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1044-0305			J AM SOC MASS SPECTR	J. Am. Soc. Mass Spectrom.	JUN	2011	22	6					1014	1021		10.1007/s13361-011-0122-z			8	Biochemical Research Methods; Chemistry, Analytical; Chemistry, Physical; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	762DD	WOS:000290451600008	21953042	Bronze, Green Accepted			2022-02-06	
J	Green, P; Montijo, J; Brockhaus, R				Green, Paul; Montijo, Jorge; Brockhaus, Robbi			High Specificity of the Word Memory Test and Medical Symptom Validity Test in Groups with Severe Verbal Memory Impairment	APPLIED NEUROPSYCHOLOGY			English	Article						dementia; effort; malingering; specificity; SVT	CLASSIFICATION ACCURACY; PERFORMANCE	By definition, false positives occur when an otherwise very easy symptom validity test (SVT) or effort test is failed because of cognitive impairment and not because of poor effort. Therefore, the highest rate of false positives will be found in those groups with the most severe cognitive impairment. For that reason, it is important to study people with severe impairment when evaluating the specificity of SVTs. Some people with various types of dementia, notably those with Alzheimer's disease, suffer from severe impairment of memory and other cognitive abilities. In this study, patients with possible or probable dementia were tested with the Word Memory Test (WMT; Green, 2003; Green Astner, 1995) and the Medical Symptom Validity Test (MSVT; Green, 2004). While some dementia patients failed the easy subtests of these instruments and had severe verbal memory impairment, they showed distinctive profiles of scores that have been reported to be characteristic of people with severe impairment. Using profile analysis, the WMT and MSVT achieved a specificity of 98.4% or higher in the patients of the current study. This suggests that there will be extremely low false positive rates using the same methods in people with relatively minor impairment of the type found in, for example, mild traumatic brain injury or depression.	[Brockhaus, Robbi] Alexianer Krankenhaus Krefeld Klin, Duisburg, Germany		Green, P (corresponding author), Suite 210,10701103 Ave, Edmonton, AB T5S 1K7, Canada.	drpgreen@telus.net					Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green P., 2003, MANUAL WORD MEMORY T; Green P., 2004, MANUAL MED SYMPTOM V; Green P., DETECTION M IN PRESS; Green P, 1995, MANUAL ORAL WORD MEM; Green P.J.E., 2008, MANUAL NONVERBAL MED; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry M, 2010, J CLIN EXP NEUROPSYC, V32, P19, DOI 10.1080/13803390902791653; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Iverson G., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Rienstra A, 2009, ARCH CLIN NEUROPSYCH, V24, P255, DOI 10.1093/arclin/acp035; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Tombaugh T.N., 1996, TEST MEMORY MALINGER	27	91	91	1	22	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2011	18	2					86	94	PII 938328944	10.1080/09084282.2010.523389			9	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	775XX	WOS:000291497900002	21660760				2022-02-06	
J	Castellanos, NP; Paul, N; Ordonez, VE; Demuynck, O; Bajo, R; Campo, P; Bilbao, A; Ortiz, T; Del-Pozo, F; Maestu, F				Castellanos, Nazareth P.; Paul, Nuria; Ordonez, Victoria E.; Demuynck, Olivier; Bajo, Ricardo; Campo, Pablo; Bilbao, Alvaro; Ortiz, Tomas; del-Pozo, Francisco; Maestu, Fernando			Reorganization of functional connectivity as a correlate of cognitive recovery in acquired brain injury	BRAIN			English	Article						brain injury; functional connectivity; magnetoencephalography; plasticity	GRAPH-THEORETICAL ANALYSIS; ALZHEIMERS-DISEASE; TUMOR PATIENTS; ALPHA-BAND; MEG; SYNCHRONIZATION; MODEL; REHABILITATION; DAMAGE; GAMMA	Cognitive processes require a functional interaction between specialized multiple, local and remote brain regions. Although these interactions can be strongly altered by an acquired brain injury, brain plasticity allows network reorganization to be principally responsible for recovery. The present work evaluates the impact of brain injury on functional connectivity patterns. Networks were calculated from resting-state magnetoencephalographic recordings from 15 brain injured patients and 14 healthy controls by means of wavelet coherence in standard frequency bands. We compared the parameters defining the network, such as number and strength of interactions as well as their topology, in controls and patients for two conditions: following a traumatic brain injury and after a rehabilitation treatment. A loss of delta- and theta-based connectivity and conversely an increase in alpha- and beta-band-based connectivity were found. Furthermore, connectivity parameters approached controls in all frequency bands, especially in slow-wave bands. A correlation between network reorganization and cognitive recovery was found: the reduction of delta-band-based connections and the increment of those based on alpha band correlated with Verbal Fluency scores, as well as Perceptual Organization and Working Memory Indexes, respectively. Additionally, changes in connectivity values based on theta and beta bands correlated with the Patient Competency Rating Scale. The current study provides new evidence of the neurophysiological mechanisms underlying neuronal plasticity processes after brain injury, and suggests that these changes are related with observed changes at the behavioural level.	[Castellanos, Nazareth P.; Ordonez, Victoria E.; Bajo, Ricardo; Campo, Pablo; del-Pozo, Francisco; Maestu, Fernando] Univ Politecn Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Madrid 28660, Spain; [Paul, Nuria; Ortiz, Tomas] Univ Complutense Madrid, Sch Med, Dept Psychiat & Med Psychol, E-28040 Madrid, Spain; [Demuynck, Olivier] Univ Politecn Madrid, Dept Signals Syst & Radiocomunicat, E-28040 Madrid, Spain; [Bilbao, Alvaro] Natl Ctr Brain Injury Treatment CEADAC, Madrid 28034, Spain; Univ Complutense Madrid, Dept Basic Psychol Cognit Sci 2, E-28040 Madrid, Spain		Castellanos, NP (corresponding author), Univ Politecn Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Campus Montegancedo 28660, Madrid 28660, Spain.	nazareth@pluri.ucm.es	Bajo, Ricardo/AAA-5541-2019; Campo, Pablo/M-3317-2019; Maestu, Fernando/E-3213-2012; Campo, Pablo/I-8156-2012; Castellanos, Nazareth/AAA-8812-2020; maestu, fernando/M-7480-2019; POZO GUERRERO, FRANCISCO DEL/H-6668-2015	Campo, Pablo/0000-0003-4539-6857; Maestu, Fernando/0000-0002-3195-0071; Campo, Pablo/0000-0003-4539-6857; maestu, fernando/0000-0002-3195-0071; Paul, Nuria/0000-0001-5462-6138; Bajo, Ricardo/0000-0003-0646-2962; Castellanos, Nazareth/0000-0002-3508-7316; POZO GUERRERO, FRANCISCO DEL/0000-0001-9919-9125	MADRI.B; Obra Social CajaMadrid; MAPFRE 2009; IMSERSO [07-2008]	MADRI.B (CAM i+d+I project), Obra Social CajaMadrid, MAPFRE 2009 and IMSERSO (07-2008).	AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Beason-Held LL, 2009, BRAIN IMAGING BEHAV, V3, P123, DOI 10.1007/s11682-008-9054-z; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; BOSMA I, 2009, NONLINEAR BIOMED PHY, V1, P3; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; Bressler SL, 2002, CURR DIR PSYCHOL SCI, V11, P58, DOI 10.1111/1467-8721.00168; Brookes MJ, 2005, NEUROIMAGE, V26, P302, DOI 10.1016/j.neuroimage.2005.01.050; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Butz M, 2009, FRONT COMPUT NEUROSC, V3, DOI 10.3389/neuro.10.010.2009; Campo P, 2010, NEUROIMAGE, V49, P2807, DOI 10.1016/j.neuroimage.2009.10.024; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cover KS, 2006, NEUROIMAGE, V29, P783, DOI 10.1016/j.neuroimage.2005.08.048; Cover KS, 2004, NEUROIMAGE, V22, P1432, DOI 10.1016/j.neuroimage.2004.04.016; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; EDOUARD L, 1893, RECREATIONS MATH, V3; Fingelkurts AA, 2007, HUM BRAIN MAPP, V28, P247, DOI 10.1002/hbm.20275; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; GLADSOJO J, 1999, NORMS LETT CATEGORY; Golden CJ., 1978, STROOP COLOUR WORD T; Gootjes L, 2006, NEUROIMAGE, V30, P245, DOI 10.1016/j.neuroimage.2005.09.015; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Hadjipapas A, 2005, CLIN NEUROPHYSIOL, V116, P1300, DOI 10.1016/j.clinph.2005.01.014; Halgren E, 2002, CEREB CORTEX, V12, P710, DOI 10.1093/cercor/12.7.710; Halligan P.W., 2005, EFFECTIVENESS REHABI; Heaton RK, 1991, COMPREHENSIVE NORMS; Hebb DO, 1949, ORG BEHAV NEUROPSYCH; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Huan NJ, 2004, J NEURAL ENG, V1, P142, DOI 10.1088/1741-2560/1/3/003; Jaakkola TS, 1999, ADV NEUR IN, V11, P487; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; KATZ DI, 2006, COGNITIVE REHABILITA; Keller PE, 2006, J PSYCHOPHYSIOL, V20, P9, DOI 10.1027/0269-8803.20.1.9; Kilner JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004925; Kolb B., 1995, BRAIN PLASTICITY BEH; Korzeniewska A, 2003, J NEUROSCI METH, V125, P195, DOI 10.1016/S0165-0270(03)00052-9; Lee JH, 2006, J NEUROSCI, V26, P3330, DOI 10.1523/JNEUROSCI.3898-05.2006; Lehmann C, 2007, J NEUROSCI METH, V161, P342, DOI 10.1016/j.jneumeth.2006.10.023; Leocani L, 2006, NEUROL SCI, V27, pS27, DOI 10.1007/s10072-006-0542-x; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Maindonald J., 2007, DATA ANAL GRAPHICS U; Mallat S., 1999, WAVELET TOUR SIGNAL, V1; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Murias M, 2007, BIOL PSYCHIAT, V62, P270, DOI 10.1016/j.biopsych.2006.11.012; NAKAMURA T, 2009, PLOS ONE, V14, P4; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Palva S, 2007, TRENDS NEUROSCI, V30, P150, DOI 10.1016/j.tins.2007.02.001; PERCIVAL DP, 1995, BIOMETRIKA, V82, P619, DOI 10.2307/2337538; PIVIK RT, 1993, PSYCHOPHYSIOLOGY, V30, P547, DOI 10.1111/j.1469-8986.1993.tb02081.x; PRIGATANO GP, 1991, AWARENESS DEFICITS B; Quigley M, 2001, AM J NEURORADIOL, V22, P294; REITAN RM, 1992, HALSTEADREITAN NEURO; Ripley B., 1996, PATTERN RECOGN; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Rubinov M, 2009, AM J GERIAT PSYCHIAT, V17, P210, DOI 10.1097/JGP.0b013e318187137a; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Schnitzler A, 2005, NAT REV NEUROSCI, V6, P285, DOI 10.1038/nrn1650; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P90, DOI 10.1080/13854049608406667; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Stam CJ, 2006, NEUROIMAGE, V32, P1335, DOI 10.1016/j.neuroimage.2006.05.033; Stam CJ, 2010, J NEUROL SCI, V289, P128, DOI 10.1016/j.jns.2009.08.028; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Stam CJ, 2002, J CLIN NEUROPHYSIOL, V19, P562, DOI 10.1097/00004691-200212000-00010; Stam CJ, 2007, HUM BRAIN MAPP, V28, P1178, DOI 10.1002/hbm.20346; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tucha O, 2000, NEUROSURGERY, V47, P324, DOI 10.1097/00006123-200008000-00011; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; von Stein A, 2000, INT J PSYCHOPHYSIOL, V38, P301, DOI 10.1016/S0167-8760(00)00172-0; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILSON B, 1996, CASE STUDIES NEUROPS; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Witte OW, 1997, ADV NEUROL, V73, P207	93	91	99	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2010	133		8				2365	2381		10.1093/brain/awq174			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	639NY	WOS:000280982700017	20826433	Green Accepted, Bronze			2022-02-06	
J	Shahrokhi, N; Khaksari, M; Soltani, Z; Mahmoodi, M; Nakhaee, N				Shahrokhi, Nader; Khaksari, Mohammad; Soltani, Zahra; Mahmoodi, Mehdi; Nakhaee, Nouzar			Effect of sex steroid hormones on brain edema, intracranial pressure, and neurologic outcomes after traumatic brain injury	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						estrogen; progesterone; neuroprotective; ICP; CPP; brain edema; neurologic outcomes	CEREBRAL-BLOOD-FLOW; CLOSED-HEAD INJURY; PERFUSION-PRESSURE; EXPERIMENTAL-MODEL; RATS; ESTROGEN; PROGESTERONE; ISCHEMIA; AUTOREGULATION; REPERFUSION	Recent studies have reported that estrogen and progesterone have a neuroprotective effect after traumatic brain injury (TBI): however, the mechanism(s) for this effect have not yet been elucidated. The aim of the present study was to investigate the role of sex steroid hormones on changes in brain edema, intracranial pressure (ICP), and cerebral perfusion pressure (CPP) after TBI in ovariectomized (OVX) rats. In this study, 50 female rats were divided into 5 groups: control (intact), sham, and 3 TBI groups consisting of vehicle, estrogen (1 mg/kg), and progesterone (8 mg/kg). TBI was induced by the Marmarou method, and the hormones were injected i.p. 30 min after TBI. ICP was measured in the spinal cord, and CPP was calculated by subtracting the mean arterial pressure (MAP) from ICP. The results revealed that brain water content after TBI was lower (p < 0.001) in the estrogen and progesterone groups than in the vehicle group. After trauma, ICP was significantly higher in TBI rats (p < 0.001). The ICP in the estrogen and progesterone groups decreased at 4 and 24 h after TBI compared with vehicle (p < 0.001 and p < 0.05, respectively). The CPP in the estrogen and progesterone groups increased after 24 h compared with vehicle (p < 0.001). Also after TBI, the neurological score (veterinary coma scale) was significantly higher than vehicle at 1 h (p < 0.01) and 24 h (p < 0.001) in the group treated with estrogen. In conclusion, pharmacological doses of estrogen and progesterone improved ICP, CPP, and neurological scores after TBI in OVX rats, which implies that these hormones play a neuroprotective role in TBI.	[Shahrokhi, Nader; Nakhaee, Nouzar] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Soltani, Zahra] Kerman Univ Med Sci, Dept Physiol, Kerman, Iran; [Mahmoodi, Mehdi] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran		Shahrokhi, N (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran.	nshahrokhisa@yahoo.com	Shahrokhi, Nader/AAV-3747-2020; Mahmoodi, Mehdi/H-2754-2017; Nakhaee, Nouzar/AAZ-2677-2020; Soltani, Zahra/AAC-1350-2019; Haddad, Mohammad Khaksari/AAB-9025-2019	Shahrokhi, Nader/0000-0002-0149-7819; Mahmoodi, Mehdi/0000-0002-8463-8364; Nakhaee, Nouzar/0000-0001-5808-6503; Soltani, Zahra/0000-0002-8423-6189; Haddad, Mohammad Khaksari/0000-0003-0770-4281	Neuroscience and Physiology Research Centers in Kerman University of Medical Sciences	This research project was approved by the Neuroscience and Physiology Research Centers in Kerman University of Medical Sciences, and the authors thank the managers of these centers for their financial support. We also acknowledge our colleagues Mr. P. Ghotbi, Miss. N. Habibpoor, Mr. R. Bakhshi, and Mr. M. Gohargazi.	AHMADMOLAI L, 2008, J KERMAN U MED SCI, V15, P47; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; Dethloff TJ, 2008, J CEREBR BLOOD F MET, V28, P916, DOI 10.1038/sj.jcbfm.9600589; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gilkes C., 2007, SURGERY OXFORD, V25, P530, DOI DOI 10.1016/J.MPSUR.2007.10.005; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Koyama Y, 2004, EUR J PHARMACOL, V489, P193, DOI 10.1016/j.ejphar.2004.03.018; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Krause DN, 2006, J APPL PHYSIOL, V101, P1252, DOI 10.1152/japplphysiol.01095.2005; Krause DN, 2002, INT CONGR SER, V1235, P395, DOI 10.1016/S0531-5131(02)00211-X; Kusaka G, 2004, J NEUROSCI METH, V135, P121, DOI 10.1016/j.jneumeth.2003.12.013; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; Marik P, 1999, J EMERG MED, V17, P711, DOI 10.1016/S0736-4679(99)00055-4; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILDE LN, 1985, ANESTHESIOLOGY, V63, P371, DOI 10.1097/00000542-198510000-00005; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Nakamura T, 2006, ACTA NEUROCHIR SUPPL, V96, P218; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Salluh JIF, 2007, ACTA ANAESTH SCAND, V51, P505, DOI 10.1111/j.1399-6576.2006.01252.x; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sunday L, 2006, AM J PHYSIOL-ENDOC M, V291, pE261, DOI 10.1152/ajpendo.00550.2005; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Reempts J, 2000, NEUROSCI RES COMMUN, V26, P161, DOI 10.1002/1520-6769(200005/06)26:3<161::AID-NRC4>3.0.CO;2-N; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; 1997, LANCET, V349, P1263, DOI DOI 10.1016/S0140-6736(97)21018-4	40	91	99	0	13	NATL RESEARCH COUNCIL CANADA-N R C RESEARCH PRESS	OTTAWA	BUILDING M 55, OTTAWA, ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	APR	2010	88	4					414	421		10.1139/Y09-126			8	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	616XB	WOS:000279243700002	20555409				2022-02-06	
J	Sarmiento, K; Mitchko, J; Klein, C; Wong, S				Sarmiento, Kelly; Mitchko, Jane; Klein, Cynthia; Wong, Sharon			Evaluation of the Centers for Disease Control and Prevention's Concussion Initiative for High School Coaches: "Heads Up: Concussion in High School Sports"	JOURNAL OF SCHOOL HEALTH			English	Article						health communication; concussion prevention; physical fitness and sport; public health; high school coaches; tool kit		METHODS: A mail questionnaire was administered to all eligible high school coaches who received the tool kit. Follow-up focus groups were conducted for additional information. Both quantitative data from the surveys and qualitative data from the focus groups were analyzed to support the objectives of the study. RESULTS: Respondents self-reported favorable changes in knowledge, attitudes, and practices toward the prevention and management of concussions. Qualitative responses augmented the quantitative data. CONCLUSION: Barriers to concussion prevention and management are complex; however, these results highlight the role that coaches can play in school settings in establishing a safe environment for their athletes.	[Sarmiento, Kelly] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, Atlanta, GA 30341 USA; [Klein, Cynthia] SRA Int Inc, Survey & Evaluat Res Div, Atlanta, GA 30329 USA		Sarmiento, K (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, 4770 Buford Hwy NE,Mail Stop F-62, Atlanta, GA 30341 USA.	KSarmiento@cdc.gov; jpmitchko@cdc.gov; Cynthia_Klein@sra.com; SWong1@cdc.gov					*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Dillman D, 1999, MAIL INTERNET SURVEY, V2nd; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; *US I MED, 2002, SOCC BAD CHILDR HEAD	6	91	91	0	11	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-4391			J SCHOOL HEALTH	J. Sch. Health	MAR	2010	80	3					112	118		10.1111/j.1746-1561.2010.00491.x			7	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	557KW	WOS:000274669000002	20236412				2022-02-06	
J	Liu, MC; Akinyi, L; Scharf, D; Mo, JX; Larner, SF; Muller, U; Oli, MW; Zheng, WR; Kobeissy, F; Papa, L; Lu, XC; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Liu, Ming C.; Akinyi, Linnet; Scharf, Dancia; Mo, Jixiang; Larner, Stephen F.; Muller, Uwe; Oli, Monika W.; Zheng, Wenrong; Kobeissy, Firas; Papa, Linda; Lu, Xi-Chun; Dave, Jitendra R.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						biomarker; cell death; ischemia; diagnosis; stroke; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SPECTRIN BREAKDOWN PRODUCTS; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; SURROGATE MARKERS; OUTCOME PREDICTION; SERUM BIOMARKER; S-100 PROTEIN; CALPAIN-I; NF-H	Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH-L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH-L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme-linked immunosorbent assay constructed to measure UCH-L1 sensitively and quantitatively showed that CSF UCH-L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH-L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain-produced alpha II-spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH-L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH-L1 levels in the 2-h MCAO group were significantly higher than those in the 30-min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH-L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).	[Liu, Ming C.; Larner, Stephen F.; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Akinyi, Linnet; Scharf, Dancia; Mo, Jixiang; Muller, Uwe; Oli, Monika W.; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Diagnost Res & Dev Dept, Alachua, FL 32615 USA; [Kobeissy, Firas; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Lu, Xi-Chun; Dave, Jitendra R.; Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD USA; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Wang, Kevin K. W.] Taipei Med Univ, Taipei, Taiwan		Wang, KKW (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	kwang@banyanbio.com	Dave, Jitendra R/A-8940-2011; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01 A1, 2R44NS048685-02]; Florida State Center for Nano-Bio Sensors (CNBS) grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, R44NS048685] Funding Source: NIH RePORTER	The authors would like to acknowledge the support of Department of Defense grant DAMD17-03-1-0066 (R. L. Hayes), NIH grants R01 NS049175-01 A1 (K. Wang) and 2R44NS048685-02 (K. K. Wang), and a Florida State Center for Nano-Bio Sensors (CNBS) grant (K. K. Wang). This article has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the true views of the Department of the Army or the Department of Defense. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals, and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 edition. K. K. Wang and R. L. Hayes hold equity in Banyan Biomarkers, Inc., a company that commercializes technology for detecting brain injury biomarkers.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Choi DW, 2002, NAT NEUROSCI, V5, P1023, DOI 10.1038/nn930; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Elkind MSV, 2003, MT SINAI J MED, V70, P27; Ge PF, 2007, STROKE, V38, P3230, DOI 10.1161/STROKEAHA.107.487108; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kwon J, 2005, BIOL REPROD, V73, P29, DOI 10.1095/biolreprod.104.037077; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lincoln S, 1999, NEUROREPORT, V10, P427, DOI 10.1097/00001756-199902050-00040; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marin R, 2003, PHYSIOL BEHAV, V80, P167, DOI 10.1016/j.physbeh.2003.06.001; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Sultana R, 2007, J ALZHEIMERS DIS, V11, P153; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zaremba J, 2001, ACTA NEUROL SCAND, V104, P288, DOI 10.1034/j.1600-0404.2001.00053.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	65	91	99	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2010	31	4					722	732		10.1111/j.1460-9568.2010.07097.x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	555XH	WOS:000274549500013	20384815	Green Accepted			2022-02-06	
J	Pontifex, MB; O'Connor, PM; Broglio, SP; Hillman, CH				Pontifex, Matthew B.; O'Connor, Phillip M.; Broglio, Steven P.; Hillman, Charles H.			The association between mild traumatic brain injury history and cognitive control	NEUROPSYCHOLOGIA			English	Article						Executive control; ERP; ERN; P-e; mTBI; Concussion	ANTERIOR CINGULATE CORTEX; ERROR-RELATED ERPS; PROFESSIONAL FOOTBALL; PHYSICAL-ACTIVITY; NEURAL SYSTEM; CONCUSSION; COMPONENTS; SYMPTOMS; ENCEPHALOPATHY; LOCALIZATION	The influence of multiple mild traumatic brain injuries (mTBIs) on neuroelectric and task performance indices of the cognitive control of action monitoring was assessed in individuals with and without a history of concussion. Participants completed a standard clinical neurocognitive assessment and the error-related negativity of the response-locked event-related brain potential and task performance were measured during a modified flanker task. The findings suggested that those individuals with a history of mTBI demonstrate certain failures in cognitive control, and indicated that a greater number of mTBIs may relate to poorer integrity in the evaluation or signaling for control during instances of conflict. Given that these neuroelectric and behavioral differences exist in the absence of disparities in standard clinical assessment, the findings suggest that measures of cognitive control may be more sensitive to signs of chronic cognitive dysfunction resulting from mTBI. (C) 2009 Elsevier Ltd. All rights reserved.	[Pontifex, Matthew B.; O'Connor, Phillip M.; Broglio, Steven P.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA		Hillman, CH (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 317 Louise Freer Hall,906 S Goodwin Ave, Urbana, IL 61801 USA.	chhilima@illinois.edu	Pontifex, Matthew B/A-4474-2009; Hillman, Charles/A-4479-2009; Hillman, Charles/AAD-4828-2019	Pontifex, Matthew B/0000-0001-9819-9625; Hillman, Charles/0000-0002-3722-5612	Disability Research and the Research Board at the University of Illinois	This work was supported by the Mary Jane Neer Fund for Disability Research and the Research Board at the University of Illinois.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; BROGLIO SP, 2009, J NEUROTRAUMA; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Coles MGH, 2001, BIOL PSYCHOL, V56, P173, DOI 10.1016/S0301-0511(01)00076-X; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Compumedics Neuroscan, 2003, OFFL AN ACQ DAT SCAN, VII; Davies PL, 2001, BIOL PSYCHOL, V56, P191, DOI 10.1016/S0301-0511(01)00080-1; DEBEAUMONT L, 2009, BRAIN; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Diamond A, 2006, LIFESPAN COGNITION M, P70; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Falkenstein M, 2001, EXP BRAIN RES, V138, P258, DOI 10.1007/s002210100712; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hillman CH, 2006, HEALTH PSYCHOL, V25, P678, DOI 10.1037/0278-6133.25.6.678; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mathewson KJ, 2005, BIOL PSYCHOL, V70, P88, DOI 10.1016/j.biopsycho.2004.12.005; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P747, DOI 10.1111/j.1469-8986.1996.tb02371.x; Pontifex MB, 2007, CLIN NEUROPHYSIOL, V118, P570, DOI 10.1016/j.clinph.2006.09.029; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Themanson JR, 2006, NEUROBIOL AGING, V27, P1335, DOI 10.1016/j.neurobiolaging.2005.07.002; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837	55	91	92	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2009	47	14					3210	3216		10.1016/j.neuropsychologia.2009.07.021			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	529SQ	WOS:000272537900021	19664646				2022-02-06	
J	Rana, AR; Michalsky, MP; Teich, S; Groner, JI; Caniano, DA; Schuster, DP				Rana, Ankur R.; Michalsky, Marc P.; Teich, Steven; Groner, Jonathon I.; Caniano, Donna A.; Schuster, Dara P.			Childhood obesity: a risk factor for injuries observed at a level-1 trauma center	JOURNAL OF PEDIATRIC SURGERY			English	Article						Childhood obesity; Trauma; Outcomes	BODY-MASS INDEX; OVERWEIGHT; MORTALITY; FRACTURES; OUTCOMES; CHILDREN; IMPACT	Purpose: Obesity is ail independent risk factor in trauma-related morbidity in adults. The purpose of this study was to investigate the effect of obesity in the pediatric trauma population. Methods: All patients (6-20 years) between January 2004 and July 2007 were retrospectively reviewed and defined as non-obese (body mass index [BMI] <95th percentile for age) or obese (BMI >= 95th percentile for age). Groups were compared for differences in demographics, initial vital signs, mechanisms of injury, length of stay, intensive care unit stay, ventilator days, Injury Severity Score, operative procedures, and clinical outcomes. Results: Of 1314 patients analyzed, there were 1020 (77%) nonobese patients (mean BMI = 18.8 kg/m(2)) and 294 (23%) obese patients (mean BMI = 29.7 kg/m(2)). There was no significant difference in sex, heart rate, length of stay, intensive care unit days, ventilator days, Injury Severity Score, and mortality between the groups. The obese children were significantly younger than the nonobese children (10.9 +/- 3.3 vs 11.5 +/- 3.5 years; P = .008) and had a higher systolic blood pressure during initial evaluation (128 +/- 17 vs 124 +/- 16 min Hg, P < .001). In addition, the obese group had a higher incidence of extremity fractures (55% vs 40%; P < .001) and orthopedic surgical intervention (42% vs 30%; P < .001) but a lower incidence of closed head injury (12% vs 18%; P =.013) and intraabdominal injuries (6% vs 11%; P = .023). Evaluation of complications showed a higher incidence of decubitus ulcers (P = .043) and deep vein thrombosis (P = .008) in the obese group. Conclusion: In pediatric trauma patients, obesity may be a risk factor for sustaining ail extremity fracture requiring operative intervention and having a higher risk for certain complications (ie, deep venous thrombosis [DVT] and decubitus ulcers) despite having a lower incidence of intracranial and intraabdominal injuries. Results are similar to reports examining the effect(s) of obesity on the adult population. (C) 2009 Elsevier Inc. All rights reserved.	[Rana, Ankur R.; Michalsky, Marc P.; Teich, Steven; Groner, Jonathon I.; Caniano, Donna A.] Ohio State Univ, Coll Med, Div Pediat Surg, Dept Surg, Columbus, OH 43205 USA; [Rana, Ankur R.; Michalsky, Marc P.; Teich, Steven; Groner, Jonathon I.; Caniano, Donna A.; Schuster, Dara P.] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Schuster, Dara P.] Ohio State Univ, Dept Internal Med, Coll Med, Columbus, OH 43205 USA		Michalsky, MP (corresponding author), Ohio State Univ, Coll Med, Div Pediat Surg, Dept Surg, Columbus, OH 43205 USA.	marc.michalsky@nationwidechildrens.org	Michalsky, Marc/E-3674-2011; Groner, Jonathan/E-3156-2011	michalsky, marc/0000-0002-7119-3634; Groner, Jonathan/0000-0002-0998-593X	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025755] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR025755] Funding Source: Medline		Alban RF, 2006, AM SURGEON, V72, P966; Arbabi S, 2003, J TRAUMA, V54, P1090, DOI 10.1097/01.TA.0000064449.11809.48; Belzberg H, 2007, J TRAUMA, V62, P1192, DOI 10.1097/01.ta.0000219701.07295.b8; Bochicchio GV, 2006, J AM COLL SURGEONS, V203, P533, DOI 10.1016/j.jamcollsurg.2006.07.001; BOSTMAN OM, 1995, J BONE JOINT SURG BR, V77B, P101, DOI 10.1302/0301-620X.77B1.7822361; BOSTMAN OM, 1994, J TRAUMA, V37, P62; BOULANGER BR, 1992, J TRAUMA, V33, P228, DOI 10.1097/00005373-199208000-00011; Brown CVR, 2006, J PEDIATR SURG, V41, P88, DOI 10.1016/j.jpedsurg.2005.10.012; Brown CVR, 2005, J TRAUMA, V58, P102, DOI 10.1097/01.TA.0000105990.05074.4A; Byrnes MC, 2005, J TRAUMA, V58, P232, DOI 10.1097/01.TA.0000152081.67588.10; Duane TM, 2006, J TRAUMA, V61, P1218, DOI 10.1097/01.ta.0000241022.43088.e1; Ferraro KF, 2003, J GERONTOL B-PSYCHOL, V58, pS110, DOI 10.1093/geronb/58.2.S110; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Mei ZG, 2002, AM J CLIN NUTR, V75, P978, DOI 10.1093/ajcn/75.6.978; Must Aviva, 2003, Nutr Clin Care, V6, P4; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; Newell MA, 2007, J AM COLL SURGEONS, V204, P1056, DOI 10.1016/j.jamcollsurg.2006.12.042; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Peskin GW, 2003, ARCH SURG-CHICAGO, V138, P354, DOI 10.1001/archsurg.138.4.354; Spaine LA, 1996, INJURY, V27, P687, DOI 10.1016/S0020-1383(96)00136-2; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301	21	91	93	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	AUG	2009	44	8					1601	1605		10.1016/j.jpedsurg.2008.11.060			5	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	481BA	WOS:000268780300021	19635312	Green Accepted			2022-02-06	
J	Ashman, TA; Cantor, JB; Gordon, WA; Spielman, L; Flanagan, S; Ginsberg, A; Engmann, C; Egan, M; Ambrose, F; Greenwald, B				Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Spielman, Lisa; Flanagan, Steve; Ginsberg, Annika; Engmann, Clara; Egan, Matthew; Ambrose, Felicia; Greenwald, Brian			A Randomized Controlled Trial of Sertraline for the Treatment of Depression in Persons With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Brain injuries; Depression; Minority groups; Randomized controlled trials [publication type]; Rehabilitation; Sertraline	STRUCTURED CLINICAL INTERVIEW; NATIONAL COMORBIDITY SURVEY; DSM-III-R; INTEGRATED CARE PATHWAY; MAJOR DEPRESSION; RATING-SCALE; MENTAL-DISORDERS; AXIS-I; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC-DISORDERS	Objective: To examine the efficacy of sertraline in the treatment of depression after traumatic brain injury (TBI). Design: Double-blind, randomized controlled trial. Setting: Research center at a major urban medical center. Participants: Subjects were a referred and volunteer sample of 52 participants with TBI, a diagnosis of major depression disorder (MDD), and a score on the Hamilton Rating Scale for Depression (HAM-D) of 18 or greater. The majority of the sample was male (58%), had less than 14 years of education (73%), had incomes below $20,000 (82%), and were from minority backgrounds (75%). Approximately one third of the sample had mild brain injuries, and two thirds had moderate to severe brain injuries. The mean age was 47 +/- 11, and the mean time since injury was 17 +/- 14 years. One participant withdrew from the study because of side effects. Intervention: Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg) or placebo for 10 weeks. Main Outcome Measures: The HAM-D, the Beek Anxiety Inventory, and the Life-3 quality of life (QOL). Results: No statistically significant differences were found at baseline between drug and placebo groups on baseline measures of depression (24.8 +/- 7.3 vs 27.7 +/- 7.0), anxiety (16.4 +/- 12.3 vs 24.0 +/- 14.9), or QOL (2.96 +/- 1.0 vs 2.9 +/- 0.9). The income level of those receiving placebo was significantly lower than those participants receiving medication. Analyses of covariance revealed significant changes from preintervention to posttreatment for all 3 Outcome measures (P<.001) but no group effects. Random-effects modeling did not find any significant difference in patterns of scores of the outcome measures between the placebo and medication groups. Conclusions: Both groups showed improvements in mood, anxiety, and QOL, with 59% of the experimental group and 32% of the placebo group responding to the treatment, defined as a reduction of a person's HAM-D score by 50%.	[Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Engmann, Clara; Egan, Matthew; Ambrose, Felicia; Greenwald, Brian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Flanagan, Steve] NYU, Rusk Inst Reliabil Med, New York, NY USA; [Ginsberg, Annika] NYU, Sch Med, Inst Canc, New York, NY USA		Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013	Flanagan, Steven/0000-0001-9005-5897			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Almeida OP, 2006, J CLIN PSYCHIAT, V67, P1104, DOI 10.4088/JCP.v67n0713; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andrews F. M., 1976, SOCIAL INDICATORS WE; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BECH P, 1984, PSYCHOPHARMACOLOGY, V84, P276, DOI 10.1007/BF00427459; Beck A., 1996, BECK DEPRESSION INVE; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1993, BECK ANXIETY INVENTO; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Booth BM, 1998, J PSYCHIAT RES, V32, P353, DOI 10.1016/S0022-3956(98)00031-4; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bowman ES, 2000, B MENNINGER CLIN, V64, P164; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burns A, 1999, INT J GERIATR PSYCH, V14, P681, DOI 10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.3.CO;2-Q; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Cipriani A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004185.pub2; Davidson JRT, 2006, J CLIN PSYCHIAT, V67, P34; Deb S, 1999, AM J PSYCHIAT, V156, P374; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Diggle P., 2002, ANAL LONGITUDINAL DA; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Fach M, 2007, GEN HOSP PSYCHIAT, V29, P257, DOI 10.1016/j.genhosppsych.2007.01.016; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faries D, 2000, J PSYCHIAT RES, V34, P3, DOI 10.1016/S0022-3956(99)00037-0; FARM JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Gibbon M., 1997, USERS GUIDE STRUCTUR; GIBBONS RD, 1993, J PSYCHIAT RES, V27, P259, DOI 10.1016/0022-3956(93)90037-3; Givens JL, 2007, GEN HOSP PSYCHIAT, V29, P182, DOI 10.1016/j.genhosppsych.2006.11.002; Glenn MB, 2005, J HEAD TRAUMA REHAB, V20, P51, DOI 10.1097/00001199-200501000-00006; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goodnick P J, 2000, Expert Opin Pharmacother, V1, P1367, DOI 10.1517/14656566.1.7.1367; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kamijima Kunitoshi, 2006, Expert Rev Neurother, V6, P945, DOI 10.1586/14737175.6.7.945; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Maier W, 1990, Psychopharmacol Ser, V9, P64; MAIER W, 1988, J PSYCHIAT RES, V22, P13, DOI 10.1016/0022-3956(88)90023-4; MAIER W, 1988, J PSYCHIAT RES, V22, P3, DOI 10.1016/0022-3956(88)90022-2; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Murray V, 2005, J CLIN PSYCHIAT, V66, P708, DOI 10.4088/JCP.v66n0606; *NIH, 1998, NIH CONSENSUS STATEM, V16; O'Shanick GJ, 2006, J HEAD TRAUMA REHAB, V21, P282, DOI 10.1097/00001199-200605000-00009; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rasmussen A, 2003, PSYCHOSOMATICS, V44, P216, DOI 10.1176/appi.psy.44.3.216; REHM LP, 1985, J PSYCHIAT RES, V19, P31, DOI 10.1016/0022-3956(85)90066-4; Robins L., 1991, PSYCHIAT DISORDERS A; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satcher D, 2001, MENT HLTH CULT RAC E; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SEGAL DL, 1994, COMPR PSYCHIAT, V35, P316, DOI 10.1016/0010-440X(94)90025-6; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Spalletta G, 2006, AM J GERIAT PSYCHIAT, V14, P220, DOI 10.1097/01.JGP.0000194647.72654.a1; Spalletta G, 2003, FUNCT NEUROL, V18, P227; Spalletta G, 2003, J NEUROL, V250, P449, DOI 10.1007/s00415-003-1023-2; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Turner-Stokes L, 2002, CLIN REHABIL, V16, P248, DOI 10.1191/0269215502cr488oa; Turner-Stokes L, 2005, CLIN MED, V5, P268, DOI 10.7861/clinmedicine.5-3-268; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wang JL, 2007, CURR MED RES OPIN, V23, P853, DOI 10.1185/030079907X182220; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	88	91	91	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2009	90	5					733	740		10.1016/j.apmr.2008.11.005			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	443ZS	WOS:000265949900004	19406291				2022-02-06	
J	Marion, D; Bullock, MR				Marion, Donald; Bullock, M. Ross			Current and Future Role of Therapeutic Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			adult brain injury; cerebral vascular disease; clinical trial; decompressive craniectomy; guidelines; head trauma; hypothermia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; HOSPITAL CARDIAC-ARREST; ACTIVATED FACTOR-VII; ACUTE LIVER-FAILURE; SEVERE HEAD-INJURY; RANDOMIZED CLINICAL-TRIAL; WHOLE-BODY HYPOTHERMIA; INTENSIVE-CARE-UNIT; MILD HYPOTHERMIA	Therapeutic moderate hypothermia has been advocated for use in traumatic brain injury, stroke, cardiac arrest-induced encephalopathy, neonatal hypoxic-ischemic encephalopathy, hepatic encephalopathy, and spinal cord injury, and as an adjunct to aneurysm surgery. In this review, we address the trials that have been performed for each of these indications, and review the strength of the evidence to support treatment with mild/moderate hypothermia. We review the data to support an optimal target temperature for each indication, as well as the duration of the cooling, and the rate at which cooling is induced and rewarming instituted. Evidence is strongest for prehospital cardiac arrest and neonatal hypoxic-ischemic encephalopathy. For traumatic brain injury, a recent meta-analysis suggests that cooling may increase the likelihood of a good outcome, but does not change mortality rates. For many of the other indications, such as stroke and spinal cord injury, trials are ongoing, but the data are insufficient to recommend routine use of hypothermia at this time.	[Marion, Donald] Childrens Neurobiol Solut Fdn, Santa Barbara, CA USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA		Marion, D (corresponding author), 35 High Rock Rd, Wayland, MA 01778 USA.	donmarion1@yahoo.com	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702			Abou-Chebl A, 2004, NEUROCRIT CARE, V1, P131, DOI 10.1385/NCC:1:2:131; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35; Aslam AF, 2006, AM J MED, V119, P297, DOI 10.1016/j.amjmed.2005.09.062; Axelrod YK, 2006, CRIT CARE CLIN, V22, P767, DOI 10.1016/j.ccc.2006.06.001; Badjatia N, 2006, NEUROLOGY, V66, P1739, DOI 10.1212/01.wnl.0000218166.54150.0a; Badjatia N, 2004, NEUROCRIT CARE, V1, P145, DOI 10.1385/NCC:1:2:145; Bernard S, 2004, CRIT CARE, V8, DOI 10.1186/cc2994; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Boti ET, 2005, ANN THORAC SURG, V79, P1767, DOI 10.1016/j.athoracsur.2003.10.102; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS26; Cheng H, 2006, ACTA NEUROCHIR, V148, P559, DOI 10.1007/s00701-006-0735-3; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; den Hertog Heleen, 2007, Expert Rev Neurother, V7, P155, DOI 10.1586/14737175.7.2.155; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Dohi K, 2006, ACTA NEUROCHIR SUPPL, V96, P409; Downey C, 2000, Can Oper Room Nurs J, V18, P9; Edwards AD, 2006, ARCH DIS CHILD-FETAL, V91, pF127, DOI 10.1136/adc.2005.071787; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; FAY T, 1959, J NEUROSURG, V16, P239, DOI 10.3171/jns.1959.16.3.0239; Fehlings MG, 2005, INJURY, V36, P113, DOI 10.1016/j.injury.2005.06.022; Fehrenbacher JW, 2007, ANN THORAC SURG, V83, P1041, DOI 10.1016/j.athoracsur.2006.09.088; Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5; Feuchtl A., 2007, Intensivmedizin und Notfallmedizin, V44, P37, DOI 10.1007/s00390-007-0740-7; FLEMMING K, 2006, GMS GER MED SCI, V4; Frelinger AL, 2003, AM J CARDIOL, V92, P1099, DOI 10.1016/j.amjcard.2003.06.007; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Goldberg CS, 2007, J THORAC CARDIOV SUR, V133, P880, DOI 10.1016/j.jtcvs.2006.11.029; Gudbjartsson T, 2003, J AM COLL CARDIOL, V41, P849, DOI 10.1016/S0735-1097(02)02923-6; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Gunn AJ, 2008, J PEDIATR-US, V152, P55, DOI 10.1016/j.jpeds.2007.06.003; Heier T, 2006, ANESTHESIOLOGY, V104, P1070, DOI 10.1097/00000542-200605000-00025; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Higgins RD, 2006, J PEDIATR-US, V148, P170, DOI 10.1016/j.jpeds.2005.12.009; Hildebrand F, 2004, AM J SURG, V187, P363, DOI 10.1016/j.amjsurg.2003.12.016; Hinz J, 2007, J NEUROSURG ANESTH, V19, P130, DOI 10.1097/ANA.0b013e318032a208; Hoedemaekers CW, 2007, CRIT CARE, V11, DOI 10.1186/cc6104; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2006, STROKE, V37, P1792, DOI 10.1161/01.STR.0000227265.52763.16; Huang HM, 2007, ASAIO J, V53, P684, DOI 10.1097/MAT.0b013e31815d055d; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Inderbitzen B, 2002, NEUROSURGERY, V50, P364, DOI 10.1097/00006123-200202000-00023; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kandzari DE, 2004, AM J CARDIOL, V93, P636, DOI 10.1016/j.amjcard.2003.11.038; Keller E, 2003, INTENS CARE MED, V29, P939, DOI 10.1007/s00134-003-1685-3; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Kheirabadi BS, 2007, J TRAUMA, V62, P1352, DOI 10.1097/TA.0b013e318047b805; Kheirabadi BS, 2007, J TRAUMA, V63, P1079, DOI 10.1097/TA.0b013e31815885f1; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kliegel A, 2005, RESUSCITATION, V64, P347, DOI 10.1016/j.resuscitation.2004.09.002; Kliegel A, 2007, RESUSCITATION, V73, P46, DOI 10.1016/j.resuscitation.2006.08.023; Konstas AA, 2006, NEUROCRIT CARE, V4, P168, DOI 10.1385/NCC:4:2:168; Kunihara T, 2005, J THORAC CARDIOV SUR, V130, P712, DOI 10.1016/j.jtcvs.2005.03.043; Laver SR, 2006, ANAESTHESIA, V61, P873, DOI 10.1111/j.1365-2044.2006.04552.x; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Leslie K, 2004, ANAESTH INTENS CARE, V32, P362, DOI 10.1177/0310057X0403200310; LUND LO, 1965, ANESTHESIOLOGY, V26, P45, DOI 10.1097/00000542-196501000-00008; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Ly HQ, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.200502.049; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mayer SA, 2007, STROKE, V38, P763, DOI 10.1161/01.STR.0000254499.46122.22; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; Merchant RM, 2006, CRIT CARE MED, V34, pS490, DOI 10.1097/01.CCM.0000246016.28679.36; Merchant RM, 2006, CRIT CARE MED, V34, P1935, DOI 10.1097/01.CCM.0000220494.90290.92; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Nara I, 1998, ACT NEUR S, V71, P22; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Patel HJ, 2006, ANN THORAC SURG, V82, P90, DOI 10.1016/j.athoracsur.2006.02.055; Perlman JM, 2006, PEDIATRICS, V117, pS28, DOI 10.1542/peds.2005-0620E; Pichon N, 2007, CRIT CARE, V11, DOI 10.1186/cc5956; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; RESNICK DK, 2007, HYPOTHERMIA HUMAN SP; Rizoli SB, 2006, CRIT CARE, V10, DOI 10.1186/cc5133; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; ROSOMOFF HL, 1956, SURGERY, V40, P328; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; Sachs B, 2007, SPINE, V32, P2285, DOI 10.1097/BRS.0b013e3181557d45; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Schulzke Sven M, 2007, BMC Pediatr, V7, P30; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SEDZIMIR CB, 1955, BRIT J ANAESTH, V27, P93, DOI 10.1093/bja/27.2.93; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Stanley TO, 2003, ANN THORAC SURG, V75, P1140, DOI 10.1016/S0003-4975(02)04545-9; Steinberg GK, 2004, NEUROSURGERY, V55, P307, DOI 10.1227/01.NEU.0000129683.99430.8C; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Su J, 2003, INT J DEV NEUROSCI, V21, P353, DOI 10.1016/S0736-5748(03)00070-4; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Tabayashi K, 2002, ACTA CHIR BELG, V102, P224; Takahashi I, 2000, NEUROL SURG TOKYO, V28, P983; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Tetik O, 2002, EUR J VASC ENDOVASC, V24, P540, DOI 10.1053/ejvs.2002.1753; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Vanden Hoek Terry L, 2004, Crit Care Med, V32, pS425, DOI 10.1097/01.CCM.0000134259.59793.B8; Vaquero J, 2005, J HEPATOL, V43, P1067, DOI 10.1016/j.jhep.2005.05.039; Visconti KJ, 2006, ANN THORAC SURG, V82, P2207, DOI 10.1016/j.athoracsur.2006.06.069; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Yanagawa Y, 2007, J TRAUMA, V62, P287, DOI 10.1097/01.ta.0000223023.98182.d9; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	137	91	99	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					455	467		10.1089/neu.2008.0582			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900021	19292697				2022-02-06	
J	Snell, D; Surgenor, L; Hay-Smith, EJ; Siegert, R				Snell, Deborah L.; Surgenor, Lois J.; Hay-Smith, E. Jean C.; Siegert, Richard J.			A systematic review of psychological treatments for mild traumatic brain injury: An update on the evidence	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Rehabilitation outcomes; Psychological interventions; Systematic review; Neuropsychological interventions	POST-CONCUSSION SYNDROME; ROUTINE FOLLOW-UP; HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; EARLY INTERVENTION; RANDOMIZED-TRIAL; INDIVIDUALS; ATTENTION; RECOVERY; IMPACT	Mild traumatic brain injury (MTBI) is common and results in persisting disability for a minority of cases. Evidence guiding clinical management of this more complex group is lacking. This study systematically reviews psychological/neuropsychological treatments for adults with MTBI, with an emphasis on external validity. A total of 8 further studies were found adding to 10 from previous reviews. Although the methodological quality remains poor, mild supportive evidence was found for educational interventions provided early following injury. However, the routine provision of interventions for all MTBI cases may not be effective. Continuing and novel research efforts are needed to identify factors associated with poor outcomes to enable efficient targeting of healthcare resources.	[Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand; [Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Sch Med Guys, London WC2R 2LS, England; [Siegert, Richard J.] Kings Coll London, St Thomas Hosp, London WC2R 2LS, England		Snell, D (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929			Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DeJong G, 2005, NZ J DISABILITY STUD, V11, P120; Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P58; Hinkle J L, 1986, J Neurosci Nurs, V18, P268; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hopewell S, 2002, STAT MED, V21, P1625, DOI 10.1002/sim.1191; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; LEONARD KN, 2004, THESIS U TEXAS AUSTI; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Leventhal H, 2008, ANNU REV PSYCHOL, V59, P477, DOI 10.1146/annurev.psych.59.103006.093643; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Onghena P, 2005, CLIN J PAIN, V21, P56, DOI 10.1097/00002508-200501000-00007; Pachankis JE, 2007, CLIN PSYCHOL REV, V27, P760, DOI 10.1016/j.cpr.2007.01.009; Palmese CA, 2000, BRAIN INJURY, V14, P535; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Peer JE, 2007, CLIN PSYCHOL REV, V27, P696, DOI 10.1016/j.cpr.2007.01.004; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rief W, 2007, CLIN PSYCHOL REV, V27, P821, DOI 10.1016/j.cpr.2007.07.005; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WILSON B, 1997, REHABILITATION STUDI, P161; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	57	91	92	2	22	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	1					20	38	PII 792843407	10.1080/13803390801978849			19	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	384IT	WOS:000261739200003	18608646				2022-02-06	
J	Wong, DK; Lurie, F; Wong, LL				Wong, David K.; Lurie, Fedor; Wong, Linda L.			The Effects of Clopidogrel on Elderly Traumatic Brain Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Clopidogrel; Traumatic brain Injury; Elderly	PERCUTANEOUS CORONARY INTERVENTION; INTRACRANIAL HEMORRHAGE; ANTICOAGULATED PATIENTS; PREINJURY WARFARIN; ISCHEMIC EVENTS; ASPIRIN; MORTALITY; TRIAL; COMPLICATIONS; THERAPY	Background: Patients are living longer with cardiovascular disease managed with antiplatelet drugs. These seniors are asked to be more physically active and are prone to falls or injuries. Few have studied the mortality or morbidity from anticoagulants in patients with traumatic brain injuries (TBI). With the increasing use of clopidogrel in the elderly, studies on the consequences of TBI are warranted. Methods: This is a retrospective case-controlled study using a trauma data registry of 3,817 closed head trauma cases (2001-2005). Patients with preinjury use of clopidogrel, aspirin or warfarin, and evidence of traumatic intracranial bleeding were identified (n = 134). These were compared with a frequency-matched control group (n = 178) with similar age, gender, Glasgow Coma Scale, and Injury Severity Scores. Main outcome measure included mortality, hospital or intensive care unit duration, and discharge disposition. Results: Of 131 patients on anticoagulants, patients on clopidogrel (n = 21) were more likely to die (OR = 14.7; 95% CI: 2.3-93.6) and be discharged to an inpatient long-term facility (OR = 3.25; 95%CI: 1.06-9.96). Length of hospital stay and intensive care unit stay were not different from control. Mortality in aspirin patients (n = 90) and warfarin patients (n = 20) did not differ from control. Warfarin patients had increased hospital and ICU stay (10.6 and 5.3 days) when compared with the control (4.7 and 0.9 days, respectively). Conclusions: TBI patients on clopidogrel may have increased long-term disability and fatal consequences when compared with patients who are not on these drugs or on other anticoagulants. Patients on clopidogrel should be advised of safety when engaging in potentially dangerous activities to avoid the consequences of TBI.	Univ Hawaii, John A Burns Sch Med, Dept Surg, Honolulu, HI 96822 USA; Queens Med Ctr, Honolulu, HI USA		Wong, LL (corresponding author), 2226 Liliha St,Suite 402, Honolulu, HI 96817 USA.	hepatoma@aol.com		Lurie, Fedor/0000-0003-0644-0560			BARNES PM, 2000, ADV DATA VITAL HLTH, V333; Bhatt DL, 2001, CIRCULATION, V103, P363; Blackman D K, 1999, MMWR CDC Surveill Summ, V48, P1; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; DAWODU ST, 2007, TRAUMATIC BRAIN INJU; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Grabowski DC, 2004, JAMA-J AM MED ASSOC, V291, P2840, DOI 10.1001/jama.291.23.2840; HE W, 2005, 65 US CURRENT POPULA; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Keysor JJ, 2001, J GERONTOL A-BIOL, V56, pM412, DOI 10.1093/gerona/56.7.M412; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NAT CTR HLTH STAT, 2002, PUBL NAT CTR HLTH ST; *NAT CTR INJ PREV, WHAT IS TRAUM BRAIN; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Ringleb PA, 2004, STROKE, V35, P528, DOI 10.1161/01.STR.0000110221.54366.49; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Yusuf S, 2000, EUR HEART J, V21, P2033; TOP 200 DRUGS 2006 S	29	91	92	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1303	1308		10.1097/TA.0b013e318185e234			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	383WV	WOS:000261706000021	19077618				2022-02-06	
J	Hilton, GD; Stoica, BA; Byrnes, KR; Faden, AI				Hilton, Genell D.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Faden, Alan I.			Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cell cycle activation; microglia; neurons; roscovitine; TBI	PROTEIN-KINASE INHIBITORS; CELL-CYCLE REGULATORS; IN-VITRO; DEATH; INJURY; EXPRESSION; APOPTOSIS; ISCHEMIA; NEUROPROTECTION; PROLIFERATION	Traumatic brain injury (TBI) causes both direct and delayed tissue damage. The latter is associated with secondary biochemical changes such as cell cycle activation, which leads to neuronal death, inflammation, and glial scarring. Flavopiridol-a cyclin-dependent kinase (CDK) inhibitor that is neither specific nor selective-is neuroprotective. To examine the role of more specific CDK inhibitors as potential neuroprotective agents, we studied the effects of roscovitine in TBI. Central administration of roscovitine 30 mins after injury resulted in significantly decreased lesion volume, as well as improved motor and cognitive recovery. Roscovitine attenuated neuronal death and inhibited activation of cell cycle pathways in neurons after TBI, as indicated by attenuated cyclin G1 accumulation and phosphorylation of retinoblastoma protein. Treatment also decreased microglial activation after TBI, as reflected by reductions in ED1, galectin-3, p22(PHOX), and Iba-1 levels, and attenuated astrogliosis, as shown by decreased accumulation of glial fibrillary acidic protein. In primary cortical microglia and neuronal cultures, roscovitine and other selective CDK inhibitors attenuated neuronal cell death, as well as decreasing microglial activation and microglial-dependent neurotoxicity. These data support a multifactorial neuroprotective effect of cell cycle inhibition after TBI-likely related to inhibition of neuronal apoptosis, microglial-induced inflammation, and gliosis-and suggest that multiple CDKs are potentially involved in this process.	[Stoica, Bogdan A.] Georgetown Univ, Sch Med, Dept Neurosci, Med Ctr, Washington, DC 20057 USA		Stoica, BA (corresponding author), Georgetown Univ, Sch Med, Dept Neurosci, Med Ctr, Res Bldg,Room WG18,3970 Reservoir Rd NW, Washington, DC 20057 USA.	stoicab@georgetown.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grant no. NS052568 to AIF.	Andreani A, 2000, ANTI-CANCER DRUG DES, V15, P447; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; BRENNER M, 1994, BRAIN PATHOL, V4, P245, DOI 10.1111/j.1750-3639.1994.tb00840.x; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Hamdane M, 2005, J CELL SCI, V118, P1291, DOI 10.1242/jcs.01724; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; Ino H, 2001, J NEUROSCI, V21, P6086, DOI 10.1523/JNEUROSCI.21-16-06086.2001; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kubo A, 1999, CLIN CANCER RES, V5, P4279; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lam LT, 2001, GENOME BIOL, V2; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maeda M, 2005, EXP NEUROL, V193, P350, DOI 10.1016/j.expneurol.2005.01.018; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Monaco EA, 2004, BIOCHEM PHARMACOL, V67, P1947, DOI 10.1016/j.bcp.2004.02.007; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Newcomb EW, 2004, ANTI-CANCER DRUG, V15, P411, DOI 10.1097/01.cad.0000127332.06439.47; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Okamoto T, 1999, INT J MOL MED, V3, P517; Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Sakurai M, 2000, STROKE, V31, P200, DOI 10.1161/01.STR.31.1.200; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sultana R, 2007, NEUROCHEM RES, V32, P655, DOI 10.1007/s11064-006-9123-x; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tian DS, 2007, BRAIN RES, V1154, P206, DOI 10.1016/j.brainres.2007.04.005; Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097-4547(20000815)61:4<430::AID-JNR9>3.0.CO;2-3; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	46	91	91	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2008	28	11					1845	1859		10.1038/jcbfm.2008.75			15	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	366IB	WOS:000260472900009	18612315	Green Accepted, Bronze			2022-02-06	
J	Zhang, ZX; Guan, LX; Zhang, K; Zhang, Q; Dai, LJ				Zhang, Z-X; Guan, L-X; Zhang, K.; Zhang, Q.; Dai, L-J			A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury	CYTOTHERAPY			English	Article						mesenchymal stromal cells; transplantation; traumatic brain injury	FUNCTIONAL RECOVERY; MARROW; TRANSPLANTATION; NEURONS; RATS	Background There is increasing evidence of therapeutic benefits from bone marrow (BM)-derived mesenchymal stromal cells (MSC) in various animal models with neurologic disorders. It is of great interest to apply the approach to clinical patients, i.e. to take the investigations from laboratory bench to the patient's bedside. This clinical trial was performed to assess the safety and feasibility of a combined procedure to deliver autologous MSC to patients with traumatic brain injury. Methods MSC were isolated by BM aspiration and expanded in culture. Seven patients received autologous cell transplantation. A primary administration of 10(7)-10(9) cells was applied directly to the injured area during the cranial operation; a second dose of 10(8)-10(10) cells was infused intravenously. All patients were followed up regularly for 6 months. Results There was no immediate or delayed toxicity related to the cell administration within the 6-month follow-up period. Neurologic function was significantly improved at 6 months after cell therapy. Discussion The procedure used is safe and feasible at ordinary medical facilities without additional invasive procedures for the patient. The combined cell delivery procedure is expected to enhance the engraftment efficacy of transplanted cells at injured brain tissue, thereby promoting neurologic recover.	[Guan, L-X; Dai, L-J] Weifang Med Coll, Weifang Peoples Hosp, Cent Lab, Weifang 261041, Peoples R China; [Zhang, Z-X; Zhang, K.; Zhang, Q.] Weifang Med Coll, Weifang Peoples Hosp, Dept Neurosurg, Weifang 261041, Peoples R China; [Dai, L-J] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada		Dai, LJ (corresponding author), Weifang Med Coll, Weifang Peoples Hosp, Cent Lab, Weifang 261041, Peoples R China.	longjundai@gmail.com					Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KALLIS Y, 2007, GUT, V716, P24; Katakowski M, 2007, J CEREBR BLOOD F MET, V27, P669, DOI 10.1038/sj.jcbfm.9600390; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Mori K, 2005, J CEREBR BLOOD F MET, V25, P887, DOI 10.1038/sj.jcbfm.9600083; Moviglia GA, 2006, CYTOTHERAPY, V8, P202, DOI 10.1080/14653240600736048; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Strauer BE, 2005, J AM COLL CARDIOL, V46, P1651, DOI 10.1016/j.jacc.2005.01.069; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhang ZX, 2007, CELL BIOL INT, V31, P645, DOI 10.1016/j.cellbi.2006.11.025	20	91	93	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy		2008	10	2					134	139		10.1080/14653240701883061			6	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	279ZO	WOS:000254394900005	18368592				2022-02-06	
J	Grasso, G; Sfacteria, A; Meli, F; Fodale, V; Buemi, M; Iacopino, DG				Grasso, Giovanni; Sfacteria, Alessandra; Meli, Francesco; Fodale, Vincenzo; Buemi, Michele; Iacopino, Domenico G.			Neuroprotection by erythropoietin administration after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						erythropoietin; neuroprotection; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; ISCHEMIA-REPERFUSION INJURY; CLOSED-HEAD INJURY; SUBARACHNOID HEMORRHAGE; IN-VITRO; BARRIER PERMEABILITY; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; SPATIAL MEMORY; PROTECTS	A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and blood-brain barrier (BBB) breakdown was evaluated by assay of Evans blue extravasation. Furthermore, extent of cerebral damage was assessed. Administration of rHuEPO markedly improved recovery from motor dysfunction compared with placebo group (P<0.05). Brain edema was significantly reduced in the cortex of the EPO-treated group relative to that in the placebo-treated group (80.6 +/- 0.3% versus 91.8%+/- 0.8% respectively, P<0.05). BBB breakdown was significantly lower in EPO-treated group than in the placebo-treated group (66.2 +/- 18.7 mu g/gversus 181.3 +/- 21 mu g/g, respectively, P<0.05). EPO treatment reduced injury volume significantly compared with placebo group (17.4 +/- 5.4 mm3 versus 37.1 +/- 5.3 mm3, P<0.05). EPO, administered in its recombinant form, affords significant neuroprotection in experimental TBI model and may hold promise for future clinical applications. (C) 2007 Elsevier B.V. All rights reserved.	[Grasso, Giovanni; Meli, Francesco] Univ Palermo, Neurosurg Clin, Dept Clin Neurosci, I-90133 Palermo, Italy; [Sfacteria, Alessandra] Univ Messina, Dept Vet Pathol, I-98100 Messina, Italy; [Fodale, Vincenzo] Univ Messina, Dept Anesthesiol, I-98100 Messina, Italy; [Buemi, Michele] Univ Messina, Dept Internal Med, I-98100 Messina, Italy		Grasso, G (corresponding author), Policlin P Giaccone, Neurosurg Clin, Via Vespro 127, I-90100 Palermo, Italy.	ggrasso@unipa.it	Sfacteria, Alessandra/AAK-1839-2020; GRASSO, GIOVANNI/A-4309-2009; grasso, giovanni/K-3774-2018; Fodale, Vincenzo/G-5554-2010; Iacopino, Domenico/C-1539-2013	grasso, giovanni/0000-0001-5362-0092; Fodale, Vincenzo/0000-0001-9540-5665; Iacopino, Domenico/0000-0003-1685-5209			Amorini AM, 2003, ACT NEUR S, V86, P261; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Buemi M, 2002, J NEPHROL, V15, P97; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; D'Andrea RJ, 2000, EXP HEMATOL, V28, P231, DOI 10.1016/S0301-472X(99)00159-9; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Gorlach C, 1998, J CEREBR BLOOD F MET, V18, P1357; Gove CD, 1997, HEPATOLOGY, V25, P295; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; Iseki K, 1996, NEPHRON, V72, P30, DOI 10.1159/000188803; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; Ozturk Erdogan, 2005, Prog Neuropsychopharmacol Biol Psychiatry, V29, P922, DOI 10.1016/j.pnpbp.2005.04.028; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uzum G, 2006, LIFE SCI, V78, P2571, DOI 10.1016/j.lfs.2005.10.027; VERDONCK O, 2007, J CEREB BLOOD FLOW M; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhao Jingxia, 2003, Sichuan Da Xue Xue Bao Yi Xue Ban, V34, P559	50	91	96	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 28	2007	1182						99	105		10.1016/j.brainres.2007.08.078			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	242CS	WOS:000251702700010	17935704	Green Published			2022-02-06	
J	Klose, M; Juul, A; Struck, J; Morgenthaler, NG; Kosteljanetz, M; Feldt-Rasmussen, U				Klose, M.; Juul, A.; Struck, J.; Morgenthaler, N. G.; Kosteljanetz, M.; Feldt-Rasmussen, U.			Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study	CLINICAL ENDOCRINOLOGY			English	Article							CORTISOL RESPONSE; SEPTIC SHOCK; HYPOPITUITARISM; GH; DYSFUNCTION; PREVALENCE; ARGININE; ADULTS; SENSITIVITY; DEFICIENCY	Objective To assess the prevalence of hypopituitarism following traumatic brain injury (TBI), describe the time-course and assess the association with trauma-related parameters and early post-traumatic hormone alterations. Design A 12-month prospective study. Patients Forty-six consecutive patients with TBI (mild: N = 22; moderate: N = 9; severe: N = 15). Measurements Baseline and stimulated hormone concentrations were assessed in the early phase (0-12 days post-traumatically), and at 3, 6 and 12 months postinjury. Pituitary tests included the Synacthen-test (acute +6 months) and the insulin tolerance test (ITT) or the GHRH + arginine test if the ITT was contraindicated (3 + 12 months). Insufficiencies were confirmed by retesting. Results Early post-traumatic hormone alterations mimicking central hypogonadism or hypothyroidism were present in 35 of the 46 (76%) patients. Three months post-traumatically, 6 of the 46 patients failed anterior pituitary testing. At 12 months, one patient had recovered, whereas none developed new insufficiencies. All insufficient patients had GH deficiency (5 out of 46), followed by ACTH- (3 out of 46), TSH- (1 out of 46), LH/FSH- (1 out of 46) and ADH deficiency (1 out of 46). Hypopituitary patients had more frequently been exposed to severe TBI (4 out of 15) than to mild or moderate TBI (1 out of 31) (P = 0.02). Early endocrine alterations including lowered thyroid and gonadal hormones, and increased total cortisol, free cortisol and copeptin were positively associated to TBI severity (P < 0.05), but not to long-term development of hypopituitarism (P > 0.1), although it was indicative in some. Conclusion Long-term hypopituitarism was frequent only in severe TBI. During the 3-12 months follow-up, recovery but no new insufficiencies were recorded, indicating manifest hypothalamic or pituitary damage already a few months postinjury. Very early hormone alterations were not associated to long-term post-traumatic hypopituitarism. Clinicians should, nonetheless, be aware of potential ACTH deficiency in the early post-traumatic period.	Univ Copenhagen Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark; BRAHMS Aktiengesellschaft, Dept Res, Hennigsdorh, Germany		Klose, M (corresponding author), Univ Copenhagen Hosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Juul, Anders/F-5864-2013	Juul, Anders/0000-0002-0534-4350			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Andersen S, 2003, THYROID, V13, P1069, DOI 10.1089/105072503770867237; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; COOLENS JL, 1987, J STEROID BIOCHEM, V26, P197, DOI 10.1016/0022-4731(87)90071-9; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HARRIS EK, 1970, CLIN CHEM, V16, P1022; Hoeck HC, 1999, GROWTH HORM IGF RES, V9, P18, DOI 10.1054/ghir.1998.0085; Hoeck HC, 2000, J CLIN ENDOCR METAB, V85, P1467, DOI 10.1210/jc.85.4.1467; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; Jochberger S, 2006, J CLIN ENDOCR METAB, V91, P4381, DOI 10.1210/jc.2005-2830; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2007, J CLIN ENDOCR METAB, V92, P1326, DOI 10.1210/jc.2006-1791; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MOLIJN GJ, 1995, J CLIN ENDOCR METAB, V80, P1799, DOI 10.1210/jc.80.6.1799; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; VAN BG, 1998, J CLIN ENDOCRINOLOGY, V83, P1827; Vanhorebeek I, 2006, J CLIN ENDOCR METAB, V91, P3803, DOI 10.1210/jc.2005-2089	38	91	97	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	OCT	2007	67	4					598	606		10.1111/j.1365-2265.2007.02931.x			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	210VI	WOS:000249483300019	17880406				2022-02-06	
J	Ohman, L; Nordin, S; Bergdahl, J; Birgander, LS; Neely, AS				Ohman, Lena; Nordin, Steven; Bergdahl, Jan; Birgander, Lisbeth Slunga; Neely, Anna Stigsdotter			Cognitive function in outpatients with perceived chronic stress	SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH			English	Article						burnout; executive functioning; memory; work stress	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; PROSPECTIVE MEMORY; PREFRONTAL CORTEX; EPISODIC MEMORY; CHRONIC BURNOUT; PERFORMANCE; DYSFUNCTION; ATTENTION; VALIDITY	Objectives The number of employees on sick leave due to stress-related syndromes has increased drastically in many industrialized countries. Cognitive dysfunction is a common complaint among patients suffering from chronic stress. Previous research on chronic stress has mainly focused on its interpersonal, attitudinal, psychological, organizational, and physical effects. Less attention has been allocated to effects of chronic stress on cognitive functioning. Hence the aim of the present study was to investigate the relationship between chronic stress and cognition. Methods The cognitive performance of 19 chronic stress outpatients and 19 matched controls was studied. A battery of standard and experimental cognitive tests assessing processing speed, attention, working memory, and episodic and semantic memory were administered. Results Performance deficits of the chronic stress patients relative to the performance of the controls were found for some but not all cognitive tasks, indicating a selective deficit. Deficits were found for episodic memory, particularly for learning across repeated trials and for tasks requiring divided attention during either the encoding or retrieval of words. Performance differences were also found for aspects of working memory, mental tempo, semantic access, and prospective memory, but not for basic perceptual speed measures. Conclusions These findings may suggest suboptimal executive functioning (eg, strategic or attentional control) among chronic stress patients. Particularly, poor performance in letter fluency and prospective memory were significantly associated with chronic stress, the finding suggesting the usefulness of these tests as clinical tools in evaluations of chronic stress states.	Umea Univ, Dept Psychol, S-90187 Umea, Sweden; Orebro Univ Hosp, Dept Occupat & Environm Med, Orebro, Sweden; Univ Tromso, Fac Med, Inst Clin Dent, Tromso, Norway; Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden		Neely, AS (corresponding author), Umea Univ, Dept Psychol, S-90187 Umea, Sweden.	anna.neely@psy.umu.se	Stigsdotter Neely, Anna/H-4140-2012				Alderson AL, 2002, J CLIN EXP NEUROPSYC, V24, P335, DOI 10.1076/jcen.24.3.335.987; Bergdahl J, 2005, SCAND J PSYCHOL, V46, P395, DOI 10.1111/j.1467-9450.2005.00470.x; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Capuron L, 2006, NEUROPSYCHOPHARMACOL, V31, P1777, DOI 10.1038/sj.npp.1301005; Grossi G, 2003, J PSYCHOSOM RES, V55, P309, DOI 10.1016/S0022-3999(02)00633-5; Hamsher K., 1989, MULTILINGUAL APHASIA; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mantyla T, 2003, MEM COGNITION, V31, P15, DOI 10.3758/BF03196078; Mantyla T, 1997, AGING NEUROPSYCHOL C, V4, P81, DOI 10.1080/13825589708256638; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MEIER ST, 1984, J OCCUP PSYCHOL, V57, P211, DOI 10.1111/j.2044-8325.1984.tb00163.x; Melamed S, 1999, J PSYCHOSOM RES, V46, P591, DOI 10.1016/S0022-3999(99)00007-0; MELAMED S, 1992, BEHAV MED, V18, P53, DOI 10.1080/08964289.1992.9935172; Melamed S, 2006, PSYCHOL BULL, V132, P327, DOI 10.1037/0033-2909.132.3.327; Meyers JE., 1995, REY COMPLEX FIGURE T; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moscovitch M., 2002, PRINCIPLES FRONTAL L, P188, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0012; Mungas D, 2001, NEUROLOGY, V57, P2229, DOI 10.1212/WNL.57.12.2229; MURDOCK BB, 1965, BRIT J PSYCHOL, V56, P413, DOI 10.1111/j.2044-8295.1965.tb00983.x; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; Nyberg L, 2003, P NATL ACAD SCI USA, V100, P13728, DOI 10.1073/pnas.1735487100; Nyberg L, 1997, EXP AGING RES, V23, P137, DOI 10.1080/03610739708254029; Osterberg E., 1971, MANUAL DS BATTERIET; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Prins JB, 2006, LANCET, V367, P346, DOI 10.1016/S0140-6736(06)68073-2; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012; Quintner JL, 1999, LANCET, V353, P1092, DOI 10.1016/S0140-6736(98)06468-X; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; REITAN RM, 1992, TRAIL MAKING TEST TU; Rey A., 1993, CLIN NEUROPSYCHOL, V7, P4; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; SALTHOUSE TA, 1993, DEV PSYCHOL, V29, P722, DOI 10.1037/0012-1649.29.4.722; Sandstrom A, 2005, BIOL PSYCHOL, V69, P271, DOI 10.1016/j.biopsycho.2004.08.003; Schaufeli W., 1998, BURNOUT COMPANION ST; Shirom A, 2003, ANXIETY STRESS COPIN, V16, P83, DOI 10.1080/1061580021000057059; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Ursin H, 2001, ANN NY ACAD SCI, V933, P119; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Wechsler D, 1987, MEMORY SCALE REVISED; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2	51	91	93	1	31	SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH	HELSINKI	TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND	0355-3140	1795-990X		SCAND J WORK ENV HEA	Scand. J. Work Environ. Health	JUN	2007	33	3					223	232					10	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	184UF	WOS:000247667400007	17572832				2022-02-06	
S	Bartfai, T; Sanchez-Alavez, M; Andell-Jonsson, S; Schultzberg, M; Vezzani, A; Danielsson, E; Conti, B		Csermely, P; Korcsmaros, T; Sulyok, K		Bartfai, Tamas; Sanchez-Alavez, Manuel; Andell-Jonsson, Siv; Schultzberg, Marianne; Vezzani, Annamaria; Danielsson, Erik; Conti, Bruno			Interleukin-1 system in CNS stress - Seizures, fever, and neurotrauma	STRESS RESPONSES IN BIOLOGY AND MEDICINE: STRESS OF LIFE IN MOLECULES, CELLS, ORGANISMS, AND PSYCHOSOCIAL COMMUNITIES	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	2nd World Conference on Stress	AUG 23-26, 2007	Budapest, HUNGARY			interleukin-1 beta; interleukin-1 receptor antagonist; neurotrauma; seizure; fever; anticonvulsant	IL-1 RECEPTOR ANTAGONIST; OVEREXPRESSION; MICE; PHASE; IL-1-BETA; BEHAVIOR; STROKE; BRAIN; GENE; RAT	Proteins of the interleukin-1 (IL-1) system include the secreted agonist IL-1 beta, and the receptor antagonist IL-1ra, both competing for binding to the IL-1 receptor (IL-1R). IL-1 beta and IL-1ra are highly inducible under different forms of stress, such as excitatory neurotransmitter excess occurring during seizures, in infection and inflammation, and during neurotrauma. In each of these conditions induction of IL-1 beta precedes that of IL-1ra, resulting in up to 10-20-fold elevation of IL-1 beta concentrations. Consequently, IL-1 beta induces the elevation of other proinflammatory molecules, including IL-6, IL-1R1, COX2, and iNOS, as well as of IL-1ra. Elevation of IL-1ra is of key importance for quenching the inflammatory response at the IL-1R1 as part of an autoregulatory loop. In seizures, IL-1ra is a strong anticonvulsant and in IL-1 beta-dependent fever, a powerful antipyretic. In traumatic brain injury (TBI), the ability of patients to mount an IL-1ra response, as measured in the CSF, strongly correlated with the neurological outcome. Selective induction or pharmacological application of IL-1ra may be sparing neurons in seizures and neurotrauma.	Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA; Stockholm Univ, S-10691 Stockholm, Sweden; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Malmo Almanna Sjukhus, Malmo, Sweden		Bartfai, T (corresponding author), Scripps Res Inst, Mol & Integrat Neurosci Dept, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tbartfai@scripps.edu	Vezzani, Annamaria/AAB-1882-2020; Schultzberg, Marianne/E-7076-2014	Vezzani, Annamaria/0000-0003-0573-6175; Schultzberg, Marianne/0000-0002-8314-0927; Sanchez-Alavez, Manuel/0000-0002-8164-8452; Conti, Bruno/0000-0002-9185-5201			Alheim K, 1998, ANN NY ACAD SCI, V840, P51, DOI 10.1111/j.1749-6632.1998.tb09548.x; Dantzer R, 1998, ANN NY ACAD SCI, V840, P586, DOI 10.1111/j.1749-6632.1998.tb09597.x; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644, DOI 10.1152/ajpregu.1999.276.3.R644; Mulcahy NJ, 2003, BRIT J PHARMACOL, V140, P471, DOI 10.1038/sj.bjp.0705462; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Sanchez-Alavez M, 2006, P NATL ACAD SCI USA, V103, P2904, DOI 10.1073/pnas.0510960103; Shavit Y, 2005, PAIN, V115, P50, DOI 10.1016/j.pain.2005.02.003; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tsai TH, 2003, NEUROREPORT, V14, P803, DOI 10.1097/00001756-200305060-00005; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Viviani B, 2003, J NEUROSCI, V23, P8692; Xia Y, 1999, J CLIN INVEST, V103, P1309, DOI 10.1172/JCI5823	16	91	97	0	12	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-675-0	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2007	1113						173	177		10.1196/annals.1391.022			5	Psychology, Biological; Behavioral Sciences; Biochemistry & Molecular Biology; Immunology; Multidisciplinary Sciences; Psychology, Social	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Behavioral Sciences; Biochemistry & Molecular Biology; Immunology; Science & Technology - Other Topics	BGX56	WOS:000251158200016	17656565				2022-02-06	
J	Urrea, C; Castellanos, DA; Sagen, J; Tsoulfas, P; Bramlett, HM; Dietrich, WD				Urrea, Carlos; Castellanos, Daniel A.; Sagen, Jacqueline; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton			Widespread cellular proliferation and focal neurogenesis after traumatic brain injury in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						neurogenesis; dentate granular neurons; trauma; subventricular zone; plasticity	NEURAL STEM-CELLS; TRANSIENT GLOBAL-ISCHEMIA; SUBVENTRICULAR ZONE; ENHANCED NEUROGENESIS; DENTATE GYRUS; PROGRESSIVE ATROPHY; CEREBRAL-ISCHEMIA; PROGENITOR CELLS; SPINAL-CORD; ADULT	Purpose: A proliferation of stem/progenitor cells is observed after brain injury. We examined the regional and temporal profile of mitotically active cells to determine whether traumatic brain injury (TBI) would increase neurogenesis in selective brain regions. Methods: Mate Sprague-Dawley rats received injections (IP) of 5-bromo-deoxyuridine (BrdU), a compound used to detect mitotic cells, before and after fluid-percussion brain injury. At 3 hr, 1, 2, 3, 7, and 14 days after moderate fluid percussion, brains were processed for immunocytochemical and confocal analysis. Sections were double-labeled for markers selective for neurons (NeuN), astrocytes (GFAP), olidgodendrocytes (CNPase and MBP) and macrophage/microglia (ED1). Results: At 3 hr post-trauma, the majority of BrdU labeled cells were associated with the subventricular zone of the traumatized hemisphere. At later time points, a significant increase in BrdU positive cells was observed throughout the traumatized cerebral cortex, hippocampus, white matter structures, and some contralateral regions. BrdU labeled cells were observed as late as 14 days post-injury. Double-label studies with confocal microscopy demonstrated that cell phenotypes including astrocytes, macrophage/microglia, oligodendrocytes, and neurons were BrdU positive with the majority of cells appearing glial in nature. Evidence for neurogenesis was seen in the granular cell layer of the hippocampus. Conclusion: These findings indicate that TBI stimulates widespread cellular proliferation for days after injury and results in focal neurogenesis in the dentate gyrus of the hippocampus. These cellular responses to injury may participate in brain repair and functional recovery.	Univ Miami, Miller Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, 1095 NW 14th Terrace,LPLC 2-23, Miami, FL 33136 USA.	ddietrich@miami.edu		Sagen, Jacqueline/0000-0002-9742-7240; Tsoulfas, Pantelis/0000-0003-1974-6366	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 PO1 NS30291, 1 RO1 NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Felling RJ, 2003, J NEUROSCI RES, V73, P277, DOI 10.1002/jnr.10670; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Yang H, 2006, J NEUROSCI, V26, P2157, DOI 10.1523/JNEUROSCI.4070-05.2005; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	44	91	96	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2007	25	1					65	76					12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195DP	WOS:000248393000007	17473396				2022-02-06	
J	McLeod, TCV; Barr, WB; McCrea, M; Guskiewicz, KM				McLeod, Tamara C. Valovich; Barr, William B.; McCrea, Michael; Guskiewicz, Kevin M.			Psychometric and measurement properties of concussion assessment tools in youth sports	JOURNAL OF ATHLETIC TRAINING			English	Article; Proceedings Paper	Rocky-Mountain-Athletic-Trainers'-Association District Meeting	MAR, 2004	Broomfield, CO	Rocky Mt Athlet Trainers Assoc		neuropsychological testing; brain injury; athletic injuries; reliability	MILD HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL TEST PROTOCOL; TEST-RETEST RELIABILITY; HIGH-SCHOOL; POSTURAL STABILITY; STANDARDIZED ASSESSMENT; NCAA CONCUSSION; RECOVERY; PERFORMANCE	Context: Establishing psychometric and measurement properties of concussion assessments is important before these assessments are used by clinicians. To date, data have been limited regarding these issues with respect to neurocognitive and postural stability testing, especially in a younger athletic population. Objective: To determine the test-retest reliability and reliable change indices of concussion assessments in athletes participating in youth sports. A secondary objective was to determine the relationship between the Standardized Assessment of Concussion (SAC) and neuropsychological assessments in young athletes. Design: We used a repeated-measures design to evaluate the test-retest reliability of the concussion assessments in young athletes. Correlations were calculated to determine the relationship between the measures. All subjects underwent 2 test sessions 60 days apart. Setting: Sports medicine laboratory and school or home environment. Patients or Other Participants: Fifty healthy young athletes between the ages of 9 and 14 years. Main Outcome Measure(s): Scores from the SAC, Balance Error Scoring System, Buschke Selective Reminding Test, Trail Making Test B, and Coding and Symbol Search subsets of the Wechsler Intelligence Scale for Children were used in the analysis. Results: Our test-retest indices for each of the 6 scores were poor to good, ranging from r =.46 to.83. Good reliability was found for the Coding and Symbol Search tests. The reliable change scores provided a way of determining a meaningful change in score for each assessment. We found a weak relationship (r <.36) between the SAC and each of the neuropsychological assessments; however, stronger relationships (r >.70) were found between certain neuropsychological measures. Conclusions: We found moderate test-retest reliability on the cognitive tests that assessed attention, concentration, and visual processing and the Balance Error Scoring System. Our results demonstrated only a weak relationship between performance on the SAC and the selected neuropsychological tests, so it is likely that these tests assess somewhat different areas of cognitive function. Our correlational findings provide more evidence for using the SAC along with a more complex neuropsychological assessment battery in the evaluation of concussion in young athletes.	AT Still Univ, Athlet Training Program, Arizona Sch Hlth Sci, Mesa, AZ 85206 USA; NYU, Sch Med, New York, NY USA; Waukesha Mem Hosp, Waukesha, WI USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ N Carolina, Chapel Hill, NC 27515 USA		McLeod, TCV (corresponding author), AT Still Univ, Athlet Training Program, Arizona Sch Hlth Sci, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Barr, William/0000-0001-7711-7758; Guskiewicz, Kevin/0000-0002-8682-2130			ATWATER SW, 1990, PHYS THER, V70, P79, DOI 10.1093/ptj/70.2.79; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; CLODFELTER CJ, 1987, CLIN NEUROPSYCHOL, V1, P243; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2001, ARCH CLIN NEUROPSYCH, V16, P461; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GARRETT HE, 1992, STAT PSYCHOL ED; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; L?ders H., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2001, J ATHL TRAINING, V36, P288; Reitan R, 1985, HALSTEAD REITAN NEUR; RIACH CL, 1987, DEV MED CHILD NEUROL, V29, P650; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Valovich TC, 2003, J ATHL TRAINING, V38, P51; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01	55	91	91	1	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2006	41	4					399	408					10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	124QU	WOS:000243385800010	17273465				2022-02-06	
J	Thomas, KE; Annest, JL; Gilchrist, J; Bixby-Hammett, DM				Thomas, K. E.; Annest, J. L.; Gilchrist, J.; Bixby-Hammett, D. M.			Non-fatal horse related injuries treated in emergency departments in the United States, 2001-2003	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							EQUESTRIAN INJURIES; RIDING INJURIES; CHILDREN; HELMETS; PATTERN; TRAUMA	Objective: To characterise and provide nationally representative estimates of persons with non-fatal horse related injuries treated in American emergency departments. Methods: The National Electronic Injury Surveillance System All Injury Program (NEISS-AIP) is a stratified probability sample comprising 66 hospitals. Data on injuries treated in these emergency departments are collected and reported. NEISS-AIP data on all types (horseback riding and otherwise) of non-fatal horse related injuries from 2001 to 2003 were analysed. Results: An estimated 102 904 persons with non-fatal horse related injuries (35.7 per 100 000 population) were treated in American emergency departments each year from 2001 to 2003 inclusive. Non-fatal injury rates were higher for females (41.5 per 100 000) than for males (29.8 per 100 000). Most patients were injured while mounted on a horse (66.1%), commonly from falling or being thrown by the horse; while not mounted, injuries most often resulted from being kicked by the horse. The body parts most often injured were the head/neck region (23.2%), lower extremity (22.2%), and upper extremity (21.5%). The most common principal diagnoses were contusions/abrasions (31.4%) and fractures (25.2%). For each year that was studied, an estimated 11 502 people sustained traumatic brain injuries from horse related incidents. Overall, more than 11% of those injured were admitted to hospital. Conclusions: Horse related injuries are a public health concern not just for riders but for anyone in close contact with horses. Prevention programmes should target horseback riders and horse caregivers to promote helmet use and educate participants about horse behaviour, proper handling of horses, and safe riding practices.	CDC, OSP, NCIPC, Atlanta, GA 30341 USA; CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Amer Med Equestrian Assoc Safe Riders Fdn, Albuquerque, NM USA		Thomas, KE (corresponding author), CDC, OSP, NCIPC, 4770 Buford Highway NE,Mailstop K-59, Atlanta, GA 30341 USA.	KEThomas@cdc.gov					*AM HORS COUNC, HORS IND STAT NAT EC; BIXBYHAMMETT D, 2002, AM EQUESTRIAN MED AS, V13, P8; BIXBYHAMMETT DM, 1992, PEDIATRICS, V89, P1173; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BOND GR, 1995, PEDIATRICS, V95, P487; BYRD JWT, 1996, PLANNING EVENT COVER; Campbell-Hewson G L, 1999, Eur J Emerg Med, V6, P37; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P329; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P335; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P341; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; CORDELL K, 2004, RECREATION STAT UPDA; FIRTH JL, 1994, SPORTS INJURIES MECH, P315; Frankel HL, 1998, AM SURGEON, V64, P151; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; Grandin T, 1999, OCCUP MED-STATE ART, V14, P195; Griffen M, 2002, SOUTHERN MED J, V95, P441, DOI 10.1097/00007611-200204000-00013; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; HUGHES KM, 1995, AM J EMERG MED, V13, P485, DOI 10.1016/0735-6757(95)90148-5; Jagodzinski Tanya, 2005, WMJ, V104, P50; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lim J, 2003, ANZ J SURG, V73, P567, DOI 10.1046/j.1445-2197.2003.02707.x; McCrory P, 2005, MED SPORT SCI, V48, P8, DOI 10.1159/000084280; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McGhee C N, 1987, Br J Neurosurg, V1, P131, DOI 10.3109/02688698709034348; Moss PS, 2002, EMERG MED J, V19, P412, DOI 10.1136/emj.19.5.412; National Center for Health Statistics, US CENS POP BRIDG RA; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON DE, 1994, AM J PREV MED, V10, P15, DOI 10.1016/S0749-3797(18)30641-X; NELSON MA, 1992, PEDIATRICS, V89, P512; NISKANEN R, 1994, ANN CHIR GYNAECOL, V83, P225; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; Robson S E, 1979, Br J Sports Med, V13, P33; Sacks J J, 1996, Inj Prev, V2, P258, DOI 10.1136/ip.2.4.258; SCHROEDER T, 2001, NEISS SAMPLE DESIGN, P1; *SPEC VEH I AM, 2005, STAT ALL TERR VEH RE; Thompson JM, 1996, CAN FAM PHYSICIAN, V42, P1103; Thompson NJ, 2002, PATIENT EDUC COUNS, V46, P191, DOI 10.1016/S0738-3991(01)00212-9; VYROSTEK SB, 2004, MMWR-MORBID MORTAL W, V53, pSS1; Watt GM, 1996, SPORTS MED, V22, P187, DOI 10.2165/00007256-199622030-00005; 1997, AM MED EQUESTRIAN AS, V7	44	91	96	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2006	40	7					619	626		10.1136/bjsm.2006.025858			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	056OH	WOS:000238533800011	16611723	Green Published			2022-02-06	
J	Staab, JP				Staab, JP			Chronic dizziness: the interface between psychiatry and neuro-otology	CURRENT OPINION IN NEUROLOGY			English	Article						anxiety; chronic dizziness; dysautonomia; migraine; traumatic brain injury	GENETIC-VARIATION; VESTIBULAR DYSFUNCTION; BEHAVIORAL-INHIBITION; VERTIGO; ANXIETY; POLYMORPHISM; ASSOCIATION; MIGRAINE; REHABILITATION; SYMPTOMS	Purpose of review This paper reviews the often-enigmatic relationships between dizziness and psychiatric symptoms. Psychiatric causes of dizziness, neuro-otologic causes of anxiety, underrecognized co-morbid conditions, and medical illnesses that masquerade as 'psychogenic' dizziness are examined. Key clinical features and data from recent treatment trials are presented with potential pathophysiologic mechanisms. Recent findings Investigations at the interface between psychiatry and neuro-otology have identified the distinguishing features of several clinical conditions that present with non-vertiginous dizziness, subjective imbalance, and psychiatric symptoms. The most common condition is chronic subjective dizziness; a refinement of earlier concepts of psychogenic dizziness, phobic postural vertigo, and space-motion phobia. Chronic subjective dizziness is consistent with advancing research on anxiety and somatoform disorders and offers greater insights into the relationships between neuro-otologic illnesses and anxiety. Migraine, post-concussional syndrome, and dysautonomias also cause persistent dizziness and may be misdiagnosed or malingering or psychogenic dizziness because they often present with comorbid psychiatric symptoms in the absence of identifiable vestibular deficits. Summary Recent research has defined the key features of several medical-psychiatric conditions that cause chronic dizziness, permitting greater diagnostic precision and insight into underlying pathophysiologic processes. Treatment studies have identified potentially effective interventions, which must be evaluated in controlled clinical trials.	Hosp Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Univ Penn, Balance Ctr, Philadelphia, PA 19104 USA		Staab, JP (corresponding author), Hosp Univ Penn, Dept Psychiat, 3400 Spruce St,Founders Pavil F11-015, Philadelphia, PA 19104 USA.	jeffrey.staab@uphs.upenn.edu	Staab, Jeffrey/B-8792-2015	Staab, Jeffrey/0000-0002-1516-3131			American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Ballas CA, 2003, CNS SPECTRUMS, V8, P20, DOI 10.1017/S1092852900008245; Brandt T, 1996, NEUROLOGY, V46, P1515, DOI 10.1212/WNL.46.6.1515; Brantberg K, 2005, ACTA OTO-LARYNGOL, V125, P276, DOI 10.1080/00016480510003165; Brignole M, 2004, EUROPACE, V6, P467, DOI 10.1016/j.eupc.2004.08.008; Bronstein AM, 2004, J NEUROL, V251, P381, DOI 10.1007/s00415-004-0410-7; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; David SP, 2005, J NEUROSCI, V25, P2586, DOI 10.1523/JNEUROSCI.3769-04.2005; Erickson K, 2005, DEV PSYCHOBIOL, V47, P196, DOI 10.1002/dev.20086; Fox NA, 2005, ANNU REV PSYCHOL, V56, P235, DOI 10.1146/annurev.psych.55.090902.141532; Furman JM, 2005, J NEUROL NEUROSUR PS, V76, P1, DOI 10.1136/jnnp.2004.048926; Gallinat J, 2005, NEUROIMAGE, V26, P123, DOI 10.1016/j.neuroimage.2005.01.001; Godemann F, 2005, J PSYCHIATR RES, V39, P529, DOI 10.1016/j.jpsychires.2004.12.006; Godemann F, 2004, PSYCHOSOM MED, V66, P783, DOI 10.1097/01.psy.0000140004.06247.c9; Graff-Guerrero A, 2005, NEUROIMAGE, V25, P1197, DOI 10.1016/j.neuroimage.2004.12.020; Guerraz M, 2001, BRAIN, V124, P1646, DOI 10.1093/brain/124.8.1646; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Horii A, 2004, OTOL NEUROTOL, V25, P536, DOI 10.1097/00129492-200407000-00022; Huppert D, 2005, J NEUROL, V252, P564, DOI 10.1007/s00415-005-0699-x; Jacob RG, 2001, J ANXIETY DISORD, V15, P131, DOI 10.1016/S0887-6185(00)00047-5; Jacob RG, 2001, CURR OPIN NEUROL, V14, P41, DOI 10.1097/00019052-200102000-00007; Kalin Ned H, 2004, Psychopharmacol Bull, V38, P8; KAUFMAN KR, 2005, MED ENG PHYS    0722; KLEMENHAGEN KC, 2005, NEUROPSYCHOPHAR 0525; Longridge NS, 2005, OTOL NEUROTOL, V26, P695, DOI 10.1097/01.mao.0000178152.21634.6d; Mayou R, 2005, AM J PSYCHIAT, V162, P847, DOI 10.1176/appi.ajp.162.5.847; Neuhauser H, 2004, CEPHALALGIA, V24, P83, DOI 10.1111/j.1468-2982.2004.00662.x; Olsson CA, 2005, PSYCHIAT GENET, V15, P109, DOI 10.1097/00041444-200506000-00007; Pavlou M, 2004, J NEUROL, V251, P983, DOI 10.1007/s00415-004-0476-2; PERNA G, 2005, NEUROPSYCHOPHAR 0720; Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463; Schinka JA, 2004, MOL PSYCHIATR, V9, P197, DOI 10.1038/sj.mp.4001405; Schwartz CE, 2003, SCIENCE, V300, P1952, DOI 10.1126/science.1083703; Simon NM, 2005, PSYCHOSOMATICS, V46, P334, DOI 10.1176/appi.psy.46.4.334; Smoller JW, 2005, BIOL PSYCHIAT, V57, P1485, DOI 10.1016/j.biopsych.2005.02.018; Staab JP, 2005, ARCH OTOLARYNGOL, V131, P675, DOI 10.1001/archotol.131.8.675; Staab JP, 2004, LARYNGOSCOPE, V114, P1637, DOI 10.1097/00005537-200409000-00025; Staab JP, 2003, LARYNGOSCOPE, V113, P1714, DOI 10.1097/00005537-200310000-00010; Staab JP, 2002, LARYNGOSCOPE, V112, P1346, DOI 10.1097/00005537-200208000-00005; Staab JP, 2002, ARCH OTOLARYNGOL, V128, P554, DOI 10.1001/archotol.128.5.554; STAAB JP, 2005, ANN M E SECT AM LARY; Staab JR, 2005, PSYCHIAT ANN, V35, P330; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989	43	91	102	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	FEB	2006	19	1					41	48		10.1097/01.wco.0000198102.95294.1f			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	013CT	WOS:000235387900007	16415676				2022-02-06	
J	Schmitz, TW; Rowley, HA; Kawahara, TN; Johnson, SC				Schmitz, TW; Rowley, HA; Kawahara, TN; Johnson, SC			Neural correlates of self-evaluative accuracy after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						fMRI; self-awareness; traumatic brain injury	ALZHEIMERS-DISEASE; BEHAVIORAL LIMITATIONS; FRONTOMEDIAN CORTEX; AWARENESS; FMRI; MIND; ANOSOGNOSIA; SCHIZOPHRENIA; UNAWARENESS; DYSFUNCTION	Individuals who have sustained a traumatic brain injury (TBI) often exhibit an array of cognitive deficits, yet perhaps most maladaptive of these sequelae is the frequent occurrence of reduced insight into one's own condition. In such cases, TBI individuals may overestimate their post-injury level of socio-cognitive functioning, leading to disparities between how they perceive themselves and what others observe. This functional MRI (fMRI) investigation examined the relationship between level of insight into one's post-injury condition (i.e. trait/ability status) and neural activation evoked during an fMRI task involving self-appraisal of one's traits and abilities. Twenty TBI patients (8-12 weeks post-injury, ER Glasgow Coma Scale Average = 10.9 +/- 2.8) were selected on the criterion that they overestimate their current trait/abilities (as detected on the patient competency rating scale, PCRS). fMRI activation on the self-appraisal task was compared between the TBI patients and 20 matched controls. For both groups, the fMRI task evoked activation at mid-line prefrontal and retrosplenial cortices. TBI patients exhibited greater signal change in the anterior cingulate, precuneus and right temporal pole. Subsequently, a linear regression analysis was conducted for the TBI group, with the PCRS and a measure of cognitive speed entered as predictor variables to determine the selective effect of insight on self-evaluative brain activation. A more accurate level of trait/ability-based insight was related to increased signal change in the right anterior dorsal prefrontal cortex (PFC). The results suggest that one's post-injury level of self-referential insight is related to a network inclusive of the medial and right dorsal PFC. (c) 2005 Elsevier Ltd. All rights reserved.	William S Middleton VA Med Ctr, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Madison, WI 53706 USA		Johnson, SC (corresponding author), William S Middleton VA Med Ctr, 2500 Overlook Terrace,11G, Madison, WI 53705 USA.	scj@medicine.wisc.edu		Johnson, Sterling/0000-0002-8501-545X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH65723] Funding Source: Medline		ADAIR JC, 1995, NEUROLOGY, V45, P241, DOI 10.1212/WNL.45.2.241; Adair JC, 1995, NEUROLOGY, V45, P2195, DOI 10.1212/WNL.45.12.2195; BELYI B I, 1975, Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova, V75, P1793; BELYI BI, 1987, INT J NEUROSCI, V32, P799, DOI 10.3109/00207458709043334; Bondi MW, 2005, NEUROLOGY, V64, P501, DOI 10.1212/01.WNL.0000150885.00929.7E; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Craik FIM, 1999, PSYCHOL SCI, V10, P26, DOI 10.1111/1467-9280.00102; D'Argembeau A, 2005, NEUROIMAGE, V25, P616, DOI 10.1016/j.neuroimage.2004.11.048; Ferstl EC, 2002, NEUROIMAGE, V17, P1599, DOI 10.1006/nimg.2002.1247; Fink GR, 1996, J NEUROSCI, V16, P4275; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Flashman, 1998, Semin Clin Neuropsychiatry, V3, P201; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Flashman LA, 2001, J NEUROPSYCH CLIN N, V13, P255, DOI 10.1176/appi.neuropsych.13.2.255; Flashman Laura A, 2002, Curr Psychiatry Rep, V4, P346, DOI 10.1007/s11920-002-0082-x; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fossati P, 2003, AM J PSYCHIAT, V160, P1938, DOI 10.1176/appi.ajp.160.11.1938; Francis W.N., 1982, FREQUENCY ANAL ENGLI; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Grady CL, 2003, J NEUROSCI, V23, P986, DOI 10.1523/jneurosci.23-03-00986.2003; GUSNARD DA, 2001, P NATL ACAD SCI USA, V20, P20; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY; Jenkinson M, 2003, MAGNET RESON MED, V49, P193, DOI 10.1002/mrm.10354; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Joseph R, 1999, PSYCHIATRY, V62, P138, DOI 10.1080/00332747.1999.11024862; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Miller BL, 2001, NEUROLOGY, V57, P817, DOI 10.1212/WNL.57.5.817; Northoff G, 2004, TRENDS COGN SCI, V8, P102, DOI 10.1016/j.tics.2004.01.004; Prigatano G., 1990, CLIN NEUROPSYCHOL, V4, P1; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Reddy H, 2000, BRAIN, V123, P2314, DOI 10.1093/brain/123.11.2314; REED BR, 1993, J CLIN EXP NEUROPSYC, V15, P231, DOI 10.1080/01688639308402560; Schmitz TW, 2004, NEUROIMAGE, V22, P941, DOI 10.1016/j.neuroimage.2004.02.018; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sperling RA, 2003, J NEUROL NEUROSUR PS, V74, P44, DOI 10.1136/jnnp.74.1.44; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; STUSS D, 2001, FRONTAL LOBES NEUROP; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Takahashi H, 2004, NEUROIMAGE, V23, P967, DOI 10.1016/j.neuroimage.2004.07.054; Turk DJ, 2003, ANN NY ACAD SCI, V1001, P65, DOI 10.1196/annals.1279.005; Turk DJ, 2002, NAT NEUROSCI, V5, P841, DOI 10.1038/nn907; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	56	91	94	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	5					762	773		10.1016/j.neuropsychologia.2005.07.012			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	032YQ	WOS:000236813200009	16154166				2022-02-06	
J	Wang, HC; Gao, JL; Lassiter, TF; McDonagh, DL; Sheng, HX; Warner, DS; Lynch, JR; Laskowitz, DT				Wang, Haichen; Gao, Junling; Lassiter, Timothy F.; McDonagh, David L.; Sheng, Huaxin; Warner, David S.; Lynch, John R.; Laskowitz, Daniel T.			Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage	NEUROCRITICAL CARE			English	Article						subarachnoid hemorrhage; traumatic brain injury; posttraumatic epilepsy; levetiracetam; vasospasm; neuroprotection	NITRIC-OXIDE SYNTHASE; DIFFUSE BRAIN-INJURY; CEREBRAL VASOSPASM; ANTIEPILEPTIC DRUGS; PHENYTOIN; SEIZURES; ENDOTHELIUM; PROPHYLAXIS; PREVENTION; MANAGEMENT	Objectives: Prophylactic treatment with antiepileptic drugs is common practice following subarachnoid hemorrhage (SAH) and traumatic brain injury. However, commonly used antiepileptic drugs have multiple drug interactions, require frequent monitoring of serum levels, and are associated with adverse effects that may prompt discontinuation. In the current study, we test the hypothesis that levetiracetam, an anticonvulsant with favorable interaction and adverse event profiles, is neuroprotective in clinically relevant models of SAH and closed head injury (CHI). Methods: A single intravenous dose of vehicle, low-dose (18 mg/kg), or high-dose (54 mg/kg) levetiracetam was administered intravenously followed CHI. Functional assessments were performed on a daily basis, and histological assessments performed at 24 hours. In a separate series of experiments, mice were randomized to receive intravenous administration of vehicle, low-dose, or high-dose levetiracetam every 12 hours for 3 days following SAH. Functional endpoints were assessed daily, followed by measurement of MCA luminal diameter on day 3. Results: A single dose of levetiracetam improved functional and histological outcomes after CHI. This effect appeared specific for levetiracetam and was not associated with fosphenytoin treatment. Treatment with levetiracetam also improved functional outcomes and reduced vasospasm following SAH. Conclusion: Levetiracetam is neuroprotective in clinically relevant animal models of SAH and CHI. Levetiracetam may be a therapeutic alternative to phenytoin following acute brain injury in the clinical setting when seizure prophylaxis is indicated.	Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharm, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; N China Coal Med Coll, Dept Histol & Embryol, Tangshan, Hebei, Peoples R China		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008600] Funding Source: Medline		Briggs Deborah E, 2004, Expert Opin Drug Saf, V3, P415, DOI 10.1517/14740338.3.5.415; BROWNE TR, 1996, NEUROLOGY S, V46, pS7; Cardile V, 2003, BRAIN RES, V976, P227, DOI 10.1016/S0006-8993(03)02720-3; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Conger LA, 1996, CUTIS, V57, P223; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Dagonnier M, 2005, J NEUROL, V252, P727, DOI 10.1007/s00415-005-0726-y; Dooley M, 2000, DRUGS, V60, P871, DOI 10.2165/00003495-200060040-00004; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gidal BE, 2005, EPILEPSY RES, V64, P1, DOI 10.1016/j.eplepsyres.2005.01.005; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; HANNON E, 2001, SEIZURE, V10, P287; HASAN D, 1993, ANN NEUROL, V33, P286; Holtzer CD, 1997, ANN PHARMACOTHER, V31, P435, DOI 10.1177/106002809703100409; IGNARRO LJ, 1987, AM J PHYSIOL, V253, pH1074, DOI 10.1152/ajpheart.1987.253.5.H1074; Ito Y, 2000, J CARDIOVASC PHARM, V35, P45, DOI 10.1097/00005344-200001000-00006; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; KORMAN LB, 1989, CLIN PHARMACY, V8, P514; Lynch BA, 2004, P NATL ACAD SCI USA, V101, P9861, DOI 10.1073/pnas.0308208101; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Meek PD, 1999, ARCH INTERN MED, V159, P2639, DOI 10.1001/archinte.159.22.2639; Mula M, 2003, NEUROLOGY, V61, P704, DOI 10.1212/01.WNL.0000078031.32904.0D; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Parra A, 2002, NEUROL RES, V24, P510, DOI 10.1179/016164102101200276; Patsalos PN, 2003, LANCET NEUROL, V2, P473, DOI 10.1016/S1474-4422(03)00483-6; Pluta RM, 1997, J NEUROSURG, V87, P746, DOI 10.3171/jns.1997.87.5.0746; Ramsay RE, 1996, NEUROLOGY, V46, P17, DOI 10.1212/WNL.46.6_Suppl_1.17S; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; Rigo JM, 2002, BRIT J PHARMACOL, V136, P659, DOI 10.1038/sj.bjp.0704766; ROSE FC, 1965, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5426.18; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Wolf EW, 1998, J NEUROSURG, V89, P279, DOI 10.3171/jns.1998.89.2.0279; YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056	38	91	93	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2006	5	1					71	78		10.1385/NCC:5:1:71			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	073UB	WOS:000239767000015	16960300				2022-02-06	
J	Lister, JP; Blatt, GJ; DeBassio, WA; Kemper, TL; Tonkiss, J; Galler, JR; Rosene, DL				Lister, JP; Blatt, GJ; DeBassio, WA; Kemper, TL; Tonkiss, J; Galler, JR; Rosene, DL			Effect of prenatal protein malnutrition on numbers of neurons in the principal cell layers of the adult rat hippocampal formation	HIPPOCAMPUS			English	Article						stereology; nutrition; CA1; subiculum; hippocampus	SPATIAL-LEARNING DEFICITS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CA1 PYRAMIDAL CELLS; 4 AGE-GROUPS; DIFFERENTIAL VULNERABILITY; STEREOLOGICAL ESTIMATION; SUPEROXIDE-DISMUTASE; NEUROTROPHIC FACTOR; DENTATE GYRUS	Malnutrition has been associated with a variety of functional and anatomical impairments of the hippocampal formation. One of the more striking of these is widespread loss of hippocampal neurons in postnatally malnourished rats. in the present study we have investigated the effect of prenatal malnutrition on these same neuronal populations, neurons that are all generated during the period of the dietary restriction. In prenatally protein deprived rats, using design-based stereology, we have measured the regional volume and number of neurons in the hilus of the dentate gyrus and the pyramidal cell layers of CA3, CA2, CA1, and the subiculum of 90-day-old animals. These results demonstrated a statistically significant reduction of 20% in neuron numbers in the CA1 subfield, while numbers in the other subfields were unchanged. There was a corresponding significant reduction of 22% in the volume of the CA1 subfield and a significant 14% decrease in the volume of the pyramidal layer of the subiculum. The change in volume of the pyramidal layer of the subiculum without neuron loss may reflect loss of CA1 afferent input to the pyramidal layer. Although the effect of nutritional deprivation on the neuronal population appears to be different in pre- and postnatal malnutrition, both dietary paradigms highlight the vulnerability of key components of the hippocampal trisynaptic circuit (consisting of the dentate granule cell mossy fibers projection to CA3 pyramids and the CA3 projection to the CA1 pyramids), which is an essential circuit for memory and learning. (c) 2005 Wiley-Liss, Inc.	Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA USA; Boston Univ, Sch Med, Ctr Behav Dev & Mental Retardat, Boston, MA USA		Rosene, DL (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, 715 Albany St W701, Boston, MA 02118 USA.	drosene@bu.edu	Rosene, Douglas L/G-1973-2015	Tonkiss, John/0000-0002-6498-7815; Rosene, Douglas/0000-0001-8719-1441; DeBassio, William/0000-0002-0073-5627; Kemper, Thomas/0000-0002-4623-4094	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01-AG00001] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01-HD22539] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD022539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG000001] Funding Source: NIH RePORTER		Almeida SS, 1996, NEUROSCI BIOBEHAV R, V20, P389, DOI 10.1016/0149-7634(95)00054-2; Andrade JP, 1996, BRAIN RES, V718, P1; Andrade JP, 1996, NEUROSCI LETT, V211, P211, DOI 10.1016/0304-3940(96)12734-8; ANDRADE JP, 1995, J ANAT, V187, P379; Andrade JP, 1998, HIPPOCAMPUS, V8, P33, DOI 10.1002/(SICI)1098-1063(1998)8:1<33::AID-HIPO4>3.0.CO;2-8; BAYER SA, 1974, J COMP NEUROL, V158, P55, DOI 10.1002/cne.901580105; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BEDI KS, 1991, J COMP NEUROL, V311, P425, DOI 10.1002/cne.903110311; Bedi KS, 2003, NUTR NEUROSCI, V6, P141, DOI 10.1080/1028415031000098549; BOITANO JJ, 1980, PHYSIOL BEHAV, V25, P273, DOI 10.1016/0031-9384(80)90216-4; Bronzino JD, 1997, EXP NEUROL, V148, P317, DOI 10.1006/exnr.1997.6653; CINTRA L, 1990, BRAIN RES, V532, P271, DOI 10.1016/0006-8993(90)91769-D; Cintra L, 1997, HIPPOCAMPUS, V7, P184, DOI 10.1002/(SICI)1098-1063(1997)7:2<184::AID-HIPO5>3.0.CO;2-N; Cintra L, 1997, HIPPOCAMPUS, V7, P192, DOI 10.1002/(SICI)1098-1063(1997)7:2<192::AID-HIPO6>3.3.CO;2-G; Davies AM, 2003, EMBO J, V22, P2537, DOI 10.1093/emboj/cdg254; DEBASSIO WA, 1994, BRAIN RES BULL, V35, P57, DOI 10.1016/0361-9230(94)90216-X; DIAZCINTRA S, 1991, J COMP NEUROL, V310, P356, DOI 10.1002/cne.903100306; DIAZCINTRA S, 1994, BRAIN RES, V662, P117, DOI 10.1016/0006-8993(94)90803-6; GALLER JR, 1991, J NUTR, V121, P762, DOI 10.1093/jn/121.5.762; Galler JR, 1996, NUTR PEDIAT BASIC SC, P196; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Granados-Rojas L, 2002, BRAIN RES, V933, P164, DOI 10.1016/S0006-8993(02)02314-4; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Hedreen JC, 1998, ANAT REC, V250, P366; JAY TM, 1989, BRAIN RES, V505, P337, DOI 10.1016/0006-8993(89)91464-9; JENNRICH R, 1988, BMDP STATISTICAL SOF, P483; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Luebke J, 2000, SYNAPSE, V37, P23, DOI 10.1002/(SICI)1098-2396(200007)37:1&lt;23::AID-SYN3&gt;3.0.CO;2-Y; Lukoyanov NV, 2000, BEHAV BRAIN RES, V112, P85, DOI 10.1016/S0166-4328(00)00164-9; MATSUYAMA T, 1994, STROKE, V25, P1417, DOI 10.1161/01.STR.25.7.1417; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Mesquita RM, 2002, NEUROSCI LETT, V330, P155, DOI 10.1016/S0304-3940(02)00743-7; Morgane PJ, 2002, NEUROSCI BIOBEHAV R, V26, P471, DOI 10.1016/S0149-7634(02)00012-X; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; ROSENE DL, 1986, J HISTOCHEM CYTOCHEM, V34, P1301, DOI 10.1177/34.10.3745909; ROSENE DL, 1987, CEREB CORTEX, P346; Rushmore J, 1998, HIPPOCAMPUS, V8, P380, DOI 10.1002/(SICI)1098-1063(1998)8:4<380::AID-HIPO6>3.0.CO;2-L; Shultz PL, 2002, PHARMACOL BIOCHEM BE, V73, P759, DOI 10.1016/S0091-3057(02)00907-3; STRUPP BJ, 1995, J NUTR, V125, pS2221, DOI 10.1093/jn/125.suppl_8.2221S; Tonkiss J, 2000, BEHAV PHARMACOL, V11, P437, DOI 10.1097/00008877-200009000-00001; TONKISS J, 1993, ANN NY ACAD SCI, V678, P215; Tonkiss J, 2003, NUTR NEUROSCI, V6, P379, DOI 10.1080/10284150310001624200; TONKISS J, 1990, BEHAV BRAIN RES, V40, P95, DOI 10.1016/0166-4328(90)90002-V; Tonkiss J, 2000, PHARMACOL BIOCHEM BE, V65, P105, DOI 10.1016/S0091-3057(99)00182-3; TONKISS J, 1990, PHYSIOL BEHAV, V48, P675, DOI 10.1016/0031-9384(90)90210-U; Tonkiss J, 1998, BEHAV PHARMACOL, V9, P49; TONKISS J, 1990, PHYSIOL BEHAV, V48, P73, DOI 10.1016/0031-9384(90)90263-4; Tuunanen J, 2000, EPILEPSY RES, V39, P171, DOI 10.1016/S0920-1211(99)00123-0; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilde GJC, 1997, J NEUROCHEM, V69, P883; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	57	91	92	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus		2005	15	3					393	403		10.1002/hipo.20065			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	916YB	WOS:000228421600012	15669101				2022-02-06	
